,nct_id,primaryOutcomes,startDate,status,study_type,phases,otherOutcomes,secondaryOutcomes
0,NCT01976351,The relationship between the mucosal morphology by imaging enhanced endoscopy and the presence of high-grade intraepithelial neoplasia from non-dysplastic specialized intestinal metaplasia.,2009-09,TERMINATED,OBSERVATIONAL,['NA'],,
1,NCT00759109,Number of Participants With the Development of Hepatocellular Carcinoma (HCC),2002-03,COMPLETED,INTERVENTIONAL,['PHASE3'],Proliferating Cell Nuclear Antigen Labeling Index (PCNA-LI) at Baseline,Change in the Proliferating Cell Nuclear Antigen Labeling Index (PCNA-LI)
2,NCT00877136,Evaluate patient experience with Therasphere.,2009-02,COMPLETED,OBSERVATIONAL,['NA'],,Tumor response to treatment with TheraSphere®
3,NCT01217450,"Tumor response, as evaluated by the RECIST",2012-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Toxicities graded using the NCI Common Toxicity Criteria
4,NCT01674309,Tumor control rate of the primary tumor and metastasis,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,metastasis response rate
5,NCT05626309,1-year disease-free survival rate,2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Percentage of Participants With Adverse Events
6,NCT03979131,Pathological complete response (pCR) rate,2019-08-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Surgical complete resection rate (R0)
7,NCT00890188,Overall response(CR+PR) and Clinical benefit (CR+PR+SD),2009-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"To determine the progression free survival, overall survival (OS)and assess the safety profile"
8,NCT04209491,Proportion of the following missions of the coordinator Nurse,2019-09-09,UNKNOWN,OBSERVATIONAL,['NA'],,Number of early unscheduled readmissions during the first month following interventional radiology treatment for patients included in the study.
9,NCT04745390,Treated lesion progression,2021-08-01,RECRUITING,INTERVENTIONAL,['NA'],,"Comparison of Quality of Life (QOL) Using a Standardly-Used Validated Instrument. Specifically, measures of physical, social/family, and functional well being. Overall symptoms, function, global health status will also be compared."
10,NCT04249739,ORR (objective response rate) per RECIST 1.1,2020-09-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Genomic analysis
11,NCT00003046,Maximum Tolerated Dose (MTD) of Intraperitoneal Interleukin-12,1997-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12,NCT03789162,Blood-based biomarkers associated with genetic and epigenetic alterations,2018-12-20,RECRUITING,OBSERVATIONAL,['NA'],,
13,NCT05523271,Adenoma detection rate,2023-01-16,RECRUITING,INTERVENTIONAL,['NA'],,Non-neoplastic detection rate
14,NCT03476434,polyp miss rate,2015-02,COMPLETED,INTERVENTIONAL,['NA'],,adenoma miss rate
15,NCT05201885,The positive rate of oncological contamination of peritoneal washings,2022-01-15,RECRUITING,OBSERVATIONAL,['NA'],,Disease free survival
16,NCT05134532,Progression-free survival (PFS) by RECIST v 1.1,2021-12-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety profiles by NCI-CTCAE version 5
17,NCT03982641,Cost relate to HCRU,2019-04-16,UNKNOWN,OBSERVATIONAL,['NA'],,Rate of preoperative chemo-radiation therapy in patients with rectal cancer
18,NCT00689702,Complete pathological remission rate,2007-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Rate of sphincter sparing surgical procedure Toxicity/safety
19,NCT04556344,Change in patient emotional skills from baseline to 15 days after the end of intervention,2020-10-26,RECRUITING,INTERVENTIONAL,['NA'],,Patient satisfaction
20,NCT03418584,radical rate,2017-12-05,UNKNOWN,INTERVENTIONAL,['NA'],,operation time
21,NCT04213794,Incidence of adverse events of cytoreductive surgery (CRS) with heated intra-peritoneal chemotherapy (HIPEC) in this patient population,2019-11-08,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Progression free survival (PFS)
22,NCT02017509,Correlation of the number of infiltrating leukocytes within a biopsy sample with pathologic response,2014-01-24,COMPLETED,OBSERVATIONAL,['NA'],,
23,NCT00982449,To evaluate the potential for enzymatic targeting as evidenced by the ability to image 124I-FIAU tracer uptake in tumor at baseline and following chemotherapy or biologic therapy with agents that may induce viral TK activation.,2010-12,COMPLETED,INTERVENTIONAL,['NA'],,To describe changes in viral DNA in plasma as a function of chemotherapy and the association with imaging by FIAU-PET
24,NCT00427804,Fractional Absorption of Calcium,2007-01,COMPLETED,INTERVENTIONAL,['NA'],,
25,NCT03110068,Presence of microvascular invasion,2017-04-10,UNKNOWN,OBSERVATIONAL,['NA'],,
26,NCT03904927,Progression-free survival,2019-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Local control
27,NCT03730558,Evaluate the efficacy of aflibercept in terms of progression-free survival (PFS) in association with FOLFIRI in patients treated in common practice for metastatic colorectal cancer (CCRM) after failure of oxaliplatin + anti-EGFR-based treatment,2017-11-08,UNKNOWN,OBSERVATIONAL,['NA'],,
28,NCT00002896,,1993-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
29,NCT03714958,Part1: Dose Maximum Tolerated,2018-12-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression-Free Survival (PFS)
30,NCT04731428,Use of analgesic (See Table 1)(postoperative 3rd day),2018-03-15,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative serum cortisol levels (3rd. assessment)
31,NCT04964297,Hydrogen (H2) gas,2021-08-09,RECRUITING,INTERVENTIONAL,['NA'],,Response time of the Perf-AlertTM device.
32,NCT05945823,ORR by investigator assessment,2023-07-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,6-month PFS rate
33,NCT02270554,Incidence of pancreatic fistula grade B/C,2014-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of pancreatic fistula stratified based on thickness of pancreas parenchyma
34,NCT03204201,Number of urethras identified under white light and fluorescence,2017-07-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of adverse events related to trial intervention
35,NCT02324023,T-stage in left sided colonic cancer determined by endoscopic ultrasound compared to histological stage,2014-11,COMPLETED,INTERVENTIONAL,['NA'],,Perfusion in left sided colonic cancer determined by contrast enhanced endoscopic ultrasound compared to histological vascular immunostaining
36,NCT00066430,,2003-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
37,NCT05999162,Onset time,2023-08-04,COMPLETED,OBSERVATIONAL,['NA'],,Re-admission
38,NCT03199989,3-year disease free survival,2017-06-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Major adverse events
39,NCT02643173,Recurrence of HCC,2015-09,COMPLETED,OBSERVATIONAL,['NA'],,
40,NCT00359333,Tumor response,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to tumor progression Overall survival Quality of life
41,NCT05519930,Evaluation of endoscopic ultrasound for early detection of pancreatic cancer in the high-risk group as defined by inclusion criteria to determine their level of risk and perform surveillance accordingly,2016-10-18,SUSPENDED,OBSERVATIONAL,['NA'],,
42,NCT06285097,Objective response rate (ORR) in Part 2 Expansion,2024-02-08,RECRUITING,INTERVENTIONAL,['PHASE1'],,AUC of PF-07820435 and its active metabolite under fasted and fed conditions (Part 2 subset) subset of participants in Part 2
43,NCT01479465,Progression Free Survival (PFS),2011-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Objective Response Rate (ORR)
44,NCT04695782,1-year local control,2020-10-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Patient reported outcomes
45,NCT04846842,Objective response rate (ORR),2021-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
46,NCT02901600,Determination of the histological localisation of DMBT1,2013-06,COMPLETED,OBSERVATIONAL,['NA'],,
47,NCT03785743,5-year overall survival,2019-03-01,RECRUITING,INTERVENTIONAL,['NA'],,intraoperative indicators
48,NCT02504983,Complete remission,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Safety and tolerability of TACE plus sorafenib therapy recorded and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0.
49,NCT04609410,Total intra-operative blood loss,2020-10-30,RECRUITING,INTERVENTIONAL,['NA'],90-day quality of life,Surgery and hepatic resection time
50,NCT00576498,Proportion of patients with biopsy confirmed intestinal metaplasia,2005-10,COMPLETED,INTERVENTIONAL,['NA'],,Inter observer variability in reading of mucosal and vascular patterns
51,NCT05609370,Phase 2: Progression Free Survival (PFS) as Assessed by The Investigator in PD-L1 Positive Arms A and C,2023-01-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Number of Participants with anti-drug antibodies (ADAs) to Tislelizumab, and Bevacizumab in Arm A, Arm B and Arm D"
52,NCT04721223,Objective response rate (ORR),2021-04-26,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants with Treatment-related Adverse Events(TRAE)
53,NCT05438797,incidence of adverse events( AE )and Serious adverse events(SAE),2021-04-02,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Progression-free survival (PFS)
54,NCT05000554,pCR rate,2021-07-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,operative mortality
55,NCT05640726,progression free survival,2023-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,objective response rate
56,NCT05445973,Local tumor progression rate,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Technical success rate of radiofrequency ablation using contrast-enhanced US-CT/MRI fusion image
57,NCT00527891,,2004-06,COMPLETED,OBSERVATIONAL,['NA'],,
58,NCT03115398,Number of Missed Scheduled Radiotherapy Treatments,2017-02-16,COMPLETED,INTERVENTIONAL,['NA'],,Survival Status
59,NCT01791322,Correct identification of tumor mutant genes,2014-01,COMPLETED,OBSERVATIONAL,['NA'],,
60,NCT00493402,Overall survival,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time to progression
61,NCT04685525,PRO-CTCAE questionnaire scores,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
62,NCT04991948,The objective response rate (ORR) at the tumor assessment on Day 94 [Visit 15]),2021-11-22,RECRUITING,INTERVENTIONAL,['PHASE1'],,
63,NCT05570279,Complete clinical response,2016-04-01,RECRUITING,OBSERVATIONAL,['NA'],,Incidence of pelvis fractures
64,NCT03515850,classifications vascular branches of IMA,2018-01-05,UNKNOWN,OBSERVATIONAL,['NA'],,
65,NCT00464893,rate of all specific postoperative complications newly observed during a period of 30 days after surgery in those study patients who received at least the first 3 doses of catumaxomab,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,"disease-free survival at 3, 6, 9, 12 18 and 24 months after EOT, defined as the time from study enrolment to the point of diagnosis of recurrent disease or death, whichever occurred first"
66,NCT06255912,Treatment Emergent Adverse Events,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,overall response rate
67,NCT04542837,ORR,2020-09-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,OS
68,NCT03575806,Recurrence-free Survival (RFS) Time,2017-01-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS) Rate at 24 Months
69,NCT05566834,To determine any increase of treatment emergent adverse events when Minnelide capsules are given in combination with paclitaxel.,2020-11-02,RECRUITING,INTERVENTIONAL,['PHASE1'],,Plasma levels of Minnelide when given with paclitaxel
70,NCT02188901,False referral rate of HCC,2014-10-15,COMPLETED,INTERVENTIONAL,['NA'],,
71,NCT00000764,,na,COMPLETED,INTERVENTIONAL,['PHASE1'],,
72,NCT03961867,disease-free survival,2020-09-15,RECRUITING,INTERVENTIONAL,['PHASE3'],,Treatment related Adverse Events
73,NCT00932308,The degree of inflammation in the rectosigmoid epithelium as judged by the density and composition of the cellular infiltration.,2006-09,COMPLETED,INTERVENTIONAL,['NA'],,Changes in bulk fecal and epithelial associated microbiota that may determine changes in colorectal epithelial cell biologic pathways.
74,NCT05095714,Incremental cost / QALY ratio,2021-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Compliance
75,NCT05386056,Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 in all participants,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Change from baseline in the EORTC Quality Of Life Questionnaire Oesophageal Module (QLQ-OES18) Score
76,NCT03621852,tissue yield,2017-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,
77,NCT05534087,3-year disease-free survival rate,2022-12-15,RECRUITING,INTERVENTIONAL,['PHASE3'],,EORTC QLQ-C30 scale
78,NCT00001428,,1995-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
79,NCT00072748,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],,
80,NCT01871363,Pathological complete remission rate (pCR),2012-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],Disease-free survival,Acute and late toxicity
81,NCT03620643,Percentage of Basket Cohort Participants With Objective Response Assessed Using RECIST v1.1,2019-05-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Assessment of overall survival in each cohort
82,NCT00531180,Correlation between 4-dimensional computed tomography (4D CT) derived ventilation and single photon emission tomography (SPECT) aerosol Tc-99m determined ventilation,2007-08-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,
83,NCT05868317,Pathologic complete response,2020-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,objective response rate to induction chemotherapy
84,NCT03312374,Disease Free Survival,2017-08-01,UNKNOWN,OBSERVATIONAL,['NA'],,
85,NCT06056336,2-year disease-free survival in non-pCR patients,2023-09-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,overall survival
86,NCT03493880,Pathological response,2015-09-01,RECRUITING,OBSERVATIONAL,['NA'],,yp TNM Stage
87,NCT04384601,Total Percentage of Patients With Pathological Complete Tumor Regression (TRG1a) and Sub-total Tumor Regression (TRG1b) in the Primary Tumour,2021-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Disease free survival (DFS)
88,NCT05443230,Long-term results,2022-06-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
89,NCT04455932,HCC detection with US surveillance versus aNC-MRI surveillance,2022-01,RECRUITING,INTERVENTIONAL,['NA'],,
90,NCT05374252,cCR rate,2022-05-07,RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence rate of Grade ≥3 PD-1monoclonal antibody-related adverse events
91,NCT00313872,Second progress-free survival,2003-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Toxicity, overall survival"
92,NCT05473156,Dose-Expansion: Overall response rate(ORR) (assessed by the Investigator according to RECIST version 1.1),2023-02,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
93,NCT05244174,Level of Fecal elastase-1,2022-01-25,RECRUITING,INTERVENTIONAL,['NA'],,Prevalence of PEI
94,NCT01759238,Progression free survival rate,2013-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Toxicity
95,NCT05342636,Objective Response Rate (ORR),2022-07-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants Who Discontinue Study Treatment Due to An AE During the Efficacy Phase
96,NCT02577393,Superiority of EGCG in reducing Grade II esophagitis as assessed by RTOG scores in patients with lung cancer receiving radiation,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Improved quality of life with usage of EGCG for treatment of radiation-esophagitis in patient with lung cancer.
97,NCT03992664,Through a randomized feasibility clinical trial to investigate the effectiveness of an educational intervention in conjunction with routine management of rash in patients receiving EGFRI therapy.,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,Assessing the quality of life in relation to the rash through the QLQI questionnaire.
98,NCT05617755,Maximal tolerated dose of AB-1015,2022-11-29,RECRUITING,INTERVENTIONAL,['PHASE1'],,Co-expression of ALPG and MSLN targets on tumor cells
99,NCT00201747,Most efficacious of two combination regimens of sequential CPT-11 and MMC in patients with advanced and previously untreated esophageal and GE junction adenocarcinomas,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Evaluate if pre- and/or post-treatment Topo I-, CE and NQ01-gene expression in fresh tumor specimens and adjacent tissue, are associated with antitumor efficacy or toxicity."
100,NCT04099901,Reduction of the incidence of fever during neutropenia,2019-11-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Tumor response evaluation
101,NCT01265979,WB-DWI as early predictor for regorafenib treatment response,2011-01,COMPLETED,OBSERVATIONAL,['NA'],,Evaluation WB-DWI parameters in correlation with progression free survival (PFS)
102,NCT04770896,Overall Survival (OS),2021-04-26,RECRUITING,INTERVENTIONAL,['PHASE3'],,Serum Concentration of Atezolizumab
103,NCT00478634,Dose Limiting Toxicities,2007-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Objective Response Rate
104,NCT00003125,,1998-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
105,NCT05045573,Pathological tumor response,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Rate of Healthy liver hypertrophia
106,NCT04821284,Progression-free survival,2021-12-06,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Tumor stiffness
107,NCT01397305,Feasibility of Pemetrexed Prior to Surgery,2011-04-14,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Pharmacokinetic parameters of [6R] 5,10-mTHF, 5-formyl-THF, 5-methyl-THF and THF calculated from plasma"
108,NCT00377936,Overall survival,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of clinically significant abnormal laboratory values
109,NCT05484908,Mortality rate,2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Model for end-stage liver disease (MELD) score variation
110,NCT04550663,The occurrence of AEs and SAEs during the study treatment,2020-09-25,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
111,NCT00593723,The study will evaluate the feasibility of using helical tomotherapy to deliver IMRT in patients with unresectable esophagus cancer.,2006-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Evaluate overall survival rates
112,NCT01970748,Bleeding,2009-08,RECRUITING,INTERVENTIONAL,['PHASE4'],,Complication survival
113,NCT05692895,Diagnosis and prognosis of colorectal carcinoma,2023-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
114,NCT00473980,Immune reactivity,1998-12,COMPLETED,INTERVENTIONAL,['PHASE4'],,
115,NCT02588781,overall response rate,2015-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of subjects with Adverse Events as a measure of safety and Tolerability
116,NCT05035914,Objective response rate,2021-07-09,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Score of quality of Life
117,NCT06017661,IL-8 level,2023-09-01,RECRUITING,INTERVENTIONAL,['NA'],,Patients' quality of life
118,NCT06259292,Prospective Longitudinal Clinical Outcomes Assessment using HHT Clinical Outcomes Scale,2023-11-13,RECRUITING,OBSERVATIONAL,['NA'],,Treatment Outcomes Assessment with HHT Treatment Outcomes Scale
119,NCT04857684,Proportion of patients with grade 3-4 treatment-related adverse events as assessed by CTCAE v5.0,2021-06-18,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Recurrence-free survival (RFS) after resection
120,NCT05541146,Rate of complete peritoneal response after 04 cycles of intraperitoneal (IP) chemotherapy (CMT) associated with systemic CMT with XP.,2022-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
121,NCT02327819,time until a new liver tumor is found,2015-01,UNKNOWN,INTERVENTIONAL,['NA'],,
122,NCT03568630,"Result of MMTT which may indicate type 3c diabetes, which may be a risk factor for pancreas cancer.",2018-07-26,RECRUITING,OBSERVATIONAL,['NA'],,
123,NCT05131698,Objective response rate,2021-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
124,NCT01859728,Overall Response Rate,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Biomarker evaluation,Safety
125,NCT02112656,Overall Survival (OS),2014-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression-free survival (PFS)
126,NCT03843853,Progression-free Survival(PFS),2019-05-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
127,NCT02050503,Pain Intensity Difference,2012-12,COMPLETED,OBSERVATIONAL,['NA'],safety of intranasal transmucosal fentanyl,number of episodes of breakthrough pain requiring additional (rescue) analgesic treatment after administration of the study medication
128,NCT00989469,disease control,2009-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall survival
129,NCT01627080,Evaluation of Cardiac Biomarker Elevation with Radiation Therapy,2014-04,WITHDRAWN,OBSERVATIONAL,['NA'],,Incidence of Adverse Cardiac Outcomes
130,NCT00403624,Tumour response,2001-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease free and Overall survival ; Adverse events
131,NCT04830618,Metachronous recurrence,2012-09-11,COMPLETED,OBSERVATIONAL,['NA'],,
132,NCT00700258,"Efficacy: best response, progression-free survival, overall survival",2008-02-13,COMPLETED,OBSERVATIONAL,['NA'],,Safety: absolute and relative incidence of therapy interruption
133,NCT03937453,Early Stage Pancreatic Cancer or Precursor Lesions,2018-01-19,RECRUITING,OBSERVATIONAL,['NA'],,Relative Risk of Pancreatic Cancer Among Individuals with Detiorating diabetes
134,NCT01211379,Change in Colorectal Cancer Screening Rate,2009-10,COMPLETED,INTERVENTIONAL,['NA'],,
135,NCT03167112,Time to Progression (TTP).,2017-07-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
136,NCT00492999,Resectability rate,2007-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Survival
137,NCT06015022,Change in Prognostic Liver Secretome signature (PLSec) score,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],HCC incidence,Change in quality of life measured by the chronic liver disease questionnaire
138,NCT02401815,Part 2e: To identify the recommended phase 2 dose (RP2D) of PLX9486 in combination with sunitinib for further evaluation,2015-03-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Part 2: To determine the progression-free survival of PLX9486 treatment in combination with PLX3397 or sunitinib.
139,NCT03175146,Response rate within the treated liver lesion,2017-09,UNKNOWN,INTERVENTIONAL,['NA'],,Overall survival
140,NCT00497224,Objective Response Rate,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tolerability of Erlotinib Dose Escalation
141,NCT03381651,Progression free survival,2018-02-22,UNKNOWN,INTERVENTIONAL,['NA'],,Overall survival
142,NCT00659113,Response rate,2008-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Initial squamous cell carcinoma antigen and C-reactive protein correlation with response and survival
143,NCT05705219,Diagnostic yield of the 3D-MPUS data acquisition,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Relationship between baseline and one-month 3D-MPUS measurements and treatment response after three-months
144,NCT00072033,Feasibility of successful study therapy completion and survival after surgery,2003-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Feasibility in Switzerland after surgery
145,NCT00564694,Reliability and clinical and psychometric validity of the European Organization of Research for the Treatment of Cancer (EORTC) quality of life questionnaire (QLQ-CR29),2007-05,COMPLETED,OBSERVATIONAL,['NA'],,
146,NCT00922896,"To assess the response rate associated with gemcitabine, erlotinib and cisplatin in patients with advanced pancreatic cancer",2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
147,NCT03790111,Project Overall Survival Rate at Month 6,2019-03-13,TERMINATED,INTERVENTIONAL,['PHASE2'],,Change From Baseline in Serum Albumin
148,NCT02112240,Evaluating the sensitivity of identifying the sentinel lymph node using a unique mobile gamma camera intraoperatively.,2013-05,WITHDRAWN,INTERVENTIONAL,['NA'],,Feasibility
149,NCT05911789,Response rate after surgery,2023-08-05,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Margins for clinical target volume(CTV) and gross tumor volume (GTV)
150,NCT04208724,Intention to get screened for cancer (type of cancer will be determined by the community-based organization) pre- and post-intervention,2020-11-18,COMPLETED,INTERVENTIONAL,['NA'],,
151,NCT03577665,2-year local control ratio of the treated liver area,2018-05-21,RECRUITING,INTERVENTIONAL,['NA'],,5-year disease-free survival rate of treated patients
152,NCT04048421,Postoperative complications,2019-12-20,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
153,NCT00869739,"Relationship functioning in survivors and partners as assessed by the Dyadic Adjustment Scale (129) and the Miller Social Intimacy Scale (130) at baseline, 2 months, and 5 months",2008-08,COMPLETED,INTERVENTIONAL,['NA'],,"Coping skills in survivors and partners as assessed by the Coping Strategies, Social Problem Solving Scale-Revised, and La Trobe Communication Questionnaires at baseline, 2 months, and 5 months"
154,NCT03821909,The difference of the exosomes acquisited from portal venous blood between patients with pancreatic cancer and benign pancreatic diseases,2018-08-01,UNKNOWN,OBSERVATIONAL,['NA'],,The difference of the exosomes between portal venous and peripheral blood
155,NCT04024917,Cardiac Coherence Program Adherence Rate,2021-09-21,RECRUITING,INTERVENTIONAL,['NA'],,Duration of cardiac coherence sessions in minutes
156,NCT05169437,Overall Response Rate (ORR) - Independent Central Review (ICR),2022-03-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
157,NCT03347292,Dose Limiting Toxicities(DLTs),2018-06-18,COMPLETED,INTERVENTIONAL,['PHASE1'],,Duration of stable disease
158,NCT00017212,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
159,NCT05643417,ORR,2022-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,OS
160,NCT01937715,Progression-Free Survival (PFS),2014-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change From Baseline in Functional Assessment of Cancer Therapy-Colorectal (FACT-C) (Phase 2)
161,NCT05320497,"Intubation rates of bile duct ends, cystic duct openings, and left and right hepatic duct bifurcations",2022-04-14,UNKNOWN,INTERVENTIONAL,['NA'],,Biopsy accuracy
162,NCT04418401,Recurrence-free rate in one year,2020-06-11,RECRUITING,INTERVENTIONAL,['PHASE1'],,Adverse effects
163,NCT04387071,Objective response rate (CR + PR),2021-04-29,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Immune cell populations,Overall survival
164,NCT06102759,Progression Free Survival,2023-11-10,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
165,NCT03695250,Objective Response Rate (ORR),2018-10-16,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
166,NCT01732393,lower grade of mucositis,2010-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,duration of mucositis
167,NCT04646928,5-year Cumulative hepatocellular carcinoma incidence,2017-03-17,UNKNOWN,OBSERVATIONAL,['NA'],,Incidence of cirrhosis regression
168,NCT01836991,the overall survival time,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
169,NCT04269083,"R0, number of patients achieving R0 resection.",2020-05-24,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,safety profile
170,NCT05084859,Part 2 - Objective response rate,2021-11-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Part 2 - Blood samples for measurement of the plasma levels of SM08502 and its metabolite
171,NCT01671449,Progression-free survival,2012-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Adverse Events
172,NCT00687778,Uptake of C11-Acetate and F18-FDG in tumor will be measured in SUV PET units,2008-05,UNKNOWN,OBSERVATIONAL,['NA'],,
173,NCT05056116,Objective response rate(ORR),2021-09-01,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival (OS)
174,NCT00622674,Maximum tolerated dose (MTD) of bortezomib,2005-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Disease response as measured by RECIST criteria
175,NCT04014101,Objective response rate(ORR),2019-06-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
176,NCT01403402,Congenital Muscle Disease Patient and Proxy Reported Outcomes,2009-09,RECRUITING,OBSERVATIONAL,['NA'],,
177,NCT03291561,Gastrointestinal function score,2017-08-01,UNKNOWN,INTERVENTIONAL,['NA'],,Physical fitness index
178,NCT01110668,To evaluate time-to-disease progression in patients with advanced gastrointestinal stromal tumor (GIST) previously treated with imatinib ≥600 mg.,2008-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,To determine progression-free survival and the response rate of nilotinib in patients with advanced GIST previously treated with imatinib ≥600 mg.
179,NCT02331641,"Number of postoperative complications after MH or MMH, graded based on the Dindo's classification (Dindo et al. Ann Surg 2004;240:205-13)",2005-01,COMPLETED,OBSERVATIONAL,['NA'],,Long-term outcome (overall and disease-free survival)
180,NCT00003780,,1998-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
181,NCT02750657,The feasibility of prospectively identifying subgroups of patients with advanced PDAC who have distinct genomic characteristics for better treatment selection while undergoing 1st-line chemotherapy using next generation sequencing.,2015-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Correlation with tumor molecular characteristics and toxicities to treatment using next generation sequencing.
182,NCT00016965,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
183,NCT04864054,To determine the Recommended Phase II Dose (RP2D) of ECT204,2022-03-11,RECRUITING,INTERVENTIONAL,['PHASE2'],,"To characterize the pharmacokinetic (PK) profile of ECT204, including the expansion and persistence of ECT204, in our study subject population"
184,NCT00081315,- Acute radiochemotherapy-induced esophagitis will be assessed from the time of randomization through up to 3 months after completion of radiochemotherapy treatment.,2003-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,- Acute radiochemotherapy-induced pneumonitis will be assessed until 6 months after the last dose of XRT.
185,NCT05657743,Safety - Adverse events,2023-08-16,RECRUITING,INTERVENTIONAL,['NA'],Urine radioactivity measurements,Efficacy-Alpha DaRT seeds
186,NCT04422249,Survival rate,2019-12-23,RECRUITING,INTERVENTIONAL,['NA'],Incidence of postoperative complications,intraoperative parameters
187,NCT02762721,Estimate the frequency of FGFR2 fusions in archived iCCA or mixed HCC-CCA tumor tissue samples,2016-06-06,COMPLETED,OBSERVATIONAL,['NA'],,Formulate genetic screening recommendations for newly diagnosed patients with iCCA or mixed HCC-CCA
188,NCT02752360,Anastomotic Stenosis Rate,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],,The time of reconstruction in the surgery of Intestinal Anastomosis
189,NCT02680990,Feasibility of Large-Scale Trial: Adherence & Contamination,2015-12,COMPLETED,INTERVENTIONAL,['NA'],,Assessing the interaction between frailty and the Band Together program
190,NCT03904537,Disease-free survival (DFS）,2019-02-19,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"The quality of life by EQ-5D-5L (EuroQol Group, Chinese versions )"
191,NCT02324127,Hsp90α Concentration of plasma,2012-10,UNKNOWN,INTERVENTIONAL,['NA'],,
192,NCT02663427,detection rate of gastric cancer among all group,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],,
193,NCT02041481,DLT defined as an adverse event or abnormal laboratory value assessed as at least possibly related to the combination of MEK inhibitor MEK162 and FOLFOX graded according to NCI CTCAE v4.03,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Survival
194,NCT04602299,focal lesion detection rate,2020-11-01,COMPLETED,INTERVENTIONAL,['NA'],,rate of procedures reaching the minimal time
195,NCT02139488,To quantify motion of the esophageal tumor over the course of chemoradiation,2014-04-18,COMPLETED,OBSERVATIONAL,['NA'],,
196,NCT04767503,Metabolomics,2021-02-20,UNKNOWN,INTERVENTIONAL,['NA'],,I-FEED scoring
197,NCT03569488,validation of the French version of the LARS score,2020-01-24,RECRUITING,OBSERVATIONAL,['NA'],,
198,NCT05631613,Deposition of of lipiodol-idarubicin emulsion,2022-12-28,RECRUITING,OBSERVATIONAL,['NA'],,Visibility of lipiodol-idarubicin emulsion under X-ray: image quality
199,NCT01285102,Overall Survival,2010-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,
200,NCT04491955,Objective Response Rate (ORR) for Quadruple Therapy,2020-09-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0),Number of Participants Hospitalized Due to Serious Adverse Events Attributed to Progressive Disease (PD)
201,NCT01633411,Esophageal Stricture,2011-12,COMPLETED,OBSERVATIONAL,['NA'],,Presence of Residual Barrett's Esophagus
202,NCT00270543,high-dose 5-FU/leucovorin chemotherapy for patients with inoperable advanced gastric cancer.,na,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival.
203,NCT05566899,Acceptability and feasibility of EGD-SC measured by Linear Scale,2023-02-08,RECRUITING,INTERVENTIONAL,['NA'],Acceptability and feasibility of EGD-SC measured by Linear Scale,Number of participants with AE's will be measured by the Cancer Therapy Evaluation Program Common Toxicity Criteria (CTC) Version 5.0
204,NCT00055848,,2001-12,COMPLETED,OBSERVATIONAL,['NA'],,
205,NCT06085365,the incidence of chemotherapy related adverse reactions,2023-07-24,RECRUITING,INTERVENTIONAL,['PHASE3'],,changes in immune microenvironment
206,NCT05693649,CRC screening completion at 3 years,2023-06-07,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Choice of test
207,NCT02207465,Number of Adverse Events,2014-07,RECRUITING,INTERVENTIONAL,['PHASE1'],,
208,NCT01126840,Compare Predictors of Health-Related Quality of Life (QOL) among Colorectal Cancer (CRC) Survivors who have Lynch Syndrome (LS) with patients who have Sporadic CRC,2010-06-20,COMPLETED,OBSERVATIONAL,['NA'],,
209,NCT01674374,Proportion of patients with severe mucositis (WHO score 3 or 4),2013-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Quality of Life as assessed by EORTC QLQ Head and Neck Cancer-Specific Module function and symptom sub-scores between groups (with 1 being not at all and 4 being very much)
210,NCT04834505,To construct a diagnosis model for distinguishing FAIP from PC and further validate its efficacy,2021-05-11,RECRUITING,OBSERVATIONAL,['NA'],,Compare the efficacy of EUS based on the model with that of CT/MRI/PET-CT in differentiating between FAIP and PC
211,NCT00956930,Time to Progression (TTP) in Patients Treated With TACE and Y90,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
212,NCT00666991,Determine maximum tolerated dose and to assess qualitative and quantitative toxicities,2008-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Determine pharmacokinetics of intraperitoneal administration
213,NCT03518502,Overall survival,2012-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Median survival time (MST)
214,NCT00001431,,1995-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
215,NCT00063401,"To determine the progression-free survival obtained with cetuximab (C225)/paclitaxel/carboplatin in subjects with newly diagnosed advanced stage ovarian, primary peritoneal, or fallopian tube cancer.",2003-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,To access EGFR expression by immunohistochemical assay.
216,NCT00394433,10-month Progression-Free Survival Rate,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-Free Survival
217,NCT02551250,sensitivity for detecting HCC,2015-09,UNKNOWN,OBSERVATIONAL,['NA'],,false referral rate for HCC
218,NCT05489289,Recurrence free survival (RFS) by BICR,2022-09-24,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Types and proportions of adverse events (AEs)
219,NCT02185768,Rate of patients in objective response (complete or partial response),2015-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Treatment tolerance
220,NCT00865709,Progression-Free Survival (PFS),2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Response
221,NCT05280210,pathological complete response rate(pCR),2022-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,prediction accuracy of PTC
222,NCT01404156,treatment response,2015-09,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,EORTC QOL
223,NCT03059147,Rate of dose limiting toxicities,2017-03-27,TERMINATED,INTERVENTIONAL,['PHASE1'],,Progression-free survival
224,NCT05246839,Impact of Brief Videos,2022-04-28,RECRUITING,OBSERVATIONAL,['NA'],,
225,NCT05286086,Comprehension Complication Index (CCI),2022-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Hospital Anxiety and Depression Scale (HADS) test : anxious and depresion scale
226,NCT04487704,Assess Safety as defined by the NCI CTCAE v5.0,2020-04-07,RECRUITING,INTERVENTIONAL,['NA'],,overall survival
227,NCT00782457,"Lymph nodes isolated, circumferential margin involved, rate of complications and length of stay",2002-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,
228,NCT00489671,Risk of pancreatic cancer as determined by urine cadmium levels,2003-06,COMPLETED,OBSERVATIONAL,['NA'],,"Predictive value of urinary cadmium alone, CA 19-9 alone, and both tests together on development of pancreatic cancer"
229,NCT00500188,Disease-free survival (DFS) time,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
230,NCT04380480,Percentage of Recent Weight Loss,2020-02-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Changes of participants' intestinal flora assessed by blood, urine and stool test"
231,NCT04077372,Difference in proportions of patients with documented goals of care,2019-09-16,TERMINATED,INTERVENTIONAL,['NA'],,Overall comparison of QOL survey
232,NCT04563416,the diagnosis efficiency of the computer-assist diagnosis tool,2020-07-10,UNKNOWN,OBSERVATIONAL,['NA'],,
233,NCT03010085,"Checklist of functional recovery (Questionnaire, liver function test of aspartate aminotransferase and alanine aminotransferase)",2017-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of life
234,NCT00414843,Establish Repository of Human Bile,2006-12,TERMINATED,OBSERVATIONAL,['NA'],,
235,NCT04427527,CRC screening - clinic level,2020-08-19,RECRUITING,INTERVENTIONAL,['NA'],,CRC screening - community level
236,NCT00878215,The Number of Participants Who Have Complete Ablation According to Early Post-ablative Imaging Studies as Well as no Recurrence of the Tumor Within 6 Months (Phase 4 Portion of the Study),2002-10-24,TERMINATED,INTERVENTIONAL,['PHASE2'],,
237,NCT00871169,Overall Response Rate (ORR),2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity
238,NCT05994001,Incidence of Treatment-Emergent Adverse Events(Phase I),2023-08-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,OS
239,NCT04940286,Incidence of adverse events,2021-09-28,RECRUITING,INTERVENTIONAL,['PHASE2'],Change in circulating tumor deoxyribonucleic acid (ctDNA) levels,
240,NCT03355443,Adenoma miss rate in the proximal colon (AMR),2017-12,UNKNOWN,INTERVENTIONAL,['NA'],,Adenoma Detection Rate in the proximal colon (ADR)
241,NCT00392899,Disease-free survival,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Types and severities of adverse events
242,NCT05312216,Objective response rate (ORR),2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events (AEs)
243,NCT01790035,Safety (phase I safety lead-in),2014-08-19,TERMINATED,INTERVENTIONAL,['PHASE1'],,Serum citrulline
244,NCT02534961,Infection after radiofrequency ablation,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,
245,NCT02143115,"Compare the test characteristics (sensitivity, specificity, positive and negative predictive value) of Computed Tomography colonography (CT-C) in the post Colorectal cancer resection using optical colonoscopy as the reference standard",2011-08,COMPLETED,OBSERVATIONAL,['NA'],,Compare the costs and outcomes of Computed Tomography Colonography versus independent Optical Colonoscopy plus Computed Tomography for post Colorectal Cancer resection surveillance.
246,NCT01754896,FIT Kit uptake,2012-04,COMPLETED,INTERVENTIONAL,['NA'],,Rejection rates
247,NCT04592393,Detection of pancreas cancer,2020-10-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Identification of super-high risk group of developing pancreas cancer,Detection of pancreas cancer
248,NCT01336049,Objective response rate,2011-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,adverse events
249,NCT03158610,Progression Free Survival 2 (PFS2),2018-01-29,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Number of participants with quality of life (QoL) as assessed by CTCAE v4.0
250,NCT01927146,Overall survival,2013-07,UNKNOWN,OBSERVATIONAL,['NA'],,
251,NCT02014025,survival rate,2013-03,COMPLETED,INTERVENTIONAL,['NA'],postoperative complications,intraoperative parameters
252,NCT01901042,Changes in quality of life,2012-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
253,NCT03283540,Average intra-balloon pressure,2017-09-25,RECRUITING,OBSERVATIONAL,['NA'],,Low Anterior Resection Syndrome score (LARS)
254,NCT04221893,Overall response rate (ORR),2020-08-07,RECRUITING,INTERVENTIONAL,['NA'],,Time to new systemic therapy
255,NCT04501913,Staff ability to act on identified threshold healthcare parameters,2019-12-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Changes in PGHD/PROs
256,NCT06041425,Pain intensity at 24hours after the end of TACE.,2023-08-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,Nausea and vomiting scale
257,NCT06226857,progression-free survival,2024-01-17,RECRUITING,INTERVENTIONAL,['PHASE3'],,progression-free survival based (per protocol)
258,NCT01071941,Characterize rRp450 pharmacokinetics and viral shedding.,2010-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Correlate radiographic and pathologic assessments of tumor response.
259,NCT00109031,Number of Participants With Severe Oral Mucositis (WHO Grade 3 and 4),2005-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With WHO Grade 4 Oral Mucositis
260,NCT04576572,Tumor recurrence,2020-06-15,COMPLETED,OBSERVATIONAL,['NA'],,The Best Criteria
261,NCT00005843,,2000-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
262,NCT05451160,30-day complete ablation rate,2022-03-16,RECRUITING,INTERVENTIONAL,['NA'],,Equipment failure rate
263,NCT04852250,Secondary intervention rate,2021-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,"Type, incidence, relatedness, and severity of adverse events with severity ≥ Grad 3 (severity according to NCI CTCAE version 5.0)"
264,NCT03250273,Objective Response Rate (ORR) Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1),2017-11-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival (PFS) at 24 Months
265,NCT05889949,Progression-Free Survival (PFS),2019-06-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Adverse events
266,NCT06144853,The number of patients with metabolic response according to FDG-PET/CT evaluated by PERCIST 1.0 one lesion after PIPAC 3,2024-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,The number of patients where FDG-PET/CT evaluated by PERCIST one lesion agrees with histological response according to PRGS after PIPAC 1 and 3
267,NCT00380055,"Proportion of individuals receiving recommended screening for prostate, breast, colorectal, and cervical cancer.",2006-10,COMPLETED,INTERVENTIONAL,['NA'],,Cost-effectiveness of using community navigators to improve cancer care among rural Native Americans.
268,NCT00376909,"Screening rates as measured by mammography, Pap test, hfoBT, sigmoidoscopy, barium enema and colonoscopy",2001-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
269,NCT03878472,Immunotherapy-related biomarkers,2019-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,R0 resection rate
270,NCT04401709,Two-year disease free survival (DFS),2021-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall Survival (OS)
271,NCT00057382,,2003-03,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
272,NCT06259149,VTE events within 28 days after surgery,2024-02-01,RECRUITING,OBSERVATIONAL,['NA'],,Any bleeding event within 28 days after surgery
273,NCT04638036,Feasibility of molecular fluorescence-guided surgery using Cetuximab-800CW,2020-11-13,COMPLETED,INTERVENTIONAL,['PHASE1'],,Evaluation of the distribution of Cetuximab-IRDye800CW
274,NCT05540483,AEs,2022-08-01,RECRUITING,INTERVENTIONAL,['NA'],,Overal Survival
275,NCT01499576,Percent Agreement Between Acetic Acid Chromoendoscopy and Endoscopic Biopsy,2011-11,COMPLETED,INTERVENTIONAL,['NA'],,Number of Participants With Adverse Events
276,NCT03403101,progression free survival (PFS),2020-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Toxicity evaluated according to the Common Terminology Criteria Adverse Events
277,NCT01892527,Study of Tivantinib (ARQ 197) plus Cetuximab in EGFR inhibitor-Resistant MET High Subjects with Locally Advanced or Metastatic Colorectal Cancer with Wild-Type KRAS,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tivantinib (ARQ 197) plus Cetuximab in EGFR inhibitor-Resistant MET High Subjects
278,NCT01349309,Functional Oral Intake Scale (FOIS),2007-06,COMPLETED,INTERVENTIONAL,['NA'],,
279,NCT02813967,Overall survival,2016-06,COMPLETED,INTERVENTIONAL,['PHASE3'],the oesophagus-specific quality-of-life,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
280,NCT06268379,RFS,2010-02-15,COMPLETED,OBSERVATIONAL,['NA'],,
281,NCT05675904,disease-free survival,2022-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
282,NCT02119676,Overall Survival (OS),2014-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
283,NCT01435525,Number of Adverse Drug Reactions,2011-09,COMPLETED,OBSERVATIONAL,['NA'],,Rate of H.Pylori eradication
284,NCT02147145,Determine the natural history of small (< 30 mm) SELs discovered evaluated by EUS.,2008-08,COMPLETED,OBSERVATIONAL,['NA'],,"Compare SEL size estimation based on EUS, EGD and computer tomography (CT)."
285,NCT06283576,Cancer detection,2024-03-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Overall survival
286,NCT05495685,The sensitivity and specificity of multi-cancer early detection by the combined model in cancer arm and benign disease arm,2022-03-24,RECRUITING,OBSERVATIONAL,['NA'],,Sensitivity and specificity of the blood miRNA-based model in detecting pancreatic cancer.
287,NCT02066701,to determine if assay of aberrantly methylated gene markers can discriminate Barrett's Esophagus tissue (and presence of dysplasia) from esophageal squamous and gastric cardia tissue.,2012-05,COMPLETED,OBSERVATIONAL,['NA'],,Assess the accuracy of candidate markers in stool for detection of Barrett's Esophagus
288,NCT05688761,Gastric adenocarcinoma,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Esophageal cancer
289,NCT01904942,Proteomic investigations,2008-10,COMPLETED,OBSERVATIONAL,['NA'],,Infrared spectroscopic investigations
290,NCT00923897,To determine the change in index symptom(s) using an 11 point numerical rating scale for patients with locally advanced hepatocellular cancer or hepatic metastases treated with 8Gy,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,To determine serum marker and radiographic response with 8Gy
291,NCT04476082,Prevalence of Malnutrition According to the Global Leadership Initiative on Malnutrition criteria (GLIM criteria),2020-06-25,COMPLETED,OBSERVATIONAL,['NA'],,Intestinal Microbiome
292,NCT04127864,Cytokines in R848 stimulated blood,2019-10-14,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Cytokines in unstimulated blood
293,NCT00003596,,1998-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
294,NCT00279292,injection for pain in pancreatic cancer patients at 1 month and 3 months.,2004-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,To estimate the effect of treatment on quality of life at 1 month and 3 month
295,NCT04980287,metastasis rate,2021-01-12,RECRUITING,OBSERVATIONAL,['NA'],,3-year DFS
296,NCT02378948,Functional recovery,2015-10,COMPLETED,INTERVENTIONAL,['NA'],,Quality of life
297,NCT04611711,Overall response rate (ORR),2020-11-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
298,NCT04432870,Interest in colon cancer screening,2020-06-09,COMPLETED,OBSERVATIONAL,['NA'],,Risk perception on COVID-19
299,NCT01506336,overall progression free survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,overall survival
300,NCT05134961,3-year survival,1999-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Duodenal cancer recurrence
301,NCT04797624,Comparison of the clinical staging and pathologic TNM staging of the patients,2021-01-15,COMPLETED,OBSERVATIONAL,['NA'],,Comparison of the demographic data
302,NCT01034189,"To determine the clinical response rate in patients with loco-regional esophageal squamous cell carcinoma treated with cetuximab combined with twice weekly paclitaxel/cisplatin concurrent chemoradiotherapy (C-TP-CCRT, 40 Gy).",2008-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Safety and toxicity of cetuximab combined with twice weekly TP-CCRT, followed by surgery."
303,NCT02150447,Time-to-bleeding event,2009-06,TERMINATED,INTERVENTIONAL,['PHASE3'],,Overall survival
304,NCT01476631,"Exercise will decrease serum markers (insulin, C-peptide, IL-6 and PGE-2) in a dose response manner.",2008-11,TERMINATED,INTERVENTIONAL,['NA'],,Participants in the 60 minute intervention will have significantly higher physical activity levels (measured by pedometer and accelerometer) than those in the 30 minute intervention at three months.
305,NCT01580631,Determine the inter-observer agreement of a consensus driven NBI classification system in Barrett's esophagus.,2012-10,SUSPENDED,OBSERVATIONAL,['NA'],,Negative predictive value of the newer NBI classification in identifying dysplasia in Barrett's esophagus.
306,NCT04246710,Reliability of PDAC molecular subtyping on biopsy samples,2018-01-28,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
307,NCT03492164,Number of Adverse Events,2018-03-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
308,NCT04207944,Percent of patients with IPMN progression as measured by a composite of several indicators,2020-07-10,RECRUITING,INTERVENTIONAL,['PHASE2'],Percent of patients with Inflammatory Marker Progression,Percent of patients with cyst progression as measured by radiographic images
309,NCT00409994,Phase II: Tumour blood flow assessed CT-PET + CTp,2006-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Phase II:Incidence of acute side effects of rapamycin, assessed according to CTCv 4.0"
310,NCT02584998,The Number of Participants Who Completed the Mailed FIT Test Screening Within 6 Months,2017-01-01,COMPLETED,INTERVENTIONAL,['NA'],,The Number of Participants Who Received Any Colorectal Cancer Screening Test in the 6-month Period After Enrollment Into the Study.
311,NCT06278064,Plasma proteins in patients with esophagus cancer,2024-02-01,RECRUITING,OBSERVATIONAL,['NA'],,
312,NCT00041665,,na,COMPLETED,INTERVENTIONAL,['PHASE3'],,
313,NCT00526617,Pharmacokinetic Profile,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
314,NCT04796818,Absolute change in the true diffusion coefficient (D),2020-08-12,RECRUITING,INTERVENTIONAL,['NA'],,Diffusion related parameters in intravoxel incoherent motion diffusion weighted imaging
315,NCT04007640,fibroinflammatory lesions at histology in obese patients,2019-06-18,RECRUITING,INTERVENTIONAL,['NA'],,Biomarkers of pathways activation measured by immunohistochemistry on resected pancreatic parenchyma
316,NCT03977220,Recommended dose for Phase II study,2020-01-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
317,NCT00091312,Disease-free survival at 5 years,2004-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"Correlation of clinical, histological, and biological prognostic factors with outcome"
318,NCT03670134,Determine association between thickness of neosquamous epithelium measured with volumetric laser endomicroscopy and recurrence of Barrett's esophagus following endoscopic therapy,2018-08-06,WITHDRAWN,INTERVENTIONAL,['NA'],,Develop a volumetric laser endomicrosopy feature scoring index to stratify the risk of disease recurrence in patients with Barrett's esophagus following treatment
319,NCT02452021,Rate of CTCAE acute grade 3 or higher adverse effects possibly attributed to neoadjuvant CRT,2015-07,COMPLETED,OBSERVATIONAL,['NA'],,Assessment of early cardiac toxicity after CRT using cardiac MRI
320,NCT03620877,Evaluation of coordinated transmission,2018-09-24,UNKNOWN,INTERVENTIONAL,['NA'],,Adherence to personalized intervention
321,NCT00002897,,1992-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
322,NCT03186326,Progression-free survival (PFS) according to the investigator,2018-04-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
323,NCT00898781,"Correlation of the number of CTCs with extent of tumor burden as measured by tumor markers, imaging, and the number of metastatic sites and proliferation and apoptotic markers",2007-11,TERMINATED,OBSERVATIONAL,['NA'],,
324,NCT03999658,Objective Response Rate,2023-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of STI-3031
325,NCT03208283,The mean independently performed flexible sigmoidoscopy completion rate in each study group,2014-10-28,COMPLETED,INTERVENTIONAL,['NA'],,Patients' satisfaction
326,NCT05844865,Development of individual patient-derived peritoneal carcinomatosis (pdPC) vascularized micro-tumor (VMT),2023-05-04,RECRUITING,INTERVENTIONAL,['NA'],,Overall Survival (OS)
327,NCT06281886,Progression free survival rate,2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Distant metastasis-free survival
328,NCT05339581,PVTT RR/NR,2022-05-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Duration of response (DOR)
329,NCT05713994,Number of Patients Amendable to Curative Surgical Interventions,2020-05-19,RECRUITING,OBSERVATIONAL,['NA'],,Quality of Life (QoL) after treatment
330,NCT03152565,Progression Free Survival,2018-03-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Immunophenotype signature in tumor biopsies before and during treatment.
331,NCT05247346,Incidence of intervention-emergent adverse events and serious adverse events,2022-07-01,RECRUITING,INTERVENTIONAL,['NA'],,Scattering parameters
332,NCT00728078,morbility,2008-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,recurrence rate
333,NCT01775267,Liver free of tumors [ Time Frame: At 3 months ] [ Designated as safety issue: No ],2012-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Postoperative liver and renal function
334,NCT03884179,Accuracy of EUS-FNA vs Radiology,2007-02-01,UNKNOWN,OBSERVATIONAL,['NA'],,Accuracy of EUS FNA vs CEA
335,NCT05741255,Montreal Cognitive Assessment,2022-01-05,COMPLETED,INTERVENTIONAL,['NA'],,
336,NCT05048524,The percentage of subjects with R0 resection after surgery,2021-09-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,Biomarkers of treatment response by single cell RNA sequencing and whole exome sequencing
337,NCT03854890,The positive number of lymph nodes retrieved,2019-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,Detection rate of indocyanine green-positive para-aortic lymph node
338,NCT04714814,recurrence or metastasis provened by imageologic diagnosis (PFS),2021-06-01,UNKNOWN,OBSERVATIONAL,['NA'],,
339,NCT04778345,Maximum standardized uptake value [SUVmax (for PET/CT only)] for peritoneal carcinomatosis,2021-03,UNKNOWN,INTERVENTIONAL,['NA'],,1-year progression patterns
340,NCT02741401,Change from baseline in anxiety and depression as assessed by Hospital Anxiety and Depression Scale (HADS) questionnaire,2016-03,UNKNOWN,INTERVENTIONAL,['NA'],,Patients' opinion and need about hand-foot massage's utility as assessed by questionnaire
341,NCT05770882,Progression-free survival (PFS),2023-04-25,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to progression (TTP)
342,NCT01384708,to determine whether or not tissue is neoplastic or non-neoplastic,2010-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
343,NCT04540081,Overall Adherence to CLOVER Metrics,2020-10-05,COMPLETED,INTERVENTIONAL,['NA'],,Hepatitis C screening
344,NCT00593060,To determine the pharmacokinetics of combined treatment with cetuximab and temsirolimus.,2007-11-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,To document objective response rate and progression-free survival in patients treated with the combination.
345,NCT01075048,Progression-Free Survival (PFS) Using Computed Best Response Following Treatment With Tivantinib (ARQ 197) in Combination With Irinotecan and Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Received Front-Line Systemic Therapy,2010-01-26,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Treatment-Emergent Infection and Infestation Adverse Events Following Treatment With Tivantinib (ARQ 197) in Combination With Irinotecan and Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Received Front-Line Systemic Therapy
346,NCT01829035,The overall survival (OS) of oral sorafenib given as monotherapy daily compared to sorafenib with combination cTACE in subjects,2013-02-21,COMPLETED,INTERVENTIONAL,['PHASE3'],,Evaluation of adverse events
347,NCT03619759,Length of stay,2018-03-22,COMPLETED,OBSERVATIONAL,['NA'],,Time to first successful oral intake
348,NCT00586235,"Primary Endpoints: Global Fiducial Registration Error (FRE) of real-time US and fused CT images, Target Registration Error (TRE) and distance between lesional epicenters of real-time US and fused CT images.",2007-02,COMPLETED,OBSERVATIONAL,['NA'],,Secondary Endpoint: Number of coregistration attempts to realize separation of lesional epicenters of real-time US and fused CT images of ≤2 cm and the number of attempts to realize a separation of ≤0.3 cm.
349,NCT05275985,Overall Survival (OS),2022-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,
350,NCT01395030,Number of Participants Comprising Two Distinct PET/CT Imaging Phenotypes (High FCH Uptake vs. Low FCH Uptake) Between the Different Tumor Sub-classes,2011-08-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,
351,NCT04609176,Objective Response Rate (ORR) According to RECIST 1.1 based on investigator assessment,2020-11-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Participants Experiencing an Adverse Event (AE)
352,NCT05592886,The incidence of metachronous recurrent colorectal adenoma at year 1 (local or at other sites),2022-12-15,RECRUITING,INTERVENTIONAL,['NA'],,Changes in the levels of bacterial gene markers
353,NCT03638141,Objective response rate (ORR) using modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria.,2019-10-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants experiencing study drug-related toxicities
354,NCT03613389,Clinical assessment of Oral Mucositis,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,
355,NCT04813913,Difference in carotid stiffness between baseline and at 4 months of bevacizumab treatment.,2019-05-05,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Progression-free survival at 12 months.
356,NCT03958435,Percentage of Participants with treatment-related Adverse Events as Assessed by CTCAE v4.0 for adjuvant therapy for stage II and stage III colon cancer,2018-11-09,UNKNOWN,OBSERVATIONAL,['NA'],,
357,NCT01464151,low- or high grade dysplasia or colorectal cancer during follow-up,2011-07,COMPLETED,OBSERVATIONAL,['NA'],,
358,NCT04136236,The diagnosis efficiency of Artificial Intelligence,2019-08-01,UNKNOWN,OBSERVATIONAL,['NA'],,Contrast the diagnosis efficiency of Artificial Intelligence with endoscopists
359,NCT04597710,Proportion of patients for whom clinically-actionable data is provided by whole genome sequencing at the time of surgery.,2021-02-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Proportion of patients for whom actionable biomarkers of drug sensitivity are identified with WGS.
360,NCT01355302,Time to Maximum Concentration (Tmax) of Golvatinib,2011-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to Progression (TTP)
361,NCT03930368,the change of glycated albumin,2019-04-15,UNKNOWN,INTERVENTIONAL,['NA'],,the change of uric acid
362,NCT00554892,Overall morbidity including infectious and non infectious complications,2007-09,COMPLETED,INTERVENTIONAL,['NA'],,Evaluate the postoperative complications classified according to the DINDO classification.
363,NCT04260191,Number of Participants Who Experienced a Treatment-emergent AE (TEAE),2020-06-29,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall Survival
364,NCT06222619,Overall survival,2020-01-30,COMPLETED,OBSERVATIONAL,['NA'],,Recurrence free survival
365,NCT06147492,urinary retention,2016-01-30,COMPLETED,INTERVENTIONAL,['NA'],,
366,NCT00075738,Objective response rate,2003-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
367,NCT01531777,ORR (Objective Response Rate),2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,QoL (Quality of Life)
368,NCT01253837,Phase II: Investigation of the anti-cancer activity of L19TNFα as measured by Objective Response Rate (ORR),2007-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Investigation of early signs of anti-tumor activity of L19TNFα
369,NCT05934643,Average daily energy expenditure in MET.h,2023-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,30-day complication rate
370,NCT05339984,Estimation of the intraoperative portocaval post-procedural gradient.,2023-01-03,RECRUITING,INTERVENTIONAL,['NA'],,Prediction of the evolution of hepatic artery and portal vein flows after surgery
371,NCT05012397,"Overall Response Rate (ORR) of treatment with milademetan, as defined as the percentage of patients who have achieved confirmed complete response (CR) or Partial Response (PR) according to RECIST v1.1 criteria",2021-11-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
372,NCT05585580,Objective response rate （ORR),2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and tolerability based on incidence of treatment-emergent adverse events as assessed by CTCAE
373,NCT04709445,anastomotic leak,2020-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,Length of hospital stay
374,NCT02479217,Number of Participants with Adverse Events,2006-07,COMPLETED,OBSERVATIONAL,['NA'],,Disease free survival (DFS)
375,NCT02267343,Overall survival,2014-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety will be analyzed through the incidence of laboratory abnormalities
376,NCT02464618,Compliance with scheduled upper endoscopy and colonoscopy,2014-06-26,COMPLETED,INTERVENTIONAL,['NA'],Social contact's activity,Bowel preparation quality
377,NCT02926716,Accuracy for identifying the status of resection margin,2015-12-14,COMPLETED,OBSERVATIONAL,['NA'],,Microvessel density
378,NCT04322539,Overall Survival (OS),2020-08-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Health Care Resource Utilization: Number of Participants With Any Concomitant Medications Prescribed
379,NCT00242086,,2004-10,COMPLETED,INTERVENTIONAL,['NA'],,
380,NCT04913480,Progression-free survival at 1 year,2020-10-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Changes in PD-L1 and PD-1 positive circulating tumor cells before and after stereotactic body radiation therapy and durvalumab
381,NCT00033241,,2001-07-23,COMPLETED,INTERVENTIONAL,['PHASE1'],,
382,NCT06018077,Dİetary Total Antioxidant Capacity (DTAC),2022-10-15,RECRUITING,OBSERVATIONAL,['NA'],,
383,NCT04701060,objective response rate,2021-01-26,UNKNOWN,INTERVENTIONAL,['PHASE2'],To investigate the clinical efficacy of PD-L1 expression in predicting the combination of Camrelizumab and apatinib,Feasibility as measured by rate of enrollment
384,NCT03008499,Relief degree of tumors,2016-12-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival（OS）
385,NCT01015118,"PFS Based on Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumors, Version 1.1 (mRECIST), and Additional Clinical Criteria (Follow up Analysis).",2009-11-17,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change in Global Health Status/ Quality of Life (QoL) Scale Over Time.
386,NCT04931420,Progression Free Survival,2025-09-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,The Effect of Interventions on Circulating Tumor DNA (ctDNA)
387,NCT05465590,Volume of distribution (VZ),2022-12,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,
388,NCT00719199,• The primary objective of this study is to determine the recommended phase 2 dose of IMO 2055 when combined with FOLFIRI and cetuximab in patients with histologically proven advanced or metastatic colorectal cancer (CRC).,2009-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,• To investigate potential markers of IMO 2055 immune activation and effect on cellular immunity.
389,NCT01914744,Incidence rate of HBV reactivation,2013-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],Incidence of drug resistance of viral variants,Incidence rate and median time of HBV DNA level normalization
390,NCT05656326,Successful implementation,2021-08-23,RECRUITING,OBSERVATIONAL,['NA'],,Satisfaction of the patient-led home-based follow-up
391,NCT04588025,Measure change in blood flow within the pancreatic cancer as measured by the P4.,2020-10-14,RECRUITING,INTERVENTIONAL,['NA'],,
392,NCT03791398,Progression Free Survival,2019-11-15,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
393,NCT05168527,ORR,2021-09-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,DOR
394,NCT01413295,Progression Free Survival,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
395,NCT02751086,Rate of patients alive,2016-04,RECRUITING,OBSERVATIONAL,['NA'],,Rate of complications after discharge
396,NCT03730948,Adverse events experienced by subjects (i.e. safety of DC vaccine in subjects with surgically resected hypermutated CRC),2019-03-12,TERMINATED,INTERVENTIONAL,['PHASE1'],,Percentage of CD8+ cells in primary tumor tissue
397,NCT00718211,,2006-05,COMPLETED,OBSERVATIONAL,['NA'],,
398,NCT03344614,PFS,2017-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,DCR
399,NCT06111872,To evaluate the efficacy of Ketamine- Midazolam as a sedative agent in ERCP in terms of sedation failure rate.,2023-07-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,To compare the depth of sedation
400,NCT02797197,"number of handgrip strength test measures per patient, number of handgrip test measures compared to the number of day hospitalisations, number of patients who had all of the measures, between 50 and 100% of measures, less than 50% of measures",2016-05-18,COMPLETED,INTERVENTIONAL,['NA'],,to study the association between the evolution of hand grip strength test and the evolution of nutritional indices (anthropometric and biologic)
401,NCT00901173,Esophageal squamous cell carcinoma,2014-02-10,COMPLETED,OBSERVATIONAL,['NA'],,
402,NCT00746161,The %body weight ratio,2002-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,"preoperative complication, PNI and QOL score"
403,NCT04074447,The proportion of ctDNA content decreased in patients with good therapeutic effect,2019-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,
404,NCT01718808,Progression free survival in week 12,2012-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Overall treatment utility (OTU) (predefined composite endpoint including clinical benefit, tolerability and acceptability of the treatment)"
405,NCT05385692,Phase Ib: Recommended Phase II Dose (RP2D),2022-06-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-free Survival (PFS)
406,NCT05434520,30-day Readmission,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],,Histological Specimen
407,NCT04868149,Amount of future liver remnant volume increment by percentage after stage I ALPPS,2020-09-02,RECRUITING,INTERVENTIONAL,['NA'],,Inflammatory markers associated with inflammation and regeneration after stage 1 ALPPS
408,NCT03377842,Progression-free survival (PFS),2018-01-31,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
409,NCT05641922,Safety,2023-07,WITHDRAWN,INTERVENTIONAL,['NA'],Assessment Module (2),Assessment Module (1)
410,NCT00529984,determine the safety of immunization with CEA(6D) VRP,2007-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,evaluate CEA-specific immune response to immunizations
411,NCT02987907,proportions of participants with severe adverse events according to CTCAE v4.03,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],,time to progression (TTP)
412,NCT02571036,Expansion Phase: Assess Antitumor Activity of DCC-2618 in all diseases,2015-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Escalation Phase: Assess Antitumor Activity of DCC-2618 in patients with advanced malignancies
413,NCT02269332,Adenomatous Polyps,2014-08,COMPLETED,OBSERVATIONAL,['NA'],,
414,NCT01465464,Overall Survival(OS),2010-12,TERMINATED,INTERVENTIONAL,['PHASE3'],,Time to Transcatheter Arterial Chemoembolization (TACE) Failure
415,NCT05895942,Degree of tumor regression,2021-09-10,RECRUITING,OBSERVATIONAL,['NA'],,
416,NCT04351880,Anxiety and Depression measured through the Hospital Anxiety and Depression Scale,2020-04-16,COMPLETED,INTERVENTIONAL,['NA'],,Re-hospitalization and Emergency Department Visits
417,NCT03233711,Disease free survival,2018-07-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence of toxicities
418,NCT02959359,The primary objective of the study is annual recurrence-free survival after curative resection of HCV-HCC for up to 5 years.,2016-11,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,Overall survival
419,NCT03172416,Tolerability of PIPAC with oxaliplatin in combination with IV nivolumab by monitoring dose limiting toxicities,2017-04-12,RECRUITING,INTERVENTIONAL,['PHASE1'],,Area under the curve (AUC) of oxaliplatin and in combination with IV nivolumab administered via PIPAC using blood drawn from patient.
420,NCT01386346,Evaluation of dose limiting toxicity (DLT),2011-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
421,NCT05114213,Mean cumulative pain index,2021-12-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Death from any cause
422,NCT00842244,Number of Participants With Cycle 1 Dose-limiting Toxicities (DLTs),2009-04,COMPLETED,INTERVENTIONAL,['PHASE1'],Maximum Tolerated Dose (MTD) of Axitinib (AG-013736) in Combination With Cisplatin and Capecitabine,Progression-Free Survival (PFS)
423,NCT02646514,Patency of metal stent,2015-09,UNKNOWN,INTERVENTIONAL,['NA'],,Complication rate
424,NCT03407495,The Sensitivity and specificity of IOP-enhanced MRI,2018-11-22,COMPLETED,INTERVENTIONAL,['PHASE2'],,The size of lesions detected in liver
425,NCT05162248,Disease-Free Survival,2021-04-01,COMPLETED,OBSERVATIONAL,['NA'],,
426,NCT05052801,Overall Survival,2022-03-07,RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of Participants with an Anti-bemarituzumab Antibody Formation
427,NCT00851968,overall survival,2008-12,COMPLETED,INTERVENTIONAL,['NA'],,"serum alanine aminotransferase (ALT), bilirubin, prothrombin time, serum albumin and pre-albumin on postoperative 1, 3, 7 day, resection rate, procedure-related complications and hospital mortality,expression of HIF and P-, E-, and L-selectin"
428,NCT03236051,Numeric rating scales (NRS) score with 24 hours after the surgery,2017-02-10,UNKNOWN,INTERVENTIONAL,['NA'],,Prealbumin
429,NCT06162468,The proportion of patients in whom EUS-PCA was completed as planned.,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,The IPMN complete response rate in the injected lesion(s) on imaging 3 months post-EUS-PCA.
430,NCT01932918,lung injury score,2011-01,COMPLETED,OBSERVATIONAL,['NA'],,
431,NCT00134069,Pharmacodynamics of the combination of irinotecan when given in combination with sorafenib and cetuximab in tumor tissues,2005-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
432,NCT02438839,Proportion of patients with locoregional tumor control with chemoradiation alone two years after end of treatment,2015-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,"Response and tumor control on MRI scans compared to clinical observations, including rectoscopic examination"
433,NCT02480114,"Change in Pain Associated With Radiation-induced Mucositis, (Pain Subscale of the Vanderbilt Head and Neck Symptom Survey (VHNSS))",2015-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Frequency and Severity of General Systemic Symptoms (Surveys Such as the Neurotoxicity Scale, Profile of Mood States, and Quality of Life Form)"
434,NCT02423811,Progression-free survival,2015-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
435,NCT06143722,Progression-Free Survival (PFS),2023-11-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
436,NCT06006286,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",2023-08-08,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
437,NCT02836925,SVR12,2016-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity - Incidence of Adverse Events
438,NCT06015035,Primary Endpoints: pCR,2021-04-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
439,NCT05622825,Image Assessment,2023-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life assessment.
440,NCT00153881,To determine the maximum tolerated dose of oral capecitabine in combination with fixed doses of weekly docetaxel and concurrent radiation for the treatment of patients with clinical stage II-III cancer of the esophagus and gastroesophageal junction.,2000-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To investigate the feasibility of assaying thymidine phosphorylase, cyclin B, MPM-2, and perturbations in cell cycle as potential markers of efficacy."
441,NCT01733628,Progression Free Survival (PFS),2012-10-23,COMPLETED,OBSERVATIONAL,['NA'],,"Number of Participants With ""White Coat"" AHT With 24 Hours Ambulatory BP Measure"
442,NCT06261125,Progression-free survival (PFS),2024-03-10,RECRUITING,INTERVENTIONAL,['PHASE2'],Correlation between serum cytokines and overall survival and immune-related adverse events,Treatment-related adverse events
443,NCT03385018,3 year relapse-free survival,2018-04-05,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life(EORTC QLC STO22)
444,NCT00005616,,1999-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
445,NCT05214820,Tumor uptake of 68Ga-PSMA,2022-01-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,Radiation dose (mGy)
446,NCT05659381,Progression-free survival,2024-03-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Residual Disease
447,NCT05407584,Confirmed ORR,2022-07-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,second objective disease progression
448,NCT05495217,Operative time,2021-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Tumor size
449,NCT04126733,Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 Assessed by Investigator,2019-10-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Different Severity Types of TEAEs Per Common Terminology Criteria for Adverse Events (CTCAE) v5
450,NCT03057288,Success rate evaluation of the placement of two fiducial markers,2017-02-03,COMPLETED,INTERVENTIONAL,['NA'],,The presence of the markers at the end of the radiotherapy
451,NCT05443087,Trough concentration (Ctrough),2022-08-29,RECRUITING,INTERVENTIONAL,['NA'],,Safety: drug toxicity
452,NCT00819208,Disease-free survival,2009-06-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Predictors of physical activity adherence as assessed by Social Cognitive Determinants of Exercise questionnaire
453,NCT03753659,Objective response rate (ORR) according to RECIST 1.1,2019-05-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Identification of molecular biomarkers in tumor tissue and blood samples by immunohistochemical and molecular analyses in a central lab
454,NCT05436275,Nasal Congestion Score (NCS),2022-08-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Anti-drug antibodies (ADA)
455,NCT06105515,Severe complication,2023-12,RECRUITING,INTERVENTIONAL,['NA'],,Health-related quality of life
456,NCT04365751,Overall survival,2019-12-26,RECRUITING,INTERVENTIONAL,['NA'],,Local rate of progression
457,NCT04510935,mean percentage change from post- to pre-operative values of invasion of HepG2 cells cultured in patients' serum,2020-08-20,COMPLETED,INTERVENTIONAL,['NA'],,serum IL-2 level
458,NCT02893982,maximum tolerated dose,2017-11-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,local control
459,NCT03233555,Use of preventive services,2013-09-03,COMPLETED,INTERVENTIONAL,['NA'],,
460,NCT03742453,Diagnostic performance of CEUS for diagnosing HCC,2018-10-16,UNKNOWN,INTERVENTIONAL,['NA'],,Diagnostic performance of gadoxetic-acid liver MRI for diagnosing HCC using KLCSG-NCC guidelinev2018
461,NCT00332280,Improvement in clinical benefit response,2006-05,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Safety and tolerability
462,NCT05304481,Relapse-free survival rate,2022-05-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,Changes in respiratory rate
463,NCT05585437,patient complication rate,2021-11-11,COMPLETED,OBSERVATIONAL,['NA'],,
464,NCT01189877,Measure pO2 in rectal cancers,2010-08,COMPLETED,INTERVENTIONAL,['NA'],,Correlate immunohistochemical analysis of endogenous markers of hypoxia
465,NCT00584597,The specific aim will be to determine the safety of TRAUMEEL S for mucositis in head and neck cancer patients undergoing radiation therapy,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
466,NCT03879395,Overall survival,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Complications according to Clavien-Dindo within 90 days.
467,NCT02376452,progression free survival,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,quality of life questionnaire
468,NCT02873598,The Maximum Tolerated Dose (MTD) of Stereotactic Body Radiotherapy (SBRT) in Locally Advanced Pancreatic Cancer (LAPC) Patients Who Have Not Developed Distant Progression After Induction Chemotherapies.,2016-11-17,COMPLETED,INTERVENTIONAL,['PHASE1'],,Quality of Life (QOL)
469,NCT05251038,Objective Response Rate (ORR),2022-09-13,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
470,NCT02495311,The corrleation coefficient between the size of myoma and Overactive Bladder Symptoms Scores,2014-11-15,RECRUITING,OBSERVATIONAL,['NA'],,Comparisons of the constipation/diarrhea rates between the adenomyosis group and the control group
471,NCT00103142,Recurrence-free Survival at 2 Years,2005-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Positive Immune Response as Measured by (Enzyme-linked Immunosorbent Spot) ELISpot Assay
472,NCT00639522,Dose limiting toxicity,2008-05,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics
473,NCT04634357,The recommended phase 2 dose (RP2D) regimen of ET140203 T cell therapy primarily based on DLT,2022-07-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determine the pharmacokinetics of ET140203 T cells after infusion.
474,NCT05431621,Establish and evaluate the non-invasive early detection model for hepatocellular carcinoma,2020-11-15,RECRUITING,OBSERVATIONAL,['NA'],,
475,NCT04303403,Maximum Tolerated Dose,2018-07-31,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall Survival
476,NCT02976142,Overall 2-year survival,2016-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life
477,NCT05032027,grade 3 entiritis,2021-08-27,RECRUITING,INTERVENTIONAL,['NA'],,Changes in intestinal flora
478,NCT00003018,Overall Survival,1997-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Resectability of patents who respond to this regimen
479,NCT04587310,endoscopy performed on patients,2008-10-01,COMPLETED,OBSERVATIONAL,['NA'],,
480,NCT01429038,"Incidence of infections (bacterial, viral, fungal, parasitic) and cancers",2012-02-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Anti-MSC donor HLA antibodies.
481,NCT02421536,"Change from baseline in ""out of clinic"" pain at 2 months",2016-01-14,COMPLETED,INTERVENTIONAL,['NA'],,Change from baseline mucositis pain at 2 months
482,NCT04317248,"Progression-Free-Survival (PFS), month",2020-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events
483,NCT00352638,Colorectal cancer screening compliance,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Cost
484,NCT01577758,AUC0-21 Days: Area Under the Curve Day 0 to Day 21 for MMAE,2012-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Antitherapeutic Antibodies (ATA)
485,NCT01762293,Progression Free Survival(PFS),2012-04,COMPLETED,INTERVENTIONAL,['PHASE2'],"body vitals, laboratory parameters",Number of Participants with Adverse Events as a Measure of Safety
486,NCT04418739,Overall Complications,2020-01-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,Ease of surgery
487,NCT02375958,Incidence rate of dose limiting toxicities,2015-04-15,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetic paramater Tmax
488,NCT00026273,,2001-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,
489,NCT03937830,"To evaluate the 6-month PFS in patients with BTC and HCC BCLC stage C treated with bevacizumab, durvalumab and tremelimumab",2021-03-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,"To determine the safety and feasibility of bevacizumab, durvalumab, tremelimumab in patients with advanced BTC"
490,NCT00737646,Changes in colorectal cancer screening rates (4 modalities),2009-07,COMPLETED,INTERVENTIONAL,['NA'],,"Changes in measures of attitudes, beliefs, opinions, and social influence surrounding CRC screening among patients, clinicians, and clinical staff."
491,NCT04493632,Resection Rates,2022-04-12,RECRUITING,OBSERVATIONAL,['NA'],,
492,NCT00605150,Progression,2008-01,COMPLETED,OBSERVATIONAL,['NA'],,Number of Participants With Unacceptable Side Effects After Treatment
493,NCT06318793,Concentration of C-reactive protein (CRP),2012-09,COMPLETED,OBSERVATIONAL,['NA'],,
494,NCT05573282,Progress Free Survival,2022-10-16,RECRUITING,OBSERVATIONAL,['NA'],,Tumor Response
495,NCT05999396,Safety 3-Hematology-White Blood Cells,2024-01-12,RECRUITING,INTERVENTIONAL,['PHASE1'],,
496,NCT04151355,incidence of mucositis,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA'],,serum levels of tumor necrosis factor α (TNF-α)
497,NCT05810792,Incidence and severity of Treatment-Emergent Adverse Events as assessed by NCI-CTCAE,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Carbohydrate antigen 19-9
498,NCT05971069,The safety and efficacy of the decision algorithm for the aberrant left hepatic artery preservation/ligation with real time near-infrared fluorescence imaging,2021-12-17,COMPLETED,INTERVENTIONAL,['NA'],,Number of participants with liver-related postoperative complications as assessed by serum aspartate transaminase(AST) and alanine transferase(ALT)
499,NCT05213312,Pathological Complete Response (pCR) rate,2022-06-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Incidence of Treatment-Emergent Adverse Events
500,NCT04377048,response rate,2020-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
501,NCT05578287,Feasibility,2023-07-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
502,NCT04704661,Differential pharmacodynamic (PD) profile of tumor tissue (DNA damage & repair) (Dose expansion phase),2021-08-09,RECRUITING,INTERVENTIONAL,['PHASE1'],"Association of TP53, ATM, and RAS mutations with ORR",PD markers
503,NCT05612347,"Incidence of advanced neoplasia in each study group, annual FIT and colonoscopy, assessed by comparing the detection of advanced neoplasia between the two study groups.",2023-06-14,RECRUITING,INTERVENTIONAL,['NA'],,"Major and minor harms within 30 days of colonoscopy, as measured through chart review and telephone interview."
504,NCT04581876,progression free survival,2019-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,adverse events
505,NCT01575574,hepatocellular carcinoma diagnosed,2012-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,magnetic resonance imaging sensitivity
506,NCT06191185,Colonoscopy completion,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Scheduled by GI for colonoscopy
507,NCT03187028,Feasibility - Participant satisfaction,2017-08-03,COMPLETED,INTERVENTIONAL,['NA'],,Wearable activity monitor (weekly minutes of physical activity)
508,NCT00151671,Factor V at day 3 after surgery,2003-04,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Infections
509,NCT01341210,The influencing factors of behavior intentions towards participating in clinical trials,2011-02,UNKNOWN,OBSERVATIONAL,['NA'],,The subjective norm and behavior intentions towards clinical trials in cancer patients
510,NCT04951804,Change in Likert pain scores,2021-10-07,RECRUITING,INTERVENTIONAL,['NA'],,Difference in Global Rating Scale of Change at T3 vs all other follow-up time points
511,NCT02908204,Overall survival,2016-10,UNKNOWN,OBSERVATIONAL,['NA'],,Long-term complications incidence rate
512,NCT04612569,Impact of a multimodal package of prehabilitation and rehabilitation in patients with low anterior resection syndrome,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,Assessment of the improvement of pelvic floor contractility
513,NCT05851534,Time to functional recovery,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Evaluation of quality of life for cancer patients
514,NCT03476421,Rates of local recurrence,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
515,NCT01278537,Quality of life,2011-02,COMPLETED,INTERVENTIONAL,['NA'],,Stress
516,NCT05117723,Risk stratification for patients with IPMN into those that require more intensive screening and possibly intervention versus those that are unlikely to progress to malignancy.,2021-08-26,RECRUITING,OBSERVATIONAL,['NA'],,
517,NCT00288444,Determine the molecular interaction,2006-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,Determine safety and efficacy
518,NCT04794465,Time to treatment,2021-04-01,UNKNOWN,OBSERVATIONAL,['NA'],,Time to symptoms
519,NCT00060502,"Change in Lean Body Mass (LBM) from baseline to the end of first cycle, as measured by bioelectrical impedance analysis (BIA).",2003-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Change in 6-minute walk test distance from baseline to the end of the first cycle; Safety, Karnofsky performance status; Survival."
520,NCT00066846,,2003-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
521,NCT02557724,post operative liver injury,2015-09,COMPLETED,OBSERVATIONAL,['NA'],,(AST) Aspartate Aminotransferase
522,NCT00408772,Conversion rate of nonresectable disease to resectable disease,2007-06,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Duration of response
523,NCT04108494,3 years relapse-free survival,2019-01-01,RECRUITING,INTERVENTIONAL,['NA'],Postoperative morbidity,5 years overall survival
524,NCT04624217,ORR,2020-11-24,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,OS
525,NCT02154737,Rate of dose limiting toxicities of each subject,2013-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Adverse events related to pulse dose erlotinib and gemcitabine
526,NCT03833700,Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs),2019-03-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
527,NCT01380262,number of patients with a severe skin toxicity,2010-06,UNKNOWN,OBSERVATIONAL,['NA'],,quality of life assessed with DLQI
528,NCT04135690,Progression free survival rate at 6 months,2019-10-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
529,NCT04111380,Objective Response Rate [ORR],2019-09-24,UNKNOWN,INTERVENTIONAL,['PHASE2'],,adverse events
530,NCT00826501,Compare median time to pseudocyst recurrence between patients undergoing EUS or Surgical Cysto-gastrostomy,2009-01,COMPLETED,INTERVENTIONAL,['NA'],Compare pain medication usage,Median time to pseudocyst recurrence at 24 month follow-up.
531,NCT00316745,PFS of 1st line treatment,2006-04,SUSPENDED,INTERVENTIONAL,['PHASE3'],,safety
532,NCT03377361,Objective response rate (ORR) by investigator (Part 1B and Part 2),2018-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests
533,NCT02600949,Incidence of adverse events (AEs),2016-05-11,RECRUITING,INTERVENTIONAL,['PHASE1'],,Levels of intracellular cytokine staining of T cells
534,NCT01756183,radical resection rate,2011-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival time
535,NCT01127425,primary: Length of stay,2006-07,TERMINATED,INTERVENTIONAL,['NA'],,"secondary: Nursing hours, pain and recovery"
536,NCT02547480,Area Under the Curve (AUC),2015-11,COMPLETED,INTERVENTIONAL,['NA'],,Technical success - total dose delivered
537,NCT03579836,DCR(Disease Control Rate) in combination therapy of BEY1107 and Gemcitabine (Phase II),2018-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of subjects with Adverse events in BEY1107 and Gemcitabine combination (Phase II)
538,NCT02658019,Number of Participants With Treatment-Related Adverse Events,2016-05-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Response (DoR)
539,NCT03063918,Quality of life assessed by City of Hope-Quality of Life-Colorectal Cancer,2017-04-28,COMPLETED,INTERVENTIONAL,['NA'],Scores from the Decisional Conflict Scale,
540,NCT02423785,Changes in retinal surface before and after therapy as measured by optical coherence tomography,2014-05,TERMINATED,OBSERVATIONAL,['NA'],,
541,NCT05330429,Randomized Cohort: Progression-free Survival (PFS) as Determined by Investigator Assessment Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1,2022-07-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety Run-in and Randomized Cohorts: Antidrug Antibodies (ADA) to Magrolimab
542,NCT04505696,Pre-post Questionnaire,2020-08-05,COMPLETED,INTERVENTIONAL,['NA'],,
543,NCT05588388,6- month Progression Free Survival (PFS) rate,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Tissue and blood based biomarkers,Incidence of adverse events
544,NCT03771508,Prospective collection of PillCam SB3 videos,2018-12-13,RECRUITING,OBSERVATIONAL,['NA'],,
545,NCT02092519,diagnostic accuracy,2013-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,
546,NCT01808417,Feasibility of real-time intraoperative NIR lymphatic mapping,2013-06-21,COMPLETED,INTERVENTIONAL,['PHASE1'],,Identification of sentinel lymph nodes
547,NCT02949258,2-year survival rate,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,in-hospital mortality rate
548,NCT01362582,Questionnaire EORTC - Quality of Life,2010-03,TERMINATED,INTERVENTIONAL,['PHASE3'],,Assessment of nutritional status
549,NCT04567069,Health-related quality of life (QoL): 36-Item Short Form (SF-36),2020-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Health-related quality of life (QoL): 36-Item Short Form (SF-36)
550,NCT00416351,Response Rate for Participants With Non-Hodgkin's Lymphoma,2006-06-27,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Participants Evaluated for Toxicity
551,NCT03983174,fecal incontinence,2017-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
552,NCT05985109,Overall response rate,2023-10-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,treatment-related adverse event
553,NCT02235246,pain score,2014-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,
554,NCT03795311,Number of Participants with Acute toxicities as a Measure of treatment specific Safety and Tolerability,2018-11-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
555,NCT05903703,Evaluation the clinical disease progression (PD) at 6 weeks intervals,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
556,NCT04741308,Change from baseline immune function at follow-up.,2021-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,Change from baseline chemotherapy response at follow-up.
557,NCT06252142,International Prostate Symptom Score (IPSS),2024-02-19,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Treatment-related toxicities
558,NCT05694949,All-cause mortality at 30 days after operation,2023-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Major Adverse Cardiovascular Events (MACE)
559,NCT03172403,Correlation between skeletal muscle and degree myostatin,2018-08-02,TERMINATED,INTERVENTIONAL,['NA'],,Analysis level of myostatin muscular expression and blood samples results
560,NCT00669370,To determine the quality of life (EORTC QLQ-C30 and QLQ-STO22),2006-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"To evaluate time to progression (TTP), overall response rate (ORR) and overall survival (OS)."
561,NCT06301386,objective response rate (ORR),2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,advert events
562,NCT03803254,Overall Survival (OS),2019-01-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Adverse Events
563,NCT04380337,Clinical complete response (cCR),2020-05-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
564,NCT00250822,"Response Rate ( CR + PR rate); namely, to determine response rate to the Gemcitabine and Oxaliplatin combination administered to patients with hepatocellular cancer. Furthermore, patients who achieve a response leading to tumor respectability.",2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
565,NCT01769248,Diagnostic Yield of EUS-FNB and EUS-FNA,2012-09,COMPLETED,INTERVENTIONAL,['NA'],,Percentage of Patients in Whom a Diagnosis is Achieved After Crossover (%)
566,NCT04761172,Primary tumor detection,2020-06-17,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Tumor to background ratio
567,NCT05730595,Overall survival,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Function score
568,NCT01617382,To improve the prognosis/survival of patients with malignancies localized on the peritoneal surface.,2012-05,RECRUITING,OBSERVATIONAL,['NA'],,
569,NCT00814086,Number of patients who have at least 1 dose-limiting toxicity or delay in therapy for more than 2 weeks,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Objective tumor response (partial or complete) assessed by Response Evaluation Criteria for Solid Tumors (RECIST)
570,NCT00954174,Overall Survival,2009-08-17,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Patient-reported Peripheral Neuropathy Symptoms - Post Baseline
571,NCT06266832,Organ retention rate,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,QoL
572,NCT00689364,The recurrence and metastasis rates for 1、2、3、4 and 5-year.,2007-04,UNKNOWN,OBSERVATIONAL,['NA'],,Survival index: the survival rate for1、2、3、4 and 5-year.
573,NCT03595540,Quantification of FMD-emergent adverse events,2017-11-22,COMPLETED,INTERVENTIONAL,['NA'],,
574,NCT02788214,Bacterial DNA sequence,2016-07-27,TERMINATED,OBSERVATIONAL,['NA'],,
575,NCT00896467,Adjustment strategies and emotional regulation as assessed by the WCC and ERQ questionnaires,2007-09,TERMINATED,OBSERVATIONAL,['NA'],,
576,NCT00002470,,1990-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
577,NCT04281784,Proportion of Patients With EHR Documentation of Goals of Care Discussions,2020-04-23,COMPLETED,INTERVENTIONAL,['NA'],,All-cause Mortality at 1 Year (Safety Outcome)
578,NCT03682289,Objective response rate (ORR) for endometrial cohort,2019-01-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall percent change in tumor size
579,NCT01564810,the rate of patients converted to resection for liver metastases,2006-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],,tumor response
580,NCT03755440,Response rate,2018-12-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Control Rate (DCR)
581,NCT00031863,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,
582,NCT04599179,Quality of life (QoL) after endoscopic or surgical treatment,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
583,NCT00262210,We expect to enter 25 patients per year and finish accrual of patients within 4 years.,1995-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
584,NCT02789826,The number of lymph nodes in the postoperative spicement.,2016-06,COMPLETED,INTERVENTIONAL,['NA'],,Duration of Surgery
585,NCT02470533,Time to progression,2015-04-30,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of life
586,NCT00074009,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
587,NCT04052152,Adverse reaction rate,2019-06-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
588,NCT04650451,Maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE),2020-12-07,SUSPENDED,INTERVENTIONAL,['PHASE1'],,Antitumor activity of BPX-603
589,NCT05545124,1-year recurrence-free survival,2022-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,adverse events
590,NCT04823793,Sensitivity and specificity of methylation biomarker and FIT for adenoma and colorectal cancer screening,2021-03-31,UNKNOWN,OBSERVATIONAL,['NA'],,
591,NCT01443481,Pharmacokinetic (PK) parameter of AUCinf following a single dose of TKI258,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics and Hepatic Function Abnormalities
592,NCT05661357,ORR,2023-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],,
593,NCT01524848,Disease control rate,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall response rate
594,NCT04303429,Disease Free Survival (DFS),2020-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Cost Utility Analysis,Overall Survival (OS)
595,NCT01830647,Safety: Incidence of adverse events,2013-04,COMPLETED,OBSERVATIONAL,['NA'],,Efficacy: Time to disease progression
596,NCT06205706,"identification of dose/dose range fulfilling favorable PK and pharmacodynamic profile, with acceptable safety",2023-12-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Duration of response (DoR).
597,NCT05233553,Incidence of SSC-COVID in hospitalized COVID-patients of the first wave,2020-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
598,NCT02699047,Serum albumin,2015-03,UNKNOWN,INTERVENTIONAL,['NA'],,
599,NCT02046278,Assessment of the overall Subject safety by incidence of pre specified procedure related Adverse Events.,2014-01,COMPLETED,INTERVENTIONAL,['NA'],,Performance Rate of anastomotic leak (both radiological and clinical leaks)
600,NCT05734105,Progression-free Survival (PFS),2023-12-13,RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall Survival (OS)
601,NCT05883176,Objective response rate (ORR) by RECIST 1.1 and mRECIST,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Treatment-related adverse events,Median overall survival time (mOS)
602,NCT05587738,Prevalence of type-specific HPV types,2023-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
603,NCT03174444,Colorectal Cancer Screening,2017-08-15,COMPLETED,INTERVENTIONAL,['NA'],,
604,NCT00636883,"Response rate (partial and complete response, stable disease, and progressive disease)",2008-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall survival
605,NCT00379782,subject satisfaction with navigation,2006-10,COMPLETED,INTERVENTIONAL,['NA'],,
606,NCT02188342,VO2 peak,2015-01,COMPLETED,INTERVENTIONAL,['NA'],,Quality of life
607,NCT00275951,Confirmed objective response rates,2005-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Progression-free survival (PFS), overall survival (OS), treatment-related toxicity"
608,NCT04045236,Distant recurrence,2021-10-01,WITHDRAWN,OBSERVATIONAL,['NA'],,Quality of life Scale (QOLS)
609,NCT04532515,Proportion of surgeries with full sealant coverage - successful application,2021-02-01,COMPLETED,INTERVENTIONAL,['NA'],,Hospital length of stay
610,NCT05747482,disease free interval,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,postoperatory mortality
611,NCT00078897,Median Selenium Blood Levels at One Year.,2005-01-20,TERMINATED,INTERVENTIONAL,['PHASE3'],,
612,NCT02473003,Change in Fatigue,2015-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Treatment completion rate
613,NCT03958890,OS,2019-06-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Duration of response
614,NCT00525915,Pathologic Complete Response Rate,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
615,NCT01245816,Efficacy of Eflornithine plus Sulindac compared to Eflornithine alone and Sulindac alone determined by change in the number of polyps 2 mm or greater in a defined focal area of the rectum or pouch at baseline and after completion of the study treatment.,2011-03,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Presence of high grade dysplasia or villous adenoma in any polyp resected.
616,NCT00582400,Number of Patients With Response to Treatment (RECIST Criteria),2004-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
617,NCT03306693,Change in patient emotional skills from baseline to 15 days after intervention,2017-10-26,TERMINATED,INTERVENTIONAL,['NA'],,Patient satisfaction
618,NCT00915863,the incidence of pancreatic fistula,2009-06,UNKNOWN,INTERVENTIONAL,['NA'],,"the incidence of other postoperative complications, mortality, delayed gastric emptying, intra-abdominal hemorrhage, and intra-abdominal abscess"
619,NCT00938080,"Safety (Adverse Events, laboratory assessments and the presence of sAGX0085 bacteria in blood)",2009-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Pharmacokinetics of serum samples, buccal smears and saliva samples"
620,NCT04840056,Gastric cancer and gastric dysplasia,2021-04-15,RECRUITING,OBSERVATIONAL,['NA'],,Area under the receiver operating characteristic curve of machine learning model
621,NCT04251403,Correlation of pathologic diagnosis from gastric aspirate compared with diagnosis from standard endoscopic inspection and biopsies.,2020-02,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,
622,NCT04357158,Diagnostic accuracy in distinguishing colorectal carcinoma from healthy controls,2020-05-25,COMPLETED,INTERVENTIONAL,['NA'],,Acceptance rate
623,NCT05298020,PFS,2022-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,AEs
624,NCT00478946,maximum tolerated dose,2006-04,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,safety and efficacy
625,NCT05156463,Use of Actigraph to measure changes in activity and sedentary behavior,2022-04-12,WITHDRAWN,INTERVENTIONAL,['NA'],,Exercise Self-Efficacy Scale This scale assesses an individual's beliefs in their ability to continue exercising on a 3 time/week basis at moderate intensities for 40+ min. per session in the future.
626,NCT04896684,Biological collection associated with clinical data,2021-04-29,RECRUITING,OBSERVATIONAL,['NA'],,Optimize treatment success rates for IBD
627,NCT03869034,Progression Free Survival (PFS) assessed by RECIST 1.1,2019-03-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Biomarkers of treatment response by single-cell RNA sequencing,Recurrence-free survival (RFS)
628,NCT05911243,Acceptability (feasibility),2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Change in body weight (kg)
629,NCT03690921,Acute Toxicity,2018-11-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Complete Response at 24 Weeks
630,NCT02534233,Number of patients with treatment-related adverse events (pain and dysphagia),2015-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Histological evaluation of treatment zone for intestinal metaplasia (BE patients)
631,NCT04961138,1-year disease free survival,2021-08,UNKNOWN,INTERVENTIONAL,['NA'],,objective response rate
632,NCT03774680,Measurement of pharmacokinetics parameters of Cetuximab for targeted colon cancer,2020-02-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
633,NCT02436902,Overall survivals,2019-02-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Recurrence rates
634,NCT02989922,6-month Overall Survival Rate,2016-11-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
635,NCT03428958,"Number of patients with treatment-emergent clinically significant changes in laboratory parameters, ECG changes, or changes in physical examinations",2018-10-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Tolerability of NUC-3373 in each combination cohort measured by dose intensity in Cycle 1
636,NCT05426135,"Treatment response of anti-cancer therapy at first evaluation in patients with lung/stomach/colorectal cancer (CR, PR, PD, SD).",2022-06-01,RECRUITING,OBSERVATIONAL,['NA'],,
637,NCT03750786,Overall Response Rate,2018-12-18,COMPLETED,INTERVENTIONAL,['PHASE3'],,Duration of Response
638,NCT00247260,"This is a multicentre, open label study to evaluate the safety and efficacy of three escalating radioactivity levels (MBq) of 32P BioSiliconTM in patients with unresectable hepatocellular carcinoma",2005-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,To evaluate the association between tumour marker serum alpha-fetoprotein (AFP) and target tumour response with the three radioactivity levels (MBq)
639,NCT05391477,Comparison of the AIOD and HOD negative predictive value (NPV) for adenoma in rectosigmoid polyps ≤ 5 mm with respect to histology,2023-02-27,RECRUITING,INTERVENTIONAL,['NA'],,Proportion of patients accepting to have their polyps diagnosed by the AI system or human optical diagnosis (designed questionnaire)
640,NCT04687163,Overall survival,2020-12-30,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Adverse Events
641,NCT02728921,Change in plasma volume,2014-04,COMPLETED,INTERVENTIONAL,['PHASE4'],"Change in heart rate, change in central venous oxygen saturation, change in haemoglobin concentration in blood, change in blood pressure, change in central venous pressure, change in plasma lactate and diuresis.",Incidence of postoperative complications
642,NCT00904839,Progression-free Survival Rate at 9 Months (PFS-9),2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Exploratory Biomarker and Pharmacogenetic Analysis for VEGF
643,NCT06001268,Participant Rating on Ease of Use the Mobile Application - Usability,2023-08-14,RECRUITING,INTERVENTIONAL,['NA'],,Malnutrition -Nutritional Status
644,NCT04915807,Progression-free survival,2021-06,UNKNOWN,OBSERVATIONAL,['NA'],,Adverse events of special interest
645,NCT06325891,Microbiome analysis using gastric mucosal brushing,2024-02-01,RECRUITING,OBSERVATIONAL,['NA'],,Microbiome analysis using gastric mucosal biopsy
646,NCT00780494,Progression-Free Survival (PFS),2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Vascular Endothelial Growth Factor Tumor Response Biomarker
647,NCT02753127,Overall Survival (OS),2016-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Patients With Adverse Events in the General Population
648,NCT01730586,Response Rate in CIMP-High Colorectal Cancer and Small Bowel Adenocarcinoma (SBA),2012-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-Free Survival (PFS)
649,NCT04827485,Left colon distension score,2022-01-13,TERMINATED,INTERVENTIONAL,['NA'],,Left colon sessile serrated lesion detection rate
650,NCT03784417,Tumor necrosis induction by EUS-guided laser ablation (LA) - Number of patients with necrosis of the tumor,2019-10-15,TERMINATED,INTERVENTIONAL,['NA'],,Overall survival
651,NCT05443321,Total clinician-reported medical errors,2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],,Time between transferred patient arrival and entry of admission orders
652,NCT03788447,total dose of remifentanil,2019-06-04,COMPLETED,INTERVENTIONAL,['NA'],,
653,NCT01641458,Predefined fluoropyrimidine-related (index) toxicity,2012-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,Progression-free survival
654,NCT03154983,progress-free survival time,2017-05-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,disease control rate
655,NCT00296062,Phase II: Determine the toxicity of bevacizumab in combination with this regimen in patients with metastatic colorectal cancer.,2006-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,Phase I: Maximum tolerated dose in patients ≥ 65 years of age measured by CTC version 3.0 at end of Safety in the Elderly component of study
656,NCT03095703,Number of participants with treatment-related adverse events,2017-10-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Immunohistochemistry of mTOR targets
657,NCT05458986,Intent to complete a colonoscopy,2023-05-15,RECRUITING,INTERVENTIONAL,['NA'],,Incidence of completed colonoscopies
658,NCT00252564,Progression-free Survival (PFS) Rate at 1 Year.,2005-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Objective Response Rate
659,NCT05651594,Overall response rate (ORR),2023-03-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,ORR
660,NCT06317896,2-year recurrence-free survival rate,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Correlation between metastasis，primary tumor and CTCs in blood through NGS and CTC-DNA
661,NCT02042430,Number of participants with an increase in CD8+ T cells,2014-08-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Changes in IDO1 expression by IHC
662,NCT00142038,Response Rate,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life
663,NCT05141721,Phase 3: Progression-free survival per Immune-based Response Evaluation Criteria in Solid Tumors (iRECIST) as assessed by blinded independent review committee (IRC),2022-02-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Phase 2 and 3: The feasibility of manufacturing a patient-specific vaccine defined by the proportion of patients for whom vaccine was successfully manufactured from those randomized to the vaccine arm.
664,NCT03993626,Immune Disease Control Rate (iDCR),2018-05-22,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment
665,NCT05735912,Rate of adverse events,2023-03-01,RECRUITING,INTERVENTIONAL,['NA'],,Pancreatic insufficiency
666,NCT03167775,DCR and/or 6-months survival rate,2016-11-28,UNKNOWN,INTERVENTIONAL,['NA'],,the rate of incidence of adverse events
667,NCT00577538,,2006-04,COMPLETED,OBSERVATIONAL,['NA'],,
668,NCT01904890,Receipt of CRC Screening,2012-03,COMPLETED,INTERVENTIONAL,['NA'],,CRC screening Intention
669,NCT04548765,Colonoscopy Ordered at 6 months,2020-07-24,COMPLETED,INTERVENTIONAL,['NA'],,Colonoscopy Result
670,NCT00079365,,2001-05,UNKNOWN,INTERVENTIONAL,['NA'],,
671,NCT04269369,The frequency of severe ﬂuoropyrimidine-related toxicity,2020-02-18,UNKNOWN,INTERVENTIONAL,['PHASE4'],,
672,NCT03750175,Feasibility of ctDNA analysis for RAS mutation analysis,2018-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Lead time
673,NCT04466631,Utilization of specific competences by participants,2020-06-15,UNKNOWN,OBSERVATIONAL,['NA'],,Number of participants maintaining their social activities
674,NCT05639972,Feasibility of administering E7 TCR-T cell therapy as induction treatment for LAHPVC,2024-06-12,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,2-year and 5-year disease free survival (DFS)
675,NCT00003714,Patient Response,na,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
676,NCT04902352,SMA margin status,2021-04-06,RECRUITING,INTERVENTIONAL,['NA'],,Disease free survival
677,NCT05061082,Genetic and epigenetic changes of the tumor,2021-10-26,UNKNOWN,OBSERVATIONAL,['NA'],,
678,NCT04593407,Percentage of surgical referral after treatment,2020-11-03,RECRUITING,INTERVENTIONAL,['NA'],,Cumulative complications rate after treatment
679,NCT05194878,Disease-free survival,2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,CT assessment of response to neoadjuvant treatment
680,NCT03176485,Modulatory effect of systemic Raf inhibition in the MEK/Erk and PI3 /AKT/mTOR pathways in patients undergoing targeted therapy for metastatic disease,2014-10-17,COMPLETED,INTERVENTIONAL,['NA'],,Modulatory effect of Ras inhibition in Epidermal Growth Factor Receptor (EGFR) and Activating Protein-1 (AP1) signaling pathways (IHC and RPPA).
681,NCT01801085,"Composite preparation, dispensing and administration time",2011-10,TERMINATED,OBSERVATIONAL,['NA'],,Capital item utilization (hospital bed and infusion pump)
682,NCT01995591,number of sentinel lymph nodes identified in pieces of colectomy from patients with colon cancer with Indocyanine Green,2013-01,COMPLETED,OBSERVATIONAL,['NA'],,
683,NCT05252390,Phase 1b Food Effect Substudy: Effect of Food on the Pharmacokinetics (PK) of NUV-868,2022-03-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
684,NCT03069508,Cmax Pharmacokinetic (PK) assessment of clemizole hydrochloride (200 mg vs. 300 mg vs. 400 mg vs. 500 mg by mouth),2017-02-13,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival associated with clemizole hydrochloride
685,NCT01765582,Progression-Free Survival During First-Line Therapy (PFS1),2013-01-23,TERMINATED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Adverse Events
686,NCT04722120,Quantitative image quality analysis,2016-06-01,COMPLETED,INTERVENTIONAL,['NA'],,
687,NCT00549276,,2006-05,COMPLETED,OBSERVATIONAL,['NA'],,
688,NCT03253939,3-years overall survival,2017-02-01,COMPLETED,OBSERVATIONAL,['NA'],,
689,NCT02900248,Time to Treatment Progression,2017-10-02,TERMINATED,OBSERVATIONAL,['NA'],,To determine rate of enrollment into existing and future therapeutic clinical trials.
690,NCT00973869,Concentration of curcumin in colorectal tissue after treatment,2009-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Presence of curcumin and its metabolites in peripheral blood and urine
691,NCT00008047,,1999-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
692,NCT03551470,Operative time,2012-10,UNKNOWN,OBSERVATIONAL,['NA'],,
693,NCT01882660,"Wnt target gene expression (APCDD1, AXIN2, DKK1, LGR5 and ASCL2)",2013-07,TERMINATED,INTERVENTIONAL,['NA'],,Tumor differentiation
694,NCT04404673,Urinary and sexual outcomes after rectal resection,2020-02-21,UNKNOWN,OBSERVATIONAL,['NA'],,
695,NCT02729948,Incidence of adverse events associated with TCE use,2016-07-28,COMPLETED,INTERVENTIONAL,['NA'],,
696,NCT04592913,Event-free survival (EFS),2020-11-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,To compare Arm A relative to Arm B on pathological complete response (pCR) rate
697,NCT00041197,Recurrence-free survival (RFS),2002-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Relationship between genetic and phenotypic characteristics of GIST and clinical outcomes
698,NCT04808466,overall survival,2021-09-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,The positive rate of cancer cells of participants by exfoliative cytology examination
699,NCT01497964,Objective Response Rate,2011-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pharmacokinetic parameter Vss
700,NCT04298489,ex vivo Maximal Inhibition Index (MI),2017-05-01,UNKNOWN,INTERVENTIONAL,['NA'],,Progression free survival (PFS) after chemotherapy
701,NCT00047112,overal survival,2002-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,recurrence free survival
702,NCT05951231,Lactate level in microdialysate from hilar plate after normothermic machine perfusion - 4 hours,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Donor associated variables - Donor risk index,Pyruvate level in microdialysate from hilar plate after of Dual-end-ischemic Hypothermic Oxygenated Perfusion machine perfusion in extended criteria donors livers - 2 hours
703,NCT02527967,Hospital length of stay (days),2013-01,COMPLETED,OBSERVATIONAL,['NA'],,Readmission rate (%)
704,NCT02503150,"Progression Free Survival, PFS",2015-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Adverse Events
705,NCT02330536,Respiratory change,2014-12,COMPLETED,INTERVENTIONAL,['NA'],,
706,NCT03776370,The five-year survival rates of rectal cancer between the two groups were compared.,2018-12-01,COMPLETED,OBSERVATIONAL,['NA'],,
707,NCT03387774,Incidence of Severe Acute Oral Mucositis (Grade of CTC-AE ≥ 3),2018-01-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,The Adverse events Related to Ulinastatin
708,NCT03652467,Progression Free Survival (PFS) in Participants With Unresectable Hepatocellular Cancer,2018-09-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Number of Participants With Drug-Related Treatment-Emergent Adverse Events
709,NCT00293462,Comparison of the Mean Number of Days for Mucositis to Heal Across by Group,2005-06-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Comparison of Combined Mean Score on the Pain Questionnaire by Group
710,NCT03192644,recurrence-free survival (RFS),2017-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall survival (OS)
711,NCT04652492,TTP assessed by independent review committee(IRC),2020-10-27,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety
712,NCT01896869,Overall Survival (OS),2013-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumor Marker Kinetics as Assessed by Median Carbohydrate Antigen 19-9 (CA19-9) Levels
713,NCT01854255,Clinical Benefit Rate,2013-11,COMPLETED,INTERVENTIONAL,['PHASE2'],median time ot progression,Observed Survival
714,NCT04004650,Perineal wound healing rate 30 days,2019-06-28,UNKNOWN,INTERVENTIONAL,['NA'],,Female sexual distress
715,NCT03731754,Complication rate of perineal wound,2018-11-20,UNKNOWN,INTERVENTIONAL,['NA'],,The operation time
716,NCT03431311,"Incidence, nature, and severity of adverse events graded according to NCI CTCAE v4.0",2018-03-08,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
717,NCT03474822,Number of participants with treatment-related adverse events as assessed by NCI CTCAE 4.0,2018-08-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Immunological index
718,NCT04172402,Overall response rate (ORR),2019-12-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
719,NCT05661643,Objective respone rate in SDH deficiency wild type GIST,2023-06-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,
720,NCT00836303,Completion of Colorectal cancer screening,2005-12,COMPLETED,INTERVENTIONAL,['NA'],,Patient adherence to physician recommended colorectal cancer screening test
721,NCT00813163,Survival Rate,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,pharmacogenetics
722,NCT03639792,Postoperative Morbidity and mortality,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
723,NCT03756051,Psychosocial Harms,2018-04-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Physical Harms
724,NCT04131426,Recruitment and Retention,2020-04-24,COMPLETED,INTERVENTIONAL,['PHASE1'],,Porportion of subjects with improved cachexia-related symptoms 3 months
725,NCT02408406,Functional Assessment of Cancer Therapy-General (FACT-G) scores,2015-07-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Individual patient changes in Functional Assessment of Cancer Therapy-General (FACT-G) total scores,Change in health resource utilization
726,NCT06090656,progression free survival，PFS,2023-10-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Patient-reported outcomes, PRO"
727,NCT04533490,DFS（disease-free survival）,2021-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Exploratory analysis of biomarkers for predicting efficacy,OS（overall survival rate）
728,NCT01696630,Variation of intraoperative Mean Arterial Pressure (MAP),2012-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Delay to intestinal transit recovery
729,NCT04718402,adverse events (AEs),2021-03-30,TERMINATED,INTERVENTIONAL,['PHASE1'],,overall survival (OS)
730,NCT02786524,Change in Patient-Reported Symptom Burden as Determined by the National Comprehensive Cancer Network Distress Screening Tool,2016-02-15,COMPLETED,INTERVENTIONAL,['NA'],,Overall Survival Rate
731,NCT01514110,to determine the Maximum tolerated dose and dose limiting toxicity of RAD001 in combination with paclitaxel and carboplatin,2008-01-23,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Toxicity of combination Paclitaxel/carboplatin/RAD001 in advanced adenocarcinoma of the stomach and gastroesophageal junction
732,NCT06184841,Adverse Events,2020-06-18,COMPLETED,INTERVENTIONAL,['PHASE1'],,The overall survival (OS)
733,NCT05959356,Progression free survival,2023-11-09,RECRUITING,INTERVENTIONAL,['PHASE2'],"Treatment-emergent genetic mutations (e.g., KRAS, NRAS, BRAF, SMAD4, HER2, Etc.)",Quality-adjusted time without symptoms or toxicity
734,NCT03404661,Methylated DNA markers as measured by mean percentage of total human DNA per pancreatic juice volume,2018-01-11,COMPLETED,OBSERVATIONAL,['NA'],,
735,NCT02738359,"Prevalence of advanced colorectal neoplasia or cancer identified by each screening strategy (OC, CC and FIT)",2017-11-03,RECRUITING,OBSERVATIONAL,['NA'],Quality assessment of colonoscopy and capsule endoscopy,Rate of colorectal cancer identified by each screening strategy
736,NCT04548752,Progression-free survival (PFS),2021-02-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,Duration of response (DoR)
737,NCT03009461,Overall survival,2017-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
738,NCT01768104,En bloc resection,2011-12,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of life
739,NCT01211210,3-year disease free survival,2010-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,quality of life
740,NCT01836653,Progression-free survival,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression-free survival among the RAS wild type subpopulation,Response rate
741,NCT05965466,Number of gallstone patients,2023-07-21,RECRUITING,INTERVENTIONAL,['NA'],,Number of patients with bile duct stones
742,NCT02202317,Number of Subjects Whose Y-90 Based PET/CT (Positron Emission Tomography/Computed Tomography)Scans Detected Extrahepatic Non-target Embolization.,2013-04,COMPLETED,INTERVENTIONAL,['NA'],,Comparison of Y-90 PET/CT to Y90 SPECT
743,NCT02502630,Overall Survival (OS),2010-06,COMPLETED,INTERVENTIONAL,['NA'],,Treatment related adverse events
744,NCT03712943,Maximum Tolerated Dose,2018-10-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Frequency and Severity of Adverse Events
745,NCT02814461,The maximal tolerated dose (MTD),2015-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
746,NCT03200249,Complete histological response rate,2016-12-22,COMPLETED,INTERVENTIONAL,['NA'],,Tolerance
747,NCT04458740,Assess how the patients and their family members face the disease,2018-10-29,COMPLETED,OBSERVATIONAL,['NA'],,
748,NCT01739894,Overall survival (OS) rate,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of participants with adverse events
749,NCT06015659,6-month Progression-Free Survival (PFS) Rate,2023-11-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Grade 3-5 Treatment-related Toxicity Rate
750,NCT01224652,progression-free survival,na,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Overall survival
751,NCT01678027,Gastric cancer incidence,2004-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,All-cause mortality
752,NCT04739696,Caregiver: Change in Center for Epidemiological Studies Depression Scale (CESD),2021-02-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Caregiver: Job Satisfaction
753,NCT05578677,"Size of biopsy specimen, as assessed by a blinded study investigator",2021-06-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,"The percentage biopsies with the presence of dysplasia, as assessed by a blinded upper GI pathologist"
754,NCT01386502,To determine the safety and tolerability of escalating doses of anti PD1 antibody (CT-011) in combination with subcutaneous p53 vaccine.,2011-06-15,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,To determine the clinical efficacy of this combination.
755,NCT04605731,Overall response,2021-08-03,RECRUITING,INTERVENTIONAL,['PHASE1'],Gene expression signatures,Overall survival
756,NCT04634526,Rate of R1 cases assessed by surgeon,2018-04-18,RECRUITING,OBSERVATIONAL,['NA'],,Disease free survival
757,NCT05512260,Feasibility regarding iDA format,2023-03-01,RECRUITING,INTERVENTIONAL,['NA'],Satisfaction with the iDA and the decision,Self-reported lifestyle behaviors
758,NCT02355353,Tumor regression grade (TRG),2015-02,UNKNOWN,INTERVENTIONAL,['NA'],,"Histopathological measurements of tumor tissue cellularity /density, Necrosis, Proliferation (ki-67)"
759,NCT06280105,objective response rate (ORR) per RECIST1.1,2024-03-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Occurence of AE and SAE
760,NCT01374451,Progression-free Survival (PFS) Per Local Radiological Review,2011-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Summary of Pasireotide Concentrations Following Intramuscular Injection of Pasireotide LAR 60mg
761,NCT00842491,Progression free survival,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,The alteration of relative regional blood volume of the tumor
762,NCT04247958,Number of SureForm™ Stapler fires and reload colors,2020-01-30,COMPLETED,OBSERVATIONAL,['NA'],,Incidence of peri-operative and short term outcomes
763,NCT00747097,Progression-free survival,2008-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,"overall survival, objective response, safety"
764,NCT04930315,1-year tumor recurrence-free rate,2021-09-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
765,NCT04192565,Complication rate (%),2020-09-09,COMPLETED,INTERVENTIONAL,['NA'],,
766,NCT02643498,maximum tolerated dose (MTD) of SBRT,2015-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
767,NCT00333788,Occurrence of at Least One Study-emergent Adverse Event During the Study (Maximum 164 Weeks),2006-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Occurrence of at Least 1 Concurrent Medical Procedure During the Overall Period
768,NCT02907099,Objective response rate (ORR) based on Response Evaluation Criteria in Solid Tumors 1.1,2016-12-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
769,NCT01044732,Detection Rates for Adenomas and for Total Polyps,2009-03,COMPLETED,INTERVENTIONAL,['NA'],,Times for Withdrawal Phase and for Complete Procedure
770,NCT05449873,Local tumor progression rate,2021-10-18,RECRUITING,INTERVENTIONAL,['NA'],,Complication rate
771,NCT01984580,Changes in zinc-regulated cellular proteins within Barrett's tissue,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Changes in cellular microRNA profile; changes in protein cancer biomarkers
772,NCT05163665,Cost of each closure,2022-08-23,COMPLETED,INTERVENTIONAL,['NA'],,Successful Tissue approximation
773,NCT02311439,Number of Participants with Adverse Events as a Measure of Safety and Tolerability of FOLFIRINOX plus Concurrent Radiotherapy with Capecitabine,2014-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Number of Cases will have radical surgery,Tumor response
774,NCT01608646,Objective tumor response,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse event incidence
775,NCT02169908,Thermal thresholds,2014-05,COMPLETED,INTERVENTIONAL,['NA'],Characterization of pain neuropathy,Tactile sensitivity
776,NCT03715517,Cumulative 72-hour opioid consumption (OC_0-72h),2018-10-04,RECRUITING,INTERVENTIONAL,['NA'],Cumulative incidence (proportion) of postoperative vasopressor and/or inotrope dependency (%),Comprehensive Complication Index (CCI) score Comprehensive Complication Index (CCI) score Comprehensive Complication Index (CCI) score
777,NCT00920803,To characterize the pharmacokinetic profile of SRT501 in blood and normal and malignant metastatic tissues when administered once daily for 14 days.,2008-08-19,COMPLETED,INTERVENTIONAL,['PHASE1'],,To examine the pharmacodynamics of SRT501 activity in both normal and malignant tissue samples and blood.
778,NCT06020885,Tolerated fraction dose,2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,The rate of grade 3 or 4 toxicities according to CTCAE5.0
779,NCT04871204,Weight change in percent (%),2021-06-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of patients completing treatment
780,NCT04599920,Changes in the intake of nutrients and nutritional status of participants as a measure of diet modification.,2020-09-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Changes in the concentrations of N-nitroso compounds in feces.
781,NCT00675194,response rate,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Analysis of the dose and efficacy of Epoetin beta weekly in anaemic patients
782,NCT04813432,time-point of highest enhancement difference between a pancreatic lesion and background pancreatic parenchyma,2018-09-10,UNKNOWN,OBSERVATIONAL,['NA'],,
783,NCT01408407,Maximum skin toxicity,2011-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,
784,NCT02869802,Number of days between biopsy and return of comprehensive genomic results.,2016-10-06,RECRUITING,OBSERVATIONAL,['NA'],Targetable mutations,Overall Survival
785,NCT01238965,To assess the safety of this regimen,2010-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall survival
786,NCT04466696,Postoperative length of stay,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
787,NCT02110953,"Maximum tolerated dose of irinotecan-eluting beads, determined by dose limiting toxicities, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0",2016-01-29,TERMINATED,INTERVENTIONAL,['PHASE1'],,Time to progression
788,NCT03983993,Clinical benefit rate (CBR),2019-10-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
789,NCT01850368,Tumor stabilization rate,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Treatment related toxicity
790,NCT00307866,"To assess the proportion of correct final, therapy deciding diagnosis based on unenhanced plus SH U 555 A enhanced MR imaging compared to contrast-enhanced dual-phase spiral CT.",2001-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,To assess safety and tolerability of SH U 555 A administration.
791,NCT01274962,Compliance to chemotherapy - patients receiving at least 85% of planned full-dose of chemotherapy prescribed at each cycle for the 12 cycles,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival rate
792,NCT05176964,pathological complete response(pCR),2021-12-31,RECRUITING,OBSERVATIONAL,['NA'],,predictive biomarkers andquality of life(QoL)
793,NCT04260139,Lymph Node Yield in Colon Cancer Resection Specimens,2019-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
794,NCT01287130,"To assess for evidence of anti-tumor activity with this combination, per tumor measurements",2011-01-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,To evaluate the safety and tolerability of the combination of AZD6244 and cetuximab in patients with K-RAS mutated metastatic colorectal cancer
795,NCT01143922,,2009-08,UNKNOWN,OBSERVATIONAL,['NA'],,
796,NCT02569242,Overall Survival,2015-12-14,COMPLETED,INTERVENTIONAL,['PHASE3'],,Duration of Response
797,NCT05775419,5-years overall survival (OS),2021-06-30,RECRUITING,INTERVENTIONAL,['NA'],,5-year progression-free survival (PFS)
798,NCT00632515,Psychosocial + External factors influencing CRC patients' communication with FDRs about CRC risk & screening information,2008-01-29,COMPLETED,OBSERVATIONAL,['NA'],,
799,NCT00332865,Objective swallowing using videofluoroscopy and endoscopic evaluation of swallowing,2006-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Swallowing scale of EORTC HN 35
800,NCT06253650,ctDNA clearance (negative ctDNA status) at 1 year,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Translational analyses,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
801,NCT02173080,Polycystic Liver Disease-specific patient reported outcomes questionnaire (PLD-Q) total score,2014-06,RECRUITING,OBSERVATIONAL,['NA'],,Total kidney volume
802,NCT03977233,Best disease control rate by Pancreatic ductal adenocarcinoma (PDAC) subtype,2019-06-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,proportion of patients whose tumor/stroma subtype changes after treatment with FOLFIRINOX
803,NCT00234416,Incidence of DLT,2002-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Nature, incidence and severity of adverse events (AEs) and serious adverse events (SAEs)"
804,NCT02032485,fluorescence intensity of tumoral and healthy tissues after IV injection of ICG to patients with peritoneal carcinomatosis from colorectal origin.,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
805,NCT01652079,Progression Free Survival,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Analysis of biopsies
806,NCT02979795,Tumor regression rate,2016-11,UNKNOWN,OBSERVATIONAL,['NA'],,Distant metastasis
807,NCT00729482,Progression-free Survival Rate at 4-month (16 Weeks),2008-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events
808,NCT02244632,Frequency and severity of dose limiting toxicity (DLT) or other Adverse Events (AE),2014-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
809,NCT04931394,Disease free time,2021-06-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Concordance between radiosensitivity test results and patients' treatment response (descriptive statistics).
810,NCT02628093,Versatility Score,2016-02-17,COMPLETED,INTERVENTIONAL,['NA'],,Operative Procedure Time
811,NCT06157814,Number of participants retained for entirety of the study,2023-06-16,RECRUITING,INTERVENTIONAL,['NA'],,Symptom Measures
812,NCT06209970,Numerical Rating Scale,2024-01-20,RECRUITING,INTERVENTIONAL,['NA'],,
813,NCT03730441,"correlation between ADR of screening and all colonoscopies (screening, surveillance, diagnostic)",2013-01,COMPLETED,OBSERVATIONAL,['NA'],,
814,NCT06216405,"Comparing the percentage of patients with at least one right colon polyp detected according to the randomization group, and adjusted for Boston Bowel preparation scale, for the operator, for the endoscope and for stratification factors.",2022-01-20,COMPLETED,INTERVENTIONAL,['NA'],,
815,NCT03165591,Effect of V3-P on tumor burden,2017-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Effect of V3-P on sugar and bilirubin levels
816,NCT03812562,Recurrence rate,2019-02-07,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Overall increase in future liver remnant (FLR)
817,NCT05029869,The specificity of MRD detection using ctDNA as the biomarker,2021-10-04,RECRUITING,OBSERVATIONAL,['NA'],,Mutation profile of gastric cancer
818,NCT04125849,Postoperative respiratory complications,2020-04,UNKNOWN,INTERVENTIONAL,['NA'],,30-day mortality after surgery
819,NCT05367687,"Recurrence-Free Survival (RFS), as Determined by the investigator",2022-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,The incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as assessed by CTCAE v5.0
820,NCT03053167,Progression Free Survival [PFS],2016-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],Quality of Life [WHO-QOL],Disease Control Rate [DCR]
821,NCT03542136,"To evaluate the efficacy of evaluating the vibrotactile sense using a multi frequency tactilometry, in patients hand and foot. This is by assessing the changes in the measurements of a multi frequency tactilometry device in between each two time points.",2018-06-04,COMPLETED,INTERVENTIONAL,['NA'],,To evaluate if Oxaliplatin induced polyneuropathy can be earlier detected by using a multi frequency tactilometry compared with Common Terminology Criteria for Adverse Events scale (CTCAE).
822,NCT01489410,Number of Patients with Post-Embolization Syndrome,2012-10,WITHDRAWN,INTERVENTIONAL,['NA'],,Overall Survival
823,NCT04287400,K-RAS Mutation,2019-03-05,RECRUITING,OBSERVATIONAL,['NA'],,Radiomics - MR image findings
824,NCT00551057,,2007-10,UNKNOWN,OBSERVATIONAL,['NA'],,
825,NCT00425425,Response rate (histological remission) (Phase II),2006-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Metabolic response rate
826,NCT01721785,Diagnostic performance of the techniques under investigation,2012-10,COMPLETED,OBSERVATIONAL,['NA'],,To determine the inter-observer agreement for the imaging techniques under investigation
827,NCT01817205,dose limiting toxicity,2013-03,TERMINATED,INTERVENTIONAL,['NA'],,treatment response by alphafetoprotein
828,NCT03186014,Recurrent dysphagia,2017-06,UNKNOWN,INTERVENTIONAL,['NA'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
829,NCT01374750,To evaluate recurrence-free survival,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,To evaluate the safety with sirolimus
830,NCT01289288,Receipt of CRC screening,2007-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
831,NCT02335151,Peak of CTC in the postoperative phase after curative tumor removal,2016-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,Number of surviving patients
832,NCT01320683,Progression-free Survival,2011-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
833,NCT02917798,baseline to post-results change in distress levels,2016-07-12,RECRUITING,OBSERVATIONAL,['NA'],,
834,NCT02272738,Number of patients with Adverse Events,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival time
835,NCT04621370,Complete response,2020-12-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Euro Qol-5 dimensions 3 levels (EQ5D-3L)
836,NCT06052332,Grade ≥3 toxicities during treatment,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
837,NCT04447352,Comparison of progression-/disease-free survival (PFS/DFS) between arms,2020-12-17,RECRUITING,INTERVENTIONAL,['PHASE3'],,Rate of post-operative morbidity/mortality at day 30 after surgery acc. to Clavien-Dindo classification
838,NCT01470586,Comparison of Oxidative stress markers in patients with colorectal cancer and controls,2009-05,COMPLETED,INTERVENTIONAL,['NA'],,Validation of oxidative stress markers in patients with colorectal cancer undergo surgical resection
839,NCT00557557,Primary endpoint is to determine the maximum tolerated dose and dose limiting toxicity of 5-FU delivered with 40mg/m² of Oxaliplatin via IHP.,2007-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Secondary endpoints will be to determine the response rate and survival after IHP with 5-FU and Oxaliplatin.
840,NCT01742806,Time to drain removal,2012-10,UNKNOWN,INTERVENTIONAL,['NA'],Time to discharge after surgery and postoperative complication,total amount of exudate drainage
841,NCT06006338,R0 resection rate,2023-09-15,RECRUITING,INTERVENTIONAL,['PHASE1'],,Blood loss
842,NCT01488552,Complete Response Rate,2011-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Observing toxicity outcomes
843,NCT05418543,CH-EUS FNA has higher diagnostic accuracy for bile tuct tumors,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],,
844,NCT05603065,Pathological complete response rate (pCR),2022-10-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],,Quality of life measurement and evaluation 2
845,NCT02969681,Progression Free Survival,2017-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Assessment of treatment-related adverse events
846,NCT03329534,Ratio of non-acidic to acidic reflux events,2018-04-01,UNKNOWN,INTERVENTIONAL,['NA'],,Gastroesophageal reflux disease-health related quality of life instrument
847,NCT04107324,Liver Function,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,Resection rate
848,NCT00996333,To Determine Response Rate to the GTX Regimen in Patients With Pancreatic Cancer,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity Assessment
849,NCT01297998,Maximum tolerated dose,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants with dose limiting toxicity
850,NCT01532804,Disease-free survival,2011-07-28,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of life by using the quality of life questionnaire score
851,NCT01434550,Number of Participants With Overall Survival (OS),2012-03,WITHDRAWN,INTERVENTIONAL,['NA'],,Number of Participants With Adverse Events (AEs)
852,NCT00955591,Comparison of anal cytology screening outcome derived from specimens collected by a flocked nylon swab vs a Dacron swab,2009-03-12,COMPLETED,INTERVENTIONAL,['NA'],,
853,NCT03803241,Liver volume,2019-05-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,Liver volume
854,NCT00005094,"Percentage of patients with adenomas, aspirin use at baseline, and covariates",2000-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Adverse events coded using the MedRA dictionary
855,NCT01379521,Time to Progression (TTP) Based on the Modified RECIST Criteria,2011-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With a Decrease in the Sum of the of Longest Diameters (SLD) of Target Lesions From Baseline to 30 Months
856,NCT03775395,Overall survival,2018-12-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Progression Free Survival (PFS)
857,NCT05230771,2-year overall survival rate,2022-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,
858,NCT01516216,Median Progression-free Survival (PFS),2012-04-13,COMPLETED,INTERVENTIONAL,['PHASE2'],,Hazard Ratio Between Baseline Plasma 25(OH)D Levels and OS
859,NCT00634751,Overall Response Rate,2008-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
860,NCT00712751,"To investigate the feasibility, tolerability, acceptability (including adherence) and efficacy of CSI-SH, a psycho-educational intervention, on the primary outcome of sexual functioning among RC survivors.",2008-06,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,"To explore baseline variables that may influence the effectiveness of CSI-SH (i.e., moderators such as socio-demographic and medical variables)."
861,NCT01171482,Progression free survival (PFS),2015-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall survival
862,NCT02288507,Safety and tolerability of concurrent sorafenib and yttrium-90 transarterial radioembolization (TARE) for patients with advanced hepatocellular cancer as measures by Adverse events,2014-11,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,"Efficacy of concurrent sorafenib and yttrium-90 transarterial radioembolization (TARE) for patients with advanced hepatocellular cancer as measured by response rate, time to progression (TTP), progression free survival (PFS), overall survival (OS)"
863,NCT00591123,"Overall Response Rate of Previously-untreated Patients With Unresectable or Metastatic Adenocarcinomas of the Upper Gastrointestinal Tract When Treated With the Combination of 5-fluorouracil, Leucovorin, Oxaliplatin, and Erlotinib.",2007-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Toxicity of the Combination of FOLFOX, 5-FU, and Erlotinib"
864,NCT05714644,CRC Screening Completion Rates,2023-05-31,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Diagnostic Colonoscopy Completion Rates
865,NCT02005965,To compare global quality of life at two years post surgery in patients according to plane of surgery with or without sphincter preservation.,2007-08-13,UNKNOWN,OBSERVATIONAL,['NA'],,Investigation of potential association between length of operation with number of complications and length of post-operative ITU/HDU stay.
866,NCT02961140,Incidence of postoperative complication,2016-11,UNKNOWN,INTERVENTIONAL,['NA'],,Length of stay
867,NCT03000816,Progression-free survival,2015-04,COMPLETED,INTERVENTIONAL,['NA'],,overall survival
868,NCT04245865,The rate of progression free patients at six months,2020-06-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
869,NCT05060471,cCR rate,2021-09-08,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2'],,overall sruvival
870,NCT04823403,Maximum Tolerated Dose (MTD),2020-11-13,RECRUITING,INTERVENTIONAL,['PHASE1'],,
871,NCT03802097,Incidence of surgical site infections within 30 days,2018-12-27,COMPLETED,INTERVENTIONAL,['NA'],,Incidence of remote non-surgical site infections
872,NCT03045484,Total Dose of Oxycodone,2016-05,UNKNOWN,INTERVENTIONAL,['NA'],,Quality-of-Life Index
873,NCT02741856,Primary endpoint in adenocarcinoma when switching chemotherapy,2016-11-04,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Health economics
874,NCT03793335,Colorectal cancer prevention,2019-04-14,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
875,NCT06304545,Pathological Complete Response rate,2024-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,3-years Overall Survival rate
876,NCT05862051,Progression free survival (PFS),2021-12-14,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life measure
877,NCT06069960,Overall survival（OS）,2023-10-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Disease-free survival，DFS
878,NCT02923622,Overall survival,2016-09,UNKNOWN,OBSERVATIONAL,['NA'],,Number of participants with treatment-related adverse events as assessed by Chinese version of CTCAE v4.0
879,NCT03882866,Objective Response Rate (ORR),2019-03-28,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of life of two treatment regimens in patients
880,NCT03428321,Thermal ablations,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
881,NCT05663203,Attentional Function Index,2023-05-01,RECRUITING,INTERVENTIONAL,['NA'],,Short Form Health Survey
882,NCT04005690,Proportion of all pharmacodynamic feasibility-evaluable participants within a study arm that have a measurable change in post-treatment tumor biology from baseline,2019-08-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Incidence of >= grade 3 toxicities for each assigned window treatment (as described in sub-protocol)
883,NCT00282672,5 Year Extension: % of All Patients Enrolled in the Extension Protocol and Available for Analysis Demonstrating CR-D at 5 Years,2006-02,COMPLETED,INTERVENTIONAL,['NA'],,5 Year Extension: All Cause Mortality of the Group From 2 to 5 Years.
884,NCT00302094,Program to fuse 3D ultrasound and PET/CT data,2006-06,COMPLETED,OBSERVATIONAL,['NA'],,
885,NCT05360420,Time benefits based on US and immediate CEUS with current routine,2022-10-26,RECRUITING,INTERVENTIONAL,['NA'],,The economic benefit based on US and immediate CEUS with current routine
886,NCT02638909,"Clinical Benefit Rate (CBR) of ceritinib, as defined as the percentage of patients who have achieved complete response, partial response, and stable disease at 2 months per RECIST 1.1) to ceritinib by investigator assessment",2015-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Objective tumor response based on computed tomography scans (or magnetic resonance imaging if patients are allergic to iodinated contrast) per RECIST 1.1 criteria
887,NCT03368963,Overall response rate based on modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1,2018-01-30,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Response rate
888,NCT01689376,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
889,NCT00199654,Time to colorectal cancer relapse,2004-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Comparison of the medical cost in the two detection strategies
890,NCT00142467,"Time to disease progression of gemcitabine, oxaliplatin and bevacizumab regimen in patients with hepatocellular carcinoma.",2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
891,NCT00733850,Progression-free survival,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Survival
892,NCT03630354,Perceived physical function incongruence,2019-01-18,COMPLETED,INTERVENTIONAL,['NA'],,Fear of recurrence
893,NCT05631041,The change between groups in response rate (RECIST),2022-12-31,RECRUITING,INTERVENTIONAL,['PHASE3'],,Changes in serum levels of the measured biological marker serum permeability glycoprotein in ng/ml
894,NCT03707444,Change in Average pain as assessed by Brief Pain Inventory Question 3,2018-10-01,WITHDRAWN,OBSERVATIONAL,['NA'],,Change in opioid use
895,NCT06202131,mOS,2023-11-01,RECRUITING,OBSERVATIONAL,['NA'],,
896,NCT05827471,Detection of protein for early rapid diagnosis of colon cancer.,2023-07-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
897,NCT00753441,Serum bilirubin,2009-02-01,TERMINATED,INTERVENTIONAL,['NA'],,Procedure-related complications
898,NCT04906733,Correlation of ex vivo sensitivity test on patient-derived organoid models with clinical outcomes,2021-04-15,UNKNOWN,OBSERVATIONAL,['NA'],,
899,NCT01970254,"Rate of a positive result (hepatitis B surface antigen [HBsAg], hepatitis B core antibody [anti-HBc], and hepatitis B surface antibody [anti-HBs]) before first chemotherapy",2013-06-24,COMPLETED,OBSERVATIONAL,['NA'],,
900,NCT05696002,Quality of life (survey),2023-01-14,RECRUITING,OBSERVATIONAL,['NA'],,
901,NCT03891472,Improvement of the overall survival.,2017-01-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
902,NCT05185245,Overall Survival,2021-04-01,RECRUITING,INTERVENTIONAL,['NA'],,Disease-Free Survival
903,NCT01379807,Objective response rate,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Exploratory Objectives
904,NCT02029326,To explore biomarkers predictive of clinical response to cetuximab-based treatment in metastatic colorectal cancer using the Prometheus Platform,2010-02-01,COMPLETED,OBSERVATIONAL,['NA'],,3. To analyze correlation between the quantity of circulating tumor cells and treatment response to cetuximab
905,NCT05365256,Level of psychological well-being,2022-04-15,RECRUITING,INTERVENTIONAL,['NA'],,
906,NCT00388700,"Primary Outcomes: Assess the efficacy and safety of GM-CT-01 administered with 5-FU, LV, and Avastin® in the first-line treatment of unresectable, locally advanced, and/or metastatic CRC.",2006-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Explore progression-free survival (PFS) and survival
907,NCT04042831,Progression-free survival (PFS) at first scan,2020-06-24,RECRUITING,INTERVENTIONAL,['PHASE2'],The number of patients that had biomarkers related to tumor evaluation and resistance,Incidence of adverse events
908,NCT04098796,Objective response rate (ORR),2019-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Exploration of biomarkers (PD-L1 expression, TMB at the baseline, changes of AFP and T lymphocyte in peripheral blood)"
909,NCT00004210,"Assessment of cancer risk perception, cancer screening practices, views regarding genetic services, and family communication about HNPCC / Lynch syndrome by family members",2000-02,COMPLETED,INTERVENTIONAL,['NA'],,
910,NCT02967848,Change in global and local liver function,2016-10-19,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Radiotherapy dose sparing of functional liver
911,NCT05926726,RP2D of JWATM214 in HCC patients,2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],,overall survival (OS)
912,NCT01533311,,2009-01,COMPLETED,OBSERVATIONAL,['NA'],,
913,NCT02565667,anastomotic leak rate,2015-09,UNKNOWN,INTERVENTIONAL,['NA'],,30-day mortality rate
914,NCT02190656,Number of participants with no LARS; minor LARS and major LARS,2014-05,COMPLETED,OBSERVATIONAL,['NA'],LARS score in participants who have had laparoscopic surgery and participants who have had open surgery,Correlation between LARS score and EORTC QLQ-C30 questionnaire score
915,NCT02951390,Adenoma detection rate,2016-07,COMPLETED,INTERVENTIONAL,['NA'],,Total procedure time
916,NCT01438385,Establishing a database that contains all Interventional Endoscopies,2011-07,UNKNOWN,OBSERVATIONAL,['NA'],,
917,NCT04811703,Dose-limiting toxicities,2021-07-30,RECRUITING,INTERVENTIONAL,['PHASE1'],,Rates of adverse events and operative complications
918,NCT01949870,The Number of Dose-limiting Toxicities,2013-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,
919,NCT02459457,overall survival,2015-07-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,adverse event
920,NCT05182762,Clavien-Dindo Grade,2020-02-01,COMPLETED,OBSERVATIONAL,['NA'],,Age comparison
921,NCT03086291,maximum tolerated dose,2018-01-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
922,NCT05783076,Overall survival will be determined,2023-06-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life will be determined
923,NCT00755534,Time To Progression,2008-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Correlation of the molecular characteristics of the tumor with the clinical outcome
924,NCT02953782,Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1),2016-11-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
925,NCT00227734,Objective response (complete response [CR] and partial response [PR]) measured after completion of study treatment,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse drug reactions measured after completion of study treatment
926,NCT04457297,Disease-free survival 1 (DFS1),2020-07-08,RECRUITING,INTERVENTIONAL,['PHASE3'],,Treatment Completion Rate
927,NCT06084689,Disease control rate (DCR),2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and tolerability of the combination
928,NCT06252649,PFS per Response Evaluation Criteria in Solid Tumors (RECIST v1.1),2024-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Maximum Plasma Concentration (Cmax) of Sotorasib
929,NCT01273662,disease stabilization,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,time-to-tumor progression
930,NCT04094675,Change in colon polyp burden by staging,2019-09-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Change in well-being assessment
931,NCT03636308,Objective response rate,2018-07-17,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The incidence of treatment related emergent adverse events（Safety and Tolerance）
932,NCT06005974,To evaluate the preliminary anti-tumor activity of REC-4881 as measured by Objective Response Rate (ORR),2024-01-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,To assess the anti-tumor activity of REC-4881 as measured by to other efficacy endpoints
933,NCT05585073,surgery complicated,2022-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
934,NCT05931445,HRQoL EORTC Quality of Life of Cancer Patients (QLQ-C30) global health status score,2021-01-26,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Communication between patients and healthcare providers (EORTC QLQ-COMU26 score)
935,NCT05334836,Prevalence of pancreatic steatosis determined by fat quantitation on MRI,2022-04-06,RECRUITING,INTERVENTIONAL,['NA'],,Risk factors for pancreatic steatosis in patients with presumed IPMN or MCN
936,NCT00330915,Feasibility of Pemetrexed Prior to Surgery,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants Receiving Sphincter Saving Surgery
937,NCT00506844,Pathologic stage Tumor regression grade,2006-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease-free survival
938,NCT04706910,Minimum lesion detectability (SUV),2021-01-20,RECRUITING,INTERVENTIONAL,['PHASE3'],,Gallbladder disease questionnaire
939,NCT02785146,Disease-free survival (DFS),2016-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],The effects of Huaier Granule on adverse events of adjuvant chemotherapy.,Metastasis-free survival (MFS)
940,NCT00003799,MTD of oxaliplatin when combined with radiation therapy and fluorouracil based on the incidence of DLT as assessed by CTC version 2.0,1999-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,
941,NCT02895464,Adverse events,2016-09,COMPLETED,INTERVENTIONAL,['NA'],,Discharge destination
942,NCT05824559,Progression Free Survival (PFS) rate at 16 weeks,2023-08-07,RECRUITING,INTERVENTIONAL,['PHASE1'],,Safety and tolerability of ME-344 administered in combination with bevacizumab
943,NCT05185947,"Evaluate efficacy of bidirectional chemotherapy using intraperitoneal and intravenous paclitaxel and oral nilotinib by calculating the rate of downstaging of peritoneal disease burden to become resectable, based on Peritoneal Carcinomatosis Inde...",2022-10-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Assess clinicopathologic response to therapy
944,NCT05830292,Diagnostic accuracy of DRS probe to differentiate normal versus tumour tissue in vivo,2022-05-20,RECRUITING,INTERVENTIONAL,['NA'],,Feasibility of DRS probe to differentiate normal versus tumour tissue in vivo
945,NCT03001505,Overall survival,2017-05-04,WITHDRAWN,OBSERVATIONAL,['NA'],,Local recurrence
946,NCT02000739,Time to Disease Progression,2014-01,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,
947,NCT06257264,Part 2: Objective Response Rate,2024-02-28,RECRUITING,INTERVENTIONAL,['PHASE1'],,Part 2: Plasma concentrations for BG-68501
948,NCT00383149,Percentage of Participants Surviving at 6 Months,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change From Baseline in FHSI-8 Total Score by Time-point
949,NCT06173466,Cumulative opioid consumption of 72 hours after surgery,2023-12-15,RECRUITING,INTERVENTIONAL,['NA'],,Sleep quality
950,NCT01718821,"Changes in pain, assessed by BPI-SF.",2012-09,COMPLETED,OBSERVATIONAL,['NA'],,"Changes in neuropathic pain. Neuropathic pain, assessed by DN4 questions."
951,NCT02424864,The estimation of tumor size of the primary esophageal tumor on 4Dvs 3D FDG PET,2014-08,COMPLETED,INTERVENTIONAL,['NA'],,"Measurement of SUV max, SUV mean, and SUV peak in 4D versus 3D images of esophageal cancer and lymph nodes and number of suspected involved lymph nodes"
952,NCT02671890,Maximum tolerated dose (MTD) (Cohort I),2016-02-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Changes in muscle messenger ribonucleic acid (mRNA) levels via real-time polymerase chain reaction,Changes in fist-grip strength as measured by hand dynamometer (Cohort II)
953,NCT01545141,Change in the Number of Tumor-infiltrating CD8+ Cells.,2012-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Treatment Related Adverse Events
954,NCT03958500,Rate of anastomotic leakage,2019-04-01,COMPLETED,INTERVENTIONAL,['NA'],,Timing of anastomosis leakage
955,NCT05669807,Objective Response Rate,2022-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life assessment
956,NCT02045680,Improved tissue oxygen delivery,2014-03,UNKNOWN,OBSERVATIONAL,['NA'],,Time taken for patient to first mobilise following surgery
957,NCT00216788,Urine sucrose level falls below 90 mg after 8 weeks of therapy,2006-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Reduction of patient symptoms consistent with GERD
958,NCT04459754,Disease-free Survival,2020-06-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,
959,NCT00152087,- Adverse experience,2002-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
960,NCT04534543,Change in PME/PDE (ΔPME/PDE): predictive,2021-12-15,RECRUITING,INTERVENTIONAL,['NA'],,Response to treatment
961,NCT02066259,"Number of participants in each of the clinicaly defined groups (0,1 and 2).",2014-08,UNKNOWN,OBSERVATIONAL,['NA'],,
962,NCT05771480,Number of participants with Grade 3 or 4 possibly related adverse event (PRAE),2023-08-16,RECRUITING,INTERVENTIONAL,['PHASE3'],,EORTC QLQ-BIL21 Score
963,NCT01088581,2-year recurrence rate and adverse events,2006-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,overall survival
964,NCT01881932,Proportion of Colorectal and Breast Cancer Patients in Each Arm Who Require Dose Reduction or Discontinuation Due to Chemotherapy-induced Peripheral Neuropathy.,2013-02,TERMINATED,INTERVENTIONAL,['NA'],,
965,NCT05017922,Number of bleeding episodes,2017-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
966,NCT00997958,Identification of maximum tolerated dose of CellCept in patients with advanced pancreatic cancer,2004-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
967,NCT05913583,Graft rejection,2023-04-01,RECRUITING,OBSERVATIONAL,['NA'],pDC to mDC ratio,Early allograft dysfunction (EAD)
968,NCT03044613,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2017-07-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Recurrence-Free Survival
969,NCT06250166,Change from baseline in mean platelet-lymphocyte ratio at 12 weeks,2023-06-15,RECRUITING,INTERVENTIONAL,['NA'],,Change in mean daily energy and protein intake at 12 weeks
970,NCT03723720,correlation between ADR and PDR for all and screening colonoscopies,2013-01,COMPLETED,OBSERVATIONAL,['NA'],,
971,NCT01836432,Overall Survival,2013-05,TERMINATED,INTERVENTIONAL,['PHASE3'],,Immune Response
972,NCT04957511,"Microbiome change through analysis of biological samples (fecal specimen, blood, vaginal swab, oral mucosal swab).",2021-06-29,RECRUITING,OBSERVATIONAL,['NA'],,
973,NCT02587884,Overall Survival,na,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Time to recurrence
974,NCT00808379,Side effects and other adverse effects in the two groups during radiotherapy and up to 2 years post radiotherapy.,2006-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Comparison of pathological downstaging between the two groups who undergo surgery.
975,NCT05650918,Incidence of Dose Limiting Toxicities (DLTs) as assessed by CTCAE v5.0,2021-08-30,COMPLETED,INTERVENTIONAL,['PHASE1'],,Radiological response rate as defined by RECIST version 1.1 and iRECIST
976,NCT00003139,Acute salivary gland toxicity,1998-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Effects of continuing pilocarpine out to 6 months from the start of treatment
977,NCT06111105,Collection of clinical plasma samples at relevant time points,2023-08-01,RECRUITING,OBSERVATIONAL,['NA'],,Prognostic value of ctDNA analysis at relevant time points
978,NCT01674959,feasibility of concurrent IMRT combined with capecitabine for the treatment of gastric cancer patients,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,efficacy of concurrent IMRT combined with capecitabine for the treatment of gastric cancer patients
979,NCT06034977,Overall survival,2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
980,NCT02606994,Oral mucositis changes,2018-05-29,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of life changes
981,NCT04087889,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
982,NCT03642561,overall survival,2019-09-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,objective response rate
983,NCT03829098,90 day mortality,2019-04-01,COMPLETED,OBSERVATIONAL,['NA'],,Hospital based costs
984,NCT04557969,Assess disease-free intervals (DFIs) between surgical resection of disease for at least 5 years,2020-12-18,RECRUITING,OBSERVATIONAL,['NA'],,Characterize genomic and clinicopathologic features of GISTs
985,NCT01523431,"Incidence of toxicity, especially neutropenia and diarrhea",2012-03-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"Pharmacokinetics of irinotecan and its metabolites, SN-38 and SN-38G."
986,NCT01885702,Safety and feasibility of vaccination with frameshift-derived neoantigen-loaded DC of CRC patients,2010-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Clinical responses, e.g. disease-free survival, determined according to the standard protocol."
987,NCT01448655,Disease-free survival time (DFS).,2010-09,UNKNOWN,OBSERVATIONAL,['NA'],,"Number of patients with unexpected adverse events (UAE) contributed to conventional oncological therapy (radio-, chemo-, targeted therapy)."
988,NCT04073615,(Phase 2) Progression Free Survival (PFS) per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator Assessment,2019-11-18,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,(Phase 1b and 2) Number of Participants with Adverse Events (AEs) that Worsen in Severity as Defined by the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
989,NCT03306901,3-year overall survival,2017-10-20,RECRUITING,INTERVENTIONAL,['NA'],,Treatment-related complications or adverse events
990,NCT00128622,Safety as measured by rate of adverse events during study drug treatment,2005-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Rate of immune response as measured by ELISPot at week 10
991,NCT03109041,Safety & Toxicity of Delivering Primary Radiation Therapy with CivaSheet using the CTCAE 4.0 scale,2017-09-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
992,NCT00532909,"Maximum tolerated dose of vandetanib in combination with capecitabine, oxaliplatin and bevacizumab",2006-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Dose limiting toxicities associated with the combination
993,NCT01706809,"The primary aim of the present study is to investigate different biomarkers like VEGF, EVGF and others ability to predict time to recidive and progressions free survival.",2011-09,UNKNOWN,OBSERVATIONAL,['NA'],,
994,NCT04426669,Safety of tumor reactive autologous lymphocytes with knockout of the CISH gene - Incidence of Adverse Events,2020-05-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Toxicity profiles resulting from treatment using these engineered tumor-infiltrating lymphocytes
995,NCT01859182,"Proportion of patients who have a response (PR or CR), assessed by the RECIST v1.1",2013-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Changes in QOL evaluated using the Functional Assessment of Cancer Therapy - General (FACT-G)
996,NCT05539417,The variation in treatment and awareness of lateral lymph nodes in patients with rectal cancer.,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Presence of presacral abscess
997,NCT04094454,incidence and grade of vaginal fibrosis,2019-10-01,RECRUITING,INTERVENTIONAL,['NA'],,assessment of quality of life
998,NCT03546660,Feasibility of imaging of the Esophagus using a SECM Capsule,2024-01-01,RECRUITING,INTERVENTIONAL,['NA'],,
999,NCT01770132,Evaluate the number of subjects with adverse events which occur when up to 3 sites within the pancreas are treated with PDT using a total dose of 50 or 100 J per site,2013-04-19,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival
1000,NCT01903018,Number of severe Radiation Induced Mucositis (WHO grade >=3),2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
1001,NCT00423150,Tumor Responses (Complete and Partial Response),2007-01-26,TERMINATED,INTERVENTIONAL,['PHASE2'],,
1002,NCT04781413,3-year relapse-free survival (RFS),2021-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Peritoneal metastasis rate
1003,NCT01042782,maximum tolerated-dose (MTD) of RAD001 in combination with Mitomycin C,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,"safety and tolerability of the combination of RAD001 and Mitomycin C as assessed by frequency, severity, and duration of treatment-related adverse effects"
1004,NCT02653521,Toxicity of treatment,2015-12-30,UNKNOWN,INTERVENTIONAL,['NA'],Dosimetric Parameters,Overall Survival（OS）
1005,NCT01271582,Association between UGT1A1 polymorphism and grade 3/4 neutropenia after 1st cycle of FOLFIRI treatment,2009-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Progression-free survival
1006,NCT03013010,Disease free survival,2016-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Proportion of patients with surgery-related complication
1007,NCT04539769,Diabetes remission rate,2017-09-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1008,NCT01108107,The frequency of patients requiring adjuvant chemotherapy based on the histological evaluation of the preparation from the operation.,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
1009,NCT02216487,Safety,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
1010,NCT05896787,pCR,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,AE
1011,NCT05359393,NED rate,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Acute toxicity associated with immunotherapy
1012,NCT05987709,Assess colorectal cancer screening completion,2022-03-17,COMPLETED,INTERVENTIONAL,['NA'],,Assess the proportion who completed follow-up testing.
1013,NCT01926769,Disease Control Rate,2012-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
1014,NCT03511170,time to failure of strategy（TFS）,2018-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,time to failure of strategy（TFS）
1015,NCT02164916,Progression-free Survival,2014-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Response Rate in Patients Who Register to Arm 3 (Crossover) After Disease Progression on Arm 1,Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug
1016,NCT04940546,Adverse events,2021-06-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
1017,NCT03887702,"Time until adverse liver outcome, assessed by incidence of adverse liver outcome",2020-01-17,TERMINATED,INTERVENTIONAL,['PHASE3'],,Death due to any cause
1018,NCT03366012,Patient Tolerability determined by Score on Likert Scale,2018-08-01,SUSPENDED,INTERVENTIONAL,['NA'],,Number of Serious Adverse Events (SAEs)
1019,NCT02092389,Percentage of Patients With Fecal Calprotectin (fC) Level ≤ 150 µg/g After 12 Months of Treatment With Adalimumab,2014-07,TERMINATED,OBSERVATIONAL,['NA'],,Correlation Between fC and Workability Determined by WPAI:UC Questionnaire
1020,NCT00107536,Proportion of Patients Demonstrating Objective Response (PR+CR) as Defined by RECIST,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Expression Profile and Mutations of Genes Critical for EGFR and ERBB2 Signaling Pathways
1021,NCT02702089,morbidity,2016-03,UNKNOWN,OBSERVATIONAL,['NA'],,Reintervention rate
1022,NCT03604237,pathologic diagnosis,2017-09-01,UNKNOWN,INTERVENTIONAL,['NA'],,
1023,NCT03176264,Overall Response Rate (ORR) per investigator assessment using RECIST v1.1,2017-09-25,TERMINATED,INTERVENTIONAL,['PHASE1'],,Antidrug antibodies (ADA)
1024,NCT00019747,Time to Progression,1999-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,
1025,NCT00079833,Control is defined as gastric acid secretory rate below 10 mEq/h or below 5 meq/h for patients with prior gastric acid reducing Surgery,2003-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,"The following safety variables will be assessed at Month 6 and Month 12: adverse events, clinical laboratory results (ie, chemistry, hematology, urinalysis), physical examinations, and EGDs."
1026,NCT03577067,renal resistive index (RRI),2015-02,COMPLETED,OBSERVATIONAL,['NA'],,
1027,NCT00997633,Detected volume measured by SPECT compared to the number of subsequent sequential postoperative intraperitoneal chemotherapy courses,1991-05,COMPLETED,OBSERVATIONAL,['NA'],,"The relationship between SPECT, feasibility of SPIC (intraperitoneal chemotherapy), and clinical variables"
1028,NCT04013152,Collection of clinical data following surgery with robotic assistance in colorectal pathologies,2018-06-13,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Quality of the mesorectum by using Quirke classification
1029,NCT03783936,Best Objective Response Rate (bORR),2019-01-24,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Grade 3-4 Treatment Related Adverse Events
1030,NCT00006269,,1999-12,TERMINATED,INTERVENTIONAL,['PHASE3'],,
1031,NCT00077987,Anti-tumor efficacy,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumor control survival safety
1032,NCT03804203,Efficacy of palliation using the short course scheme compared with the standard scheme: Likert scale,2017-11-08,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of Life (QoL): EORTC questionnaire C15-PAL
1033,NCT04832763,Change in health-related quality of life (HRQoL),2019-09-27,TERMINATED,INTERVENTIONAL,['NA'],,Biomarker analysis - C-Reactive Protein
1034,NCT00086567,Create a multi-institutional repository from which investigations of serum proteomic signature profiles of epithelial ovarian cancer and relapse will be developed and validated,2005-12-12,COMPLETED,OBSERVATIONAL,['NA'],,
1035,NCT01028495,Survival,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Karnofsky Performance Scale, Clinical Laboratory Assessment, and Molecular Markers"
1036,NCT04264702,Determine the rate of recurrence of patients diagnosed with CRC while asymptomatic using SIGNATERA™,2020-04-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Examine the number of Stage I CRC patients that have recurrent disease detected post-surgery based on SIGNATERA™ test results
1037,NCT05980221,Metabolome,2020-08-24,RECRUITING,INTERVENTIONAL,['NA'],,Response of the fed and fasted metabolome to PERT
1038,NCT05729867,Technical success rate,2020-04-27,RECRUITING,INTERVENTIONAL,['NA'],,Stent dysfunction rate
1039,NCT05275075,Proportion of African American pancreatic cancer patients with weight loss and cachexia.,2022-12-07,RECRUITING,OBSERVATIONAL,['NA'],,"Differences in cachexia-associated RNA signatures in African American pancreatic cancer patients, and other racial groups."
1040,NCT01558648,short -term quality of life (QOL),2012-03-14,COMPLETED,OBSERVATIONAL,['NA'],predict EUS T3/T4/stricture or earlier EUS disease,Complications
1041,NCT00016029,,2000-08,TERMINATED,INTERVENTIONAL,['NA'],,
1042,NCT03811379,Objective Response Rates (ORR),2018-11-21,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse Events (AEs)
1043,NCT04819516,Number of Participants With Abnormal Laboratory Values,2020-12-07,RECRUITING,INTERVENTIONAL,['PHASE1'],,Numeric rating scale
1044,NCT00268333,Response rate,2005-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life
1045,NCT02390947,Overall Survival(OS),2015-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,The severity of Adverse Events
1046,NCT03493009,rate of adequate cleansing level,2018-05-01,WITHDRAWN,INTERVENTIONAL,['NA'],,
1047,NCT04044859,To evaluate safety of ADP-A2M4CD8 as monotherapy or in combination with either nivolumab or pembrolizumab,2019-08-20,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
1048,NCT02938195,Percentage of patients completing adjuvant chemoradiotherapy and surgery,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Percentage of pathological complete response
1049,NCT01323166,Health Related Quality of life after rectal cancer surgery - possible differences due to choice of procedure,2011-03,COMPLETED,OBSERVATIONAL,['NA'],,Impact of rectal cancer surgery and the level of intrusive thoughts
1050,NCT01603004,Progression free survival,2012-05-14,COMPLETED,OBSERVATIONAL,['NA'],,best response
1051,NCT05893810,High-grade radiation-induced oral mucositis,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of Life according QLQ-H&N43
1052,NCT06048146,3 year disease free survival,2022-10-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,
1053,NCT03910699,Anastomotic leakage rate,2019-04-10,UNKNOWN,INTERVENTIONAL,['NA'],,Serious adverse events rate
1054,NCT00277303,Safety and tolerability,2005-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Pharmacokinetic (PK) and Pharmacodynamic (PD) parameters
1055,NCT04194034,Disease Control Rate (Phase II part),2020-01-17,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1056,NCT04594772,Measuring the proportion of patients undergoing surgical resection using historical data compared to 32 patients in current study.,2021-03-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Measuring the safety of neoadjuvant therapy will be determined using CTCAE v5, reported as proportions of patients experiencing toxicities, graded using CTCAE v. 5.0."
1057,NCT01007617,Mucositis scale - World Health Organization (WHO),2009-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Psychological impact
1058,NCT04296019,PFS,2021-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
1059,NCT00069108,Progression Free Survival,2003-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Marked Post-baseline Laboratory Abnormalities by Trial Treatment
1060,NCT04707482,Difference of protein expression,2021-06-01,UNKNOWN,OBSERVATIONAL,['NA'],,
1061,NCT01043835,Disease free survival,2010-02,UNKNOWN,INTERVENTIONAL,['NA'],,"Complications, recurrence, quality of life measured by EORTC QLQ-C30 V 3.0 and EORTC QLQ-STO22"
1062,NCT05699278,Rate of patients who remain in a gastric cancer clinical trial to trial completion,2024-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
1063,NCT05697107,PFS,2021-05-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,OS
1064,NCT01032850,Number of Participants Experiencing Adverse Events,2009-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival (PFS)
1065,NCT06152783,Histopathology was used as the diagnostic gold standard to evaluate the diagnostic performance of CellTouch in the diagnosis of early gastric cancer.,2023-11-21,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,"Using histopathology as the diagnostic gold standard, the diagnostic performance of CellTouch and ME-NBI in the differential diagnosis of low-grade intraepithelial neoplasia and high-grade intraepithelial neoplasia was evaluated."
1066,NCT02394795,Overall Survival (OS) in All Participants,2015-05-29,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Treatment-emergent Adverse Events (TEAE)
1067,NCT00591461,The primary outcome will be the interobserver variability in the presence of columnar epithelium as well as the measured lengths.,2007-12,TERMINATED,OBSERVATIONAL,['NA'],,variables that predict endoscopic interobserver agreement and path-confirmation
1068,NCT04481659,The damage degree of anal function,2020-07-19,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Local recurrence
1069,NCT05253716,3-year disease free survival after discharge,2022-08-01,RECRUITING,INTERVENTIONAL,['NA'],,"toxicity of chemotherapy graded according to the CTCAE, version 5.0"
1070,NCT05494060,Disease Free Survival (DFS),2022-03-16,RECRUITING,INTERVENTIONAL,['PHASE2'],Toxicity by CTCAE v5.0 criteria,Disease Free Survival (DFS) rate at 3 years
1071,NCT05245786,Number of patients with impactful finding using 64Cu-M5A positron emission tomography (PET) imaging.,2022-08-31,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Count of Adverse Events.
1072,NCT06144385,Rate and severity of clinically-significant abnormalities in laboratory testings,2022-03-24,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overal survival (OS)
1073,NCT02581709,Feasibility of intervention implementation,2016-05,TERMINATED,INTERVENTIONAL,['NA'],,Cognitive Reserve Scale
1074,NCT00830778,Reduction of clinical postoperative pancreatic fistula (POPF) rate,2009-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Reduction of the severity of postoperative complications
1075,NCT00928928,Oxidative stress markers in patients with colorectal cancer operated with open or laparoscopic approach,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,
1076,NCT01008358,Tumor response by Response Evaluation Criteria In Solid Tumors (RECIST),2008-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Changes in Hepatitis C Virus (HCV) viral load
1077,NCT04428437,Response rate (RR),2022-07-02,TERMINATED,OBSERVATIONAL,['NA'],,Adverse Events
1078,NCT05054959,complete remission rate,2021-06-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,local control
1079,NCT03410030,Phase II: Disease control rate (CR+PR+SD x18 weeks),2017-12-15,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Changes in circulating tumor stem cells,Changes in patient's self-reported pain levels
1080,NCT04745988,Major pathological response (MPR) rate,2021-11-11,RECRUITING,INTERVENTIONAL,['PHASE2'],,The incidence of adverse events
1081,NCT01025882,Tumor samples for RNA and protein harvesting (when possible) from pretreatment biopsies and surgical specimens,2009-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,
1082,NCT03944421,Genotoxic potential of Faecal extracts from volunteers consuming intervention diets rich in red and processed meat versus diets containing Quorn,2019-07-03,COMPLETED,INTERVENTIONAL,['NA'],Blood Glucose,Changes in MicroRNA Expression
1083,NCT02409472,Health Related Quality of Life,1998-04,COMPLETED,INTERVENTIONAL,['NA'],,Disease free survival (DFS)
1084,NCT05687474,Feasibility - reliability,2022-09-01,RECRUITING,OBSERVATIONAL,['NA'],,To improve the detection technique for disease related mutations that are not detected in classical screening by improving the classification of unspecified variants.
1085,NCT01252628,"The evaluation of antitumor effects of PX-866 in combination with cetuximab versus cetuximab in patients with incurable metastatic colorectal cancer and/or patients with incurable progressive, recurrent or metastatic SCC of the head and neck.",2010-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1086,NCT03168139,"Combination Therapy: Safety - adverse events, vital signs, ECG, hematology & safety laboratory",2017-04-18,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Combination Therapy: Efficacy - time to event analyses
1087,NCT03563170,"Overall Response Rate, as determined by the percentage of patients achieving Partial or Complete Response per RECIST 1.1",2018-05-25,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,ORR for Phase 2 Single Arm Component
1088,NCT04965311,Rate of clinically relevant postoperative pancreatic fistula (POPF),2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Rate of any POPF
1089,NCT01962649,Measurement of fluorescence intensity within focal hepatic lesions,2013-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
1090,NCT05908786,Major Pathologic Response (MPR) Rate,2023-12-05,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Post-Operative Mortality
1091,NCT01142388,Progression-free Survival,2010-09-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Objective Response Rate
1092,NCT04420026,"Evaluation of the primary success rate of percutaneous ablation treatment with IRE of hepatic tumors, as a function of the ultrasound visibility of the tumor, when using automatic CT cone-beam fusion and ultrasound",2020-07-06,COMPLETED,INTERVENTIONAL,['NA'],,Evaluate the global survival at 12 months
1093,NCT00051480,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1094,NCT01456156,overall survival,2008-01,COMPLETED,INTERVENTIONAL,['NA'],,Number of Participants with Adverse Events
1095,NCT00831493,Maximum Tolerated Dose (MTD) of Vorinostat + Chemoradiation,2009-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1096,NCT00467129,Progressive disease-free survival,2002-07,UNKNOWN,OBSERVATIONAL,['NA'],,
1097,NCT03158571,Overall survival,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
1098,NCT03305913,Maximum Tolerated Dose (MTD),2017-07-31,COMPLETED,INTERVENTIONAL,['PHASE1'],,Incidence of Treatment-Emergent Adverse Events
1099,NCT05453851,Proportion of patients that are free of metastatic disease to the liver from a pancreatic primary,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Incidence of adverse events (AEs),Time to overall survival (OS)
1100,NCT03033186,Everolimus TDM to predict long-term toxicity,2017-05-16,UNKNOWN,OBSERVATIONAL,['NA'],,Everolimus TDM to predict dose reductions
1101,NCT03626350,Adverse Events,2018-06-12,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Submucosal endoscopy technique and device used
1102,NCT04791176,MST,2021-04-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Rate of III-IV grade adverse events
1103,NCT03613168,Adverse events,2019-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
1104,NCT01226719,Overall Response Rate (ORR),2010-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
1105,NCT01609361,Post operative morbidity at 30 days according to DINDO CLAVIEN classification,2012-11,COMPLETED,INTERVENTIONAL,['NA'],,Duration of laxation (gas and stool)
1106,NCT04239781,HCC patients' willingness and expectation for post-operative treatment.,2020-01,UNKNOWN,OBSERVATIONAL,['NA'],,
1107,NCT05606081,Rates of colorectal neoplasia per number of colonoscopies performed,2022-09-01,WITHDRAWN,INTERVENTIONAL,['NA'],,
1108,NCT04573621,Number of participants with pelvic sepsis,2020-10,UNKNOWN,INTERVENTIONAL,['NA'],,Any complications associated with drain removal after surgery
1109,NCT06326346,16 week disease control rate,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse event assessed by NCI-CTCAE Version 5.0
1110,NCT04406714,"Proportion of subjects, ages 50-75, who complete CRC screening within 6 months (Trial - Age Group 50-75)",2020-07-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Number of days from abnormal FIT result date to diagnostic colonoscopy (Trial - Age Group 50-75),Proportion of subjects who complete a follow-up diagnostic colonoscopy at 60 days (Sub-study - Age Group 45-49)
1111,NCT03734627,Area under the curve for paracetamol at 30 minutes after a 400kcal mixed meal stimulus,2016-07-01,COMPLETED,OBSERVATIONAL,['NA'],Duodenal enteroendocrine cell mRNA expression profile,EORTC health related quality of life
1112,NCT04278222,objective response rate,2020-02-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,adverse events
1113,NCT04460937,Incidence of adverse events,2021-04-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Biomarkers
1114,NCT02718430,Safety and tolerability taking into account treatment-limiting toxicities (TLTs),2016-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Biodistribution and shedding of VXM01
1115,NCT00767234,Identify Biomarkers,2008-08,TERMINATED,OBSERVATIONAL,['NA'],,
1116,NCT03516890,Overall survival of all patients,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Recurrence-free of staged partial hepatectomy patients
1117,NCT04510064,margin-free-(R0) resection rate,2020-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival (OS)
1118,NCT05897749,PFS,2023-06-16,RECRUITING,INTERVENTIONAL,['PHASE4'],,quality of life
1119,NCT03290937,Objective response rate (Dose expansion),2017-12-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Duration of response
1120,NCT05164848,Incidence of Treatment-related Adverse Events，afety and Tolerability,2021-12-25,UNKNOWN,INTERVENTIONAL,['PHASE1'],The correlation of biomarkers with efficacy,The incidence of neutralizing antibody (Nab)
1121,NCT00345761,Safety (Common Terminology Criteria for Adverse Events [CTCAE] version 3.0),2006-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,concentrations of anti-bevacizumab antibody
1122,NCT00699569,,2008-07,UNKNOWN,INTERVENTIONAL,['NA'],,
1123,NCT01030042,Overall Survival,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression free survival
1124,NCT03215459,Survival at 6 months (followed up for 12mths),2021-02-01,UNKNOWN,OBSERVATIONAL,['NA'],,Time-to-event endpoints
1125,NCT00436501,Median Progression-Free Survival (PFS) (Phase II),2007-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With PFS (Phase II)
1126,NCT00844454,Local treatment responses,2008-05,COMPLETED,INTERVENTIONAL,['NA'],,Disease-free survivals and overall survivals
1127,NCT01774019,"Number of Serious Pre-operative, Operative and Post-operative Adverse Events to 120 Days Post Randomization or to 30 Days Post Surgery, Whichever Comes Last",2013-02-20,COMPLETED,INTERVENTIONAL,['NA'],,All-cause Mortality
1128,NCT02056041,Safety of surgery for HCC,2004-01,COMPLETED,OBSERVATIONAL,['NA'],,Score systems HCC
1129,NCT01943253,Procedure time,2011-05,COMPLETED,INTERVENTIONAL,['NA'],,complication rate
1130,NCT00440934,Response rate,2007-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,To determine the influence of the treatment on the hepatic function of patients with a diagnosis of cirrhosis. To determine the impact of the treatment by means of electromagnetic waves on the overall survival of patients.
1131,NCT00346281,Safety profile of the patients defined by the Adverse Events profile.,2006-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Will assess ease of use, tumour response, duration of response, progression free survival and overall survival. Target tumour response summaries for the study will be performed."
1132,NCT00374985,maximum tolerable dose and safety,2005-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1133,NCT00002551,Survival and Relapse-free survival,1994-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1134,NCT06291779,Urine,2022-11-30,RECRUITING,OBSERVATIONAL,['NA'],,
1135,NCT00365508,24-hour Point Prevalence Abstinence at the 6-month Follow up,2006-02,COMPLETED,INTERVENTIONAL,['PHASE4'],,Rate of Compliance During the First 2 Weeks
1136,NCT05183958,Progression-free survival (PFS),2021-12-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Duration of Response (DoR),Adverse Events (AEs)
1137,NCT04452266,Correlation between endometrial cancer and predictif factors,2020-08-14,COMPLETED,OBSERVATIONAL,['NA'],,Correlation between endometrial cancer and predictif factors in post menopausal woman
1138,NCT06017284,Rate of nausea/vomiting,2023-11-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall survival (OS)
1139,NCT01234324,Frequency of pT3/T4 categories after surgery,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Frequencies of pN2/N3 categories after surgery
1140,NCT01767857,Overall Survival (OS),2013-03-31,TERMINATED,INTERVENTIONAL,['PHASE3'],,Percentage of Participants With Disease Control
1141,NCT02017704,Number of Patients With Pathologic Complete Response,2014-06-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Local Disease Recurrence
1142,NCT03723447,Cumulative 48-hour Post Surgical Opiate Use (Oral Morphine Equivalent),2018-10-23,COMPLETED,INTERVENTIONAL,['PHASE4'],,Postoperative Complications
1143,NCT01944930,Rate of Detectable Peritoneal Metastases,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1144,NCT01928290,Number of Participants With an Objective Response,2013-11-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity and Tolerability (Arm A and Arm B) as Measured by the Number of Participants With Grade 3 or Higher Adverse Events
1145,NCT00445549,Number of Participants With Clinical Efficacy,2007-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,The Number of Participants With Adverse Events
1146,NCT02387138,Dose limiting toxicities,2014-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1147,NCT02102789,Complete resection rates (R0 resection rates) (defined as no macroscopic or microscopic residual tumor) of both arms,2014-03,RECRUITING,INTERVENTIONAL,['PHASE3'],,"Number of participants with surgical complications, AES and SAEs as a measure of safety"
1148,NCT04005521,Swallowing ability,2019-06-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Incremental Cost Effectiveness Ratio (ICER),Maximal Interincisal opening (MIO)
1149,NCT05671809,ARP,2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,MASCP and Wexner
1150,NCT04591028,Number of lymph nodes removed for each lymphatic station of gastrectomy,2022-01,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,
1151,NCT00912743,Tumour Response,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
1152,NCT05502276,R0 resection rate,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
1153,NCT05903885,Fecal Immunochemical Test (FIT) kite return rate,2023-10-02,RECRUITING,INTERVENTIONAL,['NA'],,Fecal Immunochemical Test (FIT) kit positive rate
1154,NCT03601234,operation time,2018-04-16,UNKNOWN,INTERVENTIONAL,['NA'],,hospitalization expenses
1155,NCT06045715,disease-free survival,2022-08-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,distant metastasis-free survival
1156,NCT06307938,Inflammatory bowel disease,2025-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Treatment response
1157,NCT04888546,Overall response rate (ORR),2021-04-30,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The incidence and severity of SAE
1158,NCT00839332,Phase 2: Overall Survival (OS),2009-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Deaths During the Phase 1 Post-study Period,Phase 2: Electrocardiogram QTc Prolongation
1159,NCT01044420,adverse events,2009-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,response rate
1160,NCT05706974,Rate of bile duct cancer patients who remain in a clinical study to completion,2024-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
1161,NCT01208194,Evaluation of median progression-free survival (PFS) in both treatment groups,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Assessment of the safety profile of MGN1703
1162,NCT05440357,Progression-free survival rate,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],To explore the association of cilinical outcomes with treatment pattern,Safety-TEAEs
1163,NCT00544700,Time to progression (TTP),2007-11-26,TERMINATED,INTERVENTIONAL,['PHASE3'],,Long-term bevacizumab treatment costs
1164,NCT06225609,Calculation postoperative of the Comprehensive Complication Index (CCI) for each patient,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],The number of patients with complications after total mesorectal excision for rectal cancer,Total hospitalization costs
1165,NCT04883450,Incidence of pancreatic ductal adenocarcinoma (PDAC) in the high predicted risk group,2021-02-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
1166,NCT05202600,NNT of IA for the appendiceal neoplasm,2022-02-01,UNKNOWN,OBSERVATIONAL,['NA'],Definition of the elderly group for the complicated appendicitis or death,NNT of IA for the death due to appendicits in elderly
1167,NCT01662739,"Collection of life-style, familiar, clinical, histological and biomolecular data",2010-01,UNKNOWN,OBSERVATIONAL,['NA'],"Analysis of epidemiology, risk factors, family history and unidentified susceptibility genes and proteins",Collection of biological samples (blood and cancer tissue samples)
1168,NCT01063517,Progression Free Survival (PFS) in Patients With Tumours Defined as Homologous Recombination Deficient by Loss of Ataxia-Telangiectasia Mutation (ATM) Protein [ATM Negative Patients],2010-02-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Deterioration in QoL Anxiety Domain Score in the Overall Study Population
1169,NCT04524871,Objective Response Rate (ORR),2020-11-02,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Percentage of Participants With Adverse Events During Stage 2
1170,NCT01234701,Inter-observer agreement among expert radiologists in diagnosing primary liver tumors by Magnetic Resonance Imaging (MRI).,2010-10,COMPLETED,OBSERVATIONAL,['NA'],,Investigate the diagnostic efficacy of radiologists' certainty of diagnosis (CoD) in accurately predicting primary liver tumors assessed by Magnetic Resonant Imaging (MRI)
1171,NCT03443492,progression free survival (PFS),2018-03-26,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
1172,NCT01693432,Objective response rate,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease control rate
1173,NCT03972527,IThe primary effectiveness endpoint is the severity of oral mucositis at week 6 of radiation treatment according to the Oral Mucositis Index (OMI) score.,2022-08-05,RECRUITING,INTERVENTIONAL,['NA'],,Changes in overall quality of life over the 6-week treatment period
1174,NCT04714957,"genetic and epigenetic data available for 20 ""multiplets"" biospecimens (peritoneal carcinomatosis + healthy tissue + primary tumor + tissue from other tumor metastasis - when applicable and available- )",2020-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
1175,NCT04963283,Disease Control Rate (DCR),2021-06-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Exploratory Biomarker analysis - Tumor tissue
1176,NCT02368886,Proportion of Patients in Each Arm Who Complete 2 Cycles of Protocol Treatment and Initiate Cycle 3,2015-03-27,COMPLETED,INTERVENTIONAL,['PHASE2'],Pharmacokinetics (PK) Parameters of Regorafenib Using Liquid Chromatography Mass Spectrometry,Changes in QOL (According to the Linear Analogue Self-Assessment [LASA] Questionnaire)
1177,NCT03046862,Response rate,2017-02-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and tolerability as measured by number and grade of toxicity events
1178,NCT02860546,Immune-Related Overall Response Rate (irORR),2016-08-29,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
1179,NCT05820906,Overall response rate ( ORR) per RECIST 1.1,2023-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease control rate (DCR) per RECIST 1.1
1180,NCT03225937,Objective Response Rate according to RECIST 1.1 criteria,2012-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
1181,NCT01035229,Overall Survival (OS),2010-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Pharmacokinetics Assessments - Cmax
1182,NCT03178383,Integration of health-relation practices assessed via church survey,2016-07-01,COMPLETED,INTERVENTIONAL,['NA'],,Implementation: Extent to which intervention is implemented as intended as assessed by a fidelity checklist completed by staff
1183,NCT02905968,anastomotic leak rate,2016-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Time Frame: Reoperation rate after anastomotic leak
1184,NCT03665506,Overall survival,2018-06-25,COMPLETED,OBSERVATIONAL,['NA'],Assessment of health economic parameters,Patient-reported outcomes (PROs) on quality of life (QoL)
1185,NCT00041249,,2002-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1186,NCT02763748,Tumor recurrence rate,2016-06,UNKNOWN,INTERVENTIONAL,['NA'],,"the all number of postoperative complications（ frequency,reflux esophagitis and bile reflux gastritis）"
1187,NCT04738214,Pathologic response rate,2021-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Disease free survival
1188,NCT00529113,Phase II - To determine if treatment with RTA 402 in combination with gemcitabine can increase the progression-free survival versus gemcitabine plus placebo in patients with unresectable metastatic pancreatic cancer.,2007-09-30,TERMINATED,INTERVENTIONAL,['PHASE1'],,"Phase II - To determine the changes in quality of life (Functional Assessment of Chronic Illness Therapy (Fatigue), [FACIT-F])."
1189,NCT05807646,The changes of the level of circulating tumor cells in the peripheral blood,2025-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Postoperative recovery course
1190,NCT05285358,Incidence of adverse events,2022-09-19,RECRUITING,INTERVENTIONAL,['PHASE1'],,Functional status
1191,NCT05184400,Overall survival (OS),2015-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Incidence of adverse events
1192,NCT01147991,"Demonstration by ELIspot assays of the frequency of T-lymphocytes recognizing major histocompatibility complex (MHC) class I and II-restricted epitopes within EBNA1 and LMP2 in peripheral blood at sequential time-points before, during, and up to 9 mo ...",2005-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Measurement of EBV-genome levels in plasma
1193,NCT04333927,Overall Survival,2020-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
1194,NCT03631537,nutritional status,2018-08-20,UNKNOWN,INTERVENTIONAL,['NA'],,adverse events
1195,NCT02143869,body composition,2013-12,COMPLETED,OBSERVATIONAL,['NA'],comparison of the body composition obtained by BIA and anthropometric measurements.,perioperative complications
1196,NCT03586973,24-Week Progression-Free Survival Rate (PFSR),2018-08-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
1197,NCT03531320,"Part 2: Incidence of Dose Modifications, Including Dose Reduction, Interruption, or Discontinuation of Study Drug",2018-08-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Part 2: PK- AUC
1198,NCT00467142,Percentage of Participants in Objective Response (Partial or Complete Responses),2007-01-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Duration of Response
1199,NCT02851004,ORR,2016-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",safety according to immune status,Pharmacokinetic
1200,NCT02132858,Tumor response measured using the tumor regression grading system,2014-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],PET-computed tomography parameters,Tumor heterogeneity in patients with partial response to radiation
1201,NCT02943603,number of adverse events related to toxicity,2017-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,PD-L1 expression in tumor cells
1202,NCT03714490,R0(microscopically margin-negative) resection rate,2018-10-23,RECRUITING,INTERVENTIONAL,['PHASE2'],"circulating tumor DNA, and other potential biomarkers such as T-cell receptor",QoL by QLO-CR29
1203,NCT02626728,morbidity,2015-09,COMPLETED,OBSERVATIONAL,['NA'],,short-term oncological result
1204,NCT01634126,FIT Kit adherence,2012-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
1205,NCT00190541,Relapse-free survival,2003-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Incidence of sexual and urinary dysfunction
1206,NCT01793805,To characterize common genetic/molecular profiles associated with colorectal cancer (CRC),2013-02,COMPLETED,OBSERVATIONAL,['NA'],,To conduct further analysis of tumor samples for the discovery of new potential targets and mechanisms of drug resistance
1207,NCT05223816,PFS,2024-01-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,anti-HSV-1 antibody
1208,NCT01457846,Median Progression Free Survival,2011-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Percentage of Patients Without Progressive Disease at 8 Weeks
1209,NCT00846482,Number of Patients With Excision Repair Cross-complementing Group-1 (ERCC1) Protein Change When Treated With Oxaliplatin,2008-02,COMPLETED,INTERVENTIONAL,['NA'],,Determine Extent of ERCC Polymorphism and Its Relationship to Change in Its Level
1210,NCT01048463,Serum level of proalbumin,2009-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Records of food intake
1211,NCT05573776,Comparison of muscle variation between exercise therapy alone and high protein supplement combination groups,2020-08-01,RECRUITING,INTERVENTIONAL,['NA'],,Overall Survival (OS)
1212,NCT01773785,Progression free survival,2013-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Safety of SPI-1620 when administered in combination with docetaxel
1213,NCT04834986,Feasibility as measured by rate of enrollment,2021-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],To investigate the clinical efficacy of PD-L1 expression in predicting the combination of Tislelizumab and Lenvatinib.,adverse reactions
1214,NCT01270893,Percent of Apoptotic Tumor Cells Pre- and 7 Days Post Nilotinib Treatment,2011-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
1215,NCT03039062,Relationship of serum miR-122 level and DILI or hepatic failure,2016-07,UNKNOWN,OBSERVATIONAL,['NA'],,Normal physiological range of miR-122 in healthy population
1216,NCT01357486,Time to radiologic progression,2011-11-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life
1217,NCT00099294,Overall Survival,2004-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Performance Status
1218,NCT04389502,Correct Answers (60% group),2020-05-15,UNKNOWN,INTERVENTIONAL,['NA'],,Correct Answers (80% group)
1219,NCT00289445,activity,1999-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1220,NCT04525326,Conversion liver resection rate,2020-10-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,overall survival
1221,NCT00976508,Number of Participants With Dose Limiting Toxicities (DLT),2009-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Objective Response
1222,NCT02182687,Freedom From Progression Over Time,2014-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life - Questionnaires Include PIQ-6 and SF-36v2 Health Survey
1223,NCT00857545,Progression-free Survival (PFS),2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
1224,NCT00027833,,2001-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
1225,NCT05988918,Progression Free Survival,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Median Progression- Free Survival (PFS) within each cancer subtype
1226,NCT03766945,Fatigue,2017-07-27,UNKNOWN,OBSERVATIONAL,['NA'],,Quality of Life
1227,NCT04316975,Correlation of Mean Mutational Load (ML) and Treatment Resistance,2020-04-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Correlation of Mutational Load and Stricture Formation
1228,NCT03037437,Time to tumor progression evaluated via tumor imaging,2017-02-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,
1229,NCT02272504,Biomarker assays exceeding threshold,2014-08,UNKNOWN,OBSERVATIONAL,['NA'],,Surveillance until HCC development and detection
1230,NCT04321577,Gallbladder cancer risk score,2020-03-01,WITHDRAWN,OBSERVATIONAL,['NA'],,Disease-free survival
1231,NCT02149784,Overall survival,2015-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Number of Participants with Adverse Events both in surgery group and chemotherapy group
1232,NCT04023448,anterior resection syndrome incidence,2019-09-01,UNKNOWN,INTERVENTIONAL,['NA'],,Long-term postoperative complication incidence
1233,NCT03791905,clinical complete response,2019-01-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Chemoradiotherapy-related toxicity
1234,NCT02614703,Total Number of Subjects With Neoplasia When Using Acetic Acid Chromoendoscopy Versus Standardized Random Biopsies.,2017-03-10,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
1235,NCT00788281,operation mortality,2008-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,fee
1236,NCT04674267,Association of geriatric consultation with number of unplanned ED visits/hospitalizations among older adult participants,2022-01-18,RECRUITING,INTERVENTIONAL,['NA'],,
1237,NCT05323890,Pathologic complete response rate,2022-04-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-related Adverse Events
1238,NCT02248038,5 years overall survival rate,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
1239,NCT00515866,To establish the maximum tolerated dose (MTD) or a tolerable and effective dose of KU 0059436 in combination with gemcitabine,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,To identify the dose-limiting toxicity of the combination therapy
1240,NCT05520801,Objective response rates (ORR),2020-05-01,RECRUITING,OBSERVATIONAL,['NA'],,Quality of Life (QoL) after treatment
1241,NCT04354064,Freedom from progression,2019-05-29,RECRUITING,OBSERVATIONAL,['NA'],,Distant-metastasis-free survival
1242,NCT00903396,Complete Response (no Episodes of Nausea or Vomiting),2009-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Average Level of Nausea Reported and the Proportion of Patients Experiencing a Complete Response Independent of Treatment Arm
1243,NCT01204177,Disease Control Rate (DCR),2010-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Biomarkers
1244,NCT00666107,"Determine if vaccinations will activate the subject's immune systems sufficiently that the HIV-1 viral load either increases from the baseline value, or becomes detectable and stays detectable after being undetectable at the baseline visit",2008-06,UNKNOWN,INTERVENTIONAL,['NA'],,
1245,NCT00049335,Feasibility of enrolling patients aged 70 years or older to a Phase II trial including pharmacokinetic sampling,2003-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Explore, at a preliminary level, the feasibility of studying genetic polymorphisms and gene expression levels of enzymes involved in drug metabolism and resistance to capecitabine"
1246,NCT02251782,Comparison of Adherence to Screening for Each Group,2014-10,COMPLETED,OBSERVATIONAL,['NA'],,Diagnostic yield of colonoscopy:
1247,NCT00555295,,2007-12,UNKNOWN,OBSERVATIONAL,['NA'],,
1248,NCT04561336,overall survival,2018-08-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1249,NCT04145193,ctDNA clearance,2020-10-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Number of subjects with detectable anti-drug antibody (ADA) to novel agents in combination with mFOLFOX6
1250,NCT01166490,Incidence of adverse events and laboratory abnormalities,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Incidence of antitherapeutic antibodies in blood
1251,NCT02487225,Change in Interleukin-8 (IL-8) Levels From Admission Baseline at One Week.,2015-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1252,NCT02015923,Assess the impact of overall survival in patients with unresectable metastatic colorectal cancer treated with chemotherapy alone vs surgery followed by chemotherapy.,2013-12,TERMINATED,INTERVENTIONAL,['PHASE4'],,Study of possible survival factors
1253,NCT03607656,3-year Disease Free Survival rate,2018-06-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,EORTC QLQ-C30 scale
1254,NCT06104267,Adherence rates,2023-09-01,RECRUITING,INTERVENTIONAL,['NA'],,self-rating depression scale（SDS）
1255,NCT02271646,pain score at recovery room both at rest and movement (cough),2014-08,COMPLETED,INTERVENTIONAL,['NA'],,"Distribution of local anesthetic drugs after performing ultrasound guided TPVB at T5-6, T7-8 and T9-10."
1256,NCT03957733,3-year disease free survival (DFS) rate.,2017-11-23,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Surgical complications.
1257,NCT02111941,"Incidence of dose-limiting toxicities (DLT), graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0",2014-04-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Induction of antibodies specific for FRalpha,Time to disease recurrence (TDR)
1258,NCT01867892,"the response rate, disease control rate, overall survival, and patients' quality of life.",2013-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
1259,NCT00637637,Progression-free survival at 6 months,2007-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Duration of use of anticonvulsive drugs
1260,NCT04510285,Rate of ctDNA Clearance at 6 Months,2020-08-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
1261,NCT05103501,Disease-free Survival (DFS),2021-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival Rate
1262,NCT01178944,Overall Response Rate,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2'],MicroRNA Expression - miR-215-5p,Time to Progression (TTP)
1263,NCT03816774,Adequate bowel preparation rate,2019-06-15,COMPLETED,INTERVENTIONAL,['NA'],Patients characteristics questionnaire,Tolerability to the bowel cleansing regimen:questionnaire
1264,NCT00003296,,1998-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
1265,NCT00522405,Survival rate- calculated from the start of TACE,2007-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"a) Tumor response on dual phase CECT b) Patient tolerance c) Childs' status of cirrhosis- will be ascertained at one and two years of follow up depending upon the Childs' scoreScore <6- Childs'A, 7-9 Childs'B and >10 Childs'C"
1266,NCT03037034,Complete resection rate,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Tumor status after endoscopic resection
1267,NCT04044430,Incidence of treatment-related grade 3 or higher adverse events (AEs),2020-08-31,TERMINATED,INTERVENTIONAL,['PHASE1'],,Disease control rate (DCR)
1268,NCT02569723,Feasibility of 14C Oxaliplatin Microdose as a Clinical Assay to Predict Oxaliplatin Exposure,2015-10-16,COMPLETED,INTERVENTIONAL,['NA'],,Response Rate Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
1269,NCT01917552,recurrence-free survival,2013-08-19,RECRUITING,INTERVENTIONAL,['PHASE3'],,Safety profiles
1270,NCT06084013,Perfusion status,2024-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Best practice usage of ICG for pancreatic surgery
1271,NCT02127359,Describe Impact of Information Derived from Exome Sequencing,2012-09,COMPLETED,OBSERVATIONAL,['NA'],,
1272,NCT02213692,Blood loss,2014-05,TERMINATED,OBSERVATIONAL,['NA'],,Postoperative complications
1273,NCT04802876,Overall Response rate (ORR) (Cohort 3),2021-04-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Incidence, seriousness, treatment-related and intensity of Treatment Emergent Adverse Events"
1274,NCT01116635,Histopathological correlation with surgically resected tumor,2010-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,maximum tolerated dose
1275,NCT01845805,Progression-free Survival,2014-01-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
1276,NCT00026104,Overall survival,2001-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free survival
1277,NCT04745130,Overall Survival (OS),2021-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Objective Response Rate
1278,NCT03906565,Tumor response to utidelone treatment,2019-04-12,SUSPENDED,INTERVENTIONAL,['PHASE2'],,Safety profile associated with utidelone injection
1279,NCT03796702,Postoperative morbidity,2011-11-01,TERMINATED,INTERVENTIONAL,['NA'],,Quality of life of patients after ileostomy closure
1280,NCT02273206,"Changes From Baseline in Number of Participants With Colorectal, Breast, and/or Cervical Cancer Screening",2014-01,COMPLETED,INTERVENTIONAL,['NA'],,Self-efficacy and Behavior Towards Cancer Screening/Mental Health Utilization
1281,NCT02327065,Diagnostic Yield on malignancy,2014-12,UNKNOWN,INTERVENTIONAL,['NA'],,Blood contamination and cellularity in specimens obtained by EUS-FNA and EUS-FNB with Slow-pull or suction
1282,NCT06306755,Detection rate of upper gastrointestinal (esophageal/gastric) malignant lesions,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Quality of life Scale Score
1283,NCT00332696,Number of Participants With Treatment Success From Day 10 to Day 13,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Participant's Quality of Life Using the Edmonton Scale
1284,NCT03418558,Objective Response Rate according to RECIST 1.1 criteria,2015-07-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
1285,NCT04110977,Rate of radiation dermatitis grade ≥2,2020-10-10,UNKNOWN,INTERVENTIONAL,['NA'],,Rate of radiation-induced oral mucositis grade ≥3
1286,NCT04541173,Progression free survival (PFS) by RECIST 1.1,2020-11-30,TERMINATED,INTERVENTIONAL,['PHASE2'],,Subject function
1287,NCT04275557,Radiogenomic Analyses,2020-02-18,RECRUITING,OBSERVATIONAL,['NA'],,Progression Free Survival
1288,NCT03079596,Afebrile status without major complications,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA'],,Time to first bowel motion
1289,NCT05973227,"image quality (sharpness, brightness, etc) and surgeon's feedback regarding the ergonomics and safety of Trident System v1.0 during surgery.",2023-07-06,RECRUITING,INTERVENTIONAL,['NA'],,- level of oxygenation (StO2) of the exteriorized colon before resection with the Trident System v1.0 - the level of oxygenation (StO2) provided by the system at the site chosen by the surgeon based on the clinical evaluation.
1290,NCT00003025,,1997-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1291,NCT03572582,Objective Response Rate (ORR),2018-06-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment Emergent Adverse Events as assessed by NCI CTCAE V4.03 (Safety and Tolerability)
1292,NCT06177288,converted resection rate,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Adverse events
1293,NCT05007145,Pathologic complete response (pCR) rate,2021-08-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease Free Survival (DFS)
1294,NCT01167725,Overall survival (OS),2010-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Comparison of OS and PFS according to patients' peritoneal surface tumor genotype for the NAD(P)H
1295,NCT03812874,Safety as measured by number of participants with a dose limiting toxicity (DLT),2020-10-06,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To evaluate change in AFP levels.
1296,NCT02022553,tumor reduction,2006-02,UNKNOWN,INTERVENTIONAL,['NA'],,
1297,NCT05842317,Overall response rate (ORR),2022-09-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Conversion surgery rate
1298,NCT01345773,The incidence of symptomatic or asymptomatic VTE,2010-05,COMPLETED,OBSERVATIONAL,['NA'],,Risk factors for the development of VTE
1299,NCT04530981,AUC from time 0 and extrapolated to infinity (AUC0-∞),2021-09-22,RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of Adverse Events
1300,NCT05997524,Loco-regional and Distant Tumor Control After Completion of Treatment,2021-03-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
1301,NCT06215677,the rate of R0 resection,2024-02-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Safety and tolerability of Camrelizumab administered
1302,NCT02495532,Lymph nodes harvested,2015-03,UNKNOWN,INTERVENTIONAL,['NA'],,Adjuvant therapy
1303,NCT01915472,Safety,2013-09,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Assess PK
1304,NCT06277453,3-year overall survival,2023-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
1305,NCT01653171,Visibility at upper endoscopy,2012-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,
1306,NCT04837885,Standardized uptake value (SUVmax) on liver metastases,2021-09-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,177Lu-DOTA-peptide dosimetry
1307,NCT06271980,Recurrence Free Survival,2023-04-15,COMPLETED,OBSERVATIONAL,['NA'],,Overall Survival
1308,NCT06010901,Objective response rate (ORR),2024-01-13,RECRUITING,INTERVENTIONAL,['PHASE1'],,Neutralizing antibodies (NaB)
1309,NCT03333486,Relapse Rate,2017-12-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Myeloid Chimerism Expressed as a Percentage of Donor Cells,Transplant Related Mortality
1310,NCT03401957,Percentage of detected circulating DNA RAS mutations during 1st line cetuximab exposure.,2018-01,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival from the start of 1st line treatment with cetuximab.
1311,NCT06169202,Progression-free Survival (PFS),2023-06-01,RECRUITING,OBSERVATIONAL,['NA'],,Disease Control Rate (DCR)
1312,NCT01300143,Time of tumor progression radiologically (CTScan) measured by mRECIST (Modified Response Evaluation Criteria In Solid Tumor).,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,overall survival
1313,NCT00193141,"To compare the efficacy of full dose radiation therapy versus preoperative radiation therapy plus surgical resection, when used in combination with neo-adjuvant chemotherapy, in the treatment of localized esophageal cancer",1999-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,To evaluate the toxicity of additional chemotherapy and radiation therapy following completion of neo-adjuvant treatment.
1314,NCT03211416,Overall response rate defined as partial or complete response per immune-related Response Evaluation Criteria in Solid Tumors,2017-12-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change in levels of immunosuppressive cells,Time to tumor progression
1315,NCT02921256,Neoadjuvant Rectal Cancer (NAR) Score,2017-01-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Relationship Between Radiographic Findings and Pathologic Outcomes,Rate of Sphincter Preservation
1316,NCT03117920,Disease Control rate (DCR),2017-04-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Biomarkers predictive of response to Minnelide,Pharmacodynamic effect of Minnelide on tumour using PET Scans
1317,NCT00462852,Incidence of venous thromboembolism reduction,2003-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Effect of drug combination on serological markers of thromboangiogenesis
1318,NCT01549418,Clinically significant bleeding after colorectal polypectomy,2012-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Proportion of clinically significant delayed bleeding in both groups
1319,NCT05913570,Pathological complete response (pCR) rates,2023-06-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with any treatment-related delays in the planned surgery of no more than 28 days after the last preoperative Cadonilimab dose
1320,NCT00757965,Exploration of mutations at other loci that may predispose to endometrial cancer,2008-02,UNKNOWN,OBSERVATIONAL,['NA'],,
1321,NCT01256203,Skin erythema responses of control (unprotected) and Solar Protection Formula® SPF 60-protected sites to light exposure,2013-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Proportion of subjects with adverse events as a measure of safety
1322,NCT00080873,Area under the curve (AUC) of the modified Walsh mucositis scale,2004-04,COMPLETED,INTERVENTIONAL,['NA'],,Two sample t test and the Wilcoxon sum test.
1323,NCT00731445,Phase II : Assess the objective tumor response rate in patients according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria,2008-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II: Determine the PFS
1324,NCT06332274,Efficacy of tislelizumab compared to placebo as measured by DFS (Disease-free survival),2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Cost effectiveness analysis: ICER
1325,NCT00020930,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1326,NCT04512729,Colonic Adenoma,2020-08-04,UNKNOWN,OBSERVATIONAL,['NA'],,Risk factors for Colonic adenoma
1327,NCT00311610,Objective response rate,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
1328,NCT01567631,Number of participants with operation complication,2012-01,UNKNOWN,INTERVENTIONAL,['NA'],,Number of participants with abnormal liver function or discomfort symptoms induced by the operation
1329,NCT03635619,MRI TN staging in Esophageal Cancer,2018-09-02,UNKNOWN,OBSERVATIONAL,['NA'],,MRI prediction of prognosis in esophageal cancer
1330,NCT00431756,early predictors of esophageal cancer,2002-05-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
1331,NCT06128798,Physiology Return of Bowel Function,2023-09-26,RECRUITING,INTERVENTIONAL,['NA'],,Length of Hospital Stay
1332,NCT03469479,Overall survival,2018-03-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Adverse Events
1333,NCT00455559,To determine the efficacy and safety of perifosine plus imatinib mesylate in patients with advanced GIST who develop progressive disease or recurrence while receiving imatinib mesylate.,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To determine whether inhibition of Akt phosphorylation correlates with survival, time to disease progression, or response rate in patients with advanced GIST treated with imatinib mesylate plus perifosine."
1334,NCT01646593,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
1335,NCT01675908,Complications related to stent dysfunction,2012-08-22,COMPLETED,INTERVENTIONAL,['NA'],,Procedural complications
1336,NCT01121562,Clinical Benefit Response Rate (CBR),2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Dose-corrected Trough Plasma Concentrations of Sunitinib, SU012662 and Total Drug (Sunitinib + SU012662)."
1337,NCT00003524,,1996-10-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,
1338,NCT01504256,Rate of macroscopic complete remissions of peritoneal carcinomatosis,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Detection of disseminated tumor cells via PCR
1339,NCT04390399,Progression Free Survival (PFS),2020-07-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of Life (QoL)
1340,NCT05360732,To assess the toxicity profile of a regimen of alternating FOLFOX and FOLFIRI patients assessed as per NCI's CTCAE v5.0 criteria.,2022-04-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,To assess the Delayed Toxicity Rate
1341,NCT02315625,Median Amount of Time Subject Survives Without Disease Progression After Treatment,2015-04-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Serious and Non-Serious Adverse Events
1342,NCT04803019,Time to progression,2019-12-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
1343,NCT04670588,Mean serum ctDNA concentration,2021-03-31,WITHDRAWN,OBSERVATIONAL,['NA'],,Response based on standard clinical assessments
1344,NCT00058487,Toxic effects,2001-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1345,NCT02595957,Health impacts of SF receipt,2014-09-16,RECRUITING,OBSERVATIONAL,['NA'],,
1346,NCT00455091,Primary endpoint: Primary endpoint: the 3-years recurrence rate (excluding those recur within first year).,2007-05,TERMINATED,OBSERVATIONAL,['NA'],,"Secondary endpoints: the first 2 year tumor recurrence rates,the recurrence-free survival,the overall survival.anti-viral efficacy."
1347,NCT05756725,Number of open orders for mammography screening,2023-07-25,COMPLETED,INTERVENTIONAL,['NA'],,Appropriateness of Implementation Strategies
1348,NCT03642652,Follow-up colonoscopy 120 days after a positive fecal occult blood test,2016-04-01,COMPLETED,INTERVENTIONAL,['NA'],,
1349,NCT06010303,Overall Response Rate (ORR),2023-11-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Participants with Adverse Events (AEs)
1350,NCT05838768,Frequency of dose reductions as a measure of tolerability,2023-06-27,RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of participants with anti tislelizumab antibodies
1351,NCT05709886,Effectiveness analysis,2023-02-28,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Alpha-fetoprotein levels
1352,NCT04345783,OS,2018-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
1353,NCT01759706,Adherence to the pathway,2010-10,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative outcome
1354,NCT01502410,Objective Response by RECIST Criteria v 1.1,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Presence of BRAF Mutation or RET/PTC Rearrangement
1355,NCT01037049,"The primary endpoint will be the difference in the proportion of patients in each arm, downstaged according to T stage [on MRI].",2009-10-16,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Radiotherapy related toxicity rates.
1356,NCT02710838,the lesion of early gastric cancer by infrared endoscopy,2014-01,UNKNOWN,INTERVENTIONAL,['NA'],,the invasive depth of early gastric cancer by infrared endoscopy
1357,NCT00836407,Percent of Patients Experiencing an Unacceptable Toxicity,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression Free Survival (PFS)
1358,NCT00208260,Response,2004-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Secondary resection
1359,NCT06254300,Aerobic capacity,2022-03-23,RECRUITING,INTERVENTIONAL,['NA'],,Length of hospital stay
1360,NCT05645679,Efficacy of the Hybrid Argon Plasma Coagulation Technique,2021-04-02,RECRUITING,OBSERVATIONAL,['NA'],,
1361,NCT02427269,Collaboration with other investigators,2015-04-28,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
1362,NCT01032746,"Receipt of colorectal cancer screening exam (fecal occult blood test, flexible sigmoidoscopy, or colonoscopy) within 4 months following delivery of an electronic message within the personal health record",2005-03,UNKNOWN,INTERVENTIONAL,['NA'],,Distribution of risk-status among participants who complete the web-based risk-assessment tool
1363,NCT04693377,Pain response,2021-03-16,RECRUITING,INTERVENTIONAL,['NA'],,Technical success for cryoablation
1364,NCT01546519,The Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUC[0-24hours]) Following Multiple Doses of Vismodegib,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Apparent Non-renal Clearance (CLNR/F) of Vismodegib
1365,NCT02794805,13CO2/12CO2 ratio,2015-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1366,NCT00784290,Step 2(Phase II) Response rate(RR),2003-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Step 2(Phase II) Safety
1367,NCT04057274,Cell viability (%),2019-09-23,UNKNOWN,INTERVENTIONAL,['NA'],,Concentration of Insulin-like growth factor 1 (ng/ml)
1368,NCT05493878,Expression levels of ITGA2b and SELP on Tumor Educated PLatelets for diagnosis of pancreatic and biliary cancer,2023-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Correlation between expression levels of ITGA2b and SELP on TEPs and the commonly used tumour marker CEA and CA 19-9 in the diagnosis of pancreatic and biliary cancer.
1369,NCT05871892,Metabolic function of the liver evaluated by the PET tracer 18F-FDGal,2023-09-11,RECRUITING,INTERVENTIONAL,['NA'],,
1370,NCT01126112,Progression-free survival rate at 6 months,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluation of molecular predictive markers for response.
1371,NCT02267707,Pharmacokinetics - CL,2015-05-27,TERMINATED,INTERVENTIONAL,['PHASE1'],,Gemcitabine PK profile
1372,NCT01821248,Curative resection rate,2013-07-23,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Response rate and toxicity
1373,NCT05595811,overall survival,1999-01-01,COMPLETED,OBSERVATIONAL,['NA'],,adjuvant oncologic treatment
1374,NCT04268888,Time to TACE Progression (TTTP) - phase II primary outcome,2019-05-08,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,QOL: EORTC QLQ-C30
1375,NCT05203120,Number of participants with Radiation-induced liver disease (RILD),2022-04-01,RECRUITING,INTERVENTIONAL,['NA'],,Reduction in mean liver dose
1376,NCT05321134,Assess safety & quality event rate for SP platform transabdominal and transanal colorectal operations,2022-04-28,RECRUITING,INTERVENTIONAL,['NA'],,
1377,NCT05570942,Changes of irritable bowel symptoms,2021-12-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The presence of bacteremia
1378,NCT03110939,local recurrent rate,2017-03-21,WITHDRAWN,INTERVENTIONAL,['NA'],,mortality rate after treatment
1379,NCT01861912,Time to Progression,2013-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Recurrence Rate,Safety
1380,NCT04460456,"Duration of response, defined as the time from date of first response (CR or PR)",2020-07-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression free survival
1381,NCT01439724,Incidence and / or Severity of Oral Mucositis,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Oral Mucositis Survival Free, Pain, Opioid Treatment, Hospitalization, Treatment Interruption, Treatment Delay, Patient Weight Loss, Nasogastric Tube or of a Gastrostomy."
1382,NCT05302011,pathological response,2020-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
1383,NCT00003049,,1997-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1384,NCT02876224,Percentage of Participants with Adverse Events,2016-09-30,COMPLETED,INTERVENTIONAL,['PHASE1'],,Percentage of Participants with Anti-therapeutic Antibodies (ATAs) Response to Atezolizumab
1385,NCT04563338,Progression-free survival,2021-06-04,RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression-free survival rate
1386,NCT03828227,"Health-related quality of life (HRQoL) at 6 months in the ""candidate group"".",2019-06-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Performance status geriatric (PSG) score.
1387,NCT05444478,Over-all survival (OS) rate at 36 months,2022-07-01,RECRUITING,INTERVENTIONAL,['NA'],,Complication rate
1388,NCT01237990,The number of accepted liver registrations associated with laparoscopically acquired surface data compared with the number of accepted liver registrations associated with open liver acquired surface data.,2010-08,COMPLETED,OBSERVATIONAL,['NA'],,Comparison of registration errors from the full and half sufflation pressures to determine an impact of insufflation pressure on registration accuracy.
1389,NCT01191385,"Evaluation of patient demographics, disease characteristics, methods of patient evaluation, diagnosis and follow-up of patients with HCC, regionally and globally (collection of data on demographics, medical history, diagnostic measurements, follow-up)",2010-11,WITHDRAWN,OBSERVATIONAL,['NA'],,To evaluate the comorbidities in patients with HCC and their influence on treatment options and outcome (collection of data on concomitant diseases)
1390,NCT05733598,Overall Response Rate per modified RECIST 1.1,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
1391,NCT02168426,ileus rate,2013-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,adverse effect rate
1392,NCT04743102,pathological complete remission,2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Overall Survival
1393,NCT01298011,Grade III/IV histological response in tumor specimen rate after induction therapy.,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
1394,NCT03209336,The basic information and medical history achieved (questionnaire),2015-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,The short-term complications
1395,NCT00767468,Correlation between hepatic retention and clearance of technetium Tc 99m mebrofenin (MEB) and technetium Tc 99m sestamibi (MIBI) and clearance (and other pharmacokinetic parameters) of sorafenib tosylate,2008-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,Median overall survival
1396,NCT01100372,Remission rates (complete response and partial response),2009-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Toxicity
1397,NCT02709213,Determination of the aetiologies of colitis using microbiological examination of the stools +/- colonoscopy,2016-11,COMPLETED,OBSERVATIONAL,['NA'],,"Identification of anamnestic, clinical and biological predicting factors for patients requiring diagnostic colonoscopy"
1398,NCT02645981,Overall Survival,2016-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Percentage of adverse events
1399,NCT00294203,"Post-operative hemoglobin, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte fraction measured on post-operative days 1, 4, 8, and between days 20 and 30",2006-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Post-operative quality of life related to anemia measured by Functional Assessment of Cancer Therapy - Anemia (FACT-An) between post-operative day 20 and 30 and post-operative transfusion requirement
1400,NCT04954339,Distinct immunophenotypes and dynamic changes of tumor-infiltrating immune cells in Hepatocelluar carcinoma treated with treated with atezolizumab-bevacizumab assessed by flow cytometry (and/or CyTOF),2021-10-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Dynamic changes in T-cell receptor (TCR) repertoire of peripheral mononuclear cells
1401,NCT01417611,polyp/adenoma detection rate (per-polyp/adenoma analysis and per-patient analysis),2010-09,COMPLETED,INTERVENTIONAL,['NA'],,characterization of polyp
1402,NCT01346280,,2011-04-16,COMPLETED,OBSERVATIONAL,['NA'],,
1403,NCT01129310,Overall Response Rate and dose limiting toxicity,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Progression Free Survival, overall survival, death, alterations in quality of life outcomes"
1404,NCT01589419,Determine the maximum tolerated dose (MTD) and/or establish the recommended phase two dose (RPTD),2012-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Assess the pharmacokinetic profile by area under the curve vs. dose of veliparib
1405,NCT02873442,Progress-free survival,2016-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life
1406,NCT02454686,Accuracy of Fibroscan in predicting complication after hepatectomy,2012-02,COMPLETED,OBSERVATIONAL,['NA'],,
1407,NCT00572143,Quality of life; EORTC-QLQ-C30 and EQ 5D,2007-06,COMPLETED,INTERVENTIONAL,['NA'],,Cost-effectiveness Serious clinical events
1408,NCT00897754,VEGF165b protein expression as measured by ELISA,2007-07-24,COMPLETED,OBSERVATIONAL,['NA'],,
1409,NCT02759588,Overall Response Rate (ORR) by RECIST 1.1 (Phase 2),2016-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Clinical Benefit Rate
1410,NCT02551471,Clinical resection rates in both countries,2015-05-01,COMPLETED,OBSERVATIONAL,['NA'],,Analyses of semi-structured interviews
1411,NCT00861783,maximum tolerated dose,2008-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,tumor measurement
1412,NCT03515538,Duration of Severe Oral Mucositis (SOM),2018-07-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Patient-reported pain
1413,NCT05587725,Prevalence of type-specific HPV types,2023-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
1414,NCT02175654,Progression free survival rate at 6 months,2014-06,TERMINATED,INTERVENTIONAL,['PHASE2'],Biomarkers associated with cell and tumour growth and/or the mechanism of action of regorafenib and their correlation with patients' clinical progression for efficacy and safety parameters.,Changes in ECOG performance status over time from baseline
1415,NCT04220242,Validation of predictive accuracy biophysics-visualisation model,2019-12-30,UNKNOWN,OBSERVATIONAL,['NA'],,Realtime delineation display of tumour area including margins
1416,NCT03612531,Incidence of adverse events,2018-08-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Improvement in tongue innervation on Electromyography (EMG) findings
1417,NCT04032392,Overall survival (OS),2019-07-23,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Patients-based Quality of Life Evaluation
1418,NCT05166239,6-month progression-free survival rate,2022-01-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of patients with treatment-related adverse events
1419,NCT02489838,Lung dose measured with actual lung mass vs Lung dose measured with conventional method.,2012-02-03,COMPLETED,OBSERVATIONAL,['NA'],,
1420,NCT01589471,Efficacy of intra-rectal Botox-A injection on anorectal function as documented with standardized Wexner score,2012-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety of intra-rectal Botox-A injections as documented with adverse events monitoring
1421,NCT01458353,Peritoneal contamination after finishing the ileocolonic anastomosis,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
1422,NCT01446874,Adherence to the Pre-operative Toothbrushing Regimen,2011-09-22,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Incidence of Fever
1423,NCT05767697,Number of subjects who still survive at 1 year,2020-04-15,RECRUITING,OBSERVATIONAL,['NA'],,
1424,NCT06324825,Recovery rate of Low-grade Intraepithelial Neoplasia,2022-10-24,RECRUITING,INTERVENTIONAL,['NA'],,Adverse event rate
1425,NCT02641691,Complete Response Rate,2016-05-27,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Anorectal Function as Measured by the FACT-C Questionnaire
1426,NCT05733000,Overall response rate (ORR),2023-03-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
1427,NCT01283204,progression free survival(PFS),2010-03-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1428,NCT02145416,Changes on DW MRI during CRT in anal cancer.,2015-01-27,COMPLETED,OBSERVATIONAL,['NA'],To use PET SUV data in a radiotherapy in silico modelling exercise to determine if dose sparing of active pelvic bone marrow (PBM) is possible without compromising target coverage by radiation.,Correlation of the change in functional images over CRT with outcome of CRT
1429,NCT03662035,Progression Free Survival,2018-09-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease Control Rate
1430,NCT01103479,Colorectal Cancer (CRC) Screening Completion,2010-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Provider Recommendation of CRC Screening
1431,NCT06287749,3-year Disease-free survival (DFS),2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Time to molecular recurrence
1432,NCT05453292,Disease-free survival,2024-01-15,RECRUITING,INTERVENTIONAL,['NA'],,Re-treatment rate
1433,NCT03838913,Determination of involved signal pathways,2019-02-15,UNKNOWN,OBSERVATIONAL,['NA'],,
1434,NCT02545725,Questionnaire on Quality of Life,2015-04,COMPLETED,OBSERVATIONAL,['NA'],,
1435,NCT04029857,Patient well-being improvement,2019-03-14,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,
1436,NCT05032014,(objective remission rate)ORR,2021-11-19,UNKNOWN,INTERVENTIONAL,['NA'],,OS
1437,NCT01191411,"Colorectal Cancer Screening Participation, Defined as Completion of a Guaiac or Immunochemical Stool Occult Blood Test, Colonoscopy, Sigmoidoscopy, or Barium Enem.",2010-10,COMPLETED,INTERVENTIONAL,['NA'],,
1438,NCT02316340,Efficacy Based on Progression Free Survival of Vorinostat and Hydroxychloroquine Compared to Regorafenib,2015-02-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival (mOS)
1439,NCT05776875,Grade 3 or higher Treatment Related Adverse Events,2023-06-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Time to untaceable progression
1440,NCT01483027,Hepatic Progression-Free Survival (HPFS),2012-01,COMPLETED,INTERVENTIONAL,['NA'],,Overall Survival
1441,NCT05985954,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",2024-01-18,RECRUITING,INTERVENTIONAL,['PHASE1'],,
1442,NCT05167448,Phase 2: The anti-tumor activity of ES104,2022-02-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: The immunogenicity of ES104
1443,NCT02661945,Accuracy (accurate if the distance (between margin dots and tumor margin measured by histopathology) was less than 1 mm),2015-07,COMPLETED,INTERVENTIONAL,['NA'],,
1444,NCT01477177,"Reduction in Barrett's Histology Grade, Using the Modified Vienna Classification",2011-08,TERMINATED,INTERVENTIONAL,['NA'],,"Reduction in Barrett's Histology Grade, Using the Modified Vienna Classification"
1445,NCT03291899,Response rate,2017-01-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,overall survival
1446,NCT00551759,Proportion of Patients With Pathologic Complete Response,2008-10-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,
1447,NCT05597384,Autogenous blood marker localization was not inferior to intraoperative colonoscopy localization,2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],,Adverse events related to endoscopic tattooing
1448,NCT00006387,,2000-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1449,NCT05327582,Object response rate (ORR),2022-04-12,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of participants with laboratory test abnormalities
1450,NCT00817934,"TOTAL COLON CLEANSING, TO BE ABLE TO PERFORM COLONOSCOPY",2009-01,UNKNOWN,OBSERVATIONAL,['NA'],,
1451,NCT00089362,"MTD, defined as the dose level where the observed DLT incidence in no more than one out of six patients treated at a particular dose level",2004-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1452,NCT06084780,Overall Rate of Survival,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Rate of Mortality
1453,NCT01012362,Number of Participants Who Experienced a Dose Limiting Toxicity (DLT),2009-12,TERMINATED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Treatment-Related Adverse Events
1454,NCT05480891,community education,2023-04-05,RECRUITING,OBSERVATIONAL,['NA'],,
1455,NCT04108481,Determine the maximum tolerated dose (MTD) of Yttrium-90 radioembolization combined with immunotherapy durvalumab to treat liver-predominant metastatic colorectal cancer (mCRC),2020-10-05,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Abscopal effects,Determine duration of response
1456,NCT04834661,overall postoperative complication rate,2021-10-20,COMPLETED,OBSERVATIONAL,['NA'],,
1457,NCT01649271,Dose Limiting Toxicities During cycle1,2012-07-23,COMPLETED,INTERVENTIONAL,['PHASE1'],,Clinical Benefit
1458,NCT00860665,Correlation of adenoma detection rate with case volume of endoscopists,2006-10,COMPLETED,OBSERVATIONAL,['NA'],,Patient acceptance in relation to procedural factors (e.g. sedation)
1459,NCT02309632,Detection rate of PC and precancerous lesion,2015-11,WITHDRAWN,INTERVENTIONAL,['NA'],,
1460,NCT00699816,Recurrence Free Survival(RFS) Rate,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Cancer-specific Survival Rate
1461,NCT03504618,Prognostic factor of progression free survival,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival after 24 months
1462,NCT00003118,Overall survival,1997-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1463,NCT03799731,Progression Free Survival (PFS) at 6 months,2018-07-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,AMHRII (Anti-Mullerian Hormone type II receptor) expression
1464,NCT05040815,Disease free survival (DFS),2023-05-11,RECRUITING,INTERVENTIONAL,['PHASE2'],Relationship between radiotherapy treatment planning variables and acute toxicity.,Exercise Behavior and Physical Fitness
1465,NCT02112357,The percentage of patients in whom a currently actionable molecular alteration was detected by genetic sequencing.,2014-02,UNKNOWN,OBSERVATIONAL,['NA'],Duration of response for patients who received a targeted treatment as a result of genetic sequencing.,The number needed to enroll into the trial to identify one patient with a targetable genetic alteration and the number needed to enroll into the trial to treat one patient with a targeted agent.
1466,NCT00667082,To determine the Maximum tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of the combination NPI-0052 and Vorinostat,2008-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,To evaluate the anti-tumor activity of NPI-0052 and vorinostat
1467,NCT04615806,Sensitivity and specificity of lymph node dissection,2020-09-22,UNKNOWN,INTERVENTIONAL,['NA'],,The mapping of sentinel lymph nodes in esophageal cancer
1468,NCT00660582,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1469,NCT01418222,"Progression-free survival: time from randomization to tumor progression or death, tumor assessments according to RECIST criteria",2011-09-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety: Incidence of adverse events
1470,NCT03092128,Progression free survival,2014-06,UNKNOWN,OBSERVATIONAL,['NA'],,Number of patients with objective response and adverse events
1471,NCT01531595,Efficacy,2012-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,Response
1472,NCT04905147,Postoperative time to the first passage of flatus.,2021-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,Length of postoperative hospital stay
1473,NCT06005493,Objective Response Rate (ORR),2023-07-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Preliminary antitumor activity with target expression pre- and post-delivery of AZD5863
1474,NCT00152607,"The primary outcome for recipients will be the assessment of patient and graft survival. Comparison to results of contemporaneous, non-randomized cadaver donor transplants will be made.",2000-04,TERMINATED,INTERVENTIONAL,['PHASE4'],,
1475,NCT01250158,To demonstrate the feasibility of the liver PILP intervention.,2010-09,UNKNOWN,INTERVENTIONAL,['NA'],,
1476,NCT02229071,Adverse events,2014-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Time to symptomatic progression(TTSP),Time to progression(TTP)
1477,NCT01336881,Biomarkers associated with hepatoblastoma subtypes and cancer stages,2011-04,COMPLETED,OBSERVATIONAL,['NA'],,Exome sequencing
1478,NCT00075452,Overall survival,2003-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Progression-free survival
1479,NCT00049608,,2002-07,TERMINATED,INTERVENTIONAL,['PHASE1'],,
1480,NCT05748145,Impact of metronidazole on F.n. loads in CRC tissues.,2023-09-11,RECRUITING,INTERVENTIONAL,['PHASE2'],,Potential effects of metronidazole on the intestinal metabolic profile
1481,NCT00533533,To define the dose-limiting toxicity and maximum tolerated dose in phase I study To evaluate the overall response rate in phase II study,2006-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,1) To evaluate the safety and tolerability of the treatment combination. 2) To estimate overall survival. 3) To estimate the time to progression and the duration of overall response.
1482,NCT05833594,Disease Control Rate,2023-07-01,RECRUITING,OBSERVATIONAL,['NA'],,"1-, 2-, 3-year Progression-free survival rate (PFS)."
1483,NCT00273585,Colorectal cancer screening self-efficacy,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Colorectal cancer screening decisional conflict
1484,NCT03426397,2-year non-regrowth disease-free survival,2017-05-10,RECRUITING,OBSERVATIONAL,['NA'],,Quality of life
1485,NCT01129167,Frequency of local invasion modalities in surgical population,2009-09-15,COMPLETED,OBSERVATIONAL,['NA'],,
1486,NCT06003218,Area under curve of Numerical Rating Scale of pain during and within 24 hours after surgery.,2023-10-16,RECRUITING,INTERVENTIONAL,['NA'],Incidence of postoperative complications during hospital stay.,Numeric Rating Scale of subjective sleep quality on the first and second nights after surgery.
1487,NCT02734823,Changes in markers of ovarian reserve in premenopausal women undergoing tyrosine kinase inhibitor therapy for cancer,2016-03-01,WITHDRAWN,OBSERVATIONAL,['NA'],,Ovarian response to controlled ovarian hyperstimulation in patients who elect to undergo IVF for fertility preservation
1488,NCT02013830,Percentage of Participants With Objective Response (OR),2005-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival - Percentage of Participants Event Free at 12 Months
1489,NCT03573791,Comparing gene expression differences between poor response group and complete response group by using RNA sequencing.,2018-05-21,RECRUITING,OBSERVATIONAL,['NA'],,Progression Free Survival(PFS)
1490,NCT01737827,Time to progression using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1,2013-03-25,TERMINATED,INTERVENTIONAL,['PHASE2'],,Plasma pharmacokinetic parameter: Racc
1491,NCT00920751,Primary outcome - success of cecal intubation without sedation,2009-03,UNKNOWN,INTERVENTIONAL,['NA'],,"Diagnostic yield, patients' current experience, willingness to repeat future colonoscopy, turn around time, and staff rating of satisfaction, and medication-related complications."
1492,NCT01303159,Change From Baseline in Bile Duct Stricture Diameter,2010-03,TERMINATED,INTERVENTIONAL,['NA'],,Number of Participants With Adverse Events
1493,NCT02292641,To change R0 resection rates for locally recurrent rectal cancers with the use of the proposed staging system.,2014-09-25,RECRUITING,INTERVENTIONAL,['NA'],,To map original radiotherapy volumes (including integrated boosts) against types of recurrence
1494,NCT03316222,Dose-Limiting Toxicity,2018-04-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1495,NCT05923450,Disease-free Survival,2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
1496,NCT03756636,Rate of adverse events (according to the lexiconA ASGE).,2018-06-01,COMPLETED,INTERVENTIONAL,['NA'],,
1497,NCT04200131,"Obtaining histological diagnosis by using ""The Moray"" micro forceps.",2020-01-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Quality of the sample
1498,NCT02365480,Number of Participants With Organ Toxicity Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version (v.) 4.0,2016-06-16,COMPLETED,INTERVENTIONAL,['PHASE1'],,Severity of Histologic Inflammation
1499,NCT03673501,Progression Free Survival (PFS) in the All Patient (AP) Intent to Treat (ITT) Population,2019-02-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall Survival (OS) in the All Patient (AP) Intent to Treat (ITT) Population
1500,NCT06323291,Feasibility of Utilizing the Digital Health Coaching Program,2024-03-08,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
1501,NCT00220116,Objective response rates,2002-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number undergoing liver resections/curative resection (Ro) rate
1502,NCT02420678,"Reliability of FACT-Hep, EORTC QLQ-HCC18 and NFHSI-18",2015-04,UNKNOWN,OBSERVATIONAL,['NA'],,Death rates
1503,NCT00584402,Percent of Tumors With Increased Echogenicity (Brightness) Following Contrast-enhanced Sonography,2007-04,COMPLETED,INTERVENTIONAL,['NA'],,"Number of Participants With an Increase in Echogenicity (Brightness) of Small Intrahepatic Tumors Following Contrast-enhanced Sonography Based on Tumor Type, Size, Location and Depth"
1504,NCT04088955,Compare the duration of actual vs. intended treatment for cancer patients on capecitabine who are prescribed capecitabine with sensor.,2019-09-06,UNKNOWN,OBSERVATIONAL,['NA'],,
1505,NCT00829413,Specificity: Percentage of True Negative Lesions Among All Benign Lesions Per Truth Standard',2010-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Inter-reader Agreement
1506,NCT03853278,Functional Assessment of Cancer Therapy- Colorectal,2018-01-15,COMPLETED,INTERVENTIONAL,['NA'],,The Functional Assessment of Chronic Illness Therapy-Fatigue
1507,NCT03923309,3-year overall survival,2016-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
1508,NCT04927780,Overall survival,2021-09-07,RECRUITING,INTERVENTIONAL,['PHASE3'],,Patient reported Quality of Life as assessed using Exocrine Pancreatic Insufficiency (EPI) questionnaire
1509,NCT03095781,Recommended phase II dose of the combination of XL888 and pembrolizumab as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0,2017-07-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Immune profile effects of pembrolizumab and Hsp90 inhibitor XL888 assessed in serum and tumor biopsies,Response duration as assessed by RECIST 1.1
1510,NCT03718624,Conversion to negative rate,2018-10-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse events
1511,NCT05765357,Area under drug concentration - time curve (AUC0-t),2017-07-16,COMPLETED,INTERVENTIONAL,['PHASE1'],,Apparent volume of distribution (Vd/F)
1512,NCT00202774,Determine time to disease progression,2002-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Determine safety of combination, objetive response rate, time to onset of response , duration of response, time to treatment failure, one year survival time, overall survival time"
1513,NCT05024539,Regorafenib in combination with other drugs,2021-06-20,UNKNOWN,OBSERVATIONAL,['NA'],,Survival differences among the patients with different clinical phenotypes and genotypes
1514,NCT04141449,Incidence of curative-intent treatment,2020-11-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Patients treated for cancer
1515,NCT02571725,Phase 2: Objective response rate (ORR),2016-02-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Progression free survival (PFS)
1516,NCT06114251,Postoperative recurrence of liver cancer,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
1517,NCT01694238,Stoma hernia frequency at 12 months,2013-06,COMPLETED,INTERVENTIONAL,['NA'],,30 day mortality
1518,NCT04751396,Decisional conflict scale,2022-04-20,RECRUITING,OBSERVATIONAL,['NA'],,Patient's perception of usefulness of the tool
1519,NCT00634894,Median Progression-free survival (PFS): Time to progression or death from complete response (CR),2008-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
1520,NCT03314935,Phase 2: Objective Response Rate (ORR),2017-11-21,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Tlast of INCB001158 in Participants Treated With INCB001158 in Combination With Chemotherapy Following the First Dose on Cycle 1 Day 1 and on Cycle 2 Day 1 Following Repeated Dose Administration
1521,NCT01684098,,2003-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1522,NCT04220827,Incidence of adverse events,2019-12-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
1523,NCT06304350,Pathological complete remission (pCR),2024-02-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety (incidence of adverse drug reactions)
1524,NCT01084460,,1997-01,COMPLETED,OBSERVATIONAL,['NA'],,
1525,NCT02353052,Number of participants with tumor metastasis,2013-07,UNKNOWN,OBSERVATIONAL,['NA'],,
1526,NCT05060770,IBD associated CRC oncogenesis,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
1527,NCT02885142,Number of complete excision for TEM compare to number of complete excision for ESD in rectal carcinomas staged usT1N0 and rectal adenomas.,2016-11,TERMINATED,INTERVENTIONAL,['NA'],,
1528,NCT06082648,Quality of life Scale (EORTC QLQ-CR38),2023-06-01,RECRUITING,INTERVENTIONAL,['NA'],,Proctoanal manometry
1529,NCT01048320,The primary outcome measure for the study is to establish the Maximum Tolerated Dose of the drug regimen based on the endpoint of dose-limiting toxicity,2006-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Characterise safety profile of Gemcitabine Plus Oxaliplatin in Combination with imatinib mesylate (Glivec) in Patients with Gemcitabine-Refractory Advanced Adenocarcinoma of the Pancreas
1530,NCT01403883,Evolution of Psychological anxiety score (STAI/Beck),2011-10,UNKNOWN,INTERVENTIONAL,['NA'],,Specific stoma related morbidity
1531,NCT04811833,Comparison of anastomosis leakage rate at different timepoints in postoperative course,2022-07,WITHDRAWN,OBSERVATIONAL,['NA'],,Assessment of suture material handling parameters
1532,NCT04879979,Symbol Digit Modalities Test (SDMT),2021-01-12,RECRUITING,INTERVENTIONAL,['NA'],,PROMIS Short Form: Pain 3a.
1533,NCT04498689,Progression Free Survival,2019-08-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,adverse events
1534,NCT01068132,Progression free survival,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
1535,NCT02992886,2-year disease-free survival probability (%),2016-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Exploratory endpoints,QOL
1536,NCT04886193,TRG grade,2021-04-16,UNKNOWN,INTERVENTIONAL,['NA'],,the incidence and severity of adverse events
1537,NCT03468712,Postoperative overall morbidity rate,2018-03-31,UNKNOWN,INTERVENTIONAL,['NA'],,Completion rate of laparoscopic surgery
1538,NCT02838186,number of additional identified polyps with right colon scope retroflexion,2013-05,COMPLETED,INTERVENTIONAL,['NA'],,Rate of retroflexion-related adverse events.
1539,NCT05725200,"Main Study: To evaluate the anti-tumor activity, measured as objective response rate (ORR) of MTB-nominated therapies with drugs not approved or implemented in standard of care (SOC) for treatment of mCRC.",2022-09-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,Main study: Patient-reported outcome measures.
1540,NCT05450835,Early operative morbidity,2022-09-01,RECRUITING,INTERVENTIONAL,['NA'],,The number of attempts to insert anvil fork into oesophagus
1541,NCT03237507,PFS: Progression Free Survival,2017-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,Safety
1542,NCT00853931,Response rate,2009-10,COMPLETED,INTERVENTIONAL,['NA'],,Overall survival
1543,NCT00967655,2-year survival rate,2009-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
1544,NCT04496765,Local recurrence,2008-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
1545,NCT05113134,Patient and Observer Scar Assessment Scale (POSAS),2015-03-02,COMPLETED,INTERVENTIONAL,['NA'],,Female Sexual Function Index (FSFI) questionnaire
1546,NCT02345460,Number of Patients Undergoing Surgical Resection After Receiving at Least 4 of the 6 Courses of Preoperative Chemotherapy,2015-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants Experiencing Perioperative (30-day) Mortality
1547,NCT02138981,overall survival time,2014-05-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Number of Adverse Events
1548,NCT04660929,Assess the safety and tolerability of CT-0508 in combination with pembrolizumab by estimating the frequency and severity of adverse events in subjects with HER2 overexpressing solid tumors (CT-0508 and pembrolizumab substudy only),2021-02-02,RECRUITING,INTERVENTIONAL,['PHASE1'],,Estimate progression-free survival (PFS).
1549,NCT02283372,Maximum tolerated dose (MTD),2015-01-21,COMPLETED,INTERVENTIONAL,['PHASE1'],,Frequency of RT adaptation based on MR guidance
1550,NCT03937895,Phase 2a - Objective Response Rate (ORR),2019-12-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2a - Toxicity (according to CTCAE 5.0)
1551,NCT06331273,Tumor recurrence rate,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
1552,NCT06108596,cCR,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease-free survival (DFS) and overall survival (OS)
1553,NCT03485209,Confirmed ORR per blinded independent central review (BICR) (Part E),2018-06-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of anti-therapeutic antibodies (ATAs)
1554,NCT03599778,Disease-free survival (DFS),2018-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1555,NCT05019534,Evaluate tolerability and safety and identify the recommended Phase 2 dose(RP2D),2021-08-15,RECRUITING,INTERVENTIONAL,['PHASE1'],,Preliminary efficacy
1556,NCT06216561,Drug concentration in tumor,2023-11-30,RECRUITING,INTERVENTIONAL,['PHASE1'],,Adverse Events (AEs)
1557,NCT04795661,Rate of complete pathological response (pCR) after surgery,2021-10-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,The prognostic value of lung immune prognostic index (LIPI)
1558,NCT04715633,Clinical complete response or pathological complete response,2020-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
1559,NCT04522336,Clinical complete response (cCR),2020-09-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Tumor T cell infiltrate,PFS at 24 months
1560,NCT02267213,Disease Control Rate (DCR),2014-04-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,"PK parameters, including AUC, Cmax and Tmax of S,S-TLC388, S,R-TLC388, metabolites TLC-U1, TLC-U2, and topotecan"
1561,NCT02036008,Reader diagnostic accuracy using Gdfos vs. EcGd compared to gold standard,2013-08,UNKNOWN,INTERVENTIONAL,['NA'],,Reader diagnostic accuracy of EcGd-enhanced imaging vs. Gdfos-enhanced imaging compared to gold standard (subgroup analysis for small lesions less than or equal to 1cm)
1562,NCT04512937,Rate of patients with R0 resection,2020-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Progression-free survivial (PFS)
1563,NCT05092113,Overall incidence of chemotherapy-induced diarrhea ≥ grade 1,2021-06-30,UNKNOWN,INTERVENTIONAL,['PHASE3'],Changes of fecal flora and enteritis-associated inflammatory factors,Overall incidence of grade 3/4 gastrointestinal adverse events
1564,NCT01284231,Evaluate the safety profile in adult subjects with advanced gastrointestinal (GI) adenocarcinomas who have no available standard or curative treatments.,2010-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Immunogenicity of MED-565
1565,NCT04405206,OPR(organ preservation rate),2020-05-25,UNKNOWN,OBSERVATIONAL,['NA'],,SFS(stoma-free survival)
1566,NCT00003001,,1997-04,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1567,NCT05224596,Sensitivity and specificity of the cfDNA methylation-based model in detecting gastric cancer.,2021-01-18,UNKNOWN,OBSERVATIONAL,['NA'],Sensitivity and specificity of a blood miRNA-based model in detecting gastric cancer.,"Sensitivity and specificity of a ctDNA mutation-based model and a serum protein-based model in detecting gastric cancer, respectively."
1568,NCT03763266,Bowel preparation,2018-12-06,COMPLETED,INTERVENTIONAL,['NA'],,Withdrawal time
1569,NCT04539808,Proportion of participants with R0 resection,2021-05-27,RECRUITING,INTERVENTIONAL,['PHASE2'],Proportion of LAPC participants who die within 30 days of surgery,Incidence of grade >= 3 toxicities
1570,NCT05111444,Objective Response Rate (ORR),2021-12-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
1571,NCT00014651,,2001-03,TERMINATED,INTERVENTIONAL,['PHASE3'],,
1572,NCT04084496,Disease free survival,2019-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
1573,NCT01127555,Response rate,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,To estimate overall survival
1574,NCT03609151,Progression free survival,2018-06-30,UNKNOWN,INTERVENTIONAL,['NA'],,Overall survival
1575,NCT06260111,Level of Pain,2024-04-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Triceps skinfold
1576,NCT01040559,Dose-limiting toxicity assessed according NCI CTC AE v3.0,2009-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics parameters of idarubicin and idarubicinol
1577,NCT03223662,BH3 Profiling of Pre-neoadjuvant Tumor Biopsy and Outcome of Pathological Complete Response After Neoadjuvant Chemoradiotherapy in Patients With Esophageal Adenocarcinoma or Squamous Cell Carcinoma,2017-10-31,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS) in Esophageal Adenocarcinoma (EAC) and Esophageal Squamous Cell Carcinoma (ESCC) Patients Undergoing Neoadjuvant Chemoradiotherapy (nCRT) and Esophagectomy
1578,NCT06241703,urinary dysfunction,2024-02-19,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,International Prostate Symptom Score
1579,NCT02210559,Number of Participants Who Had Surgical Complications Post-Resection,2014-07-31,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Median Progression-Free Survival
1580,NCT00384176,Progression Free Survival,2006-08-30,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Time to Worsening of Health Related Quality of Life (QOL) Based on the FACT Colorectal Symptom Index (FCSI)
1581,NCT03124498,Phase II: Disease Control Rate,2017-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1582,NCT02219854,3-year disease free survival rate,2014-07,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative recovery situation
1583,NCT03166436,Survival,2017-06-08,UNKNOWN,INTERVENTIONAL,['NA'],,Augmentation of antitumor immunity
1584,NCT03652428,Maximum Tolerated Dose of Gemcitabine and nab-Paclitaxel in LAPC patients receiving proton therapy,2019-04-02,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life through and after treatment
1585,NCT01160926,To determine the MTD (maximum tolerated dose) of AZD6244 or AZD2171 when combined with pre-operative capecitabine and radiotherapy in patients with locally advanced rectal cancer.,2010-07,TERMINATED,INTERVENTIONAL,['PHASE1'],,To explore biological and radiological markers of response or toxicity
1586,NCT06320080,Progression-free survival (PFS),2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Immunogenicity
1587,NCT01214720,Duration of Overall Survival - Time to Event,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Bevacizumab Concentration in the Presence of Gemcitabine and Erlotinib
1588,NCT04863144,plasma concentrations of 3'-p-hydroxypaclitaxel,2020-08-01,UNKNOWN,OBSERVATIONAL,['NA'],,Incidence of adverse effects
1589,NCT06251115,Number of subjects with adverse events (AEs) and laboratory abnormalities defined as dose limiting toxicities (DLT),2024-01-26,RECRUITING,INTERVENTIONAL,['NA'],Efficacy: antiviral activity of QY-1-T,Efficacy: antitumor activity of QY-1-T in subjects with HBV-related HCC
1590,NCT04104334,Clinical examination and laboratory tests show no evidence of complications or untreated medical problems,2019-05-08,TERMINATED,INTERVENTIONAL,['NA'],,Rate of hospital readmission and mortality postoperative
1591,NCT00309179,"Objective tumor response (CR or PR) and disease control (CR, PR or SD) rates will be evaluated in this study based on RECIST criteria and modified WHO criteria.",2007-09-24,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Pharmacokinetics: Blood samples will be taken on Days 1, 2, and 15 during Cycle 1 and Day 1. Pharmacodynamics: Blood will be taken prior to dosing on Day 1, Days 1, 2, and 15 during Cycle 1 and Day 1."
1592,NCT01227746,,2011-09,UNKNOWN,OBSERVATIONAL,['NA'],,
1593,NCT03017690,The total time for product preparation and administration,2017-04-12,COMPLETED,OBSERVATIONAL,['NA'],,Patient satisfaction
1594,NCT02230176,To determine the 12 months PFS,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Best response
1595,NCT06234007,pathology complete response(pCR),2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events (AEs)
1596,NCT02667925,Quantification by visual analysis the intensity of fixation of the solvent characterized in the intraperitoneal cavity,2016-03,WITHDRAWN,INTERVENTIONAL,['NA'],,Correlate site of relapse to localisation of labeled intraperitoneal solvent by nanocis in peritoneal cavity
1597,NCT00907543,Quality of life as assessed by FACT-E,2009-04,COMPLETED,INTERVENTIONAL,['NA'],,Safety and morbidity
1598,NCT01452295,Gather data,2010-06,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
1599,NCT00442507,Time to Progression (TTP),2007-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Incidence and Severity of Toxicities
1600,NCT01726452,Overall survival,2013-01-24,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1601,NCT01200316,Efficacy of Rocking Chair Motion on Surgical-Induced Stress,2012-02-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1602,NCT05880992,Adherence rate,2023-07-24,RECRUITING,INTERVENTIONAL,['NA'],,Major complications
1603,NCT04580667,To determine the cut-off values from the RadTox test results during early radiation treatment from all evaluable subjects to differentiate high toxicity score from average or low toxicity score.,2020-10-01,RECRUITING,OBSERVATIONAL,['NA'],,To determine the cut-off values from the RadTox test performed during early radiation treatment with patients categorized according to demographics and treatment options to differentiate high toxicity score from average or low toxicity score.
1604,NCT01543607,Safety: Number of Bile Leak After RFA Procedure,2012-02,TERMINATED,INTERVENTIONAL,['NA'],,Effectiveness: Change From Baseline in Bile Duct Diameter.
1605,NCT02490735,progression-free survival(PFS),2015-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Stage at diagnosis,overall survival(OS)
1606,NCT04278287,Local control rate,2019-10-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,ctDNA analysis
1607,NCT00202800,To evaluate the response rate,2002-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,To describe the toxicity profile
1608,NCT01198535,MTD of RO4929097,2010-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,
1609,NCT02302794,3-year disease free survival rate,2014-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
1610,NCT05783622,Incidence of Clinically Significant Laboratory Abnormalities,2023-04-19,RECRUITING,INTERVENTIONAL,['PHASE1'],,Correlation of EGFR expression level with anti-tumor activity and safety
1611,NCT05983133,Number of participants with DLTs by dose level,2023-11-14,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
1612,NCT04098471,5-years disease free survival rate,2019-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,postoperative quality of life as assessed by EORTC QLQ-C30 questionnaire
1613,NCT04528745,Thrombocytopenia,2020-05-04,COMPLETED,OBSERVATIONAL,['NA'],Other adverse event(s) added by patient,Hospitalization
1614,NCT01526239,Communication with primary care physicians about CRC screening,2008-11,COMPLETED,INTERVENTIONAL,['NA'],,
1615,NCT05473325,Signal to Noise,2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
1616,NCT00555672,Number of Participants With First-cycle Dose Limiting Toxicities (DLTs),2008-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression-Free Survival (PFS)
1617,NCT05604378,EBV positive gastric cancer is associated with increased Ki-67 and decreased EGFR.,2022-08-03,COMPLETED,OBSERVATIONAL,['NA'],,
1618,NCT00897039,Correlation of a statistically significant discriminator of sensitivity with complete response rate,2006-03,UNKNOWN,OBSERVATIONAL,['NA'],,
1619,NCT02572141,Disease-free survival,2015-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Postoperative complications
1620,NCT02248519,Post-operative hospital stay,2014-12,UNKNOWN,INTERVENTIONAL,['NA'],Time to return to daily activity,Oncologic outcomes (R0-resection rate and lymph node yield)
1621,NCT01135056,Overall Survival,2010-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Disease control rate
1622,NCT06261138,Progression Free Survival (PFS) per mRECIST,2019-02-01,COMPLETED,OBSERVATIONAL,['NA'],,Adverse events (AEs)
1623,NCT02343835,Characterization of the intra-tumoral and systemic immune response to IRE in unresectable pancreatic cancers,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],Overall survival and (local and distant) progression-free survival.,Comparison immune response between non-ablated and ablated pancreatic cancer and pre-ablated and post ablated serum
1624,NCT02637596,Quality of life after RFA of pancreatic cancer,2013-02,COMPLETED,INTERVENTIONAL,['NA'],Overall Survival,3- months perioperative morbidity and mortality
1625,NCT00601406,"Correlation of association between common genetic variations, reported by single nucleotide polymorphisms (SNP) in relevant candidate genes, with individual patient variability in normal tissue radiation response and toxicity",2006-03,UNKNOWN,INTERVENTIONAL,['NA'],,"PRS analyses against tumor control probability (TCP), using survival as a surrogate for TCP where necessary, and normal tissue complications vs tumor control probability"
1626,NCT03165344,Esophageal stenosis rate,2017-02-10,COMPLETED,INTERVENTIONAL,['NA'],,Side effect of drugs
1627,NCT01811277,Objective response rate for SOX sequential S-1,2010-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of Participants with Adverse Events as a Measure of Safety and Tolerability
1628,NCT03677960,Maximum Tolerated Dose (MTD) of ABI-1968 for the treatment of aHSIL,2018-12-17,TERMINATED,INTERVENTIONAL,['PHASE1'],Histopathology of areas with biopsy-proven disease following multiple doses of ABI-1968 Topical Cream.,Systemic exposure to ABI-1968 Topical Cream following topical application to the anal canal.
1629,NCT02944539,Relative copy number of mitochondrial DNA,2016-03,COMPLETED,OBSERVATIONAL,['NA'],,
1630,NCT05967143,Change scores from baseline to follow-up timepoints of the European Organization for Research and Treatment of Cancer Quality of Life Hepatocellular Carcinoma module (EORTC QLQ-HCC18),2023-06-19,RECRUITING,OBSERVATIONAL,['NA'],,Healthcare Resource Utilization summarized at follow-up timepoints
1631,NCT03273647,Disease-free survival time,2017-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,overall survival time
1632,NCT02795156,Overall Response Rate (ORR) in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations,2016-09-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-Free Survival in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations
1633,NCT02890979,Detection of gene mutations using next generation sequencing (NGS),2016-08-03,COMPLETED,INTERVENTIONAL,['NA'],,Sensitivity and specificity of the NGS probes to detect underlying esophageal dysplasia or cancer
1634,NCT00843375,Biospecimen Retention: Samples with DNA,2019-08-07,RECRUITING,OBSERVATIONAL,['NA'],,
1635,NCT03758209,Change in preoperative functional status - FVC by the end of rehabilitation,2018-11-01,COMPLETED,INTERVENTIONAL,['NA'],,"Delay in beginning of adjuvant oncotherapy (chemotherapy, radiotherapy)."
1636,NCT02715492,Number of patients with portal vein thrombosis,2018-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
1637,NCT02602249,Reduced size of the tumor.,2017-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],,"Safety, as measured by the rate of adverse events and serious adverse events"
1638,NCT05985239,Calculation postoperative of the Comprehensive Complication Index (CCI) for each patient,2023-01-01,RECRUITING,OBSERVATIONAL,['NA'],Adjuvant chemotherapy in patients after low anterior resection for rectal cancer.,Total hospitalization costs
1639,NCT00005809,,2000-07,COMPLETED,INTERVENTIONAL,['NA'],,
1640,NCT02805829,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2017-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",T cell subsets figures,Number of Participants with tumor recurrence metastasis as a Measure of effectiveness
1641,NCT03470350,Phase II: Response rate (RR) of galunisertib in combination with capecitabine in patients with chemotherapy resistant activated TGF-β signature-like CRC.,2018-08-24,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Baseline molecular status of potential predictive markers of tumor response
1642,NCT02539342,"Measure the Development of Oral Mucositis (Grade >/= 2) in Children, Adolescents and Young Adults.",2016-10,TERMINATED,INTERVENTIONAL,['PHASE3'],Tolerability of Four Times Daily Caphosol Therapy,
1643,NCT05241210,Adenoma Detection Rate,2021-12-13,RECRUITING,INTERVENTIONAL,['NA'],,
1644,NCT00313794,"To assess the best overall response rate per RECIST (BRR) in patients with metastatic adenocarcinoma of the colon or rectum treated with CP-675,206 .",2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To obtain pharmacokinetic (PK) data to be evaluated in a future meta analysis of CP-675,206 pharmacokinetics."
1645,NCT06313801,Complications from polychemotherapy.,2023-01-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,Аssessment of the quality of life
1646,NCT05445245,Self-report Questionnaire,2022-04-14,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
1647,NCT02199236,maximum tolerated dose (MTD),2014-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,tumor response
1648,NCT04442581,Number of Participants With Objective Response (Complete or Partial Response),2021-04-20,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events
1649,NCT00033657,Pathologic Complete Response Rate,2002-08-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Recurrence-free Survival Time
1650,NCT00164879,The stoma rate in the two groups of patients,2000-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Hospital stay
1651,NCT00055419,"The objective of this study will be to monitor the safety of administering cetuximab,via an access program, to subjects with metastatic colorectal carcinoma who have exhausted all standard therapies or treatment options.",2003-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1652,NCT04475640,Impact of germline genetic testing on both therapeutic management and targeted cancer prevention,2019-12-13,RECRUITING,INTERVENTIONAL,['NA'],,
1653,NCT03706742,Hepatitis C Screening,2018-09-10,COMPLETED,INTERVENTIONAL,['NA'],,Cost: Cost per-HCV diagnosis
1654,NCT00639509,Best Overall Response Rate (ORR),2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival
1655,NCT00923299,Objective response rate as assessed by RECIST criteria (Phase II),2008-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
1656,NCT05915351,Overall Response Rate (ORR),2023-06-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
1657,NCT06061328,Maintenance as assessed by maintenance of other measures,2024-02-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Feasibility of Intervention Measure (FIM)
1658,NCT06173310,To measure the reproducibility of qDCE-MRI measurement of BRPC.,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
1659,NCT02115022,Staging capability of each study procedure,2014-07,COMPLETED,OBSERVATIONAL,['NA'],,"Patient survival time, and tumor recurrence-free survival"
1660,NCT03508180,Evaluation of nausea and vomiting,2018-06-14,COMPLETED,INTERVENTIONAL,['NA'],,Body image
1661,NCT03082833,Objective response rate (ORR) by RECIST 1.1,2017-02-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,
1662,NCT02033213,Changes in Lactate Levels During Esophageal Carcinoma Surgery Using Restrictive or Liberal Fluid Management.,2011-06,COMPLETED,INTERVENTIONAL,['NA'],,Total Volume of Administered Intraoperative Fluid
1663,NCT00677079,Objective response rate,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Cancer antigen 125 response (participants with elevated CA125)
1664,NCT01904955,data concerning evolving relapse,2010-09,COMPLETED,OBSERVATIONAL,['NA'],,
1665,NCT02395016,overall survival（OS）,2015-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,To determine the safety of the treatment with Nimotuzumab and Gemcitabine (NCI Common Terminology Criteria for Adverse Events v4.03)
1666,NCT01871571,Rate of CPR in the pathology specimen,2013-08-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence and nature of AEs of special interest for bevacizumab (grades) according to NCI CTCAE v4.0
1667,NCT00450424,Impact of Standard Informed Consent vs CD-ROM Educational Intervention on Knowledge About Microsatellite Instability (MSI) Testing,2007-06,COMPLETED,INTERVENTIONAL,['NA'],,Patient Satisfaction With the Preparation to Make a Decision
1668,NCT04298320,Incidence of Treatment-Emergent Adverse Events,2020-03-15,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,PFS
1669,NCT00789893,To examine the effect of dilator use in minimizing vaginal stenosis so that patients are able to use the pre-radiation baseline dilator size 6 months after starting dilator use.,2008-11,COMPLETED,OBSERVATIONAL,['NA'],,To explore patient-reported self-efficacy as it relates to the use of the vaginal dilator.
1670,NCT02047188,NBI prediction for lesion histology and invasion,2010-01,COMPLETED,OBSERVATIONAL,['NA'],,immunohistochemical outcome of microvessel count and MMP-7
1671,NCT00953511,histopathologic response to chemoradiation,2009-08,COMPLETED,INTERVENTIONAL,['NA'],,prognosis
1672,NCT06161207,3-year disease free survival rate,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Postoperative quality of life (measured by EQ-5D)
1673,NCT04128332,The feasibility of delivering pre-operative SABR followed by immediate surgery as determined by rate of post-operative complications at 30 days.,2020-10-26,UNKNOWN,INTERVENTIONAL,['NA'],,Acute and late toxicity of pre-operative SABR: Number of adverse events
1674,NCT05600608,"To determine the diagnostic accuracy of the augmented exhaled breath test, in the prediction of oesophago-gastric cancer (OGC).",2022-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,To identify the mechanistic pathways and origins of the production of breath Volatile compounds by investigating the tumour lipidome.
1675,NCT04819971,Percentage of Participants With Pathological Complete Response (pCR),2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Percentage of All Participants That Discontinued Study Treatment Due to AE
1676,NCT01002443,Histological grading improvement rate,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1677,NCT01583361,disease free survival,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,safety
1678,NCT03942900,Peripheral CD4 anti-telomerase immunity and MDSC (Myeloid-Derived Suppressor Cells) analysis,2020-04-01,WITHDRAWN,OBSERVATIONAL,['NA'],,
1679,NCT03985046,Local Control Rate,2019-10-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
1680,NCT01606098,Overall survival,2012-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall survival in patients in whom treatment according to protocol was initiated
1681,NCT02162641,The proportion of nodes detected will be expressed per inguinal nodal basin and per number of patients,2014-09,WITHDRAWN,OBSERVATIONAL,['NA'],,Delays in receiving radiotherapy treatment
1682,NCT05839197,Objective remission rate (ORR),2023-05-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events and toxicities of Apatinib in combination with Camrelizumab
1683,NCT00328770,Percentage of Participants Surviving With no Evidence of Recurrent Tumor at One and Four Years After Liver Transplant,1996-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Sirolimus Toxicity/Intolerance
1684,NCT00615056,Progression Free Survival (PFS),2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Change From Baseline in MDASI-D Symptom Interference Score at Day 1 of Cycles 2-5, Day 1 of Every Odd-numbered Cycle Throughout the Study and End of Treatment (Cycle 65) or Withdrawal"
1685,NCT03630640,Local recurrence-free survival during a 1-year follow-up after Nivolumab neoadjuvant/adjuvant therapy and EP procedure,2018-10-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Frequency of discontinuations treatment due to AEs
1686,NCT04850027,Disease free survival,2021-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Postoperative complications
1687,NCT02423278,Relapse-free Survival,2010-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Length of Hospital stay
1688,NCT01109615,Response rate,2010-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall survival
1689,NCT06320990,"Feasibility, by retention rate",2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Objective response rate (ORR) of pancreatic MCN
1690,NCT05296369,Progression-free survival(PFS),2022-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
1691,NCT00727441,"Change in the Number and Function of Peripheral Mesothelin-specific CD8+ T Cells and CD4+, FoxP3+, and GITR+ Tregs",2008-07-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Free Survival
1692,NCT05482529,disease free survival rate,2022-08-01,RECRUITING,OBSERVATIONAL,['NA'],,R0 resection rate
1693,NCT05550025,Objective response rate (ORR) by RECIST 1.1 and mRECIST,2021-12-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,The median overall survival time (mOS)
1694,NCT03587532,An ICGA based cutoff point to predict anastomotic leakage and graft necrosis after esophageal reconstructive surgery.,2021-12-13,RECRUITING,INTERVENTIONAL,['NA'],,pulse pressure
1695,NCT00503685,"Percentage of Participants With Complete Response (CR) or Partial Response [PR, Objective Response Rate (ORR)]",2007-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Expression of IGF Binding Proteins (IGFBP2, IGFBP3)"
1696,NCT01804998,3 year disease free survival rate,2013-03-27,COMPLETED,INTERVENTIONAL,['NA'],,5 year disease specific death rate
1697,NCT05210283,To validate the association of circulating tumor DNA (ctDNA) with recurrence-free interval (RFI).,2021-12-15,RECRUITING,OBSERVATIONAL,['NA'],,To assess time from positive ctDNA to clinical recurrence
1698,NCT00056030,Surgical resectability rate as assessed by surgical resection of liver metastases,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life as assessed by UNISCALE and Symptom Distress Scale every 6 weeks
1699,NCT03122509,Overall Response Rate,2017-04-24,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1700,NCT04913077,Rate of GIST tumors,2020-03-10,SUSPENDED,INTERVENTIONAL,['NA'],,data for cost-benefit calculation
1701,NCT04227353,Data completion rates,2021-01-30,COMPLETED,INTERVENTIONAL,['NA'],,Change in Quality of life
1702,NCT03396029,A questionnaire-based lifestyle score,2014-11-01,COMPLETED,INTERVENTIONAL,['NA'],,Body weight
1703,NCT02494791,Cost-effectiveness of universal enhanced screening strategy to identify women with Lynch Syndrome and their family members via cascade testing,2015-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Discovery of novel genetic mutations and molecular events in unexplained MMR loss (Lynch-like Syndrome)
1704,NCT03109886,Overall Safety Profile,2017-07-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of overall Response (DoR)
1705,NCT06177496,overall survival,2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Progression-free survival
1706,NCT04888806,12-month progression-free survival (PFS),2021-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival(OS)
1707,NCT04536077,Amount of intratumoral conventional dendritic cells (cDCs),2021-08-13,TERMINATED,INTERVENTIONAL,['PHASE2'],,
1708,NCT01569672,"Amount of time from abnormal evaluation of the breast, cervix, and colon or rectum to needed tests and treatment",2006-11,COMPLETED,INTERVENTIONAL,['NA'],,Number of barriers and effect of barriers on receiving needed tests and treatment
1709,NCT04612530,Safety of the combination treatment IRE + immunotherapy based on adverse events,2020-09-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Pain based on the Visual Analog Score (VAS)
1710,NCT04751370,Pathological complete response,2022-02-08,SUSPENDED,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
1711,NCT00816634,Response rates of both regimens,2008-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,a) progression-free survival b) quality of life c) toxicity d) overall survival e) predictive markers
1712,NCT05721885,Degree of radiation-induced oral mucositis (RTOG criteria),2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
1713,NCT00507143,SLCO1B1 and PXR genotypes and pharmacokinetics of SN-38,2006-08,UNKNOWN,INTERVENTIONAL,['NA'],,"SLCO1B1 and PXR genotypes and response duration, time to progression and overall survival"
1714,NCT00897923,"Cellular uptake of PBMCs and PMNLs as measured by reader/visual interpretation, semiquantitative grading system, and tumor-to-background uptake ratios",2003-09,COMPLETED,OBSERVATIONAL,['NA'],,
1715,NCT04809935,Pain score,2020-09-21,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Cost-effectiveness of two types approach
1716,NCT00045526,Major response rate (complete and partial response),2002-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
1717,NCT05997056,Efficacy of nab-sirolimus,2023-11-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
1718,NCT01318239,MR perfusion parameter,2010-07,COMPLETED,INTERVENTIONAL,['NA'],,diffusion parameter
1719,NCT03825328,OS,2019-01-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
1720,NCT05990959,Disease free survival,2022-04-22,RECRUITING,OBSERVATIONAL,['NA'],,
1721,NCT05099848,Surgical conversion rate,2021-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
1722,NCT05554367,ORR (Cohort 4),2023-12-13,RECRUITING,INTERVENTIONAL,['PHASE2'],Plasma RAS allelic burden in in relation to response (Cohorts 3 and 4),Incidence of adverse events (AE) (All Cohorts)
1723,NCT06324097,negative predictive value,2024-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,intra-observer agreement
1724,NCT01111838,To Determine Overall Objective Response.,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1725,NCT04791735,The primary objective of the study will be to demonstrate the superiority of the laparoscopic approach over the open approach in reducing postoperative morbidity in HCC patients.,2021-05-21,RECRUITING,INTERVENTIONAL,['NA'],,Overall and disease free survivals.
1726,NCT00021138,,2001-04,COMPLETED,INTERVENTIONAL,['NA'],,
1727,NCT05233358,Progression Free Survival,2022-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,The incidence of adverse events and serious adverse events
1728,NCT01147380,Side Effect of Cadaveric Donor Liver NK Cell Infusion,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Anti-HCV Effect of This Treatment (If Applicable)
1729,NCT02887235,Quality of life measurement,2016-03,COMPLETED,INTERVENTIONAL,['NA'],,Food security assessment plus HDMTM from baseline to 12 weeks
1730,NCT01556399,Significant differences in molecular abnormalities.,2011-11,COMPLETED,OBSERVATIONAL,['NA'],,
1731,NCT02448056,Patient survival,2015-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
1732,NCT05301699,postoperative complications during hospitalization,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
1733,NCT03657641,Overall survival (OS),2019-06-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1734,NCT01523639,Reduction in the chemotherapy-associated steatosis,2012-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Reduction in chemo-therapy associated steatohepatitis (CASH)
1735,NCT00209742,3-years disease-free survival rate (DFS),2005-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"Dose intensity (compliance), 5-year disease-free survival rate, 3- and 5-year survival rate, incidence of other adverse drug reactions, QOL"
1736,NCT01107639,Progression-free survival (PFS),2010-05-27,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time to progression (TTP)
1737,NCT04967495,Overall survival (OS),2021-07-09,RECRUITING,INTERVENTIONAL,['NA'],,Duration of portal patency
1738,NCT06160323,The mean change in VAS pain score at 3 months,2023-11-10,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
1739,NCT05349045,PFS,2022-05-05,RECRUITING,OBSERVATIONAL,['NA'],,OS
1740,NCT00016978,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1741,NCT00191568,"To evaluate recurrence free one year survival, time to disease progression and local recurrence rate, analyzed at the end of the study",2002-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,To assess overall survival at the end of the 24 months follow up period;To assess acute and late toxicity (every month for the first 3 months and then every three months for 24 months after treatment discontinuation)
1742,NCT01872377,Toxicity defined as grade 3 or 4 gastro-intestinal or other non-haematological toxicity,2013-07,TERMINATED,INTERVENTIONAL,['NA'],,CyberKnife radiation dose measured in Gy delivered to the tumour and surrounding organs vs. the frequency of grade 3-4 toxicity defined by CTCAE v4.0
1743,NCT03232814,Adherence rates,2017-10-05,WITHDRAWN,INTERVENTIONAL,['NA'],,Participants' Overall Experiences: Qualitative Interviews
1744,NCT01938027,Total Mesorectal Excision(TME) quality,2013-09,COMPLETED,INTERVENTIONAL,['NA'],"Oncologic outcome(2-year local recurrence free survival, 5-year survival)","30-day postoperative complications, No. of harvested LN"
1745,NCT00814619,Pathological complete or near-complete response (Dworak grade 3 and 4),2008-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse events
1746,NCT03021668,Rate of Surgical Site Infection,2017-01,COMPLETED,INTERVENTIONAL,['NA'],,30-d Readmission
1747,NCT03099486,Progression Free Survival (PFS) at 2 Months,2017-10-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Toxicities Due to Regorafenib and 5-FU/LV Combination Therapy
1748,NCT04663035,1-year recurrence-free survival (RFS) rate,2020-12-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Evaluate the patient's cancer-related QoL using the European Organization for Research and Treatment of Cancer (EORTC) QOL questionnaire (QLQ), the EORTC QLQ-C30 and the EORTC QLQ-HCC18."
1749,NCT01534546,3 year Disease Free Survival,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Adverse Event
1750,NCT02396745,Safety: Long-term (Study Related Adverse Events),2016-01-25,TERMINATED,INTERVENTIONAL,['NA'],,Additional Interventions (Number of Subsequent Follow up Treatment Interventions)
1751,NCT04181645,ORR：Objective Response Rate by IRC,2019-06-29,UNKNOWN,INTERVENTIONAL,['NA'],,OS: overall survival
1752,NCT04550260,Progression free survival (PFS) per RECIST 1.1 as assessed by BICR,2020-10-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Adverse events (AEs),Progression free survival (PFS) per RECIST 1.1 as assessed by BICR
1753,NCT06242418,change in value of ctDNA concentration,2024-03-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,quality of life as assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30).
1754,NCT02626312,Maximum dose constraint,2016-02-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Tumor biomarker expression in serum,Overall survival
1755,NCT00188565,- To determine the efficacy of celecoxib in combination with preop RT and continuous infusional 5-FU. Pathologic complete response rate (pCR) will be used as the endpoint.,2004-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Quality of life (FACT, EORTC)"
1756,NCT02363218,Overall survival rate,2014-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Progression-free survival
1757,NCT01940237,Change in Hamilton Depression Scale (HAMD-17),2012-04,TERMINATED,INTERVENTIONAL,['NA'],,
1758,NCT04698915,Median Overall Survival after SBRT completion,2021-05-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,Median Progression Free Survival after SBRT Completion per RESIST 1.1
1759,NCT05284864,Determine and compare morbidity and mortality rates in patients with early and late stoma closure,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],"Determine the patient's percentage with anterior resection syndrome, after early and late ileostomy closure assisted by the LARS scale.",Determine and analyze quality of life assisted by the SF36 scale in early vs late ileostomy closure
1760,NCT00682786,Rate of Tumor Downstaging Compared With Historical Controls.,2002-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Determine Patient Fears and Expectations of Pharmacogenetics.
1761,NCT00120939,"Determine the Dose Limiting Toxicity at 8 weeks (2 cycles), and the Maximum Tolerated Dose at 24 weeks.",na,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Tumor response rate 8, 16 and 24 weeks, and common PK parameters at 24 weeks"
1762,NCT03407417,Completion of initial FIT screening,2018-11-08,RECRUITING,INTERVENTIONAL,['NA'],,Completion of repeat Annual FIT screening
1763,NCT00216437,Dose-limiting toxicity.,2004-12,TERMINATED,INTERVENTIONAL,['PHASE1'],,
1764,NCT05687318,PMR,2022-09-20,COMPLETED,INTERVENTIONAL,['NA'],,AMR
1765,NCT00020501,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1766,NCT00844168,Dose-limiting toxicity (DLT) as defined by the Common Terminology for Adverse Events (CTAE) version 3,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1767,NCT03627559,Pyruvate concentration postoperatively,2013-10-01,COMPLETED,OBSERVATIONAL,['NA'],,
1768,NCT03125980,3-year disease free survival,2017-05,RECRUITING,INTERVENTIONAL,['PHASE3'],,Relapse-free survival (RFS)
1769,NCT05698992,General Quality of life,2023-02-27,RECRUITING,OBSERVATIONAL,['NA'],Discharge destination,Rehabilitation process
1770,NCT06256185,Sub-analysis (ML Model vs. Logistic Model vs. NCCN Guideline),2010-01-15,COMPLETED,INTERVENTIONAL,['NA'],,
1771,NCT02204306,disease control rate,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],drug toxicities,median overall survival
1772,NCT02745483,Cumulative 3-year LTP rate,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Technical success rate,3-year Recurrence free survival rate
1773,NCT00346099,Percentage of patients with clinical complete response rate in tumor in the pelvis at 4 to 6 weeks after completion of radiation therapy,2006-06,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,The toxicity of panitumumab in combination with chemotherapy and in combination with chemoradiotherapy
1774,NCT05795374,Postoperative morbidity.,2022-03-01,COMPLETED,OBSERVATIONAL,['NA'],,Recurrence
1775,NCT06156748,Overall survival,2019-10-01,RECRUITING,OBSERVATIONAL,['NA'],,
1776,NCT06199973,Progressive free survive assessed by Independent Review Committee,2024-03-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Effectiveness: overall survive assessed by the researchers
1777,NCT04046133,Safety and tolerability- 12 months post CRT,2020-10-19,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Patient reported outcome - 12 months follow up
1778,NCT05466565,recurrence-free survival time,2021-12-01,RECRUITING,OBSERVATIONAL,['NA'],,Dynamic changes of cccDNA
1779,NCT05356585,Detectable ctDNA at the Completion of TNT,2023-12-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],The correlation of ctDNA at end of TNT with relapse-free survival,Correlation of Complete Response TNT
1780,NCT03821948,Blood-based biomarkers associated with genetic and epigenetic alterations.,2019-01-03,COMPLETED,OBSERVATIONAL,['NA'],,
1781,NCT05131958,Perception measure,2021-12,UNKNOWN,OBSERVATIONAL,['NA'],,
1782,NCT03493152,,na,TEMPORARILY_NOT_AVAILABLE,EXPANDED_ACCESS,['NA'],,
1783,NCT01785537,Change from baseline in the number of traditional cigarette smoked,2013-10,UNKNOWN,OBSERVATIONAL,['NA'],,Traditional and electronic smoking (overall smoking) cessation
1784,NCT03750669,Disease-free survival,2018-10-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Serious adverse events incidence
1785,NCT05620732,AE/SAE,2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],,ORR
1786,NCT02845973,differences in abundance of gut microbiota,2012-01,COMPLETED,OBSERVATIONAL,['NA'],diet difference in patients with different clinical outcomes,evidence of colorectal neoplasia
1787,NCT03111368,Diagnostic yield,2015-04-27,COMPLETED,INTERVENTIONAL,['NA'],,
1788,NCT02042859,"Improvement in size(patency of bile duct) measured by cholangiography or cholangioscopy, immediately post ablation",2013-02,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
1789,NCT00063427,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1790,NCT00980603,response rate,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,time to progression
1791,NCT02459041,Strain histogram and contrast enhancement during EUS in pancreatic masses and lymph nodes,2015-01,COMPLETED,OBSERVATIONAL,['NA'],,
1792,NCT03878524,Feasibility of implementing an individualized treatment strategy (number of participants to receive first dose),2020-04-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,Time to decline (TTD)
1793,NCT06090825,Descriptions and scores of real status of hospice care in different hospitals,2023-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
1794,NCT04592029,Progression free survival (PFS) assessed by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune-related RECIST (irRECIST).,2020-09-27,UNKNOWN,INTERVENTIONAL,['PHASE1'],,DOR assessed by investigators according to mRECIST.
1795,NCT05582018,Safety,2023-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Precision,Assessment Module (1)
1796,NCT05669521,Mucositis,2022-06-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Secondary efficacy/outcome mucositis
1797,NCT05453630,Number of participants who complete colonoscopy within 1 year of the colonoscopy referral,2022-06-16,RECRUITING,INTERVENTIONAL,['NA'],,Number of participants who have colonoscopies with cecal intubation
1798,NCT01073046,Influence of Naso-Gastric/Jejunal Tube on Postoperative complications,2010-01,COMPLETED,OBSERVATIONAL,['NA'],,Influence of Naso-Gastric/Jejunal Tube on Postoperative Patient's Comfort
1799,NCT01563133,Descriptive criteria in nCLE sequences for the characterization of pancreatic masses and lymph nodes,2012-06,UNKNOWN,INTERVENTIONAL,['NA'],,Feasibility and safety data on nCLE during EUS-FNA procedure
1800,NCT03382600,Objective Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR),2018-03-26,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants Discontinuing From Study Treatment Due to AE(s)
1801,NCT06018857,Overall Survival,2017-05-11,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
1802,NCT04885283,Time to Start Postoperative Chemotherapy,2021-01-20,COMPLETED,OBSERVATIONAL,['NA'],,
1803,NCT02216149,Frequency of coronary artery dysfunction,2015-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Survival status
1804,NCT05634720,Feasibility of HA Chemotherapy for PDAC,2024-01-02,RECRUITING,INTERVENTIONAL,['PHASE4'],,Overall Survival
1805,NCT00667628,Time to Appearance of New Lesions (TTNL),2008-04-24,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
1806,NCT03286738,percentage of use FOLFIRI regimen and target agents,2015-11,UNKNOWN,OBSERVATIONAL,['NA'],,
1807,NCT03631173,Total hospital stay,2019-04-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Number of patients expired at an average of 10 days,Risk factors of postoperative pancreatic fistula at 90 days after surgery
1808,NCT05445401,DMSM score,2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Postoperative complication rate of grade IIIa or above.
1809,NCT03908788,Proportion of patients with mCRC (metastatic colorectal cancer) who develop a RAS (rat sarcoma viral oncogene homolog) mutation under anti-EGFR (epidermal growth factor receptor) therapy,2018-07-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Evaluation of the following criterion: frequency of mutated alleles
1810,NCT05215379,The rate of cCR,2022-10-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,quality of life
1811,NCT00423293,Percentage of Subjects With Acute Gastrointestinal (GI) and Genitourinary (GU) Adverse Events (AE) ≥ Grade 2 as Defined by CTCAE v3.0 (Common Terminology Criteria for Adverse Events),2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Five-Year Rate of Colostomy-free Survival
1812,NCT02461043,3 year relapse free survival,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],5 year overall survival,3 year overall survival
1813,NCT00002933,Effectiveness of irinotecan in treating patients who have metastatic or recurrent colorectal cancer.,1996-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1814,NCT00262990,To show superiority of patupilone in overall survival compared to doxorubicin in taxane/platinum resistant patients with ovarian cancer,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,To explore relationships between Cmin (pre-dose patupilone blood concentration) and efficacy/adverse events
1815,NCT00056992,,2002-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1816,NCT03832985,Initiation of risk reduction behavior,2020-11-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Health Education Impact Questionnaire (heiQ)
1817,NCT03489707,Compliance as assessed by the number of participants who provide specimens for annual anal HPV DNA screening,2020-01-09,COMPLETED,INTERVENTIONAL,['NA'],Host/viral methylation and its association with high-grade squamous intraepithelial lesions.,Number of participants who attend high resolution anoscopy
1818,NCT01470404,germline polymorphisms in xenobiotic metabolism genes in toxicity profile,2008-07-10,COMPLETED,OBSERVATIONAL,['NA'],,
1819,NCT04138381,Clinical benefit rate (CBR) for the use of selinexor in monotherapy,2019-08-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Clinical benefit rate (CBR)
1820,NCT05303818,Deep venous thrombosis and embolic pulmonary disease,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],,Safety of rivaroxaban
1821,NCT02817126,Locoregional recurrence rate,2016-07-10,UNKNOWN,INTERVENTIONAL,['NA'],,Self reported sexual function for female patients
1822,NCT02228785,Antibody Levels,1994-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Intra-gastric pH
1823,NCT05604573,detection sensitivity of genetic mutation by mmADPS,2022-02-09,RECRUITING,OBSERVATIONAL,['NA'],,correlation of genetic mutation and prognosis
1824,NCT00005926,,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1825,NCT04806464,Part2:ORR,2021-03-16,UNKNOWN,INTERVENTIONAL,['PHASE1'],,"Part 2:PD-L1, PD-1"
1826,NCT03647839,Objective response per iRECIST,2018-09-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
1827,NCT04720521,Detection rate of gastric neoplastic lesion,2019-05-10,UNKNOWN,INTERVENTIONAL,['NA'],,Sensitivity of detecting gastric neoplastic lesion
1828,NCT02268435,Maximal tolerated dose and recommended dose,2015-03,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,"Imatinib and dovitinib plasma concentrations vs time profile, and basic pharmacokinetics parameters"
1829,NCT01196390,Disease-free Survival (DFS),2011-02-14,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Any Cardiac Adverse Events Regardless of Attribution
1830,NCT05214339,Objective response rate (ORR) by RECIST 1.1,2022-03-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
1831,NCT00005077,,2000-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1832,NCT02316834,Change in ribonucleic acid (RNA) protein expression,2015-06-02,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Change in RNA protein expression
1833,NCT02576964,Objective response rate,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
1834,NCT03396614,The cardiopulmonary (dys)function in EC survivors treated with neo-CRT followed by surgical resection will be compared to cardiopulmonary (dys)function in EC survivors treated with surgical resection alone.,2017-10-21,COMPLETED,OBSERVATIONAL,['NA'],,
1835,NCT03301454,Estimate the overall survival for patients suffering from Esophageal cancer,2018-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Estimate the consequences of pursuing chemotherapy
1836,NCT00005640,Number of Procedures Resulting in Improved Detection,1999-06,COMPLETED,INTERVENTIONAL,['NA'],,
1837,NCT03073694,Comprehensive Complication Index (CCI) score.,2017-07-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,
1838,NCT06060990,Serum copper (Cu) as a predictive biomarker of the response to systemic treatment of biliary tract cancer patients,2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],,
1839,NCT01194206,Rate of downstaging of stage B and C Hepatocellular Carcinoma using Stereotactic Body Radiotherapy,2010-08,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Survival rate
1840,NCT02597465,"Progression Free Survival (PFS) of subjects treated with SPARC1507 versus IC, per Response Evaluation Criteria in Solid Tumors version 1.1",2018-12-01,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
1841,NCT01606241,"Proportion of patients who experience severe toxicities (grades 3-5 of the National Cancer Institute's Cancer Therapy Evaluation Program [CTEP] Common Terminology Criteria for Adverse Events, version 4.0)",2012-07-24,COMPLETED,INTERVENTIONAL,['PHASE1'],Percent change in antigen-specific cytokine profiles,Percentage change in plasma concentration of cytokines and chemokines
1842,NCT03744247,Overall Survival (OS),2019-04-21,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Time to Progression (TTP)
1843,NCT00199173,,na,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1844,NCT05983367,Overall Response Rate,2023-10-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease Control Rate
1845,NCT04953585,overall survival time,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
1846,NCT05664178,Participant Treatment Outcome,2023-02-20,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1847,NCT02358395,Pharmacokinetic profile of BBI608 when administered in combination with Sorafenib.,2015-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival
1848,NCT01310699,Number of Participants With Nonpolypoid (Flat and Depressed) Colorectal Neoplasm,2013-01,COMPLETED,INTERVENTIONAL,['NA'],,Percentage of Nonpolypoid (Flat) Missed Lesions
1849,NCT05378867,AUCtau，Area under the curve over the dosing interval,2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,DOR，Duration of response
1850,NCT01250015,Comparison of the two groups' overall wish to be screened,2007-09,COMPLETED,OBSERVATIONAL,['NA'],,Impact of different summary points on subject's desire to be screened
1851,NCT03828318,Global quality of life (QoL),2019-09-01,RECRUITING,INTERVENTIONAL,['NA'],,
1852,NCT04724070,Construction of a personalized drug screening platform for individuals using novel cancer models established from patient-derived cancer cells and tissues.,2019-10-16,RECRUITING,OBSERVATIONAL,['NA'],,Describe the prevalence of actionable genomic aberrations in patients with advanced cancers in Hong Kong
1853,NCT05328960,Yearly incidence of rectal cancer,2022-02-15,RECRUITING,OBSERVATIONAL,['NA'],,Treatment changes
1854,NCT05040347,Concentration of NETs markers and anti-β2 glycoprotein I,2020-08-18,COMPLETED,OBSERVATIONAL,['NA'],,
1855,NCT02689284,Duration of Response,2016-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Terminal Half-life
1856,NCT01416168,Feasibility of the Intervention,2008-12,COMPLETED,INTERVENTIONAL,['NA'],,Effect Size Estimates for Within-group Changes Between Baseline and 1-month
1857,NCT03812796,Main Phase IIB (efficacy) phase: Objective response rate using RECIST 1.1 criteria,2019-01-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Duration of objective response according to RECIST 1.1
1858,NCT02931890,Event-Free survival,2017-12-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,Toxicity
1859,NCT00003137,response rate,1997-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,survival
1860,NCT04362449,Nausea according to the Common Terminology Criteria for Adverse Events (CTCAE) V4.03,2019-01-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,Health economics in the context of duration of hospital attendance
1861,NCT02781337,Disease-free survival,2012-05,RECRUITING,OBSERVATIONAL,['NA'],,Molecular characteristics of colorectal adenocarcinoma.
1862,NCT01143285,Toxicities frequently associated with chemotherapy,2010-04,COMPLETED,INTERVENTIONAL,['NA'],,Overall survival
1863,NCT06202066,PFS (Part 2),2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events (Part 2)
1864,NCT03198546,Number of Patients with Dose Limiting Toxicity,2017-07-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Median CAR-T cell persistence
1865,NCT02584400,"Quantification of tumor hypoxia with [18F] HX4 PET imaging, evaluated by the measurement of a tumor-to-background (T/B) ratio on the [18F]HX4 PET/CT",2016-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Spatial correlation of [18F] HX4-PET with imaging three months after treatment using a correlation coefficient
1866,NCT05190575,ORR,2022-01-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety & tolerability
1867,NCT01729221,Incidence of hepatocellular carcinoma post stem cell therapy in hepatitis C virus infected patients,2010-01,UNKNOWN,OBSERVATIONAL,['NA'],asses liver functions in both groups,Compare the incidence of hepatocellular carcinoma in patients who had received stem cell therapy to those who had received the standared line of care
1868,NCT03679910,Diagnostic value of cell migration inducing protein (CEMIP) in serum of pancreatic cancer as non invasive marker.,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
1869,NCT04623749,"Yield, as defined by the percentage of patients in whom a histologically interpretable specimen will be retrieved by Trans abdominal US-FNAC. diagnostic accuracy",2021-12,UNKNOWN,INTERVENTIONAL,['NA'],,"Yield, as defined by the percentage of patients in whom a histologically interpretable specimen will be retrieved by EUS-FNAC. diagnostic accuracy"
1870,NCT00447122,Overall Survival for Patients With Metastatic Pancreatic Cancer.,2007-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,
1871,NCT01966133,Disease-free survival,2011-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],Health-related quality of life assessment,Complications of transarterial chemoembolisation
1872,NCT01425996,Adverse Event/Serious Adverse Event,2011-10-27,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change from baseline in tumor marker/biomarkers
1873,NCT03869294,Overall survival,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,adverse events
1874,NCT04157140,Time To Progression(TTP),2019-11-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events
1875,NCT05720676,To use PDX and PDO to evaluate the efficacy of various treatments.,2023-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
1876,NCT00155103,,2004-08,UNKNOWN,OBSERVATIONAL,['NA'],,
1877,NCT05221775,adverse effect,2021-11-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,OS
1878,NCT06257030,LPFS,2024-02-05,RECRUITING,OBSERVATIONAL,['NA'],,Post-treatment dosimetry analysis
1879,NCT04124991,TTP,2020-06-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of participants with treatment-related adverse events
1880,NCT01216345,best overall response (according to RECIST 1.0),2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety of the treatment combination
1881,NCT00367861,Progression free survival,2002-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Toxicity
1882,NCT06325826,Hepatocellular Carcinoma,2022-02-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
1883,NCT06239870,pCR,2023-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,TRG
1884,NCT03889795,Maximum Tolerated Dose and/or Recommended Dose within the tested C3 dose range,2019-06-05,RECRUITING,INTERVENTIONAL,['PHASE1'],,Assess molecular changes induced by C3 administration in the blood for biomarker sensitivity/resistance assessment
1885,NCT03752086,pancreatic fistula,2019-01,UNKNOWN,INTERVENTIONAL,['NA'],,major complications (Clavien-Dindo ≥III)
1886,NCT03185988,Response Rate(RR) for each cohort in intent to treat (ITT) population,2017-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.03
1887,NCT01735955,Number of Participants With Adverse Events and Serious Adverse Events,2013-03-29,COMPLETED,INTERVENTIONAL,['PHASE4'],,Number of Participants With Clinical Benefit From Nilotinib
1888,NCT00303914,"Prevalence, severity, and interference due to physical and psychological symptoms experienced by cancer patients as assessed by MD Anderson Symptom Inventory at baseline and days 28-35 following initial assessment",2006-03-14,COMPLETED,OBSERVATIONAL,['NA'],,Focus and scope of interventions chosen to improve symptom control
1889,NCT00020787,To determine whether a concomitant G17DT-chemotherapy regimen affects tumor response in subjects with gastric or gastroesophageal cancer.,2001-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Time to disease progression, best overall response, and survival will be evaluated in the intent-to-treat population and the evaluable population."
1890,NCT05688020,Postprocedural bleeding,2023-02-01,RECRUITING,INTERVENTIONAL,['PHASE4'],,Side effects
1891,NCT03381053,Number of participants with tumor metastasis,2017-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,
1892,NCT02944188,incidence of postoperative complications,2014-12-01,COMPLETED,INTERVENTIONAL,['NA'],postoperative hospital stay,operative mortality
1893,NCT06128551,Dose Limiting Toxicities,2023-11-14,RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-Free Survival (PFS)
1894,NCT05712356,Incidence of adverse events,2023-08-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,
1895,NCT00154804,Clinical and pathological response rates,2001-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity
1896,NCT02610218,Correlation of HER2 status on CTCs and cfDNA with clinical outcomes,2016-04,UNKNOWN,OBSERVATIONAL,['NA'],,Gene variations associated with resistance in HER2-targeted therapy
1897,NCT01071655,progression-free survival,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluation of KRAS status as a molecular marker
1898,NCT02435953,Overall survival rate,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Adverse event rate
1899,NCT02659852,Median patency duration,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],,complication rate
1900,NCT00004195,Primary Goal to demonstrate that eniluracil at current clinical doses,1998-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Specific Aims,Evaluate DPD recovery and uracil levels
1901,NCT04106856,Grade 3 or higher gastrointestinal toxicity rate,2019-08-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Patient reported quality of life assessment- review of symptoms and how they interfere in life,Number patients that require a medical intervention or hospitalization due to hypotension
1902,NCT00220246,,2004-03,UNKNOWN,OBSERVATIONAL,['NA'],,
1903,NCT04395469,Tumor Hypoxia,2021-05-18,RECRUITING,INTERVENTIONAL,['NA'],,
1904,NCT05619172,Objective response rate (ORR) according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1),2022-12-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Time course of ADAs against nanrilkefusp alfa
1905,NCT03894917,Characterize the Change in disease and treatment patterns of advanced hepatocellular carcinoma (HCC) in older patients in the US.,2019-09-13,RECRUITING,OBSERVATIONAL,['NA'],,
1906,NCT05661292,Asian Pacific Colorectal Screening (APCS) score validation in Mexican population.,2019-08-01,RECRUITING,OBSERVATIONAL,['NA'],,Optimal Fecal Immunochemical Test (FIT) valued for Advanced Colorectal Neoplasia (ACN) detection.
1907,NCT04776148,Overall Survival (OS),2021-03-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Time to Deterioration (TTD) in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Colorectal Cancer-Specific 29 Items (QLQ-CR29) Bloating (Item 37) Score
1908,NCT00001254,To determine an approach to the localization and management of tumor in patients with ZES.,1991-10-29,COMPLETED,OBSERVATIONAL,['NA'],,
1909,NCT04933669,Progression free survival（PFS）,2021-09-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,R0 resection rate
1910,NCT04638868,Number of circulating tumor cells,2020-11-17,UNKNOWN,INTERVENTIONAL,['NA'],,
1911,NCT05925413,Objective response rate (ORR),2023-04-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events (safety)
1912,NCT03400592,Objective response rate,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Potential predictive biomarkers of nimotuzumab
1913,NCT03825705,Overall Response Rate(ORR),2019-04-23,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1914,NCT05743049,"To create a comprehensive system to collect, catalogue and store blood specimens from subjects with pancreatic cancer for future research use.",2023-02-27,RECRUITING,OBSERVATIONAL,['NA'],,To integrate the data and specimens to permit the most informative clinical-biologic research platform.
1915,NCT00068692,3-year Overall Survival Rate,2003-10-15,COMPLETED,INTERVENTIONAL,['PHASE3'],,Failure Pattern
1916,NCT05361954,Incidence of immune-related adverse events (IrAEs),2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Assess immunoglobulin levels
1917,NCT00004187,,1999-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1918,NCT01048216,To evaluate feasibility of conformal radiation therapy in patients with metastatic colorectal liver cancer and determine its safety,2006-11,UNKNOWN,INTERVENTIONAL,['NA'],,Set up verification with cone-beam CT (OBI on Boar Imager)
1919,NCT02404363,Response to treatment based on RECIST 1.1 criterion,2016-01-11,TERMINATED,INTERVENTIONAL,['PHASE3'],,Bleedings
1920,NCT00154102,Progression-free Survival Time (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety - Number of Patients Experiencing Any Adverse Event
1921,NCT00533975,,2007-09,UNKNOWN,OBSERVATIONAL,['NA'],,
1922,NCT00005060,Event-free survival,1999-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Rate of complete resection (RO) and postoperative mortality as measured after surgery
1923,NCT02376985,Incidence of oral mucositis (Over Grade 1) after everolimus treatment,2015-03-26,COMPLETED,INTERVENTIONAL,['PHASE3'],,Health-related quality of life (HRQOL)
1924,NCT05902988,Dose Expansion: Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1,2023-10-18,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Dose Escalation & Dose Expansion: Increase in Micronuclei in Circulating Tumor Cells
1925,NCT04469426,Assessing 'Change' via European Organization for Research and Treatment of Cancer - Quality of Life Questionnaire - C30 questionnaire after 6 months,2020-08-15,RECRUITING,INTERVENTIONAL,['NA'],,Bowel function Low Anterior Resection Syndrome score
1926,NCT00006472,,2000-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,
1927,NCT01845467,Evaluating the additive benefit of Secretin MRCP in differentiating focal AIP and Pancreatic malignancy,2013-02,WITHDRAWN,OBSERVATIONAL,['NA'],,Efficacy of Secretin MRCP in monitoring therapeutic improvement in AIP patients on steroid trial
1928,NCT03783442,Overall Survival (OS),2018-12-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of Participants Experiencing Adverse Events (AEs)
1929,NCT05718492,Progress Free Survival (PFS),2022-10-18,RECRUITING,INTERVENTIONAL,['NA'],,Adverse Events (AEs)
1930,NCT00629265,Change in Penetration-Aspiration Scale (PAS) Score,2008-03,COMPLETED,INTERVENTIONAL,['NA'],,Performance Status Scale for Head and Neck Cancer Patients (PSS); The Head and Neck Cancer Inventory (HNCI)
1931,NCT01372202,Pathological Complete Response,2011-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Esophageal Tumor CHFR Methylation and Detection in Plasma
1932,NCT04229355,Progression-free survival,2021-02-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Overall survival
1933,NCT04880772,Inflammatory cytokines,2021-07-15,COMPLETED,INTERVENTIONAL,['NA'],,Quality of life measure (Mental Adjustment to Cancer Scale)
1934,NCT06053996,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Overall survival (OS)
1935,NCT03050333,Proportion of complete resections without recurrence,2013-04-25,UNKNOWN,OBSERVATIONAL,['NA'],,
1936,NCT03888092,Number of patients with adverse events (AEs) as a measure of safety and tolerability,2017-08-18,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
1937,NCT00069940,,2000-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1938,NCT03517852,"Tumor blood flow (velocity, mm/sec)",2018-08-15,COMPLETED,INTERVENTIONAL,['NA'],,Post-operative correlation of the microscopic observation of the tumor microvasculature tumor-specific and overall survival.
1939,NCT06271291,Follow subjects longitudinally and collect biospecimens and follow-up data and record medical outcomes,2024-05-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
1940,NCT00427310,Survival,1984-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1941,NCT03566797,Incidence of SC-CIP in patients at risk,2018-07-20,RECRUITING,OBSERVATIONAL,['NA'],,NOD2 polymorphisms
1942,NCT00349817,skill in discussing these issues with patients,2005-10,UNKNOWN,INTERVENTIONAL,['NA'],,
1943,NCT00640692,,2007-12,WITHDRAWN,OBSERVATIONAL,['NA'],,
1944,NCT03661671,Detection rate of gastric neoplastic lesion,2018-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,Sensitivity of detecting gastric neoplastic lesion
1945,NCT05111795,Lung shunt prediction,2022-01-17,COMPLETED,OBSERVATIONAL,['NA'],,Number of patients downstaged to liver resection or liver transplantation
1946,NCT03464968,6 months overall survival rate,2015-07-29,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Treatment-Related Adverse Events as Assessed by NCI CTC version 4.0
1947,NCT00081237,Maximum tolerated dose and recommended dose for future trials as measured by CTC v3.0,2004-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to progression as measured by Kaplan Meier and RECIST every 6 weeks during treatment and then every 8 weeks
1948,NCT05984589,To compare the difference in WCRF/AICR score between the intervention (RISE-PSMT) and control (SSMT) groups.,2024-01-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,To assess percent change across the various component scores on the WCRF/AICR (e.g. grams of fiber) to better understand what might be driving any changes in the overall WCRF/AICR composite score.
1949,NCT05665348,Overall survival (Phase III),2023-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Objective response rate (OR) under treatment (Phase III)
1950,NCT02705105,Number of Subjects Experiencing Dose-limiting Toxicity,2016-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Objective Tumor Response Rate According to RECIST
1951,NCT01388790,Best Overall Response (BOR) Rate - Independent Review Committee (IRC) Assessments,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Progression-free Survival (PFS) Time - Independent Review Committee (IRC) Assessments
1952,NCT00448760,Pathologic Complete Response,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
1953,NCT03002051,Clinical success for obstructive jaundice,2016-10,COMPLETED,INTERVENTIONAL,['NA'],,Adverse events
1954,NCT01704690,Response rate,2012-08,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Number of Participants with Adverse Events and the degree of each adverse event
1955,NCT00062374,Histological Response Determined by FDG Uptake Correlates,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Disease Free Survival (DFS),
1956,NCT00313599,Maximum tolerated dose (MTD) of lapatinib in course 1,2006-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics during the first 2 weeks of treatment
1957,NCT02639026,Number of Adverse Events,2016-01-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1958,NCT04256226,Overall survival,2020-02-01,COMPLETED,OBSERVATIONAL,['NA'],,Recurrence-free survival
1959,NCT01316263,"Percentage of Participants With Tumor Response of Stable Disease (SD), Partial Response (PR) or Complete Response (CR) (Clinical Benefit Rate) at 12 Weeks",2011-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Human Anti-Olaratumab (IMC-3G3) Antibody Results
1960,NCT02597712,Change in Ki67 Biomarker Expression,2013-05-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Abundance of Biomarkers of ECL Cell Hyperplasia
1961,NCT04759638,Overall Survival (OS),2017-03-21,COMPLETED,OBSERVATIONAL,['NA'],,Pathological Complete Response (CR)
1962,NCT01373125,To characterize reflux symptomatology before and after radiofrequency ablation in subjects with dysplastic Barrett's Esophagus (BE).,2011-06,COMPLETED,OBSERVATIONAL,['NA'],,Correlate the physiologic and morphologic changes in the neosquamous epithelium (NSE) after ablation with the frequency and type of refluxate seen on pH-Impedance.
1963,NCT04224636,24-months survival rate,2020-06-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
1964,NCT01998230,Postoperative complication,2014-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Length of postoperative stay
1965,NCT01220999,Mean 111^In-CS-1008 Serum Maximum Concentration by Gamma Counting Following the Day 36 Infusion of 111^In-CS-1008,2010-10-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Subjects With Best Overall Metabolic Response
1966,NCT05816837,Displacement distance,2022-04-20,RECRUITING,OBSERVATIONAL,['NA'],,
1967,NCT01716949,Number of hyperthermia applications by patient,2012-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Rate of acute and late toxicity
1968,NCT02564666,Drug compliance for patients with HCC who is taking Sorafenib compliance,2015-10,UNKNOWN,INTERVENTIONAL,['NA'],The satisfaction with Information about Medicines Scale (SIMS) score,Duration of dosing period
1969,NCT02936856,Detection of numbers of confirmatory diagnosis of malignant lesions before and after hepatic arteriography,2015-11,UNKNOWN,INTERVENTIONAL,['NA'],,Detection of distribution of confirmatory diagnosis of malignant lesions before and after hepatic arteriography
1970,NCT03104283,Progression-free survival (PFS),2017-06-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
1971,NCT00768157,Overall survivals,2007-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Recurrence rate
1972,NCT05650151,Infection rate,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
1973,NCT05099237,Cohort 3 - Primary outcome measure: feasibility of monitoring for the daily weights:,2021-12-01,RECRUITING,INTERVENTIONAL,['NA'],,"Cohorts 1,2 and 3 Device acceptability"
1974,NCT02704156,The Median Survival Time Will be Determined.,2016-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,The Quality of Life Will be Analyzed.
1975,NCT00910572,Time to progression (TTP),2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time-to-symptomatic progression (TTSP)
1976,NCT04575922,Overall response rate for unirradiated lesions (ORR),2020-10-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
1977,NCT00083785,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1978,NCT00625651,Progression-free survival,2007-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The incidence of anti-AMG 655 antibody formation
1979,NCT03727633,Percentage of participants presenting a disease control at 4 months,2018-07-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life questionnaire (QLQ) QLQ-C30
1980,NCT05241249,R0 resection rate,2022-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Ki-67 expression in tumor cells
1981,NCT02677038,Objective response rate (defined as complete response or partial response) assessed using Response Evaluation Criteria in Solid Tumors 1.1,2016-11-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of unacceptable toxicity
1982,NCT00808145,Safety of the combination of gemcitabine/cisplatin/sorafenib,2009-02,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Effectiveness of gemcitabine/cisplatin/sorafenib in shrinking tumors extending time to progression of disease
1983,NCT02494687,,na,AVAILABLE,EXPANDED_ACCESS,['NA'],,
1984,NCT01298570,Progression Free Survival (PFS),2011-04-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Patients With Severe Adverse Events
1985,NCT04083651,Overall Survival,2020-01-06,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
1986,NCT02564614,Change From Baseline to Week 6 in HIF1A mRNA Level in Tumor Tissue,2016-05-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Plasma Decay Half-Life (t1/2)
1987,NCT05659251,Pathological Complete Response (PCR),2022-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,The changes in the peripheral blood immunoprofile and tumor tissue sample among non-PCR (NPCR) and PCR patients
1988,NCT03216135,Microbial community profiling,2017-07-20,UNKNOWN,OBSERVATIONAL,['NA'],,Generate a tissue microarray
1989,NCT04490733,Neuropsychological battery test,2020-08-17,RECRUITING,INTERVENTIONAL,['NA'],Self-report Questionnaire,Self-report Questionnaire
1990,NCT03200691,Pathologic Complete Response Rate,2017-08-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Numbers of adverse events and the degree of each adverse events according to the NCI CTCAE 4.0 criteria.
1991,NCT02184195,Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) Using Modified Response Evaluation Criteria in Solid Tumours. This Study Used Modified RECIST Version (v) 1.1 (RECIST v1.1),2014-12-16,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Adverse Events (AEs)
1992,NCT02226666,Survey,2013-08,COMPLETED,OBSERVATIONAL,['NA'],,Respiratory Rate
1993,NCT00512304,feasibility of treatment,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1994,NCT05897268,Objective Response Rate (ORR) evaluated by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1,2023-06-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
1995,NCT03163992,Overall Response Rate,2017-12-26,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free Survival (PFS) and Overall Survival (OS)
1996,NCT04733963,Progression Free Survival,2021-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Exploratory Endpoint,QoL
1997,NCT03096717,incidence of dysplasia in relation to therapy performed,2017-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
1998,NCT05475613,For patients with liver transplantation: The 2-year event-free survival rate,2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,For all patients with HCC downstaging: Rate of successful tumor downstaging
1999,NCT03781154,Physical Activity,2019-10-17,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of Life Assessment
2000,NCT03306966,Number of patients with adverse events related to the index-procedure.,2018-05-01,WITHDRAWN,OBSERVATIONAL,['NA'],,Number of patients with colectomy related re-interventions.
2001,NCT04151524,Overall Survival,2019-10-23,UNKNOWN,OBSERVATIONAL,['NA'],,
2002,NCT02034968,Progression free survival(PFS),2014-02,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Adverse events,Objective Response Rate
2003,NCT05458115,Adverse effect,2022-09-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
2004,NCT01173250,,na,COMPLETED,INTERVENTIONAL,['NA'],,
2005,NCT01268384,R0 resection rate,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
2006,NCT04000802,MODE-MDT scores,2019-05-23,COMPLETED,OBSERVATIONAL,['NA'],,Decision factors
2007,NCT02828124,Incidence of Laboratory Test Toxicity Grade Shifting From Baseline,2016-08-23,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of Positive Anti-drug Antibody (ADA)
2008,NCT02531620,Number of participants recruiting,2015-09,UNKNOWN,INTERVENTIONAL,['NA'],,Bowel Function Assessment
2009,NCT05008809,Progression-free survival (PFS) time,2021-12-06,RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of life (QoL)
2010,NCT05144854,Overall survival (OS),2021-11-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse event
2011,NCT00560560,Estimate of the 6 Month Survival Probability,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Counts of Circulating Tumor Cells (CTCs)
2012,NCT01857141,Heart rate variability analysis,2012-02,COMPLETED,INTERVENTIONAL,['NA'],,Epidural injection
2013,NCT04993846,Quantitative analysis of the dental plaque microbiome in patients with pancreatic cancer vs. healthy controls and IPMN patients,2021-07-26,UNKNOWN,OBSERVATIONAL,['NA'],,Qualitative analysis of OM and periodontal status between the various stages of PC
2014,NCT01924624,disease-free survival,2013-07,UNKNOWN,INTERVENTIONAL,['NA'],,Overall survival
2015,NCT03693378,Validation of IMMray™ PanCan-d test,2016-01-19,COMPLETED,OBSERVATIONAL,['NA'],,Evaluation of the IMMray™ PanCan-d test performance
2016,NCT05213637,Recurrence-free survival (RFS),2018-04-25,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse events (AE)
2017,NCT05745909,Ileus,2023-03-01,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life in patients with ostomy
2018,NCT02888743,Overall response rate,2017-08-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Patient reported symptomatic adverse events(AEs),Prognostic effect of T-cell infiltration
2019,NCT03208777,presence of telomeric abnormalities,2017-08-01,UNKNOWN,OBSERVATIONAL,['NA'],,
2020,NCT02011594,PFS (Progression free survival),2014-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Disease control rate (DCR)
2021,NCT01832467,overall response of re-treatment with cetuximab-based chemotherapy,2013-04-24,COMPLETED,INTERVENTIONAL,['PHASE2'],,progression-free survival
2022,NCT00361309,Progression free survival of hepatocellular carcinoma (HCC) patients treated with SU011248.,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
2023,NCT02062632,Change in Mouth Pain as Measured by Average Area Under the Curve Per Assessment,2014-04-14,TERMINATED,INTERVENTIONAL,['PHASE2'],Quality of Life Using European Organization for Research and Treatment of Cancer Quality of Life-Lung Cancer 13 and Functional Assessment of Cancer Therapy-Lung,Patient Preference for Continued Therapy at Initial Dose and Crossover
2024,NCT06304987,AE rate,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,immune-related adverse event rate
2025,NCT03146637,OS,2017-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,SRR
2026,NCT05191498,Feasibility of intratumoral implantation of QuiremSpheres® by SPECT imaging,2021-12-13,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Tumor response by RECIST 1.1
2027,NCT02781285,The influences of traditional Chinese medicine standardized treatment on the overall survival (OS) of patients with advanced gastric cancer by the method of Propensity Score.,2014-12,RECRUITING,OBSERVATIONAL,['NA'],,The influences of Western Medicine treatment mainly by chemotherapy on the overall survival (OS) of patients with advanced gastric cancer by the method of Propensity Score.
2028,NCT06232434,increased survival,2024-02-12,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,blood chemistry
2029,NCT00855634,Overall survival,2009-08,TERMINATED,INTERVENTIONAL,['NA'],,Quality of life Perioperative morbidity and mortality 1-year survival and 2-year survival
2030,NCT02392377,Biological Pathway Perturbation Upon Exposure to Chemotherapy,2015-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,Occurrence of Grade 3 or 4 Toxicity Per the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 4.0
2031,NCT02555501,Lesion size,2014-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2032,NCT05559229,To evaluate the efficacy of measuring value of AFP for patients with gallbladder cancer.,2021-01-15,COMPLETED,OBSERVATIONAL,['NA'],,
2033,NCT05777707,Disease-free survival (DFS),2020-10-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
2034,NCT05514769,Gastroesophagus reflux disease apprised by questionnaire,2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Long-term outcome
2035,NCT04299048,Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities,2020-11-17,COMPLETED,INTERVENTIONAL,['PHASE1'],,Serum Total Ctrough of PF-06946860
2036,NCT02723578,Progression-free survival,2015-12-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
2037,NCT02008656,disease-free survival (DFS),2013-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,major adverse events
2038,NCT04862793,Feedback from CoPS results in change in patient discomfort.,2021-06,UNKNOWN,INTERVENTIONAL,['NA'],,Make an immediate measure to assess the quality of individual colonoscopy performance.
2039,NCT01691391,The predictive value of 18F-FDG-PET for the absence of response compared to the lack of clinical benefit at convential CT at 2 months,2012-01,COMPLETED,OBSERVATIONAL,['NA'],,Grade of skin toxicity
2040,NCT04649671,Improvement of insulin resistance,2021-03-02,TERMINATED,INTERVENTIONAL,['NA'],,Adverse events
2041,NCT01751763,"Treatment pattern of Sorafenib: duration and doses of Sorafenib, dose modification/discontinuation of Sorafenib, concomitant anti-cancer therapy, treatment after observed radiological recurrence.",2013-07-09,COMPLETED,OBSERVATIONAL,['NA'],,Time to recurrence (TTR)
2042,NCT00094965,Adverse events.,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumor evaluations for response or progressive disease.
2043,NCT01726296,Percentage of eligible CRC and NSCLC survivors with medical record documentation of compliance with NCCN guidelines,2013-01,COMPLETED,INTERVENTIONAL,['NA'],,Change in percentage of eligible survivors with documentation of compliance with NCCN survivorship guidelines after conducting the targeted educational initiative at participating sites
2044,NCT01889303,Disease free survival,2013-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,feasibility (including adverse events )
2045,NCT02969473,Overall survival (OS),2010-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Acute treatment-related toxicities
2046,NCT04932187,Rate of adverse events as assessed by CTCAE v5.0,2021-08-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Duration of response
2047,NCT04354246,Evaluation of the PK profile of the Triplet combination (COM902 + COM701 + Pembrolizumab).,2020-03-31,RECRUITING,INTERVENTIONAL,['PHASE1'],Preliminary antitumor activity of the triplet combination (COM902 + COM701 + Pembrolizumab).,To characterize the immunogenicity of the Triplet combination (COM902 + COM701 + Pembrolizumab).
2048,NCT02437136,Overall Response Rate using irRECIST for Phase 2 Dose and Schedule for Cohort 3 Stage 2 (Melanoma pre-treated),2015-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to Response (TTR)
2049,NCT05114148,Rate of unacceptable toxicity.,2022-03-01,RECRUITING,INTERVENTIONAL,['NA'],,Assessment of regional liver function
2050,NCT05222854,proportion of patients with genomic alterations,2017-10-11,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,The proportion of patients with actionable genomic alterations in all patients
2051,NCT00400569,Number of Participants With Overall Response (OR),2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Serious Adverse Events (SAEs)
2052,NCT01896856,Progression Free Survival (PFS),2013-10-23,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Objective Response Rate
2053,NCT01575990,Appropriate colorectal cancer screening,2012-03,COMPLETED,INTERVENTIONAL,['NA'],,Appropriate screening for stool cards
2054,NCT04136769,Feasibility of visceral debranching,2020-02-07,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
2055,NCT00923052,To study and characterize both quantitatively and qualitatively SOCSC from various primary and metastatic solid organ cancers from time of surgery or other cancer directed therapy to time of recurrence or progression using an exhaustive list of ...,2009-02-09,TERMINATED,OBSERVATIONAL,['NA'],,"To determine whether SOCSC are present in the blood and/or bone marrow, and study their quantitative and/or qualitative changes over the course of the disease, from time of initial presentation to time of recurrence and/or metastasis.To sp..."
2056,NCT03213054,Incidence rate of adverse event,2017-07-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Tumor response
2057,NCT00508001,Tumour Stabilisation Rate,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
2058,NCT01106261,Feasibility of recruitment,2010-12-02,COMPLETED,INTERVENTIONAL,['NA'],,Survival
2059,NCT02833246,objective pill count,2016-06-28,COMPLETED,INTERVENTIONAL,['NA'],,
2060,NCT01707121,Length of hospital stay,2012-12,COMPLETED,OBSERVATIONAL,['NA'],,Health economic analysis
2061,NCT05702684,Patient experience,2023-07-31,RECRUITING,OBSERVATIONAL,['NA'],,
2062,NCT01602406,Incidence rate of Dose Limiting Toxicities,2012-09-21,COMPLETED,INTERVENTIONAL,['PHASE1'],,Frequency of stable disease according to RECIST
2063,NCT03407716,Change in general subscale of the Multidimensional Fatigue Symptom Inventory- Short Form (MFSI-SF),2019-03-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],"Change in inflammation biomarkers (adiponectin, cortisol, IL-6)",Perceived treatment efficacy as measured by the Subject Global Impression of Change
2064,NCT01945177,Detection rate of intestinal metaplasia,2012-01,COMPLETED,INTERVENTIONAL,['NA'],,Aggregate detection rate of focal gastric lesions
2065,NCT05582278,Cancer embolism withdraws,2021-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
2066,NCT03203837,"Percentage change in angiogenic, inflammatory and immune biomarkers",2017-07-05,TERMINATED,OBSERVATIONAL,['NA'],,Treatment Response- Overall Survival
2067,NCT00580021,The overall objective of the protocol is to examine the hypothesis that hereditary cancers are distinct in clinical characteristics and outcome from those that arise in the absence of a known predisposition.,2006-01,WITHDRAWN,OBSERVATIONAL,['NA'],,
2068,NCT00405561,Progression free survival;at 18 weeks after registration,2006-10,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Safety and Tolerability
2069,NCT00639314,delayed gastric empty after pancreaticoduodenectomy,2005-10,COMPLETED,INTERVENTIONAL,['NA'],,"evaluation of quality of life, early and late complications after pancreaticoduodenectomy"
2070,NCT04307901,Complete mucosal visualization combining incomplete investigations,2020-05-01,RECRUITING,OBSERVATIONAL,['NA'],,Patient preference
2071,NCT03486379,response rate (confirmed complete and partial response).,2016-03,COMPLETED,OBSERVATIONAL,['NA'],,Toxicity
2072,NCT05009069,Percentage of Participants With Pathological Complete Response (pCR),2022-03-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Adverse Events
2073,NCT03696472,5-years overall survival rate,2018-12,UNKNOWN,INTERVENTIONAL,['NA'],,Recovery time after surgery
2074,NCT01346410,Local Control Rate,2008-09,COMPLETED,INTERVENTIONAL,['NA'],,Late Toxicity Rate
2075,NCT00546065,recurrence-free survival,2006-08,TERMINATED,INTERVENTIONAL,['NA'],,
2076,NCT01439633,Number of Subjects in Which the Targeted Locations Identified Through OFDI Imaging Correlates With the Biopsies.,2010-10,COMPLETED,INTERVENTIONAL,['NA'],,
2077,NCT05017207,Risk factors relate to pancreatic fistula,2021-09-01,RECRUITING,OBSERVATIONAL,['NA'],,Short-term result in treatment of post-operative pancreatic fistula
2078,NCT03356535,Hepatocellular Carcinoma,2015-08-01,COMPLETED,OBSERVATIONAL,['NA'],,
2079,NCT03969576,Objective response rate,2020-09-15,UNKNOWN,INTERVENTIONAL,['NA'],,Duration of response
2080,NCT03178409,Survival analysis,2004-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
2081,NCT02178956,Overall Survival,2014-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Patients With Adverse Events
2082,NCT05819099,Accuracy,2023-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
2083,NCT01630239,MR Images,2012-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
2084,NCT04204382,Clinical grade of radioactive oral mucositis,2019-12-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Recovery time of oral mucositis
2085,NCT03077334,Clinical PET type assessed by surgeons from preoperatively preformed PET imaging,2014-10-07,COMPLETED,OBSERVATIONAL,['NA'],,Number of patients with recurrence of cancer or mortality from cancer following operation
2086,NCT01493713,Correlation of overall objective responses evaluated by conventional imaging techniques with the morphologic response evaluated by MDCT and the histopathologic response after the resection of hepatic metastases.,2011-11-16,COMPLETED,INTERVENTIONAL,['PHASE4'],,Examine the influence of a potential predictive and prognostic tumour biomarker -mutations in K-RAS- after start of therapy on progression free survival
2087,NCT03448835,Incidence of adverse events following treatment (safety),2018-03-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,pathological tumor regression grade
2088,NCT04654403,DOR,2022-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,ORR
2089,NCT04126655,TS inhibition in plasma,2020-02-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2090,NCT01586611,The difference Progression Free Survival (PFS) between Gemcitabine and FOLFOX treated patients in hENT1 high and hENT1 low pancreatic adenocarcinoma.,2012-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Health-related quality of life (HRQL) parameters in patients with metastatic pancreas adenocarcinoma treated in both treatment arms.
2091,NCT00679913,Survival,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Morbidity
2092,NCT01826396,R0 resection rate,2013-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],adverse reactions,disease free survival
2093,NCT01322152,Rate of Diarrhea,2011-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants with Adverse Events as a Measure of Safety and Tolerability
2094,NCT03511222,Recommended phase II dose (RP2D) of vorolanib plus nivolumab,2018-09-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,Safety and toxicity of vorolanib plus nivolumab as measured by the number and type of adverse events experienced by participant
2095,NCT00824161,Percentage of Progression Free Survival,2009-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
2096,NCT04109924,Median progression free survival (PFS),2019-12-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Aggregate rates of adverse events
2097,NCT00629486,cytokine polymorphisms increase risk for hepatocellular carcinoma,2007-01,COMPLETED,INTERVENTIONAL,['NA'],,
2098,NCT03614910,Tumor response,2018-05-15,COMPLETED,OBSERVATIONAL,['NA'],,Cancer related pain
2099,NCT04571710,Objective response rate,2020-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Cmax
2100,NCT04270500,"Sleep quality by an Actigraphy: ""change"" is being assessed",2020-09-15,UNKNOWN,INTERVENTIONAL,['NA'],"Weight: ""change"" is being assessed","Hospital Anxiety and Depression Scale (HADS): ""change"" is being assessed"
2101,NCT01860222,overall survival,2011-01,UNKNOWN,INTERVENTIONAL,['NA'],,local tumor progression
2102,NCT02634645,Overall improvement of patient outcomes in patients treated with endoscopic eradication therapy (EET).,2015-01,RECRUITING,OBSERVATIONAL,['NA'],,Median time to recurrence of neoplasia
2103,NCT06098898,Maximal Tolerable Dose,2023-11-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['EARLY_PHASE1'],,Overall response rate (ORR)
2104,NCT04718909,Progression free survival (PFS) assessed by investigators according to Response Evalutaion Criteria in Solid Tumors (RECIST) v1.1 and immune-related RECIST (irRECIST),2021-01-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,DCR assessed by investigators according to mRECIST.
2105,NCT03790059,Tumor-free survival,2016-10,UNKNOWN,INTERVENTIONAL,['NA'],,Overall survival
2106,NCT03861702,Disease Control Rate (DCR),2020-09-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of Life Assessment
2107,NCT01131689,MTD,2009-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2108,NCT03198338,opioid consumption up to 24 hours,2017-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,sedation score
2109,NCT05213221,Objective reponse rate (ORR),2022-03-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety of treatment
2110,NCT03418428,Intestinal microbiome composition,2018-04-01,COMPLETED,OBSERVATIONAL,['NA'],,Serum DAO
2111,NCT01228734,Progression Free Survival (PFS) Time,2010-09-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Subjects With Curative Surgery of Liver Metastases
2112,NCT05183776,Safety of a fractional administration device for holmium radioembolization,2022-07-12,COMPLETED,INTERVENTIONAL,['NA'],,Accurate dosimetry based on MRI and SPECT imaging of holmium-166.
2113,NCT02428101,"Correlation of single nucleotide polymorphisms of ABCG2 gene (G34A - rs2231137 and A/A -rs3114018 genotypes) with peripheral neuropathy grades, using the National Cancer Institute Common Toxicity Criteria (NCI-CTCAE)",2014-11,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
2114,NCT02824484,Change in post-traumatic growth from baseline to post-intervention assessment and at 6 months follow-up. Post-Traumatic Growth Inventory (PTGI) will be used to assess this outcome,2015-11,UNKNOWN,INTERVENTIONAL,['NA'],"Expectancy about change in personal growth as a result of the intervention (Treatment Expectancy, TE)",Change in anxiety and depression from baseline to post-intervention assessment and at 6 months follow-up. Hospital Anxiety and Depression Scale (HADS) will be used to assess this outcome
2115,NCT01291407,"To define dose limited toxicities(DLT) of S-1, peroral BID, in treatment days concurrently with radiation therapy (RT) in locally advanced or recurrent gastric cancer.",2010-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To define maximum tolerated dose(MTD) of S-1, peroral BID, in treatment days concurrently with radiation therapy"
2116,NCT00869843,Efficacy of the technique on surface liver tumors using saline lined RF Surface ablation.,2002-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Determine a safe (non-popping upper limit) of power per area that will permit a 1 cm depth of tissue destruction without inflow occlusion and a 2 cm depth with inflow occlusion.
2117,NCT04949646,"Change in the quality of life of the patient at 3 months postoperatively, based on the SF-36 questionnaire",2021-09-19,RECRUITING,INTERVENTIONAL,['NA'],,"Difference in the low anterior syndrome symptoms of the patient, based on the LARS questionnaire"
2118,NCT00366457,Time to Tumor Progression,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
2119,NCT00077259,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2120,NCT04340986,Overall survival,2020-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Progression time under chemotherapy
2121,NCT05661110,"Relationship between the status, numerical changes of ctDNA during HIPEC combined with PD1/PDL1 inhibitor conversion therapy and postoperative R0 resection rate.",2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Genetic and transcriptional profiling results.,Genomic changes of ctDNA and see if they are predictive of relapse-Free Survival.
2122,NCT05937295,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of the peptide vaccine in combination with anti-PD-L1 immune checkpoint inhibition,2023-09-26,RECRUITING,INTERVENTIONAL,['PHASE1'],,
2123,NCT06203600,Overall survival (OS) (Phase III),2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Incidence of adverse events
2124,NCT00683358,PhaseⅠ; safety (NCI CTCAE v.3) PhaseⅡ；time to progression (RECIST),2008-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Tumor regression(Imaging study, tumor marker, etc.)"
2125,NCT04689594,Proportion of subjects without stenosis,2021-02-04,TERMINATED,INTERVENTIONAL,['PHASE3'],,
2126,NCT01934829,Prophylactic topical application of ointment to reduce the hand-foot skin reactions in patients with hepatocellular carcinoma treated with sorafenib,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,The percentage of patients discontinuing treatment
2127,NCT00006221,,2000-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2128,NCT01668381,"variation of serum IL-10,TGF-β1,IFN-γ concentration of HCC patients before and 1,4 weeks after radiofrequency ablation therapy",2012-08,UNKNOWN,OBSERVATIONAL,['NA'],,"variation of suppression ability of CD4+CD25+ T cells of HCC patients on cytokine secretion before and 1,4 weeks after radiofrequency ablation therapy"
2129,NCT04196465,Major pathologic response rate,2019-09-09,RECRUITING,INTERVENTIONAL,['PHASE2'],Discovery of predictive and/or prognostic biomarkers,Patterns of cancer progression/relapse
2130,NCT03128281,Incidence of Shoulder Pain After Laparoscopic/Robotic Surgery,2018-07,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
2131,NCT03641118,Skeletal muscle radiation attenuation at L3,2017-01-01,RECRUITING,OBSERVATIONAL,['NA'],,oxygen uptake at lactate threshold
2132,NCT03383367,participation rate at future colonoscopy,2017-08-24,UNKNOWN,INTERVENTIONAL,['NA'],,Cost-utility analysis of the reminder letter for surveillance colonoscopy
2133,NCT06135558,DFS,2016-01-30,COMPLETED,OBSERVATIONAL,['NA'],,
2134,NCT01851941,"clinical response rate as assessed using RECIST criteria, with computed tomography (CT) scans at baseline and after 4cycles of chemotherapy",2004-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Pharmacologic Genetic Marker,overall survival
2135,NCT01086683,psychosocial well-being (as assessed by the EORTC-QLQ C30 Quality of life core questionnaire by the European Organization of Research and Treatment in Cancer (EORTC-QLQ C30) and the Profile of Mood States Short form (POMS-SF),2004-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,self-efficacy as measured with the General Self-Efficacy Scale (GSE)
2136,NCT00624260,Percentage of patients with a non removable recurrence,2008-06,COMPLETED,INTERVENTIONAL,['NA'],,Cost of the strategy
2137,NCT04920955,Specificity for relapse detection,2021-02-10,COMPLETED,OBSERVATIONAL,['NA'],,Sensitivity for CRC detection
2138,NCT04066491,Double-blind Part: Overall Survival,2019-09-20,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"Double-blind Part: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs (SAEs), Treatment Related TEAEs and Adverse Events of Special Interest (AESIs) According to NCI-CTCAE Version 5.0"
2139,NCT04202523,DFS,2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,OS
2140,NCT06221423,Overall Survival (OS),2020-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
2141,NCT04275986,Adverse events (AE),2020-01-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of Life (QOL): questionnaires
2142,NCT00126256,"Progression-free survival after two lines of chemotherapy, defined as the time duration from randomization until progression after two lines of chemotherapy or death whatever the cause in the absence of progression or last-follow-up",2002-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Costs
2143,NCT01398449,Overall survival,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Failure pattern
2144,NCT00002475,Survival (patients without evaluable disease),1991-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2145,NCT02153450,Dose-limiting toxicity (DLT) rate scored according to the National Cancer Institute Common Toxicity Criteria version 4,2015-05-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Overall survival
2146,NCT05786482,Hospital Anxiety and Depression Scale (HADS),2023-02-12,RECRUITING,INTERVENTIONAL,['NA'],Sleep (Exploratory),Satisfaction and Adherence
2147,NCT04780802,The change in the perfusion pattern of HCC tumors,2022-05-01,COMPLETED,INTERVENTIONAL,['NA'],,Tumor response
2148,NCT05412589,ORR,2022-06-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,TRAE
2149,NCT03794440,Progression-free survival (PFS),2019-02-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,EORTC QLQ-HCC18
2150,NCT02363374,"Number of patients with pathological complete response (pCR), i.e. ypT0N0.",2015-03-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
2151,NCT00052507,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2152,NCT01486745,,2008-09-15,COMPLETED,OBSERVATIONAL,['NA'],,
2153,NCT05234177,Recurrence-Free Survival,2022-06-21,RECRUITING,OBSERVATIONAL,['NA'],Lead Time,Positive Predictive Value
2154,NCT00336609,,2005-11,UNKNOWN,OBSERVATIONAL,['NA'],,
2155,NCT03332433,Incidence of hypoxia,2017-11-10,COMPLETED,INTERVENTIONAL,['NA'],,Other adverse events
2156,NCT03820921,Feasibility of MMR status analysis on EUS-FNB pancreatic specimens,2019-02-01,UNKNOWN,OBSERVATIONAL,['NA'],,Progression-free survival
2157,NCT04193696,Objective response rate,2020-01-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Abscopal effects rate
2158,NCT04831827,Primary Endpoint (intention-to-treat),2021-09-01,WITHDRAWN,INTERVENTIONAL,['NA'],,Secondary Outcome (per protocol analysis)
2159,NCT03988556,Rate of discontinuation due to AEs,2019-07-04,COMPLETED,INTERVENTIONAL,['NA'],Use of the device - Cumulative dose,Oral mucosa lesions assessment - Time until resolution
2160,NCT01322178,Resection rate (R0),2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of Participants with Adverse Events as a Measure of Safety and Tolerability
2161,NCT01943786,To estimate the proportion of patients with advanced colorectal cancer in whom KRAS mutation can be detected in circulating extracellular DNA,2013-04,UNKNOWN,OBSERVATIONAL,['NA'],,Number of each adverse event per cycle
2162,NCT06158919,PFS,2023-11-20,RECRUITING,INTERVENTIONAL,['NA'],,OS
2163,NCT03348150,overall survival,2017-10-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,costs and health benefits
2164,NCT02344810,Progression-free survival (Phase II),2015-03-06,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Evaluation of MET amplification and MET expression as determined by DAKO IHC (Phase II)
2165,NCT00002716,Time to progression,1996-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2166,NCT00589030,,2007-04,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
2167,NCT00614653,"Highest Tolerated Dose of Capecitabine, Erlotinib Hydrochloride, and Bevacizumab + Radiation",2008-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Response Rate of Addition of Bevacizumab and Erlotinib to Capecitabine-Based Chemoradiation
2168,NCT00215956,Side Effect Profile of Topotecan,2001-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Response Rate
2169,NCT00508443,Patient Response (Pain Relief),2002-10-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2170,NCT02964455,Maximum tolerated dose,2016-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Dynamic plasma concentration of docetaxel and nedaplatin
2171,NCT02449135,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
2172,NCT02498353,pathological complete remission rate,2015-07,UNKNOWN,INTERVENTIONAL,['NA'],,toxicity of radiotherapy based on the CTCAE v3.0 (common terminology criteria for adverse events，CTCAE v3.0)
2173,NCT01909856,Complete Response(CR) within 24-120 hours after chemotherapy,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse events
2174,NCT00154531,,2004-08,UNKNOWN,OBSERVATIONAL,['NA'],,
2175,NCT04121273,Number of patient with dose limiting toxicity,2019-10-05,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Number of Peripheral CAR-T cell
2176,NCT02328664,Sensitivity of biopsies for residual cancer,2015-08,TERMINATED,INTERVENTIONAL,['NA'],,The proportion of patients with residual cancer in the resected specimen if malignancy was unsuspected during the endoscopic polypectomy
2177,NCT05352165,Pathologic Complete Response,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,anus-saving rate
2178,NCT00025168,,2001-11-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2179,NCT04262609,faecal incontinence after prostate radiation therapy,2019-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Quality of life after prostate radiation therapy
2180,NCT05672524,Clinical complete response of study participants,2022-12-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,
2181,NCT04693754,"Rate of patient report of symptoms related to procedure (Acute pancreatitis, abdominal pain, infection/abscess, venous thrombosis, & fever)",2020-07-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
2182,NCT00602602,Progression-free survival,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of potentially resectable patients who are able to proceed to successful resection
2183,NCT04104074,Incidence of treatment-emergent adverse events,2019-11-25,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
2184,NCT02356471,Number of Patients Who Self-report Wearing the Consumer-based Activity Monitor at Least 16 Days of the 21 Day Period,2015-03,COMPLETED,INTERVENTIONAL,['NA'],,Change in Fatigue Assessment- Fatigue Visual Analog Scale (FVAS).
2185,NCT00819780,Progression-free Survival (PFS),2009-04-24,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events (AEs)
2186,NCT03375281,1 year local tumor progression,2017-11-20,COMPLETED,INTERVENTIONAL,['NA'],,
2187,NCT00508404,Objective Response Rate,2007-05-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Resection Rate
2188,NCT02060669,Progression free survival,2010-06-20,TERMINATED,INTERVENTIONAL,['PHASE3'],,
2189,NCT00538850,Summed Pain Intensity Differences (SPID) at 30 Minutes After Dosing (SPID30),2007-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Global Evaluation of the Study Medication at 30 and 60 Minutes After Dosing
2190,NCT03061435,Prevalence of abnormal anal cytology and hrHPV DNA in women with VIN 2/3 or vulvar cancer,2021-02-01,UNKNOWN,INTERVENTIONAL,['NA'],,"Assess t he correlation between abnormal anal cytology, hrHPV DNA, and AIN"
2191,NCT01160419,Collection of the R0-Resection rate,2009-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
2192,NCT03156777,Number of circulating tumor cell (CTC),2016-01,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival
2193,NCT00699881,time to progression,2008-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,toxicity
2194,NCT01318447,Local recurrence-free survival,2011-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Local recurrence-free survival
2195,NCT05394246,Tumor lesions,2022-05-20,RECRUITING,INTERVENTIONAL,['NA'],,
2196,NCT01416688,Psychometric properties of the FACT-EGFRI 18,2011-11-15,COMPLETED,OBSERVATIONAL,['NA'],,"Feasibility as measured by accrual, time to specified accrual, time to complete forms"
2197,NCT05727852,Indicators of arterial stiffness,2023-01-30,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Composite of clinical records
2198,NCT05092373,"To assess the safety and tolerability of TTF, including the maximum tolerated dose (MTD).",2022-04-29,RECRUITING,INTERVENTIONAL,['PHASE1'],,"To assess the objective response rate, progression-free survival and overall survival"
2199,NCT01178801,the relationship between the clinical data and the decision of treatment strategies,2010-03,UNKNOWN,OBSERVATIONAL,['NA'],,
2200,NCT01434147,occurence of toxicity,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,post-surgery morbidity
2201,NCT04780256,recurrence rate,2021-03-15,UNKNOWN,OBSERVATIONAL,['NA'],,costs
2202,NCT03255343,size of tumor,2017-03-13,UNKNOWN,INTERVENTIONAL,['NA'],,HPFS
2203,NCT02563054,Time to disease progression,2003-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Incidence of adverse events
2204,NCT01869088,Overall survival time,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Tumor response
2205,NCT00422877,Response Rate,2007-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Survival
2206,NCT03415919,confirmation of diagnosis by pathologist,2018-07-13,UNKNOWN,OBSERVATIONAL,['NA'],,
2207,NCT04129177,Surgical site infection rate,2018-10-01,COMPLETED,OBSERVATIONAL,['NA'],,
2208,NCT02317731,Bowel preparation quality,2014-12,TERMINATED,INTERVENTIONAL,['NA'],,Tolerability will be measured by subjective survey including a 5-point scale and a visual analog scale filled by the subjects the day of the colonoscopy
2209,NCT02106884,QOL Global Health Status Deterioration-free Median Survival,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Laboratory Safety Assessment
2210,NCT01516489,FOBT completion and return,2012-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,FOBT completion rate among previously non-adherent patients and FOBT kit return time by arm
2211,NCT04992143,1-year survival rate,2021-08-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease control rate
2212,NCT00749450,3-year disease-free survival,2008-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Quality of life as assessed by EORTC QLQ-C30, EORTC QLQ-CR29, EQ-5D, and GOG Ntx4"
2213,NCT01444495,local and systemic recurrence rate,1999-01,COMPLETED,INTERVENTIONAL,['NA'],,downstaging of rectal cancer
2214,NCT03279289,Progression-free survival,2017-10-25,COMPLETED,INTERVENTIONAL,['PHASE2'],Biomarkers in serum and tumour tissue associated with cell and tumour growth and/or involved in the mechanism of action of FOLFIRI+aflibercept and their correlation with efficacy parameters,VES-13 score (Vulnerable Elders Survey) as the utility measure for health deterioration
2215,NCT04319757,Phase Ib/II starting dose for ACE1702,2020-05-19,RECRUITING,INTERVENTIONAL,['PHASE1'],"Shift in serum tumor marker values (CA-125, CA 19-9, and CEA levels, in applicable tumor types)",Evaluate immune function after administering ACE1702
2216,NCT04941300,Colonoscopy after abnormal FIT (primary),2021-06-08,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE3'],Repeat screening (exploratory outcome),Follow-up process
2217,NCT03928652,Tumor regression grade,2019-04-24,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival
2218,NCT06201065,Overall Survival (OS),2023-12-26,RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse Events
2219,NCT03190941,Frequency and severity of treatment-related adverse events,2017-09-21,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2220,NCT02139475,Boston bowel preparation scale (BBPS),2013-12,TERMINATED,OBSERVATIONAL,['NA'],,
2221,NCT02242786,oral morphine equivalent doseresponse criteria,2014-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of Life
2222,NCT05448677,Progression-Free Survival (PFS),2022-12-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Objective response rate (ORR)
2223,NCT03192618,Disease-free survival (DFS),2017-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall survival (OS)
2224,NCT04175912,Objective response rate,2020-03-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Specimen banking,Overall survival
2225,NCT01217060,Pathologic Complete Response (PCR) Rate,2010-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease-free Survival (DFS) Time
2226,NCT00832689,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2227,NCT04602026,Health-related quality of life (composite measure),2020-09-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
2228,NCT02962063,pathologic complete response rate,2016-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall survival (OS)
2229,NCT01192971,TTP (Time to Progression),2010-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,QoL (quality of life): EORTC QLQ-C30
2230,NCT01418729,Overall survival,2011-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,time to symptomatic progression (TTSP).
2231,NCT02640586,Predictive value of preoperative MRI(7-9 weeks after the completion of preoperative chemo-radiotherapy) for assessing pCR,2016-01-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Predictive value of preoperative MRI(7-9 weeks after the completion of preoperative chemo-radiotherapy) for assessing pathological response according to Tumour Regression Grade (TRG)
2232,NCT06100692,oral mucositis scale,2023-11-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
2233,NCT03724591,Anastomosis leakage rate,2019-01,UNKNOWN,INTERVENTIONAL,['NA'],,postoperative quality of life as assessed by EORTC QLQ-C30 questionnaire
2234,NCT03329183,Objective Response Rate(ORR),2019-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease Control Rate (DCR)
2235,NCT03577535,Oral mucositis grade in patients during chemotherapy and radiotherapy treatments,2017-11-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Nutritional status of the patients during Chemotherapy and radiotherapy treatments
2236,NCT02412579,Using next-generation sequencing methods to detect isomiRs across different HCC cohorts at all stages undergoing liver transplantation.,2015-03,COMPLETED,OBSERVATIONAL,['NA'],,
2237,NCT00158886,To determine the MTD of oral topotecan in combination with pelvic radiation,2001-11-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,To evaluate the toxicity and potential efficacy of oral topotecan and concurrent pelvic radiation for the treatment of rectal cancer. To determine pathologic response to treatment and assessment of sphincter preservation.
2238,NCT02971345,Overall Survival,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Time To Progression
2239,NCT01560533,Body representations,2011-11,COMPLETED,INTERVENTIONAL,['NA'],,
2240,NCT02033070,Endoscopic clearance rate for Barrett's Esophagus,2013-11,UNKNOWN,OBSERVATIONAL,['NA'],Histological clearance rate for dysplasia,Histological clearance rate for intestinal metaplasia
2241,NCT01141478,Overall Survival Rate Between Time of Consent and Time of Death,2010-09-08,TERMINATED,INTERVENTIONAL,['NA'],,
2242,NCT02406118,TME quality & circumferential resection margin (CRM),2015-03-01,UNKNOWN,INTERVENTIONAL,['NA'],5-year overall survival,Number of harvested Lymph Nodes
2243,NCT04522908,Treatment discontinuation rate due to treatment-related adverse events,2020-10-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,"Correlation of biomarkers potentially associated with clinical efficacy (OS, PFS and ORR)"
2244,NCT02580422,"The number of patients who have changes in echocardiography, pulmonary function or one or more part of their functional evaluation tests",2015-10-01,TERMINATED,OBSERVATIONAL,['NA'],,Change in levels of cytokines
2245,NCT02426034,"Safety, which was assessed by recording the incidence and severity of adverse events",2015-05-15,COMPLETED,INTERVENTIONAL,['PHASE4'],,"Quality of life, measured by the questionnaire of EORTC QLQ-C30"
2246,NCT04280640,Correlation between treatment response in CTCs and in vivo,2021-06,WITHDRAWN,OBSERVATIONAL,['NA'],,"Sensitivity, specificity, and predictive values of CTC cultures' treatment response"
2247,NCT03107650,Evaluation of the circumferential margin status in the rectal specimen according international consensus (positive margin if tumor ≤ 1mm from circumferential margin),2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Survival
2248,NCT03753789,Percentage of Lesions Where Re-ablation is Suggested,2019-11-05,TERMINATED,INTERVENTIONAL,['NA'],,Hospital Resource Utilization
2249,NCT00538291,Response Rate,2005-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,
2250,NCT01868139,Response Rate to Therapy,2013-06,TERMINATED,INTERVENTIONAL,['NA'],,Safety of Spray Cryotherapy in This Setting;
2251,NCT02018757,time to progression,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Proportion of Participants with Adverse Events
2252,NCT00470184,Complete Response,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life Improved Rate
2253,NCT00336856,Response Rate (RR),2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
2254,NCT05607186,Correlation between mrTRG and pTRG,2011-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Prognostic value of mrTRG on survival outcomes of rectal cancer patients
2255,NCT06003673,recurrence-free survival (RFS),2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE4'],,Overall Survival (OS)
2256,NCT03637686,Patients with high risk of recurrence can be identified with ctDNA profiling performed immediately after treatment for CRC.,2018-06-14,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Can ctDNA detect recurrence earlier than standard-of-care?
2257,NCT05109130,Change of circulating tumor cells during laparoscopic or transanal endoscopic surgery,2021-10-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Disease free survival
2258,NCT02698462,Diagnostic yield,2016-04,COMPLETED,INTERVENTIONAL,['NA'],Comparison of diagnostic yield in detecting advanced neoplasia of FIT with the national CRC screening yield,Positive predictive value
2259,NCT01046487,For safety: NCI-CTCAE scale version 3.0,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,For anti tumoral efficiency : RECIST criteria
2260,NCT00003307,,1998-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2261,NCT03852238,exposure to Viral hepatitis B,2010-08-18,COMPLETED,OBSERVATIONAL,['NA'],fats,exposure to viral hepatitis C
2262,NCT01313416,"Toxicity Evaluation: From Time of First Treatment With CT-011 (Pidilizumab, MDV9300)",2012-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Disease Response: Evaluated Using the Revised Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines (v1.1)
2263,NCT00453323,To evaluate the response rate,2006-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,To estimate the overall survival
2264,NCT03013153,5-years overall survival rate,2016-12,UNKNOWN,INTERVENTIONAL,['NA'],,Sexual function scoring
2265,NCT05984576,Local control,2023-06-21,RECRUITING,OBSERVATIONAL,['NA'],,
2266,NCT05646355,Number of Participants who Completed Colonoscopy at 6 Months,2023-03-15,COMPLETED,INTERVENTIONAL,['NA'],,Number of Participants with Positive FIT Test who Complete Colonoscopy at 6 Months
2267,NCT06282809,Evaluate the safety of the HistoSonics Edison System for the destruction of pancreatic adenocarcinomas using histotripsy,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
2268,NCT03978078,Number of biological risk factors for metastatic digestive cancer,2016-09-12,RECRUITING,INTERVENTIONAL,['NA'],,
2269,NCT05964543,Objective response rate (ORR),2023-06-21,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-free survival (PFS)
2270,NCT05873972,response rate,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,overall survival
2271,NCT04694521,intestinal function,2016-09,COMPLETED,INTERVENTIONAL,['NA'],,the overall postoperative morbidities
2272,NCT02802124,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2015-06,TERMINATED,INTERVENTIONAL,['NA'],,Number of participants with tumor response as assessed by RECIST 1.1
2273,NCT02514525,percentage of all treated patients who have complete eradication of all dysplasia (CE-D),2016-03,UNKNOWN,INTERVENTIONAL,['NA'],,Number of CryoBalloon ablation treatments required to achieve CE-D or CE-IM
2274,NCT02728219,overall survival,2012-05,COMPLETED,INTERVENTIONAL,['NA'],,
2275,NCT04924075,Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR),2021-08-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Time to Surgery (TTS)
2276,NCT03640208,Difference in paired pre-/post-test score,2019-02-27,RECRUITING,INTERVENTIONAL,['NA'],,Barriers faced to scheduling colorectal cancer screening
2277,NCT02325232,Identification of celiac patients at higher risk of developing small bowel neoplasia and evaluation of the the usefulness of VCE and DBE,2012-02,UNKNOWN,INTERVENTIONAL,['NA'],A flowchart for early diagnosis of small bowel tumors in CD patients,The diagnostic yeld of DBE and VCE in this setting of patients
2278,NCT01031628,Evaluation of Lesions for Progression or Response Via RECIST Criteria,2010-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,
2279,NCT00515931,Target tumor response rate,2007-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Adverse effects of radiation therapy
2280,NCT05040464,Variation of the endoscopic response between AZA and MTX groups,2021-08-26,RECRUITING,INTERVENTIONAL,['PHASE3'],,
2281,NCT00350142,Rate of Local Control,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival Time
2282,NCT04898426,Bowel preparation quality,2021-08-13,UNKNOWN,INTERVENTIONAL,['NA'],,Polyp detection rate
2283,NCT04360577,Total AUC of FACT-Gastric TOI,2020-05-27,RECRUITING,INTERVENTIONAL,['NA'],Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],Average trajectory of Modified Edmonton Symptom Assessment Scale
2284,NCT04401787,oncological outcome,2016-12-11,COMPLETED,INTERVENTIONAL,['NA'],,early locoregional recurrence
2285,NCT03174405,Progression Free Survival Rate (PFS) @ 12 months,2017-07-17,COMPLETED,INTERVENTIONAL,['PHASE2'],,Translational research
2286,NCT01763125,Establishment of blood/tissue bank consisting of oncological samples from cancer patients and benign and healthy controls.,2003-11,RECRUITING,OBSERVATIONAL,['NA'],,
2287,NCT03659292,Overall survival (OS),2018-09,UNKNOWN,INTERVENTIONAL,['NA'],,Blood levels of ropivacaine and sufentanil
2288,NCT05568316,Biochemical Measurements,2020-11-01,COMPLETED,INTERVENTIONAL,['NA'],,Lenght of Hospital Stay of Participants
2289,NCT03116152,Overall Survival,2017-05-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Response
2290,NCT04585919,Conditional Odds Ratio of Patients Screened for Social Needs During Intervention Compared to Patients Screened During Usual Care,2020-10-01,COMPLETED,INTERVENTIONAL,['NA'],,Number of Reminders Per FIT Return
2291,NCT04535492,"Rate of successful completion of colorectal cancer screening noted via electronic health record having colonoscopy, fecal occult blood, or non invasive screening option result for the patient.",2022-01-04,WITHDRAWN,INTERVENTIONAL,['NA'],,Average score of clinician experience and satisfaction as assessed via Likert scale survey.
2292,NCT05092880,progression-free survival,2022-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Cost-effectiveness: Productivity Cost Questionnaire (PCQ)
2293,NCT05059665,Evaluate the performance (sensitivity/specificity) of the HelioLiver Test for all stage HCCs,2020-04-20,COMPLETED,OBSERVATIONAL,['NA'],,
2294,NCT00083720,Number of Participants With Serious Adverse Events,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
2295,NCT04711434,The percentage of patients from randomization to the first appearance of one of the following: adenomatous polyps or second primary tumors,2020-11-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall Survival
2296,NCT02316028,toxicity of escalating doses of decitabine administered by HAI,2014-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,measuring Global DNA methylation of cell free DNA
2297,NCT05035381,Objective response rate,2019-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse Events
2298,NCT05174845,Number of Patients With 'Excellent Plus Good' (Highly Effective) Bowel Cleansing (Colon Ascendens),2021-10-01,COMPLETED,OBSERVATIONAL,['NA'],,Sub-analyzes of the primary and secondary outcomes
2299,NCT02804802,Colorectal cancer diagnosed by colonoscopy after a positive fecal occult blood test (Hemoccult II),2013-02,UNKNOWN,OBSERVATIONAL,['NA'],,
2300,NCT00411450,Time to Response,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants Who Developed Antibodies to Panitumumab
2301,NCT03977272,Overall survival,2019-03-27,COMPLETED,INTERVENTIONAL,['PHASE2'],,EORTC QLQ - PAN26 score
2302,NCT04178759,Volume of regenerated liver after liver resection,2019-09-01,UNKNOWN,INTERVENTIONAL,['NA'],,Evaluation of short term surgical outcomes
2303,NCT03813953,Overall survival in months,2019-02-20,UNKNOWN,INTERVENTIONAL,['NA'],,Disease free survival
2304,NCT01248299,Overall survival,2011-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Cost analysis
2305,NCT00843830,"The Percentage of Participants That Patients Complete Radiation Therapy, All Three Vaccinations, and Evaluation for Tumor Response Four Weeks After the Third Vaccination.",2006-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,Number of Patients That Respond to Treatment
2306,NCT05634525,Overall survival (OS),2023-05-03,RECRUITING,INTERVENTIONAL,['PHASE1'],,
2307,NCT05176834,Proportion of patients performing at least 50% of expected daily treatments during radiotherapy period.,2022-01-31,UNKNOWN,INTERVENTIONAL,['NA'],,The proportion of the patients that will experience severe oral mucositis
2308,NCT02916511,Local control rate,2016-09-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,overall survival
2309,NCT03275974,Change in tumor size,2021-04-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival
2310,NCT00540943,The safety and tolerability of the maximum tolerated dose defined as a dose regimen where no more than 1 of 6 subjects experiences a dose limiting toxicity.,2007-07-13,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to progression
2311,NCT05713903,Mesocolic Resection Plane,2023-02-06,RECRUITING,INTERVENTIONAL,['NA'],,Overall Survival
2312,NCT01054274,Overall survival and Median Survival,2009-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Successful rate of stent placement
2313,NCT04288661,POD of intra-abdominal complication detection,2020-02-28,RECRUITING,INTERVENTIONAL,['NA'],,Readmissions
2314,NCT06289803,diagnostic efficacy,2023-09-01,RECRUITING,INTERVENTIONAL,['NA'],,Rate of R0 resection
2315,NCT01930383,Numbers of circulating tumor cells,2013-10,UNKNOWN,OBSERVATIONAL,['NA'],,Clinical characteristics
2316,NCT00513461,Change in Serum AFP Levels,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Changes in Quality of Life - Mental Score
2317,NCT01804179,Rate of Test Kit Completion,2011-02-11,COMPLETED,INTERVENTIONAL,['NA'],,Time to Kit Return
2318,NCT00069121,Disease-Free Survival (DFS) [Time to Event],2003-04-18,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With at Least One Adverse Event by Most Severe Intensity
2319,NCT00168987,improvement of quality of life at two months,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,"improvement of nutritional state (body weight, muscle mass, body cell mass, phase angle, serum albumin)"
2320,NCT06328738,Incidence of electrocardiogram abnormalities,2024-06-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Brain metastases response (Phase 1b only)
2321,NCT02009423,Recurrence Free Survival (RFS),2015-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,Overall Survival (OS)
2322,NCT03500874,3 Year Relapse Free Survival Rate,2018-05-28,TERMINATED,INTERVENTIONAL,['PHASE3'],Serum ctDNA methylation levels,Liver-specific RFS
2323,NCT04523493,Overall survival (OS),2020-06-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Tumor mutation burden (TMB),Immunogenicity
2324,NCT03459339,Natural History of Barrett's Esophagus Using Tethered Capsule Endomicroscopy,2017-04-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
2325,NCT03093870,Progression-free Survival (PFS) - Part 1,2017-07-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,ECOG Performance Status - Part 1
2326,NCT01839773,Progression Free Survival (PFS),2013-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety
2327,NCT01097265,Percentage of successful sentinel lymph node mapping procedures using multivariate analysis (stage 2),2010-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Stratified analysis of DFS and OS according to total harvested lymph nodes per resected specimen and chemotherapy regimen (capecitabine and oxaliplatin versus capecitabine alone) (stage 2)
2328,NCT04168931,Frequency of HER2 expression,2020-01-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,
2329,NCT02948985,Correlation of RAS status on CTCs with clinical outcomes,2017-01,UNKNOWN,OBSERVATIONAL,['NA'],,Correlation of mutant gene in ctDNA with cetuximab resistance.
2330,NCT03197155,Hepatocellular recurrence event,2016-06-01,COMPLETED,OBSERVATIONAL,['NA'],,
2331,NCT04430179,Change in Lund-Mackay sinus computed tomography (LMK-CT) score,2020-12-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,Change in biomarkers concentrations in nasal secretion measured by enzyme-linked immunosorbent assay (ELISA)
2332,NCT04517448,Change in the response scores to the standardized questionnaire Quality of life questionnaire in cancer patient,2020-10-16,UNKNOWN,OBSERVATIONAL,['NA'],,Change in the Activity of daily living score
2333,NCT06016829,EORTC-QLQ-CR29,2021-07-25,COMPLETED,OBSERVATIONAL,['NA'],,
2334,NCT02515344,Patient participation rate to colorectal cancer screening,2015-08,COMPLETED,INTERVENTIONAL,['NA'],,Number of cancers screened in (versus diagnosed outside) the screening procedure.
2335,NCT01434069,Maximum Tolerated Dose (MTD),2011-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Tumor Response
2336,NCT04131062,MyCode enrollment decision,2019-11-01,COMPLETED,INTERVENTIONAL,['NA'],,
2337,NCT05771584,Immunologic efficacy of AST-301 immunization,2023-07-04,RECRUITING,INTERVENTIONAL,['PHASE2'],,Change in central memory T-cell populations between Arm 1 and Arm 2
2338,NCT01652833,Proportion of oncologists who administer Vectibix simultaneously with oxaliplatin-containing chemotherapy in mCRC patients with mutant KRAS tumors or patients with tumor KRAS status unknown,2012-03,COMPLETED,OBSERVATIONAL,['NA'],,
2339,NCT00087074,"Proportion of confirmed tumor responses, defined to be either a CR or PR noted as the objective status on 2 consecutive evaluations at least 4 weeks apart",2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to treatment failure
2340,NCT03750461,Number of Participants With Wound Occurrences in Current Study Compared to Historical Controls,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Quality of Life After Mesh Implantation
2341,NCT00183885,Tumor Response,2004-10-18,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of participants with grade 3 or higher toxicity
2342,NCT05262855,"Performance [sensitivity, specificity, accuracy] of [68Ga]FAPI-46 PET imaging to detect FAP-expressing cells, using histopathology as truth standard.",2022-05-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,[68Ga]FAPI-46 accumulation observed by (PET)/ (CT) pre and post in patients undergoing Neoadjuvant treatment.
2343,NCT04140435,The increment in diagnostic yield,2019-10-22,RECRUITING,OBSERVATIONAL,['NA'],,The inter-observer agreement
2344,NCT03259828,Interfraction sigmoid colon organ motion,2017-12-06,COMPLETED,INTERVENTIONAL,['NA'],,Setup errors
2345,NCT00002783,,1996-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2346,NCT03015675,Progression Free Survival,2017-03-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Response Rate
2347,NCT00795977,To establish the maximally tolerated dose (MTD) and dose limiting toxicities (DLT) of intratumoral autologous dendritic cell vaccination in combination with OK-432,2003-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To evaluate the immune response of patients treated with this regimen based on the presence and characterization of tumor-infiltrating white blood cells
2348,NCT01774786,Overall Survival,2013-06-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Cmin of Trastuzumab
2349,NCT06193356,Performance of detecting a recurrence at an endoscopic resection scar.,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Performance of a learning tool in improving detection of recurrence at an endoscopic resection scar compared between endoscopists with different experience level
2350,NCT04649372,Incidence of Treatment-Emergent Adverse Events (CTCAE),2021-01-13,COMPLETED,INTERVENTIONAL,['NA'],,Evaluation of Pain pre and post-treatment
2351,NCT03362177,Incidence of a Thrombocytopenia-induced chemotherapy dose modification during the second or third on study chemotherapy cycles.,2019-09-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,AEs/SAEs overall safety of romiplostim
2352,NCT06202716,Progression-free Survival (PFS),2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety
2353,NCT03804255,"Factors influencing heterogeneity of capacity for biomarker testing, from among modifiable testing practice-related factors, e.g. cost, complexity, technologic complexity, lack of familiarity, physician and patient demand",2019-01-08,WITHDRAWN,OBSERVATIONAL,['NA'],,Proportion of pathology practices testing for novel biomarkers using a standard reflexive testing protocol
2354,NCT01416038,Number of reported adverse events,2011-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Levels of cell mediated immunity targeting the survivin epitopes
2355,NCT02013089,Overall survival,2013-12,UNKNOWN,INTERVENTIONAL,['NA'],Disease control rate,Response rate
2356,NCT01048892,Recommended phase II dose of Seneca Valley virus-001 (NTX-010),2009-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Development of antibodies to NTX-010
2357,NCT00155272,The primary endpoint is the feasibility and tolerability of thalidomide plus radiotherapy.,2005-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The secondary end point is correlation of parameters of tumor perfusion assessed by DCEMRI and serum cytokine levels with objective tumor response.
2358,NCT04965259,Changes in the profile of metabolome in urine and plasma as high-risk patients develop HCC.,2021-04-15,RECRUITING,OBSERVATIONAL,['NA'],,
2359,NCT04387903,Tumor recurrence,2000-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Risk factors for surgical reoperation
2360,NCT01008917,Maximum tolerated dose,2009-11-17,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Incidence of progression-free survival, overall survival, and disease control rate"
2361,NCT02507765,"Feasibility of SBRT in combination with TACE, measured by the number of patients able to tolerate all study procedures",2015-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Change in plateau signal intensity calculated from the DCE curve,Progression-free survival
2362,NCT05103631,Number of Patients with Dose Limiting Toxicity,2021-06-17,RECRUITING,INTERVENTIONAL,['PHASE1'],,Median T cell persistence
2363,NCT04288999,Locally recurrent free survival,2019-10-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,QOL
2364,NCT00054249,,2002-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2365,NCT03110510,Overall Overall Response Rate,2019-09-06,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Overall survival
2366,NCT03239184,Relief degree of tumors,2017-09-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Overall survival（OS）
2367,NCT05065515,Degree of tumor regression,2021-10-01,RECRUITING,OBSERVATIONAL,['NA'],Species richness,The relative abundance of species
2368,NCT06295094,Peritoneal disease-free survival,2024-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of patients not receiving adjuvant chemotherapy
2369,NCT01379872,"Synthesise the data obtained for objectives 1-3 together with information from previous studies and expert opinion to estimate the safety, clinical efficacy and cost-effectiveness of new technologies compared to conventional standards",2011-06,COMPLETED,OBSERVATIONAL,['NA'],,
2370,NCT00002575,Overall survival,1994-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Compare the differences in quality of life of patients treated with these regimens
2371,NCT04546802,Viral eradication,2019-09,WITHDRAWN,INTERVENTIONAL,['PHASE3'],Overall survival,Adverse events
2372,NCT03193216,Percentage of Patients With Successful Eradication,2017-08-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Treatments (Mean)
2373,NCT00427570,,1977-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2374,NCT01112046,Short-term morbidity,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Local recurrence
2375,NCT01661972,Median Progression Free Survival (PFS),2012-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Median Survival
2376,NCT01298999,Number of Participants That Experienced Change in Any Biomarker Expression,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants That Experienced Adverse Events
2377,NCT05848154,Objective response rate (ORR) of neoadjuvant therapy in patients with non-metastatic pancreatic cancer,2023-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,The mechanisms of drug resistance to neoadjuvant chemotherapy
2378,NCT00220129,2 year overall survival,2002-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to improvement of dysphagia
2379,NCT01376453,Maximum Tolerated Dose (MTD),2011-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Serious Adverse Events (SAEs)
2380,NCT05066139,Impact of EPODIG-G program on treatment.,2021-09-17,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
2381,NCT06019702,Dose-limiting Toxicity (DLT),2023-09-08,RECRUITING,INTERVENTIONAL,['PHASE1'],,Cytokines Level [immunogenicity]
2382,NCT03740165,PFS Per RECIST 1.1 as Assessed by the Investigator in All Participants,2018-12-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Pathological Complete Response (pCR) Rate
2383,NCT03306394,Abnormalities in vital signs,2016-10-18,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of life using the questionnaire EORTC QLQ-C30
2384,NCT01980407,Response rate,2013-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease control rate
2385,NCT00767936,identify mutations in the hepatitis B virus genome that predisposes these high risk individuals to the development of liver cancer,2008-03,TERMINATED,OBSERVATIONAL,['NA'],,
2386,NCT03011255,Local control,2016-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
2387,NCT05446558,Overall survival,2022-02-28,RECRUITING,INTERVENTIONAL,['NA'],,Cost of tests during hospitalization
2388,NCT02729493,Disease control rates,2015-11-14,UNKNOWN,INTERVENTIONAL,['NA'],,
2389,NCT00362739,Establish a set of normal ranges for various parameters in healthy individual specimens and compare to specimens from individuals with lung disease to determine parameters resulting in disease susceptibility and severity.,2005-09,COMPLETED,OBSERVATIONAL,['NA'],,
2390,NCT04525807,Objective response rate,2020-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival
2391,NCT02298959,Recommended combination dose of ziv-aflibercept and pembrolizumab,2015-04-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Effects on tumor vasculature and vascular active molecules,Time-to-progression
2392,NCT06060769,HCC incidence rate,2023-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
2393,NCT05380414,"Number of patients with at least one actionable alteration defined as an alteration shown to predict for sensitivity to a drug FDA/EMA approved for use in another cancer type, or a relevant alteration for inclusion in a clinical trial.",2022-07-01,RECRUITING,INTERVENTIONAL,['NA'],,Duration of response (DoR)
2394,NCT01675258,,2012-09,UNKNOWN,OBSERVATIONAL,['NA'],,
2395,NCT03896646,Tumor objective response rate (ORR),2019-10-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Development of a model correlating normal liver radiation dose to liver function using single-photon emission computed tomography computed tomography hepatobiliary iminodiacetic acid (SPECT CT HIDA) imaging
2396,NCT05962723,"sensitivity, specificity and accuracy",2023-08-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
2397,NCT02293811,Analysis of expression of P2RX7,2015-02-09,TERMINATED,INTERVENTIONAL,['NA'],,Five isoforms of the P2RX7 protein
2398,NCT03929094,Progression Free Survival,2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,adverse events
2399,NCT00815087,The Change From Baseline and Cut Point VFSS in Velocity of Displacement of Hyoid Bone at 1 to 3 Months,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Questionnaire of Life Quality
2400,NCT05493995,Disease Control Rate (DCR),2022-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression-free survival (PFS)
2401,NCT06189482,Body Mass Index,2022-06-01,TERMINATED,INTERVENTIONAL,['NA'],,Penetration-Aspiration Scale
2402,NCT02150733,Composite of plasma pharmacokinetic parameters of Tivantinib,2014-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Composite of plasma pharmacokinetic parameters of Tivantinib metabolites
2403,NCT06155383,Pathological complete response (pCR) rate,2023-11-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
2404,NCT02368236,"Participation in risk-appropriate colorectal cancer testing (i.e., participation in any CRIS-recommended test based on patients' risk factors).",2008-12,COMPLETED,INTERVENTIONAL,['NA'],,Testing difference in receipt of any type of colorectal cancer testing.
2405,NCT05751850,Overall survival (OS),2023-06-13,RECRUITING,INTERVENTIONAL,['PHASE3'],,Progression free survival (PFS)
2406,NCT00828594,Time to disease progression assessed when 60 events have been observed,2008-12,TERMINATED,INTERVENTIONAL,['PHASE1'],,Pharmokinetics of RAD001 at pre-dose and 1 hour and 2 hours post-dose
2407,NCT01715363,Clinical tolerance of immediate preoperative chemotherapy,2012-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,
2408,NCT05074589,Overall Survival(OS),2018-01-25,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of life（QoL）
2409,NCT01923948,Postoperative Opioid Consumption,2013-05,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative Pain Scores on the Visual Analog Scale
2410,NCT01771146,Progression Free Survival (PFS) as defined by the length of time that a patient survives without any signs or symptoms of that cancer or any other type of cancer,2012-10,UNKNOWN,INTERVENTIONAL,['NA'],,• R0 resection as defined as microscopically negative margins
2411,NCT00147134,Overall survival,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,The proportion of completion of LAP
2412,NCT03641313,Objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 response criteria,2020-11-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Presence of other deoxyribonucleic acid (DNA) damage response defects (DDRD),Overall survival (OS)
2413,NCT01085617,Event-free survival,2010-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Mucositis score in patients treated with palifermin
2414,NCT00005050,,1999-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2415,NCT02845479,Feasibility of study protocol,2018-12-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Natural kill cell activation,Feasibility of recruitment
2416,NCT00897403,Collection of blood and tissue,2006-12,COMPLETED,OBSERVATIONAL,['NA'],,
2417,NCT00491855,Maximum Tolerated Dose (MTD),2007-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2418,NCT03400072,M6 Health-Related quality of life (HRQoL),2018-08-03,RECRUITING,INTERVENTIONAL,['NA'],,
2419,NCT01468688,Frequency and characteristics of dose limiting toxicities (DLTs) at each dose level during the first cycle of therapy,2012-04-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Clinical benefit rate (CBR) defined as the rate of confirmed complete response (CR) or partial response (PR), or stable disease (SD) which lasts for at least 16 weeks."
2420,NCT01830270,curative resection rate,2011-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,global survival
2421,NCT04067960,"Changes in symptoms, quality of life (QOL), and perceptions about pharmacogenomics (PGx) testing",2019-06-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Provider opinions surrounding the clinical utility/relevancy of PGx testing in cancer patients
2422,NCT03286244,Percentage of patients who suffer at least one adverse event,2018-03-15,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Progression-free survival
2423,NCT05564338,Recurrence-free survival (RFS) as assessed by the investigator between Arm B and Arm D,2023-06-30,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Participants Reported Outcome as measured at Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and its hepatocellular carcinoma cancer module QLQ-HCC18
2424,NCT01524094,Overall survival,2003-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Side effects of treatment
2425,NCT03592641,Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1),2019-07-25,TERMINATED,INTERVENTIONAL,['PHASE2'],,Months of Progression-Free Survival (PFS)
2426,NCT06045975,local recurrence-free survival,2023-12-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],"Consittution of a sequential biobank comprising peripheral samples (serum, plasma)",Safety of Durvalumab/Tremelimumab infusions
2427,NCT00001603,,1996-12,COMPLETED,OBSERVATIONAL,['NA'],,
2428,NCT02450656,Progression Free Survival (Phase II),2015-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Pharmacogenetics profiling to assess predictors of response and resistance- inducing mutations,"Efficacy (Phase II) (Overall response rate (ORR), duration of response (DOR) , time to response (TTR) and overall survival (OS) per RECIST v1.1)"
2429,NCT06116136,Objective Response Rate (ORR),2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Objective Response Rate (ORR)
2430,NCT01352728,Two-year survival rate,2011-05-18,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tissue and Serum Biomarkers
2431,NCT03722121,"distance ""home of patients - treatment center""",2017-03-23,UNKNOWN,OBSERVATIONAL,['NA'],,
2432,NCT05361538,Comparison of progression-free survival between MSA and traditional MWA in HCC,2022-06-22,RECRUITING,INTERVENTIONAL,['NA'],,Comparison of the complications rate of MSA and traditional MWA in HCC
2433,NCT05128032,Radiotracer distribution,2022-03-01,RECRUITING,INTERVENTIONAL,['NA'],,Technical success of radiotracer delivery as measured by ability to deliver radiotracer
2434,NCT01961778,Percentage of Barrett's esophagus ablated during the initial treatment session.,2013-11,COMPLETED,INTERVENTIONAL,['NA'],,Patient discomfort
2435,NCT00192088,The primary objective of this study is to determine the response rate of Pemetrexed plus oxaliplatin as first-line therapy in patients with advanced gastric carcinoma.,2004-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Determinants of efficacy and toxicity of the treatment with pemetrexed and oxaliplatin in the patient population by means of pharmacogenomic and pharmacogenetics investigations: Quantitative analysis of TS, DHFR, GARFT, RFC, MRP5, DPD, TP, FPGS and ERCC1"
2436,NCT02877368,sarcopenia,2014-05,COMPLETED,OBSERVATIONAL,['NA'],,Imatinib-induced toxicities
2437,NCT00041808,,2001-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2438,NCT05422547,Tumour recurrence,2022-04-01,RECRUITING,OBSERVATIONAL,['NA'],,Possible economic impact
2439,NCT02348229,Compartition of postoperative hospital stay,2013-09,COMPLETED,INTERVENTIONAL,['NA'],,Change from baseline in C-Reactive Protein( CRP) and visceral proteins level
2440,NCT01373164,Phase 2: Overall Survival (OS),2011-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Change From Baseline in Carbohydrate Antigen 19.9 (CA19-9) Level at First Study Completion Follow-up
2441,NCT02911974,The total area of procured tissue between the FNA and FNB needles,2016-08,COMPLETED,INTERVENTIONAL,['NA'],,Diagnostic adequacy between the FNA and FNB needles
2442,NCT05530343,Diagnostic yield of intestinal metaplasia (Screening population only),2022-10-03,RECRUITING,INTERVENTIONAL,['NA'],,Diagnostic yield of dysplasia (Screening population only)
2443,NCT01266564,Progression-free survival in a real life setting assessed by computer tomography,2010-09-03,COMPLETED,OBSERVATIONAL,['NA'],,Safety: incidence of adverse events
2444,NCT06196788,Overall survival，OS,2024-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,disease control rate (DCR)
2445,NCT01610895,Quality of Bowel Cleanliness,2011-12,UNKNOWN,INTERVENTIONAL,['NA'],,Patient satisfaction with preparation
2446,NCT00121745,To determine the dose limiting toxicity and maximum tolerated dose of Rexin-G administered as intravenous infusions; To evaluate pharmacokinetics of Rexin-G,2005-07,TERMINATED,INTERVENTIONAL,['PHASE1'],,To assess anti-tumor activity of intravenously administered Rexin-G and obtain preliminary data on biochemical markers of tumor response
2447,NCT01381913,,2005-10,COMPLETED,OBSERVATIONAL,['NA'],,
2448,NCT03871790,Identification of tumor specific mutations on the genomic level,2019-04-01,COMPLETED,OBSERVATIONAL,['NA'],,Identification of neo-antigens epitopes at protein level
2449,NCT00027495,,2001-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2450,NCT05679674,Median Progression Free Survival (PFS),2023-09-21,RECRUITING,INTERVENTIONAL,['NA'],,Chemotherapy-Free Interval
2451,NCT04343950,Intervention 3: Participation in breast cancer screening program,2020-09-15,UNKNOWN,INTERVENTIONAL,['NA'],,Incremental cost ratio
2452,NCT02994888,Track and validate specific known mechanisms of resistance/response to anti-EGFR therapies through,2012-11,COMPLETED,OBSERVATIONAL,['NA'],,Identify novel biomarkers of resistance to anti-EGFR therapies through whole exome sequencing
2453,NCT05668910,The performance of each single feature and the ensemble model with integrated features for early GC detection in each clinical stage,2022-09-01,RECRUITING,OBSERVATIONAL,['NA'],,"The performance of the ensemble model in combination of possible GC related biomarkers such as PG, G17, and/or Hp levels for early GC detection"
2454,NCT05724992,Presence - absence of predisposing mutations,2022-12-20,RECRUITING,INTERVENTIONAL,['NA'],,Correlation of genetic mutations with familial oncological history
2455,NCT01630174,,2009-10,UNKNOWN,OBSERVATIONAL,['NA'],,
2456,NCT04988945,Downstaging for hepatectomy,2020-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Pathological response
2457,NCT01171924,Number of Participants With Adverse Events,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2458,NCT03349398,the incidence of Roux stasis syndrome,2017-11-10,UNKNOWN,INTERVENTIONAL,['NA'],,the quility of life according to the RGB standards
2459,NCT00695201,Determine the MTD of hepatic arterial floxuridine (FUDR) & dexamethasone (Dex) given via implanted pump in combination w biweekly intravenous Oxaliplatin + systemic irinotecan (CPT-11) in patients w unresectable hepatic metastases from colorectal cancer.,2000-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To procure normal and disease liver tissue for evaluation of TS, p53, p21, TOPO 1, DPD, and ERCC levels."
2460,NCT06010212,ORR（Objective response rate）,2023-08-25,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,PFS（Progression-free survival）
2461,NCT03083951,Total number of lymph nodes and lymph node ratio.,2017-09-01,COMPLETED,INTERVENTIONAL,['NA'],Defecatory dysfunction assessed by FSFI and erectile dysfunction questionnaires,Survival
2462,NCT04347772,Length of hospital stay,2021-05-01,UNKNOWN,INTERVENTIONAL,['NA'],,Nutritional status - Dietary Intake
2463,NCT03582306,Feasibility - adherence,2018-07-23,COMPLETED,INTERVENTIONAL,['NA'],,Acceptability
2464,NCT03002064,Progression free survival,2016-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of life--Score of the questionnaire
2465,NCT03338647,"Progression (total of local, intra- and extrahepatic)",2017-10-26,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Cost-benefit
2466,NCT06323421,Acceptability,2024-04-22,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Systemic inflammation,
2467,NCT05818982,Progression-free survival,2023-02-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
2468,NCT04117958,Number of subjects with changes in electrocardiogram (ECG),2020-01-20,TERMINATED,INTERVENTIONAL,['PHASE1'],,"Overall survival (OS), 2-year OS"
2469,NCT05208047,Part 2 - Progression Free Survival (PFS),2022-04-14,RECRUITING,INTERVENTIONAL,['PHASE3'],,Part 2 Only - European Organisation for Research and Treatment of Cancer Quality of Life (EORTC-QLQ-30)
2470,NCT03904667,Operative outcomes,2017-01-01,UNKNOWN,OBSERVATIONAL,['NA'],Disease-free survival,Postoperative survival
2471,NCT03998566,Safety Endpoint,2019-04-24,COMPLETED,INTERVENTIONAL,['NA'],"Changes From Baseline Final RT Appointment, 3 Months, 6 Months, 12 Months, and 18 Months in QLQ-PAN26","Changes From Baseline at the Final RT Appointment, 3 Month, 6 Month, 12 Month and 18 Month in EORTC QoL (QLQ-C30)"
2472,NCT02082886,Overall survival rate,2014-02,COMPLETED,OBSERVATIONAL,['NA'],,Rates of complications
2473,NCT03690323,Overall survival,2015-04-07,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of Life questionnaire
2474,NCT01324141,Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE),2011-03-18,TERMINATED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Human Immunodeficiency Virus (HIV) in Biopsy Tissue From Rectal Mucosa
2475,NCT03671252,3-year disease free survival rate,2018-11-16,RECRUITING,INTERVENTIONAL,['PHASE3'],,Long term quality of life
2476,NCT06266871,pCR rate,2024-03-10,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,2-year OS rate
2477,NCT01669044,Cardiac output,2012-05,UNKNOWN,OBSERVATIONAL,['NA'],Systemic Venous Resistance Index,Stroke Volume
2478,NCT03663062,Risk model of colorectal adenomas and CRC,2017-12-27,COMPLETED,OBSERVATIONAL,['NA'],,The incidence of colorectal adenomas or CRC in patients who are smokers or who have high alcohol intake
2479,NCT01529827,Transplant Related Mortality (TRM),2012-02-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Time to Neutrophil Engraftment
2480,NCT00125034,Best Overall Response Rate - Independent Review Committee (IRC),2005-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety - Number of Patients Experiencing Any Adverse Event
2481,NCT01310478,Dose limiting toxicity and maximum tolerance dose of continous intravenous Endostar in combination with mFOLFOX6,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Parameters of human pharmacokinetics of continous intravenous Endostar in combination with mFOLFOX6
2482,NCT03730675,Overall survival,2018-11-10,UNKNOWN,INTERVENTIONAL,['NA'],,"Treatment Safety in terms of type, incidence, severity timing, seriousness, and relatedness of adverse events and laboratory abnormalities"
2483,NCT02135822,Overall response rate,2014-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety and tolerability
2484,NCT01770275,Overall survival,2008-04,COMPLETED,OBSERVATIONAL,['NA'],,Survival distinction
2485,NCT04744831,Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review Following IV Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2-overexpressing Metastatic Colorectal Cancer,2021-03-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Percentage of Participants Positive for Treatment-emergent Anti-drug Antibodies (ADAs) and Neutralizing Antibodies (NAb) in Participants Who Were Administered T-DXd
2486,NCT04294784,objective response rate(ORR),2020-04-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,patient-reported outcomes (PROs)
2487,NCT02864849,Major adverse events,2016-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Colorectal Cancer Module 29 (EORTC QLQ-CR29)
2488,NCT00967616,"Percentage of Participants With Progression-Free Survival at 16 Weeks After Administration of CS-7017 Combined With Irinotecan, Leucovorin, and 5-Fluorouracil (5-FU) After Failure of First-line Therapy in Treatment of Metastatic Colorectal Cancer",2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Treatment-Emergent Adverse Events Occurring in ≥10% of Participants Following Administration of CS-7017 Combined With Irinotecan, Leucovorin, and 5-Fluorouracil (FOLFIRI) After Failure of First-line Therapy in Treatment of Metastatic Colorectal Cancer"
2489,NCT06178198,Duration of response according to localized mRECIST,2023-11-08,RECRUITING,INTERVENTIONAL,['PHASE2'],Post-treatment dosimetry based on Y90 PET-CT,Changes in regional liver function
2490,NCT04724239,The progression-free survival (PFS) rates at 18 weeks,2021-03-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Duration of response (DoR)
2491,NCT05385900,"Pathological complete response, pCR",2022-06-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,"major pathologic response, MPR"
2492,NCT01123876,Determine the MTD and establish the recommended phase 2 dose of Veliparib in combination with two different FOLFIRI regimens that include a reduced regimen (150 mg/m2 irinotecan) and the standard regimen (180 mg/m2) in subjects with advanced solid tumors,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To assess the safety and tolerability, pharmacokinetic profile of the combination at each of the FOLFIRI regimens."
2493,NCT01749722,Number of adverse events,2012-11,COMPLETED,INTERVENTIONAL,['NA'],,
2494,NCT05630937,Objective Response Rate (ORR) (Phase II),2020-11-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
2495,NCT03026140,Disease free survival,2017-03-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Relapse free survival
2496,NCT05578820,Pharmacokinetics (Quantitative content of plasmid DNA (pTKhGM) in patients' urine),2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,
2497,NCT01651832,proportion of eligible patients undergoing adjuvant chemo therapy,2012-07,COMPLETED,INTERVENTIONAL,['NA'],,Quality of inpatient care
2498,NCT05391321,"Preference ranking of 4 validated sexual QOL questionnaires in French, FSFI, PISQ-IR, PISQ-12, BISF assessed on the collection of questionnaire returns by patients",2023-05-12,RECRUITING,INTERVENTIONAL,['NA'],,
2499,NCT02371135,"association of the gut microbiome and dietary factors (To validate said associations, individual questions from the Brief Diet and Lifestyle Questionnaire will be primarily used in the overall analyses)",2015-02,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
2500,NCT03207724,"Maximum Tolerated Dose (MTD) of onivyde, 5-fluorouracil/folinic acid in combination with Xilonix",2017-10-16,COMPLETED,INTERVENTIONAL,['PHASE1'],,Mean change in global score of patient-reported response to therapy (FAACT questionnaire- Functional Assessment of Anorexia/Cachexia Therapy)
2501,NCT04170257,"Negative predictive value (NPV) of WLE, NBI and ISE in the diagnosis of mild, moderate, severe dysplasia and above lesions in esophagus",2019-10-18,UNKNOWN,INTERVENTIONAL,['NA'],,Discrimination of visualized abnormal features
2502,NCT04844385,progression-free survival rate,2021-02-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life assessed by QLQ-C30
2503,NCT03841110,The incidence of participants with Dose Limiting Toxicities (DLTs) within each dose level cohort.,2019-02-15,COMPLETED,INTERVENTIONAL,['PHASE1'],,Duration of FT500 persistence
2504,NCT00280007,"to assess collateral tumor vessel growth on MRT / CT after 3, 6, and 12 months",2006-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,cost
2505,NCT03283956,Safety of the DC bead TACE,2017-09-13,UNKNOWN,OBSERVATIONAL,['NA'],,Tumor response
2506,NCT03607370,Complete pathologic response assessed by pathologist Dworak scale,2017-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Urinary catheter removal timing
2507,NCT03974542,rescreening of CRC,2019-10,UNKNOWN,INTERVENTIONAL,['NA'],,
2508,NCT04443322,Recurrence-Free Survival (RFS),2020-09-19,RECRUITING,INTERVENTIONAL,['NA'],,Percentage of Participants who Experience an Adverse Event (AE)
2509,NCT00949312,Disease-free survival (time to local or distant recurrence after resection),2009-05,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival (time to death from colorectal cancer)
2510,NCT05643859,Change in microbiome colonic mucosa: microbiome diversity,2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],,
2511,NCT02041507,Adenoma Detection Rate.,2014-02,COMPLETED,INTERVENTIONAL,['NA'],Patients willingness to repeat the examination.,Need for sedation/analgesia and its dosage
2512,NCT03517488,Determine the safety and tolerability profile of XmAb20717,2018-07-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2513,NCT05411783,Anastomotic leak,2022-05-01,RECRUITING,INTERVENTIONAL,['NA'],,Post-operative complications
2514,NCT00193128,"Pathologic Complete Response Rate (PCRR), the Percentage of Patients Who Have No Evidence of Cancer in Their Surgical Specimen Following Surgery",2004-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
2515,NCT03492151,Accuracy of risk-stratification of IPMNs,2018-10-01,RECRUITING,OBSERVATIONAL,['NA'],,Imaging quality
2516,NCT00769405,Overall survival,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Morbidity from surgical complications (abdominal, extra-abdominal, aplasia)"
2517,NCT06029010,"Descriptive analysis of biomarkers of patients with mCRC who had a long-term response to regorafenib monotherapy, as indicated by a treatment duration of ≥5 months",2023-08-31,COMPLETED,OBSERVATIONAL,['NA'],,"Descriptive analysis of biomarkers of patients with mCRC who had a long-term response to regorafenib monotherapy, as indicated by a treatment duration of ≥4 months"
2518,NCT01897454,Percentage of Participants Achieving R0 Resection (R0 Resection Rate),2012-01-27,TERMINATED,INTERVENTIONAL,['PHASE2'],,Vascular Reconstruction
2519,NCT01210235,Completion of colorectal cancer screening by eligible patients within 3 months of their flu shot,2009-10,COMPLETED,INTERVENTIONAL,['NA'],,
2520,NCT02576509,Overall Survival (OS),2015-12-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Efficacy Based on PD-L1 Expression - ORR
2521,NCT04017455,clinical complete and near-complete response rate,2019-10-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,local recurrence rate at 1 year follow-up
2522,NCT00648635,Quality of Life (QOL) Survey Responses,2008-03-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
2523,NCT01944137,Change from baseline (i.e. first chemotherapy administration visit) in patient-reported symptoms as measured by the Memorial Symptom Assessment Scale-Short Form.,2013-09,COMPLETED,INTERVENTIONAL,['NA'],,"Frequency of urgent outpatient Cancer Center visits, emergency department visits, and hospital admissions during six months post-baseline"
2524,NCT00030862,,2001-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2525,NCT02461966,Serum Aflatoxin Level in Liver Cancer Patients,2014-06,COMPLETED,INTERVENTIONAL,['NA'],,
2526,NCT06239155,Progress free survival (PFS),2019-09-03,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2527,NCT02465112,relapse-free survival (RFS),2015-09,TERMINATED,INTERVENTIONAL,['PHASE3'],,Impact of the therapy on 5-year RFS in treatment and control group
2528,NCT00931229,enroll 150 patients,2009-06,UNKNOWN,INTERVENTIONAL,['NA'],,
2529,NCT00897429,Cancer-specific mortality (B6),2007-07,COMPLETED,OBSERVATIONAL,['NA'],,Evaluation of up to 768 new genes for their relationship with colon cancer recurrence (B4
2530,NCT05511116,Inter-observer reproducibility,2022-07-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Tumor response on morphological imaging vs. tumor response grade on pathology
2531,NCT00534131,Oncological safety assessment - where appropriate,2004-04-01,COMPLETED,INTERVENTIONAL,['NA'],,
2532,NCT03416699,The grade score of the specimens integrity,2017-11-15,UNKNOWN,OBSERVATIONAL,['NA'],,the grade of anastomotic leakage
2533,NCT02402699,Identify and describe observed adverse events (AEs) based on liver function abnormalities and changes in hepatitis viral load,2015-12-15,COMPLETED,OBSERVATIONAL,['NA'],,
2534,NCT00155727,,2000-01,UNKNOWN,OBSERVATIONAL,['NA'],,
2535,NCT02301481,R0 resection rate,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Comparison of dosimetric differences between radiation techniques,Overall survival
2536,NCT03158779,Overall survival,2017-05-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression free-survival of treated patients
2537,NCT05897138,Objective response rate (ORR),2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival(OS)
2538,NCT00632333,Safety(toxicities as assessed by NCI CTCAE version3),2008-02,UNKNOWN,INTERVENTIONAL,['PHASE1'],,survival
2539,NCT04296058,Disease free survival (DFS),2007-01-08,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
2540,NCT02400996,Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms,2011-03,COMPLETED,OBSERVATIONAL,['NA'],,
2541,NCT04713332,Matrix metalloproteinases(MMPs),2019-07-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
2542,NCT02442583,Change in number of minutes per day of bouts of sedentary behaviors.,2015-05,COMPLETED,INTERVENTIONAL,['NA'],,"Covariation between baseline use of an ActiGraph, and self-reporting of sedentary behaviors"
2543,NCT05431530,Frequency of major LARS after surgery,2022-06-22,RECRUITING,OBSERVATIONAL,['NA'],,EOTC QLQ-C30
2544,NCT00721916,Progression free survival (PFS),2008-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety
2545,NCT00474097,"to assess if follow-up telephone calls after surgery affects patient satisfaction, surgical outcomes and quality of life in the early post-operative phase after colorectal surgery",2006-02,COMPLETED,OBSERVATIONAL,['NA'],,"to track readmissions, complications and emergency room visits via telephone calls to ensure communication between the patients and the surgical office is optimal."
2546,NCT05281783,The efficacy,2018-10-01,COMPLETED,INTERVENTIONAL,['NA'],,Incidence of Treatment-Emergent Adverse Events [Safety]
2547,NCT01064622,Progression-free Survival,2009-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Activity (Overall Response Rate) in Crossover Patients
2548,NCT04462354,Postoperative pancreatic fistula rate (PPF),2020-06-04,UNKNOWN,INTERVENTIONAL,['NA'],,Other complications.
2549,NCT05744219,Recovery after iv Iron,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Performance status
2550,NCT00005870,,1999-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
2551,NCT01005225,Solid tumor biological insights,2008-02,COMPLETED,OBSERVATIONAL,['NA'],,
2552,NCT05497947,SOAL- VF,2021-07-03,COMPLETED,OBSERVATIONAL,['NA'],,
2553,NCT01236989,the prognostic impact of anatomical resection by means of intraoperative ultrasound (IOUS) guided vessel compression versus nonanatomical resection in terms of disease free and overall survival,2011-01,UNKNOWN,INTERVENTIONAL,['NA'],,the impact of anatomical resection versus non-anatomical resection in terms of postoperative mortality and morbility
2554,NCT01401699,Number of Subjects in Which the Entire Distal Esophagus Can be Visualized Using the Balloon Based Optical Coherence Tomography Screening,2006-09,COMPLETED,INTERVENTIONAL,['NA'],,
2555,NCT02538562,Incidence of HER2 positivity among gastric and gastroesophageal junction tumor samples,2011-10-11,COMPLETED,OBSERVATIONAL,['NA'],,Correlation between HER2 status and gender
2556,NCT04780529,Number of participants with CAR-T treatment-related adverse events as assessed by CTCAE v4.03 [ Time Frame: 24 months ],2021-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Efficacy will be assessed according to RECIST1.1 or EORTC or PERCIST criteria
2557,NCT04140318,ORR,2019-11-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],,OS
2558,NCT02448693,Number of residual neoplastic tissue detected with both techniques (NBI versus WLE),2015-05,COMPLETED,INTERVENTIONAL,['NA'],,Number of missed lesions on basal colonoscopy
2559,NCT01231399,Overall Survival,2012-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2560,NCT04548531,Shared Decision Making (SDM) Process Scale Score,2020-09-10,COMPLETED,INTERVENTIONAL,['NA'],,Colon Cancer Screening Rate
2561,NCT02280811,Duration of Response,2014-10-14,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Expression of Programmed Cell Death 1 (PD-1) by Circulating E6 T-Cell Receptor (TCR) T-Cells
2562,NCT00200200,To determine whether the addition of concurrent intravenous bevacizumab to HAI plus systemic chemotherapy increases the time to progression in patients with completely resected hepatic metastases from colorectal cancer,2004-11-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,"To compare plasma levels of VEGF-A, VEGF-C, VEGF-D, and CD133+ VEGFR2+ circulating endothelial progenitors"
2563,NCT01675505,,2012-05,UNKNOWN,OBSERVATIONAL,['NA'],,
2564,NCT05622357,Sphincter saving surgery,2018-03-18,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease free survival
2565,NCT02157246,Group B Percentage change in FMISO-PET SUVmax and uptake volume,2013-10,COMPLETED,INTERVENTIONAL,['NA'],Radiotherapy planning feasibility study,Comparison of changes in T1/T2* MRI
2566,NCT00563316,Number of Participants With Clinically Significant Adverse Events (AEs),2008-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2567,NCT01459757,Mutational status data retrospectively accessed correlated with A6181036 clinical outcomes data in GIST subjects treated with sunitinib,2011-10,COMPLETED,OBSERVATIONAL,['NA'],,
2568,NCT05642962,Change in body mass index/BMI from baseline to 4 months,2022-11-30,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2569,NCT03717519,Overall survival,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Clinic-pathological variables
2570,NCT04050345,TRACC Part C (Randomised ctDNA guided adjuvant chemotherapy versus SoC study):,2016-12-05,RECRUITING,OBSERVATIONAL,['NA'],,"Relationship between ctDNA detection before, during and after treatment"
2571,NCT00056459,Progression free survival,2003-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Tolerability and safety profile
2572,NCT05807984,local control,2023-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,progression free survival
2573,NCT05364788,Characterise the genes of appendiceal cancer.,2024-02-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Descriptive analysis in proportions
2574,NCT02526134,Patients rate in which a significant variation in the area to be irradiated will be observed between before evaluation and evaluation after laying the trustees.,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of trustees (2 up 6 maximum) and set up their positions estimated success rate of implementation and the evaluation of the safety and toxicity (complications) associated with the establishment trustees (composite measure)
2575,NCT06087289,"Evaluate the safety and tolerability of KAND567 in combination with carboplatin therapy in recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as measured by lab safety tests",2023-04-20,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determine the plasma exposure of KAND567
2576,NCT01085331,Part 2 or Phase 2 Randomised Part: Progression Free Survival (PFS),2010-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Part 2 or Phase 2 Randomized Part: Number of Subjects With TEAEs, Serious TEAEs, TEAEs Leading to Discontinuation and TEAEs Leading to Death"
2577,NCT05451719,Progression-free Survival (PFS),2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,The incidence of adverse events
2578,NCT03544736,Incidence of Treatment-Emergent Adverse Events,2018-04-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Health Related Quality of Life (EORTC QLQ-OG25)
2579,NCT06068127,GCSI score,2023-10-12,RECRUITING,OBSERVATIONAL,['NA'],,Pyloric distensibility
2580,NCT04465214,"Outcomes from: PRO-CTCAE, Neuro-QOL, Numeric Rating Scale for Pain, 6-Minute Walking Test, Stroop Test, and Normalized Reaction Time Tests",2020-11-23,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Evaluation of iPhone based tests of cognitive functioning and reaction time for reliability and validity
2581,NCT00411229,Clinical laboratory tests,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2582,NCT01462903,• the safety and tolerability of autologous tumor infiltrating lymphocytes (TIL) in combination with Interleukin-2(IL-2) in patients with nasopharyngeal carcinoma (NPC).,2011-09,UNKNOWN,INTERVENTIONAL,['PHASE1'],,• immune efficacy and anti-tumor effects of autologous tumor infiltrating lymphocytes (TIL) in combination with Interleukin-2(IL-2) in patients with nasopharyngeal carcinoma (NPC).
2583,NCT02109146,DFS(Disease free survival),2014-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,
2584,NCT03273686,postoperative complication,2017-09-15,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Length of postoperative stay
2585,NCT03254836,Actigraphy,2017-03-01,UNKNOWN,OBSERVATIONAL,['NA'],,"Follow-up cancer treatment (Adjuvant chemotherapy, timing and duration)"
2586,NCT02811666,muscle strength using a hand gauge,2016-11,UNKNOWN,INTERVENTIONAL,['NA'],,
2587,NCT04221347,Detection of spectroscopic markers differences among specified groups,2017-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,Measure of sensitivity and specificity of identified biomarkers for surveillance of HCC
2588,NCT02009774,Accuracy optical biopsy,2014-01,COMPLETED,OBSERVATIONAL,['NA'],,Adenoma detection rate
2589,NCT05165264,Overall Survival (OS),2022-02-16,RECRUITING,OBSERVATIONAL,['NA'],,OS measured by Programmed Death-Ligand 1 (PD-L1) combined positive score (CPS)
2590,NCT04936750,overall survival,2021-06-17,RECRUITING,OBSERVATIONAL,['NA'],,
2591,NCT03416582,Percentage of patients using Intervention materials,2018-11-29,COMPLETED,INTERVENTIONAL,['NA'],,Influence of Nurse-Delivered Telephone Intervention on Symptom Self-Management
2592,NCT00876148,,na,COMPLETED,OBSERVATIONAL,['NA'],,
2593,NCT04502082,The recommended phase 2 dose (RP2D) regimen of ET140203 T-cell therapy primarily based on DLT,2021-04-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determine the pharmacokinetics of ET140203 T cells after infusion.
2594,NCT01311232,Hepatitis B virus reactivation,2010-11-01,COMPLETED,OBSERVATIONAL,['NA'],,
2595,NCT04081168,One-year local tumor progression-free survival,2020-12-15,RECRUITING,INTERVENTIONAL,['NA'],,Mortality
2596,NCT01552434,"MTD of temsirolimus, defined as the dose level below the dose at which 2 of 6 patients experience DLT",2012-03-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],The properties of the tissue microvasculature.,Levels of surrogate anti-angiogenesis markers
2597,NCT05317819,Overall Survival (OS),2022-03-14,RECRUITING,INTERVENTIONAL,['PHASE3'],,Progression free survival
2598,NCT06070740,Objective Response Rate,2023-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
2599,NCT01095432,Study samples of rectal mucosa (the moist lining of the rectum) using PWS.,2010-03,COMPLETED,OBSERVATIONAL,['NA'],,
2600,NCT06144762,the integration of in vivo and ex vivo MRI with histology and molecular caracteristic in order to increase the pancreatic cancer detection and therapeutic response monitoring,2023-12-19,RECRUITING,INTERVENTIONAL,['NA'],,Correlate MRI results with hematological molecular biology results.
2601,NCT01251536,PFS Probability Rate at 9 Months in the Dose Escalation Arm,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Deaths Till 30 Days From Last Cetuximab Administration
2602,NCT02642978,Surgical Complication,2015-09-01,UNKNOWN,INTERVENTIONAL,['NA'],liver function,locoregional recurrence rate
2603,NCT01661829,Incidence of anterior resection syndrome after stoma closure,2012-03,COMPLETED,OBSERVATIONAL,['NA'],,
2604,NCT03693248,Progression free survival,2018-12-19,UNKNOWN,INTERVENTIONAL,['PHASE3'],,days of management in intensive care unit
2605,NCT00455247,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2606,NCT02702414,Objective Response Rate (ORR),2016-05-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)
2607,NCT01978249,Comparison of the overall survival between patients who underwent primary tumor resection and patients who received chemotherapy without primary tumor resection,2013-09,TERMINATED,INTERVENTIONAL,['NA'],To compare the quality of life between the two groups using the Korean version of EORTC QLQ (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire)-C30.,Analysis of primary tumor related complications in the chemotherapy group and postoperative complications in the primary tumor resection followed by the chemotherapy group.
2608,NCT05673512,Progression-Free-Survival（PFS）,2023-05-12,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
2609,NCT01394497,Graft survival,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Primary graft dysfunction
2610,NCT04148092,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA'],,
2611,NCT01617876,Diagnostic accuracy of enhanced ME (combining ME-NBI and ME-AIM),2010-03,COMPLETED,OBSERVATIONAL,['NA'],,The relationships between the microsurface patterns and the histopathological findings
2612,NCT01413451,Background ratio of maximum counts,2011-07-12,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Antibody uptake vs. IHC mesothelin expression
2613,NCT05462236,Objective response rate based on Response Evaluation Criteria in Solid tumors (RECIST) Version 1.1,2023-04-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,PK evaluation
2614,NCT04110769,The rate of genetic mutation,2019-07-17,RECRUITING,INTERVENTIONAL,['NA'],,oncologic outcome
2615,NCT05401045,Fatigue state using the Revised Piper Fatigue Scale (RPFS),2023-01-20,COMPLETED,INTERVENTIONAL,['NA'],,Quality of life using the European Organization for Research and Treatment of Cancer QLQ-C30 (EORTC-C30)
2616,NCT00844233,Tumour resectability at surgery,2009-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Safety assessed by SAE and AE monitoring (NCI CTCAE v3.0)
2617,NCT03055130,The different incidence of cervical neoplasm between controls and patients by performing Thinprep Cytology Test,2015-07,UNKNOWN,OBSERVATIONAL,['NA'],,Find drugs relating to HPV infection of IBD patients
2618,NCT02508883,mortality,2015-04,COMPLETED,OBSERVATIONAL,['NA'],,"Finding the cut-off value of highest sensitivity and specificity of Rockall, Glasgow-Blatchford and AIMS65 scores employing the receiver operating curve (ROC)."
2619,NCT00965861,To perform testing on the tissue samples to learn more about specific types of cancer and/or other diseases,2010-05,TERMINATED,OBSERVATIONAL,['NA'],,
2620,NCT02760199,"The quantitative uptake op 89Zr-AMG211 in tumor tissue, organs and blood circulation expressed in SUV (Standardized Uptake Value)",2016-08,COMPLETED,INTERVENTIONAL,['PHASE1'],Evaluate 89Zr-AMG211 as a complementary tool for improved patient selection for targeted therapy with AMG 211.,"Number of patients with adverse events after 89Zr-AMG211 injection as a measure of safety and tolerability. Incidence, nature and severity of adverse events (according to CTCAE version 4.03) will be measured."
2621,NCT02839109,Tumor response,2015-02,COMPLETED,OBSERVATIONAL,['NA'],,Disease free survival (DFS)
2622,NCT04001569,Progression-free survival rate,2019-05-14,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Adverse event
2623,NCT05096715,Dose Limiting Toxicity Rate,2022-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Out of field response rate
2624,NCT02648841,Disease-free survival,2015-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Adverse Event
2625,NCT03180437,OS,2017-06-15,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,CA 19-9
2626,NCT01064999,toxicity,2010-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,overall survival
2627,NCT03904732,Number of deaths due to any other cause,2019-04-15,COMPLETED,OBSERVATIONAL,['NA'],,
2628,NCT05216133,36-Item Short Form Survey Instrument (SF-36),2023-03-22,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
2629,NCT05730686,To describe the natural history and clinical outcomes of patients with Fibrolamellar carcinoma of the liver,2023-02-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
2630,NCT03277209,Causality of adverse events (AEs) and serious adverse events (SAEs) and grading according to NCI CTCAE v.4.03.,2017-07-25,TERMINATED,INTERVENTIONAL,['PHASE1'],Correlation between changes in T cell distribution and diurnal cortisol variation.,Assessment of metabolic changes in tumour using non-invasive imaging (18FDG-PET)
2631,NCT05551052,Specificity for CRC of the Next-Gen CRC Screening Test,2022-09-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Specificity for no colorectal neoplastic findings of the Next-Gen CRC Screening Test
2632,NCT00113763,Progression-free Survival Time,2004-01-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Duration of Stable Disease
2633,NCT01216644,median overall survival,2010-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,R0-Resection rate
2634,NCT00597610,To measure the response of primary rectal cancer to neoadjuvant chemotherapy and/or radiation therapy using 3-D TRUS,2003-11,COMPLETED,INTERVENTIONAL,['NA'],,To correlate these findings with post-operative pathologic examination
2635,NCT00582296,"To assess adherence to comprehensive, multi-organ screening and risk-reducing behavior recommendations in patients with Lynch Syndrome.",2004-12,RECRUITING,OBSERVATIONAL,['NA'],,"To evaluate predictive factors for adherence to comprehensive, multi-organ screening and risk-reducing behavior recommendations."
2636,NCT05053555,To prospectively evaluate the clinical effectiveness of the use of high dose rate brachytherapy (HDRBT) for the treatment of both primary liver malignancies.,2022-04-24,RECRUITING,INTERVENTIONAL,['NA'],,
2637,NCT06277531,Patient is diagnosed with malignant disease from biliary system,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
2638,NCT02579460,Change in esophageal mucosal inflammation using histopathological assessment from baseline to 14 days,2015-11,COMPLETED,INTERVENTIONAL,['NA'],,change in HIF expression from baseline to 14 days
2639,NCT02534337,Progression-Free-Survival,2015-09,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Time-to-Progression
2640,NCT00397384,MTD defined as the dose level at which fewer than 2 out of 6 patients experience DLT graded using CTCAE-v3,2007-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Antitumor effect observed
2641,NCT05620498,Objective response rate (ORR),2022-09-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,AE
2642,NCT05619614,Mean gaze time per area of influence,2022-11-01,RECRUITING,OBSERVATIONAL,['NA'],,
2643,NCT00844064,To determine the maximum tolerated dose (MTD) as well as the dose-limiting toxicity (DLT) of two cycles of AP 12009 administered intravenously at weekly intervals and for four days every other week.,2005-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To determine the potential antitumor activity of AP 12009 administered intravenously at weekly intervals and for four days every other week, as assessed by the effect on tumor size and tumor markers."
2644,NCT00642746,Response Rates of Radiographically Measurable Disease,2008-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Time to Second Progression (From Start of First-Line Regimen)
2645,NCT03086369,Phase 2: Overall Survival (OS),2017-06-22,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Health Status on the EuroQol 5-Dimension 5 Level (EQ-5D-5L)
2646,NCT01369329,Number of Participants With Clinical Response at Week 6,2011-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With CDAI 70-point Response at Week 3
2647,NCT00004891,Determine if fludeoxyglucose F 18 positron emission tomography (FDG-PET) is superior to CT scan,1999-09,COMPLETED,INTERVENTIONAL,['NA'],,Determine the accuracy of FDG-PET
2648,NCT03455608,Duration of feeding tube dependence,2018-09-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Hospitalization/Emergency Department (ED) Presentation
2649,NCT05441254,Progression Free Survival(PFS),2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],"Adverse event (AE) rate, serious adverse event (SAE) rate, etc",Peritoneal Cancer Index (PCI) assessed on preoperative CT (CT-PCI)
2650,NCT04324294,"The results obtained by EUS versus contrast EUS to diagnose pancreas cystic lesions, mass lesion, and origin of pancreatitis.",2020-02-26,RECRUITING,INTERVENTIONAL,['PHASE1'],,Quantitative Parameters of Pancreas Lesions
2651,NCT05220800,Changes in T-cell function - mRNA expression analysis,2022-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,5 year cancer free survival
2652,NCT02851381,FG-3019 treatment regimen to increase OS (overall survival),2016-08,WITHDRAWN,INTERVENTIONAL,['NA'],,
2653,NCT00652366,OS Assessed From Point of Randomization,2008-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,PFS Assessed From the Start of 4-Week Run-In
2654,NCT00343239,"To determine the R0 resection rate for the treatment of locally advanced gastric carcinoma with Docetaxel, Cisplatin, Fluorouracil combination.",2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2655,NCT00305643,Incidence of Hand/Foot Syndrome (HFS) > Grade 1 at 16 Weeks Based on the CTC 3.0 Criteria.,2006-02,TERMINATED,INTERVENTIONAL,['PHASE3'],,Incidence of Hand/Foot Syndrome (HFS) > Grade 1 at 16 Weeks Based on WHO Criteria.
2656,NCT06136026,The detection rate of Colorectal Adenomatous Polyp.,2023-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,The canceration rate of Colorectal Adenomatous Polyp.
2657,NCT02219529,Number of gastric focal lesions founded by MCE Versus Standard Gastroscopy,2014-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Adverse events of both procedures
2658,NCT02586987,"Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Ophthalmic examination (slit lamp fundoscopy)",2015-12-28,COMPLETED,INTERVENTIONAL,['PHASE1'],,MEDI4736 and/or tremelimumab anti-drug antibody (ADA) level in Plasma
2659,NCT00934791,Liver Volume at 2 Years After Kidney Transplantation,2009-02,TERMINATED,INTERVENTIONAL,['NA'],,
2660,NCT01941173,"Feasibility of a shorter infusion time, determined by rate of greater or equal to grade 2 hypersensitivity reactions as graded according to CTCAE version 4.0",2014-01,WITHDRAWN,INTERVENTIONAL,['NA'],Time on protocol therapy,"Incidence of grade 3 and above toxicities, graded according to CTCAE version 4.0"
2661,NCT02644863,Overall survival,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Phenotypic analysis of T cells
2662,NCT03276091,Participation to the colonoscopy,2017-05-23,COMPLETED,INTERVENTIONAL,['NA'],,cancer and adenoma detected
2663,NCT03277235,Self-report Questionnaire,2017-09,UNKNOWN,INTERVENTIONAL,['NA'],Self-report Questionnaire,Self-report Questionnaire
2664,NCT01023412,Rate of post-operative complications,2006-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,Rate of post-operative infectious complications
2665,NCT04313868,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2014-06-13,RECRUITING,INTERVENTIONAL,['PHASE1'],,"Clinical research testing for antibodies to retrovector gp70 env, replication-competent retrovirus in peripheral blood lymphocytes (PBLs); vector integration into genomic DNA of PBLs, and circulating hGM-CSF protein"
2666,NCT02670265,Weight loss,2012-06,COMPLETED,INTERVENTIONAL,['NA'],,Length of hospital stay
2667,NCT02650986,Number of Participants With Feasibility Concerns in Manufacturing of NY-ESO-1/ dnTGFbetaRII Engineered Cells,2017-07-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Tumor Response (Complete and Partial Response)
2668,NCT00017043,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2669,NCT03164486,Assessment of safe administration of 18F-αvβ6-BP,2016-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Level of αvβ6-BP expression in tumors
2670,NCT00408681,Functional Recovery,2006-06,COMPLETED,INTERVENTIONAL,['NA'],Agents Added to Treat GVHD More Than 3 Days After Enrollment,Causes of Death
2671,NCT03940417,"Docking time,min",2017-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,cost
2672,NCT04835246,Sensitivity of Spectra IMDx system,2019-10-07,UNKNOWN,INTERVENTIONAL,['NA'],,Accuracy of Spectra IMDx system
2673,NCT03976999,Proportion of patients who gave their consent to participate in the study,2017-07-05,RECRUITING,INTERVENTIONAL,['NA'],,
2674,NCT02649790,Part H: 2- Year Progression-free Survival (PFS),2016-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Part H: Overall Survival (OS)
2675,NCT02510001,Maximal Tolerated Dose (MTD) of Binimetinib and PF-02341066,2014-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetic Plasma t1/2 Etc for PF-02341066 and Binimetinib
2676,NCT00331682,Objective Response Rate as Measured by RECIST Criteria,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
2677,NCT03117348,Morbidity of infection,2017-04-15,COMPLETED,INTERVENTIONAL,['NA'],,Mortality
2678,NCT00075218,Time to Tumor Progression (TTP) as Assessed in the Double-blind Treatment Phase at End of Study,2003-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change From Baseline in EQ-5D Health State Profile Index
2679,NCT05636085,Specificity,2023-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Positive predictive value and negative predictive value
2680,NCT00553696,Number of Participants With First Cycle Dose-limiting Toxicities (DLTs),2007-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to Progression (TTP)
2681,NCT06331260,Tumor recurrence rate,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
2682,NCT01503372,progression-free survival rate at 6 months,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,evaluation of the predictive and prognostic relevance of biomarkers
2683,NCT00941967,Progression-free survival,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2684,NCT03611504,Rebleeding rate,2018-07-01,COMPLETED,OBSERVATIONAL,['NA'],,Mortality
2685,NCT03415763,Disease free survival,2018-11-05,RECRUITING,INTERVENTIONAL,['PHASE3'],,The quality of life postoperatively
2686,NCT03541629,Data accuracy,2018-07-26,COMPLETED,OBSERVATIONAL,['NA'],,
2687,NCT03961776,Predictive value of Apparent Diffusion Coefficient measured using MRgRT system,2020-06-08,RECRUITING,OBSERVATIONAL,['NA'],,
2688,NCT00515411,6 Month Progression Free Survival (PFS),2006-10-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
2689,NCT04773769,Blood Counts,2018-11-07,UNKNOWN,INTERVENTIONAL,['NA'],,
2690,NCT05524155,Overall response rate ( ORR),2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
2691,NCT00320294,Safety,2005-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life
2692,NCT00366509,"procure and analyze gastrointestinal, oropharyngeal, lung and/or blood specimens from healthy research volunteers and subjects with lung disease",2006-09-18,COMPLETED,OBSERVATIONAL,['NA'],,
2693,NCT00524706,"Evaluate the response rate of S-1, Leucovorin, and Oxaliplatin with recommended dose in phase II",2007-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II - Safety - Time to treatment failure (TTF) - Progression free survival (PFS) - Overall survival (OS)
2694,NCT00030524,,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2695,NCT02748161,Objective tumor response,2015-08,TERMINATED,INTERVENTIONAL,['NA'],,Number of repeat DEB-TACE procedures per lesion
2696,NCT01082419,The elasticity parameter will be for each patient the median of ten ARFI values (m/s) in the right liver.,2010-04,COMPLETED,INTERVENTIONAL,['NA'],,Median (m/s) of ARFI values between before and after effective treatment for liver reversible disease
2697,NCT06194786,Dietary target-red meat,2023-05-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Disease free survival
2698,NCT05493956,Overall survival,2019-04-01,RECRUITING,INTERVENTIONAL,['NA'],,Hepatobiliary symptom index
2699,NCT00637390,safety & maximally tolerated dose,2008-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,Alemtuzumab effect on patients' response rates to chemotherapy given after the discontinuation of chemotherapy.
2700,NCT01396148,Area Under the Plasma Concentration-Time Curve From Time Zero to 8 Hours Post Dose AUC(0-8) for Sunitinib and Its Metabolite,2012-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Estimated Sunitinib Plasma Concentration at Which 50% of the Maximum Effect (EC50) for Each Selected Safety Endpoint (e.g., Absolute Neutrophil Count) Was Observed"
2701,NCT05528367,the rate of resectable patients with negative incisal margin R0 resection rate,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
2702,NCT02647099,Time To Recurrence (TTR),2016-04-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Frequency and severity of adverse events (AE)
2703,NCT03292289,"Quality of life 1 year after the second intervention, using LARS score",2018-01-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,"Quality of life of patients with a second stoma placement, using LARS score"
2704,NCT02813278,Length of hospital stay,2014-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2705,NCT01880658,Disease-free Survival rate(DFS),2013-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Over all survival,genetic patterns, quality of life, toxic effects, convenience"
2706,NCT02062749,Maximum Tolerate Dose (MTD) of Oxaliplatin in Hyperthermic Intraperitoneal Chemotherapy,2014-05-19,COMPLETED,INTERVENTIONAL,['PHASE1'],"Time to Recurrence After HIPEC in Pediatric, Adolescent and Young Adult Age Colon Cancer Patients",Differences in Genetic Aberrations in Pediatric Colon Cancer Patients and Adult Patients
2707,NCT05644379,Adverse Events (AEs),2022-11-25,RECRUITING,INTERVENTIONAL,['PHASE1'],,
2708,NCT01394159,Compare the Median Number of Passes Required to Establish a Diagnosis,2011-07,COMPLETED,INTERVENTIONAL,['NA'],,Technical Failure
2709,NCT03321396,Number of Patients With Postpolypectomy Electrocoagulation Syndrome,2017-09-01,COMPLETED,INTERVENTIONAL,['NA'],,Number of Patients With Late Tissue Injury
2710,NCT04233866,Overall survival (OS),2020-08-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Geriatric assessment scores and biomarkers of aging (CRP and IL-6),Instrumental Activities of Daily Living (IADL)
2711,NCT03581435,The expression of protein A in the circulating exosomes from patients,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
2712,NCT03901651,Adenoma detection rate with standard colonoscope and retroview colonoscope.,2019-01-02,COMPLETED,INTERVENTIONAL,['NA'],,Size of lesions (adenomas and polyps) detected with the standard colonoscope and Retroview colonoscope.
2713,NCT00020579,Pharmacology and pharmacokinetics,2001-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumor response by CT scan every 12 weeks
2714,NCT05590117,variation in grades of mucositis,2022-10-11,ENROLLING_BY_INVITATION,INTERVENTIONAL,['EARLY_PHASE1'],,Change in the biological marker Citrulline
2715,NCT02562716,Overall Survival (OS),2016-01-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease-free Survival From the Time of R0 or R1 Resection.
2716,NCT03898921,3-year overall survival rate,2019-03-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],Radiation-induced liver injury,Safety profile: incidence of complications
2717,NCT04321850,Pain intensity: Visual analog scale,2019-06-10,TERMINATED,INTERVENTIONAL,['NA'],,Neutropenia
2718,NCT06046794,Percentage of alive GemCore+ patients treated with Gemcitabine,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Overall survival of GemCore- patients,Progression-free survival
2719,NCT00561990,Time to tumor progression (TTP) and overall survival (OS) in chemotherapy-naive patients. To assess the efficacy of Nimotuzumab as add on therapy to Gemcitabine in comparison with Gemcitabine and placebo,2007-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,To evaluate the objective tumor response (overall response rate [ORR]) and duration of response (DR) To evaluate the safety profile of Nimotuzumab in combination with Gemcitabine To evaluate quality of life (QoL) according to EORTC
2720,NCT05298722,Prediciton of surgical resectability,2022-12-12,RECRUITING,INTERVENTIONAL,['NA'],,Measurement of quality of life in patients with pancreatic cancer
2721,NCT02673177,Incidence of sexual and urinary dysfunction,2016-02,UNKNOWN,INTERVENTIONAL,['NA'],,Anus preservation rate
2722,NCT01468389,Progression free survival,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,adverse events
2723,NCT04400357,Percentage of patients with pancreatic adenocarcinoma who achieve administration of adjuvant chemotherapy at 8 weeks postoperatively,2020-06-15,UNKNOWN,INTERVENTIONAL,['NA'],,Comparison of perioperative inflammatory response (Interleukin-6)
2724,NCT05903456,Objective Response Rate,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,adverse event
2725,NCT04284943,The success rate of biochemical improvement of diabetes as measured by HbA1c < 6.5%,2020-12-01,RECRUITING,INTERVENTIONAL,['NA'],,The success rate of biochemical improvement of diabetes as measured by HbA1c < 6.5%
2726,NCT01788995,Treatment discontinuations/modifications,2012-10-15,COMPLETED,OBSERVATIONAL,['NA'],,Progression-free survival
2727,NCT03827967,Primary Immunologic Endpoint-Per Dosing Cohort Immunoscore of the tumor microenvironment,2019-07-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,Secondary Endpoint-CD4+ and regulatory T cells expression comparison within the Tumor Microenvironment
2728,NCT00954876,Primary objective is to assess PFS in patients with WT KRAS CRC treated with the combination regimen of capecitabine and cetuximab,2009-08,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,To perform exploratory analyses of serum and tumor biomarkers (EGFR mutations and genotyping) on toxicity and efficacy.
2729,NCT01215838,Accuracy of a new MR protocol in diagnosing HCC and other liver lesions.,2010-08,TERMINATED,OBSERVATIONAL,['NA'],,
2730,NCT01919541,Protein Synthesis,2016-12,WITHDRAWN,INTERVENTIONAL,['NA'],,
2731,NCT05928819,Evaluation of the proportion of gastric neoplastic lesions detected by a computer-aided diagnosis system (CADx) compared with experienced endoscopists and correlation with final histology reading.,2023-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
2732,NCT03017326,Response in HCC is defined as complete (CR) or partial (PR) response according to RECIST version 1.1 criteria,2017-08-24,RECRUITING,INTERVENTIONAL,['PHASE3'],,Adherence to surgical guidelines
2733,NCT01048281,NER activity by routine pathologic analysis,2002-08,RECRUITING,OBSERVATIONAL,['NA'],,
2734,NCT01885884,perceived effectiveness,2013-07,COMPLETED,INTERVENTIONAL,['NA'],caregiver depressive symptoms,patient quality of life
2735,NCT04155242,Diagnostic accuracy of methylation panel for diffuse IM at the GOJ,2020-09-01,RECRUITING,INTERVENTIONAL,['NA'],,Safety of Cytosponge
2736,NCT05840341,Overall survival (OS),2023-05-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Disease Free Survival
2737,NCT02052050,Abdominal isometric endurance,2012-09,COMPLETED,INTERVENTIONAL,['NA'],Muscle structure,Lower back muscle strength
2738,NCT02419677,Recurrence-free survival,2010-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Adverse events
2739,NCT05843955,Non-alcoholic fatty liver disease (NAFLD) grade,2015-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
2740,NCT04145726,The portion of frail patients undergoing esophageal resection and 6 -month all-cause of mortality,2019-09-25,UNKNOWN,OBSERVATIONAL,['NA'],postoperatively complications in frail vs. non-frail,One-year all-cause mortality in frail vs. non-frail patients One-year all-cause mortality in frail vs. non-frail patients One-year all-cause mortality in frail vs. non-frail patients
2741,NCT00003994,Toxicity rates assessed using National Cancer Institute (NCI) Common Toxicity Criteria (CTC),1999-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2742,NCT02229045,PFS(Progression-free survival ),2010-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],ORR (Overall tumor response),OS (Overall survival )
2743,NCT04135781,3 years Diseases-free Survival rate(3 years-DFS),2020-03-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Safety as measured by number and grade of adverse events
2744,NCT01825824,Local control rate,2012-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Treatment related toxicity
2745,NCT03472365,Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1,2018-04-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Subjects With Treatment-related Adverse Events (AEs)
2746,NCT05034692,The incidence of early complications,2022-03-21,RECRUITING,INTERVENTIONAL,['NA'],,pain score
2747,NCT05747716,Progression free survival,2023-02-28,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Toxicities
2748,NCT01942083,To investigate the maximum tolerated dose (MTD) of OPB-111077,2013-05-29,TERMINATED,INTERVENTIONAL,['PHASE1'],,Biomarker of OPB-111077
2749,NCT05532319,Progression-free survival,2022-02-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,objective response rate
2750,NCT05111314,Intraindividual intralesional difference in maximum standardized uptake value (SUVmax),2022-02-11,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,Incidence of adverse events
2751,NCT00713427,Number of Participants With Absence of Recurrent Biliary Obstruction,2007-07,COMPLETED,INTERVENTIONAL,['NA'],,Change in Bilirubin
2752,NCT05523245,The area under curve (AUC) of Receiver Operating Characteristic (ROC) curves of models in prediction tumor response,2022-06-24,RECRUITING,OBSERVATIONAL,['NA'],,The negative predictive value of models in prediction tumor response
2753,NCT05701488,Number of Participants with Adverse Events,2023-04-21,RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of Participants with Surgical Complications
2754,NCT01292681,Correlation early changes in imaging and treatment outcome,2009-08,UNKNOWN,INTERVENTIONAL,['NA'],,Correlation pretreatment imaging values and treatment outcome
2755,NCT05517343,Proportion of definite depression cases,2022-08-20,RECRUITING,INTERVENTIONAL,['NA'],,Depression score
2756,NCT00977613,Number of Participants Who Maintained an Exercise Regimen Average of 18 Metabolic Units (MET) Per Week or Greater,2007-04,COMPLETED,INTERVENTIONAL,['NA'],,Overall Survival
2757,NCT04348916,Recommended Phase 2 Dose (RP2D) of ONCR-177,2020-05-20,TERMINATED,INTERVENTIONAL,['PHASE1'],,Changes in the level of HSV-1 antibodies compared to baseline
2758,NCT02199912,biological and radiological markers,2013-10-07,COMPLETED,INTERVENTIONAL,['NA'],,loss of fat body mass and/or lean body mass
2759,NCT02080702,Frequency of anastomosis leakage rate,2014-08,TERMINATED,OBSERVATIONAL,['NA'],,Handling of the device
2760,NCT05371223,Disease Control Rate (DCR),2022-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Identification of pancreatic cancer disease evolution trough pathway analysis a in primary tumor and peritoneal sites during treatments,The Overall Survival (OS)
2761,NCT00782886,"The overall purpose of this NIH-funded study is to evaluate the effectiveness of image-guided liver surgery by measuring variables before, during and following surgery.",2008-04,COMPLETED,OBSERVATIONAL,['NA'],,
2762,NCT02100696,"Maintenance Phase: Percentage of Participants With Remission at Week 66 Among Participants Who Had Achieved a Clinical Response at Week 14, as Determined by the MCS",2014-05-21,COMPLETED,INTERVENTIONAL,['PHASE3'],,Etrolizumab Serum Trough Concentration (for Arms/Timepoints Below LLOQ)
2763,NCT03609892,Helicobacter pylori eradication,2018-08-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,adverse events
2764,NCT00030732,Gemcitabine + Capecitabine vs. Gemcitabine alone,2001-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2765,NCT05873829,Chemotherapy Induced Peripheral Neuropathy Symptoms Assessment,2022-04-25,COMPLETED,INTERVENTIONAL,['NA'],,
2766,NCT03421912,Overall patient satisfaction after 30 days treatment,2018-02-16,COMPLETED,INTERVENTIONAL,['NA'],,Use rate of dermocorticoids
2767,NCT06186089,Composition and diversity of gut microbiota,2023-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Inflammatory factor
2768,NCT06248580,The frequency of HDV in certain regions of Southern Anatolia,2024-01-31,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,The rate of HIV and HCV co-infection in HDV positive patients
2769,NCT03777540,Post-operative mortality In-hospital mortality was defined that occurred during hospitalization up to 90 days excluded post-operative mortality. Postoperative mortality,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
2770,NCT02847767,Changes in tumour vasculature as assessed by changes PL derived model parameters,2016-07,UNKNOWN,INTERVENTIONAL,['NA'],,Association (correlation) between aggregate QOL scores and PK derived model parameters
2771,NCT01882868,Percentage of Participants With Overall Response,2013-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Volume of Distribution at the Steady State (Vss) for Irinotecan: Participants With Additional Blood Sampling for Detailed PK Analysis
2772,NCT05064059,Overall Survival (OS),2021-11-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,TTD in EORTC Quality of Life Questionnaire-Colorectal Cancer-Specific 29 Items (QLQ-CR29) Bloating (Item 37) Score
2773,NCT04768660,Length of hospital stay,2021-02-14,UNKNOWN,INTERVENTIONAL,['NA'],,
2774,NCT00786643,Best Response (BR),2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Progression
2775,NCT03669237,Postoperative bowel function of 1 year after surgery,2018-10-12,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative bowel function of the long stable result
2776,NCT02079623,Tumor response,2013-11,COMPLETED,OBSERVATIONAL,['NA'],Pain registration,Overall survival
2777,NCT04201717,surgical site infection，SSI,2020-06-12,RECRUITING,INTERVENTIONAL,['NA'],,hospital stay
2778,NCT02784028,Maximum tolerated dose (MTD),2014-12,COMPLETED,INTERVENTIONAL,['NA'],,
2779,NCT03299036,Tumor response in patients with hepatoma who received Taiwan ACE beads (TACE) microspheres embolization evaluated with mRECIST criteria,2017-06-01,COMPLETED,INTERVENTIONAL,['NA'],,Serum Level of AFP
2780,NCT05198609,Overall survival,2022-01-17,RECRUITING,INTERVENTIONAL,['PHASE3'],,Disease control rate
2781,NCT02591667,Percentage of viable cells within the resected peritoneal deposits after completion of neoadjuvant chemotherapy with FOLFOXIRI + bevacizumab.,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
2782,NCT06024837,Comparison of peritoneal and hepatic lesion mapping between spectral scanning and conventional scanning,2023-06-07,RECRUITING,OBSERVATIONAL,['NA'],,Comparison of evaluation of response to chemotherapy (if indicated) in RECIST 1.1 and Radiomics
2783,NCT02030769,Detection rate of high grade dysplasia and carcinoma in iodine void lesion,2014-01,COMPLETED,INTERVENTIONAL,['NA'],observation time for esophagus,overall detection rate of iodine void lesion
2784,NCT05245331,LARS score,2022-08-04,RECRUITING,INTERVENTIONAL,['NA'],,Adverse effects related to both treatments.
2785,NCT04504565,the sensitivity of SPECT/CT with 99mTc-3PRGD2 in the diagnosis of lymph node metastasis,2020-08-01,UNKNOWN,INTERVENTIONAL,['NA'],,The Incidence of Adverse Events
2786,NCT05797883,Objective response rate (ORR),2022-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease control rate (DCR)
2787,NCT01366183,"Percent of women, who are 70 years or older, able to complete at least 4 cycles of treatment regardless of dose reduction and delays",2011-08-15,UNKNOWN,OBSERVATIONAL,['NA'],"Pharmacokinetic parameters including paclitaxel AUC, carboplatin AUC, paclitaxel total body clearance, and time that plasma paclitaxel concentration remains above threshold 0.05 uM/L",Percent of patients reporting adverse events as assessed by the National Cancer Institute's Common Terminology Criteria for Adverse Events
2788,NCT00900016,Independence of tumor fibroblast activation protein (FAP) activity and Met-α2-antiplasmin expression,2007-08,COMPLETED,OBSERVATIONAL,['NA'],,Potential plasma surrogates of plasma dipeptidyl peptidase activity and plasma antiplasmin converting enzyme
2789,NCT04521153,The rate of subjects of major pathological response (MPR),2021-03-25,RECRUITING,INTERVENTIONAL,['NA'],,Safety and toleraty
2790,NCT00233623,Time to progression (6 months after Last patient in),2004-07,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,"Objective Response Rate, Duration of Response, Disease control rate, Overall Survival, (6 months after Last patient in)"
2791,NCT00952016,"Objective response rate, to include complete response and partial response, as defined radiologically using RECIST (Response, Evaluation Criteria in Solid Tumours) on imaging CT scans performed during treatment.",2009-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,Disease stabilisation rate; progression free survival; 1 year survival and median overall survival; Quality of Life assessment; toxicity assessment.
2792,NCT03546985,Area under the curve (AUC) of pain score of oral mucositis,2017-12-26,COMPLETED,INTERVENTIONAL,['NA'],,Incidence of adverse events
2793,NCT00510354,Tumor assessments should be performed by a CT or MRI scan after 4 months. Response to treatment with RAD001 plus Imatinib mesylate at 4 months (defined as progression-free survival (PFS) at 4 months).,2006-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,Tolerability and safety assessed by AEs and SAEs. Objective tumor response rate (complete response [CR] and partial response [PR]) assessed by CT or MRI PFS at month 12 for patients with data available from follow up observation (optional)
2794,NCT05724563,Objective Response rate of combination zimberelimab and domvanalimab.,2023-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with Adverse Events (AEs) (serious / non-serious) as defined by CTCAE v5.0
2795,NCT04850040,Major Pathological Response(MPR) 10%,2021-05-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Intraoperative and postoperative complications
2796,NCT01249443,"Incidence of adverse events during paclitaxel and carboplatin treatment according to dose-limiting toxicities (DLTs), graded using Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)",2013-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,Effects of therapy on HIV viral load and CD4 cell count
2797,NCT04008030,"PFS by BICR (arm B vs C, 1L, centrally confirmed)",2019-08-05,RECRUITING,INTERVENTIONAL,['PHASE3'],,"ORR by BICR (crossover cohort, centrally confirmed)"
2798,NCT00466505,Progression-free Survival (PFS),2005-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Serum TGF-alpha: Treatment Cycle 2
2799,NCT03775473,progastrin rate,2019-02-07,TERMINATED,INTERVENTIONAL,['NA'],,
2800,NCT00006379,Evaluation of Donor Engraftment,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Event free and overall survival
2801,NCT02086461,Symptoms suggestive of delayed gastric emptying,2014-05,UNKNOWN,INTERVENTIONAL,['NA'],,Delayed gastric emptying
2802,NCT00541021,Progression-free survival,2006-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Biomarkers of response
2803,NCT03782831,Progression Free Survival (PFS),2018-12-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Adverse Events
2804,NCT03427411,Percentage of Participants That Achieved an Objective Confirmed Complete or Partial Overall Tumor Response,2018-02-27,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0),Duration of Response (Complete Response or Partial Response)
2805,NCT00390364,Response Rate: The Total Number of Participants With Progression of Disease,2006-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
2806,NCT04404491,PFS,2020-06-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,OS Qol
2807,NCT05596760,EHR documentation of Goals of Care discussions,2023-09-11,RECRUITING,INTERVENTIONAL,['NA'],,Anxiety and depression (HADS)
2808,NCT00008099,Disease Recurrence,1998-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival
2809,NCT03096899,Overall Survival,2016-01,WITHDRAWN,OBSERVATIONAL,['NA'],,
2810,NCT02934984,Rates of recurrence in pancreatic cancer patients,2016-07,UNKNOWN,OBSERVATIONAL,['NA'],,Rates of death in pancreatic cancer patients
2811,NCT02578264,Determining sensitivity of assay in known cancer patients,2015-06,COMPLETED,OBSERVATIONAL,['NA'],,
2812,NCT00538954,Recovery of gastrointestinal function: Time to pass flatus/stool (hours following the end of surgery),2006-08,COMPLETED,INTERVENTIONAL,['NA'],,Patient activity level: measured by activPAL® activity meter
2813,NCT01387295,Response Rate,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,PFS
2814,NCT05420870,Anorectal manometry,2022-05-23,RECRUITING,INTERVENTIONAL,['NA'],,
2815,NCT03045952,overall survival,2013-01,COMPLETED,INTERVENTIONAL,['NA'],,disease free survival
2816,NCT01472601,disease-free survival,2011-05-24,UNKNOWN,OBSERVATIONAL,['NA'],,
2817,NCT06005883,Recurrence of tumor,2021-04-10,COMPLETED,OBSERVATIONAL,['NA'],,
2818,NCT03974074,Serum albumin level,2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Rate of postoperative complications
2819,NCT04888299,Feasibility of Raman spectroscopy to identify mucosal healing in IBD and IBD-related dysplasia against the gold standard of histopathology,2021-04-14,UNKNOWN,INTERVENTIONAL,['NA'],,Diagnostic performance of Raman spectroscopy for assessment of mmucosal healing in IBD and IBD-related dysplasia against the gold standard of histopathology
2820,NCT03254394,Area Under the Curve (AUC) of Intensity of Oxaliplatin-induced Cold Pain/Unpleasantness vs Time,2017-09-15,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The Cumulative Dose of Oxaliplatin
2821,NCT00690300,tumor response,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,toxicity / safety
2822,NCT04407416,Breath analysis sensitivity,2020-05-02,UNKNOWN,INTERVENTIONAL,['NA'],,
2823,NCT03481296,Colorectal cancer screening test-specific adherence at 12 months (Colonoscopy),2018-08-20,COMPLETED,INTERVENTIONAL,['NA'],,Change in knowledge about colorectal cancer and colorectal cancer screening between baseline and 6 months
2824,NCT06206278,Overall survival (OS),2023-10-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,
2825,NCT01932125,Safety: Incidence of adverse events,2018-12-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],,Clinical benefit rate (complete response + partial response + stable disease)
2826,NCT02096354,Overall Survival,2014-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life (QOL) by QOL questionnaire
2827,NCT01623258,Define the rate of upstaging of colon carcinoma lymph node metastasis with define the rate of upstaging of colon carcinoma lymph node metastasis with sentinel lymph node (SLN) mapping,2002-12,COMPLETED,OBSERVATIONAL,['NA'],,
2828,NCT02132325,Change in level of distress as measured by distress scores on the Distress Thermometer,2014-04,COMPLETED,INTERVENTIONAL,['NA'],,
2829,NCT04661046,Progression Free Survival,2020-11-30,UNKNOWN,INTERVENTIONAL,['NA'],,
2830,NCT04620538,"Determine the diagnostic accuracy of breath test for detection of fibrosis, cirrhosis or hepatocellular carcinoma.",2021-04-01,RECRUITING,OBSERVATIONAL,['NA'],,
2831,NCT03658772,Define the recommended phase 2 dose (RP2D) of grapiprant combined with pembrolizumab,2018-09-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,Observed accumulation ratio
2832,NCT02132403,Maximum Tolerated Dose (MTD),2014-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,Disease Response based on RECIST Criteria
2833,NCT00052897,,2002-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2834,NCT03812705,Response rate,2018-12-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Duration of response
2835,NCT05488522,Primary Objective,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression Free survival
2836,NCT01621048,"toxicity: EORTC QLQ H&N35 questionnaire, the university of Michigan Xerostomia questionnaire (XQ) and the MD Anderson Dysphagia Inventory.",2012-06,WITHDRAWN,OBSERVATIONAL,['NA'],,
2837,NCT01196247,Determine the percent of patients who are alive at one year,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2838,NCT01418391,amount of post-operative morphine consumption,2011-06,UNKNOWN,INTERVENTIONAL,['NA'],,evaluation of post-operative pain status using visual analog scale (VAS) and superimposed face pain severity scale
2839,NCT03273920,3-year relapse-free survival,2017-09-25,UNKNOWN,INTERVENTIONAL,['NA'],,Immune response
2840,NCT03287453,Self-reported intentions to engage in behavior change to reduce risk of colorectal cancer,2017-04-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
2841,NCT00683631,,2004-01,COMPLETED,OBSERVATIONAL,['NA'],,
2842,NCT05913661,Objective Response Rate,2023-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
2843,NCT06078930,Overall Survival (OS),2021-04-06,RECRUITING,OBSERVATIONAL,['NA'],,Disease Free Survival (DFS)
2844,NCT05184946,3 years disease free survival rate,2021-10-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,overall survival time
2845,NCT03190616,Progression-free Survival(PFS),2017-07-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
2846,NCT01283893,Evaluation of operative procedure according to predetermined criteria,2010-12,UNKNOWN,OBSERVATIONAL,['NA'],,
2847,NCT03986294,Progression free survival of NaI-IRI with S1,2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],ctDNA,Quality of life QoL (QLQ-C30)
2848,NCT01606124,"Percent Change in Rectal ACF, Pre- and Post Intervention at 6 Months",2012-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Tolerability as Estimated Using the Percent Dose of Treatment Received at 6 Months
2849,NCT00192842,time to tumor progression,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,toxicity
2850,NCT02581423,Incidence of treatment discontinuation due to AEs,2005-08,COMPLETED,INTERVENTIONAL,['PHASE4'],,Incidence of toxocity-related dose reductions
2851,NCT00976612,nilotinib pharmacokinetics,2009-01,COMPLETED,OBSERVATIONAL,['NA'],,
2852,NCT00956072,Progression-free survival,2009-05,TERMINATED,INTERVENTIONAL,['PHASE3'],,Quality of life as measured by EORTC QLQ-C30
2853,NCT00925015,Number of Participants With an Adverse Event (AE),2009-06-17,COMPLETED,INTERVENTIONAL,['PHASE1'],,"AUC0-24 of Irinotecan Following Administration of Cetuximab / Irinotecan Alone, or in Combination With 10 mg/kg Dalotuzumab"
2854,NCT00005842,,2000-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2855,NCT03862885,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA'],,
2856,NCT04492033,P2: Objective response rate (ORR) of CTX-009 (ABL001) in combination with paclitaxel in patients with BTC,2020-06-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,P2: Overall survival (OS)
2857,NCT05617378,Risk factor,2022-11-01,RECRUITING,OBSERVATIONAL,['NA'],,
2858,NCT04447443,Therapeutic effect on the chemotherapy-related grade 2 to 4 diarrhea,2020-06-30,WITHDRAWN,INTERVENTIONAL,['NA'],,Gut microbiota changes in response to intervention
2859,NCT03430778,difference between SpHb value and SaHb value (SpHb - SaHb),2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
2860,NCT03140332,Scannographic evaluation of tumor response with mRECIST criteria,2017-02-27,COMPLETED,INTERVENTIONAL,['NA'],,
2861,NCT06189664,Detection of adenocarcinoma,2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
2862,NCT03891953,Tolerability of DKY709 single agent treatment or DKY709 in combination with PDR001.,2019-05-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Time to Progression (TTP)
2863,NCT00318370,Serologic Response (Change in Cancer Antigen [CA-125] Level),2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants Who Had a Prolongation of Remission
2864,NCT05807542,Pathological complete response,2022-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Objective Response Rate (ORR)
2865,NCT01571284,Number of Participants With Cycle Delay and/or Dose Modification,2012-05-30,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change From Baseline in HRQL EQ-5D-3L VAS Score
2866,NCT00003797,,1999-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
2867,NCT04292990,Pain Intensity Measure,2020-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Quality-of-Life composite Index
2868,NCT03429530,the role of circulating miRNAs in diagnosis of HCV related hepatocellular carcinoma.,2018-02-15,UNKNOWN,OBSERVATIONAL,['NA'],,
2869,NCT01281761,response rate,2010-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2870,NCT04490668,Comparison of the rate of anastomotic leakage,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
2871,NCT04310176,progression-free survival (PFS),2019-05-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,metastases resection rate (R0/R1/R2)
2872,NCT05541783,Scores on the physical function and pain symptom scales of EORTC QLQ-C30 questionnaire,2022-09-15,RECRUITING,INTERVENTIONAL,['NA'],,Scores on ST22 questionnaire
2873,NCT02123381,changes of serum vascular endothelial growth factor（VEGF）level before and after radiotherapy,2014-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,grade 3-5 adverse events
2874,NCT01333124,Complete resection rate,2011-09-28,TERMINATED,INTERVENTIONAL,['PHASE2'],,The feasibility and compliance
2875,NCT02456051,Pancreatic cancer diagnosis,2015-04,TERMINATED,OBSERVATIONAL,['NA'],,Mortality
2876,NCT02764944,En bloc resection,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],,successful closure of resection site
2877,NCT00002801,,1996-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2878,NCT04167293,24-week progression-free survival (PFS) rate,2019-11-16,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Adverse Events
2879,NCT03391687,Incidence of Pancreatic Fistula,2017-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,The mortality of Grade B and C Pancreatic Fistula
2880,NCT04790227,Secondary outcome after chemo-radiotherapy,2022-01,UNKNOWN,OBSERVATIONAL,['NA'],,
2881,NCT02937389,"The classification of gastric conduit ischemia by endoscopic findings predicts the major complications of gastric conduit (strictures, leakage, necrosis)",2015-05,COMPLETED,OBSERVATIONAL,['NA'],,Biological examination of gastric conduit as assessed by the Mitochondrial DNA copy number
2882,NCT02676349,To assess the efficacy of two neoadjuvant therapies in patients with borderline resectable pancreatic carcinoma evaluated on histological R0 resection margin rate,2016-10-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Evaluate the progression-free survival
2883,NCT01487785,Incidence rate and category of dose limiting toxicities (DLTs),2012-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Serum tumor marker Ca 19-9
2884,NCT02448979,Long term survival,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Postoperative complications
2885,NCT05524974,Objective response rate,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,"The prediction performance of Exosome contents (including proteins, nucleic acids)"
2886,NCT03469726,Diagnostic accuracy of CE-DW-MRI,2017-12-22,UNKNOWN,INTERVENTIONAL,['NA'],Progression free survival,Assess local resectability
2887,NCT03597126,Change in Female Sexual Function Index [FSFI],2018-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,
2888,NCT05616390,Overall survival (OS),2022-11-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of Life (QoL)
2889,NCT03203304,Number of participants with adverse events,2017-08-25,TERMINATED,INTERVENTIONAL,['PHASE1'],,Rate of local control of the SBRT treated lesion
2890,NCT02110498,To develop and prospectively validate a panel of molecular markers to differentiate benign pancreatic cysts from those with malignant potential using surgical pathology as the gold standard,2014-03,RECRUITING,OBSERVATIONAL,['NA'],To determine the proportion of patients with malignancy in operable pancreatic cysts,"To determine the sensitivity, specificity, and overall accuracy of imaging (CT, MRI and EUS) in patients with pancreatic cysts"
2891,NCT05853692,Oral Mucositis,2022-10-10,RECRUITING,INTERVENTIONAL,['NA'],,Severity of Oral Mucositis
2892,NCT01797224,Major malformations,2012-03,RECRUITING,OBSERVATIONAL,['NA'],,Infant follow-up
2893,NCT04266548,surgical benefit rate of fluorescent image,2018-07-09,COMPLETED,INTERVENTIONAL,['NA'],,Post operative Mortality
2894,NCT04118114,Treatment related adverse events rate,2019-09-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,
2895,NCT03326375,Local tumor control (efficacy fo SBRT),2017-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,Radiation induced liver disease (RILD)
2896,NCT05354388,1-year Progression free survival rate,2021-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,Duration of continuous medication before surgery
2897,NCT00415454,Toxicity,2006-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,Gene expression in pancreas
2898,NCT02934529,Overall Survival,2015-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Safety and tolerance as measured by the NCI-CTCAE version 4.03 criteria
2899,NCT03331406,Number of participants that adhered to physical activity program,2017-12-01,COMPLETED,INTERVENTIONAL,['NA'],,Number of participants with adverse events
2900,NCT04764006,Objective response rate (ORR),2021-10-13,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Assess the anti-tumor activity:DCR
2901,NCT03445936,Incisional hernia,2018-02-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Cost analysis
2902,NCT01821729,Number of Participants With R0 Resection,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,To Measure Utilization of Health Services
2903,NCT01912586,Changes in sexual function based on the (IIEF)-5 score and NPT,2013-05,COMPLETED,INTERVENTIONAL,['PHASE4'],,Compliance and overall patient satisfaction based on the self reported compliance diary and IIEF-5 score and NPT
2904,NCT00579891,establish a serum and tissue bank,1989-03-28,COMPLETED,OBSERVATIONAL,['NA'],,
2905,NCT03722511,Effect of amino acids in tightening the intestinal barrier and protecting from antigenic translocation by evaluating plasma circulating cytokine levels in peripheral blood sample.,2018-12-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluation of increased bacterial translocation and systemic inflammation.
2906,NCT01456585,Number of participants with adverse events,2012-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival
2907,NCT05319639,The maximum dose tolerated,2023-02-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
2908,NCT02436044,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA'],,
2909,NCT05710406,Disease free survival (DFS) (Phase III),2023-05-30,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']","• Patient Reported Outcomes Version of Common Terminology Criteria for Adverse Events for symptoms of rash, diarrhea, and fatigue",Alternative disease free survival
2910,NCT00003833,overall survival,1999-02,COMPLETED,OBSERVATIONAL,['NA'],,
2911,NCT03231176,Objective Response Rate (ORR),2017-12-19,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety and tolerability of varlitinib when combined with capecitabine
2912,NCT01853644,Overall Response Rate (ORR),2013-06-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS) in Platinum-resistant Ovarian Cancer to Treatment With Single Agent Tivozanib
2913,NCT02375581,all cause mortality,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,incidence rates of radiation-related pneumonitis and esophagitis
2914,NCT01782690,Overall Survival Stratified by Rash,2012-03-31,COMPLETED,OBSERVATIONAL,['NA'],,Score in Participant Questionnaire: Quality of Life
2915,NCT02507882,"Specific miRNA levels and their association with degree of fibrosis, cirrhosis and HCC",2016-01,UNKNOWN,INTERVENTIONAL,['NA'],,
2916,NCT02323776,Postoperative complications,2014-12,TERMINATED,OBSERVATIONAL,['NA'],,
2917,NCT01037790,Response Rates,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2918,NCT00137683,colorectal cancer screening,2001-09,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,knowledge
2919,NCT01342354,Identify the appropriate dose for treatment of unresected carcinoma of the ampulla or pancreas,2009-04-14,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change in patient reported outcomes using FACT-Hepatobiliary (FACT-Hep) quality of life questionnaire.
2920,NCT00036400,Number of red blood cell transfusions,2001-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Hemoglobin levels during preoperative chemoradiation; effect on quality of life measured by patient self-reported Linear Analog Scale Assessment, Functional Assessment of Cancer Therapy-Anemia, and Brief Fatigue Inventory; tumor response; safety"
2921,NCT03217773,Short-term morbidity,2017-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,Local recurrence
2922,NCT02917759,Number of successful xenografts established,2014-02,RECRUITING,OBSERVATIONAL,['NA'],,
2923,NCT04597151,Categorical responses to program evaluation survey,2020-10-12,COMPLETED,INTERVENTIONAL,['NA'],Change in Lifestyle Score on the National Institute of Health (NIH)/ National Cancer Institute (NCI) Automated Self- Administered 24-hour Dietary Assessment Tool (ASA24),Frequency of responses to the baseline socio-demographics survey
2924,NCT00597129,safety MTD,2004-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,efficacy
2925,NCT04642690,Serum and Tissue Biomarkers,2020-09-24,TERMINATED,OBSERVATIONAL,['NA'],,Biomarkers and disease progression
2926,NCT03962179,Technique - % of patients with successful implantation of VACStent,2019-09-22,UNKNOWN,INTERVENTIONAL,['NA'],,Sealing of leak - % of patients with successful implantation of VACStent
2927,NCT06051851,Progression-free survival（PFS）,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
2928,NCT01852890,"Number of grade 3, 4, & 5 adverse events during radiation",2014-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,"Number of grade 3, 4, & 5 adverse events post-treatment"
2929,NCT03775798,Incidence of hepatocellular carcinoma after direct-acting antivirals for HCV,2016-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,Adverse events after direct-acting antivirals for HCV
2930,NCT03462524,Global health-related quality of life (HR-QL) score as assessed by Eastern Co-operative Oncology Group QLQ-C30 questionnaire,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
2931,NCT03948958,TIVAD function,2019-06-28,COMPLETED,INTERVENTIONAL,['NA'],Patient-reported outcome measure,Catheter tip and port chamber culture
2932,NCT04074135,Characterization of the natural and clinical histories of VHL pancreatic neuroendocrine tumors and cystic lesions,2020-06-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,distribution of time from initial presentation with pancreatic tumors to the time that surgery is recommended
2933,NCT03356236,Progression-free survival (PFS),2018-04-17,RECRUITING,OBSERVATIONAL,['NA'],,severity of Adverse events (AE)
2934,NCT00336700,2-year Recurrence Free Survival (RFS),2006-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,KRAS Mutational Status
2935,NCT02195232,Percent Change in D-dimer Value,2015-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Cumulative Incidence of VTE at 56 Days
2936,NCT00165594,Response rate based on Response Evaluation Criteria in Solid Tumors (RECIST),2005-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Adverse drug reaction.
2937,NCT01155609,Decrease in mucositis severity and time to complete response,2010-09,COMPLETED,INTERVENTIONAL,['NA'],,Improvement in quality of life
2938,NCT00004895,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2939,NCT01760356,Change in the Percentage of expression of IL-2 in CD4 and CD8 subsets of T lymphocytes.,2011-05-01,TERMINATED,OBSERVATIONAL,['NA'],,Post transplant surgical complications
2940,NCT03699111,Stratification Tools,2018-09-19,COMPLETED,OBSERVATIONAL,['NA'],,
2941,NCT04868773,Recommended Phase 2 Dose [RP2D],2021-07-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of Participants with Objective Response Rate
2942,NCT04906954,"Step 2 : Number of patients with improvement of 10 points between baseline and week 8, assessed using the EORTC QLQ-C30 physical functioning scale",2021-06-29,UNKNOWN,INTERVENTIONAL,['NA'],,Overall Survival (OS)
2943,NCT05962450,Progression-Free Survival (PFS),2023-10-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,Time to Quality of Life (QoL) Deterioration
2944,NCT02545309,bile acid transporter genes,2015-12-21,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,upper gastrointestinal bleeding episodes
2945,NCT00035100,Tumor response rate,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,pharmacogenetic analyses with blood and tumor samples from these patients
2946,NCT03510923,Costs,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,Other aberrant findings requiring additional therapy
2947,NCT05376423,Recurrence-free survival rate,2022-06-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,
2948,NCT04003792,conversion rate to complete resection in patients with initially inoperable liver-only metastases due to colorectal cancer after treatment with HAI of oxaliplatin with FOLFIRI and bevacuzimab systemic treatment.,2020-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
2949,NCT03516994,Proportion of Whites who complete advance care planning,2018-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Patient Quality of Life
2950,NCT06190782,Progression-free survival difference of PD-1 inhibitor+radiotherapy and PD-1 inhibitor alone,2022-09-27,RECRUITING,INTERVENTIONAL,['PHASE3'],,local control rate
2951,NCT01111591,Short term outcome,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Long term outcome
2952,NCT00881816,maximum tolerated dose,2009-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],,dose limiting toxicity
2953,NCT01167712,Progression-Free Survival,2010-09-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Changes in the Tumor Perfusion Parameters as Quantified by Vascularity or Blood Volume; Perfusion or Blood Flow; Mean Transit Time; and Microvascular Permeability or Permeability Surface Area Product,Quality of Life Score as Measured by Functional Assessment of Cancer Therapy-Ovary-Total Outcome Index (Fact-O TOI)
2954,NCT00651742,Overall Tumor Response Rate (ORR),2006-01-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAE)
2955,NCT01283802,the technical feasibility,2004-06,COMPLETED,OBSERVATIONAL,['NA'],,Efficacy
2956,NCT02335970,Degree of physical disability estimated by the Disability Rating Index (DRI),2005-09-05,COMPLETED,INTERVENTIONAL,['NA'],,PEF (Peak Expiratory Flow)
2957,NCT01465308,Change from baseline in oral mucositis grades,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change in baseline weight in one month
2958,NCT02955069,Overall Response Rate (ORR) by RECIST 1.1 and as Per Blinded Independent Central Review (BIRC).,2017-02-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,PDR001 ADA Incidence On-treatment
2959,NCT00548236,"To evaluate the ability of a multi-center, telephone-based physical activity intervention to increase weekly physical activity levels in sedentary patients treated with adjuvant chemotherapy for Stage I-III breast or colorectal cancer.",2007-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,"To evaluate the impact of a physical activity intervention upon fitness, exercise self-efficacy, anthropometric measures, and quality of life in a group of patients with stage I-III breast or colorectal cancer."
2960,NCT01015833,Overall Survival,2010-02-15,COMPLETED,INTERVENTIONAL,['PHASE3'],,Best Overall Response Rate
2961,NCT04293835,the height of sigmoid take-off,2019-06-01,COMPLETED,OBSERVATIONAL,['NA'],,"The distances of the sacral promontory, third sacral segment, and superior, inferior margin of cancers, and anterior peritoneal reflection from the anal verge."
2962,NCT01095523,To compare the overall survival of patients at high risk for developing peritoneal carcinomatosis from colorectal cancer who undergo mandatory second look surgery + HIPEC and CRS (if applicable) vs. similar patients who receive standard of care.,2010-01-14,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,To determine recurrence-free survival in both arms. To investigate selection criteria for patients who might benefit from a strategy of MSLS with CRS + HIPEC.
2963,NCT05750290,Best objective response rate,2022-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
2964,NCT04666090,Pathological Complete Response (PCR),2020-11-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,The changes in the peripheral blood immunoprofile among non-PCR (NPCR) and PCR patients
2965,NCT03305146,Comparison between gene mutations found into the pancreatic cystic tumor fluid to gene mutations found into tissue specimen,2017-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Evaluate the feasibility of the molecular biology analysis of the pancreatic cystic tumor fluid to distinguish the pancreatic cysts.
2966,NCT02148406,Changes in fatigue (recalled),2014-08,COMPLETED,INTERVENTIONAL,['NA'],Changes in circadian disruption (daily and recalled) as assessed by actigraphy and the Godin's Leisure Score Index,Regulation of psychological stress (daily and recalled) as assessed by Positive and Negative Affect Schedule-Expanded Form and Cancer Behavior Inventory
2967,NCT03300921,Number of Adverse Events,2017-09-28,TERMINATED,INTERVENTIONAL,['PHASE1'],,
2968,NCT00103324,Confirmed response probability (complete and partial),2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
2969,NCT00444795,"Percentage of Participants With Adverse Events (AEs)/Adverse Drug Reactions (ADRs), Serious AEs (SAEs)/Serious ADRs (SADRs), Unexpected AEs/ADRs, and Unexpected SAEs/SADRs",2007-05,COMPLETED,OBSERVATIONAL,['NA'],,"Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) According to Response Evaluation Criteria in Solid Tumors (RECIST)"
2970,NCT03179540,Rate of macroscopically positive resection margin,2018-03-16,RECRUITING,INTERVENTIONAL,['NA'],,Bowel Function
2971,NCT04452396,study arm 2 - using Continuous Glucose Monitoring of interstitial fluid as a proxy marker of blood glucose to optimise hypoglycaemia treatment in patients with an established diagnosis of spontaneous or reactive hypoglycaemia,2019-12-01,TERMINATED,INTERVENTIONAL,['NA'],,assessing concordance between CGMS and lab/finger prick glucose testing
2972,NCT03397654,Incidence of treatment-emergent adverse events (safety and tolerability),2018-01-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Improvement of progression-free survival rate (PFSR; efficacy)
2973,NCT05070104,Recommended Phase 2 Dose,2023-03-30,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Overall Survival
2974,NCT03015168,overall survival,2012-01,COMPLETED,OBSERVATIONAL,['NA'],,grade 3 or higher treatment related small bowel toxicity
2975,NCT02318784,Overall Response Rate (ORR),2015-07-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability
2976,NCT01043523,Vital Signs: Mean Change From Baseline in Diastolic Blood Pressure,2009-12,COMPLETED,OBSERVATIONAL,['NA'],Change in Information About Lesion Characterization Obtained From the Combined Precontrast and Postcontrast Images as Compared With the Precontrast Images,"Sensitivity, Specificity and Accuracy of Blinded Read of Precontrast and Combined Precontrast/Postcontrast Images Based on Final Diagnosis."
2977,NCT01387555,Survival,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time-to-symptomatic-progression
2978,NCT00801294,PFS,2006-07-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Effectiveness of dose reduction guidelines in managing adverse events
2979,NCT00416494,Response Rate (Percentage of Participants With Partial or Complete Response),2003-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Effect on Wound Angiogenesis,Safety and Tolerability
2980,NCT02809534,12-week Progression-free survival rate(PFR 12w),2016-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease Control Rate (DCR)
2981,NCT06194981,Overall Survival,2024-01-11,RECRUITING,OBSERVATIONAL,['NA'],,Adverse Events
2982,NCT02284529,To evaluate the incidence of grade 0-3 neurosensory symptoms (paresthesia) in the end of study,2012-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,
2983,NCT01699399,Proportions of patients requiring sedation,2012-08,COMPLETED,INTERVENTIONAL,['NA'],post-procedure discomforts and 30 days complication rate,patient pain during insertion
2984,NCT02991638,Adverse events and severe adverse events,2016-11-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
2985,NCT02151448,"Adverse Events Possibly, Probably or Definitely Related to Study Treatment",2014-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Tumor Necrosis Factor (TFNα) Cytokine Levels
2986,NCT03329495,number of lymph nodes retrieved,2018-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,operative time
2987,NCT06102785,Progression Free Survival,2023-11-10,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
2988,NCT00427349,Four-month Progression-free Survival Rate,2008-11-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Objective Response Rate
2989,NCT01972490,the rate of patients converted to resection for liver metastases,2013-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,tumor response
2990,NCT03060642,Oral and esophageal 16S rRNA gene sequencing,2018-02-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Gastric aspirate mass spectrometry
2991,NCT02041897,Rate of change of diagnosis,2014-01,UNKNOWN,INTERVENTIONAL,['NA'],,Number of Participants with Adverse Events
2992,NCT04109105,Effectiveness and security analysis in the prevention of anastomosis leakage through the protection of ileocolic anastomosis with NHS-PEG coated collagen patch.,2019-01-15,UNKNOWN,OBSERVATIONAL,['NA'],,Number of hospital readmissions.
2993,NCT01439594,Feasibility of OFDI Imaging as Determined by Number of Successful Imaging Sessions,2008-10,COMPLETED,INTERVENTIONAL,['NA'],,
2994,NCT02668380,Adverse Events,2015-09,UNKNOWN,OBSERVATIONAL,['NA'],,Objective response rate
2995,NCT01058655,Progression-Free Survival (PFS) [Phase II],2010-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS) [Phase II]
2996,NCT04970316,Development of stoma-related issues after PE or CRS+HIPEC for colorectal cancer,2021-01-25,RECRUITING,OBSERVATIONAL,['NA'],,Risk factors associated with developing organ specific late adverse effects
2997,NCT05996276,Overall survival (OS),2023-08-01,RECRUITING,OBSERVATIONAL,['NA'],,Progression-free survival (PFS).
2998,NCT00822718,,2005-01,COMPLETED,OBSERVATIONAL,['NA'],,
2999,NCT04209933,helicobacter pylori eradication,2020-05-25,COMPLETED,INTERVENTIONAL,['PHASE4'],adverse events,symptoms effective rates
3000,NCT00388037,Objective Response (Partial Response or Complete Response) as Per the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3001,NCT02817425,Overall Survial (OS),2013-05,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Dose intensity
3002,NCT05944237,Number AEs Related to Atezolizumab (Dose Escalation and Expansion Phase),2023-07-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Assess change in tumour T cell infiltration in baseline and on-treatment biopsies
3003,NCT00081848,,2004-04-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3004,NCT04127734,1-year stomafree survival,2020-04-01,UNKNOWN,OBSERVATIONAL,['NA'],Hospital related costs,1 year mortality
3005,NCT02673710,Sarcopenia quantified via CT-scan defined as a skeletal muscle index at the 3rd lumbar vertebra below 41 for women and below 43 or 53 for men with a Body Mass Index below or above 25 respectively,2016-03-14,COMPLETED,OBSERVATIONAL,['NA'],,First Progression Free Survival (PFS1) is defined as the time between initial diagnosis and first progressive disease
3006,NCT05128708,detection of post operative wound infection in both groups,2020-08-07,COMPLETED,INTERVENTIONAL,['NA'],,
3007,NCT05704530,To observe the ctDNA MRD dynamics during adjuvant immunotherapy .,2023-03-29,RECRUITING,INTERVENTIONAL,['NA'],,
3008,NCT04777942,"Progression-free survival, PFS",2021-02-20,RECRUITING,INTERVENTIONAL,['NA'],,"Overall survival, OS"
3009,NCT05982184,Patient reported anxiety measured by the 6-item Spielberger State-trait Anxiety (STAI-6) inventory at admission.,2023-10-03,RECRUITING,INTERVENTIONAL,['NA'],Rate and type of complications during surgery as recorded in the EHR,Quality of recovery is a comprehensive 40-item questionnaire (QoR-40) used to assess the rate of recovery after surgery.
3010,NCT05304936,Determine the maximum tolerated dose (MTD),2022-10-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Duration of Response
3011,NCT04519138,Proportion of patients with pre-specified adverse events,2020-09-30,COMPLETED,INTERVENTIONAL,['NA'],,Amount of visible biopsy material over or under 5 mm at endoscopy examination
3012,NCT04624555,Participant acceptance of mt-sDNA as a follow up strategy compared to colonoscopy as measured by the Stool Test Satisfaction Survey.,2024-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
3013,NCT03792854,Qol (EORTC QLQCR29) absolute values and change over time,2018-12-01,RECRUITING,OBSERVATIONAL,['NA'],,late toxicity
3014,NCT00974389,Disease-control rate,2009-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety
3015,NCT05407519,RFS rate,2022-07-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,AEs
3016,NCT00504361,"Genomic DNA will be extracted, and genome wide SNP analysis and promoter sequences for genes will be obtained.",2006-05,COMPLETED,OBSERVATIONAL,['NA'],,
3017,NCT05967429,Assess the quality of life,2023-08,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
3018,NCT00066651,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3019,NCT01853059,Functional quality of life after chemoradiotherapy for anal cancer,2013-10,UNKNOWN,OBSERVATIONAL,['NA'],,Patient-reported treatment-related toxicity after chemoradiotherapy for anal cancer
3020,NCT03755739,Complete response (CR) rate before or at Month 6,2018-11-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Cause of death (COD) when appropriate
3021,NCT01156142,Total Pain Reduction (Mouth and Throat),2010-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Patient Preference for Continuing Therapy With Oral Doxepin Hydrochloride
3022,NCT03909724,Progression Free Survival,2019-10-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Liquid biopsies
3023,NCT00812864,"Mean value and dispersion of the main plasmatics pharmacokinetics parameters of capécitabine, 5'DFUR, 5-FU and FBAL.",2009-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,"Objective response comparing lesions' targets according to RECIST criteria, at course n°3 and n°6."
3024,NCT03406299,6-month progression-free survival rate,2018-04-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Biomarker study
3025,NCT03957902,Assessment of changes in acetylation levels of COX enzymes in platelets and non-neoplastic and neoplastic colonic tissues,2019-05-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Assessment of changes in major urinary metabolite of PGE2 (PEG-M) levels depending on drug dosis
3026,NCT06137170,Overall Survival (OS),2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,"Proportion of patients in the sequential treatment groups who received myelopoiesis supporting therapy, differentiating between prophylactic and for therapeutic purpose"
3027,NCT00454519,overall survival time,2007-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,perioperative morbidity and mortality
3028,NCT05038397,Recurrence free survival (RFS) after resection,2018-01-30,COMPLETED,INTERVENTIONAL,['NA'],,Rate of post operative hepatic decompensation
3029,NCT03702309,Collection and annotation of biospecimens,2017-08-03,RECRUITING,OBSERVATIONAL,['NA'],,Correlative Studies Questionnaire
3030,NCT03041532,Proximal retroflexion improve adenoma detection rate in colorectal cancer screening,2017-10-01,COMPLETED,INTERVENTIONAL,['NA'],,Pre-procedure factors
3031,NCT00763646,To determine the impact of chemotherapy on the ability of your surgeon to completely remove the cancer as well as the impact on your survival.,2007-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
3032,NCT02547064,Time to Intubation,2015-10,COMPLETED,INTERVENTIONAL,['NA'],,Airway Injury
3033,NCT03679338,Rate of success of the use of a treatment based on radiofrequency for all the target stenosis.,2018-03-22,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
3034,NCT00115765,Objective Tumor Response Through Week 12 (Irinotecan),2005-06-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time to Treatment Failure (Irinotecan)
3035,NCT01563991,Morbidity,2007-02,COMPLETED,INTERVENTIONAL,['NA'],,
3036,NCT00416858,,na,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3037,NCT01915693,patient-reported dysphagia,2013-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,cost
3038,NCT05601388,evaluate the immunohistochemical (IHC) expression of IMP3 in CRC and to correlate its expression with some known clinicopathological parameters.,2022-10-01,RECRUITING,OBSERVATIONAL,['NA'],,
3039,NCT04771715,Overall Survival,2019-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,Incidence of treatment-related adverse events (TRAE)
3040,NCT03362684,Prognostic and predictive value of miR-31-3p expression on Disease Free Survival (DFS),2005-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Distribution of miR-31-5p expression,Prognostic and predictive value of miR-31-3p expression on SAR
3041,NCT02340949,Number of Patients Achieving Pathologic Complete Response (pCR).,2015-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Free Survival (DFS) Rate at 3 Years
3042,NCT00020345,,2000-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3043,NCT02754180,Disease free survival,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
3044,NCT00588575,,2004-10,COMPLETED,OBSERVATIONAL,['NA'],,
3045,NCT02361320,Correlation Between Local Control and Changes in Mass Transport by Computed Tomography (CT),2015-03-09,RECRUITING,INTERVENTIONAL,['NA'],,
3046,NCT03685708,Number of Participants With HEPLISAV-B Seroprotective Titer (Anti-HBs 10mIU/mL),2018-12-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants That Did Not Complete Study Due to Intolerance of the HEPLISAV-B Vaccine Among CLL Patients.
3047,NCT01583686,Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0),2012-05-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
3048,NCT03222895,Distribution of lymph node metastases,2019-03-01,RECRUITING,OBSERVATIONAL,['NA'],,3- and 5-year overall and disease free survival
3049,NCT01143545,Tabulation of toxicity type and grade,2010-12-07,TERMINATED,INTERVENTIONAL,['PHASE1'],,"To determine if metronomic oral CP and celecoxib reduce the number, percentage and function of CD4+ CD25+ Fox P3+ regulatory T cells (T reg) in peripheral blood of thoracic oncology patients."
3050,NCT03550625,Assessment of the computer- made optical diagnosis of each colorectal polyp,2018-07-15,UNKNOWN,OBSERVATIONAL,['NA'],,
3051,NCT05185505,Proportion of Patients Receiving Liver Transplant Experiencing Acute Rejection,2023-01-30,RECRUITING,INTERVENTIONAL,['PHASE4'],,Immune Cell Biomarkers
3052,NCT01969591,solid diet time,2011-01,COMPLETED,INTERVENTIONAL,['NA'],,"Complications:anastomotic leakage,intestinal obstruction,wound infection"
3053,NCT03950141,progression-free survival,2017-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Safety and tolerability as measured by number and grade of toxicity events,overall survival
3054,NCT05944809,The highest grade of thrombocytopenia (CTCAE 4.0) during the radiotherapy and 1 month after the radiotherapy.,2023-07-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,"The highest grade of leukopenia, neutropenia,anemia (CTCAE 4.0) during the radiotherapy and 1 month after the radiotherapy."
3055,NCT04831814,Rate of accurate diagnosis of sessile serrated polyps/adenoma by the Endoscopists in the two groups.,2019-04-04,COMPLETED,INTERVENTIONAL,['NA'],,Diagnostic Characteristics
3056,NCT05961982,Efficacy of endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA),2023-04-24,RECRUITING,INTERVENTIONAL,['NA'],,Safety of EUS-guided RFA of pancreatic cystic neoplasms at one year
3057,NCT03811431,Number of patients in whom contrast enhanced ultrasound guided liver biopsy leads to the final diagnosis as compared to conventional ultrasound guided liver biopsy. The final diagnosis will be assessed based on histological examination.,2011-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,
3058,NCT00234429,Determine the progression free survival,2003-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Determine objective tumor response
3059,NCT04451512,Complete resection rate,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,related costs of treatment
3060,NCT05343013,To determine the 6-month ctDNA clearance rate in colorectal cancer patients with minimal residual disease following 6 months of TAS-102 therapy.,2022-06-06,RECRUITING,INTERVENTIONAL,['PHASE2'],,
3061,NCT06287723,3-year disease free survival,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Time to molecular recurrence
3062,NCT01930318,Insulin resistance in perioperative period of gastrointestinal laparoscopic surgery,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Self-rating anxiety scale and self-rating questionnaire for depression before surgery
3063,NCT01845753,Rate of Lynch Syndrome in a population of primary colorectal cancer,2012-10,COMPLETED,OBSERVATIONAL,['NA'],,
3064,NCT05435014,Phase II part: target lesion response at 6 weeks after TAE/TACE treatment.,2022-09-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II part: Safety variables evaluation - ECG test
3065,NCT02085460,Incidence of Grade ≥3 Oral Mucositis Determined by Clinical Examination and Assessed by Central Review According to the Common Terminology Criteria of Adverse Events (CTCAE) Version 3.0.,2014-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Subjects Who Did Not Developed Grade ≥3 Mucositis
3066,NCT03985072,Incidence of treatment-emergent adverse events (TEAEs) through stages 1 and 2 of the study,2019-04-26,COMPLETED,INTERVENTIONAL,['PHASE1'],Evaluate the exploratory response of tumor markers,Incidence of Andes-1537 anti-drug antibodies (ADAs) in the plasma
3067,NCT03645187,number of patients with improved radiology,2018-08-01,RECRUITING,INTERVENTIONAL,['PHASE4'],,
3068,NCT02314117,Progression-free Survival (PFS),2015-01-20,COMPLETED,INTERVENTIONAL,['PHASE3'],,PK: Minimum Concentration (Cmin) of Ramucirumab
3069,NCT01569282,Morbidity,2011-10,WITHDRAWN,INTERVENTIONAL,['NA'],,"The numbers of Surgical, Radiological or Endoscopical therapeutic re-interventions"
3070,NCT03516695,Effectiveness of TheraSphere® treatment in participants with liver cancers in a real-life setting,2018-02-23,TERMINATED,OBSERVATIONAL,['NA'],,TheraSphere® Dosimetry in the subgroup of HCC participants
3071,NCT05342350,GALAD performance for liver cancer early detection,2022-04-15,RECRUITING,OBSERVATIONAL,['NA'],,Establishment of a bio-repository of longitudinally collected from patients with cirrhosis to be used for future studies
3072,NCT02145013,Mortality,2013-11,UNKNOWN,OBSERVATIONAL,['NA'],Impact of PET CT on overall survival following liver resection,Survival outcomes
3073,NCT05474794,Sensitivity and Specificity of DFI-EUS in the diagnosis of SELS,2022-07-20,RECRUITING,INTERVENTIONAL,['NA'],,
3074,NCT02121366,Safety of EUS-guided ethanol ablation,2014-03,UNKNOWN,INTERVENTIONAL,['NA'],,Technical feasibility
3075,NCT05983419,Safety for full resection in BE,2023-08-01,RECRUITING,INTERVENTIONAL,['NA'],,
3076,NCT05608200,Overall survival (OS),2022-11-02,RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse Events (AEs)
3077,NCT05420415,5-year DFS,2018-09-01,COMPLETED,OBSERVATIONAL,['NA'],,5-year OS
3078,NCT04258644,R0 resection rate,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,3-year OS
3079,NCT04359732,Imaging parameters as potential predictors of tumor response,2020-05-08,RECRUITING,INTERVENTIONAL,['NA'],,Early regression model (ERI)
3080,NCT02447679,tumor recurrence,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3081,NCT05257694,Recurrence-free survival (RFS),2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Recurrence
3082,NCT05970627,Rate of pathological complete responses (pCR),2023-07-28,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,The incidences and types of adverse events (AE) and severe adverse events (SAE)
3083,NCT00502671,"Percentage of Participants With an Adverse Event (AE), Serious AE, or Death Due to an AE",2007-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,Percentage of Participants With Early Withdrawal or Discontinuation Due to an AE
3084,NCT01900002,Median Progression Free Survival (PFS),2013-09-13,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0"
3085,NCT05956990,Fear of Progression Questionaire-Short Form (FoP-Q-SF),2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Platelet count
3086,NCT04659382,Progression-free survival at 9 months,2020-10-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,
3087,NCT06246344,surgical difficulty,2023-12-01,RECRUITING,OBSERVATIONAL,['NA'],,QLQ-CR29
3088,NCT03475004,Objective Response,2018-09-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
3089,NCT05732623,Diet and the risk of eoCRC,2022-12-05,RECRUITING,OBSERVATIONAL,['NA'],,
3090,NCT00457743,Number of Subjects With Clinical Benefit Response (CBR) Based on the Extramural Review Committee Assessment in Recommended Dose Group,2005-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival Time
3091,NCT01034358,Twelve Month Antibody Response to the Human Papillomavirus (HPV) Vaccine (Geometric Mean Titers [GMT]),2010-02,COMPLETED,INTERVENTIONAL,['PHASE4'],,
3092,NCT04229537,Rate of adverse events,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
3093,NCT02057471,Hemoglobin levels,2009-09,COMPLETED,INTERVENTIONAL,['PHASE4'],Number of adverse events associated with intravenous iron infusion,C Reactive Protein levels
3094,NCT04235660,Feasibility of Recruitment (Recruitment Rate),2020-07-22,TERMINATED,INTERVENTIONAL,['NA'],,Objective Response Rate
3095,NCT05239741,Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) For RAS Wild-type Participants,2022-04-02,RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)
3096,NCT01549275,Correlation Between the Growth Speeds of the Cultured Cells and the AJCC TNM Stage (7th Eds) at Entering of the Study.,2010-04,COMPLETED,OBSERVATIONAL,['NA'],,Correlation Between the Growth Speeds of Cultured Cells and Worsening of AJCC TNM Stages or HCC Related Death 6 Months After Plating of Cells
3097,NCT02748798,Signal to Noise Ratio,2020-11-10,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Correlation with PFTs
3098,NCT03382327,Comparison of the intra-operative modifications rates,2017-10-16,COMPLETED,INTERVENTIONAL,['NA'],,Preoperative images independent analysis
3099,NCT04013841,Intestinal microbiome composition,2021-04-08,COMPLETED,INTERVENTIONAL,['NA'],,Intestinal microbiome composition
3100,NCT04158349,"Assess the maximum tolerated dose of intraperitoneal (IP) oxaliplatin with systemic IV 5-fluorouracil, leucovorin, and irinotecan (mFOLFIRI) every 2 weeks in patients with unresectable peritoneal carcinomatosis of colorectal or appendiceal origin",2021-03-22,TERMINATED,INTERVENTIONAL,['PHASE1'],,The efficacy of IP oxaliplatin plus systemic mFOLFIRI in patients with peritoneal carcinomatosis of colorectal or appendiceal origin will be measured.
3101,NCT00838656,Percentage of patients completing 12 courses of chemotherapy,2007-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Rates of optimal and suboptimal interval debulking
3102,NCT02437656,The efficacy will be assessed on the operative specimen by the complete histological response rate (absence of tumor cells : pCR).,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Sphincter preservation rate and downstaging rate
3103,NCT06068452,Cardiopulmonary Exercise Testing (CPET)/ Portsmouth - Physiological and Operative Severity Score for the enumeration of Mortality and morbidity (P-POSSUM) predicted mortality versus actual 30 day mortality,2021-03-24,COMPLETED,OBSERVATIONAL,['NA'],,Cardiopulmonary Exercise Testing (CPET) / Portsmouth - Physiological and Operative Severity Score for the enumeration of Mortality and morbidity (P-POSSUM) predicted morbidity versus actual post-operative morbidity
3104,NCT01461525,Quality of life outcome,2011-10,UNKNOWN,INTERVENTIONAL,['NA'],,Anal function
3105,NCT00991003,The primary endpoint was the number of cancerous lesions and polyps detected on CCE compared to conventional colonoscopy,2007-11,COMPLETED,INTERVENTIONAL,['NA'],,"Secondary endpoints were completeness of the exam completeness, patient acceptance and adherence to preparation regimen"
3106,NCT00215514,"To assess patient tolerance and toxicity of postoperative adjuvant regimen using epirubicin, cisplatin, and infusional 5-FU before and after a course of radiotherapy among patients with curatively resected gastric or gastroesophageal adenocarcinoma.",2000-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
3107,NCT03956940,Detection rate of total circulating free deoxyribonucleic acid (cfDNA) concentration at the baseline.,2019-10-04,TERMINATED,INTERVENTIONAL,['NA'],,Overall Survival
3108,NCT00826410,number of surgical site infections according to CDC guidelines after laparotomy in general surgery,2003-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,risk factors for surgical site infections
3109,NCT03430700,Progression-Free Survival (PFS) measured from start of study treatment to the date of objective progression (investigator assessed using RECIST 1.1) or date of death from any cause (in the absence of progression).,2019-05-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease response
3110,NCT01043484,Rate complete pathologic responses,2009-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Rate of sphincter preservation
3111,NCT01572987,Complete histological eradication of Barrett's esophagus,2011-09,TERMINATED,INTERVENTIONAL,['NA'],,Complication rates
3112,NCT01905384,Rate of Long-term Stent Failure,2017-11-08,COMPLETED,INTERVENTIONAL,['NA'],,Rates of Adverse Stent-related or Intervention-related Outcomes
3113,NCT02270450,Number of Days Alive and Outside of the Hospital,2015-03-09,COMPLETED,INTERVENTIONAL,['NA'],,Overall Survival
3114,NCT00309530,Overall survival,1990-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3115,NCT04838496,The main study parameter is the proportion of patients with a pathological complete response (pCR) and those patients who started a wait and see strategy and have sustained clinical complete response (cCR) at 1 year.,2021-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Costs
3116,NCT04771637,ASA status,2017-01-01,COMPLETED,INTERVENTIONAL,['NA'],heart rate,internal environment
3117,NCT02599324,Phase 1b/2 RP2D: Overall Response Rate (ORR) as Assessed by Investigator in Cohorts 3 to 6,2015-12-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 1b: Apparent Total Clearance at Steady-State (CLss/F) for Ibrutinib in Cohorts 1 to 4
3118,NCT06258525,To evaluate the efficacy of SAMe in preventing oxaliplatin associated liver injury as determined by lack of injury on histopathologic analysis in patients with liver only stage IV colorectal cancer.,2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,To evaluate safety and tolerability of SAMe in combination with SOC oxaliplatin based systemic therapy.
3119,NCT00140036,Correlation of genotype with safety and efficacy measures.,2002-09,COMPLETED,INTERVENTIONAL,['PHASE4'],,
3120,NCT01478594,Investigator-assessed Progression-Free Survival (PFS),2011-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-Free Survival Events by Tumor Placental Growth Factor (PIGF) RNA Level
3121,NCT02890355,Overall Survival (OS),2016-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Genomic Alterations Identified by the BROCA-homologous Recombinant (HR) Assay,Duration of Response (DoR)
3122,NCT01571024,Maximum Tolerated Dose (MTD),2012-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Biomarkers of Clinical Benefit
3123,NCT03602885,Number of Participants With Accurate Understanding of Chemotherapy Benefits at 8-12 Weeks,2018-09-01,COMPLETED,INTERVENTIONAL,['NA'],,Discussions About End-of-life Care Preferences With Healthcare Proxy and Care Team
3124,NCT06215651,Conversion success rate,2024-03-11,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
3125,NCT05963490,ORR,2023-04-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
3126,NCT00049400,dose defining,2003-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Symptomatic deterioration
3127,NCT04440605,Diagnostic Accuracy of cIII,2020-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,Diagnostic Accuracy of cTN
3128,NCT03685799,Influence of histological concordance on the risk of recurrence,2016-05,COMPLETED,OBSERVATIONAL,['NA'],,Identification of histological factors of recurrence.
3129,NCT04071184,Maximum tolerated dose (MTD) or Recommended phase 2 dose (RP2D),2019-05-26,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Objective response rate (ORR)
3130,NCT00005021,,1996-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3131,NCT02509143,Number of patients who experience moderate or severe level nausea or vomiting,2015-07,COMPLETED,INTERVENTIONAL,['NA'],,Serious adverse events
3132,NCT04257526,Improvement in lifestyle score assessed via lifestyle questionnaires,2022-03-23,RECRUITING,INTERVENTIONAL,['NA'],,
3133,NCT00637091,Response rate,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Progression free survival, overall survival"
3134,NCT00024258,Response Rate After Every 3 Courses During Treatment and Then Every 2-3 Months for 1 Year After Completion of Treatment,2001-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3135,NCT05366816,Number of Participants Achieving Overall Response,2023-10-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Related Toxicity and Adverse Events
3136,NCT03349827,radical resection rate,2018-01-05,TERMINATED,INTERVENTIONAL,['NA'],,complication rate
3137,NCT05018208,Quantification of false alerts and downstream clinical actions (Arm 2),2021-12-15,RECRUITING,OBSERVATIONAL,['NA'],,Point-in-time assessment of physiological signals from standard of care devices (Arm 1)
3138,NCT02308319,Recurrence free survival,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Reactivation of hepatitis B
3139,NCT05610826,Progression-free Survival,2023-03-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Difference in imaging characteristics
3140,NCT01351220,Change from Baseline in receipt of CRC screening at 6 months and 24 months,2010-07,COMPLETED,INTERVENTIONAL,['NA'],,Change from Baseline in frequency of patient provider communication at 6 months and 24 months
3141,NCT00212589,,2002-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3142,NCT04808687,Objective response rate,2021-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
3143,NCT02721576,Objective response rate,2016-07-05,TERMINATED,INTERVENTIONAL,['PHASE4'],,Progression free survival
3144,NCT06149481,Phase II: Overall response rate (ORR) defined as the CR+PR of the IO regimen in mCRC,2024-03-26,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
3145,NCT02589860,Melphalan exposure,2015-10-30,WITHDRAWN,OBSERVATIONAL,['NA'],,
3146,NCT01887041,Outcome of Quality of Life.,2010-01,TERMINATED,INTERVENTIONAL,['PHASE4'],,"The incidence of surgical complications and complications, with regard to the endo-scopic stent insertion, are further aspects that shall be examined in this study."
3147,NCT03743883,Incidence rates of oesophageal cancer and stomach cancer with use of low-dose ASA by sex-specific compared to non-use,2018-10-30,COMPLETED,OBSERVATIONAL,['NA'],,Incidence of oesophageal cancer and stomach cancer among new users of low-dose ASA for primary or secondary cardiovascular prevention
3148,NCT05643105,Anastomotic leak,2022-12-15,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],Intraoperative complications,Local recurrence
3149,NCT01279330,Completion of Fecal Occult Blod Test,2010-09,UNKNOWN,INTERVENTIONAL,['NA'],,Proportion of uninterpretable test.
3150,NCT05726097,Adequate cleanliness rate,2023-02-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Assessment of patient tolerance of the bowel preparations
3151,NCT04786600,Overall survival,2021-11-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Best overall response
3152,NCT05872841,disease control rate (DCR),2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,overall survival(OS)
3153,NCT00005979,,1998-07-22,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3154,NCT05629065,Proportion of patients with an SIC at 60 days for arm 1 (patient +clinician nudge) vs arm 2 (no nudge).,2022-11-28,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Patient preferences
3155,NCT02780700,Progression Free Survival (PFS),2016-07-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Percentage of Patients With Grade 3 or Worse Adverse Events
3156,NCT01801930,Dose Limiting Toxicity (DLT),2013-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumor Response Rate in Cycle 1
3157,NCT04892342,Objective Response Rate (ORR) by Independent Central Review (ICR),2021-09-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,ADA
3158,NCT00003522,,1997-08-13,TERMINATED,INTERVENTIONAL,['PHASE2'],,
3159,NCT06213519,Overall survival,2024-02-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and Tolerability
3160,NCT05265663,Overall survival,2020-10-13,RECRUITING,INTERVENTIONAL,['NA'],,Progression of disease (local and distant)
3161,NCT01861873,volumetric uptake values of 18-FDGal will be measured and the 18-FDGal PET/CT one month after stereotactic body radioation therapy will be compared to the baseline status in sub-volumes receiving more than 15 Gy,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,evaluate toxicity to SBRT by toxicity scoring system that includes biochemical measures as well as symptomatic scores.
3162,NCT04955119,Positive predictive value,2021-07-30,UNKNOWN,INTERVENTIONAL,['NA'],,The sensitivity and specificity of CEUS LR-5
3163,NCT01985763,Percent Change in Tumor Size,2013-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
3164,NCT01342653,disease free survival,2011-01,SUSPENDED,INTERVENTIONAL,['PHASE2'],,Quality of life after phase I and Phase II
3165,NCT03668418,Correspondence with chemo-sensitivity data collected in zebrafish model,2018-06-01,UNKNOWN,OBSERVATIONAL,['NA'],,Time to tumour progression
3166,NCT02898415,Cancer specific survival,2015-06,COMPLETED,OBSERVATIONAL,['NA'],,Recurrence Free Survival
3167,NCT00183833,To determine the dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of Gleevec in combination with a fixed dose of Xeloda po bid daily in patients with colon cancer.,2002-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Toxicity.
3168,NCT02465502,Percentage of participants without disease progression or death at the end of 8 weeks,2015-07-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Percentage of participants with grade 1 or higher adverse events, using NCI Common Terminology Criteria for Adverse Events (CTC-AE) Version 4.03"
3169,NCT03024684,3-year cumulative incidence of recurrent HCC between the intervention group and control counterpart,2017-01-03,RECRUITING,INTERVENTIONAL,['PHASE4'],,occurrence of clinical complications related to hepatic decompensation
3170,NCT04776655,Progression free survival (PFS) in patients with RASmut at liquid biopsy and RASwt on tissue.,2021-04-30,RECRUITING,INTERVENTIONAL,['PHASE3'],,Compliance
3171,NCT02644148,Quality of life,2016-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Complications
3172,NCT05879328,Recurrence-free survival (RFS),2022-12-23,RECRUITING,OBSERVATIONAL,['NA'],,Comparison with historical series
3173,NCT01691625,the quality of life,2012-09,COMPLETED,INTERVENTIONAL,['NA'],Immunological assessment,progression-free survival
3174,NCT04672980,Dose limiting toxicities (DLTs) of RTX-321:,2021-04-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,Anti-tumor activity of RTX-321
3175,NCT06178939,incidence of postoperative delirium,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,total score of QOR-40
3176,NCT01636674,time to recurrence,2009-07,UNKNOWN,INTERVENTIONAL,['NA'],,
3177,NCT01384240,to determine whether tissue in nepoplastic or non-neoplastic,2010-04,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,
3178,NCT05740995,Major pathological regression (MPR) rate,2020-12-01,RECRUITING,OBSERVATIONAL,['NA'],,"The correlation between detection of genomic, immune, microbial and metabolite features and the rate of therapeutic responses."
3179,NCT02323360,Local control (efficacy of SBRT in selected HCC patients with an incomplete response after TACE/TAE),2014-11,TERMINATED,INTERVENTIONAL,['NA'],,toxicity (incidence of acute and late complications)
3180,NCT03076216,Safety / Tolerability of Device as determined by the number of treatment emergent adverse events (TEAEs) evaluated according to CTCAE V4.0,2017-08-01,COMPLETED,INTERVENTIONAL,['NA'],Tumor Response,Pain Scores
3181,NCT06267417,To measure grade of oral mucositis in patients receiving laser arm placebo arm.,2023-04-10,RECRUITING,INTERVENTIONAL,['NA'],,
3182,NCT01749332,ctDNA differences,2012-12,COMPLETED,INTERVENTIONAL,['NA'],,collect preliminary data
3183,NCT01375738,Blood sugar stabilization after gastrectomy,2011-07,UNKNOWN,INTERVENTIONAL,['NA'],,
3184,NCT03242369,Quality of bowel cleansing according to Boston Bowel Preparation Scale (BBPS),2017-09-01,UNKNOWN,INTERVENTIONAL,['NA'],,Detection of colorectal neoplasia
3185,NCT05415475,Obtain the maximum tolerated dose of CEA-CAR-T cells[Safety and Tolerability],2021-09-10,RECRUITING,INTERVENTIONAL,['PHASE1'],Changes in the number of tumor-infiltrating immune cells of CEA- CAR-T treatment in patients with CEA-positive,Pharmacodynamics of CEA-CAR-T cells[Cell dynamics]
3186,NCT01639326,Overall objective response rate (RR) by RECIST criteria v1.1,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall response duration
3187,NCT04386772,Hypertrophy degree of standardized FLR,2020-05-27,UNKNOWN,INTERVENTIONAL,['NA'],,Immunohistochemical stainings of liver parenchyma
3188,NCT04980443,Sensitivity of CELTiC,2021-08-03,COMPLETED,INTERVENTIONAL,['NA'],Association between CELTiC test score and FIT concentration,C-statistic of CELTiC
3189,NCT06202781,Single-cell profiling,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],,
3190,NCT02615665,Overall survival,2013-01,COMPLETED,OBSERVATIONAL,['NA'],,
3191,NCT01941641,Objective tumour response rate,2013-10-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of response to neoadjuvant therapy
3192,NCT01865071,Mortality,2011-09,UNKNOWN,INTERVENTIONAL,['NA'],,
3193,NCT05815303,pCR,2023-03-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
3194,NCT01464593,Determine the Local Tumor Control at 1 Year Post Randomization,2011-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
3195,NCT05311319,Disease Free Survival (DFS),2022-01-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety: adverse events
3196,NCT00991094,Dose-response relationships for normal tissue toxicity after proton therapy,2005-05-27,RECRUITING,OBSERVATIONAL,['NA'],,Symptom burden
3197,NCT01359397,Progression free survival,2011-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
3198,NCT00973440,To determine the feasibility and added clinical utility of a self-administered computer-based version of an abbreviated comprehensive geriatric assessment tool.,2009-03,COMPLETED,OBSERVATIONAL,['NA'],,
3199,NCT05881746,relapse-free survival,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,postoperative mortality
3200,NCT05584540,Enrollment Rate,2024-03-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],The Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Ratings,CSQ-I Score
3201,NCT04833387,Pathological complete response,2021-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Clinical complete response (CCR)
3202,NCT02527577,consumption of morphine over the first 48 hours postoperative.,2010-04,TERMINATED,INTERVENTIONAL,['NA'],,pharmacokinetic of ropivacaine (plasma concentrations)
3203,NCT02119026,Efficacy Duration of Disease Control by Tumor Assessment (CT/MRI/Clinical Examination),2011-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumour Assessments (Based on RECIST Criteria) in 2nd-line
3204,NCT05939401,ctDNA,2023-12-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
3205,NCT03512756,Overall Survival,2018-03-27,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Progression Free Survival
3206,NCT00103168,Overall survival,2004-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Adverse events
3207,NCT04308837,Pathological Response,2018-12-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,Peritoneal Disease-free Survival
3208,NCT05620771,Progression Free Survival (PFS),2022-11-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
3209,NCT01688557,Diagnostic accuracy of innovative colonoscopy,2012-09,COMPLETED,INTERVENTIONAL,['NA'],Area under the ROC curve (AUC),Pain intensity (VAS scale)
3210,NCT03954548,Adenoma miss rate [AMR],2020-02-17,COMPLETED,INTERVENTIONAL,['NA'],,Polyp Miss Rate [PMR]
3211,NCT04479527,PFS,2021-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of AE and SAE
3212,NCT02983578,Physical Examinations,2017-03-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Radiomic measurements,Overall survival
3213,NCT03613194,Identification and characterization of the tumoral intermediaries on the hepatic metastasis and/or peritoneal),2018-06-25,UNKNOWN,INTERVENTIONAL,['NA'],,
3214,NCT01180166,progression-free survival,2010-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival time
3215,NCT01955096,food intake time,2010-09,COMPLETED,INTERVENTIONAL,['NA'],,readmission
3216,NCT00846131,To Evaluate sorafenib as an adjunct to Y-90 for control of HCC as a bridge/downstage to transplant,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,To identify predictive and prognostic markers of how the liver cancer will respond to treatment.
3217,NCT04522011,The incidence of postoperative complications,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
3218,NCT04847297,rate of serious complications,2021-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Mortality
3219,NCT02141295,"Progression-free Survival (PFS), Time to Event",2014-06-30,TERMINATED,INTERVENTIONAL,['PHASE2'],,Cmax Accumulation Ratio (AR) of Vanucizumab
3220,NCT05833815,Progression free survival,2022-11-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Chemotherapy Toxicity
3221,NCT04724226,Objective response rate (ORR) by RECIST 1.1 and mRECIST,2021-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Treatment-related adverse events,Median overall survival time (mOS)
3222,NCT04515615,The incidences and types of adverse events,2020-09-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Treatment completion rate
3223,NCT05517811,Post-operative thrombotic and hemorrhagic complications,2022-06-01,RECRUITING,OBSERVATIONAL,['NA'],,pre-operative distant metastasis
3224,NCT05797805,Evaluate efficacy of tegavivint as a single agent,2023-09-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Evaluate efficacy of combination of tegavivint plus pembrolizumab,
3225,NCT03068052,Colonoscopy participation,2017-05-08,COMPLETED,INTERVENTIONAL,['NA'],,Risk assessment completion
3226,NCT06065059,Measure anti-tumor activity using RECIST 1.1 (Phase 2 only),2023-12-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Assess changes in levels of ubPCNA in response to TNG348 as single agent or in combination
3227,NCT04891900,Objective Response Rate (ORR),2021-05,UNKNOWN,INTERVENTIONAL,['NA'],,Duration of Overall Survival (OS)
3228,NCT01432314,Time to tumor progression,2011-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Best tumor response by modified RECIST (mRECIST) and RECIST criteria
3229,NCT00077519,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3230,NCT05846594,Median Time to Diagnosis,2023-09-14,RECRUITING,INTERVENTIONAL,['PHASE4'],,Incidence and Severity of Liquid Biopsy Sample Collection-Related Adverse Events
3231,NCT02850172,severity of symptom (QLQ-OES18 questionnaire),2016-05,UNKNOWN,INTERVENTIONAL,['NA'],,length of mechanical ventilation
3232,NCT00727831,Incidence and severity of CNS toxicity and neurocognitive changes taken from patients' medical records and measured using the Mini-Mental State questionnaire and MRI data,2008-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of antibodies to glucarpidase measured serologically at the start of each methotrexate course and at follow-up visits if present during therapy
3233,NCT04182386,Future liver remnant hypertrophy,2012-08-01,UNKNOWN,OBSERVATIONAL,['NA'],,Effect of sarcopenia on hypertrophy
3234,NCT00565708,Disease-free survival,2008-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall survival
3235,NCT03716531,2 Year Overall Survival,2019-03-19,RECRUITING,INTERVENTIONAL,['NA'],,Adverse events associated with IORT
3236,NCT05291988,Demographic information,2022-10-08,TERMINATED,INTERVENTIONAL,['NA'],,COVID-19 impact assessment
3237,NCT04404777,3 year survival,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],,MDT effect on treatment of local recurrence
3238,NCT00707681,To evaluate Quality of Life (QoL) score of MS-20 versus placebo in advanced HCC patients,2008-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Overall survival, Overall survival rate, Change from baseline of the highest weight observed, Change from baseline of body weight"
3239,NCT03563248,Proportion of participants with R0 resection,2018-08-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment related serious adverse events
3240,NCT00023634,toxicity,2001-06,TERMINATED,INTERVENTIONAL,['PHASE1'],,
3241,NCT04677244,Procedure impact,2021-11-11,RECRUITING,INTERVENTIONAL,['NA'],,
3242,NCT04334421,Comprehensive Complication index,2020-04-03,COMPLETED,OBSERVATIONAL,['NA'],,Perineal hernia
3243,NCT02887612,Positive Predictive Value,2016-09,UNKNOWN,OBSERVATIONAL,['NA'],,prognostic molecular markers
3244,NCT05994638,Side effects after radiotherapy,2023-08-21,RECRUITING,INTERVENTIONAL,['NA'],,Impact of dysphagia on quality of life
3245,NCT00526578,Identification of susceptibility genes in high risk familial pancreatic cancer (FPC) pedigrees using cutting-edge genetic analysis methods,2002-06-19,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
3246,NCT04738240,Clinical anastomotic leak,2019-03-11,COMPLETED,INTERVENTIONAL,['NA'],,
3247,NCT02630420,Safety and tolerability based on regular clinical assessment and NCI Common Terminology Criteria for Adverse Events,2017-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],"Changes in genetic aberrations over the course of the disease by comparing archival, baseline and progression samples.",Progression free survival
3248,NCT00503776,Number of Patients With Each Degree of Swallowing Dysfunction,2006-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Changes in the Frequency and Types of Dietary Intakes
3249,NCT04290364,Use of healthcare services,2019-09-21,COMPLETED,OBSERVATIONAL,['NA'],,Carer satisfaction with palliative care
3250,NCT04947826,Objective response rate,2021-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Discontinuation rate due to any adverse events,Overall survival rate at 12-month time point
3251,NCT04802954,Stratification of the risk of hepatocarcinogenesis in high-risk patients by a deep learning-based cross-analysis.,2021-09-01,RECRUITING,INTERVENTIONAL,['NA'],,Characterization of the interface of the nodules with the adjacent hepatic parenchyma by a deep learning-based cross-analysis
3252,NCT02112747,Successfully following screening guidelines appropriate to the participant's risk profile,2013-09,COMPLETED,INTERVENTIONAL,['NA'],,Cost effectiveness of the interventions
3253,NCT05327738,Proportion of progression-free participants,2022-12-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Descriptive summary of tumor and tumor immune cell populations,Incidence of grade >= 3 adverse events
3254,NCT02157454,Self-efficacy for coping with cancer (measured by the German short form of the Cancer Behavior Inventory),2014-06,COMPLETED,INTERVENTIONAL,['NA'],,Patient competence (assessed by a self-rating measure of patient competence in oncology in validation process)
3255,NCT00579579,"To prospectively evaluate bowel, sexual and bladder function in patients who undergo resection for stage I-III rectal cancer.",2006-11-28,COMPLETED,OBSERVATIONAL,['NA'],,"To evaluate the expectations, informational needs and satisfaction with the surgical consent process in patients undergoing resection for stage I-III rectal cancer."
3256,NCT00326911,Progression-free Survival (PFS),2006-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Change From Baseline in Assessment of Pain Using BPI Short Form, Interference, at Cycle 2 Week 4"
3257,NCT02219893,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2014-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease free survival
3258,NCT06219096,Fluorescence imaging effect of the live,2023-12-10,RECRUITING,INTERVENTIONAL,['NA'],Disease-free survival,Postoperative hospital stay
3259,NCT01980810,response rate,2013-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,number of adverse event
3260,NCT06017323,Proglumide Recommended Phase II dose and schedule (RP2D),2023-10,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Change in tumor marker (CA19-9)
3261,NCT04512833,Local control time,2020-08-12,RECRUITING,OBSERVATIONAL,['NA'],,Adverse reaction
3262,NCT03061162,Side effects of pulsed low dose rate radiation therapy,2017-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,Time to progression
3263,NCT03869892,Progression-free Survival (PFS),2019-03-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Time to treatment failure (TTF)
3264,NCT06063928,Changes in genomic knowledge,2022-05-25,RECRUITING,OBSERVATIONAL,['NA'],,
3265,NCT05319431,Progression-free survival (PFS),2022-06-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with adverse events (AEs)
3266,NCT05727787,Maximum tolerated dose (MTD) of Single Fraction GRID SBRT,2023-02-23,RECRUITING,INTERVENTIONAL,['NA'],,Molecular correlatives: TCR repertoire analysis.
3267,NCT02859753,Time to disease progression according to American Society of Interventional Radiology criteria,2014-01-15,COMPLETED,INTERVENTIONAL,['NA'],,
3268,NCT00321100,Objective Response Rate (ORR),2006-04-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
3269,NCT03401814,"Quantify tissue mechanical properties of the liver and liver tumor using MRE in patients receiving radiation therapy + immunotherapy at baseline, mid-treatment and time of followup imaging determined by standard of care to assess response to therapy",2018-08-02,COMPLETED,OBSERVATIONAL,['NA'],,
3270,NCT05990569,Patient satisfaction assessed using the Likert scale after receiving Bupivacaine pudendal nerve block with or without Methylene Blue.,2023-08-12,RECRUITING,INTERVENTIONAL,['NA'],,Complications
3271,NCT02575339,Phase II: Time to Progression (TTP),2016-07-18,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II: Radiographic Response Rate (RRR)
3272,NCT04764409,Identification of all the kinds of complications according to the Common Terminology Criteria for Adverse Events (CTCAE v4.0) and their systematization.,2021-01-12,UNKNOWN,OBSERVATIONAL,['NA'],,
3273,NCT03896958,Assessment of benefit of return of research results by SpeciCare Outcome Monitor Board,2019-03-21,UNKNOWN,OBSERVATIONAL,['NA'],,
3274,NCT05510895,Tumor regression grade (TRG),2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Translational research 3
3275,NCT00309543,Overall survival,1993-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3276,NCT02517554,Completion of Surveys,2015-08,COMPLETED,OBSERVATIONAL,['NA'],,
3277,NCT03595904,Number of Participants Who Completed a Screening Colonoscopy,2017-11-20,COMPLETED,INTERVENTIONAL,['NA'],,Number of Participants Who Were No-show Appointments
3278,NCT05958433,duration of hospital stay,2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,assess the effects of preoperative education using stoma appliance on quality of life in colorectal cancer patients with a stoma
3279,NCT05967533,Natural killer (NK) cell killing activity,2023-06-02,RECRUITING,INTERVENTIONAL,['PHASE1'],,Immunologic effects of FWG (Immune Correlates): serum cytokines analysis
3280,NCT04779151,Overall Response Rate (ORR),2021-04-07,SUSPENDED,INTERVENTIONAL,['PHASE2'],,
3281,NCT04241276,To assess the efficacy of ATRA when given in combination with gemcitabine and nab-paclitaxel based on progression free survival (PFS).,2020-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,To assess quality of life (QOL) of patients receiving ATRA in combination with Gemcitabine and Nab-Paclitaxel: EQ-5D-5L
3282,NCT03535259,MST,2018-05-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Rate of III-IV grade adverse events
3283,NCT02198898,incidence of adhesive intestinal obstruction,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
3284,NCT01438476,Postoperative Pain Experience,2012-01-26,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3285,NCT03532204,Progression Free Survival,2019-04-15,WITHDRAWN,INTERVENTIONAL,['NA'],,Quality of life EORTC QLQ CR29
3286,NCT02792842,The discontinuation rate of oxaliplatin due to OIPN,2016-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3287,NCT02744651,Number of correct histopathological diagnoses from submucosal tumors in the upper GI tract.,2017-02-17,TERMINATED,INTERVENTIONAL,['NA'],,
3288,NCT00576940,The ratio of postoperative complications (infectious and surgical),2004-06,COMPLETED,INTERVENTIONAL,['PHASE4'],,assessment of visceral protein turnover
3289,NCT04514484,Incidence of dose limiting toxicities (DLTs),2021-11-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Change in infiltrating immune cell markers,Human immunodeficiency virus (HIV) viral loads
3290,NCT04164602,incidence of pancreatic ductal adenocarcinoma in patients with new-onset diabetes,2019-10-09,RECRUITING,OBSERVATIONAL,['NA'],,Cost-benefit analysis
3291,NCT00081900,To establish the MTD and dose limiting toxicities of DENSPM intravenous infusion in patients with unresectable HCC.,2004-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To evaluate the pharmacokinetics of DENSPM in plasma and HCC tissue in patients unresectable HCC.
3292,NCT05955833,"89Zr-trastuzumab uptake (standard uptake values (SUVmean, %ID/kg) in normal organs/tissues and bloodpool in historical controls with HER2+ breast cancer (n = 20) who underwent 89Zr-trastuzumab PET imaging.",2023-06-26,RECRUITING,INTERVENTIONAL,['PHASE1'],,HER2 expression measured by IHC on tumor biopsies
3293,NCT03255811,Evaluation of apatinib mesylate tablets as first-line maintenance treatment for advanced gastric or gastroesophageal junction progression free survival site adenocarcinoma,2017-03-25,UNKNOWN,INTERVENTIONAL,['NA'],,
3294,NCT02665741,Adenoma Detection Rate,2016-01,COMPLETED,INTERVENTIONAL,['NA'],,Withdrawal Time
3295,NCT04893876,Global Quality of Life (QoL),2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Frailty
3296,NCT01126645,Primovist®-enhanced MRI is non-inferior or superior compared with contrast-enhanced multislice CT,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,safety of SIR Spheres
3297,NCT06001372,The rate of study completion by enrolled participants. Study completion is defined as participating in at least 2 of the 3 Ketamine-Assisted Psychotherapy (KAP) sessions.,2023-10-13,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,The proportion of screened patients that meet criteria on the Existential Distress Scale (EDS: Single domain ≥ 3 or total score ≥ 6).
3298,NCT01658878,ORR for Nivolumab plus Ipilimumab plus Cabozantinib Combination Cohort,2012-10-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Effective T-Half of nivolumab
3299,NCT04861987,Maximum Plasma Concentration (Cmax) of capecitabine,2021-06-18,RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of participants with Adverse Events of Special Interest (AESI)
3300,NCT00976898,Median Overall Survival,2009-08,COMPLETED,INTERVENTIONAL,['NA'],,Patterns of Failure
3301,NCT04873895,Serious adverse event (SAE) rate,2022-01-24,RECRUITING,INTERVENTIONAL,['PHASE1'],,axitinib treatment intensity
3302,NCT05158374,"Relative genetic expression change of genes relating to energy, metabolism and stem cell signalling in the large bowel",2022-08,UNKNOWN,INTERVENTIONAL,['NA'],,Change in the proportions of bacterium the colorectal microbiome after aspirin and/or metformin medication
3303,NCT04267549,R0-surgery conversion rate,2019-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],pathological response,surgery-related complications
3304,NCT05515796,ORR (objective response rate) per RECIST 1.1,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],EORTC QLQ-CR29,R0 resection rate
3305,NCT05278728,The rate of grade 3/4 toxicity,2009-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The disease control rate
3306,NCT03041129,Hepatic fat fraction,2017-04-14,COMPLETED,OBSERVATIONAL,['NA'],,Hepatic phosphate concentrations
3307,NCT02674815,Compliance,2016-02,COMPLETED,INTERVENTIONAL,['NA'],,Clavien-Dindo Classification Sore
3308,NCT02912949,Duration of response per RECIST v1.1 as per local Investigator's assessment.,2015-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Evaluation of overall survival (OS)
3309,NCT00096070,1-year survival rate,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to treatment failure
3310,NCT00199797,"Safety as Measured by the Number of Patients With Treatment Emergent Adverse Events (TEAEs), Grade 3 TEAEs, TEAEs Resulting in Death, TEAEs Related to Treatment and Serious TEAEs in Patients With Metastatic Colorectal Cancer.",2005-04-18,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Tumor Response in Patients With Metastatic Colorectal Cancer Receiving huA33, Oxaliplatin and 5-FU Plus Leucovorin."
3311,NCT03916809,Feeding-tube-free food intake (days),2017-07-12,RECRUITING,INTERVENTIONAL,['NA'],M.D. Anderson Dysphagia Inventory (MDADI) (number),Upper esophageal sphincter (UES) opening width (mm)
3312,NCT04640103,Adverse event rate,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Incidence of second tumor in patients with Lynch syndrome
3313,NCT02062515,Number of Participants with Adverse Events,2014-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
3314,NCT05173246,Objective response rate (ORR),2020-11-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,Severe toxicity
3315,NCT01041612,Obstruction of 1st C-SEMS or presence of jaundice at death without stent exchange,2010-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,Death of patients
3316,NCT05512793,Adenoma miss rate (AMR),2023-05-24,COMPLETED,INTERVENTIONAL,['NA'],,Withdrawal time. (First/second colonoscopy)
3317,NCT00280332,The prevalence of advanced colonic adenoma in the re-screening population,2006-03,COMPLETED,OBSERVATIONAL,['NA'],,The time to adenoma adenoma development according to different baseline characteristics of patients and colonoscopy findings
3318,NCT00936832,Response rate at 3 months as assessed by RECIST criteria,2009-04,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Translational research including pharmacodynamic studies of plasma and rectal tumor biopsies and histological and molecular studies
3319,NCT02195011,The Number of Participants With Treatment-Related Adverse Events and Serious Adverse Events as a Measure of Safety,2014-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival
3320,NCT00569309,Number of Participants Experiencing Immune Reconstitution,2007-12-12,COMPLETED,INTERVENTIONAL,['NA'],,Collection of Baseline Immune Reconstitution and Quality of Life Pilot Data for Comparison in Future Post-transplant Immunotherapy Trials
3321,NCT00683085,Number of Participants Without Grade 4 Hematological or Grade 3 to 4 Non-hematological Adverse Events,2008-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Tumor Regression
3322,NCT00122291,response,2002-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
3323,NCT04509492,The number of patients with occult hepatic metastasis missed by CT or MRI during staging of pancreatic and GI malignancy.,2020-10-01,COMPLETED,OBSERVATIONAL,['NA'],,
3324,NCT04301557,Pathological Complete Response(pCR),2020-07-31,RECRUITING,INTERVENTIONAL,['PHASE2'],,3 year disease free survival
3325,NCT05443217,Long-term outcomes after treatment,2022-06-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Objective response rate
3326,NCT06067620,Time to first passage of faeces,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Incidence of incisional hernia
3327,NCT05162118,RP2D (phase 1),2022-03-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,CEA
3328,NCT03908333,Disease Control Rate,2019-05-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Changes in patient's self-reported pain levels: Brief Pain Inventory (BPI)
3329,NCT05682794,disease-free survival ratev,2014-01,COMPLETED,OBSERVATIONAL,['NA'],,DRM status
3330,NCT01373021,total amount of administered fentanyl,2011-06,COMPLETED,INTERVENTIONAL,['PHASE4'],,
3331,NCT00006081,Number of Patients with Response after 2 Cycles of Treatment,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3332,NCT01878422,Progression Free Survival (PFS) of first and second line treatment strategy,2007-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of partecipants with adverse events as a measure of safety and tolerability
3333,NCT02366819,R0 (analysis will be performed evaluating the R0 rate),2014-12-11,RECRUITING,INTERVENTIONAL,['PHASE4'],Change in SUVmax for the primary esophageal tumor,Progression free survival
3334,NCT01350167,Efficacy of screening measure to detect very early/early stage HCC (Barcelona Clinic Liver Cancer Staging System),2001-11,UNKNOWN,INTERVENTIONAL,['NA'],,Cost - Effectiveness of screening measure
3335,NCT00030108,Nerve growth factor levels before and after drug administration,2001-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Tubulin polymerization in PBMCs prior to the start of the infusion, just before the end of the infusion, 5 hours after the end of the infusion and before the start of the infusion on day 2 of the ixabepilone on course 1"
3336,NCT04854434,Arm B and C: Progression-free Survival (PFS) as Assessed by the Investigator Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1,2021-06-29,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Arm A, B and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs"
3337,NCT04010071,Progression-free Survival (PFS),2020-05-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Tumor mutation burden,Rate of 6-months and 1-year overall survival
3338,NCT00778102,Percentage of Participants With Complete Resection or Residual (Microscopic or Macroscopic) Tumor,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Complications Related to Second Resective Surgery
3339,NCT05519319,Overall survival (OS),2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Progression-free survival(PFS)
3340,NCT02243358,Frequency of R0 Resection,2014-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3341,NCT06238193,MSI status,2003-01-01,COMPLETED,OBSERVATIONAL,['NA'],PD-L1 level,Copy-number variations (CNVs)
3342,NCT02597075,Change in Patient-reported symptoms as measured by ESAS-r,2016-03-17,TERMINATED,INTERVENTIONAL,['NA'],,Initiation or increase of anti-hypertensive drugs
3343,NCT01341132,,2011-05,UNKNOWN,OBSERVATIONAL,['NA'],,
3344,NCT01676714,Overall Response Rate,2013-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients Who Experienced Treatment Related Toxicities
3345,NCT04615013,Maximum tolerated dose and recommended phase 2 dose (RP2D),2020-11-23,RECRUITING,INTERVENTIONAL,['PHASE1'],Concordance of cell free deoxyribonucleic acid (DNA),Overall survival
3346,NCT04751773,Serious adverse events,2021-03-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],LPS-induced TNF-a production of whole blood,Surgical stress: Noradrenaline
3347,NCT00414570,correlate 18F-FLT uptake with hENT1 expression with biopsy samples where available,2007-11,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,to demonstrate the safety of 18F-FLT manufactured at the Edmonton PET Centre
3348,NCT05890742,"Event Free Survival, EFS(EFS), defined as the time from randomization to the first determination using RECIST v1.1 of inoperable disease progression, local recurrence or distant metastasis after surgery, or death from any cause, whichever occurs first.",2023-05-25,RECRUITING,INTERVENTIONAL,['PHASE3'],,"Overall-survival(OS), defined as the time from randomization to death from any cause"
3349,NCT06246630,Objective Response Rate,2024-02-25,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Concordance between drug sensitivity test results and patients' treatment response
3350,NCT00569699,Progression free survival,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Safety, Response rate, Time to progression, Time to treatment failure, Overall survival, Treatment situation"
3351,NCT04070313,Relapse-free survival (RFS),2019-07-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,safety profile
3352,NCT04690972,Surgery for a hepato-bilio-pancreatic issue,2020-12-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
3353,NCT05395780,Objective response rate (ORR),2022-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Correlation between expression level and mutation of FGFR1OP2-related proteins and efficacy
3354,NCT02890511,Number of participants with dose limiting toxicity(DLT) to determine maximum tolerated dose(MTD),2010-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,PK parameters for DHP107 derived from determining their plasma concentrations using validated assays.
3355,NCT02511522,Proportion of patients achieving improvement of liver cancer pain/discomfort,2015-12-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Proportion of patients reporting clinically significant improvement in QoL from baseline to day 30 and day 90
3356,NCT00769730,HBV viral load,2008-01,COMPLETED,OBSERVATIONAL,['NA'],,
3357,NCT00673322,Determine the safety of using modified T cells by documenting the type and severity of any side effects and establishing the Maximum Tolerated Dose (MTD).,2008-05,TERMINATED,INTERVENTIONAL,['PHASE1'],,Pharmacodynamics
3358,NCT03702491,PFS,2018-08-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
3359,NCT03598166,Percentage of Participants Who Undergo Screening Within 6 Months of Outreach,2018-10-11,COMPLETED,INTERVENTIONAL,['NA'],,Self-reported Most Common Reasons for Refusing Blood Test on Questionnaire in Intervention Group
3360,NCT02980029,Malonyl carnitine and tripalmitin levels will be measured in the preand post-treatment blood samples using mass spectrometry blood samples using mass spectrometry.,2017-10-06,RECRUITING,INTERVENTIONAL,['PHASE1'],,"Toxicities will be graded as per NCI-CTCAE v4.03, based on recorded adverse events, physical examinations, and clinical laboratory assessments."
3361,NCT01908322,"Characteristics of patients with intermediate stage HCC (BCLC-B) treated with Nexavar will be determined by evaluating demographic data, medical history, previous treatment of HCC, specific concomitant conditions (amongst others).",2013-08,COMPLETED,OBSERVATIONAL,['NA'],,Safety variables will be summarized using descriptive statistics based on adverse events collection.
3362,NCT05709197,Delayed gastric emptying (DGE),2023-04-17,RECRUITING,INTERVENTIONAL,['NA'],,Functional outcome at 12 months
3363,NCT01325883,The relative decrease in exercise capacity (LT) associated with NAC prior to upper gastrointestinal cancer resection will predict outcome (1 year mortality) following surgery.,2011-04,COMPLETED,OBSERVATIONAL,['NA'],,Patients whose LT changes following NAC so that they move into a higher risk category will have a worse outcome (1 year mortality) when compared with those who do not increase risk category.
3364,NCT02125929,Pancreatic fistula rate,2014-04,COMPLETED,INTERVENTIONAL,['NA'],Hospital stay time,Mortality rate
3365,NCT01222689,Survival at 24 Weeks,2010-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Plasma Biomarkers Potentially Predictive of Dual MEK/EGFR Inhibition,Number of Patients With Dose Modifications and Reason for Dose Modification.
3366,NCT06236464,Primary Endpoint,2023-09-25,RECRUITING,OBSERVATIONAL,['NA'],,Secondary Endpoint
3367,NCT04454099,Develop a predictive model of CRC or advanced colorectal neoplasm which includes qFIT.,2020-07-01,COMPLETED,OBSERVATIONAL,['NA'],,Explore the effect of aspirin or other anticoagulants to the diagnose accuracy of qFIT
3368,NCT05502198,MELD-score,2021-02-01,RECRUITING,OBSERVATIONAL,['NA'],,Quality of life (Questionnaire)
3369,NCT06115837,Cancer specific survival,2023-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
3370,NCT00980382,"*phase I study:the maximum tolerated doses (MTD)of S-1 and docetaxel,recommended dose for subsequent phase II study *phase II study: evaluation of efficacy and toxicities of this new combination regimen in metastatic",2004-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To investigate the time to progression and overall survival
3371,NCT01879904,curative resection rate (3 month),2010-02,COMPLETED,INTERVENTIONAL,['NA'],,Curative resection rate (1 year)
3372,NCT05448846,Change in functional capacity,2022-04-08,RECRUITING,INTERVENTIONAL,['NA'],Colorectal Surgery Procedure,Rate of mortality
3373,NCT00025415,Toxicity evaluation graded according to the NCI common toxicity criteria and relationship to the study drug,2001-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Child-Pugh Classification
3374,NCT00832637,Tumor Control Rate,2007-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Toxicity
3375,NCT04136600,Objective Response Rate,2019-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse Effect
3376,NCT00799474,Willingness to Receive the Human Papillomavirus (HPV) Vaccine,2008-12,COMPLETED,OBSERVATIONAL,['NA'],,Knowledge of HPV
3377,NCT05170256,Progression free survival (PFS) .,2022-02-04,RECRUITING,INTERVENTIONAL,['PHASE2'],Frequency of PD-L1 status by CPS score,Overall survival
3378,NCT00390195,Disease control rate in Phase II,2006-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Tumor marker
3379,NCT02627729,Short Form 36 Quality of life Questionnaire,2009-06,COMPLETED,INTERVENTIONAL,['NA'],,Functional outcome measured with Overactive Bladder validated 8 scale
3380,NCT02352688,Length of postoperative hospital stay,2015-05,COMPLETED,INTERVENTIONAL,['NA'],,30-day mortality
3381,NCT00559741,Improvement of hematologic and gastrointestinal tolerance to therapy,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to progression
3382,NCT01393340,Effect of Omalizumab on nasal polyp size and evolution of nasal polyps,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Evaluation of adverse events, directly or by general physical examination, blood sampling , review of concomitant medication or symptom scores."
3383,NCT00690677,To evaluate the effect of LBH589 on overall survival (OS) in patients with colorectal cancer,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to tumor progression and response rates
3384,NCT05414461,Durable clinical benefit,2019-03-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3385,NCT06035471,cfDNA methylation markers,2023-10-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
3386,NCT02837874,Dumping syndrome,2016-03,UNKNOWN,INTERVENTIONAL,['NA'],,Gastritis
3387,NCT05178576,Recurrence-free survival (RFS) at one year,2022-06-24,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Immunogenicity
3388,NCT04867590,"The rate of full eradication of Barrett esophagus (metaplasia), which is defined by the absence of residual Barrett esophagus in the check-up endocopy after 3 months",2022-03-25,RECRUITING,INTERVENTIONAL,['NA'],,Build a model to predict incomplete response for eradication of Barrett's eosophagus on the basis of each independent predictor coefficient in the multivariate regression logistic model
3389,NCT00355212,Sustained complete response at one year after the treatment.,2001-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,costs.
3390,NCT03487523,Number of participants taking part in the Scottish national bowel cancer screening programme,2018-06-21,UNKNOWN,INTERVENTIONAL,['NA'],,
3391,NCT03542214,Safety of the calcium electroporation procedure in colorectal cancer (registration of adverse events; CTCAE v4 will be used),2018-04-24,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumorregression
3392,NCT00419159,The Number of Participants With Best Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST),2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Biomarkers Predictive of Clinical Benefit (Median PFS and OS by PTEN ) on Everolimus (RAD001) 10mg/Day
3393,NCT02724358,Time to progression,2012-12,COMPLETED,INTERVENTIONAL,['NA'],,
3394,NCT03399071,Pathological complete response rate of combination FLOT-A,2017-07-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Median overall survival by Kaplan Meir method
3395,NCT02118077,Number of Participants with Serious and Non-Serious Adverse Events,2001-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Objective tumor response
3396,NCT06054685,PFS,2023-04-17,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
3397,NCT05127759,ORR,2022-03-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
3398,NCT00004235,objective tumor response rate,2000-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,treatment response
3399,NCT03766633,Accuracy of the LiverVision® software volumetric measurements,2018-04-29,UNKNOWN,OBSERVATIONAL,['NA'],,Comparison
3400,NCT01862718,Safety of Ablation plus radiation,2013-11-19,TERMINATED,INTERVENTIONAL,['PHASE1'],,
3401,NCT02205307,Anastomotic Leak Rate,2015-01,TERMINATED,INTERVENTIONAL,['NA'],,Incidence of Post-Operative Abscess Requiring Surgical Management
3402,NCT02619266,Appetite Visual Analog Scale,2015-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",The Questionnaire of Acupuncture-related Events(QAE),Nutritional status
3403,NCT03465202,Area under the curve (AUC) of capecitabine and metabolites,2016-05,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Time of maximum plasma concentration (Tmax) of capecitabine and metabolites
3404,NCT00075686,Overall survival comparison between treatment groups,2004-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Pain and quality of life comparison between treatment groups as measured by patient questionnaire at baseline, before each course, and then completion of study treatment"
3405,NCT03611712,Fatigue by the Brief Fatigue Inventory-Taiwanese Form,2019-02-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,"The change of of biomarkers (inhibitory immune factors, dendritic cells makers, tumor-associated macrophages, immune-regulatory markers and oncogenic-mediated immune markers) will be combined to report the immune profile."
3406,NCT00220051,Acute toxicity has been evaluated in previous phase I studies and should occur to a similar extent.,2001-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Bowel function and quality of life
3407,NCT04767906,time on treatment (TT),2021-12-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,occurence of clinical symptoms of liver dysfunction (safety endpoint)
3408,NCT01192763,Frequency and severity of adverse events as measured by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE),2010-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,"Proportion of cancer stem cells (CD44+, CD24+, ESA+ population of cells) self-renewal and tumorigenesis as measured by FACS"
3409,NCT02032914,The prevalence of colonic neoplasm,2014-01,COMPLETED,OBSERVATIONAL,['NA'],,Prevalence of intestinal tuberculosis
3410,NCT04476329,Overall Survival,2021-01-21,TERMINATED,INTERVENTIONAL,['PHASE2'],,FACIT FACT-Hep Quality of Life Measurements
3411,NCT03938324,Change in Patient activation as measured by the Patient Activation Measure (PAM-13),2019-10-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Change in Emotional Health as measured by the Brief Symptom Inventory (BSI 18)
3412,NCT02558868,Overall Survival,2015-09-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
3413,NCT05138159,Overall Survival,2021-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events
3414,NCT06184594,Colorectal Cancer (CRC) Screening completion,2024-01-24,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,The Colorectal Cancer Screening Beliefs Instrument Score
3415,NCT01993472,Progression free survival (PFS),2013-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of Life
3416,NCT02948426,Overall Maximum Tolerated Dose of Actimmune (Interferon Gamma-1b),2017-02-08,TERMINATED,INTERVENTIONAL,['PHASE1'],Number of Participants With a Grade 3 or Higher Dose-Limiting Toxicity (DLT),Time to Disease Progression
3417,NCT02817178,Progression-free survival,2013-03,COMPLETED,INTERVENTIONAL,['NA'],,
3418,NCT06225921,Feasibility of combination adebrelimab and dalpiciclib as assessed by number of participants who experience adverse events,2023-12-29,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
3419,NCT01334710,Comparison of MRI/CT Scans to Pre-treatment Scan,2011-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Toxicity Assessment
3420,NCT01346839,Differences in Time to Documented Follow-up of a Red Flag Suggestive of Cancer,2011-02,COMPLETED,INTERVENTIONAL,['NA'],,Trigger Positive Predictive Value
3421,NCT05113459,"pathologic Complete Response, PCR",2021-12-18,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,"Overall survival , OS"
3422,NCT06114082,Objective response rate (ORR),2023-04-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,Treatment-related serious adverse event
3423,NCT01324856,abdominal complications,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
3424,NCT06270017,Tumour growth,2022-01-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,response evaluation
3425,NCT06269978,Half-life,2024-04-30,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall response rate
3426,NCT05493358,5 year disease-free survival by Kaplan Mayer,2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],,The percentage of pattern of recurrence/metastasis
3427,NCT06123455,Overall survival (OS),2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Changes in CD8+ T cell infiltration in tumor tissue,Safety profile
3428,NCT05534841,Complete response MRI criterion,2022-04-01,COMPLETED,OBSERVATIONAL,['NA'],,MRI accuracy
3429,NCT00004005,Disease-free survival,1998-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3430,NCT05679583,R0 rate,2022-09-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,Tumor recurrence
3431,NCT01134601,Maximum Tolerable Dose of Selumetinib (AZD6244) Hyd-Sulfate in Combination With Radiation Therapy (RT) and Capecitabine in Participants With Locally Advanced Adenocarcinoma of the Rectum.,2010-05-24,TERMINATED,INTERVENTIONAL,['PHASE1'],Dose-Limiting Toxicity (DLT),"Changes in Phosphorylated ERK (pERK) in Peripheral Blood Mononuclear Cells and Tumor, and Transforming Growth Factor Alpha (TGFa) Levels"
3432,NCT01032291,Percentage of Participants With a Response to Treatment During the Proof of Concept Period,2009-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Participants With Treatment-Emergent Adverse Events (TEAE)
3433,NCT02089737,Number of Participants With Adverse Drug Reactions,2010-06,COMPLETED,OBSERVATIONAL,['NA'],,Overall Survival
3434,NCT02550847,The tumor recurrence rate after operation at 6 months,2014-08,UNKNOWN,OBSERVATIONAL,['NA'],,The overall survival after operation at 6 months
3435,NCT00291473,adverse events,2005-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,immune responses including HER2 and NY-ESO-1 specific IgG and T cells
3436,NCT05653960,Adverse event rate of EMR or ESD for colorectal neoplasms,2023-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
3437,NCT03484195,The ratio of tumor downstaging to stage 0 and stage I,2018-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life (QLQ C30)
3438,NCT04600466,To identify environmental and clinicopathological factors in Hispanics associated with specific molecular changes,2021-01-22,RECRUITING,OBSERVATIONAL,['NA'],,
3439,NCT03614546,Overall Survival(OS),2018-10-10,UNKNOWN,INTERVENTIONAL,['NA'],,Minimal volume of liver free from radiation
3440,NCT02182804,Accuracy,2013-02,COMPLETED,INTERVENTIONAL,['NA'],,
3441,NCT01265576,failure free survival,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,clinical benefit response
3442,NCT03889093,Change in concentrations of PBMC,2018-08-09,RECRUITING,INTERVENTIONAL,['NA'],,Change in concentrations of PBMC
3443,NCT00681330,Safety(Phase I:toxicities as assessed by NCI CTCAE version3) and efficacy(Phase II:Feasibility as evaluated by RECIST),2008-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To evaluate immunological responses
3444,NCT02583815,Number of Participants Who Use PAM Device,2015-08,COMPLETED,OBSERVATIONAL,['NA'],,Brief Fatigue Inventory (BFI)
3445,NCT06217094,Maximum tolerated dose,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival
3446,NCT06181318,Predicting the posthepatectomy hemorrhage after major liver resection,2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Correlation between remnant liver function after major liver resection and postoperative mortality
3447,NCT02784652,Pain relief rate,2014-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
3448,NCT04503694,"Evaluation of the efficacy of the combination of nivolumab and regorafenib when administered before and after standard, pre-operative short-course radiation therapy.",2021-03-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Evaluation of the efficacy of the combination of nivolumab and regorafenib when administered before and after standard, pre-operative short-course radiation therapy."
3449,NCT00703365,To evaluate the efficacy (progression free survival (PFS)) of sorafenib in patients with advanced/unresectable HCC.,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To evaluate overall, survival, overall response rate (RECIST), time to progression (TTP), disease control rate (DCR) and side-effect profile of sorafenib in combination with gemcitabine in patients suffering from HCC."
3450,NCT01807325,Gene classifier that will classify lesions as benign or malignant with 95% certainty,2012-12,COMPLETED,OBSERVATIONAL,['NA'],,
3451,NCT03694431,Caregiver preparedness for caregiving using the Preparedness for Caregiving Scale,2019-01-07,TERMINATED,INTERVENTIONAL,['NA'],,HBPC clinician perception of facilitators and barriers to implementation of HBPC services
3452,NCT04986566,Intervention Acceptability as reported by participants,2021-10-19,RECRUITING,INTERVENTIONAL,['NA'],,"Healthcare resource use (e.g., hospital readmission)"
3453,NCT00342186,Collection of 3400 samples,2002-09-27,COMPLETED,OBSERVATIONAL,['NA'],,
3454,NCT03254121,"Characterisation of genomic mutations of HCC, developed in HCV patients with SVR",2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
3455,NCT00251186,To measure the response (CR/PR) for a novel chemotherapy/biologic combination-capecitabine/cetuximab for patients with metastatic colorectal cancer who are too fragile for more intensive chemotherapy doublet regimens.,2006-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,To describe the baseline quality of life and functional characteristics of elderly patients or those with multiple comorbidities enrolled in this study and assess the impact of disease and its treatment on such functional characteristics.
3456,NCT04111029,Serial Quantification of ctDNA in plasma samples by means of real-time PCR post treatment,2020-01-16,RECRUITING,OBSERVATIONAL,['NA'],,Mortality
3457,NCT01528878,Tolerability of Stereotactic Body Radiotherapy (SBRT) Based on Number of Cumulative Acute Toxicities Occurring Within 90 Days of Treatment and Related to SBRT.,2009-04,COMPLETED,INTERVENTIONAL,['NA'],,Overall Survival of Patients With Liver Cancer or Metastases to the Liver
3458,NCT02038114,Impact of Patient Pamphlets on knowledge,2013-09,COMPLETED,INTERVENTIONAL,['NA'],Impact of patient education pamphlets on patient satisfaction with care,Impact of patient education pamphlets on health-related quality of life (HRQoL)
3459,NCT00003411,,1998-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3460,NCT04214119,Difference in methylation of gene markers to discriminate gastric cancer from non-pathological esophageal squamous and gastric cardia tissue.,2016-01-12,RECRUITING,OBSERVATIONAL,['NA'],,Specificity of candidate biomarker HPP1
3461,NCT04155671,Overall Survival(OS),2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Objective Overall Response Rate (ORR)
3462,NCT04118933,objective response rate,2019-07-17,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
3463,NCT03870607,Response rate (clinical and radiological),2019-03-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Variation of systemic immune parameters
3464,NCT01754636,Inclusion in at least one Clinical trial (amendment n°3 -02/2014),2012-11,COMPLETED,OBSERVATIONAL,['NA'],,Invitation to participate in in at least one Clinical trial (amendment n°3 -02/2014)
3465,NCT03478488,Overall Survival (OS),2018-04-16,RECRUITING,INTERVENTIONAL,['PHASE3'],,Time to progression (TTP)
3466,NCT00515853,Cleveland Clinic Incontinence (CCI) Score,2006-11-27,COMPLETED,INTERVENTIONAL,['NA'],,
3467,NCT00867321,Time to Progression (TTP) (Phase II),2009-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Tumor Response at 6 Months
3468,NCT05359939,Hepatocellular carcinoma - sensitivity and specificity of two PET tracers,2023-01-16,RECRUITING,INTERVENTIONAL,['NA'],,Hepatocellular carcinoma - sensitivity and specificity of MRI and CT
3469,NCT00238394,Time to disease progression,2005-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Laboratory measures
3470,NCT04757311,Progression Free Survival (PFS),2020-08-01,COMPLETED,OBSERVATIONAL,['NA'],Percentage of use biologics in right side tumors.,Advers events
3471,NCT04410887,Pathological response rate,2020-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease free survival (DFS)
3472,NCT00382811,The primary efficacy end-point is progression-free survival (PFS). PFS is the time from randomization until disease progression or death,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,The secondary efficacy end-point is overall survival (OS)
3473,NCT03402477,Rate of regrowth,2018-01-10,RECRUITING,OBSERVATIONAL,['NA'],,Diagnostic accuracy of MRI to detect regrowth during follow-up after complete response
3474,NCT06111274,Objective Response Rate (ORR),2023-10-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,The Minimum Concentration of ABSK021
3475,NCT02526095,DIsease free survival,2014-06,RECRUITING,OBSERVATIONAL,['NA'],,Death
3476,NCT03050814,"Progression Free Survival Between the Standard of Care (SOC) Arm A, and Standard of Care (SOC) Arm B + lead-in",2017-04-05,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0),Number of Participants That Are Hospitalized Because of Adverse Events Attributed to Disease Progression
3477,NCT05270642,local tumor progression,2021-10-01,UNKNOWN,INTERVENTIONAL,['NA'],,
3478,NCT00899002,Identification of proteomic profiles and molecular pathways involved in tumor progression,2007-07,WITHDRAWN,OBSERVATIONAL,['NA'],,Association between fibrolamellar carcinoma and hepatocellular carcinoma in terms of molecular aberrations and clinicopathologic features
3479,NCT01175291,Progression Free Survival,2010-09,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Number of Participants with Adverse Events
3480,NCT02342600,Disease Control Rate (DCR),2017-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Number and type of adverse events
3481,NCT01954732,"Pancreatic tumor cell proliferation and apoptosis as measured by the percentage of cells Ki-67+, percentage of cells TUNEL+, and mitotic counts in tissue samples",2014-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Percentage of pancreatic cancer stem cells in tissue samples
3482,NCT05982197,Change in severity of radiation induced mucositis,2023-01-03,COMPLETED,INTERVENTIONAL,['NA'],,
3483,NCT00089635,Duration of Response,2004-08-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
3484,NCT01215578,Predictive molecular markers of response to sunitinib,2008-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Residual concentration
3485,NCT03077594,Mucosal Impedance as measured by an endoscopic probe,2016-09-26,COMPLETED,OBSERVATIONAL,['NA'],,Volumetric Laser Endomicroscopy
3486,NCT01916148,,na,AVAILABLE,EXPANDED_ACCESS,['NA'],,
3487,NCT02500199,Part 2 Overall Response Rate (ORR),2015-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Progression Free Survival (PFS)
3488,NCT02994693,Longitudinal assessment of the Natural History of Barrett's Esophagus Using Tethered Capsule Endomicroscopy,2016-12,RECRUITING,OBSERVATIONAL,['NA'],,
3489,NCT05438420,Tumor response using RECIST version 1.1 throughout study,2023-01-12,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change in the area under curve (AUC) of Q702 and its primary metabolites
3490,NCT04394598,the morbidity of hematological adverse events and diarrhea as assessed by CTCAE v4.0,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of the concurrent chemotherapy cycles that patients can receive during radiotherapy
3491,NCT01927497,30-day Uncomplicated Perineal Wound Healing,2013-03-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3492,NCT06220617,Sensitivity and specificity of the screening test with comparison to colonoscopy,2024-01-11,RECRUITING,OBSERVATIONAL,['NA'],,
3493,NCT00006037,,1999-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,
3494,NCT01975688,"Area under the concentration-time curve extrapolated to infinity (AUC(0-∞)) of THC, 11-hydroxy-THC, CBD, 7-hydroxy-CBD and 6-hydroxy-CBD after a single dose of Sativex",2014-02,TERMINATED,INTERVENTIONAL,['PHASE1'],,The incidence of adverse events as a measure of subject safety
3495,NCT02892305,Overall Survival,2018-05-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Intraoperative estimated blood loss
3496,NCT00577889,Six Month Survival Rate,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Confirmed Response Rate
3497,NCT05720338,Composite endpoint comparison,2023-04-13,RECRUITING,INTERVENTIONAL,['PHASE3'],,Cost analysis for overall healthcare costs
3498,NCT04385641,Non hematologic toxicity,2019-10-08,UNKNOWN,INTERVENTIONAL,['NA'],,Tumor assessment
3499,NCT02460835,Median Time to Local Progression,2016-01-26,COMPLETED,INTERVENTIONAL,['NA'],Incidence of Radiation Induced Liver Disease (RILD),Overall Survival
3500,NCT03804593,"Rate of SEPT9 gene promoter methylation positivity in patients with cirrhosis, based on the HCCBloodTest.",2018-12-17,COMPLETED,OBSERVATIONAL,['NA'],,
3501,NCT04853017,Evaluate the safety of ELI-002,2021-10-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Determine the biomarker reduction and clearance rate
3502,NCT02959151,Number of patients with adverse event,2016-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Detection of transferred T cells in the circulation using quantitative -PCR
3503,NCT01946646,maximum-tolerated dose,2013-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,
3504,NCT04130763,The number of adverse events,2019-12-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,The number of adverse events
3505,NCT06253598,Objective response rate using RECIST v1.1,2024-03-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,AE
3506,NCT01764789,Quality of life(QoL),2010-10,COMPLETED,INTERVENTIONAL,['NA'],,Inflammation
3507,NCT01621919,,2010-12,UNKNOWN,OBSERVATIONAL,['NA'],,
3508,NCT01798173,Dosage of the vitamin B12 and the folates,2008-06-20,COMPLETED,INTERVENTIONAL,['NA'],,
3509,NCT04518449,incidence of diarrhea,2022-12-01,WITHDRAWN,OBSERVATIONAL,['NA'],,
3510,NCT00005944,,1999-07-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,
3511,NCT01035385,progression free survival (PFS),2009-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"response rate, incidence of postoperative complications,pathological response rate,R0 resection rate, 5-year overall survival,duration of disease control"
3512,NCT05998122,Complete response rate (CR),2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Wexner score
3513,NCT05796245,Incidence rate of Serious infections,2023-12-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Incidence rate of malignancy
3514,NCT04601272,Shared Decision Making Process Measure,2020-09-29,COMPLETED,OBSERVATIONAL,['NA'],,Knowledge
3515,NCT01494077,Accuracy of diluted CEA level,2011-04,COMPLETED,OBSERVATIONAL,['NA'],,
3516,NCT06078709,Pathologic complete response,2023-11-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Toxicity of chemoradiation between groups receiving proton based versus photon-based radiotherapy
3517,NCT06277921,the type of complications and the incidence of it,2024-03-18,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
3518,NCT03149978,TRG,2014-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,Number of participants with chemoradiation-related adverse events as assessed by CTCAE v4.0
3519,NCT01576380,disease control rate (DCR),2012-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,progression free survival (PFS) per independent central review
3520,NCT05759923,Occurence of DLTs,2023-01-26,RECRUITING,INTERVENTIONAL,['PHASE1'],,PK parameter: AUCO-24
3521,NCT04166318,Change in FIQoL in the de-intensified CRT arm,2020-01-02,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival,Incidence of and predictors for cardiovascular toxicity in patients receiving fluorouracil or capecitabine
3522,NCT05891028,Standardized uptake value,2023-05-07,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Adverse events collection
3523,NCT05449483,R0 Surgical Resection Rate .,2022-05-11,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
3524,NCT03433092,Gastrointestinal Tract Cancer Incident Measure,2017-11-01,COMPLETED,OBSERVATIONAL,['NA'],,
3525,NCT03342417,Clinical Response,2018-02-14,TERMINATED,INTERVENTIONAL,['PHASE2'],Part 2 of the Study (Therapy of Ovarian Cancer) and Part 3 of the Study (Therapy of Gastric Cancer) - QLQ-OV28,Part 2 of the Study (Therapy of Ovarian Cancer) and Part 3 of the Study (Therapy of Gastric Cancer) - Recurrence rate
3526,NCT05824403,Diagnostic tools,2023-11-28,RECRUITING,OBSERVATIONAL,['NA'],,Clinical data access
3527,NCT04641923,Incidence of peri-hepatic adhesions at the time of repeat liver surgery,2022-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,30-day mortality and morbidity
3528,NCT02648386,Safety and Tolerability assessed by Adverse Events,2016-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Maximum Flow Rate (Qmax)
3529,NCT01744340,"If Eribulin Mesylate, up to a Maximum Dose of 1.4 mg/m2 Day 1 and 8 of a 21 Day Cycle, Can be Safely Combined With Full Dose Cetuximab for Patients With Advanced Head and Neck Cancer and Colon Cancer.",2012-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Response Rate (Whether Patient's Disease is Progressing or Being Controlled) of Patients With Head and Neck Cancer Treated With Eribulin Mesylate and Cetuximab.
3530,NCT04044651,Overall survival (OS),2019-10-30,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",AFP level change,OS stratified according to degree of PVTT (Vp0-3 vs Vp4)
3531,NCT05791136,Progression-free survival (PFS),2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Time to death or distant metastasis (TTDM)
3532,NCT04812743,Increase in knowledge and intentions related to biospecimen donation and clinical trial participation.,2020-01-10,TERMINATED,INTERVENTIONAL,['NA'],,
3533,NCT05916443,Identification of EO-CRC specific signatures and pathways,2023-08-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
3534,NCT01204749,Progression-Free Survival,2010-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall health status using EuroQOL(EQ-5D)
3535,NCT02618447,Ability of the 4D PC MRA to measure flow direction of flow as compared to reference standards of the Doppler Flow Analysis,2014-08-05,TERMINATED,INTERVENTIONAL,['NA'],,
3536,NCT00821990,Survival,2008-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3537,NCT00209638,objective tumor response,2000-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Response duration, time to progression, overall survival, and safety will also be assessed."
3538,NCT00003354,,1996-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3539,NCT05804799,Measurement of standard deviation of CT attenuation values at the liver,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Sensitivity to detect malignant liver tumor
3540,NCT02494388,Accuracy of EUS-guided nCLE in a cohort of cystic pancreatic tumors,2015-06,TERMINATED,OBSERVATIONAL,['NA'],,Number of participants with adverse events as a measure of safety
3541,NCT02514278,Rate of organ preservation and absence of stoma,2016-01-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Disease-free survival
3542,NCT01785212,transection speed,2013-03,COMPLETED,INTERVENTIONAL,['NA'],Costs and health economics,Perioperative T-cell subsets
3543,NCT05508503,Accuracy,2022-10-21,COMPLETED,OBSERVATIONAL,['NA'],,Combined specificity
3544,NCT05802056,Incidence of adverse events,2023-11-29,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival
3545,NCT05028231,Pathologic Complete Response,2021-06-05,RECRUITING,OBSERVATIONAL,['NA'],Intestinal flora,Objective Response Rate
3546,NCT05160168,"Expansion (Phase 2): Expansion Cohorts 1, 2, 3 and 4: confirmed Objective Response Rate (ORR)",2022-01-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
3547,NCT01839604,Number of Participants With Dose Limiting Toxicities During Cycle 1,2013-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Evaluation of Pharmacokinetics (PK) of AZD9150 (Following Single Administrations in Patients With HCC) by Determining Tmax, Using the Plasma Concentration Data."
3548,NCT04212286,"The sensitivity, specificity and accuracy of CEUS and EOB-MRI",2019-10-23,COMPLETED,INTERVENTIONAL,['NA'],,"The sensitivity, specificity and accuracy of combined CEUS and EOB-MRI"
3549,NCT02324374,"Unblinded Analysis of Endocytoscopic Images of Colorectal Lesions (Technical quality of the images will be compared to histology and rated on a scale of 1-5 (1-worst, 3- acceptable, 5-being equal to histology)",2011-06,COMPLETED,INTERVENTIONAL,['NA'],,
3550,NCT00686543,Participants With a Mean POS Plasma Concentration ≥/<350 ng/mL on Day 8 and ≥/<700 ng/mL on Day 15,2007-12,COMPLETED,INTERVENTIONAL,['PHASE4'],,
3551,NCT02985944,Adenoma detection rate,2016-06,COMPLETED,OBSERVATIONAL,['NA'],,Factors affecting the withdrawal time
3552,NCT03621319,Rate of stricture-free eradication of dysplastic BE,2019-07-24,TERMINATED,INTERVENTIONAL,['NA'],,Cost-effectiveness of HAPC vs. RFA in the treatment of dysplastic BE
3553,NCT04340193,Number of treated participants with laboratory abnormalities,2020-09-15,TERMINATED,INTERVENTIONAL,['PHASE3'],,
3554,NCT04593446,The rate of surgical site infection,2020-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The patient's tolerability for bowel preparation
3555,NCT01497457,Determination of the distance between a rectal tumor and the pouch of Douglas,2011-12,COMPLETED,INTERVENTIONAL,['NA'],,
3556,NCT01286428,Phase II: The number of surgical oblation procedures that present data showing equivalent location of the ablation probe when compared to the US and Pathfinder Guidance System 3D image data.,2011-01,COMPLETED,OBSERVATIONAL,['NA'],,
3557,NCT04309747,Effectiveness analysis,2020-04-01,UNKNOWN,INTERVENTIONAL,['NA'],,Secondary validity analysis
3558,NCT03402607,Change in Quality of Life (QOL) Using EORTC C-30 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30),2018-08-08,TERMINATED,INTERVENTIONAL,['NA'],,The Total Healthcare System Costs Associated With PLA vs HIGRT
3559,NCT04083053,High Resolution Anoscopy (HRA) discomfort scale,2019-09-17,COMPLETED,INTERVENTIONAL,['NA'],,
3560,NCT04145388,Number of patients identified at high risk of cancer,2020-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
3561,NCT04656249,Progression free survival (PFS),2018-01-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Clinical benefit rate (CBR),The Rate of Treatment Related Adverse Events
3562,NCT05099549,Phase 2a/Expansion,2021-11-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2a/Expansion
3563,NCT02377232,Colon Cancer Screening Intent,2015-05,COMPLETED,INTERVENTIONAL,['NA'],,Colon Cancer Screening Completed
3564,NCT05635630,Relapse-free survival (RFS) time,2022-06-24,RECRUITING,INTERVENTIONAL,['NA'],,The rate of achieving NED status when relapses happen.
3565,NCT03847636,Complete eradication rate of DAs,2019-05-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Median number of CryoBalloon treatments to complete eradication.
3566,NCT02859155,Survival,2009-01,COMPLETED,INTERVENTIONAL,['NA'],,Recurrence
3567,NCT05846971,The impact of methylation assay on physician confidence in clinical care decision-making.,2021-01-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
3568,NCT02885727,Improvement in median Progression Free Survival using the combination of RT and durvalumab.,2017-07,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
3569,NCT03587818,The Longitudinal Preparedness for Colorectal Cancer Surgery Questionnaire (PCSQ),2012-11-01,COMPLETED,INTERVENTIONAL,['NA'],,Behaviour pertaining when and how to seek health care for recovery support: Visits at outpatients clinics
3570,NCT02579330,Grade of macroscopic contamination according to adjusted Boston Bowel Preparation Score (0-3).,2015-12,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative pain (VAS-score)
3571,NCT03829410,Phase 2: Number of Participants with an Objective Response Rate (ORR),2019-05-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Area Under the Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of Onvansertib
3572,NCT02076906,Toxicity,2014-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Immune Markers
3573,NCT01627119,To measure the expression level of CTGF in patient blood and tissue,2009-07,UNKNOWN,OBSERVATIONAL,['NA'],,To determine the survival probability of gastric cancer patients after surgery
3574,NCT05800080,The pathological complete response;,2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,"major pathologic response, MPR"
3575,NCT06276764,"The number of pancreatic ductal adenocarcinomas or their precursor lesions, dysplasia, identified only with LINFU® will be compared to standard screening methods",2024-04-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Yearly survival rate of patients with early pancreatic ductal adenocarcinomas or their noninvasive precursor lesions identified only with LINFU®,Determine the number of patients with early pancreatic ductal adenocarcinomas and their noninvasive precursor lesions identified only with LINFU® that require medical or surgical intervention.
3576,NCT02420509,Progression-Free Survival,2015-08-27,TERMINATED,OBSERVATIONAL,['NA'],,Quality of Life
3577,NCT05802394,Resection rate,2023-02-01,RECRUITING,INTERVENTIONAL,['NA'],The prognostic role of targeted therapy selected based on MRD,Major pathological response
3578,NCT05676190,objective response rate (ORR),2023-01-09,RECRUITING,INTERVENTIONAL,['NA'],,
3579,NCT02133079,electrocardiogram,2012-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change from baseline in subpopulation of CD8+ T cells at the end of vaccination,changes in antigen specific T cells
3580,NCT06314646,Rate of anastomotic leak,2024-05-31,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Cancer recurrence
3581,NCT00002930,,1996-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
3582,NCT03030404,Characterization of the natural and clinical histories of hereditary gastric cancer syndromes,2017-01-27,RECRUITING,OBSERVATIONAL,['NA'],,
3583,NCT03065855,Post-operative urinary retention requiring re-catheterisation,2017-02,UNKNOWN,INTERVENTIONAL,['NA'],,Urethrorrhagia
3584,NCT02849015,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2016-07-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival（OS）
3585,NCT03040453,Immunological response,2017-01-01,WITHDRAWN,INTERVENTIONAL,['NA'],,"Number of participants with complete radiological response at follow up 3, 6, 9 and 12 months."
3586,NCT03542799,Safety: Occurrence of study related adverse events,2018-05-22,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Effectiveness: duration of in vivo survival of EGFR CART
3587,NCT05600335,incidence of various postoperative complications,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],,radicality of surgery
3588,NCT02578888,"FAMCARE Survey will be administered, a 20 item scale measuring the degree to which family members are satisfied with the healthcare providers' behaviors. Comparison of family member scores between 2 arms, as well as at face value will be evaluated.",2015-04,COMPLETED,INTERVENTIONAL,['NA'],,
3589,NCT04801459,Late postoperative recovery results,2021-04-02,UNKNOWN,INTERVENTIONAL,['NA'],Postoperative complications,
3590,NCT02970526,Intensity of neuropathy induced by oxaliplatin evaluated by the QLQ-CIPN20 Questionnaire (EORTC).,2016-07,COMPLETED,OBSERVATIONAL,['NA'],,pain assessed by visual analog scale (VAS).
3591,NCT03883919,Tolerability between two different dose levels of paricalcitol added to the combo regimen of liposomal irinotecan plus 5-FU / LV as measured by the occurrence of grade 3 and 4 toxicities,2019-07-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Duration of stable disease
3592,NCT03957564,The relationship between tumor response and mutation of ctDNA pre- and post-neoadjuvant chemotherapy and after operation.,2019-05-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,Types of tumor-associated DNA in tumor tissues after operation.
3593,NCT05246982,PFS,2022-03-23,UNKNOWN,INTERVENTIONAL,['PHASE2'],,DOR
3594,NCT02100254,Change in likelihood of CRC screening in previously unscreened subjects,2009-10-01,COMPLETED,INTERVENTIONAL,['NA'],,"Influential factors in behavior changes, assessed using qualitative analyses of text from participant interviews, including affective associations with the program, participants' cognitive-affective influences, and predisposing influences"
3595,NCT04146298,Objective response rate,2021-10-21,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
3596,NCT00950144,"Relationship among characteristics (i.e., sociodemographic, disease, health status) associated with illness perceptions, overall symptom distress, and QOL)",2008-12,COMPLETED,OBSERVATIONAL,['NA'],,
3597,NCT00004873,,1999-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3598,NCT00253812,The primary outcome measure will be the mean number of adenomas detected on the blinded video review for each endoscopy,2005-11,UNKNOWN,INTERVENTIONAL,['NA'],,Primary endoscopist adenoma count for each modality.
3599,NCT00544349,Efficacy: objective tumor response rate (RECIST criteria),2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumor progression rate
3600,NCT06311032,Number of Decisions to Continue Surveillance Imaging,2023-03-29,COMPLETED,OBSERVATIONAL,['NA'],,
3601,NCT03344289,polyp detection rates,2018-01-21,COMPLETED,INTERVENTIONAL,['NA'],,"sensitivity, specificity, and accuracy of optical diagnosis on a per polyp basis"
3602,NCT00394615,To learn whether new medical imaging technology can help predict the response of rectal cancer to preoperative chemotherapy and radiation therapy.,2003-10,TERMINATED,INTERVENTIONAL,['NA'],,
3603,NCT03094351,Overall Survival Rate,2017-07-29,RECRUITING,INTERVENTIONAL,['PHASE3'],,Disease Free Survival Rate
3604,NCT01999478,Early cancer changes in the colon,2008-02,COMPLETED,OBSERVATIONAL,['NA'],,
3605,NCT05674097,Six pattens of blood flow and AMCA based on the preoperative observation,2020-06-08,COMPLETED,OBSERVATIONAL,['NA'],,
3606,NCT01480128,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA'],,
3607,NCT04221854,"The Detection Rate of Colorectal Polyps, Advanced Adenomatous Polyps and Cancer by Two Screening Methods",2020-01-06,UNKNOWN,INTERVENTIONAL,['NA'],,
3608,NCT00336960,Pathologic complete response rate,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity
3609,NCT01991678,Pharmacokinetics (PK) of NKTR-102 and its metabolites,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Safety and tolerability of NKTR-102
3610,NCT04025437,Overall survival,2019-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Recurrence-free survival
3611,NCT03637569,Overall survival,2018-04-01,RECRUITING,OBSERVATIONAL,['NA'],,
3612,NCT00172861,,2005-01,UNKNOWN,OBSERVATIONAL,['NA'],,
3613,NCT05604716,scores of digestive physiological and social psychological functions,2001-01-01,RECRUITING,OBSERVATIONAL,['NA'],,progressive-free survival
3614,NCT02580929,mortality,2014-10,UNKNOWN,INTERVENTIONAL,['NA'],,
3615,NCT02413437,diagnostic accuracy,2015-04,UNKNOWN,INTERVENTIONAL,['NA'],,
3616,NCT01858649,the major pathological response rate,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Post operative complication
3617,NCT00988897,"Primary endpoint for the first thirteen patients according to the Simons Design: Clinical DCR (Disease Control Rate) at the end of stage I, based on Response Evaluation Criteria on Solid Tumors (RECIST) criteria.",2009-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Overall response rate of stage I and II
3618,NCT02831179,Maximum tolerated dose determined by dose limiting toxicities defined as any toxicity in the first course evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0,2017-12,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Poly-adenosine diphosphate (ADP)-ribosylated (PAR) level
3619,NCT04144907,13C Phenylalanine Oxidation,2021-04-26,RECRUITING,INTERVENTIONAL,['NA'],,
3620,NCT03414125,One-time Screening Completion,2018-09-07,COMPLETED,INTERVENTIONAL,['NA'],,Choice of FIT versus Colonoscopy
3621,NCT03634683,Safety based on Incidence of Treatment-Emergent Adverse Events (AEs) and Serious AEs,2018-08,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life of patients
3622,NCT01177631,Recurrence,2009-02,COMPLETED,INTERVENTIONAL,['NA'],,
3623,NCT00956475,Most common areas of concern,2008-10,COMPLETED,OBSERVATIONAL,['NA'],,
3624,NCT00016198,,2001-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3625,NCT05031975,"To assess the activity in terms of seroreversion of TEMIRI consolidation regimen administered to patients with high-risk stage II (pT4) or III MSS, MGMT silenced CRC and positive post-adjuvant ctDNA after standard oxaliplatin-based adjuvant chemotherapy.",2022-05-02,RECRUITING,INTERVENTIONAL,['PHASE2'],To assess the accuracy of ctDNA as disease recurrence biomarker,Quality of life as assessed using the Euro Quality of Life 5 Dimensions Questionnaire (EQ-5D-5L)
3626,NCT01009593,Overall Survival,2010-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,Overall Response Rate (ORR)
3627,NCT02305186,Safety: Incidence of Dose-Limiting Toxicities (DLTs),2015-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Response Rate (RR)
3628,NCT05095831,Clinical condition at one-year follow-up,2021-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,
3629,NCT04741152,No hidden insulinomas,2010-01,COMPLETED,OBSERVATIONAL,['NA'],,
3630,NCT04791293,MELD-Na score difference between the groups,2020-12-01,COMPLETED,OBSERVATIONAL,['NA'],,
3631,NCT04889768,R0 resection,2021-07-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Adverse Events
3632,NCT01146769,Maximum Squeeze Pressure,2010-04,UNKNOWN,INTERVENTIONAL,['NA'],,Functional Outcomes
3633,NCT02273752,Incidence of Stomatitis,2014-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Response Rate Assessed Using Response Evaluation Criteria in Solid Tumors (RECIST) Criteria
3634,NCT06192862,CRC screening uptake rate,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,qualitative factors checklist associated with CRC screening
3635,NCT04417764,Incidence of Adverse Events,2019-06-20,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall Survival
3636,NCT01741038,Overall Survival,2017-12,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Longitudinal changes in tumor burden,Health-Related Quality of Life (HRQoL)
3637,NCT03780946,Pancreatic fistula,2019-02-01,UNKNOWN,OBSERVATIONAL,['NA'],,Discharge of the magnets
3638,NCT00243841,6 Month Local In-field Control,2004-05,COMPLETED,INTERVENTIONAL,['NA'],,Phase II: Number of Patients With Treatment Related Grade 3 or 4 Adverse Events
3639,NCT01117428,Number of Participants With Adverse Events (AEs),2010-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Terminal Half-Life (T½)
3640,NCT01927978,"The effectiveness of 18F-FDG PET in the initial staging, therapy planning, and therapeutic response monitoring for esophageal cancer patients.",2012-10,UNKNOWN,OBSERVATIONAL,['NA'],,
3641,NCT02428270,"Percentage of patients who experience complete response, partial response, or stable disease",2016-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Interval between the first date of CR or PR and the earliest date of disease progression or death due to any cause.
3642,NCT04735133,surgical wound complications (SWC),2018-11-18,COMPLETED,INTERVENTIONAL,['NA'],,length of stay in the hospital
3643,NCT02829788,Peritoneal carcinomatosis staging,2015-11,UNKNOWN,OBSERVATIONAL,['NA'],,
3644,NCT05185531,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],2022-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival
3645,NCT02575014,Number of participants with hyperbaric oxygen treatment related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03,2013-10,UNKNOWN,INTERVENTIONAL,['NA'],,Change in Carcinoembryonic antigen
3646,NCT00761345,To Determine the Dose Limiting Toxicities,2008-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,To Measure Progression Free Survival and Overall Survival
3647,NCT04285008,rate of adequate cleansing level after using the Pure-Vu System as compare to sandard of care colonoscopy procedure,2020-03-03,WITHDRAWN,INTERVENTIONAL,['NA'],,
3648,NCT00704600,phase I: Incidence of any grade 3 or higher non-hematological or grade 4 or higher hematological toxicity (CTCAE v3.0) and of grade 4 or higher postoperative toxicity within 30 days post-surgery phase II:rate of pathological complete remission,2008-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
3649,NCT05316103,Accuracy of pCLE-targeted optical biopsy,2021-11-04,RECRUITING,INTERVENTIONAL,['NA'],,Complications of biopsy
3650,NCT05953662,DFS rate,2023-09-15,RECRUITING,INTERVENTIONAL,['NA'],,3 years OS Rate
3651,NCT05954871,Number of Participants with Dose-Limiting Toxicities (DLTs),2024-01-08,RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-Free Survival (PFS) After Enrollment as Determined by Investigator According to RECIST v1.1
3652,NCT01441492,60-day ≥ Grade II Complication Rate,2011-09,COMPLETED,INTERVENTIONAL,['NA'],,Composite Quality of Life Scores
3653,NCT00064181,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3654,NCT05662488,Response of total lesion activation to anti-PD1-based combination therapy shown in [68Ga]FAPI and [18F] FDG PET Scans,2020-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Progression-free survival after treatment
3655,NCT04140526,Rate of treatment related adverse events (TRAE) according to CTCAE v5.0,2020-09-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
3656,NCT02827786,"EMA (colour scale) images will be compared to baseline US grey-scale images for a specific target lesion, as determined by standard of care imaging (US, CT, MRI or PET) and/or histologically proven lesion in a given subject.",2016-09,UNKNOWN,INTERVENTIONAL,['NA'],,US grey-scale and EMA colour maps will be obtained from both target liver lesions and background liver tissue from the same subject and compared.
3657,NCT04613570,Carcinoma,2021-01-02,RECRUITING,INTERVENTIONAL,['NA'],,Advanced gastric cancer
3658,NCT00086762,Quality of life as measured by Functional Assessment of Cancer Therapy,2004-06,COMPLETED,INTERVENTIONAL,['NA'],,"Immune suppression as measured by cytotoxicity, stimulated release of IL-12, -4, -10, intracellular cytokines and lymphocyte phenotype"
3659,NCT05136326,To evaluate the rate of complete pathologic response (pCR),2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,"To assess the incidence, nature, and severity of adverse events"
3660,NCT01589146,"symptomatic objectively confirmed VTE, asymptomatic ultrasonography-confirmed DVT or VTE-related death",2010-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
3661,NCT02353936,response rate,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Progression free survival
3662,NCT03261791,recurrence-free survival,2017-07-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,safety: the potential side effects
3663,NCT01450696,Overall Survival - FAS,2011-12,TERMINATED,INTERVENTIONAL,['PHASE3'],,Trastuzumab Serum Concentration on Day 1 of Cycle 1 - FAS
3664,NCT01415063,overall survival,2011-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],,disease-free survival
3665,NCT03675243,Fecal incontinence quality of life scale,2018-04-01,COMPLETED,OBSERVATIONAL,['NA'],,Sphinctrometry
3666,NCT06036563,specificity,2023-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
3667,NCT02409199,Progression-free survival (PFS),2015-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Safety (incidence of adverse events)
3668,NCT06268015,Proportion of subjects with a best overall response of complete response or partial response according to iRECIST,2024-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Months of progression-free survival
3669,NCT05775939,Change in mean standardized uptake value (SUV) changes in the heart,2023-01-20,RECRUITING,INTERVENTIONAL,['NA'],,Cardiac related death
3670,NCT03745794,Number of Participants Discharged Opioid-Free,2019-02-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Patients and Family Free of Opioid Use
3671,NCT03440515,treatment success rate,2014-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3672,NCT03924466,Feasibility and added value of 68GaNOTA-Anti-HER2 in neoadjuvant setting of breast carcinoma,2019-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Influence image-guide biopsy on patient management
3673,NCT05609656,The incidence rate of adverse events according to CTCAE v. 4.0,2023-01-26,RECRUITING,INTERVENTIONAL,['PHASE2'],immune infiltration by PD-1 and PD-L1 staining,Overall survival
3674,NCT05615129,Overall survival,2021-10-01,COMPLETED,OBSERVATIONAL,['NA'],,Pathologic complete response rate (pCR)
3675,NCT04854213,To assess the efficacy of SBRT in inducing a regressive genetic trajectory of KRAS gene (evaluated by NGS technique) after SBRT treatment.,2021-10-06,RECRUITING,INTERVENTIONAL,['NA'],,Metabolic response (exploratory studies)
3676,NCT03693846,Number of Participants With Progression-Free Survival at 6 Months,2019-02-15,TERMINATED,INTERVENTIONAL,['PHASE2'],,Duration of Response
3677,NCT00878163,Maximum tolerated dose of erlotinib hydrochloride defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients,2009-03-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Time to treatment failure
3678,NCT00587314,Response to treatment,2004-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
3679,NCT05602792,"In part III, Evaluate the safety of multiple dose IT T3011 in the following indications,including sarcoma, Malignant head and neck tumor, breast cancer, esophagus cancer, lung cancer and non-melanoma skin cancer.",2020-04-21,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']","In part II and part III,Exploring the proliferation and activity of immune cells in blood after IT T3011","In part III,Overall Survival (OS)"
3680,NCT00051545,"Time to relapse, relapse being defined as the first recurrence of HCC (intra- or extrahepatic).",1999-11,TERMINATED,INTERVENTIONAL,['PHASE3'],,Dose of Seocalcitol
3681,NCT05026268,Post-operative complications rate,2021-09,UNKNOWN,INTERVENTIONAL,['NA'],,The time to discharge from hospital
3682,NCT02038621,Progression Free Survival (PFS),2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,health-related quality of life (HRQOL
3683,NCT00623883,"number, size, and location of ACF identified",1999-01,COMPLETED,INTERVENTIONAL,['NA'],,"complications of stain-enhanced, magnification colonoscopy"
3684,NCT02831556,Experimental ultrasound diagnosis agreement with final reference standard diagnosis,2016-07,RECRUITING,OBSERVATIONAL,['NA'],,Experimental ultrasound image quality.
3685,NCT01210027,"Measure of Liver Function Before, During and After Radiation",2007-03,RECRUITING,OBSERVATIONAL,['NA'],,Association Between Liver Perfusion and Changes in Tumor and Clinical Outcomes
3686,NCT03597672,The number of new cases of gastric carcinoma,2017-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Time of finding nee cases
3687,NCT04802486,Number of patients that adhered to the exercise conditions of the study,2016-06-29,COMPLETED,INTERVENTIONAL,['NA'],,Porportion of subjects with improved cachexia-related symptoms 3 months
3688,NCT04918459,Death adjusted cumulative incidence of rebleeding at 30-day,2021-08-06,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Mortality rate at 6 months
3689,NCT06103435,Survival,1996-01,COMPLETED,OBSERVATIONAL,['NA'],,Rate of readmissions
3690,NCT04988971,Overall incidence of chemotherapy-induced diarrhea ≥ grade 1,2021-06-30,UNKNOWN,INTERVENTIONAL,['PHASE3'],Changes of fecal flora and enteritis-associated inflammatory factors,Overall incidence of grade 3/4 gastrointestinal adverse events
3691,NCT00360971,Duration of Oral Mucositis as Measured in Terms of Days,2006-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,Time to Second Primary Tumor
3692,NCT00305760,Safety of Combining the Pancreatic Tumor Vaccine in Sequence With Cyclophosphamide and Erbitux. Safety is Defined as the Number of Treatment-related Grade 3 or 4 Adverse Events Observed in Greater Than 5% of the Patient Population,2005-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3693,NCT02785068,To correlate disease response according to RECIST with levels of irinotecan and SN-38 in tumor tissue,2016-07,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Presence of anti-drug antibodies will be assessed
3694,NCT03140670,Progression-Free Survival (PFS) at 6 Months (PFS6),2017-09-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Toxicity at Least Possibly Related to Rucaparib
3695,NCT03399331,severity of OM,2017-07-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],,pain
3696,NCT00889343,To compare the PFS between patients receiving chemotherapy (FOLFOX6 or FOLFIRI) + sorafenib with chemotherapy + placebo,2009-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Safety
3697,NCT01339754,Progression-free survival (PFS) rate at 6 months,2011-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Impact of pharmacogenomic and pharmacokinetic profile on anti-tumor activity
3698,NCT04668781,Fluid volume intraoperatively and postoperatively,2020-12-21,RECRUITING,INTERVENTIONAL,['NA'],,Mortality
3699,NCT04550494,Percent of patients who demonstrate simultaneous Rad51 activation,2021-04-26,RECRUITING,INTERVENTIONAL,['PHASE2'],Tumor genomic alterations potentially associated with sensitivity or acquired resistance to talazoparib,Overall response rate
3700,NCT04264260,survival,2019-12-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,serious adverse effect
3701,NCT04027348,Proportion of Patients With Obstruction Clearance,2019-06-26,TERMINATED,INTERVENTIONAL,['PHASE2'],,
3702,NCT03708783,the incidence of postoperative complications within 30 days,2018-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,3-year disease free survival
3703,NCT01759056,Safety and tolerability of AVX-470 over 28 days of treatment,2013-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Evaluate the effects of AVX 470 on biomarkers of ulcerative colitis activity over 28 days of treatment compared to Baseline,Measure the induction of or change in a human anti-bovine immunoglobulin antibody (HABA) response to AVX 470
3704,NCT03215355,Improved image quality after injection as determined by contrast-to-background calculation and expert observation.,2017-08,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,"Toxicity with ""off label"" dosing"
3705,NCT01229943,Progression Free Survival,2010-10-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
3706,NCT01957852,Reoperation rate for intra-abdominal bleeding after CRS and HIPEC,2008-01,COMPLETED,OBSERVATIONAL,['NA'],,Length of hospital stay
3707,NCT05600933,"To collect biologic samples from participants undergoing diagnostic or therapeutic interventions for premalignant, primary or metastatic solid tumors and hematologic malignancies",2023-05-15,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,"To collect detailed history, demographic, treatment data, and perioperative findings."
3708,NCT00507351,Pain and symptom data across multiple institutions,2006-07,COMPLETED,OBSERVATIONAL,['NA'],,
3709,NCT05543304,Objective response rate,2018-12-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Progression free survival
3710,NCT00914537,High resolution anoscopy,2009-06-02,COMPLETED,OBSERVATIONAL,['NA'],,
3711,NCT06327386,Evaluation efficacy of tumor regression level,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],,SUV
3712,NCT04742959,Dose limiting toxicity (DLT),2021-03-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Genetic Alteration Status,Volume of Distribution (Vd)
3713,NCT05609253,Itraconazole drug and blood levels,2022-09-14,RECRUITING,INTERVENTIONAL,['PHASE1'],,Effects of itraconazole on angiogenesis
3714,NCT03435666,AUC0-t,2018-05,UNKNOWN,INTERVENTIONAL,['PHASE1'],,AUC_%Extrap_obs
3715,NCT02892643,Vitamin B12 cumulative supplement quantity,2016-10-27,COMPLETED,INTERVENTIONAL,['NA'],,Overall survival
3716,NCT00192712,time to treatment failure,2002-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"response rate, survival, toxicity"
3717,NCT01181609,Percentage of Participants Achieving Overall Disease Control (ODC),2005-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,OS - Time to Event
3718,NCT04883970,Standardized uptake value（SUV）,2021-05-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
3719,NCT05890339,The Proportion of Patients With Reflux Esophagitis Within 12 Months Postoperatively,2023-06-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Proportion of participants need to rehospitalized after surgery
3720,NCT05122091,Pathological remission rate (PRR),2021-11-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,R0 resection rate
3721,NCT04193904,To assess the safety of MRx0518 in combination with hypofractionated preoperative radiation through the collection of adverse events,2019-12-20,TERMINATED,INTERVENTIONAL,['PHASE1'],Genomic changes,Margin status
3722,NCT03070574,Reduction in the occurrence of any colorectal neoplasia in LS patients,2017-11-24,TERMINATED,INTERVENTIONAL,['PHASE2'],,Significant findings & illnesses - adverse events
3723,NCT06324032,Evaluation of EUS-E accuracy quantitative,2020-12-17,RECRUITING,OBSERVATIONAL,['NA'],,"Complication rate (perforations, bleeding) of the procedure"
3724,NCT03210129,Change in physical activity behavior,2017-07-06,COMPLETED,INTERVENTIONAL,['NA'],,Cost-effectiveness of the intervention
3725,NCT03126058,occurrence rate of severe complications,2017-06-21,UNKNOWN,INTERVENTIONAL,['NA'],,Procalcitonin
3726,NCT05052671,Progression free survival (PFS),2022-05-25,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival (OS) in ctDNA positive versus ctDNA negative.
3727,NCT03689712,Cumulative Incidence of Severe Oral Mucositis,2018-10-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3728,NCT02179463,Pathological Response,2014-06,UNKNOWN,OBSERVATIONAL,['NA'],,downstage proportion
3729,NCT02166190,Clinical Success- composite,2014-06,TERMINATED,INTERVENTIONAL,['NA'],Safety Profile and Quality of Life,Mutational Profile of DNA post interventional procedure
3730,NCT03741517,Protocol adherence,2019-01-30,RECRUITING,OBSERVATIONAL,['NA'],Safety of core needle biopsy: NCI Common Terminology Criteria,
3731,NCT00003546,overall survival,1998-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3732,NCT03023436,2-year Median survival time,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Molecular biomarker alteration,Morbidity and mortality
3733,NCT04483284,Progression Free Survival,2020-06-24,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The incidence of AEs and SAEs by NCI-CTCAE v5.0
3734,NCT00515216,Overall Response Rate (ORR),2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)
3735,NCT00003531,Number of Participants With Objective Response and Stable Disease,1996-04-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
3736,NCT01552291,Morbidity,2012-05,COMPLETED,INTERVENTIONAL,['PHASE4'],,Perioperative immunocompetence
3737,NCT05041335,Aggregate specimen length (ASL),2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Adequacy of diagnosis
3738,NCT05821361,Overall response rate ( ORR) per RECIST 1.1,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease Control Rate (DCR) per RECIST 1.1
3739,NCT02565017,Acceptability of IBM Watson Oncology,2015-09-15,COMPLETED,OBSERVATIONAL,['NA'],,
3740,NCT02314052,Phase 2: Preliminary Antitumor Activity,2015-01-27,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,AUClast (hr*ng/mL) - DCR-MYC Levels in Blood (Phase 1b Only): Dosing Day 1 and Day 8
3741,NCT00589563,Severity of Chronic GVHD,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of Disease Relapse/Progression at 2 Years Post HSCT
3742,NCT01320319,Nutritional supplementation with 960mg EPA three times a day positively affects muscle function and mass,2011-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,The secondary aim is to look at the aerobic performance.
3743,NCT02326779,Overall survival,2016-03,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Adverse events
3744,NCT02567396,Tolerability of talazoparib in patients with varying degrees of hepatic and renal dysfunction,2016-06,WITHDRAWN,INTERVENTIONAL,['PHASE1'],The pharmacodynamic effects of talazoparib,Response rate
3745,NCT02173353,Evaluate the use of ultrasound to detect motion of pancrease and surrounding structures,2014-02,COMPLETED,OBSERVATIONAL,['NA'],Assess organ motion and compare in conjunction with magnetic resonance imaging or CT,Quality of ultrasound imaging for Pancreas
3746,NCT04863768,association between gene mutational status and disease-free survival,2006-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Descriptives
3747,NCT00048126,Tumor measurements (RECIST criteria),2001-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Time to progression, time to response, duration of response, time to treatment failure, survival.\n"
3748,NCT03666442,tumor area in endoscopy,2018-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,tumor thickness in TRUS
3749,NCT01987726,Proportion of patients who have multiple options recommended,2013-09-03,COMPLETED,OBSERVATIONAL,['NA'],,Presence of any oncogene or tumor suppressor gene mutations or amplifications identified by NGS on tumor tissue in each cohort
3750,NCT01225523,Progression-free survival,1997-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Rate of local recurrences and metastasis
3751,NCT00003769,,1999-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3752,NCT02238613,Tumor Response rate,2014-08,UNKNOWN,INTERVENTIONAL,['NA'],,Adverse events
3753,NCT04237441,survival following pancreatic surgery,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
3754,NCT04069949,Incidence of Treatment-Emergent Adverse Event,2019-12-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Duration of response
3755,NCT02938481,Distribution of metastatic LNs,2013-05-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Prognostic outcomes according to the central radicality
3756,NCT02882659,Safety of DKC as assessed by laboratory examinations,2014-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Efficacy of DKC as assessed by change in quality of life
3757,NCT00242788,Objective tumour response (CR and PR) at study closure based on the RECIST,2004-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Incidence of controlled disease (CR, PR and SD) at study closure"
3758,NCT06024252,Overall survival,2023-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Treatment pattern
3759,NCT01354795,"Compare the degree of cytologic quality in specimen obtained by EUS-FNA with or without suction, pushing the stylet or injecting air.",2010-09,COMPLETED,INTERVENTIONAL,['NA'],,"Compare the diagnostic yield in specimen obtained by EUS-FNA with or without suction, pushing the stylet or injecting air."
3760,NCT02456285,Adherence to an evidence-informed common pathway assessed using guidelines suggested by the European Society of Medical Oncology (ESMO),2015-05-20,COMPLETED,OBSERVATIONAL,['NA'],,
3761,NCT02238821,Scoring the expression of COX-2 in colorectal cancer tissue sections by Immunohistochemical analysis,2007-10,COMPLETED,OBSERVATIONAL,['NA'],,
3762,NCT01790230,Assessment of subject's safety by incidence of related Adverse Events,2013-01,COMPLETED,INTERVENTIONAL,['NA'],,Assessment of the device's application technique
3763,NCT05042336,MPR,2021-09-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,ORR
3764,NCT01113736,If there is a decrease on adhesion formation of AlloMEM™ used in formation of a temporary loop ileostomy.,2010-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Decrease in operative time and a promotion of peritoneal remodeling
3765,NCT05001347,Objective Response Rate (ORR) in each Tumor Type,2021-11-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Assessment of PK parameter: tmax
3766,NCT05151068,The change of sleep,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,
3767,NCT03700541,Change in number of circulating tumor cells prior to surgery to 2 - 4 weeks after surgery,2019-01-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,Pain assessment
3768,NCT00772083,self-reported seeking of medical care for diagnosis of anemia found at time of blood donation,2008-11,COMPLETED,INTERVENTIONAL,['NA'],,
3769,NCT04443816,Loss of health related quality of life (HRQL),2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Disability
3770,NCT04281511,progressive-free survival,2019-04-03,COMPLETED,OBSERVATIONAL,['NA'],,
3771,NCT01796782,overall survival (OS),2013-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of adverse events of QYHJ Formula
3772,NCT01384227,To determine whether tissue is neoplastic or non-neoplastic,2009-02,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
3773,NCT06148298,Level of c-ERBB1 in blood using Chromatin immunoprecipitation and Reverse transcription-quantitative polymerase chain reaction,2023-05-24,RECRUITING,OBSERVATIONAL,['NA'],,
3774,NCT05911217,Disease free survival (DFS),2023-07-11,RECRUITING,INTERVENTIONAL,['PHASE1'],,The immunogenicity in subjects receiving CT041 infusion in this study
3775,NCT00735917,Six Month Survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-Free Survival
3776,NCT06208371,Five-year survival rate,2024-01-15,RECRUITING,INTERVENTIONAL,['PHASE3'],,Treatment-related Adverse Events
3777,NCT06172634,treatment related adeverse event,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall response rate
3778,NCT01905969,Relapse free survival,2012-10,UNKNOWN,OBSERVATIONAL,['NA'],,
3779,NCT00810771,Colorectal Cancer (CRC) Screening Rate.,2009-02,COMPLETED,INTERVENTIONAL,['NA'],,If Colorectal Cancer Screening Screening (CRCS) Discussed With Provider.
3780,NCT01421680,Postoperative complication rate,2011-08,COMPLETED,INTERVENTIONAL,['NA'],,Patient compliance of oral nutritional supplements
3781,NCT00260585,,1999-06,RECRUITING,OBSERVATIONAL,['NA'],,
3782,NCT01492127,Variation of plasma proteasome,2011-12,UNKNOWN,INTERVENTIONAL,['NA'],,Variation of plasma proteasome
3783,NCT05631574,"To determine the OBDs/RP2Ds of BMF-219 monotherapy in subjects with KRAS-driven unresectable, locally advanced, or metastatic NSCLC, PDAC and CRC.",2023-01-12,RECRUITING,INTERVENTIONAL,['PHASE1'],,"To evaluate the efficacy of BMF-219 monotherapy in subjects with unresectable, locally advanced, or metastatic NSCLC, PDAC and CRC."
3784,NCT01356628,Time to Disease Progression,2011-05-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Response Rate (RR)
3785,NCT03566056,"Hypotension, defined as mean arterial bloodpressure <65 mmHg, measured by invasive arterial blood-pressure, the first morning after surgery at 06.00 (AM)",2018-01-18,COMPLETED,OBSERVATIONAL,['NA'],,
3786,NCT03629691,PFS (progression-free survival),2015-02-01,COMPLETED,OBSERVATIONAL,['NA'],,LRC (duration of locoregional control )
3787,NCT00072787,,2003-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
3788,NCT04625543,Major Pathological Response (MPR) rate,2020-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,The incidence of adverse events
3789,NCT04552236,Predicting early HCC recurrence after treatment by Ultrasound elastography,2021-01,UNKNOWN,OBSERVATIONAL,['NA'],,
3790,NCT04928625,Recommended Phase II Dose (RP2D),2021-08-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Objective response rate (ORR)
3791,NCT02607540,"overall survival, OS",2014-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"disease control rate,DCR"
3792,NCT05740956,Efficacy of HS-10502: Objective response rate (ORR)（Stage 2）,2023-06-09,RECRUITING,INTERVENTIONAL,['PHASE1'],,[Stage 1 and Stage 2] Efficacy of HS-10502: Time to PSA progression (for prostate cancer only)
3793,NCT01077739,Progression-Free Survival (PFS) From the Start of Treatment Beyond Progression,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Geometric Mean Values of Pro-Angiogenic Cytokine Concentrations at Baseline and Prior to Progression
3794,NCT01648894,Percentage of pathological complete response after pathological examination of surgical specimen defined by the absence of persistent tumor cell invasion and lymph node (ypT0N0) in group 7 weeks versus 11 weeks in the group,2012-10-25,COMPLETED,INTERVENTIONAL,['PHASE3'],,Functional results (LARS score)
3795,NCT03380858,fistula incidence,2017-11-02,UNKNOWN,OBSERVATIONAL,['NA'],,infection
3796,NCT03886571,"Measuring cell-free and exosomal-miRNA biomarkers using small RNA-Seq in matched tissue and plasma from patients with PDAC, PNs, pancreatitis and normal pancreas for early detection.",2018-09-15,RECRUITING,OBSERVATIONAL,['NA'],,
3797,NCT01902823,Satisfaction with Care,2011-11,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,The Inventory of Recent Life Experiences for Cancer Patients
3798,NCT05543863,platelet function testing at 5 days,2022-08-20,RECRUITING,OBSERVATIONAL,['NA'],,postoperative complications
3799,NCT03857815,PFS,2019-03-25,UNKNOWN,INTERVENTIONAL,['PHASE2'],,ORR
3800,NCT03117023,sleep time,2017-04-15,UNKNOWN,INTERVENTIONAL,['PHASE3'],,side effects
3801,NCT00075647,Overall survival (OS),2003-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Expression and phosphorylation status of p70s6k
3802,NCT04374877,[Part D] Objective response rate (ORR),2020-04-22,RECRUITING,INTERVENTIONAL,['PHASE1'],,[Part D] Summary of adverse events (AEs) based on treatment emergent AEs (TEAEs)
3803,NCT00606385,Recurrence rate,2007-12,UNKNOWN,INTERVENTIONAL,['NA'],,Survival
3804,NCT02454790,Late toxicity,2014-09,RECRUITING,OBSERVATIONAL,['NA'],Patient-rated symptoms and Quality-of-Life,Loco-regional tumor control
3805,NCT01407107,The Number of Participants Experiencing Dose Limiting Toxicities (DLT),2011-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With a Pathological Complete Response (pCR)
3806,NCT05451862,confirmed Objective Response Rate (ORR) by localized mRECIST,2023-08-21,RECRUITING,INTERVENTIONAL,['NA'],,Quality of Life using EQ-5D-5L questionnaire
3807,NCT00719641,Number of Participants Without Re-looping Among Those With Looping,2008-08-05,COMPLETED,OBSERVATIONAL,['NA'],,
3808,NCT05310565,Patient Retention,2024-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Patient-reported outcomes
3809,NCT03610100,"Number of participants that have survived throughout treatment and also into follow-up, as measured by the primary cause of death and date of death CRFs.",2015-12,SUSPENDED,INTERVENTIONAL,"['PHASE2', 'PHASE3']","Discovery of possible biomarkers which may predict any additional benefit of Acelarin over gemcitabine. These will be assessed from plasma, cell pellet and serum samples collected from participants throughout the trial.","Number of patients with treatment-related adverse events as assessed by CTCAE v4.03. Toxicity is assessed by CTCAE v4.03 alongside Quality of Life Questionnaires, QLQ-C30 and QLQ-PAN26."
3810,NCT02624895,"average relative dose intensity of every drug""",2015-12-30,COMPLETED,OBSERVATIONAL,['NA'],,Questionnaire score
3811,NCT00588367,"A reproducible technique to measure CT perfusion parameters may provide a method for non-invasively monitoring tumor response during treatment, or differentiating between autoimmune and chronic pancreatitis.",2006-04,COMPLETED,OBSERVATIONAL,['NA'],,
3812,NCT02854839,Time To progression,2016-11-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Safety of MG4101 as evaluated by Incidence of adverse events (AEs), serious adverse events (SAEs)"
3813,NCT05377034,Best Overall Response Rate (BORR) at 12-months post-randomization.,2022-10-26,RECRUITING,INTERVENTIONAL,['PHASE2'],Occurrence of adverse events leading to death.,Quality-adjusted life years at 18 months.
3814,NCT01287637,Postsurgical morbidity.,2011-02,COMPLETED,INTERVENTIONAL,['NA'],,Socio-economic effect of early reversal of temporary ileostomy
3815,NCT03435536,Kinetic of circulating tumor DNA evaluation in resected pancreatic cancer.,2018-02-26,COMPLETED,INTERVENTIONAL,['NA'],,Correlation between circulating tumor DNA rate and Ca19.9 dosage
3816,NCT02628951,objective response rate,2016-05-26,COMPLETED,INTERVENTIONAL,['PHASE2'],,response rate according to molecular subtypes
3817,NCT04316078,Feasibility of PEP (percent of patients using videos/complete questionnaires),2020-03-15,COMPLETED,INTERVENTIONAL,['NA'],,Secondary clinical outcomes 4 (treatment intensity and continuity)
3818,NCT03285867,The change of LSM(kpa) measured by FibroScan(a kind of external harmless ultrasonoscope),2018-06-25,UNKNOWN,OBSERVATIONAL,['NA'],,
3819,NCT03796884,Pharmacodynamics effect on cGMP levels,2019-10-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],PCNA expression,Guanylin levels
3820,NCT01103128,BRCA1 vs. BRCA2 mutations,2009-03,TERMINATED,OBSERVATIONAL,['NA'],,Interaction of other cancer genes with BRCA1 and BRCA2
3821,NCT06208397,Radiological assessment of CRLM,2023-12-24,RECRUITING,OBSERVATIONAL,['NA'],,
3822,NCT01978808,the overall diagnostic accuracy rate of both needles,2013-10,UNKNOWN,OBSERVATIONAL,['NA'],,
3823,NCT06121700,Overall survival (OS),2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Surgical mortality
3824,NCT03090139,Time-to-first Indicator of Sub-optimal Therapy,2017-03-28,COMPLETED,OBSERVATIONAL,['NA'],,Physician Survey Questionnaire
3825,NCT04500990,Objective Response Rate,2020-09,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival
3826,NCT06048367,Safety and Tolerability Assessment of CNSI-Fe(II),2022-10-14,RECRUITING,INTERVENTIONAL,['PHASE1'],,PK Parameters Assessment: t1/2 (h) Profile Assessment of CNSI-Fe(II)
3827,NCT05097911,Evaluable Non-Target Disease Response,2021-08-02,RECRUITING,INTERVENTIONAL,['PHASE1'],,Evaluation of Best Overall Response
3828,NCT01019382,Objective response rate (complete and partial response) on CT according to RECIST criteria,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Pharmacokinetic analysis of blood samples
3829,NCT04687410,Total tissue area,2020-06-15,UNKNOWN,INTERVENTIONAL,['NA'],,Suitability for molecular analyses
3830,NCT05371197,Pathological complete response (pCR) rates,2022-05-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,Drug feasibility
3831,NCT04694391,genomic characteristics of relapsed esophageal cancer,2012-09-14,UNKNOWN,OBSERVATIONAL,['NA'],,
3832,NCT00548626,Evaluate if the early change of needle during EUS-FNA for suspected pancreatic cancer can reduce the number of passes needed to obtain a preliminary cytological diagnosis of neoplasia.,2007-10,COMPLETED,INTERVENTIONAL,['NA'],,Influence of different factors in obtaining a positive cytological result
3833,NCT01276795,Protein balance,2010-01,COMPLETED,INTERVENTIONAL,['NA'],,
3834,NCT00801320,To gain experience in appropriate clinical processing of tumor samples and determining cell yield.,2008-09,COMPLETED,INTERVENTIONAL,['NA'],,"Based on feasibility of collection of blood samples of subjects, quantification of T cell subsets, regulatory T cells, activated memory effector cells, and DC phenotype at pre-surgery and post-surgery time points."
3835,NCT06126406,Obtained the recommended dose and infusion regimen of CAR-T cells for the treatment of patients with CEA-positive advanced malignancies[Safety and Tolerability],2023-11-06,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival(OS)of CEA CAR-T treatment in patients with CEA-positive advanced malignancies[Effectiveness],Pharmacodynamics of CEA CAR-T cells[Cell dynamics]
3836,NCT03545711,ORR,2018-05-26,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,PFS
3837,NCT03137706,Young's modulus (stiffness) on fresh tissue,2016-11-14,TERMINATED,OBSERVATIONAL,['NA'],,
3838,NCT03473574,Objective response rate (ORR),2018-05-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life
3839,NCT01243619,Feasibility: Determined by the Number of Participants Who Had All Three Sets of Completed Serial PET Scans That Were Imported for Analysis,2010-08,COMPLETED,INTERVENTIONAL,['NA'],"Analyze Correlation Between FDG and FLT PET Scans, and the Correlation Between Both Types of PET Scan and the Response to Treatment.",
3840,NCT02319187,progression free survival,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,quality of life
3841,NCT00582335,Evidence of mutations in selected candidate genes,1998-02-10,COMPLETED,OBSERVATIONAL,['NA'],,
3842,NCT06165380,Objective Response Rate,2023-10-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety
3843,NCT06120127,Progression free survival,2023-09-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Grade 3-4 adverse effect rate
3844,NCT03971747,Incidence of treatment related adverse events as assessed by CTCAE v4.0[Safety of C-TCR055],2019-08-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],DCR,OS
3845,NCT01555489,Safety of Ascorbic Acid in Combination With Gemcitabine and Erlotinib for Stage IV Pancreatic Cancer,2011-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Evaluate Quality of Life Using Functional Assessment of Cancer Therapy-General (FACT-G) Quality Assessment Instrument
3846,NCT05989724,MTD (Maximum tolerable dose) / RP2D (Recommended dose for phase II),2023-09-19,RECRUITING,INTERVENTIONAL,['PHASE1'],SON-DP concentration in tumor biopsy tissue,CL
3847,NCT06221878,Short-term outcome,2009-01,COMPLETED,OBSERVATIONAL,['NA'],,Long-term Oncologic outcome
3848,NCT04659148,Oncological outcome,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,
3849,NCT05245968,Progression-free survival (PFS),2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Metabolite ratio
3850,NCT01096745,Time to progression,2010-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,Response rate Overall survival Safety profile
3851,NCT00585221,Time to Progression (TTP).,2007-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,
3852,NCT05888675,Overall survival,2016-07-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Immune function
3853,NCT02913066,Complete Remission Rate (CR),2016-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Progression-Free-Survival (PFS)
3854,NCT03308773,Time to development of type 2 diabetes,2009-01-05,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
3855,NCT02246049,Progression-free survival (PFS) at 10 months,2014-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Treatment duration
3856,NCT04835142,ORR,2021-02-24,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Overall survival (OS)
3857,NCT05253313,One-year survival after randomization,2022-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
3858,NCT00047710,"Safety of combination Radiation, Bevacizumab, and Capecitabine.",2002-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,To evaluate quality of life in patients receiving this therapy.
3859,NCT00660205,,2008-02,COMPLETED,OBSERVATIONAL,['NA'],,
3860,NCT03385577,Program Acceptability - Plan to continue intervention exercises after completion of the study,2018-02-05,COMPLETED,INTERVENTIONAL,['NA'],,Depressive Symptoms
3861,NCT03387904,Disease Control Rate (DCR),2019-01-13,UNKNOWN,INTERVENTIONAL,['PHASE2'],,NGS(Next Generation Sequencing) detecting
3862,NCT00003704,overall survival,1999-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3863,NCT03829969,OS,2019-01-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Patient-Reported Outcomes collected via the EORTC QLQ-OES18
3864,NCT02385630,Post-prandial satiety gut hormone area under the curve,2015-03,COMPLETED,INTERVENTIONAL,['NA'],,Fasting ghrelin concentration
3865,NCT02233374,Predictive value of PET/CT and MRI 2 weeks into chemo-irradiation for developing a pathologic complete response at surgery.,2014-09,COMPLETED,INTERVENTIONAL,['NA'],,Impact of pCR rates on long term disease control
3866,NCT03274011,Progression Free Survival,2017-07-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Response Rate
3867,NCT03221127,Death,1984-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Infectious disease
3868,NCT00077142,Maximum Tolerated Dose (MTD) of TAC-101,2001-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
3869,NCT01927341,Overall Response Rate (ORR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Based on Local Radiology Assessment: Phase 2,2013-11-19,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
3870,NCT02178436,Overall Survival (Phase II),2014-10-31,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Change in Gene Expression (Including Forkhead Box Protein O, I-kappaB, Cyclin-dependent Kinase Inhibitor 1B, Par4 and Phosphorylated Signal Transducer and Activator of Transcription 3) (Phase II)",Progression Free Survival (Phase II)
3871,NCT03606928,Objective response rate,2018-07-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Safety: adverse events as assessed by CTCAE v4.0
3872,NCT00891878,Comparison of Progression-free Survival,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Response
3873,NCT02780648,Acute toxicity rates of grade 3 gastrointestinal and hematologic toxicities (as raw percentage),2016-05-01,COMPLETED,INTERVENTIONAL,['NA'],,Patient self-report of quality of life
3874,NCT00789958,Stratum-specific (R0 and R1) 2-year Overall Survival,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,2-year Overall Local Relapse Rate
3875,NCT00630084,"Efficacy - Sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period.",2006-08,COMPLETED,INTERVENTIONAL,['PHASE4'],,Safety - adverse event rate and profile
3876,NCT04362839,Recommended dose level of the combination,2020-05-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Immune response,Objective response rate (ORR)
3877,NCT05862792,Postoperative Dysphagia with Dysphagia Survey,2023-06-01,RECRUITING,OBSERVATIONAL,['NA'],,Postoperative Pain Medication Usage
3878,NCT06123117,cumulative opioid consumption during the stay at the recovery,2024-01-16,RECRUITING,INTERVENTIONAL,['NA'],pain-control failure & possible causes,cumulative opioid consumption (emergency and inpatient surgery)
3879,NCT00084643,"MTD of the combination of GTI-2040, oxaliplatin and capecitabine based on the incidence of dose-limiting toxicity (DLT) as assessed by CTCAE version 3.0",2004-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Change in biochemical and molecular correlates
3880,NCT05699655,Pathological complete response,2023-05-10,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Objective Response Rate (ORR)
3881,NCT04443036,PFS,2020-06-11,UNKNOWN,INTERVENTIONAL,['NA'],,Adverse events
3882,NCT01591733,Rate of R0 Resection,2012-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Utilization of Health Services (Emergency Room, Hospital and Intensive Care Unit)"
3883,NCT00617708,Progression-Free Survival,2008-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Toxicity
3884,NCT05697198,The percent adoption of the OmniSeq next generation sequencing (NGS) testing platform in an advanced cancer patient population compared to baseline over a 2 year period,2021-04-19,RECRUITING,OBSERVATIONAL,['NA'],,
3885,NCT03416322,Adenoma detection rate,2018-02-01,UNKNOWN,INTERVENTIONAL,['NA'],,Boston Intestinal Preparation Scale
3886,NCT03223779,The Duration of Local Control,2017-10-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Serial ctDNA
3887,NCT00516347,"Gene-environment interactions, such as smoking, alcohol, and Helicobacter pylori status, on familial susceptibility to heartburn and Barrett's esophagus",2002-06,UNKNOWN,OBSERVATIONAL,['NA'],,Comparison of the mortality from esophageal adenocarcinoma in family members with heartburn and Barrett's esophagus with deaths from other causes
3888,NCT06335576,C-index,2024-03-31,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Sensitivity and specificity of model
3889,NCT05595122,Stentdysfunction after technical successful EUS-CDS,2022-12-02,RECRUITING,INTERVENTIONAL,['NA'],,Costs
3890,NCT01783951,Progression free survival（PFS）,2013-02-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life
3891,NCT05472948,Progression-free survival (PFS),2023-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety variables (Incidence of Adverse Events [Safety and Tolerability])
3892,NCT05447715,Sequential treatment of PFS with furoquitinib in second-line (F-C group) versus third-line (C-F group),2022-08-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
3893,NCT01525771,Maximum tolerated dose,2011-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,efficacy
3894,NCT03114631,Number of Participants Who Survived at 1 Year,2017-01-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants Who Survived at 3 Years or more
3895,NCT00718354,Event Free Survival (EFS) - Composite endpoint of overall survival plus free of symptomatic VTE .,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Incidence of SVTE Overall survival Major and minor haemorrhages during chemotherapy and / or up to 30 days after last dose is provided. Serious adverse events, All reported adverse events HIT"
3896,NCT00080951,tumor response rate,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,quality of life
3897,NCT03950609,Objective response rate,2019-07-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
3898,NCT03477019,difference in measured response between treated and untreated lesions,2018-11-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Occurrence of adverse effects
3899,NCT01172028,Maximum-tolerated dose (MTD) of combination ALIMTA and Taxotere,2005-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Antitumor activity
3900,NCT01005199,Progression-free survival,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Correlation between vitamin B12 and overall survival
3901,NCT05176223,Time to progression,2022-01-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,
3902,NCT01248637,correlation of intratumoral hypoxia with patient survival rate,2010-10,COMPLETED,OBSERVATIONAL,['NA'],,to assess utility of circulating osteopontin and miR-210 for identifying hypoxia
3903,NCT00814242,tumor recurrence rate in one or two years; Disease-free survival;Overall survival.,2008-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"Overall survival rate in one, two，three or five years; Disease-free survival in one, two，three or five years; hepatic function of patients after surgery, the incidence rate of complications and the decline level of serum AFP concentration."
3904,NCT05320029,Number of Participants With Anastomosis Success,2018-08-30,COMPLETED,INTERVENTIONAL,['NA'],,
3905,NCT05142033,Percent of patients referred for molecularly targeted clinical trials,2021-11-01,RECRUITING,OBSERVATIONAL,['NA'],,Percent of patient participating in microbiome collection and analysis
3906,NCT02586285,Time to tumor recurrence,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Overall survival
3907,NCT00715325,To determine the success rate in reaching within working distance of the Cecum with no complications.,2008-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"To assess the ability to perform routine therapeutic interventions such as biopsies, polypectomies, APC etc. as compared to therapeutic interventions with standard colonoscopes found in the literature."
3908,NCT04982276,Objective response rate (ORR),2021-07-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of subjects who develop detectable anti-drug antibodies (ADAs)
3909,NCT00551421,"Objective Tumor Response Rate Defined as the Proportion of Patients With a Best Overall Response of CR or PR, Per RECIST Criteria (Phase II)",2007-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
3910,NCT03946917,Objective response rate (ORR),2019-03-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Intestinal microorganism
3911,NCT00118261,Number of patients that develop study drug related toxicity,2005-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of patients that can increase the erlotinib dose to 200mg
3912,NCT00030511,,2001-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
3913,NCT01481805,Biomarkers predictive,2010-01-14,COMPLETED,OBSERVATIONAL,['NA'],,The RTK activation status.
3914,NCT02415023,safety and tolerance,2014-11-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pharmacokinetic profiles of Fruquintinib combined with Paclitaxel
3915,NCT04971525,Cumulative Occurrence of Malignancies in CD Participants With PAF,2023-04-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Number of Participants With Comorbidities
3916,NCT01038154,all cause mortality,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],,free time of disease recurrence
3917,NCT05755594,Rate of long-term Survival,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Incidence of postoperative complications
3918,NCT05107219,Cyclic guanosine monophosphate (cGMP) levels,2022-10-25,RECRUITING,INTERVENTIONAL,['PHASE1'],Cellular response,Vasodilator-stimulated phosphoprotein (VASP) phosphorylation in normal appearing duodenal mucosa
3919,NCT06285019,objective response rate (ORR),2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,adverse event (AE)
3920,NCT06283303,Treatment Emergent Adverse Event（TEAE）,2024-04-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-free survival (PFS)
3921,NCT01836913,"Preventable locoregional recurrence by the use of PET/CT-based treatment planning, instead of CT-based",2009-05,COMPLETED,OBSERVATIONAL,['NA'],,Cost-effectivity analyses
3922,NCT01774851,Progression Free Survival (PFS),2013-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,
3923,NCT05575986,Days required for platelet recovery to ≥75×10^9/ L,2022-10,RECRUITING,INTERVENTIONAL,['PHASE4'],,Safety of treatment
3924,NCT02428907,patient perception of colonoscopy,2012-10,COMPLETED,OBSERVATIONAL,['NA'],,Staff perception of teamwork
3925,NCT03491878,R0 rescetion rate,2018-05-01,UNKNOWN,INTERVENTIONAL,['NA'],,
3926,NCT05138302,OS,2021-04-19,UNKNOWN,OBSERVATIONAL,['NA'],,
3927,NCT02345746,Determine response rate,2012-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
3928,NCT04093141,2-year survival proportion from 1) diagnosis and 2) IRE,2019-05-01,RECRUITING,INTERVENTIONAL,['NA'],,Nutritional status assessment (PG-SGA-SF)
3929,NCT01643499,DLT rate in course 1 for each of the two most common genotype groups (*1*1 and *1*28),2012-03-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,Cumulative dose intensity of irinotecan hydrochloride
3930,NCT05103020,curative-intent resection rate,2021-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall response rate (ORR)
3931,NCT00578396,Expression and cellular localization of beta-catenin in intestinal mucosa: localization of β-catenin. Expression of Wnt pathway target genes in intestinal mucosa: Wnt target gene expression,2007-12,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Monitor resveratrol content of grapes throughout the course of the study. Grapes will be obtained from the same source as participants monthly throughout the study and the content of resveratrol will be measured.
3932,NCT04341012,Utility of breath profiles for disease diagnosis or prognosis,2019-09-10,COMPLETED,OBSERVATIONAL,['NA'],,
3933,NCT04317352,Mortality,2019-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
3934,NCT02417753,Changes in Immune Parameters in the Malignant Ascites of Patients With Advanced Cancer Following Therapy With AZD9150,2015-04-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival (PFS) in Patients With Malignant Ascites Treated With AZD9150
3935,NCT02880306,the risk of developing hepatocellular carcinoma,2014-07,COMPLETED,OBSERVATIONAL,['NA'],,
3936,NCT04329494,Incidence of adverse events,2020-08-21,RECRUITING,INTERVENTIONAL,['PHASE1'],,Cytoreductive surgery rate (Arm 3)
3937,NCT05443841,number of patients who had positive pleural lavage cytology,2022-07-18,RECRUITING,OBSERVATIONAL,['NA'],,Time period from date of surgery to the date of death
3938,NCT02461979,number of HCC patients with abnormal (APAL) VDR polymorphism,2015-02,UNKNOWN,INTERVENTIONAL,['NA'],,
3939,NCT02148549,Number of participants with toxicity of FIRINOX therapy as neoadjuvant chemotherapy for borderline resectable pancreatic cancer.,2014-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,The optimal treatment schedule of FIRINOX therapy as neoadjuvant chemotherapy for borderline resectable pancreatic cancer.
3940,NCT05593458,Major Pathological Response rate,2023-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,pathological Complete Response rate
3941,NCT04443543,clinical complete response rate,2020-06-22,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,overall survival
3942,NCT05916261,Disease control rate (DCR),2023-04-26,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,overall survival (OS)
3943,NCT01133990,Phase 1b: Number of Participants With Clinically Significant Change From Baseline in Electrocardiograms (ECGs) Parameter,2010-03-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Overall Survival (OS)
3944,NCT04599777,Overall survival (OS),2020-10-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,DOR assessed by investigators according to mRECIST.
3945,NCT06152263,"Microvascular density differences between the atrophic and non-atrophic mucosa, as well as cancerous and non-cancerous mucosa",2023-09-30,RECRUITING,OBSERVATIONAL,['NA'],,
3946,NCT05621824,Number of Participants with no clear pancreas lesions,2022-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Number of Participants with other pancreas diseases
3947,NCT04744649,Major pathologic response (MPR),2021-03-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse event incidence rate
3948,NCT00713128,frequency of delayed emesis (vomiting/retching),2008-04,COMPLETED,OBSERVATIONAL,['NA'],,"Freq. of mild-severe nausea D 2-6 Freq. use of antiemetics D 2-6, Pts.with complete response(no emesis/use of rescue antiemtics)D 1, Pts. with total control (no:emesis,nausea, use of rescue antiemetics)D 2-6, Overall satisfaction"
3949,NCT05746195,Feasibility of Intervention Measure (FIM),2023-11-03,RECRUITING,INTERVENTIONAL,['NA'],,Change in mean total daily fiber intake (g/d) reported on the Food Frequency Questionnaire (FFQ)
3950,NCT06072287,Illness-related distress,2023-06-28,RECRUITING,OBSERVATIONAL,['NA'],,Cognitive and Behavioural Responses to Symptoms
3951,NCT02845999,number of patients with clinical or biological grade 3 or 4 treatment-related adverse events as assessed by CTCAE v4.0,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3952,NCT03360695,Disruptions in Cancer Care,2017-12-11,COMPLETED,INTERVENTIONAL,['NA'],,PHQ-9
3953,NCT05174117,3 month objective response rate,2022-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,3 month Quality of Life score
3954,NCT04007744,Response rate of sonidegib in combination with pembrolizumab (Part B),2020-02-13,RECRUITING,INTERVENTIONAL,['PHASE1'],Level of serum soluble PDL-1,Progression-free survival (PFS)
3955,NCT00842257,Response Rate of Single Agent Panitumumab Among Patients With KRAS Wild-type Colorectal Cancer Previously Treated With Cetuximab.,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Control Rate as Defined by RECIST Criteria
3956,NCT02834013,Overall response rate (ORR),2017-01-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression free survival (PFS)
3957,NCT03200821,Survival,2000-08-14,COMPLETED,INTERVENTIONAL,['PHASE3'],,Gastrin-17 Antibodies
3958,NCT04843215,Disease Free Survival(DFS),2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],Postoperative morbidity,Overall Survival(OS)
3959,NCT00111761,Number of Participants With Grade 3 or Grade 4 Diarrhea (Part 1),2002-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Initial Objective Tumor Response (Part 1)
3960,NCT00556803,Overall survivals,2007-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Recurrence rates
3961,NCT00834236,Number of Participants With Accurate Diagnosis for Gastric Cancer,2008-03,COMPLETED,INTERVENTIONAL,['NA'],,
3962,NCT06078982,Objective response rate (ORR),2023-06-06,RECRUITING,INTERVENTIONAL,['PHASE1'],,Drug-related safety indicators
3963,NCT05823987,Objective Response Rate (ORR) evaluated by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1,2023-05-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
3964,NCT03988998,the 2-years recurrence rate,2022-01-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,the 2-years overall survival.
3965,NCT01642446,Overall survival,2013-01,COMPLETED,INTERVENTIONAL,['NA'],,Quality of life(Qol)
3966,NCT04920019,Amount of postoperative opioid consumption,2020-10-22,COMPLETED,INTERVENTIONAL,['NA'],,Mortality
3967,NCT02704988,Increased lymph node sample,2015-03,COMPLETED,INTERVENTIONAL,['NA'],,Indication for adjuvant treatment
3968,NCT00001191,,1983-02-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3969,NCT03082378,survival,2017-03-01,UNKNOWN,OBSERVATIONAL,['NA'],,complication
3970,NCT04908813,Objective Response Rate (ORR) per RECIST 1.1 assessed by IRRC,2021-09-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events (AE)
3971,NCT06079242,Liver-specific overall response rate (ORR) according to RECIST 1.1,2023-10-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Duration of liver-specific DOR assessed by the investigator
3972,NCT01912222,Number of Participants Reporting Clinically Significant Change From Baseline in Vital Signs,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3973,NCT00789841,Gastrointestinal transit time in NET patients,2008-09,COMPLETED,OBSERVATIONAL,['NA'],,Changes in carcinoid symptoms and biomarkers
3974,NCT05628610,objective response rate,2022-11-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,progression free survival
3975,NCT02529579,6-month SR,2015-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Serum tumor biomarker,QOL
3976,NCT00262769,Overall Survival,2005-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Toxicity
3977,NCT05854368,"Characterization and validation of a signature combining plasmatic proteins related to inflammation and carcinogenesis process, associated with the presence of gastric mucosal dysplasia lesions compared with an H. pylori negative control group.",2023-07-03,RECRUITING,INTERVENTIONAL,['NA'],,"Characterization of the plasma levels of the proteins biomarker composing these signatures specific for the different stages of gastric cancer cascade, between the different studied pathology groups"
3978,NCT03813381,Body weight change,2015-11,COMPLETED,INTERVENTIONAL,['NA'],,Waist circumference reduction
3979,NCT02399228,"Patients Achieving Less Than or Equal to ""2"" RTOG Score At Visit 9",2015-10-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Safety Will be Assessed Based on the Frequency and Severity of Adverse Events.,NRPS (Numerical Rating Pain Scale)
3980,NCT01257360,Rate of pathological complete remissions,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Correlative biomarker analyses
3981,NCT02426450,Safety and Tolerability,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
3982,NCT05427383,Overall Survival (OS) according to RECIST 1.1 by IRC,2022-04-07,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Change from baseline in CA72-4 (carbohydrate antigen 724),Incidence of neutralizing Antibody，Nab
3983,NCT05350007,Tanatophobia,2022-05-25,RECRUITING,OBSERVATIONAL,['NA'],,lack of social support
3984,NCT04247165,"Incidence of treatment-related AEs, SAEs, AEs leading to discontinuation, death, and laboratory abnormalities",2020-06-02,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Rate of downstaging to surgical resection
3985,NCT01471132,Overall Survival,2011-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety
3986,NCT01924260,"Dose-limiting toxicity (DLT) defined as any related (possibly, probably, or definitely) grade 3 non-hematological toxicity or any attributable grade 4 toxicity graded according to the National Cancer Institute (NCI) CTCAE version 4.0",2013-08-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Maximum-tolerated dose (MTD) defined as the maximum dose level at which less than 2 patients experience DLT graded according to NCI CTCAE version 4.0
3987,NCT00539877,"The objectives of this study are to assess the feasibility, to determine the maximum tolerated dose, and to assess the toxicities of intraperitoneally administered CPT-11 in gastric cancer patients with peritoneal seeding.",2004-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3988,NCT02503969,Individual attended colorectal cancer screening,2015-09,COMPLETED,OBSERVATIONAL,['NA'],,Individual accepted colorectal cancer screening after refusing the initial invitation for colorectal cancer screening
3989,NCT02784639,Area under ROC curve,2013-10,COMPLETED,INTERVENTIONAL,['NA'],,
3990,NCT00047346,"Pharmacokinetic (PK) and pharmacodynamic profile, as measured by Cmax, Tmax, AUC0-24, AUC0-infinity, Cl/F, T1/2, accumulation ratio, and Cssmin",2002-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Objective response rates (partial, complete, stable disease), as measured by CT scans using RECIST criteria"
3991,NCT04495621,Best overall response rate (ORR) according to RECIST v.1.1,2020-07-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of treatment emergent adverse events (TEAEs)
3992,NCT05677113,The primary outcome will be the 2-year Progression-Free Survival (PFS) rate,2023-08-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,Five-year overall survival
3993,NCT02672657,Changes in burden of patients' caregivers as assessed by the Zarit burden inventory questionnaire,2016-02,UNKNOWN,OBSERVATIONAL,['NA'],,"Prognostic value of baseline HRQoL measurements on patient's functional decline, defined as any decrease in the ADL scale"
3994,NCT02450032,Change in Subject's World Health Organization Performance Status,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse Events
3995,NCT04076761,Median progression-free survival (PFS),2019-12-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of life: European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30
3996,NCT00477880,Response,2001-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3997,NCT03728348,"Specificity of the Multi-target Stool DNA Test in Average Risk Population, Ages 45-49",2018-11-06,COMPLETED,OBSERVATIONAL,['NA'],,
3998,NCT03521765,WHOQOL-BREF(the World Health Organization Quality of Life-BREF),2017-07-01,COMPLETED,INTERVENTIONAL,['NA'],,Barthel Index (BI)
3999,NCT00735241,Toxicity and safety,2008-07,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
4000,NCT00452751,overall survival,2006-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,cost-effectiveness
4001,NCT02449967,Number of participants with Adverse events,2015-05,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
4002,NCT01542294,chemotherapy complete rate,2011-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall survival(OS)
4003,NCT00902291,Survival rate at 6 months,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Control (Stable Disease or better per RECIST criteria)
4004,NCT05888623,Adenoma Detection Rate,2022-10-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],Bowel preparation quality,Adenocarcinoma detection rate
4005,NCT05052099,Overall response rate (ORR),2021-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence and severity of adverse events (AEs) (with severity determined according to NCI CTCAE v5.0)
4006,NCT03748134,OS in PD-L1 positive population,2018-12-24,COMPLETED,INTERVENTIONAL,['PHASE3'],,PFS - PD-L1 positive
4007,NCT04009876,cCR (clinical complete response) rate in LARC ( locally advanced rectal cancer ) patients treated with chemo - chemoradiation.,2019-05-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall toxicity
4008,NCT04338763,Determination of the maximum tolerated dose (MTD) and the recommended dose for phase II of RP72 monotherapy and RP72 in combination with Gemcitabine,2021-04-19,RECRUITING,INTERVENTIONAL,['PHASE1'],,
4009,NCT05152147,Overall survival,2021-12-02,RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence of anti-drug antibodies (ADAs)
4010,NCT03918499,Progression-free Survival,2019-04-19,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Response
4011,NCT03136406,Objective response rate by irRC,2017-08-14,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Incidence of treatment-emergent AEs, SAEs, graded using the NCI CTCAE Version 4.03."
4012,NCT02182778,Overall survival rate,2014-07-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants with Adverse Events as a Measure of Safety
4013,NCT00872014,Progression free survival (PFS) rate at 4 months,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Baseline values of and changes from baseline in pharmacodynamic, immunologic, biochemical, transcriptional, pharmacogenetic and angiogenic markers"
4014,NCT03098758,specific markers in peritoneal cells,2017-05-08,UNKNOWN,OBSERVATIONAL,['NA'],,
4015,NCT01325961,Medico-economic study : medical cost differential between 3 ways of Radiotherapy by IMRT (helical tomotherapy and dynamic arc therapy : RapidArc and VMAT).,2011-03,COMPLETED,INTERVENTIONAL,['NA'],,clinical response and safety of the treatment by radiotherapy
4016,NCT04352894,Best modality of ICG injection,2020-09,UNKNOWN,INTERVENTIONAL,['NA'],,Sensitivity of ICG fluorescence
4017,NCT02651987,Median Progression Free Survival (PFS),2015-12-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Mean Change From Baseline in PanNet Specific Tumour Biomarkers: Glucagon
4018,NCT05796700,Progession-free survival,2008-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
4019,NCT02466724,Patients with Excelent Colonoscopy preparation,2015-03,COMPLETED,INTERVENTIONAL,['NA'],,Use of web-based educational platform
4020,NCT04189809,Rate of therapeutic proposals correctly predicted by the BCLC international classification,2019-11-30,UNKNOWN,OBSERVATIONAL,['NA'],,Rates and causes of discrepancies
4021,NCT00964080,To determine the dose of MBP-426 for use in the Phase II portion of this study of MBP-426 administered every 21 days in combination with leucovorin (folinic acid or FA) and fluorouracil (5-FU),2009-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To characterize the safety profile of the combination therapy
4022,NCT04109573,Manometric indices,2018-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,Patient reported outcomes
4023,NCT03998033,The recommended phase 2 dose (RP2D) regimen of ET140202 T-cell therapy,2019-05-30,TERMINATED,INTERVENTIONAL,['PHASE1'],,Assess the persistence of ET140202 T cells circulating in blood over time.
4024,NCT01552226,Post-operative pain control day 5,2010-01,UNKNOWN,INTERVENTIONAL,['NA'],,Patient use of supplemental narcotic analgesia day 5
4025,NCT06232759,Progression-free survival,2022-04-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
4026,NCT00436774,Quality of life (QOL) as measured by pediatric cancer quality-of-life inventory or Short Form 36 questionnaires,2006-06,UNKNOWN,OBSERVATIONAL,['NA'],,
4027,NCT06276153,overall survival,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,progression-free survival
4028,NCT04564313,Objective Response Rate (ORR),2020-09-21,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Graft Rejection (GR)
4029,NCT03139487,Rate of clinical relevant bleeding,2017-08-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Time to recurrent or aggravated venous thromboembolism
4030,NCT00052910,Overall Survival,2002-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Disease Free Survival
4031,NCT01926444,"Measurements of Visceral Pain, Using a 100-mm Visual Analog Scale (VAS)",2013-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Subject Satisfaction and Acceptability of the Colonic Analgesia - Patient's Global Impression of Abdominal Pain
4032,NCT02551991,Part 1A: Number of Participants With Dose-Limiting Toxicities (DLT),2015-10-19,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Duration of Response (DoR)
4033,NCT04038736,Evaluation of the performance of the C-scan System in detecting polyps≥10 mm compared to FIT results,2019-12-26,COMPLETED,INTERVENTIONAL,['NA'],,
4034,NCT05640791,Incidence of adverse events,2022-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
4035,NCT02728427,Catherization time,2016-04,UNKNOWN,INTERVENTIONAL,['NA'],,Catheter obstruction
4036,NCT04958044,Safety,2021-05-25,COMPLETED,INTERVENTIONAL,['PHASE1'],,90 days survival
4037,NCT06076811,The prognostic value of ctDNA status,2023-08-01,RECRUITING,OBSERVATIONAL,['NA'],,Molecular characterization
4038,NCT02902575,Morbidity,2016-09-01,COMPLETED,INTERVENTIONAL,['NA'],,Adverse events
4039,NCT04721301,Number of participants and severity of treatment-related adverse Events as assessed by CTCAE v4.0,2017-01-15,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tissue Response
4040,NCT02215044,Occurence of dose limiting toxicity according to CTCAE,2007-06,TERMINATED,INTERVENTIONAL,['PHASE1'],,Tumor marker (CA19-9) response to treatment with BI 2536 and gemcitabine
4041,NCT05428553,Adverse events,2022-06-01,UNKNOWN,INTERVENTIONAL,['NA'],Number of clips,Recurrence after 6 months
4042,NCT01565811,complication rate,2010-08,COMPLETED,OBSERVATIONAL,['NA'],,To evaluate prognostic significance of perihepatic LN involvement with overall survival and disease free survival
4043,NCT03907527,Maximal tolerated dose of PRGN-3005,2019-04-30,RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of PRGN-3005 T Cells
4044,NCT01943864,Number of Participants With Indicated Non-progressive Disease as Assessed by Independent Radiologist Per Response Evaluation Criteria In Solid Tumor Version 1.1 (RECIST 1.1) at Week 12,2013-09-19,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Independent Radiologist Assessed Duration of Response
4045,NCT01411826,Feasibility,2011-07,COMPLETED,INTERVENTIONAL,['NA'],,Colon cancer screening attitudes
4046,NCT01658436,Stage 1 - Progression Free Survival (PFS) Rate Analysis at 16 Weeks as Per Local Radiology Review,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Stage 1 - Disease Control Rate
4047,NCT05014360,Percentage Change from Baseline in Colorectal Polyp Burden for Polyps >=2 mm at Week 24,2021-11-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Levels of JAK/STAT Pathway Signaling Effector Proteins including pSTAT-3 Relative to Baseline Levels in Colorectal Polyps
4048,NCT02430701,Number of participants with Adverse events,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Overall survival (OS)
4049,NCT06041945,Non-inferiority in Adenoma Detection Rate,2023-09-21,RECRUITING,INTERVENTIONAL,['NA'],,Change in the cost of polypectomy and histology in screening programs
4050,NCT03137628,metabolomics,2017-03-20,UNKNOWN,OBSERVATIONAL,['NA'],,
4051,NCT02856568,"MTD of ricolinostat or a dose up to 240 mg/day whichever is lower, of ACY-1215",2017-05-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Laboratory correlates measured from tissue by immunofluorescence,Time to treatment failure
4052,NCT06133023,Clinical success within 180 days of randomisation,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Incidence of new pancreatic cancer
4053,NCT00586989,1. The number of patients and the number of lesions with HGD or early ACA detected with WLE and ETMI 2. The number of patients with HGD and early ACA detected with targeted biopsies only with ETMI and WLE,2007-12,COMPLETED,OBSERVATIONAL,['NA'],,1. The positive predictive value (PPV) of HRE and AFI 2. The reduction of false-positive findings after NBI (both the initial in vivo NBI assessment as well as later assessment based on still images)
4054,NCT05240950,Efficacy (recurrence-free survival),2022-08-25,RECRUITING,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics (PK) indicator (AUC)
4055,NCT01193452,response rate,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of Participants with Adverse Events as a Measure of Safety and Tolerability
4056,NCT01910610,Duration of Disease Control (DDC),2013-10-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Safety profile of each treatment sequence
4057,NCT03601351,Disease free survival.,2018-05-04,COMPLETED,OBSERVATIONAL,['NA'],,Perioperative complications.
4058,NCT03798769,Rates of completion,2019-01-31,COMPLETED,INTERVENTIONAL,['NA'],Progression free survival,Cumulative dose of FOLFIRINOX received
4059,NCT01026753,Fecal Occult Blood Test (FOBT) completion rate,2010-08,COMPLETED,INTERVENTIONAL,['NA'],,"The most common patient questions and comments about colorectal cancer, screening, and the fecal occult blood test during the intervention(s). A patient and primary care provider survey."
4060,NCT00966667,Normative influences of family and friends,2009-11,COMPLETED,OBSERVATIONAL,['NA'],,
4061,NCT02681601,Anthropometric measurement: Body Composition,2016-07-19,TERMINATED,INTERVENTIONAL,['NA'],,Quality of life: Appetite
4062,NCT02047474,Progression free survival rate,2014-03-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Objective response rate
4063,NCT02599103,The changs of metabolomics profile between before and after oil consumption,2013-09,COMPLETED,INTERVENTIONAL,['NA'],,
4064,NCT02503384,Annual caseload for pediatric liver transplantation,2015-07,UNKNOWN,OBSERVATIONAL,['NA'],,
4065,NCT02785523,"Assessing the quality of life(QOL) in 5 grades and recording: appetite, mental state, sleep, fatigue, pain, attitude towards treatment, daily life ability, treatment of severity of side effects.",2016-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Vanillylmandelic acid (VMA) in urine.
4066,NCT00165568,To compare the percent change in tumor radioactivity uptake and retention after radiolabeled fluorouracil administration in subjects who receive bevacizumab versus those who do not receive bevacizumab.,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,to evaluate the relationship between initial change in tumor radioactivity uptake and retention.
4067,NCT05781581,All-cause mortality at 30 days after operation,2023-03-19,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Major Adverse Cardiovascular Events (MACE)
4068,NCT01955122,Adenoma and Polyp Miss Rate,2013-07,COMPLETED,INTERVENTIONAL,['NA'],,Patient Satisfaction
4069,NCT05420480,Overall survival(OS),2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Disease free survival (DFS)
4070,NCT01722903,Quantity of CTCs isolated during liver and/or lung metastasectomy,2012-08,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
4071,NCT04409990,SWE accuracy,2020-03-02,COMPLETED,INTERVENTIONAL,['NA'],,SWE and ADC measurement
4072,NCT05048017,Progression Free Survival (PFS),2021-10-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse Drug Reaction (ADR),Mortality at 12 months
4073,NCT02202928,Progress-free survival,2014-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Phenotypic analysis of T cells
4074,NCT01766986,Overall Survival,2008-01,COMPLETED,OBSERVATIONAL,['NA'],,
4075,NCT04780477,Change in Ki-67+ Level,2021-06-29,RECRUITING,INTERVENTIONAL,['NA'],,Change in CD68+ Lamina Propia Macrophages Count
4076,NCT01167049,Tumor response will be evaluated using RECIST criteria. Survival data will be analyzed by Kaplan Meier method. 95% CI will be provided,2009-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
4077,NCT02487992,Overall Survival(OS),2015-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events,Disease-free survival
4078,NCT01248663,Delayed gastric emptying,2007-04,COMPLETED,INTERVENTIONAL,['NA'],,Measurement of plasma intestinal peptides
4079,NCT01248403,overall survival,2011-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,disease control rate
4080,NCT05856864,Adverse Events（AEs）,2023-06-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,
4081,NCT03705013,The number of subjects with discordant results that can be attributed to intercurrent disease,2018-10-30,TERMINATED,OBSERVATIONAL,['NA'],,
4082,NCT01248273,To determine the maximum tolerated dose over three dose levels.,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,To record the progression free interval
4083,NCT00499850,"Safety and tolerability of ZD6474 in combination with 5-Fluorouracil, Leucovorin and Oxaliplatin",2005-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4084,NCT01114035,gene identification,2010-04,COMPLETED,INTERVENTIONAL,['NA'],,mutation identification
4085,NCT00040833,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4086,NCT04195828,major pathological response,2020-06-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,R0 resection rate
4087,NCT01251640,Tumor Response (Adjudicated Blinded Read Assessment): Phase II,2011-01-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS): Phase II
4088,NCT05770739,postoperative length of stay,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],,30-day readmission rate
4089,NCT00427089,"Efficacy was measured as the degree of cleansing using a 5 grades scale for each of the predefined colon areas resulting into a final grading of the overall quality of gut preparation (A or B: ""success"" versus C or D: ""failure"").",2004-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Laboratory tests (such as blood chemistry and hematology) were conducted to support the safety data as well as measurement of body weight, blood pressure and pulse rate, but also tolerance."
4090,NCT00102011,Level of participation in screening with FOBT-directed colonoscopy vs a single colonoscopy,2000-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,
4091,NCT03902379,Examine feasibility of an online CCI as defined by participant's evaluation of the online intervention,2016-07-27,WITHDRAWN,INTERVENTIONAL,['NA'],,Examine acceptability of an online CCI
4092,NCT00215722,Determine the Efficacy of the combination treatment (cetuximab plus capecitabine and oxaliplatin) as first-line therapy based on the overall response rate (ORR) according to the RECIST criteria.,2005-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Evaluate the Quality of Life
4093,NCT06123156,the patient's response,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse and suspected adverse events
4094,NCT01693848,Effect of resection of metastasis on urinary excretion of modified nucleosides,2012-09,COMPLETED,OBSERVATIONAL,['NA'],,Identification of modified nucleosides as biomarkers for colorectal cancer
4095,NCT04014478,Visual Analog Scale Changes over the time,2019-07-15,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of Life Score Changes over the time
4096,NCT05392413,Imaging examination,2022-08-01,RECRUITING,OBSERVATIONAL,['NA'],,
4097,NCT06018246,Patient-generated subjective nutrition assessment,2021-07-20,COMPLETED,INTERVENTIONAL,['NA'],Adverse reaction,Walking time
4098,NCT00716976,Incidence of Hearing Loss,2008-06-23,COMPLETED,INTERVENTIONAL,['PHASE3'],,Hearing Loss Among Patients Carrying/Not-carrying Two Key Gene Mutations (TPMT and COMT)
4099,NCT03110484,Overall response rate,2021-07-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,
4100,NCT05821452,MPR rate,2023-05-25,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,PFS
4101,NCT02362048,Number of Participants With Overall Response Advanced or Metastatic Pancreatic Cancer.,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4102,NCT00332163,Percentage of Participants With Specific Grade 2 or Higher Skin Toxicities During the 6-week Skin Treatment Period,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change From Baseline in Overall Dermatologic Quality of Life Index (DLQI) Score
4103,NCT00865527,Proportion of enrolled patients who attend for their assigned screening test,2010-03,TERMINATED,INTERVENTIONAL,['NA'],,Proportion of patients found to have invasive colorectal carcinoma
4104,NCT02698137,procedure-related adverse events,2016-03,COMPLETED,OBSERVATIONAL,['NA'],,technical failure of the procedure
4105,NCT04271813,Objecitve response rate,2020-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease control rate
4106,NCT05255588,"Sensitivity and specificity of the EarlyTect® CRC test for detecting CRC compared to the colonoscopy, both in terms of detecting CRC.",2022-02-10,RECRUITING,OBSERVATIONAL,['NA'],,Clinical sensitivity of the EarlyTect® CRC for detecting Tis
4107,NCT04695262,EUS-E accuracy in terms of qualitative and quantitative elastography,2021-01-27,RECRUITING,OBSERVATIONAL,['NA'],,
4108,NCT00827580,the frequency of HFS; evaluation of eniluracil dose response; and assessment of any toxicity related to the topical product.,2009-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,
4109,NCT05129215,Area under the curve (AUC),2020-03-06,COMPLETED,OBSERVATIONAL,['NA'],Net reclassification index (NRI),Negative prediction value (NPV)
4110,NCT01741636,"Satisfaction with the timing, content, and delivery of the intervention",2013-01,COMPLETED,INTERVENTIONAL,['NA'],,
4111,NCT01804621,Colorectal cancer screening,2010-04,COMPLETED,INTERVENTIONAL,['NA'],,
4112,NCT01580202,The cumulative probability of HBV reactivation,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Incidence of hepatic decompensation and liver-related mortality
4113,NCT01519609,Degree of bowel cleansing,2011-09,COMPLETED,INTERVENTIONAL,['NA'],,
4114,NCT02773524,Overall Survival,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],Evaluation of regorafenib Maximum Plasma Concentration [Cmax] between Asia and Rest of World cohorts.,Rates of Adverse Events
4115,NCT01916239,Gene expression profiling in colon tissues,2012-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,microRNA expression profiling in colon tissues
4116,NCT02445209,Overall Survival,2010-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety as assessed by adverse events according to CTCAE v4.0
4117,NCT01446666,Detection Rate of Patients With HCC,2011-11,COMPLETED,OBSERVATIONAL,['NA'],,Positive Predictive Value for HCC
4118,NCT00398398,Overall Response Rate,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity Profile
4119,NCT05348187,therascreen® KRAS RGQ PCR Kit,2019-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,
4120,NCT01282658,,2010-11,UNKNOWN,OBSERVATIONAL,['NA'],,
4121,NCT06208046,5-year overall survival,2023-07-01,COMPLETED,OBSERVATIONAL,['NA'],,
4122,NCT00264446,,na,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4123,NCT01406249,Progression-free survival rate,2011-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety
4124,NCT05692284,Patient Identification Form,2022-02-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,SELF CARE ABILITY SCALE
4125,NCT00427375,"Compare the proportion of patients presenting at least 1 component of the composite outcome (4 components: death, recurrence, major morbidity and severe after effects) at 2 years after",2007-03-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of life (QLQ C30 - CR38)
4126,NCT05698459,MTD (Maximum Tolerance dose),2023-05-05,RECRUITING,INTERVENTIONAL,['PHASE1'],,Immunogenicity
4127,NCT01340508,Pathological complete response rates,2011-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Sphincter Preservation rates
4128,NCT05723965,accuracy of artificial intelligence with experienced physician,2010-10-01,COMPLETED,OBSERVATIONAL,['NA'],,real life survival outcome of diagnosis by artificial intelligence.
4129,NCT00513357,Change in Appetite as Measured by ESAS,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,
4130,NCT05922930,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",2023-10-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
4131,NCT06275204,Healthcare workers' assessment of feasibility and acceptability of the proposed practical implementation of a screening program,2024-03-04,RECRUITING,OBSERVATIONAL,['NA'],,Participation rate of subjects selected for the program
4132,NCT02474537,Vz/F of INC280,2015-06-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Unbound fraction and Vz/F based on unbound concentration in plasma
4133,NCT04046887,Frequency of Dose Limiting Toxicities (DLTs),2019-09-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,European Organization for Research and Treatment of Cancer quality of life questionnaire
4134,NCT02284802,accuracy of confocal endomicroscopy,2014-09-10,COMPLETED,INTERVENTIONAL,['NA'],,
4135,NCT05759325,Progression-free survival,2023-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
4136,NCT00034333,,2002-03,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
4137,NCT01832948,Objective Response Rate (ORR),2013-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events
4138,NCT02227914,Time To Progression (TTP) - Phase 2,2014-12,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS) - Phase 2
4139,NCT01039506,Progression free survival,2009-10-15,COMPLETED,OBSERVATIONAL,['NA'],,Safety events
4140,NCT00236249,"Readiness for discharge, checked twice a day",2005-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Clinical side effects twice a day
4141,NCT01648465,15 month PFS (Progression-Free Survival) rate,2012-08-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Association of biologic markers with disease progression
4142,NCT04931381,6-month disease control rate,2021-06-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Concordance between radiosensitivity test results and patients' treatment response (descriptive statistics).
4143,NCT02139215,The pharmacoeconomic impact of panitumumab for the treatment of metastatic colorectal cancer in a real-life setting,2014-04,COMPLETED,OBSERVATIONAL,['NA'],,
4144,NCT06060704,ORR（Objective response rate）,2023-11,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life: EORTC QLQ-C30
4145,NCT04789200,Marking and distension of the bowel lumen at CT of the abdomen,2020-08-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Delineation of bowel wall enhancement related to concurrent intravenous contrast at CT of the abdomen and pelvis
4146,NCT03104569,Number of participants with Acute cholangitis,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Number of participants with Post-ERCP pancreatitis
4147,NCT06130826,Recommended phase 2 dose,2024-06-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics of M5A-IL2 (M5A-ICK blood clearance )
4148,NCT02370849,Objective response rate as measured by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1),2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Treatment safety and toxicity as measured by Common Toxicity Criteria for Adverse Effects(CTCAE 3.0)
4149,NCT00804817,Health Related Quality of Life (HRQoL),2007-12,COMPLETED,INTERVENTIONAL,['NA'],,Symptom experience (Common Terminology Criteria for adverse events - CTCAE v. 3.0)
4150,NCT04646187,cumulative incidence of out-of-range fecal calprotectin results at 48 weeks follow-up,2021-03-11,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE4'],Patients' attitudes towards deprescribing anti-TNF agents,Identification of predictors of successful de-escalation.
4151,NCT02928224,"(Phase 3) Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors (RECIST), v1.1 of Triplet Arm vs. Control Arm",2016-10-13,COMPLETED,INTERVENTIONAL,['PHASE3'],(Phase 3) Overall Survival (OS) of Triplet Arm vs. Control Arm - Final Analysis,Phase 3: Number of Participants With Shifts in Left Ventricular Ejection Fraction (LVEF) From Baseline to Maximum Grade On-treatment
4152,NCT01929915,Perioperative immunoprofile,2013-07,COMPLETED,INTERVENTIONAL,['NA'],,survival rate
4153,NCT03251417,Disease control rate,2017-09-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Median overall survival time
4154,NCT00210249,Number of Participant Deaths,2002-09,COMPLETED,OBSERVATIONAL,['NA'],,
4155,NCT03812770,Progression Free Survival (PFS),2018-08-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse Events
4156,NCT05192018,Feasibility of early reversal of adefunctioning ileostomy,2021-12-25,UNKNOWN,INTERVENTIONAL,['NA'],,
4157,NCT04730544,Progression-free survival (PFS) at week 24 for two combination schemes.,2021-04-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Time to Health-related quality of life (HRQoL) score definitive deterioration (TUDD)
4158,NCT00529412,incidence of small bowel obstruction,2003-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,intraoperative and postoperative morbidity and mortality.
4159,NCT00215644,Percentage of Participants With Objective Response Assessed by Independent Review Committee,2005-08-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,Matuzumab Serum Concentration
4160,NCT00845884,response rate,2009-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Safety, PFS, overall survival"
4161,NCT01569620,"Change from baseline of colonoscopy at 3 months, 6 months, and 12 months.",2012-04,COMPLETED,INTERVENTIONAL,['NA'],,
4162,NCT03830606,objective response rate（ORR）,2016-03-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,safety profile: assessed by CTCAE v4.0
4163,NCT02869477,Survival of patients,2002-01,RECRUITING,OBSERVATIONAL,['NA'],,Collection of patients characteristics
4164,NCT03410641,"Incidence of the group of cancers related to smoking, diet or body mass index",1972-01-15,COMPLETED,OBSERVATIONAL,['NA'],,Incidence of prostate cancer
4165,NCT03039595,Correlation Between Tumour: Stroma Ratio With Local Recurrence of Cancer,2017-03-29,COMPLETED,OBSERVATIONAL,['NA'],,Correlation Between Tumour:Stroma Ratio and Overall Survival After TEM Surgery to Remove Rectal Cancer
4166,NCT05131815,Feasibility of BurnAlong,2022-01-10,COMPLETED,INTERVENTIONAL,['NA'],,Measure of Experiential Aspects of Participation (MeEAP)
4167,NCT04699539,1-year Local Control Rate (1y-LCR),2021-03-31,RECRUITING,INTERVENTIONAL,['NA'],,Overall Survival(OS)
4168,NCT04512209,Biophysical properties of the tumor tissue - measurement of hydraulic conductivity,2019-10-11,RECRUITING,INTERVENTIONAL,['NA'],,Measurement of Pt penetration
4169,NCT04062656,Rate of pathological complete responses,2019-09-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Patient-reported outcome (PRO)
4170,NCT02130752,Surgical duration,2014-10,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative Mortality and Morbidity
4171,NCT03152487,Subject assessment of abdominal pain,2017-04-24,COMPLETED,INTERVENTIONAL,['NA'],,Pain per the VAS tool.
4172,NCT03398122,PFS,2017-11-14,UNKNOWN,INTERVENTIONAL,['NA'],,QOL
4173,NCT00838578,Number of Participants With Serious and Other (Non-Serious) Adverse Events According to the CTCAE v.3.0,2009-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
4174,NCT00903136,Comparison of participants' satisfaction with the TCE vs esophagogastroduodenoscopy (Phase II),2009-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Results of the histologic analysis of any biopsy specimens (Phase II)
4175,NCT01715233,Response,2012-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
4176,NCT01795027,overall survival,2011-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Number of Participants with Adverse Events
4177,NCT01801904,number of patients alive and without disease progression,2012-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],gene expression on tumor tissue,worst grade toxicity per patient
4178,NCT05809869,Rate of abscopal effect,2023-02-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Distant control rate
4179,NCT05429203,Number of participants with procedure-related adverse events,2022-10-25,RECRUITING,INTERVENTIONAL,['NA'],,Ability to perform interventions
4180,NCT00405873,Best overall tumour response according to RECIST; within 20 weeks after registration; confirmation 6 +/- weeks later,2007-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Safety and Tolerability
4181,NCT01443260,"Determine safety of administering GL-ONC1 intraperitoneally by the evaluation of the number of patients experiencing Adverse Events (type, frequency, and severity)",2012-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Detection of Anti-tumor Activity
4182,NCT04187937,R0 resection rate,2020-06-17,TERMINATED,INTERVENTIONAL,['NA'],,Time for resection
4183,NCT05956847,Changes in ecDNA content in different gastric precancerous lesions,2023-08-10,RECRUITING,OBSERVATIONAL,['NA'],,
4184,NCT02529007,Number of polyps detected per patient,2014-09,COMPLETED,INTERVENTIONAL,['NA'],,Patient comfort score
4185,NCT03806218,Minimum diameter of ablation zone per unit time,2015-05-16,COMPLETED,INTERVENTIONAL,['NA'],Ablation time,Local tumor progression (LTP)
4186,NCT03202992,Maximum Tolerated Dose (MTD) of ABI-1968 for the treatment of aHSIL,2017-08-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Histopathology of areas with biopsy-proven disease following single and multiple doses of ABI-1968 Topical Cream.
4187,NCT00257426,Median survival,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,number of subjects with toxicities
4188,NCT02898649,Safety (frequency of procedure-related complication and death),2015-12,UNKNOWN,INTERVENTIONAL,['NA'],,Change in CA 19-9
4189,NCT02806661,Recurrence rate,2016-07,UNKNOWN,INTERVENTIONAL,['NA'],,Inflammatory factors
4190,NCT00564265,Number of Patients Who Survived,2008-01,COMPLETED,OBSERVATIONAL,['NA'],,
4191,NCT01912131,assess the acceptability of this piloted P-COCC intervention,2013-07,COMPLETED,INTERVENTIONAL,['NA'],,qualitative analyses
4192,NCT03531632,Number of Participants With Adverse Events,2018-06-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The Number of Participants With Response Based on the Change in Tumor Volume
4193,NCT04607668,Myelopreservation,2020-10-16,TERMINATED,INTERVENTIONAL,['PHASE3'],,Anti-tumor Efficacy
4194,NCT04172714,Tumor to Normal Liver Activity Ratio (TNR),2019-12-16,COMPLETED,INTERVENTIONAL,['NA'],,Number of Participants With Tumor Response Using Imaging Modified Response Criteria in Solid Tumors (m-RECIST) Post Y90 Embolization
4195,NCT04684355,Quality of life degree,2020-12-22,UNKNOWN,INTERVENTIONAL,['NA'],,Anxiety and depression degree
4196,NCT00765869,Involvement in screening decision,2008-07,UNKNOWN,INTERVENTIONAL,['NA'],,Influence of doctor on screening decision
4197,NCT04450758,Number of patients with 90 day mortality,2020-09-01,RECRUITING,OBSERVATIONAL,['NA'],,colorectal surgeon performing resectional surgery
4198,NCT03337087,Best response rate (Phase II),2018-11-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of adverse events (Phase II)
4199,NCT04271657,The area under curve (AUC) of Receiver Operating Characteristic (ROC) curves of the radiopathomics artificial intelligence model,2020-01-10,COMPLETED,OBSERVATIONAL,['NA'],,The sensitivity of the radiopathomics artificial intelligence model
4200,NCT00743964,Failure-free survival,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,progression-free survival
4201,NCT02324114,Hsp90α Concentration(ng/ml) of plasma,2012-09,UNKNOWN,INTERVENTIONAL,['NA'],,
4202,NCT01919151,Survival,2008-06,UNKNOWN,OBSERVATIONAL,['NA'],,
4203,NCT06154785,To assess the impact of the stable low-pressure approach (using Airseal Insufflator) and its associated parameters into the the early rehabilitation program after colorectal surgery on length of stay.,2023-12-15,RECRUITING,OBSERVATIONAL,['NA'],,The Surgical and Medical morbidity at 30 days
4204,NCT01350726,,2008-01,UNKNOWN,OBSERVATIONAL,['NA'],,
4205,NCT03941184,Incidence Rate of SCAD,1995-01-01,COMPLETED,OBSERVATIONAL,['NA'],Odds of validated rheumatoid arthritis in SCAD cases compared to controls,SCAD recurrence
4206,NCT03085992,Disease-free survival rate at 2 years,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Pathological complete response rate
4207,NCT02446379,The location of PET imaging agent as measured by the LightPathTM Imaging System,na,WITHDRAWN,OBSERVATIONAL,['NA'],,Number of participants with adverse events
4208,NCT01551589,radiation pneumonitis and radiation esophagitis,2012-03,COMPLETED,INTERVENTIONAL,['NA'],,Local control rate/ Inside irrational field recurrence rate
4209,NCT00423254,To determine the immunologic response to the treatment with MKC1106-PP regimen and 2) to determine the safety and adverse event profile of MKC1106-PP,2007-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,to describe any objective tumor responses to the treatment with MKC1106-PP
4210,NCT03313596,"Progression-free survival, PFS",2013-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Median overall survival time
4211,NCT03187184,PGx Test Interpretation,2017-05-20,COMPLETED,INTERVENTIONAL,['NA'],,Chemotherapy Toxicity
4212,NCT03283761,Objective Response Rate,2017-09-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety and Toxicity Profile of the Combination of Nab-paclitaxel and FOLFOX
4213,NCT05329766,Objective Response Rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1,2022-06-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Percentage of participants with anti-drug antibodies to zimberelimab
4214,NCT02108444,the incidence of hepatitis B virus delayed reactivation,2007-01,COMPLETED,OBSERVATIONAL,['NA'],,overall survival rate
4215,NCT05039944,Optimal combination dose (only IIa),2021-11-30,TERMINATED,INTERVENTIONAL,['PHASE2'],,ADA
4216,NCT01177007,Progression-free Survival (PFS) of the Treated Lesion(s) According to RECIST and EASL Criteria,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Mean Radiation Dose Delivered to Total Liver
4217,NCT01520259,gallbladder cancer/pre-cancer,2012-01-10,COMPLETED,OBSERVATIONAL,['NA'],,
4218,NCT05980689,Complete response (CR) rate,2023-10-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Long-term anal function
4219,NCT00068575,Median Overall Survival (OS),2002-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4220,NCT00544011,Objective response (complete and partial) rate,2007-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Biomarkers predictive of efficacy
4221,NCT05138887,acute radiation-induced proctitis (ARP) incidence,2022-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],adverse events,cancer remission rate assessed by imaging
4222,NCT01982487,PFS (Phase IIb),2013-12,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Toxicity rate, graded according to NCI CTCAE version 4.0"
4223,NCT05225207,Number of Participants With Non-serious ADRs,2019-05-28,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of Participants With Overall Response
4224,NCT05501379,Comparison of physical activity assessments within 1 week after initiation of cancer therapy,2022-09-21,RECRUITING,OBSERVATIONAL,['NA'],,Relation of cancer therapy modality to changes in physical activity between assessements within 1 week and 12 weeks after initiation of cancer therapy
4225,NCT02436018,Low pulse oximetry incidence,2015-03,UNKNOWN,INTERVENTIONAL,['NA'],,Other adverse events
4226,NCT03883802,ctDNA as surrogate marker for disease free period,2019-04-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Thymidine Kinase activity,ctDNA in Wnt-5a high patients
4227,NCT00979329,,2008-05,COMPLETED,OBSERVATIONAL,['NA'],,
4228,NCT04969835,Percentage of patients with Adverse Events (AEs) at RP2D AVA6000 dose level in tumour-specific expansion arms.,2021-07-16,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
4229,NCT00068744,"Event-free survival as measured by Logrank at 12 and 26 weeks, then every 6 months thereafter (Phase III)",2003-07,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"Quality of life as measured by EORTC Quality of Life Questionnaire-C30 and ASCT at 12 and 26 weeks, then every 6 months for 2 years after entry"
4230,NCT01426490,Antioxidant and DNA methylation,2011-08,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
4231,NCT01761461,The primary endpoint of the study is disease-free survival (DFS).,2013-02-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
4232,NCT00879333,Overall Survival (OS),2009-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Everolimus Steady State Concentraions at Predose (Cmin) and Cmax by Region Asia vs. Rest of the World (ROW) at Week 5
4233,NCT01104181,HC2 can accurately test for oncogenic HPV in anal specimens,2010-03,COMPLETED,INTERVENTIONAL,['NA'],,Sensitivity and specificity of cytology with HC2
4234,NCT01504997,The Incidence of Post-operative Intra-abdominal Infectious Complications,2011-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events
4235,NCT00937482,MTD defined as the dose at which no patients develop treatment-related grade 5 toxicity and less than 30% of patients develop acute dose limiting toxicities (DLT) assessed using NCI CTCAE version 4.0,2009-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,Vascular MRI studies
4236,NCT03851939,ORR,2019-02-26,UNKNOWN,INTERVENTIONAL,['PHASE2'],,DCR
4237,NCT04091295,,na,AVAILABLE,EXPANDED_ACCESS,['NA'],,
4238,NCT05408169,Number of screening tests returned to the central laboratory and successfully processed providing an adequate result.,2022-06-20,COMPLETED,INTERVENTIONAL,['NA'],,Acceptability of interventions (qualitative)
4239,NCT00063960,overall survival,2003-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,time to hepatic recurrence or progression
4240,NCT06296706,OS,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Plasma concentration of docetaxel (free and total)
4241,NCT06094868,Progression-free survival (PFS),2023-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Security
4242,NCT01033240,Time to Progression (TTP) Following CS1008 in Combination With Sorafenib Compared to Sorafenib Alone in Participants With Advanced Liver Cancer,2010-07-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Treatment-Emergent Adverse Events Following CS1008 in Combination With Sorafenib Compared to Sorafenib Alone in Participants With Advanced Liver Cancer
4243,NCT01057953,genetic variation assessment,2010-01,COMPLETED,INTERVENTIONAL,['NA'],,
4244,NCT06261047,Progression free survival,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Duration of control
4245,NCT04099134,Quality of life in pancreatic cancer patients,2018-10-10,RECRUITING,OBSERVATIONAL,['NA'],,Evaluation of predictive and prognostic markers
4246,NCT05374122,Cholangiocarcinoma diagnosis confirmation after biopsy and six-month follow-up,2022-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Insufficient biopsy sample rate
4247,NCT05706025,Testing difference in Biomarkers between Control and BE/EAC patients,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Testing difference in Multiple Biomarkers between Control and BE/EAC patients
4248,NCT00483782,Progression-free survival,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Health economics
4249,NCT05191667,Number of participants with Dose Limiting Toxicities (DLTs),2022-01-18,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
4250,NCT05012527,Completeness rate of the procedures,2021-06-11,COMPLETED,OBSERVATIONAL,['NA'],,
4251,NCT02483884,Sensitivity and specificity of [68Ga]RM2 PET to identify lesions in comparison to whole-mount histopathology (number of histologically verified cancer lesions identified),2015-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of patients with adverse events,Evaluation of SUV threshold
4252,NCT00387387,"Plasma AUC(0-24) of pazopanib on Day 1, 14 and 21 Plasma AUC(0-46) of 5-FU and AUC(0-8) of platinum on Day 1 Plasma AUC(0-24) of capecitabine, 5-FU, and platinum on Day 1",2006-10-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Pharmacokinetic endpoints (AUC, C24, Cmax, tmax, and half-life)collected predose and 1, 2, 3, 4, 5, 6, 8, and 24 hours on Day 1. Assessment of disease by imaging"
4253,NCT01027221,Principal purpose of the study is the determination of an active local external beam radiotherapy dose leading to a maximal number of tumor infiltrating T-cells. The total T-cell activity serves as primary surrogate parameters for anti- tumoral activity,2009-11,COMPLETED,INTERVENTIONAL,['NA'],,"quality of life according to the EORTC QoL questionnaire after 6, 12, 18 and 24 months"
4254,NCT01754272,Primary colorectal cancer tumor blocks,2012-01,UNKNOWN,OBSERVATIONAL,['NA'],Residual blood samples,Metastatic tumor blocks
4255,NCT01640860,Response rate,2007-12,COMPLETED,OBSERVATIONAL,['NA'],,"progression free survival, overall survival and adverse events"
4256,NCT05517681,The number of positive lymph nodes,2020-09-07,COMPLETED,INTERVENTIONAL,['NA'],,The incidence of postoperative complications
4257,NCT03549494,Quality of Life,2018-10-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,Results of laboratory tests
4258,NCT03308552,Overall survival（OS）,2017-12-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Adverse events
4259,NCT02647476,Postoperative complication rate,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall survival
4260,NCT04164017,Accuracy,2019-06-01,UNKNOWN,INTERVENTIONAL,['NA'],,
4261,NCT03770689,Number of Participants Who Experienced Dose Limiting Toxicity (DLT) Confirmed by Safety Monitoring Committee (SMC),2019-03-20,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Apparent Terminal Half-life (t1/2) of Peposertib
4262,NCT03615599,Incident cases of breast cancer among subjects with documented dietary habits.,2002-02-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Incident cases of colorectal cancer among subjects with documented dietary habits.,Incident cases of prostate cancer among subjects with documented dietary intakes.
4263,NCT05462496,Achievement of overall immune response,2023-03-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival rate (OS)
4264,NCT02745197,Muscle fatty acid content,2017-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Plasma C-reactive protein
4265,NCT04194879,Sensitivity & specificity of colorectal cancer detection,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
4266,NCT00321958,HGD or inoperable intramucosal or submucosal carcinoma and severe squamous dysplasia: measure of reduction in size of HGD or carcinoma,2006-04,TERMINATED,OBSERVATIONAL,['NA'],,Number of treatment sessions needed to ablate dysplasia
4267,NCT02656524,Number of participants with treatment emergent adverse events as a measure of safety and tolerability,2016-07-01,COMPLETED,OBSERVATIONAL,['NA'],Time frame between the baseline computed tomography and the first drug delivery,Resource utilization per patient
4268,NCT01758965,Delayed bleeding rate after ESD,2012-12,COMPLETED,INTERVENTIONAL,['NA'],,
4269,NCT02367001,Evaluate the effect on the participation (of the population) in cancer screening of an intervention involving the general practitioner (integration of signature) in the invitation letters,2014-02,COMPLETED,INTERVENTIONAL,['NA'],,"Cost-effectiveness of different strategies for each cancer screening (breast, colorectal and cervical) as measured by cost effectiveness ratio (total costs in Euros divided by total screened people)"
4270,NCT03536208,Determine change in AXL pathway,2019-05-15,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,Antitumor effect
4271,NCT02252250,Adequacy of the total mesorectal excision(TME) based on standard guidelines on pathologic evaluation of TME specimens.,2014-10,COMPLETED,INTERVENTIONAL,['NA'],Quality of life outcomes evaluation,Oncologic outcomes in subjects receiving transanal hybrid-laparoscopic total mesentery excision.
4272,NCT03657914,Number of lymph nodes dissected,2017-07-12,UNKNOWN,INTERVENTIONAL,['NA'],Local recurrence rate of tumor within 3 years,Postoperative drainage tube indwelling time
4273,NCT04046575,Maximum tolerated dose (MTD) of hypofractionated IMRT with chemotherapy,2019-11-07,RECRUITING,INTERVENTIONAL,['PHASE1'],,Number and type of adverse events experienced by patient
4274,NCT03741088,Acute Technical Performance of the VORTX Rx® Medical Device for the Ablation of Primary and Metastatic Liver Tumors,2018-03-21,COMPLETED,INTERVENTIONAL,['NA'],,Analgesic Requirements After the Ablation Procedure
4275,NCT05124743,Results of HLA typing in combination with tumor genetic testing of subjects to identify a TCR match for treatment on the TCR001-201 study.,2021-09-24,SUSPENDED,OBSERVATIONAL,['NA'],,
4276,NCT03975465,Timing of Aspiration (category),2018-09-10,RECRUITING,INTERVENTIONAL,['NA'],M.D. Anderson Dysphagia Inventory (MDADI) (number),
4277,NCT05068752,Disease Control Rate of Vemurafenib in Combination with Sorafenib,2021-10-28,RECRUITING,INTERVENTIONAL,['PHASE2'],Clinical Activity of Vemurafenib in Combination with Sorafenib,Measure phospho ERK and phospho AKT in plasma
4278,NCT01775280,Primary endpoint ist the percentage of patients that can be downstaged to resectability,2012-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Immunological response to radioembolization
4279,NCT05163236,sensitivity of the fecal immunochemical test for the detection of colorectal cancers,2021-04-20,COMPLETED,OBSERVATIONAL,['NA'],,Treatment
4280,NCT05063019,"Predicting intraoperative PCI scores for patients with peritoneal carcinomatosis, using MR Enterography and CT",2021-09-01,RECRUITING,INTERVENTIONAL,['NA'],,
4281,NCT01167374,Maximum Tolerated Dose (MTD),2011-08,TERMINATED,INTERVENTIONAL,['NA'],,Progression-free Survival
4282,NCT00387348,Change in Hamilton Depression Rating Scale (HAM-D) Scores,2006-03,TERMINATED,INTERVENTIONAL,['PHASE3'],,Side Effect Burden
4283,NCT03515369,3-year disease free survival,2018-05,UNKNOWN,INTERVENTIONAL,['PHASE4'],safety and tolerability,EORTC QLQ-C30
4284,NCT01859858,Pharmacokinetics of SN-38,2013-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4285,NCT03991104,Response rate,2019-05-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Health-related Quality of life (HR-QoL, Phase II)",Progression-free survival time
4286,NCT04644250,Pathologic complete response rate,2020-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,R0 resection rate
4287,NCT03355391,colorectal cancer rate,2018-01-30,UNKNOWN,OBSERVATIONAL,['NA'],,
4288,NCT03071094,Overall Response Rate (ORR) According to RECIST 1.1.,2017-07-27,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
4289,NCT00299299,,2006-06,UNKNOWN,OBSERVATIONAL,['NA'],,
4290,NCT00792363,Response Rate,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression free survival
4291,NCT05319730,Objective Response Rate (ORR),2023-05-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants Who Discontinue Study Treatment Due to An AE During the Efficacy Phase
4292,NCT00010062,,2000-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
4293,NCT05583890,Health inequalities,2022-08-25,RECRUITING,OBSERVATIONAL,['NA'],,
4294,NCT03596411,Sleeve gastrectomy,2018-05-17,UNKNOWN,OBSERVATIONAL,['NA'],,Obesity related comorbidity
4295,NCT04629326,Standardized uptake value（SUV）,2021-07-20,RECRUITING,INTERVENTIONAL,['NA'],,
4296,NCT03160209,Risk factors for ESCC - Tobacco and alcohol consumption,2017-07-26,COMPLETED,OBSERVATIONAL,['NA'],,The germline genetic and epigenetic alterations associated with susceptibility to ESCC.
4297,NCT04834011,"Preoperative radiologic assessment of patients with diagnosis of right-sided colon cancer. The investigators evaluated: fascia of Fredet; vascular structures (ileocolic vessels; right colic artery, middle colic artery, trunk of Henle); lymph nodes.",2013-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,perioperative outcomes: rate of conversion
4298,NCT04950166,Clinically Significant Events (CSE),2021-11-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,Pegsitacianine fluorescence and imaging performance
4299,NCT02433639,progression-free survival at 4-months (PFS4mo),2015-04,COMPLETED,INTERVENTIONAL,['PHASE2'],"protein/genomic biomarkers of efficacy from serum, plasma or tumor",safety and tolerability as measured by number and grade of toxicity events
4300,NCT05848739,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,2023-06-05,RECRUITING,INTERVENTIONAL,['PHASE1'],,ST316 Assessment Objective Response Rate (ORR)
4301,NCT04498520,Incidence of treatment-related adverse events (AE),2021-03-31,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Median progression-free survival (PFS)
4302,NCT02151032,Gist and Verbatim Knowledge for a Colorectal Cancer Screening Program,2012-11,COMPLETED,OBSERVATIONAL,['NA'],,
4303,NCT01995084,Optimal time frame between administration of 18F-HX4 and PET scan,2012-05,COMPLETED,INTERVENTIONAL,['NA'],,
4304,NCT01863355,Pain score(VAS) within 48hrs after surgery,2013-05,UNKNOWN,INTERVENTIONAL,['NA'],,
4305,NCT04970914,Progression-free survival (PFS),2021-11-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],Number of TB cells count and interleukin-6/8/10,Overall Survival (OS)
4306,NCT06092242,Progression Free Survival,2023-10-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life score
4307,NCT05742438,MMP,2023-04-12,COMPLETED,INTERVENTIONAL,['NA'],,Mortality
4308,NCT03313700,3-year disease free survival rate,2017-09-25,COMPLETED,INTERVENTIONAL,['NA'],,operation time
4309,NCT05141617,24-week re-bleeding,2021-11-03,UNKNOWN,INTERVENTIONAL,['NA'],,24-week adverse events
4310,NCT01317069,duration of survival after operation,2010-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,disease free survival
4311,NCT02005913,tumor recurrence,2014-01,UNKNOWN,OBSERVATIONAL,['NA'],,
4312,NCT04306458,Total number of dissected lymph nodes,2021-01-18,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life after esophagectomy
4313,NCT03082911,Participation,2017-03-13,COMPLETED,INTERVENTIONAL,['NA'],,Help to decide about participation
4314,NCT03959696,Shared Decision Making Process (SDMP) Scale Score,2019-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Clinician attitude toward shared decision making,Clinician satisfaction with the visit
4315,NCT00833131,The rate of patients with R0 resection,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,The rate of complete pathological response
4316,NCT00280761,Correlation of NF-kappa B pathway activation with therapeutic outcomes,2003-12,COMPLETED,OBSERVATIONAL,['NA'],,Correlation of p53 pathway-mediated events with clinical outcomes
4317,NCT04702230,DWI/IVIM values,2017-09-11,TERMINATED,OBSERVATIONAL,['NA'],,early responders
4318,NCT04371224,Progression-free survival,2020-06-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,QOL: eortc qlq-c30
4319,NCT00091195,Survival,2004-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,
4320,NCT00188266,Phase II: Comparison of acute toxicity rates with those observed in their previous study of 20 patients treated similarly to the SWOG INT 0116 protocol.,2002-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Survival and disease-specific survival
4321,NCT04789980,Overall Survival (OS),2021-01-29,RECRUITING,OBSERVATIONAL,['NA'],Adverse drug reactions(ADR) caused delay/discontinuation of planned chemotherapy,Eastern Cooperative Oncology Group Performance Status (ECOG PS) scores
4322,NCT05999812,"Objective Response Rate of of ATRA, bevacizumab and atezolizumab combination",2023-12-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,Frequency of adverse events
4323,NCT05029102,Progression Free Survival,2021-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
4324,NCT01505530,Overall Survival (OS),2011-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Anti-LY2495655 Antibodies
4325,NCT02291133,Number of Participants With Toxicity Related to Electrochemotherapy,2014-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Clinical Response Evaluation According to RECIST v1.1
4326,NCT04358328,Mortality,2020-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Mortality
4327,NCT03303352,"Cytological diagnostic accuracy of EUS FNA, for ""fast"" and ""slow"" passages",2017-07-24,COMPLETED,INTERVENTIONAL,['NA'],Subgroup analysis for trans-gastric and trans-duodenal route,"The linear relationship between needle acceleration and outcomes 1,2,3 and 4"
4328,NCT05477576,Phase 3: PFS as determined by BICR,2022-03-24,RECRUITING,INTERVENTIONAL,['PHASE3'],Phase 3: QTc,Phase 3: DoR
4329,NCT06327269,Recurrence-free survival with adjuvant therapy,2021-04-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
4330,NCT03076567,Relation of DNA methylation marakers to gastric cancer status,2017-03-09,COMPLETED,OBSERVATIONAL,['NA'],,
4331,NCT04390724,Patient Group 2: HCC Resection,2020-07-17,RECRUITING,OBSERVATIONAL,['NA'],,
4332,NCT04761783,Examine the impact of SIGNATERA on treatment decisions on tumor assessment timepoints after initiation of immunotherapy,2021-05-28,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Determine the impact of SIGNATERA on patient reported outcomes
4333,NCT04048278,Upregulation or Downregulation of Gene Expression.,2018-11-08,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Specimen outcome measure
4334,NCT01326845,Difference in the Frequency of Overall Newly Occurring GI Adverse Events (AEs) in the Two Treatment Arms,2011-12,TERMINATED,INTERVENTIONAL,['PHASE4'],,Difference in Reducing Serum Ferritin After Each Month of Study Drug Administration Between the Two Groups
4335,NCT01287585,Overall survival,2011-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety and tolerability - number of participants with adverse events.
4336,NCT03609710,Anastomotic leak rate,2018-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,Reoperation rate after anastomotic leak
4337,NCT00061958,"Objective response (OR) defined as a complete or partial remission, evaluated using RECIST criteria",2003-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Toxicity graded according to the Common Toxicity Criteria version 2
4338,NCT05565066,Diagnostic yields of EUS-FNA with EUS-FNB for solid masses,2014-12-01,COMPLETED,OBSERVATIONAL,['NA'],,Quality of histologic specimen
4339,NCT02603757,Increase in serum Vitamin D3 level during chemotherapy in the active supplementation group compared to the control group.,2016-03,COMPLETED,INTERVENTIONAL,['NA'],,Overall survival (OS)
4340,NCT00024063,,na,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
4341,NCT06074432,Mortality,2023-07-25,COMPLETED,OBSERVATIONAL,['NA'],,
4342,NCT01712958,"identifying specific, relevant miRNAs that may serve as biomarkers to stratify CRC patients according to their clinical characteristics",2012-11,UNKNOWN,OBSERVATIONAL,['NA'],,
4343,NCT04552405,Evaluate changes in calprotectin levels,2017-09-12,COMPLETED,INTERVENTIONAL,['NA'],,Evaluate changes in stool inflammatory markers
4344,NCT06214533,Postoperative opioid use,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Post-operative hospital time
4345,NCT00746590,Overall Best Tumor Response Rate (Proportion of Subjects With Complete or Partial Response) as Defined by Modified RECIST,2008-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Changes in Laboratory Measurements
4346,NCT03121807,Overall survival,2014-09-01,COMPLETED,INTERVENTIONAL,['NA'],,Cycles of salvage chemotherapy completed
4347,NCT01002287,"The Incidence of Adhesions, Defined as the Proportion of Subjects Presenting at the Follow-up Surgery (10-12 Weeks) With One or More Adhesions to the Midline Incision, Regardless of Extent and/or Severity.",2009-10,TERMINATED,INTERVENTIONAL,['NA'],,Mobilization Time
4348,NCT01604798,Serum peptide mass fingerprinting (PMF),2007-01,COMPLETED,OBSERVATIONAL,['NA'],,Expressed peptide peaks
4349,NCT01697449,Percentage of Participants With At Least One Adverse Event (AE),2009-03,COMPLETED,OBSERVATIONAL,['NA'],,Progression Free Survival (PFS)
4350,NCT04123379,Significant Tumor Necrosis (STN),2020-03-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
4351,NCT01110941,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2009-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Tumor response according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria, and follow up till disease progression or withdrawal from study due to intolerable adverse events (AE)"
4352,NCT00270166,Proportion of patients without transfusion after first month.,1995-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Proportion of responders, change of hemoglobin (not by transfusion), cumulative transfusion rate, proportion of patients transfused during the double-blind phase, excluding the first month; mean change score of baseline quality of life parameters; safety"
4353,NCT04380103,objective response rate (ORR),2020-04-26,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,the surgical resection rate of patients with liver-only metastases
4354,NCT03704077,Overall response rate (ORR),2019-10-31,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
4355,NCT06003998,Overall survival,2022-12-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,Peritoneum/plasma ratio of intraperitoneal irinotecan
4356,NCT05845450,major pathological response rate,2023-05-11,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival,microbiota
4357,NCT05068739,Success rate of cannulation,2021-06-01,COMPLETED,INTERVENTIONAL,['NA'],,Procedure time
4358,NCT04045496,Find Recommended Phase 2 Dose (RP2D) of JAB-3312,2019-09-26,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Duration of response ( DOR )
4359,NCT03446157,Disease Control Rate,2018-03-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Toxicity of Treatment
4360,NCT01349881,"Event rate, defined as rate of high-risk adenoma or second primary colorectal cancer (CRC)",2013-08-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Cancer type (colorectal vs rectal)
4361,NCT06119425,Opted to be screened by either SOC or study diagnostic test,2023-10-12,RECRUITING,INTERVENTIONAL,['NA'],,Opted to be screened by the study diagnostic test instead of SOC
4362,NCT01849588,Decline in HCV-RNA Level,2013-05,TERMINATED,INTERVENTIONAL,['PHASE4'],Decrease Alpha-fetoprotein(AFP) Level > 20% From the Baseline,Overall Survival
4363,NCT04429542,Incidence of Dose Limiting Toxicities (DLTs),2020-06-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Immunogenicity of BCA101 and pembrolizumab
4364,NCT04466891,Confirmed objective response rate (ORR) by independent central review (ICR),2020-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of anti-drug antibodies (ADAs)
4365,NCT03806075,Mutation of gene associated with Peutz-Jeghers syndrome,2018-03-01,UNKNOWN,INTERVENTIONAL,['NA'],The association of STK11 with intestinal microbiota of patients with PJS,Intestinal microbiota of patients with PJS
4366,NCT02331914,Secondary GIST mutations in circulating tumor DNA of patients with progressive disease on TKI treatment,2014-12-08,RECRUITING,OBSERVATIONAL,['NA'],,Secondary mutations in circulating tumor DNA related to pharmacokinetics of TKI
4367,NCT06059885,Tumor recurrence rate (DRR),2021-12-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,
4368,NCT06281379,Postoperative outcome,2023-04-01,COMPLETED,INTERVENTIONAL,['NA'],,
4369,NCT04253106,Number of subjects in whom somatic mutations or methylation profiles are detected.,2020-11-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Replicability of observations over successive endoscopies. Correlation between blood and gastric fluid.
4370,NCT04939103,the accuracy of predicting pCR after nCRT,2021-07-01,COMPLETED,OBSERVATIONAL,['NA'],,
4371,NCT05043857,Local Recurrence Rate,2021-07-06,RECRUITING,INTERVENTIONAL,['NA'],,Overall Survival
4372,NCT03351647,Measurement of serum ustekinumab trough concentrations (expressed in microg/mL) at week 8.,2018-02-14,COMPLETED,OBSERVATIONAL,['NA'],,Clinical evaluation at week 24
4373,NCT00064051,Objective response rate (partial and complete response) as assessed by RECIST criteria,2003-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety and feasibility
4374,NCT00681421,Safety(Phase I:toxicities as assessed by NCI CTCAE version3) and efficacy(Phase II:Feasibility as evaluated by RECIST),2008-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To evaluate immunological responses
4375,NCT03465722,"Efficacy of Avapritinib Based on Progression-free Survival (PFS) Determined by Central Radiological Assessment Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST), Version 1.1",2018-03-26,COMPLETED,INTERVENTIONAL,['PHASE3'],,European Organisation for Research and Treatment of Cancer Quality of Life (EORTC-QLQ-30). Change in Individual Scores in Patients With Advanced GIST Treated With Avapritinib Compared to Patients Treated With Regorafenib
4376,NCT02696759,Number of Subjects Who Complete Fecal Collection,2016-07,TERMINATED,INTERVENTIONAL,['NA'],,
4377,NCT05542680,Reflux symptoms,2022-09-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Skin pressure injury
4378,NCT05969847,Organ preservation,2023-08-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Anorectal function
4379,NCT01983371,Prospectively evaluate the diagnostic accuracy of ferumoxytol-enhanced MRI in the setting of colorectal cancer with histopathologic analysis as the gold standard.,2013-12,WITHDRAWN,INTERVENTIONAL,['NA'],,
4380,NCT04656782,Standardized imaging protocol consensus among panelists,2021-01-26,UNKNOWN,OBSERVATIONAL,['NA'],,Description of heterogeneity of mCRC imaging protocols
4381,NCT03555149,Best Confirmed Overall Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1,2018-09-27,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Percentage of Participants With at Least One Adverse Event (AE)
4382,NCT02930902,Incidence of toxicities as defined by Common Terminology Criteria for Adverse Events version 4.0,2017-02-20,COMPLETED,INTERVENTIONAL,['PHASE1'],Overall survival (OS),Resection rate
4383,NCT04858009,Progression-free survival,2024-01-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,Morbidity
4384,NCT05279612,Investigate patients ORR,2021-10-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,R0 resection
4385,NCT01744639,Nutritional Status,2012-12,WITHDRAWN,INTERVENTIONAL,['NA'],,Minimal hepatic encephalopathy
4386,NCT05247164,Proportion of patients with procedure-related Adverse Events,2022-05-17,RECRUITING,INTERVENTIONAL,['NA'],,Baseline portal CTC concentration in patients with progressive versus non-progressive diseases
4387,NCT06255041,"Sensitivity of detection of any cancer (breast, lung, prostate or colorectal cancer) by the breath test.",2021-02-10,RECRUITING,OBSERVATIONAL,['NA'],The duration for which a breath sample collected on an alternative mask substrate remains effective for detection by a detection dog,Intra-observer variability among the detection dogs
4388,NCT01345175,To compare the efficacy of rifaximin and placebo in the treatment of bowel dysfunction as measured by MSKCC Bowel Function Instrument (BFI score) in patients following Anterior Resection (AR) or Sphincter Preserving Surgery (SPS) for rectal cancer.,2011-04-26,COMPLETED,INTERVENTIONAL,['PHASE3'],,efficacy of metronidazole
4389,NCT00961571,Progression-free Survival,2009-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,
4390,NCT05453760,Area under the curve (AUC) of the Lung ultrasound score,2022-08-21,RECRUITING,OBSERVATIONAL,['NA'],,Complications according to the Dindo-Clavien classification
4391,NCT03700593,Rate of postoperative complications and mortality of the SP robot,2018-10-15,UNKNOWN,OBSERVATIONAL,['NA'],,Assessment of patients' postoperative body image satisfaction
4392,NCT05034783,Metabolic parameters,2021-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],GLP-1R expression and SUV,Diagnostic value
4393,NCT02507414,"Relative changes in plasma-hormone concentrations (pro-ANP, PGF2, GLP-1, ACTH, cortisone, adrenaline, IL-1, IL-6, TNF-alfa and CRP (stress hormones)) from baseline.",2014-08,COMPLETED,INTERVENTIONAL,['NA'],,Relative changes in systemic vascular resistance from baseline measured in dyn.s/cm5
4394,NCT02682485,Anastomotic Healing Score (ordinal scale ranging from 0 to a maximum of 18),2017-03-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Anastomotic Healing Score (ordinal scale ranging from 0 to a maximum of 18)
4395,NCT00144378,median survival,2002-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,"quality of life, response rates, time to tumor progression, toxicity"
4396,NCT04258150,Objective response rate (ORR),2020-04-16,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Incidence of treatment-related AEs, SAEs, AEs leading to discontinuation, death, and laboratory abnormalities"
4397,NCT02550613,The recurrence rate at 3 months after treatment,2014-05,UNKNOWN,OBSERVATIONAL,['NA'],,The overall survival after treatment
4398,NCT05667350,The sensitivity and specificity of the combined model in detection of biliary tract cancers.,2022-02-28,RECRUITING,OBSERVATIONAL,['NA'],,The sensitivity and specificity of the combined model in detection of different stages of biliary tract cancers.
4399,NCT03524300,3-year disease free survival rate,2018-06-01,RECRUITING,INTERVENTIONAL,['NA'],,operation time
4400,NCT01705340,MTD of Akt inhibitor MK-2206 and lapatinib ditosylate in combination with trastuzumab determined by dose limiting toxicities as measured by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4,2012-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,"Overall response rate (ORR), evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1"
4401,NCT04826003,Percentage of Participants with Adverse Events,2021-07-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change on 4-1BB tumor expression levels
4402,NCT02784470,Gastric Outlet Obstruction Scoring System (GOOSS) score,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
4403,NCT03028584,EHR-based SCPs and care planning,2017-09-11,COMPLETED,OBSERVATIONAL,['NA'],,Impact of providing EHR-based care planning
4404,NCT01494506,Overall Survival,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Pharmacokinetic Measurements of Total Irinotecan
4405,NCT02599662,Maximum Tolerated Dose,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,QOL surveys
4406,NCT04652180,Respiratory postoperative complications.,2020-11-06,RECRUITING,INTERVENTIONAL,['NA'],,Postoperative quality of life.
4407,NCT02557490,Progression-free survival (PFS),2015-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,overall survival (OS)
4408,NCT06067438,"Development of atrial fibrillation (AF), or completion of seven-day course of amiodarone",2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,"Serum amiodarone level, classified as therapeutic or subtherapeutic"
4409,NCT04589234,Progression Free Survival,2020-10-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Radiologic response
4410,NCT04069468,QoL Measurements Using FACT-HEP Questionnaire Before and After Treatment,2019-03-13,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,"Determination of a correlation between Dose volume histogram (DVH) for total perfused tumour, Index lesion and whole normal liver tissue, using 99mTc-MAA (SPECT or SPECT/CT) and Y-90 (PET/CT or PET/MRI)."
4411,NCT01518829,Differantiate between post- embolization syndrom and sepsis following locoregional treatment for hepatocellular carcinoma,2012-04,COMPLETED,OBSERVATIONAL,['NA'],,
4412,NCT01389583,disaese control rate,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,response rate
4413,NCT05939063,Lymph node positive rate,2023-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival (OS)
4414,NCT05737615,SUV mean measurement,2023-02-10,RECRUITING,INTERVENTIONAL,['PHASE1'],,
4415,NCT05411679,Overall Response Rate (ORR) as measured using RECIST v1.1,2023-04,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Magnitude of response to first-line chemotherapy,Incidence of treatment-emergent AEs leading to dose reduction of trial treatment
4416,NCT02909062,EAM Max Step-count On-Chemotherapy - EAM Max Step-count Pre-Chemotherapy,2016-05,COMPLETED,OBSERVATIONAL,['NA'],,
4417,NCT06205173,The effectiveness of Cold and Hot Compress Nursing Interventions on the Quality of Life,2020-08-19,COMPLETED,INTERVENTIONAL,['NA'],,The Effectiveness of Cold and Hot Compress Nursing Interventions on the Neurological Changes in the Hands and Feet.
4418,NCT04481256,Feasibility difined as the percentage of patients completing at least two cycles of bintrafusp alfa,2020-11-11,RECRUITING,INTERVENTIONAL,['NA'],Biomarker,adverse events
4419,NCT05768282,The proportion of patients with esophageal stenosis after RFA,2016-01-01,RECRUITING,INTERVENTIONAL,['PHASE4'],,The adverse events rate
4420,NCT01786980,Overall survival,2012-10,COMPLETED,OBSERVATIONAL,['NA'],,
4421,NCT02358070,Lifestyle factors,2015-04,COMPLETED,OBSERVATIONAL,['NA'],,
4422,NCT03333967,Progress free survival,2017-09-01,UNKNOWN,OBSERVATIONAL,['NA'],adverse events,Disease-free survival
4423,NCT05898828,Phase II Component: To assess the frequency of immunologic responses to purified cancer-testis (CT) antigens in EsC participants receiving adjuvant vaccinations with H1299 cell lysate/Montanide(R) ISA-51 VG in combination with entinostat and niv...,2024-04-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II Component: To determine progression free survival (PFS) in EsC participants receiving the investigational adjuvant vaccine regimen
4424,NCT04752358,Efficacy: Overall Response Rate (ORR),2021-09-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Time taken to achieve peak expansion of genetically engineered T-cells in PBMCs
4425,NCT05627427,Progression-free Survival (PFS) (RECIST1.1),2022-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,TEAE rates
4426,NCT01572974,Health State Utility as measured by the Time Trade-off (TTO) method/Standard Gamble (SG) method,2010-01,TERMINATED,OBSERVATIONAL,['NA'],,SF-36 general health (GH) subscale
4427,NCT02494973,3-year RFS rate,2015-05-26,SUSPENDED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
4428,NCT06212817,Dietary fiber intake,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Length of hospital stay
4429,NCT00161460,Colorectal cancer screening test utilization,2005-06,COMPLETED,INTERVENTIONAL,['NA'],,Cancer worry score
4430,NCT03399253,Overall survival,2017-12-10,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,progression free survival
4431,NCT00845689,,na,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
4432,NCT00003753,,1998-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4433,NCT02682589,disease-free survival,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],,postoperative quality of life as assessed by EORTC QLQ-C30 questionnaire
4434,NCT00617981,Progression Free Survival Will be Measured From the Date of Randomization to the First Date on Which One of the Following Occurs. o Local Recurrence o Any New Distant Intrahepatic HCC Tumor o Any New Extrahepatic HCC Tumor o Death From Any Cause,2008-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety
4435,NCT02296658,Distant metastasis free survival,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Comparison of dosimetric differences between radiation techniques,Chemoradiotherapy-induced toxicities assessed by CTCAE 4.0
4436,NCT01700283,"Developing Objective Fatigue Indicators: Exploring the Relationships Among Fatigue, Muscle Power and Metabolomics Through Fatigue Management and Individualized Exercise Education Program in Colorectal Cancer Survivors",2012-10,UNKNOWN,INTERVENTIONAL,['NA'],,
4437,NCT05572801,Disease free survival,2022-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Health related quality of life
4438,NCT00857805,Overall survival,2009-01-07,COMPLETED,INTERVENTIONAL,['NA'],,Downstaging
4439,NCT06151262,Incidence of CIM,2024-01-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and Tolerability
4440,NCT01016860,Maximum tolerated dose (MTD) and the recommend phase II dose (RP2D) for the combination of irinotecan and OSI-906 in patients with advanced cancer.,2009-12,TERMINATED,INTERVENTIONAL,['PHASE1'],,
4441,NCT02359058,Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,2015-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Treatment Emergent Anti-Ramucirumab Antibodies (TE-ADA)
4442,NCT04637893,Colorectal Cancer prevention,2020-12-16,COMPLETED,OBSERVATIONAL,['NA'],,
4443,NCT04048317,Evaluate the effectiveness of drug-eluting bead trans-arterial chemo-embolization in patients of hepatocellular carcinoma,2019-09-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,
4444,NCT01977066,"Physical functioning score, as assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) EORTC QLQ-C30",2013-11,COMPLETED,INTERVENTIONAL,['NA'],Fatigue (Multidimensional Fatigue Inventory (MFI)),Overall quality of life from EORTC QLQ-C30 and the specific module for pancreatic cancer(QLQ-PAN26)
4445,NCT00851305,To compare the rate of EGCs/GCs using CLE versus conventional gastroscopy.,2008-08,COMPLETED,INTERVENTIONAL,['NA'],,To evaluate the efficacy of in vivo CLE on different pathological characteristics of EGCs.
4446,NCT01875380,Progression-free survival rate at 6 months,2013-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Biomarkers associated with cell and tumour growth and/or the mechanism of action of regorafenib and their correlation with patients' clinical progression for efficacy and safety parameters.,Changes in ECOG performance status over time from baseline
4447,NCT02089633,Time To Progression (TTP),2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],To evaluate the association between the biomarkers of ornithine transcarbamoylase (OTC) and argininosuccinate synthetase (ASS) in liver tissue and clinical response treated with PACOX regimen,Safety events
4448,NCT05478083,Liver growth,2022-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Symptoms of depression
4449,NCT03562234,Change in liver function,2018-10-22,UNKNOWN,OBSERVATIONAL,['NA'],,Post-operative 30 day complications using the International Study Group for Liver Surgery (ISGLS) complications score
4450,NCT06196775,Progression-Free-Survival,2024-01-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events
4451,NCT02965794,Length of stay,2014-10,COMPLETED,OBSERVATIONAL,['NA'],,Time to return to normal diet
4452,NCT00002955,,1995-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4453,NCT04797884,Quality of Life Survey,2023-07,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Frequency of Adverse Events - PRO-CTCAE
4454,NCT03397745,Change in Bispectral index score,2018-01-15,COMPLETED,INTERVENTIONAL,['NA'],,The changes of BIS
4455,NCT02389751,"MTD and recommended phase II dose of ganetespib, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0",2015-04-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,pCR for patients who undergo surgical resection after neoadjuvant therapy
4456,NCT00145769,Local recurrence,2001-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of life
4457,NCT01834469,Feasibility study of the (intravenously injected) ICG imaging of tumoral implants in patients with peritoneal carcinomatosis from ovarian carcinoma,2013-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
4458,NCT03316872,Overall response rate,2018-02-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival rate
4459,NCT02278458,The number of patients who suffer adverse events,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Progression-free survival
4460,NCT00354978,Median Progression-free Survival (PFS),2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4461,NCT05524012,Tumor regression grading (TRG),2022-11-30,RECRUITING,OBSERVATIONAL,['NA'],,Surrogate marker: Carcinoembryonic Antigen (CEA)
4462,NCT03465982,pathologic complete response (pCR),2018-06-05,RECRUITING,INTERVENTIONAL,['NA'],,OS
4463,NCT04776421,comprehensive complication index,2021-04-01,UNKNOWN,OBSERVATIONAL,['NA'],,Overall Survival
4464,NCT03228147,A tea product with the highest total average nutrition supplement scores as assessed by questionnaires,2017-07-25,COMPLETED,INTERVENTIONAL,['NA'],,
4465,NCT02842580,The primary objective is the percentage of patients without failure of the strategy 16 months after the randomization.,2016-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Progression free survival (PFS) at 2 years and at 3 years
4466,NCT05332821,Overall Survival(OS),2022-12-28,RECRUITING,OBSERVATIONAL,['NA'],,Adverse event(AE) per Common Terminology Criteria for Adverse Events(CTCAE) 5.0
4467,NCT05246943,Compare the D-dimer results of DVT positive subjects to DVT negative subjects to identify a specific result range seen in the DVT positive subjects.,2022-05-25,WITHDRAWN,OBSERVATIONAL,['NA'],,
4468,NCT00813072,objective tumor response,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,"progression-free survival, duration of tumor response, time to progression, time to treatment failure, disease control rate, 1-year survival rate,and overall survival; pharmacokinetics and pharmacogenetics of PEP02 and irinotecan"
4469,NCT04140500,"Part B: Progression-free Survival (PFS), Defined as the Time from the First Study Treatment to the First Occurrence of Progression per Investigator Assessment or Death from any Cause, Whichever Occurs First",2019-11-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Part B: Percentage of Participants with Adverse Events
4470,NCT01963429,local progression-free survival(LPES),2013-09-30,COMPLETED,INTERVENTIONAL,['NA'],overall survival (OS),disease-free survival (DFS)
4471,NCT04389177,Major pathologic response,2020-07-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,R0 resection rate
4472,NCT02513784,Difference in Esophageal F. Nucleatum Between Experimental Group and no Intervention Group,2015-08,COMPLETED,INTERVENTIONAL,['NA'],,
4473,NCT00964457,response rate,2009-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
4474,NCT03604614,PFS,2017-06-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Median survival
4475,NCT04714086,,na,AVAILABLE,EXPANDED_ACCESS,['NA'],,
4476,NCT06031129,Visceral Pain,2023-03-01,COMPLETED,INTERVENTIONAL,['NA'],,Visceral Pain
4477,NCT05444491,To investigate the prediction and monitoring effect of plasma ctDNA methylation on postoperative recurrence of primary colorectal cancer patients after radical surgery,2022-06-20,RECRUITING,OBSERVATIONAL,['NA'],,
4478,NCT05803928,"Recurrence-free Survival, RFS",2023-04-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Biomarkers in tumors and peripheral blood
4479,NCT05044312,Correlating the sleep disturbance and its types among patients with gastrointestinal cancers.,2024-09-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
4480,NCT04791254,Differences in patterns of plasma gut hormone and cytokine levels as measured by ELISA between study participants.,2021-07-15,RECRUITING,OBSERVATIONAL,['NA'],,"Correlation between nutritional status, body composition and physical fitness"
4481,NCT04324567,"Peak value of surgically induced C-reactive protein (CRP), expected to occur 1-3 days after surgery",2019-10-09,COMPLETED,OBSERVATIONAL,['NA'],Monitoring intermediate metabolites in the remnant muscular tissue of the pelvis floor in up to 10 patients with microdialysis catheters after neoadjuvant CRT and subsequent APR for LARC.,Dehiscence of the perineal wound at 3 months follow-up
4482,NCT03609359,"Objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumours (RECIST) version. 1.1, and immune-related (ir) RECIST",2018-10-15,COMPLETED,INTERVENTIONAL,['PHASE2'],Tests of various biomarkers,Disease control rate (DCR)
4483,NCT05689138,microbial features by 16s rRNA sequencing,2020-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
4484,NCT02233595,tumor volume,2014-10-15,TERMINATED,OBSERVATIONAL,['NA'],,
4485,NCT00980889,confirmed stent failure,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4'],,Survival
4486,NCT04745403,Analysis of modifications of tumour microenvironment caused by mRNA HBV/TCR T-cell treatment,2022-05-20,RECRUITING,INTERVENTIONAL,['PHASE1'],,Evaluation of anti-tumor efficacy of mRNA HBV/TCR T-cell treatment
4487,NCT04508387,respiratory parameters: tidal volume,2019-04-22,COMPLETED,INTERVENTIONAL,['NA'],,morphine consumption
4488,NCT03223818,Length of post-operative hospital Stay,2018-07-01,RECRUITING,INTERVENTIONAL,['NA'],,
4489,NCT03245736,Number of Participants Who Experienced a Treatment Emergent Adverse Event (TEAE),2017-08-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Increased Prostate Specific Antigen (PSA)
4490,NCT00981110,The rate of patients with a Surgical site infection,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,
4491,NCT02395523,local progression - free survival,2015-03-05,COMPLETED,INTERVENTIONAL,['NA'],,overall survival
4492,NCT05136092,The abundance of fructose in tumor extracts,2022-02-16,RECRUITING,INTERVENTIONAL,['NA'],,The abundance of Xylose and [13C]-Xylose in the in the tumor
4493,NCT02399137,Progression Free Survival,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Rate of adverse events reported with the combination of MM-141 with nab-paclitaxel and gemcitabine versus the comparator arm
4494,NCT05935579,Objective response rate,2022-12-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,overall survival rate
4495,NCT05772923,Rate of successful organ preservation,2021-04-16,RECRUITING,INTERVENTIONAL,['NA'],,Number of patients with complications after completion or salvage TME-surgery
4496,NCT01341366,Duration of hospital stay,2010-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Lymphocyte subsets
4497,NCT02734004,Second Stage Cohorts: DCR at Week 24,2016-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Initial and Second Stage Cohorts: Number of Participants With Anti-Drug Antibody (ADA) Response to MEDI4736
4498,NCT01387880,Clinical benefit (SD+PR+CR),2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4499,NCT02021500,Overall Survival,2014-01-02,COMPLETED,OBSERVATIONAL,['NA'],,Disease progression
4500,NCT02841657,Postoperative complications,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],,Oncological radicality
4501,NCT03238885,Pathological complete response(pCR),2013-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
4502,NCT00669734,"MTD of falimarev, defined as the dose level that 0/6 or 1/6 patients experience dose-limiting toxicity (DLT) and that at least 2/3 or 2/6 patients treated with the next higher dose have had DLT",2010-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Cytokine production
4503,NCT02645864,Maximum tolerance dose,2016-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival
4504,NCT04656041,Pathologic Complete Response Rate,2021-06-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
4505,NCT05041153,Overall response rate,2022-02-14,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
4506,NCT06054984,Characterize the Peak of Peripheral Blood Concentration and Area under the Peripheral Blood concentration versus time curve of TCRT cells and observe their proliferation and persistence in body,2021-09-07,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],To explore the correlation between the proliferation and persistence of TCRT cells in body and the efficacy,"Evaluate tumor size (mm) , tumor biomarker CA19-9 (U/ml), ORR/DCR/PFS and OS of patients with advanced pancreatic cancer"
4507,NCT03209349,Full colon exam,2017-06-14,COMPLETED,INTERVENTIONAL,['NA'],,Adenoma detection rates
4508,NCT04631692,Colorectal cancer screening uptake,2021-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
4509,NCT01180452,Frequency of dysplasia and adenocarcinoma,2010-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,Success of endoscopic detection
4510,NCT01642186,Efficacy Endpoints for Part 1 of the Study is Progression-free Survival at 6 Months (PFS6),2012-07-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Tissue Biomarkers Collected
4511,NCT00005036,Overall survival,1999-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of life
4512,NCT05559775,ORR,2022-08-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,
4513,NCT00127036,"Number of Participants Per Treatment Arm, Per Tumor Tissue Response Classifier",2003-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Serious Adverse Events (SAEs)
4514,NCT04215471,Objective Response,2020-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Correlation between genetic profile and tumor response
4515,NCT03379844,"Safety, expressed as the rate of unacceptable toxicity.",2017-08-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,Changes in hepatic function as determined by hepatobiliary scintigraphy
4516,NCT05739981,Minimal Residual Disease,2023-02-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,OS
4517,NCT00310362,Appointment Nonadherence-colonoscopy,2007-07,COMPLETED,INTERVENTIONAL,['NA'],,Preparation Non-adherence-flexible Sigmoidoscopy
4518,NCT00087256,To determine whether celecoxib 400 mg bid for 3 years will decrease the incidence of adenomatous polyps of the colon and rectum in participants with Stage I adenocarcinoma of the colon.,2004-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,To monitor the toxicity and safety of celecoxib in this population.
4519,NCT06012318,Prevalence and severity of adverse symptoms,2023-09-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Trajectory of adverse symptoms
4520,NCT00248053,polyp number and size,2005-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,side effects and medication compliance
4521,NCT02024009,Progression free survival,2016-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life
4522,NCT04899492,Testing the feasibility of smoking cessation interventions evaluated in French cancer patients undergoing surgery,2021-09-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Evaluate the efficacy of interventions on patient quality of life
4523,NCT05200325,CPV-measured cost savings,2021-06-06,COMPLETED,INTERVENTIONAL,['NA'],,CPV-measured use case analysis
4524,NCT05572528,The recurrence rate after LDLT in high risk patients,2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
4525,NCT03509428,Post-operative length of hospital stay,2018-03-26,UNKNOWN,INTERVENTIONAL,['NA'],,Nutrition -4
4526,NCT03006302,6 Month Survival,2018-01-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants experiencing drug-related adverse events (AEs) requiring treatment discontinuation
4527,NCT00227773,,na,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
4528,NCT05570487,The number of lymph nodes,2022-10-01,RECRUITING,OBSERVATIONAL,['NA'],,
4529,NCT02599909,"To collect blood/urine/tumor samples, stool, and rectal swabs from HCC patients undergoing resection of primary liver tumors at the Mount Sinai Medical Center and to perform an analysis of the interaction of tumors, immune responses and the gut ...",2015-11-06,WITHDRAWN,OBSERVATIONAL,['NA'],,Correlation between microbiome and patients' clinical outcome
4530,NCT04657042,DVF errors in healthy volunteers and cancer patients,2020-11-05,RECRUITING,OBSERVATIONAL,['NA'],,
4531,NCT04852211,2-year recurrence-free survival,2021-12-01,RECRUITING,INTERVENTIONAL,['NA'],,5 - year Overall survival
4532,NCT03278015,median overall survival time (mOS),2017-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease control rate(DCR)
4533,NCT05371873,MRD monitor,2021-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
4534,NCT00062426,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,
4535,NCT01312389,Number of Participants With Adverse Events,2011-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Clinical Response
4536,NCT01218841,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4537,NCT03124212,Establishing the CASCADE Cohort,2017-04-01,RECRUITING,OBSERVATIONAL,['NA'],,Cancer Surveillance
4538,NCT03958812,Discrimination between Malignant and Benign Gastric/Breast Lesions and normal group with each diagnostic method (Na-nose/GC-MS/CTC),2019-06-15,UNKNOWN,OBSERVATIONAL,['NA'],,Comprehensive diagnostic model of VOCs and CTCs
4539,NCT04640480,"Number of clinically significant Chest radiograph findings(chest x-ray, CXR)",2024-06-21,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Time to progression(TTP)
4540,NCT03468335,Time to Treatment Failure of second-line treatment (TTF2),2018-03-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Growth modulation index (GMI)
4541,NCT05858385,Incidence of severe RTOM,2022-09-22,RECRUITING,OBSERVATIONAL,['NA'],Changes from the pain in xerostomia combined with RTOM patients,Risk factors of severe RTOM
4542,NCT02231385,Additional serrated lesions diagnosed after acetic acid spraying,2014-09,UNKNOWN,INTERVENTIONAL,['NA'],,Complication rate
4543,NCT03450889,Incidence of colorectal cancer during protocolled endoscopic surveillance,2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Incidence of post-colonoscopy complications
4544,NCT05718284,POST-OPERATIVE PULMONARY COMPLICATIONS,2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],,CARDIO-VASCULAR COMPLICATIONS
4545,NCT00636948,Symptomatic anastomotic leakage following low anterior resection of the rectum for cancer with and without a defunctioning stoma. Anorectal function after one and five years without defunctioning stoma.,1999-12,COMPLETED,OBSERVATIONAL,['NA'],,Reoperation within 30 days of initial surgery.
4546,NCT05405530,The incidence of hypoxia,2022-09-01,RECRUITING,INTERVENTIONAL,['NA'],,The incidence of other adverse events
4547,NCT01632722,2 years recurrence-free survival (2Y-RFS),2012-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4548,NCT01520779,Recurrence of hepatocellular carcinoma,2012-01,COMPLETED,OBSERVATIONAL,['NA'],,
4549,NCT03785496,To evaluate efficacy of PDR001 by Objective Response rate by RECIST(Response Evaluation Criteria In Solid Tumors),2020-02-18,UNKNOWN,INTERVENTIONAL,['PHASE2'],,To evaluate antitumor efficacy of PDR001
4550,NCT00003530,,1977-03-21,TERMINATED,INTERVENTIONAL,['PHASE2'],,
4551,NCT03503071,Brief pain inventory (BPI),2018-10-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Brief pain inventory (BPI)
4552,NCT00208936,,1996-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,
4553,NCT01607788,Post-transplant survival,2009-11,UNKNOWN,OBSERVATIONAL,['NA'],,
4554,NCT03812289,Proportion of participants who are transplanted or with localized disease control per Milan criteria,2019-02-07,TERMINATED,INTERVENTIONAL,['NA'],Proportion of histopathologic changes in irradiated tumor sites relative to uninvolved liver tissue,Incidence of liver toxicity assessed per Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0
4555,NCT02452424,Treatment-emergent Adverse Events (TEAEs) in Participants Regardless of Causality While Taking PLX3397 in Combination With Pembrolizumab,2015-07-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Summary of the Percentage of Participants With Objective Response Rate Assessed by RECIST v1.1 During Pembrolizumab and PLX3397
4556,NCT00558233,Receipt of colorectal cancer screening,2007-11,COMPLETED,INTERVENTIONAL,['NA'],,Number of polyps and cancers found by screening tests performed
4557,NCT04117087,Fold change in interferon-producing mutant-KRAS-specific cytotoxic (CD8) and helper (CD4) T cells at 16 weeks,2020-05-28,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
4558,NCT06018896,Quality of life (QOL),2023-08-25,RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall survival (OS)
4559,NCT01411579,Apparent Diffusion Coefficient (ADC) value changes of the lesion during chemotherapy.,2011-02,COMPLETED,OBSERVATIONAL,['NA'],,
4560,NCT05544474,Degree of consensus,2023-11-28,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
4561,NCT02606396,Change in dysphagia severity according to validated symptom score,2015-11,UNKNOWN,INTERVENTIONAL,['NA'],,"Incidence of procedure related adverse events, classified according to the American Society of Gastrointestinal Endoscopy lexicon"
4562,NCT03415815,Numbers of lymph nodes and percentages of patients with surgeries,2017-12-12,UNKNOWN,OBSERVATIONAL,['NA'],Effects of surgeries on the extents of the patients with esophageal cancer who received surgeries,Impact factors of lymph metastases
4563,NCT00653107,Dysphagia measured with the dysphagia grading scale at week +2 after start of treatment. Pain at rest measured with ESAS at week +2 after start of treatment.,2008-06,TERMINATED,INTERVENTIONAL,['PHASE3'],,Health related quality of life
4564,NCT03682276,Incidence of treatment-emergent adverse events [Safety and Tolerability],2019-03-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pathologic response rate
4565,NCT00040859,Objective tumor response rate,2002-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life
4566,NCT01738620,items SL (sleep disorder) and QL2 of the QLQ C30,2013-01,TERMINATED,INTERVENTIONAL,['NA'],,PSQI score
4567,NCT03391232,Number of Participants With Treatment Related Adverse Events,2018-05-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants Having Induced Recruitment of TILs,Number of Predicted Antigen Specific T Cell Responses Per Patient
4568,NCT05752357,Percentage of disease recurrence,2021-09-01,RECRUITING,OBSERVATIONAL,['NA'],,Progression-free survival
4569,NCT03061591,Size of polyps,2017-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Curcumin and curcuminoid levels in urine.
4570,NCT00020774,,1998-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
4571,NCT00436267,Hepatic and systemic toxicity,2006-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Survival
4572,NCT00550563,"Relationship between serum cholecalciferol pharmacokinetic parameters and CYP24 SNPs, splicing variants, and enzyme activity",2007-08,COMPLETED,INTERVENTIONAL,['NA'],,
4573,NCT04908176,area under the plasma concentration-time curve (AUC) of midazolam,2022-08-24,RECRUITING,INTERVENTIONAL,['PHASE1'],,"area under the plasma concentration-time curve at steady state (AUC,ss) of metabolite"
4574,NCT01469598,Response rate,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Adverse Events
4575,NCT01525550,Progression-Free Survival (PFS): Investigator Assessment,2012-06-06,COMPLETED,INTERVENTIONAL,['PHASE4'],,Number of Participants With Eastern Co-operative Oncology Group Performance Status (ECOG-PS)
4576,NCT03159585,treatment-related adverse events as assessed by CTCAE v4.03,2017-04-14,COMPLETED,INTERVENTIONAL,['PHASE1'],,assess the expression of tumor markers
4577,NCT06099821,Progression free survival,2023-10-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,treatment-related adverse event
4578,NCT01344538,"Evaluate Whether 2.0g of Ginger Taken Daily, Standardized to 5%-Gingerols for Four Weeks Will Result in Bioactive Levels in Colonic Tissue Sufficient to Reduce Mucosal Prostaglandin E2 (PGE2), a Marker of Cyclooxygenase Function Versus Placebo.",2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4579,NCT02106806,oxidative stress markers,2011-05,COMPLETED,INTERVENTIONAL,['NA'],CTCAE,FACIT-F
4580,NCT00583479,Compare the clinical effectiveness of EUS-guided CB performed with a single injection versus two injections of medication into the celiac ganglion region,2002-06,COMPLETED,INTERVENTIONAL,['PHASE4'],,complications related to CB
4581,NCT00582647,"To obtain & store tissues, blood, peritoneal, pleural, cyst & other gastrointestinal fluid from patients with benign or malignant tumors in order to carry out future laboratory studies on the causes, prevention, diagnosis & treatment of certain cancers.",2000-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
4582,NCT04207918,Local control rate,2019-11-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],,ctDNA in predicting tumor response rate and prognosis
4583,NCT05212025,Overall Response Rate (ORR),2022-06,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Incidence of Grade 3 or Higher Treatment-Related Toxicity
4584,NCT03223376,Progression free survival (PFS),2017-10-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,The European Organization for Reasearch and Treatment of Cancer（EORTC ） Quality of Life Questionnaire-Core 30 V3.0 (QLQ-C30 v3.0)
4585,NCT05451043,Investigating and establishing the efficacy of propranolol in boosting the effects of immunotherapy in biliary tract tumors,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
4586,NCT04594863,SIRT-6 expression,2020-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,
4587,NCT05462717,Dose Limiting Toxicities,2022-09-19,RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-Free Survival (PFS)
4588,NCT03115008,Number of polypectomies for gastroenterology trainees to achieve competency,2017-08-01,COMPLETED,INTERVENTIONAL,['NA'],,
4589,NCT01460745,Percentage of patients who undergo liver resection following downsizing chemotherapy with or without Erbitux,2011-11,COMPLETED,OBSERVATIONAL,['NA'],,"Percentage of liver resection outcomes R0, R1 and R2"
4590,NCT03278925,"Change in gamma-hydroxy-1,N(2)-propanodeoxyguanosine (gamma-OHPdG) expression in cirrhotic liver",2018-08-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Incidence of hepatocellular carcinoma,Polyphenon E pharmacokinetic data in blood and urine in patients with cirrhosis
4591,NCT03488667,Number of Adverse Events related to toxicity.,2018-06-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Programmed cell death ligand 1 (PD-L1) expression in tumor cells
4592,NCT01717729,recurrence rate,2000-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Complete Ablation
4593,NCT01092078,Colon Cancer Screening Behavior,2010-05,COMPLETED,INTERVENTIONAL,['NA'],,Social Influence relating to colon cancer screening
4594,NCT00978549,Overall survival,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Health economic evaluation as assessed by EQ-5D
4595,NCT00019110,,1995-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4596,NCT02995850,II: Safety,2017-02-22,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,RR (response rate)
4597,NCT03316599,The Maximum Tolerated Dose of ficlatuzumab when administered in combination with gemcitabine and nab-paclitaxel,2018-01-17,COMPLETED,INTERVENTIONAL,['PHASE1'],,The progression free survival in this population of patients.
4598,NCT00968175,The efficacy of EUS-CPN and analgesic therapy in pain relief of patients with unresectable pancreatic cancer when compared with analgesic therapy,2009-06,COMPLETED,INTERVENTIONAL,['NA'],,To evaluate the efficacy of EUS-CPN and analgesic therapy in improvement of quality of life (QOL)
4599,NCT03519074,Efficacy Evaluation: Timing,2016-07-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,
4600,NCT01786850,,na,AVAILABLE,EXPANDED_ACCESS,['NA'],,
4601,NCT01688336,Median Overall Survival (OS) of FOLFIRINOX in Patients With Unresectable Locally Advanced (ULA) Pancreatic Cancer,2012-01,TERMINATED,INTERVENTIONAL,['PHASE2'],"Correlation of Tumor Markers (Ca19-9, CEA) With Outcomes (RR, DCR, PFS, and OS).",Rate of Resectability (RR)
4602,NCT04194268,survival,2019-12-03,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life EORTC QLQ Pan26
4603,NCT04022746,Change in percent non-viable/necrotic tumor,2019-06-11,RECRUITING,INTERVENTIONAL,['NA'],,Change in tumor size and enhancement
4604,NCT03811652,Percentage of patients with changes in laboratory parameters from baseline,2018-12-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
4605,NCT04670718,Visualisation of gastrointestinal tract,2020-12-10,COMPLETED,INTERVENTIONAL,['NA'],,Ability to asses depth of invasion of resected GI early tumor
4606,NCT00001693,,1998-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4607,NCT03168594,Overall response rate (ORR),2017-04-29,TERMINATED,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events （Safety and Tolerability）
4608,NCT00730353,Progression Free Survival Rate at 24 Weeks,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity Profile
4609,NCT04444921,Progression-free survival,2020-11-17,RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence of adverse events
4610,NCT05278351,Progression free survival time (PFS),2022-07-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
4611,NCT03120104,Change of The Wexner Score,2017-06,UNKNOWN,INTERVENTIONAL,['NA'],,Change of Functional assessment of Cancer Therapy - Colorectal (FACT-C)
4612,NCT02491372,Change in psychological flexibility assessed using the Acceptance and Action Questionnaire II,2015-09,WITHDRAWN,INTERVENTIONAL,['NA'],,Change in Quality of life using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Oesophageal and Gastric Cancer
4613,NCT05551416,New strategies for gastric cancer (GC) early diagnosis,2021-09-09,RECRUITING,OBSERVATIONAL,['NA'],,Characterization of the microbiome: 16S rRNA studies
4614,NCT03522649,Overall Survival (OS),2018-04-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Disease Control Rate in biomarker positive patients
4615,NCT04072198,ORR,2019-09-26,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life with QLQ-C30 questionnaire
4616,NCT00583271,,2002-06,COMPLETED,OBSERVATIONAL,['NA'],,
4617,NCT00622622,Safety(toxicities as assessed by NCI CTCAE version 3),2006-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,survival
4618,NCT03529669,Completion Rate,2018-04-18,COMPLETED,INTERVENTIONAL,['NA'],,Number of Patients Who Would be Prepared to Repeat the Procedure
4619,NCT03035279,Number of participants with dose-limiting toxicities (DLT),2017-03-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,Maximum observed serum concentration (Cmax) of SC-006
4620,NCT05433402,Disease-free survival,2022-07-20,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Biological Markers,Time occurrence of new primary colon cancer and new polyps
4621,NCT04798612,T-cell infiltration in tumor,2023-08-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,Immunological and inflammatory cytokines and interleukins
4622,NCT01669356,postoperative body composition change compared to preoperation measurement,2012-07,COMPLETED,INTERVENTIONAL,['NA'],complicatons incidence after surgery,
4623,NCT00885066,Clinical or laboratory toxicities as assessed by CTC,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4624,NCT04213222,estimated ORR,2020-10,UNKNOWN,OBSERVATIONAL,['NA'],,estimated OS
4625,NCT02871999,"Pain degree change after surgery, Graded according to Numerical Rating Scale(NRS)",2016-08,COMPLETED,INTERVENTIONAL,['NA'],,Testosterone(Male) in blood
4626,NCT03469284,Change in Pain Scores Assessed Within the Numeric Rating Scale (NRS) Component of the Modified Harris Mucositis-related Pain Assessment Tool,2019-02-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,Pain Duration
4627,NCT02215070,Percentage of GI Toxicity From the Preparatory Regimen and the GVHD Prophylaxis in Stem Cell Transplantation (SCT) Patients Who Are Treated With Pasireotide,2015-01-21,COMPLETED,INTERVENTIONAL,['PHASE2'],Evaluate GI Toxicity Assessment by Video Capsule Endoscopy.,Disease Free Survival Compared to Historical Controls
4628,NCT02632864,two-year overall survival,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Hepatobiliary phase signal change after proton beam therapy
4629,NCT05982834,objective response rate,2023-05-09,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
4630,NCT04713891,Clinically significant abnormality in physical examinations,2021-03-09,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Progression free survival (PFS)
4631,NCT02585687,Global survival,2012-07,TERMINATED,INTERVENTIONAL,['NA'],,
4632,NCT04526314,Overall survival,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
4633,NCT04103697,3-year disease-free survival,2019-08-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE3'],,Preoperative tumor-associated complications rate
4634,NCT01843829,Efficacy,2013-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Efficacy
4635,NCT04081779,Response rate among primary care providers (PCPs) to the PCP survey,2020-02-19,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Local oncology clinics' attitudes towards survivorship care implementation
4636,NCT05914389,TRG0/1,2023-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,Minimal Residual Disease (MRD)
4637,NCT00477841,"Relief of dysphagia measured by dysphagia scores, survival time from the interventional procedure to the last follow-up.",2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Successful rate of stent placement, Stent-related complications and morbidity, Overall rate of mortality"
4638,NCT05024097,Number of treated patients who achieve complete pathologic response,2022-03-31,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
4639,NCT04310839,30-day readmission rate,2020-11-03,COMPLETED,OBSERVATIONAL,['NA'],,Ileus
4640,NCT01008566,Toxicities and tolerability of this regimen as assessed by NCI CTCAE version 4.0,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression-free rate according to the Response Evaluation Criteria in Solid Tumors (RECIST)
4641,NCT01047111,Disease free survival,2010-05,COMPLETED,INTERVENTIONAL,['NA'],,Locoreginal recurrence and recurrence pattern
4642,NCT06088459,All adverse events (AE),2023-11,RECRUITING,INTERVENTIONAL,['PHASE1'],,Immunogenicity
4643,NCT03874871,R0 resection rate,2019-03-20,RECRUITING,OBSERVATIONAL,['NA'],,overall survival
4644,NCT05876338,Change from Baseline in Quality of Life Level on the EORTC QLQ-CR29 Quality of Life,2023-07-11,RECRUITING,INTERVENTIONAL,['NA'],,
4645,NCT03425058,"The concordance and accuracy of response evaluation results determined by ctDNA, CTCs compared with imaging and serum tumor biomarkers(CEA, CA19-9,CA72-4 et al)",2017-11-22,COMPLETED,OBSERVATIONAL,['NA'],,The concordance of mutations in tumor tissue and ctDNA
4646,NCT06168357,Correlation between tumor enhancement in arterial phase expressed as Hounsfield unit number and ADC value.,2024-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
4647,NCT01862003,Best overall response,2014-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Occurrence and Severity of Adverse Events
4648,NCT00023868,,2001-11-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,
4649,NCT01819766,Sensitivity and Specificity of the Exact Sciences IBD-ACRN screening test for CRC.,2013-03,COMPLETED,OBSERVATIONAL,['NA'],,Determine Sensitivity and Specificity of the Exact Sciences IBD-ACRN screening test for CRC and HGD.
4650,NCT01053182,morbidity of postoperative pulmonary complications,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"diaphragm movement, pulmonary function, stomach emptying"
4651,NCT00296114,,2004-02,COMPLETED,OBSERVATIONAL,['NA'],,
4652,NCT00107861,- Evaluate the safety of a single IV administration of Ad.hIFN-β.,2005-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Explore preliminary clinical activity.
4653,NCT02633098,Recurrence free survival at 2 years,2017-04-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,Wnt/β-catenin proliferation pathway protein expression (e.g. c-myc and cyclinD1 proteins)
4654,NCT06178848,frontal spectral power,2023-06-26,COMPLETED,INTERVENTIONAL,['NA'],,Riker sedation-agitation score
4655,NCT01003015,Adverse Event Collection,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Full Pharmacokinetics profile of BAY73-4506 and metabolites (for Korea only)
4656,NCT02407392,"Feasibility as assessed by the ratio of patients approached to recruited, percentage of patients who complete both endoscopies",2015-07,UNKNOWN,INTERVENTIONAL,['NA'],,Number of adverse events
4657,NCT01263353,Evaluate safety and tolerability profile of pasireotide LAR in combination with everolimus in patients with advanced metastatic NET,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To assess the biochemical response (chromograninA, CgA) to pasireotide LAR in combination with everolimus"
4658,NCT05577143,Area under the ROC curve (AUC) of the TFPI-1 biomarker,2022-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Extension of c-index to the 3-group case proposed by Van Calster B et al.
4659,NCT05993923,Change in functional status after colorectal cancer surgery between groups,2023-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,The rate of early unscheduled re-hospitalizations or admissions to the emergency department between groups
4660,NCT04930991,Safety and Tolerability,2021-09-07,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Correlation
4661,NCT00622557,,2007-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
4662,NCT00894725,short-term morbidity rate,2000-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,long-term outcome
4663,NCT04518852,overall survival (OS),2020-09-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],conversion rate of hepatectomy,duration of response
4664,NCT05394714,Maximum Tolerated Dose (MTD) and Recommended Phase II Dose (RP2D),2022-03-10,RECRUITING,INTERVENTIONAL,['PHASE1'],,Changes in Biomarkers (CEA and CA19-9)
4665,NCT00093379,2 Year Failure Free Survival,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Progression-Free Survival at 2-Year
4666,NCT05110378,Oxford NOTECHS II,2015-10,COMPLETED,OBSERVATIONAL,['NA'],,
4667,NCT03766607,"Progression free survival, PFS",2019-09-30,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Adverse event
4668,NCT02727153,Mortality,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Readmission rate
4669,NCT00899626,Development of new screening strategies based on substances found in tissue and biofluid samples,2002-06,RECRUITING,OBSERVATIONAL,['NA'],,
4670,NCT00489515,Ability of surgically defined sentinel lymph nodes to predict whether other lymph nodes are involved with the tumor,1999-02,COMPLETED,OBSERVATIONAL,['NA'],,
4671,NCT01617278,Mean number of adenomas per colonoscopy,2012-01,COMPLETED,INTERVENTIONAL,['NA'],,To estimate the recruitment rate
4672,NCT05639153,"Part 2: Number, severity and duration of treatment-emergent adverse events (TEAEs) according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0",2022-05-13,RECRUITING,INTERVENTIONAL,['PHASE1'],,Immunogenicity by measurement of Incidence of anti-drug antibodies (ADA)
4673,NCT00842686,Pathological complete remission rate (pCR),2009-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life
4674,NCT00884767,"Correlation of genetic profiles and peptide, protein, and neurotrophic factors with neurological toxicity",2007-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
4675,NCT05070156,Evaluate incidence of treatment-emergent adverse events [Safety and Tolerability] after B010-A injection.,2021-10-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Disease control Time (DDC)
4676,NCT00121914,time to tumour progression,2000-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,causes of death
4677,NCT03462992,AUC of the MonoMark test,2012-12-11,UNKNOWN,OBSERVATIONAL,['NA'],,
4678,NCT04278144,"Objective response rate (ORR) of confirmed complete or partial responses (CR, PR)",2020-02-24,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of potential-immune related toxicities
4679,NCT02613156,Perioperative complications,2014-06,COMPLETED,OBSERVATIONAL,['NA'],,relapse-free survival
4680,NCT00539253,Nodule Enhancement,2007-09,COMPLETED,INTERVENTIONAL,['NA'],,
4681,NCT02706184,Common toxicity criteria for diarrhea Version 4.0,2015-07,COMPLETED,INTERVENTIONAL,['PHASE3'],stool microbiome analyses,ECM/BCM-Index
4682,NCT05523778,Rate of POPF within 3 months after EN.,2023-02-06,RECRUITING,INTERVENTIONAL,['NA'],,Total cost of hospitalization
4683,NCT05464875,Duration Of Response,2022-07-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Assessment of dose effect of antineoplastic agents,Vd（volume of distribution）
4684,NCT03317119,"Maximum tolerated dose defined for the combination of trametinib, and Trifluridine and Tipiracil Hydrochloride (TAS?102) as the highest dose level at which 0-1 out of 6 patients experience dose limiting toxicities",2018-04-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival
4685,NCT05751265,Objective Response Rate (ORR),2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression-free survival
4686,NCT02349412,Change in Quality of Life (QOL) From Baseline to Week 12 Per the Functional Assessment of Cancer Therapy-General (FACT-G),2015-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Concordance Between Patient and Family Caregiver Report of Prognosis/Curability
4687,NCT04811898,The recommended phase II dose of LNA-i-miR-221 (RP2D),2019-01-14,COMPLETED,INTERVENTIONAL,['PHASE1'],,To assess the efficacy of LNA-i-miR-221
4688,NCT00786058,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA'],,
4689,NCT02328716,disease-free survival period,2012-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Study of Ex vivo correlation.
4690,NCT02818530,Changes in anterior chamber depth measured by ultrasound.,2017-06-21,TERMINATED,INTERVENTIONAL,['NA'],,Time dependent changes in anterior chamber depth during prolonged trendelenberg position.
4691,NCT01681446,disease free survival,2012-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Number of Participants with Adverse Events
4692,NCT02425683,Number of Patients Completing Full 6 Cycles,2015-03-26,TERMINATED,INTERVENTIONAL,['PHASE2'],,Disease-free survival (DFS)
4693,NCT04121286,Find Recommended Phase 2 Dose (RP2D) of JAB-3312,2020-06-10,RECRUITING,INTERVENTIONAL,['PHASE1'],,Duration of response ( DOR )
4694,NCT05785975,To assess if positive subjects are complying with follow-up screening,2023-06-15,RECRUITING,INTERVENTIONAL,['NA'],,
4695,NCT00152217,Overall survival,2001-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Relapse-free survival, adverse events"
4696,NCT00073138,Objective Response Rate in subjects with Recurrent Colorectal Cancer,2003-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicities associated with treatment administration
4697,NCT02587793,survival,2014-10,COMPLETED,OBSERVATIONAL,['NA'],,cancer progression
4698,NCT02724202,Determine the safety using curcumin in patients with metastatic colon cancer; where toxicities will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.,2016-03,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Duration of Quality of Life
4699,NCT01262417,abdominal and peri-hepatic adhesion during the second operation,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,tumour evolution in patients
4700,NCT02931929,"Preliminary targeting properties of 68Ga-NeoBOMB1 in advanced, GRP positive GIST tumours as assessed by SUV",2016-11-28,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To extrapolate absorbed tumour doses for potential application of 177Lu NeoBOMB1 (in first 6 patients)
4701,NCT00411762,Median Progression Free Survival,2006-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Median Overall Survival
4702,NCT02816879,Accuracy of cytology specimens for Dacron swab compared to flocked nylon (NF) swab in predicting histology outcome,2013-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,"Cost effectiveness analysis evaluating differences in survival, the cost of out-patient procedures & in-patient hospitalizations for invasive anal cancer."
4703,NCT06135571,Metastatic rate of No.253 lymph node,2023-09-01,RECRUITING,OBSERVATIONAL,['NA'],,5-year overall survival rate
4704,NCT03130621,Pedigree analysis,2017-01,UNKNOWN,OBSERVATIONAL,['NA'],,somatic mutation landscape of hereditary upper gastrointestinal cancer
4705,NCT03848182,Change in CD4 T cell responses after TT booster vaccine,2017-07-21,TERMINATED,INTERVENTIONAL,['PHASE2'],Change in myeloid-derived suppressor cells,Change in CD8 T cell responses after TT booster vaccine
4706,NCT00630240,"The blood levels of anticancer drugs (epirubicin, mitomycin C and cisplatin) will be determined within one hour and at the third day after TACE.",2008-02,COMPLETED,OBSERVATIONAL,['NA'],,
4707,NCT04030637,Accuracy of COLOSAFE,2019-02-11,UNKNOWN,OBSERVATIONAL,['NA'],,
4708,NCT00973193,Pathological Complete Response (pCR),2009-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Safety, pathologic R0 resection, negative Circumferential Resection Margin, pathologic downstaging, tumor regression grade, quality of mesorectal excision, rate of sphincter-preservation, Disease-Free Survival, local control rate, translational research"
4709,NCT02210039,Number of Participants With Tolerability of the Procedure,2014-06,COMPLETED,INTERVENTIONAL,['NA'],,
4710,NCT03278327,Suggest that there are significantly more than 60 % of patients with a relative decrease of at least 50 % between the total percentages of esophageal time crossed in pH4 (Ph metric dosage) before and after endoscopic treatment.,2017-06-27,UNKNOWN,INTERVENTIONAL,['NA'],,Use of Inhibitor of the pump with proton (PPI)
4711,NCT02968810,Change in serum AFP-L3%,2017-06-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Change in serum immune markers,Change in Model for End-Stage Liver Disease score
4712,NCT02607787,Feasibility,2015-04,UNKNOWN,INTERVENTIONAL,['NA'],,Capillary blood sample
4713,NCT02404753,3-year progression-free survival,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Postoperative quality of life
4714,NCT03231462,Pulmonary complications,2015-03-06,RECRUITING,OBSERVATIONAL,['NA'],,The change of symptom
4715,NCT02859415,Number of Participants Whose Best Response is a Complete Response (CR) or Partial Response (PR),2019-08-08,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With a Dose-limiting Toxicity (DLT),"To Develop Methodologies for Assessing Effects of Mithramycin on Cancer Stem Cells, Hematopoietic Stem Cells, Mesenchymal Stem Cells, and Circulating Tumor Cells (CTC)"
4716,NCT01128387,MTD of Panitumumab in Combination With Cisplatin/Fluorouracil and Radiation for Locally Advanced Esophageal Cancer Determined by Number of Participants Experiencing DLT,2010-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pathologic Response
4717,NCT03039608,the time when stricture occurs,2017-02-10,COMPLETED,INTERVENTIONAL,['NA'],,the frequency of complications
4718,NCT01023529,Effect on patient's target symptom.,2009-11,COMPLETED,OBSERVATIONAL,['NA'],,Time to improvement in patient's symptoms and QoL.
4719,NCT05728606,Total incidence of postoperative complications,2023-01-20,RECRUITING,INTERVENTIONAL,['NA'],,Robotic surgical completion rate
4720,NCT01937104,ONSD and PaCO2,2013-09,COMPLETED,INTERVENTIONAL,['NA'],ONSD and PaCO2,ONSD and PaCO2
4721,NCT01624025,disease control rate according to the RECIST v1.1,2012-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4722,NCT01962376,progression-free survival(PFS),2013-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],Adverse events,Objective response rate (ORR)
4723,NCT00201318,"We expect to enter 33 patients per year. Taking into account 10﹪dropout rate, we may finish accrual of patients within 3 years.",2001-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4724,NCT01740375,2-year disease-free survival (DFS) rate,2012-11,TERMINATED,INTERVENTIONAL,['PHASE3'],,treatment-related mortality
4725,NCT04653181,postoperative complications,2020-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Need for red blood cell transfusion
4726,NCT04885439,Patient and Caregiver Anxiety,2015-07-01,COMPLETED,INTERVENTIONAL,['NA'],,Patient Symptom Burden
4727,NCT05555888,complete response (CR) rate,2022-12-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,10 year Quality of Life
4728,NCT04969107,disease-specific survival,2012-01-01,RECRUITING,INTERVENTIONAL,['NA'],,recurrence-free survival
4729,NCT00492193,Time to upper and lower GI recovery and post-operative hospital length of stay.,2007-06,COMPLETED,OBSERVATIONAL,['NA'],,Postoperative ileus related mobidity.
4730,NCT05616039,Clinical outcomes- Microscopic positive resection margin rate,2022-11-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Complications
4731,NCT05854394,6-minute-walking-distance (6MWD),2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],,Quality of Life Scale
4732,NCT05904886,Overall Survival (OS),2023-09-14,RECRUITING,INTERVENTIONAL,['PHASE3'],,Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab
4733,NCT01730937,Overall Survival,2013-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality Adjusted Life Years
4734,NCT01996969,Predictive biomarker in terms of disease control rate,2013-10,COMPLETED,INTERVENTIONAL,['NA'],,Assessment of adequate response evaluation modality after regorafenib treatment
4735,NCT01669720,Number of Patients Who Progressed,2012-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Number of Participants Who Experienced a Toxicity Profile of Adjuvant Ziv-aflibercept, up to 2-years of Duration, for Patients Who Previously Received Systemic Perioperative Therapy (Regimen) and Surgical Resection/Ablation."
4736,NCT02576184,radiological incisional hernia rate,2015-12,COMPLETED,INTERVENTIONAL,['NA'],,Clinical incisional hernia rate
4737,NCT02484404,Ph I Determine the recommended phase II dose (RP2D) and the safety of doublet therapies of Durvalumab/olaparib (Durvalumab-O) and Durvalumab/cediranib (Durvalumab-C) in patients with advanced solid tumors,2015-06-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Ph I doublet tx: determine the pharmacokinetics of the doublets and correlate with safety.
4738,NCT01418742,"Time until unblinding of skin therapy allocation (basic skin treatment with or without doxycycline) due to insufficient efficacy (i.e. unbearable skin toxicity, measured by patient's allocating point 6 through 10 on a visual analogue scale)",2011-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Severity of panitumumab related adverse events
4739,NCT00075595,Time to death from progression,2002-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of grade 3 or 4 toxicity
4740,NCT06196658,Objective Response Rate,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,5) Volume of ascites measured by ultrasonography and/or frequency and volume of ascites aspiration
4741,NCT03253107,Discovery of predicting bio-markers for gastric cancer chemotherapy response,2015-11-30,RECRUITING,OBSERVATIONAL,['NA'],,Combination prediction model for palliative chemotherapy response in gastric cancer
4742,NCT05655494,Proportion of patients who self-refer to cancer clinical trials,2023-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Mediators of intervention effectiveness
4743,NCT05113290,Objective response rate (ORR) according to mRECIST criteria,2021-12-28,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Number of participants with adverse events
4744,NCT03898895,"Progression-free survival, PFS",2019-12-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Disease control rate, DCR"
4745,NCT05830019,local progression-free survival,2021-06-01,RECRUITING,INTERVENTIONAL,['NA'],,adverse events
4746,NCT01671891,circulating tumor cells level changes after radiotherapy,2012-02,UNKNOWN,OBSERVATIONAL,['NA'],,RECIST-based tumor response at 10 week after radiotherapy
4747,NCT03169842,Cyst fluid glucose level,2017-05-25,COMPLETED,INTERVENTIONAL,['NA'],,
4748,NCT01457287,Cognitive Function,2003-10,COMPLETED,OBSERVATIONAL,['NA'],,Potential mechanisms leading to fatigue and/or cognitive decline
4749,NCT02065037,Polyp Detection Rate,2014-06,TERMINATED,INTERVENTIONAL,['NA'],patient comfort by a validated nurse administered comfort score,advanced lesion per patient detection rate
4750,NCT00009893,survival at 6 months,2001-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,tumor response rate
4751,NCT05914987,Number of Subjects Receiving Targeted Therapy,2023-12-04,RECRUITING,OBSERVATIONAL,['NA'],,
4752,NCT04677088,Safety evaluation of the TCR-T treatment,2018-03-29,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
4753,NCT01544452,Synchronous colon cancers and liver metastasis,2010-08,TERMINATED,INTERVENTIONAL,['NA'],,sensitivity/specificity of CT versus MR versus Peroperative ultrasonography of the liver
4754,NCT03748485,disease free survival,2019-04-30,RECRUITING,INTERVENTIONAL,['NA'],,complication in 30 days post surgery
4755,NCT02808780,"Long-term Safety: Participants with Adverse Events of Interest (AEIs) and Serious Adverse Events (AEs) Including Malignancies, Pregnancies, and Non-serious Malignancies",2016-12-16,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Health Care Utilization: Evaluate the Reasons for Hospitalization in Participants in Each Cohort
4756,NCT03006926,DLT+Expansion Part: Duration of Response (DOR) Based on RECIST v1.1 Assessed by IIR,2017-02-13,COMPLETED,INTERVENTIONAL,['PHASE1'],,DLT+Expansion Part: Number of Participants Positive for Serum Anti-drug Antibodies (ADA) Status
4757,NCT02191969,To measure the change in fatigue after three months between the intervention and control arm,2014-06,COMPLETED,INTERVENTIONAL,['NA'],,To measure changes in Self-Efficacy at baseline between the intervention and control groups.
4758,NCT00988741,Evaluate time to progression among all patients treated with ARQ 197 compared to placebo,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Further evaluate pharmacokinetics of ARQ 197.
4759,NCT03544255,Number of organoids successfully generated from pancreatic cancer biopsies,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,Response of the pancreatic cancer organoids to the selected anti-cancer drugs
4760,NCT03951337,Relationship between early tumor uptake of 64Cu-ATSM PET/CT images and prediction of histological response to neo-adjuvant chemo-radiotherapy treatment,2019-04-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,64Cu-ATSM toxicity
4761,NCT06307314,Different grades radiotherapy-induced oral mucositis,2024-02-01,RECRUITING,OBSERVATIONAL,['NA'],,Tumor response
4762,NCT05419011,"Cumulative incidence rate of the composite endpoint of adenomas (tubular, tubulovillous and serrated), advanced adenomas and colon cancer",2023-03-22,RECRUITING,INTERVENTIONAL,['PHASE2'],Immune cell gene enrichment analysis,Incidence of extracolonic neoplasms
4763,NCT03221335,Severe adverse events,2016-05,RECRUITING,INTERVENTIONAL,['NA'],,Survival
4764,NCT03276156,Incidence of adverse events,2016-02-23,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Quality of life(QoL)
4765,NCT02512263,Muscular strength measured by Microfet,2015-07,UNKNOWN,INTERVENTIONAL,['NA'],,Depression measured by questionnaire
4766,NCT01897636,pancreatic tumor response rates,2013-12,UNKNOWN,INTERVENTIONAL,['NA'],,survival rates
4767,NCT05752890,To distinguish the clonality of recurrent HCC as the original or a de novo one for post-radiotherapy patterns of failure,2023-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
4768,NCT06046846,To investigate the usability in terms of user satisfaction of the asensei app to deliver a mHealth prehabilitation programme.,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Semi structured interviews,To collect preliminary data and assess for change on a participants quality of life by using the EORTC QLQ-OG25 questionnaire in order to inform the sample size for a fully powered RCT as part of the feasibility study.
4769,NCT00088933,Number of patients experiencing each of the toxicities by grade for each treatment arm,2004-06,TERMINATED,INTERVENTIONAL,['PHASE1'],,Average quantity of circulating CEA cells determined by quantitative real time RT-PCR
4770,NCT01821482,progression-free survival(PFS),2013-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],Laboratory findings,quality of life (QOL)
4771,NCT04160897,The 5-year cumulative incidence of hepatocellular carcinoma,2019-10-22,UNKNOWN,OBSERVATIONAL,['NA'],,The 5-year cumulative liver disease-related mortality
4772,NCT01618474,disease free survival,2012-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,CTC negative conversion rate
4773,NCT03126071,PFS,2017-02-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],,AEs
4774,NCT00161213,Progression-free Survival,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
4775,NCT05205187,Response of target organ,2022-02-28,RECRUITING,OBSERVATIONAL,['NA'],,
4776,NCT04192071,Information seeking behavior,2020-01-06,RECRUITING,INTERVENTIONAL,['NA'],,
4777,NCT05440708,Phase 2: Overall Response Rate (ORR) to TTI-101,2023-03-23,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Cohort A and Cohort B: Pharmacodynamics of TTI-101 as Measured By Change from Baseline in Percentage of Phosphorylated Signal Transducer and Activator of Transcription 5 (pY-STAT5) Positive Cells in Tumor Biopsy Samples
4778,NCT03554434,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
4779,NCT06250075,The use of probiotics can modify the incidence of postoperative complications,2020-12-12,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Modulation of nutritional parameters using probiotics-phase angle
4780,NCT04779554,Drug Half-Life (T1/2) - Pharmacokinetics,2021-06-04,RECRUITING,INTERVENTIONAL,['PHASE2'],,
4781,NCT01946854,Tumor Growth Rate,2013-07-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
4782,NCT04506983,Percentage of adverse events,2022-06-10,SUSPENDED,INTERVENTIONAL,['PHASE1'],,Proliferation ratio of CAR-T cells
4783,NCT01082224,Sensitivity of contrast-enhanced CT scan vs contrast-enhanced MRI for diagnosing hepatocellular carcinoma (HCC),2010-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Diagnostic value of sensitivity and PPV when patients are stratified by AFP level (elevated vs normal)
4784,NCT05358249,PhaseII: Overall Response Rate by Blinded Independent Review Committee (BIRC) per RECIST 1.1,2022-10-24,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II: Dose intensity by treatment
4785,NCT04302363,Diagnostic efficacy of colorectal cancer model in Chinese people,2018-02-01,UNKNOWN,OBSERVATIONAL,['NA'],Effects of intestinal microflora and DNA methylation under different stool characteristics,Effect of diet on intestinal flora and DNA methylation in Chinese people
4786,NCT01962246,Disease-free survival(DFS),2012-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Death related to operation
4787,NCT00385203,"Tumour Metabolic Activity as Assessed by Change in Central Review of Standardised Uptake Value (SUVMax) at Day 29, in Patients With GIST Tumours. SUVmax at Day 29 Minus SUVmax at Baseline.",2006-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Anti-tumour Activity as Measured by Total Lesion Volume at Week 16 in GIST Patients by Central Review of CT Images.
4788,NCT00511576,To determine the overall tumor response of orally administered MGCD0103 in combination with IV docetaxel according to Response Evaluation Criteria in Solid Tumors (RECIST) methodology.,2007-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,
4789,NCT03429816,Aim 2: Correlation of molecular subtypes with histological response after neoadjuvant therapy in patients,2018-04-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Aim 2: Correlation of molecular subtypes with overall survival,Aim 2: Correlation of molecular subtypes with relapse-free survival
4790,NCT00988195,"Plasma arginase and arginine levels,as well as tumour response, i.e. an effect on growth in the milieu of arginine depletion.",2008-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Overall Survival, Time to Progression"
4791,NCT00164892,Recurrence free survival and the quality of life score within the two years of study period,2004-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Overall survival in long term
4792,NCT03963726,PFS,2019-06-03,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of life score of tumor patients(0-60)
4793,NCT05533892,Objective response rate (ORR) at 6 months,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Duration of response (DOR)
4794,NCT02106871,Skeletal Muscle Fatigue,2014-04,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
4795,NCT01460589,3-year disease free survival rate,2011-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,side effects of chemotherapy
4796,NCT01972373,Sensitivity of the marker bevacizumab-IRDye800CW,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Collection of safety regarding administration of Bevacizumab-IRDye800CW
4797,NCT00507273,Current patterns of medical practice in management of patients with GIS,2005-08,COMPLETED,OBSERVATIONAL,['NA'],,
4798,NCT01227239,Phase II: pathological complete response rate,2010-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,safety
4799,NCT05818267,duration of disease control(DDC),2023-06-26,RECRUITING,INTERVENTIONAL,['NA'],,The incidence of adverse events
4800,NCT03757754,The number of dose-limiting toxicity,2015-06-03,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Area under the concentration-time curve from zero extrapolated to infinity (AUC0-∞)
4801,NCT01071824,Pouch function 4 month after closure of protective ileostomy.,2009-06,UNKNOWN,INTERVENTIONAL,['NA'],,Pouch function 2 and 12 month respectively after closure of protective ileostomy.
4802,NCT01211561,Reduction in ACF biomarkers,2010-12,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,
4803,NCT06189898,Progression free survival,2023-12-15,RECRUITING,OBSERVATIONAL,['NA'],,loco-regional recurrence free survival
4804,NCT00003431,,1998-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4805,NCT04172532,Progression-free survival rate (Phase II),2021-01-11,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Gene signature of cell-free DNA from peripheral blood,Gene signature of tumor
4806,NCT00795184,"Comparative Histopathology-confirmed Measures of Per Lesion Sensitivity and Per Lesion Specificity, by Using pCLE Associated With WLE, or WLE Alone, for the Detection of High Grade Dysplasia and Early Carcinoma in Barrett's Esophagus.",2008-11,COMPLETED,INTERVENTIONAL,['NA'],,
4807,NCT01938326,Maximum pain score using VAS at postoperative day#1,2017-09-01,COMPLETED,INTERVENTIONAL,['NA'],,EORTC-C30 and STO22
4808,NCT03115957,Morbidity of infection,2017-04-14,COMPLETED,INTERVENTIONAL,['NA'],,Laboratory examination
4809,NCT04058236,Changes in serum heparan sulfate concentrations,2019-08-15,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Changes in levels of Inflammatory markers Interleukin-1 and CRP
4810,NCT06164769,blood loss,2023-03-01,RECRUITING,INTERVENTIONAL,['NA'],,
4811,NCT00867724,Ability to screen the entire length of the colon to the cecum.,2009-09,COMPLETED,INTERVENTIONAL,['NA'],,"Safety endpoints to include incidence of bowel perforation, Colonic bleeding, Damage to colon, rectum and anus mucosa or any other Adverse events"
4812,NCT04372992,Percentage of participants with good compliance to adjuvant therapy,2020-09-01,TERMINATED,INTERVENTIONAL,['NA'],,Costs analysis
4813,NCT02138929,"Maximum Tolerated Dose (MTD) of LDE225 in Combination with Everolimus in Participants with Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction (GEJ) or Stomach in the Second or Third Line Setting",2014-11-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Safety of LDE225 in Combination with Everolimus in a Cohort of Participants with Metastatic Nuclear Gli-1 Expressing Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach per CTCAE."
4814,NCT03404076,Progression free survival after a three year follow-up,2014-12-01,COMPLETED,OBSERVATIONAL,['NA'],,
4815,NCT04246203,DFS,2021-12-12,RECRUITING,OBSERVATIONAL,['NA'],,
4816,NCT03042416,Immediate safety evaluation,2017-06-29,COMPLETED,INTERVENTIONAL,['PHASE3'],,Perceived clinical benefit
4817,NCT00094809,Grade 4 Neutropenia,2003-02-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Antibiotic Use Due to Febrile Neutropenia
4818,NCT00451022,To facilitate the continuous usage of stored research specimens collected from subjects under completed and ongoing protocols.,2004-09-13,RECRUITING,OBSERVATIONAL,['NA'],,
4819,NCT05817201,Overall survival,2022-07-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Progression-Free survival
4820,NCT00613743,difference of pain alleviation in the two branches one hour after mouthwash and as well as the duration of pain relief.,2007-12,COMPLETED,INTERVENTIONAL,['NA'],,the requirement of supplementary systemic analgesics
4821,NCT00131599,,2002-08,UNKNOWN,OBSERVATIONAL,['NA'],,
4822,NCT01246986,Time to Progression (TTP),2011-03-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Worsening (TTW) of Symptoms (FACT-Hep)
4823,NCT00010270,,2001-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
4824,NCT00982059,The proportion of screened patients with any polyp or any high risk polyp will be calculated.,2008-05,COMPLETED,OBSERVATIONAL,['NA'],,Proportion calculation/identification of: demographic/treatment influences on polyp prevalence; subgroups w/polyp prevalence >20%; pts with polyps beyond 30cm flexible sigmoidoscope; pts with adenomatous polyp(s) on colonoscopy in/outside prior RT fields
4825,NCT01640665,Maximum Tolerated Dose / Safety,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Response
4826,NCT02915965,overall survival rate,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of adverse event based on CTCAE 4.0
4827,NCT00525785,Complete Pathologic Response Rate,2004-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4828,NCT04622098,Estimating the prevalence and types of sub-epithelial lesions among patients undergoing EGDs in Egypt.,2020-11-18,UNKNOWN,OBSERVATIONAL,['NA'],,characterization of SEL in Egypt
4829,NCT06089369,Recurrence-Free Survival (RFS) at 24 Months,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Hepatocellular Carcinoma Module (EORTC QLQ-HCC18) Scale Score
4830,NCT01129206,Overall Response,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Correlation of FDG PET Response With Response Rate
4831,NCT05987514,predicting HCC response to treatment,2021-10-07,RECRUITING,INTERVENTIONAL,['NA'],,predicting disease-free survival
4832,NCT02325648,pulmonary vascular permeability index,2014-12,COMPLETED,OBSERVATIONAL,['NA'],,
4833,NCT03412994,Progression-free survival (PFS),2018-02-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life(QoL)
4834,NCT01574027,Reduction in ACF biomarkers,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4835,NCT05686499,ratio of low-fidelity simulator trained endoscopists with improved colonoscopy performance on real patients to high-fidelity simulator trained endoscopists with improved performance on real patients,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
4836,NCT04555265,Early tumor recurrence,2020-09-01,COMPLETED,INTERVENTIONAL,['NA'],,Other tutor recurrence
4837,NCT05303714,Secondary Resectability Rate (percent),2022-03-31,RECRUITING,INTERVENTIONAL,['PHASE3'],,Complication rate
4838,NCT05880472,Number of adverse event per patient per grade by CTCAE v5.0,2023-05,RECRUITING,INTERVENTIONAL,['NA'],Implantation experience by questionnaire to the operator,Operator hand and total body dose (mSv)
4839,NCT01838317,Glucose to Insulin Ratio,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Changes in Serum and MRI End Points
4840,NCT04358354,Overall Survival (OS),2020-10-22,RECRUITING,INTERVENTIONAL,['PHASE3'],,Treatment associated toxicities
4841,NCT00974948,"Absolute and relative changes in 7-point Likert-score for abdominal pain at 1 and 3 months post-randomization. Secondary endpoints were change in morphine equivalent consumption (MEQ), quality of life (DDQ-15), and overall survival.",2006-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,2. Quality of life 3. Survival
4842,NCT00994864,"Examine the predictive value of PET-assessed tumour FDG uptake response after one course of preoperative chemotherapy on the outcome of adjuvant therapy, measured by 3-year DFS.",2009-11,COMPLETED,INTERVENTIONAL,['NA'],,Create a frozen tumour bank for future studies
4843,NCT04736121,Duration of Response (DoR),2021-05-28,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life metrics - EQ-5D-5L Questionnaire
4844,NCT02988635,Functional Assessment of Cancer Therapy-General (FACT-G) (Quality of life measure),2014-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Resource utilization at the end of life (EOL): emergency room admissions
4845,NCT00449163,Overall Survival up to 2 Years,2006-03-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Rate of Toxicity in Study Participants
4846,NCT02621658,Adenoma Detection Rate,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],,Patient satisfaction
4847,NCT00882869,To evaluate the efficacy of AEG35156 in combination with sorafenib based on PFS(PII) using sorafenib alone for comparison,2009-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To determine the response rate of AEG35156 in combination with sorafenib in advanced HCC
4848,NCT01560949,Number of Participants With Resectability Rate,2012-06-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants Correlative Studies Including DPC4 (SMAD4) Staining and Circulating Tumor Cells (CTC) Post-Surgery
4849,NCT00758381,Progression Free Survival,2007-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,- overall Response Rate (RECIST Criteria) - duration of response - overall survival time
4850,NCT02845986,overall postoperative morbidity rates,2016-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The variation of prealbumin
4851,NCT02415699,Disease free survival,2015-08,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Side Effect
4852,NCT02526043,Overall survival,2015-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Incidence of postoperative complications
4853,NCT01697072,Overall Survival,2012-10,TERMINATED,INTERVENTIONAL,['PHASE3'],,Immunogenicity
4854,NCT00983801,Percentage of Participants With Overall Response Rate (ORR) Based on Modified Response Evaluation Criteria in Solid Tumors (RECIST),2009-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Best Response as Assessed With Modified RECIST,Number of Participants With Serum Chemistry Abnormalities
4855,NCT04695847,Part 2: Duration of Response (DoR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigators,2021-01-13,COMPLETED,INTERVENTIONAL,['PHASE1'],,Part 2: Number of Participants with Corrected QT Interval (QTc)
4856,NCT02961998,Incidence of participants with clinically definite Sorafenib-related Hand Foot Syndrome,2015-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,Overall survival
4857,NCT06252974,Accurate diagnose the invasion depth of early esophageal squamous cell carcinoma by endoscopy NBI images through deep neural network analysis,2024-02-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
4858,NCT02499939,Functional Assessment of Cancer Therapy Gynecological Oncology Group Neurotoxicity-12 item scale,2016-02-10,COMPLETED,INTERVENTIONAL,['NA'],,Balance Assessment
4859,NCT05621707,Overall Survival Rate,2022-11-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Treatment related complications
4860,NCT00593073,Baseline assessment while waiting to see primary care physician and 90-day follow-up telephone survey.,2005-07,COMPLETED,INTERVENTIONAL,['NA'],,Follow-up survey to assess participant discussion of colorectal cancer with their healthcare provider and compliance with CRC screening
4861,NCT01601808,Overall survival,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Patient pain assessment
4862,NCT03665714,Change of Serum Prealbumin level,2018-10-23,COMPLETED,INTERVENTIONAL,['NA'],,Incidence of postoperative Infections
4863,NCT03274427,Progression-free Survival,2017-07-18,UNKNOWN,INTERVENTIONAL,['PHASE3'],,quality of life
4864,NCT01984658,Safety and tolerability,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Safety & efficacy; Quality of life,Efficacy; Tumor change
4865,NCT02451384,the changes of CTCs countings between the pre and post-operation among the arms,2015-06,UNKNOWN,INTERVENTIONAL,['NA'],,
4866,NCT02999217,Changes in haemoglobin level,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Duration of hospital stay
4867,NCT06149546,Effectiveness of a multi-modal nutrition-led intervention in preventing loss of muscle strength (hand-grip strength) during chemotherapy,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Effectiveness of the intervention compared to the control on Overall Survival
4868,NCT00398333,"To assess the efficacy of a nutritional intervention with supplementation enriched in EPA to improve the tolerance to the antineoplastic treatment, using the variation in quality of life changes as the tolerability index.",2005-06,TERMINATED,INTERVENTIONAL,['PHASE4'],,To assess the effect of a nutritional supplement over the nutritional status of the patient with disseminated neoplastic illness.
4869,NCT02448966,Long term survival,2015-01,UNKNOWN,OBSERVATIONAL,['NA'],,Postoperative complications
4870,NCT02157974,Hepatic glucose release,2014-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Bile Acid Metabolomics: sphingosine-1-phospate,Hepatic de novo lipogenesis
4871,NCT00436514,,2007-04,COMPLETED,INTERVENTIONAL,['NA'],,
4872,NCT05612477,Feasibility -Accrual,2023-01-21,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Safety- HCC recurrence
4873,NCT01624090,Number of Participants With an Objective Response (Complete Response + Partial Response),2012-09-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Serious and Non-Serious Adverse Events
4874,NCT04692545,Length of hospital stay,2016-12-01,COMPLETED,OBSERVATIONAL,['NA'],,Prolonged length of stay
4875,NCT05022030,Progression free survival (PFS) rate at 9 months,2021-07-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse event rate
4876,NCT06181201,histological response according to Ryan classification,2024-01-19,RECRUITING,OBSERVATIONAL,['NA'],,
4877,NCT05983406,DEP accuracy,2023-08-01,RECRUITING,INTERVENTIONAL,['NA'],,
4878,NCT01583699,Qualitative MALT-features on Endomicroscopy,2012-04,COMPLETED,INTERVENTIONAL,['NA'],,Sensitivity and Specificity of Endomicroscopy to diagnose GI-MALT-Lymphoma
4879,NCT05334069,Provision of blinded reference set of cancer versus non-cancer blood samples,2022-08-01,RECRUITING,OBSERVATIONAL,['NA'],,Test performance at the time of initial cancer diagnosis by clinical stage
4880,NCT04292496,Anastomotic leakage,2018-09-01,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative surgical complications
4881,NCT04206254,2-year recurrence-free survival rate,2019-12-19,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Overall survival
4882,NCT04667403,Satisfaction of patients with advanced or metastatic pancreatic cancer of the impact of telemedicine in the management of their pain.,2022-02-07,UNKNOWN,INTERVENTIONAL,['NA'],,Number of unscheduled hospitalizations recorded of each patient.
4883,NCT00002655,,1995-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4884,NCT05327452,Change in Physical Activity Participation,2022-10-31,RECRUITING,INTERVENTIONAL,['NA'],,Biomarkers for Cardiovascular and Metabolic Health - c-reactive protein
4885,NCT05118724,Disease-free Survival (DFS),2021-12-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
4886,NCT04430985,Disease-free Survival at 3 years,2020-09-30,WITHDRAWN,INTERVENTIONAL,['PHASE2'],"Explorative analysis of biomarkers predictive of response to the combination of nivolumab, ipilimumab in combination with FOLFOX",Safety and tolerability of the treatment
4887,NCT02230553,overall response rate,2014-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
4888,NCT01196494,,na,TERMINATED,INTERVENTIONAL,['NA'],,
4889,NCT05797870,The objective response rate,2024-02-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
4890,NCT03422601,disease-free survival (DFS),2017-07-13,UNKNOWN,OBSERVATIONAL,['NA'],,
4891,NCT01464918,Total time taken to complete the ESD procedure,2011-11,UNKNOWN,INTERVENTIONAL,['NA'],,Safety
4892,NCT02869503,Survival of patients with colorectal cancer,2001-01,RECRUITING,OBSERVATIONAL,['NA'],,Collection of patients characteristics
4893,NCT02647671,Colonic-mucosal Associated Metabolomic Profile.,2016-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Biomarkers of liver function
4894,NCT05030493,Progression-Free Survival (PFS),2021-08-31,RECRUITING,OBSERVATIONAL,['NA'],,"Evaluation of Correlation between Change in Gene Expression Region in Tumor Tissue at Baseline and Discontinuation of Protocol Treatment of Main Study, and Efficacy Endpoints (OS and PFS)"
4895,NCT03890354,Post operative compliction,2019-02-21,COMPLETED,OBSERVATIONAL,['NA'],,Surgical outcome
4896,NCT00524121,Overall Survival,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response by EGFR Mutation Status
4897,NCT02916199,Incidence rate of post-endoscopic retrograde cholangiopancreatography,2016-10-04,COMPLETED,INTERVENTIONAL,['NA'],,Success rate of stone removal
4898,NCT02460822,Patient Satisfaction and Usability of the MyChemoCare Application,2014-10,COMPLETED,INTERVENTIONAL,['NA'],,Improved Quality of Life
4899,NCT06009484,Postoperative venous thromboembolic event,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
4900,NCT05453435,12-month HBV reactivation rate,2022-07-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of HBV-related chemotherapy disruption
4901,NCT06252545,The clinical trial education and communication needs,2024-02-02,RECRUITING,INTERVENTIONAL,['NA'],,
4902,NCT02119065,Absolute difference in post-therapy Yttrium-90 microsphere and pre-therapy Technetium-99m macroaggregated albumin hepatopulmonary shunt fraction values,2014-01-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,In vitro Technetium-99m macroaggregated albumin particle size and microsphere size for each patient
4903,NCT04461561,"The NoMAD Instrument, to describe respondents' experiences of using the intervention in the workplace.",2020-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,"The interview, using framework analysis, informed by normalization process theory toolkit"
4904,NCT00049296,"Determine the maximum tolerated dose of docetaxel when administered with thalidomide in patients with advanced solid tumors, multiple myeloma, and non-Hodgkin's lymphoma.",2002-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4905,NCT00621036,Safety and tolerability,2007-10-19,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Kinetics of humoral immune response development
4906,NCT02380443,To evaluate the anti-tumor effect of AlloStim combined with cryoablation at the new proposed dose and frequency schedule (Part 2),2016-09,COMPLETED,INTERVENTIONAL,['PHASE2'],"Immunological response 9whether immune response correlates with Overall Survival (OS), RECIST and histopathology)",To assess change from baseline in Health-Related Quality of Life (HRQoL)
4907,NCT05524844,Correlation between Enterobacteriaceae (from 16S) and NOTCH3 expression in BE tissue.,2021-02-09,RECRUITING,OBSERVATIONAL,['NA'],,
4908,NCT05512182,objective response rate (ORR),2022-09-15,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v 5.0
4909,NCT02239328,Patient Reported Outcomes Measurement Information System (PROMIS) Scores.,2014-08,COMPLETED,OBSERVATIONAL,['NA'],,
4910,NCT01669668,"Local recurrence, defined as the recurrence at the size of original tumor",2014-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Ability of patients who develop recurrence to undergo salvage transplantation
4911,NCT03089268,Risk of developing metachronous advanced lesions or cancers,2017-06-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Prevalence of serrated lesions in FOBT screening population
4912,NCT03628079,Tumour response: CT/MRI assessed according to RECIST 1.1,2018-05-25,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Association between S-mebendazole and efficacy and safety,Change in tumour load and TTP according to irRECIST
4913,NCT01392027,Validation of glycoprotein panel as a pancreatic cancer biomarker,2011-04,COMPLETED,INTERVENTIONAL,['NA'],,
4914,NCT01422928,Changes in immune biomarker levels,2010-12,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Changes in Symptom Scores
4915,NCT00242502,Progression-free Survival (PFS) Rate,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4916,NCT04217083,Test Sensitivity and specificity for colorectal cancer,2019-01-02,UNKNOWN,OBSERVATIONAL,['NA'],,Test Sensitivity and specificity for colorectal polyps
4917,NCT04787354,disease-free survival,2021-11-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Toxicity profiles
4918,NCT00159445,"To assess time to progression in patients with metastatic colorectal cancer treated with a combination of gemcitabine and capecitabine after progressing on two or more therapies for advanced disease, and having failed both CPT-11 and Oxaliplatin bas",2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,To test the hypothesis that increased gene expression levels predict chemoresistance to capecitabine.
4919,NCT01276379,Progression Free Survival,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumoral Response
4920,NCT02276300,Safety and tolerability of HER2-derived peptide vaccination measured by clinical and chemical parameters.,2014-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4921,NCT04033107,Progression-free survival,2020-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v3.0
4922,NCT02066233,Median Tolerability Score on 10-point Visual Analog Scale (VAS),2014-03,COMPLETED,INTERVENTIONAL,['NA'],,"Preference for Either of the Two Procedures, EG II Scan Versus Standard Endoscopy"
4923,NCT00003652,,1999-01-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,
4924,NCT05587387,Overall survival (OS 2),2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],,Adverse event
4925,NCT03828266,Abdominal Infection rate after colorectal surgery.,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Outcome of Abdominal Infection Treatment
4926,NCT04512417,Progression-free Survival (PFS) per RECIST 1.1,2020-08-31,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Failure mode
4927,NCT03995017,Overall Response Rate (ORR),2020-01-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
4928,NCT04494945,Cascade screening rate among Lynch or HBOC positive carriers,2020-03-09,RECRUITING,INTERVENTIONAL,['NA'],,
4929,NCT02044224,Patient Satisfaction With Anaesthesia Technique,2014-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,Description of patient characteristics
4930,NCT05412576,The incidence of moderate to severe pain (NRS score≥4）during movement (i.e.deep breathing) 24 hours after surgery,2021-06-01,COMPLETED,INTERVENTIONAL,['NA'],,Length of hospital stay
4931,NCT04201730,The time to first flatus,2019-12-25,COMPLETED,INTERVENTIONAL,['NA'],,Incidence of postoperative complications
4932,NCT00193817,Overall survival,2005-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of Life
4933,NCT02638766,Disease Control Rate,2015-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life by EQ-ED-5L questionnaire
4934,NCT00416793,Overall Survival Rate at 6 Months,2006-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Response Rate
4935,NCT04915599,Change in Feasability Questionnaire (regarding Patient reported tolerance of cryotherapy with Cooral ®),2021-06-22,COMPLETED,INTERVENTIONAL,['NA'],,Change in degree of acute OM up to 6 weeks after EOT
4936,NCT05801666,Arts' Dumping Questionnaire,2023-02-10,RECRUITING,INTERVENTIONAL,['NA'],,Medical charts and drug use.
4937,NCT06286956,Assess that the use of the device meet the established functional requiremnt of allowing the removal of polyps,2021-04-19,RECRUITING,INTERVENTIONAL,['NA'],,Assessment of anorectal continence
4938,NCT00004234,,1999-08-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,
4939,NCT03655223,Incidence Rates: Number of newborns who screen positive comparative to the whole sample,2018-10-15,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Impact of Screening: Semi-structured parent interviews.
4940,NCT04181970,Percentage of patients with advanced GIST with available molecular status of KIT/PDGFR before initiating systemic therapy for advanced disease,2019-06-30,RECRUITING,OBSERVATIONAL,['NA'],,Percentage of amputation
4941,NCT01060423,Progression free survival rate,2010-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall survival
4942,NCT05822752,Best Overall Response (BOR) per Investigator,2023-09-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
4943,NCT03196791,Number of Retrieved Lymph Nodes Per Participant,2017-10-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Intraoperative Blood Loss Amount
4944,NCT04718038,Progression-free survival(PFS),2016-07-01,COMPLETED,OBSERVATIONAL,['NA'],,Safety
4945,NCT00633334,"The first goal of this proposal is to collect cells from the peripheral blood, tumor draining lymph nodes and tumor infiltrating lymphocytes in patients with early or late stage gastrointestinal cancers.",2003-09,COMPLETED,OBSERVATIONAL,['NA'],,"The second goal is to evaluate using novel proteomic, CellomicTM, and genomic techniques the serum and peripheral blood lymphocytes of these patients for protein, cellular changes and genetic markers that correlate with the presence of cancer."
4946,NCT00225745,To evaluate plasma ghrelin levels in patients with pancreatic cancer and compare with age matched controls,2004-04,COMPLETED,OBSERVATIONAL,['NA'],,To generate hypotheses for future studies and treatment based on the findings
4947,NCT03895359,Time to Intrahepatic Progression,2019-05-27,RECRUITING,INTERVENTIONAL,['PHASE3'],,Cost-benefit
4948,NCT03227926,Overall response rate (ORR) to panitumumab according to RECIST v1.1.,2017-10-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity according to CTCAE version 4.03.
4949,NCT00034502,,na,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
4950,NCT05174325,Pathologic complete remission (PCR),2020-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Radiographic response
4951,NCT06325267,Clinical characteristics of overall cohort by liver disease etiology,2010-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Risk factors of prognosis in overall cohort and different etiologies
4952,NCT00711412,Determine Pathologic Complete Response,2006-05-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,Correlate Proteomic and Pharmacologic Characteristics With Prognosis and Response to Therapy.
4953,NCT05174286,CRC Screening Uptake,2023-03-19,RECRUITING,INTERVENTIONAL,['NA'],,Change in Life's Simple 7 Score (CVD Risk Screening Measure)
4954,NCT02164448,gas passing,2014-06,COMPLETED,INTERVENTIONAL,['PHASE4'],soft diet time,sips of water time
4955,NCT05179824,Create robust data set of health information,2020-10-19,RECRUITING,OBSERVATIONAL,['NA'],Review medical information for standard of care decisions and health outcomes,Evaluate longitudinal paired tissue and cell free molecular testing
4956,NCT02192983,Response rate,2008-11,COMPLETED,OBSERVATIONAL,['NA'],,
4957,NCT05247905,Progression free survival (PFS),2022-03-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Change in Overall Quality of Life Question (Q30) from the EORTC QLQ-C30 questionnaire
4958,NCT01514045,Collect detailed clinical and epidemiological information on patients with gastric cancer; with a family history of gastric cancer in a first or second degree relative; or persons with a known germline mutation in their CDH1 (E-Cadherin) gene,2011-04,RECRUITING,OBSERVATIONAL,['NA'],,
4959,NCT05829291,Safety - Adverse events,2023-10-01,RECRUITING,INTERVENTIONAL,['NA'],,To evaluate the radiological response of liver metastases using the RECIST criteria .
4960,NCT04554771,Efficacy defined as pathological response to chemoradiotherapy according to the Mandard criteria,2021-01-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Predictive biomarkers using oa RNA sequencing,Feasibility delay
4961,NCT01595217,"EHCC performance on DWI, ADC map and MRCP",2012-03,COMPLETED,INTERVENTIONAL,['NA'],,"ADC, SNR, CNR and SIR for EHCC lesion under different b values"
4962,NCT02055313,Qualitative Data Collection: Patients' Experience of Exceptional Disease Course,2012-05,COMPLETED,OBSERVATIONAL,['NA'],,
4963,NCT02868242,Percentage of Participants Who Permanently Discontinued Study Drug Due to an Adverse Event,2016-08-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Virologic Failure
4964,NCT05496270,3-year diseases free survival,2014-01,COMPLETED,OBSERVATIONAL,['NA'],,Local recurrence rate
4965,NCT02335411,Objective Response Rate For PD-L1 Positive Participants in Cohorts 1 and 3,2015-02-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Control Rate For PD-L1 Positive Participants
4966,NCT01867918,Overall survival from time of randomization,2013-05,TERMINATED,INTERVENTIONAL,['NA'],,
4967,NCT02192541,Maximum Tolerated Dose (MTD) of the Combination of Ganetespib and Ziv-aflibercept,2014-12-02,TERMINATED,INTERVENTIONAL,['PHASE1'],Number of Participants Who Had a Dose Limiting Toxicity (DLT),Number of Cycles on Treatment
4968,NCT01492907,Pharmacokinetic Metabolite Profile of Radiolabeled MeIQx in Urine,2012-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Quantify ambient adducts in the human pancreas
4969,NCT06163365,Primary hypothesis,2022-07-26,RECRUITING,OBSERVATIONAL,['NA'],,Secondary hypothesis
4970,NCT05604950,Selection of treatment modalities for elderly patients with oesophageal cancer,2009-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
4971,NCT04981665,2-year Recurrence Free Survival Rate (2-year RFS rate),2021-11-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events (AEs)
4972,NCT05190445,Overall response rate (ORR) as defined by RECIST v1.1,2021-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Compare levels of HER2 protein expression and/or gene amplification and HER2 gene amplification in ctDNA isolated before treatment initiation with clinical benefit derived from study treatment,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
4973,NCT02157363,operating time,2014-06-16,TERMINATED,INTERVENTIONAL,['NA'],,
4974,NCT03132792,"Number of subjects with dose-limiting toxicity (DLT) and adverse events (AEs) and determination of optimally tolerated dose range, including serious adverse events (SAE).",2017-05-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Interval between the date of first T cell infusion and date of disease progression or death due to any cause
4975,NCT02072486,Overall survival (OS),2013-11-18,COMPLETED,INTERVENTIONAL,['NA'],Proportion of cluster of differentiation (CD)8+ T cells expressing granzyme B,"Granzyme B level variations by presence of grade 3 or higher AE, characterized using National Cancer Institute Common Terminology Criteria for Adverse Events severity grade"
4976,NCT05788874,SUVmax,2023-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
4977,NCT01383707,Objective Response Rate (ORR) in the Per-protocol Analysis Set (PPAS),2011-08-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
4978,NCT00719797,Progression free survival,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Surrogate markers predictive of bevacizumab activity
4979,NCT06147037,Maximum tolerated dose of [225Ac]-FPI-2068 and FPI-2053,2024-02-27,RECRUITING,INTERVENTIONAL,['PHASE1'],,"To assess the immunogenicity of [111In]-FPI-2107, [225Ac]-FPI-2068, and FPI-2053"
4980,NCT00303745,Stable disease rate,2006-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Progression-free and overall survival
4981,NCT04829383,Frequency and severity of toxicities,2021-03-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Median overall survival (OS)
4982,NCT05892354,The incidence of severe oral mucositis,2023-06-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Number of participants with adverse events
4983,NCT02063230,"Dose Normalized Cmax, Unbound Selumetinib",2014-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4984,NCT05648955,Change in cross-sectional skeletal muscle mass area on the third vertebral level (L3) [cm2],2023-03-31,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Change in physical function,Change in health-related quality of life as measured with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30 global health score)
4985,NCT04102098,"Recurrence-Free Survival (RFS), as Determined by IRF",2019-12-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab
4986,NCT01349517,Health related quality of life,2011-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Morbidity Mortality Survival rate
4987,NCT04751955,Progression free survival,2022-01-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life by FACT-C v4.0
4988,NCT00868569,overall survival,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,resection rate of liver metastasis progression-free survival
4989,NCT00682227,Safety (toxicities as assessed by NCI CTCAE version 3),2006-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Immunological and clinical response
4990,NCT05194072,Number of participants with dose limiting toxicities (DLTs),2022-01-12,RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of antidrug antibodies (ADAs)
4991,NCT02613650,Incidence of dose limiting toxicities (DLTs) of combination MEK162 and mFOLFIRI,2016-08-19,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4992,NCT06167421,Severe complication rate,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Postoperative quality of life assessment
4993,NCT05051475,Level of late post-procedural pain (at day 30 after treatment),2021-12-01,RECRUITING,INTERVENTIONAL,['NA'],,The rate of complications
4994,NCT03391934,Progression Free Survival (PFS),2018-01-20,RECRUITING,INTERVENTIONAL,['PHASE3'],,immunogenicity
4995,NCT05180864,Overall survival,2024-03-01,RECRUITING,INTERVENTIONAL,['NA'],,Cost-effectiveness
4996,NCT00681876,Time To Progression,2008-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Quality of life, Symptoms improvement"
4997,NCT01541709,progression-free survival (PFS),2012-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,percentage of successful dose escalation
4998,NCT06233708,Multivariate Cox regression analysis of HCC recurrence at 5-year follow-up,2008-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Multivariate Cox regression analysis of overall survival at 5-year follow-up
4999,NCT03802747,Dose-Limiting Toxicity of Y-90+SBRT in Combination with Dual Immune Checkpoint Blockade,2019-08,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Time to Tumor Progression (TTP)
5000,NCT03482791,Physician-reported toxicity of PBT for esophageal cancer,2018-04-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Overall survival (OS)of PBT for patients with resectable versus unresectable esophageal
5001,NCT00094029,,2004-09,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA'],,
5002,NCT03449264,Proportion of patients who consent to participate in the study,2017-07-27,RECRUITING,INTERVENTIONAL,['NA'],Quality of life assessment at baseline for all participants in the study,
5003,NCT04751591,Early operative mortality rate,2021-12-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,En bloc resection rate
5004,NCT05030363,Change of FACIT-F score,2021-10-25,UNKNOWN,INTERVENTIONAL,['NA'],,"Exploratory biomarker studies - Urine malondialdehyde - ALDH2 polymorphism (ALDH2 *1/*2, rs671 A/G) - Change of inflammatory cytokines"
5005,NCT01369420,Safety,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Efficacy
5006,NCT03623984,Comparison of intraoperative findings to preoperative PET scan findings,2019-06-07,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,Determine threshold levels of gallium dotatate uptake in order to determine tumor involvement
5007,NCT01339650,Pharmacokinetic profile,2011-05-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Safety (number of subjects with adverse events and/or dose limiting toxicities)
5008,NCT05461430,BOR,2022-07-15,RECRUITING,OBSERVATIONAL,['NA'],,PFS
5009,NCT04679597,pathological complete response,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],number of participants with acute side effects,Neoadjuvant rectal cancer score
5010,NCT01415089,Quality of life,2009-05,COMPLETED,INTERVENTIONAL,['NA'],,Satisfaction with intervention
5011,NCT05613478,Recurrence-free survival (RFS),2022-11,RECRUITING,INTERVENTIONAL,['PHASE3'],,Safety and toleraty
5012,NCT04282980,Progression-Free Survival(PFS) based on independent imaging review,2020-04-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Control Rate(DCR)
5013,NCT06245356,Treatment specific safety,2024-06-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life questionnaire - Colorectal (QLQ-CR29)
5014,NCT01789658,Mucositis grade - WHO Oral Toxicity Scale,2012-10,COMPLETED,INTERVENTIONAL,['NA'],S-Albumin,Emotional and Psychological status
5015,NCT01198145,Maximum Severity of Diarrhea Toxicity as Measured by the CTCAE v4.0 During and After Radiotherapy (RT),2011-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Percentage of Patients in Each Arm That Experience Clinically Significant Deficits in Overall Quality of Life and Fatigue
5016,NCT03454620,Dose Limited Toxicity (DLT),2018-04-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Immunogenicity of GC1118
5017,NCT03258541,Clinical performance,2017-01-15,TERMINATED,INTERVENTIONAL,['NA'],,Comparative dosimetric studies
5018,NCT05674123,Incidence of adverse events,2020-01-15,COMPLETED,INTERVENTIONAL,['NA'],,
5019,NCT00256334,Test the hypothesis that resveratrol modulates Wnt signaling in vivo in colon cancer and normal colonic mucosa,2005-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5020,NCT02356276,5-year overall survival,2015-05-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],CEA mRNA expression of peritoneal lavage fluid,side effects
5021,NCT05181488,3-year local recurrence rate,2020-04-02,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
5022,NCT04947020,Overall survival,2021-08-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Lymph node ratio,Disease-free survival
5023,NCT06315101,Survival analysis,2023-09-01,COMPLETED,OBSERVATIONAL,['NA'],,Adverse Events assessment
5024,NCT04162535,Evaluation of patients serum on cell culture,2018-11-26,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Survival Comparison
5025,NCT05939687,hernia rate,2023-06-05,RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of life indicators by HerQLes scale
5026,NCT06166589,ORR,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
5027,NCT01798134,Freedom From Tumor Progression at 6 Months,2012-12,COMPLETED,INTERVENTIONAL,['NA'],,12 Month Survival
5028,NCT02009449,Pharmacokinetic (PK) parameters,2013-11-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Anti-Pegilodecakin antibody formation
5029,NCT01438450,Survival,2007-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Change from baseline in Child status at 1 year
5030,NCT00376987,Reversal of cadmium-induced inhibition of mismatch repair,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5031,NCT04232384,Yield of malignant cells,2020-06-15,TERMINATED,INTERVENTIONAL,['NA'],,Cellularity of the smear of the smear
5032,NCT01765673,Change in Swallowing Frequency 70 & 110 Hz,2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Change in Swallow Initiation Time
5033,NCT00062257,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5034,NCT00477711,Tumor response rate,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Time to progression Disease control rate Overall survival K-ras, b-raf, p53 gene mutation and EGFR gene copy number vs. tumor response safety"
5035,NCT05385549,PFS,2022-09-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,
5036,NCT03033927,Progression Free Survival,2017-01-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
5037,NCT01381822,To determine the MTD and DLT(s) of TH-302 when used in combination with sunitinib.,2011-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],,To make a preliminary assessment of the efficacy of TH-302 in combination with sunitinib as determined by the response rate and the progression-free survival in subjects with advanced RCC treated at the RP2D.
5038,NCT02748772,PFS,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,RR
5039,NCT00974610,Detection of peptide and protein markers in serum,2008-08,COMPLETED,OBSERVATIONAL,['NA'],,Identification of the protein/peptide involved
5040,NCT01845675,overall response rate,2013-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,toxicities
5041,NCT01465113,Arm 2 (high grade dysplasia): 15-Prostaglandin dehydrogenase expression,2010-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,effects on insulin resistance
5042,NCT05297955,Data analysis of relationship between CTC and pathological indicators of hepatocellular carcinoma,2013-11-01,COMPLETED,OBSERVATIONAL,['NA'],,
5043,NCT06205836,Complete Response Rate,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants experiencing grade 3 or above drug-related toxicities requiring treatment discontinuation
5044,NCT01493336,Relative bioavailability: Area under the concentration-time curve (AUC),2012-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Safety: Incidence of adverse events
5045,NCT05171166,Progression-free survival,2021-12-24,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Number of paitents with treatment-related adverse events
5046,NCT03708042,Overall survival,2018-12-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Comparison of pathological diagnosis between specimens of endoscopic biopsy and surgically resected in esophageal cancer
5047,NCT02715141,life time health effects of stool-based surveillance strategies using the ASCCA (Adenoma and Serrated pathway to Colorectal CAncer) model,2015-10,COMPLETED,OBSERVATIONAL,['NA'],,presence of previously identified progression biomarker on resected tissue samples of polyps
5048,NCT01267305,TEG values,2011-01,COMPLETED,INTERVENTIONAL,['NA'],,inhospital mortality
5049,NCT02273141,Number of Patients With 'Excellent Plus Good' (Highly Effective) Bowel Cleansing (Colon Ascendens),2014-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Polyp Detection Rate (Overall Colon)
5050,NCT02788526,Overall survival,2009-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
5051,NCT04549064,Diagnosis of Pancreatic Cancer,2020-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,
5052,NCT06214988,textbook outcome; stoma-free survival at two years without major LARS,2024-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Quality of life by European Organization for Research and Treatment of Cancer- Cancer30 (EORTC-C30)
5053,NCT00522665,To evaluate the objective response (CR or PR) rates of patients treated with irinotecan and cetuximab with or without RAD001 in patients with metastatic colorectal cancer,2007-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"To evaluate the time to progression, duration of objective response (CR or PR) and overall survival of patients treated with irinotecan and cetuximab with or without RAD001"
5054,NCT03230318,Substudy 2: Progression Free Survival at 3 Months (PFS 3),2017-09-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Grade 3-5 Treatment-emergent Adverse Events (TEAEs)
5055,NCT00786006,Progression-free survival,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety
5056,NCT06089382,Recurrence-Free Survival (RFS),2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Hepatocellular Carcinoma Module (EORTC QLQ-HCC18) Scale Score
5057,NCT05301842,Progression Free Survival (PFS) for Arm A vs Arm C,2022-03-28,RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall Survival (OS) for Arm B vs Arm C
5058,NCT02512172,Number of Patients Experiencing a DLT (dose-limiting toxicity) as defined by NCI CTCAE v4.0,2016-02-19,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
5059,NCT01393197,Time to progression,2011-03,UNKNOWN,INTERVENTIONAL,['NA'],,remission rate
5060,NCT02336087,"Toxicity of the combination of gemcitabine hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation, metformin hydrochloride, and a dietary supplement (National Cancer Institute Common Terminology for Adverse Events criteria version 4)",2016-01-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],"Quality of life, assessed using the FACT-G questionnaire",Time to treatment failure
5061,NCT01243372,Progression-free survival as measured by RECIST,2009-11,COMPLETED,OBSERVATIONAL,['NA'],,tumor response as measured by RECIST
5062,NCT04451603,"Use of prediction software or tools to estimate volume and health of the future liver remnant (FLR), monitor changes in liver volume and health post treatment",2018-10-19,COMPLETED,OBSERVATIONAL,['NA'],,
5063,NCT04294953,morphine consumption,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Postoperative patient satisfaction
5064,NCT00845039,Progression-Free Survival (PFS) Rate at 18 Weeks,2009-05,TERMINATED,INTERVENTIONAL,['PHASE2'],The Number of Participants Who Died During 30-Day Follow-Up,Serum Anti-IMC-A12 Antibody Assessment
5065,NCT00898378,Creation of an OMIC profile to predict the risk of colorectal cancer (CRC),2009-01,COMPLETED,OBSERVATIONAL,['NA'],,Identification of interactive molecular pathways that underlie the development and progression of CRC
5066,NCT03792932,Recurrence Free Survival,2019-02-02,RECRUITING,INTERVENTIONAL,['NA'],,Detected lymph node number
5067,NCT01646697,Local recurrence at the site of resection,2011-11-07,COMPLETED,INTERVENTIONAL,['NA'],,
5068,NCT01943500,The number of circulating tumor cells (CTCs) per milliliter of whole blood. Reported unit of measure will be the number of CTCs/milliliter.,2013-09-30,COMPLETED,OBSERVATIONAL,['NA'],,
5069,NCT06220058,Incidence of incisional hernia.,2024-01-15,RECRUITING,INTERVENTIONAL,['NA'],,Morbidity and mortality rates
5070,NCT01391611,Non-progression Rate Based on RECIST 1.0 Criteria (CR+PR+SD),2011-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,Response Per Choi Criteria
5071,NCT04548947,Incomplete resection rate (IRR),2021-01-12,COMPLETED,INTERVENTIONAL,['NA'],,Incomplete resection of colorectal polyps
5072,NCT01075893,Number of stem cells in the colonic crypt,2010-02,COMPLETED,OBSERVATIONAL,['NA'],,Stem cell position in colonic crypt
5073,NCT02354898,Pharmacokinetic profile of BBI503,2015-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival
5074,NCT01466569,"Safety will be assessed by analysis of adverse event, clinical laboratory tests and physical examination",2011-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumor response rate by Response Evaluation Criteria in Solid Tumors (RECIST)
5075,NCT03818997,Objective response rate,2019-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Duration of stable disease using RECIST 1.1 and iRECIST
5076,NCT04916054,to determine whether the time between each anti-tumor therapy has a prognostic impact on recurrence-free survival,2021-06-04,COMPLETED,OBSERVATIONAL,['NA'],,To evaluate the impact on overall survival
5077,NCT01054911,Number of Participants With Adverse Events,2009-10,TERMINATED,INTERVENTIONAL,['NA'],,Alteration in Diffusion and Vascularity Kinetics
5078,NCT04145141,"To establish a biospecimen repository for genomic, genetic and epigenetic analysis to study the biology of PLC development and progression",2021-07-28,RECRUITING,OBSERVATIONAL,['NA'],,To estimate 3 years progression-free survival following immunotherapy for PLC
5079,NCT01489566,RFS(Recurrence Free Survival),2011-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,QOL score
5080,NCT05264896,3 year disease free survival,2022-03-21,RECRUITING,INTERVENTIONAL,['PHASE3'],,Pathology - tumor regression grade
5081,NCT02683655,Progression free survival,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5082,NCT04715074,Impact of #iBeatCRC Mass Media Campaign on EOCRC early detection benefit.,2023-05-27,COMPLETED,INTERVENTIONAL,['NA'],,
5083,NCT03525067,Postoperative infectious complications at postoperative day 90,2017-02-01,COMPLETED,OBSERVATIONAL,['NA'],,Mortality post operative day 90
5084,NCT05435053,Incidence of treatment related adverse events [Safety and Tolerability],2022-09-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of life using EORTC QLQ-C30
5085,NCT01242605,"To investigate the safety and tolerability of the combination of cisplatin, gemcitabine and selumetinib, and to establish the recommended phase II dose of selumetinib when given in this combination.",2012-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Response rate
5086,NCT03746249,Progression Free Survival (PFS),2018-12-17,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Adverse Events
5087,NCT02646462,Ratio of malignant/total number of lymph nodes,2015-06,UNKNOWN,OBSERVATIONAL,['NA'],,Number of N1 patients
5088,NCT01766661,post-operative morbidity,2013-01,UNKNOWN,INTERVENTIONAL,['NA'],,local and/or distant recurrence of neoplasm
5089,NCT03246516,Time limit of first doctor consultation,2017-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Survival
5090,NCT00049101,,2002-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
5091,NCT00601198,"Test Drug in 28 Patients and Assess PSN. If 5 or More Have Grade 3 & 4 PSN, Trial Will be Terminated.",2006-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Assess PSN in 69 Patients. If Total Number of Cumulative PSN is > or Equal to 14, Drug Will be Rejected."
5092,NCT00674973,Progression-Free Survival,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events (AEs)
5093,NCT02889679,Incomplete resection rate (histologic),2016-09,COMPLETED,INTERVENTIONAL,['NA'],,
5094,NCT05432934,Total postoperative opioid consumption in the first 48 hours after surgery (hydromorphone equivalents.,2022-09-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Length of stay in hospital (days).
5095,NCT04888403,Pathologic Complete Response(pCR),2021-12-31,UNKNOWN,INTERVENTIONAL,['PHASE2'],,postoperative complications rate
5096,NCT05811546,Difference in DNMT1 and EZH2 expression.,2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],,
5097,NCT04473625,Stool-based test for colorectal cancer,2020-07-21,COMPLETED,OBSERVATIONAL,['NA'],,
5098,NCT01286883,Primary endpoint: correlation of stem cell markers on CTCs with response to therapy,2011-02,TERMINATED,OBSERVATIONAL,['NA'],,Secondary Outcome: Correlation of stem cell markers in primary tumors with stem cell markers in CTCs
5099,NCT02407977,Dosimetric accuracy of the device with reference to a commercially available dosimeter,2015-11-13,COMPLETED,OBSERVATIONAL,['NA'],,Feasibility of clinical application of the nanaoFOD for dosimetric monitoring of external beam radiotherapy.
5100,NCT00053222,Objective response,2003-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5101,NCT03760822,Quality of life at 4 months as assessed by the following dimension of the EORTC QLQ-ELD14 questionnaire: illness burden,2018-11-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression-free survival
5102,NCT02550119,"Proportion of patients with complete response, defined as no emesis and no use of rescue medication",2006-04-19,TERMINATED,INTERVENTIONAL,['NA'],,Proportion of patients who agreed to be randomized out of all patients who qualify for randomization
5103,NCT01360086,Non-toxicity rate,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life as assessed by QLC-C30 and STO-22 questionnaires
5104,NCT05221398,Recurrence-free survivial,2019-03-03,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
5105,NCT01217034,Overall Survival,2010-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Time to Extrahepatic spread
5106,NCT04731220,Number and percentage of cases and controls who complete each part of the study,2020-07-14,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
5107,NCT05955196,Establishment of patient derived organoids (minimum n=30) resembling the primary tissue sample,2023-01-09,RECRUITING,OBSERVATIONAL,['NA'],,"To assess the effect of immunotherapy on the antitumor activity of autologous T cells from peripheral blood samples using tumor viability measurements (cell titer glo, FACS)"
5108,NCT03286348,Local Control rate,2017-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,Overall Survival
5109,NCT06300489,MTD（maximum tolerable dose）,2024-03-03,RECRUITING,INTERVENTIONAL,['PHASE1'],,
5110,NCT03100708,Overall Survival (years),2016-04,UNKNOWN,OBSERVATIONAL,['NA'],,Quality of lfe questionnaire (EORTC QLQ-C15-PAL)
5111,NCT04037007,Cannulation success rate within 5 minutes,2019-07-03,RECRUITING,INTERVENTIONAL,['NA'],,Technical success
5112,NCT01419483,Frequency of Adverse Events (Safety),2011-07,TERMINATED,INTERVENTIONAL,['NA'],,Progression Free Survival (months)
5113,NCT02827682,Duration time in PACU,2016-07,UNKNOWN,INTERVENTIONAL,['NA'],,length of hospital stay (LOS)
5114,NCT03698253,Progression-free survival,2013-10-01,COMPLETED,INTERVENTIONAL,['NA'],,Rate of treatment-associated adverse events.
5115,NCT05038254,Rate of acute care visits,2021-05-12,RECRUITING,INTERVENTIONAL,['NA'],,Change in symptom management
5116,NCT03692429,Occurence of Dose Limiting Toxicities,2018-11-28,RECRUITING,INTERVENTIONAL,['PHASE1'],,
5117,NCT04833036,PFS,2019-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,ORR
5118,NCT03166553,Objective response rate and/or 1-year survival rate,2016-11-28,UNKNOWN,INTERVENTIONAL,['NA'],,the rate of incidence of adverse events
5119,NCT00003157,Maximum tolerated dose,1998-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Survival
5120,NCT04166435,Overall Response Rate,2020-06-17,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
5121,NCT01882478,Response,2013-06,COMPLETED,OBSERVATIONAL,['NA'],,Predictors of response
5122,NCT02614157,3-year local recurrence,2016-05,TERMINATED,INTERVENTIONAL,['NA'],,postoperative complications
5123,NCT04984096,Progression-Free Survival (PFS),2021-08-01,UNKNOWN,OBSERVATIONAL,['NA'],,Overall Survival (OS)
5124,NCT00534001,Prequit Change in Cigarettes Per Day,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Abstinence
5125,NCT05147168,Quality of Life(SF-36),2021-11-22,RECRUITING,OBSERVATIONAL,['NA'],,
5126,NCT05934981,Number of patients with pain at 24 hours after the end of the intervention by VAS ≤ 3 without taking opioids (without step 2 and step 3 analgesics).,2023-08-30,RECRUITING,INTERVENTIONAL,['NA'],,Evaluation of predictive factors of opioid intake
5127,NCT02565641,Overall objective response rate,2003-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
5128,NCT04880148,Change from baseline in Xerostomia Grade (CTCAE) at weekly assessments,2021-11-03,RECRUITING,INTERVENTIONAL,['NA'],,Change from baseline in health-related QoL (EORTC QLQ-H&N43) questionnaire
5129,NCT05571098,Psychosocial Adjustment to Illness Scale (PAIS-SR) scores should be lower in the NNP applied group than in the non-applied group.,2021-07-08,COMPLETED,INTERVENTIONAL,['NA'],,
5130,NCT04049461,Bone alkaline phosphatase,2019-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Overall survival,Incidence of distant metastasis and local recurrence
5131,NCT02216799,Achievement of target blood glucose (140 mg/dL to 200 mg/dL),2013-03,COMPLETED,INTERVENTIONAL,['PHASE4'],,Developement of hypoglycemia ( blood glucose < 70 mg/dL)
5132,NCT02396498,DFS: Disease-Free Survival,2014-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Safety as measured by Adverse Events and Serious Adverse events In the process of the total treatment according CTCAE4.0
5133,NCT00378716,Compare the relative efficacy of UFT + LV with that of 5-FU + LV in prolonging disease-free survival and survival,1997-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Compare quality of life in patients with stage II and III carcinoma of the colon treated with either 5-FU + LV or UFT + LV regimen
5134,NCT01834235,Overall Survival,2013-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Immunologic Correlates
5135,NCT03579758,Overall survival,2019-04-03,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Incidence of residual disease after or at the time of re-resection
5136,NCT03203525,Incidence of adverse events,2020-06-23,RECRUITING,INTERVENTIONAL,['PHASE1'],,Biomarker analysis
5137,NCT02861209,Change in self-management skills,2015-11,UNKNOWN,INTERVENTIONAL,['NA'],Change in perceptions on self-management in HCPs using the Clinician Support for Patient activation measure,Cost of care
5138,NCT03601923,Progression Free Survival,2018-08-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Evaluation of the safety and tolerability of niraparib as assessed by the Common Terminology Criteria for Adverse Events (CTCAE)
5139,NCT05943444,Low Anterior Resection Syndrome (LARS) score 1 year after surgery,2023-08-08,RECRUITING,INTERVENTIONAL,['NA'],,The incidence of postoperative anastomotic complications
5140,NCT05919095,Radical resection rate,2023-06-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,The incidence of treatment-related adverse event
5141,NCT01911988,Disease Free Survival,2013-06,UNKNOWN,OBSERVATIONAL,['NA'],,5 years overall survival
5142,NCT01209325,Incidence of Penile/Scrotal Condyloma in HPV 18 Naive and Prior Exposed Participants,2011-06-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Geometric Mean Titers for HPV 18 According to Participant Age, HIV Viral Load, CD4+ T Cell Count, and Nadir CD4 Level"
5143,NCT01749956,Pathologic Complete Response Rate,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,The Number of Participants Who Experienced Serious or Non-Serious Adverse Events as a Measure of Safety.
5144,NCT04517643,Number of Patients That Met the Criterion That the Dose Estimated With Tc-99m MAA SPECT Was Within 15% of the Dose Estimated From Y-90 SPECT,2020-11-12,COMPLETED,INTERVENTIONAL,['NA'],,
5145,NCT00066716,Pathological response rate at time of surgical resection,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicities and safety
5146,NCT01923987,R0 resection rate,2012-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Toxicity
5147,NCT01907607,Number of Participants With Non Progression at 4 Months,2014-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Efficacy Assessment of PD-0332991 in Terms of Overall Survival Time
5148,NCT06209099,Organ-preservation rate,2023-12-05,RECRUITING,INTERVENTIONAL,['NA'],,Major adverse events
5149,NCT03337841,One-year recurrence-free survival rate,2017-11-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
5150,NCT04010006,operating time,2019-07-15,UNKNOWN,INTERVENTIONAL,['NA'],,3-year overall survival rate
5151,NCT03560817,Health utilities for SF-6Dv2 after the start of the chemotherapy,2017-01-04,COMPLETED,OBSERVATIONAL,['NA'],,Health related quality of life (HRQoL) scores from the Functional Assessment of Cancer Therapy - General (FACT-G) questionnaires after chemotherapy
5152,NCT01695447,pancreatic fistula,2012-01,UNKNOWN,INTERVENTIONAL,['NA'],,Hospital stay
5153,NCT00383760,Objective Response (Complete and Partial) Evaluated Using RECIST Criteria,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Objective Stable Disease Rate
5154,NCT02287025,Proportion of Patients Who Discontinue Prior to Documented Progression of Disease (PD) or Death,2014-11-11,TERMINATED,INTERVENTIONAL,['PHASE4'],,Satisfaction of Investigator/Nurse With Enhanced Drug-specific Information Via SMART Questionnaire
5155,NCT00003591,To determine the one-year and median survival rates after PXRT,1998-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,To correlate p53 status with treatment response to PXRT
5156,NCT01191814,Complications related to stent dysfunction,2010-07,COMPLETED,INTERVENTIONAL,['NA'],,Procedural complications
5157,NCT05289726,incidence of grade 3 hand-foot skin reaction,2022-04-18,UNKNOWN,INTERVENTIONAL,['PHASE2'],,tumor control rate
5158,NCT04919824,Procedure time,2022-01-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Delayed post-procedural adverse event
5159,NCT03096054,Determination of the maximal dose,2017-06-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Determine the median progression
5160,NCT05170360,1. association between some risk factors and colorectal cancer,2021-12,UNKNOWN,OBSERVATIONAL,['NA'],,1. Estimation of KRAS and BRAF genes mutations associated with CRC. 3. Association between these risk factors and gene mutations on different types of CRC.
5161,NCT00677781,Postoperative morbidity,2008-02,COMPLETED,OBSERVATIONAL,['NA'],,Mortality
5162,NCT00568750,Response as assessed by fusion PET/CT scan according to EORTC PET Study Group criteria,2008-01-22,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse drug reactions according to NCI CTCAE v3.0
5163,NCT05143151,Objective response rate (ORR),2021-07-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival rate (OS)
5164,NCT04797923,Rate of R0 resection,2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5165,NCT03891784,Objective response rate (ORR),2019-10-31,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
5166,NCT03392571,To evaluate 2 year survival from date of entry into study,2018-08-15,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Time to Recurrence
5167,NCT02649361,Progress free survival (PFS),2016-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Control Rate (DCR)
5168,NCT01863745,Number of participants with adverse events,2013-06-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5169,NCT05617352,The number of lymph nodes,2022-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
5170,NCT06303583,Complete pathological response rate,2022-06-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Safety will be analyzed through the incidence of adverse events, serious adverse events"
5171,NCT01819961,infective complications,2013-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],,plasma immunological markers
5172,NCT05741372,"Maximum measured concentration of the analyte in plasma) for each component of the transporter cocktail: digoxin, furosemide, metformin, and rosuvastatin (Cmax)",2023-04-25,RECRUITING,INTERVENTIONAL,['NA'],,
5173,NCT02574637,Percentage of Participants With Crohn's Disease Activity Index (CDAI) Remission at Week 8,2016-01-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Abdominal Pain Remission
5174,NCT00427973,Progression-free Survival,2009-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
5175,NCT02425605,Overall survival,2014-12-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,toxicity defined as NCI-CTC(version 4.02)
5176,NCT05253651,Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) by Blinded Independent Central Review (BICR),2022-10-24,RECRUITING,INTERVENTIONAL,['PHASE3'],,Time to meaningful change in EORTC QLQ30 score
5177,NCT06162143,Low Anterior Resection Syndrome (LARS) score,2023-11-15,RECRUITING,OBSERVATIONAL,['NA'],,Diarrhea
5178,NCT05718349,Microbial composition,2017-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
5179,NCT05632939,The recommended dose,2023-02-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival（OS）
5180,NCT02508389,Duration (in Days) of Radiation Induced Severe Oral Mucositis (OM) Per World Health Organization (WHO) Criteria,2015-10-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Number of Participants With Tumor Outcomes Defined as Locoregional Failure, Distant Metastases, Disease Progression and Deaths"
5181,NCT04605796,ORR,2020-04-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],ADA,Overall survival (OS)
5182,NCT01750619,Technical success.,2011-07,RECRUITING,OBSERVATIONAL,['NA'],,Endoscopic en bloc resection rate
5183,NCT01175460,Maximum tolerated dose (MTD) of s-1 in combination with nedaplatin and thoracic radiotherapy,2010-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Objective response rate
5184,NCT02446574,Maximum tolerated dose of weekly paclitaxel and cisplatin with concurrent radiation(Phase I endpoint),2007-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease-free survival of weekly paclitaxel and cisplatin with concurrent radiation(Phase II endpoint)
5185,NCT01447927,Percent Change in Median pS6K1 Immunostaining Among Participants With Barrett Esophagus,2012-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Adverse Event Rates
5186,NCT02765620,Evaluate treatment response by PERCIST to RECIST 1.1 criteria after the whole treatment process,2016-04,UNKNOWN,OBSERVATIONAL,['NA'],,PFS
5187,NCT02425137,Disease control rate (DCR),2015-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,"safety profile (percentage of patients with at least one occurrence of preferred term will be included,according to the most severe NCI-CTCAE v4.03 grade)"
5188,NCT01688232,relapse in relation with the immunoscore determined on a tumor section.,2012-09-27,UNKNOWN,OBSERVATIONAL,['NA'],,relapse in relation with the immunological events and psychological status of the patient during the monitoring
5189,NCT03910140,The response to treatment,2017-11-01,UNKNOWN,INTERVENTIONAL,['NA'],,Lifetime (months)
5190,NCT02592902,Occurrence of EER (percentage),2014-04,COMPLETED,INTERVENTIONAL,['NA'],,Presence of pepsin
5191,NCT01092975,Safety: the presence or absence of mucosal or systemic toxicity related the the topical application of phenylephrine.,2010-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,"Efficacy: the the mucositis severity area-under-the-curve (AUC) where the severity of oral mucositis on each treatment day will be scored, summed, and plotted graphically."
5192,NCT03840928,RAPID-3 (MD-HAQ with visual analogue scale for pain and patient global measure for overall health),2015-04-01,RECRUITING,OBSERVATIONAL,['NA'],,
5193,NCT06229197,Incidence of reflux gastritis assessed according to RGB classification,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Long-term complications
5194,NCT04752670,Technical Success rate,2021-05-27,COMPLETED,OBSERVATIONAL,['NA'],,Adverse Events
5195,NCT06267703,Chronic atrophic gastritis,2024-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
5196,NCT03217253,Recommended phase 2 dose (RP2D) of tazemetostat in patients with varying degrees of hepatic dysfunction,2018-03-16,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Best response
5197,NCT04443049,Progressive disease requiring change of therapy in both groups,2020-07-10,UNKNOWN,INTERVENTIONAL,['NA'],,Decompensation of underlying cirrhosis in both groups
5198,NCT03338543,pain score,2017-11-01,COMPLETED,INTERVENTIONAL,['NA'],complications,times of breakthrough pain (BTP)
5199,NCT02169765,Overall survivals,2020-08-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],morbidity,Recurrence rates
5200,NCT01178151,To determine the response rate of Everolimus in patients with advanced cancer and PJS.,2010-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,To assess markers for activated mTOR pathway (including phospho-S6 and phospho-4E BP1) in all pre-treatment tissue specimens and collected specimens during treatment and correlate with response to treatment.
5201,NCT05689775,Perineal wound healing,2022-09-01,RECRUITING,OBSERVATIONAL,['NA'],,Abdominal wall strength
5202,NCT00190515,Disease-free survival,2003-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Rate of adverse event
5203,NCT03223740,Progression Free Survival,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,R0 Resection Rate
5204,NCT02860429,neural electrophysiological test,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],,"stress hormone,in blood."
5205,NCT02672488,Overall Survival,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Objective Response Rate
5206,NCT04134832,The survival will be evaluated by Kaplan Meier Method. The prognostic factors will be evaluated with univariate and multivariate analysis by Cox regression model.,2019-06-27,UNKNOWN,OBSERVATIONAL,['NA'],,
5207,NCT01056809,Overall survival,2010-01,TERMINATED,INTERVENTIONAL,['NA'],,Complications and side effects
5208,NCT04685395,Incidence of oral mucositis,2019-12-26,UNKNOWN,INTERVENTIONAL,['PHASE3'],,The pain score
5209,NCT00339183,Overall Survival,2006-06-30,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Adverse Events (AEs)
5210,NCT00423696,Progression-free survival at 6 months,2006-03-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life
5211,NCT01271166,Tumour response as assessed by CT scan and RESIST,2007-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,
5212,NCT05335460,TRG0/1,2022-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],PCR rate,ORR
5213,NCT05984485,3-year Disease Free Survival,2022-07-05,RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of participants with treatment-related adverse events
5214,NCT02581462,Phase III: Median Progression Free Survival,2016-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Phase III: Median OS
5215,NCT05047146,Clinicopathological factors of Hepatocellular Carcinoma,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
5216,NCT03722056,rates of intraoperative tumour rupture,2005-01,COMPLETED,OBSERVATIONAL,['NA'],,
5217,NCT02270606,Dose limiting toxicity for continuous infusional 5-Fluorouracil given concurrently with short course pelvic radiation,2014-12-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Postoperative mortality rates
5218,NCT00568646,Objective tumor response rate based on tumor measurements according to the RECIST,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5219,NCT02619942,Disease-free survival,2016-01-09,UNKNOWN,INTERVENTIONAL,['NA'],,Metastasis rate of central lymph node (3rd station)
5220,NCT05029882,Objective Response Rate (ORR),2021-10-13,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
5221,NCT04813523,Major pathologic response (MPR),2021-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Pathologic complete response (pCR)
5222,NCT05737953,Types and concentrations of cfDNA and proteins contained in the vesicular fluid,2022-07-13,RECRUITING,OBSERVATIONAL,['NA'],,Development of a progressive benign malignancy prediction model
5223,NCT05876026,Difference in T1 relaxation time (ms) in the rectal cancer tumor measured in IntelliSpace-software before and after neoadjuvant radiochemotherapy.,2023-05-08,RECRUITING,OBSERVATIONAL,['NA'],,
5224,NCT01589328,Reduction in depression score,2012-03-15,COMPLETED,INTERVENTIONAL,['NA'],,Overall survival
5225,NCT01324076,Progression-free survival,2010-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of life
5226,NCT03925870,Duration of response (DOR),2019-06-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival (OS) rates
5227,NCT04064034,Quiescin Sulfhydryl Oxidase 1 (QSOX1) in the blood,2019-08-01,COMPLETED,INTERVENTIONAL,['NA'],,
5228,NCT00985192,Overall Disease-control Rate in Patients With Previously Treated Unresectable or Metastatic Adenocarcinoma of the Upper Gastrointestinal Tract Treated With Everolimus.,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Biomarker Correlations: Time to Progression
5229,NCT01187901,Change in Duodenal Polyp Burden From Baseline to 6 Months,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change in Number of Duodenal Polyps From Baseline to 6 Months in Attenuated FAP Participants
5230,NCT02205047,Near Complete Pathological Response Rate,2015-07-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Toxicity
5231,NCT04498117,Investigator Assessed Progression Free Survival,2020-08-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Potential Biomarkers,Change in Quality of Life
5232,NCT02501603,compare progression free survival as measured by RECIST 1.1,2016-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,safety as measured by CTCAE
5233,NCT03215264,Maximum Tolerated Dose (MTD) of Hydroxychloroquine and Entinostat in Combination With Regorafenib,2017-10-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5234,NCT01815853,Disease-free Survival,2013-06,RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse effects
5235,NCT05527301,Change in Low Anterior Resection Syndrome score from Baseline to 8 weeks,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Change of fecal metabolites assessed by fecal analysis
5236,NCT03563274,Safety,2018-06-21,TERMINATED,OBSERVATIONAL,['NA'],,"Percentage of patients downstaged to surgery, transplantation or any local ablative therapy (RFA/MWA…)"
5237,NCT01558921,Disease related Treatment Failure (DrTF),2011-06-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of life LARS
5238,NCT00498407,• Objective response rate (RR),2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,• Characterize the quantitative and the qualitative toxicities of the CP-4055 treatment in this patient population
5239,NCT04928807,pathological complete response (pCR) rate,2021-07-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,dverse events (AEs) were graded according to the NCI CTCAE version 5·0
5240,NCT01116271,"Objective Response Rate will be assessed by the RECIST guideline documented in the European Journal of Cancer, 2009.",2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival (PFS) for patients with K-ras or B-raf mutations treated with combination of irinotecan and Selumetinib (AZD6244)
5241,NCT00896753,"Development of cell lines from primary colon tumors metastatic to the liver, lungs, or peritoneum",2003-09,COMPLETED,OBSERVATIONAL,['NA'],,
5242,NCT04511455,Time-on-treatment,2020-12-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,Translational research
5243,NCT04056260,sensitivity and specificity,2020-03-20,UNKNOWN,INTERVENTIONAL,['NA'],,
5244,NCT03038217,5y OS,2017-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Changes of ctDNA level when disease recurs
5245,NCT06197438,Objective response rate(ORR),2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease control rate(DCR)
5246,NCT05154812,Tumor progression rate,2020-10-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,quality of life (QOL) questionnaire
5247,NCT00176800,Median Recurrence Free Survival Time,2001-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Patients That Require Dose Modification Due to Toxicity
5248,NCT06107413,Progression Free Survival (PFS),2023-11-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Percentage of Participants Achieving Best Overall Response (BOR)
5249,NCT01282502,To determine Maximum Tolerated Dose (MTD) of midostaurin in combination with standard 5-FU chemoradiation,2011-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,To evaluate proteomic markers of response and resistance to midostaurin-based chemoradiation
5250,NCT01657383,Surgical Outcome,2012-04,COMPLETED,OBSERVATIONAL,['NA'],,
5251,NCT03957096,Number of patients with dose-limiting toxicities (DLTs),2019-07-17,TERMINATED,INTERVENTIONAL,['PHASE1'],,Incidence of antidrug antibodies (ADA)
5252,NCT03118349,Occurrence of graded adverse events (AEs) in each subject,2017-06-01,TERMINATED,INTERVENTIONAL,['PHASE1'],Evaluate the relationship between circulating CA19-9 levels and MVT-1075 pharmacokinetics,Cl
5253,NCT04596384,Maximum CCI,2021-02-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Change in Sleep
5254,NCT02730104,Time to disease progression,2015-11-23,COMPLETED,OBSERVATIONAL,['NA'],,Patient satisfaction with treatment
5255,NCT05957744,Length of stay,2023-06-01,RECRUITING,OBSERVATIONAL,['NA'],,
5256,NCT01320852,Overall Survival,2010-12,COMPLETED,INTERVENTIONAL,['NA'],,
5257,NCT03044587,Progression-free survival [PFS],2018-01-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Tumor Evolution under systemic therapy,Retrospective central radiological review
5258,NCT04432597,Level increase in CD3+ tumor infiltrating T cells post-treatment compared to pre-treatment,2020-08-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall response rate (ORR)
5259,NCT01963182,severe toxicity (according to NCI-CTC cotation) and response with adapted dose of irinotecan,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"evaluation of treatment efficacy (progression-free survival, duration of response)"
5260,NCT06251297,number of sessions performed,2023-05-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,concordance of peripheral neuropathy evaluation
5261,NCT04635527,Number of participants experiencing clinical and laboratory adverse events (AEs),2020-12-24,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall survival (OS) in two arms
5262,NCT03781934,Incidence of clinically significant changes in ECGs,2018-09-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Plasma levels of α fetoprotein (AFP)
5263,NCT00061815,"Compare overall survival in subjects with previously-treated metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with oxaliplatin, 5-FU, and LV (FOLFOX4) and cetuximab with FOLFOX4 alone.",2003-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Conduct an economic assessment comparing healthcare resource utilization between the two treatment arms.
5264,NCT05555316,Down stage rate,2019-11-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,TACE frequency and ablation frequency
5265,NCT01411436,Incidence of adverse drug reactions and serious adverse events in subjects who received Nexavar,2009-05,COMPLETED,OBSERVATIONAL,['NA'],,"The status of therapy with Nexavar [duration of treatment, daily dose] in a various settings according to baseline data [such as demographic data, Child-Pugh status, ECOG-PS]"
5266,NCT03803930,The diagnostic yields,2019-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,the tissue integrity
5267,NCT00386828,The primary endpoint is pathologic complete response (pCR) rate,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Post-Surgical Complication Rates:
5268,NCT00209612,Determine the DLT(Dose Limiting Toxicity) and MTD(Maximum Tolerated Dose) in Phase I setting. Determine the clinical response rate with Recommended dose in Phase II setting.,2004-04,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determine the MST(Median Survival Time) and PFS(Progression Free Survival) in Phase II setting.
5269,NCT05064670,Health-related quality of life,2022-01-11,RECRUITING,INTERVENTIONAL,['NA'],,Health-related quality of life
5270,NCT05846867,recommended phaseII dose,2023-05-10,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Correlation between biomarkers and efficacy
5271,NCT02635347,Percentage of Participants Completing Entire Intervention Protocol,2015-11,COMPLETED,INTERVENTIONAL,['NA'],,Number of Subjects Not Completing Intervention Protocol
5272,NCT05999019,ClassIntra grade,2016-08-01,COMPLETED,OBSERVATIONAL,['NA'],,3-year disease-free survival
5273,NCT03520257,overall survival,2018-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5274,NCT00119899,Economic evaluation (9 months),2002-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Economic evaluation
5275,NCT02830633,The postoperative voiding function assessed by IPSS questionnaire.,2016-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,C-reactive protein
5276,NCT00928161,Frequency of acid reflux episode (during each 24 hour pH probe),2012-11,WITHDRAWN,INTERVENTIONAL,['NA'],,
5277,NCT05193292,Objective Response Rate,2022-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Duration of Response
5278,NCT03152435,Occurrence of study related adverse events as assessed by CTCAE v4.0,2017-06-15,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determine duration of in vivo survival of EGFR CART .
5279,NCT01265810,"Assess the severity of patient-reported oral adverse events as determined by the change in the Modified-VHNSS2.0 score 3 times a week, from onset of oral adverse events during the active oral rinse period with Caphosol versus NaCl 0.9%",2011-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Side Study: Explorative analysis of polymorphism in genes encoding for pharmacokinetic and pharmacodynamic variables related to the pharmacodynamics of the TKIs
5280,NCT02707796,"Evaluation of the correlation between partial oxygen pressure in arterial blood sample and oxygen reserve index calculated by pulse co-oximetry, and sensitivity and specificity of oxygen reserve index in patients undergoing hemicolectomy",2016-05,UNKNOWN,INTERVENTIONAL,['NA'],,Sensitivity and specificity of oxygen reserve index
5281,NCT00017199,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5282,NCT03401229,Change From Baseline in NBS at Week 40,2018-01-15,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change From Baseline in SF-36v2 Mental Health at Week 56
5283,NCT03299660,Pathological Response rate,2018-04-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,Determine rate of downstaging
5284,NCT02555813,Number of participants with adverse events,2015-05-08,COMPLETED,OBSERVATIONAL,['NA'],,Best Overall Response
5285,NCT03295006,Alternative two-compartment TheraSphere dosimetry methodology,2016-10-31,COMPLETED,OBSERVATIONAL,['NA'],Normal tissue dose and tumor dose using post-procedural PET/CT Imaging,Dose reproducibility
5286,NCT04594811,Phase 2: Objective response rate (ORR),2021-01-21,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of participants with anti-drug antibodies (ADA) to NT-I7
5287,NCT06001476,Incidence of complications in the application of cold snare polypectomy for 5-9mm small bowel polypectomy in patients with PJS,2023-08-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],,Incidence of complications within 28 days after enteroscopy
5288,NCT04215731,Disease-free survival,2020-03-27,RECRUITING,INTERVENTIONAL,['PHASE3'],,local recurrence rate
5289,NCT05351931,"Incidence of diarrhoea, fecal urgency, anal skin toxicity/mucositis and anal pain CTCAEv5.0 ≥ grade 2 during and up to 6 months after RCT. Anal skin toxicity/mucositis is to be verified by photos.",2022-06,UNKNOWN,INTERVENTIONAL,['NA'],Incidence of AEs CTCAEv5.0 grade ≥ 2 considered probably related to investigational products/placebo.,Disease free and overall survival at 3 and 6 months after stop of RCT.
5290,NCT01560377,PINPOINT System Utility in Left Colectomy Surgery,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Safety of the PINPOINT System
5291,NCT05587452,Specificity,2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],,
5292,NCT00950417,Safety and toxicity of this new treatment. Both acute and chronic toxicity will be evaluated.,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,To determine the complete response rate、partial rate、disease responserate、disease control rate in the patients subject to treatment
5293,NCT03895255,Anastomotic Leakage Rate,2016-10-02,UNKNOWN,INTERVENTIONAL,['NA'],,The postoperative hospital stay
5294,NCT04380012,Objective Response Rate,2019-12-17,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The Incidence of Adverse Events
5295,NCT00011960,,2001-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5296,NCT05356117,Protein Supplementation (PS) Rate,2022-09-01,RECRUITING,INTERVENTIONAL,['NA'],,Psychosocial function - Physical Function
5297,NCT02775695,Determine the Efficacy of Doxycycline in Inducing Metakaryotic Cell Death in Primary Pancreatic Tumors as Measured by Pathologic Response,2017-04-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5298,NCT00524069,Margin status after pancreatic resection,2007-01,WITHDRAWN,INTERVENTIONAL,['NA'],,Toxicity
5299,NCT02402062,Objective Response Rate,2015-05-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Biomarkers in Serum and Tumor Tissue
5300,NCT03616574,Number of subjects with treatment-related adverse events as assessed by NCI-CTCAE v5.0,2019-04-09,COMPLETED,INTERVENTIONAL,['PHASE1'],Analysis of urinary COX-2 metabolites by LC-MS/MS,Serum concentration of CA102N
5301,NCT05872334,Incisional hernia,2021-06-01,COMPLETED,INTERVENTIONAL,['NA'],,Wound dehiscence
5302,NCT05875870,Sleep-wake rhythm,2023-07-24,RECRUITING,INTERVENTIONAL,['NA'],,Survival rate
5303,NCT02870920,Overall Survival,2016-10-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Objective Response Rate
5304,NCT03775707,overall survival (OS),2018-12-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Adverse Events
5305,NCT04323917,Assessments of diagnosis of PC by EMT-TF mRNA levels in blood,2017-11-02,UNKNOWN,OBSERVATIONAL,['NA'],,Prediction of prognosis of PC by EMT-TF mRNA levels in blood
5306,NCT00867477,Comparison Patient's PMRR + Mean Exhaled NO Measurement,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5307,NCT04891874,Participants Without Recurrence (Disease-free).,2015-08-01,COMPLETED,INTERVENTIONAL,['NA'],Number of Participants Occured Adverse Events(AE),Overall Survival (OS) Rate.
5308,NCT04478110,CRC screening rates,2010-12,COMPLETED,INTERVENTIONAL,['NA'],,
5309,NCT01781520,Treatment toxicity,2013-06-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phenotypic analysis of peripheral blood immune cells
5310,NCT00119912,1. Evaluate the effect on CRC mortality and morbidity by screen detection of CRC and removal of precursor lesions (polypectomy of adenomatous polyps).First evaluation after 5 years.,1999-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,2. Clarify possible psychosocial effects of endoscopic screening and how it may influence lifestyle and lifestyle related morbidity and overall mortality. Evaluation in 2005.
5311,NCT04584008,Objective response rate (ORR) of patients receiving targeted agent,2020-09-23,RECRUITING,INTERVENTIONAL,['NA'],,Differences of OS between 2 groups
5312,NCT05493800,The incidence of Severe Oral Mucositis(SOM).,2022-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Auto hematopoietic stem cell engraftment,Total cumulative dose of opioid analgesics
5313,NCT04159974,Evaluation of Safety and efficacy (measured by an increase of pathological complete response rate),2019-09-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,Assessment of the subject's esophageal-cancer-related quality of life using the Functional Assessment of Cancer Therapy-Esophageal (FACT-E) questionnaire
5314,NCT01121848,Progression-Free Survival (PFS),2010-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Median Overall Survival (OS)
5315,NCT05037461,Change in tumor size,2022-05-01,RECRUITING,INTERVENTIONAL,['NA'],,overall survival
5316,NCT02289547,Progression free survival,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Toxicity profile of each patients measured by NCI-CTCAE ver 4.0
5317,NCT04660695,Clinical Success,2019-08-15,COMPLETED,OBSERVATIONAL,['NA'],,Type of fluid employed
5318,NCT03357757,Proportion of subjects who complete 4 doses of Avelumab in combination with VPA,2018-02-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Hsp90 concentration in serum
5319,NCT00460681,disease-free survival,2007-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,overall survival
5320,NCT03535207,overall survival rate,2018-04-01,UNKNOWN,INTERVENTIONAL,['NA'],,toxicities
5321,NCT01271322,Correlation between change in tumor metabolism (detected by PET) and histopathological response,2010-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,association between change in tumor metabolism between PET Baseline and PET1 and overall survival as well as disease-free survival
5322,NCT00327119,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5323,NCT01416714,create a database for the collected tissue,2008-07-02,SUSPENDED,OBSERVATIONAL,['NA'],,To create tissue microarrays for each gastrointestinal cancer subtype
5324,NCT00977717,neuropathy,2008-09,COMPLETED,OBSERVATIONAL,['NA'],,
5325,NCT02466906,Disease-free survival（DFS）,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse effects (AE)
5326,NCT04513418,Rate of postoperative nutrition and immune-related complications,2020-11-10,RECRUITING,INTERVENTIONAL,['PHASE3'],,Long-term survival
5327,NCT04389086,Proportion of patients with a clear resection margin,2020-11-13,RECRUITING,INTERVENTIONAL,['PHASE3'],,Colorectal cancer specific quality of life
5328,NCT05082948,Composite of stent migration or total stent dislodgement,2021-07-20,RECRUITING,INTERVENTIONAL,['NA'],Dysphagia,Length of procedure
5329,NCT06302751,Unplanned hospital readmissions,2024-02-26,RECRUITING,INTERVENTIONAL,['NA'],,Healthcare costs
5330,NCT01262482,Progression free survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity
5331,NCT01736072,End of Conversion to Open Surgery,2011-12,COMPLETED,INTERVENTIONAL,['NA'],Sexual Disfunction Assessment,Oncological Efficacy
5332,NCT02965417,Best overall response (OR) assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1,2016-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
5333,NCT06255262,Progress Free Survival 1 (PFS1),2024-02-15,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival(OS)
5334,NCT06225622,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,2024-03-11,RECRUITING,INTERVENTIONAL,['PHASE1'],Gene polymorphism,R0 resection
5335,NCT05041608,Safety of procedure,2021-02-17,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Quality of Life after procedure
5336,NCT02998268,Disease free survival rate,2017-03-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Association of anti-PD1 therapy with increased intra-tumoral immune cell infiltration.,Reduction of local immune infiltration.
5337,NCT02154646,Number of Participants with LY2157299 Dose-Limiting Toxicities (DLT),2014-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Percentage of Participants with a Tumor Response
5338,NCT05919030,Progression-Free Survival (PFS),2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of participants experiencing Adverse Events (AEs)
5339,NCT06022887,Acceptability of the study,2023-10-18,RECRUITING,INTERVENTIONAL,['NA'],,Microbial Deoxyribonucleic acid (DNA) isolation: 16S on V4 region
5340,NCT04409002,Disease Control Rate With RECIST 1.1 Criteria,2020-07-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Treatment-Related Adverse Events Per CTCAE v5.0
5341,NCT00005877,,1999-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5342,NCT04728139,Evaluation of Glypican 3 role as a predictive and diagnostic marker of colorectal marker .,2022-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Addition of Glypican 3 to the routine markers of colorectal cancer . - Correlatin of this marker with the disease pathology and management procedures .
5343,NCT00291785,"Phase I: determine the Maximum Tolerated Dose, dose limiting toxicities, safety profile and antitumor activity",2004-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
5344,NCT01455831,Disease Free Survival,2011-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Other post-operative (day 0 - day 28) complications
5345,NCT04489368,"Perform a clinical audit of patient outcomes (OS, RFS, pCR rate) after new-adjuvant chemoradiation and esophagectomy",2020-01-16,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
5346,NCT05646511,Organ-preservation adapted DFS,2022-11-21,RECRUITING,INTERVENTIONAL,['PHASE3'],Artificial Intelligence (AI) (deep learning) analysis,Proportion of radical resection in salvage surgery cases in the NOM subgroup
5347,NCT02321969,Recurrence/Number/Size of metachronous colorectal adenoma(s),2010-08,COMPLETED,INTERVENTIONAL,['NA'],,Adverse effect(s) of GTE supplementation
5348,NCT00058474,Loco-regional disease control as assessed by evidence of tumor at 3 years,2004-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Convenience of care as assessed by NSABP C-06 convenience of care scale adapted from ECOG after definitive analysis
5349,NCT06259058,R0 resection rate,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of adverse events
5350,NCT04673448,Best objective response,2021-10-18,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival
5351,NCT04268654,Anastomotic leakage,2017-06-13,COMPLETED,INTERVENTIONAL,['NA'],,Hospital Stay
5352,NCT06122493,1-year progression-free survival,2022-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
5353,NCT03706326,Number of participants with adverse events and dose limiting toxicities as assessed by CTCAE v4.0,2018-09-28,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Median CAR-T cell persistence
5354,NCT04379596,"Part 2, Part 3 and Part 4: Endpoint assessed by Investigator per RECIST v1.1: Confirmed Objective Response Rate (ORR)",2020-06-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,Comparison of OS
5355,NCT02965248,peritoneal metastasis rate,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Toxicity by NCI CTCAE v.4.0
5356,NCT00559013,"Number of Participants With Major Colorectal Related Adverse Events: Leak, Stricture and Hemorrhage.",2007-03,COMPLETED,INTERVENTIONAL,['NA'],,
5357,NCT00557713,Pathologic Complete Response Rate,2007-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Surgical Morbility
5358,NCT00085410,Objective Response Rate,2004-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Correlation of Treatment With Changes in Phenotypic Expression of Molecular Markers
5359,NCT04171986,Incidence of 3 and 4 degrees neutropenia within 6 weeks from the start of hyperfractionated radiotherapy,2019-11-10,UNKNOWN,INTERVENTIONAL,['NA'],,
5360,NCT03956056,Safety of Neoantigen Peptide Vaccine as Measured by the Number of Serious Adverse Events,2020-02-13,TERMINATED,INTERVENTIONAL,['PHASE1'],,Immunogenicity of the Neoantigen Peptide Vaccine as Measured by Multiparametric Flow Cytometry
5361,NCT00789763,TO DETERMINE MTD,2007-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,RESPONSE (ACCORDING TO RECIST)
5362,NCT04821778,Overall survival,2002-01-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Radiomics analysis,Distant metastasis free survival
5363,NCT02319356,maximal oxygen uptake (VO2Max),2015-03,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,
5364,NCT04125914,Percent weight loss,2017-01-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Physical activity
5365,NCT02796820,Disease-free survival (DFS),2016-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],The adverse events of Huaier Granule,Metastasis-free survival (MFS)
5366,NCT00516165,Progression-free Survival Rate at 24 Weeks,2007-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
5367,NCT03677050,Boston Bowel Preparation Score,2018-09-14,COMPLETED,INTERVENTIONAL,['NA'],,Adenoma detection rate
5368,NCT03254511,R staging (residual of tumor),2016-07-22,UNKNOWN,INTERVENTIONAL,['PHASE2'],,heparin induced thrombocytopenia
5369,NCT03785210,Best Overall Response (BOR),2019-06-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0),Overall Survival (OS) of Nivolumab Combined With Oral Vancomycin and Tadalafil in Participants With Refractory Hepatocellular Carcinoma (HCC) or Liver Dominant Metastatic Cancer From Colorectal Cancer or Pancreatic Ductal Adenocarcinoma (PDAC)
5370,NCT04425122,Microbiological culture from biopsy specimens,2020-07-01,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
5371,NCT03419247,Number of participants with gene testing data available at 8 weeks from baseline tumor biopsy.,2020-01-01,WITHDRAWN,INTERVENTIONAL,['NA'],,"Potential predictive biomarkers of response to treatment such as BRCA, PALB2 and ATM mutations."
5372,NCT02736500,toxicity rate,2015-09-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression free survival in association with the receptor and metabolic status at OctreoScan and FDG PET
5373,NCT03336775,The change of Videofluoroscopic Dysphagia Scale (VDS) from baseline to week 4.,2018-06-21,UNKNOWN,INTERVENTIONAL,['NA'],,The change of Quality of Life (QOL) scores from baseline to week 4 and week 16.
5374,NCT05798884,Score Changes on the FACT/GOG-Ntx questionnaire,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Short Form 12 item(version 2) Health Survey (SF-12V2)
5375,NCT00116935,Recurrence-free survival,2004-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,GIST-specific survival
5376,NCT00114946,"To compare the efficacy, as measured by progression-free survival (PFS), of FOLFOX/Avastin followed by FOLFIRI/Avastin versus FOLFOX/Avastin followed by 5-FU/LV/Avastin as first-line therapy for previously untreated metastatic colorectal cancer.",2005-05,TERMINATED,INTERVENTIONAL,['PHASE4'],,To evaluate the tolerability of sequential treatment in subjects and to evaluate the safety of an irinotecan/Avastin-based regimen versus a 5-FU/Avastin regimen for previously untreated metastatic colorectal cancer.
5377,NCT02672774,Real-time imaging of angiogenesis in gastric and colorectal tumors by using M-NBI and pCLE examinations,2015-10,UNKNOWN,INTERVENTIONAL,['NA'],,Validation of endoscopic imaging findings from immunohistochemical analysis with MVD calculations
5378,NCT05395910,Safety Profile of PIPAC/ePIPAC with Paclitaxel by monitoring adverse events,2022-10,RECRUITING,INTERVENTIONAL,['PHASE1'],,Area under the curve (AUC) of Paclitaxel administered via PIPAC/ePIPAC using blood drawn from patient.
5379,NCT04985604,Phase 2: Evaluate the efficacy of tovorafenib monotherapy or in combination with other therapies,2021-07-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Phase 2: Assess the safety and tolerability of tovorafenib as monotherapy, or in combination with other therapies"
5380,NCT05375708,Progression-free survival,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Depth of response
5381,NCT05509478,ORR,2022-08-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS) Rate at 12 months
5382,NCT02192333,"Mean of the two z scores of the two highest scores for the symptoms that determined the participant's eligibility as ""high need"" assessed using patient-reported outcomes (PRO) survey",2015-08-03,COMPLETED,INTERVENTIONAL,['NA'],,Social support assessed using the patient-reported outcomes (PRO) survey
5383,NCT00837135,"To evaluate the feasibility of incorporating GI-4000 vaccine and activated T-cell infusion into a regimen of chemotherapy, radiation, and surgical resection to treat locally advanced pancreatic cancer.",2008-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
5384,NCT04249622,"Reduction rate of >= grade 2 abdominal toxicities including abdominal distension, abdominal pain, diarrhea, dyspepsia, stomach pain, and typhlitis",2020-09-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],"Difference in the fecal microbiome, hydrogen breath test, and permeability test","Other pertuzumab induced gastrointestinal toxicities (PIGT) such as abdominal pain, bloating and flatulence"
5385,NCT01570166,overall survival,2011-11-01,UNKNOWN,INTERVENTIONAL,['NA'],,disease-free survival
5386,NCT03125343,3-year disease free survival.,2017-01,RECRUITING,INTERVENTIONAL,['NA'],,Health economic evaluation
5387,NCT04848753,To compare IRC-assessed events-free survival (EFS) in 2 arms,2021-06-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,5- year OS rate
5388,NCT03020342,vh-chimera DNA,2016-05,UNKNOWN,OBSERVATIONAL,['NA'],current HCC marker (AFP ng/ml),recurrence-free survival time ----measurement in weeks
5389,NCT06001658,Average minimum Euclidean distance from CD8+ T cells to immunosuppressive tumor-associated macrophages (TAMs) at the per-cell level in patients with a major pathologic response versus pathologic non-responders.,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,R0 resection rate
5390,NCT02393703,successful isolation of exosomes,2015-03,RECRUITING,OBSERVATIONAL,['NA'],,evaluation of the liver microenvironment
5391,NCT04390945,Progression-free survival，PFS,2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Objective Response Rate, ORR"
5392,NCT00628784,"Confirm the feasibility and safety of endoscopic cryotherapy in patients with Barrett's esophagus with LGD, HGD, intramucosal cancer and in patients with severe squamous dysplasia.",2007-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],,"Assess the incidence of side effects, complications, adverse events and number of treatment sessions needed to reach primary endpoints."
5393,NCT00005076,Determine the complete and partial response rates and time to progression in patients with refractory advanced colorectal carcinoma treated with cetuximab and irinotecan.,1999-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Determine the tumor epidermal growth factor receptor levels in patients treated with this regimen
5394,NCT06326892,Surgical Site Infections (SSI),2023-07-31,RECRUITING,OBSERVATIONAL,['NA'],,Overall postoperative complications
5395,NCT01511146,"tumor response according to RECIST 1.1. Number of patients with CR, PR, SD and PR will be recorded.",2011-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Progression free survival, adverse events"
5396,NCT00242723,"permit evaluation of patients referred to the Thoracic Surgery Branch, NCI in order to identify individuals who will be suitable candidates for treatment/intervention protocols",2005-11-09,RECRUITING,OBSERVATIONAL,['NA'],,
5397,NCT00217568,Overall survival,2005-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5398,NCT04739202,Objective response rate,2021-03-19,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Safety, treatment-related adverse events"
5399,NCT00969410,To evaluate safety and tolerability of AV-299 (formerly SCH 900105) administered IV in subjects with advanced solid tumors who have liver metastases,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,To investigate the effect of AV-299 (formerly SCH 900105) on gene expression patterns in peripheral blood mononuclear cells and liver biopsies in subjects with advanced solid tumors who have liver metastases
5400,NCT03939975,Response,2019-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
5401,NCT06087718,Clinical feasibility of the Maastro boosting technique.,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Collecting 3D ultrasound measurements of the gross tumor volume (GTV) and intestinal wall layers at every fraction of Maastro applicator brachytherapy.,Complications within the first 30 days after completion of salvage total mesorectal excision (TME) surgery up to 3 years after treatment.
5402,NCT00660699,Incidence of Severe Toxicities,2002-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
5403,NCT02896803,Response rate,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Toxicities according CTCAE v4.03
5404,NCT04076631,Pathological stage of liver cirrhosis,2019-08-01,UNKNOWN,OBSERVATIONAL,['NA'],,The effect of cirrhotic severity and extent of hepatectomy on the incidence of post-hepatectomy liver failure (PHLF)
5405,NCT04188990,Mortality rate,2020-06-15,COMPLETED,INTERVENTIONAL,['NA'],,Patient's functional status
5406,NCT03782428,"Level of circulating inflammatory cytokines (TNF-α, IFN-γ, IL-6, IL-10, IL-12, IL-17A, IL17C &IL-22) pre and post intervention.",2016-08-26,COMPLETED,INTERVENTIONAL,['NA'],,Number of patients with chemotherapy induced diarrhoea assessed by CTCAE v3.0
5407,NCT04214990,The incidence of gastric cancer between the intervention and placebo groups,2020-02-15,RECRUITING,INTERVENTIONAL,['PHASE3'],,Improvement of atrophy and intestinal metaplasia
5408,NCT02862587,Progress-free survival,2016-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life
5409,NCT02657850,Change in rate of dysphagia symptoms,2016-06-09,WITHDRAWN,OBSERVATIONAL,['NA'],,change in rate of secondary treatment side effect
5410,NCT01164202,Percentage of Patients With Occurrence of Severe Bleeding and/or Liver Failure,2010-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Disease-free Survival
5411,NCT05485077,Negative predictive value and positive predictive value of polygene methylation in colorectal cancer,2022-07-09,RECRUITING,OBSERVATIONAL,['NA'],,
5412,NCT03204019,Objective Response Rate(ORR),2016-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Progression free survival(PFS)
5413,NCT02089763,Time to progression (TTP),2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],"Biomarker study - to explore the predictive and prognostic functions of tissue biomarkers, ornithine transcarbamylase (OTC) and arginine succinate synthetase (ASS)",Safety profile of PEG-BCT-100 treatment
5414,NCT04556253,The rate of pathologic complete response(pCR%),2020-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5415,NCT02373020,"virulence genes: eaeA, bfpA and stx. PCR",2011-01,COMPLETED,OBSERVATIONAL,['NA'],,Strains: OF E COLI
5416,NCT05068076,Comparison of treatment response two hours post procedure with Perfluorobutane with routine CECT/CEMRI done at 1 month post procedure using modified RECIST criteria for HCC.,2021-10-01,COMPLETED,INTERVENTIONAL,['NA'],,Targeting of lesions (fulfilling CEUS LIRADS 4/5 criteria) in the Kupffer phase for ablation
5417,NCT01175317,Peak Value of I-FABP,2010-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,Average Intraoperative CO2 Gap
5418,NCT05673343,disease free-survival,2023-01-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,overall survival (OS
5419,NCT03567850,Healthcare Utilization of Patients,2018-10-19,COMPLETED,INTERVENTIONAL,['NA'],,
5420,NCT02648282,Distant Metastasis Free Survival (DMFS),2016-07-18,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants Experiencing a Grade 3 or Above Treatment Related Toxicities
5421,NCT03418948,Adenoma miss rate (%),2017-12-08,UNKNOWN,INTERVENTIONAL,['NA'],,To compare patient reported outcomes e.g. pain
5422,NCT01294202,Rate of reduction/stabilisation of tumour size at 4 months according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 criteria,2011-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Treatment emergent adverse events, classified by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03."
5423,NCT04673955,Overall Survival,2020-09-03,RECRUITING,OBSERVATIONAL,['NA'],,Duration of treatment interruptions
5424,NCT05313906,ORR,2022-05-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,DCR
5425,NCT01461057,Number of Participants With Adverse Events (AEs),2011-12-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5426,NCT02370498,Overall Survival (OS) in PD-L1 Positive Participants,2015-05-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Percentage of All Participants That Discontinued Study Treatment Due to AE
5427,NCT02057146,Accuracy of single operator endoscopy plus pCLE in the biliary and pancreatic ductal system diagnosing premalignant and malignant lesions.,2013-10,COMPLETED,INTERVENTIONAL,['NA'],,
5428,NCT00737802,Pressure at the gastric sling and clasp fibers,2013-04-12,TERMINATED,OBSERVATIONAL,['NA'],,
5429,NCT03079427,2-year disease-free survival,2017-05-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
5430,NCT06322563,SAE-Safety and Tolerability,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
5431,NCT02597348,5 years overall survival (OS),2016-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,"Quality of life (QOL) of patients of Group LT followed by chemotherapy, using the NIDDK questionnaire of Liver Transplantation Database"
5432,NCT00391118,Part 2: Progression-Free Survival (PFS),2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,"PK: AUC During the Dosing Interval at Steady State (AUCτ,ss) for Part 2 of Study"
5433,NCT01717066,time to recurrence,2012-04,COMPLETED,INTERVENTIONAL,['NA'],side effect,overall survival
5434,NCT04192734,Incidence of adverse events,2019-12-18,COMPLETED,OBSERVATIONAL,['NA'],,Adverse events of special interest
5435,NCT03289533,Number of Participants With Abnormal Laboratory Parameter Values (Chemistry) as Graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE) Version (v) 4.03,2017-09-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Positive Anti-Drug Antibodies (ADAs) and Positive Neutralizing Antibodies (nAbs)
5436,NCT03030937,Adverse Event（AE）,2017-02-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of Life (QoL)
5437,NCT04915833,Polyp detection rate of computer-aided following standard colonoscopy.,2021-04-26,UNKNOWN,INTERVENTIONAL,['NA'],,Adenoma miss rate of standard high-definition colonoscopy.
5438,NCT00093782,Objective Tumor Response Rate (Defined as Partial or Complete Response as Defined by the RECIST Criteria),2003-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Progression
5439,NCT01131234,Incidence of adverse events as graded by the NCI CTCAE version 4.0,2010-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Preliminary antitumor efficacy
5440,NCT00006366,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5441,NCT03484000,Fatigue,2018-06-01,RECRUITING,INTERVENTIONAL,['NA'],,
5442,NCT00858858,Protection Against DNA Damage by UDCA,2009-03,COMPLETED,INTERVENTIONAL,['NA'],,
5443,NCT04392479,Overall response rate (ORR).,2020-09-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Exploratory biomarkers
5444,NCT00826982,To determine the if molecular biomarkers increase the sensitivity by at least 5% for detection of malignant lymph nodes in patients with pancreatic ductal adenocarcinoma as compared to EUS-FNA cytology of lymph nodes alone.,2008-01,COMPLETED,OBSERVATIONAL,['NA'],,To determine the degree of RNA overexpression of pancreas cancer specific biomarkers in the pre-operative fine needle aspirate of lymph nodes and tumors of patients with pancreatic cancer using a set of pancreas cancer specific biomarkers
5445,NCT05768178,Durable Clinical Benefit (DCB),2023-03-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,EQ-5D Standardised Area Under Index Value Curve (EQ5DSAUC)
5446,NCT03767517,Patient symptom burden (Edmonton Symptom Assessment Scale [ESAS]),2020-08-24,COMPLETED,INTERVENTIONAL,['NA'],Exploratory Aim 1f. Caregiver bereavement (Caregiver Bereavement Items ([CBI]),Patient satisfaction with care (Feeling Heard and Understood)
5447,NCT05513261,Adenoma Detection Rate (ADR),2023-11-17,RECRUITING,INTERVENTIONAL,['NA'],,Characterization of the detected lesions.
5448,NCT00325078,Efficacy of Treatment With Study Drug,2006-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Gut Immune Cell Types and Their Cytokine Profile,
5449,NCT00020917,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5450,NCT03309917,Change in internal carotid artery blood flow when mean arterial pressure (MAP) is set to 80-85 and 60-65 mmHg,2017-12-27,COMPLETED,INTERVENTIONAL,['NA'],,Comparison of the slope of linear regression of MAP and internal carotid artery blood flow for the evaluations when MAP is set to 80-85 and 70-75 mmHg and that of the evaluations when MAP is set to 70-75 and 60-65 mmHg
5451,NCT04631731,"Expression of TIM-3, LAG3, VISTA and other inhibitory checkpoint molecules on tumour-infiltrating T cells.",2020-12-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Association of pre-treatment BMI, neutrophil-to-lymphocyte ratio and other clinical parameters with irAEs."
5452,NCT06212635,Correlation between systemic inflammation and hemostasis measured by novel assays,2022-12-02,RECRUITING,OBSERVATIONAL,['NA'],,Number of participant going to transplant
5453,NCT01679054,Expected and Unexpected Provider Costs,2011-10,COMPLETED,OBSERVATIONAL,['NA'],,Expected and Unexpected Societal Costs
5454,NCT03823079,the duration after returning to normal,2019-02-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,the rate of pathological complete response.
5455,NCT02819869,relapse-free survival of hepatocellular carcinoma patients,2016-08-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,
5456,NCT02912052,Disease free survival，DFS,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],number of lymph nodes retrieved,Overall survival
5457,NCT01683864,Disease Free Survival,2012-09,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Kinetics of Mitomycin and Cisplatin,
5458,NCT03428074,Overall survivals in patients with esophageal cancer who received surgeries,2017-12-01,COMPLETED,OBSERVATIONAL,['NA'],Extents of lymph metastases,Death rates within 30 days after surgeries
5459,NCT04150874,Number of Participants with Early Tumor Response,2020-02-19,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Number of Participants with Early Signs of Radiation Induced Liver Disease (RILD)
5460,NCT05566249,Cost,2022-10-01,RECRUITING,OBSERVATIONAL,['NA'],,Oncologic outcomes
5461,NCT03543514,Crompehension Complexity Index (CCI),2022-02-02,RECRUITING,OBSERVATIONAL,['NA'],,Hospital Anxiety and Depression Scale (HADS)
5462,NCT06287814,3-year disease-free survival (DFS),2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Time to molecular recurrence
5463,NCT05512377,Objective response (OR),2022-11-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Change from baseline in EORTC QLQ-BIL21 tiredness domain score
5464,NCT01061515,Overall survival,2011-05-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
5465,NCT00021047,,2001-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
5466,NCT00290719,Pathological response (complete and partial) post-operatively,2005-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,Compare the effects of gefitinib on biomarkers that effect EGF signaling and genomic composition of tumor samples before and after treatment
5467,NCT00012324,Overall survival,2000-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Response to treatment in patients with and without prior therapy
5468,NCT02813096,early recurrence,2016-10,UNKNOWN,INTERVENTIONAL,['NA'],,overall survival
5469,NCT03616431,Determine prevalence of pancreatic enzyme insufficiency in patients with pancreatic neoplasms.,2018-07-03,COMPLETED,OBSERVATIONAL,['NA'],,"To identify, through semi structured interviews and thematic analysis, diet-related themes of interest in a subset of patients involved in this study"
5470,NCT05281211,Number of participants experiencing 90 day morbidity,2022-03-15,RECRUITING,INTERVENTIONAL,['NA'],,Number of participants being disease free (Disease free survival)
5471,NCT03511963,PFSR9m,2018-04-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Ctrough,SAE
5472,NCT04821258,Rate of complications.,2021-04,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of life assessment.
5473,NCT00962312,6-month survival rate,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumour biomarker analysis
5474,NCT01642797,number of participant with gastric IM/IN/CA,2012-08,UNKNOWN,INTERVENTIONAL,['NA'],,number of biopsies needed per patient
5475,NCT01438645,Sedation Score,2011-09,COMPLETED,INTERVENTIONAL,['NA'],,Ancillary maneuvers to facilitate procedure
5476,NCT04975932,Progression free survival(PFS),2021-07-01,COMPLETED,OBSERVATIONAL,['NA'],,Adverse event(AE)
5477,NCT05692024,Change in hepatic fat fraction.,2024-03-21,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change in stool metabolomics,Change in liver fibrosis assessment and plasma levels of liver enzymes
5478,NCT04752930,Peritoneal Metastasis Free Survival (PMFS),2020-08-24,RECRUITING,INTERVENTIONAL,['NA'],,The Overall Survival (OS) at 3 years after radical resection of colorectal cancer
5479,NCT04923932,Objective response rate (ORR) evaluated by the Independent Review Committee (IRC) (RECIST 1.1 criteria),2021-07-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,incidence of various adverse events (AE)
5480,NCT01152710,complete pathological remission rate,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,long-term rectal and urogenital morbidity
5481,NCT05336058,Screening of genetic targets for kit development,2022-02-01,UNKNOWN,OBSERVATIONAL,['NA'],,
5482,NCT00086996,Pathological Complete Response,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free Survival
5483,NCT05155124,Incidence of DLT（Dose-limited toxicity）,2022-09,RECRUITING,INTERVENTIONAL,['PHASE1'],,Adverse Eevents
5484,NCT00261378,Objective response rate measured according to RECIST and EASL,2005-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time To Progression
5485,NCT05536102,Pathological complete remission rate,2022-09-05,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events (AEs),3-year PFS rate
5486,NCT02950025,"Number of Grade 3 or Greater Toxicity Occurring in Patients Receiving Online, Adaptive, MRI-guided SBRT to the Abdomen and in Patients Receiving Non-adaptive SBRT",2017-01-19,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Local Failure
5487,NCT03148093,Reasons for dose adjustments and/or discontinuation of treatments,2017-06-30,TERMINATED,OBSERVATIONAL,['NA'],Progression free survival,Burden for caregivers providing support to patients enrolled in the registry per Modified Caregiver Strain Index (MCSI)
5488,NCT05825664,Curative rate,2023-04-07,RECRUITING,INTERVENTIONAL,['NA'],,Procedure time
5489,NCT04021277,Number of patients with adverse device effects,2019-09-17,RECRUITING,INTERVENTIONAL,['PHASE1'],,Best overall response (Part 1b only)
5490,NCT05020132,Change in the Bristol stool chart between baseline and 12 months,2015-11-01,COMPLETED,OBSERVATIONAL,['NA'],,Multivariate analysis of risk factors for LARS
5491,NCT03732768,Maximum Tolerated Dose (MTD),2020-06-08,RECRUITING,INTERVENTIONAL,['PHASE1'],,
5492,NCT04976439,Description of survival,2021-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
5493,NCT03007225,Number of Participants With Complete Response,2015-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,
5494,NCT02466009,Number of Subjects Who Experience Grade 3-5 Toxicity as a Measure of Safety and Tolerability.,2015-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Subject's Quality of Life as Assessed by the Comprehensive Geriatric Assessment Form While Receiving Study Treatment.
5495,NCT04923646,Return proportion,2021-06-30,COMPLETED,INTERVENTIONAL,['NA'],,Return proportion
5496,NCT00217581,Time to Progression,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
5497,NCT06012734,The RP2D of LB-100 when given in combination with standard doses of atezolizumab,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Concentration of LB-100 and endothall in tumor tissue,The incidence of dose-limiting toxicity
5498,NCT03585673,Overall response rate,2018-06-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse event
5499,NCT03572400,Disease-free survival rate,2018-11-29,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease control rate
5500,NCT06233253,Satisfaction with the intervention (Acceptability),2023-09-29,RECRUITING,INTERVENTIONAL,['NA'],,Intent for future CRC screening
5501,NCT05907642,Low Anterior Resection Syndrome Questionnaire Score,2019-08-01,COMPLETED,INTERVENTIONAL,['NA'],,The European Organization for Research and Treatment of Cancer quality of life questionnaire c-30
5502,NCT03843957,Percent of Patients Who Complete the mPATH-CRC Program,2019-10-31,COMPLETED,INTERVENTIONAL,['NA'],,mPATH-CheckIn Feasibility
5503,NCT00207831,Compare the rate of pathologic complete response of the primary tumor in patients with operable rectal cancer receiving preoperative chemoradiotherapy versus patients receiving radiotherapy alone,2004-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,Compare overall survival
5504,NCT00006115,,1999-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5505,NCT01063192,The primary end point is to evaluate the time to progression after gemcitabine alone versus Gemcitabine-based combination induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer.,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"The secondary end points are to evaluate the disease control rate, overall survival time, toxicity profile and compliance after induction chemotherapy and concurrent chemoradiotherapy ."
5506,NCT00030797,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5507,NCT04477343,Maximum tolerable dose [Safety and Tolerability],2020-11-23,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall Survival
5508,NCT01797770,anastomotic leak,2012-01,UNKNOWN,OBSERVATIONAL,['NA'],,Readmission
5509,NCT05710809,Dynamic Gait Index (DGI),2023-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Recurrence of cancer,Body composition
5510,NCT00855218,Time to Progression (TTP) - Independent Radiological Review (Primary Analysis),2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumor Response - Investigator Assessment
5511,NCT01129778,Percentage of Time Esophageal pH< 4,2009-11,TERMINATED,INTERVENTIONAL,['NA'],,Reflux Disease Questionnaire Score on Day 1 After Therapy Completion
5512,NCT01339273,Morphine Consumption in the First 48hours After the Operation,2011-09,COMPLETED,INTERVENTIONAL,['NA'],,Time to Hospital Discharge
5513,NCT02611024,Response Rate,2016-05-06,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
5514,NCT02979470,progression free survival,2016-09,UNKNOWN,OBSERVATIONAL,['NA'],,
5515,NCT02122523,Number of fluorescent lymph nodes,2013-01,COMPLETED,INTERVENTIONAL,['NA'],,Number of Lymph nodes with metastasis
5516,NCT04728321,Objective response rate (ORR),2021-01-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with adverse events (AEs)
5517,NCT03386825,"BRAF mutation (yes, no, unknown)",2018-01-31,COMPLETED,OBSERVATIONAL,['NA'],,Duration of treatment (months)
5518,NCT02156557,Validation of binding of peptide,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5519,NCT03606590,Overall response rate,2019-02-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Severity and frequency of adverse events
5520,NCT05722288,Percentage of patients completing 4 weeks of time-restricted eating during RT,2023-01-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Oxidative DNA damage
5521,NCT06115629,All-cause mortality,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Fear of cancer recurrence as determined by the cancer worry scale score
5522,NCT00861107,evaluation of any drug-related toxicity associated with AlloStim administration as well as the reversibility of such toxicity.,2009-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,evaluation of the immunological response to AlloStim administration
5523,NCT05270889,Overall Response,2022-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
5524,NCT00884520,Safety will be the outcome demonstrated in this clinical trial through analyses of adverse events in subjects who receive study drug.,2009-04,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
5525,NCT05182255,Number of participants with clinically relevant device migration,2022-04-28,RECRUITING,OBSERVATIONAL,['NA'],,
5526,NCT02945878,gradings of oral mucositis,2016-10,UNKNOWN,OBSERVATIONAL,['NA'],,
5527,NCT00290316,To compare the accuracy of the EUS and CT scan for detection of the primary and metastatic carcinoma of the liver.,2004-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,2.2.5 To study characteristic echoendoscopic findings of the primary and secondary liver tumor.
5528,NCT02567942,natural killer cell activity,2016-02,COMPLETED,INTERVENTIONAL,['NA'],change of percentage of CD39 and CD73,helper T cell activity
5529,NCT05051670,major complication,2021-12-16,COMPLETED,INTERVENTIONAL,['NA'],,Hospital stay
5530,NCT00059891,Determine the risk of complications and feasibility of total anorectal reconstruction using the Acticon Neosphincter prosthesis after abdominoperineal resection in patients with anal or rectal cancer.,2003-01,COMPLETED,INTERVENTIONAL,['NA'],,"Determine continence, bowel function, and quality of life of patients treated with this surgery."
5531,NCT03719716,Health related quality of life: EuroQol EQ-5D-5L,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Trial feasibility assessment: conversion rate
5532,NCT05917990,Changes in constructive communication,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
5533,NCT01202409,Response Rate (RR),2010-11-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Progression-free Survival (PFS) for CAPOX and Panitumumab
5534,NCT00557024,Overall survivals,2007-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Recurrence rates
5535,NCT02845258,Repeated drainage frequency,2006-01,RECRUITING,OBSERVATIONAL,['NA'],,Long time complication rate
5536,NCT00503867,Number of Participants With Adverse Events Grade 3 or Higher,2007-07-18,TERMINATED,INTERVENTIONAL,['NA'],,Overall Survival
5537,NCT01233713,Overall post-operative complication rate defined according to the Clavien-Dindo Classification,2006-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,In-hospital costs
5538,NCT02723942,Radiological assessment,2015-06,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,CAR-T cell testing
5539,NCT05274204,,na,TEMPORARILY_NOT_AVAILABLE,EXPANDED_ACCESS,['NA'],,
5540,NCT01683357,feasibility on an intention-to-treat basis,2001-09,COMPLETED,OBSERVATIONAL,['NA'],reliability of the procedure from an oncological standpoint,safety of the procedure
5541,NCT02632006,Overall survival,2015-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life
5542,NCT05871164,Carcinological efficacy of pancreatic radiofrequency,2023-06-12,RECRUITING,OBSERVATIONAL,['NA'],,
5543,NCT01930435,Mean Change in Quality of Life as Measured by the Subscale MDASI-HN Score.,2013-07,COMPLETED,INTERVENTIONAL,['NA'],,Rate of Hospitalization in Patients Who Use Personalized Sterile Humidification
5544,NCT02740985,The incidence of adverse events,2016-06-17,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression free survival
5545,NCT03364907,change in tissue platinum exposure before and after flushing,2018-03-01,COMPLETED,OBSERVATIONAL,['NA'],,total and unbound platinum concentration in instillate
5546,NCT00227747,Rate of complete surgical resection,2005-11-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Acute and late toxicity
5547,NCT00372450,Change in health-related quality of life from baseline to 30 days and 3 months after self-expanding plastic stent or self-expanding metal stent placement,2006-12,WITHDRAWN,INTERVENTIONAL,['NA'],,Overall rate of mortality
5548,NCT01821612,Completion rate of all preoperative and operative therapy,2013-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Overall survival
5549,NCT00666926,Percentage of Participants With Tumor Metabolic Response (Reduction of ≥15%) in Positron Emission Tomography With F-18-fluorodeoxyglucose (FDG-PET),2005-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Caspase-3
5550,NCT04148378,Correlation of Microbiome to Disease via Relative Abundance Found in Microbiome Sequencing,2020-03-02,UNKNOWN,OBSERVATIONAL,['NA'],,Validation of Sequencing Methods
5551,NCT00087191,Toxicity as assessed by NCI Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events (CTCAE) version 3.0,2004-05,TERMINATED,INTERVENTIONAL,['NA'],,
5552,NCT00687596,Overall Survival (OS),2008-08-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Relationship Between Tumor Gene Expression of Messenger Ribonucleic Acid (mRNA) Ratio of Co-activators, Co-repressors and Efficacy Parameters"
5553,NCT04329299,Gastric cancer,2012-12-03,COMPLETED,OBSERVATIONAL,['NA'],,
5554,NCT01807117,Negative Predictive Values for PET-CT and PET-MRI,2013-04,COMPLETED,INTERVENTIONAL,['NA'],,
5555,NCT00566644,Rate of atypical endometrial hyperplasia or endometrial cancer during the active follow-up period of the study,2007-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,
5556,NCT03035006,Best objective response evaluation of portal vein tumor thrombosis,2017-04-14,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival of overall disease
5557,NCT00468416,Functioning anastomosis and no occurrence of adverse events related to device use,2007-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5558,NCT04098237,Feasibility of completing pancreatic enzyme replacement therapy during the first 8 weeks of the study: daily compliance diary,2020-12-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,Mean change in daily active minutes from baseline
5559,NCT02141945,Performance of Metabiomics Colon Polyp and Colorectal Cancer Assay,2014-03,COMPLETED,OBSERVATIONAL,['NA'],,
5560,NCT05902533,Assess patient reported GI toxicity using PRO-CTCAE Diarrhea,2023-08-14,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Proportion of patients requiring a treatment break due to toxicity; measured by more than 3 consecutive fractions missed.
5561,NCT02928120,Diagnostic potential of hypermethylated DNA as a biomarker for colorectal cancer,2015-02,UNKNOWN,OBSERVATIONAL,['NA'],,Hypermethylated DNA as a follow-up biomarker for disease recurrence
5562,NCT04857203,The Role of Vitamin D in response to neoadjuvant therapy for the patients with locally advanced rectal cancer,2020-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
5563,NCT05773248,Perioperative morbidity,2023-03-13,COMPLETED,OBSERVATIONAL,['NA'],,Readmission rate
5564,NCT03658837,Quantitative Assessment using EORTC QLQ-OES-24,2019-01-03,COMPLETED,OBSERVATIONAL,['NA'],,Qualitative analysis
5565,NCT05237310,Additional Adenoma Detection,2022-02-02,UNKNOWN,INTERVENTIONAL,['NA'],,
5566,NCT00681577,safety (Phase I: toxicities as assessed by NCI CTCAE version 3) and efficacy (Phase II: Feasibility as evaluated by RECIST),2008-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To evaluate immunological responses
5567,NCT04769414,Overall response rate (ORR),2021-02-20,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
5568,NCT03311789,The percentage of patients alive and without progression at 6 months,2017-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,List of adverse event frequency and grade
5569,NCT00026234,Survival rate,2002-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse events as assessed by NCI CTC version 2.0
5570,NCT05902624,Effectiveness of Hepatitis B virus vaccine(HBV) in treatment of cutaneous warts .,2023-06-10,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
5571,NCT03535727,Progression-free Survival (PFS) Using RECIST 1.1 Criteria,2018-06-21,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Safety of the Combination of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan (GAX-CI) in Patients With Untreated Metastatic PDA."
5572,NCT00251355,To assess the maximum tolerated dose of weekly gemcitabine when administered with continuous infusion 5-fluorouracil and external beam radiation.,1998-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,to obtain a preliminary assessment of the efficacy of this regimen in this patient population.
5573,NCT06027515,Completion Rate (Feasibility),2023-12-01,RECRUITING,INTERVENTIONAL,['NA'],Patient-Reported Measures on Physical Function Score,Actigraphy Compliance Rate (Feasibility)
5574,NCT00445497,Incidence of serious adverse events (randomized and registered patients),2007-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Health service costs (randomized patients)
5575,NCT01910974,SAFETY THAT IS TO SAY PERFORATION RATE AND delayed BLEEDING ONE,2012-07,COMPLETED,INTERVENTIONAL,['NA'],,
5576,NCT00955344,Colorectal Cancer Screening Rates,2009-09,COMPLETED,INTERVENTIONAL,['NA'],,Content of practice improvement plan
5577,NCT05429866,Modification(s) in the immune blood markers of treated subjects on treatment at the occurence of any grade 3 or 4 irAE.,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
5578,NCT05280665,30-day mortality,2022-02-14,COMPLETED,OBSERVATIONAL,['NA'],Neoadjuvant treatment usage,Hospital stay
5579,NCT04828486,Progression-free survival (PFS),2021-05-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Change in quality of life (QOL)
5580,NCT01698710,Frequency of Pancreatitis,2012-11,TERMINATED,INTERVENTIONAL,['NA'],,Size of Cystic Lesion
5581,NCT00009880,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5582,NCT01391208,Safety of peptide application,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5583,NCT01258608,Time to Progression-Blinded Independent Central Review (BICR) Assessment,2011-02-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Serum Concentration of Mapatumumab
5584,NCT06117891,Overall survival (OS),2023-11-27,RECRUITING,OBSERVATIONAL,['NA'],,Treatment sequences post first-line AB or other IO combinations
5585,NCT01547845,PRO symptom measurement,2012-02-10,COMPLETED,OBSERVATIONAL,['NA'],,
5586,NCT03660449,Progression-Free Survival,2017-10-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,rate of grade 3-4 radiation pneumonitis
5587,NCT05575622,"CTC-PD-L1, exosomal PD-L1, and exosomal LAG-3",2023-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
5588,NCT05254171,Overall Survival (OS),2022-08-08,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Exploratory,Progression Free Survival (PFS)
5589,NCT00416767,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5590,NCT05970666,Occurence of AE and SAE,2023-11-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival（OS）
5591,NCT03766659,Diagnostic yield,2019-06-19,RECRUITING,INTERVENTIONAL,['NA'],,morbidity rate
5592,NCT03331562,Progression- Free Survival at 6 Months From Initiation of Trial Treatment,2017-12-27,COMPLETED,INTERVENTIONAL,['PHASE2'],Exploratory: Monitor and Compare the Gut Microbial Communities in Both Arms of the Trial,Cellular VDR Targets in the Immune Microenvironment With PD1 Blockade
5593,NCT01519817,Count of Participants With Adverse Events of Escalating Doses of Yeast Brachyury ( GI- 6301) Vaccine,2012-01-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Changes in Soluble Cluster of Differentiation 40L (sCD40L)
5594,NCT04191421,Maximal tolerated dose (MTD) of siltuximab that can be combined with spartalizumab,2020-01-17,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival time
5595,NCT00813605,Progression Free Survival,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of antibody formation
5596,NCT02843802,Relief degree,2016-07-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival（OS）
5597,NCT05233436,Objective response rate (ORR) in Dose Expansion (Part 2),2022-02-24,TERMINATED,INTERVENTIONAL,['PHASE1'],,Time to event endpoints (OS) in Dose Expansion (Part 2)
5598,NCT05500157,PLD-Q 4 weeks,2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Cost-effectiveness iMCQ
5599,NCT02217020,The ratio of tumor downstaging to stage 0 and stage I,2014-08-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Reported Adverse events
5600,NCT03113604,"Rate of expression of SLAM3 and MDR transcripts, correlation with the responder status or not with Sorafenib",2015-11-20,WITHDRAWN,OBSERVATIONAL,['NA'],,
5601,NCT04930016,specific need for QoL therapy of colorectal cancers survivors in specific QoL dimensions,2021-04-14,COMPLETED,OBSERVATIONAL,['NA'],,colorectal cancer survivors' recollections of their illness an therapy
5602,NCT00942461,Inflammatory reaction of the patients organism in laparoscopic vs open colorectal surgery for cancer,2008-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,
5603,NCT01087658,"Occurence of peripheral sensory neuropathy (PSN) grade 2, 3 and 4 assessed by the National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE)",2010-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression Free Survival / PFS (for metastatic patients)
5604,NCT05201612,Objective response rate (ORR),2022-07-07,RECRUITING,INTERVENTIONAL,['PHASE2'],Biomarker molecular substudy,Duration of response (DOR)
5605,NCT01639443,Percentage of GI Clinic Capacity Filled,2013-07-08,COMPLETED,INTERVENTIONAL,['NA'],,Cost Comparisons
5606,NCT03743428,Identify biomarkers specific to apatinib or bevacizumab by proteomic analysis,2020-10-22,SUSPENDED,INTERVENTIONAL,['NA'],,Overall Survival (OS)
5607,NCT02355249,The incidence of respiratory complications,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],blood biomarker analysis,Health-related quality of life scores（HRQoL）
5608,NCT00997802,sensitivity in the detection of colorectal polyps and cancers in CTC,2009-10,COMPLETED,INTERVENTIONAL,['NA'],,specificity and predictive values in the detection of colorectal polyps and cancers in CTC.
5609,NCT05238922,Number of Participants Discontinue study due to TEAE,2022-07-05,RECRUITING,INTERVENTIONAL,['PHASE1'],,Duration of Response (DOR)
5610,NCT05999227,18F-FDG PET analysis,2023-06-20,RECRUITING,INTERVENTIONAL,['NA'],,
5611,NCT05859581,Coincidence rate with pathological result,2023-04-02,RECRUITING,INTERVENTIONAL,['NA'],,
5612,NCT03210064,ORR,2017-05-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,QoL
5613,NCT06143579,Overall response rate (ORR),2023-12-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
5614,NCT00109850,Overall Survival at 2 Years,2005-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
5615,NCT02016274,progression free survival,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],quality of life,overall survival
5616,NCT05929820,Rate of completion of a CRC screening test,2023-09-15,RECRUITING,INTERVENTIONAL,['NA'],,Qualitative feedback on details of CRC screening test
5617,NCT04744792,Disability of patients and spouses,2006-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
5618,NCT06232538,UCAD can be used as a diagnostic technology for gallbladder cancer with the sensitivity more than 90%,2024-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
5619,NCT03017807,Number of patients with dose limiting toxicity.,2016-12,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of anti-EGFR antibody after single dose and under the stable blood concentration.
5620,NCT04119830,Objective response rate,2022-02-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Objective response rate
5621,NCT04237883,Aggregate Focus Quality Measure order rates at the first visit,2019-11-01,COMPLETED,INTERVENTIONAL,['NA'],,Number of Open Tests
5622,NCT04147481,Incidence of postoperative chronic pain,2019-10-21,UNKNOWN,INTERVENTIONAL,['NA'],The numeric rating scale of postoperative pain,Gastrointestinal decompression
5623,NCT03260179,AE,2017-08-31,UNKNOWN,INTERVENTIONAL,['PHASE1'],Exosomes,PFS
5624,NCT00003260,,1998-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
5625,NCT00620295,Maximum tolerated dose of bortezomib and gemcitabine,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Characterization of gemcitabine and metabolite pharmacokinetics (as part of co-enrollment in Population Pharmacokinetics and Pharmacogenetics of Gemcitabine in Adult Patients with Solid Tumors"")"
5626,NCT03783871,Primary Technical Efficacy,2019-02-17,COMPLETED,INTERVENTIONAL,['NA'],EORTC QLQ-HCC18 Questionnaire,Local tumor progression (LTP)
5627,NCT01543620,,2012-02,UNKNOWN,OBSERVATIONAL,['NA'],,
5628,NCT04235114,The observation of differences in 89Zr-DFO-nimotuzumab uptake between the tumors and normal tissues using PET/CT.,2020-02-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Lesion detection rate of FDG PET/CT compared with 89Zr-DFO-nimotuzumab in patients with EGFR-positive (by IHC) lung and colorectal cancers using PET/CT.
5629,NCT00532740,,2004-12,COMPLETED,OBSERVATIONAL,['NA'],,
5630,NCT02650661,Change in percentage of patients meeting the posttraumatic growth inventory (PTGI) goal,2015-11-23,COMPLETED,INTERVENTIONAL,['NA'],,Cost effectiveness analysis
5631,NCT00728585,Incidence of WHO grade 3 or 4 oral mucositis,2008-03-13,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Incidence of febrile neutropenia and invasive bacterial infections
5632,NCT06247956,ORR based on RECIST v1.1 assessment.,2024-03-11,RECRUITING,INTERVENTIONAL,['PHASE2'],,DCR based on RECIST v1.1 assessment
5633,NCT05418387,Acceptability of the intervention,2022-09-30,WITHDRAWN,INTERVENTIONAL,['NA'],,Proportion of patients who attend a scheduled appointment after their surgery with hepatologists or urologists in control vs. intervention group
5634,NCT03077685,Incidence of Treatment Emergent Adverse Events (safety and tolerability),2017-12-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change in tumor markers
5635,NCT00112099,Overall survival,2002-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,perioperative blood loss
5636,NCT00104065,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5637,NCT04798560,Development of Postoperative pancreatic fistula after pancreaticoduodenectomy,2018-10-10,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival
5638,NCT00876551,Closure of postsurgical leak,2008-01,UNKNOWN,INTERVENTIONAL,['NA'],,C reactive protein
5639,NCT05262491,Phase Ib: Recommended Phase II Dose (RP2D),2022-02-14,RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-free Survival (PFS)
5640,NCT00391183,Improvement in the physical functioning scale (containing five items) of EORTC QLQ-30 one month after after biliary stenting.,2006-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Performance status change
5641,NCT01364376,overall survival,2011-06,COMPLETED,INTERVENTIONAL,['NA'],,Number of Participants with grade 3/4 adverse Events
5642,NCT02756455,% of patients without leaks after gastric surgery correctly identified by PCT and CRP,2015-01,UNKNOWN,OBSERVATIONAL,['NA'],,PCT cut-off that gives good negative predictive value for leak after gastric surgery in 5th POD
5643,NCT02000999,"• Sensitivity accuracy of cytology, FISH and mutation profiling using histologic diagnosis in conjunction with clinical and/or imaging follow-up as the gold standard.",2013-11,COMPLETED,OBSERVATIONAL,['NA'],,• Technical success and ease of procedure
5644,NCT01126450,"Safety / Tolerability (type, frequency, severity, and relationship of adverse events to study drug)",2009-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,"Lab correlatives (FCGRIIa and FCGRIIIa polymorphisms, K-Ras and B-Raf mutations)"
5645,NCT02191878,Maximum tolerated dose (MTD),2014-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Assessment of Pharmacodynamic Effect,Clinical Benefit Rate at maximum tolerated dose (MTD) in Expansion Cohort
5646,NCT02052921,Disease-free survival (DFS),2011-11,TERMINATED,INTERVENTIONAL,['NA'],Overall survival (OS),Operative complication rate
5647,NCT03275987,screening mammography or colonoscopy,2014-04-23,COMPLETED,INTERVENTIONAL,['NA'],,
5648,NCT02236884,Composite mesure of prioperative feasibility and safety,2014-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Composite mesure of oncological outcome
5649,NCT01668680,"Length of progression free survival (PFS), measured in months.",2012-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Quality of life, as expressed by FACT-C."
5650,NCT00278876,2-year Relapse Free Survival Rate,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity Profile
5651,NCT02508532,"Part 2: Objective Response Rate (ORR) Determined by Central Radiology Assessment Per mRECIST, Version 1.1",2015-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,"KIT, PDGFRA, and Other Cancer-relevant Mutations Present in Tumor Tissue at Baseline and EOT"
5652,NCT04454762,Blood pressure [Safety and Tolerability],2020-07-22,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Health-related quality of life (HRQOL)
5653,NCT04991090,the responsive rate of dose escalation of LLN,2021-08-13,RECRUITING,INTERVENTIONAL,['NA'],,prognosis outcome-3-year Lateral Local Recurrence
5654,NCT01640782,"Progression Free Survival will be defined as the time from date of randomisation to date of first appearance of local, regional or distant relapse, or death from any cause; patients alive without relapse will be censored at date last known to be alive.",2005-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Adverse events
5655,NCT00075868,"Prevention of the incidence of moderate, severe, or life-threatening diarrhea",2003-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Prevention of the incidence of severe or life-threatening (i.e., grade 3-5) diarrhea"
5656,NCT01677468,Survival rate of the subjects,2012-08,UNKNOWN,INTERVENTIONAL,['NA'],,Complication rate of TACE
5657,NCT00151476,Time From Start of Study Follow-up to Time of First Excisional Polypectomy of a Rectal Polyp Post IPAA,2004-11,TERMINATED,OBSERVATIONAL,['NA'],,Rectal or Pouch Adenoma Burden Based on Polyp Counts
5658,NCT04984018,OS,2021-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],PD-L1 CPS,DCR
5659,NCT03724851,Maximum Tolerated Dose,2018-11-28,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pharmacodynamics of TEW-7197
5660,NCT05504265,Postoperative pain score,2022-08-10,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Rate of pulmonary infection
5661,NCT05628545,Overall Survival,2021-11-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,PFS（Progression-Free Survival )
5662,NCT03342937,Months of Progression-free Survival (PFS),2018-01-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Months of Overall Survival
5663,NCT04663763,pCR rate,2020-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of Life Scale
5664,NCT05709249,Two-year disease-free survival (DFS),2022-12-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Changes in total score on the MD Anderson Symptom Inventory for Traditional Chinese Medicine (MDASI-TCM)
5665,NCT01689792,Polyp detection rate,2011-11,COMPLETED,INTERVENTIONAL,['PHASE4'],,Acceptability and tolerability of medication using patient questionnaires
5666,NCT00855985,pancreatic fistula rate,2004-07,UNKNOWN,INTERVENTIONAL,['NA'],,major complication
5667,NCT00718562,Disease Control Rate (DCR) in all patients with either sunitinib-resistant GIST or in patients with GIST who are intolerant of sunitinib,2008-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,PK profile
5668,NCT03467308,Measure TRIM59 in the study groups.,2018-03-01,COMPLETED,OBSERVATIONAL,['NA'],,Targeting new prognostic and therapeutic markers for colorectal cancer.
5669,NCT05384444,Disease-free Survival,2022-06-08,RECRUITING,INTERVENTIONAL,['NA'],,insulin
5670,NCT03760614,Dose limiting toxicity (DLT),2021-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Overall response rate (ORR)
5671,NCT03707080,Time to HCC recurrence - Prospective Cohort,2018-03-09,COMPLETED,OBSERVATIONAL,['NA'],,Number of events of early HCC recurrence - Prospective Cohort relative to Historical Cohort
5672,NCT02439385,Progression-free survival,2015-08-24,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Fatigue (FACIT-Fatigue scale (version 4, Korean version)"
5673,NCT00096278,Disease-free Survival,2004-09-15,COMPLETED,INTERVENTIONAL,['PHASE3'],Proteinuria After Completion of Bevacizumab,Survival
5674,NCT04599140,Incidence of adverse events (AEs),2020-10-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Biomarker analysis,Overall survival (OS)
5675,NCT00568529,Response Rate,2007-10,SUSPENDED,INTERVENTIONAL,['PHASE2'],,time to progression and overall survival
5676,NCT04319354,Ryan tumor regression grade system (number of patients with complete/partial/no response),2019-11-18,COMPLETED,INTERVENTIONAL,['NA'],,Number of participants with 1 and 2-year disease free recurrence
5677,NCT06033482,The lymph node metastasis rates in No.12aa and No.12av groups.,2023-06-01,RECRUITING,OBSERVATIONAL,['NA'],,
5678,NCT04214418,Phase 1: Estimated maximum tolerated dose (MTD),2020-02-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 1: Incidence of Treatment-Emergent Adverse Events with drug combination (Safety and Tolerability)
5679,NCT02515513,Identify gene networks within the skeletal muscle between the groups,2016-03,WITHDRAWN,INTERVENTIONAL,['NA'],,Survival data
5680,NCT01293448,Treatment effect,2010-12,COMPLETED,INTERVENTIONAL,['NA'],,Post procedure pain
5681,NCT05920980,Pain scores of movement-evoked pain at postoperative 24 hours,2023-06-05,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,plasma lidocaine concentration
5682,NCT05161624,"Receiver operating characteristic curve, ROC",2021-12-15,UNKNOWN,OBSERVATIONAL,['NA'],,"Area under curve, AUC"
5683,NCT04513951,Progression-free Survival,2020-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
5684,NCT03523312,The proportion of patients who undergo definitive surgery,2018-04-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
5685,NCT03375060,Composite histologic score of neosquamous epithelium following endoscopic eradication therapy (EET),2017-08-02,COMPLETED,OBSERVATIONAL,['NA'],,Recurrence rate of intestinal metaplasia (Barrett's esophagus)
5686,NCT01585662,recurrence rate of pancreatic pseudocyst,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,The complication rate
5687,NCT03309722,distant recurrence,2008-10-10,RECRUITING,OBSERVATIONAL,['NA'],,
5688,NCT03655002,Incidence of adverse events,2019-02-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Circulating immune cell profiles circulating tumor deoxyribonucleic acid (DNA),Overall survival
5689,NCT00480584,Maximum Tolerated Dose (MTD),2007-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Recommended Phase II Dose (RPTD)
5690,NCT00517920,Objective Response Rate,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5691,NCT00003835,Survival,1999-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,
5692,NCT00902733,"Quality of life, psychological distress, symptom relief, geriatric assessment outcome, and resource use at 3 months",2008-07,COMPLETED,INTERVENTIONAL,['NA'],,Long-term impact at 6 months
5693,NCT01263002,Proportion of patients with HBV DNA levels < 60 IU/mL,2010-06,COMPLETED,INTERVENTIONAL,['PHASE4'],,
5694,NCT02633020,Percent Change From Baseline in the Percentage of Aberrant Intestinal Intraepithelial Lymphocytes With Respect to All Intraepithelial Lymphocytes,2016-04-13,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change From Baseline in Total Celiac Disease GSRS (CeD-GSRS) Score at Week 12
5695,NCT00209690,Determine the DLT(Dose Limiting Toxicity) and MTD(Maximum Tolerated Dose) in Phase I setting. Determine the clinical response rate with Recommended dose in Phase II setting.,2003-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determine the MST(Median Survival Time) and PFS(Progression Free Survival) in Phase II setting.
5696,NCT06161909,disease-free survival (DFS),2024-01-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,recurrent metastasis pattern
5697,NCT00166881,Overall survival (OS),2000-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Objective response rates (CR, PR)"
5698,NCT05625737,Objective Response Rate (ORR),2022-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Exploratory endpoint,Adverse Event (AEs)
5699,NCT03895723,disease-free survival (DFS),2019-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,Sugical complications
5700,NCT04269941,number of patients operated for gastric GIST,2000-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
5701,NCT02737228,Overall Response Rate (ORR),2016-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Clinical laboratory tests
5702,NCT05099211,Acceptability of the program in terms of the number of sessions attended,2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
5703,NCT04097444,Progression-free survival (PFS),2019-10-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Functional Assessment of Cancer Therapy (FACT) / Gynaecologic Oncology Group (GOG) Neurotoxicity 4
5704,NCT02454075,A Reduction of 25% in the Gastric ECL Cell Density.,2011-04-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Acid Control Study 3, Control of Gastric Acid Secretion Assess by Changes in Drug-controlled Gastric Acid Analysis: Acid Output"
5705,NCT01828918,postoperative early recurrence,2012-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
5706,NCT02230410,Eradication of Barrett's Esophagus,2014-08,COMPLETED,INTERVENTIONAL,['NA'],,
5707,NCT01893801,Complete Response Rate,2013-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-Free Survival
5708,NCT00642733,Overall survival; time to progression,2007-08,TERMINATED,INTERVENTIONAL,['PHASE4'],,"AEs, lab parameters"
5709,NCT04143191,Recurrence-free survival,2019-09-15,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of life
5710,NCT05636618,Area under the concentration-time curve (AUC) [Time Frame: 42 days following last dose of [212Pb]VMT-α-NET; up to 3 years,2023-09-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Biodistribution of [212Pb]VMT-α-NET using a microdose of the therapeutic surrogate, [203Pb]VMT-α-NET"
5711,NCT01302613,The primary study endpoint for the phase I portion of this study is to assess surgical complications through the Clavien grading system.,2011-03,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The primary endpoint of the phase II portion of the study is complete pathologic response.
5712,NCT05562297,2-year overall survival after the application of sintilimab and gemcitabine plus nab-paclitaxel,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,"Correlation among ctDNA, serum tumor markers, and CT evaluations before and after neoadjuvant therapy, before and after curative resection, during and after adjuvant therapy, and during and after the maintenance treatment of immunotherapy."
5713,NCT01309256,Acute-inflammatory response after undergoing robotic and laparoscopic gastrectomy,2011-03,COMPLETED,OBSERVATIONAL,['NA'],,
5714,NCT05801965,Cancer-specific Quality of Life,2023-04-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,User engagement
5715,NCT03521037,Area under the plasma rucaparib concentration-time curve from time zero up to the last time point with quantifiable concentration (AUC0-last),2018-02-27,COMPLETED,INTERVENTIONAL,['PHASE1'],Cumulative amount of rucaparib metabolite(s) excreted in urine during urine collection period post rucaparib dose,Incidence of dose modifications [Safety and Tolerability]
5716,NCT03252808,Dose Limiting Toxicity (DLT),2017-09-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],1 year survival rate,Progression-free survival (PFS) by irRECIST
5717,NCT00699374,Overall Survival (OS),2008-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,European Quality of Life (EQ-5D)- Health State Profile Utility Score
5718,NCT04304209,complete response rate,2019-10-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Tumor response
5719,NCT00611858,Pathological Complete Response Rate,2008-05,TERMINATED,INTERVENTIONAL,['PHASE2'],1-Year Disease-Free Survival Rate,1-Year Overall Survival Rate
5720,NCT00245362,Overall survival,2002-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5721,NCT03150615,Incident rate of delayed gastric emptying,2016-09,COMPLETED,INTERVENTIONAL,['NA'],,Maximum Plasma Concentration fasting plasma GLP-1 level
5722,NCT04732494,Objective Response Rate (ORR) Assessed By The Investigator's Review Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1,2021-03-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events And Serious Adverse Events
5723,NCT00165633,Relapse-free survival period.,2004-03,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
5724,NCT05297903,Objective Response Rate (ORR),2022-04-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Objective Response Rate (ORR) in patients who did not received prior immunotherapy
5725,NCT05951842,Postoperative immune function (NK cell count),2018-04-16,WITHDRAWN,INTERVENTIONAL,['NA'],,
5726,NCT04792892,Toxicity related to treatment,2021-08-01,RECRUITING,OBSERVATIONAL,['NA'],,Sexual function
5727,NCT02606305,"Dose Expansion (Regimens A and D) and Triplet (Regimen E): Objective Response Rate (ORR); Percentage of Participants With Confirmed Response, as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1",2016-03-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Immunogenicity: Number of Participants With Anti-Drug Antibody (ADA) Response to Mirvetuximab Soravtansine
5728,NCT06165328,Diagnostic yield in diagnosis colorectal tumor,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Procedure-related adverse events
5729,NCT04535401,"Maximum tolerated dose (MTD) of elimusertib (BAY 1895344) in combination with irinotecan, fluorouracil, and leucovorin (FOLFIRI)",2021-08-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Status of deoxyribonucleic acid damage repair (DDR) genes,ATM status
5730,NCT04566133,Median Progression Free Survival (PFS),2022-02-15,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0),Overall Survival
5731,NCT03852290,Assessment of C677T and A1298C MTHFR polymorphisms and response rate,2019-01-16,UNKNOWN,OBSERVATIONAL,['NA'],,Assessment of C677T and A1298 MTHFR polymorphisms and toxicity
5732,NCT01425879,Overall Response Rate (Complete and Partial Response) as Defined by RECIST 1.1,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free Survival
5733,NCT05930496,Acceptability,2024-04-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Effects of an 8 week supervised exercise intervention on fecal concentrations of other short chain fatty acids
5734,NCT00911092,Initial complete clinical response,2007-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,Prolonged clinical response at one year
5735,NCT01472250,chemotherapy regimen,2011-11,COMPLETED,OBSERVATIONAL,['NA'],,treatment expense
5736,NCT04651504,Number of colonoscopy completions after positive fecal immunochemical test,2020-12-02,RECRUITING,INTERVENTIONAL,['NA'],,Proportion of patients who complete a complete diagnostic evaluation within 60 days of positive fecal immunochemical test
5737,NCT02542670,Number of cancer patients with abnormal genetic mutations .,2015-07,UNKNOWN,OBSERVATIONAL,['NA'],,
5738,NCT00427102,Determine pharmacokinetic parameters of oral MRX-1024.,2007-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,Possibly show a trend in activity of MRX-1024 in preventing or reducing oral mucositis.
5739,NCT06190301,The cumulative occurrence rate of complications of grade ≥2 within 2 years after treatment commencement,2024-01-11,RECRUITING,INTERVENTIONAL,['NA'],,overall survival
5740,NCT01050426,"One year overall survival, measured from the date of registration.",2009-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Evaluation of the role of FDG-PET in predicting overall survival, progression free survival and objective response rate in locally advanced pancreatic cancer."
5741,NCT04632199,Incidence of Treatment-emergent adverse events,2021-03-12,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Optimal injected radioactivity range
5742,NCT00518557,"Safety and tolerability, Mortality",2007-04,UNKNOWN,INTERVENTIONAL,['NA'],,"Tumor volumetry, Changes of Tumor markers such as AFP, Curriculum survival"
5743,NCT01330186,Tumor response,2011-02,UNKNOWN,OBSERVATIONAL,['NA'],,
5744,NCT04571294,Overall Survival (OS),2020-05-26,RECRUITING,INTERVENTIONAL,['NA'],,post-operative outcomes
5745,NCT05842187,PFS (Progressive free survival),2023-03-03,RECRUITING,INTERVENTIONAL,['NA'],,DCR (Disease control rate)
5746,NCT06078657,1 year overall survival rate,2023-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],biomarker,adverse events
5747,NCT00447967,Objective Response Rates,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Symptoms improvement
5748,NCT02799251,Presence of post operative infection,2016-06,COMPLETED,OBSERVATIONAL,['NA'],,Anesthetic and surgical parameters
5749,NCT05196334,Comparison between organoid's and patient's response,2021-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
5750,NCT02761408,Number of participants with treatment-related adverse events assessed by CTCAEv5.0,2016-04,UNKNOWN,OBSERVATIONAL,['NA'],,
5751,NCT04015804,Conversion rate for robotic surgery,2015-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Operating time
5752,NCT00152243,Overall survival and relapse-free survival,1997-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Adverse events
5753,NCT00766142,Median Progression-free Survival (PFS) Time,2007-05-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS) Time
5754,NCT00637988,Measure PGE production in Barrett's metastatic tissue & determine the reduction from baseline of PGE production would be equivalent on Day 10 in esomeprazole 40mg bid + aspirin treatment compared to esomeprazole 40 mg bid + rofecoxib 25 mg qd treatment,2002-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,"To determine in which of the four treatment groups the reduction in the baseline in PGE2 production, COX-2 enzyme activity and PCNA expression in Barrett's metaplastic tissue is the greatest."
5755,NCT01926236,Overall survival,2014-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality adjusted life years (QALYs)
5756,NCT03009253,translational resection rate,2015-07,UNKNOWN,INTERVENTIONAL,['NA'],,Local control rate
5757,NCT02175992,Health-related quality of life,2012-03,COMPLETED,OBSERVATIONAL,['NA'],,
5758,NCT02975141,MTD of afatinib in combination with gemcitabine/nab-paclitaxel,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Incidence of Treatment-Emergent Adverse Events
5759,NCT03463876,Objective Response Rate (ORR),2018-02-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free survival(PFS)
5760,NCT00784446,Dose limiting toxicity.,2008-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Assessment of overall response rate and progression free survival.
5761,NCT01239355,Progression-free Survival,2010-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
5762,NCT00207051,determination of maximum tolerated dose (MTD),2006-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Efficacy based on duration of response and time to progression based on assessment
5763,NCT00759226,Primary endpoint rate of freedom of progression (PR+CR+SD).,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Secondary endpoint median survival, progression free survival and toxicity."
5764,NCT01724775,Prognosis assessment of postoperative patients,2012-11,UNKNOWN,OBSERVATIONAL,['NA'],,Safety assessment of the patients in perioperation period
5765,NCT00381706,Response Rate (Complete and Partial) in Patients With Measurable Esophageal or GE Junction Adenocarcinoma,2006-09-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Treatment Failure in Patients With Adenocarcinoma
5766,NCT04082364,Objective response rate (ORR) for non-microsatellite instability-high (non-MSI-H) patients (Cohort A),2019-09-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Number of patients who have ADA to tebotelimab
5767,NCT05290480,'Patient Mobility and Observer Mobility Scale,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
5768,NCT04852367,To quantify the enhancement in intratumoural doxorubicin concentration when delivered with ThermoDox® and mild hyperthermia generated non-invasively by focused ultrasound (FUS) compared to free drug alone,2021-06-16,WITHDRAWN,INTERVENTIONAL,['PHASE1'],To assess effects of ThermoDox® and FUS treatment compared to free drug alone on pancreatic tumour biomarkers,Change in patient symptom scores in patients with pancreatic cancer treated with of ThermoDox® and FUS compared to those treated with doxorubicin
5769,NCT02254941,Overall survival,2014-08,UNKNOWN,OBSERVATIONAL,['NA'],,Study other variables to identify whether there is group of patients who may benefit from monoclonal antibodies for the treatment of first-line chemotherapy
5770,NCT03342677,Comparison of Gd-EOB-DTPA enhanced liver MRI and CT scan images in characterizing cirrhotic nodules and HCC in liver transplant candidates,2017-11-07,UNKNOWN,INTERVENTIONAL,['NA'],,Investigation of Gd-EOB-DTPA enhanced MRI efficacy in diagnosis and staging of HCC in cirrhotic patients and its potential impact on liver transplantation eligibility in patients who are liver transplant candidates
5771,NCT02877589,hepatitis B virus (HBV) serological status,2012-05,COMPLETED,OBSERVATIONAL,['NA'],,hepatitis C virus (HCV) serological status
5772,NCT05204433,effectiveness of methylation markers from stool samples,2019-01-05,UNKNOWN,OBSERVATIONAL,['NA'],,assess the capacities of RF model in screening potential clinical biomarkers.
5773,NCT05511051,Overall Survival,2022-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Safety and tolerance evaluated by incidence, severity and outcomes of AEs"
5774,NCT01523808,Number of Patients With Dose-limiting Toxicities up to Week 4 After Treatment,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Summary of CA 19.9 Over Time
5775,NCT02636738,Technique success,2016-06-06,TERMINATED,INTERVENTIONAL,['NA'],,
5776,NCT04715308,To assess the impact of urinary diversion/reconstruction subtypes on quality-of-life,2020-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,To measure the rate of reintervention for complications associated with urinary diversion/reconstruction
5777,NCT00210106,Complete Hepatic Response Rate at 3 Months,2003-06,COMPLETED,INTERVENTIONAL,['NA'],,Event-free Survival
5778,NCT05536362,Measurement of Post-operative Pain,2021-02-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5779,NCT00601705,Feasibility of Induction Chemoradiotherapy as Measured by Resectability Rate,2008-01-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Postoperative Adjuvant Chemoradiotherapy Feasibility
5780,NCT01625351,Feasibility of haploidentical HSCT,2012-08-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,event-free survival
5781,NCT02359565,Change in the percentage of CD8+ T cells that are PD-1+ due to treatment with pembrolizumab (Stratum C),2015-05-22,RECRUITING,INTERVENTIONAL,['PHASE1'],,Changes in quantitative imaging parameters
5782,NCT04095364,Progression-free survival (PFS),2019-09-20,RECRUITING,INTERVENTIONAL,['PHASE3'],,Adherence to letrozole maintenance therapy
5783,NCT00164944,To find the prevalence of adenomas and advanced neoplasms of the first degree relatives,2004-04,COMPLETED,OBSERVATIONAL,['NA'],,
5784,NCT05409417,Drug Safety,2022-10-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,DCR
5785,NCT02975661,Disease free survival (DFS),2017-02-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Concomitant medication
5786,NCT00012389,,2000-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,
5787,NCT01939665,Safety (number of adverse events),2013-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Tumor response
5788,NCT01275664,Number of Participants With Complete Control Defined as no Vomiting and no Use of Rescue Medications (for Nausea or Emesis),2011-06,TERMINATED,INTERVENTIONAL,['NA'],,Percentages of Patients With NIDL Based on FLIE
5789,NCT03006705,Relapse-free survival (RFS),2017-01-31,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety will be analyzed through the incidence of laboratory abnormalities
5790,NCT01053104,"Toxicities (frequency at each of grades 2, 3 and 4, over all cycles)",2009-11,COMPLETED,OBSERVATIONAL,['NA'],,Dose intensity in mg/m2/week and toxicities as for stage 1
5791,NCT03447431,To develop biological tools to simplify screening in future clinical assays,2018-04-05,UNKNOWN,OBSERVATIONAL,['NA'],,
5792,NCT02591030,overall survival,2015-12-15,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,quality of life (EORTC QLQ-C30 )
5793,NCT00991952,Overall Response Rate,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5794,NCT04791644,This study will compare fecal microbiota richness and composition differences between LS patients with no previous adenoma at inclusion in AAS-Lynch study and LS patients with history of adenoma or adenoma at inclusion in AAS-Lynch study.,2021-04-20,RECRUITING,OBSERVATIONAL,['NA'],,Gut microbiota composition description
5795,NCT03748927,"Characterize the natural history of Fibrolamellar hepatocellular carcinoma (FL- HCC), including clinical presentation, family history, patterns of disease progression, response or lack of response to therapeutic interventions, disease recurre...",2019-04-08,WITHDRAWN,OBSERVATIONAL,['NA'],,
5796,NCT06309485,Efficacy of WGI-0301 in combination with Sorafenib based on ORR per RECIST 1.1.,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Anti-tumor activity if WGI-0301 in combination with Sorafenib based on OS.
5797,NCT05600309,Overall Survival (OS),2022-06-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,TTD in EORTC Quality of Life Questionnaire-Colorectal Cancer-Specific 29 Items (QLQ-CR29) Bloating (Item 37) Score
5798,NCT03721653,Progression Free Survival (PFS),2018-11-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,2nd-PFS
5799,NCT05128123,"The primary objective will be to assess the rates of curative treatment (either resection, ablation or liver transplantation) according to the social determinants of health",2022-01-21,RECRUITING,OBSERVATIONAL,['NA'],,Assessment of the relationship between social health determinants and the quality of life of patients at 6 and 18 months after inclusion in the CHIEF cohort study
5800,NCT03751176,Progression-free survival at 6 months,2018-11-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Biomarkers analysis by liquid biopsies.
5801,NCT00438906,To determine the diagnostic yield of screening high risk patients,2006-12,COMPLETED,OBSERVATIONAL,['NA'],,
5802,NCT00083122,Proportion of Confirmed Tumor Responses Defined to be Either a Complete Response (CR) or Partial Response (PR),2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Progression
5803,NCT01310972,"OS, PFS, DFS",2007-09,COMPLETED,OBSERVATIONAL,['NA'],,
5804,NCT04027088,Surgical fistulas,2019-08-10,UNKNOWN,INTERVENTIONAL,['NA'],,Weight loss
5805,NCT05019794,Objective Response Rate (ORR),2020-05-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Accumulation ratio (Racc)
5806,NCT03410914,Number of Participants With a Clinically Significant Post-operative Pancreatic Fistula (POPF),2018-08-13,COMPLETED,INTERVENTIONAL,['PHASE2'],,Average Length of Stay in Hospital
5807,NCT01790139,Colonic bubble-related image quality,2013-02,COMPLETED,INTERVENTIONAL,['NA'],,diagnostic performance
5808,NCT04820712,Overall survival,2020-09-01,COMPLETED,OBSERVATIONAL,['NA'],,Cancer-specific survival
5809,NCT00853684,Time to progression,2009-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
5810,NCT04766502,Peritoneal Regression Grading Score (PRGS),2022-01-11,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life mesure
5811,NCT03837301,complete resection rate (%) of tumor,2018-09-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5812,NCT06216743,Sensitivity and specificity of different MRI sequences to diagnose T4 colon carcinoma.,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Establishing an MRI Protocol that is optimized for the clinical staging of colon tumors
5813,NCT02495896,Progression-free survival,2015-09-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,
5814,NCT05674773,Metachronous (advanced) neoplasia,2019-05-21,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Associations with treatment choice
5815,NCT02981498,progression-free survival rate,2015-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,AE event
5816,NCT02560623,DNA Yield,2015-10-15,COMPLETED,INTERVENTIONAL,['NA'],,Specificity of Barrett's Dysplasia Detection
5817,NCT04269499,Feasibility of MR imaged administration of holmium microspheres,2019-11-11,COMPLETED,INTERVENTIONAL,['NA'],,Tumor response after 3 months based on CT imaging (according to RECIST 1.1 criteria)
5818,NCT03631641,Incidence rate of non-colonic cancers,2018-08-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
5819,NCT06251050,The incidence of Severe Oral mucositis (WHO grade ≥3),2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Taste function
5820,NCT04574245,5-year overall survival,2010-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,The prognostic predictive value for patients with different C-GCLM classification
5821,NCT04942665,Quantitative Assessment - Bile Duct-to-liver Fluorescence Intensity Ratio,2021-09-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Qualitative Assessment of Overall Intraoperative Visualization of the Extrahepatic Biliary Tree (Common Hepatic Duct, Cystic Duct, Common Bile Duct, Aberrant Ducts)"
5822,NCT02077777,Molecular analysis of gene expression levels of μ-protocadherin and other related proteins,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Evaluation of protein expression level of μ-protocadherin, Ki-67, Caspase-3 and Histone H2AXγ, evaluation of DNA oxidative damage and intra-mucosal concentration of 5-Acetylsalicylic acid"
5823,NCT00402025,Number of Participants Positive for Anti-herpes Simplex Virus-1 (HSV-1) Antibodies,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Change From Baseline in Pain Intensity
5824,NCT06314737,Overall Survival,2010-10-02,COMPLETED,OBSERVATIONAL,['NA'],,
5825,NCT04417699,Achieve a reduction by at least 5.8 in Neoadjuvant Response (NAR) score compared to historic controls with NAR of 14.59,2022-07-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety and Tolerability
5826,NCT02792023,The number of patients with colorectal cancer among those with a positive immunochemical fecal test (Positive predictive value),2016-06-30,UNKNOWN,INTERVENTIONAL,['NA'],,The number of patients without a significant lesion among those with a negative immunochemical fecal test (negative predictive value) after the colonoscopy and after the upper endoscopy
5827,NCT01505205,,2011-04,COMPLETED,OBSERVATIONAL,['NA'],,
5828,NCT03528863,Acceptability as assessed by adherence to practice instructions,2018-05-07,COMPLETED,INTERVENTIONAL,['NA'],,"Efficacy as assessed by a ""Are You at Peace?"" one-item spiritual probe"
5829,NCT03547999,Overall Survival (OS),2018-06-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression Free Survival (PFS)
5830,NCT00660894,Disease-free survival,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Identification of predictive markers
5831,NCT01133340,To define the usefulness of Endoscopic clip placement and 3T-MRI imaging for accurate target volume definition in rectal cancer patients undergoing pre-operative chemoradiation.,2010-06,COMPLETED,INTERVENTIONAL,['NA'],,To assess the differences in pelvic lymph node (CTV) volume definition between Ct and MRI images.
5832,NCT02715089,Progression-free survival (PFS),2015-12,UNKNOWN,OBSERVATIONAL,['NA'],,Adverse Drug Reaction (ADR)/Adverse Event (AE)
5833,NCT02632188,Progress-free survival,2015-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life
5834,NCT03975049,Disease-free survival,2019-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Tumor regression grade after neoadjuvant therapy,Treatment related quality of life
5835,NCT00489697,evaluation of the response to bevacizumab based chemotherapy by RECIST criteria,2007-01,COMPLETED,INTERVENTIONAL,['NA'],,survival time
5836,NCT03434834,Percentage of Imaged Sites Correctly Categorized as Barrett's Mucosa,2018-09-25,COMPLETED,INTERVENTIONAL,['NA'],,Percentage of Imaged Sites With Adequate Tissue Contact to Acquire a High Quality Image
5837,NCT00084591,Acute toxicity by CTCAE at 6 weeks following study completion,2003-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Quality of life as assessed by Quality of Life Questionnaire Core 30 Items (QLQ-C30) before and after radiotherapy and then every 6 months after surgery
5838,NCT03564912,DFS,2018-08-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
5839,NCT00620607,response rate,2007-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,effect of huC242-DM4 on tumor uptake of FDG
5840,NCT00362102,Response according to the RECIST criteria accessed every 6 weeks,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Time to progression, duration of achieved response, and the disease control rate will be accessed in all patients who received Cetuximab. The worst toxicity grades per patients will be tabulated for adverse events and laboratory measurements."
5841,NCT06331988,Relapse free survival,2022-07-21,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
5842,NCT03479645,Colorectal screening rate,2018-03-23,COMPLETED,INTERVENTIONAL,['NA'],,FIT kit return rate by insurance status
5843,NCT02942329,Overall survival rate,2016-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Safety as measured by the rate of AEs, deaths and laboratory abnormalities (e.g. Grade 3 or higher per CTCAE v4 )"
5844,NCT04711473,Colorectal Cancer Screening Completion,2021-10-27,COMPLETED,INTERVENTIONAL,['NA'],,Choice of Colorectal Cancer Screening Test
5845,NCT00587145,To evaluate the clinical responses to preoperative S-1 plus docetaxel,2006-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"the clinical downstaging,the pathologic responses, toxicity profile,the disease-free survival,overall survival,the effect of CYP2A6 genetic polymorphisms on the pharmacokinetics and the difference in pharmacokinetics between before and after gastrectomy"
5846,NCT03649321,Overall Response Rate (ORR),2019-01-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With an Adverse Event of Grade 3 or Higher
5847,NCT05522894,Objective response rate (ORR),2022-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],The level of ctDNA in blood,Incidence and severity of adverse events(AEs)
5848,NCT03124394,Overall Survival,2015-06-01,UNKNOWN,OBSERVATIONAL,['NA'],,Cost-effectiveness
5849,NCT03064828,Sensitivity and specificity of low-dose CTC for the polyp detection,2017-01,UNKNOWN,INTERVENTIONAL,['NA'],,Sensitivity and specificity of CTC for the detection of poly malignancy
5850,NCT03008343,Relief degree of tumors,2016-12-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival（OS）
5851,NCT05137899,Hepatectomy,2022-10-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Toxicity to Atezolizumab/Bevacizumab
5852,NCT02570399,Feasibility in terms of toxicity related to radiation therapy,2015-02-26,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of life questionnaire of treated patients
5853,NCT02329106,Evaluate the safety of IRE for unresectable liver cancer close to diaphragmatic dome using Common terminology Criteria for Adverse Events (CTCAE).,2014-12-01,COMPLETED,INTERVENTIONAL,['NA'],,Evaluate the efficacy of IRE for unresectable liver cancer close to diaphragmatic as measured by cell death of CRLM after IRE is demonstrated macroscopically by using vitality-staining with triphenyl-tetrazoliumchloride (TTC)
5854,NCT03302858,Percent of patients who have histologically cleared high-grade squamous intraepithelial lesions (HSIL) at the SCJ at 12 months as measured by HRA,2017-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Percent of patients who have histologically cleared low-grade squamous intraepithelial lesions (LSIL) at the SCJ at 12 months as measured by HRA
5855,NCT04843956,Quality of the sample in relation to the technique,2020-01-08,UNKNOWN,INTERVENTIONAL,['NA'],,Sample contamination relative to technique
5856,NCT05239507,"To describe the OS rate in patients with unresectable HCC including estimates of survival rates at 6, 12, and 18 months and at 2 years",2022-02-01,COMPLETED,OBSERVATIONAL,['NA'],"To investigate the correlation between survival outcomes and clinical characteristics, liver function, and underlying disease in unresectable HCC",To describe the demographic and clinical characteristics of patients with unresectable HCC
5857,NCT03137004,six-month overall survival,2017-06-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse Event（AE）
5858,NCT01465451,disease-free survival,2011-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,safety profiles
5859,NCT02498613,Objective response rate,2016-08-31,TERMINATED,INTERVENTIONAL,['PHASE2'],Changes in levels of angiogenesis/ inflammatory markers (angiome panel) (all cohorts),Progression-free survival
5860,NCT00033735,Survival of Irofulven vs. 5-FU,2000-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Objective Tumor Response of Irofulven vs. 5-FU and Clinical Benefit of Irofulven vs. 5-FU
5861,NCT00784667,To determine the response rate (RECIST criteria). Responses will be evaluated for the whole patient group and separately for k-ras wild-type and k-ras mutant tumours,2008-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
5862,NCT00874224,Time to functional Recovery,2010-01,COMPLETED,INTERVENTIONAL,['NA'],,Reasons for delay of discharge after functional recovery
5863,NCT03386500,"Count of Adverse events, serious adverse events and dose limiting toxicities",2017-11-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Single-dose and repeated-dose pharmacokinetic profiles of BMX-001,Effect of study treatment on locoreginal progression free survival survival (PFS).
5864,NCT04800497,Association between circulating tumor cells and disease-free-survival,2019-02-07,RECRUITING,OBSERVATIONAL,['NA'],,Association between circulating tumor cells and overall survival
5865,NCT05720598,The primary endpoint of this study is the identification rate of ICG-guided SN in advanced GC patients.,2022-11-04,RECRUITING,INTERVENTIONAL,['NA'],,Pathological status and regression grade of the retrieved sentinel node after neoadjuvant chemotherapy
5866,NCT05022927,Safety of ERY974 (Dose limiting toxicities) [Mono dose escalation part],2021-06-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Biomarkers of ERY974 [Mono dose escalation part]
5867,NCT00597311,recurrence rate,2007-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Impact on quality of surgical resection
5868,NCT01860846,Total Activity Impairment (TAI),2013-05,COMPLETED,OBSERVATIONAL,['NA'],,Number of Participants With Serious Adverse Events
5869,NCT03516916,"Impact of demographic, socioeconomic and religious factors on HRQoL in rectal cancer survivors with a colostomy",2019-02-01,UNKNOWN,OBSERVATIONAL,['NA'],,
5870,NCT01977053,"emotional state (anxiety, depression, confusion, angry, fatigue, force and interpersonal relation)",2013-09,COMPLETED,INTERVENTIONAL,['NA'],intervention cost,relationship between psychosocial criteria and anxiety
5871,NCT02513849,"A change in Ki67 expression following tamoxifen therapy, by comparing the pre- and post- tamoxifen biopsies",2015-12,UNKNOWN,INTERVENTIONAL,['PHASE1'],,A change in ER-β expression
5872,NCT04947696,Changes in DNA-methylation patterns from the pre to postoperative setting,2021-07-30,UNKNOWN,OBSERVATIONAL,['NA'],,Relapse of pancreatic cancer
5873,NCT00711191,Number of Participants With Dose Limiting Toxicities (DLTs),2008-06,COMPLETED,INTERVENTIONAL,['PHASE1'],Recommended Phase 2 Dose (RP2D) of CP-870893 in Participants With Advanced Pancreas Cancer,Carbohydrate Antigen 19-9 (CA 19-9)
5874,NCT02974556,Incidence of endoperitoneal recurrence at 36 months,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,EORTC QLQ-C30 Summary Score
5875,NCT02253602,Ferumoxytol dose response,2014-09,COMPLETED,INTERVENTIONAL,['NA'],,
5876,NCT03671369,Number of Participants With Serious Adverse Events (SAEs) and Fatal SAEs,2018-10-02,COMPLETED,OBSERVATIONAL,['NA'],,
5877,NCT05197933,3-year disease-free survival rate (DFS),2020-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Postoperative recovery course（Highest Body Temperature）
5878,NCT02210182,pharmacokinetics,2014-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Biomarker
5879,NCT00004248,,1999-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5880,NCT00091026,Objective Response Rate (Complete or Partial Response) Evaluated Using the Response Evaluation Criteria in Solid Tumors (RECIST),2004-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
5881,NCT00004884,,1999-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5882,NCT01539018,time to progression (TTP):recist criteria,2012-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of Life Using EQ-5D questionnaire.
5883,NCT06236568,Survival,2024-02-06,RECRUITING,INTERVENTIONAL,['NA'],,Graft survival
5884,NCT05292443,PFS: Progression-free survival,2021-12-20,WITHDRAWN,OBSERVATIONAL,['NA'],,TTD: Time to Treatment Discontinuation
5885,NCT02546973,HRQL in patient's with anal cancer 3 years after diagnosis,2015-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,"HRQL (measured by questionnaires) differences between patient groups such as age, gender and educational level"
5886,NCT02745639,Pathological response rate,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Acute Toxicity
5887,NCT01075633,Advanced colorectal neoplasm detection rate [Time Frame: 2 years] [Designated as safety issue: No],2006-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Complications rate
5888,NCT05034185,To evaluate the diagnostic performance of the CADx support tool compared to optical prediction of polyp histology by the Clinician in real-time colonoscopy in a clinical setting,2021-03-03,COMPLETED,OBSERVATIONAL,['NA'],,To determine the diagnostic performance of CADx versus optical prediction of polyp histology by endoscopist in the subgroup analysis
5889,NCT03703063,Treatment safety as assessed by CTCAE v4.03,2018-09-17,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Response rate
5890,NCT05002127,Phase 3,2022-01-15,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
5891,NCT01057355,Decrease in volume of the pancreatic cyst by cross-sectional imaging studies (CT or MR) performed before and after treatment,2010-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
5892,NCT02482259,Time taken to complete assessments,2013-12-01,COMPLETED,OBSERVATIONAL,['NA'],Biomarker assessment of frailty and associated factors,Muscle mass and timed get up and go as predictors of outcome
5893,NCT05178745,Assessment of resection rate (R0/R1),2016-09-07,COMPLETED,OBSERVATIONAL,['NA'],,Safety (serious and non-serious adverse events occurring during treatment
5894,NCT02034110,Overall Response Rate (ORR) in the Multiple Myeloma (MM) Cohort,2014-03-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events (AEs)
5895,NCT02873845,Objective burden score in the dimensions of the COBQoL questionnaire with good psychometric properties,2014-05,UNKNOWN,OBSERVATIONAL,['NA'],,
5896,NCT00345696,Progression Free Survival,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Resection rate of hepatic or pulmonary metastases
5897,NCT00004904,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5898,NCT05991947,Differences in ctDNA gene and tumor-specific proteins expression,2021-12-01,RECRUITING,OBSERVATIONAL,['NA'],,
5899,NCT00720993,- To select a threshold for Mahalanobis distance to determine the best operating characteristics (sensitivity and specificity) in subjects with cancer and subjects without cancer. - To explore other empirical metrics based on previous exploratory data,2008-08,UNKNOWN,OBSERVATIONAL,['NA'],,"- To obtain data to estimate sensitivity, specificity, and the ROC curve for a test based on M-distance. - To determine the variability of sensitivity and specificity estimates"
5900,NCT00428285,High grade dysplasia (AIN 2/3),2007-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tolerability and safety of the treatment
5901,NCT01775449,Cold pain thresholds,2013-02-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,QLQ-C30 (Quality of Life questionnaire C30)scores
5902,NCT02612077,Progression-free Survival,2008-05,COMPLETED,OBSERVATIONAL,['NA'],,Quality of Life - Global Health Status
5903,NCT03832621,"Evaluate the efficacy, measured as 8-month PFS rate, of the combination of temozolomide, nivolumab and ipilimumab in patients achieving disease control following 2-month lead-in treatment with single agent TMZ",2019-03-25,COMPLETED,INTERVENTIONAL,['PHASE2'],Evaluate the tumor mutational load,Assess quality of life
5904,NCT04720131,Objective response rate,2021-01-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety
5905,NCT00423306,Response Rate,2007-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,toxicities
5906,NCT05871099,5-years Recurrence-free survival,2022-11-20,RECRUITING,INTERVENTIONAL,['PHASE3'],,Toxic and side effects of the program
5907,NCT04687384,Changes in levels of systemic inflammatory response expressed by CRP and IL-6 in serum between the two groups,2021-08-01,UNKNOWN,INTERVENTIONAL,['NA'],Time to local cancer recurrence or metastatic spread,Time to first bowel movement
5908,NCT04383210,Objective Response Rate,2020-09-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
5909,NCT02891538,Change in methylation from baseline when compared to the control arm,2017-01-31,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
5910,NCT01544413,Completement of performance of laparoscopic sentinel lymph node biopsy,2012-02,COMPLETED,INTERVENTIONAL,['NA'],,"Detection rate of laparoscopic sentinel lymph node, learning curve"
5911,NCT01666145,Successful Insertion of Ablation Antenna Into Target Lesion,2012-02,COMPLETED,INTERVENTIONAL,['NA'],,Percentage of Participants With Significant Ease of Lesion Targeting Using Advanced Image Guidance (AIM)
5912,NCT04599790,Progression free survival (PFS) assessed by investigators according to Modified RECIST (mRECIST),2020-10-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,DOR assessed by investigators according to mRECIST.
5913,NCT03807518,Change in Physical Fitness,2019-03-01,COMPLETED,INTERVENTIONAL,['NA'],,Change in concentration of blood markers of Inflammation- White Cell Differential
5914,NCT01279291,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2011-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,"To describe any anti-tumor activity observed when KHK2866 is administered i.v. as monotherapy, or in combination with chemotherapy."
5915,NCT03034850,Blood loss,2015-04,COMPLETED,OBSERVATIONAL,['NA'],,Maximum Lysis (ML) HEPTEM Rotational thromboelastometry (ROTEM)
5916,NCT03219593,Progression-free survival (PFS),2017-09-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],Tumor biomarkers,Adverse Events(AEs)
5917,NCT01501240,"Diagnostic sensitivity of gadoxetic acid-enhanced MR imaging to detect HCC in the cirrhotic liver, using thin-section whole-explant as the standard of reference",2012-01,WITHDRAWN,OBSERVATIONAL,['NA'],,To characterize borderline hepatocelluar nodules
5918,NCT02394535,Maximum tolerated dose defined as the highest dose level in which 6 patients have been treated with at most 1 instance of dose limiting toxicity (DLT) according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0,2015-11-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Changes in MD Anderson Symptom Inventory Gastrointestinal Cancer Module (MDASI)
5919,NCT01657773,Statistical analysis,2012-04,COMPLETED,OBSERVATIONAL,['NA'],,Laboratory Assay and Measurement
5920,NCT02000089,Evaluate pancreatic juice for early cancer markers.,2014-01-06,RECRUITING,INTERVENTIONAL,['PHASE3'],Diagnostic performance of a tumor marker gene test for CA19-9 interpretation,Compare pancreas juice with pancreas cyst fluid
5921,NCT00677586,Severe complication rate after resection of primary and metastatic lesions,2010-07,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative hospital stay
5922,NCT04720716,Objective response rate (ORR),2021-02-07,RECRUITING,INTERVENTIONAL,['PHASE3'],,The incidence and severity of Treatment-Emergent Adverse Events
5923,NCT05887505,Ratio of liver failure,2023-06-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Complications after surgery
5924,NCT04803318,Assessing Incidence of Treatment-Emergent Adverse Events during the treatment and various responses to the treatment.,2021-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Assessing overall survival
5925,NCT02893930,Overall Response Rate,2017-04-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Response
5926,NCT01673607,,2012-01-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5927,NCT03960775,CRP level in blood,2019-04-30,COMPLETED,INTERVENTIONAL,['NA'],,HOD (hospital days)
5928,NCT01466504,p63 expression levels,2011-05,TERMINATED,OBSERVATIONAL,['NA'],,Tumor response
5929,NCT05242991,Hyposalivation,2021-03-01,RECRUITING,INTERVENTIONAL,['NA'],,
5930,NCT06056726,Peri-operative complications,2021-02-18,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
5931,NCT00889187,Grade 3-5 Toxicity Rate [Phase II],2009-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Surgical Mortality Rate [Phase II]
5932,NCT01321450,Total operation time,2009-03,COMPLETED,OBSERVATIONAL,['NA'],,postoperative intervention
5933,NCT02133612,3 year overall survival,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants with Adverse Events,3 year disease-free survival
5934,NCT04887805,Progression free survival,2021-07-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
5935,NCT05714878,Duke Activity Status Index before surgery,2023-03-22,RECRUITING,INTERVENTIONAL,['NA'],,30-day readmission rate
5936,NCT05021250,ORR,2021-07-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Frequency of AE
5937,NCT05853094,Microbiome functional gene capacity in postoperative stoma pouch and distal intestine by metagenomic sequencing,2023-06-23,RECRUITING,INTERVENTIONAL,['NA'],,Overall Survival
5938,NCT03778593,Response rate of treated participants,2019-03-01,COMPLETED,INTERVENTIONAL,['PHASE2'],EORTC -QoL-C30,Incidence of Treatment-Emergent Adverse Events of participants
5939,NCT03970694,5-year overall survival rate,2019-05-11,TERMINATED,INTERVENTIONAL,['PHASE3'],,3-year progression-free survival rate
5940,NCT02842749,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2016-03-14,COMPLETED,INTERVENTIONAL,['PHASE4'],,Progression free survival
5941,NCT01395563,muscle mass and strength,2009-01,WITHDRAWN,INTERVENTIONAL,['NA'],,quality of life
5942,NCT01421940,Change from baseline in International Index of Erectile Function (5-item Version) at 12 and 24 week,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,Number of patients with adverse events during 24 weeks of the study
5943,NCT04752267,Different pattern in radiomics mpMRI and FMAU PET kinetic analysis parameters,2021-02-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
5944,NCT02837029,Phase IB: Objective Response Rate (ORR),2016-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Circulating Free DNA (cfDNA) Mutation Analyses,Disease Control Rate (DCR)
5945,NCT05745857,Evaluate if the combination of tracers improves lesion detection by the number of invisible lesions detected,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Eventually further specify and objectify the improvement of qFME by standardisation
5946,NCT03187314,Objective response rate (ORR),2017-06-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Health-related quality of life (HRQoL)
5947,NCT05781568,Biomarker dosage,2023-02-24,RECRUITING,OBSERVATIONAL,['NA'],,
5948,NCT03432806,successful isolation of exosomes,2017-11-28,RECRUITING,OBSERVATIONAL,['NA'],,
5949,NCT00235898,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5950,NCT01946139,Incidence of HSIL Among Women Who Were HRA Negative for HSIL at Study Entry,2013-12-04,COMPLETED,INTERVENTIONAL,['NA'],,Acceptability of Anal Cancer Screening
5951,NCT02909530,Correct histological diagnosis of the mass assessed by each needle,2016-09,COMPLETED,INTERVENTIONAL,['NA'],,Adverse events
5952,NCT03529760,HBV-DNA positive,2018-05-08,UNKNOWN,OBSERVATIONAL,['NA'],,
5953,NCT00869258,Conversion Rate of Inoperable to Operable,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5954,NCT05693519,Overall survival,2022-12-22,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Standardized incidence of second primary malignancies
5955,NCT01261962,Gene expression,2011-02,UNKNOWN,INTERVENTIONAL,['NA'],,Humoral immunity and neutrophil function
5956,NCT02703714,Overall Response Rate (ORR),2016-05-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival (OS) Stratified by Sub-type of Biliary Cancer
5957,NCT05525286,Parts C and D: The assessment of the efficacy of SOT102 in monotherapy and in combination with first-line SoC treatment,2022-03-31,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Parts C and D (monotherapy and combination with SoC): Relationship between the intensity of CLDN18.2 expression and clinical outcome,Parts C and D (monotherapy and combination with SoC): Number of participants with antibodies against SOT102
5958,NCT01488487,Time to Progression (TTP),2011-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Objective Response Rate (ORR)
5959,NCT02564146,Overall survival (OS),2016-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Neurotoxicity Assessment FACT taxane score
5960,NCT03897543,Incidence of adverse events (AEs),2019-08-30,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Alpha Fetoprotein Serum concentrations
5961,NCT06000553,"the aim is to search for immune and metabolic abnormalities in patients with at-risk TIPMP in the blood or by echo-endoscopic sampling, then compare and combine them with the criteria used in clinical practice.",2023-10-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
5962,NCT02523053,Time to tumor recurrence,2016-04,UNKNOWN,INTERVENTIONAL,['NA'],,Overall survival
5963,NCT06225011,Immune cell composition and microenvironment,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,
5964,NCT01956812,overall survival,2013-12,TERMINATED,INTERVENTIONAL,['PHASE3'],,Clinical benefit
5965,NCT00899132,Characterization of TAB3 and its signaling networks that are involved in tumorigenesis,2007-02,TERMINATED,OBSERVATIONAL,['NA'],,
5966,NCT05954429,objective response rate (ORR),2023-07-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,adverse events
5967,NCT05133102,Intra-class correlation coefficients (ICC) by BE status,2021-03-19,RECRUITING,OBSERVATIONAL,['NA'],,
5968,NCT06179602,Safety as assessed by complications according to CTCAE v6.0.,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
5969,NCT05672316,Overall response rate (ORR) (Phase II),2023-05-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of toxicity (Phase II)
5970,NCT00189683,,na,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
5971,NCT02550743,Maximum Tolerated Dose of BYL719,2016-06-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,Pathologic Complete Response for Patients With Rectal Cancer
5972,NCT04415853,Overall survival,2021-01-21,RECRUITING,INTERVENTIONAL,['PHASE3'],,Apparent Volume of Distribution (Vd/F) of Lerotinib
5973,NCT03938623,number of patients screened positive using the patient-centered approach after training of face to face training or e-learning,2018-01-24,UNKNOWN,OBSERVATIONAL,['NA'],,
5974,NCT01774266,Early detection of gastric cancer,2012-09,UNKNOWN,OBSERVATIONAL,['NA'],Detection of H.pylori and gastric atrophy,Monitoring progression of disease
5975,NCT01904968,"Mutational status evaluation of BRAF, KRAS and PI3KCA :",2011-12,WITHDRAWN,OBSERVATIONAL,['NA'],,
5976,NCT01558947,the relapse-free survival time/rate,2011-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5977,NCT02444897,VAS score,2013-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Bowel motility
5978,NCT04611035,Efficacy of second-line therapy,2020-01-20,UNKNOWN,OBSERVATIONAL,['NA'],,Haematologic and non-haematologic toxicities
5979,NCT04204850,Disease control rate,2020-08-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Side Effects Reported
5980,NCT02578732,Response Rate of FOLFOX-A for Patients With Locally Advanced Pancreatic Cancer.,2016-07-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival for Patients With Locally Advanced Pancreatic Cancer Treated With FOLFOX-A
5981,NCT01281683,,2011-01,UNKNOWN,OBSERVATIONAL,['NA'],,
5982,NCT02850874,Peritoneal disease-free survival,2016-02,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Postoperative mortality
5983,NCT05794048,Theranostic metabolic signatures of TNEP.,2022-06-08,RECRUITING,INTERVENTIONAL,['NA'],,Comparison of metabolic profiles on surgical specimen
5984,NCT05945082,Presence of F.nucleatum in a colon cancer biopsy,2017-11-29,RECRUITING,INTERVENTIONAL,['NA'],,
5985,NCT02291614,Number of Participants With Treatment Emergent Adverse Events (TEAEs),2014-11-27,TERMINATED,INTERVENTIONAL,['PHASE1'],,Progression Free Survival (PFS) at 6 Months in Participants Treated at the MTD
5986,NCT00595985,time to progression,2007-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,toxicity
5987,NCT05245877,"Venous thromboembolism, number of patients",2022-08-17,RECRUITING,INTERVENTIONAL,['PHASE4'],,Post-operative hemoglobin below 70 g/l
5988,NCT02325323,Incidence of gastric cancer or high grade dysplasia of the gastric mucosa,2014-05,UNKNOWN,OBSERVATIONAL,['NA'],,Percentage of development of gastric cancer or high grade dysplasia
5989,NCT00209625,objective tumor response,2000-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Response duration, time to progression, median survival time, and safety"
5990,NCT04435977,PFS,2020-01-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],,safety and tolerability
5991,NCT01014039,Colorectal cancer mortality,1983-03,COMPLETED,INTERVENTIONAL,['NA'],,colorectal cancer incidence
5992,NCT05914766,Self-Efficacy (CASE-Cancer),2023-09-21,RECRUITING,INTERVENTIONAL,['NA'],,Quality of Life (FACT-C)
5993,NCT01789502,Adverse events related to the stent insertion,2012-01,COMPLETED,INTERVENTIONAL,['NA'],,Surgical outcomes
5994,NCT04911647,Re-intervention rate,2021-06,UNKNOWN,INTERVENTIONAL,['NA'],,"Procedure related complication, Postoperative complication"
5995,NCT04713241,Feasibility as measured by acceptance rate of participation in study,2022-01,WITHDRAWN,INTERVENTIONAL,['NA'],,Nasogastric tube (NG TB) output
5996,NCT04677673,Overall Survival,2021-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Disease-free survival (DFS)
5997,NCT04119622,Major pathological response rate,2019-10-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
5998,NCT00106054,To determine the rate of R0 resection or pathologically confirmed CR in patients with hepatic only metastases,2006-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,"oTo determine the resectable rate, defined as the number of subjects with R0 resection, pathologically staged CR, or undergoing non-surgical ablative procedures with curative intent divided by the total number of evaluable subjects following treatment"
5999,NCT03808272,Clinical success rate,2019-04-17,COMPLETED,INTERVENTIONAL,['NA'],,
6000,NCT00969033,Determine the difference in progression-free survival (PFS) for CS-1008 administered in combination with irinotecan and irinotecan alone.,2009-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,To determine the Incidence of anti- CS-1008 antibody formation.
6001,NCT00844675,Frequency of bleeding after EMR is performed,2007-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,Measurement of a change in the size of ulcer
6002,NCT03250078,Early Stage Pancreatic Cancer or Precursor Lesions,2016-11,RECRUITING,OBSERVATIONAL,['NA'],,Serum Bio-bank
6003,NCT05791747,social representations,2023-03-21,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Intention to turn to hypnosis
6004,NCT01832246,diagnostic accuracy between endoscopic ultrasonographic staging and conventional endoscopic staging,2014-12,UNKNOWN,OBSERVATIONAL,['NA'],,
6005,NCT01579591,The impact of the probiotic preparation on increasing the TRG1-2 rate.,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Determine whether VSL#3® can have an impact on reduction of late toxicity at 12 and 36 months.
6006,NCT00954525,"Safety, assessed by toxicity (graded by NCI CTC), urinalysis, ECG, basic metabolic panel, CBC, and osmolality.",2009-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression-free survival
6007,NCT04411589,detection rate of GIN and EGC,2020-05-01,UNKNOWN,INTERVENTIONAL,['NA'],,diagnostic accuracy in a per-biopsy analysis
6008,NCT03574493,"Efficacy of surgical method (success determined by composite of Oncologic, morbidity and functional outcomes)",2018-10-16,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
6009,NCT00810953,"Any severe events, tumor marker CA19-9, and tumor size (CT scan)",2009-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,TDP
6010,NCT03280407,Disease free survival,2017-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life (QoL)
6011,NCT00669812,Survival at 1 year,2008-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Toxicity
6012,NCT04483076,pCR rate,2021-01-13,RECRUITING,INTERVENTIONAL,['PHASE3'],,Five-year overall survival
6013,NCT03993353,Overall Survival (OS),2020-04-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse event rates
6014,NCT01125865,Stent patency,2010-05,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Technical success
6015,NCT04625894,Dose-limiting toxicities (DLT),2020-12,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Quality of life assessment
6016,NCT02489201,Number of participants with Adverse Events,2015-07-21,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-free survival
6017,NCT03524508,Progression Free Survival by independent central reviewer,2018-09-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response rates determined by the independent central reviewer
6018,NCT01453452,"Increase in fruit and vegetable consumption by 1 full serving per day (not including iceberg lettuce, potatoes, or fruit juices) OR reduce caloric intake by 100 kcal/day",2012-03,COMPLETED,INTERVENTIONAL,['NA'],,DNA methylation patterns
6019,NCT05530785,Objective Response rate,2022-08-01,RECRUITING,INTERVENTIONAL,['NA'],,number of participants with treatment-related adverse events
6020,NCT00648102,"To establish safety and tolerability profile of CDX1307 alone and with adjuvant in patients with breast, colorectal, pancreatic, bladder and ovarian cancer",2006-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Investigate clinical activity
6021,NCT05173610,Treatment efficacy (Disease free survival),2021-09-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events (acute and late toxicity) as assessed by CTCAE v4.0
6022,NCT00603863,"safety will be evaluated based upon physical examinations, hematology and chemistry laboratory testing as well as toxicity",2008-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Efficacy and Clinical benefit measures such as quality of life, pain assessments, etc."
6023,NCT04607291,Model Development for Prediction of Intent and Colorectal Cancer (CRC) Screening Behaviors,2019-09-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Prediction of Which CRC Screening Test is Most Acceptable
6024,NCT03272984,Postoperative length of stay,2015-04-01,COMPLETED,INTERVENTIONAL,['NA'],,Time to semi-liquid diet
6025,NCT04329429,Objective Response Rate (ORR),2020-08-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
6026,NCT05933122,Number and proportion of women with sexual dysfunction defined as a total FSFI,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,"Differences (Month 6 - Month -1 and Month 12 - Month 6) in the score of the ""satisfaction"" dimension of the FSFI scale (Q14-Q16) between the groups with and without treatment by a sexologist (cohort here vs. elsewhere)"
6027,NCT01132755,Number of Study Participants With Adequate Percutaneous Lavage Specimen Collection,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety of Peritoneal Lavage in Place of Laparoscopic Lavage.
6028,NCT05391867,Overall survivability,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],,
6029,NCT05181826,Independent performance measure of sensitivity and specificity of a multi-analyte blood test,2019-05-21,RECRUITING,OBSERVATIONAL,['NA'],,Ascertain Sample Stability
6030,NCT06017141,Neutrophil extracellular traps (NET) formation,2023-05-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,Changes in gene expression
6031,NCT01266720,Toxicities as assessed by NCI-CACAE ver3,2008-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Survival
6032,NCT00296322,Relapse-free Survival,2001-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall Survival
6033,NCT02422095,Natural history and disease progression in pancreatic cysts,2015-02,WITHDRAWN,OBSERVATIONAL,['NA'],,Evaluate the role of plastic stents in patients undergoing EUS-guided drainage of pancreatic fluid collections.
6034,NCT06040632,ctDNA analysis,2022-09-01,RECRUITING,OBSERVATIONAL,['NA'],,Postoperative morbidities
6035,NCT00607282,"Improvement of erectile function using IIEF-5 (International Index of Erectile Function-5), SEP Q2, Q3 (Sexual Encounter Profile Q2,Q3), and GEQ (Global efficacy Question)",2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Improvement of erectile function using IIEF-5, SEP Q2,Q3, and GEQ"
6036,NCT04169399,Progression free survival (PFS),2019-11-17,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse Events
6037,NCT03006263,overall postoperative morbidity rates,2016-11-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,The variation of C-reactive protein
6038,NCT05679050,Disease-free Survival(DFS),2022-10-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Treatment-Emergent Adverse Event Rate
6039,NCT03038984,cancer,2016-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,"Disease course, Copenhagen IBD Disease course Type"
6040,NCT02748551,"""Major"" Surgical Morbidity",2016-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Extent of lymph node dissection
6041,NCT04607057,Body weight change for 2 months after surgery,2020-12-22,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Mortality rate
6042,NCT03665571,NK cell activity,2016-07,UNKNOWN,OBSERVATIONAL,['NA'],,Survival of participants
6043,NCT05250648,Peritoneal Recurrence Free Survival,2022-03-02,RECRUITING,INTERVENTIONAL,['PHASE4'],,Quality of Life with EORTC validated questionnaire Colorectal Cancer Module (QLQ-CR29).
6044,NCT02321579,Oxidative stress marker (MDA concentation),2014-12,UNKNOWN,INTERVENTIONAL,['NA'],,Glutathione related enzyme activities
6045,NCT03833661,Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC),2019-03-26,COMPLETED,INTERVENTIONAL,['PHASE2'],,Durable Response Rate (DRR) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by an Independent Review Committee (IRC) According to According to Microsatellite Instability (MSI) Status
6046,NCT04595929,Comparison of Overall survival (OS) in both arms,2020-02-10,RECRUITING,INTERVENTIONAL,['NA'],,Rate of post-operative morbidity/mortality at day 30 after surgery acc. to Clavien-Dindo classification
6047,NCT04342676,"LNR and K ras were evaluated with correlated with different clinicopathological parameters (Gender, CEA, tumor size, tumor grade and response to treatment).",2017-03-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,LNR and K ras were evaluated and ASSOCIATION with PFS and OS.
6048,NCT05757492,Assessment of the number of participants with treatment-emergent adverse events (TEAEs) receiving CHS-006 administered in combination with toripalimab,2023-04-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS) using RECIST v1.1 assessed by the investigator
6049,NCT02043184,Medication Adherence using pill count and self report,2013-03,COMPLETED,INTERVENTIONAL,['NA'],,Healthcare Utilization is the use of Emergency room and Hospital admissions
6050,NCT04701645,Number of implanted microdevices successfully retrieved,2022-11-01,RECRUITING,INTERVENTIONAL,['PHASE1'],Correlate extent of tumor response with genetic features of the tumor tissue,
6051,NCT01286987,Part 1: Recommended Part 2 Dose of Talazoparib,2011-01-03,COMPLETED,INTERVENTIONAL,['PHASE1'],Part 1: Apparent Volume of Distribution (Vz/F) of Talazoparib,
6052,NCT04800991,Score of each domain of the 'feasibility assessment of the investigational device (website)' questionnaire for investigators,2021-03-17,COMPLETED,INTERVENTIONAL,['NA'],Frequency of Adverse Events,The investigational device(application) usage compliance by underlying disease
6053,NCT04745091,Complete pathologic response,2021-02-01,UNKNOWN,OBSERVATIONAL,['NA'],,
6054,NCT02641925,HOMA-IR change,2015-08,UNKNOWN,INTERVENTIONAL,['NA'],,HOMA-IR change according to anastomosis type
6055,NCT05645094,cCR and pCR rates,2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Acute toxicity associated with Envafolimab
6056,NCT00819559,Disease-free survival,2009-03,UNKNOWN,INTERVENTIONAL,['NA'],,Overall survival Local recurrence Early or late complication associated with preoperative radiotherapy Quality of life Accuracy of clinical staging Difference of surgical outcome between laparoscopic and open surgery
6057,NCT00629421,development of hepatocellular carcinoma,2001-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
6058,NCT06328283,glutamine synthetase,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
6059,NCT01742169,Completion of fecal occult blood test (FOBT),2013-01,COMPLETED,INTERVENTIONAL,['NA'],,
6060,NCT00730483,Safety - Number of CTCAE v3.0 Events 1 Month Post DEB-TACE,2009-02,TERMINATED,INTERVENTIONAL,['NA'],,Symptomatic Response by Assessing Symptom Severity in Patients
6061,NCT00613080,"The Percentage of Patients Experiencing Treatment-related Gastrointestinal Adverse Events ≥ Grade 2 Per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v. 3.0, Occurring Preoperatively",2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients Who Underwent Abdominoperineal Resection
6062,NCT02047513,Time to Disease free survival (DFS),2015-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumor recurrence
6063,NCT02983045,Part 2 and Part 4: Objective Response Rate (ORR) Per RECIST 1.1 at Recommended Phase 2 Dose (RP2D),2016-12-19,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6064,NCT02064803,Change from baseline Gastric Outlet Obstruction Score System - GOOSS,2013-06,COMPLETED,INTERVENTIONAL,['NA'],,Overall survival
6065,NCT03281447,Self evaluated Self Efficacy for Cancer,2016-02-26,COMPLETED,INTERVENTIONAL,['NA'],,Health-related Quality of Life
6066,NCT02954302,"Delayed gastric emptying,rate",2016-09,UNKNOWN,INTERVENTIONAL,['NA'],"nonsurgical complications,rate","wound infection,rate"
6067,NCT02363049,overall survival,2014-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Rate of secondary curative resection (R0)
6068,NCT00310050,Quantitative Toxicity of Pemetrexed When Administered With Concomitant Radiation Therapy,2005-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,Number of Participants That Survived
6069,NCT01703910,gene expression profiles,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6070,NCT01104116,Positive and Negative Predictive Value of PET Imaging for Identifying Malignant IPMN,2009-09,TERMINATED,INTERVENTIONAL,['NA'],,Change in Lesion Characteristics to Assess Benefit of PET Scans
6071,NCT04927260,Survival,2021-03-31,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Quality of life in real-life according to FACT-G questionnaire
6072,NCT04310709,Response rate,2020-06-16,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
6073,NCT01386697,,2010-11,COMPLETED,OBSERVATIONAL,['NA'],,
6074,NCT02050178,Safety and tolerability of OMP-54F28 in combination with nab-paclitaxel and gemcitabine in patients with previously untreated Stage IV pancreatic cancer,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics (PK) of OMP-54F28 when administered in combination with nabpaclitaxel and gemcitabine to patients with previously untreated Stage IV pancreatic cancer
6075,NCT04205071,Measure the improvement in balance for patients with chronic CIPN,2020-11-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Nerve conduction test (NCT) result analysis,Improvement in patient-reported chemotherapy-induced peripheral neuropathy symptoms
6076,NCT00791544,Dose-limiting toxicities (DLT) based on grade = or > 3 hematological or non-hematological toxicity and on fasting hyperglycemia,2008-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Anti tumoral activity
6077,NCT00349024,"Symptoms, other than pain, considered important to the pediatric population",2005-07,UNKNOWN,INTERVENTIONAL,['NA'],,
6078,NCT00400179,Median Survival,2005-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time to Treatment Failure (TTF)
6079,NCT01066624,Incidence of Oral Mucositis,2009-08,COMPLETED,INTERVENTIONAL,['NA'],,
6080,NCT00911820,7-month Progression-Free Survival,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-Free Survival
6081,NCT00966706,Progression-free survival at 6-months,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity
6082,NCT01102335,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Overall survival
6083,NCT00474812,Median Overall Survival,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Gait Speed
6084,NCT00536614,Overall survival,2005-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,"response to treatment, and toxicity"
6085,NCT01522677,Safety,2012-08,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Sustained immunity
6086,NCT01725321,Detection rate of proximal serrated polyp,2012-10,COMPLETED,OBSERVATIONAL,['NA'],Adenoma detection rate,Missed rate for proximal serrated polyps
6087,NCT02605265,Pathologic Complete Response,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Surgical complications
6088,NCT02189226,Complete resection rate,2013-11,COMPLETED,INTERVENTIONAL,['NA'],,adverse event
6089,NCT03546569,ctDNA/cfDNA levels in relation to colorectal stent placement,2018-05-01,COMPLETED,OBSERVATIONAL,['NA'],,Metastatic ability of the cancer cells
6090,NCT02048943,Incidence of adverse events graded by NCI CTCAE version 4.0,2015-03,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Biomarker expression levels in tumor specimens
6091,NCT03448874,Incidence of overall subject pre-specified* procedure related Adverse Events,2018-04,WITHDRAWN,INTERVENTIONAL,['NA'],,"Incidence of ""deployment failure"""
6092,NCT00230191,The primary objective of the study is to assess the effect of RK-0202 versus placebo on the incidence and severity of oral mucositis.,2003-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,The secondary objectives of the study are to assess the safety and tolerability of RK-0202 in these subjects and to explore whether the ProGelz™ vehicle alone is active in these subjects.
6093,NCT02563002,Overall Survival (OS),2015-11-30,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants Who Discontinued Study Treatment Due to an AE
6094,NCT01936233,recurrence free survival,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],,adverse events
6095,NCT02227667,Best Response Rate,2014-12-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants Evaluated for Toxicities to Determine Safety
6096,NCT03711890,Measure accuracy of using OCT to diagnose pancreatic cancer and compare with histology.,2019-03-26,RECRUITING,INTERVENTIONAL,['NA'],,
6097,NCT01130805,Response rate,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicities
6098,NCT00448838,Progression-free survival,2006-05,COMPLETED,INTERVENTIONAL,['NA'],,Time to progression
6099,NCT02145559,Pharmacodynamic Biomarker p70S6K,2014-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Fasting Serum Glucose and Triglycerides
6100,NCT03139058,"Determine the prevalence, by registry data analysis, of cirrhosis in patients with VADS cancer",2018-08-20,UNKNOWN,INTERVENTIONAL,['NA'],,
6101,NCT03233724,Maximum Tolerated Dose (MTD) of Tetrahydrouridine,2018-04-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With a Dose Limiting Hematologic Toxicity (DLT),"Changes in Gene, Endogenous Retroviral (ERV), Micro Ribonucleic Acid (RNA) Expressions, Deoxyribonucleic Acid (DNA) Methylation Signatures and Tumor Microenvironment"
6102,NCT04072679,Incicende of Adverse Events (AEs),2018-10-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Anti-drug antibody (ADA)
6103,NCT03443921,Overall mortality at one year after randomization;,2018-03,UNKNOWN,INTERVENTIONAL,['NA'],,Performance status at 3 years after randomization
6104,NCT00160836,Sensitivity and specificity for the diagnosis of malignancy with both devices,2004-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],,unusual findings at histopathological examination of surgical specimens.
6105,NCT00689715,recurrence during follow up,2006-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,predictive factors for complete resolution
6106,NCT00586053,To optimize diagnostic performance of CTC in the unprepared colon for colorectal polyp detection using electronic stool subtraction and computer-aided diagnostic techniques.,2000-08,COMPLETED,OBSERVATIONAL,['NA'],,The cost-effectiveness ratio of CTC in the unprepared colon will compare favorably with other colorectal screening tests
6107,NCT04297423,Adenoma detection rate,2020-03-11,COMPLETED,INTERVENTIONAL,['PHASE4'],,Tolerability and satisfaction with preparation
6108,NCT05593328,Overall Response Rate,2023-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety: Exposure Response Evaluation of Onvansertib
6109,NCT02910843,Pathological near complete or complete tumor response (npCR or pCR),2017-02-22,TERMINATED,INTERVENTIONAL,['PHASE1'],,Postoperative complications
6110,NCT04338191,3-year Disease-free survival,2020-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of Life assessed by SF-36
6111,NCT04344158,Overall survival (OS),2020-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Duration of Response (DOR)
6112,NCT04062721,Incidence of treatment-emergent adverse events,2021-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Potential predictive biomarkers
6113,NCT03449914,Evaluate the prognostic value of baseline G8 screening tool for survival.,2017-10-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
6114,NCT04520295,Change from baseline in molecular biomarkers at time on best overall response,2020-05-19,RECRUITING,OBSERVATIONAL,['NA'],,Change from baseline in molecular biomarkers at time on disease progression
6115,NCT05787587,Part 2 (Dose Expansion): To evaluate preliminary anti-tumor activity of IDE161 monotherapy in participants by measuring Duration of Response using RECIST criteria v1.1,2023-04-05,RECRUITING,INTERVENTIONAL,['PHASE1'],,Area Under the Plasma Concentration Versus Time Curve (AUC) of IDE161
6116,NCT04401124,assorted surgical parameters,2020-05-25,UNKNOWN,OBSERVATIONAL,['NA'],,hospitals' protection measures and extent of implementation
6117,NCT00683787,Overall Response Rate,2008-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Toxicity
6118,NCT02131441,abdominal adhesion,2013-07,UNKNOWN,INTERVENTIONAL,['NA'],,time to disease recurrence
6119,NCT05500391,2-year compliance to the customized surveillance plan,2024-02-28,RECRUITING,INTERVENTIONAL,['PHASE2'],Evaluation of the causes of recruitment failures,Support care needs identified
6120,NCT02488161,Mortality,2010-06,COMPLETED,OBSERVATIONAL,['NA'],,Number of participants with Cancer recurrence
6121,NCT00062023,"Percentage Change in Colorectal ACF Patients Treated with Sulindac, Aspirin or Ursodiol",2003-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,
6122,NCT04633122,PFS assessed by independent central review,2020-11-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To compare the safety profile of DCC-2618 (ripretinib, ZL-2307) to the safety profile of sunitinib by using AE/SAE/AESI collection during study."
6123,NCT05408221,ORR,2022-11-11,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,OS
6124,NCT01928524,Median Overall Survival,2013-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6125,NCT05761717,Overall survival (OS) after initial administration.,2023-04-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
6126,NCT04762914,Complication rate,2018-09-01,COMPLETED,OBSERVATIONAL,['NA'],,Anaerobic threshold
6127,NCT00813540,Safety (Monitoring for Adverse Events),2009-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Feasibility (Adherence to the exercise training program)
6128,NCT02988934,Incremental yield for dysplasia due to WATS sampling above that noted from routine forceps biopsies in various clinical settings.,2016-04,TERMINATED,OBSERVATIONAL,['NA'],,Outcomes of patients undergoing WATS sampling.
6129,NCT04066543,PFS,2019-08-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
6130,NCT05078515,Specificity of PREDICT score,2008-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
6131,NCT02505750,"Rate of rectum preservation either with local excision or watch and wait strategy after neoadjuvant treatment without non salvageable locally progressive disease at 3 years post treatment, or permanent stoma.",2015-06-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Quality of Life,Tumour regression score on the operative specimen
6132,NCT01270438,Progression-free survival of patients treated with FOLFOX6 plus bevacizumab with or without gamma-secretase inhibitor RO4929097,2010-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Pharmacokinetics and pharmacodynamics of gamma-secretase inhibitor RO4929097
6133,NCT01905150,12-month survival rate,2014-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Adverse Events,Overall Survival
6134,NCT04009811,Voice Handicap Index (VHI) overall score,2020-07-17,COMPLETED,INTERVENTIONAL,['NA'],,Head and Neck quality of life EORTC QLQ-H&N35 questionnaire score
6135,NCT01298401,Dose-limiting toxicity of ganitumab and capecitabine given concurrently with radiotherapy,2012-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival (for patients treated at maximum-tolerated dose of ganitumab)
6136,NCT00669292,Safety(Phase I:toxicities as assessed by NCI CTCAE version3) and efficacy(Phase II:Feasibility as evaluated by RECIST),2006-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,survival(Phase II)
6137,NCT01225757,Fluid administration decrease,2010-11,WITHDRAWN,INTERVENTIONAL,['NA'],,Cardiac complications
6138,NCT05076279,number of retrieved lymph nodes,2021-11-15,RECRUITING,INTERVENTIONAL,['NA'],,3 year relapse-free survival
6139,NCT04267575,Number of Participants With Complications Due To Cold Plasma Application,2019-07-30,UNKNOWN,INTERVENTIONAL,['NA'],,
6140,NCT03563144,Progression-Free Survival,2018-08,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Evaluation of safety as determined by incidence or treatment-emergent adverse events
6141,NCT00045747,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6142,NCT03043508,Time to Pancreatic Neuroendocrine Tumors (PNET),2015-04-10,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Overall Survival in Participants Who Have Confirmed MEN1 with or without PNET
6143,NCT04040374,Per patient diagnosis of gastric cancer,2019-07-01,COMPLETED,INTERVENTIONAL,['NA'],,Agreement on image and IOU based diagnosis of gastric cancer between AI and expert endoscopists
6144,NCT02256800,Progression-free survival,2014-08-13,COMPLETED,INTERVENTIONAL,['NA'],,overall survival
6145,NCT00051532,"Overall survival, defined as the time from start of treatment to death",1999-09,TERMINATED,INTERVENTIONAL,['NA'],,Dose of seocalcitol (seocalcitol treated patients)
6146,NCT02733809,Overall and disease-free survival genes.,2014-01,RECRUITING,INTERVENTIONAL,['PHASE4'],,Potential genetic targets for resistance.
6147,NCT05381753,"Dose adjustment of avapritinib in cohort 1, 2, and 3",2022-08-29,RECRUITING,OBSERVATIONAL,['NA'],,
6148,NCT03867370,Pathological response rate,2019-04-26,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of adverse events
6149,NCT01911832,quality of life,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,short-term complication of the surgery
6150,NCT02404935,Progression Free Survival at 6 months,2013-11-22,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6151,NCT01591421,Recommended phase II dose of BKM120 (Phase I Component),2012-09-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Translational Research
6152,NCT02919644,immunological efficacy,2016-12-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,evaluation of the predictive role of immune cells in tumor microenvironment
6153,NCT00215995,Number of Participants With Desired Response,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Overall Survival
6154,NCT06334458,Validation of igenetic biomarker testing in liquid biopsy followed by radiological exam as early cancer diagnostic tool,2023-02-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
6155,NCT02093104,Liver Tumour Perfusion using CT & C-arm systems in 40 patients at VGH over a 3 month period,2014-02,COMPLETED,OBSERVATIONAL,['NA'],,
6156,NCT01246960,Progression-Free Survival (PFS),2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Adverse Events (AEs),Number of Participants With Treatment-Emergent Anti-Ramucirumab Antibodies
6157,NCT05962502,Objective response rate (ORR),2023-08-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Drug-related adverse reactions
6158,NCT03109457,Hep C cAg by Immunohistochemistry,2017-09-06,COMPLETED,OBSERVATIONAL,['NA'],,
6159,NCT00626158,To establish the maximum tolerated dose of fixed-dose rate gemcitabine plus capecitabine given by biweekly administration in patients with advanced pancreatic and biliary tract malignancies.,2008-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Frequency, type, and grade of adverse events using this combination in this patient population"
6160,NCT03910387,Weight stability,2019-04-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Duration of response
6161,NCT00049699,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6162,NCT04400292,The number of lymph nodes visualized to be fluorescent and nonfluorescent.,2020-05-20,RECRUITING,INTERVENTIONAL,['NA'],,
6163,NCT02122185,Progression free survival (PFS) evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 and Gynecological Cancer Intergroup (GCIG) criteria,2015-02-25,SUSPENDED,INTERVENTIONAL,['PHASE2'],,"Incidence of adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0"
6164,NCT06070636,Objective response rate (ORR),2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Overall survival (OS)
6165,NCT05123209,Incidence of adverse events (AEs) and abnormal laboratory test results as assessed by CTCAE V5.0,2021-08-24,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Persistence of CAR-T cells (cell counts and cell percentage in peripheral blood)
6166,NCT01508520,diagnosis accuracy of ME-NBI,2009-12,COMPLETED,OBSERVATIONAL,['NA'],,
6167,NCT00063947,Maximum-tolerated dose (MTD) of erlotinib hydrochloride based on the incidence of dose-limiting toxicity (DLT) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 3.0,2003-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival
6168,NCT05428358,Change in treatment strategy,2022-08-30,RECRUITING,INTERVENTIONAL,['NA'],,Healthcare costs
6169,NCT03716518,Completion Rate of 8-cycle Adjuvant Chemotherapy,2018-12-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Incidence of SAEs
6170,NCT02855944,Investigator Assessed Progression-Free Survival (invPFS) by RECIST Version 1.1 for Rucaparib Versus Chemotherapy (ITT Population),2017-03-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall Survival (ITT Population)
6171,NCT00558155,"During the postoperative period, all patients were observed for both surgical and non-surgical complications",2001-06,COMPLETED,INTERVENTIONAL,['PHASE4'],,"The secondary objective of the study was to evaluate the effect of nutritional intervention on overall morbidity and mortality rates, and hospital stay."
6172,NCT02125448,"Distinct and combined sensitivity, specificity, predictive values, and accuracy of MRI and PET-CT for identifying histopathological complete response.",2013-10,COMPLETED,OBSERVATIONAL,['NA'],,Experienced patient burden (UMC Utrecht only).
6173,NCT03322280,Overall survival (OS),2018-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,Duration of portal patency
6174,NCT02181140,Diagnostic Accuracy,2011-08,COMPLETED,INTERVENTIONAL,['NA'],,Complication Rates
6175,NCT01145456,"Recommended phase II dose of RO4929097 in combination with gemcitabine hydrochloride, defined as the dose level in which no more than 1 of 6 patients or 0/3 experience DLT, graded according to NCI CTCAE version 4.0",2010-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Objective response according to RECIST criteria 1.1
6176,NCT03007212,changes in Radiological Response in the (CT/ MRI) after the intervention,2014-09,COMPLETED,INTERVENTIONAL,['PHASE4'],,
6177,NCT05450393,Prospective collection of PillCamTM SB3 capsule endoscopy and DAE procedures data,2024-05-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
6178,NCT02369757,Participation rates,2012-10,COMPLETED,INTERVENTIONAL,['NA'],,Qualitative analysis
6179,NCT02242409,4 month progression free survival,2014-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
6180,NCT01641939,Overall Survival (OS) - Phase 2 (Dose Selection Portion of the Study),2012-09-03,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Systemic Clearance (CL) - Stage 1
6181,NCT00777192,Association between inflammatory cytokines and development of treatment-related symptom burden in colorectal cancer patients,2008-08,TERMINATED,OBSERVATIONAL,['NA'],,Neurocognitive and neuropsychiatric symptoms in colorectal cancer patients
6182,NCT04127396,Time to progression,2019-09-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,adverse events(AEs)
6183,NCT00326495,Overall Rate of Response,2006-05-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Count of Participants With Adverse Events
6184,NCT05464030,Part 2A: Duration of Response (DoR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Investigators,2022-08-04,RECRUITING,INTERVENTIONAL,['PHASE1'],,Part 2A: Number of Participants with Symptomatic Adverse Events (AEs)
6185,NCT02833298,HCC screening rates,2016-11,COMPLETED,INTERVENTIONAL,['NA'],,Incidence of liver transplant
6186,NCT03485196,Disease Free Survival,2017-03-01,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival(OS)
6187,NCT02575898,Feasibility of a creative writing intervention in an advanced cancer population,2016-01-14,COMPLETED,INTERVENTIONAL,['NA'],,
6188,NCT05736705,Speed of Endoscopic Submucosal Dissection,2024-03-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Rate of esophageal stricturing post-procedure
6189,NCT01243047,To evaluate two different schedules of erlotinib in combination with a modified XELOX regimen in terms of response rate,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,To determine the effect of intermittent versus continuous erlotinib administration on pharmacodynamic endpoints using tumor biopsies
6190,NCT01234272,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4'],,
6191,NCT00986661,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of hepatic administration of PV-10,2009-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Exploratory Correlative Endpoints,Overall survival
6192,NCT05652348,Next generation sequencing of organoid cultures,2022-12-08,RECRUITING,OBSERVATIONAL,['NA'],,
6193,NCT06050200,Successful resection,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Overall morbidity
6194,NCT00549952,incidence and severity of oral mucositis,2007-10,UNKNOWN,OBSERVATIONAL,['NA'],,
6195,NCT06116019,Number of Successfully Completed Adaptive Radiotherapy Sessions in Patients with Various Tumor Entities,2023-10-11,RECRUITING,OBSERVATIONAL,['NA'],,Local Control
6196,NCT03589339,[Dose Expansion Part]: Safety Evaluation at RP2D,2019-01-16,RECRUITING,INTERVENTIONAL,['PHASE1'],,Evaluation of the body kinetic profile of intratumorally injected NBTXR3
6197,NCT03032874,To determine colonoscopy polyp and cancer detection rate,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,To detect colorectal cancer early using symptoms based assessment
6198,NCT02312817,Repeat Screening (Every 6 Months),2014-12,COMPLETED,INTERVENTIONAL,['NA'],,Suspicious Lesion
6199,NCT02067754,Circulating tumor cell,2013-09-11,COMPLETED,OBSERVATIONAL,['NA'],"Circulating Free DNA Analysis in Gastrointestinal Cancer, Genitourinary Cancer",mutation profiling of circulating free DNA
6200,NCT03062358,Overall Survival (OS),2017-04-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of Participants Who Discontinued Study Treatment Due to an AE
6201,NCT00601549,Oncologic Results,2000-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Functional recovery of patients
6202,NCT04522752,Correlation between size and pathological type of benign epithelial gastric polyp and polyp development.,2020-09-30,UNKNOWN,OBSERVATIONAL,['NA'],,Correlation between helicobacter pylori infection and pathological type of benign epithelial gastric polyp.
6203,NCT05411133,Incidence and severity of adverse events,2022-05-30,RECRUITING,INTERVENTIONAL,['PHASE1'],,Effect of Cabotamig (ARB202) on tumour as determined by changes in RECIST evaluation from baseline
6204,NCT01554059,Pathological complete response rate,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety data of this regimen
6205,NCT02118064,Number of Patients with Serious and Non-Serious Adverse Events,2001-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6206,NCT00768001,,2008-06,TERMINATED,OBSERVATIONAL,['NA'],,
6207,NCT04230018,Mutation Consistency of metastatic and primary sites of colorectal cancer patients with postoperative metastasis,2018-12-28,UNKNOWN,OBSERVATIONAL,['NA'],prediction accuracy of survival rate,Mutation Consistency of tissue and blood sample
6208,NCT05200221,Incidence of adverse events and serious adverse events.,2022-01-19,UNKNOWN,OBSERVATIONAL,['NA'],,overall survival(OS)
6209,NCT01899118,Pathology complete remission rate,2013-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events
6210,NCT04124406,Enrollment of Subjects,2019-10-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,National Rates Comparison
6211,NCT05869474,Overall survival (OS),2023-08-01,RECRUITING,INTERVENTIONAL,['NA'],,Visual analog scale (VAS)
6212,NCT03287843,Pathological Complete Response Rate,2006-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Overall Survival
6213,NCT05165602,the relationship between 68Ga SUVmax before treatment and the therapeutic effect will be assessed by SPSS26.0,2022-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,the relationship between the dynamic change of 68Ga SUVmax and the therapeutic effect will be assessed by SPSS26.0
6214,NCT02443883,Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab,2015-07-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Rate of Progression Free Survival (PFS) at the First 6-Week Tumor Assessment
6215,NCT05528783,The diagnostic sensitivity and specificity of FIT-DNA detection for local recurrence and advanced colorectal neoplasm of CRC.,2022-04-25,RECRUITING,OBSERVATIONAL,['NA'],,3.The time interval between CRC recurrence and advanced colorectal neogenesis after the first positive appearance was detected by FIT-DNA detection.
6216,NCT03464305,5 year overall survival,2018-02-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Time to Treatment Failure
6217,NCT03722498,Progression-free survival,2018-06-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Objective response rate
6218,NCT03417765,Incidence of treatment-emergent adverse events,2018-09-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Assessment of quality of life
6219,NCT04495387,change of taste chemotherapy-related alterations,2021-07,UNKNOWN,OBSERVATIONAL,['NA'],,Emotions elicited by foods
6220,NCT05336266,Feasibility determined by the number of patients that take the prescribed dose of ketorolac (4 times daily) for 5 consecutive days.,2022-07-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Mean change in calories consumed from baseline through the End-of-Treatment visit
6221,NCT03457896,Progression free survival (PFS) with neratinib plus cetuximab therapy,2018-05-18,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Frequency of adverse events assessed using CTCAE 4.0
6222,NCT03941938,Anastomotic leak,2019-05-02,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative complications
6223,NCT02842294,"time to health related quality of life score deterioration (targeted dimensions of EORTC QLQC30 : global health, fatigue, emotional functioning)",2013-05,UNKNOWN,OBSERVATIONAL,['NA'],,treatment preference
6224,NCT03888313,The patient's experience of participating in a pretreatment group consultation,2019-04-26,COMPLETED,OBSERVATIONAL,['NA'],,
6225,NCT00535041,safety,2007-09,COMPLETED,INTERVENTIONAL,['NA'],,
6226,NCT00512681,Maximal overall response rate,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Progression-free survival,Overall survival,Toxicity assessment,&genetic polymorphism and association with chemical outcomes"
6227,NCT04844112,Rate of complete ablation of the tumor after 1 month clinical follow up,2015-08-01,COMPLETED,INTERVENTIONAL,['NA'],,Safety of the approach route before and after the fusion process
6228,NCT03314961,Lymph node metastases in rectal cancer,2012-01,COMPLETED,OBSERVATIONAL,['NA'],,
6229,NCT02475889,PD-L1 expression in primary tumor,2007-11,COMPLETED,OBSERVATIONAL,['NA'],,
6230,NCT05755672,"Follow-up examination of tumour remission, progression or recurrence",2023-03-01,RECRUITING,OBSERVATIONAL,['NA'],,Quality of life changes
6231,NCT03263429,Recommended phase 2 dose of CB-839 in combination with panitumumab and irinotecan hydrochloride (Phase I),2017-08-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
6232,NCT01828762,Vital signs，physical examinations and adverse events,2012-12,COMPLETED,INTERVENTIONAL,['NA'],,
6233,NCT05337137,Overall Response Rate (ORR) by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1,2022-05-05,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of participants with adverse events (AEs)
6234,NCT05495152,Disease-free Survival (DFS),2022-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,
6235,NCT00143533,Dose limiting toxicities,2003-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6236,NCT04068610,Percentage of Participants With Objective Response (OR) Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1) in Part 2,2019-09-13,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Positive ADA to Bevacizumab in Part 1 (S1)
6237,NCT05376943,The occurrence of HCC after direct acting antiviral HCV treatment.,2022-05-10,UNKNOWN,OBSERVATIONAL,['NA'],,The difference in liver function tests among the population of patients treated with DAAs and those who were not receiving the therapy.
6238,NCT02693236,objective rate response (CR+PR) as measured by RECIST criteria,2014-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,number of participants with adverse events
6239,NCT01461148,immune response against FSP peptides,2011-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,safety
6240,NCT06143644,2-year recurrence free survival rate of the cohort evaluated by ctDNA,2022-01-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Time point of ctDNA MRD test for recurrence monitoring
6241,NCT02478892,"identifying pancreatic neoplastic lesions lesions in patients with BRCA1/2 mutations and other less common, but related mutations (ATM, PALB2) as well as mutations identified in the future.",2015-05,RECRUITING,OBSERVATIONAL,['NA'],,
6242,NCT02387307,Recommended dose (RD) of rSIFN-co,2013-07,COMPLETED,INTERVENTIONAL,['PHASE1'],"Evaluation of levels (counts) of 2'5'-oligoadenylate synthetase, before and after administration of rSIFN-co",FDG-PET response (lesion volume) before and after administration of rSIFN-co
6243,NCT05000294,Objective response rate (ORR),2021-12-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease control rate (DCR)
6244,NCT06201585,The rate of postoperative complications,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Intraoperative instrument operation error rate,
6245,NCT06246448,Time to functional recovery,2024-01-23,RECRUITING,INTERVENTIONAL,['NA'],,Abdominal wall complaints
6246,NCT00164918,Bowel function and related symptoms early post-op,2004-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
6247,NCT06008925,Phase IIa:ORR,2022-11-17,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase Ib :Pharmacokinetic parameters: Blood concentrations of VG161 at different time points after single and multiple doses
6248,NCT03855904,To evaluate the efficacy of TC-325 in preventing 30-day rebleeding following the index malignant hemorrhage: Rebleeding rate,2019-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,"1. To evaluate the efficacy of TC-325 in immediate hemostasis and rebleeding at 24 hours, 72 hours, 90 days and 180 days following presentation at initial bleeding episode as well as 6-month survival rate"
6249,NCT03578445,Clinical impact of EUS-guided microbiopsies in patients with pancreatic cystic lesions,2018-02-01,COMPLETED,INTERVENTIONAL,['NA'],,Diagnostic values of gene mutations (NGS analyses) in microbiopsy material in the surgical subcohort
6250,NCT00063141,Overall Survival,2003-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Health Economics
6251,NCT04660123,helicobacter pylori eradication,2020-12-20,COMPLETED,INTERVENTIONAL,['PHASE4'],adverse events,symptoms improvement rates
6252,NCT03608046,Tumor response rate,2018-10-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse events
6253,NCT02649868,To determine the imaging characteristic of radiopaque beads including qualitatively comparing virtual and actual bead perfusion in evaluating tumor vascularity in the treatment of hepatic tumors using bead embolization.,2016-01-12,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2'],,
6254,NCT04642547,Progression free survival,2020-12-02,COMPLETED,INTERVENTIONAL,['NA'],,Safety endpoint
6255,NCT05546879,Percentage Proportion of patients experiencing adverse events,2023-03-15,RECRUITING,INTERVENTIONAL,['PHASE1'],PK-PD evaluation,Best overall objective response rate (ORR)
6256,NCT04107623,perfusion assessment,2020-06-16,COMPLETED,INTERVENTIONAL,['NA'],,Anastomotic leakage
6257,NCT02973750,Association of Age With Changes,2016-10-20,COMPLETED,OBSERVATIONAL,['NA'],Overall Survival (OS),Impact of Inflammation on Toxicity and Relative Dose-Intensity (RDI)
6258,NCT03057171,"Expression of THRIL, PACER",2015-05,UNKNOWN,OBSERVATIONAL,['NA'],,
6259,NCT01278381,Major Complication rate,2002-01,COMPLETED,OBSERVATIONAL,['NA'],,
6260,NCT04520932,Treatment response,2021-03-30,RECRUITING,INTERVENTIONAL,['NA'],,
6261,NCT05406024,Acceptability rate,2022-09,UNKNOWN,OBSERVATIONAL,['NA'],,European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaires (EORTC-QLQ-C30)
6262,NCT00070434,"Response (confirmed and unconfirmed response, complete response, partial response)",2004-08,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
6263,NCT00005862,,2000-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6264,NCT01946711,Change of Inflammation of the Nasal Mucosa and Paranasal Sinus,2013-08-28,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Nasal Obstruction,Safety Assessment
6265,NCT04107766,Target lesion recurrence (local recurrence) rate,2020-01-15,RECRUITING,OBSERVATIONAL,['NA'],,Numeric Pain Rating Scale
6266,NCT00201331,To compare the DFS and OS of HDFL vs. weekly bolus 5-FU plus high dose LV as adjuvant chemotherapy for N2 colon cancer,2002-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"3. To assess the disease-free survival of patients with high or low TS level of N2 colon cancer, when adjuvant chemotherapy of 5-FU was administered by bolus or continuous infusion ."
6267,NCT00003044,,1996-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
6268,NCT05907824,Disease-free survival (DFS),2023-05-01,RECRUITING,OBSERVATIONAL,['NA'],,Life quality satisfaction evaluated according to a scale.
6269,NCT04559451,Postoperative liver function failure,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,Postoperative morbidities and mortalities
6270,NCT04259398,five year survival,2020-02-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,3 year survival
6271,NCT01850667,Treatment related toxicity-free survival,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Local control rate
6272,NCT03189030,Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability),2017-05-02,TERMINATED,INTERVENTIONAL,['PHASE1'],,
6273,NCT03417843,Incidence of adverse and serious adverse events,2018-02,UNKNOWN,INTERVENTIONAL,['NA'],,Technical efficiency of the method
6274,NCT00112632,"Overall tumor response (complete response, partial response, stable disease, and progression of disease)",2005-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
6275,NCT01366144,"MTD of veliparib in combination with carboplatin and paclitaxel, determined according to incidence of DLT as graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version (v) 4.0",2011-06-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Change in gamma-H2AX levels,Time to progression
6276,NCT05084833,Proportion of patients who report completing a colonoscopy or Cologuard test (Cologuard test plus colonoscopy if Cologuard is positive) within 12 months of randomization,2022-02-14,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Cost and Cost-Effectiveness Analysis
6277,NCT03421327,Qualitative analysis of how parents and children with either Huntington's Disease or hereditary cancer communicate about genetic risk information,2017-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
6278,NCT05690048,Adverse event documentation of FMT in advanced HCC,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Change of Hepatic function
6279,NCT00017082,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6280,NCT04929652,Objective response rate (ORR),2021-06-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Assess the anti-tumor activity:DCR
6281,NCT00208546,toxicity,2005-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,translational research
6282,NCT03314649,prognostic molecular markers,2017-12-21,COMPLETED,OBSERVATIONAL,['NA'],,DFS
6283,NCT05961111,Systemic Immune Response,2023-06-24,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Quality of Life Assessment
6284,NCT04196075,Symptomatic relief and quality of life after AP,2018-03-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,AP side effects
6285,NCT00327093,"Elaboration of a predictive model, based on biological and functional imaging parameters, for the response to monoclonal antibodies as assessed through RECIST criteria 2 months after the beginning of treatment",2006-05,TERMINATED,INTERVENTIONAL,['PHASE4'],,Correlation between the response at 2 months and that at 6 months of treatment (taking into account the therapeutic adjustments during the 6-month follow-up)
6286,NCT01010334,Number of courses delivered (relative dose intensity for adjuvant studies),2009-03,TERMINATED,INTERVENTIONAL,['NA'],,"Measure quality of life using a FACT G tool, before and at best response and at the end of the treatment"
6287,NCT04357873,"Objective Response Rate (ORR), investigator assessment",2020-10-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
6288,NCT02435433,Overall Survival (OS),2015-07-20,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time to Deterioration in Eastern Cooperative Oncology Group Performance Status (ECOG PS)
6289,NCT04683744,"Identify patient knowledge, attitudes, and beliefs that influence decisions to engage in cancer screening and prevention during the COVID-19 pandemic, and barriers to uptake",2021-01-11,UNKNOWN,OBSERVATIONAL,['NA'],,
6290,NCT04634448,The Prevalence of Appendiceal Tumours in Periappendicular Abscess,2020-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Surgery after follow-up MRI
6291,NCT05700110,To develop a Radiomics model based on pre-operative CT porto-venous phase imaging that accurately predicts Resection Margin status in pancreatic head malignancy,2022-05-05,RECRUITING,OBSERVATIONAL,['NA'],,
6292,NCT05738980,RFS,2023-02-01,RECRUITING,INTERVENTIONAL,['NA'],,OS
6293,NCT00006016,Survival,2000-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6294,NCT02318888,Surgery for small bowel obstruction,2009-12,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative complications
6295,NCT05913895,"Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0,Change From Baseline in Pain Scores on the Brief Pain Inventory-Taiwan Scale at 2 Weeks",2023-12-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
6296,NCT05845502,Overall survival (OS),2023-05-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
6297,NCT04593615,3-year disease free survival rate,2020-11-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Inflammatory and immune response
6298,NCT00426153,Percent Change in Liver Volume,2007-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Change in Subject Reported Outcomes Using Mean Health Related Quality of Life (HRQoL) Scores
6299,NCT05918224,The incidence of Severe Oral mucositis (WHO grade ≥3),2022-01-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Oral activities scores
6300,NCT01768741,Total survival time and disease free survival time,2012-12,UNKNOWN,INTERVENTIONAL,['NA'],Hospital costs,Regulatory T cells and associated cytokines in liver cancer、para-carcinoma and healthy liver tissue
6301,NCT03850769,R0 resection rate,2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
6302,NCT02937506,Patient Satisfaction,2013-11,COMPLETED,INTERVENTIONAL,['PHASE4'],,
6303,NCT01612546,CRLX101 (CPT) Uptake in Tumor and Nearby Normal Tissue,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events
6304,NCT00172159,Response rate and resectability after neoadjuvant therapy.,2000-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Survival of the patients.
6305,NCT05442632,The proportion of patients who require blood product infusion or intervention with platelet raising drugs due to bleeding during the perioperative period,2022-07-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of liver failure
6306,NCT05558436,Diagnostic sensitivity,2022-06-01,RECRUITING,OBSERVATIONAL,['NA'],,"Diagnostic specificity, accuracy, positive predictive value and negative predictive value"
6307,NCT00471328,Progression-free Survival (PFS) From Local Investigator's Assessment Based on Treatment Crossover Analysis Set,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall Clinical Benefit (Complete Response [CR]/Partial Response [PR] or Stable Disease [SD]) From Local Investigator's Assessment Based on Treatment Crossover Analysis Set
6308,NCT04455282,Difference in CTC detection rate between peripheral and tumor draining veins.,2021-02-01,RECRUITING,OBSERVATIONAL,['NA'],,Dynamic Biobank
6309,NCT03680508,Objective Response Rate,2019-12-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.0
6310,NCT05438459,Progression Free Survival (PFS) rate at 6 months (Phase II),2022-06-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Biomarker of GAIA-102(Phase II)
6311,NCT00006062,,2000-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6312,NCT06245785,overall survival,2023-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
6313,NCT02314871,Change from baseline number of circulating cancer cells at 3 weeks after surgery,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,Pain intensity assessment
6314,NCT03040986,Proportion of Participants With an Objective Response (Partial Response + Complete Response),2017-07-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Overall Percent Change in Variant Allele Fraction (VAF, %) of KRAS in Participants With Detectable KRAS Mutant Circulating Tumor Deoxyribonucleic Acid (ctDNA) at Baseline and After Treatment"
6315,NCT05810402,Percentage of patients with CTCs-PD-L1+ by CellSearch® technique,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Progression Free Survival
6316,NCT04796025,Objective response rate (ORR) by RECIST 1.1 and mRECIST,2021-09-23,RECRUITING,INTERVENTIONAL,['PHASE2'],Treatment-related adverse events,Median overall survival time (mOS)
6317,NCT03505320,Objective Response Rate (ORR) of zolbetuximab as a single agent by central review (Cohort 1),2018-06-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Minimal Residual Disease (Cohort 5)
6318,NCT06028724,Real world prevalence of clinically useful mutations in solid tumors,2023-05-26,RECRUITING,OBSERVATIONAL,['NA'],,To evaluate the association between somatic genetic alterations and the clinical characteristic of the enrolled patients
6319,NCT01651013,Percentage of patients with K-Ras mutation,2010-10,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],predictive factors for response to treatment,
6320,NCT01097304,Reversal of Oxidative DNA Damage as Assessed by Changes in 8-hydroxy-2' -Deoxyguanosine (8OHdG) Immunostaining,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Changes in Cell Proliferation in BE Epithelium From Baseline to Post-intervention as Assessed by Proliferation-related Ki-67 Antigen (Ki67) Immunostaining, Percentage of Positively Stained Nuclei, in BE Tissue Sections"
6321,NCT00103298,Response and duration of response,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Correlation of health-related quality of life with length of survival
6322,NCT03303495,Overall survival,2011-11-14,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Incidence of Adverse Events (Adverse Reactions)
6323,NCT01482520,Genotypes,2008-08,COMPLETED,OBSERVATIONAL,['NA'],,
6324,NCT02568748,Number of patients with ablated hcc,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
6325,NCT02843191,Pathologic complete response,2016-12,RECRUITING,INTERVENTIONAL,['PHASE3'],,Peripheral neuropathy
6326,NCT03356002,Sensitivity and specificity of C-Scan Capsule System in detecting per segment polypoid lesions 10 mm and up as compared with Colonoscopy,2018-01-28,COMPLETED,INTERVENTIONAL,['NA'],,Quantify the variance of the Interpretation of the data from the C-Scan System between the reviewers
6327,NCT05924997,Adverse events (AEs) and serious adverse events (SAEs),2023-07-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
6328,NCT00958841,Percentage of Responders at Month 6 - Pooled Pancreatic NETs (PNETs),2009-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Nelson's Syndrome: Number of Patients Attaining Normalization or a More Than 50% Reduction in Primary Biochemical Tumor Marker
6329,NCT05674526,Maximum Tolerated Dose,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall Response Rate
6330,NCT05009953,Objective Response Rate (ORR),2021-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,UGT1A1
6331,NCT02453490,Objective response rate,2015-10-11,TERMINATED,INTERVENTIONAL,['PHASE3'],The early tumor shrinkage （ETS）and depth of response(DPR),R0 resection rate of liver
6332,NCT02486198,The relief of neurotoxicity in patients with grade 2 or higher neurotoxicity by means of CTC 4.03 and EORTC QLQ-CIPN20,2015-05-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,quality of life
6333,NCT02672865,Post Operative Complications,2016-02-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6334,NCT00633607,"Establish a Hereditary Colorectal Tumor Registry to facilitate development and implementation of epidemiological, clinical and cancer control research.",2012-04,COMPLETED,OBSERVATIONAL,['NA'],,
6335,NCT03360461,To investigate the ability of EMI-137 to produce visible fluorescence in regional lymph nodes draining the colon cancer.,2018-02-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Study of in vivo imaging compared against ex vivo fluorescent detection
6336,NCT01905202,Number of patients with adverse events,2013-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],48 hour gastroesophageal pH measurement,Number of participants who develop C. difficile induced diarrhea
6337,NCT02774512,ZAK expression level by immunohistochemistry on frozen material (surgical specimen) by Western blot and on paraffinembedded tissues section using an immunohistochemistry approach,2016-05,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,Half-life of nilotinib
6338,NCT03482102,Best Overall Response rate,2018-05-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,Time to Disease Progression
6339,NCT04256707,Combination Therapy Period: Arm C: Number of Patients With Adverse Events (AEs),2020-01-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Combination Therapy Period: Arm C: Overall Response Rate (ORR) as Assessed by RECIST 1.1
6340,NCT00599833,Progression-free survival rate at 6 months,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Clinical benefit response
6341,NCT05187481,Overall survival,2021-11-15,RECRUITING,INTERVENTIONAL,['PHASE3'],,the United States Eastern Oncology Collaboration Group (ECOG) score scale
6342,NCT02399306,Body Weight Change from baseline to the end of treatment,2014-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall Survival
6343,NCT00706576,Number of participants with opioid growth factor toxicity,2008-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Change in plasma opioid growth factor levels
6344,NCT05877573,pCR rate,2023-07-01,RECRUITING,INTERVENTIONAL,['NA'],,SAE
6345,NCT03388190,Primary - progression-free survival (PFS),2018-05-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Exploratory 5 - Histologic and molecular tumor biomarkers,Secondary 8 - Quality-of-life (QoL)
6346,NCT03350945,Tumor localization time,2017-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,Blood loss
6347,NCT02162758,Percentage of Participants With Recurrence of Intestinal Metaplasia (IM),2014-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,Change From Baseline in the Gastroesophageal Reflux Disease-Health Related Quality of Life (GERD-HRQL) Total Score
6348,NCT02757859,Overall Survival,2016-04-27,RECRUITING,INTERVENTIONAL,['NA'],Presence of cells in cytologic washing,Site of first recurrence
6349,NCT05236972,Disease Free survival [ Time Frame: 3 years ],2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall Survival [ Time Frame: 5 years ]
6350,NCT00803647,Reported Adverse Events.,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Recurrence-free Survival (RFS). Time From Study Entry Until First Recurrence.
6351,NCT04217954,Overall response rate,2020-07-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free survival
6352,NCT00059982,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6353,NCT01312857,to determine if panitumumab with Hepatic Arterial Infusion (HAI) in combination with systemic chemotherapy can increase the recurrence free survival (RFS) for colorectal cancer patients with resected liver metastases,2011-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,to analyze tumor tissue for predictive biomarkers
6354,NCT00072332,,2003-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6355,NCT00488332,Optical assessment of oral mucositis in patients undergoing radiation or chemoradiation for head and neck cancer treatment,2006-03,TERMINATED,OBSERVATIONAL,['NA'],,
6356,NCT04821895,genetic profiles in gastrointestinal stromal tumor (GIST) patients,2021-08-28,RECRUITING,OBSERVATIONAL,['NA'],,To help for search the potential targeted agents for the treatment of these wild type GIST patients
6357,NCT02983500,Rate of patients with loss of > 5 % body weight,2016-08-28,COMPLETED,OBSERVATIONAL,['NA'],,Cachexia assessment
6358,NCT02435186,progress-free survival,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"safety as measured by adverse events, vital signs, clinical lab tests, ECG and physical examination"
6359,NCT01659632,,2010-04,UNKNOWN,OBSERVATIONAL,['NA'],,
6360,NCT05715632,pCR rate,2023-02-01,RECRUITING,INTERVENTIONAL,['NA'],,Adverse reactions and perioperative complications (Security)
6361,NCT00137592,colorectal cancer screening,2005-10,COMPLETED,INTERVENTIONAL,['NA'],,colorectal cancer screening knowledge
6362,NCT01080248,Response Rate by RECIST Criteria.,2010-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
6363,NCT03654131,Freedom from local lesion progression (analyzed on patient-level),2018-07-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life as descriptive statistics: EORTC QLQ-C30
6364,NCT06017583,Complete response rate,2023-09-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Disease free survival
6365,NCT02051283,Predictive value of MRI determined contrast-enhanced and diffusion-weighted sequence pattern towards outcome (tumour recurrence < 1 year versus > 1 year),2014-02,UNKNOWN,OBSERVATIONAL,['NA'],,"Correlation of predictive MRI parameters with histology obtained from biopsy during radio-frequency ablation (tumor grade, microvascular invasion, Keratin 19 status)"
6366,NCT04909866,PFS,2021-01-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,OS
6367,NCT06109961,Phase 1 recruitment rate,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2 numbers of closure all external openings of fistula tracts
6368,NCT02071862,Safety and tolerability of CB-839: Incidence of adverse events,2014-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Clinical activity: Change in tumor volume from baseline
6369,NCT02523170,Diagnostic accuracy,2014-07,COMPLETED,INTERVENTIONAL,['NA'],,Assess margins
6370,NCT01338948,rate of conversion (to laparotomy or laparoscopy assisted),2009-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6371,NCT05322486,Overall survival,2020-10-29,UNKNOWN,OBSERVATIONAL,['NA'],,Progression free survival (PFS)
6372,NCT01070355,Histological Ki67 cancer cell proliferation index,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Urinary markers of prostaglandin metabolism
6373,NCT05894837,Objective Response Rate,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overal survival
6374,NCT00826384,Overall survival,2008-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6375,NCT03735511,Overall Survival,2018-11-20,UNKNOWN,OBSERVATIONAL,['NA'],,Progression-Free Survival
6376,NCT02289183,3-year disease free survival rate,2015-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,3-year recurrence pattern
6377,NCT02521129,Number of participants with complications,2015-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6378,NCT00393068,Pathologic Complete Response (pCR) Rate,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-Free Survival
6379,NCT03528785,"Number of patients achieving R0 resection after preoperative nanoliposomal irinotecan (nal-IRI), Oxaliplatin, Leucovorin (LV), 5-FluoroUracil (5-FU)",2018-03-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,assess surgical morbidity
6380,NCT04083573,Consistency between the result from medical monitor and that from medical augmented reality glass,2019-09,UNKNOWN,OBSERVATIONAL,['NA'],,
6381,NCT00995358,Overall survival after the 1st vaccination,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Time to progression after the 1st vaccination
6382,NCT02425930,Disease-Free Survival,2013-08,COMPLETED,OBSERVATIONAL,['NA'],,Expenditure of hospitalization
6383,NCT01951521,Complete response rate,2014-09-01,UNKNOWN,INTERVENTIONAL,['NA'],,(disease-free) survival
6384,NCT00058201,Overall survival,2001-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Survival rate at 2 and 5 years
6385,NCT05367284,Treatment acceptability questionnaire,2022-01-15,UNKNOWN,OBSERVATIONAL,['NA'],,
6386,NCT01471353,Sorafenib Activity,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Correlative Tissue Analysis
6387,NCT03914170,Median Progression free survival (PFS),2017-04-01,COMPLETED,OBSERVATIONAL,['NA'],,Liver metastases resection rate
6388,NCT00165490,"To determine the response to the combination of cetuximab, cisplatin, irinotecan, and radiation therapy in resectable esophageal carcinoma.",2004-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,To determine the progression-free survival of patients treated with combination chemotherapy and radiation therapy.
6389,NCT02172651,VDR Binding Sites,2014-07-14,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Number of Participants with Serious and Non-Serious Adverse Events
6390,NCT05033392,Pathological complete response rate,2021-09-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events
6391,NCT03078361,Rate of Feedback from Community Advisory Board,2014-04-28,COMPLETED,INTERVENTIONAL,['NA'],,Rate of Receipt of Assessments from Participants
6392,NCT01139138,Dose limiting toxicities,2010-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
6393,NCT04357483,Incidence of POPF,2018-02-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Postoperative complication
6394,NCT05632328,Objective Response Rate,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Grade 3-5 Treatment-related Toxicity Rate
6395,NCT02358161,Dose limiting Toxicity (DLT) and MTD of LDE225 co-administered with gemcitabine and nab-paclitaxel,2015-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression free survival
6396,NCT06091423,Progression free survival (PFS),2023-10-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse event (AEs)
6397,NCT04329000,Number of tablets consumed,2010-02-02,COMPLETED,INTERVENTIONAL,['NA'],,
6398,NCT05004831,PFS,2022-03-11,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and tolerance
6399,NCT05681949,The reproducibility of the therapy recommendations made by ADBoard (yes/no),2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Time between primary presentation and start of diagnostics/therapy as recommended
6400,NCT00892424,Determine the MTD of sorafenib and RT in patients with liver metastases using an iso-toxicity radiation dose allocation scheme. Determine the acute toxicity (< 3 months) of sorafenib when combined with RT in patients with liver metastases.,2008-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Document any observed late toxicities of treatment. Determine 1) the in-field local control based on CT response at 3 months;2)the time to progression and overall survival of this cohort, 3)changes in quality of life in these patients"
6401,NCT02300922,To determine the maximum tolerated dose for 90Y-IMP288.,2015-01-27,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6402,NCT04269746,Evaluate the diagnostic value of long noncoding RNA (CCAT1) expression,2020-12,UNKNOWN,OBSERVATIONAL,['NA'],,
6403,NCT06308445,Evaluation of the safety profile of two doses of rapamycin in adolescents with Familial Adenomatous Polyposis.,2024-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,"Evaluation of the effect of rapamycin on the size of the largest polyp in each segment (rectum, left colon, transverse colon and right colon) in adolescents with Familial Adenomatous Polyposis"
6404,NCT01344330,Cruciferous vegetable intake correlated with SFN and I3C urinary metabolites,2012-01,COMPLETED,OBSERVATIONAL,['NA'],,Cruciferous vegetable intake correlated with HDAC activity (in PBMCs)
6405,NCT01077999,Percentage of pathologic complete responses,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity profile
6406,NCT04610086,Satisfaction,2020-11-19,UNKNOWN,OBSERVATIONAL,['NA'],,Participation in cancer decision making
6407,NCT03097666,Efficacy: Percent Eradication by therapeutic dose,2017-03-20,COMPLETED,INTERVENTIONAL,['NA'],,Efficacy: Treatment
6408,NCT04952688,retinal vascular density retinal vascular density,2020-12-14,RECRUITING,INTERVENTIONAL,['NA'],,
6409,NCT01342705,Cumulative incidence of HepatoCellular Carcinoma during follow-up,2011-05,TERMINATED,INTERVENTIONAL,['PHASE3'],,Number of Participants with Adverse Events as a Measure of Safety and Tolerability
6410,NCT01224392,reduction in metabolic tumor activity,2010-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,cost evaluation
6411,NCT03488537,sensitivity/specificity for CRC,2018-02-28,COMPLETED,INTERVENTIONAL,['NA'],,Sensitivity/specificity for detection of CRC and/or polyps before and after bowel preparation
6412,NCT04660058,corelation between the bile acid profile and gastric microbiota in different groups,2020-12-20,COMPLETED,OBSERVATIONAL,['NA'],,
6413,NCT02812628,3-year local recurrence,2012-12,UNKNOWN,INTERVENTIONAL,['NA'],Perforation rate,3-year disease-free survival
6414,NCT05608967,Usability,2021-09-01,RECRUITING,OBSERVATIONAL,['NA'],,Complications
6415,NCT03642067,Cohort C: Objective response rate (ORR),2019-02-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants experiencing study drug-related toxicities
6416,NCT01621295,Frequency/duration/content of routine cancer consultations surrounding key topics in the clinical dialogue.,2012-05,COMPLETED,OBSERVATIONAL,['NA'],,
6417,NCT03426904,Relapse free survival after randomization,2018-10-24,RECRUITING,INTERVENTIONAL,['PHASE3'],,Pathological tumor stage
6418,NCT02407561,Gene expression profiling will be undertaken to determine if RNA is a superior biomarker to protein,2015-02,TERMINATED,OBSERVATIONAL,['NA'],,
6419,NCT00379743,Difference between the two intervention groups in the proportion of participants who complete at least one of the recommended screenings.,2006-10,COMPLETED,INTERVENTIONAL,['NA'],,Stage at diagnosis.
6420,NCT05415345,evaluate the concentration of IgG antibodies to HEV,2021-10-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],,Serious adverse events occurred throughout the study
6421,NCT03619668,Changes in position and shape of the tumour during RT.,2018-06-29,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Change in functional imaging parameter: Ktrans.
6422,NCT03727763,Objective Response Rate(ORR),2018-10-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,adverse events
6423,NCT04670445,"Change in participant knowledge, using the Immunotherapy Knowledge Assessment",2021-01-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Patient questions asked in visit with oncologist
6424,NCT03667911,Boston bowel preparation score,2018-09-15,UNKNOWN,INTERVENTIONAL,['NA'],,cecal intubation rate
6425,NCT00003864,,1999-09-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6426,NCT03069664,Change in experienced quality of life,2017-11-17,RECRUITING,INTERVENTIONAL,['NA'],,Change in need for pancreatic enzyme supplements
6427,NCT04103567,"The ratio between the proportions of poor response to neoadjuvant treatment in populations so-called ""exposed"" (patients colonized by bacteria producing toxins (cyclomodulin) and unexposed (patients not colonized by bacteria producing toxins)",2020-01-14,RECRUITING,INTERVENTIONAL,['NA'],,Types of other bacteria forming the overall bacterial composition before neoadjuvant treatment
6428,NCT05317325,The number of treatment-related adverse events,2022-04-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Disease-free Survival
6429,NCT00001568,,1997-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6430,NCT01477814,colorectal cancer screening,2008-07,COMPLETED,INTERVENTIONAL,['NA'],,cost-effectiveness of various strategies for screening
6431,NCT04406831,Analysis of miRNA profile,2015-04,RECRUITING,OBSERVATIONAL,['NA'],,miRNA PCR expression
6432,NCT04229004,Overall Survival,2020-01-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Duration of Clinical Benefit
6433,NCT02375880,"Composite Safety parameters as assessed by new or changing physical examinations, vital signs, electrocardiograms (ECGs), clinical laboratories, concomitant medication reviews, and assessment of adverse events.",2015-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Efficacy - Response to treatment evaluated using the Response Evaluation Criteria in Solid Tumors guidelines (RECIST 1.1)
6434,NCT06152419,Patient questionnaire on radiotherapy-related anxiety,2023-10-17,RECRUITING,INTERVENTIONAL,['NA'],,
6435,NCT05252078,DFS,2022-06-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,3-year OS rate
6436,NCT06109467,Objective Response Rate (ORR),2024-01-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
6437,NCT03323996,Semi-Structured interviews,2017-07-26,UNKNOWN,OBSERVATIONAL,['NA'],,
6438,NCT02863770,"The yield of EUS versus contrast EUS to diagnose pancreas cystic lesions, mass lesion, and origin of pancreatitis.",2016-07,RECRUITING,INTERVENTIONAL,['NA'],,Quantitative Parameters of Pancreas Lesions
6439,NCT03436563,Clearance of circulating tumor DNA (cohort D),2018-03-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease-Free Survival (DFS) - cohort D only
6440,NCT02958683,Change in volume of each thoracoabdominal compartment during breathing,2011-07,COMPLETED,OBSERVATIONAL,['NA'],,Synchrony of chest wall movement
6441,NCT00949273,postoperative complications,2009-07,UNKNOWN,OBSERVATIONAL,['NA'],,3-years overall survival
6442,NCT00780169,"Toxicity spectrum of Sorafenib (MTD, DLT) and the recommended dose (RD) for phase II studies of Sorafenib when combined with FOLFIRI in first line patients with metastatic colorectal cancer (mCRC)",2008-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to Progression and Overall Survival
6443,NCT02522520,Maximum oxygen uptake - ( VO2 peak),2015-06,COMPLETED,INTERVENTIONAL,['NA'],,Pedometer Step Count
6444,NCT02987296,"NK cell killing as measured on peripheral blood mononuclear cells (PBMC) between the control (placebo) and experimental cohorts, using a standard NK cell killing assay.",2017-03-01,COMPLETED,INTERVENTIONAL,['NA'],,Compliance with perioperative arginine supplementation
6445,NCT01666184,,2012-09,UNKNOWN,OBSERVATIONAL,['NA'],,
6446,NCT00389935,Blood Transfusion requirements,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Hemoglobin overall complication rate Constipation Neuropathy
6447,NCT03132922,Measurement of RCL in genetically modified T cells.,2017-05-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],MAGE-A4c1032T cell trafficking in tumor lesion(s).,Number and % of subjects having any Long Term Follow Up Adverse Events (AEs)
6448,NCT05484687,the concentration of tumor micrometastasis markers were determined by ELISA,2020-03-24,COMPLETED,INTERVENTIONAL,['NA'],,the concentration of immune indexes were determined by ELISA
6449,NCT03217643,Evaluate the 2-year progression-free survival,2018-02-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
6450,NCT02017015,Overall Response Rate (ORR) Based on Independent Radiological Review (IRR),2013-12-24,COMPLETED,INTERVENTIONAL,['PHASE2'],,Kaplan-Meier Estimate of Overall Survival (OS)
6451,NCT02433938,bowel function recovery (Time to first bowel movement or flatus),2015-07,COMPLETED,INTERVENTIONAL,['NA'],,Use of NG Tubes (Nasogastric tube (re)insertions)
6452,NCT05030246,Overall Survival (OS),2021-07-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],,adverse events
6453,NCT04666558,Lower Extremity Functional Scale (LEFS),2020-11-30,COMPLETED,INTERVENTIONAL,['NA'],Program acceptability (Unified Theory of Acceptance and Use of Technology - UTAUT),General health-related quality of life (5-Level EQ-5D [EQ-5D-5L])
6454,NCT03144765,Quality of Mesorectal Excision,2018-01-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,3-year oncologic outcomes
6455,NCT03800602,Overall response rate (ORR),2019-01-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Biological response: carcinoembryonic antigen (CEA)
6456,NCT05138094,Time to functional recovery,2021-08-06,RECRUITING,INTERVENTIONAL,['NA'],,Three and five-year overall survival
6457,NCT00702884,Progression-free Survival Rate,2008-06-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quantitative Assessment of Proliferating Tumor Cells and Apoptosis
6458,NCT03448341,To assess the changes of deglutition function by means of Videofluoroscopy (VFS) from before to after radiochemotherapy,2016-07-16,COMPLETED,OBSERVATIONAL,['NA'],,"To correlate radiation dose features received by the different swallowing related structures (SWOARs) to the changes of MDADI, FEES and VFS scores from before to after treatment by using a Machine Learning Methodology"
6459,NCT06326437,the Kessler psychological distress scale-10,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Locke-Wallace Marital Adjustment Scale
6460,NCT02460198,Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor,2015-08-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Response (DOR) Per RECIST 1.1 as Assessed by the Central Imaging Vendor
6461,NCT05732181,Pain severity,2017-05-09,COMPLETED,INTERVENTIONAL,['NA'],,
6462,NCT02010567,Pathological Complete Response (pCR) Rate,2013-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS) Based on Pathological Complete Response (pCR).
6463,NCT04337879,Progression-free survival (PFS),2020-07-20,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Duration of response (DOR)
6464,NCT00898768,"The main outcome measure will be the number of neoplastic small bowel lesions, with determination of size, location and histological characteristics at baseline and at follow-up after 2 years.",2009-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,The secondary endpoint will be the number of complications following endoscopic procedures: rates of capsule retention and postpolypectomy bleeding and perforation.
6465,NCT05257135,Number of biological risk factors for colorectal cancer,2021-12-23,RECRUITING,INTERVENTIONAL,['NA'],,
6466,NCT00686569,Early detection of postoperative complications,2007-04,COMPLETED,OBSERVATIONAL,['NA'],,
6467,NCT00390416,1-year Survival,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Patients With Measurable Disease the Confirmed Response Rate
6468,NCT02870010,Tolerance: toxicities will be defined according to the scale: National Cancer Institute - Common Toxicity Criteria for Adverse Events (NCI CTC AE v3.0) to determine the limiting dose,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6469,NCT01679756,Overall surgical morbidity,2013-03,UNKNOWN,INTERVENTIONAL,['NA'],,Readmission
6470,NCT01938313,Recovering Rate,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life
6471,NCT06115174,Difference in overall survival 'OS' between the two groups.,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],,
6472,NCT05901519,Mitigation of liver inflammation as reflected by sTNFR1 levels,2024-02-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Assess tumor response
6473,NCT03310632,tumor assessment in millimeters,2017-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Eastern Cooperative Oncology Group (ECOG) status
6474,NCT03038100,Overall Survival - PD-L1-Positive Subpopulation,2017-03-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab
6475,NCT02839954,Phase I: Adverse events attributed to the administration of the anti-MUC1 CAR-pNK cells,2016-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II: Objective Response Rate
6476,NCT06037343,Hypervascular capsule,2023-02-23,RECRUITING,OBSERVATIONAL,['NA'],,Infiltrative nature Classification of the hepatic lesion by LI-RADS in MRI
6477,NCT05168163,Progression-free survival (PFS),2022-05-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events (AEs)
6478,NCT00696696,4-month Progression Free Survival (PFS) Rate,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival (mOS)
6479,NCT06206707,Clinical remission of immune-mediated diarrhea,2024-01-23,RECRUITING,INTERVENTIONAL,['NA'],,Endoscopic remission
6480,NCT01130142,Overall survival comparison,2010-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Comparison of PFS, TTP and ORR"
6481,NCT03065868,Compare regression rate of gastric polyps between H. pylori eradication and non-eradication groups. Regression of gastric polyp: one of below 1) Disappearance of gastric polyp 2) Reduction of polyp size over 50%,2015-12-09,COMPLETED,INTERVENTIONAL,['PHASE4'],,
6482,NCT04139135,EFS,2019-12-12,RECRUITING,INTERVENTIONAL,['PHASE3'],,5-year OS rate
6483,NCT05278078,"Expression analysis of slimming myokines, cachectic factors, cytokines genes by Real-Time PCR",2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
6484,NCT05655780,Molecular profile of the tumor,2023-01-09,RECRUITING,OBSERVATIONAL,['NA'],,
6485,NCT04547725,6-month disease control rate,2020-09-16,RECRUITING,INTERVENTIONAL,['NA'],,Safety evaluation
6486,NCT05053191,Frequency of nurses' use of family centered care practices,2021-09-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
6487,NCT02704130,Intrahepatic Disease-free Survival,2016-03,TERMINATED,INTERVENTIONAL,['NA'],,Postoperative Morbidity
6488,NCT05497726,Safety of SLN(s) or lymph node metastases with intravenous bevacizumab-800CW,2023-01-27,COMPLETED,INTERVENTIONAL,['NA'],,Number of SLN identified
6489,NCT02110082,"The primary safety endpoint is the incidence, potential significance, and clinical importance of adverse events",2014-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Trough observed concentration (Cmin) of BMS-663513 in combination with Cetuximab
6490,NCT02012023,mortality,2014-01,COMPLETED,INTERVENTIONAL,['NA'],hospital costs,operation data
6491,NCT00553332,Objective Response Rate (CR and PR),2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Protein Levels of RAS/RAF/MEK/ERK Signaling Pathway Activation
6492,NCT02609451,Quality Of Life (GQLI - Questionnaire),2007-11,TERMINATED,INTERVENTIONAL,['NA'],,Quality Of Life (GQLI - Questionnaire)
6493,NCT02691052,Global Health Status/Quality of Life Score at 3 months,2014-12,COMPLETED,OBSERVATIONAL,['NA'],,Correlations of tumor response and survival with genetic alterations
6494,NCT06106750,Clinical success,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Adverse events
6495,NCT00813696,overall survival,2002-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],,time to progression
6496,NCT02198092,Septin9 Plasma Levels,2014-07,COMPLETED,OBSERVATIONAL,['NA'],Circulating Colonic Epithelial Cells at Blood Draws,Septin9 Levels Versus Circulating Colonic Epithelial Cell Numbers
6497,NCT03448549,3 year disease free survival,2018-01-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,The accuracy of assessment of preoperative CT images on the stage
6498,NCT04674228,Number of participants who required endoscopic resection of advanced upper gastrointestinal (GI) neoplasms,2021-05-07,COMPLETED,OBSERVATIONAL,['NA'],,Number of participants with evidence of progression of upper GI disease
6499,NCT01094561,S-MRCP and S-EUS Concordance,2006-07,COMPLETED,INTERVENTIONAL,['NA'],,The Positive Predictive Value of S-MRCP
6500,NCT03526952,Change in mutual identity from four different time points,2018-05-04,UNKNOWN,INTERVENTIONAL,['NA'],Therapeutic Alliance,Patients' change in adjustment to bladder cancer from four different time points
6501,NCT04224480,Number of CD8+ Ki67+ T cells found in resected tumour from subjects,2019-12-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
6502,NCT02301091,Overall survival rates,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Number of participants with adverse events
6503,NCT04599660,To evaluate the onset of other neoplasms in very-low and low risk GIST patients,2020-11-25,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival (OS).
6504,NCT05006326,Sensitivity and specificity of 68Ga-PSMA PET/MR for diagnosis and staging in hepatocellular carcinoma.,2021-08-16,UNKNOWN,INTERVENTIONAL,['NA'],,Correlation of 68Ga-PSMA uptake in HCC patients with PSMA expression levels in tissues.
6505,NCT03188432,Quality of life (QOL) assessed using Functional Assessment of Cancer Therapy-Ovarian questionnaire,2017-10-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Response rates evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
6506,NCT02347904,The percentage of patients completing the preplanned number of 6 cycles of SOX.,2014-12,COMPLETED,INTERVENTIONAL,['PHASE1'],AUC of S-1,Overall survival
6507,NCT02423226,Progression free survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Treatment related adverse events
6508,NCT04042298,Brachial artery flow mediated dilation (FMD),2019-06-25,UNKNOWN,OBSERVATIONAL,['NA'],,Arterial blood pressure
6509,NCT05121571,Progression free survival,2016-04-21,COMPLETED,INTERVENTIONAL,['NA'],,tumor response
6510,NCT03502317,Global Health Score,2018-08-14,UNKNOWN,INTERVENTIONAL,['NA'],,Health care utilization
6511,NCT03936179,overall survival rate,2018-08-01,UNKNOWN,INTERVENTIONAL,['NA'],,acute and late toxicities
6512,NCT00647153,Tumor targeting properties of iodine I 123 anti-CEA recombinant diabody T84.66,2006-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Safety of iodine I 123 anti-CEA recombinant diabody T84.66
6513,NCT00473941,Depressive symptoms,2005-09,COMPLETED,INTERVENTIONAL,['NA'],,
6514,NCT00149578,chemotherapy and concurrent chemoradiotherapy in locally advanced pancreatic cancer. .,2004-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"The secondary end points are to evaluate the distant metastasis rate and time to tumor progression, overall survival time and quality of life after induction"
6515,NCT01309126,Overall Survival (OS),2011-04,TERMINATED,INTERVENTIONAL,['PHASE3'],,Change in Quality of Life
6516,NCT01880918,The rate of anastomotic leakage.,2012-10,UNKNOWN,OBSERVATIONAL,['NA'],,Rate of other device related complications and measures during hospitalization and post procedure.
6517,NCT02832882,12 month local tumor progression (LTP) rate,2016-10-21,COMPLETED,INTERVENTIONAL,['NA'],Technical efficacy 2,Technical success rate
6518,NCT02164136,Sexual function,2014-06,UNKNOWN,INTERVENTIONAL,['NA'],,5-year recurrence pattern
6519,NCT05721846,Adverse events,2023-05-03,RECRUITING,INTERVENTIONAL,['PHASE1'],,Disease control rate
6520,NCT03889626,Progression Free Survival (PFS),2019-03-22,UNKNOWN,INTERVENTIONAL,['PHASE3'],Adverse Events,Overall Survival (OS)
6521,NCT00686114,overall survival,2008-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Health-related quality of life
6522,NCT03564834,Postoperative complication rate,2018-08-23,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Postoperative pain
6523,NCT04668976,Percent frequency liver toxicity,2020-11-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression free survival
6524,NCT00061308,response rate,2002-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,response duration time to response time to progression survival safety
6525,NCT05180565,To measure the incidence of serious adverse events related to using the device,2019-12-18,COMPLETED,INTERVENTIONAL,['NA'],,To measure the patient tolerability of the device using a patient questionnaire
6526,NCT03653377,HPV vaccination,2018-12-17,COMPLETED,OBSERVATIONAL,['NA'],,
6527,NCT04696757,DFS,2018-02-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
6528,NCT06168084,Helicobacter pylori eradication,2023-06-06,RECRUITING,INTERVENTIONAL,['PHASE4'],,adverse events
6529,NCT00268463,Progression-free Interval (PFI),2006-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,"Quality of Life as Measured by the Functional Assessment of Cancer Therapy Trial Outcome Index at Baseline, at 4-6 Weeks Following Surgery (Before Initiation of Chemotherapy), and Periodically During Study"
6530,NCT04956640,To assess the antitumor activity of LY3537982 monotherapy in participants with advanced pancreatic cancer with KRAS G12C mutation,2021-07-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To characterize the PK properties of LY3537982: Maximum drug concentration (Cmax)
6531,NCT04948034,Objective Response Rate,2021-08-23,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Acute Toxicity
6532,NCT03959150,One year disease-free survival,2020-01-05,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Exploratory biomarkers
6533,NCT06189547,overall survival (OS),2023-02-02,COMPLETED,OBSERVATIONAL,['NA'],,cancer-specific survival (CSS)
6534,NCT04331184,Local tumor progression,2020-01-28,UNKNOWN,INTERVENTIONAL,['NA'],,technical success rate
6535,NCT05667259,Overall Survival,2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
6536,NCT01249638,TFS,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"ORR, OS, Quality of Life, PFS-1"
6537,NCT05322499,Objective response rate (ORR),2022-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
6538,NCT01704703,Objective response rate (TRO),2012-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse events
6539,NCT02848638,Degree and distribution of Y90 particle uptake,2012-07,COMPLETED,OBSERVATIONAL,['NA'],,
6540,NCT00568308,Disease-free Survival,2007-12,TERMINATED,INTERVENTIONAL,['PHASE3'],,Compliance
6541,NCT04212026,The objective response rate (ORR) after the 5th dose of nivolumab of the reference liver metastasis that was not biopsied.,2020-06-28,TERMINATED,INTERVENTIONAL,['PHASE2'],,Adverse events
6542,NCT02337673,Change of regional ventilation partition (ROI analysis in 8 pulmonary ROIs) from preoperative to postoperative state.,2014-05,COMPLETED,OBSERVATIONAL,['NA'],,Ventilator-obligatory-free days
6543,NCT03766776,PFS,2018-12-31,UNKNOWN,INTERVENTIONAL,['NA'],,
6544,NCT01335074,Maximum Tolerated Dose,2011-04,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall response rate
6545,NCT05742568,Changes in the diversity and structure of fecal microbiota,2022-12-01,RECRUITING,INTERVENTIONAL,['PHASE4'],,Eradication rate of Helicobacter pylori
6546,NCT01471470,R0 resection rate,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Angiogenetic biomarkers
6547,NCT00002883,,1996-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
6548,NCT05044676,Measurement of the phenotype of expression of CD226 3 weeks after the start of treatment,2023-09-08,RECRUITING,OBSERVATIONAL,['NA'],,Correlation between pathology features (tumoral and non-tumoral liver) and the frequency and phenotype of expression of CD226
6549,NCT00166465,Proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Confidence intervals for the true success proportion will be calculated using the exact binomial distribution.,2003-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6550,NCT05580445,Recommended phase 2 dose (RP2D) of CT-707 in combination with toripalimab and gemcitabine,2022-08-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Predictive biomarkers for response to the combination of CT-707, toripalimab and gemcitabine",Disease control rate (DCR) according to RECIST v1.1
6551,NCT03316053,Cell Markers,2017-11-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
6552,NCT02997956,Median Progression Free Survival,2017-07,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of patients alive at two years post treatment
6553,NCT01203163,Proportion of patients experiencing Adverse Reactions of Special Interest,na,WITHDRAWN,OBSERVATIONAL,['NA'],,Overall safety in patients with renal insufficiency (disease)
6554,NCT02704299,Progression-Free-Survival(PFS),2016-03,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Incidences of adverse events or serious adverse events
6555,NCT04112940,Amount of Residue in the Pharynx,2016-12-19,COMPLETED,OBSERVATIONAL,['NA'],,Number of Participants Reporting Dislike of Thickened Liquid Stimuli
6556,NCT02688712,Evaluation of pathologic response,2016-03-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Immunologic monitoring parameters
6557,NCT00209703,Incidence and severity of adverse event,2005-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Determine the clinical response rate, disease-free survival(DFS), overall survival(OS)"
6558,NCT01747642,Number of patients who have prolonged survival,2012-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Reduction in serum alpha-fetoprotein level and decrease in tumor size
6559,NCT04609813,Diagnostic performance of the sponge cytology-based machine learning model for the main target lesions,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Diagnostic performance of abnormal cell count
6560,NCT02385578,The rates of EGC detection,2015-03,UNKNOWN,INTERVENTIONAL,['NA'],,
6561,NCT00084461,Objective response rate,2004-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Incidence of toxicity
6562,NCT00594984,Safety and tolerability of interventions will be collected,2008-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Efficacy on tumor progression and progression free survival will be collected on all enrolled subjects
6563,NCT01982994,Percentage of patients with diagnosed gastrointestinal cancer who showed daily compliance using activity monitors and tablet computers to measure physical activity.,2013-10,COMPLETED,INTERVENTIONAL,['NA'],,Percentage of patients with a diagnosis of gastrointestinal cancer that benefit from an intervention of physical activity daily planning and education.
6564,NCT00004909,,1999-11,COMPLETED,OBSERVATIONAL,['NA'],,
6565,NCT00687843,Relapse-free survival,2008-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"Overall survival, quality of life, drug compliance, adverse events, serial changes of tumor markers"
6566,NCT02018107,"Number and Percentage of Tumors With Complete, Circumferential Ablation Margin Visibility During FDG PET/CT-guided Liver Ablations (AP-PET-1 v. Contrast-enhanced MRI)",2014-01,COMPLETED,INTERVENTIONAL,['NA'],,Does an Inadequate Ablation Margin on PET Predict Local Progression? Compare to MRI?
6567,NCT01032057,Progression-free survival at 39 weeks (from registration) according to RECIST criteria,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Radiotherapy quality assurance (adherence to protocol)
6568,NCT01191632,Purpose of the study is the determination of an active local external beam radiotherapy dose leading to a maximal number of tumor infiltrating T-cells. The total T-cell activity serves as primary surrogate parameters for anti- tumor activity,2010-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"To determine the number of patients with adverse events as a measure of safety and tolerability according to CTCAE, Version 4.0 criteria"
6569,NCT00730860,disease free survival,2009-12,UNKNOWN,INTERVENTIONAL,['NA'],,overall survival
6570,NCT01313078,"Evaluation of Safety in Patients With Ovarian, Fallopian Tube, and/or Primary Peritoneal Cancer.",2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6571,NCT00040183,,2001-11-29,COMPLETED,INTERVENTIONAL,['PHASE3'],,
6572,NCT01251237,Overall Acceptance on VAS (100mm) rating,2010-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Efficacy on five-grade scale for pre-defined colon areas
6573,NCT05438771,Oral Care Control Chart,2021-06-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],patient education,Number of participants with abnormal laboratory test results
6574,NCT04152265,Completion of the assigned screening strategy,2019-11-01,UNKNOWN,INTERVENTIONAL,['NA'],,Determination of anthropometric data
6575,NCT02517268,Percentage of Patients Discharged by Post-operative Day 5,2015-06-24,COMPLETED,INTERVENTIONAL,['NA'],,"Incidence of Post-operative Complications (DGE, Anastomotic Leaks, Intra-abdominal Abscesses, Wound Infection, UTI, Respiratory Compromise, Renal Failure, Etc.)"
6576,NCT05205330,Disease Control rate (DCR),2021-11-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Safety and Tolerability of CR6086 combined with AGEN2034
6577,NCT04798898,Overall survival,2022-11-14,RECRUITING,INTERVENTIONAL,['NA'],Complications,Recurrence rate
6578,NCT05352204,overall survival,2020-04-30,COMPLETED,OBSERVATIONAL,['NA'],,disease-free survival
6579,NCT00227617,Best Objective Response,2005-06-08,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Biochemical Marker Response
6580,NCT00875615,Number of Subjects Experiencing Adverse Events,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients Achieving Clinical Benefit
6581,NCT00004102,,1999-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6582,NCT04952753,Expansion: Progression-free survival (PFS) by investigator assessment per RECIST 1.1,2021-11-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,ADA incidence on treatment
6583,NCT03646591,Completion rate of preoperative FLOT regimen,2017-11-15,COMPLETED,OBSERVATIONAL,['NA'],,Postoperative mortality
6584,NCT00554372,Proportion of Subjects Achieving Disease Control (Non-progressive Disease) at 8 Weeks After Initiation of Treatment,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival
6585,NCT03463616,Percentage of patients who needed additional radiology examination/s before treatment planning after routine MRI of abdominal organs compared with routine CT of abdominal organs.,2018-03-15,COMPLETED,OBSERVATIONAL,['NA'],,Disease free survival after 3 years
6586,NCT06061432,Rate of complications during endoscopic gastrointestinal anastomoses using transmural self-expandable prostheses to restore the gastrointestinal continuity in patients after Hartmann procedure (Endo-HARP),2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Rate of clinical success of endoscopic gastrointestinal anastomoses using transmural self-expandable prostheses to restore the gastrointestinal continuity in patients after Hartmann procedure (Endo-HARP)
6587,NCT04697303,Overall survival,2020-10-26,COMPLETED,OBSERVATIONAL,['NA'],,FSFI-6
6588,NCT04569331,Quality of life related to health (European Organization for the Research and treatment of Cancer Quality of Life Questionnaire (QLQ-CR29).,2020-05-15,COMPLETED,INTERVENTIONAL,['NA'],Percentatge of patients with postoperative paralytic ileus,Low anterior resection syndrome (LARS)
6589,NCT04892927,Improved information sharing,2021-05-03,UNKNOWN,OBSERVATIONAL,['NA'],,
6590,NCT00155558,To determine the maximum tolerated dose and dose limiting toxicity,2001-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,response
6591,NCT02531607,Sensitivity and specificity of biomarkers in the diagnosis of cancer,2014-11-13,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Medical Record Review
6592,NCT05638438,the objective response rate (ORR),2022-12-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Adverse events
6593,NCT05448222,progression free survival,2022-07-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Hospital cost
6594,NCT04107077,The PD-L1 expression can be upregulated after administration of HIPEC with greater frequency,2019-11-11,RECRUITING,INTERVENTIONAL,['PHASE2'],,Perioperative mortality at 30 days
6595,NCT01385748,Cumulative Radiation Dose at Which Severe Oral Mucositis (World Health Organization [WHO] Score ≥ 3) Was First Observed,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Treatment Compliance According to the Patient Diary,Overall Survival
6596,NCT00897494,Analysis of serum proteins directly by mass spectrometry to identify new biomarkers of pancreatic cancer that can be used for early diagnosis,2005-02,COMPLETED,OBSERVATIONAL,['NA'],,
6597,NCT06196671,Overall survival，OS,2024-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,disease control rate (DCR)
6598,NCT01528059,Glycemic control,2012-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Nutritional status assessment
6599,NCT02502760,Post operative complications,2015-08,COMPLETED,INTERVENTIONAL,['NA'],Cost Effectiveness of treatment,Health Related Quality of Life
6600,NCT06332716,Progression-free survival（PFS）,2022-08-26,RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall survival（OS）
6601,NCT01844375,Meters Walked During 2-Minute Walk Test,2013-05,COMPLETED,INTERVENTIONAL,['NA'],,Nitrogen Balance
6602,NCT04024345,Multidimensional Scale of Perceived Social Support,2017-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,
6603,NCT00357474,overall survival rate,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Disease free survival rate and recurrence rate
6604,NCT03599362,Number of Participants Who Proceeded to Surgical Resection,2018-07-31,TERMINATED,INTERVENTIONAL,['PHASE2'],,
6605,NCT00732745,Progression-free survival (Phase II) at 5 months,2008-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,Correlation of tumor characteristics and tumoral expression with response and outcome (Phase II)
6606,NCT01264952,"Evaluation of Toxicity Related to Electrochemotherapy (Toxicity, Symptoms)",2008-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Treatment Evaluation of Tumor Response - Measurements of Tumor Lesions by Contrast Enhanced Ultrasonography (US-Doppler), Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Histology"
6607,NCT02005419,Recurrence-free survival at one year after curative resection,2013-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of grade 3 and 4 toxicities according to NCI CTCAE version 4.0
6608,NCT06130644,MSI status,2003-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Tumor Mutation Burden (TMB)
6609,NCT02809287,Blood loss,2015-01,COMPLETED,OBSERVATIONAL,['NA'],,
6610,NCT03428126,Immune-related Best Overall Response Rate.,2018-03-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Control Rate
6611,NCT05314101,progression free survival,2022-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival (OS),Objective Response Rate (ORR)
6612,NCT01723969,Tumour markers assessment,2013-09,COMPLETED,OBSERVATIONAL,['NA'],,
6613,NCT02556281,Number of patient with a first relapse,2012-10-15,UNKNOWN,INTERVENTIONAL,['NA'],,Number of free tumoral DNA in blood of patient with colorectal cancer
6614,NCT04489238,Establish a prospective database of patients with Young Onset Colorectal Cancer,2020-07-22,RECRUITING,OBSERVATIONAL,['NA'],,
6615,NCT00107250,Dose limiting toxicity,2005-01-21,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumour Response
6616,NCT04755907,Response of 3D tumor models/organoids to the same chemotherapy drugs as the corresponding patients.,2021-03-01,RECRUITING,OBSERVATIONAL,['NA'],Response of the colorectal cancer patients to adjuvant chemotherapy.,Response of the colorectal cancer patients to neoadjuvant chemotherapy.
6617,NCT04111692,Change in Polycystic Liver Disease Quality of Life,2017-11-06,RECRUITING,OBSERVATIONAL,['NA'],,
6618,NCT04857528,Rate of Participants With Detectable Circulating HPV DNA in Blood/Tumor Samples,2020-10-06,RECRUITING,OBSERVATIONAL,['NA'],,Accuracy of HPV DNA Levels in Predicting Cancer Recurrence at 24 Months
6619,NCT00710632,"Clinical condition, defined as diagnosis and stage of disease, treatment, and performance status at baseline",2007-09,UNKNOWN,INTERVENTIONAL,['NA'],,
6620,NCT01183780,Overall Survival (OS),2010-12-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Observed Maximum Concentration (Cmax) and Observed Minimum Concentration (Cmin) of Ramucirumab
6621,NCT01203969,rate of 30 day morbidity and mortality,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Duration of postoperative hospital stay
6622,NCT05216653,The primary objective of the study is to evaluate the pathologic complete response (pCR) rate following short-course radiation then Envafolimab Plus CAPEOX,2022-04-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life of the patients in a neoadjuvant setting of short-course radiation then Envafolimab Plus CAPEOX as assessed by FACT-C questionnaire
6623,NCT05991544,Oral Mucositis Grading Index:,2023-11-01,RECRUITING,INTERVENTIONAL,['NA'],,
6624,NCT01034865,,2001-05,COMPLETED,OBSERVATIONAL,['NA'],,
6625,NCT04448652,Postoperative opioid-consumption,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],,mortality
6626,NCT04609137,"Number of patients (n, %) developing a clinically-relevant pancreatic fistula (CR-POPF)",2020-10-13,COMPLETED,INTERVENTIONAL,['NA'],,"Number of patients (n, %) requiring an unplanned hospital readmission after discharge"
6627,NCT00486954,Overall Survival (OS) in the Randomized Part of the Study,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Mutations That May Correlate With Response and Toxicity to Lapatinib
6628,NCT04484636,"Distribution of mutations in patients with HCC, intra- and extrahepatic CCA, GBCA, PDAC and gastric cancer",2020-10-28,RECRUITING,INTERVENTIONAL,['NA'],,Number of patients receiving therapies in accordance to their genomic profiles
6629,NCT04090450,MR radiomics extracted features.,2019-09-23,UNKNOWN,OBSERVATIONAL,['NA'],,
6630,NCT04672005,Time to treatment failure (TTF),2021-01-06,RECRUITING,INTERVENTIONAL,['PHASE2'],Correlation between variation of ctDNA and progression free survival,Correlation between variation in variant allele fraction (% cfDNA) or amplifications and tumor objective response during chemotherapy
6631,NCT05537129,3 year-DFS,2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],,morbidity and mortality rates
6632,NCT01734967,"Describe confocal imaging criteria for pancreatic masses, lymph nodes or liver metastases",2012-11,COMPLETED,INTERVENTIONAL,['NA'],,Feasibility
6633,NCT06138028,PFS,2023-09-20,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,toxicities
6634,NCT04603339,Feasibility - acceptability of the intervention (2),2021-05-01,COMPLETED,INTERVENTIONAL,['NA'],,Bio-sample Collection
6635,NCT06121089,Disease-free survival.,2022-09-01,RECRUITING,INTERVENTIONAL,['NA'],Quality of life in patients after ICR and RHC using questionnaire.,Number of days of inpatient treatment.
6636,NCT06231524,Overall survival,2024-02-01,RECRUITING,OBSERVATIONAL,['NA'],,Progression-free survival
6637,NCT02195180,Progression free survival (PFS),2014-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life status
6638,NCT01049620,To assess the maximum tolerated dose (MTD),2010-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Response rate
6639,NCT03848962,Collection of Biospecimens for Novel Research Uses,2016-06-30,RECRUITING,OBSERVATIONAL,['NA'],,
6640,NCT04006301,Part 2: Overall Response Rate (ORR),2019-07-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,Change From Baseline in QTc Interval Based on the Fridericia Correction (QTcF) Method
6641,NCT03416803,2-year overall survival,2018-02,UNKNOWN,INTERVENTIONAL,['NA'],,
6642,NCT01704664,Phagocytic activity of blood platelets in gastric cancer patients.,2007-03,UNKNOWN,INTERVENTIONAL,['NA'],,
6643,NCT00066274,,2002-07-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6644,NCT04749862,Participant Recruitment,2021-03-22,RECRUITING,OBSERVATIONAL,['NA'],Information systems,Intervention implementation process measures: frequency of reported problems
6645,NCT04822506,time to first flatus (TFF),2021-07-31,RECRUITING,INTERVENTIONAL,['NA'],,Adverse Event Assessment
6646,NCT00445861,"Determine the safety of neoadjuvant radiotherapy in combination with cetuximab, docetaxel, and cisplatin",2007-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determine the duration of response and patterns of failure
6647,NCT01008475,Randomized Part: Progression Free Survival (PFS),2009-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to Treatment Failure (TTF)
6648,NCT03926039,Decisional Conflict Scale,2019-05-01,COMPLETED,INTERVENTIONAL,['NA'],Decision Regret Scale,Liver Cancer Treatment Options Related Knowledge Scale
6649,NCT03109639,Tissue adequacy rate will be measured by assessing for the presence of histological core tissue representative of the lesion in the samples obtained using the two needles,2017-04-13,COMPLETED,INTERVENTIONAL,['NA'],,Qualification of the sample obtained using the two needles will be performed by spectroscopic analysis.The ratio of absorbance at 260 nm and 280nm; the ratio of absorbance at 260nm and 230nm will be measured
6650,NCT03685591,"Number of Participants With Tumor Reponse per PCWG2 and RECIST v1.1 (Parts 2A, 2B)",2018-10-04,TERMINATED,INTERVENTIONAL,['PHASE1'],,"Median Intra-Tumor T cells (Parts 2A, 2B)"
6651,NCT04371042,Registry creation,2019-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
6652,NCT04002778,Procedure duration,2015-08,COMPLETED,INTERVENTIONAL,['NA'],,Diagnostic yield
6653,NCT01596790,Predictive value of the CTC on the Progression Free Survival,2012-04,COMPLETED,INTERVENTIONAL,['NA'],,Comparison of the results with the CellSearch system vs EPISPOT
6654,NCT00113360,Progression Free Survival (PFS),2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6655,NCT00047229,Rate of objective response (complete and partial),2002-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety and tolerability
6656,NCT02013154,Number of subjects with treatment emergent adverse events related to study treatment (DKN-01 as monotherapy or in combination with paclitaxel or pembrolizumab),2014-05-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression Free Survival (PFS)
6657,NCT02101918,Objective Response Rate According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1,2014-06-18,COMPLETED,INTERVENTIONAL,['PHASE2'],Tumor Perfusion Parameters at Time of Progression,Baseline Permeability Surface (PS)
6658,NCT04254107,Number of participants with a dose-limiting toxicity (DLT) at each dose level,2020-05-29,TERMINATED,INTERVENTIONAL,['PHASE1'],,Number of participants with antidrug antibodies (ADA)
6659,NCT01708824,Whether the PA and dietary intake targets are met at the end of intervention;,2013-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Possible side effects arising from the intervention
6660,NCT05648006,Progression-free survival,2023-10-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,Toxicity by CTCAE v5.0
6661,NCT03589131,Operative time of robotic-assisted rectal cancer surgery.,2015-04-29,COMPLETED,INTERVENTIONAL,['NA'],,Accurate safety margin
6662,NCT01042028,Phase II: Progression-free survival as measured from inclusion to either documentation of disease progression or death,2010-01,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Survival All events grade 1-5 according to NCI-CTCAE in fase I All Adverse events grade 1-5 according to NCI-CTCAEW in Fase II Correlation between effect of treatment and tumourmarkers Quality of life - EORTC QLQ Time to failure of Strategy
6663,NCT00654342,Accuracy & sensitivity of sentinel lymph node mapping,2007-10,UNKNOWN,INTERVENTIONAL,['NA'],,
6664,NCT06075836,Reader speed with vs without AI assistance.,2023-10-31,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
6665,NCT02199002,acid pocket position,2014-07,COMPLETED,INTERVENTIONAL,['NA'],acid pocket contents,number of reflux episodes
6666,NCT00286130,the percentage of patients surviving without disease progression in each arm at 9 months,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety
6667,NCT02268006,Pathological complete remission rate (pCR),2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life
6668,NCT01628640,Tumor necrosis,2012-08-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
6669,NCT00898495,Comparison of pretreatment clinical tumor staging vs post-treatment pathologic staging (at resection),2007-05-11,COMPLETED,OBSERVATIONAL,['NA'],,
6670,NCT04110093,Progress Free Survival,2019-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Adverse Effect
6671,NCT04938986,Number of cases where the recommendations for patient care according to the Immunoscore® are considered beneficial compared to the standard care decision,2022-04-04,RECRUITING,INTERVENTIONAL,['NA'],,"Actual survival (patient alive without recurrence, alive with recurrence, dead)"
6672,NCT00022698,Tumor Response Rate Based on Tumor Measurement as Per Response Evaluation Criteria In Solid Tumors Version 1.0 (RECIST 1.0),2001-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Number of Participants With Any Adverse Events, Serious Adverse Events and Deaths"
6673,NCT04030624,The Feasibility of Remote Electronic Patient Monitoring Intervention,2020-09,WITHDRAWN,INTERVENTIONAL,['NA'],,Health Care Utilization
6674,NCT01339169,Visual assessment of the distribution of gastric carcinoids.,2011-01-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Plasma or serum concentrations of biomarkers such as gastrin or chromogranin A (CgA).
6675,NCT02809846,Change in Daily Opioid Use Assessed as Recorded by the Subject in Their Analgesia Diary.,2016-07,TERMINATED,INTERVENTIONAL,['NA'],,
6676,NCT06242457,Complete resection of adenocarcinomas located in the jejunum or ileum is associated with 5-year survival rates of 20% to 30%.,2023-07-15,COMPLETED,OBSERVATIONAL,['NA'],,
6677,NCT04430738,Incidence of dose alterations (Cohort 1D),2020-09-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Objective response rate (ORR) (Cohorts 1C, 1E, 1F, and 1G)"
6678,NCT00051987,,2002-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6679,NCT03005756,"Total radiation exposure (DLP, mGy*cm)",2017-01-25,UNKNOWN,INTERVENTIONAL,['NA'],,Procedure time
6680,NCT04471194,Difference in Percentage of Participants Who Completed Any Cervical PLUS Colorectal Cancer Screening Tests,2021-02-18,COMPLETED,INTERVENTIONAL,['NA'],,Difference in Percentage of Participants Who Completed At-home Cervical PLUS Colorectal Cancer Screening Tests
6681,NCT00039793,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6682,NCT00101998,"Change in weekly SCBM frequency. A SCBM is a spontaneous and complete bowel movement, which means a bowel movement that occurs with no laxative use in the prior 24 hours and leaves the subject with the feeling of complete evacuation of the rectum.",2003-10-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Additional measures of Bowel movement (BM) frequency and symptoms, safety profile of the treatment regimens and any changes in pain intensity or opioid use."
6683,NCT04348084,impact of clinically relevant (CR-) POPF,2009-01-30,COMPLETED,OBSERVATIONAL,['NA'],,identifying positive and negative prognostic factors
6684,NCT05943951,"the analysis of lymphadenectomy in the course of right hemciolectomy, in relation to the radicality of surgical resection that is performed",2022-04-01,COMPLETED,OBSERVATIONAL,['NA'],,Vascular anatomical variability
6685,NCT01460641,Tumor stage change from Computed Tomography (CT) perfusion measurement,2011-11,COMPLETED,OBSERVATIONAL,['NA'],,Tumor perfusion as measured by perfusion CT.
6686,NCT06069297,Cancer cachexia related factors,2023-07-14,RECRUITING,INTERVENTIONAL,['NA'],,Disease-specific health-related quality of life
6687,NCT05628038,Local objective response rate,2022-08-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and tolerability of the treatment
6688,NCT03831698,Retention rate of participants,2019-02-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Proportion of participants with treatment-related adverse events in each arm.
6689,NCT01541683,measurement of Palatability of the PEG-electrolyte solution,2012-01,COMPLETED,INTERVENTIONAL,['NA'],,Side effects
6690,NCT03298451,Overall Survival (OS) - Treme 300 mg x1 Dose + Durva 1500 mg vs Sora 400 mg,2017-10-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Summary of Tremelimumab Concentration Over Time
6691,NCT04683497,Number of new liver metastases identified using CE-IOUS,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,Number of new liver metastases using CE-IOUS in the subgroup of patients with missing metastases.
6692,NCT05375604,To characterize the safety and tolerability of CDK-004.,2022-06-28,TERMINATED,INTERVENTIONAL,['PHASE1'],,
6693,NCT00209651,objective tumor response,2004-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Response duration, time to progression, overall survival, and safety will also be assessed."
6694,NCT05299411,Serum Hb level,2023-04-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life associated anemia,Serum hepcidin level
6695,NCT01598077,Dose-limiting toxicities (DLTs),2012-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Serum concentration of LJM716,"
6696,NCT01346917,Prevalence of postoperative nausea and vomiting.,2011-04,COMPLETED,INTERVENTIONAL,['NA'],,Duration of postoperative hospital stay.
6697,NCT04144738,Specificity with the mt-sDNA 2.0 test,2019-11-15,COMPLETED,OBSERVATIONAL,['NA'],,Specificity for no colorectal neoplastic findings
6698,NCT01099631,Number of Participants With Dose Limiting Events to Determine the Maximum Tolerated Dose (MTD) of Salmonella Typhimurium,2010-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Peripheral Blood T Cells Count
6699,NCT00177242,Ascertain the median survival of advanced pancreatic cancer patients treated with Gefitinib and docetaxel.,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Determine the time course of serial CA19-9 measurements during treatment.
6700,NCT04295473,3-year survival rate,2020-03-02,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life in PGSAS-45 scale
6701,NCT05708872,Effect of methods of self-regulation of mental state on postoperative pain perception changes,2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Effect of methods of self-regulation of mental state on anxiety changes
6702,NCT01363739,Progression-Free Survival,2009-04,UNKNOWN,OBSERVATIONAL,['NA'],,Overal survival
6703,NCT01504711,Percentage of Participants With Control of Vomiting and Rescue Medication Control,2012-06,COMPLETED,INTERVENTIONAL,['NA'],,Overall Survival
6704,NCT05920863,Major pathological response,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Recurrence-free survival (RFS)
6705,NCT04436679,Relationship between known prognostic histological markers of pancreatic adenocarcinoma and patient survival.,2021-02-02,RECRUITING,OBSERVATIONAL,['NA'],,Relationship between newly described histological markers for pancreatic adenocarcinoma and patient survival.
6706,NCT03001726,overall survival,2017-01,UNKNOWN,OBSERVATIONAL,['NA'],adverse events,progression-free survival
6707,NCT03944447,Treatment of Symptoms,2018-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Monitoring Adverse Events
6708,NCT05350501,Response to treatment at 6 months,2023-03-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Immunogenicity and cross-reactivity
6709,NCT01360801,Accuracy of Agreement Between Imaging and Histology,2011-02,TERMINATED,OBSERVATIONAL,['NA'],,Presence of Residual Disease
6710,NCT04943419,Level of MDSC in patients with postoperative complications,2016-04-01,COMPLETED,OBSERVATIONAL,['NA'],,Level of MDSC in patients with left and right sided tumours
6711,NCT04851132,Progression-free survival (PFS),2021-03-11,UNKNOWN,INTERVENTIONAL,['NA'],Quality of Life (QOL): questionnaire EORTC QLQ-OES18,Quality of Life (QOL): questionnaire EORTC QLQ-C30 (version 3)
6712,NCT02195141,• Pathological complete remission rate (pCR),2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],• Disease-free survival,Number of participants with adverse events (according to the National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events v3.0 (CTCAE)
6713,NCT00716157,Assess incidence and patterns of nausea and vomiting in patients undergoing concurrent chemotherapy and radiation,2004-10,COMPLETED,OBSERVATIONAL,['NA'],,Study the incidence of mucositis and esophagitis
6714,NCT04482257,λz,2020-07-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
6715,NCT01125020,tumor recurrence and metastasis,2008-12,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative survival
6716,NCT00848783,Number of Patients With One-year Recurrence-free Survival,2008-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival Rate; Toxicity; Evaluation of Sites of Relapse of Failing Patients
6717,NCT02421354,"Objective Response Rate, Defined as Complete Remission + Partial Remission + Clinical Improvement",2015-05-14,TERMINATED,INTERVENTIONAL,['PHASE2'],,
6718,NCT03699319,MTD of CPI-613 when given in combination with mFOLFIRINOX,2018-12-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Surgical resection rates
6719,NCT02841800,survival benefit,2016-06,COMPLETED,INTERVENTIONAL,['NA'],,repeated biliary interventions
6720,NCT00003225,To assess the toxicity profile of Irinotecan and Ethyol when administered together on this schedule.,1997-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"To determine the clinical benefit of intravenous Irinotecan and Ethyol in patients with colorectal cancer, as measured by performance status, analgesic consumption, quality of life and survival."
6721,NCT06200363,Adverse event,2023-09-21,RECRUITING,INTERVENTIONAL,['PHASE1'],,Quality of life questionnaire (QLQ-C30)
6722,NCT02943837,"Diagnostic accuracy (proportion of correctly classified subjects (ture positive + true negative) among all subjects ) , compared to the gold standard diagnosis",2016-10-01,WITHDRAWN,INTERVENTIONAL,['NA'],,
6723,NCT03844620,"Treatment-related adverse events (TRAEs) of interest (grade 3/4 toxicity, intolerable grade 2 toxicity, or any toxicity requiring dose reduction) between arms",2019-01-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Proportion of patients referred to clinical trial
6724,NCT05212012,Disease control rate 12 weeks after randomization (ITT-population),2022-02-17,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Adverse events
6725,NCT04965597,Graft-Versus Host-Disease (GVHD)-Free Event-Free Survival (EFS),2022-04-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of cytomegalovirus (CMV) reactivation requiring therapy by day 180 post-HCT
6726,NCT02290977,Adverse event assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 after scheduled TACE-RT for HCC with PVTT,2014-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Radiologic response assessed by modified Response Evaluation Criteria for Solid Tumors (mRECIST) after scheduled TACE-RT for HCC with PVTT
6727,NCT03116984,3-year overall survival(OS),2017-01-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
6728,NCT00774839,Self-reported expenses associated with colon cancer treatment and living with this illness.,2008-10,COMPLETED,OBSERVATIONAL,['NA'],,"Identify the medical, social and economic risk factors that are most closely associated with perceived adverse impact on financial and social well-being and unmet resource and service needs."
6729,NCT04672603,Incidence of urinary dysfunction,2021-04-08,RECRUITING,INTERVENTIONAL,['NA'],,Positive Circumferential Resection Margin Rate
6730,NCT04842812,Safety of TILs/CAR-TILs treatment in advanced solid cancers,2021-01-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Primary clinical efficacy of the TILs/CAR-TILs treatment in advanced solid cancers
6731,NCT03023722,Response Rate as Measured Per RECIST 1.1 Criteria,2017-05-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Drug Toxicity
6732,NCT02013492,Effect of beta-adrenergic blockade on the host immune system,2014-01-21,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Overall survival
6733,NCT05836246,Quantitative ultrasound information,2020-09-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
6734,NCT04005170,clinical complete response rate,2019-06-25,COMPLETED,INTERVENTIONAL,['PHASE2'],The impact of IDO1 expression on clinical response,Incidence of treatment-related adverse events as assessed by CTCAE v4.0
6735,NCT05188573,Clinical performance of test: Specificity,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Stage Shift
6736,NCT02806076,12 month local tumor progression (LTP) rate,2016-07-01,UNKNOWN,INTERVENTIONAL,['NA'],Technical efficacy 2,Technical success rate
6737,NCT01313026,changes in LARS score,2011-01,TERMINATED,INTERVENTIONAL,['NA'],,Patient Satisfaction
6738,NCT00416507,,2000-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
6739,NCT04500392,The incidence of hypoxia,2021-05-06,RECRUITING,INTERVENTIONAL,['NA'],,Other adverse events include other adverse events recorded by tools proposed by the World Society of Intravenous Anesthesia International Sedation Task Force and HFNC supportive oxygen therapy-related adverse events.
6740,NCT03294252,Recommanded dose for the extension phase,2017-05-24,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-Free Survival
6741,NCT04993131,Overall survival,2021-09-01,RECRUITING,INTERVENTIONAL,['NA'],,Survival in relation to biological markers
6742,NCT04947995,The sensitivity and specificity of blood-based multi-omics assay for early detection of gastric cancer with comparison to EGD and/or histological diagnosis.,2021-06-15,UNKNOWN,OBSERVATIONAL,['NA'],,
6743,NCT00902902,,2008-01,UNKNOWN,OBSERVATIONAL,['NA'],,
6744,NCT05833672,ORR (objective response rate),2023-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,R0 resection rate
6745,NCT01584830,Overall Survival (OS),2012-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety variables will be summarized using descriptive statistics based on adverse events collection
6746,NCT02547142,Quality Of Life,2016-01-18,TERMINATED,INTERVENTIONAL,['NA'],,Total duration of time from date of metastatic diagnosis to date of death
6747,NCT04488159,Disease-free survival (DFS),2024-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Cost analysis
6748,NCT03824899,pathological response rate,2018-10-10,UNKNOWN,INTERVENTIONAL,['NA'],,
6749,NCT00815308,Number of Participants With Overall Response Rate (RR),2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With K-ras Gene Mutation
6750,NCT01929122,Stool Microbiome Composition and Metabolome,2010-08,COMPLETED,INTERVENTIONAL,['NA'],,"Navy Bean or Rice Bran metabolites in stool, urine and blood."
6751,NCT00492752,Overall Survival,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time of Maximum Concentration (Tmax) After 21 Days of Sorafenib Treatment
6752,NCT02129218,"Individual patient compliance, defined by following assigned target glycemic load index >= 75% of the time between weeks 4 and 12",2015-02-16,COMPLETED,INTERVENTIONAL,['NA'],Change in serum levels of proteins affected by carbohydrate metabolism,Hours of nutritionist time per week
6753,NCT03817567,Objective response rate (ORR),2018-07-17,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
6754,NCT04937738,Histopathological regression rate (Becker regression criteria),2021-07-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Median overall survival
6755,NCT01222208,Whole body protein balance,2011-03,COMPLETED,INTERVENTIONAL,['NA'],,Synthesis rates of hepatic secretory proteins
6756,NCT02299843,mortality during perioperation,2014-10,UNKNOWN,INTERVENTIONAL,['NA'],,
6757,NCT02984501,Incidence of Treatment-Emergent Adverse Events,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of Local-regional Tumor Control
6758,NCT00908752,"To compare the Overall Survival (OS) of HCC patients who receive brivanib as adjuvant treatments to TACE therapy, with the OS of HCC patients who receive matched placebo with TACE therapy",2009-07-20,COMPLETED,INTERVENTIONAL,['PHASE3'],,To evaluate the safety of brivanib in combination with TACE
6759,NCT01257035,Response to chemoradiotherapy measured by TRG,2010-11,TERMINATED,OBSERVATIONAL,['NA'],,Survival
6760,NCT02557061,Number of alive patients,2009-04,COMPLETED,INTERVENTIONAL,['NA'],,Rate of preoperative blood T-lymphocytes
6761,NCT05199584,Objective Response Rate (ORR),2022-05-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Change in steady-state exposure to study medication
6762,NCT00766155,Disease-free survival,2008-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Toxicity according to CTCAE v.3.0 weekly during treatment, at 4-8 weeks after surgery, at therapy completion, and every 6 months for 5 years after therapy completion"
6763,NCT05958550,Whether hypothermia occurs,2024-03-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
6764,NCT01598597,Percentage of subjects who complete the survey and who provide evaluable genetic information (DNA),2012-03,COMPLETED,OBSERVATIONAL,['NA'],,"Demographic distribution (age, sex) of subjects participating in this study"
6765,NCT04906174,Incidence of complications after liver resection,2021-04-10,RECRUITING,OBSERVATIONAL,['NA'],,
6766,NCT00646100,survival rates,2007-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,quality of life
6767,NCT01744054,Evaluate y90-PET/MRI and PET/CT for potential on reporting technical success of radioembolization,2012-10-25,TERMINATED,INTERVENTIONAL,['PHASE1'],,
6768,NCT05196867,Change in FIB-4 score,2022-02-11,RECRUITING,INTERVENTIONAL,['NA'],,
6769,NCT01525082,Radiographic Response (RR),2012-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,O6-methylguanine DNA Methyltransferase (MGMT) by Promoter Methylation
6770,NCT05551247,ORR,2022-09-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,SAE
6771,NCT03126435,Overall Survival,2018-10-16,COMPLETED,INTERVENTIONAL,['PHASE3'],"Change From Baseline in European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score",Serum Carcinoma Antigen 19-9 (CA 19-9) Response Rate
6772,NCT02564263,Overall Survival (OS) in All Participants,2015-12-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants Discontinuing Study Treatment Due an Adverse Event (AE)
6773,NCT02290574,Adverse Event of Laparoscopic TME and Hyperthermia With CCRT,2014-11,TERMINATED,INTERVENTIONAL,['NA'],,Pathologic Complete Response of Hyperthermia With CCRT
6774,NCT03365986,The incidence of hereditary colorectal cancer,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,cost-effect for hereditary colorectal cancer screening
6775,NCT02368977,Device usability factors,2013-11-12,UNKNOWN,INTERVENTIONAL,['NA'],,Patient safety assessed by number of subjects with adverse events as a measure of safety and tolerability
6776,NCT00288925,"Safety, Pharmacokinetics",2005-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Tumour shrinkage, Tumour objective response rate"
6777,NCT02724436,Postoperative complication,2012-12,COMPLETED,INTERVENTIONAL,['NA'],,
6778,NCT04328948,Major progression-free survival,2020-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Long term toxicity
6779,NCT02982486,Response to therapy as evaluated by RECIST 1.1,2017-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival
6780,NCT05540951,objective response rate,2018-06-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,
6781,NCT01043016,Maximum tolerated dose,2009-03,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Treatment efficacy as measured by computed tomography (CT) or magnetic resonance imaging (MRI) and endoscopy exam 3 weeks after the start of study treatment according to the Response Evaluation Criteria In Solid Tumors (RECIST) standard
6782,NCT04290806,Course of treatment (treatment reality),2019-12-04,RECRUITING,OBSERVATIONAL,['NA'],,
6783,NCT03141034,Progression-free survival (PFS),2017-11-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity and tolerability of regimen as measured by the count of the worst grade of adverse event experienced by each participant
6784,NCT00004911,,2000-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6785,NCT05663450,Rate of R1-resection during oncologic surgery,1996-05-01,COMPLETED,OBSERVATIONAL,['NA'],,Post-surgical survival
6786,NCT01436721,the size of any subphrenic collection or pleural effusion,2011-08,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,incidence of postoperative morbidity
6787,NCT04970498,Changes of ADC map of MRI,2021-02-01,UNKNOWN,OBSERVATIONAL,['NA'],,
6788,NCT02013050,Duration of Severe Oral Mucositis (SOM),2013-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Percent of Patients With RECIST 1.1 Classification of ""Complete Response"""
6789,NCT03738111,Maximum Tolerated Dose,2018-12,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Molecular Marker,Overall Survival
6790,NCT01456598,3 year relapse free survival,2011-11-21,COMPLETED,INTERVENTIONAL,['NA'],,3 years overall survival
6791,NCT05749900,"Phase II: Objective response rate, ORR",2023-03,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of Life (QoL)
6792,NCT03732235,time to progression,2018-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,Number of adverse events
6793,NCT00495625,Number of Participants With Progressive Disease (PD) at Interim Analysis,2006-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Serious Adverse Events (SAEs)
6794,NCT05397444,Hospital readmissions,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],,prolonged length of stay
6795,NCT03352349,Change of Portal vein pressure,2017-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse effect of Terlipressurinum
6796,NCT01032590,Impact of an Internet-based intervention on weight loss,2009-07,WITHDRAWN,INTERVENTIONAL,['NA'],,Potential moderators of weight loss
6797,NCT05141656,OS,2019-08-31,UNKNOWN,OBSERVATIONAL,['NA'],,PFS
6798,NCT05451901,Time to clinical success from randomization,2022-07-29,RECRUITING,INTERVENTIONAL,['NA'],,Morphological change of pancreas
6799,NCT02841865,Response to treatment,2015-07-24,COMPLETED,OBSERVATIONAL,['NA'],,Impact of Choi criteria and Progression of Disease
6800,NCT01888965,Biomarker Discovery,2013-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Safety
6801,NCT03856255,Mean Score Indicating Ease of Use in Taking a Picture That Included the Measuring Device and Polyp in Order to Photo-document the Measurement Reading,2019-06-24,TERMINATED,INTERVENTIONAL,['NA'],,Mean Difference in Size of Polyp
6802,NCT00588900,The Percentage of Patients Who Are Progression-free at 12 Weeks From the Start of Second-line Therapy,2008-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
6803,NCT01676194,Survival,2012-08,TERMINATED,INTERVENTIONAL,['PHASE3'],,Efficacy of TACE
6804,NCT01618643,"Timing of disappearance of aceto-whitening for Barrett's metaplasia, HGD and cancer",2010-11,UNKNOWN,OBSERVATIONAL,['NA'],,To differentiate mucosal neoplasia from invasive cancer
6805,NCT05152472,Progression-Free Survival (PFS),2022-01-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,Tolerability profile
6806,NCT00306137,Percent of patients requiring a blood transfusion anytime in the intra-operative or post-operative period,2005-12,TERMINATED,INTERVENTIONAL,['PHASE3'],,Health related quality of life measurements
6807,NCT03838796,Disease free survival,2019-01-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
6808,NCT00023933,Maximum tolerated dose of 131I-HuCC49^CH2 based on dose-limiting toxicities,2001-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Immune response
6809,NCT00316420,MTD and DLT for the combination therapy of gemcitabine and capecitabine,2003-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumor Response
6810,NCT00139633,local control at 4 years,2000-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
6811,NCT03419663,the relationship between overall cereal consumption and gastric cancer occurance,2017-09-12,COMPLETED,OBSERVATIONAL,['NA'],,the relationship between other grain and gastric cancer occurance
6812,NCT01776346,Progression to esophageal adenocarcinoma,2011-01,UNKNOWN,OBSERVATIONAL,['NA'],,"Evaluate the natural history of BE with and without treatment based on clinical, functional and economic outcomes of the cases"
6813,NCT01498289,Overall Survival (OS),2012-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs
6814,NCT03093688,Objective Response Rate (ORR),2017-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Progression-Free Survival (PFS),Tumor Marker
6815,NCT04117945,Overall survival (OS),2020-03-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
6816,NCT00123825,To determine the response rate of the combination gemcitabine and cisplatin in patients with advanced biliary tract and gallbladder cancers,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,To assess the biomarker CA 19-9 response to the regimen and to correlate the CA 19-9 response with radiologic response and survival
6817,NCT04490551,Yield of Advanced Neoplasia,2019-12-05,COMPLETED,INTERVENTIONAL,['NA'],,Yield of Proximally Located Advanced Neoplasia
6818,NCT02466113,Disease free survival,2016-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
6819,NCT03082495,Change in Cardiorespiratory fitness,2017-06-26,COMPLETED,INTERVENTIONAL,['NA'],Number of positive lymph nodes,Safety: Adverse event rate
6820,NCT01639352,Disease Control Rate (DCR),2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity Profile of Protocol Therapy
6821,NCT02394834,Overall survival (OS),2015-05-29,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,"Evaluation of the Relationship between a Change in Each Biomarker in Tumor Tissue at Baseline and the Discontinuation of the Protocol Treatment of the Main Study, and Efficacy Endpoints"
6822,NCT04810585,Progression free survival,2020-04-20,RECRUITING,INTERVENTIONAL,['PHASE4'],,Prognostic or Predictive Biomarker for Aflibercept (plasma biomarker)
6823,NCT05334719,Incidence of treatment-related adverse events (TRAE) that have led to treatment discontinuation,2022-02-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Incidence of Adverse Events (AEs)
6824,NCT00910676,To reduce by 30 % the frequency of folliculitis by a local corticotherapy beginning at the same time that the treatment by EGF-R inhibitors began,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,To assess the patient quality of life with the DLQI questionnaire
6825,NCT01684904,To assess overall survival of patients treated with proton-chemotherapy (PCT) followed by surgery in patients with resectable primary esophageal or esophagogastric cancer,2013-02-20,RECRUITING,INTERVENTIONAL,['NA'],,Number of participants with adverse events as a measure of safety and tolerability
6826,NCT03393182,Postoperative 30-day morbidity rate,2018-03-01,COMPLETED,INTERVENTIONAL,['NA'],,QOL measurement : EORTC QLQ-C30/STO22
6827,NCT06198400,Evaluation of the blood flow in pancreatic remnant with use of ICG,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Correlation between ICG perfusion and development of pancreatic fistula
6828,NCT05243966,Proportion of participants with treatment emergent adverse events during the study,2022-01-10,RECRUITING,OBSERVATIONAL,['NA'],,Percentage of split thickness skin graft take at 1 week post Matrix™ application
6829,NCT04197310,Objective Response Rate (ORR),2019-12-26,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants with Treatment Related Adverse Events
6830,NCT04640792,Comparison of the Adenoma Per Extraction (APE) between the two arms,2020-10-01,COMPLETED,INTERVENTIONAL,['NA'],,Comparison of the Adenoma Detection Rate (ADR) between the two arms
6831,NCT00052364,Time to progression,2002-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free survival
6832,NCT00469443,Time To Progression,2006-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Symptoms improvement
6833,NCT01641887,Participant Satisfaction,2014-01,UNKNOWN,OBSERVATIONAL,['NA'],,Patient decisions
6834,NCT04355156,Overall survival,2012-09-17,COMPLETED,INTERVENTIONAL,['PHASE2'],,Monitoring dose reductions and the reasons behind them
6835,NCT06242613,Compare robotic gastrectomy with the conventional laparoscopic approach in terms of oncologic safety.,2023-05-13,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Compare robotic gastrectomy with the conventional laparoscopic approach in terms of cost-utility outcomes.
6836,NCT06070623,Role of elastography and color Doppler to follow up after TACE.,2023-11-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
6837,NCT02759601,Determine Maximum Tolerated Dose,2013-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase I & II: To determine the impact of HDACi on anti-tumour immune responses.,Phase I & II: To determine pharmacokinetic parameters for tefinostat and CHR-2847 when administered orally at different dose levels and dose schedules.
6838,NCT00386399,6-month overall survival,2006-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,To explore pharmacogenetic factors that may influence the toxicity and efficacy of MMC in this patient population.
6839,NCT06110598,Relapse-free survival (RFS),2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
6840,NCT05970705,PFS,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],AE,DOR
6841,NCT01831310,neutrophil functions,2007-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,Length of stay
6842,NCT03721952,Hospital Anxiety and Depression Scale (HADS) - family,2019-04-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Key Implementation Outcomes,QUAL-E (Fam)
6843,NCT00335491,Patient perception and pattern of change,2006-03,COMPLETED,INTERVENTIONAL,['NA'],,Structural and function changes
6844,NCT01799044,Safety,2012-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Feasibility,Efficacy
6845,NCT04637698,The objective response rate of patients with pancreatic cancer receiving OH2 injection.,2021-02-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To evaluate the impact of OH2 in patients with pancreatic cancer on the quality of life
6846,NCT01568151,Number of participants who undergo colorectal screening because of interventions,2009-04,COMPLETED,INTERVENTIONAL,['NA'],,Number of problems associated with intervention program
6847,NCT03511703,overall survival,2018-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
6848,NCT05476796,Progression free-survival,2023-06-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life questionnaire - Core 30 (QLQ-C30)
6849,NCT05652894,Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Independent Review Committee(IRC),2022-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse events
6850,NCT05540925,Overall survival (OS),2022-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Local recurrence
6851,NCT02173990,Progression-Free Rate will be assessed according to RECIST 1.1 with central radiological review.,2014-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,Safety and tolerance
6852,NCT04966143,Overall Response rate（ORR）,2021-08-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
6853,NCT02023541,Overall survival,2014-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,Toxicity
6854,NCT05529940,2-year survival rate,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Response rate in neoadjuvant setting
6855,NCT02929797,Disease-free survival,2016-08,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Quality of life
6856,NCT02439580,Nutritional Status,2013-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Cytotoxicity
6857,NCT05211323,Progression free survival (PFS),2022-12-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall response rate
6858,NCT03144804,Overall Response Rate,2017-10-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Disease Control Rate
6859,NCT00165464,"To assess the response rate of patients with esophageal or gastric carcinoma to weekly Taxotere, Cisplatin, and Irinotecan (CPT-11).",2001-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,To assess the toxicity of this combination in esophageal or gastric carcinoma.
6860,NCT05635279,Death,2022-11-01,RECRUITING,OBSERVATIONAL,['NA'],,Censored
6861,NCT04753359,Exfoliated intestinal epithelial cell transcriptomics,2022-02-01,RECRUITING,INTERVENTIONAL,['NA'],Bowel habits,Fasting insulin
6862,NCT06229340,Objective response rate,2023-10-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
6863,NCT02013986,Change from baseline in salivary cortisol at the first day after surgery,2013-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Days of stay in intensive care unit (ICU) after surgery
6864,NCT00444093,Treatment Efficacy,2007-03-05,TERMINATED,INTERVENTIONAL,['PHASE3'],,Diarrhea Assessment
6865,NCT04180033,Diagnostic yield advanced colorectal neoplasia,2020-02-18,COMPLETED,INTERVENTIONAL,['NA'],,Burden of colonoscopy
6866,NCT06206096,ORR,2021-05-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Safety and tolerability by incidence, severity and outcome of adverse events"
6867,NCT03411707,"Sensitivity and Specificity of Multiple Screening Methods With Comparison to Colonoscopy, Both With Respect to Cancer.",2018-03-19,RECRUITING,OBSERVATIONAL,['NA'],,
6868,NCT00019006,,1995-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6869,NCT05062889,ct-DNA clearance rate after the end of target-driven adjuvant treatment (ERASE-CRC part 1 target-driven),2023-05-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival TD1 (OS-TD1)
6870,NCT02900664,Frequency of dose reductions,2016-08-23,COMPLETED,INTERVENTIONAL,['PHASE1'],,Presence and/or concentration of anti-CJM112 antibodies.
6871,NCT02150135,ECOG score change,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression free survival rate
6872,NCT00506207,Blood level of irinotecan and S-1 and their metabolites,2006-09,UNKNOWN,INTERVENTIONAL,['PHASE1'],,"Maximal response rate, progression-free survival, survival"
6873,NCT03246438,CRC screening completion,2017-11-14,COMPLETED,INTERVENTIONAL,['NA'],,Choice of screening test
6874,NCT02649569,Number of patients who successfully use the activity monitor (i.e. wearing the activity monitor throughout the treatment course),2015-06,COMPLETED,OBSERVATIONAL,['NA'],,
6875,NCT00960167,Maximally tolerated dose of RT,2009-09,UNKNOWN,INTERVENTIONAL,['PHASE1'],,"Tumor control, patterns of failure and survival"
6876,NCT05406167,Health Related Quality of Life (HRQOL) scores,2022-04-12,RECRUITING,OBSERVATIONAL,['NA'],,Long-term toxicities related to Radiotherapy
6877,NCT03704727,Intestinal permeability,2018-07-01,COMPLETED,INTERVENTIONAL,['NA'],,Gastrointestinal adverse events
6878,NCT05522738,RP2D,2022-08-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Safety and tolerance evaluated by incidence of SAE
6879,NCT04796454,Progression-free survival (PFS),2022-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Jaundice scale
6880,NCT02665312,Assessment of the incidence of cardiovascular events during the first three cycles of therapy with capecitabine or 5-FU,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],,
6881,NCT04023136,"Estimation of the intraoperative portocaval post-hepatectomy gradient This pressure differential is performed before the parietal closure, after resection. We consider that the simulation is accurate if the difference with the measurement is ≤ 4 mmHg.",2019-07-15,UNKNOWN,INTERVENTIONAL,['NA'],,Prediction of changes in portal vein flow
6882,NCT01186705,Overall Objective Response Rate (ORR),2010-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,
6883,NCT02624154,The survival rate,2015-12,UNKNOWN,OBSERVATIONAL,['NA'],,
6884,NCT01384253,Safety and tolerability: To measure the number of participants who experience adverse events after intraperitoneal (IP) administration of ²¹²Pb-TCMC-Trastuzumab.,2011-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics: To determine the plasma pharmacokinetics and assess the extent of exit of radioactivity from the peritoneal cavity by γ-camera imaging.
6885,NCT00303758,Overall survival,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Duration of hospitalization
6886,NCT00602147,Association between SNPs in genes that influence melphalan metabolism and development and/or severity of mucositis,2007-07,TERMINATED,OBSERVATIONAL,['NA'],,
6887,NCT03428477,Progression Free Survival (PFS),2018-05-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Change in lean body mass (exploratory endpoint),New Primary Cancers
6888,NCT02129322,Time to Recurrence (TTR),2015-07,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Circulative tumor cell (CTC) level change,Overall survival (OS)
6889,NCT01893294,"MTD of gemcitabine hydrochloride defined as the dose at which no more than 3 of 6 patients experience grade 3 or greater adverse events, as graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0",2013-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Incidence of delayed adverse events associated with this treatment, graded according to the NCI CTCAE v3.0"
6890,NCT02395705,Overall survival rate,2015-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,predictive factors
6891,NCT01721954,Overall Survival (OS),2013-05-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression-free Survival
6892,NCT01333917,Apoptosis,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants with Adverse Events
6893,NCT03096951,Change in cardiorespiratory fitness,2017-04-04,COMPLETED,INTERVENTIONAL,['NA'],,Adherence
6894,NCT02720926,Determine the recommended phase 2 dose of TKI258 in combination with XELOX (Capecitabine and Oxaliplatin),2011-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,Measure the Area under the plasma concentration versus time curve (AUC) of TKI258 at specific timepoints
6895,NCT02523911,Overall bowel cleansing,2016-03,WITHDRAWN,INTERVENTIONAL,['NA'],Degree of haziness,Number of patients completing the bowel preparation
6896,NCT05481476,objective response rate (ORR),2023-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,adverse events (AE)
6897,NCT01702116,measurement of circumferential resection margin,2011-07,UNKNOWN,INTERVENTIONAL,['NA'],,estimated blood loss
6898,NCT05232357,"Expression levels of PGP9.5, GFAP, VIP, nNOS, TH, ChAT and SOM of different gastrointestinal lesions",2022-03-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,
6899,NCT00297791,locoregional recurrence rate,2004-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,out-of-hospital postoperative costs
6900,NCT00462553,Maximum tolerated dose (MTD) determined according to dose-limiting toxicities (DLTs) graded using Common Terminology Criteria for Adverse Events,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival
6901,NCT01272791,Overall survival of patients with stage IV pancreatic cancer treated with gemcitabine alone or gemcitabine with bavituximab.,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety
6902,NCT02969148,the 3-year disease-free survival rate,2016-11,RECRUITING,INTERVENTIONAL,['NA'],the time of hospital stay,the number of bowel obstruction
6903,NCT03781193,Correlation between psychological predictors questionnaires outcome and quality of life,2018-03-06,UNKNOWN,OBSERVATIONAL,['NA'],,
6904,NCT03474861,The adverse events associated with infusion of the anticancer medication or the immune cells will be assessed.,2018-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Tumor Response of the treatment in patients with advanced gastrointestinal cancer.
6905,NCT05202236,objective response rate (ORR),2021-10-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,
6906,NCT06109207,Feasibility of combination camrelizumab and dalpiciclib as assessed by number of participants who experience adverse events,2023-10-31,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
6907,NCT02047305,Complete Response,2009-01,COMPLETED,INTERVENTIONAL,['NA'],,
6908,NCT02081469,To compare the HBV relapse rate during the follow-up period in HBV carriers with malignant tumor receiving tenofovir for 24 and 48 weeks after the end of chemotherapy.,2014-03-17,COMPLETED,INTERVENTIONAL,['PHASE4'],,"To estimate the efficacy of TDF during chemotherapy with after chemotherapy and post-chemotherapy,as measure by the HBV reactivation, clinical relapse and adverse events in all patients."
6909,NCT03645980,Phase II: Time to progression (TTP2),2018-10-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II: Adverse Events
6910,NCT01995240,"Reproducibility of DCE, T2* and DWI MRI in pancreatic cancer.",2013-04,COMPLETED,INTERVENTIONAL,['NA'],,"To explore the relation between in vivo measurements of tumor vascularity, hypoxia and stroma using DCE-MRI, T2* MRI and DWI and treatment outcome."
6911,NCT03779009,Tumor status of the sentinel lymph node (SLN) and other lymph nodes (LN's),2018-03-01,RECRUITING,INTERVENTIONAL,['NA'],,Immunological markers
6912,NCT03028155,Assessment of 3-month overall morbidity and mortality,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Assessment of health related quality of life (HRQOL): SF-36
6913,NCT06081647,The incidence of hypoxia,2023-10-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],The incidence of other adverse events,The incidence of severe hypoxia
6914,NCT04058964,Progression free survival (PFS),2020-02-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Overall survival,Incidence of adverse events
6915,NCT00982592,Median Progression-free Survival (PFS),2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of Toxicities (grades1 and 2)
6916,NCT01836120,Progression-free survival (PFS),2013-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
6917,NCT06030895,Safety Outcomes,2022-12-12,COMPLETED,INTERVENTIONAL,['NA'],,
6918,NCT00411112,Survival without recurrence after 3 years,2007-03,UNKNOWN,INTERVENTIONAL,['NA'],,
6919,NCT03482362,Doubling of progression free survival,2018-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],"Overall response rate of vinorelbine in patients with KRAS mutant, BRAF wildtype, BRAF-like colon cancer vs. KRAS wildtype, BRAF mutant, BRAF-like colon cancer.","Gene alterations/expression profiles (i.e. baseline, relapse) in tumor tissue upon progression"
6920,NCT05158907,Improvement in detection rate of adverse effects of patient reported adverse effect (AE) scale versus the standard CTCAE grading by a physician.,2021-11-23,SUSPENDED,INTERVENTIONAL,['NA'],,Reduction in cost of cancer care using patient reported AE scale.
6921,NCT02443948,Correlation of change in cf-DNA levels with disease status in GIST patients harboring specific DNA mutations,2014-06,UNKNOWN,OBSERVATIONAL,['NA'],,Correlation of the level of cf-DNA related to disease status in GIST patients harboring specific DNA mutations
6922,NCT05368805,PK parameter for dabigatran and rosuvastatin: Cmax:,2022-03-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,PK parameters of fruquintinib and metabolite M11: Cmax:
6923,NCT00229567,passage of stool.,2005-09,TERMINATED,INTERVENTIONAL,['NA'],,time to readiness for discharge from hospital
6924,NCT05296681,Tumor Response by RECIST v1.1 Criteria,2022-05-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,
6925,NCT00323011,,2006-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,
6926,NCT01291420,Immunogenicity of intradermal DC vaccination,2010-05-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6927,NCT01031056,None: Biospecimen will be collected for future research.,2010-01,WITHDRAWN,OBSERVATIONAL,['NA'],,
6928,NCT00518349,Patient Assessment of Pain Experienced During Colonoscopy,2003-08,COMPLETED,INTERVENTIONAL,['NA'],,
6929,NCT01668498,Percentage of patients developing no skin toxicity ≥ grade 2,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Skin-toxicity related dose reductions of panitumumab
6930,NCT03452501,Incidence of adverse events (AEs) to Remsima®,2018-08-26,COMPLETED,OBSERVATIONAL,['NA'],,Proportion of switched patients with UC achieving disease control.
6931,NCT06100016,Specificity,2023-10-18,RECRUITING,OBSERVATIONAL,['NA'],,
6932,NCT03189719,PFS Per RECIST 1.1 As Assessed By Investigator in All Participants,2017-07-25,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change From Baseline in the EORTC QLQ-OES18 Subscale Scores in Participants Whose Tumors Are PD-L1 Biomarker-Positive (CPS ≥10)
6933,NCT01941953,Disease Control Rate according to RECIST 1.1,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse Events
6934,NCT04633382,Reduction of bed-days,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,
6935,NCT03146234,Safety and tolerance,2017-03-17,COMPLETED,INTERVENTIONAL,['NA'],Anti-tumor responses to CAR-GPC3 T cell infusions,Engraftment
6936,NCT01441453,Cut-off value of liver stiffness measured in kilopascal (kPa) able to predict the occurrence of postoperative liver failure.,na,UNKNOWN,INTERVENTIONAL,['NA'],,
6937,NCT04097028,Number of Patients With a Pathologic Complete Response,2019-12-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Patients With Grade 3 or Higher Treatment Related Adverse Events
6938,NCT02129829,Incidence of HCC or decompensated cirrhosis,2011-10,COMPLETED,OBSERVATIONAL,['NA'],Accuracy of non-invasive fibrosis assessment,Treatment rate
6939,NCT05596370,correlation of genetic mutation burden and prognosis,2022-01-06,RECRUITING,OBSERVATIONAL,['NA'],,correlation of microbiome in stool and prognosis
6940,NCT03807947,Pain and discomfort during and after procedures,2019-01,UNKNOWN,INTERVENTIONAL,['NA'],,Access-related adverse events
6941,NCT02228200,Change in quality of life,2012-06,COMPLETED,INTERVENTIONAL,['NA'],Intervention nurses' experience,Health care utilization
6942,NCT04866290,Overall Survival,2016-09-22,COMPLETED,OBSERVATIONAL,['NA'],,Time to Progression
6943,NCT04449874,Percentage of Participants With Dose-Limiting Toxicities (DLTs),2020-07-29,RECRUITING,INTERVENTIONAL,['PHASE1'],,Relationship Between Tumor Pharmacodynamic Effects of GDC-6036
6944,NCT05647941,Detection of levels of circulating exosomal lncRNA-GC1,2018-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
6945,NCT05179486,Significant factors that may contribute to the etiology of biliary tree cancer,2017-09-25,RECRUITING,OBSERVATIONAL,['NA'],,
6946,NCT05063565,Objective Response Rate (ORR),2023-11-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,Whole liver and remnant liver volumes at baseline and follow-up imaging assessments measured using Simplicit90Y software.
6947,NCT03515252,Incidence of Treatment-Emergent Adverse Events [Safety],2005-04-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,Quality of Life (QOL)
6948,NCT06282120,Progression Free Survival,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],,EORTC-QLQ (European Organization for Research and Treatment of Cancer - Quality of life Questionnaire) C30 (version 3.0)
6949,NCT04957407,pepsinogen value for precanceous lesion and Gastric cancer,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
6950,NCT04272268,Rate of respiratory complications within 30 days after surgery,2019-10-01,RECRUITING,OBSERVATIONAL,['NA'],,Recruitment rate
6951,NCT03990675,Growth rate,2018-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,
6952,NCT04104672,Number of participants with clinically significant changes in vital signs and clinical laboratory parameters,2019-11-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],AB680 gene expression,Overall response rate
6953,NCT04000906,Determine the maximal tolerated dose (MTD) of Nab paclitaxel (Abraxane®) administered IP by PIPAC in concomitance with cisplatin.,2020-11-11,RECRUITING,INTERVENTIONAL,['PHASE1'],,The QoL
6954,NCT05301556,Serum Pre-Albumin,2022-06-24,COMPLETED,INTERVENTIONAL,['NA'],Adverse Events,Nutritional Risk Screening (NRS) 2002
6955,NCT06202417,DCR,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
6956,NCT03254498,Adenoma miss rate,2016-04,COMPLETED,INTERVENTIONAL,['NA'],comparison of surveillance intervals,Comfort score
6957,NCT00497107,Disease-free survival,2007-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"Overall survival, compliance, adverse events, QOL, tumor markers"
6958,NCT00048139,Tumor measurement (RECIST criteria),2001-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Efficacy: Time to progression, time to response, duration of response, time to treatment failure, survival."
6959,NCT06066138,Feasibility of reducing drug exposure while maintaining plasma drug concentration,2024-04-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,"Minimal frequency (median, range) of atezolizumab dosing to keep the trough concentration at or above 6 microgram/mL"
6960,NCT02149914,gastroesophageal reflux disease questionnaire,2014-05,UNKNOWN,INTERVENTIONAL,['NA'],,Upper gastrointestinal endoscopy
6961,NCT05986890,Gastric emptying as per gastric emptying scintigraphy at 7 days post-operatively.,2023-08-17,RECRUITING,INTERVENTIONAL,['NA'],,Improvement of quality of life as measured GIQLI
6962,NCT01127698,"Fractures, hip fractures",1987-03,COMPLETED,OBSERVATIONAL,['NA'],,
6963,NCT04114591,Life,2018-07-01,COMPLETED,OBSERVATIONAL,['NA'],,
6964,NCT05799820,Objective Response Rate (ORR),2022-09-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
6965,NCT06031285,"RFS, recurrence-free survival",2023-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
6966,NCT04158908,Potential Improvements to the Oncolo-GIST Manual According to Structured Qualitative Surveys,2020-01-17,COMPLETED,OBSERVATIONAL,['NA'],,
6967,NCT00423345,findings compared across investigation modes,2006-10,TERMINATED,OBSERVATIONAL,['NA'],,Delayed diagnosis of CRC
6968,NCT00637728,Average Daily Caloric Intake Over the Course of the 8-week Double-blind Phase,2006-06,TERMINATED,INTERVENTIONAL,['PHASE3'],,Change in Appetite Over the 8-week Double-blind Phase as Measured by a VAS Appetite Scale
6969,NCT00461929,~ presence or absence of genetic abnormality as seen in CML patients on imatinib,2005-02,TERMINATED,INTERVENTIONAL,['PHASE4'],,
6970,NCT00165048,Symptom-free susrvival and the quality of life score within the two years of study period.,2004-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Overall survival in long-term.
6971,NCT05789485,proportion of patients achieving (ratio of delivered to planned treatment) RDI ≥ 90%,2023-04-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,
6972,NCT01371942,,2010-05,UNKNOWN,OBSERVATIONAL,['NA'],,
6973,NCT01114087,Average difference of the concentration of spermatozoa in the ejaculate measured before treatment and after 6 months of treatment.,2008-10,COMPLETED,INTERVENTIONAL,['NA'],,Plasmatic concentration of the inhibitors of tyrosine kinase
6974,NCT01579721,morbidity,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4'],,oncology
6975,NCT00664482,Treatment-emergent changes in localized injection site reactions following each dose,2007-05,COMPLETED,INTERVENTIONAL,['NA'],,Feasibility
6976,NCT05200299,2-year Disease-free survival,2022-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of Life assessed by SF-36
6977,NCT00357682,Conversion of Barrett's esophagus to adenocarcinoma of the esophagus or high-grade dysplasia,2005-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,All causes of mortality
6978,NCT00924690,Elaboration using the Elaboration Likelihood Scale,2009-06,COMPLETED,INTERVENTIONAL,['NA'],,Behavioral Intention to Engage in Colorectal Cancer Screening or Physical Activity
6979,NCT04663789,Clinically relevant postoperative pancreatic fistula (CR-POPF),2020-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,Length of postoperative hospital stay
6980,NCT05186116,Disease free survival,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Donor quality of life
6981,NCT02873455,Change of APAIS ((Amsterdam preoperative anxiety and information scale) from baseline APAIS to watching video.,2016-08,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative hospital stay
6982,NCT01676259,ORR at 6 months,2018-03-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
6983,NCT01325909,Maintain or improve physical fitness (anaerobic threshold measured by CPET)after treatment with neoadjuvant chemoradiotherapy in colorectal cancer patients.,2011-03,COMPLETED,INTERVENTIONAL,['NA'],,Activity levels before during and after neoadjuvant chemoradiotherapy
6984,NCT03222076,"Safety and Tolerability of Presurgical Nivolumab With or Without Ipilimumab, Defined as the Number of Participants With of Adverse Events.",2017-09-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival (PFS)
6985,NCT01922492,Changes of insulin secretory function,2008-05,UNKNOWN,INTERVENTIONAL,['NA'],,Adverse effects
6986,NCT05197322,Pathological complete response rate (pCR),2022-07-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Health-related Quality of Life (QoL) and functional outcome
6987,NCT02454673,Disease Free Survival,2013-09,COMPLETED,OBSERVATIONAL,['NA'],,Estimate of TN Change From Baseline to Surgery
6988,NCT04341337,qualitative analysis of the interviews,2019-03-02,COMPLETED,OBSERVATIONAL,['NA'],,
6989,NCT02483832,CRC screening follow-up rate,2015-02,COMPLETED,INTERVENTIONAL,['NA'],,Changes in attitudes towards CRC and CRC screening as measured by survey
6990,NCT05954702,Mortality,2023-07-21,RECRUITING,INTERVENTIONAL,['NA'],,Drain use time
6991,NCT04138212,overall survival,2019-10-22,RECRUITING,INTERVENTIONAL,['PHASE3'],,postoperative complications
6992,NCT06221657,Proportion of subjects maintained at HBV DNA <29 IU/mL,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],,blood Phosphorus levels
6993,NCT06319404,The immune function of tumor draining lymph nodes of colorectal cancer patients was previously identified based on radiomics,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
6994,NCT01591109,,2010-01,COMPLETED,OBSERVATIONAL,['NA'],,
6995,NCT04370574,Predictive value of each protein contained in Cytolyt® for the positive diagnosis of pancreatic ductal adenocarcinoma,2021-01-14,RECRUITING,OBSERVATIONAL,['NA'],,Identification of prognostically significant biomarkers
6996,NCT01308645,Evaluating Tumor Response Rate,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Determine duration of response rate by measuring time to progression
6997,NCT05148767,Toxicity effect,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE4'],,
6998,NCT01154335,To Determine the Maximum Tolerated Dose (MTD) of the Combination of OSI-906 and Everolimus for the Treatment of Patients With Refractory Metastatic Colorectal Cancer.,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Response Rate
6999,NCT02215889,Percent of transplanted patients receiving second stage hepatectomy within 4 weeks of segment 2/3 transplantation.,2014-06,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
7000,NCT04826432,postoperative digestive leakage,2020-09-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,
7001,NCT05657210,5-year Overall survival (OS) of KRAS wildtype and each codon-specific KRAS mutation,2009-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Recurrence-related factor
7002,NCT01537107,MTD (Cohort I) ) and toxicity profile of combination of vismodegib plus sirolimus every 28 days.,2012-03-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Antitumor effect of molecularly targeted agents non-invasively by F18-FDG PET or PET/CT (Cohort II)
7003,NCT03946033,Modification rate of adjuvant therapeutic strategy,2019-05,WITHDRAWN,INTERVENTIONAL,['NA'],,
7004,NCT06114420,Cancer-specific survival,2023-01-30,RECRUITING,OBSERVATIONAL,['NA'],,Find a differentially expressed gene
7005,NCT06236282,Operation time,2012-05-01,COMPLETED,OBSERVATIONAL,['NA'],,TME quality (Operative outcome)
7006,NCT06048926,PFS evaluated by IRC,2022-07-30,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Progression-free survival evaluated by Researchers
7007,NCT05891301,gastrointestinal dysfunction,2023-05-01,RECRUITING,OBSERVATIONAL,['NA'],,Patient Mobility in the hospital
7008,NCT06316882,number of gastric adenocarcinoma,2023-02-03,RECRUITING,INTERVENTIONAL,['NA'],,Socio-demographic characteristics of population in screening program
7009,NCT04418843,Complete resection of the lesion,2020-06-08,COMPLETED,INTERVENTIONAL,['NA'],,Sub-analysis by center participating in the study
7010,NCT02813824,Number of patients with at least one adenoma seen on chromo-endoscopy 48 months after complete withdrawal of polyps and initiation of treatment (aspirin or placebo),2017-11-14,RECRUITING,INTERVENTIONAL,['PHASE3'],,Load serrated polyps after 24 and 48 months of treatment
7011,NCT04291755,Checkpoint inhibitor response,2019-06-28,UNKNOWN,OBSERVATIONAL,['NA'],,
7012,NCT05468177,Objective response rate (ORR),2022-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,R0 resection rate
7013,NCT03706157,Histological analysis of biopsy samples for the evaluation of the kinetics of distribution of doxorubicine in tumor compartments depending on the solvent used for drug reconstitution,2018-11-26,COMPLETED,INTERVENTIONAL,['PHASE4'],,"In vivo evaluation of the kinetics of distribution of doxorubicine in tumoral tissue with confocal laser endomicroscopy, depending on the solvent used for drug reconstitution"
7014,NCT00602082,Objective response rate,2005-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life
7015,NCT04982653,Radiographic incidence rate of incisional hernia,2022-01-04,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events (AEs)
7016,NCT03288987,Progression Free Survival (PFS),2016-10-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Positive Anti-drug Antibody (ADA) Samples Among Patients (Immunogenicity)
7017,NCT00336648,Number of Patients with Resection,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7018,NCT05348668,Progression-free Survival,2022-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
7019,NCT04737213,Ability of SGM-101 and a near-infrared camera system to detect colorectal lung metastases.,2020-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
7020,NCT04560894,Progression-free survival(PFS)evaluated by the Blinded Independent Central Review Committee (BICR) based on RECIST V1.1,2020-11-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Anti-drug antibody (ADA)
7021,NCT02289378,Progression-free survival,2014-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Response rate
7022,NCT04169347,Efficacy/objective response rate,2019-12-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Evaluating for the velocity of tumor response to this regimen
7023,NCT05226572,Diagnostic yield (%) of repeated EUS-fine needle biopsy of pancreatic masses after previous non-diagnostic or inconclusive results,2017-07-01,COMPLETED,OBSERVATIONAL,['NA'],,"Sensitivity (%), specificity(%), positive predictive value(%), negative predictive value(%), specimen adequacy(%), Bethesda classification, adverse events incidence (%) and factors that influenced repeated EUS-fine needle biopsy performance."
7024,NCT06275958,Progression-Free Survival,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Cost-effectiveness
7025,NCT00002793,,1991-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
7026,NCT05244798,"Pathology complete response rate, pCR",2022-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,"Circulating tumor DNA, ctDNA"
7027,NCT00069095,PFS as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored) - Superiority of Chemotherapy Plus BV Over Chemotherapy Alone,2003-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Duration of Complete Response as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
7028,NCT05195970,Correlation of colonic lesion gene expression with urolithin production,2022-01-24,RECRUITING,INTERVENTIONAL,['NA'],,Correlation of dietary behavior with urolithin production
7029,NCT05056896,Change of ISC marker gene expression,2022-06-03,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Change in Microbiome
7030,NCT02628067,Objective Response Rate (ORR),2015-12-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Percentage of Participants who Discontinue Study Intervention due to AEs
7031,NCT03813641,Progression-free Survival (PFS) Time,2019-01-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Percentage of Participants Achieving a Stable Disease (SD) or a confirmed CR or PR (Disease Control Rate)
7032,NCT03531125,Comparison of whole transcriptome RNA sequencing of EUS derived pre-operative sample and whole transcriptome RNA sequencing of biopsies either taken from the pancreatic cancer during resection or repeat biopsy using EUS,2018-07-02,TERMINATED,OBSERVATIONAL,['NA'],,"Percentage and number of patients that undergo EUS and follow up EUS or surgery that have a) histopathological evidence of adenocarcinoma in their biopsy and surgical samples, and b) of suitable RNA quality for analysis"
7033,NCT00963612,To assess the ability of BOLD MRI to predict microvascular invasion in hepatocellular carcinoma via assessment of intratumoral oxygenation.,2009-09,COMPLETED,INTERVENTIONAL,['NA'],,To identify a quantitative threshold tumor R2* value using BOLD MRI technique reasonably sensitive of predicting microvascular invasion in HCC pre-operatively.
7034,NCT02234986,Overall Response Rate,2015-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Frequency and severity of adverse events,Progression Free Survival (PFS6) rate
7035,NCT04244552,"Incidence of DLTs (dose escalation cohorts only), treatment emergent adverse events (TEAEs), and changes in safety parameters",2020-02-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,For the PLD Combination Therapy Cohort: ATRC-101 immunoreactivity in tumor biopsies at baseline and during treatment
7036,NCT01167816,Toxicity,2010-07,TERMINATED,INTERVENTIONAL,['PHASE1'],,Determine the effect of azacitidine therapy on DNA methylation in peripheral blood cells
7037,NCT02981641,Overal survival,2015-12,UNKNOWN,INTERVENTIONAL,['NA'],,Local control rate
7038,NCT04880044,Proportion of participants negative via EC/EG who subsequently are proven negative via EGD,2022-01-05,RECRUITING,INTERVENTIONAL,['NA'],,
7039,NCT05908643,"Safety of pTTL administration, as determined by assessment of incidence and severity of adverse events (AE). Immunological AEs and AEs known to be associated with T cell therapies will be classified as AEs of special interest (AESI).",2023-03-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Evaluation of the importance of neoantigen selection to clinical outcome.,Disease-specific survival
7040,NCT01229839,overall survival,2013-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time to progression
7041,NCT03207594,Number of patient who self-report smoking cessation,2016-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Compliance with smoking cessation
7042,NCT00986518,"Tumor size of hepatic and/or lung metastases, as measured with tomodensitometry (RECIST 1.1 criteria)",2012-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Laboratory test: hepatic function, immune function, haematology"
7043,NCT01315795,Reduction of total liver volume after 18 months of treatment by means of CT-scan,2011-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Assessment of quality of life after 18 months of treatment
7044,NCT04560751,Objective response rate（ORR）,2020-09-30,UNKNOWN,OBSERVATIONAL,['NA'],,Adverse events(AEs)
7045,NCT01861691,Early complication rate,2008-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Health-related QOL score
7046,NCT02669992,Number of participants with postoperative stoma site hernia,2015-06,RECRUITING,INTERVENTIONAL,['NA'],,Postoperative Hospital stay
7047,NCT01433861,Rate of reflux esophagitis,2012-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,
7048,NCT00280618,Time to Tumor Progression (TTP) and Response Rate: evaluated by RECIST,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse Events collections and evaluation
7049,NCT04437212,Major Pathological Response Rate (MPR),2020-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Perioperative complication rate
7050,NCT03927898,1 year Progression-Free-Survival (PFS),2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Expression of PD-L1 on circulation tumor cell
7051,NCT05883683,Identification of effective drugs or drug combinations,2023-07-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Correlation between organoid and PDX drug sensitivities
7052,NCT00234182,Occurrence of recurrent disease,2000-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Death of the patient
7053,NCT03695952,Objective response rate,2018-07-01,RECRUITING,OBSERVATIONAL,['NA'],,Adverse events
7054,NCT04738188,Downstaging success rate,2020-03-18,RECRUITING,INTERVENTIONAL,['NA'],,Recurrence rate of Hepatocellular carcinoma
7055,NCT01163812,Compliance of lymph node dissection,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,distance to resection margin and number of harvested lymph nodes
7056,NCT05068635,Number of patients who developped morbidity after subgastrectmy for gastric cancer,2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
7057,NCT05623150,Primary outcome measure CHALNA2,2022-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,7th outcome measure CHALNA2
7058,NCT00008281,,2000-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
7059,NCT03145558,Progression Free Survival,2017-12-05,SUSPENDED,INTERVENTIONAL,['PHASE2'],Time to local recurrence,Duration of CR
7060,NCT04371198,Number of Participants With Biopsies That Form Spherical Organoids,2020-09-18,COMPLETED,INTERVENTIONAL,['NA'],,
7061,NCT01072981,The primary objective is to assess overall survival,2010-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,The secondary objective is to assess disease free survival and to conduct correlative scientific studies of subject samples to determine the mechanism of any observed anti-tumor effect.
7062,NCT02128100,Grade 3 or Higher Adverse Event(s) as a Measure of Safety and Tolerability,2014-09-19,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of Life Assessment at 12 Months Post-treatment,Overall Response Rate for Participants as Assessed by Contrast-enhanced CT Scan of the Abdomen at 12 Months.
7063,NCT04258111,ORR,2020-08-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events (AE)
7064,NCT03152370,Number of participants with any non-serious adverse event (AE),2017-05-17,COMPLETED,INTERVENTIONAL,['PHASE1'],,Mean peak-trough fluctuation (PTF) of E7046 and its metabolite ER-888188 in plasma
7065,NCT05742750,Objective Response Rate (ORR),2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
7066,NCT00923520,Determine the Maximum Tolerated Dose,2009-03-25,COMPLETED,INTERVENTIONAL,['PHASE1'],,Anti-tumor Effects
7067,NCT01666730,Median Overall Survival (OS),2013-02-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Grade 3 and 4 Toxicities According to NCI CTCAE Version 4.0
7068,NCT05027711,Treatment related Toxicity,2021-08-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Evaluation of potential prognostic biomarkers
7069,NCT05756699,HCC detection rate,2023-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Positive predictive value
7070,NCT06014372,Rate of pCR,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],OS,DFS
7071,NCT02582034,"The primary endpoint is to compare the response rate of the treated lesion at the first radioembolization, evaluated using European Association for the Study of the Liver (EASL) criteria of yttrium-90 marked glass microspheres SIRT",2015-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Post-therapeutic dosimetry measured by Positron emission tomography-computed tomography PET / CT
7072,NCT05201404,Overall Survival (OS),2023-03-15,RECRUITING,INTERVENTIONAL,['PHASE3'],"Quality of Life (QOL), using the hepatocellular carcinoma- (HCC-) specific module of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Hepatocellular Carcinoma 18-question Module (EORTC QLQ-HCC18)",Pharmacokinetics (PK) of namodenoson in this population
7073,NCT06326502,Dose-limiting Toxicity (DLT),2024-02-07,RECRUITING,INTERVENTIONAL,['PHASE1'],,
7074,NCT02941861,Recurrence rate of Liver Carcinoma after surgery,2016-08,COMPLETED,OBSERVATIONAL,['NA'],,
7075,NCT02078804,Mortality from colorectal cancer in the Swedish population.,2014-03,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,To study the flora of fecal bacteria among participants and outcome of FIT and colonoscopy.
7076,NCT03683446,Postoperative Complications,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
7077,NCT04156087,Progression-free survival (PFS),2020-05-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
7078,NCT04352023,Comparison of analgesic efficacy after major surgery in pancreatobiliary cancers: Intravenous patient-controlled analgesia versus patient-controlled epidural analgesia,2018-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Investigation and comparison of pain and clinical progress during rest after surgery, side effects of drugs administered to IV-PCA and PCEA, and complications related to PCEA procedure"
7079,NCT03694977,Identification of potential biomarkers of MCS110 in combination with PDR001,2019-01-17,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety as measured by number and grade of toxicity events
7080,NCT00006015,Overall toxicity,2000-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,
7081,NCT02822352,To compare the rates of neoplasia detection using virtual chromoendoscopy compared to high definition white light (HDWL) endoscopy,2016-08,COMPLETED,INTERVENTIONAL,['NA'],,To compare the duration of time taken using each technique
7082,NCT02745509,Overall survival,2016-03,COMPLETED,INTERVENTIONAL,['NA'],,Post-operative quality of life
7083,NCT04159363,Caregivers' quality of life,2020-02-01,UNKNOWN,INTERVENTIONAL,['NA'],,Caregivers' anxiety and depression
7084,NCT02347956,morbidity,2015-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,mortality
7085,NCT04968145,30-day re-admission,2017-07-19,COMPLETED,INTERVENTIONAL,['NA'],,Patient reported outcomes
7086,NCT03890731,Severity (by Worst Grade) of Participants With Drug-related Adverse Events (AEs) and Serious AEs (SAEs),2019-04-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Dose Modifications
7087,NCT04317599,First-line Systemic anticancer therapy (SACT) treatment patterns in BRAFV600E mutant mCRC patients,2020-04-12,COMPLETED,OBSERVATIONAL,['NA'],,Time to treatment cessation
7088,NCT02364024,Time to Recurrence (TTR),2005-11,COMPLETED,OBSERVATIONAL,['NA'],,Disease-Free Survival (DFS)
7089,NCT01664169,Number and percentage of responder,2012-08,COMPLETED,OBSERVATIONAL,['NA'],,
7090,NCT02608229,Maximum Tolerated Dose (MTD) of BVD-523,2016-06-06,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
7091,NCT00237172,To study the antineoplastic effect of the investigational drug.,2002-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,To study the safety and pharmacokinetics of the investigational drug.
7092,NCT02632448,Maximum Tolerated Dose(s),2016-05-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
7093,NCT02718729,Incidence of anastomotic leakage,2015-06-01,COMPLETED,INTERVENTIONAL,['NA'],,30 days postoperative morbidity and mortality
7094,NCT05679960,Accuracy of Urine PolypDx device in detecting colorectal cancer,2022-08-15,RECRUITING,INTERVENTIONAL,['NA'],,Negative Predictive Value Urine PolypDx device in detecting colorectal cancer (CRC)
7095,NCT01308190,Local recurrence,2010-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,
7096,NCT01045200,Patient satisfaction,2002-01,COMPLETED,OBSERVATIONAL,['NA'],,Resource utilisation
7097,NCT01791361,The prevalence of KRAS testing and impact of the KRAS test results on patterns of Vectibix use in patients with metastatic colorectal cancer (mCRC) treated with Vectibix,2012-09-19,COMPLETED,OBSERVATIONAL,['NA'],,"To characterize the results of KRAS testing in the three rounds of chart abstraction that will be carried out at 0, 12 and 24 months to indicate if there are any differences in results from each of the three rounds"
7098,NCT06205472,The 3-year Overall Survival,2024-01-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,Local Control Rate
7099,NCT05238584,3y Disease Free Surveillance,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],Duration of the hospital stay,Postoperative immunological changes (Interleukin monitoring)
7100,NCT04853043,Progression free survival (PFS),2021-11-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS).
7101,NCT03952442,Quality of Life (QOL),2019-02-21,UNKNOWN,INTERVENTIONAL,['NA'],,Knowledge-Attitude-Practice
7102,NCT00150670,Overall survival,2002-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Overall response rate, lesion-directed response rate, time to treatment failure (TTF), hospitalization-free survival period within the periods of TTF, and safety profile"
7103,NCT05192044,Feasibility of enhanced recovery after pancreatico-dudenectomy,2021-12-25,UNKNOWN,INTERVENTIONAL,['NA'],,
7104,NCT01042041,"Dose adjustment, number and percentage of subjects with adverse events, laboratory changes, number and percentage of subjects with laboratory values that are outside the pre-determined ranges, cumulative toxicity, and TLT.",2009-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to Disease Progression
7105,NCT02785887,Relative dose intensity,2014-08-01,COMPLETED,INTERVENTIONAL,['NA'],Optional Translational Substudy: Blood metabolites,Early mortality
7106,NCT02017678,Radiographic response of ovarian peritoneal carcinomatosis to JX-594 treatment,2014-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Time to progressive disease
7107,NCT03298204,Overall survival,2017-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Distant metastasis free survival
7108,NCT03688906,"Diagnosis of colorectal cancer or advanced adenomas in patients undergoing routine screening colonoscopy, or post-colonoscopy",2018-01-12,COMPLETED,OBSERVATIONAL,['NA'],,
7109,NCT03492671,Curative Intent Resection (R0) rate,2019-07-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival Rate
7110,NCT03732781,Explore efficacy (expansion cohort),2020-05-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
7111,NCT01218880,Maximum tolerant dose,2010-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],,objective response rate
7112,NCT01492049,Colorectal cancer screening (CRCS) Rate of Participants,2012-08-07,COMPLETED,INTERVENTIONAL,['NA'],,
7113,NCT04948398,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
7114,NCT00464919,To determine the progression- free survival of sorafenib plus tegafur/uracil (UFUR®) for the treatment of advanced or metastatic HCC.,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,To evaluate the changes of circulating biomarkers indicating the angiogenesis activity and their correlation with objective tumor response.
7115,NCT00447330,Median Progression-Free Survival (PFS),2007-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Survival
7116,NCT03847428,Recurrence-free survival (RFS) for Arm A vs Arm C,2019-04-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Time from randomization to recurrence/progression on next therapy (RFS2/PFS2) for Arm A vs Arm C and Arm B vs Arm C
7117,NCT02252913,safety and tolerability,2014-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,PK parameters
7118,NCT01086267,Toxicity will be evaluated according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 3,2010-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pharmacokinetics (PK) for BMS-908662 as determined by accumulation index [AI].
7119,NCT05116696,All-cause mortality,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],,Hospital adverse event
7120,NCT06099314,Overall survival 2(OS2),2023-10,RECRUITING,OBSERVATIONAL,['NA'],,"Disease control rate 2 (DCR2, investigators based on RECIST1.1)"
7121,NCT01310062,,2010-08,UNKNOWN,OBSERVATIONAL,['NA'],,
7122,NCT01660971,"Maximum tolerated dose of gemcitabine hydrochloride and dasatinib given together with erlotinib hydrochloride, determined by incidence of dose-limiting toxicity graded according to NCI CTCAE v 4.0",2012-07-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,"Serious and other significant adverse events (AEs), graded according to NCI CTCAE v 4.0"
7123,NCT06197425,The time to recurrence (TTR),2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,
7124,NCT00189657,,na,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
7125,NCT03413514,The cycle of neoadjuvant chemotherapy,2018-01-03,UNKNOWN,INTERVENTIONAL,['NA'],,The involvement of patients during the shared decision making
7126,NCT04534075,Intensity of the urgency syndrome,2020-09-02,RECRUITING,INTERVENTIONAL,['PHASE3'],Composition of microbiota,Acute side-effects
7127,NCT05632744,Safety of the CG-100 Intraluminal Bypass Device,2023-03-15,RECRUITING,INTERVENTIONAL,['NA'],,Safety of the CG-100 Intraluminal Bypass Device
7128,NCT06237582,Evaluate the incidence of IELN invasion by ovarian cancer,2022-06-16,COMPLETED,INTERVENTIONAL,['NA'],,"In cases of IELN positivity, review thoroughly preoperative scans and MRIs in order to detect radiological features, usually overlooked, that could help identify the positivity of these LNs prior to pathological analysis."
7129,NCT05592626,Phase 2 (Dose Expansion): Percentage of Participants with Overall Objective Tumor Responses (ORR),2023-01-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 1 and 2 (Dose Escalation and Expansion): Anti-drug Antibody (ADA) formation
7130,NCT05043987,Number of participants with dose-limiting toxicities (DLTs) during the DLT evaluation period.,2022-11-16,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,CPO102 immunogenicity: Number of participants with anti-drug-antibody (ADA)
7131,NCT04090060,Number of persons who practice the companion examination,2020-01-17,COMPLETED,INTERVENTIONAL,['NA'],,Concordance between self-examination and clinician examination stratified by waist circumference.
7132,NCT01343212,,2011-03,UNKNOWN,OBSERVATIONAL,['NA'],,
7133,NCT05773144,Chemotherapy Relative Dose Intensity,2023-05-01,RECRUITING,INTERVENTIONAL,['NA'],,
7134,NCT02617134,Adverse events attributed to the administration of the anti-MUC1 CAR-T cells,2015-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Objective Response Rate
7135,NCT01938716,To Quantifiably Assess Intratumoral Gemcitabine Levels in Human Pancreatic Cancer Tissue After a Single Intraoperative Infusion in Patients.,2012-03,TERMINATED,INTERVENTIONAL,['NA'],,To Correlate Intratumoral Gemcitabine Levels and Its Tumoricidal Activity With Ki67 Index and Intratumoral Apoptosis.
7136,NCT05142709,OS from start of 1st line treatment in metastatic ESCC,2021-10-31,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,the role of radiotherapy for patients treated with 1st immunotherapy.
7137,NCT02053805,"Prevalence, stage and pathology of screen-detected prostate cancer in BRCA1/BRCA2 founder mutation carriers and Lynch mutation carriers",2014-02,UNKNOWN,INTERVENTIONAL,['NA'],Genomic and biological profiles in samples from BRCA and Lynch mutation carriers and characterize changes related to prostate cancer.,"Accuracy of different screening tests (PSA, free to total PSA, prostate MRI) in detecting prostate cancer among men with genetic predispositions."
7138,NCT00659022,Difference in response of liver metastases between control group and experimental groups determined by FDG-PET,2008-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Complications of surgery
7139,NCT02893540,PFS1,2016-09,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,QOL
7140,NCT04999007,The morbidity of anastomotic leakage.,2021-09-02,RECRUITING,INTERVENTIONAL,['NA'],,
7141,NCT01743300,The feasibility of midazolam as a phenotyping probe for sunitinib exposure (area under concentration time curve)in cancer patients,2007-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,The influence of sunitinib on CYP3A4 activity
7142,NCT03688230,Progression Free Survival (PFS),2019-04,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events summarized by CTCAE severity grade (v5.0).
7143,NCT02596113,Genes' mutations rate in patients who are submitted screening colonoscopy and they presented with cancerous lesion,2015-07,COMPLETED,OBSERVATIONAL,['NA'],,
7144,NCT04297280,Objective Response Rate (ORR),2020-04-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
7145,NCT01390194,image quality outcome,2011-07-01,COMPLETED,OBSERVATIONAL,['NA'],,
7146,NCT01516944,Disease-free survival(DFS),2012-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,R0-resection rate
7147,NCT01370928,Patients´ evaluation of pain and discomfort,2011-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Caecum intubation rate
7148,NCT04259762,Completion of a Pap Smear test to screen for cervical cancer,2021-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Change in Self-Efficacy measured using the Health Behavior Survey
7149,NCT01450046,Number of Participants With Treatment Related Adverse Events,2011-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacodynamic (PD) Markers of Vitamin E δ-Tocotrienol Activity in Peripheral Blood
7150,NCT05224882,The assessment of the prevalence of oral adverse events induced by chemotherapy in pediatric cancer patients .,2023-08-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Assessment of dental awareness among parents of pediatric cancer patients .
7151,NCT05267275,incidence of complications related to rectal anastomosis,2021-11-30,RECRUITING,INTERVENTIONAL,['NA'],,
7152,NCT00728650,Survival,2003-10,COMPLETED,OBSERVATIONAL,['NA'],,Efficacy
7153,NCT01921751,Overall Survival,2013-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Correlation Between SMAD4 Status Determined by Immunohistochemistry (IHC) and Genetic SMAD4 Status
7154,NCT00265876,Response (complete [CR] and partial response [PR] or stable disease [SD]) at 8 weeks,2006-04-26,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Toxicity
7155,NCT04555135,Average Number of Adenomas Per Extraction,2020-09-28,TERMINATED,INTERVENTIONAL,['NA'],,Procedure Time
7156,NCT02318095,Feasibility as Measured by Number of Participants Who Complete the Neoadjuvant Gemcitabine/Nab-paclitaxel and HIGRT Regimen,2015-02-17,COMPLETED,INTERVENTIONAL,['NA'],,Number of Participants Who Received an R0 Resection
7157,NCT00460837,Patient experience and compliance with reduced laxative tagging versus standard preparation,2007-11,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,Comparison of per polyp specificity between the two preparation regimens
7158,NCT00005858,,2000-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7159,NCT01897610,To assess progression-free survival (PFS),2013-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of participants with adverse events
7160,NCT02623621,Progression Free Survival,2015-11,COMPLETED,OBSERVATIONAL,['NA'],,
7161,NCT00629863,Overall survival at 12 months of patients last randomized and at 48 months of patients first randomized,2004-09,COMPLETED,INTERVENTIONAL,['NA'],,"Health resource utilization, including the selection of treatments and subsequent use of health service resources"
7162,NCT02032953,Net protein balance,2013-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],,
7163,NCT06031779,serum bile acid profile before treatment,2023-05-01,RECRUITING,OBSERVATIONAL,['NA'],,concentration of serum tumor markers before treatment
7164,NCT00116389,6 month survival,na,TERMINATED,INTERVENTIONAL,['PHASE2'],,performance status
7165,NCT00002722,,1996-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7166,NCT04917276,Specificity,2021-06-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
7167,NCT05911152,3-year overall survival,2016-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Postoperative pain score
7168,NCT00943449,Progression Free Survival Rate (PFSR) of repeated oral doses of 4SC-201 and of the treatment combination of Sorafenib plus 4SC-201,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,To investigate biomarkers
7169,NCT06037980,median PFS,2023-11-07,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Perioperative morbidity and mortality
7170,NCT04616534,Overall survival (expansion cohort),2021-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],"Pharmacodynamic (biological endpoints, toxicity and efficacy) parameters",Increase in deoxyribonucleic acid (DNA) damage level (expansion cohort)
7171,NCT06321081,progression free survival,2024-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overal survival
7172,NCT04028479,Progression-free survival (PFS) - 5th line of therapy,2021-05-05,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival (OS)
7173,NCT00303888,Safety,2006-05,TERMINATED,INTERVENTIONAL,['PHASE1'],,
7174,NCT03610490,Objective response rate (ORR),2018-08-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Health-related quality of life,Incidence of adverse events
7175,NCT01524783,Probability of Participants Remaining Event-Free in Progression-Free Survival (PFS) Based on Central Radiology Assessment,2012-03-30,COMPLETED,INTERVENTIONAL,['PHASE3'],,Pharmacokinetics (PK): Predose Concentration (Cmin) of Everolimus at Day 29
7176,NCT01403103,Comparison of the expression of 15-PGDH mRNA and protein levels in normal colorectal mucosa,2012-04,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,"Number of patients with grade 3 related toxicities of a single 100,000 IU dose of 25-OH-vitamin D3"
7177,NCT00263354,To evaluate the progression-free survival in the ITT population,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,To investigate safety using NCI-CTC criteria version 2
7178,NCT00385515,Duration of Ulcerative Oral Mucositis,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Ulcerative Oral Mucositis
7179,NCT02754856,Incidence of adverse events,2016-07-28,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7180,NCT00003085,,1996-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,
7181,NCT03681600,3-year disease free survival,2018-01-01,TERMINATED,OBSERVATIONAL,['NA'],,"Availability/performance of CT chest, abdomen and pelvis scan performed for pre-operative staging"
7182,NCT02940496,Incidence of dose limiting toxicity (DLT),2016-12-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
7183,NCT05397171,All Substudies: Incidence of AEs leading to discontinuation of AZD8853,2022-06-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Substudy 1 - Part B: Change in CD8 tumor infiltration in paired biopsies
7184,NCT04774679,Correlation of a macroscopically visible fragments in the 22g EUS-FNA needle specimens with final histologic diagnosis,2021-02-06,UNKNOWN,INTERVENTIONAL,['NA'],,Area Under the size of the macroscopically visible core size versus histologic core size
7185,NCT02314819,overall survival,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Safety and tolerance evaluated by incidence, severity and outcomes of AEs"
7186,NCT01015820,Mean Blood Vessel Radius (BVR),2010-06,COMPLETED,INTERVENTIONAL,['NA'],,
7187,NCT03724435,Survival,2019-12-06,TERMINATED,OBSERVATIONAL,['NA'],Impact on Quality of Life and Cost,
7188,NCT02465593,anti-tumor activity,2015-06,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
7189,NCT05419479,Switch Maintenance-Progression Free Survival,2022-11-30,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Treatment-Related Adverse Events
7190,NCT05201872,The positive rate of bacterial contamination of peritoneal washings,2022-01-15,UNKNOWN,OBSERVATIONAL,['NA'],,Postoperative complications
7191,NCT00611507,Response rate - RECIST criteria (unidimensional),2002-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free Survival (PFS)
7192,NCT01156831,Locoregional control,2007-11,COMPLETED,OBSERVATIONAL,['NA'],,Tumor regression grade
7193,NCT01964027,PFS and OS,2013-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
7194,NCT00422773,"To assess a maximal tolerable dose and the safety of a chemotherapy-combination of cetuximab, irinotecan, oxaliplatin and 5-FU/folinic acid as first-line treatment for metastatic colorectal cancer",2007-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"To assess the treatment regarding the following: feasibility, toxicity, response rate, resection rate, progression free and overall survival"
7195,NCT04783831,POPF,2018-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,Position and degradation of biodegradable stents
7196,NCT01659346,First Variceal Bleeding,2016-02,WITHDRAWN,INTERVENTIONAL,['NA'],,Reappearance of Esophageal varices in presence of Portal Vein Thrombosis
7197,NCT03427268,Progression-free Survival Rate at Three Months,2018-01-16,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Response Rate (ORR)
7198,NCT03734068,Tumor response,2018-06-13,UNKNOWN,OBSERVATIONAL,['NA'],,number of treatment required to achieve objective response in HCC patients
7199,NCT02984566,Difference in accumulated patient dose distribution with and without KIM,2020-01-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Patient-reported quality of life as measured by the European Organization for Research and Treatment of Cancer Quality-of-Life-Questionnaire-Hepatocellular Carcinoma 18 Module (EORTC QLQ-HCC18)
7200,NCT06265844,Serum prealbumin,2024-03-01,RECRUITING,INTERVENTIONAL,['NA'],,Feeding amount
7201,NCT04601610,ORR,2021-06-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,OS
7202,NCT05648084,Artificial intelligence's sensitivity and accuracy to predict the stage of the cancer,2022-12-15,RECRUITING,OBSERVATIONAL,['NA'],,"to evaluate the post-treatment mortality, morbidity rates and complication rates of the patients"
7203,NCT00350753,Time to progression,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Biomarkers
7204,NCT02308345,Length of visit (minutes),2014-12,COMPLETED,INTERVENTIONAL,['NA'],,Participant-rated usefulness of video summary
7205,NCT02638051,Objective Response Rate (ORR),2014-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life (QoL)
7206,NCT00250835,Pathologic Complete Response (PCR),2005-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Pelvic Local Control Rate
7207,NCT06134011,The differences of the metabolism information,2023-09-10,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
7208,NCT01538550,colorectal cancer mortality,2012-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Pain reduction during Colonoscopy,Psychological effects of screening
7209,NCT04677192,OS,2021-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Complete ablation rate
7210,NCT03771456,Anastomotic Leakage rate,2019-01-07,UNKNOWN,OBSERVATIONAL,['NA'],,Length of postoperative hospital stay
7211,NCT00031616,,2001-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
7212,NCT05128890,Hospital charges,2016-04-16,RECRUITING,OBSERVATIONAL,['NA'],,
7213,NCT02246725,"Quality of Life, such as pain, anxiety.",2014-10,UNKNOWN,OBSERVATIONAL,['NA'],Numbers of chemotherapy cycles,Survival
7214,NCT04784520,progression-free survival,2021-06-22,TERMINATED,INTERVENTIONAL,['PHASE2'],HA121-28 plasma concentration,duration of response
7215,NCT05625932,Incidence of any VTE,2023-03-02,RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence of bleeding events according to genetic risk
7216,NCT06086457,Overall survival (OS),2024-02-04,RECRUITING,INTERVENTIONAL,['PHASE3'],Biomarkers for the predicting of efficacy,QUALITY OF LIFE: Change From Baseline in the EORTC QLQ-OES18 Subscale Score in Participants
7217,NCT05529667,PFS,2019-05-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment
7218,NCT03042442,Rate of patients with loss of > 5% body weight,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],,"Assessing the survival rate by phone-calls follow-up every 6 months, up to 2 years"
7219,NCT00900432,Quantitation of T cells specific for tumor peptides (carcinoembryonic antigen and MUC1),2004-07,COMPLETED,OBSERVATIONAL,['NA'],,
7220,NCT00293436,Disease-free survival (phase II),2005-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (phase II)
7221,NCT00128596,Safety and tolerability,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7222,NCT02575807,Phase 2: Progression Free Survival (PFS),2016-03-08,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
7223,NCT00604721,Number of Participants With Radiographic Objective Response (OR),2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival (OS)
7224,NCT02124317,Objective response rate,2014-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety and tolerability
7225,NCT01180088,OVERALL BLOOD LOSS,2010-08,UNKNOWN,INTERVENTIONAL,['NA'],,BLOOD TRANSFUSION RATE
7226,NCT02069145,Safety and tolerability of OMP-54F28 in combination with sorafenib in patients with hepatocellular cancer,2014-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics (PK) of OMP-54F28 and sorafenib when administered in combination to patients with hepatocellular cancer
7227,NCT05727163,Objective Remission Rate (ORR),2022-07-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Safety (including chemotherapy-related adverse events, catheterization-related adverse events, surgical complications, etc.)"
7228,NCT03982121,Recommanded phase 2 dose (RP2D),2019-06-04,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
7229,NCT01232829,Survival Rate,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Disease Progression
7230,NCT04230772,Incidence of surgical complications,2021-02-01,UNKNOWN,INTERVENTIONAL,['NA'],,Number of retrieved lymph nodes
7231,NCT00103311,Objective Response (CR or PR) as Determined by the RECIST Criteria,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
7232,NCT04973631,histologic type,2003-05,COMPLETED,OBSERVATIONAL,['NA'],,
7233,NCT03853733,Genitourinary toxicity after the end of radiotherapy,2016-10-01,COMPLETED,OBSERVATIONAL,['NA'],,palliative colostomy after the end of palliative radiotherapy
7234,NCT02853474,Overall survival (as intent-to treat analysis),2016-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of patients treated with chemotherapy
7235,NCT05509751,Acceptability of the intervention and the study,2023-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Effect of the intervention on unplanned healthcare utilization
7236,NCT00533884,Delirium and delirium symptoms by the NEECHAM Confusion Scale and Confusion Assessment Method (CAM),2007-10,COMPLETED,OBSERVATIONAL,['NA'],,"Falls, injuries, and other complications"
7237,NCT02005809,Post-ESD bleeding rate according to second look endoscopy,2013-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Post ESD bleeding rate according to bleeding degree during endoscopic submucosal dissection
7238,NCT00478140,Objective Response (Complete and Partial Response),2007-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
7239,NCT02261844,Improved metabolic profile of liver cells,2015-12,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Decreased hepatic inflammation
7240,NCT04224415,Objective Response Rate,2020-01-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse events(AE) and severe adverse events(SAE)
7241,NCT04299880,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],2020-02-24,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7242,NCT05229783,Rate of both high grade dysplasia and esophageal adenocarcinoma lesions detected by electronic chromoendoscopy versus rate of such lesions detected by white light endoscopy plus systemic biopsies according to Seattle protocol.,2022-05-11,RECRUITING,INTERVENTIONAL,['NA'],,Cost effectiveness of the detection of both early esophageal adenocarcinoma and high grade dysplasia with electronic chromoendoscopy versus cost effectiveness of Seattle protocol.
7243,NCT06308510,Sensitivity mFast-SeqS,2024-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Concordance detection rates peritoneal dissemination
7244,NCT00949949,"MTD of the combination of everolimus, gemcitabine hydrochloride, and cisplatin",2009-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Timed endpoints
7245,NCT00511264,,2007-05,COMPLETED,OBSERVATIONAL,['NA'],,
7246,NCT05016245,Safety assessed within 60 days post treatment using NCI-CTCAE v5.0,2021-09-13,RECRUITING,INTERVENTIONAL,['PHASE3'],,Procedure technical success
7247,NCT00915382,progression-free survival,2009-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,overall survival
7248,NCT03099031,Venous thromboembolism recurrence,2015-05,COMPLETED,OBSERVATIONAL,['NA'],Premature treatment discontinuation,Heparin induced thrombocytopenia
7249,NCT02401971,time to progression(TTP),2014-08,UNKNOWN,INTERVENTIONAL,['PHASE4'],,overall survival (OS)
7250,NCT01595321,Number of participants with adverse events as a measure of toxicity,2012-10-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Time to disease progression using immune correlates
7251,NCT04005365,ORR,2019-11-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
7252,NCT05229874,Total Number of Retrieved Lymph Nodes,2022-01-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Postoperative lymph node anatomy duration
7253,NCT03874026,Activity,2019-09-05,RECRUITING,INTERVENTIONAL,['PHASE2'],Type of cells infiltrating the tumor microenvironment.,Toxic effects
7254,NCT05055635,Local control,2021-07-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,To investigate 6-month surgical site morbidity
7255,NCT01569984,Tumor perfusion,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Blood flow
7256,NCT05822557,Health and feeding related quality of life,2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],,Adverse Events
7257,NCT05839002,Five-year survival of patients,2010-05-21,COMPLETED,OBSERVATIONAL,['NA'],,
7258,NCT00137852,"Response rate of combination of chemotherapy, radiation therapy and surgery in resectable esophageal carcinoma",2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Determine the side effects of chemotherapy and radiation therapy in patients with resectable esophageal carcinoma
7259,NCT01158274,Incidence of adverse events graded according to NCI CTCAE version 4.0 (Parts 2a and 2b),2010-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall response rate (Parts 2a and 2b)
7260,NCT01715441,Non-progression rate,2012-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Cmax and Tmax of sorafenib and irinotecan,Response rate
7261,NCT05961423,The time to recurrence of cancer after curative resection,2020-06-19,RECRUITING,INTERVENTIONAL,['NA'],,Assessment of disability
7262,NCT05313854,Patient overall survival,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA'],Progression-free Survival,Pathology diagnosis
7263,NCT00426829,Toxicity (during and within 1 month after completion of radiotherapy),2007-05,TERMINATED,INTERVENTIONAL,['PHASE1'],,
7264,NCT01954745,Median Progression Free Survival (PFS),2013-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival (OS)
7265,NCT05462873,Dose intensity,2023-04-04,RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of anti-drug antibody (ADA)
7266,NCT04007770,Cognitive difficulties as measured by the Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog),2019-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
7267,NCT02365441,Objective tumour response (complete or partial response) as determined by RECIST v1.1,2015-06-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Macroscopically complete removal of all residual disease by surgery,Overall survival
7268,NCT00220649,"To determine the maximum tolerated dose (MTD) and the dose-limiting toxicity (DLT) of biweekly oxaliplatin in combination with fixed doses of irinotecan, 5-fluorouracil/leucovorin and gemcitabine",2004-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To document any antitumor activity with biweekly oxaliplatin in combination with fixed doses of irinotecan, 5-fluorouracil/leucovorin and gemcitabine administered on this schedule"
7269,NCT00193167,overall response rate,2004-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,toxicity
7270,NCT05870748,Objective Response Rate (ORR),2023-07-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and tolerabilty
7271,NCT01180153,objective response rate,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival
7272,NCT03966209,Acute Graft Rejection Rate,2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Over all survival Rate
7273,NCT00560365,Overall survival by intention-to-treat analysis,2004-03,UNKNOWN,OBSERVATIONAL,['NA'],,NHS cost per life-year saved
7274,NCT02978612,Functional decline in instrumental activities of daily living (IADL) and/or activities of daily living (ADL),2016-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
7275,NCT06011473,feasibility of CGM system,2023-08-27,RECRUITING,INTERVENTIONAL,['NA'],,SSI rate
7276,NCT05338307,Determine whether oral BHB supplementation is safe and tolerable,2022-05-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Investigate whether oral BHB supplementation leads to transcription and protein expression changes in the colonic mucosa
7277,NCT01632020,Mucosal Apoptotic Status of CRC Tumor and Adjacent Normal Tissue Following Metformin Therapy,2012-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,
7278,NCT04737187,Survival Probability at 18 Months,2020-11-25,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Treatment-emergent Adverse Events (TEAE) and Treatment-emergent Serious Adverse Events (TESAEs)
7279,NCT03594422,Safety and tolerance,2018-07-11,RECRUITING,INTERVENTIONAL,['PHASE1'],,Anti-tumor activities of HQP1351
7280,NCT00002525,5-year Overall Survival Rate in Patients With Dukes' B3/C Disease,1993-10-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,5-year Disease-free Survival Rate in Patients With Dukes' B2 Disease
7281,NCT04718701,Progression-free survival (PFS),2021-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The incidence and severity of adverse events (AEs) and severe adverse events (SAEs)
7282,NCT00112658,Survival (Phase III),2004-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Overall response rate (Phase III)
7283,NCT02830594,Changes in Myeloid-derived Suppressor Cells (MDSC) in Non-irradiated Sites Assessed by Flow Cytometry,2016-10-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
7284,NCT05937438,1-year disease-free survival,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,3-year overall survival
7285,NCT01233505,Dose-limiting toxicities of veliparib in combination with oxaliplatin and capecitabine as assessed by NCI CTCAE version 4.0,2010-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,Anti-tumor response according to Response Evaluation Criteria in Solid Tumors (RECIST)
7286,NCT02921139,freedom form local progression,2016-11,UNKNOWN,INTERVENTIONAL,['NA'],,Grade of toxicity
7287,NCT02603159,"overall survival, OS",2014-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,pathologic complete response rate
7288,NCT03222635,"Overall survival (descriptive statistics in SPSS, percentages, survival analysis)",2017-07-25,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life during follow-up endoscopies (questionnaires)
7289,NCT04246125,Maximum absorbed skin dose and dose distribution,2020-10-13,COMPLETED,OBSERVATIONAL,['NA'],,
7290,NCT03346005,The ability of AeonoseTM to distinguish between patients with and without colorectal cancer in a FIT-positive population in terms of sensitivity and specificity.,2017-11-09,COMPLETED,INTERVENTIONAL,['NA'],,Acceptance rate of AeonoseTM.
7291,NCT05182112,determine the maximum tolerated dose of focal simultaneously integrated boost (SIB),2021-12-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
7292,NCT02100189,Specificity of Sponge Cytology Using FISH,2014-02,COMPLETED,INTERVENTIONAL,['NA'],,Tolerability of FISH Spongy Cytology
7293,NCT04782557,"Variant allelic fraction (expressed in %) of serum ctDNA from HVB, PVB and peripheral blood",2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Adverse events of EUS-PVA and HVA
7294,NCT01894828,Improvement of nutritional status,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Reducing number of complications
7295,NCT03138044,Overall survival rate,2017-05-20,UNKNOWN,INTERVENTIONAL,['NA'],,Tumor response rate
7296,NCT03902600,Acute grade 3 or higher GI AEs,2018-05-10,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,overall survival
7297,NCT00145860,,2002-04,TERMINATED,OBSERVATIONAL,['NA'],,
7298,NCT04948762,Resection status,2021-08-01,UNKNOWN,OBSERVATIONAL,['NA'],,Return of bowel function
7299,NCT04506398,molecular-subtype heterogeneity between primary HCC and post-transplant HCC recurrence,2020-09-10,UNKNOWN,OBSERVATIONAL,['NA'],,Recurrence-Free Survival (RFS)
7300,NCT05101616,major pathologic response rate,2022-07-01,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,perioperative complications
7301,NCT05201105,Recurrence-free survival after abdominal-perineal amputation in case of failure of radiochemotherapy,2021-10-15,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival after abdominal-perineal amputation
7302,NCT03365765,disease-free survival,2018-02-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,incidence of adverse reactions after chemotherapy
7303,NCT05507632,Objective response rate (ORR),2022-08-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival rate
7304,NCT05518032,Objective response rate,2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Objective response rate
7305,NCT00494299,Time to Progression (TTP),2006-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall Survival (OS)
7306,NCT02061956,Efficacy,2011-01,COMPLETED,OBSERVATIONAL,['NA'],,Safety
7307,NCT00363051,Objective Response Rate: Percentage of Participants With Best Over All Response of Complete Response or Partial Response by Central Radiology Review (Stratum 1) Based on Response Evaluation Criteria in Solid Tumors (RECIST),2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Effect of Octreotide Depot on the Trough Concentrations of Everolimus
7308,NCT01658943,Overall Survival,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Objective Response Rate,Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
7309,NCT04767984,Reduction in mutant p53 staining in biopsy samples obtained during colonoscopies done before and after intervention,2021-09-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Banking of colorectal specimens
7310,NCT05352802,The incidence and severity of postoperative complications,2022-05-01,RECRUITING,INTERVENTIONAL,['NA'],,Oncological outcomes
7311,NCT04741490,1-year disease-free survival rate (1-year DFS),2021-02,UNKNOWN,INTERVENTIONAL,['NA'],,Overall survival (OS)
7312,NCT04141995,Number of patients able to undergo resection surgery,2021-02-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Percentage of subjects with grade 4 thrombocytopenia and grade 3-4 diarrhea
7313,NCT06119906,Contrast of neoplastic vs non-neoplastic Barrett's,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Image quality of Hyper-Spectral Endoscopy after post-hoc analysis
7314,NCT00091117,MTD,2004-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7315,NCT04972149,complication,2021-05-18,UNKNOWN,OBSERVATIONAL,['NA'],,number of use for each surgical instruments
7316,NCT04351321,The incidence of postoperative morbidity,2020-07,UNKNOWN,INTERVENTIONAL,['NA'],,Overall incidence of postoperative morbidity
7317,NCT02872779,Difference from baseline in the number of free mutant DNA in blood,2016-08,UNKNOWN,INTERVENTIONAL,['NA'],,Evaluation of response based on the RECIST 1.1 guideline
7318,NCT04172194,overall survival,2009-01-01,COMPLETED,OBSERVATIONAL,['NA'],,tolerance
7319,NCT02687230,Half-life (T1/2) of MVT-2163 alone and in combination with MVT-5873,2016-07-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,Presence of anti-drug antibodies (ADA) using an MVT-5873 ADA assay
7320,NCT04172779,Modulation of gene expression signatures associated with hepatocellular carcinoma (HCC) risk,2024-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Changes in GSTp levels in the liver,Change in quality of life (QOL)
7321,NCT00474734,,2007-05,UNKNOWN,OBSERVATIONAL,['NA'],,
7322,NCT05100446,Helicobacter pylori eradication,2021-05-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,
7323,NCT05344820,level of fatigue,2022-05-19,RECRUITING,INTERVENTIONAL,['NA'],,level of rumination
7324,NCT05411757,Adverse Events (AEs),2022-06-30,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Lymphocyte subtype,Best of response (BOR)
7325,NCT02677129,Short Physical Performance Battery,2014-08,COMPLETED,INTERVENTIONAL,['NA'],,Activities of daily living
7326,NCT05368688,"The molecular features of Fusobacterium (Fn) correlated with colorectal cancer (onset, recurrence, metastasis and survival)",2022-06-30,TERMINATED,OBSERVATIONAL,['NA'],,
7327,NCT02089919,The number of participants with adverse events,2014-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",The dose of CSC vaccine,The secondary objectives are to evaluate vaccine immune responses to the immunizations by the data of body measurements
7328,NCT05216120,Overall response rate of pemigatinib,2022-06-14,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE V4.0
7329,NCT00732082,To determine the dose limiting toxicities of IMP321 in patients being treated with gemcitabine for advanced pancreas cancer.,2009-02,TERMINATED,INTERVENTIONAL,['PHASE1'],,To evaluate the clinical response and time to disease progression with computed tomography examinations at two month intervals (current standard of care in gemcitabine-treated patients).
7330,NCT03830801,The number of subjects from which we will be able to collect biopsy samples using IVLCM technique,2017-12-06,RECRUITING,INTERVENTIONAL,['NA'],,
7331,NCT01288612,Percentage of Subjects Who Agreed to Participated in the Esophageal Assessment,2011-02,COMPLETED,INTERVENTIONAL,['NA'],,Acceptability
7332,NCT04009954,The time ranging from operation day to the day of first defecation,2019-04-01,UNKNOWN,OBSERVATIONAL,['NA'],,Concentration of fecal calprotectin
7333,NCT04978350,Reach of Genetic Testing Among Family Members,2021-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Integration of Workbook into Genetic Counselor Work Environment
7334,NCT05646030,Feasibility of CEA assessments at home using (automated) capillary sampling,2022-03-25,RECRUITING,INTERVENTIONAL,['NA'],,Clinical laboratory sample processing time:
7335,NCT05938322,Adherence to the ketogenic diet,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Investigate indices of quality of life
7336,NCT05181865,Phase 2a (Expansion): ORR (CR + PR) assessed centrally by RECIST v1.1,2022-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 1 (Exploratory): Explore the predictive potential of biomarkers measured in blood and/or tumor tissue in response to FL-301,Phase 1: PK parameters - Half-life (t1/2)
7337,NCT02857218,Technical feasibility of ultrasmall superparamagnetic iron oxide (USPIO) - magnetic resonance imaging (MRI) of the chest,2018-04-27,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,Sensitivity and specificity of PET/CT imaging
7338,NCT02280070,3-years Disease Free Survival rate,2013-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Pattern of first recurrence
7339,NCT02393248,Highest Serum Phosphate Concentration Following Pemigatinib as Monotherapy in Parts 1 and 2,2015-02-27,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Part 3: Accumulation Ratio of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)
7340,NCT05742620,3y-DFSR,2023-06-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,3y-OSR
7341,NCT05186402,Overall survival,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
7342,NCT02529774,Liver Relapse-Free Survival Rate,2015-09,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Disease free survival
7343,NCT00531245,"In a phase I study, to determine the maximum tolerated dose(MTD) In a phase II study, to evaluate the efficacy(response rates) and toxicities",2006-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"To investigate the time to progression(TTP), overall survival and toxicity"
7344,NCT01539993,Assess efficacy of percutaneous and transarterial treatments for liver cancer.,2008-11,COMPLETED,OBSERVATIONAL,['NA'],,long term follow up
7345,NCT06155318,Diagnostic Accuracy,2019-09-05,RECRUITING,OBSERVATIONAL,['NA'],,
7346,NCT00438737,Safety (rate of perioperative safety findings),2007-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
7347,NCT06187961,Number of Patients Amendable to Curative Surgical Interventions,2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of Life (QoL) after treatment
7348,NCT02278653,Functional outcome,2014-03,UNKNOWN,OBSERVATIONAL,['NA'],,Early detection of local failure (standard surgery still possible)
7349,NCT05859477,1-year progression-free survival (PFS),2022-06-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,Toxicity Summary
7350,NCT05805956,progression-free survival,2022-02-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
7351,NCT04994093,Optimization of pHLA:TCR binding affinity and toxicity,2021-10-06,UNKNOWN,OBSERVATIONAL,['NA'],,
7352,NCT05131243,ctDNA dynamic detection,2021-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,Tumor Marker examination
7353,NCT01372735,Local recurrence rate,2011-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
7354,NCT05833126,Objective Response Rate,2023-12-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,Graft Rejection
7355,NCT03859128,BICR-RFS,2019-03-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Incidence of AEs
7356,NCT02478996,peak oxygen uptake (VO2peak),2015-08,UNKNOWN,INTERVENTIONAL,['NA'],feasibility of the online-based sports program,quality of life
7357,NCT01786694,functional success of microdialysis,2013-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,the quality of life after the surgery
7358,NCT05790590,lesion conspicuity on portal venous phase,2023-05-30,RECRUITING,INTERVENTIONAL,['NA'],,Contrast media (CM) dose
7359,NCT06030180,Clinical Utility,2023-02-23,RECRUITING,INTERVENTIONAL,['NA'],,Patient Compliance
7360,NCT00335829,Time to Tumor Progression (TTP) of Targeted Lesions,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety and Treatment Toxicity - Cycles 2 and 3
7361,NCT01716546,Objective response rate,2011-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Maximum Tolerated Dose of the combination
7362,NCT02940067,Peak power - measured using cardiopulmonary exercise testing,2017-03-28,COMPLETED,INTERVENTIONAL,['NA'],,Well-being
7363,NCT02209441,,na,AVAILABLE,EXPANDED_ACCESS,['NA'],,
7364,NCT00578838,To determine whether magnetic resonance techniques can detect changes in normal liver morphology and metabolism caused by chemotherapy in patients with colorectal cancer.,2006-08,COMPLETED,OBSERVATIONAL,['NA'],,
7365,NCT05067374,Adherence to the hepatitis C screening,2022-03-23,RECRUITING,OBSERVATIONAL,['NA'],,Care access and prospective care cascade : percentage of cured women
7366,NCT03585062,R0 resection rate,2017-11-20,TERMINATED,INTERVENTIONAL,['PHASE2'],,The quality of life
7367,NCT00760721,Obtaining HBV Screening Test,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Knowledge and Attitudes Regarding HBV Screening
7368,NCT00249301,The safety of MLN8054 will be based on the continuous monitoring and observation of patients and the collection and evaluation of adverse events and serious adverse events and the assessment of their potential relationship to the study medication.,2005-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,
7369,NCT03182270,Diagnostic performance of the Cellvizio nCLE system in the characterization of pancreatic cysts,2016-07,UNKNOWN,INTERVENTIONAL,['NA'],,Feasibility data on nCLE during EUS-FNA procedure (rate of successful nCLE procedure)
7370,NCT05426811,Progression-free Survival (PFS),2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence and severity of adverse events (AE) and serious adverse events (SAE)
7371,NCT02886104,Overall survival,2016-08,RECRUITING,INTERVENTIONAL,['NA'],,Complete ablation rate in CRLM
7372,NCT02883790,Quality of sleep assessed using the PSQI scale,2015-10,TERMINATED,INTERVENTIONAL,['NA'],Number and typology of adverse events,Quality of Life evaluated according to SF-12 scale
7373,NCT01555762,Progression-Free Survival,2012-03-05,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of Participants With Balducci Score
7374,NCT04966819,Short Form-Survivor Unmet Needs Survey (Unmet needs) at 12 months,2022-03-01,RECRUITING,INTERVENTIONAL,['NA'],,Short Form-Survivor Unmet Needs Survey (Unmet needs)
7375,NCT02860234,Organ preservation rate,2016-08,COMPLETED,OBSERVATIONAL,['NA'],,European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Colorectal Cancer Module 29 (EORTC QLQ-CR29)
7376,NCT03186898,Overall Survival (OS),2017-06-22,RECRUITING,INTERVENTIONAL,['PHASE3'],,Exploratory - Overall Quality of Life (QOL)
7377,NCT00075465,Time to tumor progression,2001-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Tolerability
7378,NCT01993784,Objective response rate,2013-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,adverse events
7379,NCT00253370,The Proportion of Patients With Objective Response (Complete Response or Partial Response),2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
7380,NCT02148562,genetic variants of Hepatitis B,2014-04,UNKNOWN,OBSERVATIONAL,['NA'],,genetic variation in host-specific immune markers
7381,NCT05844371,The 1-year DFS rate,2021-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
7382,NCT01362127,Pathological Complete Histological Response (pCR) After Resection Than Chemotherapy Alone in Patients With Resectable Carcinoma of the Esophagus and Cardia.,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,HRQOL and Swallowing Function
7383,NCT03156036,Pathologic complete response rate(Pathologic staging and tumor regression grade.),2017-11-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7384,NCT01332669,tumor response,2011-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,Number of treatment required to achieve objective response
7385,NCT01013649,Overall survival (Phase III),2010-04-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Changes in fatigue
7386,NCT06307327,Evaluation consistency,2024-03,RECRUITING,OBSERVATIONAL,['NA'],,
7387,NCT01423734,reproducibility of diffusion weighted imaging for neuroendocrine liver metastases.,2011-08-23,COMPLETED,OBSERVATIONAL,['NA'],,evaluate the reproducibility perfusion insensitive diffusion coefficients (ADC high) of liver metastases
7388,NCT04924179,Progression-free survival (PFS),2021-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,AEs
7389,NCT02829918,Overall Response Rate (ORR) After 4 Cycles of Treatment,2016-10-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival (PFS)
7390,NCT03734952,overall survival,2023-05-01,RECRUITING,INTERVENTIONAL,['NA'],,Side effects
7391,NCT00936572,"Primary Efficacy Parameters: morphological and microbiological evaluation of the colonic microflora, gastrointestinal function",2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Secondary Efficacy Parameters: immune and inflammatory response, bacterial translocation"
7392,NCT00955097,identification of liver tumors,2008-05,TERMINATED,INTERVENTIONAL,['PHASE1'],,improved ablation of liver tumors
7393,NCT01429961,Time to progression (TTP),2011-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,toxicity
7394,NCT02189421,Technical success of the direct peroral cholangioscopy,2014-04,UNKNOWN,INTERVENTIONAL,['NA'],,Adverse events associated with direct POC
7395,NCT03847532,Patients with germIine mutations in MutYH,2018-10-10,UNKNOWN,INTERVENTIONAL,['NA'],,
7396,NCT00004941,,1996-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
7397,NCT02928627,presence of miR-221 and mR-222 in the blood,2017-06-01,UNKNOWN,OBSERVATIONAL,['NA'],,correlation of expression of miR-221 and miR-222 in tissue and blood samples
7398,NCT02213419,Rate of Subjects with Complete or Partial response of treatment,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Incidence rate of adverse events after treatment
7399,NCT01462994,"Percentage of patients with histologically proven GIST, measurable lesion in imaging and activating CKIT and PDGFRA mutation, where detection of tumor specific DNA encoding for mutated CKIT or PDGFA is possible in the plasma at least at one timepoint",2011-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,
7400,NCT01364493,Objective response rate,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,adverse events
7401,NCT05800561,predictive accuracy of HVPG and ICG-r15 on PHLF,2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
7402,NCT06029829,Compare Progression Free Survival (PFS) Regimen using RECIST 1.1.,2023-01-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,
7403,NCT05361668,Incidence of treatment-emergent adverse events (TEAEs),2022-06-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Pharmacokinetics (PK) of paltusotine
7404,NCT02494037,Survival,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Qualitative Experience of Care (QEC)
7405,NCT03846726,PFS,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,OS
7406,NCT03775525,Dose-limiting toxicity,2019-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Apparent Volume of Distribution (Vd/F)
7407,NCT05608044,Objective Response Rate,2022-11-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Participants Positive for Balstilimab Anti-drug Antibodies Following Treatment with Balstilimab
7408,NCT03151564,Metastasis Detection Accuracy,2017-05-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
7409,NCT04152343,Rate of Local Occurrence,2019-12-07,COMPLETED,INTERVENTIONAL,['NA'],,
7410,NCT04941287,Progression free survival (PFS),2021-12-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Tumor microenvironment modulation and immunologic response,Immunogenicity
7411,NCT00415168,Percentage of Participants With Objective Response (Objective Response Rate),2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants Who Died During the Study
7412,NCT02928081,5-year overall survival rate,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],,5-year disease-free survival rate
7413,NCT02963207,Accuracy measures in comparison to the final histopathology in regards to polyps' subtype (SSA/P versus non-SSA/P),2013-06,COMPLETED,INTERVENTIONAL,['NA'],,Agreement in predicting post-colonoscopy surveillance interval with final histopathology
7414,NCT02208804,Posttreatment tumor to non-tumor activity concentration ratio on SPECT/CT,2014-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Clinical and laboratory toxicity
7415,NCT04384575,Specificity,2020-02-22,COMPLETED,OBSERVATIONAL,['NA'],,
7416,NCT00660140,To determine the response rate and time to failure for patients treated with this regimen,2002-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Survival times
7417,NCT00215982,response rate,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,toxicity and tolerability
7418,NCT04106024,PFS,2018-10-23,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
7419,NCT03244683,Postoperative complications,2017-08-28,TERMINATED,INTERVENTIONAL,['NA'],,Length of stay and readmission
7420,NCT05709899,postoperative analgesia,2023-08-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
7421,NCT02028949,tolerance: toxicity will be evaluated according to the NCI CTC AE version 4.03 scale to determine the limiting dose,2012-11-22,COMPLETED,INTERVENTIONAL,['PHASE1'],,Evaluate the rate of objective response
7422,NCT05471401,"Percentage of participants who undergo successful inflation of the gastric balloon with oral contrast agent, with verification by MR or CT imaging",2023-04-25,RECRUITING,INTERVENTIONAL,['NA'],,Translation movement of stomach between CBCT scans with and without balloon insufflation
7423,NCT05421702,Type of anastomosis,2022-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Preoperative colonoscopic examination result
7424,NCT04721132,Incidence of adverse events (AEs),2021-02-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
7425,NCT05159440,Recommended Phase 2 Dose (RP2D),2022-01-20,RECRUITING,INTERVENTIONAL,['PHASE1'],,Accumulation ratio (Rac) of TORL-2-307-MAB
7426,NCT04091165,Acceptability of Smart Phone Application,2019-09-23,COMPLETED,OBSERVATIONAL,['NA'],,Adherence to Recommended Nutritional Plan
7427,NCT00123851,"To determine the response rate of OSI-774 when given in combination with oxaliplatin and capecitabine in patients with previously-treated locally advanced, locally recurrent, or metastatic colorectal adenocarcinoma",2003-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To evaluate the toxicities of the combination of OSI-774, oxaliplatin and capecitabine in this population of patients with colorectal cancer"
7428,NCT04392609,pTRG,2020-01-15,UNKNOWN,OBSERVATIONAL,['NA'],,
7429,NCT02486601,Complete pathological response rate,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Assessment of genetic polymorphism involved in tumor-response when appropriate
7430,NCT01870791,Survival,2012-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Safety profile
7431,NCT00051688,,2003-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,
7432,NCT01917617,Completion rate during the 12 weeks in the short hydration group,2013-05-22,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
7433,NCT02823860,Presence of biological and tumoral factors related to resistance to oncological treatments,2016-02-12,COMPLETED,INTERVENTIONAL,['NA'],,"behavioral characteristics of patients by HADS Scale, according to their therapeutic car modalities"
7434,NCT05044728,Immune Related Adverse Events (irAEs),2021-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,2-year survival rate
7435,NCT01828047,Postoperative ileus symptoms; microvascular flow index (MFI),2013-11,COMPLETED,OBSERVATIONAL,['NA'],,
7436,NCT06178445,ORR,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,"The incidence, nature, causality, seriousness, and severity of adverse events using NCI CTCAE 5.0"
7437,NCT06010862,Obtain the maximum tolerated dose of CEA CAR-T cells[Safety and Tolerability],2023-09-30,RECRUITING,INTERVENTIONAL,['PHASE1'],Duration of Response (DOR) of CEA CAR-T treatment in patients with CEA-positive advanced malignancies[Effectiveness],Pharmacodynamics of CEA CAR-T cells[Cell dynamics]
7438,NCT04037787,Length of stay,2019-09-01,COMPLETED,INTERVENTIONAL,['NA'],,Healthcare costs
7439,NCT05980403,Lymphatic metastases,2023-07-18,RECRUITING,OBSERVATIONAL,['NA'],,
7440,NCT01629524,Association between immune related cytokine and number of lymph nodes retrieved.,2012-06,COMPLETED,OBSERVATIONAL,['NA'],,
7441,NCT00698204,Clinical Oral Mucosal Injury Score at Cumulative Radiation Dose of 5000 cGy,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluation of Pain Severity at 5000 cGy Radiation
7442,NCT01929499,DFS (Disease free survival),2013-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,QoL (quality of life)
7443,NCT05470452,AFROC-AUC,2021-07-28,RECRUITING,INTERVENTIONAL,['NA'],,Cancer Identification Diagnosis Compliance Rate
7444,NCT05678218,Lymph nodes identified compared to surgery,2022-09-05,RECRUITING,OBSERVATIONAL,['NA'],,Short term and long term complications of the EUS (+/- tissue acquisition) procedure for patients with pCCA and iCCA
7445,NCT05281276,Pharmacokinetics profiles-(DF),2022-09-20,RECRUITING,INTERVENTIONAL,['PHASE1'],,Objective response
7446,NCT01214512,Colonoscopy and CD24 assay correlation,2011-01,COMPLETED,OBSERVATIONAL,['NA'],,
7447,NCT04799431,Number of participants experiencing study drug-related toxicities,2023-05-03,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
7448,NCT05576571,Evaluate efficacy (methylation profiling results),2020-10-16,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
7449,NCT00019084,,1996-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7450,NCT03731910,Treatment response mRECIST,2018-12-11,UNKNOWN,INTERVENTIONAL,['NA'],,Time to Progression
7451,NCT01307878,Progression-free survival,2012-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Toxicity of chemotherapy
7452,NCT04644068,"The number of subjects with dose-limiting toxicity (DLT), as defined in the protocol.",2020-11-12,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Module 6: To evaluate the effect of AZD5305 on the PK of Camizestrant.
7453,NCT00566800,Histologic regression of Barrett esophagus with high-grade dysplasia by chemoprevention with erlotinib hydrochloride,2007-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Toxicity
7454,NCT03328065,Type of determinants which are privileged by the patients to choose a treatment,2017-12-19,TERMINATED,OBSERVATIONAL,['NA'],,
7455,NCT02140034,Overall Survival,2013-05,UNKNOWN,INTERVENTIONAL,['NA'],,Peritoneal Recurrence Rate
7456,NCT05487443,Progression free survival (PFS),2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Overall survival (OS)
7457,NCT04722133,Objective response rate (ORR),2020-06-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of treatment related adverse events (TRAE)
7458,NCT03069599,Immunological outcome,2017-02-15,TERMINATED,OBSERVATIONAL,['NA'],,Cancer specific survival
7459,NCT00883454,The primary outcome was to investigate the value of preoperative cholinesterases in predict postoperative adverse outcome after hepatic resection for hepatocellular carcinoma in cirrhosis.,na,COMPLETED,OBSERVATIONAL,['NA'],,
7460,NCT01289028,Percent of Patients Achieving Complete Response (CR),2008-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression Free Survival (PFS) of the Patients Who Were Included Due to an Intolerability of a Prior Treatment.
7461,NCT03977090,"Extended period recommended dose,RDE",2019-04-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],,"Antidrug antibody, ADA"
7462,NCT05833971,pathologic complete response (pCR),2023-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease-free survival(DFS)
7463,NCT01163396,Progression-free survival (PFS),2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluation of potential surrogate markers predictive of bevacizumab activity
7464,NCT05587972,Create data set,2022-10-06,RECRUITING,INTERVENTIONAL,['NA'],,
7465,NCT03010813,Perioperative complications,2016-12,COMPLETED,INTERVENTIONAL,['NA'],,Voice function after TORS
7466,NCT01458509,feasibility of electronic PRO assessment,2011-10-11,COMPLETED,OBSERVATIONAL,['NA'],,problems people experience
7467,NCT04114006,Diagnostic yield of the WATS approach versus standard gastric biopsy mapping,2019-10-01,COMPLETED,OBSERVATIONAL,['NA'],,
7468,NCT02491593,Number of patients with high fecal blood output in relation to colorectal cancer,2014-04,COMPLETED,OBSERVATIONAL,['NA'],,Number of patients with low fecal blood output in relation to colorectal polyps
7469,NCT04270929,Safety of oxaliplatin PEDD-PRVI: maximum tolerable dose (MTD),2019-12-23,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Serologic response rates (CA 19-9)
7470,NCT04334395,Complication rate,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],,The survival time
7471,NCT00006112,,1996-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
7472,NCT00132067,Toxicity as assessed by CTCAE v 3.0,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of survival
7473,NCT00116506,Evaluate 1 year progression-free survival,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Determination of the observed response rate, median duration of response and overall survival"
7474,NCT03281070,Anastomotic leakage,2017-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,
7475,NCT00960557,To determine the safety and tolerability of OXi4503 in subjects with relapsed or refractory carcinomas with hepatic tumor burden.,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,To determine progression-free survival (PFS).
7476,NCT03285230,Health outcomes,1990-06-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
7477,NCT05893667,Overall survival Disease-free survival,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Pathological response through Ryan Tumor Regression Grade
7478,NCT02829359,HBV reactivation on the recovery of liver function,2012-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
7479,NCT01910909,To evaluate the SBRT effect on adverse events,2013-08,COMPLETED,INTERVENTIONAL,['NA'],RT response prediction probability evaluation by diffusion-weighted (DW) MRI and positron emission tomography,To measure the progression free survival
7480,NCT04519151,PFS of patients treated with pembrolizumab in combination with lenvatinib.,2021-04-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Impact of the treatment protocol on health-related quality of life using the QOL questionnaire (EORTC) QLQ-OV28.
7481,NCT01137162,,2008-08,TERMINATED,OBSERVATIONAL,['NA'],,
7482,NCT04967482,Success rate of conversion to resection,2021-07-09,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival (OS)
7483,NCT00003220,,1998-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7484,NCT02025036,OS-2 year,2014-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,pathologic complete response rate
7485,NCT03475953,Phase II (cohort A'): Assessment of the antitumor activity of regorafenib,2018-05-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II (cohort B): assessment of the antitumor activity of regorafenib
7486,NCT04813406,Overall survival(OS),2021-03,UNKNOWN,INTERVENTIONAL,['NA'],,Disease Control Rate (DCR)
7487,NCT01776307,Disease Control Rate,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Adverse Events and Serious Adverse Events
7488,NCT02920944,single diagnostic yield of the histologic core,2016-07,COMPLETED,INTERVENTIONAL,['NA'],,total diagnostic yield of the histologic core
7489,NCT05400122,Persistence of donor NK cells,2022-09-09,SUSPENDED,INTERVENTIONAL,['PHASE1'],,Clinical Response
7490,NCT02640924,Local control rate (treatment in-field control rate),2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Patient report outcome - quality of life as assessed by the EQ-5D-3L
7491,NCT02113683,active tumor growth before and after cancer therapy,2014-05,TERMINATED,OBSERVATIONAL,['NA'],,
7492,NCT00205322,"Does the combination of oxaliplatin, 5-FU, leucovorin and capecitabine improve the activity of the FOLFOX regimens in metastatic colorectal cancer patients",2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Is the oral drug an advantage in this patient population
7493,NCT02116894,Recommended phase II dose (RPTD) for the combination of PF-03446962 plus regorafenib,2014-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression free survival associated with PF 03446962 plus with regorafenib
7494,NCT00109226,,2000-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7495,NCT01677884,Efficiency of treatment based on objective response rate,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Total area under the curve of contrast-enhanced liver ultrasound,Hepatic metastasis resection rate
7496,NCT02125409,Assessment of the degree of COX-1 acetylation by ASA administered for 1 week.,2014-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"Change from baseline in eicosanoid biosynthesis and protein expression of markers of growth and progression of colorectal cancer (such as COX-2, NF-Kb and PI3K/Akt/mTOR pathway)."
7497,NCT03732105,"Recurrence Free Survival,RFS",2019-03-06,RECRUITING,INTERVENTIONAL,['NA'],,health related quality of life
7498,NCT05576506,AUC (95% CI),2022-10-08,RECRUITING,OBSERVATIONAL,['NA'],,To record and evaluate any unknown risks and adverse events of hyperspectral imaging in specimen image acquisition
7499,NCT02017002,Overall survival duration,2014-03,UNKNOWN,INTERVENTIONAL,['NA'],,Change of lung function after surgery
7500,NCT00353457,Pathologic complete response,2006-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,Disease free survival
7501,NCT04995809,Reason for attrition,2021-06-25,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Microbiomic profiling by bacterial 16S rRNA metabarcoding sequencing,The number of participants required to take part in a larger multicentre trial which will identify potential therapeutic targets from metabolomic and microbiomic profiling
7502,NCT02641873,AUC0-24h (Area under the plasma concentration versus time curve),2015-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression Free Survival (PFS)
7503,NCT02630056,the grade of acute hematologic toxicity,2015-12,UNKNOWN,OBSERVATIONAL,['NA'],,
7504,NCT05633641,ORR,2022-10-19,RECRUITING,OBSERVATIONAL,['NA'],,
7505,NCT00357422,overall survival rate,2005-10,COMPLETED,INTERVENTIONAL,['NA'],,disease free survival rate and recurrence rate
7506,NCT03460769,"Protocol and Regulatory Compliance Monitoring of Regulatory Documents for Consortium Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC)",2017-11-01,RECRUITING,OBSERVATIONAL,['NA'],,
7507,NCT04895709,Incidence of AEs leading to death,2021-05-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-free survival rate (PFSR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by investigator
7508,NCT02033538,response rate,2014-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Adverse events
7509,NCT00536809,Overall Response in Phase II,2007-09-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Change From Baseline to Study Completion in Aspartate Aminotransferase, Alanine Aminotranferease, and Alkaline Phosphatase"
7510,NCT06206876,CL/F,2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival
7511,NCT05687617,Number of patients with peritoneal metastases detected only with ICG.,2022-12-15,TERMINATED,INTERVENTIONAL,['PHASE2'],,
7512,NCT01766349,"Changes of respiratory muscle performance (MIP/MEP, PFT)from baseline",2011-09,COMPLETED,OBSERVATIONAL,['NA'],,Total length of hospital stay
7513,NCT05535894,Concomitant Analgesic/Narcotic Use,2022-08-10,RECRUITING,OBSERVATIONAL,['NA'],,
7514,NCT00444678,Response Rate for the Combination Treatment,2004-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Survival
7515,NCT01202136,Prevalence and incidence of malignant pancreatic cysts,2012-10,COMPLETED,OBSERVATIONAL,['NA'],,Model for prediction of malignant pancreatic cysts
7516,NCT00522795,Complete Pathologic Response,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7517,NCT03620916,Severity of pain at rest,2018-08-17,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative complications
7518,NCT04911517,pathologic complete response（pCR）,2021-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,3-year overall survival (OS)
7519,NCT00384800,To assess the overall response rate of tegafur/uracil (UFUR®) and thalidomide in the treatment of advanced or metastatic hepatocellular carcinoma.,2006-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,To evaluate the changes of circulating factors indicating the angiogenesis activity and their correlation with objective tumor response.
7520,NCT04541875,To use the MAR-Scale to identify the top patient-reported reasons for non-adherence to specific medications indicated to treat these rare diseases.,2021-01,WITHDRAWN,OBSERVATIONAL,['NA'],,To perform psychometric analysis of the MAR-Scale questionnaire based on data collected from rare disease patients.
7521,NCT04574050,Feasibility: the number of patients recruited into this study over a 12-month period,2021-01-11,COMPLETED,INTERVENTIONAL,['NA'],,
7522,NCT05241574,Rate of patients with clinical complete response.,2021-08-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Acute and late toxicity assessed by Common Terminology Criteria for Adverse Events (CTCAE), version 5."
7523,NCT04151719,Overall Survival,2020-02-03,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,
7524,NCT03170310,Progress free survival,2017-02-21,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
7525,NCT05429697,Progression Free Survival,2022-06-09,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Quality of Life
7526,NCT06041490,EFFICACY: One-year recurrence-free survival rate (1-year RFS rate),2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,SAFETY: Incidence of adverse events and serious adverse events
7527,NCT03050879,Total Number of Retrieved Lymph Nodes,2017-10-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,3-year overall survival rate
7528,NCT03611309,Patient quality of life,2018-09-25,COMPLETED,INTERVENTIONAL,['NA'],,Caregiver prognostic awareness assessment
7529,NCT00005591,,1999-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
7530,NCT00662688,Thromboembolic events,2007-10,TERMINATED,INTERVENTIONAL,['PHASE3'],,Tolerance of regimens
7531,NCT03274349,"Muscle mass maintenance or increase, as assessed by Bioelectrical Impedance Analysis",2017-03-17,UNKNOWN,INTERVENTIONAL,['NA'],,Maintenance or increase in Body Mass Index (BMI) in kg/m^2-analysis (combination of weight in kilograms and height and in meters
7532,NCT01814631,image quality,2013-03,WITHDRAWN,OBSERVATIONAL,['NA'],,
7533,NCT03130712,Safety of CAR-T cell infusion mediated by intratumoral injection as measured by number of participants with adverse Events,2017-04-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Serum cytokine levels
7534,NCT03554395,Objective response rate,2018-04-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Symptom remission rate
7535,NCT05775120,"To assess the state of the gastric mucosa according to endoscopic and morphological studies using the OLGA system, and their correlation with serological markers of atrophy",2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],Develop recommendations for GC prevention and early detection strategy.,To determine the prevalence of H. pylori in the Moscow population according to the serological method - level of IgG antibodies to H.pylori.
7536,NCT03408665,SBRT efficiency in term of L-PFS for patient who are to be treated with SBRT in patients with primitive hepatic tumor of hepatic metastatis,2019-03-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Estimate the impact of the different SBRT techniques on SBRT efficacy according to OS.
7537,NCT05759975,Oral Mucositis evaluation according NCI scale,2023-01-13,RECRUITING,INTERVENTIONAL,['NA'],,Saliva analysis
7538,NCT03738280,Lesion borders (smooth or irregular),2016-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
7539,NCT06314022,Compliance with the laxative intake with the use of the mobile application,2024-05-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Evaluate colonoscopy quality indicators
7540,NCT05263219,Overall survival (OS),2022-02-10,RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse Events (AEs)
7541,NCT05331911,The presence of disease progression,2022-04-26,RECRUITING,INTERVENTIONAL,['PHASE4'],blood loss and blood transfusion,Length of hospital stays
7542,NCT01661114,The Percentage of Untreated and Previously Treated Patients That Had a Partial Response to Treatment,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival of Previously Treated and Previously Untreated Patients
7543,NCT02144727,overall survival,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Finding biomarkers predicting lymph node metastasis and recurrence
7544,NCT04709510,The incidence of thromboembolic events by radiological assessment,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Rate of predisposing factors of the patients
7545,NCT03940131,Overall response rate (ORR),2020-06-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
7546,NCT03881111,OS in PD-L1 biomarker-positive participants,2019-01-21,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Change from baseline in the EORTC Quality Of Life Questionnaire Oesophageal Module (QLQ-OES18) Score
7547,NCT03618758,Overall survival (Phase 2),2018-12-24,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Conversion surgery ratio
7548,NCT05629442,Rate of successful pathologic complete response,2023-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Overall Survival (OS)
7549,NCT03435770,To measure side effects and adverse event of EUS-guided RFA,2018-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,
7550,NCT02504229,Progression free survival,2014-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
7551,NCT00274885,Relationship between residual platinum levels in the blood and persistent neurotoxicity,2005-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Pharmacokinetics
7552,NCT00002759,,1996-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7553,NCT01209962,Diffusion MRI,2008-05,COMPLETED,OBSERVATIONAL,['NA'],,Apparent Diffusion Coefficient (ADC)
7554,NCT02040142,Evaluate the technical parameters,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Patient Reported Outcomes,Progression-free survival
7555,NCT04653818,HCC recurrence,2020-10-05,COMPLETED,INTERVENTIONAL,['PHASE4'],,changes in Child-Pugh scores over time
7556,NCT02307500,"activity of regorafenib screening, in terms of 2-months progression free survival rate",2014-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,safety profile of regorafenib according to NCI-CTC v.3
7557,NCT02610764,"Change of numbers of CTCs in patients with resectable EAC at diagnosis, after neoadjuvant treatment and after surgery.",2015-11,COMPLETED,INTERVENTIONAL,['NA'],Progression free survival,"Number of patients with detectable CTCs at diagnosis, after neoadjuvant treatment and after surgery."
7558,NCT00094861,Number of Participants With Grade 2 or Higher Dysphagia,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Maximal Body Weight Loss
7559,NCT04688242,Major LARS at 1 years after proctectomy,2021-02-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Other complications within 1 years after proctectomy
7560,NCT05278260,Number of participants who develop grade 3 oropharyngeal mucositis,2022-05-25,RECRUITING,INTERVENTIONAL,['NA'],,
7561,NCT00044512,Percentage of Participants for Each Type of Response,2002-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
7562,NCT02787954,Time to progression,2016-01,TERMINATED,OBSERVATIONAL,['NA'],,1 year survival
7563,NCT05592197,Overall Survival (OS),2018-10-01,WITHDRAWN,INTERVENTIONAL,['NA'],,ncidence of Adverse Events (AE)
7564,NCT02966054,Physical activity,2014-08,COMPLETED,INTERVENTIONAL,['NA'],,Colorectal cancer-specific quality-of-life (FACT-C)
7565,NCT01570075,overall survival,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],,disease-free survival
7566,NCT04559139,Difference in overall survival,2021-02-24,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Difference in progression-free survival
7567,NCT04050085,Incidence of adverse events,2019-08-15,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival
7568,NCT00501306,,2007-06,COMPLETED,OBSERVATIONAL,['NA'],,
7569,NCT00410579,"Comparison of patient-reported outcomes prior to randomization, 1 year after completion of study treatment, and in long-term follow up > 5 years after diagnosis in patients treated in NSABP C-06 or NSABP C-07 trials",2006-11,COMPLETED,OBSERVATIONAL,['NA'],,
7570,NCT06171321,Accuracy of postoperative ctDNA in monitoring recurrence and metastasis,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,ctDNA clearance rate
7571,NCT04905082,Recall rates of personal genomic results,2021-12-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],HOPE-Genomics tool usage,Operationalization of contextual guideline concordant care
7572,NCT01931644,Biospecimen & Clinical Data Collection,2013-07,RECRUITING,OBSERVATIONAL,['NA'],,
7573,NCT02431715,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
7574,NCT00002533,,1993-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
7575,NCT00178763,"Tumor response, disease-free survival",2003-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Allow inoperable pancreatic cancer to be converted to operable disease
7576,NCT00561522,The primary end point was to determine the effect on disease-free survival and overall survival by oral capecitabine.,2007-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,The secondary end point was to analyze the relationship between preventive effectiveness of capecitabine with thymidine phosphorylase expression level of tumor tissue.
7577,NCT06011772,Immunogencity of vaccine,2023-12-04,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Progression free survival
7578,NCT04075305,Toxicity in common toxicity criteria for adverse events (CTCAE).,2019-02-01,RECRUITING,OBSERVATIONAL,['NA'],,
7579,NCT02843945,Safety of CivaSheet Radiation Treatement,2017-05-31,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Length of Hospital Stay
7580,NCT02837159,Body Mass Index,2016-10,WITHDRAWN,INTERVENTIONAL,['NA'],,Lower-body flexibility
7581,NCT05864105,Objective Response Rate,2022-04-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,
7582,NCT02240212,Assessment of PR (vital signs) in Phase I Dose Escalation,2014-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Assessment of composite pharmacokinetics of afuresertib and paclitaxel in expansion cohort
7583,NCT01673269,the frequency of bacteremia after ERCP with direct cholangioscopic examination of the CBD,2012-07,COMPLETED,INTERVENTIONAL,['NA'],,To measure the frequency of fever or sepsis after ERCP with direct cholangioscopic examination of the CBD
7584,NCT01955629,Part 2: Number of Participants With Progression Free Survival (PFS) at 6 Months After the Start of Maintenance Therapy,2013-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Part 2: Aflibercept Biomarkers Evaluation
7585,NCT04792684,Samples Collected for Plasma Circulating Free-DNA (cfDNA) Marker Testing,2020-12-30,RECRUITING,OBSERVATIONAL,['NA'],,
7586,NCT02840890,episode of nausea and / or vomiting,2015-11-05,COMPLETED,INTERVENTIONAL,['NA'],,Quality of life questionnaire(QLQ-C30)
7587,NCT02799420,The percentage of cancer cells in biopsy samples,2016-06-20,COMPLETED,INTERVENTIONAL,['NA'],,The expression ratio of tumor marker in biopsy samples
7588,NCT04466592,general quality of life,2019-12-13,COMPLETED,INTERVENTIONAL,['NA'],,Number of participants maintaining their social activities
7589,NCT03033225,Tumor response,2016-12-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7590,NCT05452668,Pain Assessment,2023-05-16,RECRUITING,INTERVENTIONAL,['NA'],,Oral Mucositis Severity:
7591,NCT00501605,"primary objective is to evaluate the safety and tolerability of ascending single&multiple oral doses of AZD2171 by assessment of AEs,BP,HR,RR,ECG,clinical chemistry,haematology,urinalysis incl 24hr collection for protein&creatinine and physical exam.",2003-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,"PK,assess the effects of AZD2171 on surrogate markets of activity and to make a preliminary assessment of anti-tumor activity by measurement of tumor response and time to progression"
7592,NCT01120288,Determine the modulation of HIF-1 alpha mRNA in tumor biopsies pre- and post- administration of EZN-2968.,2010-04-29,COMPLETED,INTERVENTIONAL,['PHASE1'],,Assess the safety of EZN-2968 in patients with liver-predominant solid tumors. Determine the modulation of HIF-1 alpha protein levels in tumor biopsies pre- and post-administration of EZN-2968.
7593,NCT01335555,What is the effect of chemotherapy on the fitness of patients prior to cancer surgery?,2007-08,COMPLETED,OBSERVATIONAL,['NA'],,Survival outcome at 1 year
7594,NCT03585530,Overall survival(OS),2018-09-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life(QOL)
7595,NCT02082782,Efficacy,2014-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7596,NCT05929885,The Grade 3-5 Toxicity Rate.,2023-08-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS).
7597,NCT00525655,Pilot Test FAP Website (Interviews),2007-08,COMPLETED,INTERVENTIONAL,['NA'],,Participant Assessment of FAP Website (Questionnaire)
7598,NCT00199277,Preoperative variations in hemoglobin.,na,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Length of hospital stay
7599,NCT04699188,Dose expansion: ORR per RECIST 1.1 of JDQ443 single agent in patients with non-small cell lung cancer (JDQ443 dose randomization group only),2021-02-24,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Dose expansion: Duration of intracranial response (DOIR) per mRANO-BM
7600,NCT02560779,Overall Response Rate (ORR),2016-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,TRC105 Immunogenicity as Assessed by Anti-Product Antibody (APA)
7601,NCT04739072,Detection of recurrences post completion of curative therapies,2019-11-22,RECRUITING,OBSERVATIONAL,['NA'],"Nature and frequency of detection of incidental non-colorectal cancer related DNA, RNA and / or proteomic alterations",Overall survival (OS)
7602,NCT01823471,"The primary endpoint of the study was the difference in adenoma detection between HD-WLE and i-scan, expressed as the miss rate for polyps for each technique.",2010-11,COMPLETED,INTERVENTIONAL,['NA'],The difference in advanced adenomas between HD-WLE and i-scan and between the first and second inspection round.,The difference in overall adenoma detection between HD-WLE and i-scan
7603,NCT04810299,Nausea-vomiting,2021-04-16,COMPLETED,INTERVENTIONAL,['NA'],,
7604,NCT00835185,Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response ),2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Kirsten Rat Sarcoma (KRAS) Mutation Status
7605,NCT00258297,Effect on the signaling pathways by immunohistochemistry after 2-3 weeks of exposure to gefitinib,2004-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,
7606,NCT02454140,Maximum Tolerated Dose,2014-06-20,COMPLETED,INTERVENTIONAL,['NA'],,Overall Survival
7607,NCT06218511,Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability),2022-11-22,RECRUITING,INTERVENTIONAL,['PHASE1'],Assessment of the potential impact of the standard therapy on the natural immune response to peptides contained in IMA970A,OS
7608,NCT04730102,Existence of intraluminal malignant cells in fluid samples from rectal washout,2020-02-13,COMPLETED,OBSERVATIONAL,['NA'],,Fluid volume needed to perform rectal washout during transanal total mesorectal excision to eliminate intraluminal malignant cells
7609,NCT00100841,Progression Free Survival Rate,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7610,NCT05064410,"Change in Knowledge Related to Colorectal Cancer Risk, Prevention, and Screening",2017-05-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
7611,NCT05320328,Prospectively evaluate the safety and efficacy of combining intraductal Radio frequency ablation with biliary metal/ plastic stent placement for patients with malignant biliary obstruction.,2021-06-10,UNKNOWN,OBSERVATIONAL,['NA'],,Stent patency at 1 year
7612,NCT01521780,Expression Levels of Beta-catenin Protein From Core Needle Biopsy (CNB) Equivalents of Resected HCC.,2012-04,TERMINATED,INTERVENTIONAL,['PHASE1'],,Expression Levels of Low Density Lipoprotein Receptor (LDL-R) in Resected HCC and Adjacent Liver From Whole Tissue Sections.
7613,NCT03680261,3-year Overall Survival,2018-10-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Adverse effect (Safety and Tolerability)
7614,NCT00525200,Tumor response (clinical and pathological) to neoadjuvant treatment in relation to p53 genotype,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Disease free and overall survival and relation to p53 genotype
7615,NCT03559335,Postoperative inflammatory complications,2018-01-15,COMPLETED,OBSERVATIONAL,['NA'],,
7616,NCT03460080,PIVKA-II,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Prothrombin Time (PT) (%)
7617,NCT03097224,Change in cardiorespiratory fitness,2017-04-04,UNKNOWN,INTERVENTIONAL,['NA'],,Adherence
7618,NCT03032224,Changes in Body composition after surgery for esophageal cancer with curative intent.,2015-03-23,COMPLETED,OBSERVATIONAL,['NA'],,Mortality
7619,NCT00188305,Colon screening behaviour,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Satisfaction
7620,NCT01726465,A decrease of 100 UI/L of AST and ALT compared with placebo.,2012-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Difference in blood transfusions.
7621,NCT00526110,Progression Free Survival,2004-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Median Overall Survival
7622,NCT01570452,,2005-09,COMPLETED,OBSERVATIONAL,['NA'],,
7623,NCT01142713,Dose and irradiated volume of small bowel and urinary bladder,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
7624,NCT00561548,Relative variation (%) in apoptotic cells calculated according to the formula: (% of induced apoptotic cells) - (% of spontaneous apoptotic cells),2007-05,TERMINATED,INTERVENTIONAL,['NA'],,Lymphocyte activation markers and macrophage activation markers
7625,NCT03594188,cell proliferation,2018-07-23,COMPLETED,INTERVENTIONAL,['NA'],,cell metastasis
7626,NCT06149741,Low anterior resection syndrome (LARS),2023-11-20,RECRUITING,INTERVENTIONAL,['NA'],,Bowel ischaemia
7627,NCT05269381,Incidence of adverse events,2022-03-31,RECRUITING,INTERVENTIONAL,['PHASE1'],Pre-existing Immunity,Immunogenicity responders
7628,NCT01696695,PFS by Therapeutic Regimens,2011-07,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of Participants With Dose Modification of Capecitabine
7629,NCT01277120,Correlation of the time from the start of chemotherapy to the start of Avastin treatment with progression-free survival,2010-04,TERMINATED,OBSERVATIONAL,['NA'],,Safety: Incidence of adverse events
7630,NCT00661154,Determine whether[18F]-5-Fluorouracil PET/CT scanning can demonstrate a difference in [18F]-5-Fluorouracil tumor uptake before and after the administration of Avastin,2008-02,COMPLETED,OBSERVATIONAL,['NA'],,Determine if [18F]-5-Fluorouracil PET/CT imaging demonstrates that there is a difference in maximal [18F]-5-Fluorouracil tumor uptake that is dependent on the time point of post-Avastin scanning
7631,NCT00909558,Is there any measurable effect upon the underlying cancer as assessed by an increase or decrease in the tumor as measured from baseline using established criteria?,2009-05,SUSPENDED,INTERVENTIONAL,['PHASE1'],,"Are the dosages administered during the study safe, as measured by the number of unexpected and serious adverse events associated with the study drug, as defined by FDA regulations and as measured by established criteria?"
7632,NCT04910386,Progression-free survival (PFS),2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease control rate (DCR)
7633,NCT02316535,disease free survival,2014-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,quality of life
7634,NCT01116687,Number of Participants With Objective Radiographic Response (ORR),2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Related Serious Adverse Events (SAEs)
7635,NCT01034332,To determine whether clinical response to one cycle of induction chemotherapy (TP-HDFL) could predict the pathologic complete response to preoperative chemoradiotherapy (TP-CCRT,2007-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
7636,NCT02932956,Number of Patients with Dose Limiting Toxicity,2018-12-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Median T cell persistence
7637,NCT02308722,Maximum tolerated dose (MTD),2015-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival and progression free survival at 12 and 24 months post D1 SBRT
7638,NCT00020605,,2000-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
7639,NCT01727388,realization of a full digital rectal examination,2012-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Evaluation of the position by the patient
7640,NCT00270647,Major cardiovascular events,1997-07,COMPLETED,INTERVENTIONAL,['NA'],,Colorectal cancer
7641,NCT04031872,Phase II: Response rate (RR) of galunisertib in combination with capecitabine in patients with chemotherapy resistant activated TGF-β signature-like CRC.,2020-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression free survival (phase II only)
7642,NCT03046979,Objective Response Rate(ORR),2016-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events [Safety]
7643,NCT04926376,Overall Response Rate (ORR) by mRECIST,2021-11-02,COMPLETED,INTERVENTIONAL,['NA'],,
7644,NCT02726854,ORR (Objective response rate),2016-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by NCI-CTC（V3.0）
7645,NCT01344902,Determine the carcinoma- and adenoma lesion true detection rate,2009-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
7646,NCT02532478,Stoma closure rate,2007-02,COMPLETED,OBSERVATIONAL,['NA'],5-year overall survival,
7647,NCT00829465,OS of 1 years; TTP,2008-12,COMPLETED,INTERVENTIONAL,['PHASE4'],,
7648,NCT04188145,The Time-to-Treatment Failure (TTF),2020-01-27,RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of Life (QoL)
7649,NCT04418895,complete pathologic response (pCR) rate,2021-08-13,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Median Neoadjuvant Rectal Score (NAR)
7650,NCT06282016,Asthma,2024-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Area deprivation
7651,NCT01918527,Two-year disease free survival,2013-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Rate of patients fulfilling the criteria for adjuvant chemotherapy
7652,NCT02785835,Overall survival,2014-05,COMPLETED,OBSERVATIONAL,['NA'],,
7653,NCT04192539,serum taurine levels,2017-01-18,COMPLETED,INTERVENTIONAL,['NA'],,
7654,NCT05733611,Objective Response Rate (ORR),2023-06-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Complete Response Rate
7655,NCT03719573,30-second chair stand test (30s-CST),2019-02-21,COMPLETED,INTERVENTIONAL,['NA'],,doses of adjuvant chemotherapy
7656,NCT03042000,3y-DFS,2017-02,UNKNOWN,INTERVENTIONAL,['NA'],,pCR
7657,NCT04527939,"Degree of parietal invasion (T),",2020-08-07,UNKNOWN,INTERVENTIONAL,['NA'],,
7658,NCT03648073,Number of Patients Demonstrating Somatostatin Receptor Positivity in Hepatocellular Carcinoma Using [68Ga]DOTATATE-PET,2019-01-30,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
7659,NCT00942266,Disease Control Rate (Stable Disease or Objective Response),2009-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Fluorouracil Steady-state Pharmacokinetics
7660,NCT03935763,Overall survival,2019-03-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Quality of life using Patients Reported Outcomes
7661,NCT00005648,Overall survival of patients with advanced pancreatic cancer after treatment with gemcitabine with or without R115777.,1999-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,The incidence of adverse events with respect to severity and relationship to the study medication as a measure of safety
7662,NCT01244022,Postoperative changes of serum cytokine levels,2010-08,COMPLETED,OBSERVATIONAL,['NA'],,Early postoperative complications
7663,NCT00003172,,1997-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7664,NCT00565487,To determine optimal dosage for Capecitabine and Tarceva combination in the setting of radiation.,2007-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,To assess treatment efficacy and overall survival.
7665,NCT02016534,Objective Response Rate (RECIST v1.1) in subjects with MET Amplified measurable G/GEJ/E adenocarcinoma (Cohort 1),2014-02,TERMINATED,INTERVENTIONAL,['PHASE2'],"Response to AMG 337 and MET amplification, expression or presence of mutation in tumor specimens",Objective Response Rate (per RECIST v1.1) in subjects with other MET amplified solid tumors (subjects with measurable disease in cohort 2).
7666,NCT00517621,Validation of a french version of FACT-GOG/NTX of peripheral neurotoxicity questionnaire,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,- Incidence of the thrombo-embolic events according to whether the patients are treated or not by EPO
7667,NCT00319007,"Pouch mucosal apoptosis index at 0, 1 and 2 months",2006-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Faecal cytotoxicity at 0, 1 and 2 months"
7668,NCT02951273,Changes in Internal Carotid Artery Blood Flow by Treatment of Anaesthesia-induced Hypotension,2016-12-08,COMPLETED,OBSERVATIONAL,['NA'],,Changes in Stroke Volume From Baseline Before Induction of Anaesthesia.
7669,NCT02292173,Maximum Tolerated Dose (MTD),2015-02-18,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
7670,NCT06129812,Overall survival,2007-01,COMPLETED,OBSERVATIONAL,['NA'],,
7671,NCT00975897,Efficacy of IrMdG with vs without bevacizumab in K-ras mutant tumors,2009-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Attitudes of patients about tests and treatment
7672,NCT00935779,,2002-10,COMPLETED,OBSERVATIONAL,['NA'],,
7673,NCT01164215,Achievement of targeted AUC using pharmacokinetic (PK)-guided 5 fluorouracil as part of mFOLFOX6 therapy,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Toxicity differences between PK-guided therapy versus non-PK-guided therapy
7674,NCT02964468,Gastrointestinal toxicity,2016-09,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of Life during the treatment
7675,NCT06042842,(1) To evaluate the clinical utility of plasma circRNAs (hsa_circ_0004001)by Q-PCR as a non invasive diagnostic biomarker for HCC patients and to differentiate between malignant and nonmalignant hepatic disorders,2023-11,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
7676,NCT05126290,Number of CTNNA1 genotypes associated with a cancer phenotype,2021-03-16,RECRUITING,OBSERVATIONAL,['NA'],,
7677,NCT02735057,maximum tolerated dose (MTD),2016-04-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall survival
7678,NCT02862704,Number of patients with adverse event,2016-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Detection of transferred T cells in the circulation using quantitative -PCR
7679,NCT01534923,describe doctor-patient communication about CRC screening,2012-02-07,COMPLETED,OBSERVATIONAL,['NA'],,examine the association between the quality of doctor-patient communication about CRC screening and low-income patients' screening outcomes
7680,NCT01989000,"Predictive value of pretreatment DWI, DCE-MRI, T2*, and 18F-HX4-PET/CT on overall survival in patients with pancreatic cancer treated with surgery and adjuvant chemotherapy or with neoadjuvant radiochemotherapy, surgery and adjuvant chemotherapy.",2013-11,COMPLETED,INTERVENTIONAL,['NA'],Immunohistochemically determined parameters of the tumor microenvironment assessed in pretreatment tumor biopsies and post-surgery resection material correlate,Immunohistochemically determined parameters of the tumor microenvironment assessed in a pretreatment tumor biopsy to predict overall and recurrence-free survival
7681,NCT02291211,PFS: Progression Free Survival,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety as measured by recording the subjects' Adverse Events from randomization to termination
7682,NCT00961077,To evaluate response rate of attenuated SOX as first-line chemotherapy in elderly patients with relapsed or metastatic AGC,2009-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"To evaluate progression free survival, overall survival, and toxicities of aSOX-regimen"
7683,NCT00290524,Hospitalisation stay measured in days,2006-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Post-surgery complications
7684,NCT02114359,comparison of overall survival,2014-02,COMPLETED,INTERVENTIONAL,['PHASE3'],comprehensive geriatric assessment,comparison of quality of life
7685,NCT01517009,"The number of patients with (serious) adverse events receiving the combination of 4 courses of docetaxel, cisplatin and capecitabine as neoadjuvant chemotherapy and standardized surgery in resectable localized or locally advanced gastric cancer.",2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,The number of patients receiving a D1-extra-resection as protocolized surgery in resectable gastric cancer
7686,NCT03531606,Anterior resection syndrome improvement change,2016-12-12,COMPLETED,INTERVENTIONAL,['NA'],,Other biomarkers
7687,NCT00735566,"Relationship between antiangiogenic factor and tumor, node, metastasis",2006-04,COMPLETED,OBSERVATIONAL,['NA'],,"Overall survival, treatment failure"
7688,NCT04736485,Pathologic response after pre-operative treatment,2021-06-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Treatment-Related Adverse Events
7689,NCT00045175,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7690,NCT04603586,1-year Disease Progression-Free-Survival (DPFS),2020-10-20,UNKNOWN,INTERVENTIONAL,['NA'],,Overall Survival
7691,NCT04380766,Changes in pancreatic cancer management during the COVID-19 pandemic,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
7692,NCT03788499,Incidence of severe radioactive oral mucositis,2019-01-11,COMPLETED,INTERVENTIONAL,['NA'],,the time at which the radioactive oral mucosa occurred; Difficulty in opening your mouth.
7693,NCT05637567,Hematogenous metastases-free survival,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of resected lymph nodes
7694,NCT04411524,Pathologic Complete Response Rate,2020-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Quality of Life Scale, range 0-60. It evaluates the quality of life from 12 aspects, including appetite, mental status, sleep quality, fatigue, etc. The higher scores mean a better quality of life."
7695,NCT04759794,The usefulness of new staining method,2021-02-04,RECRUITING,INTERVENTIONAL,['NA'],,
7696,NCT04759846,Encorafenib AUC(0-inf),2021-01-21,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,MRAUC
7697,NCT02687009,Dose limiting toxicity,2017-11-07,TERMINATED,INTERVENTIONAL,['PHASE1'],,Niclosamide blood levels
7698,NCT00003873,Overall survival,1999-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,
7699,NCT03647540,the number of the dissected lymph nodes,2018-08-30,UNKNOWN,INTERVENTIONAL,['NA'],,The mean postoperative hospital stay
7700,NCT05117047,Disease free Survival,2015-02-14,COMPLETED,OBSERVATIONAL,['NA'],,Textbook Outcome in liver surgery (TOLS)
7701,NCT03698643,Patient effective radiation dose per TACE,2018-04-01,COMPLETED,OBSERVATIONAL,['NA'],,Tumor response
7702,NCT01863303,incidence of CRC,2012-06,UNKNOWN,OBSERVATIONAL,['NA'],,
7703,NCT01305980,Evaluating Tumor Response Rate,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Determine duration of response rate by measuring time to progression
7704,NCT01834963,Two-year overall survival rate,2013-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,toxicity
7705,NCT00024375,,2001-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
7706,NCT00397878,Median Progression Free Survival (PFS),2006-11,TERMINATED,INTERVENTIONAL,['PHASE2'],Pre- and Post-treatment Expression Values for Each Biological Correlate,Time to Progression
7707,NCT02570529,Gastrointestinal ulcer incidence,2015-10,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,Adverse event of gastrointestinal hemorrhage
7708,NCT02712112,disease control rate,2016-03-16,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7709,NCT01288833,Rate of Accurate High Confidence Polyp Histology Predictions by the Endoscopist in the Two Groups.,2011-03,COMPLETED,INTERVENTIONAL,['NA'],,Learning Curve
7710,NCT00487552,Success Rate Associated With the Creation of a Gastro-jejunal Anastomosis Using the Cook Magnetic Anastomosis Device With Trans-anastomotic Deployment of a Gastro-jejunal or Duodenal Stent,2008-01,TERMINATED,INTERVENTIONAL,['NA'],,
7711,NCT02882269,disease-free survival,2016-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,number of lymph nodes retrieved
7712,NCT02380131,progression-free survival(PFS),2013-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],The number of Participants with adverse events,Objective response rate (ORR)
7713,NCT00443196,"Complete Response, No Response",2006-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
7714,NCT00598117,To prospectively evaluate the quality of life of patients before and after esophageal cancer resection.,2003-08,COMPLETED,OBSERVATIONAL,['NA'],,To describe a cohort of long term survivors of esophageal cancer in order to identify significant features in patients more than 18 months post surgery.
7715,NCT04002128,Number of the patients with hoarseness,2008-01,COMPLETED,INTERVENTIONAL,['NA'],,One year survival and complications
7716,NCT00777894,Best objective response of target liver lesions (TLLs),2008-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Serum alpha-fetoprotein level (Phase II)
7717,NCT00440167,TTF2,2006-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Toxicity
7718,NCT04993378,EV-Score,2018-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,Survival significance of EV-Score
7719,NCT02866383,Clinical benefit rate (CBR),2016-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,QoL
7720,NCT02405585,Progression Free Survival,2015-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Resection Rate
7721,NCT02947165,"Incidence of DLTs, AEs, SAEs and dose reductions/interruptions for NIS793 in combination with PDR001",2017-04-25,COMPLETED,INTERVENTIONAL,['PHASE1'],,Characterization of tumor infiltrating lymphocytes by immunohistochemistry using markers such as CD8 and PD-L1
7722,NCT05953337,Incidence of serious adverse events (SAEs),2023-09-21,RECRUITING,INTERVENTIONAL,['NA'],,
7723,NCT05576909,Downstaging success rate,2023-03-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
7724,NCT03322995,Completion of all intended neoadjuvant therapy and surgical therapy,2018-06-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression-free survival
7725,NCT02484079,Complete resection rate,2015-05-18,COMPLETED,INTERVENTIONAL,['NA'],,Factors explaining the primary outcome
7726,NCT05970159,Postoperative complications,2023-08,RECRUITING,OBSERVATIONAL,['NA'],Days of ICU stay,Mortality
7727,NCT03981497,Time to Local Progression,2018-02-28,RECRUITING,OBSERVATIONAL,['NA'],,Organ specific Progression Free Survival (PFS)
7728,NCT05498194,The neoantigen landscape of patients with gastric cancer,2022-08-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,The ratio of predicted neoantigens being immunogenic.
7729,NCT02961374,Number of Participants With Grade 2/3 Adverse Event (AE),2017-10-27,COMPLETED,INTERVENTIONAL,['PHASE2'],Change in Differentially Expressed Genes of Duodenal Polyps and Uninvolved Tissue,Absolute and Percent Change in Desmoid Tumor Size
7730,NCT03331055,visal analogue scale (VAS) score,2017-10-27,COMPLETED,INTERVENTIONAL,['NA'],complications,times of breakthrough pain (BTP)
7731,NCT02872831,Diagnostic Accuracy of the 22G SharkCore™ and the 22G BNX EUS-FNA needle,2016-07,TERMINATED,INTERVENTIONAL,['NA'],,Specificity of the 22G SharkCore™ needle and the 22G BNX EUS-FNA Needle for the diagnosis malignancy in solid lesions of the pancreas and gastrointestinal tract.
7732,NCT01386931,Compare the percent of patients with inadequate samples (defined by an absence of cellular elements to account for a mass/lesion) between the two groups,2011-06,COMPLETED,OBSERVATIONAL,['NA'],,Compare the percent of patients requiring repeat procedures between the groups
7733,NCT01503983,Overall Survival,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,time to response
7734,NCT05871333,change in severity of intestinal mucositis,2023-07-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,Laboratory evaluation of Interleukin-1β level
7735,NCT00273247,Recurrence Free Survival,1998-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall Patient Survival
7736,NCT01276002,Recurrence of pancreatic pseudocyst,2011-01,WITHDRAWN,INTERVENTIONAL,['NA'],,
7737,NCT05836064,Re-scheduled colonoscopy,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,GastroBot functionality
7738,NCT00065117,,2003-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,
7739,NCT04410302,Establish and characterize at least 200 patient-derived cancer xenografts (PDXs),2019-11-12,RECRUITING,OBSERVATIONAL,['NA'],,
7740,NCT01116804,"To evaluate the efficacy of PET-imaging versus classic response assessment (MRI, CT-scam) in patients with inoperable liver cancer",2010-06-16,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7741,NCT03154190,Hospitalization Visits (Chart Review),2017-08-08,UNKNOWN,INTERVENTIONAL,['NA'],,Palliative Care Consult (Chart Review)
7742,NCT03246321,Major toxicity,2017-10-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Procedure-related characteristics: blood loss
7743,NCT04987788,Colonoscopy completion,2021-08-19,COMPLETED,INTERVENTIONAL,['NA'],,
7744,NCT01383538,The maximum tolerated dose (MTD) for FOLFIRINOX plus IPI-926 in patients with advanced pancreatic cancer.,2011-08-23,COMPLETED,INTERVENTIONAL,['PHASE1'],,Objective response rate (ORR) by RECIST criteria
7745,NCT05476978,The model's ability to differentiate pancreatic cancer from other pancreatic solid lesion,2022-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,"The model's ability to specify the pancreatic solid lesions such as pancreatic cancer, CP, AIP and NET"
7746,NCT01598194,Comparison of Diagnostic Adequacy Scores With SST vs. CST for Histologic Diagnosis Using a 22G Core Needle.,2012-01-30,COMPLETED,INTERVENTIONAL,['NA'],,Comparison of Diagnostic Adequacy of Single Pass With 22G Core Needle and Standard 25G Needle for Cytologic Diagnosis
7747,NCT00931840,Response Rate,2009-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Progression Free Survival (PFS)
7748,NCT03189576,ctDNA level,2015-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
7749,NCT00059826,Overall survival at 18 months,2003-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Distant disease control
7750,NCT06332079,Progression-free survival (PFS) Rate,2024-03-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of Life (QoL) assessed using the EuroQol EQ-5D questionnaire
7751,NCT01506167,Overall Survival,2012-07-06,COMPLETED,OBSERVATIONAL,['NA'],,Response to the Burden of Illness Question: Has your cancer resulted in a family member seeking support?
7752,NCT02692365,Exploratory study for the determination of tissue changes of advanced hepatocellular carcinoma induced by electromagnetic waves amplitude modulated low energy specific frequencies during image MRIstudy.,2015-09,COMPLETED,INTERVENTIONAL,['NA'],,
7753,NCT04136522,2 years recurrence free survival,2020-01-10,RECRUITING,INTERVENTIONAL,['NA'],,Recurrence pattern
7754,NCT04708951,Comparison between adenoma detection rate of G-EYE® colonoscopy and EndoCuff Vision®,2021-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
7755,NCT03885817,Patient reported peripheral sensory neuropathy,2019-03-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Diagnosed with type 2 diabetes.,Overall- and disease free survival
7756,NCT02082691,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
7757,NCT03916510,MRI tumour regression grade,2019-07-01,COMPLETED,INTERVENTIONAL,['PHASE1'],Analyse the immune microenvironment as evidenced by immune cell infiltrates,Neoadjuvant Rectal (NAR) score
7758,NCT00487851,"Primary outcome consist of a composite score (i.e. number of hospitalizations, episodes of cholangitis, degree of jaundice, other complications requiring therapeutic interventions). Secondary outcome are QoL,hospital stay and health economic burden.",2007-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
7759,NCT03578224,Accuracy rate of traditional endoscopic ultrasonography (EUS) with suspicious node biopsy and lymphosonography for sentinel node identification,2018-09-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Number of nodes identified
7760,NCT03806426,Total Number of Polypectomies (polyps > 5mm in the rectum) conducted during the 24 months study period,2018-12-05,RECRUITING,INTERVENTIONAL,['PHASE3'],,Change in score on the InSIGHT Polyposis Staging System (IPSS) at 24 months
7761,NCT02848443,Changes in ECOG (Eastern Cooperative Oncology Group) performance status as a measure of safety and tolerability for S95005-oxaliplatin,2016-05,COMPLETED,INTERVENTIONAL,['PHASE1'],Peripheral blood mononuclear cells,"PDL-1 expression, tumour-infiltrating CD8 T cell density, for S95005-oxaliplatin + nivolumab"
7762,NCT05162352,Progression free survival (PFS) assessed by investigators according to modified Response Evalutaion Criteria in Solid Tumors (mRECIST).,2021-12-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,DCR assessed by investigators according to RECIST 1.1.
7763,NCT01861678,Anastomotic leakage rate,2006-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Amount of blood loss
7764,NCT02807337,Oral mucositis will be assessed daily for all 75 pediatric patients at the oncology ward and at home by use of the Children International Mucositis Evaluation Scale (ChIMES scale) and WHO oral mucositis scale.,2016-08-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7765,NCT00275210,Every 3 years colonoscopy for polyp free patient,1998-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Every 2 weeks clinical and laboratory tests (hematological, creatinine and liver tests) for safety evaluation during treatment then every 6 months neurological examination Date of death for OS"
7766,NCT00738478,Quality of life,2006-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,"complication, hematological data,"
7767,NCT05281926,Area Under the Concentration-Time Curve(ACU 0-22 weeks),2021-10-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Area Under the Concentration-Time Curve(ACU 0-24 weeks)
7768,NCT02184910,the change of pepsinogen level before and after H. pylori eradication,2013-12,UNKNOWN,OBSERVATIONAL,['NA'],,
7769,NCT05276973,Incidence of adverse events,2022-09-08,RECRUITING,INTERVENTIONAL,['PHASE1'],Tumor response,Tumor response
7770,NCT00428220,Number of Participants With Treatment-emergent AEs (Treatment-Related),2007-07,COMPLETED,INTERVENTIONAL,['NA'],Summary of Duration of Clinical Benefit,
7771,NCT05995821,Biological specimens obtained from cancer patients,2016-08-25,RECRUITING,OBSERVATIONAL,['NA'],,
7772,NCT02488746,Rate of cases in which a complete macroscopic en bloc resection of the gastric subepithelial tumor could be achieved,2015-03,TERMINATED,OBSERVATIONAL,['NA'],,Number of participants with needs of surgical therapy or endoscopic re-resection
7773,NCT01384994,Progression Free Survival,2011-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall Survival
7774,NCT01829178,Urine concentration of NGAL,2013-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Tissue activity of caspase 3
7775,NCT03248661,Primary endpoint is a received completed FIT kit within 15 months after the participant received results from the original FIT test,2015-08-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,
7776,NCT04776837,Treatment Response at 1st Scan,2019-05-15,COMPLETED,OBSERVATIONAL,['NA'],,Skeletal Muscle Analyses
7777,NCT01609504,oncological result in term of local and/or systematic recurrence,1997-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,cancer-related mortality
7778,NCT06228209,The proportion of screened eligible patients,2024-01-26,RECRUITING,INTERVENTIONAL,['NA'],,Patient-Reported Goals of Care Discussion (GOCD)
7779,NCT02327494,the central venous oxygen saturation (ScvO2),2015-01,UNKNOWN,OBSERVATIONAL,['NA'],,postoperative outcome
7780,NCT01396707,Overall response rate,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
7781,NCT05498766,3-year DFS rate,2023-10-12,RECRUITING,OBSERVATIONAL,['NA'],,"Incidence and severity of adverse reactions, serious adverse reactions, suspicious and unexpected serious adverse reactions"
7782,NCT04595058,Recurrent biliary obstruction (RBO),2020-11-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Survival
7783,NCT04047771,Occurrence of adverse events (AEs) and serious adverse events (SAEs),2019-09-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics (AUC 0-inf)
7784,NCT01750918,Part 3: Progression Free Survival (PFS),2012-12-19,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Part 3: Number of Participants With Treatment Emergent Adverse Events
7785,NCT04359498,Surgical complications,2020-04-01,COMPLETED,OBSERVATIONAL,['NA'],,
7786,NCT04939051,Mean change Leucine-rich repeat-containing G-protein coupled receptor 5 (LGR) 5+ cells,2023-07-27,RECRUITING,INTERVENTIONAL,['PHASE2'],Safety profile of treatment with OCA,
7787,NCT03644459,AUC(0-∞) of T1h after Each Subsequent Introduction (multiple dose),2019-04-03,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Half time (t1/2) of T1h after Each Subsequent Introduction (multiple dose),PGA after Each Subsequent Introduction (multiple dose)
7788,NCT06284226,To evaluate the safety and the efficacy,2022-03-25,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,To assess the modulation in tumor markers
7789,NCT02071069,The progression free-survival,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Grade 3 and 4 adverse Events as a Measure of Safety and Tolerability
7790,NCT03006432,progression-free survival,2016-12-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Toxicity events according to NCI-CTC v4.0
7791,NCT05547828,Objective Response Rate (ORR),2022-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Drug-Related Safety Indicators
7792,NCT01284413,one year survival rate,2010-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Toxicity and response rate
7793,NCT00358683,"For ethical reasons, provide the opportunity for patients > 18 years suffering from Crohn's disease who both completed the therapeutic confirmatory study C87055 of certolizumab pegol and benefited from the treatment, to receive treatment with certolizum",2007-11,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Incidence of adverse events reported by the patients during the long-term treatment period of the study.
7794,NCT05171335,Percent Tumor Necrosis,2022-06-20,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2'],,Explant Biomarkers
7795,NCT00802555,To evaluate the safety of ARQ 197 when administered in cirrhotic patients diagnosed with HCC,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To evaluate dynamic changes of hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), and soluble c-Met in patients' peripheral blood that are associated with ARQ 197 treatment"
7796,NCT01651949,Percentage of Participants Who Had Study Vaccine Discontinued Due to an Adverse Event,2012-10-29,COMPLETED,INTERVENTIONAL,['PHASE3'],,Percentage of Participants With Seroconversion to the HPV Types Contained in the 9vHPV Vaccine
7797,NCT00039611,,2002-05,COMPLETED,INTERVENTIONAL,['NA'],,
7798,NCT03284684,Change in integrity index of circulating DNA for KRAS gene,2018-01-22,COMPLETED,OBSERVATIONAL,['NA'],,Change in plasma concentration of BRAF DNA fragments with V600E mutation
7799,NCT01693835,Circadian rhythms in urinary excretion of modified nucleosides,2012-08,COMPLETED,OBSERVATIONAL,['NA'],,
7800,NCT01963117,Time to Local Tumor Progression After Combined Hyperthermia and RT,2013-10,TERMINATED,INTERVENTIONAL,['NA'],,Overall Survival Rate After Combined Hyperthermia and RT
7801,NCT04205097,total dose of remifentanil,2019-12-23,COMPLETED,INTERVENTIONAL,['NA'],,
7802,NCT00004604,Safety,1997-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Immune response
7803,NCT05121038,Drug Safety: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,2021-10-20,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pathological response rate (PCR) .
7804,NCT01830621,Overall Survival,2013-05-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change of Global Quality of Life at 8 Weeks From Baseline
7805,NCT00662246,all cause mortality,2007-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7806,NCT02692911,Cancer/precancer,2017-01-11,COMPLETED,OBSERVATIONAL,['NA'],,
7807,NCT06010225,Total medical costs,2020-05-01,COMPLETED,OBSERVATIONAL,['NA'],,adherence to the ERAS protocols
7808,NCT05171517,Microflora analysis accomplished,2022-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
7809,NCT05986383,Postoperative liver failure rate (50-50 criteria),2023-08,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Clavien-Dindo grade of postoperative complications
7810,NCT01946282,FIT Completion Among Patients Offered Any Incentive vs. Outreach Alone Each Year,2013-11,COMPLETED,INTERVENTIONAL,['NA'],,"FIT Completion for Groups Offered $5 vs. Outreach Alone, $10 vs. Outreach Alone, and $5 vs. $10 Incentive"
7811,NCT00176774,Toxicity,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,To determine the success rate of TM leading to target levels of copper depletion in patients treated concurrently with chemotherapy
7812,NCT04128657,Validation of the moroccan arabic version of the Wexner score,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
7813,NCT00172640,,2005-01,UNKNOWN,OBSERVATIONAL,['NA'],,
7814,NCT01529164,response rate,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of participants with adverse events
7815,NCT04547881,Total time for lesion removal,2016-12-12,COMPLETED,OBSERVATIONAL,['NA'],,
7816,NCT05838391,Time to plan and deliver treatment fractions.,2023-05-18,RECRUITING,INTERVENTIONAL,['NA'],,Complete Clinical Response Rate
7817,NCT00410774,Disease-free survival rate at 1 year,2006-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Median overall survival rate at 1 and 2 years
7818,NCT04358341,Disease control rate (DCR),2020-06-17,UNKNOWN,INTERVENTIONAL,['PHASE2'],,EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores
7819,NCT00510627,To evaluate Overall Survival in subjects receiving chemotherapy + RFA compared to chemotherapy alone.,2007-08,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,To determine if there are differences in the incidence or severity of adverse events in the RFA + chemotherapy arm compared to the chemotherapy only arm.
7820,NCT04258566,ICG Fluorescene,2022-01-27,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE1'],,Exvivo fluorescence
7821,NCT00588549,To assess if whole body 18F-FDG-PET enhances our ability to detect metastatic colorectal cancer restricted to liver and lung over conventional imaging such as CT and to determine the accuracy of PET in imaging extrahepatic tumors.,1998-07,COMPLETED,OBSERVATIONAL,['NA'],,To determine whether PET plays a role in altering clinical management of patients undergoing evaluation for liver resection for hepatic colorectal metastases.
7822,NCT05738421,To provide objective data on the bolus transit during swallowing in tracheostomized patients with tracheal tube and without tracheal tube,2021-12-06,RECRUITING,OBSERVATIONAL,['NA'],,To evaluate the features of swallowing
7823,NCT00693342,Progression-free survival,na,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Correlation of outcome with antigen-specific immune titers in a limited sampling of patients
7824,NCT01939275,"Number of HER2 Negative, Positive, or Equivocal Participants With Either Negative or Positive Tumor Readings",2014-11-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
7825,NCT04561453,Success Rate of Obtaining circulating tumor DNA (ctDNA) quantification and Ability to assess change in ctDNA levels across those time points,2020-07-08,RECRUITING,OBSERVATIONAL,['NA'],,Predictive Value of circulating tumor DNA (ctDNA) for Response to Medical Therapy
7826,NCT04379999,Genome-wide expression analyses using RNA-Seq,2018-09-10,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Acceptability of the pilot study intervention and the willingness of the subject to participate in a similar larger study.
7827,NCT00002773,,1996-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7828,NCT01633203,Rate of downstaging,2010-08,COMPLETED,OBSERVATIONAL,['NA'],,HER 2 expression
7829,NCT00584129,"To test whether pre-treatment swallowing exercises compared with ""usual care"" (where exercises are taught post-treatment) improves quality of life in patients undergoing chemoradiation therapy for advanced head and neck cancer.",2006-02,COMPLETED,INTERVENTIONAL,['NA'],,To test whether pre-treatment swallowing exercises compared with usual care improves secondary outcome measures related to dysphagia in this patient population.
7830,NCT02253511,Overall survival,2014-07,UNKNOWN,INTERVENTIONAL,['PHASE4'],Number of participants with adverse events,Recurrence-free survival
7831,NCT02310477,Overall survival (OS),2014-02,COMPLETED,OBSERVATIONAL,['NA'],,Progression-free survival (PFS)
7832,NCT03177681,Percentage Change in Firmicutes in Stool from Baseline to Day 12,2022-03-01,WITHDRAWN,INTERVENTIONAL,['NA'],,Adherence Rate of Dannon® Oikos® Yogurt Intake
7833,NCT04161781,Feasibility of 18F-BMS-986229 PET in participants with Gastroesophageal Cancer,2019-11-12,COMPLETED,OBSERVATIONAL,['NA'],,
7834,NCT03008304,Relief degree of tumors,2016-12-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival（OS）
7835,NCT01628211,overall survival,2012-04,RECRUITING,INTERVENTIONAL,['PHASE2'],,list of therapies and clinical outcomes of patients who had radiologic evidence of disease within 6 months after initial surgery
7836,NCT04694183,R0 resection rate,2020-08-17,COMPLETED,INTERVENTIONAL,['PHASE2'],,Serious adverse events(≥grade 3）
7837,NCT04775056,Immunogenicity index-seroconversion rates of neutralizing antibody,2022-08,WITHDRAWN,OBSERVATIONAL,['NA'],,Immunogenicity index-seropositive rates of neutralizing antibody
7838,NCT03192462,Number of Patients Who Received 6 Infusions of multiTAA-specific T Cells,2018-01-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival Using the Kaplan-Meier Method
7839,NCT03180411,Development of Decision Tool to Guide Participants in Making Individualized Decisions Regarding Colorectal Cancer (CRC) Surveillance Through the Use of Cognitive Testing Interviews,2017-02-14,COMPLETED,OBSERVATIONAL,['NA'],,
7840,NCT00633295,To evaluate the efficacy of nilotinib in GIST patients resistant or intolerant to imatinib and or 2nd line TK inhibitor as measured by tumor up take of FDG PET quantitated by maximum,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,To assess the safety and tolerability of nilotinib as measured by rate and severity of adverse events
7841,NCT04827732,Maximum tolerated dose (MTD) of reirradiation using hypofractionated IMPT,2021-05-04,RECRUITING,INTERVENTIONAL,['NA'],,Frequency of late adverse events as measured by CTCAE v 5.0
7842,NCT04855448,learning curve of surgicla failure,2017-05-01,COMPLETED,INTERVENTIONAL,['NA'],,Disease free survival
7843,NCT05449860,Local tumor progression rate,2020-01-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Technical success rate
7844,NCT01378013,Sepsis,2011-08,COMPLETED,OBSERVATIONAL,['NA'],,Mortality
7845,NCT02732483,Rebleeding rate,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Mortalities
7846,NCT02457624,Detection rate for gastric premalignant lesion,2008-03,UNKNOWN,OBSERVATIONAL,['NA'],,Detection rate for gastric dysplasia
7847,NCT00972465,Safety and toxicity of this new treatment. Both acute and chronic toxicity will be evaluated.,2009-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"To determine the complete response rate, partial rate, disease response rate, disease control rate in the patients subject to treatment"
7848,NCT05768503,Progression-Free Survival (PFS),2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CR29 (EORTC QLQ-CR29)
7849,NCT04673526,Quality of life associated to incontinence as assessed by Faecal incontinence quality of life scale (FIQL),2009-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Post-operative complications
7850,NCT00220168,Time to disease progression (TTP),2003-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,"Toxicity (incidence of febrile neutropenia, in-patient admissions, severity of diarrhea, mucositis, aesthesia, transfusion requirements)."
7851,NCT06061263,recurrence-free survival,2022-05-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
7852,NCT00143403,Disease Free Survival (DFS),2001-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall Survival Rates
7853,NCT01763489,feeling able to judge the applicability of the trial,2014-01,WITHDRAWN,INTERVENTIONAL,['NA'],,
7854,NCT06233877,Response Rate,2024-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
7855,NCT03949907,Combined endpoint - overall survival and weight maintenance,2020-04-14,RECRUITING,INTERVENTIONAL,['NA'],Serum levels of immunologic profiles,Abnormal values in safety laboratory variables
7856,NCT05673772,5-year disease-free survival,2020-10-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,Distant metastasis
7857,NCT01751919,Area under the plasma concentration-time curve from zero time until the last measurable concentration (AUClast) of Imatinib mesylate,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Terminal Elimination Half-life (t1/2) of Imatinib mesylate
7858,NCT01919879,Non progression rate at 6 months,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tolerance of the treatment
7859,NCT04414306,Change in non-screening cancer prevention behaviors,2020-10-08,COMPLETED,INTERVENTIONAL,['NA'],,Uptake of tobacco quitting behaviors
7860,NCT03812783,Overall Survival (OS),2018-11-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse Events
7861,NCT00960518,the progression free survival (PFS),2009-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,the rate of overall survival
7862,NCT05688033,Number of Participants Experiencing Adverse Events,2021-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Number of Participants in Who Experienced Tumor Down-staging
7863,NCT05341622,FIT Completion,2022-05-27,COMPLETED,INTERVENTIONAL,['NA'],,FIT Positive Follow-up Completion
7864,NCT00883792,Comparison of the screening group vs. the control group in an intention-to-treat model after 15 years of follow-up with regard to CRC mortality and CRC incidence,2009-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Mortality from all causes
7865,NCT02142322,response rate,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,resection rate
7866,NCT00003426,,1998-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7867,NCT02934958,Colonoscopy Completion,2015-10,UNKNOWN,INTERVENTIONAL,['NA'],,
7868,NCT01522209,Detection of Liver Metastasis during Operation,2011-12,COMPLETED,INTERVENTIONAL,['NA'],,Comparison of Specicivity of all imaging modalities
7869,NCT04411537,Pathologic Complete Response Rate,2020-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Quality of Life Scale, range 0-60. It evaluates the quality of life from 12 aspects, including appetite, mental status, sleep quality, fatigue, etc. The higher scores mean a better quality of life."
7870,NCT05046756,"Change of body composition (weight, kg)",2021-05-11,RECRUITING,INTERVENTIONAL,['NA'],,The Wexner score
7871,NCT00114842,Sensitivity/specificity for water versus air for distension of colon in MR colonography,2006-03,COMPLETED,INTERVENTIONAL,['PHASE4'],,Sensitivity/specificity of MR colonography versus colonoscopy
7872,NCT00019786,Overall survival,1999-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7873,NCT01140347,Overall Survival (OS),2010-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Treatment Emergent Positive Anti-Ramucirumab Response [Serum Anti-Ramucirumab Antibody Assessment (Immunogenicity)]
7874,NCT04330716,Rate of patients who have germline genetic tests,2020-12-01,COMPLETED,INTERVENTIONAL,['NA'],,Cascade testing in positives
7875,NCT00093496,Proportion of Patients Who Experience a Confirmed Response According to Modified RECIST Criteria.,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity
7876,NCT01169220,Quality of colon cleansing,2010-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,Patient satisfaction
7877,NCT02165215,"Maintenance Phase: Percentage of Participants in Remission at Week 62 Among Randomized Participants With a Clinical Response at Week 10, as Determined by the Mayo Clinic Score (MCS)",2014-08-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Maintenance Phase: Etrolizumab Serum Trough Concentration (for Arms/Timepoints Below LLOQ)
7878,NCT03234465,Efficacy of AG013 Compared to Placebo for Reducing OM as Measured by Duration (in Days) of Severe Oral Mucositis (WHO Grades 3 or 4),2017-07-18,TERMINATED,INTERVENTIONAL,['PHASE2'],,
7879,NCT01366833,To investigate the change in dysphagia score (0-4 Likert scale) measured at baseline and at 10 weeks,2011-06,TERMINATED,INTERVENTIONAL,['NA'],,
7880,NCT03274882,Progression free survival (PFS) rate,2017-03-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Abnormalities in 12-leads ECG parameters [safety and tolerability]
7881,NCT03432676,Best objective response rate,2019-07-31,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
7882,NCT02287168,elimination,2014-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,dissemination
7883,NCT05419531,rate of young endurance athletes that have colorectal cancer on screening colonoscopies.,2022-10-18,RECRUITING,OBSERVATIONAL,['NA'],,Comparison of the rate of young endurance athletes that have colorectal cancer on screening colonoscopies with that of the historical controls (those in the average risk group).
7884,NCT05163873,Assessing the feasibility of the trial based on overall QoL reported in intervention group compared with standard care group,2021-12-09,RECRUITING,INTERVENTIONAL,['NA'],,
7885,NCT02415829,The tumor regression grade of all the patients enrolled,2014-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of Participants with Adverse Events as a Measure of Safety and Tolerability
7886,NCT03321630,Progression-Free Survival (PFS),2017-10-24,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7887,NCT03748667,The presence or absence of deep invasion according to the gold standard (histology),2018-12-01,COMPLETED,OBSERVATIONAL,['NA'],,Number of genome copies using SNP-arrays
7888,NCT02645084,"Percentage of all included patients who have received a recommendation for regular surveillance colonoscopies for himself/herself and/or relatives, provided by a clinical geneticist.",2015-02,COMPLETED,INTERVENTIONAL,['NA'],,Usability of the questionnaire for health care providers and patients by using a self-created online or paper questionnaire
7889,NCT01368419,Objective Response Rate (ORR),2011-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events
7890,NCT02269631,Change in Weight,2014-12,COMPLETED,INTERVENTIONAL,['NA'],,Satiety
7891,NCT00195585,Relapse-free survival time,2002-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Disease-free survival time, survival time, safety"
7892,NCT00354601,Objective Tumor Response,2006-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of Life
7893,NCT03333265,Cumulative the numbers and diameters of those colorectal adenomas during Berberine hydrochloride or placebo treatment in patients with familial adenomatous polyposis,2017-09-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
7894,NCT06157996,Progression-free Survival (PFS),2024-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Duration of response (DoR)
7895,NCT05318404,Percentage of body weight loss,2020-12-08,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative daily protein intake
7896,NCT01130701,"To estimate the 3 year progression-free survival of patients with localized, resectable pancreatic cancer",2010-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,To estimate resection rate
7897,NCT05108428,Feasibility of MRI guided dose adaptive chemoradiation therapy,2021-12-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Number of Participants with Disease-Free Survival (DFS),Number of Participants with Pathological Complete Response (pCR)
7898,NCT00057395,,na,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
7899,NCT01839630,Summarized patient characteristics,2013-05-30,COMPLETED,OBSERVATIONAL,['NA'],,Treatment pattern of Sorafenib
7900,NCT02436564,Number of tumour-derived organoids successfully cultured in vitro for a minimum of 3 months.,2015-07,UNKNOWN,OBSERVATIONAL,['NA'],,Proportion of tumour-derived organoids that are genetically identical to the source tumour.
7901,NCT05498506,the number of linear stapler cartridges,2022-12-01,COMPLETED,OBSERVATIONAL,['NA'],,
7902,NCT02142803,Most Common Related Toxicities That Led to Dose Hold/Reductions,2014-05-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Mutation Analysis of Tissue From Biopsies of Patients With Ovarian and Endometrial Cancers,Number of Patients That Discontinue Study Drugs Due to Treatment Related Toxicity
7903,NCT04919577,Roux stasis syndrome,2014-03-01,COMPLETED,OBSERVATIONAL,['NA'],,Gender
7904,NCT05670561,Pain Intensity at 12hours after the beginning of TACE operation,2023-01-05,RECRUITING,INTERVENTIONAL,['PHASE4'],Quality-of-Life Assessment at 24hours after the beginning of TACE operation,Analgesic Consumption
7905,NCT01384617,Incidence of pancreatic fistula defined by ISGPF classification,2011-06,COMPLETED,INTERVENTIONAL,['NA'],,Incidence of pancreatic fistula stratified based on thickness of pancreas parenchyma
7906,NCT06203613,To assess the sensitivity and specificity of using [18F]F-H3RESCA-3A12 and [68Ga]Ga-NOTA-3A12 for the diagnosis of metastatic gastric and pancreatic cancer,2023-12-01,RECRUITING,INTERVENTIONAL,['NA'],,
7907,NCT00278863,Response Rate,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Adverse Events
7908,NCT00478374,To assess the safety and tolerability of the administration of sorafenib in patients with hepatocellular carcinoma treated with TACE by determining the MTD.,2007-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,changes in the blood concentration of tumor marker AFP
7909,NCT03797625,Progression Free Survival,2017-05-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
7910,NCT05043363,Clinician experience of LumenEye examination,2020-11-14,COMPLETED,OBSERVATIONAL,['NA'],,"Diagnostic accuracy of the LumenEye for the detection of rectal pathology including tumour, polyps and inflammation"
7911,NCT02812550,adenoma detection rate in the two different colonoscopies,2015-05,COMPLETED,INTERVENTIONAL,['NA'],,colonoscopy withdrawal time
7912,NCT04696055,Overall Response Rate (ORR) Per RECIST 1.1 by Central Assessment,2021-02-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Participants With Dose Modification
7913,NCT04516174,The prognosis of aged patients,2020-09-01,UNKNOWN,INTERVENTIONAL,['NA'],,
7914,NCT05546411,Major pathological response rate (MPR),2023-01-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival (OS)
7915,NCT05354856,Difference in gastric perfusion,2022-03-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],,Short term outcome
7916,NCT00267046,Median Maximum Score for Patient Reported Outcomes in 2 Blinded Cycles,2005-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7917,NCT06157463,Change of FAPI SUV,2024-02-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Correlation of FAPI SUV
7918,NCT06085976,Incidence on intraoperative bleeding.,2023-08-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,Rate of postoperative complications
7919,NCT03070613,Number of dysplastic and cancerous lesions identified under white light and under fluorescence,2017-04-23,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Resection margin of of lesions undergoing TEMS resection under white light and under fluorescence.
7920,NCT05617872,cfDNA concentration,2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],,Weight
7921,NCT05507411,1-year DFS of CCR-Watch and Wait group,2022-08-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,EORTC QLQ-30
7922,NCT05936931,CRC screeningintentions,2024-02,WITHDRAWN,INTERVENTIONAL,['NA'],,
7923,NCT02703545,Proportion of patients and resected lesions with pancreatic cancer in situ (high grade dysplasia) or invasive malignancy,2014-02,COMPLETED,OBSERVATIONAL,['NA'],,Calculate survival time from point of diagnosis and treatment
7924,NCT04923672,Steps per day,2023-02-20,RECRUITING,INTERVENTIONAL,['NA'],,Fitness level
7925,NCT02437851,To determine if the proportion of participants who develop treatment failure by 3 years is less than 25%.,2015-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Collection of clinical specimens (composite),"The rate of treatment related adverse events including non-healing ulcer, fissure, persistent pain and bleeding, stricture, incontinence, and colostomy 6 months after excision of SISCCA."
7926,NCT00757640,Reduced biliary complications,2008-09,COMPLETED,INTERVENTIONAL,['NA'],,Improved quality of life
7927,NCT01911000,Hyperthermia effect and averse event in RT for HCC with PVTT,2013-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,To evaluate RT response prediction probability by diffusion-weighted (DW) MRI
7928,NCT03385434,Evaluation of the adenoma detection rate during screening colonoscopy,2018-02-01,UNKNOWN,INTERVENTIONAL,['NA'],,
7929,NCT00685763,"Cumulative Incidence of grade3+ Bowel Perforation, Grade 3+ Bleeding (Ocurring Withing 1 Years) and grade4+ Nonhematologic Acute Adverse Events (Limited to Within 90 Days of Treatment Start)",2008-03,COMPLETED,INTERVENTIONAL,['NA'],,Collect and Analyze Tumor Control Measures
7930,NCT03649945,3 year disease-free survival rate,2018-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival
7931,NCT05181332,Hepatic decompensation,2021-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
7932,NCT03110328,overall survival,2018-02-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7933,NCT01083537,Time to Resolution of Bowel Obstruction,2010-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Evaluation of Toxicity
7934,NCT02782949,Absolute Change in IL-1beta Cytokine Levels in the Gastric Mucosa,2017-04-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],"Proinflammatory Cytokine Genotype Status (IL-1beta, IL-8, and TNFalpha Single Nucleotide Polymorphisms)",Gastric Mucosal Deoxyribonucleic Acid (DNA) Damage
7935,NCT01824953,Newly developed gastric neoplasm,2010-01,COMPLETED,OBSERVATIONAL,['NA'],Helicobacter pylori,Degree of gastric atrophy
7936,NCT04246177,Overall Survival (OS),2020-05-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,TTP per RECIST 1.1
7937,NCT00918827,Relapse-free survival,2009-04-01,COMPLETED,OBSERVATIONAL,['NA'],,
7938,NCT00002650,,1995-06-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7939,NCT02403024,Change in VO2peak,2015-08,COMPLETED,INTERVENTIONAL,['NA'],,Change in VO2peak (secondary comparisons)
7940,NCT03824366,Feasibility of Same-session MRI-only Simulation as Defined as More Than 70% of Patients Receiving at Least 70% of Their Scheduled Treatment Fractions on the First On-table Attempt for Each Respective Fraction.,2019-04-23,COMPLETED,INTERVENTIONAL,['NA'],,
7941,NCT05497869,pectoralis minor length through Rigid standard plastic transparent right angle,2022-08-10,COMPLETED,INTERVENTIONAL,['NA'],,
7942,NCT04101929,Progression Free Survival,2019-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall Response Rate
7943,NCT00276302,To recommend a dose for subsequent studies of IPI-504,2005-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,To explore potential pharmacodynamic (PD) markers of biologic activity of IPI-504 in GIST and STS.
7944,NCT05070598,ORR (Objective control rate),2021-09-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,OS(Overall survival)
7945,NCT02587247,Evaluate the sensitivity of the immuno-PET PET / CT pretargeted with the bispecific anti-CEA x anti-HSG TF2 antibody and IMP-288 peptide labeled with Gallium-68,2016-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To evaluate the clinical impact (new lecture of imaging, new examens)"
7946,NCT04340401,pathologic complete response rate(pCR rate),2020-05-25,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Major adverse events
7947,NCT04923620,Pathological response rate,2021-10-20,RECRUITING,OBSERVATIONAL,['NA'],,disease-free survival
7948,NCT02649348,The proportion of postoperative complications,2015-09,COMPLETED,INTERVENTIONAL,['NA'],,
7949,NCT02186886,Clinical response,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],molecular spectral range,Calprotectin stool levels
7950,NCT02436395,Superficial incisional surgical site infections,2015-05,UNKNOWN,INTERVENTIONAL,['NA'],,
7951,NCT01074996,Progression Free Survival(PFS),2010-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,safety and tolerance
7952,NCT04662346,correlation to post-operative complication,2020-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,
7953,NCT03485027,PFS,2018-01-24,COMPLETED,INTERVENTIONAL,['PHASE2'],,OS
7954,NCT03912857,Objective Response Rates (ORR),2018-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease Control Rate (DCR)
7955,NCT01490203,Correlation of hepatic extraction fraction (HEF) of future remnant liver function (RLF) obtained from Gd-EOB-DTPA enhanced MRI with postoperative ICG R15 clearance test results,2011-12,COMPLETED,OBSERVATIONAL,['NA'],,Exploratory analysis of MRI parameters and ICG R15 derived from potential liver donors
7956,NCT04639284,Objective response,2020-12-23,UNKNOWN,OBSERVATIONAL,['NA'],,"Time to deterioration in patient-reported quality of life, physical functioning, and role functioning"
7957,NCT00002935,,1995-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7958,NCT03941626,"Number of Participants With Adverse Events evaluated with NCI CTC AE, version 4.0",2019-09-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Clinical response
7959,NCT05794750,Pathologic complete response rate (pCR),2023-04-24,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],"Relationship between the expression of immune markers in tumor tissues and blood,the distribution of immune cells, and the efficacy and prognosis of patients",Incidence and severity of adverse events (AEs) and clinically meaningful abnormal laboratory test results
7960,NCT00383695,Pathological complete response rate at time of total mesorectal excision (TME),2005-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Quality of life, including long-term bowel function"
7961,NCT04707365,overall survival,2021-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
7962,NCT00070213,Compare health assessment in patients treated with MdG vs Cap and in patients treated with OxMdG vs OxCap at baseline and 14 weeks,2003-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Compare health economics in patients treated with MdG vs Cap and in patients treated with OxMdG vs OxCap
7963,NCT00875771,Progression free survival (PFS),2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Rate of hepatic metastases resection
7964,NCT05618821,Total Number of Retrieved Lymph Nodes,2022-06-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,Intraoperative situation
7965,NCT05634590,Progression-Free Survival (PFS),2022-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
7966,NCT05362344,Sensitivity of multi-target stool DNA test and quantitative fecal immunochemical (FIT) test,2022-09-01,RECRUITING,OBSERVATIONAL,['NA'],Ease of stool testing,Specificity of multi-target stool DNA test and quantitative fecal immunochemical (FIT) test
7967,NCT02138617,Progression Free Survival,2014-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
7968,NCT03884868,Grade of distress experienced by patients,2019-04-01,COMPLETED,INTERVENTIONAL,['NA'],,Grade of understanding of the information reported by patients
7969,NCT03670199,Variation of the Medical Outcome Study Short Form 36 score,2019-01-29,RECRUITING,INTERVENTIONAL,['NA'],,Length hospitalization
7970,NCT04093687,Endoscopist adjusted painful colonoscopy rate change,2019-11,UNKNOWN,INTERVENTIONAL,['NA'],,Adjusted painful colonoscopy rate for screening centres (in which assessed endoscopists are working)
7971,NCT01707758,,2012-10,WITHDRAWN,OBSERVATIONAL,['NA'],,
7972,NCT04183218,Cardiac event rate at 12 months,2019-09-23,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Imaging changes,Overall survival
7973,NCT01472770,Rate of patients progression free at 3 months,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
7974,NCT02156700,Tumor stiffness,2013-09,COMPLETED,OBSERVATIONAL,['NA'],,tumor to parenchyma stiffness ratio
7975,NCT03754192,Pefusion parameters,2019-01-30,UNKNOWN,INTERVENTIONAL,['NA'],,Pathological examination
7976,NCT00958386,Objective response rate,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluation of molecular predictive markers
7977,NCT03986541,Progression free survival,2019-09-23,UNKNOWN,OBSERVATIONAL,['NA'],,Disease control rate
7978,NCT01423604,Overall Survival,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Summary of Clinical Benefit
7979,NCT02310230,Average minute ventilation in patients cared for using the ExSpiron Respiratory Variation Monitor (RVM) compared to patients with routine monitoring in patients undergoing upper gastrointestinal endoscopy,2014-09,UNKNOWN,INTERVENTIONAL,['NA'],,The ability of respiratory parameters with capnography to assess states of hypoventilation between the two groups
7980,NCT03142516,Progression-free survival at one year,2017-10-31,COMPLETED,INTERVENTIONAL,['PHASE2'],RAS/BRAF mutations' detection proportion,Combined analysis of prognostic factors in metastatic disease
7981,NCT05055726,Number of responders,2021-12-06,COMPLETED,INTERVENTIONAL,['PHASE4'],,Frequency of adverse events
7982,NCT02519140,Lift Efficacy,2014-08-01,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Dissection Adequacy
7983,NCT00003867,,1999-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7984,NCT05799443,Objective response rate(ORR),2023-04-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
7985,NCT05234450,Establishment of the number of tumor subgroups by integrating data from all multi-omics analyses,2021-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,
7986,NCT00304135,Overall survival,2005-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Biliary complication rate
7987,NCT06218888,Objective Response Rate（ORR）,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease Control Rate (DCR)
7988,NCT05742425,Disease-free survival (DFS),2023-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence rate of adverse events
7989,NCT00588263,determine the prevalence of recurring BRCA1 and BRCA2 mutations,2000-07,WITHDRAWN,OBSERVATIONAL,['NA'],,
7990,NCT06253949,rectal cancer-low anterior resection syndrome (LARS),2023-12-01,RECRUITING,INTERVENTIONAL,['NA'],,1-year overall survival
7991,NCT01787500,Maximum tolerated dose of vemurafenib defined as the highest dose studied in which the incidence of dose limiting toxicity was less than 33% as graded by the National Cancer Institute Common Toxicity Criteria version 4.0,2013-02-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
7992,NCT00950820,Progression-free survival rate at 6 months for subjects with KRAS wild-type tumours,2009-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,safety-endpoints
7993,NCT00148226,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7994,NCT00550589,Safety and Tolerability of Topical Cidofovir as Assessed by NCI CTCAE v3.0,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Changes in Gene Expression in Perianal HSIL After Exposure to Cidofovir as Assessed by RNA Microarray Analysis
7995,NCT01703026,,2009-08,COMPLETED,OBSERVATIONAL,['NA'],,
7996,NCT03816358,Maximum tolerated dose (MTD),2019-12-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Biomarker analysis
7997,NCT04842968,At least 12 lymph nodes harvested,2021-04-15,UNKNOWN,INTERVENTIONAL,['NA'],,Overall survival
7998,NCT02863107,Adherence score,2012-06-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
7999,NCT03460925,Clinical response to the treatment in terms of resectability,2018-05-02,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of life
8000,NCT02764268,Number of Participants With Dose Interruptions,2016-11-02,COMPLETED,INTERVENTIONAL,['NA'],,Disease Control Rate(DCR)
8001,NCT01313377,Quality of life,2009-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Toxicity of adjuvant chemotherapy
8002,NCT03205501,"Safety: the number of participants with symptoms or changes in vital signs (blood pressure, heart frequency and temperature) and/or (serious) adverse events that are related to administration of EMI-137.",2017-02-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Visualization of the localization and distribution patterns of EMI-137 in the esophagus using ex vivo fluorescence microscopy.
8003,NCT06018714,2-year recurrence and metastasis rate,2023-05-01,RECRUITING,INTERVENTIONAL,['PHASE2'],completion rate of maintenance therapy,2-year disease-free survival rate
8004,NCT06217016,secondary catheterization owing to urinary retention,2024-01-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Postoperative complications
8005,NCT02311803,Sexual function,2015-02,UNKNOWN,INTERVENTIONAL,['NA'],,5-year recurrence pattern
8006,NCT04487002,recurrence rate,2016-01,COMPLETED,INTERVENTIONAL,['NA'],,post-operative complications
8007,NCT03632746,The specificity of the Nomogram combining sentinel lymph node in predicting lymph node metastasis in early gastric cancer patients,2018-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,The sensitivity of the Nomogram alone in predicting lymph node metastasis in early gastric cancer patients
8008,NCT01303393,,2007-01,COMPLETED,OBSERVATIONAL,['NA'],,Information needs - patients' and next of kins'
8009,NCT04365946,Analysis of microbiome in subtypes of intestinal metaplasia and gastric cancer,2020-04-18,UNKNOWN,OBSERVATIONAL,['NA'],,
8010,NCT03168152,Time to local tumor progression,2017-05-11,WITHDRAWN,INTERVENTIONAL,['NA'],,Incidence of intrahepatic failure
8011,NCT02047500,Number of Subjects Experiencing Dose Limiting Toxicity (DLT),2014-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,Number of Subjects With Treatment-emergent Adverse Events (TEAEs)
8012,NCT01787006,Rate of Participants Who Were Alive at 2 Years,2011-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change in Quality of Life Between Baseline and End of Treatment (After 5 to 13 Weeks)
8013,NCT01824004,Disease free survival,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Health -related quality of life,Number of participants with adverse events as a measure of safety and tolerability
8014,NCT03150992,Change in incidence of pain,2017-07-19,UNKNOWN,INTERVENTIONAL,['NA'],,Nutritional intake
8015,NCT02973685,Overall survival,2016-10-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of of Patients developed Adverse Events
8016,NCT01373320,Proportion of participants reporting the health behavior of interest (depending on which intervention component(s) were selected),2010-03,COMPLETED,INTERVENTIONAL,['NA'],,"Retention (i.e., number of participants who complete all planned assessment timepoints)"
8017,NCT00677144,overall response rate,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Safety, time to progression, and overall survival"
8018,NCT01203787,Cumulative Dose of Sorafenib,2010-12,COMPLETED,INTERVENTIONAL,['PHASE4'],,Number of Subjects With Dose Reductions
8019,NCT05802485,Predict response to systemic therapies in patients with non-metastatic pancreatic adenocarcinoma,2023-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
8020,NCT04465734,tumor assessment,2022-11-15,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,
8021,NCT00628186,the length of hospital stay after pancreaticoduodenectomy,2005-04,COMPLETED,INTERVENTIONAL,['NA'],,early and late complications after pancreaticoduodenectomy
8022,NCT05476432,Overall survival,2022-07-26,RECRUITING,INTERVENTIONAL,['PHASE3'],,the predictive power of thymidylate synthase (TYMS)
8023,NCT00609310,Recurrence rate of neoplasia,2015-05,SUSPENDED,INTERVENTIONAL,['PHASE2'],,"Recurrence free survival, Overall survival, Serum-Flavonoid levels of patients"
8024,NCT06037655,Objective response rate (ORR),2023-09-25,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Major Pathological Response Rate (MPR),overall survival (OS)
8025,NCT01784861,Objective Response Rate (Complete Response + Partial Response) - Phase II,2013-05-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Toxicity - Phase II
8026,NCT05830097,Incidence and severity of Adverse Events (AEs),2023-03-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,MTD/RP2D of CBP-1019.
8027,NCT04648020,To demonstrate the efficacy of HCl MBT to prevent SOM in OPC patients receiving CRT.,2021-02-11,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
8028,NCT01094600,Primary outcome: correlation between S-MRCP with ePFT,2012-06,WITHDRAWN,INTERVENTIONAL,['NA'],,
8029,NCT05516628,"Recurrence-free-survival (RFS) in relation to the multi-omics (epigenomics, genomics, transcriptomics, proteomics and metabolomics) and spatial TME profiles of both tissue and peripheral blood.",2023-02-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS).
8030,NCT02845908,"Progression-Free Survival,PFS",2015-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival(OS)
8031,NCT05690958,Intended uptake of EAC screening,2023-02-13,RECRUITING,OBSERVATIONAL,['NA'],Acceptability of screening test accuracy,Views on the organization of EAC screening
8032,NCT04606888,S100 calcium-binding protein β,2020-07-01,COMPLETED,INTERVENTIONAL,['NA'],,Numeric Rating Scale score
8033,NCT03156582,Number of participants whose tumoral characteristics on the liver explant were under the criteria of the AFP score,2016-04-01,COMPLETED,OBSERVATIONAL,['NA'],,Progression free survival after LT for HCC
8034,NCT04943653,6-month progression free survival (6-month PFS),2021-06-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Ascites response
8035,NCT04027764,objective response rate,2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival
8036,NCT00059865,Survival after 6 months of treatment,2004-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Toxicity as assessed by CTC v3 every 4 weeks
8037,NCT03909997,Number of patients with severe 30-day or in-hospital morbidity,2019-04-05,UNKNOWN,OBSERVATIONAL,['NA'],,Median and percentage of patients with long-term survival
8038,NCT05178095,ADR,2020-09-30,COMPLETED,INTERVENTIONAL,['NA'],,Procedural time
8039,NCT03869151,increased over all survival,2019-04-05,UNKNOWN,OBSERVATIONAL,['NA'],,
8040,NCT02399033,Hepatocellular carcinoma recurrence rate in the three years after hepatectomy,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],,The incidence of adverse reaction.
8041,NCT04310111,Tumor size,2020-03-01,COMPLETED,INTERVENTIONAL,['NA'],,Adverse events
8042,NCT00497497,Incidence and nature of dose-limiting toxicities,2007-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Incidence and severity of infusion reactions
8043,NCT03792269,Progression-free Survival (PFS),2016-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse Events (AE)
8044,NCT03398512,radical resection rate,2018-02-01,TERMINATED,INTERVENTIONAL,['NA'],,complication rate
8045,NCT02170090,Disease free survival (DFS),2014-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,locoregional control (assessed by the rate of patients with hepatic or locoregional recurrence)
8046,NCT02530593,QoL in colon cancer patients,2015-06,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Analyse health economy aspects of QoL and morbidity in the patient population
8047,NCT03925662,number of patients with tumour response,2019-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,
8048,NCT04068896,Number of Patients with Clinically Significant Laboratory Abnormalities:,2019-10-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Skeletal muscle index during therapy with NGM120
8049,NCT03307941,Phase II: pCR rate,2017-07-20,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II: Number of the tumour-infiltrating lymphocytes (TILs)
8050,NCT01941992,"Proportion of subjects with Grade III or IV of mucositis assessed by the WHO mucositis scale, developing at any time during the whole study period.",2012-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of life assessed by European Organization for Research and Treatment of Cancer quality of life core questionnaire (EORTC QLQ-C30) and specific head and neck module (QLQ-H&N35),Incidence of adverse events assessed by NCI-Common Terminology Criteria for Adverse Effects (CTCAE version 4.0)
8051,NCT02570711,Overall Response Rate (ORR),2015-10-13,TERMINATED,INTERVENTIONAL,['PHASE2'],,
8052,NCT01915589,Objective tumor response according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST) assessed by central radiological review,2013-09-16,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of participants with adverse events as a measure of safety and tolerability
8053,NCT04952272,Assessing safety and treatment efficacy on intratumor injection of CpG-ODN and in situ tumor antigen release for advanced tumors,2021-03-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,
8054,NCT05076591,Number of patients with Adverse Events（AEs）,2022-06-20,RECRUITING,INTERVENTIONAL,['PHASE1'],,
8055,NCT02542436,Overall Survival (OS),2015-09-01,WITHDRAWN,OBSERVATIONAL,['NA'],,Percentage of Participants with Adverse Events of Special Interest
8056,NCT02024412,The incidence of neurotoxicity including acute neurotoxicity and accumulating neurotoxicity,2013-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,quality of life
8057,NCT03458975,Objective response for liver metastases,2019-10-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Dosage of cytokines
8058,NCT03567629,"Progression-free Survival: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first.",2018-05-29,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The incidence of treatment related emergent adverse events（Safety and Tolerance）
8059,NCT03698461,Serial changes in Cluster of Differentiation(CD) 8+ T cell densities,2019-05-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Microbiome profile
8060,NCT02581215,Progression Free Survival (PFS),2016-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Characterize Adverse Events (AE)
8061,NCT00419614,,na,UNKNOWN,OBSERVATIONAL,['NA'],,
8062,NCT05344924,Progression free survival (PFS),2022-10-12,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Adverse effects
8063,NCT05753163,1-year recurrence-free survival rate (1-year RFS),2022-08-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,health-related quality of life (HRQol)
8064,NCT02543762,"Prevalence and incidence of dysplasia and colitis-associated colorectal cancer in patients with longstanding colonic inflammatory bowel disease (N-IBD), in Spain",2012-02,COMPLETED,OBSERVATIONAL,['NA'],,Usefulness of advanced endoscopy in displasia characterization (chromoendoscopy ) for the diagnosis and endoscopic differential diagnosis of NIBD.
8065,NCT05221320,"The incidence and frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type, severity (as defined by the NCI CTCAE, version 5.0), seriousness, duration, and relationship to study treatment.",2022-05-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression-free survival (PFS) as defined as the time from study drug initiation to the time of documented disease progression (as assessed by RECIST 1.1) or death from any cause.
8066,NCT01442649,Progression-free survival (PFS) at 4 months,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life
8067,NCT04854668,Progression Free Survival (PFS) assessed by IRC,2020-07-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Duration of Response (DOR)
8068,NCT04484909,Recommended phase II dose (RP2D),2020-07-01,RECRUITING,INTERVENTIONAL,['PHASE1'],Resection status,Overall survival (OS)
8069,NCT01157039,To evaluate potential pharmacokinetic interactions between oxaliplatin and glutamine at 30g and 40g in patients with metastatic colorectal cancer.,2011-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,To compare the toxicity profile of glutamine and FOLFOX to historical data.
8070,NCT00910494,surgical complication rate,2010-01,TERMINATED,INTERVENTIONAL,['NA'],,local control
8071,NCT05552729,Cognitive function,2022-09-22,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Asthenia
8072,NCT05040438,Objective Response Rate (ORR) of administering VAX-NK/HCC combined with HAIC,2019-10-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,The serum cytokine levels
8073,NCT01956864,Number of participants on high dose Vitamin D with adverse events,2013-09,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Changes in the expression of serum and imaging biomarkers
8074,NCT00136227,colorectal cancer screening initiation rate,2005-10,COMPLETED,INTERVENTIONAL,['NA'],,making decisions about colorectal cancer screening that are consistent with their values and preferences
8075,NCT00253526,,na,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
8076,NCT03602417,Clinical success rate,2017-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
8077,NCT06304597,Temperature,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Evaluate targeted detection with nivolumab-800CW and durvalumab-680LT of the tumor by ex vivo visualization of the resection specimen with PEARL Trilogy
8078,NCT03648879,Percentage of Participants With Detectable Confocal Endoscopic Microscopy (CEM) w/Greater Sensitivity for Detection of Signet Ring Cells (SRC)Foci in Cadherin-1 (CDH1) Germline Mutation Carriers Compared to Current Method of Standard White Light Endoscopy,2019-02-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0),Percentage of Participants Who Have Signet Ring Cells (SRC) Foci Not Identified by Confocal Endoscopic Microscopy (CEM)
8079,NCT03136354,Complication,2009-05,COMPLETED,INTERVENTIONAL,['NA'],,Disease free survival
8080,NCT03570996,Pain scores,2018-01-01,TERMINATED,INTERVENTIONAL,['NA'],,Hypotension
8081,NCT00238381,Composite evacuation score after total mesorectal excision,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Morbidity
8082,NCT01068483,Maximum Tolerated Dose (MTD) of BKM120,2008-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Clinical tumor response in patients with tumors that show PI3K pathway activation
8083,NCT05002686,1 year Progression Free Survival (PFS),2021-08-07,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Potential biomarker to predict prognosis,Percentage of pathologic complete response(pCR)
8084,NCT01818973,The pathologic tumor regression grade (TRG),2013-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,5-y local relapse free survival
8085,NCT02241499,Improvement of dysphagia.,2014-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Metabolic response,Endoscopic response of the primary tumor.
8086,NCT01627379,Overall Survival,2012-05,TERMINATED,INTERVENTIONAL,['PHASE3'],,Quality of life
8087,NCT01243346,The primary end-point is overall response rate,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,PKPD analysis
8088,NCT03722628,The level of Matrix metalloprotinease-1 genotypes polymorphism in the study population,2018-12-15,UNKNOWN,OBSERVATIONAL,['NA'],,
8089,NCT06044311,Metabolic Response,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Ability to take vactosertib before and after standard of care chemoradiation
8090,NCT06210971,Pathologic Complete Response,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
8091,NCT03206827,Changes in the intake of nutrients and nutritional status of participants as a measure of diet modification,2016-11-29,COMPLETED,INTERVENTIONAL,['NA'],,Genotoxicity testing of human fecal water in 2D and 3D cell cultures
8092,NCT01224990,The aim of the study is to asses whole body diffusion weighted imaging (WB-DWI) in patients with proven gastro-intestinal tumors and to evaluate this non-invasive method for staging and therapy monitoring.,2010-11,UNKNOWN,INTERVENTIONAL,['NA'],,
8093,NCT05694559,genetic risk screening tool (GRST) questionnaire,2022-11-23,RECRUITING,INTERVENTIONAL,['NA'],,
8094,NCT04287868,Best Overall Response (BOR) in Checkpoint Naive and Immune Checkpoint Blockade (ICB) Resistant Disease in Participants With Advanced or Metastatic Human Papillomavirus (HPV) Associated Malignancies,2020-06-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0),Duration of Response (DOR)
8095,NCT04161092,Five-year overall survival,2020-12-01,RECRUITING,INTERVENTIONAL,['NA'],,Health economic evaluation
8096,NCT04252456,"Overall survival (OS) according to VEGFR2 levels, evaluating the difference in terms of median OS among patients with high VEGFR2 activity and patients with low VEGFR2 activity",2018-04-23,UNKNOWN,INTERVENTIONAL,['NA'],,Angiogenetic factors levels concentration before and during treatment.
8097,NCT05702385,CPV-measured differences in cost of care between control and intervention arms,2023-09-01,WITHDRAWN,INTERVENTIONAL,['NA'],,
8098,NCT01921283,procedure satisfaction score of propofol addition,2011-09,COMPLETED,INTERVENTIONAL,['NA'],,
8099,NCT00327652,Dose-limiting toxicities (DLTs) for 7 days after dosing,2006-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8100,NCT04009265,Overall Survival,2019-08-23,RECRUITING,INTERVENTIONAL,['PHASE3'],,Scores of Quality of Life
8101,NCT05155475,Evaluation of the common bile duct size,2019-06-04,COMPLETED,OBSERVATIONAL,['NA'],,
8102,NCT02660671,Colonoscopy participation,2016-01,COMPLETED,INTERVENTIONAL,['NA'],,Scheduling of colonoscopy
8103,NCT04705363,Credibility score,2021-06-29,RECRUITING,INTERVENTIONAL,['NA'],,
8104,NCT03133286,Obtain pre- and post-irradiation participant-collect blood samples,2017-04-06,UNKNOWN,OBSERVATIONAL,['NA'],,
8105,NCT03461341,Utilisation of routine surveillance imaging across European Centers,2009-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Health-related quality of life (HR-QL) as assessed by EORTC QLQ-C30 questionnaire
8106,NCT00625586,Number of Patients Alive at 8 Months,2008-04-15,TERMINATED,INTERVENTIONAL,['PHASE2'],,Cmax
8107,NCT05608213,Overall survival (OS),2022-11-02,RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse Events (AEs)
8108,NCT01722162,Progression Free Survival (Arm B),2013-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence and Severity of Adverse Events as Measured by Number of Participants Who Experience Grade 3 and Higher Adverse Events
8109,NCT02222753,Disease-specific survival,2014-01,UNKNOWN,OBSERVATIONAL,['NA'],Disease-free survival,Overall survival
8110,NCT03713229,Incidence of anal cancer,2010-09-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
8111,NCT00936689,survival of all randomized patients at month 24 (favorable event). Mortality by month 24 and withdrawal from the study will be considered to be unfavorable events.,2008-03,COMPLETED,INTERVENTIONAL,['PHASE4'],,Radiological tumor response; TTSP; TTP; Overall duration of response; Quality of life; ECOG score; Impact on liver function; No.of treatments administered.
8112,NCT04348838,Variation of overall survival time (OS) after pharmaceutical treatment,2019-08-26,RECRUITING,OBSERVATIONAL,['NA'],,Variation of serious adverse event rate of HCC treatments in clinical practice
8113,NCT02857270,Number of Participants with LY3214996 Dose Limiting Toxicities (DLTs),2016-09-29,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS) (Dose Expansion Arms Only)
8114,NCT02743221,Progression Free Survival (PFS),2016-04-29,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
8115,NCT00004190,overall response rate,1999-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,objective tumor response
8116,NCT06172205,ORR,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,conversion rate
8117,NCT02421432,TME quality & circumferential resection margin (CRM),2017-12-01,UNKNOWN,INTERVENTIONAL,['NA'],5-year overall survival,Number of harvested Lymph Nodes
8118,NCT06041009,"The diagnostic value (sensitivity, specificity, accuracy, and positive and negative predictive values)",2023-12-20,RECRUITING,OBSERVATIONAL,['NA'],,"The diagnostic value (sensitivity, specificity, accuracy, and positive and negative predictive values)"
8119,NCT06301672,Body Mass Index,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Feeding amount
8120,NCT04018872,Percentage of pathological complete response with itraconazole,2019-06-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Levels of itraconazole and metabolites in esophageal tissue
8121,NCT05040425,Mucositis pain,2021-08-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],Electrical body conductivity,Body mass index (BMI)
8122,NCT04980950,The impact of immunonutrition on gut microbiota in gastric and colorectal cancer patients.,2021-08-01,UNKNOWN,INTERVENTIONAL,['NA'],,The impact of immunonutrition on intestines in gastric and colorectal cancer patients.
8123,NCT00003360,,1998-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8124,NCT03037385,(Phase 2) Number of Participants with AEs and SAEs,2017-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,(Phase 2) Assess Intracranial Response Rate and Time to Intracranial Progression in Participants With NSCLC
8125,NCT00084721,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8126,NCT05957016,Pathologic complete response (pCR),2023-08-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,overall survival (OS)
8127,NCT02246634,Liver metastases found on the additional DW-MRI scans will be discussed at MDT and treated according to local site policy.,2014-08,RECRUITING,INTERVENTIONAL,['NA'],,To describe the impact of MR screening on treatment received by patients who are diagnosed with liver metastases.
8128,NCT06129604,EP2 and EP4 receptor subtypes tumor biomarker expression within the PGE2 signaling pathway.,2024-04-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidences of TPST-1495 drug therapy based potential adverse events
8129,NCT00002692,,1994-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
8130,NCT00034827,Overall objective response and clinical benefit response,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Time to objective response, duration of response, time to progression and survival"
8131,NCT02458573,soft diet intake after surgery,2015-06-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,postoperative pain
8132,NCT01196000,Rate of conversion to open surgery as an indicator of surgical technical difficulty,2011-12,WITHDRAWN,INTERVENTIONAL,['NA'],,Health economics
8133,NCT04604158,Absolute change in patient-reported anxiety scores at Day 30 compared with baseline.,2020-12-02,UNKNOWN,INTERVENTIONAL,['NA'],,Participant's experience with Elly app at Day 180-360.
8134,NCT02613221,Progression Free Survival (PFS) Rate at 6 Months,2015-12-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants Reporting One or More Treatment-Emergent Adverse Events (TEAEs)
8135,NCT01545063,Number of catheter related infections,2012-05,COMPLETED,OBSERVATIONAL,['NA'],,
8136,NCT02161029,Amount of submucous tissue in gastrointestinal submucosal tumors harvested with a new drill biopsy instrument used with flexible endoscopes.,2014-07-02,COMPLETED,INTERVENTIONAL,['NA'],,
8137,NCT02046174,Overall Survival,2014-04-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Necrosis Comparison of Tumors Using PET-CT Scan,Pain Assessment
8138,NCT00005053,,1999-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8139,NCT04762953,Incidence of Treatment-Emergent Adverse Events [Safety],2021-02-18,RECRUITING,INTERVENTIONAL,['PHASE2'],Correlation of Plasma and Ascite Exosomal Gene Signature (EXOSIG) to Treatment Response,Patient Reported Quality of Life Outcomes
8140,NCT04202978,R0 resection rate,2020-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,pathologic complete response
8141,NCT00560846,Length of stay,2007-11,TERMINATED,INTERVENTIONAL,['NA'],,Body composition
8142,NCT03997188,Degree of dysphagia,2015-12-21,COMPLETED,INTERVENTIONAL,['PHASE3'],,
8143,NCT04416854,Overall survival,2020-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,The proportion of surgical intervention in control group
8144,NCT00576654,Recommended phase II dose (RP2D) of study drugs,2007-12-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Excision repair cross-complementation group 1 (ERCC1) expression levels,Tumor response
8145,NCT02767752,Disease-free survival (DFS),2016-11,TERMINATED,INTERVENTIONAL,['PHASE2'],Determination of plasma IL-6,Quality of Life
8146,NCT01697488,Safety: Incidence of adverse events,2012-02-02,COMPLETED,OBSERVATIONAL,['NA'],,Treatment duration
8147,NCT03731130,QoL (EORTC QLQCR29) absolute values and change over time,2018-10-05,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
8148,NCT05500027,Differentiation expression of serum sCD58 and TGfbeta1 among pancreatic cancer and other conditions,2021-05-01,RECRUITING,OBSERVATIONAL,['NA'],,
8149,NCT05816902,lung metastasis,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
8150,NCT00514761,Progression event count,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,safety and tolerability
8151,NCT03968406,Maximum tolerated dose (MTD),2019-09-26,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall quality of life as assessed by the FACT questionnaire,Overall survival
8152,NCT01062919,Postoperative functional recovery,2009-07,TERMINATED,INTERVENTIONAL,['NA'],,length of hospital stay
8153,NCT00848094,"Toxicity was graded using the CTCAE 3.0. Dose-limiting toxicity was defined as acute ≥ grade 3 hepatic or gastrointestinal toxicity, or any grade 5 treatment-related adverse event, or late complication of radiation-induced liver disease.",2005-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,"1,2 and 3 years survival"
8154,NCT06324357,Dose optimization (Phase II): Objective response (OR),2024-05-15,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Dose optimization (Phase II): Patient-reported outcome (PRO) - EORTC IL19
8155,NCT03775850,Evidence of anti-tumor activity of EDP1503 based on ORR,2018-12-19,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival
8156,NCT00471146,Overall Survival (OS),2007-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Population Pharmacokinetic (PK) Analysis for Axitinib (AG-013736)
8157,NCT02568046,"Number of Participants With Adverse Events (AEs) by Nature, Severity, and Occurrence Measured From Baseline to End of Trial Participation, as Assessed by the Common Terminology Criteria for AEs (Version 4.03) (CTCAE v4.03).",2016-03-15,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
8158,NCT05594927,Overall survival (OS),2022-12-12,RECRUITING,INTERVENTIONAL,['PHASE3'],,Mean area under the concentration-time curve during the dosing interval (AUC0-t)
8159,NCT04270851,Change in decision making on technical resectability,2020-04,UNKNOWN,OBSERVATIONAL,['NA'],,Level of agreement between liver surgeons on technical resectability
8160,NCT02539225,Progression Free Survival (PFS),2015-10-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Anti-Ramucirumab Antibodies
8161,NCT01312467,"Change in Activated S6serine235 (i.e., the Ratio of pS6serine235/S6serine235)",2011-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety and Tolerability of Metformin Hydrochloride Treatment
8162,NCT03102229,Number of patients hospitalized during treatment or within 4 weeks after completing radiotherapy.,2016-07,COMPLETED,INTERVENTIONAL,['NA'],,Modified Glasgow Prognostic Score
8163,NCT02394769,Change in Urinary Prostaglandin Metabolites (PGE-M),2015-07-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Spectral Biomarkers of Colorectal Cancer
8164,NCT02781532,Evaluation of ingesta,2014-04,COMPLETED,OBSERVATIONAL,['NA'],,
8165,NCT03542422,Progress free survival（PFS）,2018-06-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall Survival
8166,NCT00310882,,2006-05,WITHDRAWN,OBSERVATIONAL,['NA'],,
8167,NCT03980288,Dose limited toxicity and Maximum Tolerated Dose,2019-07-23,COMPLETED,INTERVENTIONAL,['PHASE1'],,Antitumor efficacy-Disease control rate (DCR)
8168,NCT00617071,Screening utilization over the 6-month observation period,2007-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Identification of predictors of CRC screening use and screening preference
8169,NCT00612586,Progression Free Survival (PFS),2008-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,PFS From Start of First Line Therapy
8170,NCT02960282,"Best tumor response, defined as a complete response or a clear decrease in tumor burden",2016-10-20,TERMINATED,OBSERVATIONAL,['NA'],,
8171,NCT03253289,Change in mRNA levels,2017-10-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,A panel of CAR downstream target genes
8172,NCT02332499,Overall Survival (OS),2014-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Number of Participants with Adverse Events as a Measure of Safety and Tolerability
8173,NCT03762590,"Change of genetic testing among family members of mutation positive PDAC patients, among family members of mutation positive individuals with a family history of PDAC and among first-degree relatives of PDAC patients",2019-05-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,"Uptake of surveillance for pancreatic, other associated cancers and health behaviors"
8174,NCT01483144,Number of Subjects With Any FAP-related Event.,2013-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Improvement in Investigator Lower GI Assessment
8175,NCT02530398,the grade of adverse events,2015-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
8176,NCT03945799,Disease free survival,2019-04-22,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
8177,NCT00010088,,1999-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
8178,NCT05420584,Imaging Tumor Regression Rate,2022-11-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Pathological Tumor Regression Rate
8179,NCT05397548,Detection of levels of circulating exosomal lncRNA-GC1,2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],,
8180,NCT00665197,Dysphagia relief,2007-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Treatment Toxicity
8181,NCT02305459,Description of the clinical context in which SIR-Spheres are applied,2014-11,COMPLETED,OBSERVATIONAL,['NA'],,Hepatic PFS
8182,NCT02724397,Number of Proximal Serrated lesions and colorectal adenomas in proximal colon,2016-05-01,UNKNOWN,INTERVENTIONAL,['NA'],,Improvement of histological diagnosis for serrated lesions and colorectal adenomas using LCI/BLI by comparing with that under white endoscopy
8183,NCT02548780,Area under the Curve (AUC),2016-04,COMPLETED,INTERVENTIONAL,['NA'],,Progression Free Survival
8184,NCT01158287,Disease control rate after 4 months,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tolerability and toxicity
8185,NCT03280511,The number of patients with peritoneal recurrence,2017-12-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,"1-, 3- and 5-year overall survival rate"
8186,NCT03776435,Age and sex-standardized incidence rate ratio (IRR) for malignancies of hematologic system,2018-01-15,UNKNOWN,OBSERVATIONAL,['NA'],Subgroup analysis,Age and sex-standardized incidence rate ratio (IRR) for all cancers
8187,NCT04006041,Pathologic complete response rate,2019-06-25,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Perioperative mortality
8188,NCT06333561,Overall survival,2021-01-01,RECRUITING,OBSERVATIONAL,['NA'],Objective response rate,Progression-Free-Survival
8189,NCT04150081,Validation of molecular signatures,2019-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,Sensitivity and specificity of follow-up tests
8190,NCT01522820,"Incidence of adverse events in patients receiving the DEC-205/NY-ESO-1 fusion protein CDX-1401 with and without sirolimus, as evaluated according to the NCI CTCAE scale version 4.0",2012-03,COMPLETED,INTERVENTIONAL,['PHASE1'],Time to disease progression,NY-ESO-1 specific humoral immunity
8191,NCT03422120,Natural Killer Cell Activity (NKA) at baseline compared to POD1 in CRC surgery patients,2016-08-01,COMPLETED,OBSERVATIONAL,['NA'],,Natural Killer Cell Activity (NKA) in healthy donors (HD) as compared to colorectal cancer (CRC) patients (at baseline)
8192,NCT03403465,Progression free survival (PFS),2018-03-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,Measure the potential sparing of radiation dose to critical normal tissue
8193,NCT06040021,OS,2008-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
8194,NCT03662659,BICR-Assessed Objective Response Rate (ORR) in Randomized LAG-3 Positive (>=1 %) Participants,2018-10-16,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests
8195,NCT05961709,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",2025-01-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
8196,NCT06023758,pCR rate,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,overall survival (OS)
8197,NCT03353753,Progression-Free Survival (PFS),2018-02-27,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of Life & Disease-Related Symptoms - EuroQol Visual Analogue Scale
8198,NCT01212510,Prediction of tumor progression,2010-10,COMPLETED,INTERVENTIONAL,['NA'],,Prediction of tumor response
8199,NCT04262687,The rate of patients alive and without progression at 10 months after inclusion,2021-04-06,RECRUITING,INTERVENTIONAL,['PHASE2'],,Histological response in case of secondary resection
8200,NCT05166577,Phase 2: Overall response rate (ORR),2021-10-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pharmacokinetic parameter - area under the plasma concentration-time curve [AUC]
8201,NCT04774757,3-year DFS,2021-03-10,RECRUITING,INTERVENTIONAL,['NA'],,1-year DFS
8202,NCT04538677,Attitude and satisfaction with video consultation,2017-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Satisfaction of surgeons: Questionnaire
8203,NCT04682665,Effect of human faecal samples from patients treated with EPA or placebo on anti-tumour immune response in gnotobiotic mice with colorectal cancer liver metastasis,2021-09-16,RECRUITING,OBSERVATIONAL,['NA'],,
8204,NCT02801500,Bilioenteric anastomotic leakage,2017-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,Bilioenteric anastomotic stricture
8205,NCT01816607,Presence of metastatic disease 5 years after rectal cancer treatment,2013-10,COMPLETED,OBSERVATIONAL,['NA'],Detection of regional malignant lymph nodes at time of diagnosis,Histomorphological response to preoperative chemoradiotherapy
8206,NCT01191684,Safety and tolerance of modified vaccinia virus ankara vaccine expressing p53 assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 4 toxicity scale,2011-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Immunogenicity
8207,NCT00004002,,1999-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8208,NCT02919787,Overall survival 18 month after randomization,2016-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Health economics
8209,NCT02576548,"Number and percentage of subjects with adverse events (AEs), serious adverse events (SAEs) and dose-limiting (DLTs).",2015-09-23,COMPLETED,INTERVENTIONAL,['PHASE1'],,Area under the plasma concentration versus time curve (AUC)
8210,NCT00033371,Number of Participants With Adverse Events Occurring at a Frequency of 5% or Grade 3 and Higher,2001-12-13,COMPLETED,INTERVENTIONAL,['PHASE2'],Percent Change in Polyp Size in Focal Area(s) of the Colorectum,Percent Change in the Area of Plaque-like Duodenal Polyps
8211,NCT01876927,the difference in percentage of patients receiving all the planned chemotherapeutic cycles between the two arms.,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Biologcal profile of treatment response
8212,NCT06249672,Low anterior resection syndrome,2023-01-17,RECRUITING,OBSERVATIONAL,['NA'],,
8213,NCT03280277,Technical feasibility of ultrasmall superparamagnetic iron oxide (USPIO) - magnetic resonance imaging (MRI) of the chest,2018-04-27,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Accuracy of USPIO - MRI
8214,NCT00155805,,2004-02,UNKNOWN,OBSERVATIONAL,['NA'],,
8215,NCT00508690,Incidence and classification of surgical site infection (SSI),2007-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Incidence of colitis, other infectious diseases and other postoperative complications."
8216,NCT00568425,Evaluate the late effects of radiation treatment,2005-09,TERMINATED,OBSERVATIONAL,['NA'],,
8217,NCT03358095,Emerged complications related to surgery or preoperative endoscopy within 120 days of surgery,2017-11-26,WITHDRAWN,INTERVENTIONAL,['NA'],,
8218,NCT00976976,"This protocol will evaluate the possible benefit of adjuvant docetaxel, capecitabine, and cisplatin combination chemotherapy in patients with resected gastric cancer pathologic stage IIIB and IV in terms of relapse free survival.",2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Investigate the safety profiles, patient tolerance, and overall survival in this population"
8219,NCT00508846,Patient Responses to Questionnaire,2003-05,COMPLETED,OBSERVATIONAL,['NA'],,
8220,NCT03590275,Overall survival,2017-10-02,COMPLETED,OBSERVATIONAL,['NA'],,Toxicity rate
8221,NCT02194829,Progression-free Survival,2014-08-19,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease Control Rate
8222,NCT01897038,Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs),2013-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Anti-therapeutic Antibodies (ATAs) Against Onartuzumab
8223,NCT05171426,incidental cancer,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
8224,NCT04286711,Dose-Limiting Toxicity [DLT],2020-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival [OS]
8225,NCT01570010,Overall survival,2012-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Health related quality of life and fatigue
8226,NCT04222530,Diagnostic accuracy,2020-01-28,UNKNOWN,INTERVENTIONAL,['NA'],,Operating time
8227,NCT01901692,Progression-free survival (PFS) rate,2013-07-29,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Exploratory analysis for overall patient survival rate
8228,NCT02725125,Disease control rates,2015-11,UNKNOWN,INTERVENTIONAL,['NA'],,Duration of remission
8229,NCT06194877,Part 2: ORR as Assessed by Initial Investigator Review,2024-03-29,RECRUITING,INTERVENTIONAL,['PHASE1'],,Part 2: Number of Participants with Reductions in Dosing with BGB-3245
8230,NCT03079778,Intrahepatic progression,2019-07-31,WITHDRAWN,INTERVENTIONAL,['NA'],Extrahepatic failure,QoL-quality of life
8231,NCT02999893,Establish the safety profile of combined APR-246 plus cisplatin and 5FU as measured by the satisfactorily low rate of adverse events described according to NCI CTCAE v 4.03.,2017-04-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of patients who will benefit from APR-246 therapy as assessed by quantitation of ctDNA levels in patient serum and plasma samples.,Evidence of clinical efficacy of a combined APR-246 and cisplatin/5FU chemotherapy regimen as confirmed by CT/PET/MRI scan.
8232,NCT00869271,overall survival,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,progression free survival
8233,NCT05934331,PFS,2023-07-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
8234,NCT00288093,MTD as assessed by the number of patients with dose-limiting toxicity (DLT),2006-12-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,Therapeutic response as assessed using the Response Evaluation Criteria in Solid Tumors (RECIST)
8235,NCT04776590,Pathologic complete response rate,2021-01-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,overall survival
8236,NCT01833832,Intraperitoneal Progression Free Survival (PFS),2013-04-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)
8237,NCT00006981,,2000-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8238,NCT04392050,Successful completion of the key contact interviews and focus groups leading to the development of the culturally tailored educational intervention,2020-01-31,RECRUITING,OBSERVATIONAL,['NA'],,
8239,NCT04104230,Knowledge and Tissue Bank,2012-03-12,RECRUITING,OBSERVATIONAL,['NA'],,
8240,NCT01260168,The primary endpoints are point estimates of the sensitivity of the diagnostic tests for detection of colorectal neoplasms.,2010-10,COMPLETED,OBSERVATIONAL,['NA'],,To collect samples from patients diagnosed with colorectal cancers.
8241,NCT01633333,Pain during colonoscopy,2012-06,COMPLETED,INTERVENTIONAL,['NA'],,Dose of medication
8242,NCT01903694,determination of the tumor according to the evaluation criteria of Response Evaluation Criteria in Solid Tumors,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
8243,NCT03297710,Maximum tolerated dose (MTD),2017-12-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Time until treatment related grade 3+ toxicity,
8244,NCT04595864,OS,2020-11-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,PFS
8245,NCT05129787,Local tumor progression,2021-12-16,RECRUITING,INTERVENTIONAL,['NA'],,Inflammatory response
8246,NCT00005864,,2000-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8247,NCT01129700,To evaluate the pathologic response,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Acute/ late toxicities
8248,NCT01781403,Recommended Dose (RD),2013-05-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Disease-free Survival,Pathological Complete Response
8249,NCT03415451,The success rates of fiberscope-guided NG tube insertion,2017-10-01,COMPLETED,INTERVENTIONAL,['NA'],,
8250,NCT02942901,Overall Survival,2015-01,COMPLETED,OBSERVATIONAL,['NA'],,Number and sites of metastases detected by PET-CT
8251,NCT02779608,response rate of ascites,2017-01-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,side effects of chemotherapy
8252,NCT01306630,"To determine the safety, tolerability, and maximum tolerated dose of tivozanib when administered in combination with capecitabine (Xeloda®) to subjects with advanced solid tumors",2010-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To evaluate the antineoplastic activity of tivozanib and capecitabine, when given together, to slow the growth of or shrink tumor as measured by CT/MRI imaging assessment and according to RECIST criteria."
8253,NCT06203327,early gastric neoplasm,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
8254,NCT00899210,Kinetics of postoperative changes of serum matrix metalloproteinases (MMP) and their inhibitors (TIMP),2003-09,COMPLETED,OBSERVATIONAL,['NA'],,Correlation of postoperative serum HGF/SF with plasma levels in MMPs
8255,NCT01082315,Safety,2009-04,COMPLETED,OBSERVATIONAL,['NA'],,Clinical efficacy
8256,NCT04063683,Progress free survival (PFS),2019-10-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Duration of Response(DOR)
8257,NCT06143748,Progression-free survival,2024-03-02,RECRUITING,INTERVENTIONAL,['PHASE2'],Correlation between genetic biomarkers and survival,Treatment-related adverse events
8258,NCT00952003,To determine efficacy in terms of response rate according to RECIST criteria,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,To determine overall survival time following treatment with a chemoimmune therapy
8259,NCT03892681,Specificity,2019-04,UNKNOWN,INTERVENTIONAL,['NA'],,Inter-reader agreement between two radiologists
8260,NCT03645655,Change of PIVKA-II,2018-10-01,COMPLETED,OBSERVATIONAL,['NA'],,Change of AFP
8261,NCT02403544,Maximum Tolerated Dose (MTD) for capecitabine and oxaliplatin,2013-09,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Tumor response rate including complete response and partial response rates
8262,NCT00335959,Pathologic Complete Response,2006-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug
8263,NCT06283134,MTD,2024-04-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Serum neutralizing antibody level
8264,NCT05898789,Disability,2023-07-07,RECRUITING,INTERVENTIONAL,['NA'],,Physiological measures of performance
8265,NCT00392470,Pathologic response rate and histological degree of tumor regression as measured by Mandard TRG score,2006-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
8266,NCT02057562,Adenoma detection rate,2014-02,UNKNOWN,OBSERVATIONAL,['NA'],,Frequency of colon diverticulosis
8267,NCT04572633,Primary Safety: Procedure-Related Major Complications,2021-01-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Secondary Safety: All Adverse Events
8268,NCT05408897,recurrence,2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
8269,NCT02089269,Treatment reality in Germany,2013-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
8270,NCT05637268,3-year DFS rate,2020-11-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,5 years OS rate
8271,NCT06208436,Recurrence-free survival,2023-10-07,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
8272,NCT00862524,Assess the efficacy of the study drug in combination with gemcitabine in terms of progression-free survival (PFS) at 16 weeks.,2009-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Characterize the safety profile of study drug in combination with gemcitabine in terms of adverse events, clinical laboratory tests and electrocardiograms."
8273,NCT02786602,"Clinical characteristics (age, sex, tumor location) compared between LRP1 high and low methylation groups.",2016-05,COMPLETED,OBSERVATIONAL,['NA'],,
8274,NCT04143048,Genetic mutations of patients with stromal tumor assessed by next-generation sequencing,2019-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,Genetic mutations of patients with stromal tumor assessed by next-generation sequencing
8275,NCT03161925,Overall survival,2016-11-28,UNKNOWN,OBSERVATIONAL,['NA'],,
8276,NCT04440735,DSP107 Serum Concentration,2020-10-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Preliminary Efficacy (Part 2 only)
8277,NCT05834543,ORR,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of serious adverse events (SAEs)
8278,NCT01074333,Safety and toxicity of Erbitux treatment,2008-09,TERMINATED,OBSERVATIONAL,['NA'],,Clinical efficacy of Erbitux treatment
8279,NCT01568723,Response to therapy,2012-01,COMPLETED,OBSERVATIONAL,['NA'],,
8280,NCT02250053,"1. The biological efficacy of aerobic exercise on soluble intercellular adhesion molecule-1 (sICAM-1), and soluble vascular adhesion molecule-1 (sVCAM-1) prognostic biomarkers.",2015-12,COMPLETED,INTERVENTIONAL,['NA'],,Circulating tumor cells measured at baseline and six-months.
8281,NCT00590278,"This study will evaluate the value of TOMUDEX in combination with a 'standard' course of pelvic radiotherapy for inoperable/recurrent rectal cancer, in terms of response rate and increasing the resectability rate",2002-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8282,NCT04704960,correlation between circulating tumor DNA (ctDNA) before and after local treatment (surgery or radiation) and recurrence of lung metastases from colorectal cancer,2021-02,UNKNOWN,OBSERVATIONAL,['NA'],,mutations related to target drug
8283,NCT01816256,Incidence of asymptomatic portal vein thrombosis (PVT) and/or portal hypertension (PHTN) in patients with Philadelphia negative myeloproliferative neoplasms (MPNs),2013-05,COMPLETED,INTERVENTIONAL,['NA'],Identify any genetic markers or biomarkers associated with asymptomatic PVT and PHTN,Comparison of survival and number of patients with leukemic transformation in patients with or without asymptomatic PVT/PHTN
8284,NCT05498779,Recurrence after ablation,2022-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival related to HCV virus
8285,NCT06313190,Progression-free survival (PFS) rate,2024-04-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Correlation between ctDNA and overall survival,Treatment-related adverse events
8286,NCT02624115,FAZA PET uptake in locally advanced rectal cancers prior to and after chemoradiotherapy,2016-05-01,COMPLETED,OBSERVATIONAL,['NA'],,Correlation of FAZA-PET and blood oxygen level-dependent MRI to Pimonidazole staining in locally advanced rectal cancer
8287,NCT03495674,Retention,2018-04-04,COMPLETED,INTERVENTIONAL,['NA'],,
8288,NCT04198766,MTD and/or RP2D of INBRX-106 as single agent and in combination with pembrolizumab,2019-12-10,RECRUITING,INTERVENTIONAL,['PHASE1'],Anti-tumor activity of INBRX-106 as single agent and in combination with pembrolizumab,Immunogenicity of INBRX-106
8289,NCT00088816,Overall survival,2003-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse events
8290,NCT02919969,Overall Response Rate,2016-10-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events to Evaluate the Safety and Tolerability of Pembrolizumab
8291,NCT02584244,"Correlate LUM015 fluorescence in gastrointestinal cancers (pancreatic, esophageal, and colorectal) with pathology results",2016-08-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Number of safety events in humans with colorectal, pancreatic, and esophageal cancer."
8292,NCT01486251,Echography measure,2011-09,COMPLETED,INTERVENTIONAL,['NA'],,
8293,NCT03332576,Safety as measured by adverse event reporting (CTCAE),2013-08-23,COMPLETED,INTERVENTIONAL,['PHASE1'],,Impact on residual tumour
8294,NCT04422002,Survival,2019-12-01,COMPLETED,OBSERVATIONAL,['NA'],,Surgical complications
8295,NCT00640081,Failure-free survival at 10 months,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity of each treatment regimen by NCI CTCAE v3.0
8296,NCT03592550,Difference in liver position after set-up,2018-09,UNKNOWN,OBSERVATIONAL,['NA'],,Number of available imaging positions
8297,NCT00500292,Number of Patients With an Objective Disease Progression Event,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8298,NCT02293954,Tumor Uptake of 64Cu-DOTA-hT4.66-M5A at Day 2,2015-11-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,The Average Increase of Tumor-to-blood (T:B) Ratio From Day 1 to Day 2
8299,NCT00426127,Tumor Response Measured by CT Scans After Each Set of 3 Cycles of Chemotherapy,2006-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Safety and Effect of Chemo Regimen on D-Dimer Measured by Drawing D-Dimer Levels Every Cycle
8300,NCT01831726,Clinical Benefit Rate (CBR),2013-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
8301,NCT05080907,Collection of Biospecimens for Novel Research Uses,2016-07-15,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Number of subjects enrolled
8302,NCT02520453,Disease-free survival,2016-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
8303,NCT02077881,Overall Survival,2014-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to Progression of Disease
8304,NCT04274868,Establish a national bank of rare biological material,2015-09-10,RECRUITING,OBSERVATIONAL,['NA'],,
8305,NCT02470559,Toxicity profile of IP and IV HER2Bi-aATC at the MTD or technically feasible dose graded using NCI CTCAE version 4.0,2015-06,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Progression free survival
8306,NCT00558051,The primary endpoint of this study is to evaluate the feasibility and safety of semi-continuous intralymphatic vaccination dendritic cells.,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,"The secondary objective of this study is to evaluate the immunity results from either single injections or semi-continuous infusion, intradermal or intranodal, administered immunization with the DC vaccine for colorectal cancer (CRC) patients."
8307,NCT02703571,Objective Response Rate (ORR),2016-06-29,TERMINATED,INTERVENTIONAL,['PHASE1'],,overall survival
8308,NCT05536427,Tolerance(DLT/ MTD/ OBD),2022-10-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
8309,NCT06061445,ORR,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
8310,NCT04520737,Physical Fitness- 6MWT,2020-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Nutritional status- UMA
8311,NCT05576480,Pathological complete remission rate (pCR),2022-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number and severity of adverse events
8312,NCT04544046,Proportion of participants requiring a hospital admission or emergency department visit,2020-09-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Change in Instrumental Activities of Daily Living (IADLs)
8313,NCT03844750,Proportion of patients with a >= 2-fold increase in the tumor-infiltrating cells per unit area (5 high power fields) in post- versus pre pembrolizumab treatment tumor specimens.,2019-07-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,Median Relapse-free survival (RFS) per RECIST 1.1
8314,NCT01264822,Transition rate to secondary therapy for eradication of Helicobacter pylori,2011-01-13,COMPLETED,OBSERVATIONAL,['NA'],,
8315,NCT04032119,Overall procedural time,2020-01-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Lymphovascular invasion
8316,NCT03396705,Gene expression,2017-09-12,TERMINATED,OBSERVATIONAL,['NA'],,
8317,NCT03391843,Pelvic complete resection rate,2017-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,The incidence of >=3 grade adverse events
8318,NCT02098239,Patient Survival,1999-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Injection Tolerability
8319,NCT04775862,Progression-free survival (PFS),2021-02-21,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Determine the prevalence of RAS G12C mutation via using cfDNA
8320,NCT02966223,Primary,2017-08-17,TERMINATED,INTERVENTIONAL,['NA'],,Secondary
8321,NCT04777162,objective response rate,2021-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival
8322,NCT00037804,,na,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8323,NCT01443065,Progression-free survival at 4 months,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tolerance of the treatment
8324,NCT03959839,local recurrence rate,2019-04-01,UNKNOWN,INTERVENTIONAL,['NA'],,Short-term local recurrence rate
8325,NCT00972036,"To determine the safety, toxicity, and maximum tolerated dose of SIR-Spheres® in patients with unresectable metastatic colorectal cancer to the liver (CLM) who have received previous hepatic arterial infusion chemotherapy (HAC).",2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,To obtain preliminary evidence of any clinical efficacy of the SIRT therapy in these heavily pretreated patients with unresectable CLM who have received hepatic arterial infusion pump and have failed at least one line of prior chemotherapy.
8326,NCT02679495,gastric caner occurrence,2015-03-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,gastric tissue DNA methylation change of selected genes
8327,NCT01688817,Effect of primary care physician's (PCP) counseling on participation rate in primary colonoscopy screening program,2008-05,COMPLETED,INTERVENTIONAL,['NA'],,Effect of primary care physician's (PCP) counseling on a patient's decision to choose unsedated colonoscopy (not in sedation).
8328,NCT01393249,Risk of pancreatitis,2011-07,COMPLETED,OBSERVATIONAL,['NA'],,Course of pancreatitis
8329,NCT02851784,"Cumulative survival rates were calculated by the Kaplan-Meier method, and comparison between MWA and combination treatment will be done by the log-rank test.",2009-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']","Local tumor progress rates were calculated by the Kaplan-Meier method, and comparison between MWA and combination treatment will be done by the log-rank test","disease free survival rates were calculated by the Kaplan-Meier method, and comparison between MWA and combination treatment will be done by the log-rank test"
8330,NCT04678011,Advanced neoplasia,2020-11-24,RECRUITING,OBSERVATIONAL,['NA'],,Complications
8331,NCT01640522,Depression,2008-01,COMPLETED,INTERVENTIONAL,['NA'],,Fatigue
8332,NCT05369650,Immediate postoperative plasma lidocaine concentration,2019-07-27,RECRUITING,INTERVENTIONAL,['NA'],,Patient satisfaction scores
8333,NCT02136836,The proportion of HER2 overexpression in gastric cancer patients,2014-05,UNKNOWN,OBSERVATIONAL,['NA'],The practice pattern of Herceptin use in stage IV gastric cancer,Gastric cancer specific survival according to HER2 expression in each stage
8334,NCT05332002,Adverse Event Rates,2022-07-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,
8335,NCT06249841,"The primary endpoint of this study is feasibility of percutaneous cryobiopsy in the bile duct, i.e., successful retrieval of at least one cryobiopsy specimen per patient.",2024-03-04,RECRUITING,INTERVENTIONAL,['NA'],,"Rate of safety-relevant aspects, like for example bleeding, post-bleeding, perforation, infection and abscess"
8336,NCT02792881,Morbidity,2016-06,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,The Surgery Task Load Index (SURG-TLX)
8337,NCT02444572,Incidence of asymptomatic Deep Venous Thrombosis (DVT),2015-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,Incidence of both Enoxaparin formulations immunogenicity
8338,NCT00897832,Determination if a method of extracting and identifying biomarkers from tissues of the quantity obtained from typical biopsy can be applied in the setting of pancreatic cancer,2007-01,COMPLETED,OBSERVATIONAL,['NA'],,
8339,NCT01317433,reduction of Grade > or = 2 acne-like skin rash by 30%,2010-12-29,TERMINATED,INTERVENTIONAL,['NA'],,Resectability rate
8340,NCT00580281,"This pilot study will collect longitudinal data on bone metabolism for patients treated with imatinib. Sixty patients will be followed over a two-year period on this protocol, with bone marker assessments ascertained every 3 months (+2 weeks).",2006-11,COMPLETED,INTERVENTIONAL,['NA'],,
8341,NCT02081755,"Disease free survival (DFS) defined as the time from randomization to the time of tumor recurrence or death, whichever occurs first.",2014-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],,Hepatic arterial thrombosis
8342,NCT02311907,"Paclitaxel/Carboplatin (PC) Induced Peripheral Neuropathy as Assessed by EORTC QLQ-CIPN20 (European Organization for Research and Treatment of Cancer (EORTC), Quality of Life (QLQ), Chemotherapy Induced Peripheral Neuropathy 20 (CIPN20)).",2009-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Times to Onset of CTCAE Grade 3+ PN
8343,NCT05181605,Overall Survival,2022-04-15,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Adverse events
8344,NCT00663741,Safety and pharmacokinetics,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Duration of response
8345,NCT02640781,Duration of stent patency between stent insertion and recurrence of obstructive symptoms,2015-12,UNKNOWN,INTERVENTIONAL,['NA'],,Number of patients with complications
8346,NCT02008539,Safety and tolerability as indicated by Common Toxicity Criteria (CTC-AE) of the National Cancer Institute,2013-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
8347,NCT03775863,Incidence of recurrent hepatocellular carcinoma after liver transplantation.,2017-11-11,COMPLETED,OBSERVATIONAL,['NA'],,Survival in patients with hepatocellular carcinoma after liver transplantation.
8348,NCT00534053,Our primary outcome is FOBT card return rate,2007-06,COMPLETED,INTERVENTIONAL,['NA'],,Predictors of Non-compliance to fecal occult blood testing
8349,NCT00060411,The relationship between CYP3A4 activity and OSI-774 clearance,2003-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Pharmacokinetics of OSI-774 given with FOLFOX 4, and Bevacizumab"
8350,NCT00075439,Proportion of patients progression-free at 6 months,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to treatment failure
8351,NCT02227940,"MTD and RP2D of ceritinib in combination with gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation, defined as the highest dose level at which < 2 of 6 patients experience treatment-related DLT (Arms 2 and 2E)",2015-01-08,COMPLETED,INTERVENTIONAL,['PHASE1'],Levels of serum and tumor biomarkers,Response rate as assessed by the RECIST 1.1
8352,NCT01673334,Diagnostic Yield,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4'],,
8353,NCT01198743,local recidivism or metastasis reappearance,2005-11,COMPLETED,OBSERVATIONAL,['NA'],,specificity and global safety
8354,NCT00920023,To Determine the Specificity of High Resolution Magnetic Resonance Imaging With Lymphotrophic Superparamagnetic Nanoparticles to Identify Small and Otherwise Undetectable Lymph Node Metastases.,2008-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,
8355,NCT01945879,Incidence of NCI CTC Toxicity III°/IV° and severe bleedings,2003-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall survival
8356,NCT04050462,Objective Response Rate (ORR) of Cabiralizumab or BMS-986253 in combination with Nivolumab in comparison to Nivolumab monotherapy,2019-09-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
8357,NCT03046849,Pathogenic germline mutation,2017-03-08,COMPLETED,OBSERVATIONAL,['NA'],,Variant of uncertain significance of germline mutation
8358,NCT01956149,Disease Control Rate (DCR),2013-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Correlation of circulating tumor cells with the clinical response
8359,NCT00482586,"Development of a data repository for health-related quality of life outcome measures by administering the Medical Outcomes Study Short Form questionnaire at baseline, during routine follow-up after image-guided therapy, and then annually thereafter",2003-10,COMPLETED,OBSERVATIONAL,['NA'],,
8360,NCT06276140,Overall morbidity,2024-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Values of different erythrocyte indices
8361,NCT02815150,preoperative gastric residual volume of gastric fluid,2016-04-01,COMPLETED,INTERVENTIONAL,['NA'],,Reoperation rate within 30 days post operation
8362,NCT01068769,"Clinical Benefit as Defined by the Composite of Complete Response, Partial Response and Stable Disease Lasting 16 Weeks or More Per RECIST 1.1 as a Measure of Disease Control",2010-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free Survival (PFS)
8363,NCT06218810,1-year Progression Free Survival rate,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,irORR
8364,NCT00237185,Best Tumor Response (Core + Extension),2000-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Progression (Core + Extension)
8365,NCT06010888,Objective Response Rate（ORR）,2023-10-31,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival（OS）
8366,NCT03301805,Part II: Overall response rate (PR + CR),2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Part II: Incidence of grade 3/4 hematological toxicity
8367,NCT03393234,3-year disease free survival,2017-06-01,UNKNOWN,INTERVENTIONAL,['NA'],,sexual function
8368,NCT04331743,Recommended Phase II Dose (RP2D),2021-06-05,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Duration of Response (DoR)
8369,NCT03498885,Anastomotic leakage,2018-01-01,RECRUITING,INTERVENTIONAL,['NA'],,5-years disease free survival rate
8370,NCT00650988,Number of patients that experience toxicity with cryotherapy,2005-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Assess the degree of tumor ablation of inoperable early esophageal cancer
8371,NCT05250843,Recurrence-free Survival,2022-05-30,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Adverse effects
8372,NCT06249321,"progression-free survival, PFS",2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,disease control rate (DCR)
8373,NCT02502474,Number of patient with Staphylococcus aureus colonic carriage,2015-02-02,COMPLETED,INTERVENTIONAL,['NA'],,Number of patient with Staphylococcus aureus carriage in the groin
8374,NCT03816163,Number of participants with Eastern Cooperative Oncology Group (ECOG) performance status abnormalities and or adverse events,2019-03-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Health Related Quality of Life (HRQoL) measured by the Patient Global Impression of Severity (PGIS) Scale
8375,NCT03768687,Progression free survival,2018-12-20,UNKNOWN,OBSERVATIONAL,['NA'],,
8376,NCT01477229,"To describe QoL, symptoms and functional impairments in an unselected population of rectal cancer patients",2012-02,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,QoL in an unselected population of rectal cancer patients
8377,NCT01189929,To determine the maximum tolerated dose of demcizumab (OMP-21M18) when combined with gemcitabine +/- Abraxane®,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,To determine the exploratory biomarker changes of gemcitabine plus demcizumab (OMP-21M18)
8378,NCT01549327,Empowerment,2012-05,COMPLETED,INTERVENTIONAL,['NA'],,Cost-effectiveness
8379,NCT03693170,Confirmed Overall Response Rate (cORR) Based on Local Tumor Assessments,2019-01-17,COMPLETED,INTERVENTIONAL,['PHASE2'],,PGIC Scores Over Time
8380,NCT02500043,Overall Survival (OS),2016-02-24,COMPLETED,INTERVENTIONAL,['PHASE3'],EORTC Quality of Life Questionnaire - Gastric-specific Module (EORTC QLQ-STO22): Percentage of Participants With Overall Compliance,Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAE)
8381,NCT05736731,Phase 2: The Overall Response Rate (ORR) for patients,2023-04-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Cytokine analysis
8382,NCT02632682,Probe-based confocal laser endomicroscopy (pCLE) will be compared to standard histologic analysis in the evaluation of Barrett's esophagus.,2016-02,COMPLETED,OBSERVATIONAL,['NA'],,
8383,NCT03043183,complication,2017-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,
8384,NCT00005639,Minimal Effective Dose (MED) of Azacitidine with Phenylbutyrate,2000-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Gene-re-expression of epigenetic modulation in Peripheral Blood Mononuclear Cells (PBMC) as measured by change in Epstein-Barr Virus (EBV) viral load (number of copies per 1 million cells) after treatment with Azacitidine
8385,NCT00321685,Pathologic Complete Response Rate,2006-07-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,5-year Recurrence-free Survival Rate
8386,NCT05789433,Whole-Body Intermuscular Adipose Tissue,2023-05-01,RECRUITING,INTERVENTIONAL,['NA'],,
8387,NCT02316496,Objective response rate (ORR),2015-09-23,TERMINATED,INTERVENTIONAL,['PHASE2'],,PFS
8388,NCT05156866,Recommended Phase 2 Dose (RP2D),2022-02-02,RECRUITING,INTERVENTIONAL,['PHASE1'],,Accumulation ratio (Rac) of TORL-2-307-ADC
8389,NCT03445585,Number of participants in the study.,2017-01,RECRUITING,OBSERVATIONAL,['NA'],,Number of clinical phenotypes and/or endpoints observed (per category)
8390,NCT01509911,Disease Control Rate as defined by Percentage of patients experiencing a Complete Response or a Partial Response or a Stable Disease according to RECIST measured at 16 weeks after treatment initiation,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall Survival
8391,NCT02331927,Randomized part: PFS rate at 6 months after first cycle after randomization,2015-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Prognostic value of CAF at baseline and/or during treatment
8392,NCT00504998,"Clinical toxicity (DLT and MTD) as defined by patient performance status, toxicity assessment score, hematologic, and metabolic profiles.",2007-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To identify an objective tumor response to Rexin-G
8393,NCT04699994,"Histological response rate (Grade 2 or 3 in Japanese Classification of Esophageal Cancer, 11th Edition)",2020-06-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence rate of all adverse event
8394,NCT00003939,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8395,NCT00764595,Progression-free survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Types and severities of adverse events
8396,NCT05775159,Progression free survival (PFS),2023-04-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Objective response rate (ORR)
8397,NCT01252498,Salivary levels of PGE2 and PGI2 during and after radiotherapy,2010-12,COMPLETED,OBSERVATIONAL,['NA'],,Patient reports of oral pain during and after radiation therapy
8398,NCT04315883,Evaluate the efficacy and clinical utility of TARE-Y90 by examining clinical course,2021-02-11,RECRUITING,OBSERVATIONAL,['NA'],,
8399,NCT00838968,5-years survival rate,2008-01,WITHDRAWN,INTERVENTIONAL,['NA'],,
8400,NCT05495776,Frequency of microsatellite instability and Lynch syndrome,2022-08-01,RECRUITING,OBSERVATIONAL,['NA'],,Impact of the presence of microsatellite instability/deficiency
8401,NCT01082757,Mutational status of KRAS: study of codons 12 and 13 in exon 1 of KRAS gene,2009-06,COMPLETED,OBSERVATIONAL,['NA'],,Subject and tumour characteristics and their association with KRAS mutational status
8402,NCT00834158,the rate of tumor resection after intervention,2009-01,COMPLETED,INTERVENTIONAL,['NA'],,rate of survival
8403,NCT00960284,1-year progression-free survival (Phase II),2003-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Pattern of relapse
8404,NCT05854498,Progression Free Survival (PFS),2023-10-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Efficacy of irinotecan measured by PFS for patients with and without irinotecan containing regimens
8405,NCT02137343,Overall Survival,2014-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,"Incidence of subject adverse events, laboratory abnormalities and immunogenicity"
8406,NCT01034683,objective response rate(ORR) time to progression (TTP) toxicities,2009-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,1-year survival rate KPS score
8407,NCT00003063,,1991-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
8408,NCT01897584,arterial oxygenation (PaO2),2013-07,COMPLETED,INTERVENTIONAL,['NA'],,cerebral perfusion pressure
8409,NCT03659357,the size in centimeters,2018-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,intensity of the neoplasms measured in the CTE in Hu
8410,NCT05816980,Resection rate,2015-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Comparative dose planning study
8411,NCT01186081,Disease-free survival,2004-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Treatment related toxicities
8412,NCT02980510,Evaluation of complete response rate on treatment combining FOLFIRINOX and panitumumab.,2016-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
8413,NCT00960609,First outcome was the rate of CVs detectable with e-flow IOUS along clamping of the HV for which resection could be needed.,2008-01,COMPLETED,OBSERVATIONAL,['NA'],,"Secondary outcome was safety (morbidity, mortality, blood loss, blood transfusions) of the procedure."
8414,NCT04810156,Time to response or downgrading of liver injury in days,2021-04-07,RECRUITING,INTERVENTIONAL,['PHASE2'],Description of changes in the fecal microbiome,Overall survival rates at 6 months
8415,NCT02005614,Rate of Local Control Over time (RECIST Criteria),2013-11,TERMINATED,INTERVENTIONAL,['NA'],,
8416,NCT00838318,"To look at the knowledge, beliefs, and attitudes toward screening for colorectal cancer among Hispanic colorectal cancer patients and their close relatives.",2004-02,COMPLETED,OBSERVATIONAL,['NA'],,To study how these families communicate with each other and health care providers about colorectal cancer risk and screening.
8417,NCT03781050,Total load of PJS-related intestinal polyps Total load of PJS-related intestinal polyps Total load of PJS-related intestinal polyps,2018-09-16,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Adverse events
8418,NCT01867697,Response rate (RR),2012-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Frequency of secondary micro-radical surgical resection (R0 resection)
8419,NCT00920868,To determine the maximum tolerated dose(MTD)/recommended phase II dose (RPTD) of capecitabine/oxaliplatin/bevacizumab/dasatinib for patients with advanced solid tumors.,2009-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To explore any correlation between blood, urine, and paraffin biomarkers and clinical outcomes"
8420,NCT05494086,Early operative morbidity,2022-08-01,RECRUITING,INTERVENTIONAL,['NA'],,5 year overall survival rate
8421,NCT00010023,,2000-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8422,NCT02279134,Disease-free survival (DFS),2014-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Adverse events,Overall survival (OS)
8423,NCT00257322,Participants Exhibiting Immune Response,2003-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response Rates and Overall Survival.
8424,NCT05978193,PFS,2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Grade III and higher treatment-related adverse events
8425,NCT01440959,Disease Control Rate (DCR; OR + Stable Disease),2011-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
8426,NCT04582981,progression free survival (PFS),2020-09-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],quality of life score (QOL),disease control rate (DCR)
8427,NCT03862378,Predictive value of the nomogram prediction model (APPEAL-GC score),2019-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Abdominal infection outcome.
8428,NCT02827201,Rate of patients alive without progression 6 months after inclusion,2015-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free survival:
8429,NCT02675738,Number of cases with confirmed preoperative diagnosis,2015-12,UNKNOWN,OBSERVATIONAL,['NA'],,
8430,NCT00009737,Disease-free Survival,1998-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Any Adverse Events and Serious Adverse Events
8431,NCT04276909,Assess the initial safety and efficacy of the LUM Imaging System for detection of primary pancreatic cancer and peritoneal invasion from primary pancreatic cancer during surgery,2026-01,WITHDRAWN,INTERVENTIONAL,['NA'],,Correlate resected tissue with LUM Imaging System to identify imaging threshold
8432,NCT02960620,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
8433,NCT00576134,Respiratory evaluation,2008-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Nasofibroscopy
8434,NCT00356161,Safety of device and regional therapy,2002-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,quality of life
8435,NCT02726399,Progression Free Survival,2016-03-18,TERMINATED,INTERVENTIONAL,['PHASE2'],,
8436,NCT05645198,Ratio of (patient who suffers from) pancreatic fistula,2022-10-26,RECRUITING,INTERVENTIONAL,['PHASE4'],,
8437,NCT05440864,Number of greater than grade 3 adverse events (AEs) or immune related adverse events that leads to treatment cessation,2023-10-26,RECRUITING,INTERVENTIONAL,['PHASE2'],Taxonomic profiling of gut microbiome,Rates of R0 resection
8438,NCT05018182,Pathological response,2021-08-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of patients with 30-day post-operative mortality
8439,NCT01643070,R0 resection rate after simultaneous surgery of the rectum and the liver,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
8440,NCT03519997,Overall Response Rate,2018-04-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Treatment response,Safety and Tolerability: rates of adverse events according to the CTCAE
8441,NCT04343456,Disease free survival,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
8442,NCT03452774,Proportion of patients Eligible for CTE versus Actual CTE,2018-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Time from Intervention to Actual CTE (months)
8443,NCT02113202,"Number of fluorescent adenomatous polyps during surveillance endoscopy using the near-infrared fluorescence endoscopy platform in patients with Familial Adenomatous Polyposis (FAP), after administration of the fluorescent tracer bevacizumab-IRDye800CW.",2014-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Measure the mean fluorescent intensity of adenomas and compare this between the three different dosing groups to determine the best tracer dose for the fluorescence endoscopy procedure.
8444,NCT01622569,Change in Total Polyp Grade,2013-11-19,COMPLETED,INTERVENTIONAL,['PHASE3'],,Nasal Polyp Surgery Eligilbilty
8445,NCT03925428,Maximum tolerated dose,2020-09-18,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Effect of GSK525762C and entinostat combination therapy on gene expression patterns,Duration of response
8446,NCT00296335,Relapse-free Survival Rate,2002-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Patients With Adverse Events
8447,NCT04104139,Proportion of dose limiting toxicity (DLT)s for TAS-102 at the maximum tolerated dose (MTD),2019-12-11,RECRUITING,INTERVENTIONAL,['PHASE1'],Rate of pathologic complete response after standard total mesorectal excision (TME),Incidence of grade 3 or higher treatment emergent adverse events (TEAEs) during FOLFOX or CAPOX treatment
8448,NCT00159471,"To see if patients with advanced pancreatic cancer treated with gemcitabine, docetaxel and capecitabine who bear more favorable genotypes of genes involved in drug metabolisms are more likely to have response and survive longer than those that do not.",2005-02,TERMINATED,INTERVENTIONAL,['NA'],,"To assess time to progression, toxicity and to identify other molecular correlates of response, toxicity, and survival."
8449,NCT00976768,Progression-free survival,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response rate
8450,NCT03442569,Overall Response Rate,2018-03-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Toxicity of Treatment
8451,NCT01152645,Antitumor effect,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse events
8452,NCT01305993,Evaluating Tumor Response Rate,2011-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Determine duration of response rate by measuring time to progression
8453,NCT03876561,Severity of Low Anterior Resection Syndrome Score (LARS score),2019-05-27,UNKNOWN,INTERVENTIONAL,['NA'],,Medico-economic impact of pelvic floor prehabilitation including the fecal incontinence related costs
8454,NCT02198976,Number of Serious and Non-Serious Adverse Events,2014-04,RECRUITING,OBSERVATIONAL,['NA'],,Number of Participants with Serious and Non-Serious Adverse Events
8455,NCT04825288,Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v5.0,2021-05-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Cardiotoxicity measured by the number of required ECGs and cardiotoxicity related events summarized by treatment arm and compared over time,Change in (CD14+CD16+IL-1⍺+) triple positive tumor associated monocytes in peripheral blood
8456,NCT01171755,Response rate,2008-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,
8457,NCT01766765,The time to the first adjuvant chemotherapy,2013-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Rehospitalization rate
8458,NCT04656392,Specificity of the eNose for detecting confirmed BE,2021-04-20,RECRUITING,INTERVENTIONAL,['NA'],,Safety of eNose based on reported Adverse Events.
8459,NCT00837031,"Six-Month Overall Survival (OS) Probability, the Percentage of Patients Estimated to be Alive Six Months After Beginning Protocol Treatment",2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death"
8460,NCT00905710,"The primary endpoints of the study are the number of adenomas, advanced adenomas, carcinomas at baseline and the number of the number of adenomas, advanced adenomas, carcinomas and the number of patients requiring colectomy at 2-year follow-up.",2008-09,COMPLETED,INTERVENTIONAL,['NA'],,The secondary endpoints of the study are the number of complications from colonoscopy at baseline and at 2-year follow-up.
8461,NCT00042939,Proportion of Patients With Objective Response Evaluated by RECIST (Solid Tumor Response Criteria),2003-12-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Proportion of Patients With Thromboembolic Events
8462,NCT03499808,Overall confirmed hematologic response rate,2018-06-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression free survival
8463,NCT05101382,Number of retrospectively recruited CRC cases,2020-10-28,RECRUITING,OBSERVATIONAL,['NA'],Biomarkers correlation with OS,
8464,NCT02095678,Mean Transit Time (MTT),2013-12-01,COMPLETED,INTERVENTIONAL,['NA'],,Minimal Breathhold Time
8465,NCT04751448,Microbiome-Based Prediction of Chemotherapy-induced Diarrhea in Colon Cancer,2021-02-01,RECRUITING,OBSERVATIONAL,['NA'],,Dietary-Based Prediction of Chemotherapy-induced Diarrhea in Colon Cancer
8466,NCT04444622,Incidents of Adverse Events (AE),2021-07-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,
8467,NCT01821105,Detection of Position Accuracy With Handheld Probe on Anatomical Location.,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumor Detection
8468,NCT01458925,safety - transit time (less than 300 hours),2011-11-20,TERMINATED,INTERVENTIONAL,['NA'],,"Colon Capsule correlation map (Empirical, qualitative)"
8469,NCT03581773,CTCAE Mucositis,2017-12-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,QOL MDASI
8470,NCT04180072,Best overall response rate,2020-03-12,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
8471,NCT05832372,Prevalence or occurrence of upper gastrointestinal diseases,2023-05-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
8472,NCT05368506,Incidence of adverse events,2023-07-30,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],Cellular and molecular characteristics,Overall survival
8473,NCT00224601,Number of pre-cancer lesions or early cancer detected.,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Anatomopathologic criteria (size of lesions, …)."
8474,NCT03447951,Objective Response Rate (ORR),2018-06-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,EQ-5D-5L quality of life score
8475,NCT04406974,Patient experiences after local recurrence,2018-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
8476,NCT02650271,overall survival,2021-02-02,COMPLETED,INTERVENTIONAL,['PHASE3'],Perioperative reactivation of hepatitis B virus replication,Recurrence rate
8477,NCT05699746,Recurrence-free survival,2023-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Clearance of circulating tumor DNA (ctDNA)
8478,NCT01774344,Overall Survival (OS),2013-05-14,COMPLETED,INTERVENTIONAL,['PHASE3'],Overall Survival (OS),Disease Control Rate (DCR)
8479,NCT01767597,Percentage of Patients Appropriately Seeking Care,2012-02,COMPLETED,INTERVENTIONAL,['NA'],,
8480,NCT02766842,Diagnostic accuracy of needle as assessed by diagnostic yield of needle and final diagnosis method,2016-04,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Procedure time
8481,NCT03144843,Progression-free survival (PFS),2017-01-13,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety (incidence of adverse events) [
8482,NCT02656134,Genetic profile in FAP patients,2015-03,UNKNOWN,OBSERVATIONAL,['NA'],,
8483,NCT01185483,,2009-11,UNKNOWN,OBSERVATIONAL,['NA'],,
8484,NCT00441337,Percent of Participants With Prostate-Specific Antigen (PSA) Response After the First Dose by Day 85 In Participants With Hormone-Refractory Prostate Adenocarcinoma (HRPC),2006-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Mean Systolic Blood Pressure at Baseline and Post-Infusion Day 1 (Cycle 1) in in 1mg, 3mg, and 10 mg Cohorts - Safety Population"
8485,NCT04273477,The prediction accuracy of the radiomics prediction model,2020-01-10,UNKNOWN,OBSERVATIONAL,['NA'],,The area under curve (AUC) of Receiver Operating Characteristic (ROC) curves of the radiomics prediction model
8486,NCT03043950,Overall Survival (OS) of pre-defined risk groups low vs. high,2017-01-25,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Adverse Drug Reactions,Antineoplastic treatment in later lines
8487,NCT04726319,Changes in risk-appropriate screening based on family history,2021-09-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Attitudes towards the FHAMe intervention
8488,NCT01763450,To assess the objective response rate(ORR),2012-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],To assess the incidence of adverse events of level 3-4 （Bleeding、Gastrointestinal Perforation、Anastomotic Fistula、Hypertension、Wound Healing Delay）,To assess the R0 resection rate of liver metastases
8489,NCT02858206,Adverse events,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Recurrence rate
8490,NCT01792934,Overall survival,2013-05,RECRUITING,INTERVENTIONAL,['NA'],,Safety and efficacy of the additional local treatment measured by number of serious adverse events.
8491,NCT02200250,Reviewing patients symptoms following resection,2021-10-01,WITHDRAWN,OBSERVATIONAL,['NA'],,
8492,NCT03682744,Safety of Intraperitoneal CAR-T Cell Infusions as Measured by Number of Participants with Adverse Events,2018-09-13,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Serologic response rates
8493,NCT03840590,"Adenoma detection rate, ADR",2019-07-10,COMPLETED,INTERVENTIONAL,['NA'],,"Polyp detection rate, PDR"
8494,NCT05919758,Recurrence rate,2023-05-01,RECRUITING,OBSERVATIONAL,['NA'],,Health related Quality of Life at follow-up moment for this study
8495,NCT05990257,pain control,2018-07-01,RECRUITING,INTERVENTIONAL,['NA'],,
8496,NCT01427647,Plasma levels of several cytokines after colorectal cancer surgery,2007-06,COMPLETED,INTERVENTIONAL,['NA'],,Incidence of adverse clinical outcomes between groups
8497,NCT02078245,MRI accuracy,2010-08,RECRUITING,OBSERVATIONAL,['NA'],,Outcome of surveillance program
8498,NCT02178644,pCR Rate,2014-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8499,NCT01303172,Safety and Tolerability.,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival in Metastatic Patients Only
8500,NCT05547568,Major postoperative complications (Dindo-Clavien ≥ 3 grade),2012-09,COMPLETED,OBSERVATIONAL,['NA'],,
8501,NCT00210184,2-month Response Rate,2004-07-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free Survival
8502,NCT00972881,Histologically confirmed R0 resection rate,2009-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Local failure-free survival
8503,NCT00182611,Overall survival,2004-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Adverse events
8504,NCT02618850,change from baseline in highest value SUVmax (maximum standardized uptake values in PET/CT scan),2014-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],"prognostic value of metabolic response (SUVmax, SUVmaxsum, TLGmax, TLGsum) by different cut off values (other than 50% reduction)","prognostic value of metabolic response (SUVmax, SUVmaxsum, TLGmax, TLGsum) and recist response"
8505,NCT05004350,Randomized Phase 2: Progression-free Survival (PFS) by Blinded (to treatment received) Independent Central Review (BICR),2021-09-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Randomized Phase 2: Microsatellite Instability (MSI) status in Formalin-fixed and Paraffin Embedded (FFPE) samples using established Polymerase Chain Reaction (PCR) assays in tumor sample versus germline control at screening,Randomized Phase 2: Population pharmacokinetic (PK) analysis using the ARRAY 818 302 study PK data
8506,NCT02979691,Overall survival,2016-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Clinical target contouring guided by MRI or CT simulation,Chemoradiotherapy toxicities
8507,NCT05183425,The consistency of drug sensitivity,2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],,The establishment of PDO
8508,NCT04005742,Serum high-sensitivity C-Reactive Protein concentrations (marker of systemic inflammation),2017-03-13,COMPLETED,OBSERVATIONAL,['NA'],Sedentary behaviour assessed using Lifestyle Questionnaire,HbA1c in whole blood
8509,NCT05620485,Long-term complications,2022-11-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,length of nutritional support in hospital
8510,NCT00352833,safety and efficacy data,2006-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8511,NCT04179773,"Frequency of patients with ENT, upper digestive-tract or colorectal cancer with a diagnosis of cirrhosis",2019-01-24,RECRUITING,OBSERVATIONAL,['NA'],,Frequency of chemotherapy side effects according to CTCAE version 5.0 classification in cirrhotic patients who have received chemotherapy
8512,NCT05924880,The incidence of Possible related adverse events(PRAE) Grade 3 or 4,2023-07-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse Events(AEs) resulting in study intervention interruption and discontinuation
8513,NCT03843905,Overall survival (OS),2018-11-15,UNKNOWN,OBSERVATIONAL,['NA'],,Microbiota composition
8514,NCT00524186,"Maximum tolerated dose of sunitinib malate when administered with FOLFIRI chemotherapy (i.e., irinotecan hydrochloride, fluorouracil, and leucovorin calcium)",2007-05,TERMINATED,INTERVENTIONAL,['PHASE1'],,Correlation of pre- and post-therapy changes in CEC number and VEGF expression with response rate and survival
8515,NCT01593475,feasibility and compliance,2011-09-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,disease-free survival.
8516,NCT02054598,Colorectal cancer screening completion,2014-01,COMPLETED,INTERVENTIONAL,['NA'],,Colorectal cancer screening related intent
8517,NCT05665322,Efficacy of conventional CT versus porto-scanner for thermoablation of colorectal cancer liver metastases between groups,2023-01-31,RECRUITING,INTERVENTIONAL,['NA'],,Reason for for failure of technique requiring switch to different guidance technique
8518,NCT01777698,Changes in body composition,2012-04,COMPLETED,OBSERVATIONAL,['NA'],,
8519,NCT03993327,Percent of known liver lesions per standard staging scans identified on iodine I-124 (I-124) M5A imaging,2020-07-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of adverse events
8520,NCT04665947,[177Lu]Lu DOTA-ABM-5G dose escalation therapy,2020-12-18,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Assessment of organ dosimetry of [177Lu]Lu DOTA-ABM-5G
8521,NCT03165721,Number of Participants With an Overall Response (Complete Response or Partial Response) of SGI-11 Using the Response Evaluation Criteria in Solid Tumors (RECIST),2017-08-16,TERMINATED,INTERVENTIONAL,['PHASE2'],,Change in Distress From Baseline
8522,NCT05257408,Progression-free Survival as Assessed by BICR,2022-06-29,RECRUITING,INTERVENTIONAL,['PHASE3'],,Combined Response According to RECIST v1.1 and GCIG Criteria
8523,NCT00036790,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8524,NCT02891447,Patterns of tumor recurrence,2016-09-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
8525,NCT03093116,Overall Response Rate (ORR) Phase 2,2017-03-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Intracranial objective response rate (Phase 2)
8526,NCT03650517,Clavien Dindo Complication,2018-11-01,UNKNOWN,OBSERVATIONAL,['NA'],Pain evaluation,C-Reactive Protein value (CRP) days 1 & 3 postoperative
8527,NCT04716062,Clavien Dindo score (post-operative complications),2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Lenght of specimen
8528,NCT03177317,Complete response (CR),2017-05-01,COMPLETED,INTERVENTIONAL,['NA'],,Complete protection (CP)
8529,NCT01607255,Number of Participants With Detected Proximal Diminutive (<10 mm) Adenoma Detection Rate,2013-05-16,COMPLETED,INTERVENTIONAL,['PHASE4'],,
8530,NCT01657175,Quality of Life,2009-01,COMPLETED,INTERVENTIONAL,['NA'],,Contacts with the health care system
8531,NCT05940740,Nightingale Symptom Evaluation Scale,2023-03-01,RECRUITING,INTERVENTIONAL,['NA'],,Self-Care Needs Evaluation Form
8532,NCT05495048,disease-free survival rate,2023-07-01,RECRUITING,INTERVENTIONAL,['NA'],,
8533,NCT04303286,Species differential analysis,2018-10-01,COMPLETED,OBSERVATIONAL,['NA'],,
8534,NCT06178211,pCR rate,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Potential biomarkers such as ctDNA or PD-L1 expression
8535,NCT02031536,Disease Free Survival (DFS),2014-04-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
8536,NCT04177797,Complete pathologic response rate,2020-03-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
8537,NCT01686880,Peri-operative morbidity,2012-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Contra-lateral Lobe Hypertrophy
8538,NCT05643989,Bowel preparation (absence of feaces) according to Boston Bowel Preparation Scale,2019-11-01,RECRUITING,INTERVENTIONAL,['NA'],,Late complications rate during resectional surgery
8539,NCT06199115,Neuropathic Pain Synptom Inventory : pain,2023-05-31,RECRUITING,INTERVENTIONAL,['NA'],,Evaluation of sensitive and motor symptoms
8540,NCT03415126,"Part B: evaluate the overall response rate (number of Complete Responses + Partial Responses) in subjects receiving ASN007 for the treatment of metastatic melanoma, CRC, NSCLC, or pancreatic cancer.",2018-01-19,COMPLETED,INTERVENTIONAL,['PHASE1'],Evaluate the change from baseline in the amount of circulating tumor DNA,Calculate the terminal elimination rate (T 1/2).
8541,NCT03205176,Incidence of dose-limiting toxicity (DLT).,2017-06-30,COMPLETED,INTERVENTIONAL,['PHASE1'],,Clearance (CL).
8542,NCT05002452,Tumor Response,2021-12-20,RECRUITING,OBSERVATIONAL,['NA'],,Distant control
8543,NCT00969657,Pathological complete response (ypT0N0),2009-08,COMPLETED,OBSERVATIONAL,['NA'],,"Several extra outcomes are registered for research: Local relapse at 2 years, metastases free survival, survival and relapse free survival"
8544,NCT06006390,Obtained the recommended dose and infusion regimen of CAR-T cells for the treatment of patients with CEA-positive advanced malignancies[Safety and Tolerability],2023-09-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival(OS)of CEA CAR-T treatment in patients with CEA-positive advanced malignancies[Effectiveness],Pharmacodynamics of CEA CAR-T cells[Cell dynamics]
8545,NCT05771025,Overall survival time,2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],,Unplanned reoperation rate
8546,NCT05519202,Pathological complete response(pCR),2022-08-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,tumor regression grade(TRG)
8547,NCT06307548,Changes in carcinoembryonic antigen (CEA) and circulating tumor deoxyribonucleic acid (ctDNA) (Phase II),2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Correlation between disease free survival and changes in levels of ctDNA (Phase II)
8548,NCT02473094,Pathological Complete Response,2015-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of Life
8549,NCT06228599,Adverse Events,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
8550,NCT01399684,Progression-Free Survival Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 as Determined by the Investigator,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change From Baseline in ATAs Levels of MEGF0444A
8551,NCT04680104,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2015-11-03,COMPLETED,OBSERVATIONAL,['NA'],,economical impact
8552,NCT02002195,progression-free survival,2013-11,UNKNOWN,OBSERVATIONAL,['NA'],,time to treatment failure
8553,NCT02427841,R0 Resection Rate Defined as Macroscopically Complete Tumor Removal With Negative Microscopic Surgical Margins by Pathologic Assessment,2016-01-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response Rate by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Defined as the Percent of Subjects With Complete or Partial Disease Response as Confirmed Through Tumor Imaging With Computed Tomography (CT)
8554,NCT00408070,Progression Free Survival Rate at 9 Months,2006-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Determine Tolerability to 12 Months (q 3 Weeks) of Bevacizumab Maintenance Therapy
8555,NCT05793554,Validation of tissue classification through fluorescence perfusion,2023-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Usability of video sharing and annotation technology in multiple sites
8556,NCT05061537,Objective response rate in the dose expansion (Part 2) arms,2021-10-20,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall survival (Part 2)
8557,NCT01637805,Objective response rate,2012-05,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
8558,NCT02560376,Standardized uptake value of 68Ga-NOTA-exendin-4 PET/CT in Diagnosis of Insulinoma and Nesidioblastosis,2014-02,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Adverse events collection
8559,NCT01205022,Maximum tolerated dose of yttrium-90 (90Y) M5A anti-CEA antibody when given in combination with FOLFIRI chemotherapy and bevacizumab,2011-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Estimation of radiation doses to whole body, normal organs, and tumor through serial nuclear imaging"
8560,NCT05448157,"To evaluate the diagnostic efficacy and the safety of the combined approach with β-probe and 68Ga-DOTA-TOC PET/CT in the correct identification of primary tumor and lymph node metastases, in patients with GEP-NETs candidates to surgery",2022-05-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
8561,NCT06154538,pCR rate,2023-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],serious adverse event,OS
8562,NCT04038619,Clinical response/remission of immune-related diarrhea/colitis,2021-02-01,RECRUITING,INTERVENTIONAL,['PHASE1'],"Frequencies of immune cells (CD4/8 T cells, regulatory T cells [Treg], macrophages, etc.) in tissue/blood/stool samples",Recurrent immune-related diarrhea/colitis within 3 months post-FMT after initially achieving clinical remission/response
8563,NCT03602079,Phase I: Maximum Tolerated Dose,2018-07-16,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase I Volume of distribution at steady state (Vss).
8564,NCT04250402,Number of gallstone patients,2020-02-14,RECRUITING,OBSERVATIONAL,['NA'],,"Number of physical regurgitation, nausea, vomiting, diarrhea, constipation"
8565,NCT06107920,the success of a full curative therapeutic,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of life evaluated using EORTC QLQ-C30 and QLQ-CR29 dedicated to CRC
8566,NCT03357991,Determine the predictive value of HPV E6/E7 mRNA for the detection of HSIL and its ability to predict incident cases.,2015-01-11,UNKNOWN,OBSERVATIONAL,['NA'],,Cost-effectiveness analysis of an anal cancer screening strategy based on HPV E6/E7 mRNA analysis.
8567,NCT00578721,Rectal Tissue Putrescine Reduction,2008-09-24,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety/Toxicity
8568,NCT06141031,Phase 2: To assess pathologic response rate (R0 resection) for those who revert to resectable status,2024-01-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Assess quality of life associated with treatment protocol using EORTC QLQ-C30
8569,NCT02728193,Death,2012-12,COMPLETED,INTERVENTIONAL,['NA'],,
8570,NCT00045461,Quality of life,2000-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
8571,NCT04258969,Feasibility of Pedaling Concurrent to Chemotherapy Infusion,2020-12,WITHDRAWN,INTERVENTIONAL,['NA'],,Symptom Severity
8572,NCT05339230,Incidence of diarrhoea CTCAEv5.0 ≥ grade 2.,2020-12-15,RECRUITING,INTERVENTIONAL,['NA'],Change in liver metastasis tumor blood flow.,Incidence of adverse events CTCAEv5.0 grade ≥ 3 considered probably related to investigational products/placebo.
8573,NCT00002455,Survival rate,1971-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
8574,NCT05845294,Anxiety of patients was assessed by Hospital Anxiety and Depression Scale,2019-08-01,COMPLETED,INTERVENTIONAL,['NA'],,
8575,NCT03164655,Curative-intent (R0-R1) resection (and/or ablation) rate (CRR) of CRLM,2018-07-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8576,NCT05879861,Status of frailty,2022-08-01,RECRUITING,OBSERVATIONAL,['NA'],,
8577,NCT01538680,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
8578,NCT05769959,Part 1 and 2: Number of Participants With Dose Limiting Toxicities (DLTs),2023-06-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Part 1, 2, 3: Overall survival (OS)"
8579,NCT04466267,The molecular mechanism of patients primary or secondary resistance to cetuximab,2017-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
8580,NCT02674100,Adverse Events,2016-01,RECRUITING,OBSERVATIONAL,['NA'],,Overall Survival
8581,NCT00637559,"To compare the total percent time during the 24-hour monitoring period that gastric pH is above 4.0 at steady state in patients when taking: esomeprazole 40mg twice daily, esomeprazole 40mg three times daily, esomeprazole 20 mg three times daily.",2002-03,COMPLETED,INTERVENTIONAL,['PHASE4'],,Compare total percent time distal esophageal pH is above 4.0 at steady state for each treatment period.
8582,NCT05286814,Determine overall response rates,2022-10-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Determine hepatic progression-free survival (PFS)
8583,NCT03334708,Change in biomarkers to determine sensitivity and specificity of the assay to diagnose early stage pancreatic cancer,2017-10-30,RECRUITING,OBSERVATIONAL,['NA'],,
8584,NCT01659502,Clinical Benefit Measurement,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Progression Free Survival (PFS)
8585,NCT05232721,Diagnostic performance of advanced neoplasms,2022-02-20,UNKNOWN,OBSERVATIONAL,['NA'],,Diagnostic performance of Colorectal Cancer
8586,NCT02229058,Progression-free survival,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease control rate
8587,NCT04652440,Measure Tolerability,2020-12-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Median Disease-free survival (mDFS)
8588,NCT04917289,Overall Survival,2021-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse event
8589,NCT01895504,Cecal intubation rate,2013-04,COMPLETED,INTERVENTIONAL,['NA'],,Pain
8590,NCT00578279,The Change in Mean Pain Scale Rating in Patients Following Treatment With 10mL or 20mL of Alcohol Injection,2007-03,COMPLETED,INTERVENTIONAL,['PHASE4'],,
8591,NCT05372198,Progression-Free Survival (PFS),2022-03-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,adverse events (AE)
8592,NCT01473940,Number of Dose Limiting Toxicities (DLTs) Seen in Patients With Pancreas Adenocarcinoma Treated With Ipilimumab and Gemcitabine Combination in Order to Define the Maximum Tolerated Dose (MTD),2012-06-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Recovery of Tumor Immune Surveillance: T-cell Response to Defined Pancreatic Cancer Tumor Antigens
8593,NCT01845337,The primary endpoint of the study will be a difference in the duration of ST deviation pre-treatment and during treatment.,2014-02-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8594,NCT04391049,Dose Limiting Toxicity,2020-06-29,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall Survival
8595,NCT00154778,To evaluate the response rate,2003-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,To determine time to progression and safety
8596,NCT03563157,"Overall Response Rate, as determined by the percentage of patients achieving Partial or Complete Response per RECIST 1.1",2018-05-25,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"QoL for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component"
8597,NCT06218914,Adverse events and Serious adverse events,2024-02-05,RECRUITING,INTERVENTIONAL,['PHASE1'],,"Preliminary anti-tumor activity of NT-112 in subjects with unresectable, advanced, and/or metastatic solid tumors"
8598,NCT02027948,feasibility of a nutritional management algorithm,2013-12-23,COMPLETED,INTERVENTIONAL,['NA'],,treatment toxicity of chemoradiotherapy
8599,NCT04628182,post-operative anastomotic leakages,2021-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
8600,NCT05582109,Objective response rate,2022-10-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
8601,NCT03417570,Number of Participants Who Had a Diagnostic Yield Obtained,2017-12-22,TERMINATED,INTERVENTIONAL,['NA'],,Safety as Measured by Number of Participants With Procedure-related Adverse Events
8602,NCT03048123,Disease control rate,2015-10-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse Events
8603,NCT02861690,Response rate,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events (Toxicity)
8604,NCT03678428,Overall Response Rate and bilateral 95% confidence interval,2021-12-31,TERMINATED,INTERVENTIONAL,['PHASE3'],,"Adverse events, servere adverse events and surgery-related adverse events rates"
8605,NCT04516083,Number of patients who have a somatic mutation at the same time as a germline mutation,2019-12-21,UNKNOWN,OBSERVATIONAL,['NA'],,
8606,NCT05250895,To investigate the variability of hypoxia in HCC at baseline as quantified by immunohistochemistry,2022-04-28,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Treatment response
8607,NCT02372929,Evaluate the relationship between tightness of esophageal stricture encountered at endoscopy with cancer staging at EUS.,2012-04,COMPLETED,OBSERVATIONAL,['NA'],,
8608,NCT02767375,Recurrence Free Survival,2015-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Adverse Events That Are Related to Treatment
8609,NCT00779688,Comparative histopathology-confirmed measures of Cellvizio endomicroscopy and ERCP accuracy in the differential diagnosis of suspicious lesions.,2008-11,COMPLETED,OBSERVATIONAL,['NA'],,
8610,NCT01052922,Adherence to FOBT test kit,2009-08,COMPLETED,INTERVENTIONAL,['NA'],,
8611,NCT03856658,Hepatic progression-free survival,2019-02-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,EORTC Quality of Life Questionnaire
8612,NCT03471403,Number of serious and non-serious adverse events,2017-10-10,RECRUITING,OBSERVATIONAL,['NA'],,Change in Spigelman stage
8613,NCT02589483,"Evidence of clinical anastomotic leak( elevated C reactive protein and white blood corpuscles, fever, nausea). Suspicion of a leak will be investigated with a Ct scan.",2016-02,UNKNOWN,INTERVENTIONAL,['NA'],,
8614,NCT01850654,Determine the Incidence of Hereditary Cancer Syndromes among Newly Diagnosed Colorectal Cancer Patients,2012-12-26,COMPLETED,INTERVENTIONAL,['NA'],,
8615,NCT03231722,Overall response rate,2017-09-13,COMPLETED,INTERVENTIONAL,['PHASE3'],,R0 Resection Rate
8616,NCT05691491,Dose limiting toxicity and the maximum tolerated dose,2023-09-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Rate of >= grade 3 adverse events (AE)
8617,NCT01138904,Response rate by RECIST,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,overall survival
8618,NCT00004095,,1999-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8619,NCT00647530,Pathological down-staging as measured by depth of extramural spread among patients allocated to preoperative chemotherapy with or without panitumumab,2008-05-15,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Adverse events
8620,NCT00425841,Clinical response rate as assessed by RECIST criteria,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Histologic response rate
8621,NCT00533078,efficacy of an omega-3 PUFA containing lipid emulsion in reducing the incidence of °3-4 colitis (CTC AE v3.0),2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8622,NCT00777478,Maximum Tolerated Dose,2008-12,UNKNOWN,INTERVENTIONAL,['PHASE1'],,determine the safety and toxicity profile using the CTCAE criteria.
8623,NCT00898287,To determine the maximum tolerated dose (MTD) of P276-00 administered along with Gemcitabine.,2009-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To characterize toxicities of P276-00 in combination with Gemcitabine.
8624,NCT00497263,functioning anastomosis & no occurrence of adverse events related to device use,na,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8625,NCT02321202,hospital stay (time of hospital stay after surgery),2010-03,COMPLETED,INTERVENTIONAL,['PHASE4'],,mortality
8626,NCT00639327,"In phase II part, progressive disease rate will be measured for the safety. In phase III part, overall survival will be measured for the benefit of doublet.",2008-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"Adverse events, response rates, progression free survival, time to treatment failure, change over rates to 3rd line"
8627,NCT00287755,Overall survival rate,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Side effect
8628,NCT05706558,. Preoperative variables associated with overall survival and progression-free survival (measured from date of surgery),2016-12-13,RECRUITING,OBSERVATIONAL,['NA'],,"Survival outcomes stratified by use of adjuvant therapy (i.e., adjuvant therapy or no adjuvant therapy)."
8629,NCT01405573,overall survival,2011-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,progression free survival
8630,NCT00004136,Efficacy of Radiofrequency Ablation in Patients with Primary or Metastatic Liver Cancer,1998-03-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8631,NCT05384184,Build the next generation biobank of liver-derived organoids,2019-06-06,RECRUITING,OBSERVATIONAL,['NA'],,Evaluate the clinical relevance of the generated organoids
8632,NCT01754623,Margin-negative (R0) Resection Rate,2013-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS) Rate
8633,NCT02192671,Hospital mortality,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Recurrence rate
8634,NCT06290505,Progression free survival rate is the proportion of patients alive and progression free (the cancer has not worsened) assessed by CT Scan and clinical review.,2021-12-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival.
8635,NCT04903548,SPECT CT,2021-04-20,RECRUITING,OBSERVATIONAL,['NA'],,
8636,NCT01341197,Important Lower and Upper GI tract Lesions,2011-03,COMPLETED,OBSERVATIONAL,['NA'],,
8637,NCT04379830,Change in Mesorectal Fat Volume (efficacy),2022-08-01,WITHDRAWN,INTERVENTIONAL,['NA'],,Intraoperative Adverse Events
8638,NCT03215017,"Bowel function, Low anterior resection syndrome (LARS)",2017-05-15,COMPLETED,INTERVENTIONAL,['NA'],,Quality of Life (QoL)
8639,NCT03086993,Overall Survival,2018-04-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Incidence of Treatment-Emergent Adverse Events (Safety),Objective response rate (CR + PR) as determined by the Investigator
8640,NCT01621243,Part B: Overall Survival,2012-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Part B: Duration of progression-free survival
8641,NCT03974984,Changes in neutrophil to lymphocyte ratio from preoperatively to day 1 postoperatively,2020-06-04,WITHDRAWN,OBSERVATIONAL,['NA'],,Changes in quality of recovery-15 score from preoperatively to day 1 postoperatively.
8642,NCT00006094,Latent toxicities graded using the Common Toxicity Criteria (CTC) version 2.0,2000-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
8643,NCT01428141,Determination of the maximum tolerated dose (MTD),2011-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8644,NCT03827044,Primary End point: Disease Free survival,2018-08-31,TERMINATED,INTERVENTIONAL,['PHASE3'],,Secondary End Points: Toxicity of Investigational Medicinal Product according to the NCI-CTCAE (Common Terminology Criteria for Adverse Events) version 4.0.
8645,NCT02678806,overall survival,2017-11-01,UNKNOWN,INTERVENTIONAL,['NA'],,
8646,NCT03083613,Objective Response Rate,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free survival
8647,NCT05074966,median PFS,2021-09-06,RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall Survival OS
8648,NCT01291823,Tumor response rate,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The safety (The safety was evaluated according to the National Cancer Institute Common Toxicity Criteria version 3.0.)
8649,NCT05977764,to identify D-CEUS quantitative parameters useful for characterizing FLLs.,2020-03-13,RECRUITING,INTERVENTIONAL,['NA'],,
8650,NCT04230759,Disease-free survival (DFS),2020-01-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life questionnaires
8651,NCT04770207,Assessing safety and treatment efficacy on intra-tumor injection of DEB for advanced tumors,2020-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
8652,NCT04164797,progression-free survival(PFS),2019-11-25,UNKNOWN,INTERVENTIONAL,['PHASE4'],,overall survival (OS)
8653,NCT00002485,Determine why eligible patients are not enrolled on available Pediatric Oncology Group therapeutic clinical trials.,1992-02,COMPLETED,OBSERVATIONAL,['NA'],,
8654,NCT00892255,Measure of the tissue destruction with the MedWaves Microwave Ablation/ Coagulation Ablation System,2009-04,WITHDRAWN,OBSERVATIONAL,['NA'],,
8655,NCT04298021,Disease control rate of AZD6738 + Olaparib cohort,2020-06-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,quality of life measurement of AZD6738 + Olaparib cohort
8656,NCT04662853,Gut-microbiota-based color-rectal cancer diagnosis.,2017-01-17,UNKNOWN,OBSERVATIONAL,['NA'],,Dietary habits
8657,NCT01791374,Part 2: Dose-limiting toxicities (DLT) for each dose level of rilotumumab in combination with cisplatin and capecitabine (CX) chemotherapy tested,2012-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Part 2: Evaluate efficacy based on the treatment effects of rilotumumab in combination with cisplatin and capecitabine as measured by the following: Objective Response Rate, duration of response, progression-free survival, overall survival."
8658,NCT01686412,Autonomic response monitoring (blood pressure digital and manual monitoring),2012-07,COMPLETED,INTERVENTIONAL,['NA'],,Baroreflex sensitivity (by the method of sequence)
8659,NCT04777708,Objective response rate (ORR),2021-10-13,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Incidence of adverse events
8660,NCT02254889,A 10-cm VAS was used to evaluate pain after ESD.,2011-04,COMPLETED,INTERVENTIONAL,['NA'],,
8661,NCT05875558,ORR,2022-07-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,OS
8662,NCT04573738,The distant metastasis rates of rectal cancer,2017-05-01,COMPLETED,INTERVENTIONAL,['NA'],,
8663,NCT06271629,Impairment in the quality of sleep and quality of life in patients with Low Anterior Resection Syndrome (LARS).,2022-02-26,COMPLETED,OBSERVATIONAL,['NA'],,European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-CR29)
8664,NCT05751733,Progression-Free survival (PFS),2023-02-01,RECRUITING,INTERVENTIONAL,['NA'],,Disease Control Rate (DCR)
8665,NCT01681368,Objective Response (Complete Response (CR) or Partial Response (PR) Defined by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Criteria) or Disease Stabilization for Greater Than 6 Months,2012-08-15,TERMINATED,INTERVENTIONAL,['PHASE2'],,Total Clearance of Birinapant After Administration
8666,NCT05001321,Texture of nuclei,2021-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Recurrence/metastasis
8667,NCT04164069,Incidence of adverse events,2020-09-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Dasatinib on pharmacokinetics (PK) of oxaliplatin,
8668,NCT00069953,Overall Survival (1-year Rate Reported),2003-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Frequency of Patients With Persistent or Recurrent Disease Eligible for Surgical Salvage Resection
8669,NCT06016725,Physical function,2023-08-28,RECRUITING,INTERVENTIONAL,['NA'],,Anthropometry measuring waist circumference in centimeters
8670,NCT03129607,Pancreatic fistula,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,Mortality
8671,NCT05217446,Progression-free Survival (PFS),2022-07-11,RECRUITING,INTERVENTIONAL,['PHASE2'],,Objective Response (OR)
8672,NCT02343692,Presence of pancreatic cyst,2016-03,UNKNOWN,INTERVENTIONAL,['NA'],,Preliminary health economics analysis from questionnaires and cost diaries (Self-completed EQ-5D-5L questionnaire and cost diary.)
8673,NCT01358812,Response Rate,2010-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Analyses of Potential Predictive Factors
8674,NCT01566474,Oxidative stress,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,The presence of DNA anomalies (tetraploidy and aneuploidy.
8675,NCT01996306,Overall survival,2013-12-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Correlation between UGT1A1 genotype and safety
8676,NCT04461275,Rate of the successful and safe application of the 23-hour accelerated ERAS 2.0 protocol for patients undergoing elective colorectal surgery.,2020-06-19,COMPLETED,INTERVENTIONAL,['NA'],• Groningen Frailty Index (GFI),• Patient satisfaction evaluation by means of a questionnaire to evaluate the patients subjective experience during the duration of this study.
8677,NCT00828672,"Pathologic Response at Surgery. Overview of Complete Pathologic Responses, Good and Little Tumour Regression Rates at Surgery.",2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Death Rates and Overall Survival
8678,NCT05568095,Overall survival,2022-11-21,RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
8679,NCT05303740,PFS,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],,OS
8680,NCT04669951,Tumor-to-background ratio,2019-11-18,COMPLETED,INTERVENTIONAL,['NA'],,uPAR in patient groups
8681,NCT02970136,Percentage of Participants Who Are Screened for All Conditions,2017-04-11,COMPLETED,INTERVENTIONAL,['NA'],,Median Number of Screenings Completed
8682,NCT05268549,"The first recurrence of colorectal cancer with liver metastasis (CRLM) after radiofrequency/microwave ablation, assessed up to 18 months",2022-03-12,UNKNOWN,OBSERVATIONAL,['NA'],,"Patients with colorectal cancer with liver metastases (CRLM) developed new metastases after radiofrequency/microwave ablation,assessed up to 18 months"
8683,NCT02359968,Short-term benefit of 2 preoperative regimen: complete resection rate AND severe (grade ≥ 3) postoperative morbidity/mortality according to the Clavien-Dindo classification,2015-02-26,COMPLETED,INTERVENTIONAL,['PHASE2'],Prognostic factor and treatment effect controlling for possible confounding factors,Evaluation of the efficacy of both regimen in term of quality of life
8684,NCT03195699,Pharmacokinetics - AUC(0-t),2017-11-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Assess the bioavailability between different formulations of TTI-101,Best Overall Response
8685,NCT04929392,Clinical complete response (CR),2022-01-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
8686,NCT06109779,Recurrence free survival (RFS) for Arm A vs. Arm B,2023-12-04,RECRUITING,INTERVENTIONAL,['PHASE3'],Progression Free Survival (PFS) following recurrence Arm A vs. Arm B.,Overall Survival (OS) for Arm A vs. Arm B
8687,NCT05343832,Plasma samples of patients with and without HCC to evaluate test performance(accuracy) of the kit. diagnostic(sensitivity and specificity) of the kit.,2021-11-29,UNKNOWN,OBSERVATIONAL,['NA'],,
8688,NCT00573404,Maximum tolerated dose of imatinib mesylate in combination with sunitinib malate,2007-07,TERMINATED,INTERVENTIONAL,['PHASE1'],,Preliminary data on anti-tumor activity of these drugs as assessed by RECIST
8689,NCT05141643,Tumor drug uptake within PDAC tumors prior at pre-treatment baseline,2021-11-18,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,changes in [18F]-FAC drug uptake during or following SOC chemo- and/or radiation therapy.
8690,NCT02721550,pathologic Complete Response,2016-08-01,TERMINATED,INTERVENTIONAL,['PHASE4'],,Disease-Free Survival
8691,NCT00394602,Longitudinal Quality of Life + Symptom Assessment Data,2004-04-07,TERMINATED,OBSERVATIONAL,['NA'],,
8692,NCT00491140,Association of different biomarkers with Cetuximab sensitivity,2006-12,COMPLETED,OBSERVATIONAL,['NA'],,Association of different biomarkers with time to progression and survival
8693,NCT00440817,Occurrence of lymphoma,2006-02,COMPLETED,OBSERVATIONAL,['NA'],,Evaluation of association of Epstein-Barr Virus (EBV) with the lymphoma
8694,NCT04144751,Blood-based biomarkers associated with genetic and epigenetic alterations.,2019-11-15,COMPLETED,OBSERVATIONAL,['NA'],,
8695,NCT04348643,Adverse events that related to treatment,2020-02-20,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Levels of CRP in Serum
8696,NCT01587872,Cecal intubation rate,2011-10,TERMINATED,INTERVENTIONAL,['NA'],,Detection of additional colonic pathology
8697,NCT00867113,Kaplan-Meier Estimates for Recurrence-free Survival up to 60 Months,2009-07-22,COMPLETED,INTERVENTIONAL,['PHASE2'],,Kaplan-Meier Estimates for Overall Survival (OS) up to 60 Months
8698,NCT04373928,OS,2017-11-10,RECRUITING,INTERVENTIONAL,['NA'],,DFS
8699,NCT01211132,The primary outcome is the prevalence of adenomas in the two groups.,2009-09,UNKNOWN,INTERVENTIONAL,['NA'],,"The secondary outcomes are the number of adenomas detected per subject, cecal intubation rate, insertion times, withdrawal times and complication rates in the two arms."
8700,NCT04408105,"To characterize the association between patient-level knowledge, attitudes, and barriers regarding BE screening.",2020-02-19,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
8701,NCT01739608,Participation rate to FS and CT Colonography,2013-12,COMPLETED,INTERVENTIONAL,['NA'],,Type of false positive detections of Computer-aided detection for CTC in a CRC screening program
8702,NCT05520619,Progression-free survival,2022-09-15,RECRUITING,INTERVENTIONAL,['PHASE2'],Tumor mutational burden at baseline,Treatment-related adverse events
8703,NCT02259725,PFS,2016-08-16,COMPLETED,INTERVENTIONAL,['PHASE2'],Biomarkers Such as Messenger Ribonucleic Acid (mRNA) Levels or Germline Variations of Genes Related to Angiogenesis,"Incidence of Adverse Events, Assessed According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0"
8704,NCT03487939,The ratio of tumor downstaging to stage 0 and stage I,2018-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life (QLQ C30)
8705,NCT05161143,1 year RFS rate,2021-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,AFP
8706,NCT01821196,Density of PGP9.5 in gastric adenocarcinoma related to TNM stage and survival of stomach cancer,2012-12,WITHDRAWN,INTERVENTIONAL,['NA'],,
8707,NCT00643682,Boston Bowel Preparation Scale Score,2006-02,COMPLETED,INTERVENTIONAL,['NA'],,Number of Repeat Procedures Recommended Due to Inadequate Bowel Preparation.
8708,NCT05879172,success rate of anastomosis,2021-07-01,COMPLETED,INTERVENTIONAL,['NA'],,time period of recovery
8709,NCT04820179,Overall Response Rate or Stable Disease,2021-10-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,T2 Signal
8710,NCT02328677,Recurrence,2007-03,RECRUITING,OBSERVATIONAL,['NA'],,Treatment toxicities
8711,NCT02165800,Sexual function,2014-01,UNKNOWN,INTERVENTIONAL,['NA'],,5-year overall survival rate
8712,NCT04313114,CRC Screening,2021-09-20,RECRUITING,INTERVENTIONAL,['NA'],,
8713,NCT04683783,Percentage of patients who complete the entire cycle,2019-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Morbidity rate
8714,NCT00006155,,2000-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8715,NCT02905578,Overall survival,2018-11-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse event frequency and categorization
8716,NCT00039078,Adverse experiences,2000-08,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
8717,NCT00982618,Postoperative functional recovery,2009-07,COMPLETED,INTERVENTIONAL,['NA'],,opioid side effects
8718,NCT03727126,Lymph node yield,2018-11-01,UNKNOWN,INTERVENTIONAL,['NA'],,Conversion rate
8719,NCT04479111,1-year local recurrence,2020-01-01,COMPLETED,INTERVENTIONAL,['NA'],,3-year disease free survival
8720,NCT04090164,Prevalence of HCV Seropositivity in Breast Cancer Patients.,2019-09-01,COMPLETED,OBSERVATIONAL,['NA'],,Disease-related Events
8721,NCT05493930,diagnosis of lymph node metastasis,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
8722,NCT04163627,Technical procedures evolutiveness,2019-11-30,UNKNOWN,OBSERVATIONAL,['NA'],,Regional disparities
8723,NCT02482909,The patient survival,2005-07,TERMINATED,INTERVENTIONAL,['NA'],,The disease-free survival
8724,NCT05732493,pCR,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Surgical complications
8725,NCT01895790,Complications (Safety),2014-07,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Survival
8726,NCT05760391,OS from start of 1st line treatment in metastatic ESCC,2023-02-28,RECRUITING,INTERVENTIONAL,['NA'],,Disease control rate
8727,NCT05877352,Availability of potential primary outcome data,2022-05-18,RECRUITING,INTERVENTIONAL,['NA'],,Resource use and cost
8728,NCT04420013,Plasma CD154 level dosage,2020-09,UNKNOWN,OBSERVATIONAL,['NA'],,Clinical evolution parameters
8729,NCT04137289,"Phase Ib - Progression-free survival (PFS) is defined as the time from first treatment administration until tumor progression according to RECIST 1.1 or death from any cause, whichever occurs earlier.",2020-03-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Phase Ib - AUC0-t2: area under the concentration-time curve of BI 905711 in plasma
8730,NCT05629845,90-day death adjusted cumulative incidence of variceal rebleeding after secondary prevention by EUS-guided therapy or conventional endoscopic therapy,2022-11-22,RECRUITING,INTERVENTIONAL,['NA'],,procedure related adverse events within 30 days of secondary prevention
8731,NCT01175733,Phase II: safety and tolerability,2010-07-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time-to-progression (TTP) and overall survival
8732,NCT03815461,PFS,2019-02-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse reaction rate
8733,NCT00096083,To determine the response rate and duration of response to intra-hepatic infusion of melphalan with subsequent venous hemofiltration in patients with primary and metastatic hepatic malignancies,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,To determine the progression free and overall survival in patients with hepatic malignancies following this therapy
8734,NCT00494611,Safety of peri operative Cetuximab.,2007-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,
8735,NCT00582829,Phone follow-up interview. Participants will be contacted by study assistant and the survey administered.,2003-06,COMPLETED,OBSERVATIONAL,['NA'],,
8736,NCT02032368,Change of circulating tumor cell(CTC) count at different timepoints,2010-07,COMPLETED,INTERVENTIONAL,['NA'],,
8737,NCT01262183,1-year overall survival,2011-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,CTCs and CECs
8738,NCT00233935,Toxicity defined according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (Version 3.0),2005-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Dose-related biologic effects and pharmacodynamic properties of Poly E
8739,NCT01186263,Percentage of liver volume for which the accumulation of SIR spheres was correctly predicted by the preceding Tc-99m MAA scintigraphy,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse events as elicited upon indirect questioning.
8740,NCT02074046,The primary study purpose to determine the safety of immunization with cancer stem cells vaccine by the number of participants with adverse events,2014-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",The dose of CSC vaccine,The secondary objectives are to evaluate vaccine immune responses to the immunizations by the data of body measurements
8741,NCT00093652,Response (phase II),2003-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Immunohistochemistry
8742,NCT05839470,Overall Response Rate (ORR),2023-11-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression free survival (PFS)
8743,NCT01665937,Phase 2 dose of STA 9090 given once weekly in patients with advanced hepatocellular carcinoma,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival
8744,NCT04654247,Gastric precancerous detection rate,2019-04-20,COMPLETED,INTERVENTIONAL,['NA'],,Adcanced ADR
8745,NCT01605318,Percentage of Participants With Laboratory Abnormalities,2013-02-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change from Baseline in Carcinoembryonic Antigen (CEA) Serum Levels
8746,NCT04296630,Screening intention,2020-08-01,UNKNOWN,INTERVENTIONAL,['NA'],,Post comments
8747,NCT01831609,Biomarker analyses to predict treatment response in metastatic cancer,2011-08-31,RECRUITING,OBSERVATIONAL,['NA'],,
8748,NCT01035008,"Differentiate between non-mucinous, mucinous non-malignant & malignant pancreatic cysts in vivo",2009-12,COMPLETED,INTERVENTIONAL,['NA'],,
8749,NCT02992340,Phase 2B: Progression Free Survival (PFS),2016-12-13,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Pharmacokinetics of Gemcitabine, dFdU (gemcitabine metabolite) and Cisplatin (Phase 2B)"
8750,NCT00585637,"Levels of Plasma 25(OH)D at Baseline, 3 Months and 6 Months.",2007-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Change in CRP From 0 to 3 Months.
8751,NCT02633436,optical density (ODs) of each slice by immunohistochemistry assay,2015-12,UNKNOWN,OBSERVATIONAL,['NA'],,SLC1A5 expression detected by WesternBlot
8752,NCT00081536,,na,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
8753,NCT03143270,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2017-04-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
8754,NCT00979680,Sphincter preservation rate,2001-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall Survival
8755,NCT01515046,Overall Survival,2012-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Ascorbate Levels
8756,NCT00006368,,1998-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8757,NCT05461235,Progression-free Survival (PFS),2022-07-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
8758,NCT00385970,3-Year recurrence-free survival rate,2006-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"5-Year survival rate, incidence of adverse events, treatment compliance, QOL, type of metastasis/recurrence, and 3-year and 5-year recurrence-free survival rates and survival rates based on each parameter including colon/rectum, stage, and IAP."
8759,NCT00118105,Correlation of clinical outcome with expression of biomarkers and telomere length,2006-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
8760,NCT03335813,Percent Volume of the Tumor Receiving the Prescription Dose (V100),2018-03-06,COMPLETED,INTERVENTIONAL,['NA'],,Number of Participants With the Need for Dilation
8761,NCT00866957,HIF-1alpha bio-marker,2006-02,COMPLETED,OBSERVATIONAL,['NA'],,Understand biological behavior of the tumors
8762,NCT00294827,Survival,2006-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Time to progression side-effects
8763,NCT01454180,Overall survival,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8764,NCT05143619,Teaching rates of the hepatocellular carcinoma diagnosis guidelines,2019-05-10,RECRUITING,OBSERVATIONAL,['NA'],,
8765,NCT00295035,,2006-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
8766,NCT03387098,Objective response rate by RECIST,2018-01-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03."
8767,NCT02942238,Disease-free survival,2017-01,UNKNOWN,INTERVENTIONAL,['NA'],,The accuracy of preoperative staging with CT
8768,NCT02514551,Progression Free Survival (PFS) in Ramucirumab 12mg/kg Arm I4T-MC-JVCZ,2015-10-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Anti-Ramucirumab Antibodies
8769,NCT05313282,The progression-free survival (PFS) by RECIST 1.1,2022-06-15,RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
8770,NCT03603756,objective response rate,2018-07-31,UNKNOWN,INTERVENTIONAL,['PHASE2'],,treatment-related adverse events
8771,NCT00816491,"The primary endpoint of the study will be to compare the accuracy of two procedures (FICE with target biopsies only, versus conventional white light colonoscopy)",2008-10,COMPLETED,INTERVENTIONAL,['NA'],,To quantify the number of true positive and false positive lesions by comparing the number of targeted biopsies performed for suspicious lesions and the resulting histological findings.
8772,NCT00025532,,2001-04,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
8773,NCT05356897,Progression-free survival rate,2023-11-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
8774,NCT02894775,Number of participants included in a clinical trial,2013-01,COMPLETED,OBSERVATIONAL,['NA'],,
8775,NCT01515787,DFS,2012-06-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Neoadjuvant Rectal Score
8776,NCT01306058,Phase II: Time to Progression (TTP) for the Combination of TR105 With Sorafenib in Hepatocellular Cancer (HCC),2011-02-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Percentage Signal Change in Response on Magnetic Resonance Imaging (MRI)
8777,NCT00955721,Phase II: Obtain an Estimate of the 9-month Progression-free Survival Rate in Patients With Advanced BTC Receiving the RPTD of the Combination Sorafenib and GEMOX.,2009-08,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II: Explore Biomarkers of Response to the Combination
8778,NCT03510858,Proportion of patients which have been tested for CRC,2018-03-14,UNKNOWN,INTERVENTIONAL,['NA'],,Intention to prescribe colonoscopy vs. FIT within the next 6 months
8779,NCT03791918,Overall survival,2019-01-01,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Progression free survival
8780,NCT05291728,the detection rate of early gastric cancer,2020-10-01,RECRUITING,OBSERVATIONAL,['NA'],,"the prevalence of dyspepsia, gastroesophageal reflux disease and precancerous lesions in the natural population of Shaanxi Province, as well as the prevalence of helicobacter pylori infection, radical treatment and recurrence rate."
8781,NCT04733521,preliminary antitumor activity of SC-43,2021-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",phosphorylated signal transducer and activator of transcription 3(p-STAT3) status in peripheral blood mononuclear cells (PBMCs) of subjects,overall survival(OS) according to RECIST criteria version 1.1
8782,NCT00568438,,2000-10,COMPLETED,OBSERVATIONAL,['NA'],,
8783,NCT01997684,Rates of primary colorectal anastomosis,2013-07,UNKNOWN,INTERVENTIONAL,['NA'],Clinical success,Recurrence of colorectal cancer
8784,NCT04517032,Catastrophic Expenditure at 6 months,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Colorectal cancer stage at the time of diagnosis
8785,NCT01485744,Toxicity,2011-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Response Rate
8786,NCT03634982,Number of participants with dose limiting toxicities (DLTs),2018-09-28,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Duration of Response (DOR)
8787,NCT01557101,Participation to colorectal cancer screening in first-degree relatives of patients with colorectal cancer,2012-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,
8788,NCT00091078,"Toxicity defined as any of the following events: regimen-related death, transaminitis, infection, or leukopenia grade 3 or higher using NCI CTCAE version 3.0",2005-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall survival
8789,NCT05425472,Objective response rate,2022-07-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,ECOG Score for performance status
8790,NCT05491616,Disease Free survival 18 months,2022-09-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,overall survival at 2 years
8791,NCT02520154,Progression-free survival,2016-07-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Change in biomarker expression level,Overall survival
8792,NCT02352935,Safety using Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 criteria.,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],Over Survival (OS),Treatment efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria by Computed Tomography (CT) or Magnetic Resonance (MR) imaging.
8793,NCT03236883,Survival,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Karnofsky Performance Status（KPS）
8794,NCT02243384,Survival rate,2014-09-01,COMPLETED,INTERVENTIONAL,['NA'],,postoperative complications
8795,NCT05723562,Number of Participants with Sustained Complete Clinical Response for 12 Months (cCR12) as assessed by Independent Central Review (ICR),2023-04-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Participants with Anti-Drug Antibodies against Dostarlimab
8796,NCT05068180,Incidences of POD after general anesthesia in elderly patients undergoing non-cardiac major surgery,2021-10-05,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Duration of postoperative delirium
8797,NCT05971199,Progression-free survival(PFS),2021-11-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,Time to progression(TTP)
8798,NCT06207981,Disease-related event free survival (DREFS) at 2 years,2024-02-26,RECRUITING,INTERVENTIONAL,['PHASE3'],,
8799,NCT05029973,Overall response rate ( ORR),2021-05-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events (AEs)
8800,NCT00468455,Evaluate the quality of life in patients with abdominal wall hernias using a user-friendly survey that is designed specifically for this population of patients,2005-10,COMPLETED,OBSERVATIONAL,['NA'],,
8801,NCT04542291,Tolerability as Measured by Number of Participants With Related Adverse Events,2021-02-25,COMPLETED,INTERVENTIONAL,['PHASE1'],,Change in Tumor Necrosis
8802,NCT01234051,Response rate,2010-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
8803,NCT03193814,Progression-free Survival (PFS) Time,2019-12-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
8804,NCT02297607,Quality of Life after surgery,2014-11,TERMINATED,INTERVENTIONAL,['NA'],Length of hospital stay,Jejunostomy tube-specific complications
8805,NCT03960008,To compare the duration of disease control in treated lesions when utilizing SBRT versus TACE as a bridging strategy for patients with HCC eligible for liver transplantation,2020-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,To assess 90 day Post-transplant mortality
8806,NCT03219723,Percentage of Participants Who Had One or More Adverse Drug Reactions,2015-09-01,COMPLETED,OBSERVATIONAL,['NA'],,H. Pylori Eradication Rate
8807,NCT04170556,Incidence of Treatment-Emergent Adverse Events,2020-03-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Serum and tissue marker characterization
8808,NCT00839111,"Progression-Free Survival (PFS) ,defined as the time from treatment to disease progression or death due to any cause",2008-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Secondary endpoints are disease control rate, defined as a complete response, partial response, and stable disease; Response rate and overall survival; and safety are also evaluated."
8809,NCT04413526,The survival rates for one-year to five-year,2020-05-25,COMPLETED,OBSERVATIONAL,['NA'],,The Child-Pugh score after therapy
8810,NCT02407119,Incidence of metachronous gastric cancer,2003-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall survival
8811,NCT00576056,Determine Progression-free Survival in This Patient Population Treated With the Proposed Combination Treatment Modality,2008-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Determine the Overall Survival in Patients Treated With This Combination Regimen
8812,NCT02571374,Number of participants with colorectal cancer on symbiotic to prevent postoperative infection,2013-10,UNKNOWN,INTERVENTIONAL,['NA'],,
8813,NCT04795063,Morbidity rates,2021-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Time of digestive tract reconstruction
8814,NCT04685759,Proportion of patients with a primary GI tumor who complete neoadjuvant treatment and are cleared for surgical resection,2022-04,WITHDRAWN,INTERVENTIONAL,['NA'],Mean total Patient Satisfaction score of In-Person Exercise Therapy,Change in quality of life assessment
8815,NCT03881332,Glomerular filtration rate,2019-12-26,COMPLETED,OBSERVATIONAL,['NA'],,
8816,NCT00806663,"reduction of tumor vessel permeability (TVP) and blood flow (BF) measured by DCE-MRI and DCE-USI, measured on liver metastases.",2008-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,drug treatment safety
8817,NCT00723996,The primary outcome will be determined through review of medical records or a telephone follow-up 6 months after enrollment,2003-09,COMPLETED,OBSERVATIONAL,['NA'],,
8818,NCT01141114,completion of colorectal cancer screening,2008-09,COMPLETED,INTERVENTIONAL,['NA'],,Comparison of detection of polyps and cancers in intervention vs. control groups
8819,NCT06195254,progression-free survival (PFS),2020-12-01,COMPLETED,OBSERVATIONAL,['NA'],,Pain relief rate (PRR）
8820,NCT03884400,Distribution of Biospecimens From Biorepositories/Biobanks for Research Use,2021-01-01,WITHDRAWN,OBSERVATIONAL,['NA'],,
8821,NCT00039273,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8822,NCT04229849,Overall Survival (OS),2020-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Assessment of Health-related quality of life
8823,NCT04036643,Tumor response assessed by modified the Ryan tumor regression grading system obtained by quantification of the residual cancer cells compared to fibrosis on the surgical specimen,2019-11-27,UNKNOWN,INTERVENTIONAL,['NA'],,Calculation of the Net Reclassification Index (NRI) by comparing the sensitivity of [18F] -FDG-PET / MRI and the sensitivity of MRI alone for TRG1
8824,NCT04878783,Predictive performance of radiomics analysis on the pre-treatment CT scan.,2019-12-20,UNKNOWN,OBSERVATIONAL,['NA'],,Association between radiomics and molecular expression in regards to long-term outcomes
8825,NCT05595473,Number of participants with adverse events (AEs) in part 1 and 2 as graded by NCI-CTCAE,2022-07-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To determine safety and efficacy of RZ-001 by changes in overall survival (OS) of the partipants in Part 1 as graded by RECIST v1.1 and mRECIST
8826,NCT06326879,Incidence rate ratio of colorectal cancer recurrence,2023-11-30,RECRUITING,OBSERVATIONAL,['NA'],,Correlation between socioeconomic characteristics and incidence rate of colorectal cancer recurrence
8827,NCT00926536,"Cumulative Dose (CD), a Measure of Radiation Dose",2009-04,COMPLETED,INTERVENTIONAL,['NA'],,
8828,NCT01283906,To evaluate the efficacy of MuGard on reducing the symptoms of oral mucositis using an Oral Mucositis Daily Questionnaire (OMDQ),2011-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,To evaluate the efficacy of MuGard on delaying the onset of oral mucositis symptoms and reducing the impact on health and resource outcomes.
8829,NCT02221245,"Percentage of samples with identifiable Notch, Wnt and Hedghog pathways in the chemo naive esophageal tumor as well as in cancer stem cell populations (CSC).",2013-04-05,TERMINATED,OBSERVATIONAL,['NA'],,
8830,NCT06153368,Objective response rate (ORR),2023-12-19,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events (safety)
8831,NCT04057365,Overall Response Rate,2019-10-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Median Overall Survival
8832,NCT05576896,Objective Response Rate (ORR),2022-10-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
8833,NCT05941481,pathological complete remission (pCR) rate,2023-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
8834,NCT04168346,The need for blood transfusion,2019-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],,Use of IV iron after operation
8835,NCT06205862,CRA recurrence rate,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Changes in intestinal mucosal microbiota Pre- and Post-FMT
8836,NCT02351765,Maximum Tolerated Dose (MTD) of Aclerain in combination with Cisplatin,2016-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Exploration of the pharmacokinetic profile for the combination of Acelarin with Cisplatin
8837,NCT01950442,Safety of gentle dilation,2013-10,COMPLETED,INTERVENTIONAL,['NA'],,impact on staging
8838,NCT02648880,Change in 400-meter Walk Time,2016-05-10,COMPLETED,INTERVENTIONAL,['NA'],,Determination of Hospital Readmission
8839,NCT01744821,Other Surrogate Endpoint Biomarkers Markers of Cancer Prevention,2012-10,TERMINATED,INTERVENTIONAL,['NA'],,Review of the Differences in the Types and Incidence of Toxicities Associated With Vitamin D3 Replacement.
8840,NCT05753748,Neoplastic Progression,2023-01-24,RECRUITING,INTERVENTIONAL,['NA'],,Patient-Reported Gastroesophageal Reflux
8841,NCT02713386,Progression-free survival (PFS) (Phase II),2016-11-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change in serum C-reactive protein (CRP),Overall survival (OS) (Phase II)
8842,NCT01777594,Time to progression,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
8843,NCT02226380,The 3-year overall survival rate in patients who will receive mFOLFOX6 regimen as neoadjuvant chemotherapy regimen,2013-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],The R0 resection rate in the patients who will receive mFOLFOX6 regimen as neoadjuvant chemotherapy regimen,The 3-year disease-free survival rate in the patients who will receive mFOLFOX6 regimen neoadjuvant chemotherapy regimen
8844,NCT05807776,MPR rate,2023-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,AE and SAE
8845,NCT03775980,Local Tumor Control,2019-09-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Treatment specific quality of life
8846,NCT02559024,Immune Score,2016-03-14,TERMINATED,INTERVENTIONAL,['PHASE1'],,
8847,NCT04792515,pathologic complete response (PCR),2021-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Percentage of Progression-free survival (1-PFSR)
8848,NCT02269995,Safety and Tolerability as measured by Adverse Events,2014-03-06,COMPLETED,OBSERVATIONAL,['NA'],,Efficacy of DC bead as assessed by embolic performance
8849,NCT04080414,Feasibility of home-based high-intensity interval training among colorectal cancer survivors,2019-08-02,COMPLETED,INTERVENTIONAL,['NA'],,
8850,NCT04091620,Incidence rate of achieving a composite of pathologic endpoint indicating adequate surgical resection,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA'],,Direct/indirect medical costs and out-of-hospital economic costs
8851,NCT01150045,Disease-free Survival,2010-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Overall Survival
8852,NCT01484444,Analyzed of DNA mutations,2011-09,UNKNOWN,OBSERVATIONAL,['NA'],,
8853,NCT00845611,Safety(Phase I:toxicities as assessed by NCI CTCAE version3),2008-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,evaluate immunological responses
8854,NCT02101099,Peak push force is increased in patients receiving propofol as compared to conscious sedation.,2014-03,COMPLETED,OBSERVATIONAL,['NA'],,
8855,NCT01024504,Overall response rate,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
8856,NCT05438108,AEs,2022-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
8857,NCT05660213,ORR,2024-01-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],,Incidence and severity of adverse events of special interest (AESI)
8858,NCT03557216,Presence of ACN,2018-06-15,COMPLETED,INTERVENTIONAL,['NA'],,Fecal calprotectin test predictive value for ANC detection
8859,NCT00479752,"The primary endpoint of the trial is: • Objective response (CR/PR), as assessed by RECIST criteria",2008-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,• Progression Free Survival (PFS) • Overall survival • Safety/Adverse events Safety
8860,NCT04478929,gastroscopy image data set,2020-08,UNKNOWN,OBSERVATIONAL,['NA'],,
8861,NCT01053923,Primary tumor apparent diffusion coefficient at simulation and during week 3 and last week of fractionated radiotherapy from MRI,2009-12,WITHDRAWN,OBSERVATIONAL,['NA'],,Change with time from start of radiotherapy course in primary tumor apparent diffusion coefficient from MRI
8862,NCT05787535,"Incidence of treatment related AEs, AEs of special interest and serious adverse events (SAEs).",2023-03-21,RECRUITING,INTERVENTIONAL,['PHASE1'],,Duration of TCR T cells in-vivo persistence
8863,NCT01258868,Tabulation of patient toxicities and their grades,2010-12-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,Number of patients of first 20 lung CA patients with cell line development greater than or equal to 5.
8864,NCT03129139,Anti-tumor activity,2017-10-10,RECRUITING,INTERVENTIONAL,['PHASE1'],,
8865,NCT05990231,Objective response rate,2023-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
8866,NCT03035136,Adenoma detection rate,2017-01-15,COMPLETED,OBSERVATIONAL,['NA'],,Polyp detection rate
8867,NCT05146297,Change in Clinical Trial Accrual,2022-12-24,RECRUITING,INTERVENTIONAL,['NA'],,Physician Post -intervention survey
8868,NCT03428529,Clinical downstaging,2011-01-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Pathological downstaging
8869,NCT01561014,Toxicity rate of combination chemotherapy followed by surgery and erlotinib hydrochloride,2007-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Test the predictive value of FDG-PET-CT imaging in identifying patients who will have a complete response
8870,NCT04686747,"Rate of advanced Esophageal, Gastric, Pancreatic and Colorectal cancer in 2020 compared to 2019.",2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Rate of patient unable to performer adjuvant treatment in 2020 compared to 2019
8871,NCT02823691,incidence of SAEs and AEs,2016-04,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,biochemical responses to Lanreotide ATG 120 mg in combination with Metformin
8872,NCT04770623,Overall response rate (ORR),2021-03-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
8873,NCT03241680,Study of Anal Cytologies in Patients With High Grade Cervical Intraepithelial Neoplasia (CIN II and III),2017-08-02,UNKNOWN,INTERVENTIONAL,['NA'],,
8874,NCT04843397,Define the prevalence of pre-malignant upper GI tract lesions as measured by standardised endoscopy and biopsy protocol,2021-06-01,UNKNOWN,OBSERVATIONAL,['NA'],,Correlation between life-style factors and pathological outcomes
8875,NCT03801668,Progression-free Survival (PFS),2019-03-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Safety as measured by number and grade of adverse events
8876,NCT01233544,Local progression-free survival,2010-09,TERMINATED,INTERVENTIONAL,['PHASE3'],,Quality of life
8877,NCT00536770,Overall survival rate at 6 months,2007-09,SUSPENDED,INTERVENTIONAL,['PHASE2'],,Duration of overall survival
8878,NCT03540953,dysphagia,2015-01-05,TERMINATED,INTERVENTIONAL,['NA'],,number of sessions of endoscopic dilations
8879,NCT00057876,Overall Survival Time,2003-08-29,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall Response
8880,NCT05555901,Progression-Free Survival (PFS),2023-06-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
8881,NCT01051596,Percent of Patients With Disease Control,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percent of Patients With an Objective Response
8882,NCT00006786,,2000-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8883,NCT04677998,Advanced neoplasia,2020-11-24,RECRUITING,OBSERVATIONAL,['NA'],,Surgery
8884,NCT00954655,response,2008-12,COMPLETED,OBSERVATIONAL,['NA'],,
8885,NCT06334926,overall survival,2017-12-01,COMPLETED,OBSERVATIONAL,['NA'],,
8886,NCT00521404,Progression-Free Survival Rate at 16 Weeks Following Treatment With CS-1008 in Combination With Gemcitabine in Chemotherapy-Naïve Participants With Unresectable or Metastatic Pancreatic Cancer,2007-08-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Treatment-Emergent Adverse Events Considered by the Investigator at Least Possibly Related to Gemcitabine Experienced by ≥5% of Participants by System Organ Class and Preferred Term
8887,NCT06043921,Cohort of patients with resectable pancreatic cancer; Success rate of WES assays and selections of personalized genes using tumor tissue specimens obtained by EUS-FNA/FNB,2022-11-01,RECRUITING,OBSERVATIONAL,['NA'],,Cohort of patients with resectable pancreatic cancer; to investigate the lead time of ctDNA detection of recurrence before detection of recurrence via imaging methods
8888,NCT02564835,Program Evaluation,2015-09,COMPLETED,INTERVENTIONAL,['NA'],Beliefs about Treatment,Pro-inflammatory Markers
8889,NCT01023984,Incidence of recurrence at 12 months,2012-01,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,Number of days not spent in hospital from initial treatment until 2 years afterwards
8890,NCT03732508,Duration of Progression-Free Survival (PFS),2018-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse Events(AE)
8891,NCT01869725,Compare Specificity of 68Ga-DOTATOC PET/CT With Octreoscan,2013-04-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8892,NCT01356030,Direct comparison of tissue sampling techniques for patients with suspected pancreaticobiliary cancers.,2011-05,COMPLETED,INTERVENTIONAL,['NA'],,
8893,NCT02595320,Twelve-week Progression Free Survival (cohort 1 only),2015-10-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],Objective response rate (cohorts 1 and 2),Grade 3 or higher toxicity (cohorts 1 and 2)
8894,NCT02707159,Change in levels of circulating tumor cells (CTCs) during treatment,2014-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Changes in quality of life during treatment
8895,NCT02560298,Best ORR defined as the percentage of patients achieving confirmed partial (PR) or complete responses (CR) as per RECIST v1.1,2016-08-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Changes in expression of tumor biomarkers,Sensitivity analysis of ORR
8896,NCT03783156,Number of participants with presence of adenomatous tissue al the base of polypectomy,2019-02-18,COMPLETED,INTERVENTIONAL,['NA'],,Number of participants with Postpolypectomy Complications
8897,NCT05379907,Impact of SIGNATERA™ on treatment decisions,2022-08-23,WITHDRAWN,OBSERVATIONAL,['NA'],,Patient satisfaction of SIGNATERA™ ctDNA on treatment recommendations
8898,NCT00748449,Percentage of patients who refuse to undergo an examination,2008-06,TERMINATED,INTERVENTIONAL,['NA'],,
8899,NCT04545957,Proportion of patients with QOL decline exceeding 2 x MID,2020-10-14,RECRUITING,INTERVENTIONAL,['NA'],,Performance of the synthetic CT in RT planning
8900,NCT03644511,"Identification of current treatment patterns by means of individual treatment lines in the systemic HCC therapy with regards to Nexavar and Stivarga, i.e. when both drugs are used in ≥ 2nd-line under current practice conditions",2019-01-24,TERMINATED,OBSERVATIONAL,['NA'],,Incidence of treatment-emergent adverse events (TEAE)
8901,NCT02688023,3-year disease-free survival,2014-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of participants with surgery complications
8902,NCT01815463,Correlation of Adnab-9 stool result with outcome of colonoscopy,2006-08,TERMINATED,OBSERVATIONAL,['NA'],,Define the origin of the Adnab-9 bound antigen
8903,NCT04095468,Percentages of pCR in the patients after total mesorectal excision performed because of tumour persistence.,2017-09-18,RECRUITING,OBSERVATIONAL,['NA'],,Anorectal function assessed by low anterior resection syndrome (LARS) score
8904,NCT02215837,Progress-free survival,2014-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Severity of adverse events
8905,NCT02906397,Safety based upon standard laboratory and clinical adverse event monitoring,2017-03-30,COMPLETED,INTERVENTIONAL,['PHASE1'],,Promotion of anti-tumor immunity with addition of intervention to SBRT
8906,NCT02092298,Overall Survival (OS) From the First Laparoscopic HIPEC,2014-05-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8907,NCT01806272,The incidence of grade II and less oral mucositis at the end of treatment,2013-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Tumor response to chemoradiotherapy
8908,NCT05889806,Enrollment and collection totals for a diverse population of subjects/conditions involved in diseases and in healthy/control populations.,2023-05-10,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
8909,NCT02699073,Tumor response rate at 2 months according Choi Criteria,2016-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Correlation between Baseline cell free DNA and survival outcomes (PFS and OS)
8910,NCT05336643,Lymph node detection with technetium 99m colloid and SENSEI gamma probe,2023-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Concordance of nodes seen on PET MRI/CT and SPECTCT
8911,NCT03605706,Overall Survival,2019-05-31,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Overall Survival (OS) rate at 9 months and 12 months
8912,NCT05589675,Participation rates to the screening program,2023-04-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Participation rates to the screening program
8913,NCT02480361,Remnant sitz markers in small intestine at postoperative day 7,2013-01,COMPLETED,INTERVENTIONAL,['NA'],serum albumin level in postoperative day 7,hospital stay
8914,NCT01365910,Overall Response Rate (Complete Response + Partial Response) With a Target of at Least 15%,2011-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Each Worst-Grade Toxicity
8915,NCT01548482,Safety profile of trebananib and temsirolimus as assessed by NCI CTCAE version 4.0,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,PD effects of both drugs when administered in combination
8916,NCT03904121,Postoperative mortality,2019-04-01,COMPLETED,OBSERVATIONAL,['NA'],,Functional performance
8917,NCT01084746,Increase patient completion of colorectal cancer screening (CRCS) among patients ages 50 to 64 years old.,2005-01,COMPLETED,INTERVENTIONAL,['NA'],,Secondary goals are to increase understanding of factors that predict completion of CRCS and to assess the cost-effectiveness of the intervention.
8918,NCT00328887,"Since this is a dose escalation, phase I design to evaluate toxicity, the analysis for this section will be purely descriptive. Adverse events will be considered on an individual basis.",2004-11,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
8919,NCT00716820,Objective Response Rate,2008-04,COMPLETED,OBSERVATIONAL,['NA'],Number of Participants With Treatment-Related Adverse Events Grade 3 or Higher in Common Toxicity Criteria for Adverse Events (CTCAE),Numbers of Participants With Treatment-Related Adverse Events Corresponded to Items for Priority Investigation
8920,NCT00849264,overall survival,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,disease-free survival
8921,NCT03754075,Risk of recurrence,2008-06-01,UNKNOWN,OBSERVATIONAL,['NA'],,Number of mesocolic lymph nodes
8922,NCT02604784,Overall Response Rate (ORR) according to RECIST criteria (version 1.1) after 2 and 3 cycles of PIPAC.,2015-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The Peritoneal Carcinomatosis Index (PCI) before and after therapy
8923,NCT00325611,Quality and cost of care,2002-04,COMPLETED,INTERVENTIONAL,['NA'],,Lower total costs 6 months past hospitalization
8924,NCT01778595,"Participation rate, data quality",2013-01-08,COMPLETED,OBSERVATIONAL,['NA'],,
8925,NCT01469611,Determine the maximum-feasible dose,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8926,NCT03918369,Rate of Re-interventions,2019-03-07,COMPLETED,INTERVENTIONAL,['NA'],,
8927,NCT00403052,Occurrence of adverse events,2006-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall survival time
8928,NCT05835947,The incidence of anal HSIL and cancer in women with genital HSIL and/cancer in England,2022-09-01,RECRUITING,OBSERVATIONAL,['NA'],,The amount of time in years and months between the diagnosis of genital HSIL/SCC and anal HSIL/SCC
8929,NCT02850991,Overall Survival,2016-04,COMPLETED,INTERVENTIONAL,['NA'],"local control rate, recurrence pattern",Progression-free survival
8930,NCT04843306,Effectiveness of motion management for SBRT for pancreatic cancer with real-time coaching for the ABC procedure using an augmented reality platform,2021-06-24,RECRUITING,INTERVENTIONAL,['NA'],,Anxiety of patient with the ABC procedure with real-time coaching using an augmented reality platform during SBRT for pancreatic cancer as assessed by patient reported outcome measures (PROMs)
8931,NCT05172713,Retrospective study of the patient outcomes who had an incomplete colonoscopy after a positive immunological fecal test,2021-01-16,UNKNOWN,OBSERVATIONAL,['NA'],,
8932,NCT01219543,To investigate the safety and tolerability of AZD1480,2010-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,To obtain a preliminary assessment of the anti-tumour activity of AZD1480
8933,NCT00259402,"Efficacy endpoints include tumor response, progression free and overall survival.",2000-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Safety endpoints include summary of adverse events assessed by history, physical exams and laboratory evaluations."
8934,NCT02943031,Overall Survival (OS),2016-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Progression-Free Survival (PFS)
8935,NCT00990860,"Safety and tolerability (such as adverse events and laboratory changes (haematology, clinical chemistry))",2009-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,No. of TACE cycles
8936,NCT03705442,Incidence of grade III/IV diarrhoea between the two groups of patients,2018-02-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Difference in quality of life using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire core 30 (EORTC QLQ-C30) between the two groups of patients
8937,NCT03526328,cell-specific expression patterns of putative intestinal stem cell biomarkers in BE patients; correlation of markers with serum/plasma protein expression and disease progression.,2013-03,COMPLETED,OBSERVATIONAL,['NA'],,
8938,NCT02716766,Time to progression (TTP),2016-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of life (QoL),Frequency and severity of adverse events and laboratory abnormalities
8939,NCT01379482,Overall survival,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8940,NCT03243734,Change from baseline dysphagia scale at 14 days post cryotherapy procedure,2017-11-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Mean change in the amount of residual tumor from baseline to follow-up cryospray delivery session
8941,NCT05027737,Complications,2022-02-22,RECRUITING,INTERVENTIONAL,['NA'],,EORTC QLQ-CR29 score
8942,NCT00807300,Time to untreatable progression,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
8943,NCT02955901,Score of mucosal visualization,2017-01-01,COMPLETED,INTERVENTIONAL,['NA'],Patients characteristics questionnaire,Withdrawal time
8944,NCT03022110,Cyst recurrence rate,2017-02,UNKNOWN,INTERVENTIONAL,['NA'],,Complication rate
8945,NCT01362361,progression free survival,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8946,NCT01609660,Mucosal cytokine,2010-03,COMPLETED,INTERVENTIONAL,['PHASE4'],,Short chain fatty acids
8947,NCT00226941,Dose-limiting Toxicity (DLT) - Number of Participants Affected,2004-06,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Survival at 5 Years
8948,NCT04050787,3-year disease free survival rate,2019-07-21,UNKNOWN,INTERVENTIONAL,['NA'],,The number of positive lymph nodes
8949,NCT06060847,Comprehensive Complication Index,2024-03-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Control of obesity-induced comorbidities
8950,NCT05447221,The diagnostic performance of AI model to assess the severity of intestinal metaplasia,2022-08-01,RECRUITING,OBSERVATIONAL,['NA'],,"Accuracy of digital pathological AI models to identify glands, mucosal epithelium, and intestinal metaplasia in non-neoplastic areas"
8951,NCT01268943,Dose Related Toxicity,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8952,NCT05115786,Recurrence of colorectal cancer,2023-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
8953,NCT01855724,Objective Response Rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1),2013-06-28,TERMINATED,INTERVENTIONAL,['PHASE2'],,Evaluation of potential prognostic and/or predictive biomarkers in tissue and blood samples
8954,NCT01180959,Progression Free Survival (PFS),2011-04-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
8955,NCT05187338,Duration of remission (DOR),2021-11-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
8956,NCT02355262,Total number of months uninsured (total gap months),2014-07-01,COMPLETED,OBSERVATIONAL,['NA'],,
8957,NCT03304210,Maximally Tolerated Dose (MTD) of Abraxane,2017-09-16,COMPLETED,INTERVENTIONAL,['PHASE1'],,Decreased Platelets - Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0
8958,NCT03161522,Overall survival (OS),2018-02-19,RECRUITING,INTERVENTIONAL,['PHASE2'],Time to disease progression,Time to local or regional disease recurrence
8959,NCT00035919,dose-limiting toxicity and maximum tolerated dose,2002-11,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,objective tumor response by CT scan or MRI
8960,NCT04723004,Overall survival (OS),2020-10-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,ADA
8961,NCT00026338,Overall survival,2001-10-29,COMPLETED,INTERVENTIONAL,['PHASE3'],,Pharmacokinetics
8962,NCT01009801,Time to progression (Phase II),2010-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to treatment failure (Phase II)
8963,NCT02468362,Disease Free survival,2014-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,5 year survival
8964,NCT04597268,Ramsy sedation score (RSS),2020-11-01,COMPLETED,INTERVENTIONAL,['NA'],,
8965,NCT04608786,Recommended phase II dose (RP2D),2021-02-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,the number of subjects presenting detectable anti drug antibodies (ADAs)
8966,NCT04177407,postoperative complications,2017-03-23,UNKNOWN,INTERVENTIONAL,['NA'],,Overall complication rate within 30 days after surgery.
8967,NCT00410618,Nature and long-term ramifications of CNS injury as a result of cancer treatment,2003-04,COMPLETED,OBSERVATIONAL,['NA'],,Relationship between MRI measures and cognitive performance
8968,NCT02043821,DDC:Duration of Disease Control,na,UNKNOWN,INTERVENTIONAL,['NA'],Safety,DCR:Disease Control Rate
8969,NCT00470951,Disease free survival,2006-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],Immunologic response,Quality of life
8970,NCT01748851,Progression free survival,2012-12,TERMINATED,INTERVENTIONAL,['PHASE3'],,performance status (quality of life)
8971,NCT05732129,"Objective response rate of Metastatic Colorectal Cancer,inculdthe proportion of patients with complete response or partial response",2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,The Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.
8972,NCT01930864,Non-Progression at week 12th of treatment,2015-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety
8973,NCT02485561,Intentions to Get Screened for Colon Cancer,2015-06-01,COMPLETED,INTERVENTIONAL,['NA'],Perceived Benefits and Barriers of Colorectal Cancer Screening,Absolute Perceived Susceptibility to Colon Cancer
8974,NCT04601727,16s rRNA pyrosequencing analysis of microbial flora of rectal cancer patients,2020-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Categorisation of microbial flora against response to neoadjuvant chemoradiotherapy
8975,NCT03983057,Progression-free survival,2019-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Carbohydrate antigen 19-9
8976,NCT02577588,Safety,2016-05-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,evaluation of p53 specific T cell Responses by analysing data from EliSpot assay
8977,NCT04508452,Reintroduction Rate,2020-05-18,UNKNOWN,INTERVENTIONAL,['PHASE2'],,ORR2
8978,NCT00956436,To evaluate the safety and tolerability of BIIB022 given once every 3 weeks in combination with sorafenib in subjects with advanced HCC.,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,To assess the anti-tumor response in this study population
8979,NCT03802214,"Analysis of blood and tissue leukocytes (T cells, B cells and Dendritic cells)",2020-10-29,TERMINATED,OBSERVATIONAL,['NA'],,Analysis of the serum and tissue concentrations of vedolizumab
8980,NCT04748744,Value of Butyrylcholinesterase as a Marker of Surgical Site Infection Following Surgery for Colorectal Diseases,2019-11-06,COMPLETED,OBSERVATIONAL,['NA'],,
8981,NCT04296851,Mean percentage change of the number and size of polyps in colon and/or duodenum.,2020-02-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],,A qualitative assessment of the total extent of colorectal polyposis
8982,NCT06216834,psychosocial status,2023-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
8983,NCT01368094,Surgical Site Infection at D30,2011-06,COMPLETED,INTERVENTIONAL,['NA'],,
8984,NCT03267524,Geriatric assessment,2017-11-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
8985,NCT05951127,2-year OS,2022-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,3 years PFS
8986,NCT01004978,Progression-free Survival (PFS),2009-10-28,COMPLETED,INTERVENTIONAL,['PHASE3'],To Evaluate the Effects of Intra-hepatic vs. Extra-hepatic Progression on OS.,Progression-free Survival (PFS) Among Patients With Intra-hepatic Progression
8987,NCT02437071,response rate,2015-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Toxicity
8988,NCT02296736,Review pre-operative imaging to distinguish the organ of origin of pancreatic head tumours,2014-10,COMPLETED,OBSERVATIONAL,['NA'],,Resectabilty of the pancreatic tumour
8989,NCT04368182,Safety of C-TCR055,2020-04-13,UNKNOWN,INTERVENTIONAL,['PHASE1'],,DOR
8990,NCT05130073,Overall survival (OS),2019-07-31,COMPLETED,OBSERVATIONAL,['NA'],,
8991,NCT05981066,Clinically significant abnormal changes in laboratory tests,2023-07-10,RECRUITING,INTERVENTIONAL,['NA'],,"Overall Survival, OS"
8992,NCT04564898,activity,2022-01-25,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Clearance,survival
8993,NCT05658016,Mucositis,2022-06-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence Adverse Events That Are Related to Treatment
8994,NCT04935853,Rate of patients with advanced bile duct cancer (BDC) experiencing overall survival (OS) less than 6 months,2022-05-23,RECRUITING,OBSERVATIONAL,['NA'],,The complications and postoperative mortality rates in patients who underwent surgery
8995,NCT05185739,"Major pathological response rate, defined as the proportion of patients with less than 10% viable tumour at resection.",2022-08-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Determine the toxicity of pre-operative therapy according to Common Terminology Criteria for Adverse Events (CTCAE) V5.
8996,NCT02050659,tumorload in the greater omentum,2012-03,COMPLETED,OBSERVATIONAL,['NA'],,
8997,NCT02299648,molecular screening ( biopsy of their tumor and will be analyzed using cancer panel/nanostring CNV and immunohistochemistry),2014-07-25,COMPLETED,INTERVENTIONAL,['NA'],,OS/PFS
8998,NCT03639935,Proportion of patients alive and without radiological or clinical progression at 4 months,2019-03-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS) time as measured from start of 1st line platinum therapy
8999,NCT01134666,Safety and tolerability evaluated based on the incidence and severity of AEs.,2009-11-30,TERMINATED,OBSERVATIONAL,['NA'],,Response rate
9000,NCT00868114,Overall Survival,2006-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,
9001,NCT02376478,"Number of anogenital warts, anogenital HPV DNA positivity and mucosal HPV seropositivity",2009-12,COMPLETED,OBSERVATIONAL,['NA'],,
9002,NCT01714726,Percentage of Participants With Crohn's Disease Activity Index (CDAI) Response at Week 8,2013-02-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With ADA Positive to MEDI2070 in Open-label Period
9003,NCT06101836,Patient comfort during colonoscopy - Sedation,2020-10-01,COMPLETED,INTERVENTIONAL,['NA'],,
9004,NCT03793322,The accuracy of positive margins of resection detected by ICG fluorescence.,2017-01-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
9005,NCT04430231,Disease-free overall survival,2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
9006,NCT01103492,Number of Participants With Adverse Events,2008-07,COMPLETED,INTERVENTIONAL,['NA'],,
9007,NCT02260440,Objective Response Rate (ORR),2015-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
9008,NCT05163028,"To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), of HBI-2376 as an oral monotherapy for advanced solid tumors harboring KRAS or EGFR mutations.",2021-12-13,RECRUITING,INTERVENTIONAL,['PHASE1'],,Pharmacokinetic variables including volume of distribution
9009,NCT03908255,Overall Survival,2021-06-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],International normalized ratio (INR),Quality of life using FACT-Hep
9010,NCT01279278,Completion of Fecal Occult Blod Test,2010-09,UNKNOWN,INTERVENTIONAL,['NA'],,"Compare the rate of completion of colonoscopy after a positive test (information received by ADECA in the follow-up), according to the specifications."
9011,NCT00314353,One-year Progression-free Survival (PFS),2006-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Duration of Response
9012,NCT02927626,Survival rate,2016-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,quality of life(QOL)
9013,NCT01318200,Freedom from local progression,2011-02,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Freedom from local progression
9014,NCT05887531,Post-surgical readmisions,2023-06-01,RECRUITING,INTERVENTIONAL,['NA'],,Strength
9015,NCT05462470,overall survival,2008-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Severe complication rate after resection of primary and metastatic lesions
9016,NCT05546970,Efficacy of the echo-guided TAP Block on analgesia,2022-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
9017,NCT01255007,To establish superiority of Primovist-enhanced liver MRI and DWI to MDCT in the preoperative detection of colorectal liver metastases in patients who have received prior chemotherapy by comparison against pathology or Intra-operative ultrasound.,2010-09,COMPLETED,INTERVENTIONAL,['NA'],,To compare accuracies of Primovist-enhanced MRI and DWI to MDCT in the characterization of non-metastatic liver lesions against histopathology or intra-operative ultrasound.
9018,NCT04896879,Needs and experiences of healthcare professionals caring for patients with LARS through focus groups,2016-11-22,COMPLETED,OBSERVATIONAL,['NA'],,
9019,NCT06085560,Anticipatory Racism,2023-07-12,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,
9020,NCT00351572,,2006-07,COMPLETED,OBSERVATIONAL,['NA'],,
9021,NCT03189992,Complete patient recruitment,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
9022,NCT01887717,Overall Survival (OS) From Time of Randomization,2014-02-27,TERMINATED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Treatment Emergent Adverse Events (TEAE)
9023,NCT05264688,diagnose accordance rate,2022-01-20,UNKNOWN,OBSERVATIONAL,['NA'],,Total Glycolysis (TLG)
9024,NCT04833699,time to the first passage of flatus after surgery,2021-04-05,COMPLETED,INTERVENTIONAL,['NA'],,The time to the first bowel movement
9025,NCT04655807,Change from Baseline in the Crohn's Disease Activity Index (CDAI) Score at Week 12,2021-03-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Change in PD Biomarker Levels of Fecal Lactoferrin from Baseline Compared with Placebo
9026,NCT05984342,disease-free survival rate,2023-08-02,RECRUITING,INTERVENTIONAL,['PHASE1'],,Rate of adverse events
9027,NCT02931981,Overall Survival,2016-10,UNKNOWN,OBSERVATIONAL,['NA'],,Relapse-free Survival
9028,NCT03951389,"The correlation between wild type PIK3CA, PIK3CA exon 9 and PIK3CA exon 20 mutations and developing of metastatic disease and overall colorectal patient survival",2012-05-22,COMPLETED,OBSERVATIONAL,['NA'],,
9029,NCT02347852,Amount of physical activity assessed by a pedometer (smartLAB) and an international physical activity questionnaire,2015-01-20,COMPLETED,OBSERVATIONAL,['NA'],,"Relation of the amount of physical activity to PFS (Progression Free Survival) data assessed in CORRELATE (NCT02042144, 'Safety and Effectiveness of Regorafenib in Routine Clinical Practice Settings')"
9030,NCT00191607,"- Progression free survival (PFS) in patients who have failed one, but no more than two, prior treatments",2002-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of life
9031,NCT01290536,Number of Participants With Adverse Events,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Radiographic Response
9032,NCT01934179,"Incidence of chemotherapy related grade 3 or higher adverse events, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0",2013-10,TERMINATED,OBSERVATIONAL,['NA'],"Association of each geriatric scale, and pro-inflammatory markers to the incidence of chemotherapy related adverse events and TL",Change in TL after chemotherapy
9033,NCT03814369,Adenoma detection rate,2017-03-01,COMPLETED,INTERVENTIONAL,['NA'],,caecal intubation time
9034,NCT05811195,Oral mucositis Children's International Mucositis Evaluation Scale (CHIMES),2023-03-10,RECRUITING,INTERVENTIONAL,['NA'],,Analysis NET and TSE
9035,NCT01328223,Response rate,2010-09,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival
9036,NCT00019474,,1998-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9037,NCT02421185,Number of participants with Objective Response,2015-05-25,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Duration of Objective Response (DOR)
9038,NCT03491709,Pharmacokinetic Parameters: Area Under the Serum Concentration-time Curve From Time Zero to the Last Sampling Time (AUC0-t) After First Infusion,2018-07-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Immunogenicity indicators: neutralizing antibodies
9039,NCT06236594,Image quality rate,2023-09-18,RECRUITING,OBSERVATIONAL,['NA'],,Diagnosis accuracy according to image
9040,NCT00006479,,2000-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
9041,NCT01417000,Overall Survival (OS) in Subjects Receiving Test Treatments (FAS),2011-09-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To Assess Safety of the Cyclophosphamide, GVAX Pancreas Vaccine, and CRS-207 Treatment Regimen"
9042,NCT03003078,Safety / Tolerability of Device according to CTCAE V4.0,2017-03-27,COMPLETED,INTERVENTIONAL,['NA'],tumour response,Pain Scores
9043,NCT06223763,Overall Survival at 5 years,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Homologous Recombination Deficiency (HRD) deficiency influence
9044,NCT00985777,Maximum Tolerated Dose (MTD),2009-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Adverse Events (AEs)
9045,NCT02619435,the rate of evaluable patients alive and not progressed at 6 months,2015-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,overall survival
9046,NCT00095927,"Median duration of dependence on percutaneous endoscopic gastrectomy (PEG) for adequate nutrition at 8, 12, 24, and 52 weeks after completion of study treatment",2003-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Swallowing function
9047,NCT05957822,CRT maximal amplitude,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],,re-operation
9048,NCT00065234,,2003-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,
9049,NCT00081354,Case Control,2004-04-06,COMPLETED,OBSERVATIONAL,['NA'],,
9050,NCT00222664,,1983-09,COMPLETED,INTERVENTIONAL,['PHASE4'],,
9051,NCT00823290,Maximum tolerated dose of LBH589,2009-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,Laboratory abnormalities (CTC grade 3 or grade 4 toxicities)
9052,NCT06061874,Correlation of the Ga68-FAPI PET/CT derived PCI (peritoneal cancer index) score with the intraoperative PCI based on histopathology of resected specimen (the reference standard),2023-05-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,Assessment of the impact of neoadjuvant chemotherapy on the FAPI expression of target lesions at baseline.
9053,NCT06052202,Receipt of Colorectal Cancer Screening Test at Month 6,2023-12-08,RECRUITING,INTERVENTIONAL,['NA'],,Change from Baseline in Colorectal Cancer Knowledge at Month 6
9054,NCT02066363,Changes in body composition,2014-03-01,TERMINATED,INTERVENTIONAL,['NA'],Survival in study,Time to to exacerbate Quality of Life
9055,NCT01111292,The Effect of Myo-inositol (Inositol) on P-β-catenin Staining in Areas of Low Grade Dysplasia in Subjects With Known Colitis-induced Low Grade Dysplasia.,2010-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
9056,NCT02511756,CTP as predictive marker for efficacy measured by progression-free survival,2015-07,TERMINATED,INTERVENTIONAL,['NA'],,Local and distant recurrences
9057,NCT06133439,Implementation outcomes,2023-01-03,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],Maintenance,
9058,NCT05394129,Diagnostic accuracy,2019-04-09,RECRUITING,OBSERVATIONAL,['NA'],,Cytomorphologic feature
9059,NCT05345678,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA'],,
9060,NCT05682898,Incidence of surgical complications,2023-01-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
9061,NCT04850716,Progression-Free Survival (PFS),2021-04-27,RECRUITING,OBSERVATIONAL,['NA'],,Disease Control Rate (DCR)
9062,NCT02718235,The HCC immune score (HCCIS) is a survival prognosticator of patients after liver resection for HCC,2016-06,UNKNOWN,OBSERVATIONAL,['NA'],,The HCC immune score (HCCIS) to prognosticate disease free survival of patients after liver resection for HCC
9063,NCT04568200,pathological response,2020-06-19,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
9064,NCT02442362,Tumor respone,2012-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Side-effect
9065,NCT02015169,complete resection rate (R0 resection rate) (defined as no macroscopic or microscopic residual tumor).,2012-07-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Exploratory biomarker analysis
9066,NCT01736813,"safety as occurence of adverse events ≥ Grade 3 according to CTCAE, Version 4.0 criteria, that are definitely, probably, or possible related to the administration of the investigational agent",2012-11,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
9067,NCT04071431,Rate change,2019-05-29,UNKNOWN,INTERVENTIONAL,['NA'],,
9068,NCT02073435,Complications,2010-10,COMPLETED,OBSERVATIONAL,['NA'],,
9069,NCT04871321,collected blood samples,2021-04-14,RECRUITING,OBSERVATIONAL,['NA'],,Biomarkers on the efficacy of Gemcitabine/Cisplatin/Nab-paclitaxel for advanced biliary tract cancer
9070,NCT01489865,Dose limiting toxicities,2011-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Objective Response
9071,NCT01479608,Overall survival,2012-04-11,RECRUITING,INTERVENTIONAL,['NA'],,
9072,NCT02758977,1 Year Disease-free Survival,2016-05,UNKNOWN,INTERVENTIONAL,['NA'],,Incidence of posthepatectomy renal failure
9073,NCT05014776,Objective response rate (irORR) using immune Response Evaluation Criteria for Solid Tumors (iRECIST),2022-08-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants experiencing grade 3 or above drug-related toxicities
9074,NCT02043288,Overall survival (OS),2014-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of life (QoL) using EORTC QLQ-C30
9075,NCT06136845,To characterize the microbiota of esophageal cancer patients differentiating it by: - demographic criteria - tumor characteristics,2020-01-13,RECRUITING,OBSERVATIONAL,['NA'],,
9076,NCT05292417,Progression-free survival (PFS),2022-03-25,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety:Percentage of Participants With Adverse Events (AEs)
9077,NCT04972994,early recurrence of the cancer,2021-06-01,UNKNOWN,INTERVENTIONAL,['NA'],,
9078,NCT06048913,Overall Survival,2022-07-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE1'],,Toxic side reactions
9079,NCT03053544,Pathological Complete Response (pCR) rate,2016-12-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumor Hypoxia
9080,NCT03868228,Progression free survival assessed by laparoscopy and cross sectional imaging,2019-02-05,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,PIPAC related safety regulation breaches / adverse events in theatre
9081,NCT05159050,Determine the maximum tolerated dose (MTD) of intraperitoneal Paclitaxel-loaded Tumor Penetrating Microparticles (TPM),2022-04-26,RECRUITING,INTERVENTIONAL,['PHASE1'],,Assess whether intra-abdominal pressure is location-dependent
9082,NCT02870036,Adverse events (AE),2016-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],,accumulative excretion rate
9083,NCT04262635,Efficacy: Maintenance PFS,2021-09-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Change from Baseline in Mutation Status of Selected Genes tested by Next-Generation Sequencing during Treatment Period,Overall Survival
9084,NCT02785783,Number of polyps per patient,2016-05-13,COMPLETED,INTERVENTIONAL,['NA'],,
9085,NCT03852693,Frequency of distant metastases in aNET measuring 1-2 cm,2020-10-01,COMPLETED,OBSERVATIONAL,['NA'],,Long-term survival after complete resection of aNET measuring 1 - 2 cm with or without oncological right-sided hemicolectomy
9086,NCT03311750,Evaluation of overall response rate of the addition of panitumumab rechallenge to standard third-line therapy,2018-03-26,TERMINATED,INTERVENTIONAL,['PHASE2'],,Mutations analysis on platelet-resorbed tumour RNA (with Real-time PCR) in exon 20 of PIK3CA gene mutations
9087,NCT03694600,Independent performance measure of sensitivity and specificity of a multi-analyte blood test vs Ultrasound,2019-02-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,To compare the performance (sensitivity and specificity) of ultrasound alone to the multi-analyte Test alone for the detection of liver cancer lesions that are ≤ 2cm in diameter.
9088,NCT01959087,Length of postoperative hospital stay,2014-01-27,COMPLETED,INTERVENTIONAL,['NA'],,Post-operative quality of life
9089,NCT00436241,Overall response rate,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,"AEs, laboratory parameters."
9090,NCT03257033,Overall Survival,2018-03-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"Safety, defined as adverse event rate, and tolerability, defined as occurrence of treatment discontinuation"
9091,NCT00881504,Progression-free Survival,2009-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Safety and Toxicity
9092,NCT00890305,The primary endpoint will be the median progression free survival in patients treated with CT-011 plus FOLFOX compared to that of patients treated with FOLFOX alone.,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumor and immunological markers.
9093,NCT03471052,Change in surface area of residual inlet patch post ablation,2018-03-06,UNKNOWN,INTERVENTIONAL,['NA'],,"Symptomatic response for cough, hoarseness and sore throat using Visual Analogue Scale (VAS)"
9094,NCT01926743,To compare the number of retrieved lymph node in each nodal station after additional application of near infra-red fluorescence imaging,2013-08-01,COMPLETED,INTERVENTIONAL,['NA'],,
9095,NCT05654896,Liver abscess and intervention,2022-11-26,RECRUITING,INTERVENTIONAL,['PHASE3'],,
9096,NCT00104689,Efficacy in terms of stabilization or improvement by 1 point on Katz's Activities of Daily Living scale,2003-06-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,Pharmacokinetics
9097,NCT02325739,Overall Response Rate (ORR) Based on Local Assessment: Group 3 (Phase II Only),2014-12-29,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,T1/2 of FGF401: Phase I
9098,NCT05030870,The incidence of hypoxia,2021-09-01,COMPLETED,INTERVENTIONAL,['NA'],,The incidence of other adverse events
9099,NCT01456923,,na,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9100,NCT00213486,clinical complete response defined as no tumor detectable on esophagus endoscopy and no appearance of distant metastasis on CT scan,2002-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,overall survival rate at one and two years
9101,NCT02678013,Recurrence-free survival,2016-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0
9102,NCT02247336,Number of Patients With Provider Referral for Risk-appropriate Colorectal Cancer Screening,2017-08-01,COMPLETED,INTERVENTIONAL,['NA'],,Number of Patients Who Received Referral for Genetic Consultation
9103,NCT00003544,,1998-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9104,NCT03640572,Overall survival (OS),2007-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Systemic recurrence
9105,NCT03723304,Tumour-specific liver transplant failure rate,2018-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
9106,NCT05248048,Maximal Tolerable Dose#MTD#,2021-09-13,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Antitumor efficacy-Overall survival (OS)
9107,NCT05267080,Local Tumour Control,2023-01-25,RECRUITING,OBSERVATIONAL,['NA'],,Economic aspects
9108,NCT00265824,Progression-free survival during maintenance therapy,2005-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,
9109,NCT05965531,Objective response rate,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
9110,NCT05927584,Success rate,2024-02-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Radical rescue surgery specimen quality
9111,NCT02866019,Proportion of participants without stenosis until 8 weeks after endoscopic submucosal dissection (ESD),2016-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,QOL assessed by the EORTC QLQ-OG 25
9112,NCT00005629,Safety,1999-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Survival
9113,NCT03716089,3-year disease free survival rate,2018-10-11,RECRUITING,OBSERVATIONAL,['NA'],,The variation of C-reactive protein
9114,NCT04224402,Regression Free Survival,2020-01-31,COMPLETED,INTERVENTIONAL,['PHASE2'],EORTC Quality of Life Questionnaire(QLQ)-C30,Overall Survival
9115,NCT00485316,Overall survival and disease-free survival,1993-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Direct cost
9116,NCT05084456,The hematological and non-hematological toxicity profile of oral docetaxel in combination with ritonavir,2017-07,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
9117,NCT01046864,"Safety-Toxicity, evaluated according to NCI Common Terminology Criteria for Adverse Events v3.0. Assessments based on medical review of adverse events, results of vital signs, ECGs, echocardiography, physical examinations, and clinical laboratory tests",2010-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Exploratory Measures (Biomarkers for Predictive Analysis): Potential predictive markers, including activity of FGF, VEGF and related pathways as well as K-RAS mutation status, will be evaluated based on blood or tumor samples"
9118,NCT01585428,Number of Participants With an Objective Clinical Response,2012-04-13,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Serious and Non-serious Adverse Events
9119,NCT01005875,Determine the Safety and Tolerability of Sequential SBRT and Sorafenib in Patients With Unresectable Hepatocellular Carcinoma,2009-11,TERMINATED,INTERVENTIONAL,['NA'],,The Degree of Change in Necrosis and Vascular Permeability Via Dynamic Contrast Enhanced (DCE) and Diffusion-weighted Imaging (DWI) Magnetic Resonance Imaging (MRI) as Measured by ADC (Apparent Diffusion Coefficient).
9120,NCT01640405,Progression free survival (PFS),2012-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Correlation of molecular status of bio markers related to the cellular and tumoral reproduction and/or mode of action and clinical anti-tumour activity outcome ( PFS, OS, RR)"
9121,NCT04272619,Change in intentions about communicating with healthcare provider - liver cancer risk,2020-02-11,COMPLETED,INTERVENTIONAL,['NA'],,
9122,NCT01786278,The highest improvement of stricture diameter,2013-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Cost analysis,Quality of life
9123,NCT00081549,,na,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
9124,NCT02806648,Activity of palbociclib (PD0332991) considering objective response rate,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Positive expression of tumor biomarkers (Cdk4, Cdk6, fosfo-Rb1, D1 cyclin, p53, Ki67)"
9125,NCT03330964,Levi sensory nerve toxicity classification standard,2017-09-01,UNKNOWN,INTERVENTIONAL,['NA'],National Cancer Institute(NCI)Common Toxicity Criteria,The quality of life questionnaire(QLQ)-C30
9126,NCT05916846,Assess the efficacy of EUS-RFA post-procedure after one year,2023-04-24,RECRUITING,INTERVENTIONAL,['NA'],,Assess the long-term response to EUS-RFA for efficacy of significant and durable ablation response
9127,NCT05133544,Adenoma detection rate,2022-05-01,RECRUITING,INTERVENTIONAL,['NA'],,Total number of polyp or adenoma per patient.
9128,NCT03172884,Area Under the Concentration-time Curve of Copanlisib in Plasma Over the Time Interval From 0 to 168 h.,2017-06-14,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Subjects With Treatment-emergent Adverse Events (TEAEs) in Different Severity.
9129,NCT03823144,"4. Tumor blood flow (velocity, mm/sec)",2019-02-28,COMPLETED,INTERVENTIONAL,['NA'],,Post-operative correlation of the microscopic observation of the tumor microvasculature tumor-specific and overall survival.
9130,NCT01494012,The rate of grade 3 or greater non-hematologic acute toxicity as graded by the CTCAE v. 4.0,2012-04,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall survival
9131,NCT02016391,Patient Satisfaction With Sedation Technique,2013-12,COMPLETED,INTERVENTIONAL,['PHASE4'],,Maximal pain intensity
9132,NCT02312284,Distant metastasis free survival,2011-01,COMPLETED,OBSERVATIONAL,['NA'],,Surgery complication
9133,NCT03475615,overall survival,2018-03-16,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
9134,NCT06153394,Number pf participants with hypercoagulability identified via TEG testing,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Disease Free Survival
9135,NCT01540461,Accumulation index calculated as the ratio: AUC(TAU) at steady-state (Day 8) divided by AUC(TAU) after the first dose (Day 1) [AI] of Brivanib,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Preliminary evidence of anti-tumor activity as measured by objective response rate (ORR) and disease control rate (DCR) in Chinese subjects with advanced HCC treated with Brivanib
9136,NCT06126419,Liver regeneration improvement after high-dose insulin therapy after LVD measured CT volumetry,2023-11-08,RECRUITING,INTERVENTIONAL,['NA'],,
9137,NCT00052962,Progression Free Survival,2003-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With an Adverse Event
9138,NCT00496678,"To develop, implement, and evaluate a primary care-based, patient navigation program using specially-trained community health workers. We will investigate the effect of this intervention on timing and quality of cancer-related care.",2007-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,"Secondary aims examine the impact of navigation on disparities in care, improvement in patient activation and total costs."
9139,NCT03009747,Risk factors of bowel dysfunction after sphincter-preserving surgery,2017-01,UNKNOWN,OBSERVATIONAL,['NA'],,Incidence of bowel dysfunction after sphincter-preserving surgery
9140,NCT00287976,Best overall response (complete response and partial response),2003-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Surgical resection (complete or incomplete)
9141,NCT04163068,Treatment burden,2020-01-08,COMPLETED,OBSERVATIONAL,['NA'],,
9142,NCT00032110,Objective response or disease stabilization,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Molecular changes with therapy
9143,NCT05409482,Progression-free survival（PFS）,2022-08-20,RECRUITING,OBSERVATIONAL,['NA'],,Occurence of AE and SAE
9144,NCT02023593,Disease control rate,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression free survival
9145,NCT00810719,Progression Free Survival,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
9146,NCT00003557,Objective Response Rate,1999-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9147,NCT01646554,Progression free survival,2012-12,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Safety
9148,NCT03242187,Number of lymph nodes retrieved,2017-05-25,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Functional outcome
9149,NCT01650766,,2012-02,UNKNOWN,OBSERVATIONAL,['NA'],,
9150,NCT03370198,The occurrence of DLTs until 14 days after the last NKR-2 study treatment administration (Visit Day 43),2017-10-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,The overall survival (OS).
9151,NCT04862260,Characterization of dose-limiting toxicities,2021-10-04,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],To explore the feasibility of a larger multicenter trial,CD36 (Cluster of Differentiation 36) changes in response to the multipathway cholesterol embargo
9152,NCT06244537,Pathological complete response (pCR),2024-02-29,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
9153,NCT05160740,3-year disease free survival rate,2021-09-23,RECRUITING,INTERVENTIONAL,['NA'],,Mortality rates
9154,NCT03971201,overall survival,2019-09-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,progression free survival
9155,NCT04725994,Dose Limiting Toxicities (DLTs),2021-06-28,RECRUITING,INTERVENTIONAL,['PHASE1'],,
9156,NCT00556413,Complete response rate,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Survival
9157,NCT01065688,the postoperative quality of life (QOL),2009-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,"the incidence of postoperative complications, nutritional status, and the incidence of the remnant gastritis and the reflux esophagitis"
9158,NCT00653484,Physical activity-energy expenditure,2008-03,COMPLETED,INTERVENTIONAL,['NA'],,Body weight and composition
9159,NCT01904656,Rates of colorectal cancer screening-within-guidelines (status obtained by medical record review).,2009-09,COMPLETED,INTERVENTIONAL,['NA'],,Effect Modification
9160,NCT00940563,tumor response /RecIST criteria),2002-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,"which early predictive factors of tumor response may be of relevance, i.e. conventional pathologic characteristics of tumor and radiological aspects."
9161,NCT00877045,,2008-01,COMPLETED,OBSERVATIONAL,['NA'],,
9162,NCT04959448,Baseline Disease Characteristics,2021-08-12,RECRUITING,OBSERVATIONAL,['NA'],,Physician Assessment: Global Impression for Disease Severity (Global Physician Assessment)
9163,NCT00602329,"Analysis of tumor blood flow, assessed by DCE-MRI as percentage change in Ktrans, after 2 courses of FOLFOX and bevacizumab or FOLFOX alone compared to baseline value",2006-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Correlation of markers of apoptosis in tumor cells with response to therapy, time to progression, and overall survival"
9164,NCT00189566,Progression-free survival of patients in the three groups,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life
9165,NCT01215565,Objective response,2009-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Biomarkers of radiological response
9166,NCT00671996,Neutropenia,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life
9167,NCT04653701,Technical success,2020-11-14,UNKNOWN,OBSERVATIONAL,['NA'],,
9168,NCT06220045,Incidence of surgical wound infection,2024-01-15,RECRUITING,INTERVENTIONAL,['NA'],,Morbidity and mortality rates
9169,NCT00335816,Effect of different chemoradiation-to-surgery intervals on postoperative complications,2008-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
9170,NCT05407272,"the knowledge, attitudes, service intentions and service start-up effects of the eight major non-cancer disease end-stage caregivers on well-being and palliative care",2021-09-14,COMPLETED,INTERVENTIONAL,['NA'],,
9171,NCT00967291,Progression-free survival at 6 months,2006-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall survival
9172,NCT05281159,Opening link within SMS Text message,2022-02-21,COMPLETED,INTERVENTIONAL,['NA'],,Overall completion of any CRC screening test
9173,NCT00088894,Grade 3-4 neutropenia in terms of specific single-nucleotide polymorphisms (SNPs) and/or copy number variations that are associated with the prevalence of these events (Clinical endpoint),2004-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,OS (Clinical endpoint)
9174,NCT00901732,The primary objective is to estimate ht incidence of OM in H&N cancer patients undergoing radiation therapy with or without chemotherapy and/or sensitizer who receive Caphosol.,2009-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"The secondary objective of this study is to correlate components of OM data with clinical outcomes (pain, narcotic use, oral intake)"
9175,NCT05004376,Screening,2022-01-03,COMPLETED,INTERVENTIONAL,['NA'],,Phone Interview for refinement of Intervention
9176,NCT02903498,Progression Free Survival (PFS),2009-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants with Adverse Events
9177,NCT01437514,local recurrence,2011-08,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,short-term complication of the surgery
9178,NCT04046601,impedance,2019-10-09,COMPLETED,INTERVENTIONAL,['NA'],,differences in impedance
9179,NCT04837833,measurement differences between ultrasound tumor volumes,2021-04-06,RECRUITING,INTERVENTIONAL,['NA'],,
9180,NCT02545751,The proportion of patients with tumor responses after the initiation of treatment.,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"The proportion of patients alive with tumor responses from the date of enrollment until date of death from any cause, assessed up to 2 years from the opening of the study."
9181,NCT05497778,"National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0",2022-10-21,RECRUITING,INTERVENTIONAL,['PHASE1'],,
9182,NCT01590719,Progression-free survival (PFS) in patients with Met-positive tumors,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of response (DOR)
9183,NCT00082862,Changes in quality of life,2002-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Changes in cellular and cytokine immune function
9184,NCT04034355,Moderate or Severe Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN),2019-01-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,Patients With Disease Free Survival
9185,NCT02413476,Five-year disease free survival rate,2015-05,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"Intraoperative situation (The number of lymph node dissection,the number of positive lymph nodes,extra-cavity anastomosis time,intraoperative blood loss,the rate of conversion)"
9186,NCT05963087,Objective response rate (ORR),2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Overall survival time
9187,NCT04216251,Change in the Marine Omega-3 Polyunsaturated Fatty Acid (MO3PUFA) Composition in Colorectal Tissues as a Result of the AMR101 Treatment.,2020-12-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change in Stool Metabolite Profile
9188,NCT00575640,The study design calls for an initial phase of dose-escalation in cohorts of 3 patients. There are no intra-patient changes in dose.,2004-11,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Subsequent to this Phase I scheme, the study will continue with the selected dose-level (on toxicity and tolerability grounds) to accrue patients in a phase II scheme."
9189,NCT00276705,Event-free and overall survival following tumor resection,2005-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Efficacy and tolerability following course 2 and 4 of pre-operative chemotherapy
9190,NCT00003926,,1998-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,
9191,NCT04491929,Feasibility and translational analysis,2020-11-01,RECRUITING,OBSERVATIONAL,['NA'],,Overall Survival
9192,NCT00851045,Progression free survival based on tumor assessments (CT/MRI),2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Safety in the CT-322 plus irinotecan, 5-FU and leucovorin arm as measured by incidence of serious and non-serious adverse events, significant laboratory evaluations and significant physical examination findings in subjects"
9193,NCT00606619,Days of hospital stay after operation,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Postoperative morbidity rate in hospital days: Clinically definite morbidity confirmed by physicians according to offered protocol
9194,NCT05265754,Sujok Therapy's positive cahange in nausea and vomiting Experienced by Patients with Gastrointestinal System Cancer,2022-02-01,COMPLETED,INTERVENTIONAL,['NA'],,
9195,NCT04160962,EORTC Questionnaire QLQ-C30,2020-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
9196,NCT03264898,FIT Result,2017-10-02,UNKNOWN,OBSERVATIONAL,['NA'],,
9197,NCT01640808,Recurrence-free Survival,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time to Recurrence
9198,NCT00081094,Relative sensitivity and specificity of positron emission tomography (PET) scanning with carbon-11 acetate and fludeoxyglucose F 18,2003-09,COMPLETED,INTERVENTIONAL,['NA'],,Obtain a preliminary estimate of the impact of PET on management of patients with HCC.
9199,NCT00467116,Maximum Tolerated Dose,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumor response rate
9200,NCT01375972,Progression-free survival rate at 6 months,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,overall survival
9201,NCT03515356,Sensory neuropathy at 8 weeks,2018-06-13,COMPLETED,INTERVENTIONAL,['NA'],MI Fidelity Measure at 9 months,Mood at 8 weeks
9202,NCT00044031,Survival,2001-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants with Serious and Non-Serious Adverse Events
9203,NCT00499486,Severity of Adverse Events as Assessed by NCI CTCAE v3.0,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9204,NCT00855348,Clinical/surgical diagnosis of invasive colorectal adenocarcinoma detected by optical colonoscopy and confirmed by histology compared to the Septin 9 Biomarker classification.,2008-06,COMPLETED,OBSERVATIONAL,['NA'],,"Detection of adenomatous polyp(s) equal to or greater than 10 mm, flat lesion (s) or non-invasive adenocarcinoma by colonoscopy and confirmed by histology compared to the Septin 9 Biomarker classification will also be described."
9205,NCT06328868,Concentration of Serum prealbumin,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Feeding amount
9206,NCT03621644,Gastrointestinal toxicity assessed using Common Terminology Criteria for Adverse Events (CTCAE) v5,2019-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Patient-reported quality of life (QOL)
9207,NCT04795869,Overall objective response rate (ORR),2020-03-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Overall survival
9208,NCT01679340,replase free survival,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of Participants with Adverse Events as a Measure of Safety and Tolerability
9209,NCT03193710,Cancer free survival,2017-09-01,UNKNOWN,OBSERVATIONAL,['NA'],Days of hospitalization,Colorectal cancer antibodies
9210,NCT02048540,R0 resection rate,2009-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",circulating tumor cell number change,safety of peroperative treatment and surgery
9211,NCT01582750,Endoscopic ultrasound measurement of the primary tumor maximum diameter changes in absolute / relative values,2010-10,UNKNOWN,OBSERVATIONAL,['NA'],,
9212,NCT02510911,Time to first bowel movement,2015-08,TERMINATED,INTERVENTIONAL,['NA'],preoperative caffeine consumption,Consumption of sleep inducing drugs
9213,NCT05287672,Weight gain by BMI by kg/m2,2022-06,UNKNOWN,OBSERVATIONAL,['NA'],,
9214,NCT03479814,complete pathological response (pCR),2016-08-01,UNKNOWN,INTERVENTIONAL,['NA'],,Evaluation of PET-response as predictive factor
9215,NCT01249352,Overall survival and assessment of the complete endoscopic response,2009-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Complete clinical response rate
9216,NCT00318604,,na,UNKNOWN,OBSERVATIONAL,['NA'],,
9217,NCT00628810,Tolerability evaluated by NCI CTC v. 2.0 criteria,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life using the EuroQOL EQ5D questionnaire
9218,NCT03917017,Postoperative survival,2019-01-01,RECRUITING,INTERVENTIONAL,['NA'],Intraoperative blood loss,Disease-free survival
9219,NCT01301495,Palliation assessment based on Dysphagia Scores,2010-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Assessment of Complications and MD Anderson Dysphagia Score
9220,NCT05237921,Number of participants that adhere to a Combined Exercise and Dietary Intervention (CEDI),2018-06-15,COMPLETED,INTERVENTIONAL,['NA'],,Number of participants that meet estimated dietary intake and exercise goals
9221,NCT01183559,Maximum Tolerated Dose of Vandetanib,2008-08-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,The Number of Participants With Adverse Events
9222,NCT06031480,"Objective response rate (ORR, RECIST v1.1)",2023-10-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
9223,NCT05898854,Patient management,2024-02-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Prognostic value
9224,NCT05056714,Develop a severity score for PNS using latent variable modeling: Polyps Severity Index (PSI),2022-01-27,RECRUITING,OBSERVATIONAL,['NA'],,
9225,NCT04842565,Progression-free survival time (mPFS) (mRECIST),2021-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Time to Progression (TTP)
9226,NCT05568420,genomic analysis of tissue,2022-09-30,RECRUITING,OBSERVATIONAL,['NA'],,
9227,NCT05982301,"Progression-Free survival 2, PFS2",2023-02-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,After Effects
9228,NCT04506138,Major Pathologic Response (MPR),2020-08-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",FACT-E questionnaire,Event Free Survival（EFS）
9229,NCT03257332,Global health status/quality of life: EORTC QLQ-C30,2019-11-12,WITHDRAWN,OBSERVATIONAL,['NA'],Physical performance,Low anterior resection syndrome
9230,NCT01196260,To determine prognosis of patients with metastatic colorectal cancer received the combination of drugs,2004-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,To evaluate the time to progression of metastatic colorectal cancer after treatment
9231,NCT01697371,Phase I of study: Number of participants with adverse events as a measure of safety and tolerability,2012-08-22,RECRUITING,INTERVENTIONAL,['NA'],,Phase II -local control within irradiated fields at 2 years
9232,NCT02997228,Progression free survival (PFS),2018-01-19,RECRUITING,INTERVENTIONAL,['PHASE3'],Mechanism of immune resistance to PD-1 blockade in mismatch repair deficient (dMMR)/microsatellite instability-high metastatic colorectal cancer (mCRC) by comparative analysis of tumor samples collected,Duration of SD
9233,NCT00525005,overall response rate,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,"safety, progression-free survival, and overall survival"
9234,NCT00969046,To identifymaximum tolerated dose (MTD),2003-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To evaluate the blood concentrations profile (pharmacokinetics [PK]) of patupilone by multiple blood sampling before, during and after drug administration"
9235,NCT01286818,Number of Participants With Ramucirumab Drug-Related Adverse Events or Serious Adverse Events,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Best Overall Response [Anti-Tumor Activity of FOLFIRI Plus Ramucirumab (IMC-1121B)]
9236,NCT02460991,Overall Survival,2015-11,TERMINATED,INTERVENTIONAL,['PHASE3'],FACT-Hep Quality of Life,Frequency of Treatment Emergent Adverse Events
9237,NCT00288119,Assay of DNA and RNA markers,2005-10-01,RECRUITING,OBSERVATIONAL,['NA'],,Score of tolerability and acceptability
9238,NCT01837446,Mucositis severity,2011-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Patient's satisfaction
9239,NCT00920192,Safety and tolerability of foretinib at the MTD as measured by number and severity of AEs,2009-08-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,PK profile of foretinib
9240,NCT06105203,intersphincteric resection (ISR),2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,3-year defecation function
9241,NCT00381173,"Determine the feasibility, safety and tolerability of administering ZYC300 intramuscularly every other wk for 6 doses (400 micrograms DNA/total dose) to the study pop. pre-dosed with 600 mg/m^2 cyclophosphamide intravenously 3 days prior to study drug.",2006-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Assess the effect of cyclophosphamide on T reg number and function. Assess the generation of CYP1B1-specific immun. as a result of vac. regimen. Assess the effect of vac. regimen on tumor response, if any, in pat. pop."
9242,NCT05988814,Progression-free survival (PFS),2024-01-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life (QoL)
9243,NCT00226746,One-year overall survival rate,2003-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Occurrence of pathological response or shrinkage of the tumor (becomes resectable)
9244,NCT04409223,Progression-free survival (PFS),2020-09-12,TERMINATED,INTERVENTIONAL,['PHASE3'],,Adverse Events and Serious Adverse Events
9245,NCT04524676,1-year rebleeding rate,2020-08-31,UNKNOWN,INTERVENTIONAL,['NA'],,Complications of portal hypertension
9246,NCT05921942,Progression free survival,2020-04-15,COMPLETED,INTERVENTIONAL,['PHASE3'],,Common terminology criteria adverse events (CTCAE 4.0)
9247,NCT03559543,Nutritional status,2018-10-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9248,NCT04165031,Phase 2: Progression-Free Survival (PFS) Non-Small Lung Cancer (NSCLC Cohorts),2019-11-28,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Phase 1: Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of CR, PR, and SD"
9249,NCT05731726,Pathological complete response rates,2023-02-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,single cell sequence
9250,NCT05353582,Progression free survival,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Hospitalization time
9251,NCT02272699,Disease-free survival,2014-11,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Numbers of adverse events and the degree of each adverse events according to the NCI CTCAE 4.0 criteria.
9252,NCT02585362,Change in physical performance,2016-03,COMPLETED,INTERVENTIONAL,['NA'],,Overall survival
9253,NCT05980416,Number of patients with clinically significant changes in laboratory tests,2023-08-10,RECRUITING,INTERVENTIONAL,['PHASE1'],,
9254,NCT03383159,Differences In Microbiota,2016-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,Predictive model validation
9255,NCT00860691,"Fe, transferrin, ferritin",2008-01,UNKNOWN,INTERVENTIONAL,['NA'],,"loss of blood during the surgery, postoperative hospital stay, morbidity, and mortality within 30 days after surgery"
9256,NCT01282333,Maximum-tolerated dose of veliparib in combination with cisplatin and gemcitabine,2011-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,Recommended phase II dose
9257,NCT03777462,Overall time,2019-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease free time
9258,NCT05249114,Establish the maximal tolerated dose of cabozantinib in combination with Lu-177 dotatae at a standard dose of 7.4 GBg in four 8-week cycles followed by continuation of cabozantinib.,2022-12-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Establish objective response rate as measured by RECIST 1.1
9259,NCT02555358,The pathological complete response rate,2014-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse events
9260,NCT03061370,Survival,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
9261,NCT01566942,disease-free survival（DFS）,2012-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,overall survival(OS)
9262,NCT03747588,Intra-abdominal infection,2018-12-01,RECRUITING,INTERVENTIONAL,['NA'],progression-free survival,Length of hospital stay (day)
9263,NCT05357196,To obtain best disease control rate (DCR) data(Phase II),2020-04-13,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Area under the plasma concentration versus time curve (AUC)
9264,NCT05404347,Overall Survival,2018-01-01,RECRUITING,OBSERVATIONAL,['NA'],,RFS
9265,NCT05184803,Evaluation of R0 resection rate in patients who underwent prior chemotherapy as a clinical trial.,2022-03-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,
9266,NCT04416490,Overall Survival (OS),2020-03-25,RECRUITING,OBSERVATIONAL,['NA'],Results on blood pressure,Quality of Life Assessment (FACT/GOG-NTX-12)
9267,NCT03568669,Neurocognitive Outcomes,2016-01,RECRUITING,OBSERVATIONAL,['NA'],,Neourcognitive Outcomes
9268,NCT00131586,,2003-04,TERMINATED,OBSERVATIONAL,['NA'],,
9269,NCT01277406,Phase II: Progression free survival (PFS),2011-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Phase II: Pharmacokinetics: AUClast, AUCtau, cmax, tmax, t ½, CL/F of resminostat, Irinotecan (SN-38), 5-FU and folinic acid"
9270,NCT04645251,Map the natural course of PLD,2021-01-21,RECRUITING,OBSERVATIONAL,['NA'],,Determine whether rate of liver growth can be used to predict disease progression
9271,NCT00963092,"Creation of repository of blood, saliva, and tumor samples",2002-08,UNKNOWN,OBSERVATIONAL,['NA'],,
9272,NCT02969122,Overall survival,2016-11,UNKNOWN,INTERVENTIONAL,['NA'],,morbidity and mortality of HIPEC and EIPL
9273,NCT05379972,Objective Response Rate (ORR) of unirradiated tumors,2023-01-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0 during concurrent SBRT/olaparib
9274,NCT02026583,Progression free survival,2013-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9275,NCT01853618,Number of Participants With Serious and Non-Serious Adverse Events Regardless of Attribution,2013-05-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
9276,NCT05093907,Objective Response Rate(ORR)(Phase 2) assessed by investigator following administration of BEY1107 in combination with Capecitabine,2021-08-31,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease control rate(DCR) assessed by investigator following administration of BEY1107 in combination with Capecitabine
9277,NCT00001276,Treatment Outcomes,1991-05-21,RECRUITING,OBSERVATIONAL,['NA'],,
9278,NCT05547919,Number of patients with identified tumor lesion sites,2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],,PSMA uptake on 18F-PSMA-1007 PET
9279,NCT03817411,ORR,2019-01-25,UNKNOWN,INTERVENTIONAL,['PHASE2'],,DCR
9280,NCT05664139,Objective tumor response rate (ORR),2023-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],"Changes of CD4+ cells count, CD8+ cells count, Th1 cells count, Th2 cells count, Treg cells count in peripheral blood",Adverse event collection
9281,NCT04739722,Colosense specificity for subjects with negative findings,2021-04-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
9282,NCT00137449,Number of Participants With Clinical Benefit Response (CBR) According to RECIST,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Score of EQ-5D (Euro Quality of Life-5 Dimension) Weighted Health Index
9283,NCT00419978,,2004-06,TERMINATED,INTERVENTIONAL,['NA'],,
9284,NCT05839951,Cohort R-T or Cohort T-R: Descriptive analysis of biomarker Kirsten rat sarcoma 2 viral oncogene homolog (KRAS),2023-04-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Cohort R-T or Cohort T-R: Overall survival of patients with Regorafenib followed by TAS-102 and vice versa in 3rd line treatment and 4th line treatment
9285,NCT06241066,DFS,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
9286,NCT00609505,Patient satisfaction,2008-08,COMPLETED,INTERVENTIONAL,['NA'],,Cost-effectiveness
9287,NCT01856322,Difference in Circulating S100A4 Transcript in Patients Receiving Sulindac 150 mg BD (Twice Daily) by Mouth Following Resection of Colorectal Cancer Metastases Compared to Those Who do Not.,2013-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,
9288,NCT04700410,Boston Bowel Preparation scale (BBPS)-score after cleaning with the Pure-Vu system.,2021-06-01,COMPLETED,INTERVENTIONAL,['NA'],,Number of adverse events after study intervention
9289,NCT02985034,Local tumor progression (LTP),2010-10,COMPLETED,OBSERVATIONAL,['NA'],,immediate technical success on registration-software assessment
9290,NCT04810663,Efficacy of Radiotherapy in operated gastric cancer,2021-04-01,UNKNOWN,OBSERVATIONAL,['NA'],,
9291,NCT01434485,Number of Adverse Drug Reactions,2011-09,COMPLETED,OBSERVATIONAL,['NA'],,
9292,NCT06262581,pathological complete regression rate,2023-09-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease free survival
9293,NCT03930888,Progression of the self sufficiency,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Effect of tumor localization
9294,NCT05051423,"Correlations with statistical significance between time-intensity curve analysis parameters, immunohistochemical markers of angiogenesis and clinico-pathological parameters.",2019-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,
9295,NCT01066741,Rate of occurrence of grade ≥ 3 (RTOG classification) mucositis during irradiation (only the first occurrence will be reported),2009-05,TERMINATED,INTERVENTIONAL,['PHASE3'],,Evaluation of the cost of severe mucositis treatment
9296,NCT02967094,"""Visibility score"" evaluated by blinded performing endoscopist",2016-11,UNKNOWN,INTERVENTIONAL,['NA'],,Duration of endoscopy
9297,NCT04641637,The completeness of coverage of the tumor vasculature by therapeutic agent at the completion of the treatment as evaluated on non-contrast CT scan,2022-06-30,COMPLETED,INTERVENTIONAL,['NA'],,Tumor response
9298,NCT01522573,Safety,2011-11,UNKNOWN,OBSERVATIONAL,['NA'],,Survival duration
9299,NCT02375672,Median Progression Free Survival (mPFS),2015-05-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Grade 3 or Higher Treatment Related Adverse Event
9300,NCT02646241,diagnostic accuracy,2016-01-02,COMPLETED,INTERVENTIONAL,['NA'],,accuracy of malignant potential on contrast enhanced EUS
9301,NCT00689624,Objective Response Rate,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Q-Twist analysis of Quality of life
9302,NCT05208372,Expression of ctDNA,2022-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
9303,NCT02525952,overall survival,2015-10,UNKNOWN,INTERVENTIONAL,['NA'],,Time to recurrence
9304,NCT04224896,SPECIFICITY OF THE TWO DIAGNOSTIC STRATEGIES,2011-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
9305,NCT05981235,"Changes from baseline in vital signs, laboratory parameters, physical examination, and 12-lead ECG.",2023-12-14,RECRUITING,INTERVENTIONAL,['PHASE1'],,PFS
9306,NCT01304602,Maximum tolerated dose,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Biological half life of BKM120
9307,NCT01927328,Hemoglobin differences between groups,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Differences in hematinic markers.
9308,NCT06172647,Proportion and abundance of bacterial taxa (defined as total percentage of bacterial DNA sequences),2022-06-01,RECRUITING,OBSERVATIONAL,['NA'],,
9309,NCT04694404,PFS,2016-05-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The number of participants with treatment-related adverse events as assessed by CTCAE v4.0
9310,NCT00355004,Rate of colorectal cancer screening,2005-03,COMPLETED,INTERVENTIONAL,['NA'],,Number and dates of sigmoidoscopies and colonoscopies scheduled and performed
9311,NCT02572050,Number of retrieved lymph nodes in the topographical N2 area,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life
9312,NCT02488577,Overall percent of postoperative complications.,2015-06,UNKNOWN,INTERVENTIONAL,['NA'],,Recurrence.
9313,NCT01582841,Implementation effectiveness,2012-02,COMPLETED,INTERVENTIONAL,['NA'],,
9314,NCT00027534,Safety,2002-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Immune response
9315,NCT04929587,Frailty assessed by Frailty Phenotype (FP),2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Sleep assessed by Pittsburgh Sleep Quality Index (PSQI)
9316,NCT02650427,Safety (Number of adverse events. Toxicity grade > 3),2016-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Infiltration of leucocytes in tumor tissue
9317,NCT02967289,Disease Free Survival (DFS),2017-03-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
9318,NCT01218854,The difference between MD-NASS and standard method,2012-03-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9319,NCT05872828,Depression score,2023-04-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Immune variables 8
9320,NCT01315548,Contrast enhanced harmonic endoscopic ultrasound,2011-03,COMPLETED,OBSERVATIONAL,['NA'],,
9321,NCT03780439,diagnostic accuracy of procalcitonin to detect post-operative infection,2018-06-01,COMPLETED,OBSERVATIONAL,['NA'],,diagnostic accuracy of procalcitonin to detect overall post-operative complications
9322,NCT02045030,A biomarker (in blood or tissue) that may be predictive of level of response to aflibercept,2014-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,The quality of life impact of treating with FOLFIRI in combination with Aflibercept
9323,NCT03620461,Assess adverse events (per CTCAE v4.0 criteria),2013-12-01,COMPLETED,OBSERVATIONAL,['NA'],,
9324,NCT05957367,Objective response rate (ORR) (Expansion Phase),2023-09-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Area under the concentration-time curve (AUC)
9325,NCT00747136,"Determine sensitivity/specificity to identify dysplasia/cancer in the esophagus WavSTAT System alone, endoscopist alone/combination of WavSTAT and endoscopist. Sensitivity of the endoscopist will be compared to combination of endoscopist and WavSTAT.",2008-08,TERMINATED,OBSERVATIONAL,['NA'],,
9326,NCT02325999,DFS,2013-12,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,
9327,NCT02465736,Toxicities of neo-adjuvant chemoradiotherapy,2015-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Health Related Quality of Life
9328,NCT00002828,,1995-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9329,NCT06275165,Change from Baseline in gastrointestinal symptom distress Scale at study day 5(end day),2024-03-27,RECRUITING,INTERVENTIONAL,['NA'],,
9330,NCT04515082,"Sensitivity, specificity, positive predictive value and negative predictive value of bi-target stool DNA testing (the methylation status of SDC2 and SFRP2) with comparison to colonoscopy, both with respect to cancer and advanced precancerous neoplasm.",2020-08,UNKNOWN,OBSERVATIONAL,['NA'],,"To compare the performance of the bi-target stool DNA testing to a commercially available FIT assay, both with respect to cancer and advanced precancerous neoplasm."
9331,NCT01306799,Volumetric bone mineral density as measured by pQCT,2010-01,COMPLETED,OBSERVATIONAL,['NA'],,measure vitamin B12 levels at each study visit
9332,NCT02873195,Progression Free Survival (PFS),2017-07-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,The Number of Participants Who Experienced at Least One Grade 3 or Higher Adverse Event Deemed at Least Possibly Related to Treatment (Toxicity)
9333,NCT02347735,Anastomotic leakage,2015-08,COMPLETED,OBSERVATIONAL,['NA'],,
9334,NCT05894694,PFS,2023-06-11,RECRUITING,INTERVENTIONAL,['PHASE4'],,1-year PFS rate
9335,NCT00780988,To assess the feasibility of using an autologous tumor cell vaccine in combination with standard chemotherapy followed by investigational autologous hematopoietic and immune cell rescue in terms of acceptable clinical toxicity.,na,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Ex vivo analysis of immune response
9336,NCT04865601,Correlation of DNA adduct and DNA repair products,2021-02-15,RECRUITING,OBSERVATIONAL,['NA'],,Correlation of DNA adducts with CRC causes
9337,NCT02933944,Immunological Activation in Tumour Mass by Assessing Number of Patients With Increased Intra-tumoural Lymphocytes.,2016-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,Changes in the Tumour Marker Carcinoembryonic Antigen (CEA) Throughout Treatment Will be Assessed by Analysis of Blood Samples to Follow the Evolution of Disease Under Treatment
9338,NCT00193882,Relief of dysphagia,2003-07-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time to achieving a complete response i.e. dysphagia score of 0.
9339,NCT05861336,Resectability rate,2023-06-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life questionnaire (QLQ)
9340,NCT01921673,Progression-free survival,2013-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Biomarker
9341,NCT03033719,Global postoperative morbidity in both arms,2017-07-04,UNKNOWN,INTERVENTIONAL,['NA'],To compare our molecular classification with the different classifications already published in the literature on colorectal cance,Timed Get-up-and-go (TGUG)
9342,NCT01596582,Concordance Between Patient Preference and Test Ordered,2012-04,COMPLETED,INTERVENTIONAL,['NA'],Concordance Between Patient Preferences for a Screening Tests Other Than Colonoscopy and Test Ordered for High Versus Low Risk Patients,Provider Satisfaction
9343,NCT03817489,"Change of Week 1 Practice Compliance at Week 2 to 7 of intervention, and 6-month post-intervention",2017-01-04,UNKNOWN,INTERVENTIONAL,['NA'],,
9344,NCT03053999,Identification of Somatic Mutations and Inherited Genetic Variants to Help Predict the Development of Pancreatic Neuroendocrine Tumors (PNET) in Participants with Hyperparathyroidism by Genome Sequencing,2012-10-09,UNKNOWN,OBSERVATIONAL,['NA'],,Identification of Somatic Mutations and Inherited Genetic Variants to Help Predict the Development of Pancreatic Neuroendocrine Tumors (PNET) in Participants with Hyperparathyroidism by Data Review
9345,NCT00259922,To compare alvimopan with placebo for efficacy in the treatment of OBD,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Safety and tolerability, quality of life, pharmacogenetics (dependent on results from other data)"
9346,NCT03330028,Dose Limiting Toxicity (DLT) of Paclitaxel via Intraperitoneal Route Combined with Fixed Doses of Mitomycin and Cisplatin during Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC),2017-10-27,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9347,NCT00001165,,1978-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9348,NCT00835133,Collection of familial data and biospecimens in a data and tissue repository for familial pancreas research,2002-08,RECRUITING,OBSERVATIONAL,['NA'],,
9349,NCT05879783,Accuracy of pCLE optical biopsy,2022-09-15,RECRUITING,INTERVENTIONAL,['NA'],,The positive predictive value and negative predictive value of pCLE optical biopsy
9350,NCT04385316,DNA extraction of tumer tissue samples and high-throughput sequencing,2019-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,"DNA extraction of tumer tissue samples, blood tissue and urine samples and high-throughput sequencing"
9351,NCT05053971,Objective response rate (ORR) (Phase II),2022-11-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Non-sequencing biomarker analysis,Progression free survival
9352,NCT05623787,Early peritoneal recurrence,2022-09-01,RECRUITING,INTERVENTIONAL,['NA'],,Early distant recurrence
9353,NCT02021604,Accuracy of PET imaging compared to intraoperative pancreatic biopsy in patients with congenital hyperinsulinism,2013-10-09,RECRUITING,INTERVENTIONAL,['PHASE1'],,Ratio of Standard Uptake Value max to sub max
9354,NCT00256932,to compare alvimopan with placebo for efficacy in the treatment of OBD,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Safety and tolerability, quality of life, pharmacokinetics, pharmacogenetics (dependent on results from other data)"
9355,NCT00282100,To study the changes of selected genetic or protein markers through the treatment and find out whether some of them can be potential biomarkers for disease relapse.,2005-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,To evaluate the effect of gefitinib as an adjuvant therapy on recurrence free survival in patients with resectable hepatocellular carcinoma; to evaluate the treatment toxities of genifitib.
9356,NCT00812942,Participation to colorectal cancer screening,2003-11,COMPLETED,INTERVENTIONAL,['NA'],,
9357,NCT00019591,Response rate every 3 months for up to a year after completion of study treatment,1999-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
9358,NCT00343668,response rate,2005-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,treatment-related toxicities
9359,NCT03425773,Incidence of Serious Adverse Events assessed with CTCAE v4.03,2018-02-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,Change of tumor burden
9360,NCT00105443,Time to Symptomatic Progression (TTSP),2005-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Patients Reported Outcome (PRO) by Use of the FACT-Hep Questionnaire
9361,NCT03984578,Immune T-cell infiltration before and after treatment,2019-06-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Percentage of cell viability and cell death at fixed time points (e.g. 24 or 48 hours)
9362,NCT03278106,16-Week Progression-free Survival (PFS) Rate,2017-10-20,COMPLETED,INTERVENTIONAL,['PHASE2'],Mutation Status of the Tumor,"Overall Toxicity Rates (Percentages) for Grade 3 or Higher Adverse Events Considered at Least Possibly Related to Treatment, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 (v4)"
9363,NCT00149396,Clinical Laboratory Safety - Coagulation,2004-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pharmacodynamic Effects of NV1020: Serum Cytokines (TNF-alpha)
9364,NCT05161572,Pathological complete regression (pCR) rate,2021-09-28,RECRUITING,INTERVENTIONAL,['PHASE2'],To study the influence of preoperative therapy on the tumor immune microenvironment (TIME) and systemic immune status.,Safety of surgery after preoperative therapy include chemo(radio)therapy and PD-1 antibody.
9365,NCT04812054,Model for early graft dysfunction score,2021-04-05,UNKNOWN,INTERVENTIONAL,['NA'],Allograft ATP content,Postoperative complications
9366,NCT03189953,Tumor visualization by 68Ga-NODAGA-exendin-4 PET/CT and standard imaging,2015-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,GLP-1 receptor expression by histology compared to tracer uptake
9367,NCT04241523,Resection rate,2020-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Exploratory serum biomarker research
9368,NCT02292758,6-month and 12-month Progression-free Survival (PFS) Rates,2014-12-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Dynamic Change in Mutation Concentration While the Patient is Receiving Cetuximab Treatment,Relative Dose Intensity (RDI)
9369,NCT03738787,Rate of postoperative mortality,2015-01-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,Variation of Body Mass Index after pancreatoduodenectomy
9370,NCT00101036,Response Rate,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Control Rate.
9371,NCT00785785,Time to Progression Free Survival (PFS),2009-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
9372,NCT00324428,"Pain (visual analog scale, CGI,PGA); Medication use (medication diary)",2006-05,COMPLETED,INTERVENTIONAL,['NA'],,Safety (cognitive assessment - neuropsychological battery)
9373,NCT06289712,Correlate 3D numerical simulations of the IRE electric field with patient imaging follow-up,2023-11-23,RECRUITING,OBSERVATIONAL,['NA'],,Develop software solutions potentially usable in real-time and tailored for clinical use.
9374,NCT06096896,5-years overall survival (OS) after MWA for early HCC,2023-08-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Rate of completed ablation after MWA
9375,NCT05934058,Impact of major gastric cancer risk factors on its aetiology in rarer patients subgroups,2023-07-25,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Development of a genome-wide modelling of Polygenic risk score (PRS) in gastric cancer
9376,NCT02500004,Brown adipose tissue (BAT) activity measured by PET(-MRI),2015-06,COMPLETED,INTERVENTIONAL,['NA'],,"Lean tissue mass measured by MRI, DXA, and doubly labeled water"
9377,NCT06205732,Progression-Free-Survival,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
9378,NCT02135419,Anal Cancer Incidence,2014-09-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Quality of Life Assessment Measured by the A-HRSI (Validated Tool),Change in Physical Symptom Score From Baseline (2-7 Days Post Randomization) Until 4 Weeks Post Randomization
9379,NCT02503631,To provide stool and blood specimens to assess new markers for the detection of CRC,2014-10,TERMINATED,OBSERVATIONAL,['NA'],,To provide quality control material for use in assessing performance of developed assays
9380,NCT05954078,ctDNA clearance rate,2023-07,RECRUITING,INTERVENTIONAL,['PHASE3'],,Treatment Completion Rate
9381,NCT05355155,"Objective Response Rate (ORR) ,Based on RECIST 1.1",2022-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety as measured by number and grade of adverse events
9382,NCT06104579,Rate of Organ-space surgical site infection,2011-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
9383,NCT04389957,Provider Screening Adenoma detection rate (Sceening colonoscopies only),2020-06-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Bowel Preparation Quality (provider level)
9384,NCT02595086,"Incidence of Dumping syndrome, assessed by Sigstad score (≥7)",2015-07,UNKNOWN,INTERVENTIONAL,['NA'],,Gross and microscopic changes measured by gastroscopy (composite)
9385,NCT05657145,Visualization of papilla,2023-01-27,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
9386,NCT05910970,Recurrene-free survival,2024-02-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse events
9387,NCT05421689,Anterior tongue pressure measured from Iowa Oral Performance Instrument (IOPI),2022-05-26,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Patient-reported Quality of Life based on FACT-HN score,Patient-reported dysphagia symptoms based on Eating Assessment Tool EAT10 score
9388,NCT00710710,Best Objective Response Evaluated According to the RECIST Criteria by Independent Review,2006-08-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Incidence and Intensity of Adverse Events Graded According to Common Terminology Criteria for Adverse Events (CTCAE)
9389,NCT01133951,Gastric cancer incidence,2010-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Histopathological changes
9390,NCT04684095,Changes of quality of life (QoL) at 1 year after randomization compared with baseline,2021-05-26,RECRUITING,INTERVENTIONAL,['NA'],Economic assessment for ePRO compared to regular follow-up,Patient satisfaction
9391,NCT06131840,Number of participants with DLTs by dose level,2023-11-20,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
9392,NCT03854799,The primary objective of this trial is to evaluate the rate of complete pathologic response (pCR),2019-04-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Sphincter preservation rate
9393,NCT02406508,Progression free survival in months of patients receiving Melphalan/HDS treatment followed by Sorafenib,2014-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Quality of life questionnaires,
9394,NCT03594630,Time to surgery or death,2024-03-13,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Pathologic Findings
9395,NCT04059731,Postoperative complications,2019-06-20,UNKNOWN,INTERVENTIONAL,['NA'],,Hospital Stay
9396,NCT05233540,Overall survival according to circulating tumour DNA status,2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival according to circulating tumour DNA and immune markers.
9397,NCT00003617,,1995-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
9398,NCT03007407,Overall Objective Response Rate (ORR) of Dual Immune Checkpoint Blockade by RECIST 1.1,2017-07-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Frequency of Adverse Events Assessed by CTCAE 4.0, From Beginning of Treatment to 90 Days After Last Dose"
9399,NCT04823416,Risk Factors for Mortality in cases of obstructed left colonic Carcinoma,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
9400,NCT04457193,Percentage of participants with normal esophageal acid exposure time,2018-06-07,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Change in Gastroesophageal Reflux Disease (GERD) symptoms assessed by the Reflux Symptom Index (RSI)
9401,NCT00605800,To determine qualitatively and quantitatively whether bone marrow derived liver associated stem cells are mobilized from the bone marrow in patients undergoing major liver resections (3 or more liver segments).,2006-03,WITHDRAWN,OBSERVATIONAL,['NA'],,To determine whether a difference exist in the baseline levels of bone marrow derived liver associated stem cells between normal healthy subjects/ volunteers and cancer patients prior to liver surgery.
9402,NCT02345889,Adenomas Per Colonoscopy,2015-02,COMPLETED,INTERVENTIONAL,['NA'],,"Percent of Sessile Serrated Polyps in the Right Side of the Colon, Which Includes the Cecum, Ascending Colon, and Hepatic Flexure."
9403,NCT01149434,Tumor Response in the Ovarian Cancer Cohort,2010-09,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Tumor Response
9404,NCT00182715,Overall survival at 2 years,2005-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Time of disease control at 2 years
9405,NCT03774589,Bilioenteric anastomotic leakage,2019-02-01,UNKNOWN,INTERVENTIONAL,['NA'],,Bilioenteric anastomotic stricture
9406,NCT00182130,Hospital rate of local recurrence,2002-05,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of life
9407,NCT00779311,Determination of the Maximum Tolerated Dose (MTD) of Sorafenib When Given in Combination With mFOLFOX6 and Bevacizumab,2008-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,Determination of Quality of Life (QoL) as Indicated by Patient Care Monitor (PCM) Data Among Patients on This Regimen
9408,NCT00685568,Toxicity,2002-11-21,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics (plasma drug trough concentrations)
9409,NCT03188991,Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability),2017-09-29,COMPLETED,INTERVENTIONAL,['PHASE2'],,Cyst Volume Response
9410,NCT01378507,Short-term result after ESD,2009-01,UNKNOWN,INTERVENTIONAL,['NA'],,The safety of ESD procedure
9411,NCT05514158,The incidence and severity of adverse events (AE),2022-09-28,RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-free survival
9412,NCT00508872,Complete Gross Resection Rate,2005-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,
9413,NCT04896931,Establishment of BTC population,2022-07-12,RECRUITING,OBSERVATIONAL,['NA'],,establishment of sample collection (tumorblocks and blood)
9414,NCT00003368,,1998-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9415,NCT05424159,2-year cumulative local regional progression rate (LRP),2022-07-01,RECRUITING,INTERVENTIONAL,['NA'],,Late toxicity
9416,NCT01758679,Progression-free survival,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,
9417,NCT00033306,"Determine the clinical activity of BMS-247550, as measured by the tumor response rate, in patients with metastatic colorectal cancer previously treated with a fluoropyrimidine and irinotecan.",2002-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Determine the response duration, time to progression, and survival in patients treated with this drug."
9418,NCT05057845,Objective Response Rate (ORR),2021-09-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
9419,NCT05242757,The size (tumor diameter) and number (tumor recurrence lesions) of PHC tumors were examined by enhanced abdominal CT,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,
9420,NCT04147494,To define and document the biodistribution of gallium Ga 68 FAPi-46 (68Ga-FAPi-46) and gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11) in normal and cancer tissues of patients with various non-prostate malignancies,2019-11-05,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Additional correlation of biodistribution of standard of care tracer,evaluate the 68Ga-FAPI-46 biodistribution correlation with 18F-FDG biodistribution
9421,NCT00646139,Maximum tolerated dose,2007-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Biological effects
9422,NCT03705754,Number of tumors visualised from peritoneal cavity/number of tattoos visualised form peritoneal cavity,2019-02-06,RECRUITING,INTERVENTIONAL,['NA'],,
9423,NCT02395250,Adverse events attributed to the administration of the anti-GPC3 CAR T cells,2015-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9424,NCT05363722,Objective response rate (ORR),2022-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Immune Best Overall Response（iBOR）according to iRECIST criteria
9425,NCT05088304,postoperative complications,2015-09-01,COMPLETED,OBSERVATIONAL,['NA'],,hospitalization cost
9426,NCT01943318,"Liver-related outcome: Decompensated liver cirrhosis (ascites, variceal bleeding, hepatic encepahlopathy), occurence of hepatocellular carcinoma",2013-01,COMPLETED,OBSERVATIONAL,['NA'],,Liver-related mortality
9427,NCT03853473,6 Minute Walk Test Distance (Pre Surgery),2019-02-22,COMPLETED,INTERVENTIONAL,['NA'],Length of Hospital Stay,Intraoperative Blood Pressure Variability
9428,NCT00552058,Percentage of Subjects in Clinical Remission at Week 6,2008-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Percentage of Subjects in Subgroup With 10 mg/L or Greater C-reactive Protein (CRP) at Entry Achieving a Clinical Response at Week 6
9429,NCT00900419,Genetic mutations or altered growth factor expression,2001-05-03,RECRUITING,OBSERVATIONAL,['NA'],,Establishment of a tissue repository of normal and dysplastic respiratory epithelium
9430,NCT04825470,Graft Survival,2022-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Disease free survival
9431,NCT03167125,Increased colorectal cancer screening rates,2017-09-05,COMPLETED,INTERVENTIONAL,['NA'],,
9432,NCT02252926,Reduction of oral and pharyngeal pain measured on Visual Analogue Scale (VAS),2014-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety: Peak plasma concentrations of bupivacaine
9433,NCT04400136,Percentage of post-operative GERD based on the trial protocol. Clinical evaluation,2020-07-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,evaluate in each group of the study (arm type) the endoscopic finding of peptic lesions of the esophagus-gastro-duodenal mucosa at 24 months of follow-up
9434,NCT03065257,Number of participants with reduction in clinical symptoms,2017-03-15,UNKNOWN,OBSERVATIONAL,['NA'],Number of participants with successful completion of treatment,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
9435,NCT00001587,,1997-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9436,NCT02700555,Incidence of newly developed diabetes mellitus,2016-02,TERMINATED,OBSERVATIONAL,['NA'],,3-year recurrence-free survival & 5-year recurrence-free survival
9437,NCT00005981,Determine the response rate of patients with metastatic colorectal carcinoma treated with O6-benzylguanine and carmustine.,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9438,NCT01105806,To document advance directive (AD)completion,2010-04,COMPLETED,OBSERVATIONAL,['NA'],,To longitudinally follow discussions about ADs and nature of hospitalizations
9439,NCT04177316,disease free survival (DFS),2018-12-01,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
9440,NCT05040360,Recurrence-free survival (RFS),2022-05-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
9441,NCT04516681,Objective Response Rate,2020-09-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Overall Survival
9442,NCT04894643,Perioperative Mortality and Complications,2020-09-14,RECRUITING,INTERVENTIONAL,['NA'],,Quality of Life questionnaire: Brief Pain Inventory
9443,NCT04280393,adenoma detection rate per patient,2020-02-10,COMPLETED,INTERVENTIONAL,['NA'],,Demonstrate the non-inferiority of patient experience when comparing Endocuff Colonoscopy and Standard Colonoscopy
9444,NCT04739501,Post_TACE hepatic cell failure,2020-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,
9445,NCT04445532,Collected samples,2020-10-11,RECRUITING,OBSERVATIONAL,['NA'],,Multi-omics analysis to further type and find therapeutic targets
9446,NCT02743065,Progress-free-survival (PFS),2016-09,UNKNOWN,OBSERVATIONAL,['NA'],,Objective Response Rates
9447,NCT00006812,,2001-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,
9448,NCT01020006,Number of Participants With Treatment Emergent Adverse Events (AEs),2009-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9449,NCT00585312,Time to Disease Progression,2006-09,TERMINATED,INTERVENTIONAL,['PHASE3'],,Colorectal Polyp Burden
9450,NCT03322592,EUS-FNB diagnostic accuracy,2018-03-29,COMPLETED,INTERVENTIONAL,['NA'],,Macroscopic on-site evaluation [MOSE]
9451,NCT03367611,Colonic lesion.,2018-03-15,COMPLETED,INTERVENTIONAL,['NA'],,
9452,NCT05279677,ORR,2022-08-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse events
9453,NCT00327457,Medical record verified flexible sigmoidoscopy or colonoscopy,2002-06,COMPLETED,INTERVENTIONAL,['NA'],,
9454,NCT05624099,Objective Response Rate(ORR),2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression free survival(PFS)
9455,NCT00978107,Maximal tolerated dose,2009-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumor response of injected and non-injected lesions Viral dissemination Proof of concept: 5-FU concentration in plasma and in tumors
9456,NCT01525069,Dose-limiting toxicities (DLTs),2012-04-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,Time to progression (TTP)
9457,NCT05943041,Incidence of Adverse Events from baseline to 8 weeks,2023-04-28,RECRUITING,INTERVENTIONAL,['PHASE1'],Changes of LARS(Low Anterior Resection Syndrome) score from baseline to 8 weeks,
9458,NCT03906110,Fecal Immunochemical Test (FIT) Use- Time Point 3,2018-04-03,COMPLETED,OBSERVATIONAL,['NA'],,
9459,NCT00957424,Number of Participants Willing to Continue With Preferred HRP,2009-06,COMPLETED,INTERVENTIONAL,['NA'],,
9460,NCT05734820,Diagnostic performance of AI-assisted polyp detector,2020-01-11,RECRUITING,INTERVENTIONAL,['NA'],,Adenoma Miss Rate (AMR)
9461,NCT03028831,colonic mucosal proliferation,2017-12-11,COMPLETED,INTERVENTIONAL,['NA'],,colonic secondary bile acids
9462,NCT00262171,,2002-05,UNKNOWN,OBSERVATIONAL,['NA'],,
9463,NCT02723253,Number of patients defined as good responders (G1 or G2) according to the Mandard regression grading system.,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,The number of patients still alive at the end of follow-up
9464,NCT01669109,Health-related quality of life,2012-09,COMPLETED,INTERVENTIONAL,['NA'],Qualitative Interviews,Spiritual well-being
9465,NCT05889325,Progression-Free Survival (PFS),2023-07-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Duration of Response (DoR)
9466,NCT04369053,Specificity of the Freenome test,2020-05-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
9467,NCT03894384,Diagnostic value of trefoil factor family 3 (TFF3) in serum of gastric cancer as non invasive marker,2019-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,
9468,NCT04902144,Clinical and Patient Reported Outcomes Following Genetic Test Results,2020-08-03,COMPLETED,INTERVENTIONAL,['NA'],,
9469,NCT05677490,Overall survival (OS),2023-01-23,RECRUITING,INTERVENTIONAL,['PHASE3'],Feasibility and compliance of intervention,Patient reported outcomes
9470,NCT00320320,Response rate after FOLFIRI reintroduction,2005-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall survival
9471,NCT02887313,Pathological complete response rate,2016-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease free survival
9472,NCT05846035,the prevalence of Paraneoplastic Syndrome in cirrhotic Patients with HCC.,2023-04-15,RECRUITING,OBSERVATIONAL,['NA'],,
9473,NCT04547153,hematological response rate (HeRR),2021-01-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,quality of life assessed by EORTC QOL C-30 and STO-22 (QoL)
9474,NCT00002515,,1992-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9475,NCT00265356,proportion of patients who have a change in management resulting from PET,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,prognostic ability of the PET standard uptake value (SUV) in predicting 3-year overall survival
9476,NCT02772029,time to progression,2016-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall survival
9477,NCT01839539,Progression-free survival (PFS),2013-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Laboratory findings (The number of CD3+ (or CD8+ or CD4+ or CD56+)T cell)
9478,NCT00882973,The recommended phase II dose of the combination therapy with Genexol-PM and gemcitabine,2008-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Safety profiles
9479,NCT05189730,Incidence of adverse events,2021-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall Survival
9480,NCT02137356,Number of patients with adverse events,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Number of patients whose tumors demonstrate pathological complete response at resection
9481,NCT02471313,Number of Participants for Which Uptake of [18F]-FMISO Was Successful and Hypoxic Tumors Were Observed During PET Scan Imaging Post TACE Procedure,2015-06-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9482,NCT03183219,Overall survival（OS）,2017-06-15,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
9483,NCT04787341,Overall survival,2020-12-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Objective Response Rate
9484,NCT03259009,Progression-free survival (PFS),2017-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival (OS)
9485,NCT00487409,this study will evaluate the surgical approach using the Ligasure device at six weeks post operative.,2006-12,COMPLETED,INTERVENTIONAL,['NA'],,Will evaluate the surgical approach using electrocautery with surgical clips and staples
9486,NCT00748215,Number of Participants With Grade 3/4 Diarrhea,2009-02-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9487,NCT04619342,Progression Free Survival（PFS）,2020-10-30,UNKNOWN,INTERVENTIONAL,['NA'],,Adverse Events
9488,NCT02569645,To determine the pathological complete response rate in patients with high-risk locally advanced rectal cancer treated with standard neo-adjuvant chemotherapy and radiation in combination with rosuvastatin.,2015-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Dose normalized AUC will be collected as pharmacokinetic data
9489,NCT02077868,Overall survival,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of life (QoL)
9490,NCT01292369,System performance,2011-02,UNKNOWN,OBSERVATIONAL,['NA'],,
9491,NCT00608595,Change of gene and protein expression pattern from pre- to post-treatment levels,2002-07,TERMINATED,INTERVENTIONAL,['NA'],,
9492,NCT06242470,Number of participants with adverse events (AEs) and serious AEs (SAEs),2024-03-06,RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of participants who develop anti-MGC026 antibodies (immunogenicity)
9493,NCT02997241,patients treated with chemotherapy based on clinical prognosis compared to Oncocare detection prognosis,2017-01,UNKNOWN,INTERVENTIONAL,['NA'],,Overall survival at 5 years
9494,NCT01846520,Effects of FCPCI on psychological distress,2013-10,COMPLETED,INTERVENTIONAL,['NA'],,Caregiver out-of-pocket costs
9495,NCT02127541,Measuring the accuracy of the Tumour-Localisation of 68-DOTA-Exendin-4 PET/CT and 111 In-DOTA-exendin-4 SPECT/CT.,2014-01-06,COMPLETED,INTERVENTIONAL,['NA'],,Comparison of the angiogenesis markers with the those of breast carcinoma patients
9496,NCT06109805,Plasma metabolite content,2023-10-20,RECRUITING,OBSERVATIONAL,['NA'],,
9497,NCT02506803,Number of participants with toxicity of NAC-GEMABR therapy as neoadjuvant chemotherapy for borderline resectable pancreatic cancer.,2015-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],,The R0 resection rate of NAC-GEMABR therapy as neoadjuvant chemotherapy for borderline resectable pancreatic cancer.
9498,NCT01740947,anastomotic leakage and/or abscess,2013-01,TERMINATED,INTERVENTIONAL,['PHASE4'],In hospital and out-of-hospital costs,Disease free survival
9499,NCT06002789,pCR rate,2022-05-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,3 years OS Rate
9500,NCT04357171,The rate of readmissions due to severe dehydratation,2012-01-14,COMPLETED,INTERVENTIONAL,['NA'],,The rate of early postoperative complications after stoma closure operation
9501,NCT05095519,True Negative Rate per lesion.,2021-09-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,GLUT-1 expression
9502,NCT05942768,Overall Survival (OS),2019-07-01,COMPLETED,OBSERVATIONAL,['NA'],,Treatment-Related Adverse Events (TRAE)
9503,NCT02511821,Percentage of patients who are able to wear the wristband device for at least 1 week post-operatively,2015-07-22,COMPLETED,INTERVENTIONAL,['NA'],,"Suggestions for items that were not covered but should be added, as measured by responses from Satisfaction Tool"
9504,NCT06121622,Development of New Personalised 3D Preclinical Models of Pancreatic Neuroendocrine Tumours,2024-01-16,RECRUITING,OBSERVATIONAL,['NA'],,
9505,NCT01523353,Anaerobic threshold prior to liver resection,2011-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Recovery of fitness
9506,NCT00187109,To evaluate whether recombinant human thrombopoietin will reduce the time necessary for platelet counts to recover following chemotherapy.,2000-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
9507,NCT04345770,overall survival,2020-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,complication rate
9508,NCT04620473,Objective Response Rate（ORR）,2023-11-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Postoperative complications
9509,NCT05149807,Phase III : Event-free Survival (EFS),2022-01-26,ENROLLING_BY_INVITATION,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,30-day postoperative mortality.
9510,NCT03401294,Rate of liver metastasectomy,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
9511,NCT00147147,Overall survival,1993-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,the site of recurrence
9512,NCT05339763,bowel function,2019-08-12,COMPLETED,INTERVENTIONAL,['NA'],,fecal incontinence
9513,NCT03359616,Disease-free survival (DFS),2018-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,mortality rate
9514,NCT04207463,Overall response rate (ORR),2020-06-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
9515,NCT00513331,"To standardize physician recommendations and provide cutting edge technology to patients with BE and GERD, and establish a Valley Hospital Center for Barrett's Esophagus and GERD",2007-07,COMPLETED,OBSERVATIONAL,['NA'],,"To assess clinical outcomes of patients enrolled in The Valley Hospital Center for Barrett's Esophagus and GERD, and modify algorithms as appropriate."
9516,NCT05022719,"The interference level of detrimental effects on the visualization of the colonic mucosa during CCE, due to use of MB-MMX per colonic segment.",2021-10-04,COMPLETED,INTERVENTIONAL,['NA'],,To evaluate the safety of CCE procedure while using MB-MMX.
9517,NCT01600209,Sensitivity and Specificity of the Exact CRC diagnostic screening test.,2011-10,COMPLETED,OBSERVATIONAL,['NA'],,
9518,NCT04163237,Disease-free Survival,2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Overall Survival
9519,NCT06117241,Stool,2023-10-17,RECRUITING,INTERVENTIONAL,['NA'],,
9520,NCT01697462,Number of Participants With Non-Serious Adverse Events (AEs) and Serious Adverse Events (SAEs),2009-07,COMPLETED,OBSERVATIONAL,['NA'],,Number of Participants With Hand-Foot Syndrome (HFS)
9521,NCT00003571,disease free survival,1998-08,COMPLETED,OBSERVATIONAL,['NA'],,determine the prognostic and predictive values for response to this therapy
9522,NCT01187641,"The primary endpoint will be the accuracy of MRI and CT in determining T stage using histology as the gold standard, on a per patient basis.",2010-08-18,COMPLETED,OBSERVATIONAL,['NA'],,"We will also compare the accuracy of 1.5T against 3.0T MRI scans, and T2 weighted against T1 weighted images"
9523,NCT03904043,Clinical complete response rate,2020-07-01,RECRUITING,INTERVENTIONAL,['NA'],,Organ preservation rate
9524,NCT05720559,Overall Survival (OS),2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
9525,NCT02572687,Number of Participants with Dose Limiting Toxicities (DLTs),2016-02-19,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants with Treatment Emergent Anti MEDI4736 Antibodies
9526,NCT05021172,Responses to Qualitative Acceptability survey,2021-08-24,COMPLETED,INTERVENTIONAL,['NA'],Proportion of patients screened for colorectal cancer,
9527,NCT00797732,Treatment Compliance Rate,2008-12,COMPLETED,INTERVENTIONAL,['NA'],,MDADI Scores
9528,NCT05571644,Pathological complete response (pCR) rates,2023-07-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Local recurrence rate
9529,NCT02601079,Highest proportion (number) of representative biopsies for diagnostic purposes from the tumor tissue.,2016-09,TERMINATED,INTERVENTIONAL,['NA'],,Number of fusion genes in tissue harvested from esophageal neoplasms prior to neoadjuvant oncological treatment.
9530,NCT03919461,Biomarkers in blood samples assessing pro- and anti-metastatic processes,2019-02-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,Fatigue
9531,NCT04807972,Phase 2: Overall Survival,2021-05-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Percentage of Participants Experiencing Adverse Events
9532,NCT05837065,the Harrell concordance index (C-index),2022-09-15,RECRUITING,OBSERVATIONAL,['NA'],,the time-dependent area under the receiver operating characteristic curve(tdAUROC)
9533,NCT01959061,Progression-free survivial,2013-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],,
9534,NCT01807390,Change in pain perceptions,2012-07,UNKNOWN,OBSERVATIONAL,['NA'],,Change in general health related quality of life
9535,NCT02502656,"Concordance regarding the mutation of RAS (yes vs no, dichotomous variable) between the two methods",2015-07,UNKNOWN,OBSERVATIONAL,['NA'],,Comparisons of the costs between the two methods
9536,NCT04353882,MOR-1 expression by polymerase chain reaction (RT-qPCR) in tumor tissue and adjacent healthy tissue.,2020-06-01,UNKNOWN,OBSERVATIONAL,['NA'],Concomitant Diseases,MOR-1 expression by immunohistochemistry in tumor tissue and adjacent healthy tissue.
9537,NCT02710812,Rate of organ preservation,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],,European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Colorectal Cancer Module 29
9538,NCT00812240,Progression Free Survival (PFS),2009-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,Overall Survival (OS)
9539,NCT01269567,Pelvic sepsis,2011-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Rate of closure of stoma
9540,NCT01932385,progression free survival and overall survival,2013-08-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,response rate
9541,NCT05347745,therascreen® KRAS RGQ PCR Kit,2022-01-07,UNKNOWN,INTERVENTIONAL,['NA'],,
9542,NCT00184782,Increase in metabolic activity of liver metastases after resection of the primary tumor compared to the activity of metastases in patients without primary tumor resection,2003-09,UNKNOWN,INTERVENTIONAL,['NA'],,
9543,NCT01975077,safety and tolerability,2012-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall survival (OS)
9544,NCT00587184,,2006-07,COMPLETED,OBSERVATIONAL,['NA'],,
9545,NCT01525056,"efficacy of PET, CT-perfusion and MRI to stage patients with rectal cancer",2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9546,NCT05163483,Objective Response Rate（ORR）,2022-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival(OS)
9547,NCT05609695,Overall Survival,2023-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Progress Free Survival
9548,NCT06287671,Correlation between biomarker in plasma and tissue,2024-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
9549,NCT00154700,Response rate,2001-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity
9550,NCT05027425,Cellular rejection rates,2021-12-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Recurrence-free survival and overall survival outcomes based on survival follow up reporting
9551,NCT00683241,To determine the feasibility and safety of administering DCVax-L intradermally combined with intravenous bevacizumab and oral metronomic cyclophosphamide in patients with recurrent ovarian or primary peritoneal cancer.,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To assess the immunogenicity of DCVax-L administered intradermally in patients with recurrent ovarian or recurrent primary peritoneal cancer, combined with intravenous bevacizumab and oral metronomic cyclophosphamide."
9552,NCT05923255,3-year disease free survival,2023-05-14,RECRUITING,INTERVENTIONAL,['NA'],,5-year overall survival rate (OS)
9553,NCT03453164,Disease control rate,2018-03-28,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Peak antigen-specific cytotoxic T lymphocyte population
9554,NCT00837239,Progression Free Survival at 4 Months,2007-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival
9555,NCT05444088,Objective Response Rate,2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-Free-Survival assessed by investigator
9556,NCT03507140,"Comparison of the relative abundance of pathobionts and symbionts before and 6 months after liver transplantation, in the bile of recipients.",2019-04-16,UNKNOWN,OBSERVATIONAL,['NA'],,"Biobanking of blood, saliva, bile, feces and urine for further analyses such as metabolomic studies on blood, urine and feces metagenomic studies on saliva, and immunomonitoring on blood."
9557,NCT05412082,Incidence of Toxicity Among Participants After Start Receiving MRI-g Pelvic ART,2022-10-05,RECRUITING,INTERVENTIONAL,['PHASE1'],,Health-related Quality of Life (HRQOL) Scores: Pittsburgh Sleep Quality Index (PSQI)
9558,NCT00003446,,1997-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9559,NCT03766295,Overall Survival (median),2014-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression Free Survival
9560,NCT02824835,percentage of cells in G2/M arrest after dose-dependent exposure,2016-07,UNKNOWN,OBSERVATIONAL,['NA'],,
9561,NCT02177084,LARS score,2014-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,morbidity
9562,NCT03558724,Safety of bevacizumab-800CW administration by monitoring vital signs and/or (serious) adverse events.,2018-10-29,TERMINATED,INTERVENTIONAL,['PHASE1'],,The variation in fluorescence intensity between fluorescence molecular endoscopy before and after neoadjuvant chemoradiotherapy defined as the tumor to background ratio and intrinsic fluorescence.
9563,NCT00145015,Apoptosis in colonic biopsy samples,2004-12,COMPLETED,INTERVENTIONAL,['NA'],,gene transcription
9564,NCT01666756,"Recommended phase II dose, determined according to incidence of dose-limiting toxicity (DLT) graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4",2014-06-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Change in levels of soluble biomarkers,Sorafenib tosylate concentration after co-administration with Chinese herbal formulation PHY906
9565,NCT03260647,Optimization of multidisciplinary care,2017-08-04,RECRUITING,OBSERVATIONAL,['NA'],,Evaluate cannabis use in patient population
9566,NCT06097416,Overall survival,2024-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Progression-free survival
9567,NCT03022734,complete resection (R0) rate for rectal and liver lesions,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Response rate (RECIST V1.1)
9568,NCT02552745,Pain scores,2014-10,COMPLETED,OBSERVATIONAL,['NA'],,Hospital Stay
9569,NCT00642603,Progression-free Survival (PFS) in U.S. Patients Only,2008-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,
9570,NCT03957031,Exposure to a variety of potential sources of GC risk factors,2019-05-31,UNKNOWN,OBSERVATIONAL,['NA'],,
9571,NCT03638206,"Number of Participants With Adverse Events evaluated with NCI CTC AE, version 4.0",2018-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,CAR-T cells testing
9572,NCT01271192,5-year disease free survival,2010-12,UNKNOWN,INTERVENTIONAL,['NA'],,"Side effect of chemo radiotherapy, postoperative complications, recurrent rate, distant metastatic rate,biomarkers, quality of life, toxic profile, convenience"
9573,NCT02094105,incidence and mortality of ESCC,1999-11,COMPLETED,INTERVENTIONAL,['NA'],,"Cumulative incidence and mortality of total cancer, and gastric cardia cancer"
9574,NCT00031837,Quality of life as measured by FACT-Hep version 4 every 4 weeks,2002-10,TERMINATED,INTERVENTIONAL,['PHASE3'],,Safety as measured by the occurrence of bleeding complications
9575,NCT03300544,Incidence of dose limiting toxicities of TVEC,2017-09-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival
9576,NCT00526786,The eradication of LGD and HGD within BE at 24 months after the final treatment. The primary safety endpoint is the incidence of all adverse events.,2007-09,TERMINATED,INTERVENTIONAL,['PHASE4'],,1.Eradication of all BE by 24 months after the final treatment. 2.The proportion of lesions that decreased in length by the 24-month follow-up. 3.The proportion of lesions where severity was downgraded by the 24-month follow-up.
9577,NCT03421288,Comparison of Event free survival (EFS) between arms,2018-09-14,RECRUITING,INTERVENTIONAL,['PHASE2'],ctDNA clearance on treatment,Overall survival (OS) and EFS in the subgroup of patients with PD-L1 CPS score ≥ 5 and ≥ 10 and patients with MSI
9578,NCT02352259,Evaluation of Safety Related to Electrochemotherapy,2013-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response to Treatment (Determined by Modified RECIST Criteria).
9579,NCT02855788,response rate,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival
9580,NCT03803267,Postoperative pain score,2019-05-01,COMPLETED,INTERVENTIONAL,['NA'],,Serum C-reactive protein (CRP)
9581,NCT00475722,Adherence to Dietary Goals,2007-05,COMPLETED,INTERVENTIONAL,['NA'],,
9582,NCT03622229,"EUS-FNB procurement yield of tissue ""core"" using two different FNB needles.",2018-11-01,COMPLETED,INTERVENTIONAL,['NA'],,Macroscopic on-site evaluation (MOSE)
9583,NCT06231680,RCCEP response rate at 3 weeks,2024-01-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,Thalidomide treatment-related adverse events
9584,NCT01833546,Number of Participants Who Experienced Any Dose-Limiting Toxicity (DLT) During First Cycle - Day 1 to 28,2013-04-18,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 2 or Higher Than 2
9585,NCT04387695,Progression-free survival (PFS) rate,2020-04-30,RECRUITING,INTERVENTIONAL,['PHASE3'],,Disease control rate
9586,NCT02106858,Percentage of patients with adverse drug reactions (ADRs),2014-06-25,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival (OS)
9587,NCT03875781,Survival,2019-06-05,RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of life - physical functioning: QLQ-C30
9588,NCT05546892,Anastomotic leak rate,2023-02-10,RECRUITING,INTERVENTIONAL,['NA'],,Bowel preparation compliance
9589,NCT03536793,"Measurement of the accuracy of protein markers (e.g., TF, AM) in detecting early stage pancreatic cancer by comparison of laboratory results from ELISA assays and platform technologies to patient clinical data.",2018-10-24,RECRUITING,OBSERVATIONAL,['NA'],,
9590,NCT01247506,,2010-02,UNKNOWN,OBSERVATIONAL,['NA'],,
9591,NCT05611034,safety as measured by acute lung injury findings,2023-02-06,RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of mechanical ventilation
9592,NCT01671592,Ability to track the labeled DC vaccine by MRI,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,May assess the disease-free survival and overall survival
9593,NCT04363801,Part C: Progression Free Survival (PFS) in G/GEJ DKK1 high and overall patients treated with DKN-01 in combination with tislelizumab and chemotherapy vs tislelizumab and chemotherapy as a first-line therapy,2020-07-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Dickkopf-1 (DKK1) concentration in serum and plasma relative to safety and efficacy outcomes in G/GEJ patients treated with DKN-01 in combination with tislelizumab as a second-line therapy,Part C:To characterize the frequency of toxicity ≥Grade 3 treatment-related adverse events (TRAE) associated with each of the treatment arms.
9594,NCT05872295,Objective Response Rate (Part 2),2023-09-14,RECRUITING,INTERVENTIONAL,['PHASE1'],,Evaluation of the immunogenicity of IKS014 (Part 1 and 2)
9595,NCT04727307,Recurrence-free survival,2021-01-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,
9596,NCT03755921,M. D. Anderson Dysphagia Inventory (MDADI),2018-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,Deglutition evaluation
9597,NCT04500548,Incidence of adverse events,2021-01-28,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Overall survival
9598,NCT02579278,To determine if there is a link between EMVI status and ctDNA,2015-11,RECRUITING,OBSERVATIONAL,['NA'],,To investigate the effect of ctDNA status on patient survival outcomes
9599,NCT06098560,Correlation of ctDNA changes with pCR rate and the duration of cCR,2023-08-16,RECRUITING,OBSERVATIONAL,['NA'],,Correlation of ctDNA changes with 2 years PFS
9600,NCT01116791,Overall survival time (OS) following CRS+HIPC (from surgery to cancer-related death),2010-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,In-hospital perioperative complications
9601,NCT00238160,,na,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,
9602,NCT05641233,"Hardness of pancreas texture, determined by Durometer measurement",2020-12-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,30-day mortality and in-hospital mortality
9603,NCT00006245,,2000-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9604,NCT04082455,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2018-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,progression-free survivals
9605,NCT02915393,Detection of helicobacter pylori by Urea Breath Test(UBT),2016-09,UNKNOWN,OBSERVATIONAL,['NA'],,TCM syndrome type diagnosed by two professional TCM doctors
9606,NCT06057350,CRC recurrence or sign of lymph nodes or distant metastases,2023-10-27,RECRUITING,INTERVENTIONAL,['NA'],Cost-effectiveness,Health related quality of life and functional outcomes after 30 days and one year
9607,NCT06172036,12-month EFS rate,2024-01-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events
9608,NCT05396937,"Objective response rate, ORR",2022-01-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
9609,NCT03209765,Compliance rate,2017-06-16,COMPLETED,INTERVENTIONAL,['NA'],,Compliance rate of second round
9610,NCT02384005,Kappa agreement will be calculated between lay person and nurse practitioner on the anal exam results.,2015-02,COMPLETED,INTERVENTIONAL,['NA'],,Number of persons who state they intend to seek subsequent care in the event of an abnormal result to a self-DAE.
9611,NCT05101265,Total plasma dose-normalized AUC0-∞,2021-03-09,RECRUITING,INTERVENTIONAL,['PHASE1'],,Pharmacogenetics
9612,NCT05491889,mortality,2022-10-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
9613,NCT04628780,Objective response rate (ORR) in the Expansion cohorts (Part 2),2020-12-16,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall survival (OS) in the Expansion Cohorts (Part 2)
9614,NCT01151007,Frequency of KRAS mutation,2011-07,COMPLETED,OBSERVATIONAL,['NA'],,The incidence of the colorectal carcinoma
9615,NCT05355662,Recurrence of the primary disease after surgery,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Post-operative complications in patients who underwent liver transplantation
9616,NCT03499795,Percentage of Participants With no Histologic Evidence of Anal or Anal/Peri-Anal HSIL and no Evidence of HPV-16/18 at Week 36,2018-05-15,COMPLETED,INTERVENTIONAL,['PHASE2'],"Percent Change From Baseline in the Size of Peri-Anal Lesions as Determined by the Investigator at Weeks 36, 64, and 88",Percentage of Participants With no Histologic Evidence of Anal or Anal/Peri-Anal HSIL or no Evidence of HPV-16/18 at Week 36
9617,NCT04441580,Rate of patients detected with 3 or more adenomas.,2020-05-04,RECRUITING,INTERVENTIONAL,['NA'],,Specific contribution of AI
9618,NCT02547610,The imaging biomarkers determined by MR-PET,2014-05,UNKNOWN,OBSERVATIONAL,['NA'],,
9619,NCT00603460,"Disease status will be assessed with CT (or MRI) of chest/abdomen/pelvis at enrollment, after vaccine 2 and at the conclusion of the study . Rates of disease progression will be recorded at the time of study conclusion.",2012-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
9620,NCT04221555,Pathologic complete regression (pCR) rate,2020-05-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease free survival (DFS)
9621,NCT00443573,"Safety measured by major hemorrhage (NCI CTCAE v3.0 grade 3 or greater), during and up to 30 days after completion of study drug administration or, if treatment is ongoing, by 8 months after study enrollment (Stage I) or randomization (Stage II)",2006-12,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Tumor response rate, as assessed by RECIST criteria"
9622,NCT03561142,Clinical complete response rate,2018-06-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
9623,NCT03658044,Self empowerment measured by Cancer Behavior Inventory (CBI) scale,2018-12-01,COMPLETED,INTERVENTIONAL,['NA'],,Generated Knowledge in Online Discussions
9624,NCT00629759,"To determine the maximum tolerable dose (MTD) and/or the maximum feasible dose (MFD), as well as to evaluate the safety of JX-594 injected within unresectable solid tumor(s) within the liver",2006-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Secondary objectives include determination of JX-594 pharmacokinetics, replication and shedding, immune response, and injection site tumor responses."
9625,NCT02573974,Measurement of muscle mitochondrial bioenergetics,2016-01-19,COMPLETED,INTERVENTIONAL,['NA'],,Determining the isotopic composition of nitrogen hair
9626,NCT05510388,The incidence of hypoxia,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Complications related to high-flow nasal cannula
9627,NCT05118451,Main evaluation indicators,2020-07-01,RECRUITING,INTERVENTIONAL,['NA'],,Secondary evaluation index
9628,NCT02870049,Screening completion rate,2016-08,UNKNOWN,INTERVENTIONAL,['NA'],,
9629,NCT01409499,Overall survival (OS),2011-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,cost of treatments
9630,NCT04904042,Pathological evaluation,2021-06-01,COMPLETED,INTERVENTIONAL,['NA'],,Global mortality.
9631,NCT04560270,Correlation of the ctDNA level to the response to chemotherapy,2016-04-25,COMPLETED,INTERVENTIONAL,['NA'],,Progression free survival
9632,NCT06199466,Overall Response Rate (ORR) of YL-13027 in combination with gemcitabine and nab-paclitaxel,2024-01-22,RECRUITING,INTERVENTIONAL,['PHASE1'],,
9633,NCT01622543,Progression Free Survival,2012-10-26,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
9634,NCT04420130,6-month PFS rate,2020-08-01,WITHDRAWN,INTERVENTIONAL,['NA'],,Incidence of Treatment-Emergent Adverse Events
9635,NCT01846650,Area Under Curve (AUC),2012-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9636,NCT06204835,HCC lesions,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,
9637,NCT03875235,Overall Survival (OS) Rate at 24 Months,2019-04-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Disease Control Rate (DCR) - 48 Weeks
9638,NCT05990543,Progression free survival,2023-08-30,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
9639,NCT01248962,Number of Participants With and Without Hypersensitivity Reaction,2010-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,The Odds Ratio for the Relationship of Baseline Variables to the Carboplatin Hypersensitivity Rate
9640,NCT02211443,Number of participants with SCT200-related adverse events,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],Time to Disease Progression (TTP) of SCT200,Area Under the plasma concentration versus time curve (AUC) of SCT200
9641,NCT02651974,Percentage of individuals who complete FIT screening measured by return FIT kit,2015-09,COMPLETED,INTERVENTIONAL,['NA'],,"Pre-post analysis of current results reporting strategy (which will utilize a white envelope for normal results, and a red envelope for abnormal results) to prior generic envelope for FIT result reporting for both normal and abnormal results."
9642,NCT06050707,Change in locoregional failure (LRF) at Year 2,2023-09-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life (QOL)
9643,NCT00307736,"Maximum Tolerated Dose (MTD) of Erlotinib When Administered in Combination With 5-fluorouracil (5-FU), Bevacizumab, and External Beam Radiation Therapy",2006-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Pathologic Complete Response,"Post-operative Complications After Resection of Rectal Cancers Following Preoperative 5-FU, Bevacizumab, Erlotinib, and External Beam Radiation Therapy."
9644,NCT04975516,Progression free survival,2023-07-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
9645,NCT01794793,Incidence of adverse events to evaluate long term safety data,2013-06-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],,Percentage of patients with clinical benefit as assessed by the investigator
9646,NCT05754229,False negative findings: Adenomas (histopathologically verified) characterized as non-adenomas by the AI system,2022-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
9647,NCT05978882,Detection rate of Sentinel lymph nodes,2023-08-17,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,5 year recurrence free survival rate
9648,NCT01890213,Number of participants with adverse events,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9649,NCT05705791,Objective response rate,2023-02-07,RECRUITING,INTERVENTIONAL,['NA'],,Evaluate alternative response evaluation criteria
9650,NCT00790140,Preservation of body compostition after surgery,2005-07,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Reduced immuno-inflammatory response to surgery
9651,NCT01374074,To examine the association between BE and environmental factors,2011-03,COMPLETED,OBSERVATIONAL,['NA'],,To investigate the association between BE and genetic and epigenetic status of Cdx1/Cdx2
9652,NCT04096118,Survival rates,2018-04-01,COMPLETED,OBSERVATIONAL,['NA'],,
9653,NCT00171912,To assess the efficacy and the safety of imatinib mesylate therapy,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,To evaluate the effects of imatinib on quality of life and healthcare resource use
9654,NCT02197351,Detection of Intestinal Metaplasia or Dysplasia,2014-07,RECRUITING,INTERVENTIONAL,['NA'],,Helicobacter pyrlori detection
9655,NCT04906343,Advanced neoplasia and colorectal cancer incidence at 3 years,2021-06-05,UNKNOWN,INTERVENTIONAL,['NA'],,
9656,NCT03473327,Oxidative and immunological gene-expression before and after laparoscopic surgery for colon cancer using whole blood gene expression profiling from blood samples,2016-01,COMPLETED,OBSERVATIONAL,['NA'],,Assessement of inflammatory tumor invasion using immunohistochemestry on tumor tissue samples
9657,NCT02697058,Progression Free Survival (PFS) in Part 2 of Study,2016-03-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Volume of Distribution at Steady-State (Vss)-Total Irinotecan, SN-38, and SN-38-Glucuronide (SN-38G)"
9658,NCT01972672,time to progress（TTP）,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Gene expression profiling of blood cells and tumor biopsies,Laboratory abnormal findings
9659,NCT02164240,Number of Participants With Serious and Non-Serious Adverse Events,2014-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Median Progression Free Survival (mPFS)
9660,NCT00547612,Proportion of tumors detected by [18F]-labeled substance P antagonist receptor quantifier positron emission tomography,2007-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9661,NCT06316466,OS,2023-06-01,RECRUITING,OBSERVATIONAL,['NA'],,PFS
9662,NCT03031171,Colonoscopy completion,2010-04,COMPLETED,INTERVENTIONAL,['NA'],,
9663,NCT05427669,3-year Disease-free Survival (DFS),2022-10-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,3-year distant metastatic-free survival （DMFS）
9664,NCT05352542,CAR transgene levels in peripheral blood,2022-05-19,RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of anti-LCAR-H93T antibody
9665,NCT01273090,Toxicities of imetelstat sodium,2011-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9666,NCT02402842,Progression-free survival rate,2014-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,HPV-specific T cell responses measured by ELISPOT assay before and after DCF treatment
9667,NCT00265850,Overall Survival,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Duration of Tumor Response
9668,NCT03151642,Number of MRIs,2017-04-05,COMPLETED,OBSERVATIONAL,['NA'],,
9669,NCT01253161,Progression-free Survival (PFS) at One Year,2011-02-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse Events Possibly Related to Study Treatment
9670,NCT01052376,"Evaluate and validate CEM in terms of its ability to diagnose neoplastic lesions and to distinguish between normal and neoplastic mucosa in vivo, based on comparison between ""optical biopsies"" and standard histology.",2008-12,TERMINATED,INTERVENTIONAL,['NA'],,
9671,NCT03708952,Numbers of participants with polyps,2018-05-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Numbers of participants died,Numbers of participants with cardiometabolic diseases
9672,NCT05351398,Objective Response Rate,2022-04,UNKNOWN,OBSERVATIONAL,['NA'],,R0 resection rate
9673,NCT00769483,Progression Free Survival,2008-11-13,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Correlation Between Plasma IGF-I Expression in Patients Treated With MK-0646 and OS,Treatment Toxicity
9674,NCT02490111,Proportion of patient developing gallstone at 12 month after gastrectomy,2015-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time to gallstone formation
9675,NCT02194387,Change in waist circumference (Pilot II),2014-09-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
9676,NCT02985801,Change in Body Weight,2016-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change in Body Weight Composition
9677,NCT00812175,The safety of Nexavar in all patients with unresectable HCC who are candidates for systemic therapy and in whom a decision to treat with Nexavar has been made under real-life practice conditions,2009-01,COMPLETED,OBSERVATIONAL,['NA'],,Reports of adverse events
9678,NCT02404909,to investigate the influence of the liver resection on hemodynamic status in terms of hemodynamic indexes changes,2005-01,COMPLETED,OBSERVATIONAL,['NA'],,
9679,NCT05802407,Disease-free survival,2023-02-01,RECRUITING,INTERVENTIONAL,['NA'],The prognostic role of targeted therapy selected based on MRD,Overall survival
9680,NCT06186609,Progression-free survival,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
9681,NCT01665625,overall surviva,2012-08,UNKNOWN,INTERVENTIONAL,['NA'],,surgical complications
9682,NCT06013657,Mortality,2021-12-01,COMPLETED,OBSERVATIONAL,['NA'],,Length of stay
9683,NCT04582500,Patient Satisfaction,2021-02-15,RECRUITING,OBSERVATIONAL,['NA'],,Assessing Workflow of incomplete colonoscopies
9684,NCT00837876,Number of Patients With Progression-free Survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Worst Grade Toxicities
9685,NCT03289273,"Number of patients with treatment emergent adverse events (TEAEs) leading to dose modifications (including reductions, interruptions and permanent discontinuation)",2017-09-13,COMPLETED,OBSERVATIONAL,['NA'],,Duration of regorafenib treatment
9686,NCT01484925,,2011-11,COMPLETED,OBSERVATIONAL,['NA'],,
9687,NCT04823754,Evaluate the concordance between the patient's perception of his prognosis and treatment side effects with the one of his treating physician.,2021-07-12,COMPLETED,OBSERVATIONAL,['NA'],,Evaluate the association between individual prognosis expectation (patient and physician) and data from the available literature.
9688,NCT06124131,Difference in proportion of participants completing colorectal cancer screening between study arms,2023-11-11,RECRUITING,INTERVENTIONAL,['NA'],Number of patients who receive intended treatment,"Difference in proportion of participants completing all three services between study arms: colorectal cancer screening, COVID-19 shot, flu shot"
9689,NCT00007618,,1998-01,COMPLETED,OBSERVATIONAL,['NA'],,
9690,NCT03948763,Number of Participants Who Discontinued Study Treatment Due to an AE,2019-06-26,COMPLETED,INTERVENTIONAL,['PHASE1'],T-cell receptor (TCR),Mutant KRAS Specific T cells
9691,NCT05823584,Sensitivity (vh-DNA vs AFP) (the vh-DNA which could be detected in the pre-operative plasma of participants.),2019-12-22,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Sensitivity (TERT C228T vs AFP/AFP-L3/PIVKA-II)
9692,NCT02746224,Anorectal functional outcome at 12 months assessed by LARS scale,2016-04-01,COMPLETED,INTERVENTIONAL,['NA'],,Distance to surgical margins
9693,NCT00482222,Progression-free survival,2007-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Safety
9694,NCT03398291,Real overall survival,2018-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Postoperative mortality
9695,NCT01323400,Progression-free survival,2011-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Overall survival in patients not randomly assigned to pazopanib, but receiving pazopanib on a compassionate basis after progression"
9696,NCT04231929,Tumor response,2020-05,WITHDRAWN,INTERVENTIONAL,['NA'],,Best overall response
9697,NCT00383266,Overall Response Rate (ORR),2006-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
9698,NCT02706782,Number of patients with adverse event,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Detection of transferred T cells in the circulation using quantitative -PCR
9699,NCT03642093,Frailty Measurement,2018-08-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Quality of Life (QoL) Assessment
9700,NCT00655499,Objective Response Rate (ORR) During the Combination Therapy Phase,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
9701,NCT05002608,change from baseline health insurance literacy to 5-month follow-up,2021-11-01,RECRUITING,INTERVENTIONAL,['NA'],,
9702,NCT05127096,Specificity of the FirstSight test,2020-12-15,UNKNOWN,OBSERVATIONAL,['NA'],,
9703,NCT05419362,"To assess the anti-tumor activity of GEN-001, when administered as combined with avelumab",2022-04-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Microbiota,Overall Survival (OS)
9704,NCT03647527,the highest grade of oral mucositis,2016-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,
9705,NCT01360411,Malignant or benign lesion,2007-01,COMPLETED,OBSERVATIONAL,['NA'],,Value of a Visual Analog Scale for strain image categorisation
9706,NCT00264979,Rate of patients with at least one postoperative severe complication within 60 days after each surgery,2006-03-02,TERMINATED,INTERVENTIONAL,['NA'],,Two years recurrence rate
9707,NCT06314958,Recurrence-Free Survival,2023-03-15,RECRUITING,OBSERVATIONAL,['NA'],,Overall Survival
9708,NCT03868215,Sensitivity,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,
9709,NCT03819088,Quality of life scores,2019-04-17,COMPLETED,INTERVENTIONAL,['NA'],,Serum albumin level
9710,NCT01712971,intra-operative blood loss,2012-11,WITHDRAWN,OBSERVATIONAL,['NA'],,hospital costs
9711,NCT01921699,proliferation and migration of PANC1 cell line in the tested groups.,2013-08,UNKNOWN,INTERVENTIONAL,['NA'],,To determine whether direct cell-to-cell interaction or soluble factors participate in MIC.
9712,NCT03668431,"Number of participants with grade 3, 4 and 5 adverse events",2018-10-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Mechanisms of response and resistance to dabrafenib, trametinib, and PDR001"
9713,NCT02204150,Feasibility of OFDI Imaging in Subjects Swallowing the OFDI Capsule,2012-02,COMPLETED,INTERVENTIONAL,['NA'],,
9714,NCT02559687,Objective Response Rate (ORR) According to Response Evaluation Criteria for Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR),2015-12-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
9715,NCT00278889,Progression Free Survival,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,QOL: Time to Worsening of FACT Colorectal Cancer Symptom Index(FCSI)
9716,NCT00922181,Variability of ablation diameters,2008-08,COMPLETED,INTERVENTIONAL,['NA'],,
9717,NCT00677612,safety(Phase I:toxicities as assessed by NCI CTCAE version3) and efficacy(Phase II:Feasibility as evaluated by RECIST),2008-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To evaluate immunological responses
9718,NCT03601156,Pathological Complete Response (pCR),2014-06,UNKNOWN,INTERVENTIONAL,['NA'],,Number of Postoperative Complication
9719,NCT02726997,"Pharmacodynamic Changes Induced by Treatment with Durvalumab in Combination with Paclitaxel and Carboplatin in Women with Advanced Stage, Metastatic Ovarian Cancer Using a 2-Sample T-Test",2016-07-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Feasibility of Treatment with Durvalumab in Combination with Paclitaxel and Carboplatin in Women with Advanced Stage, Metastatic Ovarian Cancer Determined by Methods of Thall et all"
9720,NCT03556384,Overall Response Rate,2018-09-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events related to TMZ
9721,NCT05256381,Objective Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1),2022-06-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Participants with Anti-drug Antibodies (ADAs)
9722,NCT03706248,"Sensitivity, specificity, positive predictive value and negative predictive value",2018-07-28,COMPLETED,OBSERVATIONAL,['NA'],,
9723,NCT03228043,Number of Participants overall survival,2020-03-01,WITHDRAWN,INTERVENTIONAL,['NA'],Number of Participants overall survival,Number of Participants overall survival
9724,NCT02204332,"The efficacy of cabazitaxel measured by estimating the overall response rate (ORR), as the percentage of individuals who achieve a complete tumor response (CR) or partial tumor response (PR) in each arm and between arms.",2013-03,TERMINATED,INTERVENTIONAL,['PHASE2'],"Safety and toxicity in the experimental arm. Toxicity is graded according to the Common Terminology Criteria for Adverse Events (NCI-CTCAE, v 4.0).",Progression-free survival (PFS)
9725,NCT02251977,rates of grade 2 or more chronic cumulative neurotoxicity of both arms,2014-09,COMPLETED,INTERVENTIONAL,['PHASE3'],genetic polymorphisms of oxaliplatin induced severe and cumulative neurotoxicity,rates of 3 year disease free survival of both arms
9726,NCT04943406,Prognostic impact of ctDNA positivity,2020-05-08,RECRUITING,OBSERVATIONAL,['NA'],,Prognostic impact of ctDNA positivity in peritoneal lavage and peripheral blood on the risk of peritoneal and distant metastases
9727,NCT00867126,"Changes in symptoms and quality of life as measured by the validated FACT-Hep scale version 4 questionnaire at baseline, every 4 weeks during therapy, and then at the completion of therapy",2009-03-02,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Time to disease progression
9728,NCT04223401,Postoperative morbidity rate by Clavien-Dindo,2020-02-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Psychological status by Hospital Anxiety and Depression Scale (HADS).
9729,NCT03973112,ORR,2019-09-24,UNKNOWN,INTERVENTIONAL,['PHASE2'],,DOR
9730,NCT05843188,Overall response rate,2023-08-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidences and severity of adverse events
9731,NCT03675737,Overall Survival (OS) In Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10,2018-11-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of Participants Who Discontinued Study Treatment Due To an Adverse Event (AE)
9732,NCT00354679,Evaluation of Safety and Toxicity,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9733,NCT05038098,Safety of endoscopic peritumoral gastric injection of FerroTrace,2024-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,
9734,NCT06229041,The PCR rate between total neoadjuvant treatment ±immunotherapy,2023-03-29,RECRUITING,INTERVENTIONAL,['PHASE3'],,
9735,NCT03636893,Total Percentage of Patients With Pathological Complete Tumor Regression (TRG1a) and Sub-total Tumor Regression (TRG1b) in the Primary Tumour,2018-08-24,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS) Disease Free Survival (DFS)
9736,NCT00177853,"Determine efficacy of combination of irinotecan, celecoxib and concurrent radiotherapy on pancreatic cancer; determine highest/safest doses of these drugs",2006-12,TERMINATED,INTERVENTIONAL,['PHASE1'],,Tumor diminishment for safe excision
9737,NCT00483080,Progression Free Survival (PFS),2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety according to NCI-CTCAE criteria (version 3)
9738,NCT00417287,Determine if there is a difference in effect on circulating Trx-1 protein levels between two dose levels of PX-12,2006-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Assess the effects of metabolic excretion of PX-12
9739,NCT00225784,Objective Response of Tumor by RECIST 1.0 Criteria,2005-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Pattern of Failure After Therapy
9740,NCT06022861,Objective Response Rate(ORR) as assessed by IRC,2023-10-12,RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence of Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (Nab)
9741,NCT05001009,Percent of patients with a goals of care conversation note documented in Stage 2,2022-09-13,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Percent of patients with a goals of care conversation note documented in Stage 1
9742,NCT01752933,Disease Control Rate (DCR) at 16 Weeks for Patients Treated With Guadecitabine After Failure of Sorafenib,2012-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
9743,NCT04753879,Progression-free Survival (PFS) after 6 months according to IRECIST criteria.,2021-09-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants experiencing grade 3 or above drug-related toxicities
9744,NCT01764802,"Sexual pain graded using the International Pelvic Pain Society Pelvic Pain Assessment, patient/physician version",2010-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Body change stress graded according to the Impact of Treatment Scale (ITS)
9745,NCT04989387,"Evaluation of Recommended Dose for Expansion (RDE) of INCA00186 as monotherapy and in combination with retifanlimab and/or INCB106385 as measured by safety, PK and PD data",2021-10-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,"Duration of Response (DOR) from earliest date of disease response until earliest date of disease progression as determined by radiographic disease assessment, or death if occurring sooner than progression"
9746,NCT04927897,Maximum distance of microscopic tumor spread per patient in all directions from the macroscopic tumor remnant in the pathology specimen,2022-08-16,RECRUITING,OBSERVATIONAL,['NA'],Analysis of (re)biopsy material,Evaluation of risk factors for the presence and/or the extent of microscopic tumor spread identified by the meta-analysis we performed
9747,NCT03768531,Number of participants experiencing study drug-related toxicities,2019-06-14,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Disease free survival (DFS)
9748,NCT00132041,Proportion of Participants With Successful Control of Disease at 18 Months,2005-12,COMPLETED,INTERVENTIONAL,['NA'],,Remote Tumor Occurrence Rates
9749,NCT03189914,Number of Participants With Progression Free Survival (PFS) and/or Objective Clinical Response (Phase 2),2017-10-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Quality of Life (QOL) (Phase 1 and 2),Maximum Observed Concentration [Cmax] of Abraxane (Phase 1 and Phase 2) - Day 15
9750,NCT02762448,HCV clearance and complete regression of NHL by ASV+ DCV,2016-07,WITHDRAWN,OBSERVATIONAL,['NA'],,
9751,NCT02611700,Median time of overall survival(OS),2015-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Incidence of adverse events
9752,NCT04694794,Utility of Educational Brochure assessment,2021-03-24,COMPLETED,INTERVENTIONAL,['NA'],Feasibility Assessment,Baseline Educational Assessment
9753,NCT02611661,Safety and tolerability of administering hepatic locoregional therapy following radioembolization as measured by occurrences of grade 3 or higher toxicities of interest,2016-01-19,TERMINATED,INTERVENTIONAL,['PHASE1'],,Response rates associated with radioembolization followed by dosimetry-guided subsequent hepatic locoregional therapy
9754,NCT00775073,Time to Progression,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
9755,NCT05616533,The coincidence rate of tumor response obtained from 50 PDX models with clinical real tumor response acquired from corresponding patients received neoadjuvant therapy.,2023-09-12,RECRUITING,OBSERVATIONAL,['NA'],,
9756,NCT00798746,Reflux Symptoms: Open Esophagectomy versus Minimally Invasive,2008-11,COMPLETED,OBSERVATIONAL,['NA'],,
9757,NCT02069041,Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,2014-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Percentage of Participants With Best Response of Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])
9758,NCT05668793,validity,2023-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,reliability
9759,NCT04825574,Safety as assessed by the number of serious adverse events and adverse events of special interest,2021-05-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],,
9760,NCT06255379,Progression Free Survival (PFS),2024-03-22,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,adverse events (AE)
9761,NCT01559844,Number of Participants Who Died,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Proportion of Participants With Virologic Failure Prior to Transplant
9762,NCT04736043,Overall survival rate,2021-01-31,RECRUITING,OBSERVATIONAL,['NA'],,
9763,NCT03153332,The primary outcomes was the precise allocation of hepatic disease,2017-07-01,COMPLETED,OBSERVATIONAL,['NA'],,Time spent to judge tumor location
9764,NCT03814005,"Part A, Cmax: Maximum Observed Plasma Concentration for Pevonedistat Following a Single Dose",2019-07-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Part B, Percentage of Solid Tumors Participants with CR or PR"
9765,NCT05124704,Predicted effect-site concentration of propofol (Ceprop) at certain time points,2021-07-01,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative exhaust time
9766,NCT01542177,Measure the hypoxia level in Patients with Pancreatic Cancer using Positron Emission Tomography (PET) with 18F-Fluoroazomycin Arabinoside (18F-FAZA).,2012-02,COMPLETED,OBSERVATIONAL,['NA'],,Determine the feasibility of using dynamic and static PET imaging of FAZA uptake in patients with pancreatic cancer.
9767,NCT04616950,Hospital course of patients with cancer of the digestive system,2020-12-01,COMPLETED,OBSERVATIONAL,['NA'],,Modeling of the hospital journey based on observations made during the period preceding the COVID-19 epidemic
9768,NCT05640609,the objective Response Rate (ORR) of the experimental group.,2023-03-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,disease control rate (DCR)
9769,NCT05220020,Two-Years Overall Survival Rate,2022-05-18,RECRUITING,INTERVENTIONAL,['PHASE3'],,"Evaluate the patients cancer-related QoL using the European Organization for Research and Treatment of Cancer (EORTC) QOL questionnaire (QLQ), the EORTC QLQ-C30."
9770,NCT04138654,Change in whole genome gene expression analyses in colonic biopsies and blood between baseline levels and each intervention period (transcriptomics),2014-04-17,COMPLETED,INTERVENTIONAL,['PHASE1'],Change in O6-MeG in colonic biopsies between baseline levels at the start of the intervention and each intervention period,Change in the microbiome in feacal samples and in saliva between baseline levels at the start of the intervention and each intervention period
9771,NCT03944252,Primary endpoint is Objective Response Rate (ORR).,2018-09-18,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
9772,NCT04633512,"Support personnel satisfaction with ActivSightTM, as quantified by Likert scale.",2020-11-17,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Ability of ActivSightTM to display biliary tree.
9773,NCT01581840,Response to treatment,2012-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
9774,NCT00484211,Antitumour activity defined as progression free survival (PFS),2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Experimental imaging study (DCE-MRI)
9775,NCT05651672,Overall response rate (ORR),2022-12-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events (AEs)
9776,NCT01703585,Patient recruitment for paired core and fine needle biopsy greater than or equal to 50% of those screened or approached.,2012-10-04,COMPLETED,OBSERVATIONAL,['NA'],,Actionable genomic result analysis of fresh core needle biopsy samples and fresh fine needle biopsy samples greater than or equal to 30%
9777,NCT04635488,metastasis rate of lateral lymph node,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
9778,NCT02051868,Best overall response rate by 24 weeks post treatment,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Identification of potential tumour biomarker
9779,NCT04843189,Number of lymph nodes harvested,2021-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,5-year overall survival
9780,NCT03120195,Feasibility of EndoRotor® for the ablation of Barrett's mucosa,2017-01-27,COMPLETED,INTERVENTIONAL,['NA'],,Ease of performing the EndoRotor® procedure
9781,NCT02282722,Number of Patients With Accurate Understanding of Chemotherapy Benefits,2015-06-10,COMPLETED,INTERVENTIONAL,['NA'],,Patient-Reported Prognostic Understanding in Median Years
9782,NCT01735799,,2012-11,UNKNOWN,OBSERVATIONAL,['NA'],,
9783,NCT02781935,Negative Predictive Value (NPV) of the diagnostic imaging (DW-MRI),2016-11,COMPLETED,OBSERVATIONAL,['NA'],,Long term outcomes of patients who underwent surgery in terms of: - recurrence rates for 2 years after surgery - progression free survival for 2 years after surgery - overall survival for 2 years after surgery
9784,NCT06330441,Number of participants with newly diagnosed pancreatic ductal adenocarcinoma,2022-01-07,RECRUITING,INTERVENTIONAL,['NA'],,KRAS mutation status evaluation
9785,NCT03412877,Response rate,2018-09-06,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and tolerance
9786,NCT03113318,5-year overall survival,2015-10,UNKNOWN,INTERVENTIONAL,['NA'],,30-day mortality
9787,NCT03044743,Number of participants with Adverse Events using Common Terminology Criteria for Adverse Events (CTCAE v4.0) in patients,2017-04-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Th1/Th2 change in the peripheral blood
9788,NCT00545545,To determine safety and maximum tolerated dosage of Imprime PGGwhen used in combination with cetuximab with and without irinotecan therapy in patients with recurrent/progressive colorectal carcinoma previously treated with a 5-FU regimen.,2007-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"To determine the tumor response rates (complete response, partial response, stable disease, overall response rate), time to progression, duration of overall tumor response, and the duration of stable disease in patients receiving the combination therapy."
9789,NCT00449995,diagnostic accuracy of confocal laser scanning microscopy for detection of metaplasia or neoplasia in Barrett´s esophagus,2007-03,COMPLETED,INTERVENTIONAL,['NA'],,inter- and intra observer variability for confocal laser scanning microscopy
9790,NCT00398086,Number of Participants With Dose-limiting Toxicities,2006-11-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Maximal Degree of Anemia
9791,NCT00407186,overall survival,2007-01-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,health-related quality of life
9792,NCT04312633,Primary Outcome Measure:,2020-04-01,RECRUITING,OBSERVATIONAL,['NA'],,Secondary Outcome Measure:
9793,NCT03259867,Overall Response Rate,2017-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
9794,NCT03829852,"Effectiveness of regorafenib use in routine clinical practice setting, assessed by tumor response",2019-02-11,COMPLETED,OBSERVATIONAL,['NA'],"Exploratory outcome: Image pattern as the potential predictive factor for regorafenib treatment outcome in overall cohort and long-term responders, assessed by changes in image patterns","Eligibility of subsequent therapies and the outcome, assessed by PFS"
9795,NCT00824785,Overall survival,2008-05,TERMINATED,INTERVENTIONAL,['PHASE3'],,"response rate, toxicity, quality of life and PFS"
9796,NCT00238212,Response probability (confirmed complete and confirmed partial responses),2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to progression
9797,NCT06006026,The safety profile of combining ropivacaine and lidocaine,2023-08-28,COMPLETED,INTERVENTIONAL,['NA'],,The plasma concentration of lidocaine
9798,NCT01460888,Maximum Tolerated Dose (MTD) of olaparib in combination with radical radiotherapy in patients with oesophageal cancer,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Exploration of blood and tissue borne pharmacodynamic markers to establish the biological efficacy of the addition of Olaparib to radiotherapy.
9799,NCT02349958,measure treatment response to HIPEC and tumor debulking,2006-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],QOL,Toxicity Monitoring
9800,NCT05055648,Pulmonary complications,2022-05-01,RECRUITING,INTERVENTIONAL,['NA'],Concordance of observed cardiac complications with predicted,Overall survival (OS)
9801,NCT03162510,MTD of Oxaliplatin,2018-06-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival
9802,NCT00260559,Change from baseline in SF36 Quality of Life Questionnaire at 36 month,1999-05,RECRUITING,OBSERVATIONAL,['NA'],,
9803,NCT03187951,Change in 6 Minute Walk Test (6MWT),2017-06-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
9804,NCT04174079,Disease-free survival,2019-12-11,RECRUITING,INTERVENTIONAL,['NA'],,overall survival
9805,NCT00382720,Time to Progression,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
9806,NCT05010681,Objective Response Rate (ORR),2021-08-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
9807,NCT03368859,Progression Free Survival (PFS),2018-03-20,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
9808,NCT05266300,Adverse events,2020-09-01,COMPLETED,OBSERVATIONAL,['NA'],,Rate of discontinuation of fluoropyrimidines due to adverse events
9809,NCT04923529,16-week progression-free survival (PFS) rate,2021-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety outcome measures
9810,NCT02465060,Objective response rate,2015-08-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression free survival
9811,NCT00220064,Disease stabilization rate or tumour marker response,2000-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9812,NCT02276768,Mean visceral pain intensity score following dosing with GIC-1001 375 mg TID,2014-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Standard laboratory measures (biochemistry, hematology, urinalysis)"
9813,NCT05057052,Objective Response Rate (ORR),2021-09-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
9814,NCT04973306,Overall survival(OS),2022-03-02,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Correlation between genetic profile and tumor response
9815,NCT06039280,Prevention of post-embolization syndrome,2023-09-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Adverse events of Dexamethasone and NAC in patients undergoing transarterial chemoembolisation for HCC
9816,NCT00305877,Proportion of Patients With Specific Protocol Defined Adverse Event at Conclusion of All Therapy,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Two-year Disease-free Survival (DFS)
9817,NCT04740346,3-year overall survival,2021-07-05,RECRUITING,INTERVENTIONAL,['NA'],,Incidence of vitamin B12 deficiency
9818,NCT00006006,,2000-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9819,NCT01186731,Response rate of tumor size reduction at 110 mg/m2 LE-DT dose level,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,SPARC tumor expression following the treatment of LE-DT at 110 mg/m2 dose level
9820,NCT04375930,means of quality of life change,2019-01-18,COMPLETED,INTERVENTIONAL,['NA'],,
9821,NCT02381561,Maximum tolerated dose (MTD) defined as the dose below which 2 or more of 6 patients experience dose-limiting toxicity,2016-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Tumor response relationship to the %iododeoxyuridine (IUdR)-deoxyribonucleic acid (DNA) incorporation using Response Evaluation Criteria in Solid Tumors (RECIST) criteria based on high-pressure liquid chromatography (HPLC) and flow cytometry measurements
9822,NCT03258398,Part 2: Overall Response Rate,2017-09-18,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9823,NCT02563158,Serum total bilirubin on postoperative day 5,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],,Long-term survival
9824,NCT02024607,The Objective Response Rate of Napabucasin Administered in Combination in FOLFIRI in Patients With FOLFIRI/XELIRI-refractory Metastatic Colorectal Cancer,2014-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival of Patients With FOLFIRI/XELIRI-refractory Metastatic Colorectal Cancer
9825,NCT01003600,"Assess colorectal cancer survivors' basic knowledge of their own cancer history, including date of diagnosis, stage, and treatments received.",2009-10,COMPLETED,OBSERVATIONAL,['NA'],,Assess whether survivors who had concerns about working after cancer treatment spoke with health care professionals about their concerns.
9826,NCT01133132,Change in level of physical activity,2010-02,COMPLETED,INTERVENTIONAL,['NA'],,
9827,NCT00114179,Overall survival rate,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response rate
9828,NCT00002664,,1995-07,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
9829,NCT05025826,Demonstrate a 50% decrease of the grade> or = 2 neurotoxicity at 4 months after oxaliplatin-based chemotherapy start in the PHYCOCARE arm,2022-04-01,RECRUITING,INTERVENTIONAL,['NA'],,Comparison between the two arms of Neurological toxicities
9830,NCT05425940,Overall Survival,2022-09-07,RECRUITING,INTERVENTIONAL,['PHASE3'],Duration of Response (DOR) as assessed by the Investigator per RECIST 1.1,Overall Survival
9831,NCT00364364,"For patients who undergo surgery after the 111In-hPAM4 study, targeting will be correlated against surgical findings.",2007-05,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,"Targeting with 111In-hPAM4 will be compared to other radiological (e.g., CT) and nuclear (FDG-PET; optional)findings."
9832,NCT04638959,differences in abundance of gut microbiota,2019-09-30,UNKNOWN,OBSERVATIONAL,['NA'],Basic information of patients with different clinical outcomes,evidence of gastric carcinoma
9833,NCT00031694,Response Rate of at Least 30%,2002-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Bryostatin 1 Pharmacokinetics,Overall Survival
9834,NCT03866525,The anti-tumor activity of OH2 monotherapy and in combination with irinotecan or HX008,2019-04-02,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The immunogenicity of OH2
9835,NCT01474642,response rate,2008-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,predictive marker
9836,NCT00590239,Pathologic and Clinical Outcomes,2007-05-15,RECRUITING,OBSERVATIONAL,['NA'],,Efficacy of endoscopic detection of early esophageal lesions
9837,NCT05732662,ORR,2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Treatment Related Severe Adverse Effects
9838,NCT06104241,Dose-limiting toxicity (DLT）,2023-10-22,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,PFS
9839,NCT03171298,intraoperative complication,2017-06-01,UNKNOWN,INTERVENTIONAL,['NA'],,Mesorectal completeness
9840,NCT04293497,The comparison of sensitivity between conventional staining method and new staining method,2020-02-17,COMPLETED,INTERVENTIONAL,['NA'],,The evaluation of correlation index of staining at three type slides
9841,NCT05172635,Pathological response of the primary tumour,2014-06-01,COMPLETED,OBSERVATIONAL,['NA'],,90 day mortality
9842,NCT05188209,Adverse Events (AEs),2021-05-24,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The proportion of patients with positive of anti-drug antibody (ADA)
9843,NCT01712347,Overall survival from the time of starting first-line therapy,2012-10-11,COMPLETED,OBSERVATIONAL,['NA'],,Number of participants with adverse events
9844,NCT05226169,Maximum change of Hb concentration,2022-04-29,RECRUITING,INTERVENTIONAL,['PHASE3'],,OS
9845,NCT02997293,Hospital length of stay,2017-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
9846,NCT03474354,CORRELATION OF LUMI DISTRIBUTION WITH NECROSIS,2018-05-02,COMPLETED,OBSERVATIONAL,['NA'],,Distribution of radiopaque beads and correlation with necrosis
9847,NCT00415155,Phase 2: Time to progression,2008-08,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Safety
9848,NCT06323382,Progression-Free-Survival (PFS),2021-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Adverse events
9849,NCT06051695,Phase 2: The Overall Response Rate (ORR) for patients,2024-03,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Cytokine analysis
9850,NCT04186117,Isolation of circulating tumoral cells,2016-09-09,RECRUITING,INTERVENTIONAL,['NA'],,
9851,NCT00353262,AUC0-inf for Free Platinum,2005-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Marked Laboratory Abnormalities
9852,NCT00535353,"Correlation, if any, between the toxicity profile and pharmacokinetics",2008-01-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacodynamic outcomes
9853,NCT04203641,Adverse events (as per CTCAE v. 5.0),2019-12-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Proportion of patients expressing anti-L-DOS47 antibodies
9854,NCT03343301,Number of Participants With Dose Limiting Toxicities (DLTs),2017-11-30,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Treatment Induced Anti-bemarituzumab Antibodies
9855,NCT04446793,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
9856,NCT03699371,Long-term quality of life at 6 months,2018-11-01,UNKNOWN,INTERVENTIONAL,['NA'],PCS SF-36 change,Antibiotic-free days
9857,NCT02442323,Patient-reported outcome of quality of life,2013-08-09,COMPLETED,INTERVENTIONAL,['NA'],,
9858,NCT04689347,"To evaluate the safety and to determine the recommended phase 2 dose of the combination of FLIRT- bevacizumab in patients with MGMT silenced and MSS mCRC, previously untreated for advanced disease",2021-01-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],OS of FLIRT bevacizumab,Quality of life as assessed using the Euro Quality of Life 5 Dimensions Questionnaire (EQ-5D-5L)
9859,NCT05718115,Predict response to anti-HER2 directed therapy using DLR,2023-02-15,RECRUITING,OBSERVATIONAL,['NA'],,
9860,NCT04161287,Local control rates,2019-10-11,RECRUITING,OBSERVATIONAL,['NA'],,Adverse reaction
9861,NCT02069704,AUC at Steady State (AUCss) of BEVZ92 and Avastin®,2014-10-29,COMPLETED,INTERVENTIONAL,['PHASE1'],,Volume of Distribution (Vd) of BEVZ92 and Avastin®
9862,NCT02256514,Effect of hepcortespenlisimut-L (V5) immunotherapy on tumor size or clearance,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Effect of hepcortespenlisimut-L (V5) immunotherapy on patients' performance
9863,NCT01364805,Determine safety of combined gemcitabine chemotherapy with IV ascorbate.,2011-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Assess pharmacokinetic and pharmacodynamic interactions when adding IV AA to front-line gemcitabine chemotherapy in the treatment of locally advanced or metastatic pancreatic cancer not eligible for surgical resection.
9864,NCT02586701,Six Minute Walk Test (6MWT),2013-09,COMPLETED,INTERVENTIONAL,['NA'],,
9865,NCT00297648,Mean Change From Baseline in CDEIS (Crohn's Disease Endoscopic Index of Severity) Score at Week 10 Using Central Blinded Assessments,2006-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change From Baseline in Crohn's Disease Activity Index (CDAI) Score at Week 54
9866,NCT03042169,Overall survival,2021-08-25,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Number of interventional palliative procedures per patient
9867,NCT05829057,Number of participants with physical examinations,2023-05-23,RECRUITING,INTERVENTIONAL,['PHASE1'],,changes of cytokines relative to the baseline
9868,NCT02664077,"Disease-free survival (DFS) - time from randomization until first colon cancer recurrence, second primary colon cancer, or death due to any cause.",2016-06,TERMINATED,INTERVENTIONAL,['PHASE3'],,Compare the symptoms experienced by patients receiving regorafenib to patients receiving placebo during treatment as measured by Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
9869,NCT04866381,Objective Response Rate,2021-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Subject safety
9870,NCT03777475,OS,2016-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,PFS
9871,NCT03839706,18F-FDG PET/MRI results can identify aggressive HCC behavior and recurrence post transplant,2018-08-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,18F-FDG PET/MRI are related to presence of circulating tumor DNA in plasma
9872,NCT05059717,Magnetic Resonance Displacement Encoding with Stimulated Echo (MR DENSE) imaging data of patients treated with chemotherapy prior to resection of metastases to explore its utility in detecting sinusoidal liver injury.,2018-07-12,WITHDRAWN,INTERVENTIONAL,['NA'],,
9873,NCT02352337,Rate of patients alive and without radiological and/or clinical progression,2014-12-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression survival
9874,NCT01770405,performance evaluation,2013-09,COMPLETED,OBSERVATIONAL,['NA'],,Safety and feasibility evaluation
9875,NCT02965209,Diagnostic yield of NMSE in patients with suspected small bowel diseases,2015-11,COMPLETED,INTERVENTIONAL,['NA'],,Adverse events
9876,NCT04152889,DFS,2020-04-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
9877,NCT04525313,response rate,2020-08,UNKNOWN,OBSERVATIONAL,['NA'],,progression free survival
9878,NCT04039360,stoma rate,2014-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
9879,NCT02600143,Genetic predisposition for immunotherapy-induced colitis,2013-08,COMPLETED,OBSERVATIONAL,['NA'],,Analysis of the gut microbiome in stool samples
9880,NCT01659424,Phase II Trial of Preoperative High-dose-rate Endorectal Brachytherapy (BT) Improve Compliance,2011-06,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,4) Quality of Life
9881,NCT05594914,AE,2022-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
9882,NCT01467921,disease-free survival,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
9883,NCT01605305,TPP,2008-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,OS
9884,NCT03072472,Adenoma Detection Rate,2017-02-14,COMPLETED,INTERVENTIONAL,['NA'],,Compare the baseline ADR of each colonoscopist prior to trial recruitment with their individual ADR in patients where EndocuffTM Vision was not used.
9885,NCT01214343,Overall survival,2010-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Biomarker predicting the efficacy
9886,NCT05856305,Acute Toxicity,2023-07-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,Tumor Volume reduction kinetics
9887,NCT02837263,Recurrence rate at 1 year,2016-08-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Expression levels of PDL1,Overall survival estimated using the Kaplan-Meier method
9888,NCT05432193,Treatment emergent adverse events,2022-07-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Uptake of the [Ga-68]-PNT6555 imaging agent and optimal scanning specifications for future studies,Uptake of [Ga-68]-PNT6555 in tumor lesions
9889,NCT04180761,Incidence of peritoneal metastases and proportion of patients free from peritoneal metastasis after one year after HIPEC.,2019-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by grading according to CTCAE v5.0 and Clavien-Dindo.
9890,NCT00971126,"Terms of efficacy assessment: objective tumor response, overall survival, progression-free survival. Terms of safety assessment: adverse effects, laboratory values.",2009-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
9891,NCT01853319,Progression-Free Survival (PFS),2013-07-24,COMPLETED,INTERVENTIONAL,['PHASE3'],,
9892,NCT01110798,Major anastomotic leak rate,2009-10,UNKNOWN,INTERVENTIONAL,['NA'],,"Bowel function, fecal incontinence, and quality of life, evaluated with validated questionnaires"
9893,NCT03676075,Sensitivity and specificity of the model in the diagnosis of colorectal cancer and adenoma,2018-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,
9894,NCT04469556,Progression free survival(PFS) in mFFX and GA arms pancreatic ductal adenocarcinoma (PDAC) in a randomized phase II trial.,2020-10-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Cluster Tendency analysis using artificial neural networks and radiomic methods combined
9895,NCT05520385,"an association between occurrence of CRC and blood group A+ , O + .",2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],,an association between occurrence of CRC and overweight and class І obesity patients
9896,NCT00188110,To evaluate the performances of the WE-CT in patients suspected of having a colon tumor,2003-03,UNKNOWN,INTERVENTIONAL,['NA'],,To demonstrate the advantages of the WE-CT compared to the CT and magnetic resonance (MR) colonography for the diagnosis and local staging of colon tumors
9897,NCT01269216,pathologic complete response rate,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9898,NCT06311396,Omics studies and functional morphological studies,2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],,
9899,NCT04131192,Rate of dose limiting toxicities of each subject,2019-11-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
9900,NCT04177602,Rate of pathological complete remissions (pCR)/Phase 2 part,2019-11-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Rate of perioperative complications
9901,NCT05605600,Development of LARS Severity tool,2022-10-03,COMPLETED,OBSERVATIONAL,['NA'],,Commence initial psychometric evaluation of the New LARS score
9902,NCT00769782,Recurrence-free survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Types and severities of adverse events
9903,NCT05051358,Safety of procedure,2021-02-11,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Cost Effectiveness
9904,NCT05323409,Instrument to measure Self-Management (IMSM),2022-04-01,RECRUITING,INTERVENTIONAL,['NA'],,Supportive Care Needs Survey (SCNS)
9905,NCT02665026,Postoperative complication,2016-01-04,COMPLETED,INTERVENTIONAL,['NA'],,Disease-free survival
9906,NCT05480306,Progression Free Survival (PFS),2022-08-30,RECRUITING,INTERVENTIONAL,['PHASE2'],Exposure-response relationships for DKN-01 as data permit.,Incidence of ≥Grade 3 related treatment-related adverse events (TRAEs).
9907,NCT02140463,feasibility,2014-02,COMPLETED,OBSERVATIONAL,['NA'],,response rate
9908,NCT04949672,Completeness of mesorectal fascia and specimen quality (specimen integrity after rectal resection),2017-01,COMPLETED,OBSERVATIONAL,['NA'],,Cancer specific survival (CSS)
9909,NCT02714374,Number of participants with treatment-related adverse events as defined by CTCAE v4.03.,2016-03-25,TERMINATED,INTERVENTIONAL,['PHASE1'],,Amount of lymphocyte infiltration in pre-treatment biopsy and post-treatment resected tumor tissue
9910,NCT00267020,Overall Survival (OS),2005-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants Experiencing Serious Adverse Events (SAEs) and Adverse Events (AEs) (Toxicity)
9911,NCT03976739,corelation between the bile reflux and gastric mucosa diseases,2019-06-17,COMPLETED,OBSERVATIONAL,['NA'],,the risk factors of primary bile reflux gastritis
9912,NCT04361162,Overall response rate (ORR),2020-05-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS) in patients
9913,NCT04552093,Completion of 2 combined chemotherapy cycles (feasibility),2020-09-09,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Quality of life assessment,Conversion rate colorectal liver metastases (CRLM)
9914,NCT04521491,Recurrence free survival(RFS),2020-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,Overall survival(OS)
9915,NCT06210724,Colorectal Cancer,2023-10-09,RECRUITING,OBSERVATIONAL,['NA'],Blood tests,Microscopic colitis
9916,NCT02636088,Local tumour Control,2011-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life
9917,NCT01521104,,2009-01,COMPLETED,OBSERVATIONAL,['NA'],,
9918,NCT01802203,Collect efficacy and outcome data related to the use of trūFreeze® spray cryotherapy for treatment of unwanted tissue in the pulmonary and gastrointestinal settings.,2013-04,COMPLETED,OBSERVATIONAL,['NA'],,Collect safety data related to the use of trūFreeze® spray cryotherapy for treatment in the pulmonary and gastrointestinal settings.
9919,NCT01802320,Overall Response Rate (CR+PR) Evaluated Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Validation of the Enrichment Biomarker Signature in Metastatic Sites,Progression-free Survival (PFS)
9920,NCT02070822,tumor response,2011-08,UNKNOWN,OBSERVATIONAL,['NA'],,change of baseline MRI parameters
9921,NCT04450732,Maximum Tolerated Dose (MTD) or Dose Recommended for Dose Expansion (DRDE),2020-07-07,RECRUITING,INTERVENTIONAL,['PHASE1'],,Preliminary Efficacy
9922,NCT01505972,Participation rate,2011-03,COMPLETED,INTERVENTIONAL,['NA'],,Response rate in FOUR&TWO group
9923,NCT05613621,clinical outcomes of MAFLD vs. non-MAFLD.,2022-11-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
9924,NCT02191566,"3-year recurrence-free survival, RFS",2015-05,TERMINATED,INTERVENTIONAL,['PHASE2'],compliance for chemotherapy,"5-year overall survival, OS"
9925,NCT06111326,Phase II: Dose Expansion Part-objective response rate (ORR),2023-10,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
9926,NCT04793958,Progression-free Survival (PFS),2021-03-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of Life Assessment
9927,NCT05641896,Positive predictive value will be determined on a per-lesion basis for all lesions with tissue available for FAP analysis.,2023-04-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,Further characterize the safety profile of [18F]FAPI-74 in subjects utilizing Common Terminology Criteria for Adverse Events (CTCAE v5)
9928,NCT03841799,Characterization of colorectal tissue microenvironment of patients with locally colorectal neoplasia.,2019-05-02,RECRUITING,OBSERVATIONAL,['NA'],,Identification of potential molecular abnormalities in cancer cells from colorectal tissue and from blood samples.
9929,NCT05181306,Recurrence,2010-10-01,COMPLETED,OBSERVATIONAL,['NA'],,Cost
9930,NCT05067153,Prothrombin fragment F1+2,2021-05-01,RECRUITING,INTERVENTIONAL,['PHASE4'],,Mortality
9931,NCT00625573,"To evaluate the efficacy by means of response rate of Abraxane and capecitabine in combination, in the treatment of patients with colorectal cancer in the 2nd or 3rd line metastatic setting following failure of irinotecan or oxaliplatin based therapy",2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To evaluate overall survival, time to progression, response duration, time to response and safety of this combination"
9932,NCT06148636,Determine recommended therapeutic dose of [212Pb] VMT-α-NET,2023-11-10,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Maximum tolerated radiation dose for kidneys
9933,NCT01214681,Faecal calprotectin concentration,2010-05,UNKNOWN,INTERVENTIONAL,['NA'],,Plasma short chain fatty acid concentration
9934,NCT00081289,Pathologic Complete Response Rate,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change From Baseline in EORTC QLQ-CR38 Defecation Symptom Score at Two Years
9935,NCT02785380,Overall survival,2016-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],Number of Participants With Treatment-Related Adverse Events as Assessed by,Recurrence-free survival
9936,NCT06054308,pathologic response,2024-02-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Disease free and overall survival
9937,NCT01438437,Local tumor response,2001-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Change from baseline in Child status at 1 year
9938,NCT04454476,Safety of Trametinib treatment: adverse events,2022-11-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
9939,NCT05013697,Progression free survival (PFS， RECIST assessment),2021-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-related adverse Events
9940,NCT06006923,"Progression-free Survival (PFS), Randomize Phase",2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,"Objective Response Rate (ORR), Randomized Phase"
9941,NCT03111823,Total number of minutes exercised per week with >80% total weekly minutes (48/60 minutes) completed,2016-07-07,TERMINATED,INTERVENTIONAL,['NA'],Change in endothelial function,Change in QOL
9942,NCT04486651,Overall Survival (OS) in Participants With PD-L1 CPS≥1,2020-09-16,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
9943,NCT02789891,3-year disease overall survival rate,2016-06,UNKNOWN,INTERVENTIONAL,['NA'],,EORTC QLQ-C30 and QLQ - STO22
9944,NCT01284504,"Blood Samples Taken Before Initiation of Study, Day of Surgery, Days 1 and 3 Post-op, and 30 Days Post-op. Analyzed for 50 Serum Cytokines, Cell-specific Gene Expression, and TCR Repertoire.",2011-01,TERMINATED,INTERVENTIONAL,['NA'],,"Surveys to Evaluate Patient Pain, Fatigue, and Quality of Recovery, Recorded From Day of Surgery to 30 Days Post-op."
9945,NCT04195373,Determine MTD and dose for phase II,2020-11-23,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Efficacy of therapy assessed by changes in tumor marker level
9946,NCT01998152,Change in skeletal muscle area (cm2) between individualized nutritional counselling versus usual nutritional care,2013-11,COMPLETED,INTERVENTIONAL,['NA'],,"Associations of (changes in) muscle area with (changes in) mid-upper arm muscle circumference, whole body fat free mass (BIA) and whole body lean body mass (DEXA)."
9947,NCT03563326,EpCAM CAR-T cells treatment related adverse events,2018-08-30,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Progress free survival outcome
9948,NCT00005030,,1999-09-29,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
9949,NCT01915225,"Collection of biologic samples from patients undergoing diagnostic or therapeutic interventions for premalignant, primary or metastatic solid tumors for the purpose of identifying novel molecular and biologic therapeutic targets",2013-07-21,RECRUITING,OBSERVATIONAL,['NA'],,"Collection of detailed history, demographic, treatment data, and perioperative outcomes data related to surgical quality and safety in order to categorize and track the specific procedures."
9950,NCT04768218,To externally validate the EGGIM score classification using BLI,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
9951,NCT01198548,Rate of Sufficient Cholecalciferol,2010-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,PFS of Patients Receiving Study Treatment
9952,NCT05091346,Phase 2 Part: Objective Response Rate (ORR),2021-10-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2 Part: Apparent Clearance for Lenvatinib When Co-administered With E7386 and Pembrolizumab
9953,NCT03542877,12-Week Progression Free Survival,2018-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS) by PIK3CA Mutation Status
9954,NCT05382364,Percentage of participants discontinuing from study therapy due to AE,2022-06-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Duration of Response (DOR) Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1)
9955,NCT05440552,Detection rate,2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
9956,NCT00353015,Participant Response Rate of Irinotecan and Cisplatin,2003-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9957,NCT04833959,Incidence of treatment emergent adverse events assessed by CTCAE v5,2021-03-26,SUSPENDED,INTERVENTIONAL,['PHASE1'],,
9958,NCT05156788,R0 resection rate,2021-12-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,RFS
9959,NCT00125021,To assess the response rate associated with capecitabine and OSI-774 in patients with advanced pancreatic cancer,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,to estimate the time to progression and overall survival of patients with advanced pancreatic cancer treated with capecitabine and OSI-774
9960,NCT03604991,Disease-free survival (DFS) (Step 2),2019-05-03,SUSPENDED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Percent change in mean volumetric apparent diffusion coefficient (ADC),DFS
9961,NCT05225844,progression-free survival（PFS）,2019-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease control rate(DCR)
9962,NCT06207656,Efficacy of cetuximab in combination with encorafenib plus binimetinib as induction therapy for the treatment of BRAF-V600E mutated MSS aCRC to perform radical treatment of the primary and/or metastases,2024-01-19,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],To determine the presence/expression level/levels of serum and tumour tissue biomarkers associated with cell and tumour growth and/or involved in the mechanisms of action of EBC,Incidence and severity of AEs CTCAE v5 criteria
9963,NCT02231723,Determination of the Recommended Phase 2 Dose by assessing dose-limiting toxicities (DLTs),2014-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Assess pharmacodynamic activity of BBI608 when administered in combination with standard chemotherapies
9964,NCT04001101,Out-of-field ORR improvement,2019-10-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Quality of life score
9965,NCT05583292,rate of mortality,2023-02-11,COMPLETED,OBSERVATIONAL,['NA'],,
9966,NCT00054912,,2003-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9967,NCT00408122,,2007-01,COMPLETED,OBSERVATIONAL,['NA'],,
9968,NCT01691664,Disease free survival,2012-09,UNKNOWN,INTERVENTIONAL,['NA'],Immunological assessment,quality of life
9969,NCT02350166,30-day complications,2013-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,C-reactive protein
9970,NCT05718882,Progression free survival,2023-07-01,RECRUITING,INTERVENTIONAL,['NA'],,Safety endpoint
9971,NCT00053924,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9972,NCT01652196,Proportion of patients alive and progression-free,2012-11-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Proportion of patients who go off treatment due to adverse reactions or even those who refuse further treatment for lesser toxicities that inhibit their willingness to continue participation on the trial
9973,NCT03757455,Days until discharge from university hospital,2020-09-01,TERMINATED,INTERVENTIONAL,['NA'],,Readmission frequency
9974,NCT05305001,BRCA 1/2 germline mutation prevalence,2020-09-09,COMPLETED,OBSERVATIONAL,['NA'],The proportion of germline mutation carriers who accept pancreatic cancer surveillance.,Clinical and pathological characteristics
9975,NCT00502177,PedsQL 4.0 Generic Core Scale,2007-06-19,COMPLETED,OBSERVATIONAL,['NA'],,
9976,NCT04186156,Proportion of patients alive and progression free at 4 months,2020-03-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,To determine the pharmacodynamic response to KA2507
9977,NCT00695227,The primary aim of the study is to establish that patients with symptoms of LPR who are referred to an otolaryngology clinic have a prevalence of Barrett's metaplasia equivalent to that of a population with GERD symptoms.,2004-05,COMPLETED,INTERVENTIONAL,['NA'],,
9978,NCT05449847,Relation between MicroRNA and HCV,2021-05-13,COMPLETED,OBSERVATIONAL,['NA'],,
9979,NCT03963206,survival of the patient after start of treatment,2019-09-09,COMPLETED,INTERVENTIONAL,['PHASE4'],,Number of patients with each dose of Cabozantinib
9980,NCT03579199,Histological analysis of explanted liver parts,2019-03-18,UNKNOWN,INTERVENTIONAL,['NA'],,bilirubin and prothrombin levels
9981,NCT03490461,A new lesion with radiographic features compatible with HCC was defined as recurrence of HCC.,2017-11-22,COMPLETED,OBSERVATIONAL,['NA'],,
9982,NCT06275997,Miss rate reduction,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,patient satisfaction
9983,NCT04727151,Phase 2: Evaluate Progression-Free survival (PFS) or Time to progression (TTP),2021-04-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 1 and Phase 2: Cytokine level detection
9984,NCT04397601,Overall Survival (OS).,2020-05-11,RECRUITING,OBSERVATIONAL,['NA'],Serum level of PlGF (Placental Growth Factor).,Progression-free survival (PFS).
9985,NCT02012699,Development and implementation of a web-based Cancer Collaborative Registry at the University of Nebraska Medical Center (UNMC)/Nebraska Medical Center (NMC),2013-11-01,RECRUITING,OBSERVATIONAL,['NA'],"Collection and banking of blood, DNA, and urine samples for future analysis that will be proposed in future studies",Procurement and banking of excess biological material for future analysis
9986,NCT04294160,Dose intensity,2020-07-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Tmax derived from Serum/plasma concentration of individual investigational drugs within combination treatments
9987,NCT01047293,"Evaluate Safety of the Combination at a Daily Dosing of 2.5mg RAD001, 5 mg RAD001 or 10 mg RAD001 (Phase 1 Part)",2010-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
9988,NCT05992584,Progression free survival (PFS) according to mRECIST,2023-08-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events (AEs)
9989,NCT05116085,Major pathological response (MPR) rate,2022-01-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Participants with Treatment-emergent Adverse Events (TEAEs)
9990,NCT06091930,Part IV: Objective response based on the response evaluation criteria in solid tumors (RECIST v1.1),2024-01-31,RECRUITING,INTERVENTIONAL,['PHASE1'],,Part IV: Area under the concentration-time curve of BI 765049 over a uniform dosing interval τ (AUCτ) after multiple administrations
9991,NCT02702986,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2016-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Disease specific survival (DSS)
9992,NCT02384759,Radiological progression-free survival according to the investigator,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,progression-free survival
9993,NCT01608022,Overall Response Rate,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9994,NCT03959774,demonstrate that the adherence rate of digital follow-up is greater than 70% in a population of elderly patients.,2020-12-30,UNKNOWN,INTERVENTIONAL,['NA'],,
9995,NCT03653052,Clinical response to therapy (durvalumab),2018-10-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Ex-vivo effect of compounds on tumour/cell models,
9996,NCT00021320,,2000-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9997,NCT04798781,Progression-free survival,2021-07-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence and severity of adverse events
9998,NCT03229096,Objective response rate (ORR),2017-02-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,3-year overall survival rate
9999,NCT06050447,Mortality rate,2023-09-01,RECRUITING,OBSERVATIONAL,['NA'],,Recurrence-free survival
10000,NCT00940303,Progression-free survival,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Proportion of patients with NCI-CTC grade 3-5 adverse events; adverse events, laboratory parameters, ECOG performance status."
10001,NCT03099564,Progression free survival (PFS),2017-03-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Estimate overall survival (OS)
10002,NCT04295811,Primary Efficacy,2020-06-18,RECRUITING,INTERVENTIONAL,['NA'],"Safety outcome of EsoCheck Device (510k cleared, non-invasive, esophageal cell collection device) on all patients who undergo the device procedure.",Secondary Efficacy
10003,NCT01487343,adherence to oral chemotherapy,2011-11,COMPLETED,OBSERVATIONAL,['NA'],,improve the care of patients
10004,NCT04692454,The number of CD8+ T,2020-08-31,COMPLETED,INTERVENTIONAL,['NA'],,
10005,NCT02319928,Colorectal cancer incidence,2015-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
10006,NCT05610904,Accuracy of stoma implementation,2022-12-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Rate of stoma reverse
10007,NCT00108953,Time to Progression (TTP),2005-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants for Whom Disease Control Was Achieved
10008,NCT05158621,Primary,2021-12-14,COMPLETED,OBSERVATIONAL,['NA'],,
10009,NCT00626639,Pharmacokinetics of Palifermin,2005-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
10010,NCT05038813,Objective Response Rate(ORR),2022-03-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival(OS)
10011,NCT04151394,Overall survival,2019-01-31,COMPLETED,OBSERVATIONAL,['NA'],,
10012,NCT06227325,pathological complete response (pCR) rate,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Percentage of Participants who experience one or more adverse events (AEs).
10013,NCT05975749,Disease-free survival,2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Side effects
10014,NCT01402089,Steady-state partial area-under the plasma concentration-time curve over 24 hours (AUC24h) of sunitinib and erlotinib and CYP3A4/1A2-phenotype activity as defined in the protocol,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,"Concentrations of Sunitinib, Erlotinib and probe drugs (Midazolam, Caffeine) in whole blood, sampled from patient's dried blood spots (DBS)"
10015,NCT02821559,Evolution of Raltitrexed plasma levels,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,overall survival (OS)
10016,NCT04877340,Compare the diagnostic yield,2020-11-26,UNKNOWN,INTERVENTIONAL,['NA'],,adverse event rate
10017,NCT02836977,Disease free survival,2016-03,UNKNOWN,INTERVENTIONAL,['NA'],,
10018,NCT05579353,expressional quantity,2023-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
10019,NCT04167436,Changes in immunological function,2019-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Remission and cancer free survival
10020,NCT03131102,Acute Fatigue Score (AFS),2017-08-29,COMPLETED,OBSERVATIONAL,['NA'],Quality of life,Hospital length of stay
10021,NCT05291156,OS,2022-07-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of treatment-related adverse events as assessed by CTCAE v5.0
10022,NCT01091558,"L-Arginine (L-Arg) availability in ulcerative colitis (UC) patients and normal control subjects, and correlate with disease activity",2009-09,COMPLETED,OBSERVATIONAL,['NA'],,L-Arg intake in the diet of UC patients and control subjects
10023,NCT05640830,Progression-free survival,2023-01-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10024,NCT01611506,Dose limiting toxicity,2012-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Toxicity (according to NCI-CTCAE, Version 4.0)"
10025,NCT00474903,Change in Mean Tissue Prostaglandin E2 (PGE2) Concentration as Determined From Barrett's Research Mucosal Biopsy Samples,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity
10026,NCT02909114,local control assessed by RECIST,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival
10027,NCT02836535,Number of complications,2016-07,COMPLETED,OBSERVATIONAL,['NA'],,
10028,NCT00911196,Expression of c-MET in the same hepatocellular carcinoma tumor samples,2008-11,COMPLETED,OBSERVATIONAL,['NA'],,
10029,NCT02243267,Response to Treatment,2014-09,COMPLETED,OBSERVATIONAL,['NA'],,
10030,NCT00507598,"•Perform metabolic profiling of tissue,serum & urine from pts w/ colorectal cancer (stages I-IV), healthy controls & pts w/ colorectal polyps & correlate results.",2007-07,COMPLETED,OBSERVATIONAL,['NA'],,"Correlate changes of serum & urine biomarkers /p trt to predict response or toxicity,& correlate w/other treatment outcomes. Compare the metabolic profile between pts w/various stages of colorectal cancer."
10031,NCT02399735,GVHD,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Acute rejection
10032,NCT00033319,,1997-05,UNKNOWN,INTERVENTIONAL,['NA'],,
10033,NCT03819387,Number of patients with treatment-related adverse events as assessed by CTCAE v5.0,2019-03-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],To evaluate correlation between KRAS mutations and clinical outcome,Additional pharmacokinetic parameters for siRNA
10034,NCT02958059,Rate of complication that related with infection.,2016-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,Grade of post-ERCP infectious complication
10035,NCT03797443,Disease control rate (CR+PR+SD x18 weeks),2019-01-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Changes in patient's self-reported pain levels
10036,NCT00966251,To assess the safety and tolerability of CT-011 in patients with Primary Hepatocellular Carcinoma,2009-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10037,NCT02630004,Number (percentage) of patients who develop severe oral mucositis (grade 3-4 according to the RTOG scale),2015-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number (percentage) of patients with progression disease using the RECIST 1.1 criteria,Pharmacokinetics evaluation [Clearance]
10038,NCT00134758,SPIGELMAN severity score of duodenal lesion after 2 years of follow-up,2004-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Compliance to the treatment
10039,NCT05732389,Complete clinical response,2023-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Change in Quality of life (EORCT QLQ-CR29)
10040,NCT03722875,Overall survival(OS),2018-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,
10041,NCT00047333,Progression-free survival,2002-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall survival
10042,NCT03872908,Cohort 2: Efficacy of compression induced by surgical gloves vs peripheral neuropathies development in patients treated by oxaliplatine after a cumulative dose of 595 mg/m2,2019-09-29,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Cohort 2: Evaluation of the peripheral neuropathies percentage for each hand
10043,NCT01367275,Number of Participants With Median Progression-Free Survival (PFS),2011-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,
10044,NCT02874885,Change in circulating tumor cells status,2013-09-05,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
10045,NCT06194734,Overall survival (OS),2024-02-05,RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of Life (QOL) scores
10046,NCT03928678,length of hospital stay in days,2019-05-01,COMPLETED,INTERVENTIONAL,['NA'],,
10047,NCT00452205,,2007-04,UNKNOWN,OBSERVATIONAL,['NA'],,
10048,NCT04171141,Objective Response - Number of Participants With Objective Response for Dose Expansion (Part 2),2019-11-19,TERMINATED,INTERVENTIONAL,['PHASE1'],,Change from baseline of immune cells from tumor biopsies
10049,NCT01624363,Prevalence of Pancreatic Cysts During Routine EUS,2009-09,COMPLETED,OBSERVATIONAL,['NA'],,
10050,NCT00465023,"To determine the maximum tolerated dose (MTD) of proton beam irradiation in patients with unresectable or locally recurrent hepatocellular cancer, cholangiocarcinoma, or hepatic metastases.",2003-06,COMPLETED,INTERVENTIONAL,['NA'],,"to evaluate tumor response, local control and survival in this patient population."
10051,NCT03488953,Overall survival three years after 2nd-stage of hepatectomy,2018-04-10,UNKNOWN,INTERVENTIONAL,['NA'],,Morbidity of the donor
10052,NCT02364154,metabolic phenotype of colorectal cancer,2014-12,COMPLETED,OBSERVATIONAL,['NA'],,tumor stage
10053,NCT03630068,Recurrence-free survival,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Clinical and radiological complications
10054,NCT05908916,Progression-free survival,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
10055,NCT05026905,Best objective response rate (ORR),2021-12-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-related Adverse Events [Safety and Tolerability]
10056,NCT05114798,Weight change (% kg),2022-05-17,RECRUITING,INTERVENTIONAL,['NA'],,Saliva microbiota
10057,NCT04734249,Objective response rate (ORR),2021-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Assess the anti-tumor activity:DCR
10058,NCT05989789,Procedure-Safety (No residual source of radiation),2020-06-15,COMPLETED,INTERVENTIONAL,['NA'],,Number of patients without side effects
10059,NCT05759741,Wexner incontinence score,2023-01-17,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Rate of postoperative complications
10060,NCT00168155,disease free survival,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10061,NCT00958737,Disease-free survival (DFS),2009-05-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Treatment compliance
10062,NCT02561546,glycosylated hemoglobin (A1C),2015-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,postprandial glucose (PPG)
10063,NCT05293041,Blood loss,2022-03-27,RECRUITING,INTERVENTIONAL,['PHASE4'],,I-FABP (change in organ damage markers)
10064,NCT01388101,The performance of e- Ab sensor,2010-09,UNKNOWN,INTERVENTIONAL,['NA'],,
10065,NCT02592304,"DECT as imaging tool for diagnosing response to chemo radiotherapy of malignant lymph nodes, and tumors.",2014-09,UNKNOWN,INTERVENTIONAL,['NA'],,
10066,NCT03707574,Obtaining tumor tissue and blood specimens,2019-04-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Genomic analysis
10067,NCT03693677,The progression free survival at 6 months according to the RECIST 1.1 criteria,2018-11-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Treatment safety
10068,NCT01574677,Performance characteristics of the Septin 9 biomarker among patients who have a positive FIT result,2012-06,WITHDRAWN,OBSERVATIONAL,['NA'],,Concordance and discordance (Kappa scores) between Septin 9 test results and colonoscopy findings associated with specific medication use practices.
10069,NCT00031941,,2002-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10070,NCT02587689,Phase I: Adverse events attributed to the administration of the anti-MUC1 CAR T cells,2015-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10071,NCT03003065,Safety (will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0),2014-03-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Quality of life (in every visit, European Organization for Research and Treatment of Cancer core questionnaire [EORTC QLQ-C30] will be filled and specific symptom enquiry is made; itchiness, fever and general well-being over a Likert 0-4 scale."
10072,NCT05528952,objective response rate (ORR),2022-09-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,disease control rate (DCR)
10073,NCT03962478,6-month survival rate,2019-05-31,COMPLETED,INTERVENTIONAL,['NA'],,Stent dysfunction free survival
10074,NCT00845819,Incidence of oral mucositis of grade 2 or higher (NCI CTCAE 3.0),2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,OMDQ (oral mucositis daily questionnaire) score during treatment
10075,NCT01200121,paracentesis-free survival (ParFS),2010-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Changes in laboratory values and vital signs.
10076,NCT02163785,Assessment of the circumferential resection margin,2014-06,TERMINATED,INTERVENTIONAL,['NA'],Morbidity of the perineal incision.,Histopathological quality of surgical specimen
10077,NCT04242199,Number of treatment-emergent adverse events,2020-09-04,RECRUITING,INTERVENTIONAL,['PHASE1'],,Vz/F of INCB099280
10078,NCT00427713,Disease-free survival at 3 years,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Toxicity
10079,NCT00230399,"To determine the objective response rate to the combination of celecoxib, capecitabine, and irinotecan in patients with metastatic colorectal cancer.",2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To evaluate the time to progression of metastatic colorectal cancer after treatment with celecoxib, capecitabine, and irinotecan."
10080,NCT02620865,Median Overall Survival (OS),2015-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,TTP
10081,NCT00043199,,na,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
10082,NCT06261008,adherence rate,2024-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,qualitative factors associated with repeat FIT adherence
10083,NCT05007613,Overall response rate,2021-06-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety
10084,NCT03039322,Golgi protein correlated with presence of HCC,2014-12-22,COMPLETED,OBSERVATIONAL,['NA'],,
10085,NCT06101277,Number of participants with controlled disease,2023-10-05,RECRUITING,INTERVENTIONAL,['NA'],,Time to treatment failure
10086,NCT05308732,Maximum tolerated dose,2021-05-11,RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of Oral Mucositis
10087,NCT05635929,"Quality of life evaluation of radiotherapy, with or without chemotherapy, long-term symptoms (6 months) after 1 month of use of the tested composition in head & neck cancer patients.",2022-10-11,COMPLETED,INTERVENTIONAL,['NA'],,Comparison between oral mucositis severity in patients receiving radiotherapy with patients receiving radiotherapy plus chemotherapy.
10088,NCT01099085,Progression free survival of XP ± simvastatin,2009-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,
10089,NCT00753675,Progression Free Survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
10090,NCT00160030,Percentage of patients having completed the full treatment and Endoscopic complete response rate,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity profile (NCI-CTC).
10091,NCT01748773,Change from Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status Score,2013-01-29,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
10092,NCT01326000,Progression-free survival: tumour assessments by CT scan or MRI according to RECIST criteria,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Effect of concomitant FOLFIRI on pharmacokinetics of RO5083945 and vice versa
10093,NCT05644249,Objective tumor response according to RECIST v 1.1 after second PIPAC,2022-12-01,RECRUITING,INTERVENTIONAL,['NA'],,Adverse events of chemotherapy drugs
10094,NCT05875402,Adverse Events (AE),2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],,
10095,NCT05340569,Unexpected abortion,2022-03-28,RECRUITING,INTERVENTIONAL,['NA'],,Early distant recurrence
10096,NCT05535998,Progression-free survival,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Conversion rate
10097,NCT04913233,Colorectal cancer screening sensitivity,2021-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
10098,NCT03368131,The pathological complete response rate(pCR),2017-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse events
10099,NCT04484311,Residual neoplasia,2020-08-01,UNKNOWN,OBSERVATIONAL,['NA'],,
10100,NCT04265417,Disease-free survival,2015-01-06,COMPLETED,OBSERVATIONAL,['NA'],,Postoperative C-reactive protein
10101,NCT02301962,Number of subjects with adverse event.,2015-07-28,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Duration of response.
10102,NCT03413254,Proportion of peritoneal metastases detected after a negative second look DLS,2018-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of life assessed with the EQ-5D-5L questionnaire
10103,NCT04095195,"This clinical study will assess the diagnostic yield of a clinical surveillance program for pancreatic neoplasia or predisposing conditions (PanIN, IPMNs) in high risk individuals",2019-08-20,RECRUITING,OBSERVATIONAL,['NA'],,"This study will investigate possible risk factors for the incidence or the progression of for pancreatic neoplasia or predisposing conditions (PanIN, IPMNs) in high risk individuals"
10104,NCT05427227,Tumor associated proteins expression level of exosomes,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],,
10105,NCT04602611,Overall Survival,2020-11-03,COMPLETED,INTERVENTIONAL,['NA'],Oncology Nurse Navigation Provider Comparison for Outcomes,Oncology Nurse Navigation Comparison for Satisfaction
10106,NCT00002711,,1995-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10107,NCT03200834,5-year survival,2017-01-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Disease free survival 5 years after initial surgery
10108,NCT05125094,Overall Survival,2021-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,tumor response
10109,NCT03457844,Progression Free Survival(PFS),2018-01-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease Control Rate(DCR)
10110,NCT05132244,Frequency of glucose levels maintained within range in Arm 1 compared to Arm 2,2024-02,RECRUITING,INTERVENTIONAL,['NA'],"Amount of circulating biomarkers, measured in molar, for participants in each study arm from screening until the end of study visit",Overall survival (OS) in each study arm from the initiation of FOLFIRINOX
10111,NCT01395459,Change in population level cancer screening level at the health clinics involved.,2008-09,COMPLETED,INTERVENTIONAL,['NA'],For the substudy: return rate of gFOBT kits vs. FITs,
10112,NCT02330913,Anastomosis related complication rate,2014-12,COMPLETED,INTERVENTIONAL,['NA'],,
10113,NCT01087268,Gastrointestinal symptoms score using the IBDQ quality-of-life questionnaire,2009-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Health economics data
10114,NCT00910143,"Local recurrence, recurrence-free survival, overall survival",1993-01,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of patients undergoing transcatheter arterial embolisation
10115,NCT05953961,Disease Progression,2023-08-08,RECRUITING,INTERVENTIONAL,['NA'],,Duration of Response
10116,NCT05110573,Major complication rate,2000-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Oncological outcomes
10117,NCT00004547,Number of Participants With Adverse Events,2000-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Signal Transduction Pathways in Tumor Tissue Versus Normal Tissue
10118,NCT04807673,Event Free Survival (EFS),2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of life differences (EORTC QLQ-OES18)
10119,NCT01423799,"Quality of Life (QOL), measured with the EORTC QLQ-C30",2012-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,QOL assessed by the EORTC QLQ-OG 25
10120,NCT03548948,Change in colonic inflammation,2015-07-15,COMPLETED,INTERVENTIONAL,['NA'],,Change in serum hepcidin
10121,NCT02246153,Postoperative complication rate,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Postoperative recovery index
10122,NCT06231017,Objective response rate (ORR),2024-01-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events (Safety）
10123,NCT04638010,Number of participants who complete needed cancer screening and prevention services,2011-02-16,COMPLETED,INTERVENTIONAL,['NA'],,
10124,NCT01047618,To evaluate the incidence of VTE in advanced gastric cancer with chemotherapy and to identify risk factors and biomarkers for VTE in this population,2009-12,COMPLETED,OBSERVATIONAL,['NA'],,To investigate the significant impact of VTE on overall survival and in this population
10125,NCT01486134,Rate of complete ablation one month after one RFA procedure,2012-06-20,TERMINATED,INTERVENTIONAL,['NA'],,Agreement of 2D and 3D measurements of ablations zones on IRMT° images and those measured on conventional magnitude MR images.
10126,NCT02169388,Frequency and severity of Adverse effects during Chemotherapy,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],,The observed changes in nutritional status after chemotherapy
10127,NCT02659241,Change in level of protein expression in p53-related pathways,2016-02-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
10128,NCT03550885,Change in the mucosal abundance of bacterial genes associated with sulfur and bile acid metabolism,2018-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Change in colonocyte proliferation
10129,NCT01182922,Percentage of invitees attending screening colonoscopy in each invitation letter group,2010-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,"Percentage of forms with consent for examination, sent back after invitation letter but before reminding letter. Differences in attendance between men and women depending on type of the invitation."
10130,NCT01822613,Phase II primary outcome measure: Progression free survival (PFS),2013-07-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression free survival (PFS) per RECIST 1.1 (Ph 1b )
10131,NCT05845268,cCR rate,2022-10-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,immune-related adverse event rate
10132,NCT05420909,Duration of Systemic Treatment,2019-01-28,COMPLETED,OBSERVATIONAL,['NA'],,
10133,NCT05775146,Progression free survival (PFS),2024-09-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Exploratory endpoints/outcomes. To identify blood biomarkers that can correlate with disease events,Toxicity Assessment
10134,NCT00375024,Questionnaire Results Regarding Time to Diagnosis,2007-05,COMPLETED,INTERVENTIONAL,['NA'],,Questionnaire Results Regarding Patient Navigators
10135,NCT01790425,Cecal intubation,2011-08,COMPLETED,INTERVENTIONAL,['NA'],Patient discomfort Patient pain rating during and after procedure,Amount of opiate and benzodiazepines used for sedation.
10136,NCT02682394,Blood levels of free DNA,2015-09,UNKNOWN,OBSERVATIONAL,['NA'],,
10137,NCT00909402,"Use National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) to establish the MTD, Dose Limiting Toxicity (DLT(s)) and safety profile of BMS-833923 administered in combination with Cisplatin and Capecitabine",2009-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,The pharmacokinetic parameters that will be assessed include: AUC(TAU) (Area under the concentration-time curve in one dosing interval)
10138,NCT01329809,Delivery to and replication within tumors,2011-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Toxicity: Grade I-IV Adverse Events (according to CTCAE)
10139,NCT04936581,Vaizey score,2021-09-01,RECRUITING,OBSERVATIONAL,['NA'],,Postoperative complications
10140,NCT03361150,Oxygen consumption (VO2),2016-01,COMPLETED,INTERVENTIONAL,['NA'],,Hospital Anxiety and Depression Scale (HADS) score
10141,NCT03585166,"The survival rate of primary liver cancer treated by laparoscopic hepatectomy and laparoscopic hepatectomy,Telephone pays a return visit",2017-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,Comparison between laparoscopic hepatectomy and laparoscopic hepatectomy in primary hepatocellular carcinoma Unit: times
10142,NCT00553813,Survival,2007-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Evaluate the gene expression profile in relation to clinical outcomes
10143,NCT02106650,Grade 2 Oral Mucositis Prevention,2014-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Objective Response Rate
10144,NCT05095636,PFS,2021-03-17,UNKNOWN,INTERVENTIONAL,['PHASE2'],,AEs
10145,NCT01270698,Safety,2011-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,efficacy
10146,NCT01198392,Time to progression,2008-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Response rate
10147,NCT05417230,ORR,2022-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],ctDNA,AEs
10148,NCT02499783,Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4,2015-08-17,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change From Baseline in Fecal Calprotectin Level Over Time (Any Adalimumab Set)
10149,NCT01067053,Time to progression,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety of treatment according to the number of adverse events reported
10150,NCT03981679,AUC,2018-06-05,COMPLETED,INTERVENTIONAL,['NA'],,Intplex parameters
10151,NCT04130399,Local control rate among PDAC patients treated with neoadjuvant chemotherapy followed by SBRT,2019-07-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Rate of grade 3-4 non hematological toxicity rates
10152,NCT01478373,Antitumor Activity of Dovitinib in Terms of Disease Control Rate (DCR): Complete Response+Partial Response +Stable Disease,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,DCR (CR+PR+SD) at the End of Treatment
10153,NCT00173277,,2003-06,UNKNOWN,OBSERVATIONAL,['NA'],,
10154,NCT04223635,Volume of Distribution in the Terminal Phase (Vz/F) Following a Single Dose in Participants With Moderate Hepatic Impairment Compared to Healthy Participants,2020-01-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Number of Participants Reporting Treatment-Emergent Adverse Events (TEAE) by System Organ Class and Preferred Term Following a Single Dose of Pexidartinib in Participants With Moderate Hepatic Impairment Compared to Healthy Participants
10155,NCT02591082,Survival,2015-12,COMPLETED,OBSERVATIONAL,['NA'],,Tumor response
10156,NCT05280444,Objective Response Rate(ORR),2022-05-28,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Adverse Events(AEs)
10157,NCT05620706,AE/SAE,2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],,ORR
10158,NCT05202314,Pathological complete remission,2021-12-12,RECRUITING,INTERVENTIONAL,['NA'],,Overall Survival
10159,NCT04801355,R1 resection rate,2020-12-01,RECRUITING,INTERVENTIONAL,['NA'],,The incidence and structure of postoperative complications
10160,NCT05971108,Stage of hepatocellular carcinoma at diagnosis,2024-01-08,RECRUITING,INTERVENTIONAL,['NA'],,Survival rates
10161,NCT00327132,Hp eradication rate and complete histological rate,2006-07,COMPLETED,INTERVENTIONAL,['NA'],,overall survival (OS)Relapse-free survival (RFS)
10162,NCT06186700,The incidence of mucositis in the two groups using WHO grading of oral mucositis,2023-12-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,The incidence of adverse effects
10163,NCT05325528,Objective Response Rate (ORR),2022-04-10,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,progression-free survival
10164,NCT01655693,Overall Survival (OS),2012-06,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Participants Experiencing Clinically Significant Changes in Left Ventricular Ejection Fraction (LVEF) and the Severity of the Event,Objective Response Rate (ORR)
10165,NCT01896531,Progression-Free Survival (PFS) in All Randomized Participants and Participants With PTEN Loss Tumors at Primary Analysis,2013-08-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Serum Concentration of Ipatasertib
10166,NCT04707560,Quantification of tissue quality,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA'],Complication,Diagnostic performance between different suction method
10167,NCT01762254,pain score,2009-06,COMPLETED,INTERVENTIONAL,['NA'],length of hospital stay,wound complication
10168,NCT00858338,toxicity of IP FUDR after surgery prior to chemoradiation,2002-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Time to relapse, disease specific survival"
10169,NCT02694536,Percentage of Participants With Adverse Events (AEs),2006-08-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression-Free Survival (PFS) According to RECIST
10170,NCT03917966,Major pathological response（MPR）,2020-04-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,R0 resection rate
10171,NCT05130710,presence of peritoneal seeding,2020-02-25,COMPLETED,OBSERVATIONAL,['NA'],,presence of peri-gastric lymph node involvement
10172,NCT01688700,Pathology complete remission rate,2012-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life
10173,NCT03974672,Measuring severity of complications with the Dindo Clavien complications scale,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
10174,NCT01863862,The final three-year rate of local and distant recurrences taking into consideration results of rescue surgery for pelvic recurrence.,2012-08,UNKNOWN,INTERVENTIONAL,['NA'],,Multivariable analysis of prognostic factors associated with clinical complete response.
10175,NCT03350412,Thoroughness to report molecular profiling,2015-10,UNKNOWN,OBSERVATIONAL,['NA'],,Percentage of complete data capture for treatment-related check-point events
10176,NCT00230646,Minutes of moderate-intensity physical activity (PA) at 3 months among 134 sedentary patients who have completed treatment for colorectal cancer (CRC).,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Examine the maintenance of outcomes (minutes of moderate intensity activity, physical functioning, vigor, fatigue and body esteem) at 6 and 12 months."
10177,NCT02278133,Overall response rate in phase II,2014-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of participants with dose interruptions and dose reductions (phase Ib/II)
10178,NCT02788669,LRP1 molecular expression,2015-11,UNKNOWN,OBSERVATIONAL,['NA'],,
10179,NCT06316401,Safety of ESD under SA,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Median ESD duration
10180,NCT05193604,Overall response rate (ORR),2022-03-24,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
10181,NCT02117466,Clinical Benefit Rate,2014-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life (QoL) and health related QoL
10182,NCT03412773,Safety Run-In Substudy[Japan only]: Percentage of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Findings,2017-12-28,COMPLETED,INTERVENTIONAL,['PHASE3'],,Percentage of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Findings
10183,NCT04319302,Bile drainage,2005-01,COMPLETED,OBSERVATIONAL,['NA'],Complications,Complications of procedure
10184,NCT04230603,Inflammatory classification with HSI,2019-06-06,UNKNOWN,INTERVENTIONAL,['NA'],,Tissue perfusion
10185,NCT04194775,Overall survival (OS),2019-12-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,"Time to deterioration (TTD), defined as the time from randomization to the first deterioration of European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) scale"
10186,NCT03558048,Relationship between IBD and PSA,2019-08-01,RECRUITING,OBSERVATIONAL,['NA'],,Location of disease
10187,NCT04573881,Primary Safety: Procedure-Related Major Complications,2021-06-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Secondary Safety: All Adverse Events
10188,NCT05426850,Relationship between ctDNA status after chemoradiotherapy and relapse.,2021-06-01,RECRUITING,OBSERVATIONAL,['NA'],,"Relationships between radiomics features, ctDNA status and relapse."
10189,NCT01728480,"The percentage of patients with mucositis, measured using the World Health Organization (WHO) mucositis global severity score and the oral mucositis daily questionnaire (OMDQ)",2014-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
10190,NCT05970302,Objective Response Rate (ORR),2023-07-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
10191,NCT05227014,Transfusion rate,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],,Postoperative hemoglobin values
10192,NCT03323944,Number of study subjects with treatment-related adverse events using NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.03,2017-09-15,RECRUITING,INTERVENTIONAL,['PHASE1'],,Objective response rate
10193,NCT02730533,The total bleeding rate according to grading of intraoperative bleeding during ESD procedure,2016-03,COMPLETED,INTERVENTIONAL,['NA'],,The mean percentage of mucosal defect reduction at follow-up endoscopy on 28 days after ESD procedure.
10194,NCT05692037,Progression Free Survival Rate of Liver Target Lesions,2022-12-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease control rate (DCR)
10195,NCT00823810,Survival,2008-12,TERMINATED,INTERVENTIONAL,['NA'],,Time to progression
10196,NCT03113955,Number of Participants With Objective Tumor Response at 6 Months by MRI (Magnetic Resonance Imaging),2017-10-24,COMPLETED,INTERVENTIONAL,['NA'],,Kaplan-Meier Analyses the Percent of Participants for Time to Extrahepatic Spread
10197,NCT01600196,Survival time,2006-01,TERMINATED,INTERVENTIONAL,['PHASE4'],,Number of Adverse Events
10198,NCT01898741,Safety,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
10199,NCT04202601,Arms 3:≥second-line therapy group,2019-12-13,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Arms 3:≥second-line therapy group
10200,NCT02511223,Objective Response Rate (ORR) by using RECIST 1.1,2016-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10201,NCT01629004,Uptake of appropriate CRC screening,2011-04,COMPLETED,INTERVENTIONAL,['NA'],,Uptake of lower gastrointestinal investigations
10202,NCT04291976,detection rate of neoplasia for each technique,2020-03-13,COMPLETED,INTERVENTIONAL,['NA'],,Size of the lesion in mm
10203,NCT00627042,Progression Free Survival (PFS) in Participants With Unresectable Hepatocellular Cancer Treated With the Monoclonal Antibody Ramucirumab,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Drug-Related Treatment-Emergent Adverse Events
10204,NCT05663788,Pooled sensitivity of endoscopic optical diagnosis for predicting deep submucosal invasion in routine colonoscopies,2022-07-01,RECRUITING,INTERVENTIONAL,['NA'],,Pooled LR- of endoscopic optical diagnosis for predicting deep submucosal invasion in a 20-image test before and after the learning module in the intervention group
10205,NCT04831632,diagnostic performance,2021-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,qualitative iFOBT positivity rate
10206,NCT01333033,Complete Pathological Response (pCR) of PET/CT Non-responders,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival (PFS) Among PET/CT Non-responders Within Each Induction Treatment Group
10207,NCT05193253,Disease-free survival (DFS).,2000-02-01,COMPLETED,OBSERVATIONAL,['NA'],,
10208,NCT04518579,anti tumour immunity,2018-04-15,COMPLETED,INTERVENTIONAL,['NA'],,change in pain intensity
10209,NCT00225641,Overall and cancer-specific mortality,2006-03,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of life. Cost-effectiveness of follow-up
10210,NCT02835924,Percentage of patients with G3/G4 treatment-related AEs in each arm according to CTCAE v4.03 criteria.,2016-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
10211,NCT06305728,Sensitivity of ImmunoPET to identify presence or absence of adenocarcinoma,2024-03-04,RECRUITING,OBSERVATIONAL,['NA'],,
10212,NCT05093608,Maximum Tolerated Dose,2021-11-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall Survival
10213,NCT00502502,Patient Symptom Assessment (Questionnaire),2002-11,COMPLETED,OBSERVATIONAL,['NA'],,
10214,NCT03315195,Postoperative complications,2017-11-25,UNKNOWN,INTERVENTIONAL,['NA'],,
10215,NCT00471965,Overall survival,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Response rate, secondary resection rate, quality of life"
10216,NCT00014079,Determine the clinical and pathologic significance of unstable DNA elements,1997-09,COMPLETED,OBSERVATIONAL,['NA'],,Determine the clinical and pathologic significance of loss of heterozygosity
10217,NCT06310902,Bioinformatics analysis of single-cell sequencing results,2024-03-01,RECRUITING,OBSERVATIONAL,['NA'],,
10218,NCT00499395,Sensitivity and specificity of fludeoxyglucose F 18 (FDG)-PET imaging in early diagnosis of residual disease,2005-07,COMPLETED,INTERVENTIONAL,['NA'],,Findings on day 7 after RFA using FDG-PET imaging
10219,NCT00008398,,2000-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
10220,NCT03740360,Mutations in pancreatic cystic neoplasm,2017-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Relation between pancreatic fluid and serum molecular analysis
10221,NCT03182179,Change in LARS score,2016-11-01,COMPLETED,INTERVENTIONAL,['NA'],,Irritable Bowel Syndrome-Quality of Life
10222,NCT02215447,Response rate,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Rates of adverse events as defined by NCI- Common Terminology Criteria for Adverse Events (CTCAE) V4.0
10223,NCT03116945,"Uptake of positron emitting radiotracer, 68Gallium Citrate will be measured in the lesions of hepatocellular carcinoma.",2016-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
10224,NCT01385956,Number of Participants With Serious Adverse Events,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Overall Survival (OS)
10225,NCT02866344,Local disease control at the site of intervention,2016-08,TERMINATED,INTERVENTIONAL,['NA'],,Postoperative mortality
10226,NCT00136669,To determine the duration of acupuncture effects,2003-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,
10227,NCT05088889,"Objective tumor response rate 2 (ORR2) after first progression, assessed by RECIST v1.1",2022-01-25,RECRUITING,INTERVENTIONAL,['PHASE1'],Assessment of disease biomarkers as a surrogates or predictors to response following administration of SBRT and immunotherapy: Exploratory,"Incidence of Treatment-Emergent Adverse Events, as assessed by CTCAE version 5.0"
10228,NCT02527772,Progression-Free-Survival,2015-09,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Time-to-Progression
10229,NCT05537402,Progression-free survival,2023-09-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,Time to deterioration of quality of life
10230,NCT00917384,Overall Survival (OS),2009-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants Who Developed Antibodies Against IMC-1121B
10231,NCT00919009,Time to progression (TTP) in patients treated with TACE plus sorafenib,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall response rate will be evaluated
10232,NCT02764801,Percentage of Patients Correctly Identified as Requiring Tumor Re-treatment One Month After Initial Chemoembolization,2016-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,
10233,NCT01789073,Overall postoperative complications after major gastrointestinal (GI) elective surgery.,2013-02,COMPLETED,INTERVENTIONAL,['NA'],"Weight stability, functional capability and patients´ satisfaction with the overall study course.",Length of hospital stay after major gastrointestinal (GI) elective surgery
10234,NCT06133062,Progression free survival (PFS),2023-11-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence and severity of adverse events
10235,NCT05515315,progression free survival,2022-05-31,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
10236,NCT05139199,Quality of Life (EORTC QLQ-PAN26 ),2022-02-23,COMPLETED,INTERVENTIONAL,['NA'],,Physical Activity(Exercise Counseling and Programming Preferences)
10237,NCT06099119,Change in body weight over study period.,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],,
10238,NCT03083002,Transcriptomics characterization of liver tissue: the purpose is molecular evaluation of possible predisposing factors to development of hepatocellular carcinoma in patients with cirrhosis.,2013-05,UNKNOWN,OBSERVATIONAL,['NA'],,Transcriptomics characteristics of newly diagnosed hepatocellular carcinoma: the purpose is to verify if we can predict the survival of patients considering the molecular features of HCC at first diagnosis.
10239,NCT04466254,Best of Response (BOR),2020-12-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Deepness of Response (DpR)
10240,NCT03287375,"Number of patients with major/complete histologic response (PRGS 1+2) peritoneal biopsies, within a series of three PIPAC procedures.",2016-12-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of patients where MRI is accurate in describing PM distribution and progressive/regressive disease
10241,NCT04809142,Overall survival (OS),2021-02-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Overall survival at 12 months
10242,NCT01434199,caecal intubation rate,2011-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Caecal intubation time
10243,NCT06223230,Median progression-free survival time,2022-06-01,RECRUITING,INTERVENTIONAL,['NA'],,Duration of Response
10244,NCT03546998,Detection of epidermoid carcinoma of the esophagus,1973-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Result of achalasia treatment by investigating dysphagia and gastro-esophageal reflux
10245,NCT03108885,Esophageal Cancer Mutation,2017-10-01,TERMINATED,OBSERVATIONAL,['NA'],,Marker for Recurrence
10246,NCT04408859,Quality of life index,2018-04-17,UNKNOWN,OBSERVATIONAL,['NA'],,
10247,NCT00973609,Time to failure of maintenance and reinduction treatment strategy measured from randomization,2009-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,"TFS, Toxicity, QoL, PFS 1, PFS 2, ORR (first induction), ORR (reind. treatm.), Treatment free interval/duration of maintenance therapy, second. Resection rate, Reasons for discontinuation, OS, Translational research."
10248,NCT04021056,Evaluate the recurrence free survival rate of HCC patients after curative treatments,2011-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
10249,NCT04074538,Adenoma or advanced adenoma incidence,2013-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Second primary cancer incidence
10250,NCT02595931,"Recommended phase 2 dose (RP2D) of ATR kinase inhibitor M6620 (VX-970, berzosertib) and irinotecan hydrochloride",2016-07-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Change in biomarker levels,"Pharmacodynamic parameters of M6620 (VX-970, berzosertib) in combination with irinotecan hydrochloride"
10251,NCT04130971,Tumour response to treatment,2019-02-01,RECRUITING,OBSERVATIONAL,['NA'],,Normal tissue response to treatment
10252,NCT02817308,correlation of CA19-9 levels in urine and saliva with those in the serum,2016-07,UNKNOWN,INTERVENTIONAL,['NA'],,Number of participants needed to standardize the measurements in urine and saliva according to those measured in the serum.
10253,NCT03384316,Recommended Phase 2 Dose (RP2D),2018-01-31,COMPLETED,INTERVENTIONAL,['PHASE1'],Number of Dose Limiting Toxicities (DLTs),Overall Survival (OS)
10254,NCT04592211,dose limiting toxicity,2021-10-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall response rate
10255,NCT04752215,Number of patients with dose limiting toxicities (DLTs) in the maximum tolerated dose (MTD) evaluation period,2021-05-06,RECRUITING,INTERVENTIONAL,['PHASE1'],,Objective response based on Response Evaluation Criteria in Solid Tumors (RECIST v1.1) in patients with measurable disease
10256,NCT00619541,"N° of non progressive disease (complete and partial responses, stable disease)",2007-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Toxicity of the combination,ORR,Duration of responses, TTP and OS.PK, PD,Baseline pERK concentration, phospho VEGF-R2 concentration, plasma proteomics and gene expression profiling on blood cells and tumor biopsy"
10257,NCT01006577,Side-to-end anastomosis is not inferior not colon J pouch in terms of fecal incontinence. fecal incontinence (Wexner score),2010-06,UNKNOWN,INTERVENTIONAL,['NA'],,cancer related deaths
10258,NCT00183872,"Objective Response (Complete, Partial, Stable and Progression)",2005-04-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
10259,NCT01442935,The main objective is to compare resection rates (R0 or R1) for hepatic metastases,2011-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
10260,NCT03071237,Distribution of IPA origin,2017-03-04,COMPLETED,OBSERVATIONAL,['NA'],,Reconstruction rate of IPA by CT scan
10261,NCT00107315,Time to Progression,2004-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,Toxicity
10262,NCT04523389,Association between the number and size of exosomes and their content on cancer stage and progression,2020-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,
10263,NCT05210322,Tube free survival,2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Complication rate
10264,NCT02585479,Progression-Free-Survival,2015-10,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Time-to-Progression outside the liver
10265,NCT03801876,"Incidence of specific grade 3+ cardiopulmonary adverse events (AEs) that are definitely, probably, or possibly related to protocol treatment",2019-03-15,RECRUITING,INTERVENTIONAL,['PHASE3'],,Cost-benefit economic analysis of treatment
10266,NCT02525237,Safety will be assessed by incidence of adverse events,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life (QoL)
10267,NCT03375320,Progression-free survival (PFS),2018-10-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Radiographic response rate
10268,NCT03989310,Disease control rate (DCR),2019-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of participants with laboratory test abnormalities
10269,NCT00590434,"proportion of patients with complications including perforation, bleeding, MI or CVA within 24 hours of colonoscopy in >80 vs. <80 agr group",2006-08,COMPLETED,OBSERVATIONAL,['NA'],,Five year disease free survival and five year mortality rates after the diagnosis of colon cancer in older (>80 yrs) vs. younger group (<80 yrs)
10270,NCT04028375,MSCT and MRI staging in Gastric Cancer.,2019-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,MSCT and MRI prediction of prognosis in gastric cancer
10271,NCT05515185,Maximum tolerable dose,2022-09-09,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
10272,NCT00559676,Pharmacogenetic and pharmacokinetic predictors of therapeutic response and toxic effects,2005-03,COMPLETED,INTERVENTIONAL,['PHASE4'],,Predictive value of pharmacogenetic and pharmacokinetic parameters on disease-free and overall survival
10273,NCT03275376,Overall survival,2017-12-21,TERMINATED,INTERVENTIONAL,['PHASE2'],,Progression free survival
10274,NCT00769106,Time to recurrence (TTR),2008-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,AEs and SAEs
10275,NCT05004441,objective response rate (ORR),2021-07-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,adverse events (AE)
10276,NCT04678583,Intrahepatic disease-free survival (iDFS),2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],,"Assessment of additional oncological and perioperative outcomes: Assessment of ""Quality of life"" (QoL)"
10277,NCT02831842,Overall Survival (OS) in Participants With mCRC and a Documented KRAS Mutation who Received Bevacizumab-Containing Treatment or Chemotherapy Alone in Routine Clinical Practice,2016-06-09,COMPLETED,OBSERVATIONAL,['NA'],,OS in Participants With mCRC and a Documented KRAS Wild Type Status who Received Bevacizumab-Containing Treatment or Anti-EGFR Treatment in Routine Clinical Practice
10278,NCT05274945,pathological assessment of response to treatment,2020-01-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,adverse events of chemotherapy
10279,NCT01318161,Long-term (up to 5 yrs) all-cause mortality,2011-03,TERMINATED,INTERVENTIONAL,['PHASE3'],Postoperative pain and early recovery,Cancer recurrence detected by MRI; perioperative complications
10280,NCT05307926,Disease-free survival,2019-02-01,COMPLETED,OBSERVATIONAL,['NA'],,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
10281,NCT00271011,Percentage of Patients With an Objective Response,2005-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Proportion of Patients Experiencing Hematologic and Non-hematologic Adverse Events
10282,NCT00318903,The determination of pathologic response in patients who undergo surgical resection.,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,To assess the toxicities associated with this treatment and any impact on surgery.
10283,NCT01254617,"Maximum-tolerated dose of lenalidomide with cetuximab, defined as the highest dose level at which 0 or 1 patients out of 6 experiences a dose limiting toxicity graded by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0",2011-02-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Immune cell activation,Natural killer cell activation
10284,NCT01822444,Identification of biomarkers,2012-11,COMPLETED,OBSERVATIONAL,['NA'],,Validation of identified biomarkers
10285,NCT00152230,Relapse-free survival and overall survival,1996-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Adverse events
10286,NCT02751606,Sensitivity and specificity of 7 Tesla MRI in combination with ferumoxtran-10 on nodal level.,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Comparison of 7 Tesla and 3 Tesla MRI
10287,NCT01822210,Change of tumor volume in the stomach.,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,performance status
10288,NCT03801915,Number of Grade 3-5 Adverse Events Related and/or Not Related to Drug,2019-11-13,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0),Define Disease Free Survival (DFS) for Participants Treated With Preoperative MVT-5873
10289,NCT02623153,response rate,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,adverse events
10290,NCT00033462,Proportion of patients who are progression-free at 24 weeks,2002-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall response rate in EGFR positive patients
10291,NCT01796145,Overall survival,2013-02-27,RECRUITING,INTERVENTIONAL,['NA'],,Liver stiffness (kPa)
10292,NCT05720195,Overall survival among HCC patients as assessed by the platelet-albumin-bilirubin (PALBI) score,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival among HCC patients according to treatment modality as assessed by the platelet-albumin-bilirubin (PALBI)
10293,NCT00034216,"Collection of tissue, urine, saliva, stool and blood components, which include serum, leukocytes, peripheral blood mononuclear cells (PBMC), and circulating tumor cells (cTC), of human subjects.",2002-07-16,RECRUITING,OBSERVATIONAL,['NA'],,
10294,NCT00519324,To Assess disease control rate (DCR) as defined CR + PR + SD assessed by RECIST criteria,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To describe the safety profile (incidence and severity of adverse events, serious adverse events) assessed by NCI CTCAE version 3.0"
10295,NCT03656627,Dose-Limiting Toxicity (DLT),2019-06-27,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall Survival
10296,NCT02861430,Concordance between immunochemistry and molecular biology,2014-04,UNKNOWN,OBSERVATIONAL,['NA'],,Disease-free survival
10297,NCT01746043,Proportion of Patients Under Each Treatment Arm Who Experienced a Mean Symptom Increase of 2 Units or More From Baseline to 6 Weeks.,2013-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10298,NCT04293315,Effective Screening,2018-06-09,UNKNOWN,INTERVENTIONAL,['NA'],,Implementation outcomes according to the RE-AIM framework
10299,NCT02078726,Adenoma Detection Rate (ADR) During Colonoscopy Procedure,2014-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,
10300,NCT05192460,Objective Response Rate (ORR),2022-03-28,RECRUITING,INTERVENTIONAL,['NA'],,The concentration of Lymphocyte
10301,NCT02558504,complete histological eradication of the high grade glandular epithelial neoplasia,2013-01-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,"Percentage of patients with severe adverse reaction and minor adverse reactions linked to the procedure used, described by anatomical site"
10302,NCT06258434,Sensitivity and specificity of the multiomics Colorectal Cancer (CRC) screening test (CRC-Appareo) with comparison to colonoscopy,2024-02-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,"Sensitivity of the multiomics Colorectal Cancer (CRC) screening test (CRC-Appareo) with comparison to FIT, with respect to advanced adenoma (AA) and CRC"
10303,NCT04906382,T-cell receptor (TCR) diversity,2021-07-01,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Incidence of adverse events
10304,NCT01419769,Safety - Freedom From Major Complications: SAE's,2011-08,COMPLETED,INTERVENTIONAL,['NA'],,Clinical Success
10305,NCT02736552,Disease-free survival,2016-03,WITHDRAWN,INTERVENTIONAL,['PHASE3'],Treatment expense,Side effects
10306,NCT01801163,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2012-02,WITHDRAWN,INTERVENTIONAL,['PHASE1'],"3.2.4 To evaluate biologic markers such as VEGF, eNOS and HIF1-alpha, VEGF-R2 genetic polymorphisms as well as serum VEGF and soluble VEGFR2 levels and correlate with efficacy outcomes.",Time from start of treatment until death from any cause or date of last patient contact.
10307,NCT06139042,"The sensitivity and specificity of the cfDNA methylation model in detection of liver, biliary tract and pancreatic cancers.",2023-11-01,RECRUITING,OBSERVATIONAL,['NA'],,"The sensitivity and specificity of the combined model in detection of different stages of liver, biliary tract and pancreatic cancers."
10308,NCT05241899,Progression free survival (PFS),2022-05-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,"Safety and tolerance evaluated by incidence, severity and outcomes of AEs"
10309,NCT03349255,Toxicity profile of ET1402L1-CART-cell treatment,2017-10-06,TERMINATED,INTERVENTIONAL,['PHASE1'],,AUC of serum cytokine levels
10310,NCT03602703,Pattern of immunity in patients with de novo HCC develped after treatment with DAAs,2018-07-01,COMPLETED,OBSERVATIONAL,['NA'],,
10311,NCT03519308,Number of Adverse Events,2020-07-29,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Proportion of Margin Negative Surgical Resections
10312,NCT03819920,Screening Behavior: Differences in colorectal cancer screening completion rates between usual care (UC) and CCRAT,2015-10-06,COMPLETED,INTERVENTIONAL,['NA'],Fear: Health Belief Model Likert Scale,Colorectal cancer screening rates at 12 months as a function of CCRAT score
10313,NCT05815082,5-year progression-free survival,2023-02-20,RECRUITING,INTERVENTIONAL,['PHASE3'],,Complications
10314,NCT04797507,ORR based on RECIST v1.1,2021-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
10315,NCT06232395,The performance of the new biomarkers in the post-operative monitoring of gastric cancer,2024-02-18,RECRUITING,OBSERVATIONAL,['NA'],,The performance of the new biomarkers as prognostic biomarkers
10316,NCT00290485,Patient response rate according to RECIST criteria,2005-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Evaluate whether the response rate can predict survival
10317,NCT04015245,Series changes of Prothrombin Time-Intemrnational Normalized Ratio,2018-04-12,COMPLETED,INTERVENTIONAL,['PHASE4'],,Series changes of blood pressure levels before and after TACE
10318,NCT05718232,Overall Survival (OS),2023-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Time to Progression （TTP）
10319,NCT01666444,Overall Survival,2012-10-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,Frequency and Severity of Adverse Events (AEs)
10320,NCT04272034,Number of treatment-emergent adverse events,2021-03-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Vz/F of INCB099318
10321,NCT05628194,MSM awareness of strategies to decrease anal cancer risk,2023-06-08,RECRUITING,OBSERVATIONAL,['NA'],,
10322,NCT01188876,Best Overall Response,2010-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Area Under the Plasma Drug Concentration-Time Curve (AUC)
10323,NCT06217250,Success rate of resection defined as absence of residual/recurrence in SC1 and/or SC2,2024-02-26,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Avarage time of procedure and polyp resection time
10324,NCT05620537,postoperative overall survival,2022-11-10,COMPLETED,OBSERVATIONAL,['NA'],,
10325,NCT03001518,immune response,2017-05-04,COMPLETED,OBSERVATIONAL,['NA'],,disease-free survival
10326,NCT02135757,The pharmacoeconomic impact of panitumumab for the treatment of metastatic colorectal cancer in a real-life setting,2014-08,COMPLETED,OBSERVATIONAL,['NA'],,Identification of blood biomarkers that confer significant improvement in progression-free survival in patients treated with panitumumab.
10327,NCT05122221,"Incidence of treatment related AEs, AEs of special interest and serious adverse events (SAEs).",2022-07-17,RECRUITING,INTERVENTIONAL,['PHASE1'],Negative conversion rate among HPV-16 positive patients detected by tissue biopsy,Progression-Free Survival（PFS）
10328,NCT06096779,Percentage of Participants with Adverse Events,2024-03-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Change From Baseline in IL46 Scores
10329,NCT06185556,Local control,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Cost-effectiveness ratio (ICER) per patient
10330,NCT01908478,Maximum-tolerated dose (MTD) of veliparib based on the incidence of dose-limiting toxicity (DLT) as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I),2013-10-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Change in PAR [Poly(ADP-ribosyl)ation] levels in peripheral blood mononuclear cells
10331,NCT02269904,DFS (Disease Free Survival),2014-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,adverse event
10332,NCT00418938,Progression-free Survival (PFS),2006-11-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Response
10333,NCT01396668,Time to progression,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,clinical benefit rate
10334,NCT04747600,the incidence of the pancreatic fistula,2014-06-01,COMPLETED,OBSERVATIONAL,['NA'],,recurrence rate in percentage
10335,NCT05169528,6-minute-walk-test,2020-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Patient Satisfaction Survey
10336,NCT02809898,Pathological diagnosis of gallbladder polyps （Cholesterol / Adenoma / Others）,2016-07,UNKNOWN,OBSERVATIONAL,['NA'],,Tumor status （worse/ maintain/ better）
10337,NCT01130337,Percentage of Participants With Disease-free Survival (DFS) at Month 18,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Objective Response
10338,NCT06272214,2-year DFS,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Recurrence
10339,NCT00887822,Overall Survival,2009-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change From Cycle 1 in EORTC QLQ-STO22 Scale Over Time
10340,NCT01995396,Rates ot postoperative surgical complications within 30 days.,2014-02,TERMINATED,INTERVENTIONAL,['NA'],Late complications after surgery,Other postop complications
10341,NCT02872519,Number of lesions detected by (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG) PET imaging before and after neoadjuvant chemotherapy treatment,2018-06,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,Conditional predictive models of imaging performance and agreement
10342,NCT01843400,Number of patients with serious adverse events(SAEs) from the first administration of regorafenib.,2013-04-22,COMPLETED,OBSERVATIONAL,['NA'],,Tumor response assessed by RECIST or physicians own evaluation
10343,NCT01705002,Pharmacokinetic (PK) profile of PROMITIL,2012-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Toxicity profile of PROMITIL
10344,NCT05176860,CBCT Image Quality,2022-12-20,COMPLETED,INTERVENTIONAL,['NA'],,Patient Experience
10345,NCT04568330,Scale,2014-03-21,COMPLETED,INTERVENTIONAL,['NA'],Scale,Scale
10346,NCT05171075,"Time to first event of centrally adjudicated VTE recurrence consisting of new proximal deep venous thrombosis, new pulmonary embolism (PE) or fatal PE, including unexplained death for which PE cannot be ruled out",2022-09-27,RECRUITING,INTERVENTIONAL,['PHASE3'],,"Net clinical benefit defined as survival without VTE recurrence, or major or CRNM bleeding"
10347,NCT04999072,Relapse free survival,2020-04-19,UNKNOWN,OBSERVATIONAL,['NA'],,
10348,NCT00610389,Response rate,2008-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Immunological response
10349,NCT04140552,Overall Survival,2008-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
10350,NCT01719926,Number of dose limiting toxicities at each dosage cohort,2012-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Efficacy
10351,NCT06265883,Time to progression (TTP),2019-07-01,COMPLETED,OBSERVATIONAL,['NA'],,treatment-related adverse events (TRAEs)
10352,NCT03565029,Distant Relapse-Free Survival (DRFS),2018-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Patient reported outcomes
10353,NCT02702401,Overall Survival (OS),2016-05-26,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)
10354,NCT04589975,Conversion to open rate: predictive factors oncological outcomes,2000-01,COMPLETED,OBSERVATIONAL,['NA'],,
10355,NCT03366155,Response rate (RR),2019-06-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Extra-hepatic progression-free survival
10356,NCT03174574,"Genomic and risk factor differences among family members who share identical predisposing CDKN2A gene mutations, with different phenotypes; will discover patterns of tumorigenesis, tissue specificity, gene-gene, and gene-environment interactions.",2016-08-17,COMPLETED,OBSERVATIONAL,['NA'],,
10357,NCT02250209,3-year disease-free survival (DFS),2014-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Prognostic value of biomarkers
10358,NCT01360541,Prevalence of low grade dysplasia 3 years after randomization,2010-12-22,COMPLETED,INTERVENTIONAL,['PHASE2'],,Detection rate of dysplasia and Barrett's oesophagus with the confocal endomicroscopy technique
10359,NCT05701553,Incidence of adverse events,2023-01-26,RECRUITING,OBSERVATIONAL,['NA'],,12-month survival rate
10360,NCT05849571,Children's International Mucositis Evaluation Scale (ChIMES),2023-03-01,COMPLETED,INTERVENTIONAL,['NA'],,
10361,NCT05920928,Clinical complete response,2023-09-23,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
10362,NCT05458388,Early gastric cancer detection rate,2022-07-12,RECRUITING,INTERVENTIONAL,['NA'],,
10363,NCT01886287,Number of Participants With Improved Frequency of Diarrhea,2013-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Rate of Progression Free Survival (PFS) at 6 Months
10364,NCT00562380,Pharmacokinetic profile,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Circulating levels of IGF-1R and IGF-BP3
10365,NCT01395667,Maximally tolerated dose,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Improved rate
10366,NCT03244787,Percentage of patients in intervention and control groups who completed any colorectal cancer screening during the six-month study period,2017-01,COMPLETED,INTERVENTIONAL,['NA'],,Number of polys found in intervention polyps (histology)
10367,NCT02510378,percentage of patients undergo R0 surgery during the follow-up,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The rate of early toxicity of radiotherapy according to the NCI Common Toxicity Criteria for Adverse Effects (version 3.0)
10368,NCT01783171,MTD of dinaciclib in combination with Akt inhibitor MK2206 defined as the highest dose at which 0 or 1 dose-limiting toxicities are observed in six patients,2013-01-15,COMPLETED,INTERVENTIONAL,['PHASE1'],Protein expression in serum as measured by fluorescence activated cell sorting (FACS),Progression-free survival
10369,NCT01934634,Percentage of patients with Dose-Limiting Toxicities,2014-03,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Objective Response Rate
10370,NCT01534637,Number of Patients With Gastrointestinal Toxicities (Grade 3 and 4 Nausea and Vomiting) Associated With Delivering Fluorouracil/Gemcitabine Hydrochloride-based Chemotherapy With Upper Abdominal Radiation,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Impact of Aprepitant/5HT-3 Antagonist Therapy on the Patient Quality of Life as Measured by the Number of Patients Taking Anti Nausea Drugs
10371,NCT03071458,Genetic and transcriptomic landscape,2008-01,COMPLETED,OBSERVATIONAL,['NA'],,Validation of the molecular classification by integrative analysis
10372,NCT06228963,6-months CR rate,2024-03,RECRUITING,INTERVENTIONAL,['PHASE2'],Exploratory biomarkers,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
10373,NCT02871245,Number of participants and classification with operation-related adverse events as assessed by CTCAE v4.03.,2016-09-21,UNKNOWN,INTERVENTIONAL,['NA'],,Immune cell number ratio in blood.
10374,NCT00003677,Number of Patients with Toxicity,1999-02-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10375,NCT00869570,Pathological near complete or complete tumor response (Dworak grade 3 and 4) (Phase II),2009-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Adverse events as assessed by NCI CTCAE v3.0
10376,NCT02639065,Percentage of Participants With One-Year Relapse Free Survival (RFS) With Post-Operative Durvalumab,2016-04-27,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Adverse Events as a Measure of Safety and Tolerability
10377,NCT04730388,predictive factor for progression-free survival,2021-01-18,UNKNOWN,OBSERVATIONAL,['NA'],,
10378,NCT00741676,2 year survival,2008-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],,efficacy and clinical out come
10379,NCT05162755,Assessment of antitumor activity using RECIST v1.1 (Dose expansion part),2021-10-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS) (Dose escalation and dose expansion parts)
10380,NCT02889328,Disease control rate,2016-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity profile by the NCI-CTCAE v4.03
10381,NCT02437916,AMG 228 half-life (t1/2),2015-04-21,TERMINATED,INTERVENTIONAL,['PHASE1'],,Changes in numbers of cytotoxic T lymphocytes (CTL)
10382,NCT04692987,Number of participants with colorectal cancer screening completion,2021-03,UNKNOWN,INTERVENTIONAL,['NA'],,Barriers towards the colorectal cancer screening uptake
10383,NCT01266187,Disease free survival,2011-07,TERMINATED,INTERVENTIONAL,['NA'],,Secondary objectives
10384,NCT00310115,Number of Patients with Smoking Abstinence,2002-04,COMPLETED,OBSERVATIONAL,['NA'],,Number of Cigarettes Smoked Daily
10385,NCT04117100,Assess the number of patients with intraprocedural bleeding,2018-06-01,RECRUITING,OBSERVATIONAL,['NA'],,
10386,NCT04228614,prediction accuracy of recurrent rate,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,Mutation Consistency of tissue and blood sample
10387,NCT03955224,Rate of patients who didn't need a dose increase or introduction of new analgesics for mouth pain during the study compared to baseline,2021-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Frequency of adverse events related to the LLLT using the National Cancer Institute Common Toxicity Criteria for Adverse Effects (NCI CTCAE) version 5.0
10388,NCT06185907,Duration of stay,2021-04-15,COMPLETED,OBSERVATIONAL,['NA'],,
10389,NCT02455648,Post-operative stenosis,2012-01,COMPLETED,INTERVENTIONAL,['NA'],,
10390,NCT00114244,Objective Response (OR = CR or PR) as Determined by the RECIST Criteria,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free Survival
10391,NCT02386397,Limiting toxicity,2014-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10392,NCT06034860,Proportion of participants with objective response,2023-11-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Evaluate the immunogenicity of MT-8421 in patients with selected advanced solid tumors.
10393,NCT00006046,Number of Patients With Dose-limiting Toxicities (DLTs),2000-07-12,TERMINATED,INTERVENTIONAL,['PHASE1'],,Number of Patients With Tumor Responses
10394,NCT01145404,Objective response rate (ORR),2010-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Biomarker analysis
10395,NCT01953419,ORR,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10396,NCT00867334,Number of Patients With Adverse Events,2009-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Stabilization or Reduction in Tumor Size
10397,NCT01326065,Long term outcome,2011-02,TERMINATED,OBSERVATIONAL,['NA'],,Quality of the surgical specimen
10398,NCT02485834,Overall Survival,2015-08,TERMINATED,INTERVENTIONAL,['PHASE2'],Change in FDG-PET SUV Measures,Number of Participants Who Reported Grade 3 or Higher Adverse Events
10399,NCT01483014,Objective response using the RECIST criteria,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
10400,NCT02789709,Disease-free survival,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],,Postoperative mortality
10401,NCT04292366,Number of residents participating in colorectal cancer screening,2020-10-02,COMPLETED,INTERVENTIONAL,['NA'],,
10402,NCT03598998,Overall response rate (ORR) according to Lugano classification (Phase II),2019-02-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of unacceptable toxicity assessed by NCI CTCAE version 5.0
10403,NCT03272659,fluorescence with photodynamic diagnostics (PDD) in colorectal cancer,2018-04-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Accurate depiction of the extent of disease burden by correlating pre-and post surgical results after neoadjuvant chemotherapy and radiation.,Detect malignant lesions
10404,NCT04889742,Local tumor recurrence,2024-05-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Patient reported quality of Life
10405,NCT00022139,Proportion of successes,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life
10406,NCT06241079,Overall survival,2003-03-31,COMPLETED,OBSERVATIONAL,['NA'],,
10407,NCT03388047,Level of confidence in delineating the area of interest by multispectral imaging,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Correlation with molecular biomarkers
10408,NCT02264886,"Feasibility of the online, adaptive, MRI-guided SBRT",2015-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Patient-reported quality of life
10409,NCT01650428,Pathological Complete Response (PCR),2013-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumour Cell Density
10410,NCT05003700,Objective response rate (ORR),2021-04-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
10411,NCT05195502,Evaluation of metabolic profile,2022-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Colonic biofilm
10412,NCT03476057,cfDNA,2018-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,Tumor mutation burden
10413,NCT04137107,Chronic neuropathic pain response (Phase III),2020-05-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"Incidence of adverse events, including duloxetine side effects of nausea, dry mouth, dizziness, somnolence, fatigue, and insomnia (Phase III)"
10414,NCT06048458,Change in myocardial blood flow from baseline with adenosine stress assessed by quantitative perfusion cardiac MRI,2022-05-18,RECRUITING,OBSERVATIONAL,['NA'],,Change in retinal vessel density
10415,NCT04354662,Pathological complete response rate (pCR),2019-09-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,5-year Survival Rate
10416,NCT04044313,Progression free survival rate at 6 months,2019-08-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse events
10417,NCT06320301,the effectiveness of first-line treatment with Adebrelimab and a tyrosine kinase inhibitor (TKI) in combination with gemcitabine and oxaliplatin (GEMOX) in patients with advanced BTC,2024-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],The DoR based on an immunomodified RECIST (imRECIST）,To evaluate the overall survival (OS).
10418,NCT05319314,Recommended Phase 2 dose (RP2D) based on incidence of dose-limiting toxicities (DLTs) during 3+3 dose escalation study,2022-08-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Tmax: The time to reach maximum(peak) in peripheral blood or other body fluid drug concentration after single dose administration (days)
10419,NCT04332705,Prevalence of Cryptosporidium,2020-06-30,RECRUITING,OBSERVATIONAL,['NA'],,Rate of development of a neoplastic lesion in the human explants
10420,NCT00856375,Kaplan-Meier Estimate of PFS by Central Radiological Review: ITT Population,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,PK Parameters of NKTR-102 or Irinotecan and Respective Metabolites
10421,NCT01084629,detection of dysplasic areas,2010-11,COMPLETED,OBSERVATIONAL,['NA'],,
10422,NCT03181334,Increase in colorectal cancer screening rate of the 5 tested invitation approaches.,2017-09-05,COMPLETED,INTERVENTIONAL,['NA'],,
10423,NCT05278195,Overall Survival(OS),2022-04-01,UNKNOWN,OBSERVATIONAL,['NA'],,Accuracy
10424,NCT03334890,mSEPT9 level,2016-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,"CR,PR,SD,PD"
10425,NCT03470883,Complete long-term remission (> 12 months),2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Endoscopic description and anatomopathological results
10426,NCT03392103,The ratio of patients occured Grade 3 or higher adverse events,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,3-year overall survival probability
10427,NCT06038578,Progression free Survival (PFS),2023-10-04,RECRUITING,INTERVENTIONAL,['PHASE2'],,Change from Baseline in Patient Reported Quality of Life assessed by Questionnaire - EuroQOL Five Dimensions questionnaire 3L (EQ-5D-3L) scores
10428,NCT03969784,percentage of microparticule,2019-09-01,UNKNOWN,INTERVENTIONAL,['NA'],,
10429,NCT01230697,Identify the value variations of hormones involved in phosphate homeostasis during sorafenib administration,2010-06,UNKNOWN,OBSERVATIONAL,['NA'],,Identify correlations between phosphate related hormones variations and patients outcome (TTP and overall survival)
10430,NCT01838109,Body weight decrease rate 8weeks after discharge compared with preoperative body weight,2013-04,COMPLETED,INTERVENTIONAL,['NA'],ONS related gastrointestinal adverse event,serum albumin
10431,NCT06014944,cCR rate,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
10432,NCT05526846,Effect of the intervention on participant's Healthy Plant-Based Diet Index,2024-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Secondary health gains associated with adopting a plant-based diet
10433,NCT00625625,Disease-free survival,2004-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
10434,NCT00999882,Evaluate the pharmacokinetics of AZD8055 following both single and multiple dosing,2009-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,To collect and store DNA for future exploratory research that may influence response to AZD8055
10435,NCT05179837,Proportion of participants that have a lesion that can be adequately evaluated with OCT,2022-01-24,RECRUITING,INTERVENTIONAL,['NA'],,Weighted kappa
10436,NCT03419481,Response rate (RR) according to RECIST1.1,2018-04-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
10437,NCT05083247,R0 Resection rate,2023-03-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Technical and quality success rate of EUS-delivered fiducials.
10438,NCT05855200,Event-free Survival (EFS) Assessed by Blinded Independent Central Review (BICR),2023-08-02,RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of Participants with Anti-Drug Antibodies against Dostarlimab
10439,NCT04963088,ORR,2021-03-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-free survival
10440,NCT00504322,Expression of CD40L and cytokines,2011-07,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10441,NCT06151223,Collection of radiology images and videos,2021-07-13,RECRUITING,OBSERVATIONAL,['NA'],,
10442,NCT00265798,Objective Response Rate,2005-09-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
10443,NCT06328101,Standardized incidence ratio (SIR) of first invasive cancer,2024-05-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Risk factor associated with cancer diagnosis.
10444,NCT02025842,risk for hepatocellular carcinoma,2000-01,COMPLETED,OBSERVATIONAL,['NA'],,survival
10445,NCT04039607,Overall Survival (OS),2019-09-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Time to Symptom Deterioration (TTSD)
10446,NCT01236300,NPV (Negative Predictive Value),2010-07,COMPLETED,INTERVENTIONAL,['NA'],,Overall Complication Rate
10447,NCT04241835,"To evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, fu: unbound fraction of drug in plasma",2020-01-28,RECRUITING,INTERVENTIONAL,['PHASE1'],,To evaluate the number of participants with adverse events (AEs) as assessed by CTCAE v5.0
10448,NCT00079066,Overall survival,2003-12-30,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety profile
10449,NCT04499924,Incidence of dose modifications (Phase 2 only),2021-03-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Utility index values as assessed by the EQ-5D-5L
10450,NCT00575523,Occurrence of dysrhythmias,2003-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,Clinical complications
10451,NCT03524677,Early recurrence,2019-01-23,UNKNOWN,OBSERVATIONAL,['NA'],,N stage
10452,NCT02066272,The frequency of adverse events on induction of remission and maintenance treatment using anti-TNFs (including biosimilars) in a cohort of IBD patients,2014-01,UNKNOWN,OBSERVATIONAL,['NA'],,
10453,NCT06024980,Swallowing ability to four different textures,2023-01-03,RECRUITING,INTERVENTIONAL,['NA'],,The time in weeks of nasogastric feeding
10454,NCT04562727,DFS,2021-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Tumor reactivity assessment
10455,NCT05568017,objective response evaluation,2020-09-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,analysis of tumor specific circulating NET transcripts
10456,NCT01596283,Postoperative Complications,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Postoperative Length of Stay
10457,NCT00056537,Maximum Tolerated Dose (MTD) as a function of pre-treatment anti-SEA/E-120 levels,2003-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to progression and Survival
10458,NCT02730663,Number of Participants With Clinical Success,2016-03-21,COMPLETED,INTERVENTIONAL,['NA'],,Other Adverse Events
10459,NCT00861094,Progression-free survival (Phase III),2008-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Quality of life as assessed by EORTC QLQ-C30 (version 3) and EORTC QLQ-OES18 (Phase III)
10460,NCT01718873,Objective Response Rate,2012-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Toxic Effects
10461,NCT04595604,Change in preoperative functional status - FVC by the end of rehabilitation,2020-09-07,SUSPENDED,INTERVENTIONAL,['NA'],,Change of alpha- and beta-diversity of fecal microbata
10462,NCT04150120,Cost-utility ratios,2019-10-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,EQ-5D-3L
10463,NCT01375088,NCI.CTC Scale,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,hyposalivation scale
10464,NCT00981162,Maximum tolerated dose of everolimus (Phase I),2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Toxicity and adverse events as assessed by NCI CTCAE v3.0
10465,NCT05572788,Rate of post-procedure pancreatitis following EUS-guided fine needle aspiration of pancreatic cysts,2022-09-26,RECRUITING,INTERVENTIONAL,['NA'],,Length of hospitalization in any patient hospitalized with acute pancreatitis
10466,NCT05010434,ORR (objective response rate),2021-08-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse effects
10467,NCT00449137,Thymidylate synthase expression,2005-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10468,NCT02029157,Progression-free survival (PFS),2014-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall survival
10469,NCT04003181,Serum concentration of FGF19,2017-09-28,COMPLETED,INTERVENTIONAL,['NA'],,Quality of life after treatment with antibiotics or bile acid binder
10470,NCT01341756,Response of bleeding to radiotherapy,2009-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Number of patients who develop anorexia, nausea, vomiting as per common toxicity criteria v3.0"
10471,NCT00084773,Safety profile,2004-03,COMPLETED,INTERVENTIONAL,['NA'],,Activity in terms of pathological complete response rate
10472,NCT05153746,Adenoma detection rate,2022-02-10,RECRUITING,INTERVENTIONAL,['NA'],,Flat adenoma detection rate
10473,NCT05364918,Acute radiotherapy-induced oral mucositis,2020-08-17,COMPLETED,INTERVENTIONAL,['PHASE3'],,Oral pain
10474,NCT00055250,6-month survival,2003-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,PK
10475,NCT06126120,Participant non-adherence to 2-yearly colonoscopy check-up.,2024-01-17,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,The four most important challenges to having colonoscopy check-up for participants.
10476,NCT01647776,Efficacy of sDNA testing for the detection of advanced adenomas,2012-04-01,COMPLETED,OBSERVATIONAL,['NA'],,"To investigate the association of activated (phosphorylated) IRS1, AKT and mTOR with colon adenomas."
10477,NCT04079049,Survival,2020-01-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,
10478,NCT05135364,Progression-free survival (according to mRECIST),2021-11-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease control rate (according to mRECIST and RECIST 1.1)
10479,NCT00630890,To determine the maximal tolerated dose of the Cyberknife radiosurgery boost,2007-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,To estimate disease specific and overall survival
10480,NCT00809081,To evaluate the impact of early postoperative enteral feeding,2007-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,To evaluate the nutritional status
10481,NCT01927016,To identify predictors of recurrence after esophageal cancer surgery,2012-07,COMPLETED,OBSERVATIONAL,['NA'],,"Impact of patient preconditioning (such as nutritional support, esophageal prosthesis, mini-invasive approach…) on outcomes"
10482,NCT03045497,Ability of contrast-enhanced ultrasound to predict response to transarterial chemoembolization with drug eluting beads,2012-12-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Changes in contrast fill time
10483,NCT00541125,Toxicities by NCI-CTC v. 2.0,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to treatment failure
10484,NCT04606992,Resection margin,2020-02-10,COMPLETED,INTERVENTIONAL,['NA'],,Complication rate
10485,NCT01355107,measurement of selenium levels in hcv- infected patients,2011-04,COMPLETED,OBSERVATIONAL,['NA'],,selenium levels and MELD(Na)score
10486,NCT00891332,Overall Response Rate (ORR),2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Pharmacokinetics
10487,NCT01789229,Establishment of blood/tissue bank consisting of oncological samples from cancer patients and benign and healthy controls.,2003-09,RECRUITING,OBSERVATIONAL,['NA'],,
10488,NCT05985798,Overall survival (OS),2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse Events (AEs)
10489,NCT00436657,Maximum Tolerated Dose (MTD) of continuous hyperthermic peritoneal perfusion (CHPP) with cisplatin in children with peritoneal cancer,2007-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10490,NCT04472767,Complete Response Rate,2020-08-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Conversion Rate to Resectable
10491,NCT06313268,Adverse events,2022-04-21,RECRUITING,OBSERVATIONAL,['NA'],,
10492,NCT00237900,"Parts 2 and 3: Safety and tolerability of gefitinib in combination with 5-FU, LV and radiotherapy",2003-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Exploratory outcome: Parts 2 and 3: sVEGF levels, EGFR activation, Biomarkers such as cyclin D1, IL-1, GI-associated TOP2A, GAS, EST AA552509"
10493,NCT01150916,diagnostic accuracy of BNP for the diagnosis of ascites due to heart failure,2010-06,COMPLETED,INTERVENTIONAL,['NA'],,
10494,NCT02080260,Number of Patients Progression Free and Surviving at 16 Weeks as a Percent of All Enrolled Subjects,2014-06-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Control
10495,NCT03623464,Readmission rate,2017-05-31,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life: Return to Baseline Function-Activities of Daily Living (ADLs)
10496,NCT03449030,Recommended Phase 2 Dose (RP2D) of TAK-164,2018-04-23,TERMINATED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Positive Antidrug Antibody (ADA) Levels in Serum
10497,NCT01048580,"Safety and tolerability of the combination of perifosine and capecitabine (i.e., dose limiting toxicity)",2009-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetic (PK) data for the combination of perifosine and capecitabine
10498,NCT02534142,Variables related to non-completion of colonoscopy following a positive fecal occult blood test,2015-10,COMPLETED,OBSERVATIONAL,['NA'],,
10499,NCT01643447,the overall survival rate of each group,2012-05,COMPLETED,INTERVENTIONAL,['NA'],,
10500,NCT01377220,,2011-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
10501,NCT02081547,IPC status,2012-04,UNKNOWN,OBSERVATIONAL,['NA'],,Survival
10502,NCT02117674,polyp detection rate,2014-04,COMPLETED,INTERVENTIONAL,['NA'],,patients' satisfaction
10503,NCT01229813,To demonstrate that maintenance treatment with bevacizumab + erlotinib following first line chemo- and anti-angiogenetic therapy results in a significant increase in progression free survival (PFS) compared to treatment with only bevacizumab.,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,To explore the activity of bevacizumab and low dose metronomic capecitabine in patients with KRAS mutated tumors.
10504,NCT01372527,Cancer completion for all eligible cancers,2011-06,COMPLETED,INTERVENTIONAL,['NA'],,TopCare system measures (intervention practices)
10505,NCT01549795,Time to recurrence after liver transplant,2012-01,UNKNOWN,INTERVENTIONAL,['NA'],,Complication rate due to radiotherapy (Hepatic artery thrombosis and Portal vein thrombosis)
10506,NCT06321913,vital signs,2024-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],CLDN18.2 expression level,Overall Survival (OS)
10507,NCT05374369,Tumor detection rate in the positive screening results,2022-03-29,COMPLETED,OBSERVATIONAL,['NA'],,
10508,NCT00436410,Comparison of the impact of distribution time and histology on accumulation of treatment particles in tumor vs normal tissues,2006-12,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Long-term toxicity of treatment as assessed by CTCAE v3.0
10509,NCT02425735,Reduced size of the tumors,2015-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10510,NCT05935384,Sensitivity of ctDNA to Detect Disease Progression,2023-10-25,RECRUITING,OBSERVATIONAL,['NA'],,Lead Time
10511,NCT05415709,Incidence of chemotherapy-related adverse events,2022-06-13,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Quality of life (QOL) assessment EORTC QLQ-C30
10512,NCT06248528,Overall survival,2019-12-01,RECRUITING,INTERVENTIONAL,['NA'],,Adverse effects
10513,NCT05642338,HGD/EAC,2022-11-01,RECRUITING,OBSERVATIONAL,['NA'],,The rate of progression to HGD/EAC after a WATS-positive-biopsy-negative diagnosis for HGD/EAC
10514,NCT06283121,Objective response rate (ORR),2024-04-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
10515,NCT02867592,Objective Response (Osteosarcoma Stratum),2017-05-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Change in Immune Biomarkers,Overall Survival (OS)
10516,NCT04239261,Development of Oral Mucositis during ChemoRadiation Treatment,2020-01-17,TERMINATED,INTERVENTIONAL,['PHASE2'],,Change in Bowel Movements
10517,NCT00001332,,1992-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10518,NCT03403296,overall survival(OS),2016-07-13,COMPLETED,OBSERVATIONAL,['NA'],,
10519,NCT06138769,Progression-free survival,2023-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
10520,NCT02799212,presence of postoperative ascites during the postoperative course,2018-01-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Postoperative morbidity on Renal failure
10521,NCT03135652,Disease free survival,2017-08-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Toxicities
10522,NCT03632850,Decisional Conflict Scale,2019-02-19,COMPLETED,OBSERVATIONAL,['NA'],,Usability: System Usability Scale (SUS)
10523,NCT01609075,Proportion of patients with Avastin treatment discontinuation due to either disease progression or Avastin-related adverse events,2012-06,COMPLETED,OBSERVATIONAL,['NA'],,Progression-free survival (patients with treatment discontinuation due to disease progression or Avastin-related toxicity as compared to patients with treatment discontinuation due to other causes)
10524,NCT04314349,Correlation of radiogenomics,2020-08-01,COMPLETED,OBSERVATIONAL,['NA'],,Treatment response and survival
10525,NCT01510730,Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of gastric tumor.,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,effect of eradication of Helicobacter pylori on incidence of High grade dysplasia development after endoscopic resection of gastric tumor.
10526,NCT05458791,Quantification of Parameters for Intra-arterial Perfusion,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],,Impact of low dose radiation technique on intra-arterial perfusion parameters
10527,NCT01539824,Disease stabilisation rate,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumour Markers
10528,NCT02981719,Safety (number of adverse effects),2016-10-01,COMPLETED,INTERVENTIONAL,['NA'],,Technical success of ablation
10529,NCT02677597,PFS,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
10530,NCT00956254,Cmax of Fentanyl,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,AUC0-last of Fentanyl
10531,NCT00956241,Primary endpoint was the function of the neo-rectum as assessed by a validated functional outcome questionnaire at 4 months.,2002-04,COMPLETED,INTERVENTIONAL,['NA'],,Quality of life
10532,NCT04178642,The survival rate without hepatic recurrence at 1 year,2020-09-22,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Overall survival
10533,NCT02937519,Number of Participants with Adverse Events as a Measure of Safety,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
10534,NCT04722055,Kappa coefficient,2021-01-26,COMPLETED,OBSERVATIONAL,['NA'],,
10535,NCT04721470,AFP variation rate,2017-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
10536,NCT00955149,To examine the safety and tolerability of Tarceva (Erlotinib) in patients with primary sclerosing cholangitis and trisomy 7 on biliary cytology.,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,To assess among patients with primary sclerosing cholangitis and trisomy 7 the resolution of this cytologic abnormality following treatment with Tarceva (Erlotinib).
10537,NCT00162110,Evaluate the efficacy of Erbitux in the treatment of mucinous gastrointestinal adenocarcinoma involving the peritoneal surfaces based on clinical response rate.,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To evaulate surgically resected tumor specimens of the EGF receptor, mucins 1-6, and anglogenic indices such as vessel counts, VEGF expression, and Ki-67 expression. To evaluate the safety of Erbitux monotherapy in this patient population."
10538,NCT05426005,Objective response rate (ORR),2023-02-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Toxicity assessed using the The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0."
10539,NCT05658679,5-year survival rate,2016-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
10540,NCT01766479,"Number of patients in whom colorectal polyps and colorectal neoplasia have been detected by CT colonography, by adopting colonoscopy as gold standard, as a measure of efficacy.",2009-05,COMPLETED,INTERVENTIONAL,['NA'],,
10541,NCT00594529,Curative resection rates of liver metastases,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Completion rates of neoadjuvant chemotherapy
10542,NCT05964361,Safety of IL15/IL15Ra/WT1 DC vaccine administration: total (S)AEs (grade),2023-12-06,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Evaluation of changes in quality of life: How patient-reported quality of life evolves over time
10543,NCT04597970,Progression free overall survival，PFS,2020-10-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival， OS
10544,NCT01493206,clinical outcomes,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,toxicities
10545,NCT04008511,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,2019-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall response rate (ORR)
10546,NCT03817866,Disease Progression,2019-01-29,COMPLETED,OBSERVATIONAL,['NA'],,
10547,NCT04245683,patient preferences for operative vs. non-operative management of rectal cancer,2020-02-01,RECRUITING,OBSERVATIONAL,['NA'],,Patient adherence to surveillance protocols
10548,NCT03206151,Progression-free Survival (PFS),2017-12-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence of anti-CMAB009 antibody
10549,NCT00434161,Incidence of Cataract Development or Progression at Month 12.,2006-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Incidence of Second Primary Malignancies or Other Malignancies
10550,NCT05856500,Appendicular skeletal muscle mass index(kg/㎡),2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Survival rate(%)
10551,NCT00574353,"the feasibility of a non-invasive method of detecting hypoxia, using F-FMISO-PET imaging in colorectal cancer patients.",2007-12,WITHDRAWN,INTERVENTIONAL,['NA'],,"determine volume of hypoxic tumor ROIs as a proportion of the entire tumor volume by this non-invasive imaging technique. ROIs are defined as those voxels, within the tumor volume defined on FDG PET/CT, for which the 18F-F-FMISO radioactivity concent"
10552,NCT04072224,Description of volume of in vivo ablation,2018-10-23,COMPLETED,OBSERVATIONAL,['NA'],,liver response
10553,NCT01161316,progression-free survival,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse events
10554,NCT04149613,microRNA expression Level,2018-05-25,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Dietary pattern
10555,NCT00885885,Objective response rate,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluation of molecular predictive markers for response.
10556,NCT03399110,DFS,2017-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,OS
10557,NCT00712790,Tumour response rate (liver ± any site).,2008-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Rate of downstaging to surgical resection or ablative therapy.
10558,NCT03172377,Cumulative incidence of persistent disease flares.,2017-05-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],,The decremental cost effectiveness ratio of this interval lengthening strategy
10559,NCT03729687,Pathological complete response (pCR) rate and clinical complete response (cCR) rate,2016-07-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Long-term Adverse Events
10560,NCT01457976,"Survey respondents are presented with scenarios that seek to elicit views and attitudes on the concepts of personal responsibility, and the acceptability of financial incentives. The analysis will present these views and attitudes in aggregate form.",2011-09,WITHDRAWN,OBSERVATIONAL,['NA'],,
10561,NCT05088733,Survival rate,2020-07-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,quality of life (QOL) questionnaire
10562,NCT02273167,Number of Patients With 'Excellent Plus Good' (Highly Effective) Bowel Cleansing (Colon Ascendens),2014-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Polyp Detection Rate (Overall Colon)
10563,NCT00454116,Number of Patients With an Objective Disease Progression Event,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10564,NCT04845490,overall survival,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,The positive rate of cancer cells of participants by exfoliative cytology examination
10565,NCT00379639,Best Overall Response,2006-07-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10566,NCT04123574,To characterize the quantitative and qualitative effects of BXCL701 on relevant immune effector cytokines and various immunological effector cells that are consistent with its known mechanism of action.,2019-10-15,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,Genomic analysis before and after treatment.
10567,NCT00854971,Determine response rate,2009-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Determine safety of combination,time to treatment failure, overall survival time"
10568,NCT04771520,Overall response rate (ORR),2021-01-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
10569,NCT03985891,ORR,2020-12-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,OS
10570,NCT05517239,Progression free survival,2015-05-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
10571,NCT00962494,Health Behaviors,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Satisfaction with intervention
10572,NCT00530010,Patient Completion,2004-12,COMPLETED,OBSERVATIONAL,['NA'],,
10573,NCT05025371,Overall survival,2021-04-01,COMPLETED,OBSERVATIONAL,['NA'],,
10574,NCT05589480,Recurrence-free survival,2022-08-01,COMPLETED,OBSERVATIONAL,['NA'],,
10575,NCT04979663,Safety: the incidence of adverse events and serious adverse events,2020-12-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
10576,NCT00441311,Colorectal cancer screening recommendations,2003-05,COMPLETED,INTERVENTIONAL,['PHASE4'],,
10577,NCT00582452,To assess levels of intention in prophylactic colectomy among individuals at increased familial risk of colorectal cancer and to identify distinctive decision types based on profiles of perceived pros and cons of prophylactic colectomy;,2004-11,COMPLETED,OBSERVATIONAL,['NA'],,
10578,NCT03731442,"1-, 2-, 3-year overall survival",2018-11-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,"Toxicities according to RTOG and CTCAE criteria, including hematological and non-hematological toxicities"
10579,NCT04912258,liver relapse-free survival,2021-08-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,response rate
10580,NCT00030342,Safety as measured by NCI common toxicity table at study completion,2001-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10581,NCT05493332,Conversion therapy success rate,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Patient reported outcome（PRO）
10582,NCT00792350,"Efficacy: status of tumor, patients performance status",2008-04,COMPLETED,OBSERVATIONAL,['NA'],,Reports of adverse events
10583,NCT02124148,Part E: Maximum Tolerated Dose of Prexasertib in Combination with LY3023414,2014-06-18,COMPLETED,INTERVENTIONAL,['PHASE1'],,"B2, E2, E3 Dose Expansion: Duration of Response"
10584,NCT04104633,Feasibility of molecular karyotype performed from liquid biopsy: copies number variations (CNV),2018-06-14,UNKNOWN,INTERVENTIONAL,['NA'],,Identification of patient's tumor genomic profile with blood sample
10585,NCT05093231,Objective Response Rate (ORR),2022-03-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,European Organisation for Research and Treatment of Cancer Pancreatic Cancer Quality of Life Questionnaire (EORTC PAN26)
10586,NCT01505166,Percent of Patients Who Survived After Treatment (Part 2),2012-03,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Alive Subjects (Part 1),
10587,NCT03387982,Difference in pain quality 4 weeks post-procedure for subjects receiving Balloon Cryotherapy or Radiofrequency Ablation via the Pain Quality Assessment Scale (PQAS),2017-11-01,COMPLETED,OBSERVATIONAL,['NA'],,
10588,NCT05104268,Change in Patient-Reported Oral Mucositis Symptom (The Modified PROMS Questionnaire) Pain Score,2024-11-30,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,"Change of oral mucositis grade in the World Health Organization Grade,(WHO Mucositis Grade)"
10589,NCT01285557,Overall Survival (OS),2011-04-14,TERMINATED,INTERVENTIONAL,['PHASE3'],,Time to Tumor Response (TTR)
10590,NCT05318027,Number of triage visits,2023-05-22,RECRUITING,INTERVENTIONAL,['NA'],,Quality of Life scores
10591,NCT02383797,Number and severity of adverse events to vaccination,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],,
10592,NCT00153998,"Tumor response, defined as partial and complete response according to RECIST (Response Evaluation Criteria in Solid Tumors) - criteria in the intention-to-treat [ITT-] population",2004-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Molecular predictive markers for response and toxicity
10593,NCT01324882,Intubation of Cecum,2010-06,COMPLETED,INTERVENTIONAL,['NA'],,
10594,NCT01825603,"Recommended dose of ADH-1, defined as the highest dose tested which results in dose-limiting toxicities in no more than 1 of 6 evaluable patients based on the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0",2013-04-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Survival
10595,NCT02751736,Low Anterior Resection Syndrome score,2016-04,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative complication
10596,NCT04996914,1-year local control rate,2022-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Quality of life based on EORTC QLQ-HCC18
10597,NCT02238847,"Sustained Biliary Drainage, Defined as Absence of Reinterventions for the Management of Biliary Obstructive Symptoms",2015-03-24,COMPLETED,INTERVENTIONAL,['NA'],,"For Participants Not Undergoing Curative Intent Surgery, Sustained Biliary Drainage to One Year After Stent Placement"
10598,NCT06278883,Uptake of genetic testing recommendations by the provider,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
10599,NCT00479050,overall survival,2001-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,tumor response
10600,NCT00054262,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10601,NCT01643824,local progression-free survival,2012-06-07,COMPLETED,INTERVENTIONAL,['NA'],,overall survival
10602,NCT05178628,The number of VTE events during the trial,2022-02-10,RECRUITING,INTERVENTIONAL,['PHASE3'],,Change from baseline in QoL
10603,NCT06199895,Objective Response Rate,2023-11-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
10604,NCT03292991,"Safety as per CTCAE 4.03, incidence of AEs and baseline change in liver function paired t-test or Wilcoxon signed rank test.",2015-06-09,UNKNOWN,OBSERVATIONAL,['NA'],,Liver transplantation rate
10605,NCT05755607,Rate of long-term Survival,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Incidence of postoperative complications
10606,NCT03466593,PaO2,2017-12-18,COMPLETED,INTERVENTIONAL,['NA'],,Lenght of stay
10607,NCT01473121,Descriptive analysis of clinical profile of newly diagnosed HCC patients,2012-08-13,COMPLETED,OBSERVATIONAL,['NA'],,Descriptive analysis of tumor properties
10608,NCT03257163,Recurrence-free survival (RFS) rate,2017-09-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,
10609,NCT02006030,Determine time to tumor progression (TTP),2014-10-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumor response rates
10610,NCT01508000,Progression free survival,2013-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Safety
10611,NCT01260194,Median Progression Free Survival (PFS),2011-06,TERMINATED,INTERVENTIONAL,['PHASE4'],,Number of Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Gastric Cancer
10612,NCT05316818,Rate of adverse events,2018-01-16,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival time (OS)
10613,NCT02418988,overall survival,2014-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,progression-free survival
10614,NCT00130689,Overall Response Rate,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10615,NCT00746317,Determine the safety and tolerability of escalating doses of GC33,2008-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Perform a preliminary assessment of anti-tumor activity of GC33
10616,NCT04975620,Comparison of EUS-FNB sensitivity using two types of FNB needles,2021-08-01,COMPLETED,INTERVENTIONAL,['NA'],,Comparing the score of blood content n for each pass in two types of FNB needles.
10617,NCT00019344,,1997-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10618,NCT00076609,"Alphafetoprotein measurements every 3 weeks for first 3 courses, then every 6 weeks thereafter",2003-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Survival follow-up every 2 months
10619,NCT02910960,Total area of procured tissue between the two FNB needles,2016-12,COMPLETED,INTERVENTIONAL,['NA'],,Diagnostic adequacy between the two FNB needles
10620,NCT00420394,Feasibility of the study regimen.,2007-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall and progression free survival following the study treatment plan
10621,NCT05503381,disease-free survival rate,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
10622,NCT04673968,Body composition,2020-02-25,RECRUITING,INTERVENTIONAL,['NA'],,Mitochondria functionality
10623,NCT00437268,Percentage of Participants With Progression-Free Survival (PFS) at 6 Months (PFS Rate),2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events (AEs) or Who Died
10624,NCT04597294,Peritoneal recurrence rate,2021-08-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Treatment-related quality of life assessed by Quality of Life Questionnaire-Stomach (STO22)
10625,NCT04535414,Determine if Bethesda protocol provides improved sensitivity for detection of early stage gastric cancer in CDH1 germline mutation carriers compared to the Cambridge method,2023-06-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,To estimate and compare the difference in crude cancer detection rates between endoscopy using the Bethesda protocol and the Cambridge method
10626,NCT01482442,Median overall survival time,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Health care costs
10627,NCT01196130,Rate of Successful Biomarker Determination,2010-08,COMPLETED,OBSERVATIONAL,['NA'],,
10628,NCT05722275,The aera under the receiver operating characteristic curve (AUC) of intelligent analysis system,2023-01-01,RECRUITING,OBSERVATIONAL,['NA'],Overall survival,The accuray of intelligent analysis system in predicting peritoneal metastasis
10629,NCT04395118,Hepatitis C Screening,2020-08-15,WITHDRAWN,INTERVENTIONAL,['NA'],,Cost Per HCV Diagnosis
10630,NCT02902484,Maximum Tolerated Dose (MTD),2017-09-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10631,NCT05625893,Incidence of adverse event assessed according to the Common Terminology Criteria for Adverse Events (CTCAE version 5.0),2022-09-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Local tumor progression rate
10632,NCT03069950,Resection rate assessed using RECIST (version 1.1),2017-02-28,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
10633,NCT05545046,Visual Analogue Scale (VAS),2019-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
10634,NCT00056446,Overall survival,2003-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Tolerability and safety profile
10635,NCT06086002,Technique efficacy,2023-09-18,RECRUITING,INTERVENTIONAL,['NA'],,
10636,NCT01982227,Sensitivity (true positive) of the fluorescence ex vivo compared to histological analysis s detected by fluorescence ex vivo,2013-03,COMPLETED,OBSERVATIONAL,['NA'],,Specificity (true negative) of the in-vivo fluorescence compared to histological analysis s detected by fluorescence ex vivo PCI score with and without fluorescence
10637,NCT03693807,% frequency liver toxicity,2018-10-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,progression free survival
10638,NCT01348503,Number of Participants with Dose Limiting Toxicities as a Measure of Safety of the combination of lenalidomide and sorafenib.,2011-05,TERMINATED,INTERVENTIONAL,['PHASE1'],,
10639,NCT05505370,Intubation of terminal ileum and cecum,2022-04-21,COMPLETED,INTERVENTIONAL,['NA'],,User feedback for operating characteristics of the device
10640,NCT04763824,Percent change in evidence based cancer screening,2020-11-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Participation rates in the Telementoring and Practice Facilitation Sessions,
10641,NCT01526200,new colorectal liver metastases detected at contrast-enhanced intraoperative ultrasonography,2007-10,COMPLETED,OBSERVATIONAL,['NA'],,new colorectal liver metastases detected during 6-month postoperative follow-up
10642,NCT05291338,Interleukin 28 B (IL28B) rs12979860.,2022-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
10643,NCT02217891,qualitive data,2014-08,COMPLETED,OBSERVATIONAL,['NA'],,
10644,NCT01182272,Significant pathological changes,2010-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Tolerance of liver resection after sorafenib tosylate treatment
10645,NCT02103322,AUC0-tau,2014-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Fluctuation Rate
10646,NCT05965817,To assess the feasibility of simultaneous use of ICG and SGM-101 for intraoperative imaging of colorectal liver metastases.,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
10647,NCT01472419,Overall Survival,2012-03,COMPLETED,OBSERVATIONAL,['NA'],,
10648,NCT03100409,Changes in food intake,2017-02-01,TERMINATED,INTERVENTIONAL,['NA'],,Change in quality of life for cervical cancer patients: (European Organization for Research and Treatment of Cancer Cervical cancer module- EORTC QLQ-CX 24)
10649,NCT05424692,The difference of 3-year disease-free survival rate of patients in both group,2021-09-01,RECRUITING,INTERVENTIONAL,['NA'],,The difference of OS of patients in both group
10650,NCT04703101,Complete clinical response rate,2021-02-11,RECRUITING,INTERVENTIONAL,['PHASE1'],,Prediction of complete clinical response rate status by radiomics
10651,NCT05362617,ORR（objective response rate）,2020-01-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,QoL（quality of life）
10652,NCT05948449,Pathological complete response rate (pCR),2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and Tolerability
10653,NCT03095209,Serum inflammation markers,2017-02-24,COMPLETED,OBSERVATIONAL,['NA'],,Quality of life and pain
10654,NCT05988645,Number of mural injuries.,2023-08-01,RECRUITING,INTERVENTIONAL,['NA'],,Perception of difficulty.
10655,NCT02930278,3-year disease overall survival rate,2016-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,Visual Analog Score for pain
10656,NCT02010801,Complete treatment,2012-04,COMPLETED,INTERVENTIONAL,['NA'],,adverse effect
10657,NCT00019019,,1994-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10658,NCT00660426,"To define the maximum tolerated dose of oxaliplatin, gemcitabine and capecitabine in the treatment of patients with advanced gastrointestinal malignancies and other solid tumors.",2005-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,To perform correlative pharmacogenomic and pharmacokinetic tests for this novel regimen.
10659,NCT02017366,overall survival from day of surgery,2018-10,WITHDRAWN,INTERVENTIONAL,['NA'],,postoperative weight loss
10660,NCT01843218,assess erectile dysfunction,2008-03,TERMINATED,INTERVENTIONAL,['NA'],,Evaluate objectively the presence of erectile dysfunction before and 12 months after the medico-surgical treatment of rectal cancer
10661,NCT01637350,,2012-08,UNKNOWN,OBSERVATIONAL,['NA'],,
10662,NCT00952497,The primary objective is to assess progression free survival (PFS). PFS will be measured from the date of first study drug administration to the date of first scan that first documents disease progression.,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Other efficacy variables are overall survival, overall response rate, safety and tolerability. Exploratory analyses may be performed to investigate the correlation of biomarker status with treatment effect and response."
10663,NCT03533920,Objective Response Rate by independent evaluator,2017-10-25,COMPLETED,INTERVENTIONAL,['NA'],,
10664,NCT03500068,Developing organoids from advanced pancreatic cancer patients that predict non response or response,2017-09-04,UNKNOWN,INTERVENTIONAL,['NA'],,Functional studies will be done with the patient derived organoids to find biomarkers that correlate with response in organoids and patients.
10665,NCT01076517,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA'],,
10666,NCT03520790,Overall survival,2018-12-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression free survival
10667,NCT01134276,Incidence of Infectious Complications After Biliary Drainage,2010-08,COMPLETED,INTERVENTIONAL,['NA'],,Total Hospital Cost During Admission After Biliary Drainage
10668,NCT03450447,The first day of food intake of enrolled patients,2018-03-10,UNKNOWN,OBSERVATIONAL,['NA'],,The severity of stenosis
10669,NCT00334984,,2007-01,WITHDRAWN,INTERVENTIONAL,['NA'],,
10670,NCT04012021,Evaluate the correlation between the characteristics detected by the MRI equipment and the histological composition of ex-vivo specimens from hepatic and pancreatic tissues and lesions,2019-05-24,UNKNOWN,INTERVENTIONAL,['NA'],,
10671,NCT00333099,Frequency and grade of mucositis,2006-05,COMPLETED,INTERVENTIONAL,['PHASE4'],,Cost
10672,NCT05628857,Objective Response Rate (ORR),2022-11-11,RECRUITING,INTERVENTIONAL,['PHASE2'],,Terminal elimination half life
10673,NCT00033540,Response,2003-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Survival Time for Participants With Relevant Biologic Markers
10674,NCT00004910,,2000-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10675,NCT01437618,Progression-Free Survival,2009-06,COMPLETED,OBSERVATIONAL,['NA'],,
10676,NCT02728596,Incidence of Febrile Neutropenia Among Intermediate Risk Participants,2016-10-07,COMPLETED,INTERVENTIONAL,['NA'],Differences Among Cohort Components and Intervention and Usual Care Components,Overall Survival (OS)
10677,NCT04361682,Predictive value of PIBs and drains amylase values for Pancreatic Fistula (PF),2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
10678,NCT00070265,Rate of complete resection (R0 resection),2003-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Positron emission tomography response rate
10679,NCT00995202,Overall survival rate,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Disease-free survival rate
10680,NCT00448682,Number of Patients Achieving Clinical Response,2005-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants Experiencing Adverse Events
10681,NCT01887158,quality of bowel preparation rated according to a modified Ottawa bowel preparation scale,2013-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,Lesion detection (type and lesion detection rate/patient)
10682,NCT00504153,Progression-free Survival Rate,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change in Plasma Vascular Endothelial Growth Factor (VEGF) Levels Over 15 Days
10683,NCT05361161,OS,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
10684,NCT00881036,,2006-08,COMPLETED,OBSERVATIONAL,['NA'],,
10685,NCT04965454,Lack of Objective Response,2022-03-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease Control
10686,NCT05977478,Correlating tissue biochemical composition with the Raman spectra and histopathologic results to differentiate between the gastric disease states based on distinct features in the biochemical composition of pre-cancerous / cancerous lesions.,2022-10-27,RECRUITING,INTERVENTIONAL,['NA'],,
10687,NCT02453464,Maximum Tolerated Dose (MTD),2015-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
10688,NCT05396755,"occurrence of cholangiosepsis (defined by SEPSIS-3 criteria and diagnosis of acute cholangitis according to the Tokyo Guidelines), whatever occurs first.",2022-11-14,TERMINATED,INTERVENTIONAL,['NA'],occurrence of serious adverse events,Occurrence of unplanned hospital admissions (necessity and days free of hospital care within 6 months)
10689,NCT02268825,Safety of combination mFOLFOX and MK-3475,2015-01-23,TERMINATED,INTERVENTIONAL,['PHASE1'],,
10690,NCT04223141,Mortality,2020-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Medical complications
10691,NCT04162158,Overall survival,2019-03-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease control rate
10692,NCT03528876,Progression free survival,2018-09-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Decline in quality of life
10693,NCT03277716,Overall survival (OS),2017-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,Distant metastasis-free survival
10694,NCT04622423,Definition of the antigenic landscape and TCR repertoire of CRC and PDAC liver MTS,2019-11-06,RECRUITING,OBSERVATIONAL,['NA'],,Biobanking of biospecimens collected from CRC and PDAC patients and from healthy donors
10695,NCT05359042,Change in overall score of EQ-5D,2024-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Predictive value of ED Visit and/or hospital admission
10696,NCT03374293,Local control,2017-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
10697,NCT05238558,Summary of Adverse Events,2022-01-31,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10698,NCT02198274,Anti-tumour response,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Mean residence time (MRT)
10699,NCT00019760,,1999-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10700,NCT05969171,PFS,2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,DCR
10701,NCT05621629,Pena's questionnaires score before treatment,2022-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
10702,NCT01798251,Progression Free Survival (PFS),2012-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],K-ras gene type,adverse events (AE)
10703,NCT04949282,Overall response rate (ORR),2021-05-10,RECRUITING,OBSERVATIONAL,['NA'],,Health-related Quality of Life (HRQoL)
10704,NCT02184663,Health-related quality of life (HRQoL) at 16 weeks,2014-11-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,anxiolytic / antidepressant consumption
10705,NCT00737373,response (WHO criteria),2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10706,NCT05743426,Disease-free survival,2023-03-17,RECRUITING,OBSERVATIONAL,['NA'],,Quality of life Toronto Extremity Salvage Score (TESS)
10707,NCT00002984,Number of subjects experiencing adverse events,1997-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Efficacy of treatment
10708,NCT04875793,The enrollment rate of individuals who underwent CRC screening in the intervention group vs. control group,2021-06-10,COMPLETED,INTERVENTIONAL,['NA'],,The percentage of individuals who screened positive and enrolled in colonoscopy for follow-up in the intervention group vs. control group.
10709,NCT02495051,presence of gastric and / or intestinal metaplasia diagnosed at histology,2010-02,COMPLETED,OBSERVATIONAL,['NA'],,"evaluation of actual other symptoms (respiratory, dysphagia)"
10710,NCT00386594,Elimination of high-grade dysplasia in Barrett's esophagus,2006-10,TERMINATED,INTERVENTIONAL,['NA'],,
10711,NCT01659619,degree of food stasis,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10712,NCT05991102,Overall response rate (ORR),2023-12-15,RECRUITING,INTERVENTIONAL,['NA'],,Acute and late toxicity
10713,NCT03314532,disease-progression-free period,2017-11-01,UNKNOWN,INTERVENTIONAL,['NA'],,overall survival period
10714,NCT00939666,Local recurrence,2009-07-01,COMPLETED,INTERVENTIONAL,['NA'],,Percentage of patients that chooses the minimal invasive strategies over standard surgery
10715,NCT00041691,,na,TERMINATED,INTERVENTIONAL,['PHASE1'],,
10716,NCT02879227,Feasibility of treatment: Number of patients with completed treatment,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life
10717,NCT06060899,Intraoperative blood loss,2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Length of hospital stay
10718,NCT01269229,complete resection (R0) rate for rectal and liver lesions.,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity profile
10719,NCT03223142,Local control rate,2017-07,UNKNOWN,INTERVENTIONAL,['NA'],,Complication rate
10720,NCT03132740,Impact on complication of three dimensional visualization technique,2017-03-15,UNKNOWN,OBSERVATIONAL,['NA'],,Postoperative results of paraffin wax and immunohistochemical index
10721,NCT01319890,Return to normal activity/work,2011-07,UNKNOWN,OBSERVATIONAL,['NA'],,Cancer free survival
10722,NCT02295930,10 months-progression free rate (10m-PFR),2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall toxicity rate
10723,NCT03469258,Effect of Pancreatic Enzyme Replacement Therapy on the Completion Rate of Adjuvant Chemotherapy and Radiation After Surgery for Early Stage Pancreatic Cancer,2018-04-13,TERMINATED,INTERVENTIONAL,['PHASE2'],,Measure Grip Strength Before and After Surgery and Adjuvant Treatment for Early-stage Pancreatic Cancer
10724,NCT00083226,Objective Response Rate Measured by Response Evaluation Criteria In Solid Tumors (RECIST),2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
10725,NCT04943679,Incidence of adverse events,2021-06-15,RECRUITING,OBSERVATIONAL,['NA'],,12-month survival rate
10726,NCT04954521,OS,2021-06-30,RECRUITING,OBSERVATIONAL,['NA'],,PFS
10727,NCT02541149,"serum Annexin A2 in patients with hepatocellular carcinoma, chronic liver disease and healthy subjects",2014-06,COMPLETED,OBSERVATIONAL,['NA'],,
10728,NCT00605722,Percentage of Participants With Progression-free Survival (PFS),2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
10729,NCT05068206,Disease Control Rate (DCR),2021-10-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,Duration of disease remission (DOR)
10730,NCT03844347,Manifestations of Psychological Well-being Measurement,2019-10-21,RECRUITING,INTERVENTIONAL,['NA'],,Physical activity evaluation
10731,NCT03654950,Patient reported experiences in themes,2018-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Patient reported experiences divided into themes
10732,NCT02441998,"ASGE PIVI Thresholds: >90% NPV in rectosigmoid, > 90% agreement in surveillance intervals",2013-10,COMPLETED,OBSERVATIONAL,['NA'],,"Ex vivo overall and individual performance assessed by accuracy, sensitivity, specificity, positive predictive value, negative predictive value"
10733,NCT00324987,Progression Free Survival,2008-04,TERMINATED,INTERVENTIONAL,['PHASE3'],,Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
10734,NCT04882423,Hydroxylated PhlP profile with both cruciferous and apiaceous vegetables,2013-09-19,TERMINATED,INTERVENTIONAL,['NA'],,
10735,NCT00576563,"The metabolic tumour response by PET scan will be determined according to the EORTC criteria (appendix 1)61. The pathological tumour response will be determined according to Dworak and Wheeler.62,63",2007-03,COMPLETED,INTERVENTIONAL,['NA'],,"Clinical examination(weight, performance status including the CTCv3.0 scale for acute and late reactions)"
10736,NCT02147301,Number of Patients Who Developed New Severe Adverse Events,2014-12-17,TERMINATED,INTERVENTIONAL,['NA'],,Median Area Under Curve (AUC)
10737,NCT05978349,Follow-up and record DFS of patients,2022-02-14,RECRUITING,INTERVENTIONAL,['NA'],,Follow-up and record OS of patients
10738,NCT01047475,The Primary Efficacy Endpoint of This Study is the Best Overall Response (Complete Response + Partial Response),2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10739,NCT05893056,Objective Response Rate (ORR) evaluated by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1,2023-06-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
10740,NCT05725473,Clinical efficacy,2023-01-12,RECRUITING,INTERVENTIONAL,['NA'],,
10741,NCT00541112,Complete remission at ≥ 6 months by abdomino-pelvic-thoracic scan and a pelvic MRI,2007-10-29,TERMINATED,INTERVENTIONAL,['PHASE2'],,Predictive biomarkers of response to cetuximab
10742,NCT03172559,Difference between the two treatment arms in the proportion of participants that get to be transplanted (do not drop-out from the waiting list due to tumor progression).,2020-09,WITHDRAWN,INTERVENTIONAL,['NA'],,Difference between the two arms in disease-free survival
10743,NCT06241352,Decrease rate of CA19-9,2024-01-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease control rate
10744,NCT02834169,Incidence of rare peritoneal surface malignancies,2010-10,UNKNOWN,OBSERVATIONAL,['NA'],,Impact of specific treatment strategies
10745,NCT00059930,"Correlate thymidylate synthase, dihydropyrimidine dehydrogenase, and ERCC-1 with survival and recurrence as measured by normal and tumor liver tissue",2003-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
10746,NCT04774952,Number of participants with dose limiting toxicities (DLTs),2021-04-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Duration of Response (DOR)
10747,NCT04105062,Phase II only: Ability of LS301 to predict presence of positive margins,2021-12-31,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10748,NCT05498051,Safety of SLN identification,2022-09-01,COMPLETED,INTERVENTIONAL,['NA'],,number of SLNs identified
10749,NCT00123318,The percentage of major radiotherapy protocol violations,2003-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Median survival and overall survival at 3 years
10750,NCT02924714,Progression free survival (PFS),2017-01,SUSPENDED,INTERVENTIONAL,['NA'],,Quality of Life (QoL)
10751,NCT01625702,circulating tumor cells in blood,2012-06,COMPLETED,INTERVENTIONAL,['NA'],,
10752,NCT01189903,,2011-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
10753,NCT03336216,Progression free survival (PFS) by Blinded Independent Central Review (BICR),2017-12-19,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of clinically significant changes in lab assessment: Urine
10754,NCT00316914,Percentage of Patients With Oxaliplatin-induced Grade 2+ Chronic Neuropathic Adverse Event,2006-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change From Baseline in Quality of Life (QOL) at One Month
10755,NCT05976282,Acceptability of Participants Who Feel FIT is an Acceptable Method of Screening,2016-03-15,COMPLETED,INTERVENTIONAL,['NA'],,
10756,NCT04611165,Progression-free survival (PFS),2019-11-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
10757,NCT00844688,RECIST criteria for response evaluation by CT sacan abdomen in Target lesion of HCC,2008-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Toxicity evaluation in accordance with CTCAE v3.0
10758,NCT02702323,Progress Free Survival,2016-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Toxicity as measured by CTCAE V4.0
10759,NCT05257057,Lynch Syndrome Screen Positive Rate,2019-05-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
10760,NCT06314971,Recurrence-free Survival,2023-03-15,RECRUITING,OBSERVATIONAL,['NA'],,
10761,NCT01160367,family decision-making self-efficacy,2010-08-26,COMPLETED,INTERVENTIONAL,['NA'],,"family psychological outcomes (depression, caregiver burden, decision making distress)"
10762,NCT05828381,The pathological complete response rate,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,The disease free survival rate
10763,NCT00041340,Response rate,2002-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10764,NCT04142203,Analgesic consumption postoperatively,2017-05-16,COMPLETED,OBSERVATIONAL,['NA'],Adverse events after 23 h surgery,Analgesic use after 23 h surgery
10765,NCT04231552,Pathological complete response,2019-11-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,3-year overall survival rate
10766,NCT05034627,Incidence of dose-limiting toxicities (DLTs),2022-08-09,RECRUITING,INTERVENTIONAL,['PHASE1'],Therapy induced changes in the tumor and tumor ecosystem,Mean plasma asparaginase activity
10767,NCT00573911,The specific aim of this proposal will be: To assess the association between acid reflux and subepithelial fibroblasts in Barrett's esophagus.,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10768,NCT00711672,"Correlation of degree of ""narrative agreement"" with validated quality of life measures",2008-07,COMPLETED,OBSERVATIONAL,['NA'],,
10769,NCT05587088,Safety and efficacy,2022-12-15,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Survival
10770,NCT00414492,,2006-12,COMPLETED,OBSERVATIONAL,['NA'],,
10771,NCT04237740,3 years recurrence-free survival rate,2020-05-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,5 years overall survival rate
10772,NCT05305820,Change in Cardiorespiratory Fitness,2022-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Change in Smoking Status,Change in Nutritional Status- Blood Screening
10773,NCT05714553,Number of patients achieving a reduction in tumour volume (Objective response rate; ORR),2023-03-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10774,NCT00428597,Progression Free Survival (PFS),2007-06,TERMINATED,INTERVENTIONAL,['PHASE3'],,EORTC QLQ-C30 - Pain Subscale
10775,NCT06315855,oral health related quality of life,2024-03-25,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,comorbidities
10776,NCT01871545,SubStudy 2: Perfusion Fraction (PF),2013-06,COMPLETED,INTERVENTIONAL,['NA'],,Tumor Response
10777,NCT02261714,Patients' Immune Response,2012-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Relationship Between (KRAS) Status and Clinical Efficacy,Clinical Efficacy
10778,NCT04460352,Eating restrictions,2020-11-27,RECRUITING,INTERVENTIONAL,['PHASE3'],,Gender stratified analyses of all endpoints
10779,NCT01293942,conversion to resectability during downsizing therapy with IXO+A patients with initially unresectable liver-only metastases associated with colorectal cancer,2011-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,"R0, R1, R2 resection rate after up to 8 cycles of downsizing therapy with IXO+A"
10780,NCT01807936,Overall survival,2013-03-20,COMPLETED,INTERVENTIONAL,['NA'],locoregional recurrence and recurrence pattern,Disease free survival
10781,NCT04374175,Serum adiponectin concentration,2020-04-01,RECRUITING,OBSERVATIONAL,['NA'],,Serum adiponectin concentration
10782,NCT02148731,Occurrence of Adverse Events,2010-01,COMPLETED,OBSERVATIONAL,['NA'],,Performance of the brief screening tool
10783,NCT00905047,patients preference after randomization and cross-over,2005-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,safety of each treatment
10784,NCT02371304,Recurrence free at 3 year follow-up,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Treatment related morbidity
10785,NCT05263336,Anastomotic leak,2021-01-03,RECRUITING,INTERVENTIONAL,['NA'],,Postsurgical Ileus
10786,NCT05641129,Primary outcome,2023-01-16,COMPLETED,OBSERVATIONAL,['NA'],,Secondary outcome 9
10787,NCT04389632,Number of participants with dose-limiting toxicities (DLTs),2020-06-08,RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of participants with antidrug antibodies (ADAs)
10788,NCT03297255,Time of Death,2013-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Time of metastasis
10789,NCT04618692,Biliary complications after living donor liver transplantation,2020-12-02,COMPLETED,INTERVENTIONAL,['NA'],,Time to biliary complications
10790,NCT00083616,Duration of Response,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
10791,NCT04643366,Three-year disease free survival (DFS),2021-01-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of patients who do not require an ostomy at time of surgery
10792,NCT04813861,Lesion Response,2010-01-04,COMPLETED,OBSERVATIONAL,['NA'],,Delayed Lesion Response
10793,NCT03998202,Number of Chemotherapy Toxicities (Grade 3 - 5),2019-09-23,RECRUITING,OBSERVATIONAL,['NA'],,Overall Survival
10794,NCT02340975,Progression Free Survival at 6 (PFS-6) Month in Phase 2,2015-03-31,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Percentage of Participants With Objective Response in Phase 2 by Programmed Death-ligand (PD-L1) Status
10795,NCT00959738,Severe stoma specific morbidity rate,2008-08,TERMINATED,INTERVENTIONAL,['NA'],Number of stoma bags and self-adhesive plates needed in the first month after the operation,Predictive factors for stomal complications
10796,NCT04823715,Disease-free survival of the patient after start of treatment,2020-10-15,COMPLETED,OBSERVATIONAL,['NA'],,
10797,NCT00003237,,1998-06-22,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10798,NCT05810714,Number of Participants to Return Fecal Immunochemical Test (FIT),2021-11-20,COMPLETED,INTERVENTIONAL,['NA'],,
10799,NCT03801083,Objective Response Rate (ORR),2019-02-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,EuroQol 5 dimensions 5 levels (EQ-5D-5L)
10800,NCT01188980,determine if early increase blood supply (EIBS)can predict presence of Dysplasia,2010-06,COMPLETED,OBSERVATIONAL,['NA'],,determine if EIBS can predict presence of BE in patients undergoing upper endoscopy
10801,NCT02430662,Number of participants with Adverse events,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Overall survival (OS)
10802,NCT05616494,Overall response rate (ORR) by Independent Review Committee (IRC),2022-12-06,RECRUITING,INTERVENTIONAL,['PHASE2'],Plasma concentration of docetaxel (free and total),Disease control rate (DCR) by IRC and investigator
10803,NCT05938504,Skeletal Muscle Index (SMI) change rate,2023-03-14,RECRUITING,INTERVENTIONAL,['NA'],,Oral nutritional supplement (ONS) sensory evaluation
10804,NCT04242342,local control at 2 years,2020-01-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
10805,NCT00675012,To determine the feasibility and safety of NGRhTNF administered at low (0.8 mcg/sqm) and high (45 mcg/sqm) doses in combination with a standard oxaliplatin-based regimen in two sequential cohorts of patients with metastatic colorectal cancer.,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluate the pharmacokinetic profile of NGRhTNF and to measure plasma levels of sTNF-RI and sTNF-RII
10806,NCT03791073,Predictive value of each protein contained in Cytolyt® for the positive diagnosis of pancreatic ductal adenocarcinoma,2018-01-01,RECRUITING,OBSERVATIONAL,['NA'],,"Biomarkers that are prognostically significant on disease free or overall survival in patients with pancreatic cancer, identified using the survival analysis"
10807,NCT03650348,Incidence of DLTs and recommended Phase 2 dose (RP2D) of PRS-343 administered in combination with atezolizumab,2018-08-21,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Presence and/or concentration of anti-PRS-343 and anti-atezolizumab antibodies (anti-drug antibodies [ADAs])
10808,NCT01862562,Early complication rate,2008-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Health-related QOL score
10809,NCT05485909,Objective response rate (ORR),2022-07-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Time to disease progression (TTP)
10810,NCT04002479,Safety - Adverse events,2020-10-20,RECRUITING,INTERVENTIONAL,['NA'],,Change in quality of life: QLQ-PAN26
10811,NCT01924741,Morbidity and mortality (peripoerative),2013-08,UNKNOWN,OBSERVATIONAL,['NA'],Inclusion criteria by registry participants,Liver Growth as assessed by imaging-based volumetry
10812,NCT00516230,,2006-01,UNKNOWN,OBSERVATIONAL,['NA'],,
10813,NCT02209415,Number of patients eligible for treatment,2011-04,UNKNOWN,INTERVENTIONAL,['NA'],,
10814,NCT05329597,Genotyping,2020-06-24,UNKNOWN,OBSERVATIONAL,['NA'],,
10815,NCT01360255,"comparison of liver cancer markers AFP, AFP-L3% and DCP before and after TACE",2010-05,COMPLETED,OBSERVATIONAL,['NA'],,progression- free - time
10816,NCT04089657,Disease control rate(DCR),2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse events（AE）
10817,NCT02120911,% of patients completing trastuzumab and pertuzumab treatment.,2014-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",SUV of pre-treatment trastuzumab-PET,Pharmacokinetics of pertuzumab and trastuzumab
10818,NCT01079780,Progression-free Survival,2011-01-18,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
10819,NCT00513266,Pathological complete response rate of lesions of less than or equal to 30 mm in size assessed by pathologic examination in resected specimens,2007-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Toxicity as assessed by NCIC criteria
10820,NCT05545436,"Pathological complete response rate (pCR, Becker criteria, TRG 1A)",2022-09-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,"R0 resection rate and objective response rate (ORR, RECIST 1.1)"
10821,NCT02721563,Objective response rate,2016-02-25,COMPLETED,INTERVENTIONAL,['PHASE4'],,Progression free survival
10822,NCT00268840,Overall response rate,2001-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,To evaluate the frequency and severity of the adverse events related to the combination of gemcitabine and docetaxel
10823,NCT02942706,Progression Free Survival 1 (PFS1),2021-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Quality of life (QoL)
10824,NCT05402124,Measurement of Adverse Events,2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,"Factors related to uptake, in-study adherence and post-study maintenance using measurement of chemoprevention knowledge"
10825,NCT06202001,Objective Response Rate (ORR),2022-10-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Safety and tolerability by incidence, severity and outcome of adverse events"
10826,NCT01946061,3-year disease-free survival,2015-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,
10827,NCT04381130,Overall survival,2024-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change in quality of life assessed with European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 version 3.0
10828,NCT03572101,Quality of life (EQ-5D-5L scores),2018-01-11,COMPLETED,OBSERVATIONAL,['NA'],"Overall level of support received by patients/caregivers from homecare, cancer centre, long term care, hospital and hospice services at end of life","Patient-reported concerns (emotional, social/family/spiritual, practical, physical, mobility, nutrition, informational, other)"
10829,NCT02897375,Recommended phase 2 dose (RP2D) as the highest doses of palbociclib and cisplatin or palbociclib and carboplatin,2016-10-24,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetic (PK) characteristics of cisplatin including maximum concentration (Cmax)
10830,NCT00006103,overall survival,2000-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
10831,NCT02141906,Response,2015-01-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression
10832,NCT00190385,Incidence of small hepatocellular carcinoma (HCC),2000-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Clinical value of serum alfa-fetoprotein assay
10833,NCT00003344,,1998-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10834,NCT01924533,Overall Survival,2013-09-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Duration of Response
10835,NCT01668849,Pain caused by oral mucositis,2012-08-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Level of immune biomarkers in mucosal tissue
10836,NCT04258956,"Participants Achieving 3-Month Progression-Free Survival (PFSR) Rate of participants who are progression-free at 3 months after the start of protocol therapy, using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 criteria",2019-04-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
10837,NCT02552017,Adenoma detection rate,2014-11,UNKNOWN,INTERVENTIONAL,['NA'],,Adenoma detection rate of individual endoscopist before and after trial commencement
10838,NCT05430841,Diagnostic accuracy,2022-06-01,RECRUITING,INTERVENTIONAL,['NA'],,Number of lesions
10839,NCT01148056,Bowel Quality of Life,2010-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Accuracy
10840,NCT01836926,Early Complications number,2013-04,COMPLETED,INTERVENTIONAL,['NA'],,Clinical functional outcome
10841,NCT06193733,Disease-free survival,2024-02-19,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
10842,NCT00414271,Number of Participants With Pathological Response,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Correlation of CGH and Gene Expression Profile and Their Changes After Chemotherapy With the Same Clinical Outcomes
10843,NCT02503696,Sensitivity and Specificity of the Exact CRC diagnostic screening test.,2014-09,COMPLETED,OBSERVATIONAL,['NA'],,
10844,NCT00711243,Response Rate in Patients With Adenocarcinoma of the Stomach or Gastroesophageal Junction (Phase II),2005-04-20,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Toxicity Profile
10845,NCT06200259,"Test the hypothesis that ""Spot Delete"" technique in proton therapy reduces late toxicity in low- and intermediate-risk prostate cancer patients",2024-01-08,RECRUITING,INTERVENTIONAL,['NA'],,
10846,NCT04210115,Overall Survival (OS),2020-02-28,RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of participants discontinuing study treatment due to an adverse event (AE)
10847,NCT01236690,"The evaluation of the patient's respondence for the therapy is carried out every phase, according to RECIST:CR,PR,SD and PD.",2010-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
10848,NCT00963352,3-year disease free survival (DFS),2007-01,UNKNOWN,OBSERVATIONAL,['NA'],,5-year overall survival (OS)
10849,NCT00162669,"The main response parameter will be the disease control rate, defined by the objective response and stable disease rate (Response Evaluation Criteria in Solid Tumors [RECIST criteria]) after two consecutive tumor evaluations during treatment.",2005-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Evaluation of vascular changes will be performed using Doppler ultrasound with injection of sonographic contrast agent
10850,NCT04120701,3-year Disease-Free Survival in ctDNA positive patients,2020-01-17,RECRUITING,INTERVENTIONAL,['PHASE3'],,
10851,NCT01703390,Response,2012-12-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of adverse events during study treatment
10852,NCT00349336,Weekly Steady-state Exposure of Bevacizumab,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Terminal Half-life of Bevacizumab
10853,NCT03627390,Sum CTC score,2014-12-19,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of registered adverse events
10854,NCT03478449,Migration of pN stage in gastric cancer patients,2018-04-01,UNKNOWN,INTERVENTIONAL,['NA'],,
10855,NCT04005339,"The efficacy of fluorouracil, leucovorin, and nanoliposomal irinotecan in advanced biliary tract cancers following progression on or intolerance of gemcitabine and platinum chemotherapy.",2019-07-29,RECRUITING,INTERVENTIONAL,['PHASE2'],"Archived tumor tissue using next-generation sequencing (NGS) and immunohistochemistry (IHC) in order to elucidate potential mutational biomarkers predictive of response to fluorouracil, leucovorin, and nanoliposomal irinotecan.","Maximum change in tumor marker, CA19-9."
10856,NCT00256321,Determine time to progression,2004-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Evaluate the expression of the Cox-2 on paraffin-embedded tumor sections from patients enrolled on the study and correlate expression with clinical response
10857,NCT03779035,Disease free survival (DFS) rate,2018-12-15,UNKNOWN,INTERVENTIONAL,['PHASE3'],,The rate of patients with hepatic or locoregional recurrence
10858,NCT00531297,Recurrence rate,2005-12-01,TERMINATED,INTERVENTIONAL,['NA'],,Perioperative mortality
10859,NCT00573131,Overall Tumor Response at the Primary Tumor Site Based on Measurement of Primary Tumor Volume (Excluding Involved Lymph Nodes) by Spiral CT,2008-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,
10860,NCT02424838,Proportion of diagnostic cell block specimens obtained according to needle size and the use of suction.,2014-07-28,COMPLETED,INTERVENTIONAL,['NA'],,Rate of complications
10861,NCT05575765,"Tumor images of multimodal digestive endoscopy, combination of high-definition white light endoscopy, endoscopic cerenkov luminescence imaging (ECLI) and probe-based confocal laser endomicroscopy (pCLE)",2023-08-14,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
10862,NCT03173729,Sensitivity and specificity of a point of care device to diagnose colorectal cancer and polyps,2017-02-11,RECRUITING,OBSERVATIONAL,['NA'],,Cost per patient of point of care urine test for diagnosing patients with colorectal cancer and polyps.
10863,NCT01665274,3-year DFS,2013-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,overall survival
10864,NCT05572684,Define a recommended Phase 2 dose (RP2D) of NC410 when combined with standard dose Pembrolizumab,2022-10-06,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-free Survival (PFS) per RECIST
10865,NCT06236321,To assess if subsets of Rectal Cancers can be correlated with FFC scan hydrogen ion dissociation curves,2022-11-04,RECRUITING,INTERVENTIONAL,['NA'],,To determine correlation between faecal microbial composition and response to neoadjuvant chemoradiotherapy
10866,NCT04540159,Immune Checkpoint levels,2022-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
10867,NCT00531115,Confirmed objective response rate,2007-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Treatment safety
10868,NCT00587067,Number of Patients With Treatment Related Toxicity,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Survival
10869,NCT03646110,Overall survival rate,2018-08-17,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative pulmonary complication
10870,NCT05340231,PFS,2022-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Pathological response rate (PCR+MPR)
10871,NCT00049322,Neovessel Formation as Measured by Angiogram at 14 Weeks,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Measure (Vascular Endothelial Growth Factor)VEGF Before and After TACE With and Without Bevacizumab
10872,NCT05916040,Response to therapy,2023-10-03,RECRUITING,OBSERVATIONAL,['NA'],,Anxiety and depression state via HADS
10873,NCT02847429,Progression-free survival (PFS) will be measured from the date of randomization to the date of the first objective radiological disease progression according to centralized committee assessment using modified RECIST version 1.1 or death.,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Overall survival (OS) will be measured from the date of randomization to the date of death from any cause. OS will be estimated using the Kaplan-Meier method.
10874,NCT06328361,Disease-free survival,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Complication rates
10875,NCT03131921,Resting energy expenditure,2016-04-05,COMPLETED,OBSERVATIONAL,['NA'],,Total energy expenditure
10876,NCT06235164,pathological complete response,2019-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,major pathological response
10877,NCT04683731,"Decision Quality assessed using the multi-dimensional measure of informed consent (MMIC) which incorporates knowledge, intent, and behavior.",2021-01-19,COMPLETED,INTERVENTIONAL,['NA'],,Number of providers who open their provider notification
10878,NCT01362790,Recommended Phase 2 Dose (RP2D) in Drug Lot FIL129J01,2011-05-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Count of Participants SS1P Cycles Received Following Onstudy,Duration of Response
10879,NCT04891016,pathological complete response rate,2021-06-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,disease-free survival
10880,NCT00177307,Progression Free Survival (PFS),2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,"1-, 2-, and 3-year Overall Survival"
10881,NCT02905188,Number of Patients with Dose Limiting Toxicity,2019-03-28,COMPLETED,INTERVENTIONAL,['PHASE1'],,Median T cell persistence
10882,NCT03009227,Overall survival,2017-02-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Quality of life in patients after D2 and D3 lymph node dissection using questionnaire
10883,NCT05585814,Tumor regression grade (TRG),2022-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life score (QoL score)
10884,NCT03404921,The procedure time,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],,The rate of injury to the muscular layer
10885,NCT06248879,Body Mass Index,2024-02-28,WITHDRAWN,INTERVENTIONAL,['NA'],,Feeding amount
10886,NCT05786716,Durable Clinical Benefit (DCB),2023-03-07,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Mean change from baseline in the PedsQL 4.0 Standardised Area Under total Scale Score Curve (PedsSAUC) in parents from paediatric participants
10887,NCT03209076,Urinary dysfunction,2018-02-01,UNKNOWN,INTERVENTIONAL,['NA'],,Costs
10888,NCT05200611,The efficacy of fecal immunochemical test to detect advanced adenoma,2022-01-04,UNKNOWN,OBSERVATIONAL,['NA'],,The efficacy of fecal immunochemical test to detect colorectal neoplasms
10889,NCT03191604,Altered chosen treatment modality due to NBI,2017-11-01,COMPLETED,OBSERVATIONAL,['NA'],,Differences in pathology identification between subgroups
10890,NCT04447092,Objective Response Rate,2020-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Immune-related response
10891,NCT05877599,Adverse events and serious adverse events,2023-07-27,RECRUITING,INTERVENTIONAL,['PHASE1'],,"Preliminary anti-tumor activity of NT-175 in subjects with unresectable, advanced, and/or metastatic solid tumors"
10892,NCT06210360,2-year Overall Survival Rate,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
10893,NCT01267695,Rate of disease recurrence at 2 years,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Determine the safety and tolerability of this drug in these patients.
10894,NCT00033748,Recurrence free survival,2001-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity
10895,NCT06293014,Time to treatment failure (TTF),2024-02-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30)
10896,NCT02647177,Detection of early progression to Tumor,2015-05,RECRUITING,OBSERVATIONAL,['NA'],,
10897,NCT03494543,technical success,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],,concordance of histology pre- and post endoscopi papillectomy
10898,NCT03263663,Progression-free-survival,2017-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
10899,NCT02138422,Response Rate,2014-07-31,COMPLETED,INTERVENTIONAL,['PHASE3'],,
10900,NCT00827554,time-to-progression(TTP),2008-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Progression Free Survival (PFS)
10901,NCT06071507,Clinical Success,2023-11-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Overall Survival,Nutritional status
10902,NCT03206866,serum regucalcin in HCC patients,2016-12-30,UNKNOWN,OBSERVATIONAL,['NA'],,
10903,NCT06187597,Progression-free survival,2024-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Correlation between serum cytokines and overall survival and immune-related adverse events,Treatment-related adverse events
10904,NCT02790333,Pancreatic fibrosis accessed by histopathology and pancreatic stellate cell,2016-05,COMPLETED,INTERVENTIONAL,['NA'],,Readmission rate
10905,NCT01101906,Time to progression (TTP),2011-01-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Safety assessed via physical examination, vital signs, clinical laboratory tests, electrocardiograms (ECGs) and recording adverse events"
10906,NCT02112162,Radiosensitivity index,2014-06,TERMINATED,INTERVENTIONAL,['PHASE1'],,
10907,NCT02374931,Standard uptake value (SUV) measured as percent injected dose per cc,2015-04,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,IHC staining intensity in tissue samples
10908,NCT00005910,,2000-06,COMPLETED,INTERVENTIONAL,['NA'],,
10909,NCT01747096,Detection of Gastroenteropancreatic Neuroendocrine Tumors lesions in the initial assessment or during the search of recurrence.,2012-11,COMPLETED,INTERVENTIONAL,['NA'],Tolerance of 68-Ga-DOTANOC,Compare the diagnostic performance of PET / CT with 68Ga-DOTANOC with the standard process
10910,NCT04969029,3-year relapse-free survival,2021-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
10911,NCT00469963,Tumor response,2003-12,TERMINATED,INTERVENTIONAL,['NA'],,Survival
10912,NCT03689231,Could the evolution of the initial liver tumor volume (on two follow-up CT scans / MRI over a period of 3 to 6 months) be predictive of progression-free survival according to the RECIST criteria?,2018-03-01,UNKNOWN,OBSERVATIONAL,['NA'],,Could the evolution of the initial liver tumor volume (on two follow-up CT scans / MRI over a period of 3 to 6 months) be predictive of progression-free survival according to the RECIST criteria?
10913,NCT03606863,morbi-mortality,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
10914,NCT00008060,,2000-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,
10915,NCT00241722,To compare alvimopan with placebo for long-term safety and tolerability,2005-08-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Quality of life, pharmacokinetics, pharmacogenetics (dependent on results from other data)"
10916,NCT03674801,"Percentage of different managements according to the described method : The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon (Gastrointest. Endosc. 58, S3-43 (2003)",2019-02-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,"""SF36"" questionnaire"
10917,NCT02089373,The percentage of cancer cells in biopsy samples,2014-03,COMPLETED,INTERVENTIONAL,['NA'],,
10918,NCT06125262,Overall survival and disease-free survival.,2022-11-01,RECRUITING,OBSERVATIONAL,['NA'],,Event-free survival
10919,NCT05010226,To evaluate clinical benefit response (CBR),2021-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Impact on Quality of Life and Cost,
10920,NCT00790569,CO-confirmed 7-day Abstinence,2008-09,COMPLETED,INTERVENTIONAL,['NA'],,Change in Cigarettes Per Day
10921,NCT00544362,Tolerance to neoadjuvant therapy,2007-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Mortality
10922,NCT04011982,Determination of the correlation between clinical characterizations and biological characterizations of patients suffering from exocrine pancreatic cancer,2020-09-01,RECRUITING,OBSERVATIONAL,['NA'],,Comparison of healthy tissu and tumor stroma from primitive tumor versus from metastases
10923,NCT00457691,Progression-free Survival (PFS),2007-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change From Baseline in EuroQol (EQ) Visual Analog Scale (VAS) (EQ-VAS)
10924,NCT04518800,Incidence of degree 3-4 neutropenia in each cycle of chemotherapy,2020-08-18,UNKNOWN,INTERVENTIONAL,['NA'],,The proportion of patients receiving antibiotics during the entire chemotherapy period.
10925,NCT03458949,variation of the rate of participation in colorectal cancer screening,2018-06-18,UNKNOWN,INTERVENTIONAL,['NA'],,
10926,NCT00006468,,2000-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
10927,NCT01966081,Measure of polyunsaturated fatty acids in adipose tissue lipids.,na,UNKNOWN,INTERVENTIONAL,['NA'],,
10928,NCT02476045,Efficacy,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival
10929,NCT05016869,progression-free survival (PFS),2022-04-12,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Adverse events (AEs)
10930,NCT02581059,Subject Fatigue Assessment,2016-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Evaluate Overall Survival (OS)
10931,NCT02071043,The primary study end point was the response rate of preoperative XELOX followed by surgery in gastric cancer patients with PAN involvement,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Grade 3 or 4 Adverse Events as a Measure of Safety
10932,NCT05363007,12W-PFS,2022-05-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
10933,NCT01321957,progression free survival rate,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life evaluated by questionnaire
10934,NCT03127007,Rate of complete pathological response,2017-04-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10935,NCT04812912,"Change in testosterone, inhibin B, steroid hormone binding globulin (SHBG) and FSH in young male patients (<50y) undergoing therapy for colorectal cancer",2021-03-18,RECRUITING,OBSERVATIONAL,['NA'],,
10936,NCT01335958,Nature of dose-limiting toxicities (DLTs) graded per NCI CTCAE v4.0,2011-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Volume of distribution
10937,NCT00460603,Percentage of Participants With Objective Response: Phase 2,2006-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change From Baseline in M.D. Anderson Symptom Assessment Inventory - Diarrhea (MDASI-D) Symptom Severity and Interference Subscale Scores at Day 1 of Cycle 2 Through Day 1 Cycle 42 and Follow-up: Phase 2
10938,NCT02853500,Capillary permeability (Ktrans) calculated by software that analyzes enhancement on post-contrast MRI.,2016-07,RECRUITING,INTERVENTIONAL,['NA'],,Time To Tumor Progression
10939,NCT04185779,Occurrence of colorectal neoplasia,2019-12-13,RECRUITING,OBSERVATIONAL,['NA'],,Number of participants who consent for future contact
10940,NCT05018156,Genetics referrals,2021-11-10,COMPLETED,INTERVENTIONAL,['NA'],,Genetic testing
10941,NCT04716010,Percentage of Red Meat Containing Products,2021-10-18,COMPLETED,INTERVENTIONAL,['NA'],Ease of Store Use,Intention to Reduce
10942,NCT05245474,pCR rate,2022-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,quality of life score
10943,NCT01831531,3-yr local control rate,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
10944,NCT05442749,Efficacy of niraparib in patients with HR-deficient pancreatic cancer,2022-10-28,RECRUITING,INTERVENTIONAL,['PHASE2'],PD biomarkers of response and resistance to niraparib,Safety and tolerability of niraparib in pancreatic cancer patients
10945,NCT03469557,Host immunogenicity: BGB-A317 anti-drug antibody (ADA),2017-07-18,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10946,NCT00044863,"Determine the response rate of cetuximab in patients with EGFR-positive, metastatic carcinoma",2002-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10947,NCT06049511,World Health Organization Oral Mucositis Toxicity Scale,2021-08-15,COMPLETED,INTERVENTIONAL,['NA'],,Oral assessment guide
10948,NCT00003487,"Number of Participants With Objective Response, Stable Disease, Progressive Disease or Not Evaluable",1996-05-30,TERMINATED,INTERVENTIONAL,['PHASE2'],,
10949,NCT02870582,Overall Survival (OS),2016-12-28,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety variables will be summarized using descriptive statistics based on adverse events collection
10950,NCT05494320,neurotoxicity,2021-08-15,RECRUITING,OBSERVATIONAL,['NA'],,
10951,NCT02296203,percentage of patients achieving a decrease equal or more than 30% in the sum of the longest diameters of target lesions,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
10952,NCT04506840,Strength,2020-01-21,RECRUITING,INTERVENTIONAL,['NA'],,Depression and anxiety
10953,NCT03355612,Disease Free Survival(DFS),2017-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Percentage of Participants With Adverse Events
10954,NCT00444782,Response rate (Partial and Complete Response) according to modified RECIST.,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Immune Response
10955,NCT01775514,"Number of Participants with Gastric Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region",2012-10,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of Participants Categorized by Tumor Localization
10956,NCT05450484,2) Incidence of (severe) adverse events (SAE/AEs) related to administration of durvalumab-680LT assessed by CTCAE,2023-04-05,RECRUITING,INTERVENTIONAL,['PHASE1'],,
10957,NCT04278274,The area under curve (AUC) of Receiver Operating Characteristic (ROC) curves of AI prediction system and expert radiologists in prediction tumor response,2020-02-08,RECRUITING,OBSERVATIONAL,['NA'],,The sensitivity of AI prediction system and expert radiologists in prediction tumor response
10958,NCT05544812,AE,2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],,OS
10959,NCT04835402,Serious adverse reaction (SAR) rate according to CTCAE v5,2021-05-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,"Adverse event rate (CTCAEv5, all grades)"
10960,NCT01806649,disease control rate,2013-07-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,overall survival
10961,NCT00272051,Clinical evaluation of peripheral sensory neuropathy using the Oxaliplatin specific scale for dose adjustment : Q2W ; response rate using RECIST criteria : Q8W,2002-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety : Q2W ; Nerve conduction studies : Baseline + cycle 12 ; Progression Free Survival : Q8W ; Survival
10962,NCT05782608,Assessment of Pain,2023-04-01,COMPLETED,INTERVENTIONAL,['NA'],,
10963,NCT03151759,Matrilysin levels,2002-11-06,COMPLETED,OBSERVATIONAL,['NA'],,
10964,NCT06060106,Recurrence free survival (RFS),2011-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Post-operative hospitalization days
10965,NCT03069833,"Sensitivity, Specificity, False Positive, False Negative",2017-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,
10966,NCT02806037,localization rate of liver tumor,2015-11,COMPLETED,OBSERVATIONAL,['NA'],,
10967,NCT03958032,Postoperative complications,2016-12-03,COMPLETED,OBSERVATIONAL,['NA'],,Major complication
10968,NCT02767557,Overall survival at 6 months,2017-01-26,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life (Quality of Life Questionnaire C30 (QLQ-C30) Version 3.0).
10969,NCT01488045,Patient Satisfaction Scores (Absolute Value),2011-06,COMPLETED,INTERVENTIONAL,['NA'],,Physician Perceptions (Absolute Value)
10970,NCT02497157,Response rate (RR) by response evaluation criteria in solid tumors (RECIST v1.1),2015-05-21,COMPLETED,INTERVENTIONAL,['PHASE2'],Deepness of response (DoR),Incidence of adverse events
10971,NCT03517176,Optimal Biological Dose (OBD) of CEND-1 when given in combination,2018-07-31,COMPLETED,INTERVENTIONAL,['PHASE1'],Immunohistochemical assessment of tumor biopsies for the expression of Neuropilin-1 in order to study if the response to CEND-1 therapy can be predicted based on the Neuropilin-1 expression level,Preliminary evidence of anti-tumor activity of CEND-1 when given in combination with nabpaclitaxel bound and gemcitabine by objective radiographic assessment according to RECIST 1.1
10972,NCT00135005,To determine the MTD which will be the Phase II dose of AMN107 when given in combination with Imatinib. The MTD is defined to be the highest dose of AMN107 in combination with Imatinib given for at least 21 days in the first treatment cycle,2005-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,patients showing progression of disease on Imatinib. The patient will be followed-up for at least 4 cycles (28 days for one cycle)
10973,NCT00022373,,2000-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
10974,NCT02965521,Adherence,2017-04-10,COMPLETED,INTERVENTIONAL,['NA'],,Change in fasting glucose
10975,NCT05862181,Overall Survival (OS),2023-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Duration of Response (DoR)
10976,NCT05036265,Prognostic factors,2011-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
10977,NCT00937456,To decrease postoperative major 30-days morbidity from 45% in the open arm to 25% in the laparoscopically-assisted arm.,2009-10-07,COMPLETED,INTERVENTIONAL,['NA'],,economical interest of the surgical technique apprehended through a hospital point of view
10978,NCT02460432,Cumulative stent patency during 6months after stent placement,2015-05,COMPLETED,INTERVENTIONAL,['NA'],,Adverse events
10979,NCT05785325,Objective Response Rate,2023-08-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overal survival
10980,NCT01896986,Immunogenicity to HPV Vaccine Gardasil,2012-03,TERMINATED,OBSERVATIONAL,['NA'],,
10981,NCT03840239,Rate of clinical complete response,2018-12-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,5 year overall survival
10982,NCT04181931,"Progression-free survival, PFS",2019-12-16,RECRUITING,INTERVENTIONAL,['NA'],,"Overall survival, OS"
10983,NCT00410462,"Six-month progression-free survival, in terms of complete response, partial response, or no change",2006-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
10984,NCT03880877,Progression-free survival,2019-02-26,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Duration of treatment
10985,NCT06048133,"Estimate the progression free survival (PFS) with gemcitabine, cisplatin, quemliclustat (AB680) and zimberelimab (AB122) in patients with advanced BTCs.",2024-03-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,Evaluate safety of the proposed drug combination.
10986,NCT03191110,Quality of life (EORTC QLQ-C30),2010-08-03,RECRUITING,OBSERVATIONAL,['NA'],,Co-morbidities
10987,NCT01874665,Clinical Benefit Rate (CBR) in Cohort A,2013-06-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Cmax, SS: Maximum Observed Plasma Concentration at Steady State for Ponatinib"
10988,NCT02238769,SUVratio of FECH PET,2014-07,UNKNOWN,OBSERVATIONAL,['NA'],Data analysis,Patients' lifespan
10989,NCT04768686,Overall response rate in subjects treated with FLX475 in combination with pembrolizumab,2021-05-18,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10990,NCT01663272,Maximum Tolerated Dose,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Median Progression-free Survival (PFS)
10991,NCT01049880,"Blood cell counts (neutropenia, thrombocytopenia) and serum chemistries (liver function tests, creatinine)",2009-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Survival
10992,NCT04115163,Overall response rate (ORR),2020-06-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
10993,NCT03781960,Objective Response Rate,2019-07-31,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
10994,NCT03652896,prognosis,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA'],volume of transfusion,hospital stay
10995,NCT05870969,Early diagnosis rate of HCC patients,2023-03-01,RECRUITING,OBSERVATIONAL,['NA'],The compliance rate of each risk group defined at the initial risk stratification,The 3-year cumulative incidence of liver cancer in each subject category according to the risk stratification at the time of initial diagnosis
10996,NCT05366881,Detection of cancer,2022-05-03,RECRUITING,OBSERVATIONAL,['NA'],,Clinical outcomes
10997,NCT01292356,Main criteria is the variation of skin pro-inflammatory cytokines in pre and post-therapeutic punch skin biopsies,2010-12-20,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10998,NCT03373188,Evaluate treatment effects of the study drugs on tumor cluster of differentiation 8+ (CD8+) T cell infiltration between the treatment groups.,2017-12-15,COMPLETED,INTERVENTIONAL,['PHASE1'],,Incidence of adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events scale version 4.0
10999,NCT02800005,postoperative complications,2015-07,UNKNOWN,INTERVENTIONAL,['NA'],,Change of the postoperative AFA
11000,NCT00438256,Number of Participants With Grade 3 or Greater Toxicity in Phase II,2007-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Treatment Related Serious Adverse Events
11001,NCT03099629,Changes of forced vital capacity (FVC),2015-03,COMPLETED,INTERVENTIONAL,['NA'],,Changes of dyspnea using Modified Borg Dyspnea score
11002,NCT05111860,Peri-operative complications,2022-11-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
11003,NCT04756648,Adverse Event of Special Interest （ AESI）,2021-03-10,RECRUITING,INTERVENTIONAL,['PHASE1'],,Antitumor efficacy-Duration of disease control (DDC)
11004,NCT00692770,Recurrence Free Survival (RFS) by Independent Assessment,2008-08-15,COMPLETED,INTERVENTIONAL,['PHASE3'],The Correlation Between Plasma Biomarker Levels at Baseline With RFS to Determine Prognostic Value of Biomarkers - MET,Overall Survival (OS)
11005,NCT02360605,Repeat Screening,2015-02,COMPLETED,INTERVENTIONAL,['NA'],,
11006,NCT05700656,Objective response rate (ORR),2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"RNA sequencing, THG-b signaling, other"
11007,NCT04066894,Sacral Nerve Stimulation (SNS) Success,2019-04-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Colorectal 29
11008,NCT06173375,Proportion of Follow-up colonoscopy after abnormal stool blood test result,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Number of colorectal cancer cases detected
11009,NCT01507545,Progression-Free Survival (PFS),2012-03-27,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Biomarkers Based OS, Within Treatment Group"
11010,NCT02868632,Overall Survival,2016-08-07,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Immune-related Response Criteria (irRC)
11011,NCT03708705,relapse rate of tumor,2018-11-20,UNKNOWN,OBSERVATIONAL,['NA'],,
11012,NCT00565370,Progression-free Survival,2007-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Toxicity Profile (According to National Cancer Institute Common Terminology Criteria for Adverse Event Version 3.0)
11013,NCT00025129,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11014,NCT02181556,Rate of Patients Alive and Progression-free 6 Months After Inclusion.,2014-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free Survival
11015,NCT04890171,3-year disease-free survival in the ITT population,2021-06-11,RECRUITING,INTERVENTIONAL,['NA'],,Cost-effectiveness measured with Incremental cost effective ratio (ICER)
11016,NCT02852161,Diagnostic accuarcy,2016-07,COMPLETED,INTERVENTIONAL,['NA'],,comfort
11017,NCT04086888,OS (overall survival),2016-12-12,UNKNOWN,OBSERVATIONAL,['NA'],,progression-free survival (PFS)
11018,NCT01527409,"Changes from Baseline in Exercise, Diet, and Posttraumatic Growth Inventory(PTGI)",2012-02,UNKNOWN,INTERVENTIONAL,['NA'],,Cancer Belief System(CBS)
11019,NCT03849352,"To evaluate whether patients who have undergone CRC treatment are able to comply with remote follow-ups using telephone reviews and digital technology to help promote and track individual healthy lifestyle, diet and PA changes.",2019-03-18,UNKNOWN,INTERVENTIONAL,['NA'],,To ascertain whether there was any change in diet and lifestyle factors from baseline to end of intervention (2 months)
11020,NCT03253822,CRC screening participation,2017-08-15,COMPLETED,INTERVENTIONAL,['NA'],,Ethnicity
11021,NCT00680420,Gene expression profile is 95% accurate in diagnosis of malignancy,2008-06,COMPLETED,OBSERVATIONAL,['NA'],,
11022,NCT00091286,Number of patients with an immune response to the peptides,2003-03-24,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Immunogenicity of the peptide mixture measured in the peripheral blood
11023,NCT03645148,Number of participants experiencing clinical and laboratory adverse events (AEs),2017-10-24,COMPLETED,INTERVENTIONAL,['PHASE1'],Peripheral blood T cell receptor sequencing analysis,Progression Free Survival
11024,NCT05559151,mortality rate,2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],,
11025,NCT00698451,The Primary Efficacy End Point is the Number of Patients With an Objective Response.,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,The Secondary Efficacy Endpoints is Duration of Objective Response.
11026,NCT01520324,Intraepithelial Neoplasia (IN) Detection Rate (False Negative Findings),2012-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Bowel Cleansing Quality Evaluated by Boston Bowel Preparation Scale After Intake of Bowel Cleansing Formulation and of a Total Dose of 200 mg of Methylene Blue MMX Tablets Administered During and at the End of the Intake of the Bowel Cleansing Formulation
11027,NCT02526953,3-year disease-free survival,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Quality of life according to European organization for research and treatment of cancer (EORTC) Quality of Life questionnaire (QLQ)-C30 (v.3) scale,Late toxicity measured according to Radiation Therapy Oncology Group (RTOG) criteria
11028,NCT02828865,Tumor response,2012-11,COMPLETED,INTERVENTIONAL,['NA'],,Assess for presence of adverse events
11029,NCT01536054,"Safety of ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine in combination with varying dose levels and schedules of sirolimus, assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4",2012-08-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to disease progression
11030,NCT00188292,,2002-08,COMPLETED,OBSERVATIONAL,['NA'],,
11031,NCT02980146,"The phenotype of TIL will be precised by immunohistochemisry and flow cytometry using various combinations of monoclonal antibodies to identify different subset of TIL and their frequency, especially those expressing NKG2A or NKG2C chain.",2016-06-01,COMPLETED,OBSERVATIONAL,['NA'],,
11032,NCT03260842,Pancreas Cancer,2017-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
11033,NCT01270360,"To determine the performances (sensitivity, specificity and likelihood ratios) of a panel of blood and/or faecal molecular DNA markers",2010-09,COMPLETED,OBSERVATIONAL,['NA'],,To create biological collections for screening purposes (asymptomatic subjects)
11034,NCT04062058,PCR rate,2019-11-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,R0 resection rate
11035,NCT00207298,Change in management based on PET procedure,2005-06,COMPLETED,OBSERVATIONAL,['NA'],,Safety of 18F-FDG
11036,NCT04183088,Randomized cohorts: Progression-free survival (PFS) (co-primary),2020-12-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Randomized cohort: progression-free survival (PFS)
11037,NCT02174575,Postoperative acute kidney injury,2014-07,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,Urine albumin concentration
11038,NCT02867865,Overall Survival,2016-09-06,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Deterioration free rate of quality of life (QOL) scores at baseline and three monthly
11039,NCT02544737,"The proportion of patients with response (CR, PR, SD and PD based on RECIST version 1.0) assessed at 5-6 weeks after the initiation of treatment.",2015-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"The proportion of patients alive (overall survival rate) from the date of enrollment until date of death from any cause, assessed up to 2 years from the opening of the study."
11040,NCT05648318,Bowel preparation,2022-01-08,COMPLETED,INTERVENTIONAL,['NA'],,withdrawal time
11041,NCT05216237,Objective Response Rate (ORR),2022-02-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events (AEs)
11042,NCT02243735,Normalization of Hb-level.,2014-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Difference in Morbidity score
11043,NCT01453894,Completion of a Fecal Occult Blood Test (FOBT),2012-03,COMPLETED,INTERVENTIONAL,['NA'],,
11044,NCT00341575,,2005-09-28,COMPLETED,OBSERVATIONAL,['NA'],,
11045,NCT02534246,Direct Comparison of pancreatic mass histologic tissue adequacy using two EUS guided fine needle biopsy needles,2016-08,WITHDRAWN,INTERVENTIONAL,['NA'],,
11046,NCT01099111,Colonic-Mucosa Associated Microbial Species Per Compiled Participants in 5 Different Arms,2010-07,COMPLETED,OBSERVATIONAL,['NA'],,
11047,NCT03448757,non-invasive hemodynamic parameter measurements during exposure AM RF EMF,2018-02-15,RECRUITING,INTERVENTIONAL,['NA'],Searching for cancer-specific frequency modulation,Hemodynamic alteration´s comparison among advanced cancer patients and healthy controls
11048,NCT00331786,Effects of nitric oxide-releasing acetylsalicyclic acid (NCX 4016) on aberrant cryptic foci (ACF) multiplicity after the second dose at 6 months,2006-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Safety and tolerability of long-term oral administration of NCX 4016 as measured by NCI CTCAE v3.0
11049,NCT02753465,disease-free survival rate,2016-04,UNKNOWN,INTERVENTIONAL,['NA'],,30-day mortality rate
11050,NCT00327496,,2005-06,UNKNOWN,INTERVENTIONAL,['NA'],,
11051,NCT01555450,Reduction of social inequalities,2011-03,COMPLETED,INTERVENTIONAL,['NA'],,Evaluation of psychological mechanisms
11052,NCT00737230,"Improvement in gastrointestinal symptoms as measured by the modified IBDQ-B score, Rockwood Fecal Incontinence Quality of Life score, St Mark's Incontinence score, and the LENTSOMA score at baseline, 6 months, and 1 year",2007-04,COMPLETED,INTERVENTIONAL,['NA'],,Other unmet healthcare needs as a direct result of pelvic radiotherapy
11053,NCT02221778,Local Progression Free Survival,2014-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
11054,NCT01189942,To the determine the maximum tolerated dose of OMP-21M18 plus FOLFIRI,2010-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,To determine the preliminary efficacy of FOLFIRI plus OMP-21M18
11055,NCT04318756,Syntactic and semantic equivalence of Cancer worry scale' items between English and Italian language and vice versa,2020-04-01,UNKNOWN,OBSERVATIONAL,['NA'],,Exploratory comparison between Patients Health Questionnaire and Irritability Depression Anxiety Scale and cancer worry scale
11056,NCT06162650,Complete response (CR) rate,2023-11-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety profiles
11057,NCT05420064,Comparison of participant perceived quality of care,2022-12-01,RECRUITING,INTERVENTIONAL,['NA'],,
11058,NCT04137822,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
11059,NCT01909362,number of drug targetable genetic changes found in tumor tissue sample,2013-07,COMPLETED,OBSERVATIONAL,['NA'],,number of physicians who took into consideration regimens that were suggested by the results of the sequencing analysis when deciding their patients' next line of therapies.
11060,NCT03433014,measure pain scores (Visual Analog Scale) in the postoperative period,2018-03-31,COMPLETED,INTERVENTIONAL,['NA'],,objective is to compare the VAS scores between the two types of technique used for specimen retrieval incision
11061,NCT00767377,Time to progression,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],PET Scan response,Toxicity
11062,NCT04135313,3-year disease-free survival,2019-10-20,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE3'],,Sphincter preservation rate
11063,NCT05193162,16sRNA and metagenomics,2019-02-01,RECRUITING,OBSERVATIONAL,['NA'],,
11064,NCT01686971,,2012-11,UNKNOWN,OBSERVATIONAL,['NA'],,
11065,NCT02519075,Variation of SUVmax (Maximal Standardized Uptake Value) in patients undergoing TARE for HCC,2015-04,COMPLETED,OBSERVATIONAL,['NA'],,
11066,NCT02075385,Swallowing function,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11067,NCT03790475,Completion of the assigned screening strategy within 18 weeks of enrollment,2018-08-25,UNKNOWN,INTERVENTIONAL,['NA'],,Diagnostic yield for CRC and advanced adenomas
11068,NCT02606292,Sensitivity and specificity of PA endoscopic imaging for identification of Barrett's epithelium compared to esophageal biopsy,2014-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
11069,NCT04948697,Objective Response Rate (ORR) as assessed by the investigator,2021-08-20,COMPLETED,INTERVENTIONAL,['PHASE2'],,Immunogenic Response to BAT1706
11070,NCT03040180,Histopathologic tumor regression following electrochemotherapy,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Tumor Immunologic response following electrochemotherapy
11071,NCT03439761,Disease Control Rate (DCR),2018-03-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,AE
11072,NCT02632305,Overall response rates,2016-07-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
11073,NCT06076252,The rate of POPF,2023-07-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,
11074,NCT04143516,Tumor response,2019-10-25,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
11075,NCT00622804,Bile reflux by Dual scintigraphy,2007-07,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Morbidity and Mortality
11076,NCT00919061,Median PFS,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11077,NCT00955019,,2007-10,COMPLETED,OBSERVATIONAL,['NA'],,
11078,NCT01025570,To estimate the median disease-free survival rate of patients with completely resected pancreatic cancer treated with this combination,2010-05,TERMINATED,INTERVENTIONAL,['PHASE1'],,To estimate both disease-free and overall survival at one and two years of patients with completely resected pancreatic cancer treated with this combination
11079,NCT02374255,Number of Patients Perception of Improved Goals of Care Discussions,2016-03-15,COMPLETED,INTERVENTIONAL,['NA'],,Communication Skills Training
11080,NCT00494221,Progression Free Survival,2007-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
11081,NCT01392131,Number of patients who have prolonged survival after receiving Oncoxin,2011-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Reduction in serum alpha-fetoprotein level and decrease in tumor size
11082,NCT02471170,Collection of blood and tissue samples from subjects with pancreatic diseases,2015-09-10,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
11083,NCT03834272,Initial efficacy of LUM015 in labeling peritoneal surface malignancies by molecular imaging by comparing imaging results with pathology,2019-03-18,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of patients with reported adverse events
11084,NCT02564887,Tongue Pressure Generation (i.e. Tongue Strength) in Kilopascals (kPa) Using the IOPI Device,2016-01,TERMINATED,INTERVENTIONAL,['NA'],,Swallowing Impairment-Objective
11085,NCT00742729,Receipt of a colorectal cancer screening test,2004-09,COMPLETED,INTERVENTIONAL,['NA'],,Knowledge and attitudes regarding CRC screening.
11086,NCT00776399,Primary Outcome Measures:3-year survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Secondary Outcome measures:safety, change in respiratory function, cancer-specific survival, and local tumor progression, Radiological studies"
11087,NCT00927485,Size of Polyps,2007-11,COMPLETED,INTERVENTIONAL,['NA'],,
11088,NCT01301417,Rate of anastomotic leakage,2011-02,COMPLETED,OBSERVATIONAL,['NA'],,Rate of other device related complications and measures during hospitalization and post procedure:
11089,NCT05638698,Molecular disease control rate,2022-12-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Correlation between molecular response and disease free survival
11090,NCT01470742,Overall survival of XELOX(XELODA/oxaliplatin) vs X(XELODA),2010-09,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,response rate
11091,NCT01294826,Incidence of dose limiting toxicity (DLT),2011-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival of patients treated with AUY922.
11092,NCT00165217,To assess the anti-tumor activity of capecitabine and thalidomide when administered to patients with previously treated metastatic colorectal cancer.,2001-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,To evaluate the safety of capecitabine and thalidomide in this patient population.
11093,NCT03380689,Maximum tolerance dose,2018-01-05,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Overall survival
11094,NCT01721174,Stent patency rate,2012-11,TERMINATED,INTERVENTIONAL,['NA'],,Unscheduled readmission rates
11095,NCT03265418,Positional stability of BioXmark liquid fiducial markers during the treatment course,2018-01-02,COMPLETED,INTERVENTIONAL,['NA'],,Potential BioXmark induced alterations in the surgical specimen
11096,NCT01258192,response to induction therapy,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,safety and tolerability
11097,NCT05332496,Overall Survival(OS),2022-12-28,RECRUITING,OBSERVATIONAL,['NA'],,Adverse event(AE) per Common Terminology Criteria for Adverse Events(CTCAE) 5.0
11098,NCT02168608,survival rate,2014-09,UNKNOWN,INTERVENTIONAL,['NA'],,complications
11099,NCT04518280,Complete response (CR) rate,2021-05-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Scores of Quality of Life
11100,NCT06238167,1-year Disease-free survival rate,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,"Safety will be analyzed through the incidence of adverse events, serious adverse events"
11101,NCT02015754,"Safety, Defined as Demonstrating Tolerable Device-related Toxicity Profile in the Use of DEBIRI Beads Used to Treat Hepatic Metastases in Patients With Colorectal Cancer",2014-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Exploratory Endpoint - Angiogenesis,One-year Survival Percentage
11102,NCT01609231,Assessment of Progression-free Survival (PFS),2012-07-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Objective Response Rate (ORR)
11103,NCT00897819,Correlation of MSI and LOH to outcome and response,2007-01-03,COMPLETED,OBSERVATIONAL,['NA'],,
11104,NCT01232296,Overall Survival - Overall Survival,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Pharmacokinetic (PK) Parameter of AUCtau Following a Single Dose of TKI258
11105,NCT00003798,,2000-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11106,NCT05009550,Numeric Pain Scale assesment,2021-05-15,UNKNOWN,INTERVENTIONAL,['NA'],,Incidences of adverse effects (like nausea and vomiting)
11107,NCT02087878,Collection of Samples,2014-03-31,WITHDRAWN,OBSERVATIONAL,['NA'],,
11108,NCT05808712,Rate of supportive care needs in cancer,2023-03-01,RECRUITING,OBSERVATIONAL,['NA'],,
11109,NCT05682768,Post operative Pancreatic Fistula,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
11110,NCT01497444,Overall response rate (Phase II),2012-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,AFP response rate (Phase II)
11111,NCT00082082,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11112,NCT02728804,Cumulative Incidence Rate of Treatment-related Major Financial Hardship,2016-06-22,COMPLETED,OBSERVATIONAL,['NA'],,"Financial Stress (Patient, Caregiver, or Bereaved Caregiver)"
11113,NCT05465512,AUC for BNCISS,2022-01-04,COMPLETED,OBSERVATIONAL,['NA'],,disease free survival
11114,NCT00320515,Objective Best Tumor Response,2004-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
11115,NCT02558959,Progression Free Survival,2015-09-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
11116,NCT05764551,The correlation between serum DNA methylation and HCC recurrence or treatment response,2023-03-28,RECRUITING,INTERVENTIONAL,['NA'],,
11117,NCT01687673,Median Time to Progression (TTP),2012-10-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants Whom Discontinued Treatment Due to Intolerable Toxicity
11118,NCT00445653,"Polymorphisms in DNA repair genes or the p53 pathways (e.g., ERCC2, XRCC1, p53, p73, CCND1, p21)",2005-08,COMPLETED,OBSERVATIONAL,['NA'],,
11119,NCT06134089,Number of messages generated by participants,2023-12-05,COMPLETED,OBSERVATIONAL,['NA'],,
11120,NCT01693419,Objective response rate,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity profiles
11121,NCT06307080,Safety and efficacy assessment,2023-10-08,RECRUITING,INTERVENTIONAL,['NA'],The application of medical-mechanical combination therapy mode,Survival benefit
11122,NCT01308840,The Number of Participants With Response to GEMOX-Panitumumab (GEMOX-P) in Chemotherapy naïve KRAS/ BRAF Wild Type Stage IV Biliary Tract Cancer Using the Response Evaluation Criteria In Solid Tumors (RECIST) Criteria.,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,The Number of Participants Who Experience an Adverse Event
11123,NCT04835324,overall survival,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,Incidence of Adverse Events (AEs)
11124,NCT03218345,Severe adverse events,2016-08,RECRUITING,INTERVENTIONAL,['NA'],,Survival
11125,NCT00892658,Determine the MTD of sorafenib and RT in patients with hepatocellular carcinoma using an iso-toxicity radiation dose allocation scheme. Determine the acute toxicity (< 3 months) of sorafenib when combined with RT.,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Determine late toxicities, in-field local control at 3 months, overall survival, progression time, and progression free survival. Quantify alteration in perfusion parameters.Assess serum and tissue biomarkers. Assess quality of life in these patients."
11126,NCT00552149,Evaluation of treatment efficacy by assessing the crude progression-free survival (PFS) rate at 4 months,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluation of PFS and over
11127,NCT04391348,Demonstrate that the identification of new tumour lesions by an experimental procedure combining PET-TDMs with 18F-FDG and 18F-Fluorocholine in patients with HCC modifies the initially planned therapeutic strategy,2020-07-17,COMPLETED,INTERVENTIONAL,['NA'],,Number of patients who had an additional examination proposed by the MCM (multidisciplinary consultation meeting) following the PET-TDMs performed
11128,NCT05720910,Quality of life assessed by the EORTC quality of life questionnaire (EORTC QLQ-C30 ),2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,GERONTE patient-centered system implementation and usage
11129,NCT02562976,Number of patients with severe gastric atrophy and/or intestinal metaplasia in early gastric cancer and non-early gastric cancer,2013-05,COMPLETED,OBSERVATIONAL,['NA'],,"correlations between Helicobacter pylori infection and moderate-to-severe EGA classification, OLGA stage III-IV, OLGIM stage III-IV"
11130,NCT02615574,overall survival,2016-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Changes of tumor microenvironment,immune-related Progression-Free Survival (irPFS)
11131,NCT01927965,To establish the dose of Minnelide™ recommended for future phase 2 protocol,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,To determine pharmacodynamic effect of Minnelide™ on HSP70 levels. And to explore pharmacodynamics effect of Minnelide™ on PET Scans and using Choi criteria on the CT scans.
11132,NCT02039336,Progression free survival,2014-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
11133,NCT00004108,,1999-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11134,NCT04547166,PFS,2021-03-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,DCR
11135,NCT03950102,Rate of transplant complication,2015-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,Rate of dropout from transplant waitlist
11136,NCT03996681,Disease control rate (DCR),2019-07-20,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Adverse Events
11137,NCT04929912,Incidence of Treatment-Emergent Adverse Events (CTCAE),2021-06-24,RECRUITING,OBSERVATIONAL,['NA'],,Modified FACE-Q evaluation for Skin Cancers
11138,NCT01704651,Postoperative Length of Hospital Stay,2013-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Postoperative Ileus Incidence
11139,NCT00006467,overall survival at 6 months,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,response rate
11140,NCT04230499,Efficacy of eRapa in delaying polyp progression in patients with FAP as measured by change in polyp burden over time.,2021-01-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Explore correlation between immune markers influenced by mTOR inhibition and clinical outcomes,Clinical effect of eRapa on duodenal polyp number and burden.
11141,NCT01171651,Determine safety and tolerability of intravenous infusion of JX-594 followed by intratumoral injections with JX-594 prior to standard sorafenib therapy,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Determine overall survival time
11142,NCT00003485,,1996-04-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
11143,NCT04368078,Objective Response Rate (ORR),2020-07-11,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events (AE)
11144,NCT00907166,"To determine the safety and MTD of CPI-613, when used in combination with Gemcitabine, in cancer patients.",2009-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To compare the safety and efficacy of CPI-613 Gemcitabine combination vs. Gemcitabine alone in patients with carcinoma of the pancreas.
11145,NCT01512589,Total Toxicity Burden (TTB),2012-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
11146,NCT05518201,Number of subjects with Severe adverse events (SAE),2022-09-23,RECRUITING,INTERVENTIONAL,['PHASE1'],,The immunogenicity of subjects receiving 3 doses of vaccination was assessed by IgG antibodies and neutralizing antibodies
11147,NCT01489332,Pathological complete remission rate (pCR),2011-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life
11148,NCT00365144,Safety and Toxicity,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Proportion of Patients With ≥ 25% Decline in Serum CA19-9 Biomarker
11149,NCT00281736,Efficacy,2004-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response
11150,NCT05529615,3-year disease-free survival rate,2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],,
11151,NCT00668161,Proliferation rate in the upper part of colon and rectal mucosa crypts.,2001-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,quality of life (measured by standardized self-report instruments) and sleep quality
11152,NCT01895673,Local site recurrence (LSR) detection,2013-06,COMPLETED,OBSERVATIONAL,['NA'],,Patients experience with PET-CT and PET-MRI
11153,NCT01579071,Abdominal pain related to each insufflation,2012-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,Number of Participants with Adverse Events as a Measure of Safety and Tolerability
11154,NCT01238042,Optimal Light Dose,2003-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Resolve Barrett's mucosa
11155,NCT05795296,Objective response rate (ORR),2022-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
11156,NCT02438436,xerostomia,2015-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
11157,NCT03034473,Number of patients with histopathologically confirmed complete remission (pCR) (ypT0N0 R0) after preoperative RCTx related to pretherapeutically determined gene expression signature predicting tumor response to RCTx.,2011-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Wexner-Score-Questionnaire
11158,NCT00155883,tumor response rate,2004-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,"clinical benefit response, toxicities, quality of life, time to disease progression, overall survival"
11159,NCT01155258,To assess the response rate based on the Response Evaluation Criteria in Solid Tumors (RECIST),2010-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression-free and overall survival
11160,NCT03687515,"Clinical responses including 4 major symptoms(nasal obstruction, rhinorrhea, loss of smell,and headache/facial pain)",2015-01-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Physicians' assessment of nasal polyp size reduction
11161,NCT06043999,Three years disease-free survival rate,2023-09-01,RECRUITING,INTERVENTIONAL,['NA'],,Urinary function
11162,NCT00293124,Time to Disease Progression,2004-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall Survival
11163,NCT05966246,Quantitative intestinal motility measurement using radio-opaque markers,2022-01-25,COMPLETED,INTERVENTIONAL,['NA'],,"Measurement of the amount of food intake, first flatus time and first defecation time"
11164,NCT00392366,Accuracy of predicted lesion geometry to histologically measured dimensions,2006-07,COMPLETED,INTERVENTIONAL,['NA'],,
11165,NCT00112528,Survival at 6 months,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
11166,NCT01457599,Sensitivity,2011-07,COMPLETED,OBSERVATIONAL,['NA'],,
11167,NCT00709826,Progression Free Survival,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
11168,NCT04160650,"The rate of self care activation (Patient Activation Measure PAM, Insignia Health; Hibbard et al. 2004)",2019-10-21,COMPLETED,INTERVENTIONAL,['NA'],Incidence of morbidity,"The rate of quality of life (The Functional Assessment of Cancer Therapy Scale - Colorectal, FACT-C, Cella et al. 1993)"
11169,NCT02966509,Number of Participants With Completed Goals of Care Documentation. We Will Evaluate if 75% of Patients in the Intervention Arm Have a Documented Goals of Care Titled Medical Note Within 6 Months of Patient Enrollment in the Study.,2013-08,COMPLETED,INTERVENTIONAL,['NA'],,Patient Satisfaction With Decision-Making Using the Satisfaction With Decision Survey
11170,NCT05690035,Objective Response Rate (ORR),2023-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events
11171,NCT04592861,Overall survival duration,2020-11-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,"Quality-of-life, measured using the EORTC (European Organisation for Research and Treatment of Cancer) QLQ-C30 questionnaire"
11172,NCT00176813,"To determine the overall survival time in patients with metastatic pancreatic cancer treated with the combination of gemcitabine, cisplatin and celecoxib.",2003-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,To determine the influence of therapy on the blood levels of prostaglandins and angiogenesis
11173,NCT00003434,Progression Free Survival,1998-06,TERMINATED,INTERVENTIONAL,['PHASE1'],,
11174,NCT04995354,WHO grade of mucositis,2022-06-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
11175,NCT00335543,Median survival,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Quality of life before, during, and after therapy"
11176,NCT04425226,Recurrence-Free Survival (RFS),2020-08-06,RECRUITING,INTERVENTIONAL,['NA'],,Objective Response Rate (ORR)
11177,NCT01098344,Adverse event and severity according to NCI CTCAE Version 4.02,2010-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Plasma concentrations of MK0752
11178,NCT02837679,Change in Quality of life,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],Health costs per patient,Length of hospital stay
11179,NCT01533740,Impact of Tregs frequency on overall survival,2012-03,COMPLETED,OBSERVATIONAL,['NA'],,Impact of Tregs frequency radiologic response rate
11180,NCT01591798,Quality of mesorectal excision,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Long-term outcome
11181,NCT01784900,Progression Free Survival,2012-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
11182,NCT03836352,Safety as measured by the rate of adverse events,2018-12-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Changes in immune cell infiltration,Overall survival
11183,NCT05862337,Recurrence-free survival (RFS),2023-05-10,RECRUITING,INTERVENTIONAL,['PHASE3'],,Objective response rate (ORR) after first recurrence
11184,NCT02305615,Progression-Free Survival (PFS),2015-01-13,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of Participants with Adverse Events (AEs) and Serious AEs
11185,NCT01212718,Best response to first-line chemotherapy (recist),2001-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,"overall survival, toxicity, treatment related complications, time to progression"
11186,NCT04069455,CR29 scores,2019-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
11187,NCT04734691,Progression free survival,2021-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life C30
11188,NCT04724291,Comparison to EGD in Identifying Lesions.,2021-02-10,COMPLETED,INTERVENTIONAL,['NA'],,Safety of MCC Compared to EGD. Documentation of Any Adverse Event Patient Encounters up to the 30 Day Follow-up.
11189,NCT02385617,Ad libitum calorie intake,2014-01,COMPLETED,INTERVENTIONAL,['NA'],,Subjective symptom scores
11190,NCT00035035,,na,COMPLETED,INTERVENTIONAL,['PHASE3'],,
11191,NCT00003610,severity of mouth pain,1998-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
11192,NCT02558881,Acceptance rate of colonic capsule versus virtual colonoscopy.,2014-06,COMPLETED,OBSERVATIONAL,['NA'],,Additional costs generated by the implementation of a complementary action of screening for patients with a positive FOBT and did not realize optical colonoscopy
11193,NCT06190665,Disease control rate (DCR) for target lesions 1 month after the last TACE treatment,2023-12-19,RECRUITING,INTERVENTIONAL,['NA'],,Number of TACE treatments for target lesions
11194,NCT04929223,Objective Response Rate,2021-10-22,RECRUITING,INTERVENTIONAL,['PHASE1'],,Plasma Concentrations of Divarasib
11195,NCT05880446,Mean Delta of EORTC Proctitis Module (PRT20) score,2023-10-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Low Physical Activity Level prevalence and its association with PRT20 and QLQ-C30 Delta,Mean Delta of EORTC Quality of Life Questionnaire (QLQ-C30) score
11196,NCT03039309,Curative resection rate,2016-08-05,RECRUITING,OBSERVATIONAL,['NA'],,Mortality rates
11197,NCT00655655,"Efficacy outcomes in patients with metastatic kidney cancer, neuroendocrine carcinoma, non-small cell lung cancer, or melanoma (Cohort II)",2004-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11198,NCT00829335,Technical feasibility,2007-01,COMPLETED,OBSERVATIONAL,['NA'],,Morbidity and mortality
11199,NCT04361227,Closure time after ESD,2020-07-02,COMPLETED,OBSERVATIONAL,['NA'],,Clips used post-ESD
11200,NCT03741166,Blood-based biomarkers associated with genetic and epigenetic alterations.,2018-11-08,COMPLETED,OBSERVATIONAL,['NA'],,
11201,NCT06243393,Progression Free Survival (PFS),2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Overall Survival (OS)
11202,NCT04027556,HCC conspicuity,2019-06-27,COMPLETED,INTERVENTIONAL,['NA'],,Radiation dose
11203,NCT04337333,Cumulative patency of inner covered stent and Two-in-one stent,2016-05-01,UNKNOWN,INTERVENTIONAL,['NA'],,Stent dysfunction-free patient survival
11204,NCT04001478,Determine the diagnostic accuracy of breath test for detection of early oesophageal cancer and Barrett's high grade dysplasia,2019-10-01,RECRUITING,OBSERVATIONAL,['NA'],,Diagnostic validation study of the breath profile for prediction of early oeosphageal cancer and high grade dysplasia
11205,NCT02948348,Pathological complete response,2016-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,macroscopic evaluation of (rectal cancer) resected specimen
11206,NCT00075712,Quality of life by Quality of Life Questionnaire Core 30 Items (QLQ-C30) and QLQ-ovarian cancer (QLQ-OV28),2003-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
11207,NCT00655785,toxicities as assessed by NCI-CACAE ver3),2007-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Survival
11208,NCT01054924,,2009-11,COMPLETED,OBSERVATIONAL,['NA'],,
11209,NCT01269060,Harvested numbers of lymph node,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Postoperative mortality, morbidity"
11210,NCT00467974,progression free survival,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,consumption of hospital resources
11211,NCT02959541,THF - adjacent mucosa,2016-09,UNKNOWN,INTERVENTIONAL,['NA'],,Gene expression - correlation adjacent mucosa tissue concentration of the reduced folates
11212,NCT04238637,Objective Response rate (ORR) according to RECIST 1.1,2019-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Translational research,Overall Survival (OS)
11213,NCT00238147,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11214,NCT03072095,FIT completion within 3 months,2017-04-17,COMPLETED,INTERVENTIONAL,['NA'],,Response to text-based CRC screening outreach
11215,NCT05447611,"The main objective of the EMPACOL project is to investigate, in non-metastatic CRC patients, a possible correlation, between perceived HCP's empathy and survival (OS and DFS).",2022-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,"The relationship between caregiver empathy, as perceived by the patient, and quality of life (QoL) will be studied."
11216,NCT03598348,PFS,2018-01-16,UNKNOWN,INTERVENTIONAL,['PHASE3'],,OS
11217,NCT01549067,,2011-09,UNKNOWN,OBSERVATIONAL,['NA'],,
11218,NCT03175679,Incidence of Treatment-Emergent Adverse Events [Safety],2017-05-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],Disease Control Rate (DCR),Biological activity of infused iNKT cells
11219,NCT03092518,Overall survival,2017-06-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,morbidity
11220,NCT05228431,Rate of pCR,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
11221,NCT00714077,3-year disease free survival rate,2008-04,UNKNOWN,OBSERVATIONAL,['NA'],,safety
11222,NCT00109070,,2000-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,
11223,NCT02127645,incidence of local and distant recurrence,2011-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,anorectal function
11224,NCT04264962,Recurrance rate,2017-01-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,quality of life (QOL) questionnaire
11225,NCT05313191,To determine the cumulative rate of CTCAE v5.0 Grade ≥3 acute and late treatment related adverse events within 1 year of definitive reirradiation completion using proton therapy for recurrent or second primary tumor.,2022-01-24,RECRUITING,INTERVENTIONAL,['NA'],,To characterize patient reported outcomes within 1 year of reirradiation using the MDASI SP form for spinal tumors.
11226,NCT00009906,"Toxicity defined as any grade 3 or greater organ toxicity, or any grade 4 or greater hematological toxicity as assessed by CTCAE version 2.0",2000-12,TERMINATED,INTERVENTIONAL,['PHASE3'],,
11227,NCT04037319,"Incidence of atrial fibrillation within 90 days of colorectal cancer surgery, defined as ≥30 seconds of atrial fibrillation identified on a 24-hour cardiac monitor OR absence of p waves and irregularly irregular rhythm on an electrocardiogram",2020-01-16,UNKNOWN,OBSERVATIONAL,['NA'],,Number of events of use of health services for atrial fibrillation or sequelae of atrial fibrillation
11228,NCT03220711,"Depth-imaging capability of the confocal endomicroscope using an imaging contrast agent, fluorescein",2017-07-28,TERMINATED,INTERVENTIONAL,['NA'],,
11229,NCT05276037,Survival,2019-01-01,RECRUITING,OBSERVATIONAL,['NA'],,FDG PET-CT value in Milan-in patients
11230,NCT04081831,Incidence rate ratio of esophageal cancer among users of low-dose-aspirin (exposed) and users of paracetamol monotherapy (non-exposed),2019-07-31,COMPLETED,OBSERVATIONAL,['NA'],,Case-fatality and survival rate
11231,NCT01914068,Change in physical fitness measured by CPET (ml/kg/min),2013-08,COMPLETED,INTERVENTIONAL,['NA'],TNM Staging,Physical activity
11232,NCT04188002,Metabolic Equivalent Task Hours (METs) for Physical Activity,2017-03-25,COMPLETED,INTERVENTIONAL,['NA'],,Number of Times Visiting the Site
11233,NCT03101475,Best overall immune response rate (iBOR) of lesions not treated by ablation/radiotherapy including the extrahepatic lesions according to iRECIST (with response confirmation),2018-11-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety: Safety analyses will be performed on the Safety population. The worst toxicity grade per patient over the treatment period according to the CTCAE criteria version 4.0 will be displayed.
11234,NCT04495088,disease-free survival,2020-09-30,RECRUITING,INTERVENTIONAL,['PHASE3'],,Patient reported outcome: Functional outcome according to Wexner score
11235,NCT05208775,2-year disease-free survival rate,2022-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Esophageal stenosis rate at 3 months
11236,NCT00654160,Maximum tolerated dose of genotype-based dosing of FOLFIRI with or without monoclonal antibody therapy,2008-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Response rate of genotype-based dosing in the subset of patients that has colorectal cancer
11237,NCT05382741,Disease Free Survival,2022-03-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
11238,NCT06069778,Phase 2 - Disease-free survival (DFS),2024-03,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2 - Occurrence of abnormal laboratory parameters
11239,NCT02969096,Rate of complete tumor ablation,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse Events
11240,NCT05892289,The Proportion of Patients With Reflux Esophagitis Within 12 Months Postoperatively,2023-06-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Proportion of participants need to rehospitalized after surgery
11241,NCT03820531,Pancreas cyst with HGD or carcinoma,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
11242,NCT00064259,Maximum Tolerated Dose (MTD) of Oblimersen in Combination With Cisplatin and 5-FU,2003-06,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Microarray Data
11243,NCT03551951,Quantity of cfDNA in bone marrow,2016-07-01,RECRUITING,OBSERVATIONAL,['NA'],,
11244,NCT03865563,"Safety as measured by number of participants with Grade 3, 4, and 5 toxicities",2019-07,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Efficacy as assessed by change in levels of gemcitabine and dFdu in peripheral blood samples
11245,NCT01375816,Tumor response,2011-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Correlation of UGT1A family polymorphism and the toxicity of liposome-encapsulated irinotecan hydrochloride PEP02 or irinotecan hydrochloride
11246,NCT01890291,To evaluate recurrence-free survival,2013-06,COMPLETED,OBSERVATIONAL,['NA'],,To determine the response rate to evaluate overall survival and cause specific survival and changes of Alpha feto protein (AFP) figures from baseline to the last observation date.
11247,NCT00207155,Prediction of response to Erbitux in subjects with metastatic colorectal cancer,2003-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Radiographic Response
11248,NCT02950064,Part 2 - Progression-free survival (PFS) measured as the time from the date of initiation of BTP-114 treatment to the documented disease progression (PD) or death from any cause.,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE1'],Part 1 - Plasma Pharmacokinetics (PK) estimates of platinum concentration Half-life (T1/2).,
11249,NCT02582970,Percentage of Participants With Adverse Events,2005-05,COMPLETED,INTERVENTIONAL,['PHASE4'],,Mean Direct Medical Cost for Cancer Related Medical Care Utilization
11250,NCT02423174,Intraoperative Serious Adverse Events as a Measure of Safety and Feasibility,2016-01,WITHDRAWN,OBSERVATIONAL,['NA'],,Evaluation of post-operative complications
11251,NCT00217555,Quality of life,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
11252,NCT01668017,Number of Subjects Who Experienced at Least One Dose Limiting Toxicity (DLT),2012-09-30,TERMINATED,INTERVENTIONAL,['PHASE1'],,Percentage of Subjects With Disease Control
11253,NCT05601505,"Disease-related treatment failure, DrTF",2022-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,"overall survival, 2yOS"
11254,NCT04054518,Six-month progression-free survival,2019-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Six-month progression-free survival according to immune biomarkers,Incidence of distant progression
11255,NCT05055323,Incidence of dose limited toxicity (DLT),2021-07-29,RECRUITING,INTERVENTIONAL,['PHASE1'],,Fatty tissue accumulation of PP
11256,NCT00012246,Frequency and severity of toxic effects,2002-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,
11257,NCT04748380,Change in CRC Screening Intentions,2023-01-18,RECRUITING,INTERVENTIONAL,['NA'],,Feelings of usefulness of the decision aid
11258,NCT00003843,,1998-10,TERMINATED,OBSERVATIONAL,['NA'],,
11259,NCT05714111,Local progression free survival,2022-03-04,RECRUITING,OBSERVATIONAL,['NA'],,Overall Survival
11260,NCT01187212,Progression-free survival,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Biomarker for sorafenib
11261,NCT02392637,Median Progression Free Survival (PFS),2015-04-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Treatment Response Rate
11262,NCT02288728,postoperative mortality and morbidity,2014-12,TERMINATED,INTERVENTIONAL,['NA'],,reflux esophagitis
11263,NCT04150042,Overall incidence rate of Grade 3-5 adverse events,2021-01-13,RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-Free Survival
11264,NCT02146703,Objective reponse rate,2005-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Progression free survival, median overall survival, disease control rate, and over grade 3 hematologic toxicities (neutropenia, thrombocytopenia, and febrile neutropenia)"
11265,NCT04232735,SOURCE observational scale,2020-10-13,RECRUITING,INTERVENTIONAL,['NA'],SOURCE evaluation questionnaire (tailor made evaluation questionnaire),Health care providers' (numerical) precision of treatment outcome information measured with SOURCE observational scale simulated patient consultations (effect intervention)
11266,NCT03295500,Overall survival rate,2017-11-01,COMPLETED,OBSERVATIONAL,['NA'],,the value of ICG R15
11267,NCT03954756,Overall survival rate,2019-06-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
11268,NCT06177522,pCR rate,2023-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,
11269,NCT00919282,overall survival,1997-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,safety of treatment
11270,NCT04196816,Overall survival,2020-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Progression-free survival
11271,NCT05378919,disease-free survival,2015-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
11272,NCT02632201,Overall survival,2015-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life
11273,NCT03503162,The Rate of Adequate Cleansing Level Before and After the Use of the Pure-Vu System,2018-05-17,COMPLETED,INTERVENTIONAL,['NA'],,
11274,NCT04643041,1 year DFS rate,2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],,3 years OS rate
11275,NCT02589496,Response Rate,2016-03-26,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11276,NCT02186574,Rate of reverse seroconversion,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,All-cause mortality
11277,NCT03500380,Progression-free Survival (PFS) as Assessed by an IRC,2018-04-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Overall Survival
11278,NCT05203549,Establishment of patient-derived organoids,2021-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,Correlation between results of the drug sensitivity tests in patient-derived organoid models and clinical outcomes
11279,NCT04761614,Dose limiting toxicities (DLTs),2021-04-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Change in levels of circulating cytotoxic T cells,Pharmacokinetic (PK) profile of riluzole (AUC)
11280,NCT00613730,Overall Survival at 1 Year,2007-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Overall Response
11281,NCT00987766,Maximum tolerated dose and recommended phase II dose of erlotinib hydrochloride in combination with gemcitabine hydrochloride and oxaliplatin,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,"E-cadherin, vimentin, fibronectin, amphiregulin, and Kras status in the tumors and their relationship to response"
11282,NCT02086656,Pathological response rate,2013-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,RECIST Response rate
11283,NCT04753203,Progression Free Survival,2021-02-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Duration of response
11284,NCT04005118,Rate of prolonged postoperative ileuss,2019-05-28,UNKNOWN,OBSERVATIONAL,['NA'],,Expression intensity in cytoplasm of protein ligase HACE1 in tumoral and non-tumoral tissues
11285,NCT01319877,Percentage of Participants With Bevacizumab-related Serious Adverse Events,2011-03,COMPLETED,OBSERVATIONAL,['NA'],,Quality of Life: European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 Questionnaire
11286,NCT01837381,overall survival and treatment-related toxicity,2007-02,COMPLETED,INTERVENTIONAL,['NA'],,Tumor response
11287,NCT03740503,Genomic Characterization of Tumor Samples,2013-11-01,RECRUITING,OBSERVATIONAL,['NA'],,
11288,NCT03678883,Part 3 Arm B,2019-01-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
11289,NCT03818165,Assess preliminary efficacy by overall survival,2019-07-29,TERMINATED,INTERVENTIONAL,['PHASE1'],Assess if circulating tumor cells (CTC) correlate with response,Assess preliminary efficacy by in-liver progression free survival (PFS)
11290,NCT04779125,Complications,2021-03-19,COMPLETED,INTERVENTIONAL,['NA'],,Gluteus muscle function measured by time stands test
11291,NCT01992705,Rate of downstaging to resectability in patients with borderline resectable pancreatic cancer receiving FOLFIRINOX and SBRT as preoperative therapy.,2014-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],Quality of life through and after treatment,Survival status (disease-free-survival vs. overall survival) time to recurrence and site of recurrence in patients with borderline resectable pancreatic cancer receiving preoperative FOLFIRINOX followed by SBRT
11292,NCT04382079,oral mucositis,2020-04-08,UNKNOWN,INTERVENTIONAL,['NA'],,"IL-1, IL-6, IL-10,TNF"
11293,NCT01139242,"Higher incidence of CRC screening, if needed, among experimental participants.",2008-02,COMPLETED,INTERVENTIONAL,['NA'],,
11294,NCT03061708,Objective response rate (ORR) by RECIST 1.1,2017-02-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,
11295,NCT02401802,Inadequate bowel preparation.,2015-01,COMPLETED,INTERVENTIONAL,['NA'],,"Acceptability of the preparation (interference with work, leisure activities or sleep"
11296,NCT00003786,Clinical Response Rate,1999-04,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
11297,NCT04293419,Pathological complete response (pCR) rate,2019-12-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Calculation of the neoadjuvant rectal (NAR) score
11298,NCT05760599,DCR per RECIST 1.1,2023-02-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,Biomarkers such as PD-L1 expression
11299,NCT03320733,Negative predicative value,2018-07-01,COMPLETED,INTERVENTIONAL,['NA'],,Parameters optimization keV
11300,NCT00016900,,2000-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11301,NCT00111904,Safety,2005-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11302,NCT03941093,Overall Survival (OS),2019-05-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,"Best Overall Objective Response Rate (ORR), as Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1"
11303,NCT02948309,Overall survival (OS),2016-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Incidence of treatment-emergent adverse events (AE)
11304,NCT01188785,Number of Participants with Adverse Events,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11305,NCT01239082,The primary outcome is colorectal cancer mortality.,2012-04-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,FIT Positive - If Colonoscopy is Warranted
11306,NCT03028311,Incidence of adverse event assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0,2017-01-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
11307,NCT06002425,Influence Rate of ChatGPT on Treatment Plans,2023-08-29,RECRUITING,INTERVENTIONAL,['NA'],5-year Overall Survival (OS) Rate,3-year Progression-Free Survival (PFS) Rate
11308,NCT04037046,Acceptance of the interventions,2019-03-01,COMPLETED,INTERVENTIONAL,['NA'],,Effectiveness of each strategy: rate of HCV positivity
11309,NCT04836741,Disease free survival,2015-07-01,COMPLETED,INTERVENTIONAL,['NA'],,
11310,NCT01587534,the change in body weight at eight weeks after the randomisation,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Frequency of bowel movements per day
11311,NCT04403022,Adverse Events Rates,2021-06-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
11312,NCT03395938,The proportion of siblings that contacted the study team within 4 weeks from point of engagement by the index colorectal cancer patient.,2017-05-01,COMPLETED,INTERVENTIONAL,['NA'],,
11313,NCT01093755,Change in Esophageal Inflammation Biomarker COX-2 Gene Expression,2010-03,COMPLETED,INTERVENTIONAL,['PHASE4'],,
11314,NCT01550055,Overall response rate,2009-05-31,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Progression-free Survival
11315,NCT00475293,objective response rate,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,adverse events
11316,NCT04667351,overall survival,2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Adverse Events
11317,NCT00787787,Median Progression-free Survival,2008-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival
11318,NCT01782573,"the positive rate of the baseline culture , the preoperative culture , and the postoperative culture",2011-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,the post - operative surgical site infection
11319,NCT04560712,Retention,2020-08-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Postoperative length of stay,Satisfaction of pain control
11320,NCT04693546,"Sensitivity and specificity for the LifeKit Prevent Colorectal Neoplasia Test for adenoma, including advanced adenoma",2021-06,UNKNOWN,OBSERVATIONAL,['NA'],,Sensitivity of the LifeKit Prevent Colorectal Neoplasia Test is superior to that of FIT for advanced adenoma
11321,NCT05801211,Stoma rate at 1 year after tumor resection,2023-05-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,type of chemotherapy regimen
11322,NCT02864381,Objective Response Rate (ORR),2016-09-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants Who Experienced Treatment-emergent Laboratory Abnormalities
11323,NCT01701310,To determine if the use of intravenous ferric carboxymaltose can reduce the need for allogeneic blood transfusion compare to oral ferrous sulphate in patients with colorectal adenocarcinoma related anaemia,2012-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,To determine differences in anemia symptomatology response between groups.
11324,NCT03281382,Toxicity of the gene therapy,2017-07-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,PET imaging
11325,NCT00486356,Toxicities of combined chemotherapy regimen,2004-10-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Antitumor activity
11326,NCT03027895,clinical success,2018-09,UNKNOWN,INTERVENTIONAL,['NA'],,technical success
11327,NCT05711433,incidence of postoperative pancreatic fistula,2014-07-01,COMPLETED,OBSERVATIONAL,['NA'],,
11328,NCT03122548,Objective Response Rate (ORR),2017-08-14,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
11329,NCT04652271,Mortality,2021-09,UNKNOWN,OBSERVATIONAL,['NA'],,Morbidity
11330,NCT00467194,Maximum tolerated dose,2006-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Change in DCE-CT scan assessment of angiogenesis
11331,NCT00554905,Overall Survival,2006-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Recurrence rates
11332,NCT03687853,Death,2017-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,
11333,NCT05375370,Change in tcDNA dosage between baseline and 3 Months,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Survival at 2 years
11334,NCT04899908,Local Recurrence,2021-09-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Neurocognitive function: cognitive impairment
11335,NCT00509561,Overall survival,2008-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Health economics
11336,NCT03788226,3-year disease-free survival,2019-02-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,safety (The incidence of chemotherapy related adverse events)
11337,NCT02333721,3-year disease free survival rate,2015-01,UNKNOWN,INTERVENTIONAL,['NA'],,Technical performance
11338,NCT01103323,Overall Survival,2010-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Tumor Response
11339,NCT01639911,Optimally Tolerated Dose,2013-08-14,COMPLETED,INTERVENTIONAL,['PHASE1'],,Toxicity Profile
11340,NCT05237193,Assess the value of UCAD for malignant biliary obstruction patient follow-up,2021-09-03,RECRUITING,OBSERVATIONAL,['NA'],,Comparison of the sensitivity and specificity of the UCAD analysis versus bile cytology
11341,NCT04287335,Sensitivity and specificity of the ColoClear screening test with comparison to colonoscopy,2018-09-18,COMPLETED,OBSERVATIONAL,['NA'],,"Sensitivity of the ColoClear screening test with comparison to FIT, with respect to advanced adenoma (AA) and CRC"
11342,NCT00001241,,1989-01-27,COMPLETED,OBSERVATIONAL,['NA'],,
11343,NCT03853772,Demographic and clinical data obtained via chart review and questionnaires,2019-04-27,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
11344,NCT02237157,Determine the Maximum Tolerated Dose of Gemcitabine to be Delivered Locally to the Pancreas,2015-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,CA19-9 Tumor Reduction
11345,NCT04254939,Phase II: ORR based on mRESIST 1.1,2019-08-15,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
11346,NCT05603039,Objective remission rate (ORR),2021-07-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival (OS),Duration of remission (DOR) Duration of remission (DOR) Duration of remission (DOR) Duration of remission (DOR)
11347,NCT03990974,30-day postoperative infection rate,2020-09,SUSPENDED,INTERVENTIONAL,['PHASE3'],,Distant infection rate
11348,NCT05022511,Participation,2021-09-01,COMPLETED,INTERVENTIONAL,['NA'],Survey evaluation,Rate of compliance to follow-up with colonoscopy after a positive FIT
11349,NCT01768988,Pain intensity (Visual Analogue Scale; VAS Score),2012-08,TERMINATED,INTERVENTIONAL,['PHASE4'],,Neuropathic Pain
11350,NCT05665868,Anxiety tendency of patients in the past week assessed by self rating anxiety scale,2022-04-01,RECRUITING,INTERVENTIONAL,['NA'],,
11351,NCT03957486,difference between SpHb value and SaHb value (SpHb - SaHb) in g/dL,2019-05-14,COMPLETED,INTERVENTIONAL,['NA'],,
11352,NCT00906997,Colorectal cancer-related mortality,2008-11,COMPLETED,INTERVENTIONAL,['NA'],,Advanced colorectal neoplasm detection rate
11353,NCT01760694,Efficacy - Progression Free Survival,2013-01,TERMINATED,INTERVENTIONAL,['NA'],,Safety
11354,NCT05215535,Cost effectiveness,2022-04-12,RECRUITING,INTERVENTIONAL,['NA'],,Survival
11355,NCT01535326,Proportion of Patients Without Pain,2012-02,COMPLETED,INTERVENTIONAL,['NA'],Post-procedure Discomforts and 30 Day Complication Rate,Number of Participants With at Least One Adenoma
11356,NCT05104567,Objective Response Rate (ORR),2021-12-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Cend of infusion of cetuximab
11357,NCT04612309,effectiveness,2020-10-28,RECRUITING,OBSERVATIONAL,['NA'],,
11358,NCT03466424,Pathological complete response(pCR) rate,2022-08-01,RECRUITING,OBSERVATIONAL,['NA'],,Incidence of acute toxicities during radiation or chemotherapy
11359,NCT02304978,TNM primary colorectal tumor stage,2009-06-22,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Interaction plate / tumor cell
11360,NCT04404647,90-day complication rate and severity,2020-06-01,WITHDRAWN,INTERVENTIONAL,['NA'],,Longitudinal changes in nutritional status assessment
11361,NCT01661270,Progression-free Survival (PFS),2012-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Percentage of Participants With Objective Response
11362,NCT01273493,Pharmacokinetics of trabectedin,2010-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Evaluate survival data
11363,NCT04988191,"Pathological complete response rate based on blinded, independent, central review",2020-12-24,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of Treatment-Related Adverse Events
11364,NCT03787537,Change in nutritional status,2017-08-01,COMPLETED,OBSERVATIONAL,['NA'],,length of hospital stay
11365,NCT02525380,The rate of Time to progression of hepatocellular carcinoma 30 patients.,2015-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],,
11366,NCT02688114,Change in the Percent of Mucosa Healed by Neosquamous Epithelium,2017-10-18,COMPLETED,INTERVENTIONAL,['NA'],,Change in inflammatory cell infiltrate
11367,NCT02738606,Overall survival,2016-05-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Patients who abandon treatment
11368,NCT00527111,Percentage of Pathologic Response Rate (pCR) With 95% Confidence Interval.,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,KRAS Mutation Rate
11369,NCT01333631,Number of the patients with side effects,2011-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of the patients survived
11370,NCT06266091,"Puncture-free survival, PuFS",2021-11-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Peak serum concentration (Cmax)
11371,NCT06251726,Lymph node invasion rate,2024-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Molecular profile of the tumor
11372,NCT00544193,Measurement of biochemical parameters in tumors that may correlate with the effectiveness of therapy,1997-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11373,NCT02602067,Dose Limiting Toxicity evaluated using NCI Common Toxicity Criteria (CTCAE 4.03),2015-11,TERMINATED,INTERVENTIONAL,['PHASE1'],Tumor response,Adverse Events
11374,NCT03552744,"Number of PCPs who have at least one patient ever tested with FOBT, or who prescribe at least one FOBT to eligible patients (patients not already tested within recommended intervals, with no contra-indication for screening).",2018-04-26,COMPLETED,INTERVENTIONAL,['NA'],,Change in PCPs' future intentions to prescribe colonoscopy vs. FOBT over the next 6 months
11375,NCT01124994,Accuracy of CLE-EMR,2011-07,COMPLETED,INTERVENTIONAL,['NA'],,
11376,NCT00754468,Depth of Injury,2009-02,COMPLETED,INTERVENTIONAL,['PHASE4'],,Side Effects of Subjects Receiving Cryospray Therapy.
11377,NCT01700062,biochemistry data; Various inflammation-related cytokines ;,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,clinical outcome(hospital stay..)
11378,NCT03923335,disease free survival,2019-04-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
11379,NCT00585728,The utility of CT virtual proctoscopy (CTVP) for evaluation of rectal cancer.,2007-09,COMPLETED,INTERVENTIONAL,['NA'],,
11380,NCT04664504,R0 resection rate,2020-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,3yLRRFS
11381,NCT02707328,Maximum tolerable dose,2015-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,quality of life
11382,NCT05070247,Dose Expansion: Overall Response Rate (ORR),2022-04-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Dose Expansion: Number of Participants With one or More TEAEs Leading to Dose Modifications and Treatment Discontinuations
11383,NCT05177484,"the feasibility of running the study, to see if it could be run as a large multi-centre study",2022-05-30,RECRUITING,INTERVENTIONAL,['PHASE3'],,postoperative allogenic red blood cell transfusion rates
11384,NCT02752698,complication,2015-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,change of blood and biochemiacl
11385,NCT01670110,Change in Kidney Volume,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change in Quality of Life
11386,NCT00209677,Determine the clinical response rate with Recommended dose in Phase II setting.,2004-12,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determine the MST(Median Survival Time) and DFS(Disease Free Survival) in Phase II setting.
11387,NCT03346915,HPV vaccine series start and completion,2018-08-14,COMPLETED,INTERVENTIONAL,['NA'],,Wheel of Wellness (WoW) feasibility
11388,NCT00003543,,1998-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11389,NCT01441336,3 year recurrence free survival,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11390,NCT00561275,Toxicity of multiple peptide vaccinations,2007-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Immune responses including LY6K, VEGFR1 and VEGFR2 specific T cells"
11391,NCT03748680,DFS,2018-10-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,TR
11392,NCT00066677,Progression-free Survival,2003-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Thromboembolic Events
11393,NCT01584544,Number of Participants Experienced Dose Limited Toxicity,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11394,NCT03450512,the arisen of EC in the CT scan,2019-01-14,RECRUITING,OBSERVATIONAL,['NA'],,
11395,NCT01053013,Overall Survival - Based on Most Recent Scan,2010-04-15,COMPLETED,INTERVENTIONAL,['PHASE2'],Pain Assessment of Pancreatic Cancer Participants,Overall Survival - Based on Stage IV Disease Diagnosis
11396,NCT05203978,Complete colonoscopy defined by caecum intubation (binary criterion : yes or no),2022-03,UNKNOWN,OBSERVATIONAL,['NA'],,Polyp removal (binary criterion : yes or no)
11397,NCT03410758,Overall survival,2016-02-15,COMPLETED,OBSERVATIONAL,['NA'],,
11398,NCT01865565,progression free survival,2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival (OS)
11399,NCT01266707,Toxicities as assessed by NCI-CACAE ver3,2007-03,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Survival
11400,NCT00933816,Dose limiting toxicity in phase I and Time to progression in Phase II,2009-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase I and II: Adverse effect (AE)
11401,NCT01386242,Overall survival (OS),2011-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Control Rate
11402,NCT05619016,Percentage of HER2-positive lesions,2022-11-23,RECRUITING,INTERVENTIONAL,['PHASE2'],Dynamic PET parameters,Safety aspects of ABY-025
11403,NCT02776878,"Progression-free survive, calculated from registration until progression or death",2016-05,UNKNOWN,INTERVENTIONAL,['NA'],,"Tumor control probability, defined as CR＋PR＋SD, determined according to RECIST 1.1 criteria"
11404,NCT03517618,Disease Control Rate (DCR),2014-07-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Incidence of adverse events (AEs), serious adverse events (SAEs) [Safety and Tolerability]"
11405,NCT04047004,Surgical complications,2020-03-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Adjuvant chemotherapy
11406,NCT05886465,Progression free survival rate at 6 months,2023-05-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
11407,NCT05801783,Systemic immune response,2022-12-02,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Quality of Life Assessment
11408,NCT04170179,Progression free survival rate at 6 months,2019-11-19,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse events
11409,NCT05171530,Maximum tolerated dose of lenvatinib,2022-01-05,UNKNOWN,INTERVENTIONAL,['PHASE1'],Exploratory Outcome,Overall survival (OS)
11410,NCT01416662,capability of CDA to predict the occurrence of early severe hematological toxicity upon gemcitabine,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
11411,NCT00036517,,2002-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
11412,NCT02862015,European Organisation for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ)-C30 score change,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse effect
11413,NCT03755791,Duration of Overall Survival (OS) for the experimental arm vs. the control arm,2018-06-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Duration of Progression Free Survival (PFS) for the single-agent arm vs. the control arm
11414,NCT00559858,Incidence of capecitabine dose modifications (dose delay and dose reductions) due to toxicity,2004-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Measurement of biomarkers that might predict the occurrence of HFS
11415,NCT05797467,median of disease-free survival,2023-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Complications
11416,NCT05738772,Serum level of Soluble PDGFRβ,2023-02-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
11417,NCT05445778,Assess Progression-free survival (PFS),2022-12-27,RECRUITING,INTERVENTIONAL,['PHASE3'],,Patient-reported outcome health-related quality of life (HRQoL) of disease-related symptoms using the NCCN-FACT Ovarian Symptom Index (NFOSI-18) DRS-P (disease-related symptom subscale - physical).
11418,NCT04851106,The negative predictive value (NPV) determined from shear wave elastography,2021-09-21,UNKNOWN,OBSERVATIONAL,['NA'],,
11419,NCT06310564,Progression-free survival (PFS).,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,questionnaire QLQ-C30
11420,NCT00989651,Incidence of DLTs occurring in the first 4 courses of treatment (feasibility phase),2009-10-28,COMPLETED,INTERVENTIONAL,['PHASE1'],Genomic BRCA mutation status,"Incidence of toxicity, graded according to National Cancer Institute CTCAE version 4.0"
11421,NCT05496491,Disease Free Survival,2022-08-30,RECRUITING,INTERVENTIONAL,['NA'],,Treatment Compliance
11422,NCT05069766,Registration of treatment related side effects assessed by CTCAE V 5.0,2021-09-01,COMPLETED,INTERVENTIONAL,['NA'],,
11423,NCT00439517,Progression-free Survival (PFS),2007-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety - Number of Patients Experiencing Any Adverse Event
11424,NCT00006389,Observed Response Rate.,2000-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free Survival
11425,NCT00389610,Number of Patients Experiencing a Grade 3 or Above Treatment- Related Toxicity,2006-09-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease-free Survival (DFS)
11426,NCT05223673,"Overall Survival (OS) (In Double Negative, KRAS/NRAS and BRAF Wild Type Patients) (Phase III Part)",2022-04-21,TERMINATED,INTERVENTIONAL,['PHASE3'],,Adverse Events (Phase III Part)
11427,NCT05497271,diagnostic accuracy by cystic fluid analysis,2017-01-01,RECRUITING,OBSERVATIONAL,['NA'],,DNA mutation profile of cystic fluid
11428,NCT01694277,Overall Survival (OS),2012-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression Free Survival (PFS)
11429,NCT05439993,Progression-free survival rate (PFSR) at 4 months,2022-03-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
11430,NCT03550001,lymph node yield,2018-06-01,UNKNOWN,INTERVENTIONAL,['NA'],,Local recurrence rate
11431,NCT03075553,Response Rate for Participants Who Achieve a CR or PR [CT-based Response],2017-05-17,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants Who Experienced at Least One Grade 3 or Higher Adverse Events
11432,NCT01017822,Overall survival (Phase II),na,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Response rate (Phase II)
11433,NCT02399813,Progression Free Survival,2016-06-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events
11434,NCT01102569,Frequency of Three BRCA1/2 Mutations in Ashkenazi Jewish Patients,2008-01,RECRUITING,OBSERVATIONAL,['NA'],,Frequency of disease modifying mutations
11435,NCT04967183,Adverse effects,2022-06-01,RECRUITING,INTERVENTIONAL,['NA'],,Preferences of the subjects
11436,NCT05580393,The number of cases with subtypes of human Blastocystis isolates in Sohag,2022-11,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,The number of cases with Blastocystis infection is recorded.
11437,NCT00474994,Overall Objective Response,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11438,NCT03259763,Rate of gastric outlet obstruction recurrence,2020-10-26,RECRUITING,INTERVENTIONAL,['NA'],,Duration of stent patency
11439,NCT01373047,Determine the safety of modified T cells delivered into the hepatic artery by documenting the type and severity of any side effects and establishing the Maximum Tolerated Dose (MTD).,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Designer T cell survival and phenotype following infusion
11440,NCT04216901,Accuracy of Vision location,2019-12-24,UNKNOWN,OBSERVATIONAL,['NA'],,Consistent of vision positioning between diagnostic system and endoscopists
11441,NCT00644618,Survival,2003-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,"response rate, clinical benefit response, and safety"
11442,NCT04185454,Osteocalcin ratio,2018-09-01,COMPLETED,INTERVENTIONAL,['NA'],,Lipid profil 2
11443,NCT00490373,To evaluate the efficacy.,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,To characterize the quantitative and qualitative toxicities of pemetrexed in this population of pancreatic cancer patients.
11444,NCT03370432,Incidence of colorectal cancer in the DCH cohort,1993-12,COMPLETED,OBSERVATIONAL,['NA'],,
11445,NCT01149304,HDR-brachytherapy isodose (measured in Gy) that corresponds to the irradiated liver tissue without enhancement of Gd-EOB-DTPA in MR imaging using an axial T1 THRIVE sequence.,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety of the study drugs.
11446,NCT00055692,To Collect Information on Hepatic Function and Hepatitis Viral Activity in Cirrhosis and Upon Potential Alterations in the Setting of VEGF-inhibition,2003-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Disease Stability,
11447,NCT03524287,overall postoperative morbidity rates,2018-03-01,COMPLETED,INTERVENTIONAL,['NA'],,Lymph node noncompliance rate
11448,NCT03609489,Progression-free survival,2018-09-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease Control rate
11449,NCT04647045,Serum cytokine level,2017-05-02,COMPLETED,INTERVENTIONAL,['NA'],,Constipation related symptoms
11450,NCT02563548,"Dose Expansion Phase: Objective Response Rate (ORR): Percentage of Participants With Objective Response, as Assessed by Investigator Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1",2015-10-22,COMPLETED,INTERVENTIONAL,['PHASE1'],,Dose-Expansion Phase: Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG)
11451,NCT01315522,The stent patency,2010-06,COMPLETED,INTERVENTIONAL,['PHASE4'],,adverse events
11452,NCT02325453,Compare the three treatment arms in terms of tumor recurrence after treatment. (Disease-free survival),2015-05,UNKNOWN,OBSERVATIONAL,['NA'],,"Verify whether robotic gastrectomy, compared with laparoscopic or open techniques, is capable of improving postoperative surgical stress. (Granulocyte-to-lymphocyte ratio.)"
11453,NCT02588560,Increase (log) of HCV Viral Load between Baseline and after Chemotherapy,2015-09,UNKNOWN,OBSERVATIONAL,['NA'],,Number of Participants with Early Stop of Chemotherapy due to Hepatotoxicity
11454,NCT00267787,"Genetic analysis of blood sample as well as tissues , will provide us with any possible tumor marker for a better prognostic indicator.",2004-09,TERMINATED,OBSERVATIONAL,['NA'],,
11455,NCT01843725,To determine the maximum tolerated dose and the recommended phase II dose of capecitabine in association with aflibercept,2013-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,"The secondary endpoint is preliminary data on efficacy, and this will be evaluated using CT scan or MRI using RECIST (Response Evaluation Criteria in Solid Tumors) v1.1"
11456,NCT03843554,Oral mucosal severity,2019-09-23,TERMINATED,INTERVENTIONAL,['NA'],,Overall survival
11457,NCT03064490,Number of Participants With Pathologic Complete Response (pCR),2017-10-17,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety of the Combined Drug Therapy With Radiation Therapy.
11458,NCT00925769,Part 1: PRD of Bevacizumab for Part 2,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Part 2: Overall Survival
11459,NCT00004042,,1998-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11460,NCT03405272,Objective response rate,2018-02-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
11461,NCT02713269,Local tumor control rate,2016-08-29,COMPLETED,INTERVENTIONAL,['PHASE2'],,Changes in quality of life (QOL) assessed by SF-12 healthy survey (v2)
11462,NCT05545293,Postoperative nutritional status and quality of life,2022-09-14,RECRUITING,OBSERVATIONAL,['NA'],,Postoperative intestinal function recovery time
11463,NCT03384511,Tumor response defined by RECIST criteria,2016-09-30,COMPLETED,INTERVENTIONAL,['PHASE4'],,Treatment-Related Adverse Events as Assessed by CTCAE
11464,NCT00454636,Percentage of Participants With Grade 3 Hand-Foot Syndrome (HFS),2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Response
11465,NCT03676426,New documentation of advance care planning in the EHR,2018-10-15,COMPLETED,INTERVENTIONAL,['NA'],,Surrogate preferences
11466,NCT05997147,Recurrence-free survival,2023-05-01,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
11467,NCT01183156,Attendance to screening colonoscopy,2010-08,UNKNOWN,INTERVENTIONAL,['NA'],,Response rate to the re-invitation letter or invitation to the educational meeting
11468,NCT06070376,Reinterventions,2023-06-26,RECRUITING,INTERVENTIONAL,['NA'],,Patency time of the prostheses.
11469,NCT05383066,Progression-Free Survival,2022-05-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,disease control rate
11470,NCT05648487,R0 resection,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Relapse-Free Survival
11471,NCT04390958,Pathological complete response (pCR) rate,2020-05-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Surgical complications
11472,NCT01471756,Efficacy of Two Devices used in EMR,2011-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,Compare the Use of Two Injectates
11473,NCT05259488,LOS,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Time of tolerated food intake
11474,NCT02919878,Estimate the rate of pathological complete response following neoadjuvant combined-modality therapy using weekly Gemcitabine and radiation therapy in rectal cancer.,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,R0 resection rate
11475,NCT05442502,The rate of early postoperative complications.,2018-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Time of esophagojejunostomy
11476,NCT04139967,Number of participants who experience a grade 2 adverse event,2020-01-20,TERMINATED,INTERVENTIONAL,['NA'],,Number of participants with improved symptoms
11477,NCT06301464,The level of serum pepsinogens,2003-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
11478,NCT05906615,Pain score,2021-01-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Dose reduction of opioids
11479,NCT05098197,Overall Survival (OS),2021-09-26,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Change in Quality of Life
11480,NCT05178043,The Objective Response Rate (ORR) (confirmed) as evaluated by an Independent Review Committee (IRC) according to RECIST v1.1,2021-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Presence of Anti-Drug Antibodies (ADAs) to GT90001 and Nivolumab during the study relative to the presence of ADAs at baseline
11481,NCT06287788,The AUC of the predictive model,2024-03-01,RECRUITING,OBSERVATIONAL,['NA'],,The important predictors of severe oropharyngeal mucositis in the predictive model
11482,NCT04154124,"Number of patient that shown the different between diagnostic value of single PET/MR scan in RC staging and compare it to that of MRI alone, PET/CT alone, and combined MRI and PET/CT",2019-11-23,UNKNOWN,INTERVENTIONAL,['NA'],,
11483,NCT00261092,Overall response rate based on RECIST criteria,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life
11484,NCT00041275,Survival measured weekly,2002-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of life as measured by EORTC quality of life instrument monthly
11485,NCT02864485,disease-free survival,2016-08-03,RECRUITING,INTERVENTIONAL,['NA'],,disease-free survival
11486,NCT02305290,Observed procedural data,2014-08,RECRUITING,OBSERVATIONAL,['NA'],,Analysis of the costs of this procedure compared to previous treatments
11487,NCT02841436,Tumor response,2012-11,COMPLETED,INTERVENTIONAL,['NA'],,Assess for presence of adverse event
11488,NCT04535024,Objective Response Rate,2021-03-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Acute Toxicity
11489,NCT04856046,Multi-target hepatocellular carcinoma panel (MHP) score,2021-11-06,RECRUITING,OBSERVATIONAL,['NA'],,
11490,NCT03029988,Visualization of Lesions by FDG PET/CT Imaging and by Tc 99m Tilmanocept SPECT/CT Imaging.,2017-07-26,TERMINATED,INTERVENTIONAL,['PHASE1'],,
11491,NCT06214611,Accumulated dose distribution in CTV,2023-11-15,RECRUITING,INTERVENTIONAL,['NA'],,Side effects (CTC AE)
11492,NCT00768937,Safety of Sorafenib in combination with TACE,2008-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
11493,NCT00599924,Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs),2005-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Initial Area Dnder the Contrast Agent Concentration-Time Curve (IAUC) of Tumors in a Selected Group of Subjects Assessed by DCE-MRI
11494,NCT02308384,The positive predictive value for detecting colorectal cancer in relation to indications of using iFOBT,2015-09,COMPLETED,INTERVENTIONAL,['NA'],,The rate of performed colonoscopies
11495,NCT02069561,Changes of apoptosis,2014-01,COMPLETED,INTERVENTIONAL,['NA'],,Change of Microbiota composition from baseline
11496,NCT05299840,progression-free survival,2023-06-07,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life of patients
11497,NCT02748304,Overall survival,2016-04,TERMINATED,INTERVENTIONAL,['NA'],,Number of patients with treatment-related bleedings who use aspirin
11498,NCT03563586,Surgical Site Infections,2018-04-01,UNKNOWN,INTERVENTIONAL,['NA'],,Time to beginning of adjuvant treatment for colorectal cancer
11499,NCT03087864,feasibility defined as percentage completion of treatment with atezolizumab.,2017-06-28,COMPLETED,INTERVENTIONAL,['PHASE2'],"Potential biomarker development based on assessment of tumour biopsies, blood- and faecal samples and the proposed mechanism of action of study drugs.",Overall survival
11500,NCT05520840,Number of patient with presence of best isolated serum biomarkers selected from different candidates,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Number of patient with presence of other isolated serum biomarkers selected from different candidates
11501,NCT04024358,PNI and VI correlation with DFS,2015-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Correlation of neurotoxicity with PNI
11502,NCT02416609,Progression-free survival,2014-01,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
11503,NCT02332213,VOCs differentiating the study groups,2014-01,COMPLETED,OBSERVATIONAL,['NA'],Gastrointestinal microbiome in cancer patients,Groups of gastrointestinal microbiota correlating to VOCs
11504,NCT02078843,Number of patients correctly identified as not having GEP-NET by using Gallium-68-DOTATATE PET/CT and Indium-111-pentetreotide scintigraphy (SPECT/CT),2014-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of patients with adverse events
11505,NCT05201352,Overall survival,2022-10-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
11506,NCT04163900,Overall Survival (OS),2019-12-24,TERMINATED,INTERVENTIONAL,['PHASE3'],,
11507,NCT02880020,Overall response rate defined as the number of subjects with a best objective response of confirmed CR or PR divided by the number of subjects,2016-12-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response rate by Choi criteria
11508,NCT00685828,Progression-free survival,2001-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Toxicity as assessed by NCI CTC v2.0
11509,NCT05719480,Achieve the expected number of enrolled cases,2022-11-20,RECRUITING,OBSERVATIONAL,['NA'],,
11510,NCT05646043,Individual patient compliance,2022-12-01,RECRUITING,INTERVENTIONAL,['NA'],,Laboratory examinations - coagulation factors (fibrinogen)
11511,NCT01697943,Change in QOL (Quality of Life),2012-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Nutritional status of patients
11512,NCT02686944,Adverse events according to CTCAE v 4.03,2016-06-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Levels of alloimmunization parameters
11513,NCT05229822,Change in number of Participants with Post-operative infectious and inflammatory complications,2021-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,16s rRNA in mesenteric lymph nodes
11514,NCT02291289,Progression-Free Survival (PFS),2015-04-17,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Improvement and/or Stayed the Same on the Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score
11515,NCT06248554,Disease-free survival,2019-12-01,RECRUITING,INTERVENTIONAL,['NA'],,Adverse effects
11516,NCT00927680,"We will recruit individuals with colorectal cancer with and without family history of CRC and their immediate family members and obtain the following: paraffin-embedded tumors blocks, blood samples, risk factor and food frequency questionnaires.",2007-07,RECRUITING,OBSERVATIONAL,['NA'],,"We will study the following parameters that we help us plan the larger population-based study such as: response rate of probands and their selected relatives, response rate of participants (probands and relatives), etcetera."
11517,NCT01308723,Part II: Safety/tolerability: Incidence of adverse events,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Safety: additional anti-drug antibodies sampling after termination of study drug treatment
11518,NCT03192735,Radical surgical resection rate,2017-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,adverse event
11519,NCT06166576,Duration of response according to localized mRECIST,2023-11-20,RECRUITING,INTERVENTIONAL,['PHASE2'],Post-treatment dosimetry based on Y90 PET-CT,Changes in ECOG (Eastern Cooperative Oncology Group) performance status scale
11520,NCT00964171,Non-morphological progression as defined by RECIST criteria,2008-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Tolerability and safety as assessed by NCI CTCAE v 3.0
11521,NCT03905967,Overall survival,2019-06-16,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Time to progression
11522,NCT00865189,Percentage of Participants With Tumor Sterilization Defined by ypT0-N0,2007-10-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Surgery
11523,NCT05399394,Incidence of Treatment-Emergent Adverse Events,2016-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Local-regional Tumor Control
11524,NCT03691090,OS,2018-12-03,COMPLETED,INTERVENTIONAL,['PHASE3'],Antidrug Antibodies (ADAs),AE
11525,NCT03631407,Number of Participants Who Discontinued Study Treatment Due to an AE,2018-09-24,COMPLETED,INTERVENTIONAL,['PHASE2'],,Trough Plasma Concentration (Ctrough) of Vicriviroc
11526,NCT03139942,Diagnostic accuracy of hyperplastic vs adenoma classification,2017-03-14,COMPLETED,INTERVENTIONAL,['NA'],,Mean time added to endoscopy due to additional imaging
11527,NCT02697084,time of disease-free survival,2014-11,UNKNOWN,OBSERVATIONAL,['NA'],,best treatment response criterion: complete or partial metabolic response according to EORTC or PERCIST criteria
11528,NCT00691054,Overall Survival Rate at 6 Months,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival of Participants
11529,NCT02613728,Cumulative Hospital Length of Stay (LOS),2016-05-13,COMPLETED,INTERVENTIONAL,['NA'],,Patient Satisfaction
11530,NCT03273608,Overall survival,2016-09-14,UNKNOWN,OBSERVATIONAL,['NA'],"Exploratory Objectives, Downstaging",Adverse Event (AE)
11531,NCT02608203,level of changes (%) between care management before DOTANOC PET and care management after DOTANOC PET,2016-05-26,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,number of patients for whom PET allowed the detection of lesions not described by standard imaging
11532,NCT06145074,Overall survival 5-years after surgery,2024-03-20,RECRUITING,INTERVENTIONAL,['PHASE2'],Feasibility of implementing preoperative propranolol in the preoperative setting for patients with pancreatic cancer using the APEASE framework.,Safety of 40 mg propranolol twice daily on heart rate.
11533,NCT00526331,Length of Hospital Stay (LOS) by Participant,2007-08,COMPLETED,INTERVENTIONAL,['PHASE4'],,
11534,NCT06054906,Percentage of participants with ≤10% tumor cell survival in resection specimens,2023-09-25,RECRUITING,INTERVENTIONAL,['PHASE2'],Distribution of immune cells in tumor tissue,Number of participants with treatment-related adverse events as assessed by NCI-CTC
11535,NCT04617522,Percentage of Participants who Develop Positive Anti-Sacituzumab Govitecan-hziy Antibodies,2021-04-06,RECRUITING,INTERVENTIONAL,['PHASE1'],,
11536,NCT03475680,Postoperative 30-day surgical site infection (SSI).,2018-08-08,TERMINATED,INTERVENTIONAL,['PHASE3'],,Date of adjuvant chemotherapy beginning
11537,NCT05336539,Application value of polygene methylation detection in colorectal cancer in community population,2022-04-01,RECRUITING,OBSERVATIONAL,['NA'],,
11538,NCT00101582,Number of Participants With Severe (Grade 3 or 4) Oral Mucositis,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Unplanned Breaks in Radiotherapy
11539,NCT00607828,Maximum tolerated dose,2007-11-16,COMPLETED,INTERVENTIONAL,['NA'],,
11540,NCT04735198,To evaluate the rate of biliary stone disease associated to patients with midgut NET that have gone through primary tumor surgery.,2021-01-20,RECRUITING,INTERVENTIONAL,['NA'],,To compare quality of life in patients who went through a prophylactic cholecystectomy against those who did not.
11541,NCT06001567,Proportion of patients with PLT >75×10^9/L or doubling from baseline,2023-08-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events (AEs)
11542,NCT02037399,present pain intensity (PPI),2013-07,UNKNOWN,INTERVENTIONAL,['NA'],,
11543,NCT02075086,Progression Free Survival,2011-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Feasibility
11544,NCT02232490,changes in plasma AFP,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],adverse effects,CT scan
11545,NCT02406170,Toxicity graded according to NCI Common Terminology Criteria for Adverse Events Version 4.0,2015-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
11546,NCT03430635,Identification of PET/CT parameters that can be predictors of survival,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
11547,NCT04499586,ORR(Objective Response Rate) includes CR(Complete Rate) and PR(Partial Rate),2019-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,the morbidity of hematological adverse events and diarrhea as assessed by CTCAE v4.0
11548,NCT05006131,Proportion of screening patients found to have high-risk pancreatic lesions amenable to treatment,2020-07-10,RECRUITING,OBSERVATIONAL,['NA'],,Proportion of screening patients who experience complications/adverse events of screen-related procedures
11549,NCT04907864,Median change (kg) in handgrip strength,2020-01-31,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Rate of toxicity with clinical significance, and possible relationship to either study intervention"
11550,NCT00268398,disease-free survival,2002-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Pharmacogenetics
11551,NCT05901779,postoperative infectious complications,2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],,total bilirubin
11552,NCT03063554,Efficacy of Stent Patency,2016-10-18,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of Life
11553,NCT01572428,Number of Serrated Lesions Proximal to the Sigmoid Colon Per Patient,2011-04,COMPLETED,INTERVENTIONAL,['NA'],,Patients With 1 or More Conventional Adenomas
11554,NCT05125614,Overall survival,2020-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
11555,NCT04709055,Percentage of patients with postoperative complications of grade II or higher in the Clavien-Dindo,2021-01-14,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Patient and professionals experience (ancillary study using semi-directive interviews)
11556,NCT00001228,,1988-10-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11557,NCT05220046,Retention Rate,2023-04-10,RECRUITING,INTERVENTIONAL,['PHASE1'],,Change in Demoralization Scale (D-II) total score from Baseline to 1 week post-dose
11558,NCT05855291,Overall survival,2018-01-22,COMPLETED,INTERVENTIONAL,['NA'],,
11559,NCT02350530,The conversion rate of liver metastases,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life (QLQ C30)
11560,NCT00433576,Concentrations of biomarkers,2006-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11561,NCT05385250,Rate of PIFs,2021-08-23,RECRUITING,INTERVENTIONAL,['NA'],,Quality of Life measures (EORTC)
11562,NCT00028626,,2001-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11563,NCT04527861,3-year disease free survival rate,2021-04-08,RECRUITING,INTERVENTIONAL,['NA'],,5-year overall survival rate
11564,NCT02882620,Annual Completion of the FIT Kit,2016-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Change in Self-Efficacy
11565,NCT05913674,Feasibility of mEPIC,2024-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Satisfaction of care team
11566,NCT04880811,Objective response rate,2021-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
11567,NCT05606848,Change in serum prealbumin,2022-11-30,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Energy intake in kcal / kg BW
11568,NCT05444686,SUV of primary and metastases lesions,2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
11569,NCT02311465,Functional Assessment of Cancer Therapy: General (FACT-G) Health Related Quality of Life Questionnaire,2015-12,WITHDRAWN,INTERVENTIONAL,['NA'],,Hospitalizations
11570,NCT01678664,Rate of hepatic progression free survival at 24 months,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicities treatment
11571,NCT02027363,progression-free survival (PFS),2010-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety
11572,NCT05791448,Incidence of adverse events,2023-03-29,RECRUITING,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics evaluation - Peak time (Tmax)
11573,NCT02795104,Percentage of Participants Who Received All Needed Screening and Any Needed Screening Across the Three Randomized Arms,2016-11,COMPLETED,INTERVENTIONAL,['NA'],,Cost of the Interventions
11574,NCT03471273,recur or not in 2 years after endoscopic surgical procedure or surgery,2017-09-18,UNKNOWN,INTERVENTIONAL,['NA'],,
11575,NCT05350384,funduscopic examination,2021-06-18,COMPLETED,OBSERVATIONAL,['NA'],Therapy,abdominal CT-scan
11576,NCT04227886,Toxicities,2019-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,pCR
11577,NCT04657848,Rate of reflux esophagitis after operation,2020-06-01,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative nutrition status
11578,NCT06013098,the occurrence of atelectasis,2023-09-06,RECRUITING,INTERVENTIONAL,['PHASE4'],,oxygenation index
11579,NCT06247293,Intra-abdominal recurrence-free survival (RFS),2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,survival rate
11580,NCT06192719,Gallbladder Cancer/Dysplasia development,2019-12-01,RECRUITING,OBSERVATIONAL,['NA'],,
11581,NCT04336839,Progression-Free Survival,2020-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,Histology predictive value
11582,NCT00845247,Quality of Life measures(questionnaire),2009-03,COMPLETED,INTERVENTIONAL,['NA'],,Care process measures in terms of monitoring of data from the National Patient Registry
11583,NCT04717765,"Treatment of osteonecrosis of the jaws with LLL phototherapy, evaluation using Notani scale - grade 1 to 3 - Radiotherapy",2021-02-10,COMPLETED,INTERVENTIONAL,['NA'],,Pain assessed by EVA - score 0 to 10 - all patients
11584,NCT03278626,Phase 2: Number of Subjects Who Achieved cCR (Clinical Complete Response) or pCR (Pathological Complete Response),2017-06-27,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
11585,NCT04977739,signal intensity of the probes,2021-08-03,COMPLETED,OBSERVATIONAL,['NA'],,
11586,NCT05606549,Fear of Progression Questionnaire-Short form (FoP-Q-SF) for Partners,2022-10-19,RECRUITING,INTERVENTIONAL,['NA'],,Dyadic Coping Inventory(DCI)
11587,NCT01356264,six minute walk test,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Fatigue
11588,NCT05726864,Phase 2: Compare ELI-002 7P versus standard of care (SOC; observation) in DFS (disease free survival),2023-04-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Determine the objective response rate (ORR) in subjects who crossover from Observation to ELI-002 7P treatment after confirmed progressive disease according to iRECIST
11589,NCT04844970,Weight change,2023-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Chemotherapy Dose change,AEs
11590,NCT00655876,Overall Survival (24-month Rate Reported),2008-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Quality-adjusted Survival (Using EQ-5D), Only if Primary Hypothesis is Supported"
11591,NCT02292745,overall survival,2014-12-02,COMPLETED,INTERVENTIONAL,['NA'],,predictive value of a set of biological markers for treatment response
11592,NCT05789797,"Difference of average ALP values in both of the groups, between the two timepoints: Visit 3 vs. baseline at Visit 1 (before starting therapy with the study medicines).",2022-05-12,RECRUITING,OBSERVATIONAL,['NA'],,"Proportion of patients with detected toxic damage to at least one system or organ (by selected parameters), according to the criteria of common toxicity grade III of the CTCAE scale, from the baseline (Visit 1) to Visit 4, measured in both groups."
11593,NCT01693523,Average Area Under the Curve (AUC) of Apriori Selected MDASI Symptoms,2013-01-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Relationship Between Dynamic Changes in Inflammation Biomarkers and Symptom Outcomes, Controlling for the Grouping Variables (Tumor Markers, Weight Loss), Evidence of Infection, ECOG PS, Age and Gender Examined"
11594,NCT04897854,Quality adjusted overall survival,2021-04-22,RECRUITING,INTERVENTIONAL,['PHASE3'],Level of CA 19.9,Number of patients with adverse events
11595,NCT04191551,Progression of intestinal metaplasia,2018-07-30,RECRUITING,OBSERVATIONAL,['NA'],,
11596,NCT00509964,response rate,2007-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,safety
11597,NCT06122636,Quality of life rate,2022-10-03,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,
11598,NCT00844883,Safety Will be Assessed by Grading Toxicities Reported at Intervals Throughout the Study. Higher Grade Toxicities Will be Assessed for Their Degree of Relatedness to the Study Treatment.,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Median Overall Survival OS Stratified by BCLC Criteria,Efficacy - Factors Associated With Overall Survival (OS) After Combination Treatment With Sorafenib and TACE
11599,NCT00952029,Disease-control duration,2010-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Geriatric evaluation
11600,NCT04976634,Confirmed Objective Response Rate (ORR) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR),2021-08-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Arm 2: Number of Participants Who Discontinued Study Treatment Due to an AE
11601,NCT02616692,"Preference weight scores for 13 selected HCC treatment attributes associated with Sorafenib, repeated TACE, and HAIC",2016-05-09,COMPLETED,OBSERVATIONAL,['NA'],,Maximum acceptable risk of life-threatening side effect willing to take for oral anti-cancer therapy (Sorafenib) therapy that will stop cancer from getting worse for a specified period of time
11602,NCT04513808,Recurrence-free survival,2020-08-15,RECRUITING,INTERVENTIONAL,['PHASE3'],,QoR-15
11603,NCT02223078,Antibody Levels,2000-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants with Serious and Non-Serious Adverse Events
11604,NCT04592289,Incisional surgical site infection (SSI) rate,2020-10-30,RECRUITING,INTERVENTIONAL,['NA'],,Bowel preparation compliance
11605,NCT00561418,Safety and Tolerability of Vorinostat (SAHA) After Autologous Stem Cell Transplantation,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to Progression
11606,NCT03826862,postoperative complication,2018-10-01,UNKNOWN,INTERVENTIONAL,['NA'],,disease-free survival
11607,NCT00348699,Plasma area under the curve (AUC) of AFP464,2006-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Percent change in CYP1A1
11608,NCT02658214,Tumor assessment based on RECIST 1.1 (for cohort 6 only),2016-04-28,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11609,NCT03651154,Packed Red Blood Cell Transfusion Rates,2018-09-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Changes in physiologic parameters (Pulse Pressure Variation)
11610,NCT02425059,Number of participants with Adverse events,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],Overall survival (OS),Percentage of lesions that show no sign of recurrence 12 months after IRE
11611,NCT02419716,Positive and Negative Predictive Value,2015-04,COMPLETED,OBSERVATIONAL,['NA'],The adverse event rate (events occurring between collection kit distribution and sample submission),Colorectal Cancer Incidence
11612,NCT06300463,"Mean CD8:Treg ratio, as determined by flow cytometry of tumor tissue, at time of surgical resection in each treatment arm",2024-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Participants Per Arm with ctDNA Clearance
11613,NCT00941655,Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm II,2009-07-22,COMPLETED,INTERVENTIONAL,['PHASE3'],,Patterns of Disease Recurrence Between the Two Therapeutic Approaches and Their Clinical Implications
11614,NCT06190847,pCR,2023-07-01,RECRUITING,OBSERVATIONAL,['NA'],,the surgical conversion rate
11615,NCT04025567,To evaluate the effect of oral vancomycin therapy in the relative CXCR6 gene expression levels in the liver,2020-03-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
11616,NCT05184283,Change in mean muscle fat,2022-06-16,TERMINATED,OBSERVATIONAL,['NA'],,Delta HOMA-IR
11617,NCT05263830,evaluate concentration of circulating GPC-3,2023-09-08,RECRUITING,OBSERVATIONAL,['NA'],,Evaluation of the HCC response to treatment on Imaging assessment (CT-scan and MRI) every 3 months according to the miRECIST criteria (combination of mRECIST and iRECIST criteria)
11618,NCT00587652,Any dysplasia or adenocarcinoma detected over all biopsies using each method.,2002-12,COMPLETED,OBSERVATIONAL,['NA'],,The association between staining patterns and histologic grade of the biopsies obtained using methylene blue will be assessed.
11619,NCT02412683,Oxaliplatin-Specific Neurotoxicity Scale,2014-01,COMPLETED,OBSERVATIONAL,['NA'],,Sense of Coherence scale (SOC-scale)
11620,NCT03210948,Diagnostic accuracy,2019-01-23,UNKNOWN,INTERVENTIONAL,['NA'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
11621,NCT00939848,Progression free survival,2011-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"• Response Rate (RECIST) • Toxicity • Survival (as part of the follow-on phase III study) • Biomarker evaluation (inc. circulating VEGF, sVEGFR-2, bFGF, LDH and CA 19-9) • Quality of Life"
11622,NCT06311565,Healthy lifestyle behaviors scale II,2024-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
11623,NCT04071964,Number of participants with an anastomotic leak,2019-07-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Number of participants with cancer reoccurence
11624,NCT00026403,overall survival,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,quality of life
11625,NCT05546619,RFS,2022-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,OS
11626,NCT00317772,Maximum Tolerated Dose (MTD) of Topotecan,2004-09-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Response Rate
11627,NCT06061276,Objective response rate (ORR),2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Overall survival (OS),Progression free survival (PFS)
11628,NCT04395352,Adenoma detection rate (ADR),2018-11-01,COMPLETED,OBSERVATIONAL,['NA'],,Number of patients with delayed adverse events
11629,NCT06071052,"Time to progression, TTP",2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Safety evaluation
11630,NCT00825474,overall survival,2008-08,COMPLETED,INTERVENTIONAL,['NA'],,
11631,NCT03908671,Number of participants with treatment-related adverse events as assessed by CTCAE v4.03,2019-10-18,RECRUITING,INTERVENTIONAL,['NA'],,Overall Survival (OS)
11632,NCT01032044,"Number of Barrett's Esophagus (BE) Participants With a Composite Outcome of ""Optimally Treated""",2010-02,COMPLETED,INTERVENTIONAL,['NA'],,
11633,NCT02005484,Percentage of Participants With a Response by Response Evaluation Criteria In Solid Tumors (RECIST) Category,2004-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Time to Progression
11634,NCT00368329,Patients' responses to therapy will be evaluated clinically after completion of their neoadjuvant chemoradiation.,2006-06,TERMINATED,INTERVENTIONAL,['PHASE1'],,Patterns of failure and the 2-year progression-free survival (PFS) rate.
11635,NCT05586061,objective response rate (ORR),2022-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,duration of response (DOR)
11636,NCT06084884,"1. Incidence of participants with dose-limiting toxicities (DLTs), adverse events (AEs), including adverse events of special interest (AESI) and serious adverse events (SAEs). Determination of the recommended dose of AZD5851 for expansion phase",2023-11-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,12. Pharmacokinetics - Exposure of AZD5851
11637,NCT01775644,Median Progression-Free Survival Time in Defined Participant Subgroups as Assessed by Response Evaluation Criteria In Solid Tumors (RECIST),2012-12-14,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of Participants in Defined Participant Subgroups Showing Overall Response in Daily Routine Practice as Assessed by RECIST
11638,NCT02534389,Check effects of daily consumption of 2.4 g of EPA + DHA for adults with rectal adenocarcinoma in neoadjuvant chemoradiation treatment on Glasgow Prognostic Score (GPS).,2015-01,COMPLETED,INTERVENTIONAL,['NA'],,Check for effects of daily consumption of 2.4 g of EPA + DHA for adults with rectal adenocarcinoma in neoadjuvant chemoradiation treatment on pathological response.
11639,NCT03638193,Safety of CART-meso infusion: number of adverse events,2018-07-11,UNKNOWN,INTERVENTIONAL,['NA'],,CAR-T cell detection
11640,NCT03001362,"Feasibility of a ""wait and see"" approach",2015-03,RECRUITING,INTERVENTIONAL,['NA'],,
11641,NCT04443985,Lymph node,2020-06-01,COMPLETED,OBSERVATIONAL,['NA'],,
11642,NCT03245788,Rates of unplanned hospitalization and ER visits,2017-02-15,COMPLETED,INTERVENTIONAL,['NA'],,Utilization of non-treatment-related cancer services
11643,NCT03322267,1-year relapse-free survival (RFS) rate.,2018-10-27,RECRUITING,INTERVENTIONAL,['PHASE2'],Blood-based biomarkers,Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
11644,NCT05308446,Progression-free survival (PFS),2022-07-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
11645,NCT04276090,Percent Completion of 1st Cycle of Hepatic Artery Chemotherapy,2020-05-01,TERMINATED,INTERVENTIONAL,['NA'],,Percent of Patients Who Remain on Hepatic Artery Infusion Pump Chemotherapy at 6 Months.
11646,NCT03982407,Evaluation of PSMA PET-MR for identification of intra and extrahepatic hepatocellular carcinoma in patients,2019-06-27,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
11647,NCT02385604,Disease-free survival,2014-01,COMPLETED,OBSERVATIONAL,['NA'],,Histopathologic response
11648,NCT05390398,Change in cancer-related fatigue,2022-01-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Clinical parameters,Cost-effectiveness evaluation
11649,NCT03422432,Time to adjuvant systemic chemotherapy,2017-09-28,UNKNOWN,INTERVENTIONAL,['NA'],,
11650,NCT04920214,Specificity,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
11651,NCT01307956,Complete Pathological Response (pCR) Rate,2011-02-28,TERMINATED,INTERVENTIONAL,['PHASE2'],Overall Survival,Number of Patients Who Can Undergo Resection
11652,NCT03958747,Tibial Nerve Cross-Sectional Area Comparison,2019-12-17,RECRUITING,INTERVENTIONAL,['NA'],,Reduction of Intraepidermal Nerve Fiber Density
11653,NCT04300959,12 months OS rate,2020-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent 3/4 Adverse Events
11654,NCT03291106,Distribution of Lynch syndromes in endometrial cancer,2017-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,Reliability of clinical criteria for screening Lynch syndromes
11655,NCT03236649,Overall survival (OS),2017-09-20,TERMINATED,INTERVENTIONAL,['PHASE3'],"Genome level (DNA, mRNA, miRNA) biomarker analysis",Assessment on Quality of life 2
11656,NCT01444456,Percentage of Participants Receiving Darbepoetin Alfa With Improvement in Patient Perceived Fatigue (PPF) and Increase in Hemoglobin ≥ 1 g/dL,2011-10,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of Participants With Increase in Hemoglobin ≥ 1 g/dL at Any Time
11657,NCT05472896,Progression-free survival (PFS) by Independent Review Committee,2022-06-09,RECRUITING,INTERVENTIONAL,['PHASE3'],Adverse event/ serious adverse event,2 year survival rate
11658,NCT06017297,Incidence of related treatment emergent adverse events,2024-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,Event Free Survival (EFS)
11659,NCT05810805,Concentrations of different gas in digestive tract,2023-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,The correlation between the severity of gastrointestinal symptoms and gas concentrations in various parts of the digestive tract.
11660,NCT05783570,Development of anti-drug antibodies (ADA),2023-08-24,RECRUITING,INTERVENTIONAL,['PHASE1'],Immunological assessment,OS
11661,NCT04194359,Adverse Events and Serious Adverse Events,2021-02-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression free survival
11662,NCT02551237,IADL (Instrumental Activities of Daily Living) Score,2016-01-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,EORTC QLQ-C30 + EDL14
11663,NCT02686424,overall survival,2010-03,SUSPENDED,OBSERVATIONAL,['NA'],,
11664,NCT02777814,Incidence of hepatitis B virus associated hepatitis,2015-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Interruption of chemotherapy due to hepatitis
11665,NCT06103890,pCR,2023-05-22,RECRUITING,OBSERVATIONAL,['NA'],,OS
11666,NCT01879943,Number of patients with full colonic exploration and detection of lesions,2013-10-18,TERMINATED,INTERVENTIONAL,['NA'],,Health-economic assessment
11667,NCT02002806,Pain Control,2012-01,COMPLETED,INTERVENTIONAL,['NA'],,"Disease-specific, recurrence-free survival"
11668,NCT06315361,Prevalence of significant fibrosis by non invasive tests,2019-05-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Identification of MACE
11669,NCT01433146,Temperament in non-metastatic colorectal cancer patients,2011-09,COMPLETED,OBSERVATIONAL,['NA'],,
11670,NCT06146946,3-year disease free survival rate,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,3-year overall survival rate
11671,NCT05366829,Safety as assessed by number of participants experiencing adverse events,2022-07-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Response and progression will be evaluated in this trial using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee (v1.1).
11672,NCT02374411,Collect questionnaire data from 150 HIPEC surgeons,2014-09,COMPLETED,OBSERVATIONAL,['NA'],,HIPEC surgeon attitudes toward patient nutritional support self-assessed by questionnaire
11673,NCT05009927,Progression-free-rate at 6 months (PFR 6m),2022-01-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,Duration of response (DOR)
11674,NCT01998347,median overall survival,2013-11,WITHDRAWN,INTERVENTIONAL,['PHASE3'],time to progression,median progression free survival
11675,NCT01755767,Overall Survival (OS) Rate At Different Time Points Following Treatment With Tivantinib 120 mg BID Compared to Placebo Group in Participants With MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated With One Prior Systemic Therapy,2012-12-27,COMPLETED,INTERVENTIONAL,['PHASE3'],,Treatment-Emergent Adverse Events Reported (>20% in Tivantinib Cohort) Following Treatment With Tivantinib Compared With Placebo in Participants With MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated With One Prior Systemic Therapy
11676,NCT05518643,Rate of Postoperative Pancreatic Haemorrhage (PPH),2022-07-15,RECRUITING,OBSERVATIONAL,['NA'],,Cancer recurrence rate
11677,NCT02510469,Disease free survival,2015-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
11678,NCT06161233,Change in health-related QoL outcomes in RCC patients,2023-05-16,COMPLETED,INTERVENTIONAL,['NA'],,User experience of the CAPABLE system in other cancer types patients
11679,NCT01528683,Safety and Efficacy,2012-12,COMPLETED,INTERVENTIONAL,['NA'],,
11680,NCT00855452,CR:disappearance of disease.PR:<50% decrease in the total tumor load of the lesions SD:<50% reduction and 25% increase in the sum of the products of the longest perpendicular diameters of the measured lesions.PD:>25% increase in the size of lesion.,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11681,NCT05482516,Rate of ctDNA Progression of Disease (POD) or Clinical/radiographic Relapse,2023-03-29,RECRUITING,INTERVENTIONAL,['PHASE3'],,Reasons for failure of enrollment
11682,NCT02184182,Percentage of R0 resections,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,hepatic diesease free survival
11683,NCT00131638,Incidence percentage of severe oral mucositis (Grades 3 or 4 on the WHO oral mucositis scale),2005-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Incidence of >/equal to 5 missed consecutive fractions of scheduled RT (to include discontinuations of RT)
11684,NCT02904031,"Progression Free Survival (PFS). PFS is defined as the time from randomization to the first documentation of objective disease progression or death due to any cause, whichever occurs first.",2016-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
11685,NCT05482477,Clock Drawing Task(CDT),2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,The time of get out of bed for the first time after operation
11686,NCT00410956,"Antitumor efficacy (complete and partial response, stable and progressive disease)",2007-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Toxicity as measured by NCI Common Toxicity Criteria
11687,NCT03931980,Conversion to open surgery,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Time of surgery
11688,NCT06134193,Progress free survival (PFS) per RECIST v1.1,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence rate of adverse events
11689,NCT05101629,Objective response rate (ORR) according to RECIST 1.1 criteria,2022-05-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and toxicity
11690,NCT02688699,effectiveness of EndoClotTM in preventing post-procedural bleeding,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],,
11691,NCT05495529,Clinical success,2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Progression free survival
11692,NCT06059170,Frequency of LARS,2017-03-17,COMPLETED,INTERVENTIONAL,['NA'],,
11693,NCT02280278,Disease free survival,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,toxin-side effect
11694,NCT05303298,Objective gastro-oesophageal reflux (GOR),2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Survival
11695,NCT00790322,Compare the proportion of patients in the two arms who develop severe oral mucositis,2008-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
11696,NCT06280495,3-year Progression-Free Survival Rate,2024-02-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Treatment-related adverse events
11697,NCT00002631,,1995-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,
11698,NCT03179579,Median overall survival,2017-08-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Risk factors for morbidity and mortality
11699,NCT06313567,Disease-free survival,2024-03-10,RECRUITING,INTERVENTIONAL,['PHASE3'],,Side effects
11700,NCT03133650,Maximum tolerated laser fluence rate,2017-04-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
11701,NCT02024087,Number of Participants With Adverse Events as a Measure of Safety and Tolerability.,2014-08-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease Control Rate (DCR)
11702,NCT00241020,Overall Survival,2002-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,· Safety
11703,NCT03964753,OS,2019-04-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Rate of Adverse Event
11704,NCT00743678,To evaluate overall R0 resection rates following neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Correlative analyses between pretreatment EGFR, KRAS mutation and response rate/survival"
11705,NCT05800418,Area under drug concentration - time curve (AUC0-t),2019-11-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Apparent volume of distribution (Vd)
11706,NCT04755036,Measurement of consensus in therapeutical decisions in pancreatic cancer between low/mid vs high volume hospitals,2020-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
11707,NCT06056804,pCR rate,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],The expression of CD8,irAE
11708,NCT01397747,"Sensitivity and Specificity of the Exact CRC Screening Test With Comparison to Colonoscopy, Both With Respect to Cancer.",2011-06,COMPLETED,OBSERVATIONAL,['NA'],,
11709,NCT01613469,To assess the complete clinical response rate following neoadjuvant chemoradiation in patients with distal rectal cancer.,2011-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,The proportion of subjects with complete pathological response at surgical resection
11710,NCT03457454,Assess the care coordination and communication with primary care providers by colonoscopy clinics/practitioners,2017-09-08,COMPLETED,OBSERVATIONAL,['NA'],,
11711,NCT05908747,Surgical complete resection rate (R0),2023-05-31,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events (AEs)
11712,NCT05957640,Objective response rates (ORR),2023-05-05,RECRUITING,INTERVENTIONAL,['PHASE1'],,Resection rate of liver target lesions
11713,NCT00020267,,2000-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11714,NCT02949947,Complete Response Rate in Hemoglobin (HGB),2017-12-18,TERMINATED,INTERVENTIONAL,['PHASE2'],,
11715,NCT06074029,Progression free survival,2021-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to treatment discontinuation
11716,NCT06219941,Objective Response Rate (ORR).,2023-12-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,"ADA status will be determined along with prevalence and incidence of anti-drug antibodies to AZD0901, and titer established."
11717,NCT03890198,Systemic Cytokine Concentrations,2019-04-22,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Overall Survival (OS) after administration
11718,NCT04328740,Determine recommended Ph2 dose (RP2D) of TP-1454,2020-07-08,RECRUITING,INTERVENTIONAL,['PHASE1'],,Determine antitumor activity of TP-1454.
11719,NCT01124630,Progression Free Survival,2010-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Serum concentrations
11720,NCT03857737,5-year DSS,2019-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Complication
11721,NCT01595256,Exploration the Effect of Walking Program in Patients With Colorectal Cancer.,2011-10,COMPLETED,INTERVENTIONAL,['NA'],,
11722,NCT04479436,Objective Response Rate (ORR) As Assessed By Blinded Independent Central Review (BICR) Following Administration of U3-1402 In Participants with Advanced or Metastatic Colorectal Cancer,2020-09-14,TERMINATED,INTERVENTIONAL,['PHASE2'],,Pharmacokinetic of Area Under the Serum Concentration-Time Curve Up to Last Quantifiable Time (AUClast) and During Dosing Interval (AUCtau) of analytes of U3-1402 Following Administration In Participants with Advanced or Metastatic Colorectal Cancer
11723,NCT05794971,Overall Survival (OS),2023-06-10,RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse enents
11724,NCT05514561,The diagnostic performance of fecal calprotectin in diagnosis of significant ileocolonic lesions,2020-03-22,COMPLETED,OBSERVATIONAL,['NA'],,The diagnostic performance of fecal immunochemical test in diagnosis of significant ileocolonic lesions
11725,NCT05301465,PFS,2021-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,
11726,NCT00898846,mRNA levels,2006-10,COMPLETED,OBSERVATIONAL,['NA'],,Histopathological examination
11727,NCT05446129,Composite endpoint: Proportion of patients with at least one occurrence of a safety or feasibility event,2022-09-27,TERMINATED,INTERVENTIONAL,['PHASE1'],,"Radiographic response on pre-surgical imaging, following receipt of the neoadjuvant therapy, as per response evaluation criteria in solid tumors (RECIST) v1.1"
11728,NCT04749303,Adenoma Detection Rate (ADR),2020-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,Severe adverse events
11729,NCT02575300,Overall Radiographic Response Rate (ORR),2015-10-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Response
11730,NCT04389892,Differentiation between murale nodules and mucus clots or debris,2018-04-01,COMPLETED,INTERVENTIONAL,['NA'],,Guiding EUS-FNA by the enhancement pattern
11731,NCT03318380,Negative Predictive Value of contrast-enhanced ultrasound evaluation (CEUS) for diagnosis of Hepatocellular cancer using a 95% confidence interval,2018-01-19,COMPLETED,INTERVENTIONAL,['NA'],,
11732,NCT00085163,"Disease-free survival as measured by Logrank every 3 months in year 1, every 6 months in years 2-3, and annually thereafter",2004-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Toxicity as measured by CTC AE version 2.0 every 3 months in year 1, every 6 months in years 2-3, and annually thereafter"
11733,NCT00501410,"Maximum Tolerated Dose (MTD) of Dasatinib, Cetuximab and FOLFOX",2007-04-23,COMPLETED,INTERVENTIONAL,['PHASE1'],,Response-Rate of Dasatinib and Modified FOLFOX6 With or Without Cetuximab
11734,NCT01032928,Optimal Respiratory - Swallow Phase,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Impairment According to the Penetration-Aspiration Scale
11735,NCT02952859,Time from diagnosis to death for any reason,2017-01,TERMINATED,OBSERVATIONAL,['NA'],,
11736,NCT06047015,Abscopal effect: percent change in non-treated colorectal liver metastasis.,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life questionnaire
11737,NCT01338558,Progression-free survival: native versus mutated K-RAS; tumour assessments according to RECIST criteria,2011-06,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Progression-free survival: comparison of the two treatment regimens in the native K-RAS arms
11738,NCT04508140,Safety: Adverse Events,2020-06-17,TERMINATED,INTERVENTIONAL,['PHASE2'],,Survival Rate
11739,NCT00247338,Infectious complications,2005-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,Post-operative nutritional cost & total treatment cost
11740,NCT04227041,Progression-free survival (PFS),2020-01-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of Treatment-Emergent Adverse Events [Safety]
11741,NCT03384940,Number of Participants With Objective Response Rate Based on Independent Central Review (Confirmed and Unconfirmed) Following DS-8201a Treatment in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Advanced Colorectal Cancer,2018-02-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Treatment-Emergent Adverse Events (TEAEs) Reported By ≥20% Of Participants Following Treatment With DS-8201a in Participants With HER2-expressing Advanced Colorectal Cancer
11742,NCT05580224,Local tumor progression rate,2022-10-04,RECRUITING,INTERVENTIONAL,['NA'],,Recurrence-free survival
11743,NCT06302660,Identify microbiome dysbiosis in stool associated with long-term functional symptoms.,2022-03-09,RECRUITING,OBSERVATIONAL,['NA'],,Propose a strategy for treatment of long-term symptoms in oesophageal adenocarcinoma survivors.
11744,NCT04666727,Somatic mutation burden,2020-09-29,RECRUITING,OBSERVATIONAL,['NA'],,
11745,NCT04196062,Complete (R0) resection,2020-05-01,COMPLETED,INTERVENTIONAL,['NA'],,Technical Success
11746,NCT03829748,Increase in diagnostic yield of pancreatic solid lesions,2019-01-16,COMPLETED,INTERVENTIONAL,['NA'],,Number of passes to reach diagnosis
11747,NCT00489268,Percentage of Participants With Histological Clearance of Barrett's Metaplasia,2003-11,COMPLETED,INTERVENTIONAL,['NA'],,Percentage of Participants With Sub-squamous Intestinal Metaplasia
11748,NCT00931203,"The primary objective is to determine the pathological complete response (pCR) of combining preoperative tegafur-uracil, folinate, radiation and celecoxib for locally advanced rectal cancer.",2008-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Sphincter preservation rate.
11749,NCT05723978,Disease-free survival (DFS),2011-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
11750,NCT02591784,The rate of AE(adverse event) or toxicity ( Both acute and chronic toxicity will be evaluated.),2008-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
11751,NCT03978702,"Measurement of immune effectors (Tcells, NK) levels after pancreatectomy",2021-02-24,UNKNOWN,INTERVENTIONAL,['NA'],,
11752,NCT01872104,Survival rate,2013-08,SUSPENDED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Quality of life,Progression-free survival
11753,NCT03697239,Disease Control Rate,2019-06,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Changes in patient's self-reported pain levels
11754,NCT05907772,Overall survival,2022-08-27,COMPLETED,OBSERVATIONAL,['NA'],,
11755,NCT03579784,Disease control rate,2018-11-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and tolerability as measured by number and grade of toxicity events
11756,NCT00516269,Mean Difference Between Post-Methylphenidate and Post-Placebo Measurement,2004-08,TERMINATED,INTERVENTIONAL,['PHASE3'],,
11757,NCT02288611,Change from baseline in large intestinal microbiota composition verses control intervention (0-3 months),2012-05,COMPLETED,INTERVENTIONAL,['NA'],,Change from baseline in Bowel function verses the control intervention (0-3 months
11758,NCT05722327,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)",2023-12-06,RECRUITING,INTERVENTIONAL,['PHASE1'],,
11759,NCT01764087,Tumor Overall Response Rates (ORRs) in Phase II Portion,2012-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Exploratory Biomarker Evaluation in Phase II Portion,Pharmacokinetic (PK) Evaluation in Phase II Portion
11760,NCT03478943,Disease-free surviva,2016-01-30,UNKNOWN,OBSERVATIONAL,['NA'],,Disease Control Rate
11761,NCT04010227,Short-form of Zarit Burden Interview,2019-09-16,COMPLETED,INTERVENTIONAL,['NA'],,Value Progress Subscale of the Valuing Questionnaire.
11762,NCT05959564,Intentions toward HPV vaccination,2023-07-26,COMPLETED,INTERVENTIONAL,['NA'],,Ratings of the Chatbot
11763,NCT03110926,Disease-free survival rate,2017-06-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall disease-free survival
11764,NCT05105828,Shear wave elastography score,2020-07-01,COMPLETED,OBSERVATIONAL,['NA'],,
11765,NCT03390517,Anastomotic Leak Rate,2017-11-09,COMPLETED,INTERVENTIONAL,['NA'],,
11766,NCT05025631,PFS,2020-11-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Correlation between geriatric assessment and efficacy and safety
11767,NCT01127711,"Fractures, hip fractures",1997-09,COMPLETED,OBSERVATIONAL,['NA'],,
11768,NCT03480971,Mucositis,2019-05-13,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Mucositis
11769,NCT04067986,Objective response rate,2019-08-20,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of Treatment-Emergent Adverse-Events
11770,NCT04903340,Average dose value (Gy) of tumor liver and healthy liver obtained according to reconstruction configuration.,2021-04-12,COMPLETED,OBSERVATIONAL,['NA'],,
11771,NCT03081494,Incidence of Dose-limiting toxicity (DLT),2017-06-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Severity of AEs and SAEs
11772,NCT01621217,To establish maximum tolerable dose of the two cytotoxic drugs 5-fluoruracil and mitomycin C when given together with the antibody cetuximab and radiotherapy in patients with locally advanced cancer in the anal region,2012-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11773,NCT02624271,Sensitivity of GastroPanel blood test,2016-08-04,COMPLETED,INTERVENTIONAL,['NA'],,
11774,NCT01219920,Response rate (RR),2001-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of life (QoL)
11775,NCT00693290,Clarity of the mucosa evaluated by the Ottawa Scale.,2008-06,UNKNOWN,INTERVENTIONAL,['NA'],,Concordance with the bowel preparation.
11776,NCT02509169,overall survival,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,progression free survival
11777,NCT04665687,Indentify prognostic biomarkers for predicting recurrence of early gastric cancer and precancerous adenoma lesion.,2020-12-17,UNKNOWN,OBSERVATIONAL,['NA'],,"Change in the tumor's molecular profile on serial biopsies at the time of initial treatment, 2 months after treatment, 1 year after treatment, or recurrence."
11778,NCT04878185,Change in maximal walking distance,2021-05-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Mortality
11779,NCT05452473,Gastric lesion detection rate,2022-07-06,RECRUITING,INTERVENTIONAL,['NA'],,Lesion classification accuracy
11780,NCT03491540,Postoperative 30-day surgical site infection (SSI).,2018-09-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Temporary stoma closure rate
11781,NCT05242237,Time to progression or death (months),2021-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,
11782,NCT00766636,Difference in Positive Margin Resection (R1) Rate in Patients Undergo Surgery Between the Two Treatment Groups.,2008-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,
11783,NCT05647122,Proportion of patients with radiological response (ORR),2022-12-22,RECRUITING,INTERVENTIONAL,['PHASE1'],,Immunogenicity of AZD9592: Anti-Drug Antibodies (ADA)
11784,NCT01504126,Proportion of patients who successfully complete 6 cycles of chemotherapy with propranolol hydrochloride,2012-03-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],"Changes in immune response, measured by serum levels of VEGF",Changes in mood state as measured by Center for Epidemiologic Studies Depression Scale (CES-D
11785,NCT01112280,Adenoma detection rate,2010-04,COMPLETED,INTERVENTIONAL,['NA'],,Surveillance
11786,NCT03008278,Objective response rate (Phase II),2018-02-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Tumor cells for PDX model, and biobanked tumor tissue and peripheral blood",Incidence of adverse events
11787,NCT01685632,heat shock protein expression (blood/cell ratio)compared to baseline values,2012-09,TERMINATED,INTERVENTIONAL,['NA'],,
11788,NCT00393822,Incidence of Grade ≥ 2 (WHO scale) oral mucositis,2005-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Incidence of grade ≥ 2 (WHO scale) oral mucositis
11789,NCT05994859,Success rate of conversion to resection,2023-08-10,RECRUITING,INTERVENTIONAL,['NA'],,Adverse Events (AEs)
11790,NCT02025244,To compare the yield and success of KHB and EUS-FNA in cytological / histological and immunohistochemical diagnostics of Upper Gastrointestinal Submucosal Tumors.,2010-11,UNKNOWN,INTERVENTIONAL,['NA'],,Detection of mitotic activity in case of Gastrointestinal Stromal Tumors
11791,NCT04612504,The response rate of patients with HCC receiving SynOV1.1,2022-06-23,RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
11792,NCT05438836,"Early Rate of Common Terminology Criteria for Adverse Events (CTCAE) Gastrointestinal Toxicity grade 2 or more (scale from 0-5, 5 being the highest)",2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Treatment Related Hospitalization
11793,NCT03676517,pathologic complete response (pCR) rate,2019-03,UNKNOWN,INTERVENTIONAL,['NA'],,Cost effectiveness
11794,NCT03946852,Ischemic Cholangiopathy,2019-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Re-operation rate,Graft survival
11795,NCT01743469,"Progression Free Survival (PFS) Rate, Defined as the Percentage of Patients Who Had Neither Progressed Nor Died as Measured by Centrally Analysed RECIST v1.1 (All Cohorts).",2012-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Further Cancer-related Treatment During Follow-up Period (All Cohorts).
11796,NCT01423708,Everolimus monotherapy,2010-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events
11797,NCT03863236,Postoperative complications,2019-04-01,RECRUITING,INTERVENTIONAL,['NA'],,Hospital stay
11798,NCT06172049,Survival,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
11799,NCT00557102,Tumor response rate,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tolerability
11800,NCT05731336,"Overall Survival, OS",2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],,"Adverse events, AEs"
11801,NCT00577902,"To study baseline antioxidant capacity (ORAC), selected biomarkers of nutritional status and nutritional risk of patients beginning therapy for head and neck cancers.",2005-06,COMPLETED,OBSERVATIONAL,['NA'],,"To assess antioxidant capacity, nutritional biomarkers and nutritional risk of patients during and after concurrent radiation and chemotherapy."
11802,NCT04868747,serum concentration of NET(neutrophil extracellular trapping)-related biomarker,2021-04-01,WITHDRAWN,INTERVENTIONAL,['NA'],,survival of patients
11803,NCT04085211,"Sensitivity, specificity, positive predictive value of specific endoscopic image enhancement findings to diagnose or stage the severity of different gastrointestinal conditions",2019-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,median duration for image enhanced endoscopy procedures
11804,NCT02584556,recurrence free survival,2015-10,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Time of tumor distant metastasis
11805,NCT02901301,The overall response rate using RECIST 1.1,2017-02-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to response
11806,NCT02324556,Number of specimens with grade I specimen according to Quirke,2015-01,TERMINATED,OBSERVATIONAL,['NA'],,Postoperative complications scored according to Clavien-Dindo within the first 12 months
11807,NCT02301143,Kaplan-Meier Estimates for Time to Treatment Failure (TTF),2015-04-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,Participants With Treatment Emergent Adverse Events (TEAEs)
11808,NCT04907591,"Change of body composition (weight, kg)",2021-05-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,"Muscle mass (lumbar 2,㎠)"
11809,NCT00411151,Objective Response Rate (ORR),2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety and Tolerability: Adverse Events in ≥10% of Patients
11810,NCT04717648,Early predictive factors of anastomotic leakege,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
11811,NCT00932724,Tumor assessment by using CT scans and/or MRIs,2009-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Assessment of survival by ""physical exam"""
11812,NCT03443661,pCR,2016-02-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety
11813,NCT03291288,Overall Summary of Treatment-emergent Adverse Events,2018-02-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetic Analysis: Metabolite to Parent Ratio (MPR) for Midazolam
11814,NCT00447746,5 year overall survival,2007-03,UNKNOWN,INTERVENTIONAL,['NA'],,: Postoperative morbidity and mortality rates
11815,NCT00003912,Resection rate,1998-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,
11816,NCT06083974,OS and DFS of patients with metastatic colorectal cancer patients received anti_EGFR targeted therapy,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Response rate (RR) in patients received chemotherapy only or with combination with targeted therapy.
11817,NCT03699761,Grade III-IV complications,2020-09-01,RECRUITING,INTERVENTIONAL,['NA'],,Treatment cost
11818,NCT05165446,Novel MRE technique to assess tissue viscoelasticity as a risk factor for liver cancer,2022-01-27,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Studies on liver injury and glycemic control.
11819,NCT05170282,The diagnostic accuracy of infantile liver tumors with deep learning algorithm,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,The diagnostic negative predictive value of infantile liver tumors with deep learning algorithm
11820,NCT03615170,Disease free survival,2017-07-19,UNKNOWN,OBSERVATIONAL,['NA'],,
11821,NCT00422864,Tolerability rate,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Distant response rate
11822,NCT05277766,Maximally tolerated dose (MTD) of Nal-IRI,2022-11-21,RECRUITING,INTERVENTIONAL,['PHASE1'],Exploratory outcome: Expression of human carboxylesterase 2 (hCE2),Overall treatment response
11823,NCT05849480,Phase II: Overall response rate (ORR),2024-04-07,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,5-year overall survival
11824,NCT03668158,recurrence rate,2018-11-20,UNKNOWN,OBSERVATIONAL,['NA'],,
11825,NCT02814864,Decrease of one grade on the LENT SOMA,2021-04-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Frequency of diarrhea
11826,NCT06035731,Patient Centricity Questionnaire (PCQ): Patient reported outcome: impact of supportive care,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Anxiety
11827,NCT03513198,Change of Wash-in Perfusion Index (WiPI) from baseline to 2 months after the first course of treatment,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,Tumor response to treatment
11828,NCT02193594,The patient's survival time and recurrence time,2014-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",The pathologic profiles and the pathologic response rates,The number of patients with complications
11829,NCT01205828,Clinical Benefit Rate,2010-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Biomarker Analysis
11830,NCT00906373,Progression Free Survival (PFS),2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,The Number of Participants With Serum Anti-Cixutumumab Antibody Assessment (Immunogenicity)
11831,NCT04198025,Number of post operative complications (Clavien-Dindo grade 3-4) during inpatient hospital stay.,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Post operative complications beyond hospital discharge.
11832,NCT00516841,Efficacy as measured by objective response rate (ORR). Tumor response based on RECIST criteria.,2007-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,
11833,NCT00089401,Duration of response,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life
11834,NCT02964260,Overall survival,2016-05,UNKNOWN,INTERVENTIONAL,['NA'],,Times of interventional procedures
11835,NCT04889495,Safety profile,2024-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Efficacy profile
11836,NCT05779553,Tumor endothelial marker 1 in colorectal cancer,2023-05-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
11837,NCT02070146,Progression free survival,2013-05,RECRUITING,OBSERVATIONAL,['NA'],,Work Ability Index (WAI)
11838,NCT04460066,major pathologic response rate,2020-11-18,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,adverse events rate
11839,NCT01304160,Number of participants with adverse events,2010-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall survival
11840,NCT03080701,CRC Screening Within 6 Months Following Randomization,2017-03-23,COMPLETED,INTERVENTIONAL,['NA'],,
11841,NCT04069975,Detection rate of precancerous lesions and cancer of upper digestive system improvement,2019-06-02,UNKNOWN,OBSERVATIONAL,['NA'],,
11842,NCT01042743,surgical quality based on pathological examination,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,complication
11843,NCT03979547,Acceptability-scientifically adequate,2019-01-03,TERMINATED,INTERVENTIONAL,['NA'],,visceral adipose tissue (VAT)
11844,NCT02248805,Characterize dose limiting toxicity and establish a maximum tolerated dose and schedule,2014-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Describe any evidence of anti-tumor activity
11845,NCT01570582,24month progression free survival,2010-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Toxicity Profile
11846,NCT03913962,Maximal lipid oxidation rate during submaximal incremental exercise,2019-05-02,RECRUITING,INTERVENTIONAL,['NA'],,Blood sample calprotectin
11847,NCT03473925,Number of Participants Who Discontinue Study Treatment Due to an AE,2018-04-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Navarixin Trough Plasma Concentration (Ctrough)
11848,NCT02626091,Correlation between the perfusion evaluated by the ICG fluorescence-based enhanced reality and the metabolic state of the intestine,2016-09-14,COMPLETED,INTERVENTIONAL,['NA'],,Distance between the resection site based on the surgeon's appreciation and the resection site based on the digital analysis and the peri-operative samplings
11849,NCT04859400,QoL,2021-06-07,RECRUITING,INTERVENTIONAL,['NA'],,Success of recruitment rate in comparison to former studies
11850,NCT02718859,Relief degree,2016-03-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival（OS）
11851,NCT01175447,Maximum tolerated dose (MTD) of s-1 in combination with thoracic radiotherapy in elderly patients (> 70 years old) with esophageal Cancer,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Objective response rate (e.g. complete response [CR], partial response [PR], stable disease [SD], or progressive disease [PD])."
11852,NCT04893252,Objective response rate,2021-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
11853,NCT03013972,Cancer-related fatigue evaluation by brief fatigue inventory-Taiwanese form(BFI-T),2015-11,UNKNOWN,OBSERVATIONAL,['NA'],,Quality of life assessments by functional assessment of cancer therapy-general 7 (FACT-G7)
11854,NCT03561350,MSI status in blood sample,2017-09-28,UNKNOWN,OBSERVATIONAL,['NA'],,
11855,NCT02651701,the concordance rate between rectal cancer staging performed by WB MR-PET and the current standard of care (chest/abdominopelvic CT and rectal MRI,2016-01,COMPLETED,OBSERVATIONAL,['NA'],Transient dyspnea,concordance rate of clinical stagings and true M staging obtained by biopsy or follow-up
11856,NCT05286099,Effective detection of early hepatocellular carcinoma,2022-01-15,UNKNOWN,OBSERVATIONAL,['NA'],,
11857,NCT05571956,simultaneous establishment of pancreatic ductal adenocarcinoma organoids and cancer-associated fibroblasts,2020-07-01,RECRUITING,INTERVENTIONAL,['NA'],,
11858,NCT03381352,Response rate,2015-12-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse events
11859,NCT03736824,Correlation of endoscopic findings and symptoms,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,The infection rate of Helicobacter Pylori
11860,NCT03867799,Disease Control Rate (DCR),2019-03-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
11861,NCT05880667,To assess the ability of adaptive SBRT to deliver increased doses of radiation safely to patients with challenging anatomical locations of metastatic disease without causing unacceptable toxicity.,2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,
11862,NCT00088660,,2004-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
11863,NCT03211598,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2016-10,UNKNOWN,INTERVENTIONAL,['NA'],,FACT Hep4 Questionnaire
11864,NCT01732783,Percentage of Participants With at Least One Concomitant Chemotherapy Dose Delay,2012-12-10,COMPLETED,OBSERVATIONAL,['NA'],,Type of Post-Panitumumab Anti-cancer Treatment
11865,NCT00232453,Assess acute toxicity and complete remission rate of combined preoperative radiation and chemotherapy,2001-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11866,NCT03506529,CT scan with measurement,2018-09-17,COMPLETED,OBSERVATIONAL,['NA'],,
11867,NCT03123042,detection rate (%),2017-03-20,RECRUITING,INTERVENTIONAL,['NA'],,False negative rate
11868,NCT04789486,Compare Local Control at 12 months of Maximum tolerated dose MTD - Phase 2,2021-05-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of Life (QoL)-Completion of Daily Activities utilizing PROMIS Physical and Mental Health batteries
11869,NCT00156975,Disease free survival,2004-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"Secondary outcomes:overall survival,acute- and longtime toxicity of chemotherapy, molecular predictive markers for the risk of relapse and toxicity"
11870,NCT04937673,biomarkers related to pCR,2021-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety
11871,NCT03027427,Clinical and laboratory evaluation and molecular profiling of tumor tissue,2017-02-01,RECRUITING,OBSERVATIONAL,['NA'],,
11872,NCT02090153,Overall Response Rate (ORR),2011-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse Events (AEs)
11873,NCT03753399,Average trajectory of C-ESAS over time,2019-01-04,COMPLETED,INTERVENTIONAL,['NA'],,Number of Circulating tumor cells detected using microfluidic chip
11874,NCT05800054,Body weight and body mass index (BMI),2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],,ORR
11875,NCT03505229,freedom of local failure,2018-12-18,RECRUITING,INTERVENTIONAL,['NA'],,Feasibility of Using Kilovoltage Intra-fraction Monitoring (KIM) to determine pancreas motion
11876,NCT00352131,Maximum tolerated dose,2005-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Antitumor activity
11877,NCT00433550,Confirmed Tumor Response Rate (Proportion of Participants With Complete Response),2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Treatment Failure
11878,NCT05189171,MOS generation,2022-10-25,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
11879,NCT00514228,Progression-free survival,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Serum alpha fetoprotein level
11880,NCT01830582,determine the best MR imaging schedule,2013-04-09,COMPLETED,INTERVENTIONAL,['NA'],,Determine if the best imaging schedule for DCE is the same as for DWI
11881,NCT02405416,Normalized transection-related blood loss,2015-03,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative mortality
11882,NCT03509298,Objective response rate,2018-04-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Symptom remission rate
11883,NCT02448173,Disease-Free Survival,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Recurrence-Free Interval
11884,NCT04517227,Discontinue rate caused by any AEs,2021-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
11885,NCT03553004,Objective Response Rate (ORR),2019-01-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Proportion of participants with adverse events (AEs)
11886,NCT03837782,overall survival,2019-02-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,
11887,NCT04280666,"sensitivity, specificity, positive predictive value, and negative predictive value",2019-06-20,UNKNOWN,OBSERVATIONAL,['NA'],,Characteristics of the gene map and the correlations with clinical characteristics
11888,NCT00385021,The primary objective is to determine if the rate of adverse events among patients receiving chronoFOLFOX plus Avastin is acceptable compared to that in previous studies using the FOLFOX4 regimen.,2006-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
11889,NCT00930410,The principal outcome is the percentage of successful in vivo examination according to the localisation of the stenosis. A successful examination is defined by the obtention of exploitable image for the anatomopathology.,2008-09,COMPLETED,INTERVENTIONAL,['NA'],,Frequency and grade of adverse effects induced by the confocal endomicroscopy
11890,NCT00036959,,2002-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11891,NCT01055743,To assess the clinical benefit of fluorouracil implants regional chemotherapy during the radical resection in early stage hepatocellular carcinoma patients. The primary endpoint is disease-free survival (DFS).,2009-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse Events
11892,NCT03082053,Determine the DLT(Dose Limiting Toxicity) and MTD(Maximum Tolerated Dose) or Recommended Phase II Dose (RP2D) in Phase I setting.,2017-01-31,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Pharmacokinetics: varlinitib, capecitabine and 5-FU metabolites levels in terms of Elimination half-life of Phase β (t1/2β)"
11893,NCT04920032,Percentage of ctDNA positivity in treatment cohort after 6 cycles or at least 3 months of adjuvant treatment,2021-08-26,RECRUITING,INTERVENTIONAL,['PHASE1'],,Percentage of Grade 3-5 Adverse Events
11894,NCT03712774,Quality of life,2018-10-12,RECRUITING,OBSERVATIONAL,['NA'],,late toxicity
11895,NCT00875147,Overall complications,2009-04,COMPLETED,OBSERVATIONAL,['NA'],,"specific complications such as liver insufficiency, length of hospital stay"
11896,NCT04103398,Overall Survival,2019-10-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Scoring of Quality of Life
11897,NCT03447106,cost of treatment,2018-02-28,UNKNOWN,INTERVENTIONAL,['NA'],"the all number of postoperative complications（ frequency,reflux esophagitis and bile reflux gastritis）",the operation time
11898,NCT02305043,Percentage of Participants With Objective Response,2014-03,COMPLETED,OBSERVATIONAL,['NA'],,overall survival
11899,NCT05179889,Disease free survival (DFS),2021-07-06,ENROLLING_BY_INVITATION,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Incidence of treatment-related adverse events
11900,NCT06206603,Traceability of microRNA/mRNA expression of polyps and cancer in blood,2024-01,RECRUITING,OBSERVATIONAL,['NA'],,Correlation of Intestinal microbiota and microRNA/mRNA expression
11901,NCT01280825,Feasibility of incorporating pharmacogenomic testing into routine medical care,2011-01-14,RECRUITING,OBSERVATIONAL,['NA'],To determine whether access to pharmacogenomic information improves satisfaction with care.,Find out whether availability of pharmacogenomic information impacts drug decision making in the health care setting
11902,NCT01259024,Monitor Safety After Treatment of DEB by Measuring Liver Function Tests and Assessing Performance Status.,2011-12,TERMINATED,INTERVENTIONAL,['NA'],,To Track Survival Following Treatment With DEB to Confirm That Any Gains in Response Are Associated With an Increase in Survival.
11903,NCT00820053,Overall survival,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to recurrence
11904,NCT03565354,Preoperative change in serum ferritin (mcg/L),2018-07-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Median waiting time to surgery (days),Days (alive and) at home within 30 days of surgery (DAH30)
11905,NCT04720430,"Incidence of ""Wait List Drop Off""",2019-12-03,COMPLETED,OBSERVATIONAL,['NA'],,Clinical Status of the subset of patients successfully reaching liver transplant
11906,NCT05101889,Severe oral mucositis graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 criteria,2013-01-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,overall survival (OS)
11907,NCT00253617,,na,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,
11908,NCT05871567,survival rate,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,recurrence rate
11909,NCT02424279,Change from baseline pain intensity at 1 year (BPI questionnaires),2014-09,UNKNOWN,INTERVENTIONAL,['NA'],,"Quality of life and pain intensity measurement (measured with the QLQ- C30, FACIT and BPI questionnaires)"
11910,NCT03278444,Overall Survival,2017-07-18,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Chinese Quality of Life Questionnaire - EORTC QLQ-C30 score
11911,NCT00578201,"objective response rate (ORR) at 12 weeks with radiochemotherapy (first evaluation), and if applicable, within 2 to 4 weeks following the end of additional treatment with the combination Cetuximab-FOLFOX (second evaluation)",2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression free survival Quality of life Dysphagia score Overall survival toxicity of this regimen
11912,NCT02008383,Objective response rate (ORR) of cabozantinib monotherapy in patients with prospectively identified MET amplified metastatic colorectal cancer,2014-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,To describe the safety and tolerability of cabozantinib monotherapy in patients with MET amplified colorectal cancer
11913,NCT01676922,Treatment duration in patients receiving chemotherapy with Avastin as first-line therapy in daily clinical practice,2011-08,COMPLETED,OBSERVATIONAL,['NA'],,Correlation between Comprehensive Geriatric Assessment (CGA) scores and initial treatment
11914,NCT04678492,Helicobacter pylori eradication,2020-12-20,COMPLETED,INTERVENTIONAL,['PHASE4'],,adverse events
11915,NCT01839981,Overall Survival,2013-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Safety profile assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
11916,NCT00661882,"Development of the Pancreatic Cancer Collaborative Registry (PCCR) infrastructure as a repository for socio-demographic, environmental, clinical, and family history data",2003-02,COMPLETED,OBSERVATIONAL,['NA'],,
11917,NCT00464295,To evaluate response rate and overall survival after completing minimum of three cycles of Capecitabine in Advance HCC,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To evaluate the time to progression, toxicity and quality of life for patients on chemotherapy"
11918,NCT00429858,Correlate Intratumoral Expression Level of Ribonucleotide Reductase Subunit 1 (RRM1) With Response to Gemcitabine in Patients With Advanced Pancreatic Cancer.,2007-01-22,TERMINATED,INTERVENTIONAL,['PHASE2'],,Percentage of Patients With at Biomarker Response
11919,NCT02504411,Complete adenoma resection rate (CARE) for adenoma > 10 mm in diameter as determined by Colonoscopy,2015-08,WITHDRAWN,INTERVENTIONAL,['NA'],,Cecal Intubation Rate (CIR)
11920,NCT05029453,Progression Free Survival [PFS],2021-08-26,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Adverse Events [AEs]
11921,NCT06317272,Reproducibility DIBH,2021-02-10,TERMINATED,INTERVENTIONAL,['NA'],,
11922,NCT04591821,QoL,2018-02-15,COMPLETED,OBSERVATIONAL,['NA'],,Correlation LARS score QoL
11923,NCT01801852,Occurrence of study related adverse events,2013-01,UNKNOWN,INTERVENTIONAL,['NA'],,Anti-tumor responses to NKT cells infusions
11924,NCT02852096,The positive rate of cohort using dual or multiple tumor tissue paraffin blocks,2015-11,UNKNOWN,INTERVENTIONAL,['NA'],,
11925,NCT05039333,Complication rate,2021-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,
11926,NCT04894370,Progression-Free Survival (PFS) rate at 1 year.,2022-06-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression-Free Survival (PFS) median.
11927,NCT04246970,Progression in the activities of daily life (ADL),2021-04-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Change in Quality of life
11928,NCT00848237,Adverse Event Incidence,2007-07,COMPLETED,INTERVENTIONAL,['NA'],,
11929,NCT00005638,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11930,NCT02675946,Number of participants with adverse events and/or abnormal laboratory values that are related to treatment,2016-02,UNKNOWN,INTERVENTIONAL,['PHASE1'],,CGX1321 half-life
11931,NCT02429622,Disease-free survival (DFS),2015-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Adverse events,Overall survival (OS)
11932,NCT01609309,3-year disease free survival rate,2012-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Inflammatory and immune response
11933,NCT01841294,Dosage of NKs activity after surgery,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Major adverses events
11934,NCT06152471,Occurrence of Abemaciclib induced diarrhea - STIDAT,2023-06-07,RECRUITING,INTERVENTIONAL,['PHASE3'],,Breast cancer recurrence
11935,NCT03497819,The Percentage of Adverse Events (AEs) ≥ grade 3 assessed through MedDra and CTCAE v4.03 [Time frame: from infusion to 3 month afterward],2017-10-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Overall Response Rate defined as any improvement measured by imaging following RECIST 1.1 [Time Frame: Day 14 and 1 month after infusion]
11936,NCT04562428,FACT-G,2020-11-20,UNKNOWN,INTERVENTIONAL,['PHASE4'],,pulse diagnosis
11937,NCT04228601,Objective Response Rate,2020-01-21,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to maximum concentration (Tmax)
11938,NCT05730673,"Overall response rate (ORR, defined as Complete Response (CR) + Partial Response (PR)) in subjects with CCR5+ mCRC treated with Leronlimab (PRO 140) and Regorafenib.",2022-09-20,WITHDRAWN,INTERVENTIONAL,['PHASE2'],"Measure serum level of CCL2, CCL3, CCL4 and CCL5 and correlate with therapeutic benefit (PFS) in patient with mCRC.",The change from baseline in circulating tumor cells (CTC) in the peripheral blood.
11939,NCT04803994,Time to failure of treatment strategy,2021-07-06,RECRUITING,INTERVENTIONAL,['PHASE3'],Exploratory endpoint - PD-L1 expression,QoL (EORTC QLQ-C30 and HCC18 sub-questionnaire)
11940,NCT03439891,Overall response rate (ORR) (Part 2),2018-04-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Proportion of participants with Child Pugh B Liver Function reporting immune-related adverse event (irAE)
11941,NCT05678257,Number of patients achieving progress-free survival (PFS),2023-04-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of patients reporting treatment-emergent adverse events (TEAEs)
11942,NCT00254267,The objective response rate as assessed by modified RECIST,2005-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Duration of response, progression-free survival, time to response, overall survival, PK and safety profile"
11943,NCT01599052,Social cognitive performance,2011-03,COMPLETED,OBSERVATIONAL,['NA'],,Influence of Biographical/Medical characteristics
11944,NCT00324415,Local Failure Rate at 3 Years,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Objective Response Rate (Complete and Partial)
11945,NCT02120885,QoL(quality of life),2014-03-14,COMPLETED,INTERVENTIONAL,['PHASE3'],,nutrition condition
11946,NCT02956876,Number of side effects of chemotherapy for WHO grade greater than 2,2016-12-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Number of provisional chemotherapy orders
11947,NCT03218423,Detection of colorectal cancer,2017-08-18,UNKNOWN,OBSERVATIONAL,['NA'],,Assay Failure Rate
11948,NCT06135649,Metastatic involvement of second nodal echelon,2013-01,RECRUITING,OBSERVATIONAL,['NA'],,Recurrence-free survival
11949,NCT00587236,Compare the dysplasia detection rate between scope modalities and biopsy type; surveillance or targeted biopsies in CUC patients with concurrent PSC.,2006-03,COMPLETED,OBSERVATIONAL,['NA'],,Assess the impact of patient related factors on the difference in dysplasia detection rate between while light colonoscopy and the AFI and NBI techniques in patients with CUC and concurrent PSC.
11950,NCT05786924,Dose Expansion: Progression-free survival (PFS),2023-04-18,RECRUITING,INTERVENTIONAL,['PHASE1'],,Dose Escalation/Expansion: Overall survival
11951,NCT04348058,Participation rate to screening colonoscopy within PCSP per recruitment strategy,2020-08-20,UNKNOWN,INTERVENTIONAL,['NA'],,Response rate to invitation to screening colonoscopy
11952,NCT03778957,Progression Free Survival (PFS) for Arm B vs Arm C,2018-11-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Pharmacokinetics (PK) of Durvalumab and Bevacizumab as determined by peak serum concentrations,Disease-related symptoms measured by European Organization for Research and Treatment of Cancer (EORTC) 18-item hepatocellular cancer health-related quality of life questionnaire (QLQ-HCC18)
11953,NCT05176665,Clinical benefit rate(CBR) as assess by RECIST v1.1,2021-10-21,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Clinical benefit rate(CBR) as assess by RECIST v1.1
11954,NCT00005594,The primary outcome measure of this study is to estimate the response rate and observe the time to tumor progression of the patients treated on this study.,2000-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Determine the duration of response in responding patients. Further characterize the safety profile of ISIS 2503 at the recommended dose and schedule.
11955,NCT02971631,Nadir Blood Glucose,2017-08-10,COMPLETED,INTERVENTIONAL,['NA'],,Total Meal Consumption
11956,NCT06282575,Progression Free Survival (PFS) in participants with Immunohistochemistry (IHC) 3+ tumors,2024-03-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,"TDD for all participants in patient-reported symptoms scores as measured by the EORTC QLQ-BIL21 (Pain, Jaundice, Abdominal Pain, and Pruritis)"
11957,NCT04790695,Overall survival,2021-03-29,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11958,NCT03510416,Time To Progression,2018-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall Survival
11959,NCT03781778,Feasibility: Retention,2019-05-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,Variability in Gut Microbial Communities From Human Stool Samples -- BETA DIVERSITY
11960,NCT06173986,Treatment completion rate,2023-01-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of Adverse events (AE) or severe adverse events (SAE)
11961,NCT03011268,Proportion of patients in sustained clinical remission,2017-06-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Adverse events and serious adverse events frequency and severity
11962,NCT03776487,Incidence of adverse events,2019-01-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease-free survival
11963,NCT03934606,baseline to post-results change in distress levels,2018-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
11964,NCT01648504,Completion rate of colonoscopy procedure,2012-06,COMPLETED,INTERVENTIONAL,['NA'],Feasibility of intervention in practice,Patient satisfaction
11965,NCT05606523,Body weight changes in mice after fecal material transplantation.,2022-08-01,RECRUITING,OBSERVATIONAL,['NA'],,GALT function and systemic inflammation
11966,NCT03807687,Overall survival,2016-12-01,RECRUITING,OBSERVATIONAL,['NA'],,Postoperative morbidity
11967,NCT05655949,Incidence of Grade 3 or Higher Treatment-Related Toxicity,2024-02-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease Control Rate (DCR)
11968,NCT03838029,Biomarkers in blood samples,2019-11-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Fatigue
11969,NCT00584363,To diagnose Pancreatic Cancer,2004-06,COMPLETED,OBSERVATIONAL,['NA'],,Preventing patient form being misdiagnosed
11970,NCT02977702,overall survival,2015-12,COMPLETED,OBSERVATIONAL,['NA'],,
11971,NCT04442984,Progression-Free Survival,2019-11-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,Treatment associated toxicities
11972,NCT00032123,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11973,NCT06192030,Peritoneal-free survival,2022-08-27,RECRUITING,OBSERVATIONAL,['NA'],,Rates of key gene mutation
11974,NCT06179459,Treatment outcomes in patients undergoing endoscopic treatment of pancreatic fluid collections.,2021-05-01,RECRUITING,OBSERVATIONAL,['NA'],,Timing of intervention
11975,NCT01273051,Response,2010-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,The number of sphincter saving procedures
11976,NCT06021015,Disease control rate (DCR) of target lesions 1 month after the last TACE treatment,2023-09-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Equipment performance evaluation
11977,NCT03291379,Concentration of N-desmethyl Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814,2017-05-17,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],"Study Tissue Biomarkers to Explore Key Immune, Inflammatory and Drug Related Mechanisms","Assessment of Changes in Blood Flow on Dynamic Contrast-Enhanced (DCE) MRI Following Treatment With BTG-002814. The Following Parameters Will be Derived From DCE-MRI Images: Ktrans, Kep and Ve."
11978,NCT03281369,For Arm 1L-A : Percentage of Participants with Serious and Non-serious Treatment-related AEs,2017-10-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Percentage of Participants With ADA to BL-8040
11979,NCT05411926,4) the dose and drug concentration of tacrolimus after liver transplantation in patients with hepatocellular carcinoma;,2021-03-17,UNKNOWN,OBSERVATIONAL,['NA'],,5) the overall survival (OS) and relapse-free survival(RFS) after liver transplantation in patients with hepatocellular carcinoma.
11980,NCT00901901,Overall Survival,2009-05-21,COMPLETED,INTERVENTIONAL,['PHASE3'],Tumor Response,Health-related Quality of Life and Utility Values as Measured by EQ-5D - VAS
11981,NCT01997957,Time to progression(TTP),2013-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Number of Participants with Serious and Non-Serious Adverse Events
11982,NCT01972451,Procedure time and withdrawal time,2014-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Colonoscopy procedure completeness,Number of people attending the screening
11983,NCT00777504,"Signs of progressive disease on CT-scan, DCE-MRI or Avastin scan",2008-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Effect on Quality of life as record by questionaires
11984,NCT05482451,Overall response,2021-03-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Overall survival,Progression-free survival
11985,NCT06089330,Incidence and severity of adverse events (AE) and serious adverse events (SAE),2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
11986,NCT00630786,Number of Participants With an Objective Response,2008-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Post-baseline Laboratory Values Grade 3 or Higher
11987,NCT02847468,Vital status,2017-03-27,TERMINATED,INTERVENTIONAL,['NA'],,Questionnaire of quality of life (EORTC QLQ-C30)
11988,NCT03976284,Stool weight,2019-03-17,UNKNOWN,INTERVENTIONAL,['NA'],,Sugary beverage intake
11989,NCT00002968,Survival,1997-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Disease-free survival
11990,NCT04632459,Objective Response Rate (ORR),2021-06-16,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Best Overall Response Rate (ORR)
11991,NCT05009979,Positive predictive value,2023-01-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Change in 18F-DCFPyL PET/CT uptake between pre- and post-treatment
11992,NCT02028442,Phase 1b - Selection of suitable schedule for repeat cycle IV administration,2012-09-20,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
11993,NCT05972655,Pathological complete response (pCR) rate,2023-08-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,Validation of the Wexner score
11994,NCT05095467,"3-year Overall Survival, OS",2021-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,NCI CTC Adverse Events Version 4.0
11995,NCT05174169,Disease-Free Survival (DFS),2022-03-10,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Compliance with adjuvant chemotherapy
11996,NCT04393220,OS,2020-05-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11997,NCT00372840,Number of sections of the Facing Forward manual read with satisfaction and comprehension,2006-05,COMPLETED,INTERVENTIONAL,['NA'],,Changes in psychological outcomes from baseline to 8-week follow-up
11998,NCT00843934,response rate,2009-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
11999,NCT04367805,Incidence of COVID-19 infection in patients with hepatocellular carcinoma in France,2020-04-27,RECRUITING,OBSERVATIONAL,['NA'],,
12000,NCT00459901,To document the antitumor activity of capecitabine in combination with erlotinib in patients with previously untreated metastatic colorectal cancer,2004-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,To determine the qualitative and quantitative toxicity of this combination and sequence of drug administration
12001,NCT05518929,Incidence of hypoxia and severe hypoxia,2022-09-08,RECRUITING,INTERVENTIONAL,['PHASE4'],,Proportion of corrective hypoxic measures
12002,NCT02430298,"Percentage of occurrence of mucositis level 3 or more by using the criteria of CTCAE version 4.0, World Health Organization scale and MTSscores",2013-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life (FACT- H&N Version 4)
12003,NCT06254248,Rate of Acute cellular rejection (ACR) (defined by a Histological Banff score ≥ 5) at 6 months (confirmed by an external expert center),2024-05-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Donor Specific Antibodies (DSA) median
12004,NCT02662959,Overall Survival,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of Adverse Events
12005,NCT04901741,Go/no-go decision for a randomized expansion study,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Time-to-next-anticancer-treatment (TTNT)
12006,NCT01420588,Discrimination between Malignant and Benign Gastric Lesions with Na-nose,2011-08-01,COMPLETED,OBSERVATIONAL,['NA'],Proof seeking from metabolomics and transcriptomics,Geographical comparison of VOCs between China and Latvia
12007,NCT05996666,Performance of liver cancer early detection model based on selected cfDNA methylation markers using qPCR,2023-07-01,RECRUITING,OBSERVATIONAL,['NA'],,Comparison of currently used biomarkers for liver cancer detection
12008,NCT03049215,Decrease in Pancreatic Fluid Collection (PFC),2017-11-06,TERMINATED,INTERVENTIONAL,['NA'],,Incidence of Early (<30 Days) Endoscopic Reintervention
12009,NCT00042510,To evaluate the effects of G17DT in combination with cisplatin and 5-FU chemotherapy on tumor response assessed by radiographic means.,2000-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To evaluate the clinical efficacy of G17DT in combination with cisplatin and 5-FU chemotherapy as measured by time to disease progression, best overall response and survival."
12010,NCT04276857,1 year progression free survival rate of patients with locally advanced pancreatic cancer who are treated with IRE and combination chemotherapy.,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Prognostic bio-markers
12011,NCT00225290,overall survival,2003-02,TERMINATED,INTERVENTIONAL,['PHASE3'],,
12012,NCT00242190,Occurrence of dose limiting toxicity up to three weeks following the second cycle of chemotherapy.,2004-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Characterize pattern of responses, progression free survival, and survival after treatment"
12013,NCT03426371,Progression Free Survival (PFS) Time,2018-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,quality of life score
12014,NCT03167268,Skin toxicity reduction,2016-08-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
12015,NCT01412294,Progression-free survival,2011-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of Participants with Adverse Events as a Measure of Safety and Tolerability
12016,NCT04427761,Extent of the change experienced by patients with pancreatic cancer,2020-06-05,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
12017,NCT00289003,"To assess actual grade of mucositis upon completion of radiotherapy or chemoradiotherapy and after prophylactic treatment with soluble beta-1,3/1,6-glucan or placebo.",2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,To assess the safety of the investigational product
12018,NCT00897741,Gene expression profiles,2004-12,COMPLETED,OBSERVATIONAL,['NA'],,
12019,NCT04339374,Area under the receiver operating curve (ROC),2017-07-19,RECRUITING,OBSERVATIONAL,['NA'],,Performance characteristics of the novel endorectal ultrasound probe as measured by variability in image production
12020,NCT04358185,To assess efficacy of Itacitinib by overall response rate: objective response rate (ORR),2018-12-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Correlation of JAK1 mutations with treatment,Efficacy of Itacitinib by overall survival
12021,NCT01802684,Progression free survival at 6 months,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Curative salvage surgery
12022,NCT00556023,Dose Limiting Toxicities: assessed through adverse event data collected weekly,2008-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression-Free Survival:
12023,NCT05939661,Pathological complete response (pCR),2023-05-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,
12024,NCT01474187,toxicity,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE1'],,pathological complete response (pCR)
12025,NCT00004861,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12026,NCT03959800,Tumor infiltrating cells which express immune checkpoints,2015-06-22,RECRUITING,OBSERVATIONAL,['NA'],,Response to chemotherapy
12027,NCT06165094,Overall survival,2009-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
12028,NCT00583934,"Early detection of esophageal cancer or dysplasia in patients without symptoms, after treating their primary cancer, may improve their chances of being cured of a secondary disease.",2007-09,COMPLETED,OBSERVATIONAL,['NA'],,
12029,NCT02150408,"interest of the realization of 68Ga-DOTATATE PET-CT in the detection of tumor sites in TNE diagnosis, staging and restaging",2014-04-22,COMPLETED,INTERVENTIONAL,['NA'],"therapeutic impact of 68Ga-DOTATATE PET-CT in addition to reference imaging (SRS, CT, MRI): we will document the rate of changes in treatment options induced by PET-CT","therapeutic impact of 68Ga-DOTATATE PET-CT in addition to reference imaging (SRS, CT, MRI): we will document the rate of changes in treatment options induced by PET-CT"
12030,NCT01540968,Quality of life,2012-03,COMPLETED,INTERVENTIONAL,['NA'],,
12031,NCT05085548,Determine Recommended Phase 2 Dose (RP2D),2021-10-29,RECRUITING,INTERVENTIONAL,['PHASE1'],,Assess serum tumor marker CA19-9 or appropriate tumor specific marker.
12032,NCT02639403,Change of the obstructive symptoms,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Obstruction/colostomy-free survival
12033,NCT03784326,Pathological complete response (PathCR),2019-02-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,Tumor regression determined by CT or MRI
12034,NCT05022654,Optimal combination dose (only IIa),2021-12-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,ADA
12035,NCT01531452,Progression Free Survival,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,number of participants with adverse events
12036,NCT03058926,"Protocol and Regulatory Compliance for Consortium Studies for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC)",2017-01-19,UNKNOWN,OBSERVATIONAL,['NA'],,
12037,NCT00582062,The primary objective of this pilot trial is to investigate the ability of quantitative RT-PCR to detect cancer cells in peritoneal washings of patients undergoing laparoscopy for gastric or pancreatic cancer.,2006-03,COMPLETED,OBSERVATIONAL,['NA'],,"The secondary objective of this pilot study is to estimate the sensitivity, specificity, false positive, and false negative rate of peritoneal cancer cell detection by quantitative RT-PCR."
12038,NCT01280643,"Feasibility, Defined as a Sufficient Proportion of Subjects Having Available Tissue and an Acceptable Composite Assay Success Rate Among Tested Subjects",2010-03,TERMINATED,INTERVENTIONAL,['NA'],,Progression-free Survival
12039,NCT03634202,"maximum tolerated radiation dose (MTD) delivered by IMRT with SIB, in combination with oral capecitabine, for initially metastatic, low and middle rectal cancer after 4 induction cycles of mFolfox6 regimen.",2015-05-05,TERMINATED,INTERVENTIONAL,['NA'],,The prognostic value of PET
12040,NCT01652976,Progression Free Survival (PFS),2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Quality of Life, as Measured by the Functional Assessment of Chronic Illness Therapy; Hepatobiliary Cancer (FACT-Hep) Questionnaire (Version 4.0)"
12041,NCT00520013,Consolidation Treatment-related Toxicity Rate,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Consolidation Objective Response Rate
12042,NCT01882218,Morbidity,2012-09,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,Cytokine levels
12043,NCT04096417,Overall Response Rate (ORR),2020-08-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events
12044,NCT03395847,Objective response rate (ORR),2018-02-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Incidence of adverse events
12045,NCT02967107,Number of participants with residual or recurrent adenoma as assessed at surveillance endoscopy,2016-06,COMPLETED,INTERVENTIONAL,['NA'],,Number of participants with pain after EMR as assessed by VAS score and telephone interview at 2 weeks
12046,NCT04274972,Microbiome evaluation,2020-02-01,RECRUITING,OBSERVATIONAL,['NA'],,Microbiome long-term evaluation
12047,NCT01846611,Overall Survival (OS),2013-10-16,COMPLETED,INTERVENTIONAL,['PHASE3'],,Objective Response Rate (ORR)
12048,NCT05788744,Sub-study 2 eccDNA,2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],,
12049,NCT03581344,TRG (Tumor Regression Grade),2018-10-01,UNKNOWN,INTERVENTIONAL,['NA'],,Impact of therapy on quality of life (QoL)
12050,NCT06253897,Qualitative interview: patients' injection experiences and satisfaction with the Ipsen lanreotide syringe and with the Pharmathen lanreotide syringe;,2024-03-26,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Qualitative interview: experiences that are unique to patients between disease indications
12051,NCT01447199,Time to Onset for Colorectal Cancer,1994-09,UNKNOWN,OBSERVATIONAL,['NA'],,
12052,NCT01628328,Changes of circulating tumor cell level before and after colonic stenting for patients with obstructive colorectal cancer,2010-07,COMPLETED,OBSERVATIONAL,['NA'],,
12053,NCT06256328,Progression-free survival (PFS) (site investigator assessment),2023-12-06,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse event (AE)
12054,NCT00040898,,2001-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12055,NCT02727179,Overall survival,2005-02,COMPLETED,INTERVENTIONAL,['NA'],,Morbidity
12056,NCT05494866,occurrence of DLTs,2022-12-07,RECRUITING,INTERVENTIONAL,['PHASE1'],,
12057,NCT00608361,Pharmacokinetic parameters of dasatinib,2008-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Liver dysfunction data,
12058,NCT03602092,To establish the database for GIST,2018-10-16,RECRUITING,OBSERVATIONAL,['NA'],,
12059,NCT03257761,Tumor response (dose expansion),2018-02-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-free survival
12060,NCT01855854,Objective response rates,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
12061,NCT00103545,The primary endpoint is drop-out due to toxicity as the overall measure of feasibility,2003-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Duration and strength of the immune response induced by ACA 125 vaccination
12062,NCT00003950,Reduction in occurrences of severe diarrhea due to CPT-11 administration,2000-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12063,NCT02135887,"The primary endpoint is the incidence of grade 4 neutropenia during the chemotherapy period, defined as an absolute neutrophil count (ANC) <500/mm3.",2013-11-04,UNKNOWN,OBSERVATIONAL,['NA'],,Increase in Body Weight
12064,NCT03798132,peritoneal carcinomatosis,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,surgical decision making.
12065,NCT02402972,disease-free survival,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,adverse events of Chemotherapy and IPC
12066,NCT00785889,Increments of medications used for sedation,2008-03,COMPLETED,INTERVENTIONAL,['NA'],,willingness to repeat colonoscopy
12067,NCT03524274,Objective response rate,2018-04-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Symptom remission rate
12068,NCT02489422,Fatigue Assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS),2016-08,COMPLETED,INTERVENTIONAL,['NA'],,Number of Participants With Successful Qualitative Data Collection
12069,NCT05108753,incidence of anastomotic leakage,2017-02-01,COMPLETED,OBSERVATIONAL,['NA'],,incidence of positivecircumferential resection margin
12070,NCT01193517,"Maximum Tolerated Dose (MTD) of Azacitidine, and Capecitabine and Oxaliplatin (CAPOX)",2010-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Response Rate of Azacitidine, and Capecitabine and Oxaliplatin (CAPOX)"
12071,NCT06118437,Overall detection rate of gastrointestinal cancer,2023-11-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
12072,NCT04920422,Percentage of patients that follow each dosing patterns during first two cycles of treatment,2021-07-15,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of patients that start cycle 3 based on dosing patterns.
12073,NCT04179305,Change in Prognostic Understanding,2020-10-25,COMPLETED,INTERVENTIONAL,['NA'],,Patient Performance Status
12074,NCT02115542,Overall Survival (OS) at 6 Months,2014-06-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival (PFS)
12075,NCT03970616,Incidence of Treatment Emergent Adverse Events (TEAEs),2019-09-30,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
12076,NCT04503902,Objective response rate（ORR） as determined by the Invertigator using RECIST V1.1,2020-10-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression free survival (PFS)
12077,NCT01447667,Number of patients who experienced HCC recurrence after RFA,2011-10,COMPLETED,INTERVENTIONAL,['NA'],,Sensitivity and specificity of each indicator of hepatic fibrosis compared to the gold-standard histology score
12078,NCT03774134,Risk of recurrence,2008-06-01,UNKNOWN,OBSERVATIONAL,['NA'],,Mesocolic lymph nodes yield
12079,NCT03608540,Incidence of all Adverse Device Effects,2018-07-09,TERMINATED,INTERVENTIONAL,['NA'],,R0 resection
12080,NCT01365169,ECOG Performance Status,2011-05-25,RECRUITING,INTERVENTIONAL,['NA'],,"CYCORE Data availability for clinicians and researchers in order to be able to daily monitor patients using home-based health monitor devices (e.g. Fitbit, Actigraph, CO monitor, weight scales)."
12081,NCT00290693,Rate of Participants Achieving Complete Response or Partial Response to Therapy.,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Study Participants Experiencing Toxicity After Receiving Protocol Therapy
12082,NCT04595747,Objective radiographic response,2021-05-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],"Banking of tumor material, germline deoxyribonucleic acid, and peripheral blood",Incidence of adverse events
12083,NCT01640444,progression free survival (PFS),2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Correlation of molecular status of bio markers related to the cellular and tumoral reproduction and/or mode of action and clinical anti-tumour activity outcome ( PFS, OS, RR)"
12084,NCT00202787,Determine confirmed objective response rate,2005-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,"determination of polymorphisms of the intron 1 of the EGFR gene, TS, XRCC1, XPD, serum levels of EGFR and ATP7A and ATP7B, nº of copies of EGFR gene, the levels of PTEN, EGFR, AKT y MAPK proteins, and mutations at EGFR, PI3KCA, K-RAS y B-RAF genes"
12085,NCT05087992,Phase 1b: Number of patients with DLTs during the MTD evaluation period assessed in the first 6 patients,2021-11-24,COMPLETED,INTERVENTIONAL,['PHASE1'],,Phase 1b: AUC0-t2: Area under the concentration-time curve of BI 9057 after multiple cycles
12086,NCT05334251,sPO2,2022-04,UNKNOWN,OBSERVATIONAL,['NA'],,
12087,NCT05683470,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
12088,NCT01682031,Incidence of >= Grade 3 Mucositis,2009-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Plasma Cisplatin and Selenium PK and PD Markers (NZ Only)
12089,NCT01444547,Overall response rate (ORR),2007-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Time to event efficay
12090,NCT03992599,3 year disease-free survival (DFS),2019-08-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Distribution of metastatic LNs
12091,NCT02074124,Change in arterial flow during adenosine vasodilation test (CT perfusion parameter),2012-10,COMPLETED,OBSERVATIONAL,['NA'],,Change in Permeability (CT perfusion parameter) during adenosine vasodilation test.
12092,NCT03155542,colorectal cancer diagnosis,2016-12,COMPLETED,OBSERVATIONAL,['NA'],,
12093,NCT02041065,Peroperative bloodloss,2011-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Hospital stay in days
12094,NCT00524316,Progression-free Survival,2007-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Tumor Marker Response (AFP)
12095,NCT04729205,Evaluate Disease Control Rate,2021-01-13,TERMINATED,INTERVENTIONAL,['PHASE1'],,Plasma MLP level after Promitil infusion
12096,NCT01939210,Changes in the length of the end expiration or end inspiration defined as when the breathing trace or internal motion change direction,2010-02,TERMINATED,INTERVENTIONAL,['NA'],,"Change in patients' self-reported levels of psychological distress, physical pain and discomfort, and post-traumatic stress associated with cancer diagnosis and radiation treatment"
12097,NCT05836584,Event-free survival (EFS),2023-12-06,RECRUITING,INTERVENTIONAL,['PHASE2'],,Circulating tumor-derived deoxyribonucleic acid (ctDNA)
12098,NCT01409733,Proportion of patients completing scheduled treatment plan,2010-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
12099,NCT06265272,Assessment of LI-RADS with Ga-PSMA-PET/MRI,2023-12-10,RECRUITING,OBSERVATIONAL,['NA'],,PET/MR protocol in liver cirrhosis
12100,NCT02967770,4 month progression free survival rate,2016-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Change in tumor marker levels
12101,NCT01851174,Overall Survival Based on Toxicity Profile of Adverse Events.,2013-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival Time
12102,NCT04109755,Tumour regression grade,2020-06-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,EORTC QLQ-CR29
12103,NCT01272557,Time to progression (TTP) according to RECIST 1.1 criteria,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"• Assessment of overall survival (OS) of disease control rate (CR, PR, SD) to RECIST 1.1 criteria and to EASL criteria • Assessment of safety and quality of life (FACT-Hep) and potential of biomarkers to predict the tumor response"
12104,NCT00369109,Level of p-Chk1 and phospho-histone 2AX (p-H2AX) and possibly downstream pathway markers in hair follicles from skin biopsies of patients treated with gemcitabine hydrochloride or irinotecan hydrochloride for advanced solid tumors,2006-02,COMPLETED,OBSERVATIONAL,['NA'],,Dynamic time course of p-Chk1 and p-H2AX after administration of a DNA-damaging agent
12105,NCT02795988,Clinical efficacy of IMU-131 (Phase 2),2017-08-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Exploratory Outcome (Phase 2): Measurement of immunological and biochemical markers,Incidence of TEAE's (Phase 2)
12106,NCT06181656,Impact of grade IV radiation-induced lymphopenia on serologic responses to pneumococcal vaccination,2024-02-05,RECRUITING,OBSERVATIONAL,['NA'],,
12107,NCT00172757,,2002-01,UNKNOWN,OBSERVATIONAL,['NA'],,
12108,NCT01051284,To demonstrate that radiation treatments can be reproduced as determined by evaluation of the prescription isodose curves,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,The feasibility of measuring pancreatic cancer stem cell populations by analysis of fine needle aspirate specimens
12109,NCT06044506,Optimal treatment dosage,2022-08-29,RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-free survival
12110,NCT00138242,Reduction rate of myelosuppression,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to disease progression
12111,NCT02915432,Objective response rate (ORR) evaluated based on Response Evaluation Criteria in Solid Tumors (RECIST 1.1),2016-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Correlation of the changes of TBNK lymphocytes subgroup in patients receiving chemotherapy combined with JS001 and its correlation with the anti-tumor activity,Apparent volume of distribution of steady state (Vss) after multiple dose injection of Anti-PD-1 mAb
12112,NCT03283527,Response prediction by EC-PDO,2017-12-01,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival (OS) in months
12113,NCT03502343,Disease control rate,2018-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse event
12114,NCT02734680,Overal survival,2016-02,UNKNOWN,INTERVENTIONAL,['NA'],,Local control rate
12115,NCT04431076,Pancreatic fistula,2020-05-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Return to preoperative exercise capacity
12116,NCT05106244,Degree of satisfaction of patients and their families,2022-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,
12117,NCT02038296,overall survival,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,
12118,NCT05848843,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",2023-04-25,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
12119,NCT00431925,,na,UNKNOWN,OBSERVATIONAL,['NA'],,
12120,NCT00898482,Test new hypotheses as they emerge,2005-05,COMPLETED,OBSERVATIONAL,['NA'],,
12121,NCT01441388,Dose Limiting Toxicities (DLTs).,2011-12,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Peak plasma concentration (Cmax) of crizotinib and each VEGF inhibitor
12122,NCT05750329,Three-year overall survival rate after surgery,2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Postoperative tumor-free survival period
12123,NCT02918162,Pathologic Complete Response (pCR) Rate,2017-11-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Response Rate (ORR)
12124,NCT00494806,Time to First Postoperative Flatus in Days Was the End of Postoperative Ileus (POI) Indicator.,2005-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
12125,NCT01870817,Participant recruitment and retention rates,2012-07,COMPLETED,INTERVENTIONAL,['NA'],,Nutritional parameters
12126,NCT00841035,Epidermal Growth Factor Receptor Signaling(EGFR) in the Presence of Pancreatic Tumor Related to the Mechanism to Erlotinib.,2009-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,The Secondary Objectives Include Analysis of Recurrence-free and Overall Survival and the Development of a Predictive Assay for Response to Erlotinib Based on Selected Bio-markers in Endoscopic Ultrasound-Fine-needle Aspiration Specimens.
12127,NCT01075113,Determine the appropriate Doses for the combination of sorafenib tosylate and vorinostat appropriate for phase II study in hepatocellular carcinoma (HCC).,2010-08-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Anti-tumor effects of the combination of sorafenib tosylate and vorinostat
12128,NCT01777477,Maximum tolerated dose (MTD) of orally administered Chloroquine with concomitant intravenous Gemcitabine.,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12129,NCT04224363,Image Quality,2020-01,UNKNOWN,INTERVENTIONAL,['NA'],,Tolerance
12130,NCT03126708,Progression free survival,2017-04-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
12131,NCT00101686,Time to Progression (TTP) at Primary Completion: FOLFIRI and mIFL,2003-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall Relative Dose Intensity of Irinotecan
12132,NCT01152853,progression-free survival at 4-months (PFS4mo),2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,toxicity
12133,NCT04969874,patient attendance at monthly remote monitoring,2024-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,felt swallowing
12134,NCT03168737,Incidence of adverse events per Common Terminology Criteria for Adverse Events version 4.03,2017-09-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
12135,NCT04601428,HCC blood flow,2021-01-26,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Determine tumor response to intra-arterial infusion of CSR02-Fab-TF
12136,NCT02936193,Progression-free Survival,2017-08-01,UNKNOWN,INTERVENTIONAL,['NA'],,3 years overall survival
12137,NCT01424293,Evaluate the Vascular Supply of the Bowel Intra-operatively and Correlate This With Postoperative Complications Identified During Their Hospital Stay at One Week and One Month Postoperatively.,2010-05,COMPLETED,INTERVENTIONAL,['NA'],,
12138,NCT00961129,supportive cancer care needs,2009-03,UNKNOWN,OBSERVATIONAL,['NA'],,
12139,NCT04434508,the number of lymph nodes (LNs) harvested among both groups,2017-07-01,COMPLETED,INTERVENTIONAL,['NA'],,post-operative complications
12140,NCT02085005,Progression Free Survival rate at 10 months (PFS@10m),2014-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Number of participants with adverse events
12141,NCT04515394,Number of Participants With Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Investigators,2021-01-28,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With At Least 1 Postive Anti-Drug Antibodies (ADAs) for Cetuximab
12142,NCT02156505,The patency rate at 8 weeks after placement.,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,migration rate
12143,NCT03098108,local control rate at 3-year,2017-02-09,UNKNOWN,INTERVENTIONAL,['NA'],,Colonrectum Quality of life (QOL-CR) assessment
12144,NCT00591981,"Morbidity (Cardiac, pulmonary, infectous, etc.) and Mortality in Cohort",2007-08,COMPLETED,OBSERVATIONAL,['NA'],,
12145,NCT03940001,"major pahological response, MPR",2019-05-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,
12146,NCT04623515,Urinary Dysfunction - International Consultation on Incontinence Questionnaire - Female Lower Urinary Tract Symptoms (ICIQ-FLUTS),2021-05-05,TERMINATED,OBSERVATIONAL,['NA'],,Short Form-12 Questionnaire - General Health and Well Being
12147,NCT01515748,"Percentage of Participants With 3-Year Progression-Free Survival (PFS), as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)1.1",2011-12-30,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Shift of Laboratory Parameters (Creatinine Clearance [Chronic Kidney Disease]) From Baseline Grade to Worst NCI-CTCAE Grade >=3
12148,NCT04831944,Pharmacokinetics Parameter : AUC(0-t) of parsaclisib,2021-03-29,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics Parameter : Vz/F of parsaclisib
12149,NCT03328234,Overall survival (OS),2017-09-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Adverse events
12150,NCT03698825,Maximum Tolerated Dose (MTD),2018-08-15,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",pSMAD as a pharmacodynamic marker,pharmacokinetics of TEW-7197
12151,NCT02309788,overall survival,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],,
12152,NCT06008288,Objective response rate (ORR) by independent central radiological review (IRC) according to RECIST 1.1.,2023-10-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with adverse events
12153,NCT03798626,Part 2 (Expansion) and Part 1b (Safety run-in): Progression free survival (PFS) rate [Cohort C subjects at RDE level],2019-05-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of patients with anti-drug antibodies for ramucirumab in the combination regimens
12154,NCT02271464,progression-free survival (PFS),2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall toxicity rate
12155,NCT00137878,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12156,NCT06018142,Perfusion ratio,2022-06-01,RECRUITING,OBSERVATIONAL,['NA'],,
12157,NCT03258034,3 year OS,2017-08-24,UNKNOWN,INTERVENTIONAL,['PHASE2'],,adverse events
12158,NCT01793168,"To accelerate research into rare disorders by connecting individuals who are interested in research and who have been diagnosed with a rare disorder (or a disorder of unknown prevalence, or who are undiagnosed) with researchers who study rare diseases.",2010-07,RECRUITING,OBSERVATIONAL,['NA'],,
12159,NCT01952951,downstaging rate,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,quality of life
12160,NCT04627363,Progression free survival rate at 6 months,2021-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse events
12161,NCT04607590,The patient 6-minute walk test (6-MWT) over the 6-month follow up (6-MFU),2019-05-31,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Treatment efficacy,Patient and partner short form survey (SF-36) domains
12162,NCT03176082,Polypectomies,2016-10,COMPLETED,INTERVENTIONAL,['NA'],,
12163,NCT04631445,Progression-free survival per RECIST 1.1,2020-12-02,RECRUITING,INTERVENTIONAL,['NA'],,To compare quality of life between arms via the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire QLC-C30 (EORTC QLQ-C30) assessment.
12164,NCT02319304,Primary Outcome Measure (Overall Survival Rate),2015-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Secondary Outcome Measure (Number of Adverse Events)
12165,NCT02413853,Progression free survival (PFS),2015-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Intratumoral gene expression of Wnt related biomarkers,Survivin mRNA expression levels
12166,NCT00154752,oncologic results,1999-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,functional results
12167,NCT00569387,The primary objective of this Phase II trial is to assess disease-free survival (DFS) at one (1) year following initiation of treatment as the primary endpoint of the study in subjects treated with the HyperAcute®-Pancreatic Cancer Vaccine,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,We will use overall survival and adverse events rates as secondary endpoints.
12168,NCT05269056,Area under curve of the model for detecting stage I/II gastric cancer,2021-09-01,RECRUITING,OBSERVATIONAL,['NA'],,Area under curve of the early detection model at sequencing depth downsampling
12169,NCT05100082,Number of Participants with Grade 3 or higher Adverse Events,2021-11-17,RECRUITING,OBSERVATIONAL,['NA'],,Overall Survival (OS)
12170,NCT04755920,To determine the feasibility of SGM-101 for intraoperative imaging of colorectal brain metastases.,2022-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
12171,NCT04443478,The number of lower mediastinal lymph nodes retrieved,2020-08-01,RECRUITING,OBSERVATIONAL,['NA'],Number of patients that can be screened and successfully recruited,Overall survival in 3 years
12172,NCT01079533,Colorectal Cancer Screening,2008-07,COMPLETED,INTERVENTIONAL,['NA'],,
12173,NCT02079363,Number of methylated genes for each participant.,2013-08,UNKNOWN,OBSERVATIONAL,['NA'],Number of methylated genes in patients with chronic pancreatitis.,Number of methylated genes for each participant related to prognosis
12174,NCT01959269,Overall survival,2013-10-31,COMPLETED,OBSERVATIONAL,['NA'],,Incidence of treatment emergent adverse events (TEAE)
12175,NCT05304572,feeding vessels detectability,2022-05-01,COMPLETED,OBSERVATIONAL,['NA'],,inter-observer agreement
12176,NCT02585271,Creation of stoma,2015-10-01,TERMINATED,INTERVENTIONAL,['NA'],,Overall survival
12177,NCT02628665,Partial remission rate,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,The recent incidence of adverse reactions
12178,NCT01247298,Local Recurrence Rate,2010-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Percentage of Participants With Local Failure Patterns
12179,NCT04896073,disease control rate,2022-03-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
12180,NCT01232101,The primary aim of the present study was to compare and stent patency between covered and uncovered bileduct SEMS,2007-03,COMPLETED,INTERVENTIONAL,['NA'],,"Secondary objectives were to study difference in technical success, efficacy of drainage and complication rate between covered and uncovered metal stents"
12181,NCT01590732,Incidence of adverse events,2012-10-29,COMPLETED,INTERVENTIONAL,['PHASE1'],,Complete response
12182,NCT04435197,Pathologic complete response,2020-08-11,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
12183,NCT01862198,The stent patency rate,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4'],,Complication rate related to the hybrid stents
12184,NCT05281003,Major hypoxia signals in baseline or post-treatment tumor samples from all eligible participants with locally advanced ESCC,2023-02-20,RECRUITING,INTERVENTIONAL,['PHASE2'],"EFS in eligible participants with locally advanced ESCC, stratified by PD-L1 biomarker expression (CPS ≥10, ≥1 and <1)",Cell lineage-specific hypoxia signals in baseline or post-treatment tumor samples from all eligible participants with locally advanced ESCC
12185,NCT02973672,Number of patients with treatment-related adverse events,2016-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Serum SGM-101 concentrations
12186,NCT04809870,Long-term survival,2020-10-01,COMPLETED,OBSERVATIONAL,['NA'],,Pulmonary complications
12187,NCT00489359,Phase 2 - Percentage of Participants With Overall Tumor Response (Response Rate),2005-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2 - Progression-Free Survival
12188,NCT00453661,Screening Rates,2007-03,COMPLETED,OBSERVATIONAL,['NA'],,Compliance Rate Across 5 Cancer Types
12189,NCT02991092,recovery time of intestinal function,2016-11,UNKNOWN,INTERVENTIONAL,['NA'],body weight（Kg）,hospitalization time after operation（day）
12190,NCT02285660,Whole body 4D PET-CT for improved Target Definition/Delineation (feasibility and benefit) (ability to identify the cancer and ability to show areas within the cancer that are potentially more active allowing target of higher dose to these areas),2011-06,UNKNOWN,INTERVENTIONAL,['NA'],,
12191,NCT04561830,feasibility of procedure,2015-04,COMPLETED,INTERVENTIONAL,['NA'],,recurrence
12192,NCT02815436,Rate of completion of FOBT in the year of receiving the interventions/control,2016-04,COMPLETED,INTERVENTIONAL,['NA'],,Rate of return of FOBT tubes in the year of receiving the interventions/control
12193,NCT04459468,Predictive accuracy of Proteomic biomarker(s) measured with bead-based X-aptamer library for overall survival in hepatocellular carcinoma patients,2022-11-04,RECRUITING,OBSERVATIONAL,['NA'],,Predictive accuracy of Proteomic biomarker(s) measured with bead-based X-aptamer library for Progression free survival in Hepatocellular carcinoma patients.
12194,NCT02057874,"Correlation of Changes in Imaging Biomarkers (Ktrans, ADC, MTR, and APTasym) as Measured by DCE-, DW-, MT-, and CEST-MRI at 3 Tesla, Respectively, With Changes in Tumor Volume (mRECIST).",2014-02,TERMINATED,INTERVENTIONAL,['NA'],,"Correlation of Changes in Ktrans, ADC, MTR, and APTasym (Measured by DCE-, DW-, MT-, and CEST-MRI at 3 Tesla, Respectively) With Overall Survival (OS)"
12195,NCT02277158,Maximum Tolerated Dose (MTD),2014-11,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Quality of Life
12196,NCT00498225,Over all survival(OS),2007-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,"progression-free survival (PFS), response rate (RECIST, if measurable), incidence rate of adverse events, incidence rate of adverse drug reactions, QOL (EQ-5D)"
12197,NCT02481635,Type and the severity of side effects,2016-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to Progression
12198,NCT00725400,Objective tumor response rate,2010-02,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Quality of life
12199,NCT05484024,Disease-free survival rate,2022-08-06,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Quality of life (QoL)
12200,NCT03551444,Recurrence rate,2017-10-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Identifications of predictive factors of HCC recurrence
12201,NCT04752384,The number of subjects who achieve at least a 30 percent decrease in pain from baseline in VAS pain score calculated from BPI questionnaire.,2021-07-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,The number of subjects who achieve at least a 30 percent decrease in pain from baseline in average daily pain score calculated by OM pain app.
12202,NCT05965843,All-cause mortality in patients with underline disease after Covid-19 infection.,2023-08,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Severe disease in patients with underline disease after Covid-19 infection.
12203,NCT02136277,Changes in microvascular blood flow during colorectal surgery,2015-01,UNKNOWN,OBSERVATIONAL,['NA'],,
12204,NCT05476380,pCR,2021-02-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,DFS
12205,NCT04867525,Course of treatment (treatment reality).,2021-05-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,"Carcinoma Health-related quality of life (Patient-reported outcome, PRO)."
12206,NCT00456599,Two-year Disease Free Survival.,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
12207,NCT00551213,Number of Participants With a >20% Decrease in Positron Emission Tomography (PET)-Assessed Tumor Glucose Metabolism: Fluorodeoxyglucose (FDG) Standardized Uptake Value (SUV) in the Target Lesion,2007-11-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change From Baseline in Tumor Growth Rate
12208,NCT04746469,Overall colorectal cancer screening uptake (any modality),2020-09-02,COMPLETED,INTERVENTIONAL,['NA'],,Colorectal cancer screening uptake by modality
12209,NCT03586050,Number of Patients Whose Ablation Resulted in Technical Success,2017-12-11,COMPLETED,INTERVENTIONAL,['NA'],,Number of Patients Whose Ablation Resulted in Technique Efficacy
12210,NCT01387932,Median Overall Survival,2011-06,TERMINATED,INTERVENTIONAL,['PHASE3'],Number of TACE-Related Adverse Events in Subjects Treated With HepaSphere/QuadraSphere vs Subjects Treated With Conventional TACE.,Objective Response Rates (ORR)
12211,NCT01924819,Overall survival,2009-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Surgical complete resection rate (R0)
12212,NCT02349867,Recommended phase 2 dose and schedule,2015-01-29,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival
12213,NCT02080221,Survival for Patients With Metastatic Pancreatic Cancer With First-line Treatment With FOLFOX-A as Compared to Historical Controls of Gemcitabine Alone.,2014-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response of Patients With Metastatic Pancreatic Cancer Who Receive the FOLFOX-A Regimen
12214,NCT00893503,"Compare the diagnostic performance characteristics of the guaiac based Hemoccult II FOBT and two FIT's, the Hemoccult ICT and MagStream HemSp, using colonoscopy as the gold standard.",2008-04,COMPLETED,OBSERVATIONAL,['NA'],,Estimate the probability of participants of the SCOPE pilot who have adenomas or colorectal cancer using urine metabolomics and correlate those with results from the FOBT / FIT's and screening colonoscopy.
12215,NCT00619814,,2003-09,COMPLETED,INTERVENTIONAL,['NA'],,
12216,NCT00458809,Maximum tolerated dose,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Change in the phenotypic expression of proteins involved in the apoptotic and heat-stress inducible pathways
12217,NCT01908504,The number of subjects with benefit from an intra-treatment PET-CT,2012-01,COMPLETED,INTERVENTIONAL,['NA'],,Measure late toxicities
12218,NCT03484962,Objective response rate,2018-03-25,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Symptom remission rate
12219,NCT05542030,Lesions recurrence in a three-month follow-up after EMR,2022-09-12,RECRUITING,INTERVENTIONAL,['NA'],,Recurrence risk after EMR
12220,NCT02725996,Overall Survival(OS) :Overall survival was measured from the date of randomization until death from any cause.,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
12221,NCT02000050,Complete pathological response (pCR),2013-10-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Intention-to-treat (ITT) population
12222,NCT00019513,,1998-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12223,NCT05610332,Objective response rate,2022-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,"The prediction performance of Exosome contents (including proteins, nucleic acids)"
12224,NCT00873275,Pharmacokinetics of ursodiol,2009-03-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
12225,NCT06243757,Appetite level score according to the MDASI-GI,2024-01-08,RECRUITING,OBSERVATIONAL,['NA'],,
12226,NCT03608878,time-to-ITTVP,2019-04-26,TERMINATED,INTERVENTIONAL,['PHASE2'],,
12227,NCT00023972,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
12228,NCT04912765,Induced immune response against vaccinated NAs,2021-04-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
12229,NCT04060342,"Phase 2 - Basket Cohorts 1, 2 and 3: Objective Response Rate (ORR)",2019-08-13,TERMINATED,INTERVENTIONAL,['PHASE1'],,"Phase 2 - Basket Cohort 1, 2 and 3: PK profile of GB1275"
12230,NCT05499195,Disease-free Survival (DFS),2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
12231,NCT01237665,Pathological complete response (pCR),2010-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,OS
12232,NCT00848952,Report of proportion of the positives truths and the positive wrong for an examination,2009-03,UNKNOWN,INTERVENTIONAL,['NA'],,
12233,NCT01035437,Determine the toxicity of sequential PDT and chemoradiation in obstructing esophageal cancer,2009-12,WITHDRAWN,INTERVENTIONAL,['NA'],,Evaluate the efficacy of PDT in palliation of dysphagia
12234,NCT05475366,Objective Response Rate (ORR) at 4 months based on thorax-abdomen-pelvis (TAP) CT scan every 8 weeks according to RECIST v1.1.,2022-12-12,RECRUITING,INTERVENTIONAL,['NA'],,Feasibility of study procedure
12235,NCT01973725,Disease control rate,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,EORTC QLQ-C30 and QLQ-OES18
12236,NCT02982694,Overall Response Rate,2017-11-24,TERMINATED,INTERVENTIONAL,['PHASE2'],,Safety and tolerability (adverse event assessment according to CTCAE v 4.0)
12237,NCT04194801,Phase II: Objective Response Rate (ORR) Assessed by Investigator Based on RECIST Version 1.1,2019-12-16,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pharmacokinetic Parameters of Time to Maximum Serum Concentration (Tmax) of Sugemalimab (CS1001)
12238,NCT01991522,Transfer of Skills to Clinical Colonoscopy,2011-06,COMPLETED,INTERVENTIONAL,['NA'],,Retention of Clinical Skills
12239,NCT03097848,Disease free survival,2017-05-04,UNKNOWN,INTERVENTIONAL,['NA'],,mortality
12240,NCT02431078,three-year disease free survival rate,2015-06,UNKNOWN,OBSERVATIONAL,['NA'],,baseline detection of ZEB1 expression
12241,NCT05557838,≥Grade 3 Adverse Events and Adverse Events of Special Interest of Cohort 1,2023-02-22,RECRUITING,INTERVENTIONAL,['PHASE3'],,Duration of response (DoR) per RECIST 1.1/mRECIST
12242,NCT04191655,Detection rate of dysplastic lesions in High Definition White Light Colonoscopy versus Dye Spraying Chromo-colonoscopy,2019-04-03,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Appropriateness of reported follow up recommendations per standard guideline recommendations
12243,NCT03460197,The classification of Papanicolaou was used for the terminology in pancreatobiliary cytological evaluation of biopsy samples.,2018-04-20,COMPLETED,OBSERVATIONAL,['NA'],,
12244,NCT00224562,,2004-02,UNKNOWN,OBSERVATIONAL,['NA'],,
12245,NCT00110721,frequency of stable disease,2005-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,safety of GM-CT-01 plus 5-FU
12246,NCT06204523,"Investigate pathways of interest at a deeper level, as well as identify other potential pathways/functions impacting clinical outcomes.",2018-10-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
12247,NCT05622136,Proportion of patients who complete 4 cycles of treatment,2023-09-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Score in the The 5-level EuroQol EQ-5D-5L questionnaire
12248,NCT03790553,Overall survival in ITT population,2018-10-15,RECRUITING,INTERVENTIONAL,['PHASE3'],,Questionnaire EORTC-QLQ-OES18
12249,NCT03102047,Median modified Neoadjuvant Rectal (mNAR) Score,2018-05-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Frequency of adverse events assessed by CTCAE 4.0
12250,NCT02761356,Visual assesment of Tc-99m-MAA in liver lesions compared to visual assesment of Y-90 sirtex.,2010-01,COMPLETED,OBSERVATIONAL,['NA'],,
12251,NCT05856188,Change in the level of salivary transforming growth factor beta 1 during radiotherapy.,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Change in Pain visual analog scale during radiotherapy.
12252,NCT05865756,acoustic cough features in HNC patients as biomarkers for dysphagia/aspiration.,2021-04-01,RECRUITING,INTERVENTIONAL,['NA'],,
12253,NCT02272894,overall survival,2014-07,UNKNOWN,OBSERVATIONAL,['NA'],,disease free survival
12254,NCT01329718,Effectiveness of the Epi proColon test,2011-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
12255,NCT03300414,Associate viral sequences and host gene expression signatures with established HCC risk factors in Asian Americans.,2017-03-20,COMPLETED,OBSERVATIONAL,['NA'],,
12256,NCT05238831,Proportion of participants who receive an ACT therapy based an ACT Tumor Board recommendation.,2023-01-30,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,Overall survival
12257,NCT05086601,Disease-free survival time,2020-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,Pathological TNM stage
12258,NCT02305810,"Circulating angiogenic factors, molecular imaging and tumor tissue factors changes during treatment with RAD001 at baseline, week 4, week 12 and at disease progression.",2013-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,"TTP, time to progression"
12259,NCT02557503,Progression-free survival (PFS),2015-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,overall survival (OS)
12260,NCT03837132,Impact of early palliative care on quality of life in patients with advanced pancreatic cancer,2018-10-15,COMPLETED,OBSERVATIONAL,['NA'],,"To explore the impact of early palliative care on symptom management, depression, anxiety and survival in patients with advanced pancreatic cancer"
12261,NCT05488587,Serum level of Zinc in cirrhotic patients and HCC,2022-08,RECRUITING,OBSERVATIONAL,['NA'],,serum level of Zinc and the Barcelona clinic classification
12262,NCT06152978,Event-free survival (EFS),2023-12-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,adverse events
12263,NCT05497453,Duration of Response (DOR) (for Part 1 and Part 2 expansion),2022-08-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
12264,NCT02216578,Progression Free Survival (PFS),2017-02-02,COMPLETED,INTERVENTIONAL,['PHASE2'],circulating plasma DNA,Occurence of adverse events
12265,NCT01465425,"Rates of Follow Up Imaging, Hospitalization, Intervention",2011-09,UNKNOWN,OBSERVATIONAL,['NA'],,Estimate Differences in Cost
12266,NCT05410977,Specificity of mt-sDNA 2.0 test to detect colorectal dysplasia,2022-03-30,RECRUITING,OBSERVATIONAL,['NA'],,
12267,NCT02140021,Sensitivity and specificity of the combination of anal pap testing + anal HPV testing to diagnose anal dysplasia,2014-10-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
12268,NCT02106910,Mean Procedure Preference Rating,2014-10-27,COMPLETED,INTERVENTIONAL,['NA'],,Cytosponge™ Operating Characteristics
12269,NCT03779464,PFS,2019-08-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety profile :Adverse events of nab-Paclitaxel plus S-1
12270,NCT00087360,Colorectal cancer (CRC) screening rates by chart review at 4 months,2003-11,COMPLETED,INTERVENTIONAL,['NA'],,CRC risk perception by questionnaires at 4 and 12 months
12271,NCT04437953,"Number of patients who achieve platelet counts of ≥ 100,000/mcL",2020-05-27,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Number of patients who can undergo systemic cancer therapy without more than one dose delay or dose reduction
12272,NCT01277653,the difference of curative treatments & survival rates,2007-06,UNKNOWN,OBSERVATIONAL,['NA'],,the difference of early detection rates of HCC between both groups
12273,NCT01991847,Target sample size,2014-01,COMPLETED,INTERVENTIONAL,['NA'],,Adverse and serious adverse events
12274,NCT00577109,Progression-free survival,2007-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,"AEs, laboratory parameters."
12275,NCT05637788,"Evaluate the association between different radiomics and computer-vision features, and the survival after surgery",2021-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,"Evaluate the association between different radiomics and computer-vision features, and the short-terms results after surgery"
12276,NCT00576199,Progression-free Survival,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumor Necrosis
12277,NCT01411189,The proportion of patients had no or mild peristalsis during the therapeutic procedures,2011-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Adverse events and adverse drug reactions
12278,NCT06134687,Total Procedure Time,2024-03-18,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,User-feedback post-procedure
12279,NCT06030934,Objective Response Rate (ORR),2022-10-24,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2'],,Adverse Events (AEs)
12280,NCT02777710,part 2 (extension part) : objective response rate (ORR),2016-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Peak Pexidartinib plasma concentration (Cmax)
12281,NCT02282059,Percentage of Participants With Treatment-Related Adverse Events (AEs) or Serious Adverse Events (SAEs),2014-12-12,COMPLETED,OBSERVATIONAL,['NA'],,Progression-free survival by clinical judgment
12282,NCT03467529,Concordance between FFOCT findings and pathology based on the Paris classification of superficial esophageal cancer in pathology,2018-11-06,COMPLETED,OBSERVATIONAL,['NA'],,
12283,NCT05904665,Secondary resection rate,2023-06-15,RECRUITING,INTERVENTIONAL,['NA'],,ctDNA clearance rate
12284,NCT05262335,Objective response rate (ORR),2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Radical Resection Rate of Liver Metastases
12285,NCT03295084,Maximal Tolerated Dose (MTD) and Dose Limiting Toxicity (DLT) of oral Irinotecan based on incidence of Treatment-Emergent Adverse Events,2015-07-15,COMPLETED,INTERVENTIONAL,['PHASE1'],,Objective tumor response to treatment based on RECIST 1.1 criteria
12286,NCT05554744,Imaging response,2015-06-18,RECRUITING,INTERVENTIONAL,['NA'],,Safety of EUS-FNI
12287,NCT01661049,,2012-03,COMPLETED,OBSERVATIONAL,['NA'],,
12288,NCT01123811,objective response rate,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free survival
12289,NCT01260701,Overall Survival (OS),2011-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug
12290,NCT03253250,Recurrence-free Survival Rate (RFS）,2017-09-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Overall Survival Rate (OS）
12291,NCT01519232,Changes in hepatobiliary single photon emission tomography (SPECT) after radiation therapy,2008-08,COMPLETED,OBSERVATIONAL,['NA'],,"measuring values between regional radiation dose and local hepatic function as measured by hepatobiliary SPECT, in normal liver parenchyma"
12292,NCT04654975,Odds ratio (OR) for brain metastasis,2020-06-02,UNKNOWN,OBSERVATIONAL,['NA'],,Characteristics of brain metastases
12293,NCT00808743,Change in number and size of duodenal adenomas (assessed directly and by evaluation of video and photographic material from endoscopic procedures),2009-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Biliary acid profile (if present)
12294,NCT04183478,overall survival,2017-09-26,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Hematology Index,QOL
12295,NCT04753996,Number of participants in study.,2021-03-08,RECRUITING,OBSERVATIONAL,['NA'],,Number of clinical phenotypes and/or observations.
12296,NCT04652947,"compare diagnostic MRI performance of gadoteric acid, gadoxetic acid and P03277 for suspected CHC nodules",2016-12-07,COMPLETED,OBSERVATIONAL,['NA'],,
12297,NCT03021135,Local recurrence.,2018-06-07,COMPLETED,INTERVENTIONAL,['NA'],,Sydney resection ratio (characterized by the following equation - lesion size in millimeters
12298,NCT02533271,Disease-free survival rate,2015-08,RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of life (QoL)
12299,NCT00303628,5-year Overall Survival Rate,2006-05-11,TERMINATED,INTERVENTIONAL,['PHASE3'],Change in Oxaliplatin-related Neurotoxicity Between Baseline and 12 Months,Proportion of Patients Who Completed 12 Cycles of Treatment
12300,NCT04584996,circRNAs for diagnosis,2020-10-04,UNKNOWN,OBSERVATIONAL,['NA'],,Bioinformatics
12301,NCT02009176,Survival rate,2013-03,UNKNOWN,INTERVENTIONAL,['NA'],,postoperative complications
12302,NCT06231160,overall survival,2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Pain relief rate
12303,NCT03599752,Overall survival (High risk),2018-07-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
12304,NCT01751880,"changes of result of blood sample test, cardio pulmonary function test and vital signs reflecting of inflammation level and nutrition condition in patients with minimally invasive gastrectomy",2012-08-08,COMPLETED,INTERVENTIONAL,['NA'],,
12305,NCT03393403,analgesic effect - pain intensity,2017-12-23,UNKNOWN,INTERVENTIONAL,['NA'],,analgesic effect - opioid consumption
12306,NCT01530503,Progression Free Survival (PFS),2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
12307,NCT00203411,Number of Subjects Requiring Dose Modifications,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life of Patients
12308,NCT05594381,Pathological complete response rate (pCR),2022-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Genomic changes of ctDNA,Incidence of Treatment-Emergent Adverse Events（Safety）
12309,NCT04053972,RFS,2018-01-31,UNKNOWN,INTERVENTIONAL,['PHASE3'],,recurrence rate
12310,NCT01963702,objective response,2012-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],overall survival(OS),progression free survival (PFS)
12311,NCT05978141,Number of participants populating the T-cell Lymphoma Master Repository/TCLMR,2023-07-27,RECRUITING,OBSERVATIONAL,['NA'],,
12312,NCT01348009,Progression-free survival rate (in Phase 2 portion of study),2011-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Percentage of patients with adverse events (in Phase 1 and Phase 2 portions)
12313,NCT03674294,Complete response rate during the overall phase,2015-08-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Effects of CINV on daily life
12314,NCT01575730,Area under the plasma concentration versus time curve (AUC) of platinum,2012-05-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tissue Concentration (Cmax) of Platinum
12315,NCT05495308,The main objective of the study is to update long-term oncologic follow-up of those patients treated for LARC with nCRT and surgery (either TME or subtotal TME; S-TME) who had obtained a pCR.,2021-09-01,COMPLETED,OBSERVATIONAL,['NA'],,"To analyze clinical data in search of related factors to adverse oncologic outcomes, like distant recurrence or tumor-related deaths."
12316,NCT03359681,Expression of Ki67 on tumor samples,2018-07-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,microbiota
12317,NCT03699410,Negative Prognostic Value (NPV),2018-08-28,TERMINATED,OBSERVATIONAL,['NA'],,
12318,NCT01305200,Duration of Severe Oral Mucositis (WHO Grade 3 or 4),2011-03,COMPLETED,INTERVENTIONAL,['PHASE3'],Ancillary Validation Study of ChIMES,Severity of Mucositis
12319,NCT05187182,Expansion dose of CA-4948 in combination with FOLFOX/PD-1 inhibitor with/without trastuzumab,2023-06-02,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
12320,NCT04027543,Overall survival (OS),2018-11-14,COMPLETED,OBSERVATIONAL,['NA'],,30-day postoperative or in-hospital mortality
12321,NCT02054533,Post-Operative Infection,2014-02,COMPLETED,OBSERVATIONAL,['NA'],,Hypomotility complication
12322,NCT01322633,Incidence Rate of Gastric Cancer,2004-07,COMPLETED,OBSERVATIONAL,['NA'],,Incidence Rate of Overall Cancer
12323,NCT05199649,Species and abundance of gut microbiota,2021-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,Explore the changes of intestinal flora and metabolomics before and after medication
12324,NCT01472198,Progression free survival,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Objective response
12325,NCT03092895,The safety and tolerability,2017-04-27,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
12326,NCT02063412,"Composite preparation, dispensing, and administration time",2013-08,WITHDRAWN,OBSERVATIONAL,['NA'],,
12327,NCT04363983,Overall survival (OS),2021-01-13,RECRUITING,INTERVENTIONAL,['NA'],,Survival without progression (SWP)
12328,NCT02704520,To show that patients can successfully avoid surgery after achieving a good response to treatment as measured on MRI (mrTRG).,2016-03,RECRUITING,INTERVENTIONAL,['NA'],,To assess whether the detection of ctDNA predicts for relapse in patients with locally advanced rectal cancer
12329,NCT00073905,Ability of palliative capecitabine and gemcitabine,2003-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Clinical benefit response alone as measured after 3 courses
12330,NCT01181557,"Questionnaire number 1, to Assess the Quality of Life of Rectal Cancer Patients With or Without Stoma",2008-09,COMPLETED,OBSERVATIONAL,['NA'],,"Questionnaire number 3, to Assess the Quality of Life of Rectal Cancer Patients With or Without Stoma"
12331,NCT04084249,FCI,2020-01-01,RECRUITING,INTERVENTIONAL,['NA'],,CE
12332,NCT05716477,Beliefs about colorectal screening,2022-12-23,RECRUITING,OBSERVATIONAL,['NA'],,
12333,NCT00008294,,2000-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12334,NCT01646853,Objective Tumor Response,2012-08,UNKNOWN,INTERVENTIONAL,['NA'],,adverse events
12335,NCT01622803,The time taken to insert bilateral stent,2011-08,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,
12336,NCT06027086,Objective response rate (ORR) using immune Response Evaluation Criteria for Solid Tumors (RECIST 1.1),2024-02-06,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
12337,NCT04732286,Incidence of Treatment Discontinuations of Atezolizumab and/or Bevacizumab Due to Adverse Events of Grade ≥ 3,2021-05-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Albumin-Bilirubin (ALBI) Assessment Grades of 1 to 3
12338,NCT00439608,Reponse Rate at Time of Surgery by Tissue,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Number of Participants With Grade 2 and/or 3 Rash in Patients With Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus, Gastroesophageal Junction, or Stomach."
12339,NCT03460483,Incidence of tumors with microsatellite instability and/or somatic POLE mutations,2018-03-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
12340,NCT00873002,Assessment of Safety and Tolerability,2009-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,Adverse events and abnormal laboratory value severity as assessed by NCI CTCAE version 3.0
12341,NCT03414983,Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR),2018-02-20,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Disease Control Rate (DCR) Per Investigator
12342,NCT01632306,Change From Baseline to 4 Hours Post-Treatment on Day 0 in Glycogen Synthase Phosphorylation,2013-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)]
12343,NCT04157985,Progression-free Survival (PFS),2019-11-15,RECRUITING,INTERVENTIONAL,['PHASE3'],,Best Objective Response (BOR)
12344,NCT06301399,ORR,2024-03-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,DCR
12345,NCT00271986,anastomotic leakage,2006-01,COMPLETED,OBSERVATIONAL,['NA'],,
12346,NCT01507740,Progression free survival under antiangiogenic therapy,2009-07,TERMINATED,OBSERVATIONAL,['NA'],,
12347,NCT05730361,Objective Response Rate (ORR),2023-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Detection of Lentivirus Copy Number
12348,NCT03964064,Progression-free survival (PFS),2019-06-11,UNKNOWN,INTERVENTIONAL,['NA'],,Adverse reactions
12349,NCT01839500,"Cohort III, V: Disease-Free Survival (DFS), as Assessed by the Investigator Using RECIST V1.1 Criteria",2013-04-25,COMPLETED,OBSERVATIONAL,['NA'],,Cohort II: Percentage of Participants Who Decline to the Recommendation Categorized by Reasons
12350,NCT06096623,Electronic patient-reported outcome (ePRO) confirming treatment initiation,2023-11-06,RECRUITING,INTERVENTIONAL,['NA'],,Time to treatment in days
12351,NCT06236633,Safety of endovascular inferior mesenteric artery embolisation prior to surgical resection of the rectum in patients with tumours of the lower and middle rectum.,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Operative data,Markers of epithelial-mesenchymal transition : transcription factors
12352,NCT00496704,Overall response rate as assessed by RECIST criteria,2007-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to response
12353,NCT04710758,Overall survival,2021-01-20,RECRUITING,INTERVENTIONAL,['NA'],,Postoperative recovery course
12354,NCT05025748,Self-efficacy in managing patient-physician interactions,2021-08-25,COMPLETED,INTERVENTIONAL,['NA'],,Perceptions of the Question Prompt List
12355,NCT02711033,Early complication rate,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Metastasis rate of lymph nodes posterior to splenic vessel
12356,NCT06225843,Treatment-Emergent Adverse Events,2024-02-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Presence of ADA
12357,NCT03212625,Cumulative incidence of Hand-Foot Skin Reaction(HFSR) on each group,2016-01-28,COMPLETED,INTERVENTIONAL,['PHASE4'],,"Incidence of HFSR on 2, 4, 8, and 12 weeks on each group"
12358,NCT00028015,,2001-10-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12359,NCT04016948,Accuracy of optical biopsy,2017-06-28,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative function recovery
12360,NCT03900871,disease free survival,2019-04-10,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
12361,NCT01159171,Percentage of Participants by Best Overall Response,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
12362,NCT04191889,Objective response rate (ORR) by RECIST 1.1,2020-04-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Exploratory outcome measure: The quality of life (QoL)
12363,NCT03042611,Overall Survival (OS),2017-03-14,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants Per QOL Dimension Response as Measured by the EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire
12364,NCT00999843,The safety and tolerability of maintenance Sorafenib.,2009-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Time to progression (TTP), progression-free survival (PFS) and overall survival (OS)"
12365,NCT00359320,The primary endpoint will be the pancreatic fistula rate.,2006-05-25,TERMINATED,INTERVENTIONAL,['NA'],,Death
12366,NCT01226979,Number of Participants With Pathologic Complete Response,2010-10-26,COMPLETED,INTERVENTIONAL,['NA'],,Number of Participants With Acute Gastrointestinal Toxicity Associated With High-Dose-Rate Endorectal Brachytherapy (HDRBT) as Assessed by CTCAE v4.0
12367,NCT05772546,Response Rate of CIT Treatment in Placebo Group,2023-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Rate of Serious Treatment-Emergent Adverse Events (TEAEs) in Placebo Group
12368,NCT00021281,,2000-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
12369,NCT05692323,PREHAB Program feasibility will be measured by tracking participant attendance at PREHAB sessions. PREHAB will be considered feasible if 50% of participants attend at least 60% of scheduled sessions.,2023-04-04,RECRUITING,INTERVENTIONAL,['NA'],,PREHAB Program safety will be assessed through the reporting of unanticipated problems from the baseline visit through to the 3 Month visit.
12370,NCT02731313,Simple Kappa Coefficient of Human Epidermal Growth Factor Receptor 2 (HER-2) Status Between Local and Centralized Laboratory Assessments,2012-07,COMPLETED,OBSERVATIONAL,['NA'],,Weighted Kappa Coefficient Between Immunohistochemistry (IHC) 4B5 and Silver in Situ Hybridization (SISH) Techniques for HER-2 Testing in Centralized Laboratories
12371,NCT05374044,pathological tumor regression grade(pTRG),2020-05-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,local recurrence
12372,NCT00757172,Number of Participants With Pathologic Complete Response Following Surgery,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Frequent (>=15% Grade 3/4 Incidence) Adverse Events Regardless of Attribution
12373,NCT02452853,Number of Complications reported using the National Cancer Institute Common Toxicity Criteria grading version 4.0,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
12374,NCT01563484,"Change from Baseline in serum creatinine, blood urea nitrogen, direct bilirubin, indirect bilirubin, alanine aminotransferase, aspartate aminotransferase, γ-glutamyltransferase, lactate dehydrogenase, alkaline phosphatase, cholinesterase.",2012-03,UNKNOWN,OBSERVATIONAL,['NA'],,
12375,NCT01651624,Costs of the three different screening strategies proposed,2012-12,COMPLETED,INTERVENTIONAL,['NA'],,Number and type of complications in all groups
12376,NCT05675059,Malnutrition: Low Skeletal Muscle Mass,2022-12-21,RECRUITING,INTERVENTIONAL,['NA'],,
12377,NCT04996355,"The accuracy, specificity and sensitivity of organoids-on-chip for drug sreening",2021-05-31,RECRUITING,OBSERVATIONAL,['NA'],,
12378,NCT02249650,Dose limiting toxicities (DLTs),2017-07-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12379,NCT01834742,Primary Variable,2011-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Safety profile
12380,NCT05401318,"Induction of immunotherapy efficacy by chemotherapy in colorectal cancer, measured by advanced imaging analysis",2022-03-28,RECRUITING,OBSERVATIONAL,['NA'],,
12381,NCT00003422,"Local recurrence by biopsy, imaging, or imaging and carcinoembryonic antigen result",1998-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Economic implications
12382,NCT06326619,Survival,2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
12383,NCT02254486,Number of Patients With 'Excellent Plus Good' (Highly Effective) Bowel Cleansing (Colon Ascendens),2014-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Polyp Detection Rate (Overall Colon)
12384,NCT05101772,The acquisition rate of the core tissue sample,2021-09-24,UNKNOWN,OBSERVATIONAL,['NA'],,the incidence of adverse events and the incidence of device defects
12385,NCT00202969,Response rate,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Safety profile, time to treatment failure"
12386,NCT01567917,The incidence of symptomatic or asymptomatic VTE,2011-06,UNKNOWN,OBSERVATIONAL,['NA'],,Risk factors for the development of VTE
12387,NCT05721872,Response to D-isoascorbic Acid (D-VC) in combination with arsenic trioxide (ATO),2023-02-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change from baseline number of participants with treatment-related adverse events as assessed by CTCAE v4.0 at 24 hours
12388,NCT03803553,Clearance rate of ctDNA,2020-04-16,RECRUITING,INTERVENTIONAL,['PHASE3'],,Clearance rate of Arm 6: Herceptin/Perjeta
12389,NCT01199250,"Role of FGFR2 mutations in low, intermediate and high risk endometrial cancers (Project 1)",2100-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
12390,NCT00624546,gene expression,2009-01,TERMINATED,OBSERVATIONAL,['NA'],,
12391,NCT03300401,Local tumor response to therapy,2017-11-07,WITHDRAWN,INTERVENTIONAL,['NA'],,
12392,NCT03975452,The reduction of gastrointestinal (GI) toxicity,2007-11,UNKNOWN,INTERVENTIONAL,['NA'],,The disease-free survival (DFS)
12393,NCT02161822,pathologic complete response rate,2014-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,lipid lowering effect of simvastatin
12394,NCT04965714,Necrosis of tumors,2022-04-13,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Immune biomarker analysis,Overall survival (OS)
12395,NCT04177810,Objective Response Rate (ORR) Using Immune RECIST (iRECIST) Criteria,2020-11-16,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants Experiencing Grade 3 or Above Drug-related Toxicities
12396,NCT05023720,Regorafenib in combination with other drugs,2021-07-20,UNKNOWN,OBSERVATIONAL,['NA'],,Survival differences among the patients with different clinical phenotypes and genotypes
12397,NCT00159484,Once MTD is established we propose to expand the dose level of the MTD to 62 new patients to evaluate whether the addition of Celebrex to EPO906 can reduce the incidence of grade 3-4 diarrhea to 6% or less.,2004-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"To investigate whether the molecular biomarkers including protein expression changes from plasma, the expression levels of VEGF, E-cadherin, TP, COX-2, and β-tubulin in tumor tissue associated with clinical outcome for this regimen."
12398,NCT05850130,2-point improvement in the global NRS,2023-11-22,RECRUITING,INTERVENTIONAL,['NA'],,Peripheral sensory neuropathy grading scale
12399,NCT02299596,Recovery measured as physical recovery measured in questionnaire,2015-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Health economic analysis
12400,NCT06234072,Objective response rate (ORR),2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Proportion of participants with R0 resection
12401,NCT05694936,Progression free survival,2023-01-23,RECRUITING,INTERVENTIONAL,['PHASE2'],Quantification of total circulating tumour DNA (ctDNA),Quantification of the incidence of treatment-emergent adverse events according to CTCAE V5.0
12402,NCT00714701,This clinical study will assess the diagnostic yield of a clinical screening program for early pancreatic neoplasia in high risk individuals.,2008-06,COMPLETED,OBSERVATIONAL,['NA'],,
12403,NCT06090916,Calorie intake from Myfitness Pal,2023-01-17,RECRUITING,INTERVENTIONAL,['NA'],,
12404,NCT03314896,Overall survival,2016-10,RECRUITING,INTERVENTIONAL,['NA'],,Adverse events (mortality and morbidity)
12405,NCT01670851,Perineal wound healing,2013-03,COMPLETED,OBSERVATIONAL,['NA'],,Incidence of parastomal hernia
12406,NCT00026130,Overall Survival,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity
12407,NCT02014116,Maximum Tolerated Dose (MTD) of LY3009120,2013-11-26,TERMINATED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to the End of Dosing Interval at Steady State (AUC[0-τ]) of LY3009120 Cycle 1 Day 28
12408,NCT05900648,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",2023-05-17,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
12409,NCT04594655,MPI and major morbidity,2017-10-01,COMPLETED,OBSERVATIONAL,['NA'],,Prediction of complication
12410,NCT00173472,,2002-07,UNKNOWN,OBSERVATIONAL,['NA'],,
12411,NCT00305188,Clinical evaluation of peripheral sensory neuropathy using the Oxaliplatin specific scale for dose adjustment,2005-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Other: progression free survival and survival
12412,NCT03140592,Successful generation of pancreatic organoids,2015-01-14,UNKNOWN,OBSERVATIONAL,['NA'],,
12413,NCT06076837,Safety and Tolerability,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Baseline neutrophil lymphocyte ratio (NLR),"CA 19-9 (or CA 125, or CEA if not expressers of CA 19-9)"
12414,NCT00621556,"MR & MRCP - Images will be evaluated for quality, main and branch duct visualization, ductal diameter and improved visualization of structural abnormalities with and without use of RG1068.",2008-02,TERMINATED,INTERVENTIONAL,['PHASE1'],,Laboratory
12415,NCT02232152,"MTD of 6,8-bis(benzylthio)octanoic acid in combination with fluorouracil based on the incidence of dose-limiting toxicities graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0",2015-01-06,COMPLETED,INTERVENTIONAL,['PHASE1'],"Disease control rate (DCR) (i.e., sum of CR, PR, and stable disease)","PK parameters (maximum observed concentration, area under the curve, half-life, elimination rate constant, drug clearance, and volume of distribution) of 6,8-bis(benzylthio)octanoic acid in plasma samples"
12416,NCT00929097,The number of colorectal cancer patients following the most optimal follow up program according to the guidelines.,2009-10,UNKNOWN,INTERVENTIONAL,['NA'],,Costs of the implementation procedure
12417,NCT03630978,Morbidity,2018-07-01,COMPLETED,OBSERVATIONAL,['NA'],,Readmission rate
12418,NCT04187352,Overall survival (OS),2019-12-19,COMPLETED,INTERVENTIONAL,['PHASE3'],,Duration of response (DoR) assessed by BICR and investigators according to RECIST v1.1
12419,NCT02519348,Number of Participants With Electrocardiogram (ECG) Abnormalities Reported as Treatment-Emergent Adverse Events,2015-10-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
12420,NCT02031952,Recurrence-free survival,2005-12,COMPLETED,INTERVENTIONAL,['NA'],,Post-operation complication
12421,NCT04871399,Disease-free survival at 3 years,2020-07-13,RECRUITING,INTERVENTIONAL,['NA'],,Other Oncologic outcomes.
12422,NCT03222557,GI-2 recovery,2017-11,UNKNOWN,INTERVENTIONAL,['NA'],,Adverse events related to EA/SA
12423,NCT03766178,Objective Response Rate (ORR),2021-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,12-month survival rate
12424,NCT03094884,Rate of severe acute esophagitis in patients with lung cancer and esophageal cancer treated with concurrent CRT using PLDR technique.,2017-02-24,RECRUITING,INTERVENTIONAL,['PHASE1'],,Response rate based
12425,NCT02387203,Overall survival,2015-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Analyze number of live bacteria in PMP tumor and mucin,"Progression-free survival measured by no evidence of disease progression, i.e. tumor markers within normal limits, no radiographical evidence of disease"
12426,NCT04475159,Best Overall Response Rates (BORR),2020-08-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Recurrence free survival (RFS)
12427,NCT03984214,Standardized area under the curve of the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30 symptom summary score over the on-treatment period.,2019-12-16,RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall survival (OS)
12428,NCT05662644,Nature of gross picture of specimen,2022-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Occurence of ostoperative reflux
12429,NCT00159432,Median Time for Progression Free Survival,2005-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Grade 3 or Higher Toxicity
12430,NCT04674956,Progress free survival,2021-03-04,RECRUITING,INTERVENTIONAL,['PHASE3'],CA19-9 in serum,Duration of Response
12431,NCT06147180,score of Quality of life,2023-11-27,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Recurrence or metastasis
12432,NCT02521649,Measurable Antibody Titer,1998-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Injection Site Reaction
12433,NCT05776524,Overall Survival,2023-06-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease Control Rate
12434,NCT00756509,"To evaluate the efficacy of Nilotinib in patients with unresectable or metastatic gastrointestinal stromal tumors. Efficacy is defined as the proportion of patients showing stable disease (SD), partial response (PR) or complete response (CR) during the",2008-08-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],,population pharmacokinetics of Nilotinib
12435,NCT05328908,OS in all randomized participants,2022-04-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,DoR by investigator per RECIST v1.1 in all randomized participants
12436,NCT05311176,Objective Response Rate of HER-Vaxx in combination with chemotherapy or pembrolizumab,2022-08-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],"Exploratory Outcome: Associations between clinical outcome and HER2/neu, PD-L1 expression",Duration of Response
12437,NCT04567615,Overall response rate (ORR) assessed by blinded independent central review (BICR) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1,2021-02-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
12438,NCT00209729,Determine the DLT(Dose Limiting Toxicity) and MTD(Maximum Tolerated Dose) in Phase I setting. Determine the clinical response rate with Recommended dose in Phase II setting.,2005-04,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determine the OS(Overall Survival) and DFS(Disease Free Survival).
12439,NCT05516394,Postoperative complications,2020-07-01,RECRUITING,OBSERVATIONAL,['NA'],,Number of patients readmitted to hospital after discharge
12440,NCT02005315,Phase 1b: Safety and tolerability of vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated Stage IV pancreatic cancer,2013-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics (PK) of vantictumab when administered in combination with nab-paclitaxel and gemcitabine to patients with previously untreated Stage IV pancreatic cancer
12441,NCT01314105,Dose Limiting Toxicities During Treatment Course 1,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Change From Baseline in Safety Laboratory Parameters
12442,NCT01073384,Preliminary Efficacy,2009-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
12443,NCT02200055,Bioimpedance Assessment,2012-05,COMPLETED,INTERVENTIONAL,['NA'],,Amount of Intraoperative Fluids
12444,NCT04818476,overall mortality,2020-02-10,UNKNOWN,OBSERVATIONAL,['NA'],,
12445,NCT04905329,Relative dose-intensity (RDI) of the myelosupressive therapy course,2020-04-28,UNKNOWN,OBSERVATIONAL,['NA'],,Serious adverse events frequency
12446,NCT05141149,PART 1 (PHASE 1): Determine the recommended Phase 2a dose (R2PD) of PBP1510,2023-06-05,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PART 2 (PHASE 2a) Exploratory Endpoint: Analysis of PAUF in tumour tissue pre-treatment and after treatment with PBP1510 administered in combination with gemcitabine.,PART 2 (PHASE 2a): Presence of ADA and NAb against PBP1510 administered in combination with gemcitabine.
12447,NCT05882396,Total Neuropathy Score,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,The 4-Stage Balance Test
12448,NCT02385552,Adenoma detection rate,2011-03,UNKNOWN,OBSERVATIONAL,['NA'],,Colonoscopy quality indicators
12449,NCT04996095,Analysis of Predictive Markers,2021-10-01,RECRUITING,OBSERVATIONAL,['NA'],,
12450,NCT01387061,Overall survival plus multivariate analysis,2001-06,COMPLETED,INTERVENTIONAL,['NA'],,Disease-free survival
12451,NCT02281266,Recurrence-free Survival,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,"number of patients with abnormal laboratory value, vital signs and ECG result"
12452,NCT01804790,disease-free survival,2012-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall survival
12453,NCT05516641,Gut Flora modulation,2022-07-25,RECRUITING,INTERVENTIONAL,['NA'],,Immune Profile
12454,NCT03599154,Overall survival,2018-01-30,COMPLETED,OBSERVATIONAL,['NA'],,
12455,NCT03725254,Progression-free survival,2018-10-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,local control rate
12456,NCT01264705,Number of Patients With Dose Limiting Toxicity,2011-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Median Months of Disease Specific Survival Calculated From Treatment Initiation to Death From Advanced HCC (Hepatocellular Carcinoma) or Last Follow-up.
12457,NCT06093009,Disease-free survival,2002-06,COMPLETED,OBSERVATIONAL,['NA'],,
12458,NCT01824875,Progression-free Survival,2013-08-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Association Between Methyl Guanine Methyltransferase (MGMT) Status by Promoter Methylation and Response
12459,NCT00359476,"The Response Rate (RR: Complete Response [CR]+Partial Response [PR], as defined by Response Evaluation Criteria in Solid Tumors [RECIST]",2007-03,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,The evaluation of the safety profile of vinflunine
12460,NCT04351009,Upstaging rate,2020-06-08,COMPLETED,INTERVENTIONAL,['NA'],,Aberrant lymph node drainage
12461,NCT05461794,Arms A and C: Overall Response Rate (ORR),2022-10-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of participants with clinically significant changes from baseline in vital signs
12462,NCT02772965,Percent of Participants Experiencing Treatment Failure,2016-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Percent of Patients With Positive Anti-TNF Antibody
12463,NCT02041312,Cholesterol level in paitents with and withoutgastric neoplasm,2014-02,UNKNOWN,OBSERVATIONAL,['NA'],,Degree of decresed serum cholesterol levels in paitents with gastric neoplasm
12464,NCT05105815,DFS,2021-12-31,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,EORTC-QLQ30
12465,NCT05635149,Progression-Free Survival (PFS),2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],Exploratory endpoint,Gut microbiome analysis
12466,NCT00579865,"To determine how surgical or percutaneous drainage affects HRQL scores in patients with MBO, and to determine if these changes are sustained or change over time.",2005-05,COMPLETED,OBSERVATIONAL,['NA'],,"To identify factors associated with changes in HRQL after drainage(e.g. diagnosis, level of obstruction, degree of pruritus)"
12467,NCT03279198,"Primary Outcome:differences in stage of adoption (precontemplation, contemplation, action) when controlling for adherence to BC screening at baseline, among women who are randomized to 1) usual care; 2) a TIWeb; 3) a CSC, and 4) a TIWeb plus a CSC.",2010-07-22,COMPLETED,INTERVENTIONAL,['NA'],,Secondary outcome:Intervention Costs
12468,NCT00003687,,1998-06-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,
12469,NCT00636610,Progression-free Survival (PFS),2008-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free Survival (PFS) in Patients With Various Degrees of Hedgehog Antigen Tumor Expression
12470,NCT03839277,"Adenoma detection rate, ADR",2019-06-12,SUSPENDED,INTERVENTIONAL,['NA'],,"Polyp detection rate, PDR"
12471,NCT03347162,Cohort 2: Medical treatment complications,2017-12-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Change in physical activity level
12472,NCT00537121,Recommended phase II dose (RPTD) of SAHA when administered continuously and intermittently with standard doses of FOLFIRI,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival
12473,NCT02784262,adverse events,2016-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,change in quality of life expressed by Patients' Global Impression of Change (PGIC)
12474,NCT00028496,"Maximum tolerated dose of recombinant fowlpox-CEA(6D)/TRICOM vaccine determined by dose-limiting toxicities graded according to NCI Common Toxicity Criteria, version 2.0",2001-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12475,NCT05943210,Number of research specimens obtained at the time of surgery.,2023-05-22,RECRUITING,INTERVENTIONAL,['NA'],,Comparing levels of cell death related to radio responsiveness will be measured by quantifying cleaved caspase-3
12476,NCT02378389,The maximum-tolerated dose (MTD) of Pyrotinib and that of Pyrotinib with Docetaxel in patients with HER2 positive advanced gastric cancer,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE1'],,preliminary antitumor activity for the regimen
12477,NCT03196232,Progression-free Survival (PFS),2017-09-13,COMPLETED,INTERVENTIONAL,['PHASE2'],,Treatment Delay or Reduction
12478,NCT01554969,Tumor response and disease progression will be evaluated in this study using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST).,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12479,NCT02833363,Difference of Gastric Microbiota in the Process of Correa's Model.,2016-07,UNKNOWN,OBSERVATIONAL,['NA'],,Difference of Gastric Microbiota in the Process of Correa's Model.
12480,NCT03888638,Survival,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
12481,NCT04587739,Drop-out rate,2021-01-31,RECRUITING,INTERVENTIONAL,['PHASE1'],,Actuarial overall survival and disease-free survival.
12482,NCT06301763,Body Mass Index Level,2022-06-01,COMPLETED,INTERVENTIONAL,['NA'],,Penetration-Aspiration Scale
12483,NCT00657371,Number Polyps Detected With the Standard Colonoscope and Third Eye Retroscope (TER),2008-03,COMPLETED,INTERVENTIONAL,['NA'],,Number Participants With Polyps Who Would Have Incorrectly Been Classified as Polyp-free Had the Third Eye Retroscope Not Been Used.
12484,NCT04008537,"Feasibility of the device as measured by successful completion of the full CBCT-guided online ART workflow, from volumetric imaging through phantom delivery in at least 90% of attempted fractions",2019-09-04,COMPLETED,INTERVENTIONAL,['NA'],,
12485,NCT03875612,Specificity of registered level of tie,2016-12-12,COMPLETED,OBSERVATIONAL,['NA'],,Cancer recurrence by tie level
12486,NCT02249975,Presence of residual Barrett's Esophagus,2015-01,COMPLETED,INTERVENTIONAL,['NA'],,Device Performance
12487,NCT06195111,PFS (Progression-free survival),2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Quality of life: EORTC QLQ-C30
12488,NCT02128425,Progression-free survival after induction and maintenance chemotherapy (PFS1),2014-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Translational research
12489,NCT00709462,"To establish the safety and tolerability profile of CDX-1307 in patients with incurable breast, colorectal, pancreatic, ovarian or bladder cancer, alone and in combination with adjuvants.",2004-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To evaluate dose-limiting toxicities, immune response, and clinical activity (tumor response and time to progression)"
12490,NCT02445456,Number of Operations Where There Was Any Surgical Difficulty Due to Tracer Injection Based on Qualitative Assessment by Surgeon,2016-12,TERMINATED,INTERVENTIONAL,['NA'],,Number of TEM Operations Where the Sentinel Lymph Node Can be Identified and Removed
12491,NCT05651971,The distance from LCA to IMA and IMV,2022-11-01,RECRUITING,OBSERVATIONAL,['NA'],,postoperative anastomotic leakage rate
12492,NCT05222204,overall survival,2021-07-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
12493,NCT00997022,Maximum tolerated dose of daily sorafenib,2009-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Duration of progression free survival
12494,NCT02138383,Maximum Tolerated Dose (MTD),2014-05-22,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12495,NCT04368702,Rate of Pathologic complete response-Gastric,2021-05-01,SUSPENDED,INTERVENTIONAL,['NA'],,Characterizing MRI-based tumor alterations/changes following MR-image guided radiation
12496,NCT04585516,Presence of upper GI pathology,2020-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Patients characteristics in patients < 50 years who were admitted for a gastroscopy 9,patient characteristics of colorectal cancer 7
12497,NCT00102752,Overall objective response rate,2004-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Serum CA-19-9
12498,NCT00718055,,2006-11,WITHDRAWN,OBSERVATIONAL,['NA'],,
12499,NCT01207895,Utility of [18F]-FLT PET to assess cellular proliferation in neoadjuvant trials of patients with rectal cancer,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Correlative biology
12500,NCT04430842,Determination of maximum tolerated dose (MTD),2020-07-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to maximum concentration of QBS10072S in plasma (Tmax)
12501,NCT02529878,radical resection rate,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,reaction rate
12502,NCT01738139,Maximum tolerated dose (MTD),2013-02-19,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12503,NCT02004782,Rate of symptomatic stricture formation,2022-03,WITHDRAWN,INTERVENTIONAL,['PHASE4'],Cost,Recurrence
12504,NCT00616941,Overview of Treatment-emergent Adverse Events (TEAEs),2008-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumor Measurement Results According to the Response Evaluation Criteria for Solid Tumors (RECIST) Up to 16 Weeks Post-Baseline
12505,NCT02123407,the number of harvested lymph nodes,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,the diameter of harvested lymph nodes
12506,NCT00858429,Time to tumor progression,2009-04-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12507,NCT01683422,One-year Survival Rate,2013-01-02,TERMINATED,INTERVENTIONAL,['NA'],,
12508,NCT04258657,DFS,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,OS
12509,NCT03101566,The Percentage of Patients Alive and Without Progression at 6 Months Following the Initiation of Treatment,2017-09-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Response Rate (ORR)
12510,NCT05785780,Up-to-date CRC screening,2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],Implementation Fidelity,Rate of CRC Screening Uptake by Glucose Control (Controlled vs. Uncontrolled) Among Participants with Type 2 Diabetes
12511,NCT01975454,Progression-free survival(PFS),2012-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Adverse events
12512,NCT06212700,Acceptability of the virtual multimodal hub.,2024-02-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Implementation Outcome: Maintenance
12513,NCT05171439,Bioinformatics analysis of single-cell sequencing in hepatocellular carcinoma,2022-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,adverse events(AE)
12514,NCT02052908,Incidence of toxicity,2014-01-27,COMPLETED,INTERVENTIONAL,['PHASE1'],,Changes in the number and type of immune and mesenchymal cells recruited to the colorectal mucosa
12515,NCT05961969,Completion of transabdominal ISR,2022-02-21,RECRUITING,OBSERVATIONAL,['NA'],,Fecal incontinence
12516,NCT05669482,To determine the efficacy of the RP2D identified in Part A,2023-03-22,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of abnormal laboratory values
12517,NCT03007550,Early operative morbidity and mortality rate,2017-01-04,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative hospital stay
12518,NCT03255434,Evaluation of neurotoxicity associated with Oxaliplatin,2017-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
12519,NCT02829385,Objective Response Rate (ORR),2016-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
12520,NCT05188586,Specificity,2022-12-06,RECRUITING,INTERVENTIONAL,['NA'],,Stage Shift
12521,NCT01147965,"The primary objective of this protocol is to determine the safety of immunization with Ad5 [E1-, E2B-]-CEA(6D), in patients with advanced or metastatic CEA-expressing malignancies, including Maximum Tolerated Dose (MTD).",2010-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The secondary objectives of this protocol are to evaluate CEA-specific immune responses to the immunizations and to obtain preliminary data on clinical response rate.
12522,NCT03161574,The rate of R0 resection,2017-08-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Reported Adverse events
12523,NCT00716209,,2012-09,UNKNOWN,OBSERVATIONAL,['NA'],,
12524,NCT04659603,Incidence of dose-limiting toxicites (DLTs)- Cohort C Part 1,2021-03-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Maximum concentration observed after infusion (Cmax) of gemcitabine metabolite
12525,NCT01105377,Confirmed Tumor Response,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Progression
12526,NCT02037048,Recurrence Free Survival (RFS) compared to historical averages,2014-02-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],"Prognostic effect of CTCs, Ki-67, and HER2 overexpression on pathologic response",Loco-regional control (LRC)
12527,NCT02054923,Change in screening centre adenoma detection rate before and after intervention,2014-03,COMPLETED,INTERVENTIONAL,['NA'],,Rates of proximal (to the splenic flexure) serrated polyps ≥10mm in size
12528,NCT05354674,progression free survival,2023-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,overall survival
12529,NCT00476970,Percentage of Eligible Patients In Study and Control Groups Who Undergo CRC Screening,2007-09,COMPLETED,INTERVENTIONAL,['NA'],,Number of Polyps and Cancers per 100 Patients in the Study vs Control Group
12530,NCT05561504,H. pylori resistance profiles,2021-03-31,RECRUITING,OBSERVATIONAL,['NA'],,risk factors for gastric cancer
12531,NCT02423343,Phase 1b: Maximum Tolerated Dose (MTD) of Galunisertib in Combination With Nivolumab,2015-01-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Overall Survival (OS)
12532,NCT03010722,"disease control rate (DCR), measured in months",2015-01,COMPLETED,OBSERVATIONAL,['NA'],,Median values of volume transfer constant (Ktrans) and enhancing fraction (EF) and their product KEF (product of summarised median values of Ktrans x EF/100) will be compared at baseline and on day 15
12533,NCT02159339,Metastasis and/ or recurrence of gastric carcinoma,2012-12,COMPLETED,OBSERVATIONAL,['NA'],,Disease-free (Recurrence/metastasis-free) survival (DFS) and overall survival (OS) of patients with gastric carcinoma after surgical resection
12534,NCT02946138,Progression-free survival of all patients,2016-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Objective responses rate
12535,NCT02762266,Number of Participants With a Local Progression Event,2016-02-27,TERMINATED,INTERVENTIONAL,['PHASE3'],,The Impact of Elevated Serum Alpha-Fetoprotein Level (AFP) on Overall Survival (OS)
12536,NCT01471743,Number of participants with post-op Infections,2011-11,COMPLETED,INTERVENTIONAL,['NA'],,
12537,NCT02181075,Patients Demonstrating >Two-fold Increase in the Amount of Intratumoural Doxorubicin Before and After Focused Ultrasound,2014-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Patients With Significant (Grade 3-5) Adverse Event(s) Deemed Related to FUS Procedure
12538,NCT04855331,Postoperative complications,2021-04-15,RECRUITING,INTERVENTIONAL,['NA'],Postoperative quality of life,The 90 days mortality rate after operation
12539,NCT05831150,Number of study participants who remain in clinical research until completion.,2024-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
12540,NCT05864755,Overall response rate ( ORR) per RECIST 1.1,2023-06-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Time To Progress(TTP) per RECIST 1.1
12541,NCT04523467,Progression-free survival (PFS),2020-12-01,UNKNOWN,INTERVENTIONAL,['NA'],Conversion rate,Adverse events
12542,NCT01892072,"the variation of the quantity of VEGF signal pathway genes in normal liver tissue,peri tumor,tumor and metastasis.",2012-10,UNKNOWN,OBSERVATIONAL,['NA'],,
12543,NCT01064375,To evaluate the safety and immunogenicity of a DNA immunisation approach where tetwtCEA DNA will be administered in combination with electroporation.,2009-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To compare effects (safety and immunogenicity) of additional adjuvance with GM-CSF
12544,NCT06329102,Surgical complications defined by Calvien Dindo II to V,2021-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Quality of life after surgery measured with the 15D instrument
12545,NCT00583674,Progression Free Survival (PFS),2007-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Patient Reported Outcomes
12546,NCT03777813,cPFS (centrally reviewed cPFS),2018-12-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Quality of Life OES18, used for patients with oesophageal cancer always complemented by the QLQ-C30 measuring 5 functional scales (physical, everyday activity, cognitive, emotional and social) and 3 symptoms scales (fatigue, pain, nausea and vomiting)"
12547,NCT00033384,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12548,NCT04415385,ORR,2020-06-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events (AEs) in the treatment of Camrelizumab in combination with apatinib
12549,NCT03600831,Disease-free survival (DFS),2018-08-20,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Quality of life(QOL)
12550,NCT02277834,"Compare the proteomic signature of pancreatic adenocarcinoma , pancreatic cancer and control participants to the disease process",2014-08,COMPLETED,OBSERVATIONAL,['NA'],,Compare the proteomic profile between pancreatic cancer and pancreatitis
12551,NCT01479894,Compare the prognosis of colon cancer patients compared to gene expression.,2011-11,COMPLETED,OBSERVATIONAL,['NA'],,
12552,NCT01276483,Radiologic-pathologic correlation,2011-02,COMPLETED,OBSERVATIONAL,['NA'],,
12553,NCT02420691,Number of Participants With Response Rate Per Response Evaluation Criteria in Solid Tumors Version 1.1,2015-08-25,COMPLETED,INTERVENTIONAL,['PHASE2'],Change in Ki-67 With Treatment,Progression Free Survival (PFS)
12554,NCT00480298,endoscopic evaluation of the nasal polyp size compared to baseline,2002-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Nasal Polyp score: endoscopic evaluation of the nasal polyp size compared to baseline. Nasal polyposis signs and symptoms including nasal discharge, nasal congestion, postnasal drip, sense of smell,olfactory test (sites Gent, Stockholm and Huddinge) and"
12555,NCT00681252,safety (Phase I: toxicities as assessed by NCI CTCAE version 3) and efficacy (Phase II: Feasibility as evaluated by RECIST),2008-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To evaluate immunological responses
12556,NCT03541304,clinical response rate,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],,overall survival
12557,NCT00003287,,1998-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
12558,NCT04342910,Overall Survival (OS) in PD-L1 Positive Participants.,2020-09-21,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Plasma concentration of apatinib
12559,NCT05389527,Major pathological response (MPR),2022-09-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse event (AE)
12560,NCT05039736,To evaluate overall response rate,2023-02-24,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
12561,NCT04021589,progression free survival,2019-07-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,overall survival
12562,NCT00725335,Disease free survival,2008-09,COMPLETED,INTERVENTIONAL,['NA'],,"overall survival,morbidity,postoperative mortality;blood loss,Liver function test,etc"
12563,NCT06325410,type of resected tumor,2013-01,COMPLETED,OBSERVATIONAL,['NA'],,
12564,NCT01285778,Three-year disease-free survival rate,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Predictive potential of different biomarkers
12565,NCT03710486,Number of Participants With Change From Baseline in Endoscopic Findings,2019-02-19,COMPLETED,OBSERVATIONAL,['NA'],,Number of Participants with AE Outcome
12566,NCT04137536,Evaluate toxicity,2019-10-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
12567,NCT04222114,Overall survival (OS),2020-10-06,RECRUITING,INTERVENTIONAL,['PHASE3'],,Tendency of theperipheral blood lymphocyte counts change associated with the intra-peritoneal infusion of catumaxomab
12568,NCT06123494,Overall survival (OS),2024-01-09,RECRUITING,INTERVENTIONAL,['PHASE3'],,Serum concentrations of SHR-A1811 toxin-binding antibodies and free toxin SHR169265
12569,NCT00003254,Confirmed Response Rate,1998-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicities
12570,NCT01745107,Disease-free survival time,2012-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,overall survival time
12571,NCT03520088,Changes in sexual dysfunction pre- and post-Total Mesorectal Excision,2018-09-03,UNKNOWN,INTERVENTIONAL,['NA'],,
12572,NCT02900677,Self-report Questionnaire,2015-08,UNKNOWN,INTERVENTIONAL,['NA'],Self-report Questionnaire,Self-report Questionnaire
12573,NCT05779917,Number of Patients with Dose Limiting Toxicity,2023-03-10,RECRUITING,INTERVENTIONAL,['PHASE1'],,Median CAR-T cell persistence
12574,NCT00862082,Maximum Tolerated Dose (MTD) of PR104 When Used in Combination With Standard Dose Sorafenib in the Phase I Population,2009-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pharmacokinetics (AUC) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group)
12575,NCT05141747,Adverse Events (AEs),2022-01-19,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Immunogenicity (ADA)
12576,NCT02970916,FOLFIRI+aflibercept efficacy in terms of Progression-free survival (PFS) with or without ACE polymorphisms.,2016-11,COMPLETED,INTERVENTIONAL,['PHASE2'],"Other biomarkers in serum and tumour tissue associated with cell and tumour growth and/or involved in the mechanism of action of FOLFIRI+aflibercept and their correlation with tumour-efficacy parameters (ORR, PFS and OS)",Number of participants with adverse events as assessed by CTCAE v4.0.
12577,NCT02935634,Kaplan-Meier Analysis of Progression Free Survival Rate (PFSR) at 24 Weeks,2016-11-29,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Laboratory Abnormalities in Specific Liver Tests
12578,NCT01628913,Progression Free Survival (PFS),2012-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Time to Treatment Failure (TTF)
12579,NCT00005869,,1998-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
12580,NCT01430052,Two year survival rate,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response rate
12581,NCT05996484,Pathologic complete remission (PCR),2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Change From Baseline in HRQoL Score Using EORTC Quality of Life Questionnaire-Oesophageal Module (QLQ-OES18)
12582,NCT02724267,Overall Survival,2012-11,COMPLETED,INTERVENTIONAL,['NA'],,Time to Progression
12583,NCT01219985,Number of Detected Uptakes on PET Images,2008-04,COMPLETED,INTERVENTIONAL,['NA'],,Lesions Uptake Measurement (SUVmax)
12584,NCT00626054,"Cleanliness of the bowel, as determined by the examiner, and ease of use, as determined by a patient satisfaction questionnaire in the two study arms",2009-03,COMPLETED,INTERVENTIONAL,['PHASE4'],,"Effect of external factors (demographic parameters, length of hospitalization, procedural diagnosis) on the quality of the bowel preparation"
12585,NCT05412355,long-term survival,2022-06-01,RECRUITING,OBSERVATIONAL,['NA'],,Postoperative complications
12586,NCT02588248,Adenoma Detection Rates,2017-04-27,TERMINATED,INTERVENTIONAL,['PHASE3'],,Patient Comfort Level Recorded on Post-procedure Survey
12587,NCT05883800,Incidence of acute gastro-intestinal toxicity equal or higher than grade 2,2023-06-22,RECRUITING,INTERVENTIONAL,['NA'],Patient reported bowel-related outcome measures,Incidence of late gastro-intestinal toxicity equal or higher than grade 2
12588,NCT01764477,The Maximum Tolerated Dose (MTD) of PRI-724 + Gemcitabine measured by the number of dose limiting toxicities (DLTs) that occur.,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Gene expressions in hair follicle epithelial cells
12589,NCT05502666,Colorectal Cancer Screening,2017-07-08,COMPLETED,INTERVENTIONAL,['NA'],,
12590,NCT03456206,CID diagnosis,2018-11-10,UNKNOWN,OBSERVATIONAL,['NA'],,
12591,NCT00641147,Polyp Number,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Change in Akt Phosphorylation Levels,Change in Apoptosis Index Levels
12592,NCT02826837,Maximum tolerated dose,2022-09-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Changes in global health/QoL standardized score at post-treatment visits compared to baseline
12593,NCT02863172,Variations in Clinical Features Compared Between Proband Group and Family Member Group,2012-05-22,RECRUITING,OBSERVATIONAL,['NA'],,Variations in the Overall Disease Phenotype Between Proband Group and Family Member Group
12594,NCT02140593,Surgical Rating Score,2014-09,COMPLETED,INTERVENTIONAL,['PHASE4'],,The Surgical Rating Score During Fascial Closure
12595,NCT01201655,,2010-01,UNKNOWN,OBSERVATIONAL,['NA'],,
12596,NCT02021253,Area under the plasma concentration versus time curve (AUC) of endotoxins circulating levels,2013-04,COMPLETED,INTERVENTIONAL,['NA'],,
12597,NCT03638297,Response rate,2018-08-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,duration of response
12598,NCT03486574,Genes with logarithm of odds (LOD)>2 in linkage analysis,2016-12-07,COMPLETED,OBSERVATIONAL,['NA'],,
12599,NCT05350917,Objective Response Rate (ORR),2022-06-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Study on the mechanism of drug resistance after progression
12600,NCT02672917,Group F - Determine the MTD and/or the RP2D of MVT-5873 administered in combination with the modified FOLFIRINOX regimen (mFOLFIRINOX) in the PDAC adjuvant setting,2016-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Group F - Evaluate time to recurrence
12601,NCT04566367,Detection rate of a second cancer or precancerous lesions,2020-09-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
12602,NCT02631590,Progression Free Survival (PFS),2016-07-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
12603,NCT00191412,Antitumor activity as measured by Response Evaluation Criteria in Solid Tumors,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival: Enroll. to death of any cause
12604,NCT03287947,Disease Control Rate,2017-11-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Treatment Administration of Nintedanib, as Measured by Average Daily Dose of Nintedanib."
12605,NCT00254436,Patient Iron Levels,2001-10-31,TERMINATED,INTERVENTIONAL,['PHASE3'],,
12606,NCT00005832,Survival rate in patients with advanced adenocarcinoma of the pancreas treated with R115777,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Assess confirmed response (complete & partial) in patients with measurable advanced adenocarcinoma of the pancreas
12607,NCT00003862,,1999-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12608,NCT01831037,Hepatocellular carcinoma,2015-07,WITHDRAWN,OBSERVATIONAL,['NA'],Regression of liver fibrosis,Profile with lowest risk for hepatocellular carcinoma
12609,NCT00260884,We expect to enter 50 patients per year and finish accrual of patient within 2.5 years.,1993-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
12610,NCT02729298,Incidence of dose-limiting toxicities (DLTs) and treatment emergent adverse events,2016-12-14,COMPLETED,INTERVENTIONAL,['PHASE1'],,Objective response rate using RECIST v1.1 and iRECIST
12611,NCT04298008,disease control rate (DCR) of AZD6738 and Durvalumab combination,2020-06-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,quality of life measurement
12612,NCT05345054,A database linking socioecological determinants of health with nationally validated surgical outcomes.,2022-08-01,COMPLETED,OBSERVATIONAL,['NA'],,
12613,NCT04111172,Antigen-specific T-cell response to guanylyl cyclase C (GCC),2020-11-10,SUSPENDED,INTERVENTIONAL,['PHASE2'],,
12614,NCT02131493,DFS,2015-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,OS
12615,NCT02446925,Y-90 distribution and concentration as determined by post embolization PET-CT,2015-05-01,TERMINATED,INTERVENTIONAL,['NA'],,Secondary outcome (time to death from first treatment)
12616,NCT05468008,Evaluate the utility of ESD for treatment of gastrointestinal lesions,2022-02-04,RECRUITING,OBSERVATIONAL,['NA'],,Safety- Adverse Events
12617,NCT03047837,NFκB,2017-03-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Metformin concentration
12618,NCT02898077,Overall Survival (OS),2017-03-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change From Baseline in Participant-Reported EQ-5D-3L Visual Analog Scale (VAS) Score
12619,NCT03307408,Dosage of the inflammatory cells in liver,2017-02-28,UNKNOWN,OBSERVATIONAL,['NA'],,Dosage of the glucose
12620,NCT00384878,"The primary end point of the study is confirmed objective response rates (by RECIST, Response Evaluation Criteria in Solid Tumors).",2006-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"The secondary end points of the study are progression-free survival, overall survival, and treatment-related toxicities."
12621,NCT01001377,Overall Survival,2010-02-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Adverse Events (AEs)
12622,NCT00844623,Adverse Events,2002-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumor response by WHO criteria
12623,NCT04843644,oral mucositis,2021-04-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Microbiota
12624,NCT00024427,Open Label Randomized Phase 3 Multi-Center Trial of PN401 plus high dose 5-FU versus Gemcitabine in Advanced Pancreatic Cancer Patients,2001-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,
12625,NCT05086627,Pathological complete response rate,2022-10-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
12626,NCT00482625,Reduction in Number of Positive IPMN Celss and Staining Intensity After Treatment,2007-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants Reported at Least 1 Adverse Event With a Grade of 3 and Above
12627,NCT05265221,Resection speed,2022-03-01,COMPLETED,OBSERVATIONAL,['NA'],,Complication rate
12628,NCT05086614,3-year disease-free survival rate,2021-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,rate of adverse events related to thymosin-alpha 1
12629,NCT05162898,RFS,2022-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,2-year OS%
12630,NCT03042091,"Incidence of post-operative surgical site infection (SSI) including superficial/incisional, deep, and organ space, anastomotic dehiscence and leak",2016-09,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Incidence of mortality
12631,NCT00006039,,1999-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12632,NCT00906984,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA'],,
12633,NCT01580410,"The Difference in the Number of Grade 3 or 4 Hematologic Toxicities (Leukopenia, Thrombocytopenia, and Neutropenia) Between the Mitomycin C and Oxaliplatin Treatments",2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life as Assessed by Functional Assessment of Cancer Therapy: General (FACT-G)
12634,NCT00020826,psychometric validity of the STO22 module,2001-04,COMPLETED,OBSERVATIONAL,['NA'],correlation between QLQ-C30 and STO22 scores,debriefing questionnaire information
12635,NCT02620228,Difference in mean between measured bioimpedance spectra from tumorous and nontumorous tissue,2016-06-09,COMPLETED,INTERVENTIONAL,['NA'],,
12636,NCT05245565,Postoperative anal function assessed by Vaizey scale,2021-05-01,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
12637,NCT04977882,Tolerance to solid diet,2020-10-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,C-Reactive Proteine
12638,NCT04323618,Improvement in reproducibility of respiratory-related tumour motion (via fiducial maker surrogacy) for liver cancer patients treated with the AV biofeedback respiratory guidance system.,2014-04,COMPLETED,INTERVENTIONAL,['NA'],,
12639,NCT04133324,CRP_D4/CRP_D2 Colorectal,2018-04-01,UNKNOWN,OBSERVATIONAL,['NA'],,CRP_D2 colorectal
12640,NCT04457284,Response,2020-11-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
12641,NCT01138124,Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin,2010-03,COMPLETED,OBSERVATIONAL,['NA'],,
12642,NCT05346146,R0-surgery resection rate,2021-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Biomarkers predictive of response and toxicity,All the adverse events by NCI CTCAE v 5.0
12643,NCT05982899,frailty trajectories,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
12644,NCT00321828,Major Morbidity Related to the Intact Primary Tumor,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival as Measured by Death From Any Cause
12645,NCT01020812,Freedom From Local Progression of TACE and SBRT at 12 Months,2009-09,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Median Progression Free Survival
12646,NCT01479907,"Assessment of gastrointestinal function-related quality of life at 1, 3 and 6 months postoperatively",2010-11,COMPLETED,INTERVENTIONAL,['NA'],,
12647,NCT01912443,Laboratory parameters,2013-08,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival (OS) of treatment line
12648,NCT01363843,Incidence of Complete Resection,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluate the Toxicity of Study Therapy
12649,NCT03563352,The way patients with cancer choose and obtain nutritional supplements to support medical management,2018-08-30,WITHDRAWN,OBSERVATIONAL,['NA'],,Associations of gastrointestinal side effects with specific diagnoses and respective medical therapies
12650,NCT04600154,Change in cachexia staging score from baseline,2021-08-10,RECRUITING,INTERVENTIONAL,['NA'],Progression free survival,QLQ-C30 Global health status/QoL
12651,NCT01850316,One year local progression-free rate,2013-07,UNKNOWN,INTERVENTIONAL,['NA'],,Functional imaging with 11C-choline/18F-FDG CT-PET and perfusion CT to that characterize treatment-related effects
12652,NCT01525953,Identification of prognostic factors for overall survival,2012-01,COMPLETED,OBSERVATIONAL,['NA'],,Disease-free survival
12653,NCT00103103,Response rate as measured by RECIST every 8 weeks,2005-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Molecular correlates on and off study treatment
12654,NCT03127072,Overall survival in subjects receiving RFA plus chemotherapy ± target therapy compared to chemotherapy ± target therapy alone was assessed from the date of study entry until death from the disease.,2017-04-30,UNKNOWN,INTERVENTIONAL,['PHASE4'],,The differences in the incidence or severity of adverse events in the RFA plus chemotherapy ± target therapy arm compared to the chemotherapy ± target therapy only arm were was assessed by of complications after therapy.
12655,NCT06134024,Rate of safety of endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections with use of double pigtail plastic stents introduced through the LAMS.,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Rate of long-term success of endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections with use of double pigtail plastic stents introduced through the LAMS.
12656,NCT00660153,"To determine the safety, tolerability, and maximum tolerated dose of tivozanib (AV-951) in combination with FOLFOX6 chemotherapy.",2008-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To characterize the pharmacokinetic profile of tivozanib (AV-951) and FOLFOX6 chemotherapy when administered together, and to assess the antineoplastic activity of the combination of tivozanib (AV-951) and FOLFOX6 chemotherapy."
12657,NCT01767675,determine the proportion of patients who are without evidence of disease progression,2013-01-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,pharmacokinetics
12658,NCT02702960,1 year disease-free survival (at 1 year after BMT),2016-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Efficacy measure- proportion off immunosuppression without graft versus host disease (GVHD) or liver rejection,Liver allograft failure
12659,NCT03902899,Proximal serrated polyp detection rate (PSPDR),2014-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Adenoma detection rate (ADR)
12660,NCT03172572,Major morbidity,2017-02-01,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
12661,NCT02000180,Difference Between Progressive and High-Fidelity Groups on Clinical Colonoscopy Peformance (JAG/DOPS),2013-06,COMPLETED,INTERVENTIONAL,['NA'],,"Colonoscopy Specific Performance, Communication Skills, and Global Performance on an Integrated Scenario"
12662,NCT06238843,overall survival(OS),2024-03-29,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,neutralizing antibody (NAb)
12663,NCT01420874,"Determining in a dose-escalation phase Ib trial the safety of 3 infusions of EGFR2Bi aATC, and a booster infusion after 3 months, for patients with advanced colorectal or pancreatic cancer.",2011-08-17,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival
12664,NCT00433602,"Incidence of symptomatic pulmonary embolism as assessed by ventilation/perfusion lung scan, pulmonary angiogram, or CT lung scan within 72 hours of detection of symptoms or during autopsy (during the 3-month observation period)",2006-11,COMPLETED,OBSERVATIONAL,['NA'],,
12665,NCT04397783,parastomal hernia rate by imaging,2019-04-15,UNKNOWN,INTERVENTIONAL,['NA'],,Ease / difficulty in the management of stomatherapy devices
12666,NCT02606097,Overall clinical benefit rate,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Changes in vital signs by body temperature,Overall survival (OS)
12667,NCT01626781,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
12668,NCT05052931,AE,2021-10-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
12669,NCT05552651,Rate of pCR,2022-09-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Rate of SAE,Rate of MPR
12670,NCT00675636,Identification of patients at high risk of developing hereditary colorectal cancer,2007-01,COMPLETED,OBSERVATIONAL,['NA'],,Establishment of a tissue and data repository
12671,NCT04123340,Feasibility of the use of co-registration software (>80%),2019-08-26,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quantitatively assessed ablation margin
12672,NCT03104439,Disease Control Rate,2017-05-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Median Overall Survival
12673,NCT04212598,Percentage of patients with disease progression within 2 years after treatment,2020-08-03,RECRUITING,INTERVENTIONAL,['PHASE2'],The number of patients with treatment-related toxicity between the treatment period and half a year after treatment,Percentage of patients who died within 2 years after treatment
12674,NCT02486094,"Apoptotic index, Ki67 and Geminin in cells per mm cubed from resected tumour",2015-06,COMPLETED,OBSERVATIONAL,['NA'],,Overall Survival (OS)
12675,NCT02024633,The number of patients who suffer adverse events,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Progression-free survival
12676,NCT00004142,Patient Tumor Response Rate,1998-08-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12677,NCT06125145,Describe the percentage of participants that complete 2 out of 3 study visits,2024-03-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Quality of Life
12678,NCT00952926,Frequency of local recurrence,2009-10,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
12679,NCT05827796,To evaluate the objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) in subjects with advanced pancreatic cancer.,2022-12-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of Treatment-Related AEs
12680,NCT03519412,Overall response rate (ORR),2019-01-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and Tolerability
12681,NCT03634332,Progression Free Survival,2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Evaluate Blood Translational Biomarkers--T cell receptor (TCR) sequencing,Overall Survival
12682,NCT01839877,Progression-free survival rate at 9 months,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
12683,NCT00912847,,1997-10,COMPLETED,OBSERVATIONAL,['NA'],,
12684,NCT00294476,"and Serum tumor markers as appropriate CEA, PSA. Additionally, ECOG performance status is evaluated before each treatment cycle",2005-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety assessments include Adverse events and laboratory values which are measured and evaluated before every treatment cycle
12685,NCT04482309,Objective Response Rate (ORR),2020-08-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,The immunogenicity of T-DXd assessed by the presence of ADAs for T-DXd
12686,NCT01060501,overall survival,1992-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Toxicity (WHO)
12687,NCT05841134,Percentage of Participants With Pathological Complete Response (pCR),2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events during the treatment and follow-up (safety)
12688,NCT02703142,"Number of participants with the major complications of gastric conduit (strictures, leakage, necrosis)",2015-10,COMPLETED,OBSERVATIONAL,['NA'],,Biological examination of gastric conduit as assessed by the Mitochondrial DNA copy number
12689,NCT02755311,Overall survival,2014-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Mortality
12690,NCT04500171,ColoCARE Completion Efficacy,2020-09-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
12691,NCT03043664,Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1),2017-07-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,ORR as Measured by Immune-related Response Criteria (irRC)
12692,NCT06055387,"Utilize CTCAE v5.0 to assess the grade and frequency of adverse events and treatment-related toxicity in frail and non-frail patient groups, and compare the differences between the two.",2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],,To compare overall survival between two distinct groups: frail and non-frail patients.
12693,NCT00636298,Progression-free survival,2008-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Response rate
12694,NCT04826406,Objective Response Rate (ORR),2021-02-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Safety as measured by the rate of AEs, SAEs and laboratory abnormalities"
12695,NCT02304289,"Pharmacokinetic analysis of Cmax, Cmin, Tmax, and AUC.",2014-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,"Quality of life based on the ""Functional Assessment of Cancer Therapy Hep-30 scale"" (FACT-Hep-30)"
12696,NCT05984602,Number of patients who proceeded to surgical resection,2023-07-14,RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of changes in outcome of surgery that is attributed to study drug
12697,NCT05318794,Feasibility and safety of combined neoadjuvant systemic chemotherapy and pressurised intraperitoneal aerosol chemotherapy (PIPAC),2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease recurrence and survival
12698,NCT05261542,Accuracy of intraoperative Flow Cytometry for cancer cell identification in colorectal cancer.,2017-01-26,COMPLETED,OBSERVATIONAL,['NA'],,
12699,NCT03759756,the diagnosis efficiency of the AI model,2018-12-01,COMPLETED,OBSERVATIONAL,['NA'],,
12700,NCT00429078,,2007-07,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
12701,NCT04734821,Evaluation of the usefulness of ICG fluorescence to guide lymphadenectomy in oncological esogastric resections,2021-04-01,RECRUITING,INTERVENTIONAL,['NA'],,Evaluation of the impact of fluorescence guidance in intraoperative evaluation of pre-anastomotic tissue perfusion
12702,NCT04486131,Lateral local recurrence,2020-10-06,RECRUITING,OBSERVATIONAL,['NA'],,Quality of life as assessed by the QLQ-C30
12703,NCT01786538,Progression-free survival,2013-06,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Number of participants with adverse events
12704,NCT06063941,Visual analogue scale scores at 30 minutes after chromoendoscopy,2023-10-10,RECRUITING,INTERVENTIONAL,['NA'],,Associated factors for visual analogue scale scores
12705,NCT01804166,Number of Samples Collected for the Identification of Biomarkers for Early Evaluation of Risk of Developing Hepatosplenic T-cell Lymphoma (HSTCL),2013-03-21,COMPLETED,INTERVENTIONAL,['PHASE4'],,
12706,NCT05360277,Disease-free survival,2023-08-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
12707,NCT05056337,Tumor response: Objective response rate (assessed based on mRECIST criteria),2021-08-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Adverse Events as assessed by CTCAE 5.0 criteria
12708,NCT06335420,Number and size of polyps found at the one-year follow up colonoscopy,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Acceptability of treatment
12709,NCT02625623,Overall Survival (OS),2015-12-28,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Stomach Cancer Specific (EORTC QLQ-STO22) Questionnaire Scores at End of Treatment (EOT)
12710,NCT00280176,Dose-limiting toxicity,2003-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Gene expression pattern of tumors as assessed by cDNA microarray analysis pre- and post-treatment
12711,NCT00149279,overall survival,1995-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,quality of life
12712,NCT00060268,,1997-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
12713,NCT02041819,response rate,2014-02,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Adverse events
12714,NCT02199223,Safety of regorafenib + panitumumab,2014-06,TERMINATED,INTERVENTIONAL,['PHASE1'],,
12715,NCT05113186,One-year local recurrence-free survival,2022-02-02,RECRUITING,INTERVENTIONAL,['PHASE2'],"Consittution of a sequential biobank comprising peripheral samples (serum, plasma)",Per nodule assessment of local recurrence
12716,NCT01729923,"Rate of CR, Assessed According to CEA and CA 19-9 Measurements and Response Evaluation Criteria in Solid Tumors (RECIST) 1.1",2013-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Relapse Free Survival in Patients Achieving CR
12717,NCT00778830,Percentage of Subjects With Best Overall Confirmed Response Rate (BORR),2009-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (SAEs), TEAEs Leading to Discontinuation and TEAEs Leading to Death"
12718,NCT06224738,Adverse effects,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Overall Survival (OS)
12719,NCT04310553,Overall survival,2017-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,"clinical benefit rate, CBR"
12720,NCT03471468,"Microparticles level will be assessed by automated and standardised measure of their procoagulant power using Kit STA©Procoag-PPL (Diagnostica Stago, Asnière, France)",2018-07-23,TERMINATED,INTERVENTIONAL,['NA'],,"Khorana score does assess the risk of thrombosis uner chemotherapy according to 3 levels :Score 0, 1, 2 or 3"
12721,NCT04915144,Compare the 12-month progression-free survival (PFS) of subjects receiving personalized or standard injected activity PRRT with Choi criteria.,2023-01-15,WITHDRAWN,INTERVENTIONAL,['PHASE2'],PFS and QoL scores to ctDNA levels,Correlation of QoL scores (EQ-5D) to ctDNA
12722,NCT05599347,Anti-drug antibody development,2023-04-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Endoscopic remission
12723,NCT03345563,Functional Assessment of Chronic Illness (FACIT)-Fatigue Scale,2019-07-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Consensus Sleep Diary
12724,NCT01423214,Surgical quality based on pathological examination,2013-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,5-year disease-free survival rate
12725,NCT00760604,"Disease free survival defined as the time from surgical resection to the time of recurrent disease, death from esophageal cancer, or death from any cause.",2008-09,TERMINATED,INTERVENTIONAL,['PHASE3'],,To determine mortality and morbidity in arm A vs. arm B
12726,NCT05575635,pCR,2022-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,TRAEs
12727,NCT02469480,Rise or normalization of hemoglobin,2015-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
12728,NCT00325494,"Safety and Tolerability as a measure of physical examinations, vital signs, and ECGs",2006-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Objective Tumor Response Rate Assessed by Investigator
12729,NCT01891539,tumor response,2013-05,UNKNOWN,OBSERVATIONAL,['NA'],,time to progression
12730,NCT06305169,Measurement of the specificity and negative predictive value of serum biomarkers in gastric cancer,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Creating a scoring system for patients that warrant urgent endoscopy on the cancer pathway
12731,NCT04739046,Objective Response Rate,2021-02-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
12732,NCT00606983,Re-insertion rate of urinary catheter after removal,2007-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Scores of IPSS (International Prostatic Symptom Score) and the results of uroflowmetry
12733,NCT02022852,Disease free survival,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],Compliance,Pathologic complete response
12734,NCT03511183,Time to failure of strategy（TFS）,2018-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Time to failure of strategy（TFS）
12735,NCT00395252,disease free survival,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events
12736,NCT03702998,Incidence of HCC,2018-12-01,COMPLETED,OBSERVATIONAL,['NA'],,Mortality due to HCC or liver-related conditions
12737,NCT00160875,pathological complete response,2009-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,PET scan parameters (radiological)
12738,NCT04431791,Time To Treatment Failure,2020-05-25,UNKNOWN,OBSERVATIONAL,['NA'],,Incidence of adverse events（AEs）
12739,NCT02002416,Overall survival,2006-01,UNKNOWN,OBSERVATIONAL,['NA'],,Positive rate of C-met
12740,NCT05410197,Objective Response Rate (ORR),2022-10-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events (AE)
12741,NCT04906044,The incidence of serious adverse events,2021-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Wexner score
12742,NCT01980238,"anastomotic leakage, reoperation and mortality rate",2011-01,UNKNOWN,INTERVENTIONAL,['NA'],hospital stays and costs,ileus rate
12743,NCT04856787,Phase 3:PFS,2021-06-22,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Duration of response
12744,NCT01212822,Disease-free Survival,2011-04-27,COMPLETED,INTERVENTIONAL,['PHASE2'],Change in Biomarker Levels,Progression Free Survival
12745,NCT03323866,Disease specific quality of life questionnaire,2017-05-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,Endoscopic evaluation of the nasal cavities
12746,NCT06033716,depression,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
12747,NCT03809403,Presence of ctDNA,2019-02-05,UNKNOWN,OBSERVATIONAL,['NA'],,MSI status
12748,NCT01126866,surgically complete resectability; S-CR,2009-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Survival rate (OS) and progression free survival (PFS)
12749,NCT02472249,Liver blood flow,2016-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,
12750,NCT00591279,evaluate strategies for the surveillance of post-polypectomy patients,1981-02,COMPLETED,OBSERVATIONAL,['NA'],,
12751,NCT05915637,Fatigue Assessment,2021-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
12752,NCT00003748,To determine the antitumor activity of irinotecan hydrochloride (CPT-11) in patients with unresectable adenocarcinoma of the esophagus and gastric cardia who have failed prior chemotherapy,1998-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluate the toxicities of irinotecan hydrochloride (CPT-11) in the patient population
12753,NCT04913662,Recommended dose,2021-04-26,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
12754,NCT01662869,OS in the Intent-To-Treat (ITT) Population,2012-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,European Quality of Life-5 Dimensions (EQ-5D) Questionnaire Score
12755,NCT03358849,Maximum Tolerated Dose,2017-10-17,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12756,NCT00601627,One Year Survival Rate,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Treatment Failure
12757,NCT03068403,Area under the echo-power curve (AUC),2018-06-18,COMPLETED,INTERVENTIONAL,['NA'],,mrTNM staging
12758,NCT02448810,Part 1: Number of Participants With Occurrence of Dose Limiting Toxicity (DLT),2015-06-15,TERMINATED,INTERVENTIONAL,['PHASE2'],,Change From Baseline for Quality of Life (QoL) Measure - European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
12759,NCT00397904,Complete and Partial Response Rate,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12760,NCT02665702,Progression Free Survival,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
12761,NCT01964235,Time to progression using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1,2016-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Tolerability of study drug
12762,NCT00766220,Progression Free Survival,2009-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
12763,NCT02435758,Sexual function,2015-04,COMPLETED,INTERVENTIONAL,['NA'],,Urinary function
12764,NCT00019435,,1998-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12765,NCT00797251,The primary outcome is the safety of the anatomical right posterior sectionectomy performed IOUS-guided finger compression.,2007-09,UNKNOWN,OBSERVATIONAL,['NA'],,The secondary outcome is the efficacy of the anatomical right posterior sectionectomy performed by IOUS-guided finger compression.
12766,NCT01308086,Relapse Free Survival,2010-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Safety Profil according to NCI-CTAE v 3.0
12767,NCT04401800,Overall Response Rate (ORR) as assessed by Central Imaging Facility based on RECIST v1.1,2020-09-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-Free Survival (PFS)
12768,NCT00407407,Primary: Safety/tolerability endpoints are the maximum tolerated dose and dose-limiting toxicities,2006-11-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,"Safety-AEs, SAEs, Lab abnormalities, incidence of patients experiencing dose modification of those interruptions &/or premature of d/c pf study drug"
12769,NCT02980861,Number of group Splenic Hilum (No.10) lymph nodes harvested,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of life
12770,NCT01531621,Resectability,2012-02,RECRUITING,OBSERVATIONAL,['NA'],,Radiological assessment
12771,NCT00238407,Proportion of patients without local failure measured 6 months after completion of study treatment,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Dysphagia as measured 6 months after completion of study treatment
12772,NCT03686254,"Overall survival (OS), Month",2018-07-16,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"Time to progression (TTP), Month"
12773,NCT00027768,Recurrence-free survival,2001-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Overall survival
12774,NCT01857726,Overall survival,2013-07,WITHDRAWN,INTERVENTIONAL,['NA'],,Progression-free survival
12775,NCT03210298,Overall survival,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],,Quality of life according to QLQ-30 of EORTC
12776,NCT04229459,Incidence of Treatment-Emergent Adverse Events (Safety),2019-12-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
12777,NCT05984511,Overall survival (OS),2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Adverse events (AEs)
12778,NCT04416685,peri-operative or postoperative complication,2014-05-01,COMPLETED,INTERVENTIONAL,['NA'],in hospital mortality,hospital stay
12779,NCT02188615,Overall survival rate,2011-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Mortality of perioperation
12780,NCT03853928,Number of patients developing Hepatocellular carcinoma,2019-05-01,UNKNOWN,INTERVENTIONAL,['NA'],,Adverse events found in cirrhosis with or without treatment with probiotics.
12781,NCT06276686,withdrawal rate,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Physical activity levels
12782,NCT02607826,Response to therapy on MRI or CT scancs will be measured using the RECIST criteria version 1.1.,2016-11,UNKNOWN,INTERVENTIONAL,['NA'],,
12783,NCT01641783,progression free survival,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,biomarkers
12784,NCT05357846,Overall survival,2022-11-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Perioperative mortality
12785,NCT06034197,Feasibility of VGT-309,2023-09-27,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
12786,NCT04139070,Incidence of Treatment-Emergent Adverse Events (CTCAE),2020-06-15,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Tumor volume
12787,NCT04428905,Quality of life: survey,2020-07-11,RECRUITING,INTERVENTIONAL,['NA'],Outcome Measure for facilitators,
12788,NCT02222259,Quality of life,2014-09,COMPLETED,INTERVENTIONAL,['NA'],,Functional status
12789,NCT05943288,Positive Predictive Value (PPV),2023-04-25,RECRUITING,OBSERVATIONAL,['NA'],Non-neoplastic resection rate,Endoscope withdrawal time
12790,NCT03800693,Effect of 2 versus 6-hour oxaliplatin infusion time on neuropathy as measured by patient reported outcome (PRO) scores on the European Organization for Research and Treatment of Cancer (EORTC) chemotherapy-induced peripheral neuropathy (CIPN-20) scale,2019-03-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,Frequency of dose holds or reductions
12791,NCT04070898,Development of acute urine retention after removal of the bladder catheter after colon surgery.,2019-09-15,UNKNOWN,INTERVENTIONAL,['NA'],,Morbidity changes
12792,NCT00726622,Comparing Laparoscopic-assisted Resection to Open Rectal Resection for Rectal Cancer as Measured by the Percentage of Patients With Successful Resection Based on Pathological Evaluation.,2008-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Bowel and Stoma Function
12793,NCT05620004,"Number of participants with treatment-related adverse events as assessed by NCI-CTCAE 5.0.""",2021-11-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change in tumor volume before and after treatment
12794,NCT03648632,Resection rate for all patients starting SBRT,2018-08-22,COMPLETED,INTERVENTIONAL,['NA'],,Mortality
12795,NCT01412684,Splenic function,2011-09,WITHDRAWN,OBSERVATIONAL,['NA'],,Lymph node retrieval
12796,NCT03533582,Response rate for Group F patients,2018-05-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Percentage of participants with adherence to surgical guidelines,
12797,NCT06163729,Pathologic complete response (PCR),2022-08-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,R0 resection rate
12798,NCT03485105,overall survival,2017-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,
12799,NCT03592407,Incidence of adverse events per Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.0,2018-07-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
12800,NCT03781323,Proportion of Patients With a Complete Clinical Response.,2019-05-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Proportion of Patients With Survival
12801,NCT05275530,Overall completion of any Colorectal Cancer Screening test,2022-02-21,COMPLETED,INTERVENTIONAL,['NA'],,Colorectal cancer screening uptake by modality
12802,NCT04348188,Changes in Health Related Quality of Life: EORTC QLQ-30,2020-06,UNKNOWN,INTERVENTIONAL,['NA'],,Valuation of the measured force
12803,NCT02226107,Colonoscopy Completion,2014-01,COMPLETED,INTERVENTIONAL,['NA'],,
12804,NCT06264921,Objective Response Rate (ORR),2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Accumulation ratio (AR)
12805,NCT04937647,neoplasia detection rate,2021-06-16,RECRUITING,OBSERVATIONAL,['NA'],,Endoscopist neoplasia detection rate
12806,NCT06109272,Stage 2: Overall Survival (OS),2024-01-11,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Change from Baseline in Global Health Status (GHS)/Quality of Life (QoL) Domain as Measured by the GHS/QoL Domain of the EORTC QLQ-C30
12807,NCT03931044,Accuracy (%; 95% CI),2019-04,UNKNOWN,INTERVENTIONAL,['NA'],,Mean difference of total number of LNs retrieved during the lymphadenectomy of the D2 anatomical plane (mean±DS).
12808,NCT05507112,Pathological complete response (pCR) rates,2022-09-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Patient reported outcome: Functional outcome according to Wexner score
12809,NCT05866172,overall survival,2023-05-10,RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse Events
12810,NCT00717756,Response Rate by Recist Criteria,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12811,NCT01683240,Efficacy of cholangioscopy in gallstone therapy and stricture diagnosis,2011-02,COMPLETED,INTERVENTIONAL,['NA'],,Stricture diagnostic
12812,NCT00495924,,2006-10,COMPLETED,OBSERVATIONAL,['NA'],,
12813,NCT02647125,Local control rate,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,progress-free survival
12814,NCT00022477,Response rate of BMS-247550 in colon cancer,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12815,NCT02945566,Phase III Primary Outcome: Organ Preservation,2017-06-14,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Phase III: For analyses incorporating the non-randomised standard surgery comparator - Decision Regret
12816,NCT06030622,Primary Outcome: Safety and tolerability,2023-12-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Secondary Outcome: Biomarkers
12817,NCT03572283,Change in cell proliferation by Ki-67 expression in tumor cells,2018-04-08,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Number of Adverse Events
12818,NCT01195415,Median Percent at Baseline and 3 Weeks in CD44+/ CD24+/ ESA+ Cells From Needle Biopsy Calculated Using FACS,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Treated Patients Experiencing Grade 3+ Toxicity Per National Cancer Institute Common Toxicity Criteria (CTC) Version 3.0
12819,NCT03351959,Overall Survival,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Molecular Profile of N+
12820,NCT03465501,Evaluation of the tolerance of interstitial brachytherapy of the anal canal,2007-08-17,COMPLETED,OBSERVATIONAL,['NA'],,Comparison of the incidence of toxicities (CTCAE v4) between the 2 groups
12821,NCT04651634,Incidence of severe OM,2021-06-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,Analgesic use for OM
12822,NCT04763707,serum Visfatin & serum Vaspin levels,2021-04-01,COMPLETED,OBSERVATIONAL,['NA'],,
12823,NCT00220142,,2003-11,COMPLETED,OBSERVATIONAL,['NA'],,
12824,NCT04773626,Evaluate the relationship between tumor deposits and prognosis of colorectal cancer patient.,2021-06,UNKNOWN,OBSERVATIONAL,['NA'],,
12825,NCT01523457,Progression Free Survival,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Correlate Time to Progression, Objective Response, and Overall Survival With Early Changes in Glucose Metabolism Using FDG-positron Emission Tomography (PET) Scanning"
12826,NCT00002947,,1996-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,
12827,NCT03958188,Standardization of a reading grid for PreOPerative Imaging of NeuroEndocrine Tumors,2019-03-31,UNKNOWN,OBSERVATIONAL,['NA'],,
12828,NCT00003548,,1998-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12829,NCT04598984,The Role of Serum Adipokines in Predicting Response to Neoadjuvant Therapy in Patients with Rectal Cancer,2020-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
12830,NCT00247676,Objective Response (CR or PR),2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Plasma Concentration of Soluble KIT (sKIT)
12831,NCT05475301,Overall survival of patients with locally recurrent rectal cancer,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
12832,NCT02596256,Progression free survival,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
12833,NCT01847495,Number of participants with adverse events related to toxicities from concurrent SBRT and irinotecan,2013-10,WITHDRAWN,INTERVENTIONAL,['NA'],,Overall survival
12834,NCT04720924,Detection rate of early cancer and precancerous lesions on upper gastrointestinal tract confirmed by pathological examination,2021-01-16,UNKNOWN,INTERVENTIONAL,['NA'],,"Detection rate of early cancer and precancerous lesions on upper gastrointestinal tract from senior, intermediate and primary endoscopist with assistance of AQCS."
12835,NCT02608879,Oral Mucositis Severity - NCI Scale,2014-03,COMPLETED,INTERVENTIONAL,['NA'],,Change in Quality of Life as Measured by the Composite Score of the EORTC
12836,NCT00763776,Intra-operative blood loss during liver transection (ml).,2008-07,TERMINATED,INTERVENTIONAL,['NA'],,60-day postoperative complications
12837,NCT00405587,Percentage of Participants With BOR of CR or PR According to RECIST v1.0 - Dose Escalation: MBP Formulation,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Tumor Levels of Phosphorylated Extracellular Signal-Regulated Kinapse (ERK), Cyclin D1, and Ki-67"
12838,NCT01967875,Progression-Free Survival (PFS),2013-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of Life(QOL)
12839,NCT02443324,Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs),2015-07-29,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab
12840,NCT05225116,Number of patients who complete pre-op treatment and proceed to surgery,2023-01-08,RECRUITING,INTERVENTIONAL,['PHASE1'],,Recurrence free survival(RFS)
12841,NCT01350648,Progression of liver disease in patients with HBV,2011-08-23,COMPLETED,OBSERVATIONAL,['NA'],,
12842,NCT02298010,Topographic pattern of metastasis to regional lymph node stations,2016-01,COMPLETED,OBSERVATIONAL,['NA'],,recurrence pattern
12843,NCT04517708,Change of quality of life after 8 weeks: European Organisation for Research and Treatment of Cancer (EORTC) version 3.0,2016-01-15,COMPLETED,INTERVENTIONAL,['NA'],,
12844,NCT03749005,Impact on operation strategy of three dimensional visualization technique,2017-04-18,UNKNOWN,OBSERVATIONAL,['NA'],,1-year disease free survival rate
12845,NCT05755685,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2023-02-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,the recurrence rate of metastasis and long-term survival of participants accepted the treatment of rmhTNF in the treatment of peritoneal metastases in colorectal cancer.
12846,NCT00646022,Study the natural history of familial carcinoid tumors,2008-08-25,RECRUITING,OBSERVATIONAL,['NA'],,Screen for occult disease and determine whether early detection affects the natural history of the disease
12847,NCT00623831,"Number of Participants With Pyrogenicity at Each Dose Level Tested in the Intrasubject Dose Escalation Performed Over a Dose Range of 250 to 547,000 EU",2007-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Best Overall Tumor Response
12848,NCT05456165,Incidence and Severity of Adverse Events,2022-05-19,TERMINATED,INTERVENTIONAL,['PHASE2'],,T-cell response using Peripheral Blood Mononuclear Cells (PBMCs)
12849,NCT01741597,Change in volume transfer coefficient (Ktrans) during DCE-MRI with tumor-homing peptide iRGD compared to a baseline DCE-MRI without tumor-homing peptide iRGD,2014-07,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,The potential for tumor-homing peptide iRGD to enhance uptake of key anti-cancer agents
12850,NCT04658147,Number of patients who complete pre-op treatment and proceed to surgery,2021-05-28,RECRUITING,INTERVENTIONAL,['PHASE1'],,Disease free survival (DFS) at 5 years
12851,NCT05506696,25OHD level,2012-09-24,COMPLETED,INTERVENTIONAL,['NA'],,
12852,NCT05774964,Progression Free Survival (PFS),2023-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
12853,NCT06152289,Develop an artificial intelligence solution to help with diagnosis in VCE,2023-02-10,RECRUITING,OBSERVATIONAL,['NA'],,Evaluation of the diagnostic performance of the A.I. solution in terms of quality of preparation of the various segments of the digestive tract
12854,NCT01882920,rate of abdominal complications,2010-06,COMPLETED,INTERVENTIONAL,['NA'],length of hospital stay,Overall Survival
12855,NCT04907539,RXC004 + nivolumab Combination: Objective response rate (ORR) using each patients BOR according to RECIST 1.1,2021-11-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of patients with adverse events (AEs)
12856,NCT05498168,The ratio of predicted neoantigens being immunogenic,2022-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
12857,NCT00005938,,2000-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12858,NCT01065805,Phase II: To determine general biodistribution of 18F-FLT and correlate 18F-FLT uptake with hENT1 expression and Ki-67 scores.,2009-03-20,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Phase II: to correlate 18F-FLT uptake with patient outcomes (treatment response, progression-free survival, overall survival), over the first 12 months of follow-up after completion of tx, subsequently over the remainder of the disease course"
12859,NCT05035108,The incidence of adverse events (safety and tolerability).,2020-11-10,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Electrolyte level
12860,NCT04615312,To determine the maximum tolerated dose of a CDK4 / 6 inhibitor and a MEK inhibitor therapy,2020-11-14,UNKNOWN,INTERVENTIONAL,['PHASE1'],,ORR
12861,NCT00209716,Determine the DLT(Dose Limiting Toxicity) and MTD(Maximum Tolerated Dose) in Phase I setting. Determine the clinical response rate with Recommended dose in Phase II setting.,2003-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determine the MST(Median Survival Time) and PFS(Progression Free Survival) in Phase II setting.
12862,NCT05115916,Overall Colorectal Cancer Screening Uptake,2019-08-28,COMPLETED,INTERVENTIONAL,['NA'],,Effect of electronic primer message on CRC uptake among participants who opened
12863,NCT04338685,Number of Participants with Adverse Events (AEs) According To NCI CTCAE v5.0,2020-07-16,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
12864,NCT01952353,overall survival time,2006-02,COMPLETED,INTERVENTIONAL,['PHASE4'],,Number of Adverse Events
12865,NCT02089386,Extent of Barrett's involvement and changes in histology,2014-07-09,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Changes in the length of Barrett's esophagus involvement
12866,NCT05579340,Change in peak oxygen consumption (VO2peak),2023-04,RECRUITING,INTERVENTIONAL,['NA'],,Postoperative complications
12867,NCT05703555,intratumoral DM4 concentration,2024-02-16,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,features in tumor micro-environment
12868,NCT03238820,Complications,2014-01-10,COMPLETED,INTERVENTIONAL,['NA'],,Body composition
12869,NCT01225744,Objective response rate (according to RECIST criteria),2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to progression (TTP)
12870,NCT00044343,Tumor response rate (complete or partial).,2002-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to response duration of response time to progression 4-month progression-free survival 6-month progression-free survival overall survival safety data biomarkers
12871,NCT05631015,The accuracy of recommentions for different disease with deep learning algorithm,2012-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,The F-score of gastric diseases with deep learning algorithm
12872,NCT04439812,evaluate the influence of positive margins on the tumour's recurrence and OS after gastrectomy for GC,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,The secondary outcome was to analyse the possible confounding factors that could affect the recurrence and OS after gastrectomy.
12873,NCT00752570,To estimate the treatment effect as measured by progression free survival (PFS) in subjects treated with AMG 386 + FOLFIRI relative to subjects treated with FOLFIRI + placebo.,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To evaluate patient reported outcomes (PROs), relative dose intensity, incidence of anti AMG 386 antibody formation, pharmacokinetics of AMG 386 (Cmax and AUC) and safety (incidence of AEs and significant laboratory changes)"
12874,NCT03455595,Evaluation of the CONECCT endoscopic score so as to improve colon therapeutic treatment polyps,2017-02-01,COMPLETED,OBSERVATIONAL,['NA'],,
12875,NCT04889456,30-day morbidity with Clavien-Dindo grading,2021-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,"Long term morbidity: incisional hernia, adhesion related small bowel obstruction, readmissions, reinterventions"
12876,NCT05051592,Detection rate of alterations of anti-epidermal growth factor receptor primary resistance using Circulating tumour DNA,2021-03-26,UNKNOWN,OBSERVATIONAL,['NA'],,Adverse reactions experience by patient
12877,NCT03263741,Objective response rate(ORR),2017-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease control rate(DCR)
12878,NCT00335595,Determine the free time to disease progression,2006-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Prognostic factor of the K-Ras gene mutation
12879,NCT02576080,Rate of metastatic relapse in GIST patient,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Patients' quality of life
12880,NCT03674073,Safety of neoantigen-based DC vaccine as measured by the number of subjects experiencing each type of adverse event according to the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0.,2018-10-15,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Progression-free survival at 2 years
12881,NCT01586117,Acute radiation-induced toxicity: daily diarrhea frequency,2012-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
12882,NCT00183846,"To determine the maximum tolerated dose of irinotecan when administered as a 5-day continuous infusion with concomitant radiation therapy in patients with upper gastrointestinal tumors (pancreas, stomach, duodenum, and common bile duct)",2000-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,To obtain preliminary information related to the efficacy of this combination
12883,NCT00243633,Medical and economic interest of CEUS,2005-04,COMPLETED,INTERVENTIONAL,['NA'],,Harmony inter-readers
12884,NCT02711553,Progression Free Survival (PFS),2016-05-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Change From Baseline in Participant-Reported EQ-5D-5L Visual Analog Scale (VAS) Score
12885,NCT01505413,Response rate,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
12886,NCT03051464,TME-free survival,2017-04-25,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Overall Quality of life
12887,NCT01995227,Safety,2013-12,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival (OS),Tumor Biomarker Status
12888,NCT01510561,Safety (change in hematology and chemistry laboratory values from baseline),2012-03,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Efficacy
12889,NCT00338039,Median Overall Survival,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12890,NCT04636008,Adverse reaction,2020-08-14,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life questionnaire
12891,NCT01041404,Overall Survival - Time to Event,2005-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Trastuzumab Maximum Serum Concentration (Cmax)
12892,NCT00281996,Overall survival at 6 months,2005-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,
12893,NCT00068068,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12894,NCT02339116,Progression Free Survival 2 (PFS2),2015-02-26,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Toxicity Rate
12895,NCT01626963,Operative Time,2014-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,CRP
12896,NCT01655641,Primary objective of the study is to compare transfusion requirements and Mortality in patients receiving Tranexamic acid (Cyklokapron®) and those not receiving it.,2012-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Secondary outcome measure
12897,NCT04523662,PFS,2020-08-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
12898,NCT01789723,Optimal dose and schedule of Fusilev to prevent or reduce mucositis,2013-03,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Overall Response Rate (ORR),Relationship between Fusilev use and oral mucositis
12899,NCT04617067,Overall survival (OS),2020-10-16,COMPLETED,INTERVENTIONAL,['PHASE2'],Incidence of hypercalcaemia,Tumour response rate Duration of response
12900,NCT04913896,Predictive value of CT and MRI after the neoadjuvant treatment for developing a pCR at surgery,2021-06-01,UNKNOWN,OBSERVATIONAL,['NA'],,Prediction model based on CT and MRI of response in AGC
12901,NCT03078348,Rate of Fecal Immunochemical Test (FIT) Kit Return Per Study Arm,2011-12-05,COMPLETED,INTERVENTIONAL,['NA'],,Rate of Diagnostic Colonoscopy
12902,NCT04936399,Distribution of patient quality of life through EQ-5D-3L (EQ-5D) every two weeks for 24 weeks post-treatment initiation following patient enrolment into the EAMS,2020-06-25,COMPLETED,OBSERVATIONAL,['NA'],,
12903,NCT00178698,Survival,2002-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of Life
12904,NCT04391426,Composition of the biliary microbiota,2021-06-03,UNKNOWN,OBSERVATIONAL,['NA'],,
12905,NCT03556345,Objective Response Rate （ORR）,2018-07-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival(OS)
12906,NCT05883644,Objective response rate (ORR),2023-06-27,RECRUITING,INTERVENTIONAL,['PHASE3'],,Change from baseline in HRQoL as assessed by EORTC QLQ-HCC18
12907,NCT01859442,Exponential rate constant of post-chemoradiotherapy and post-exercise phosphocreatine recovery.,2012-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Alterations in mitochondrial energetics post-chemoradiotherapy and exercise
12908,NCT05356039,Resection,2022-04-19,RECRUITING,OBSERVATIONAL,['NA'],,Quality of Life at 24 months after inclusion
12909,NCT04415567,Disease-free survival (DFS),2018-06-01,COMPLETED,OBSERVATIONAL,['NA'],3-year Recurrence rate (RR),Overall survival (OS)
12910,NCT06078787,To evaluate the ORR according to RECIST 1.1 following Olaparib administration,2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,To evaluate the OS according to RECIST 1.1 following Olaparib
12911,NCT04423354,Perioperative mortality,2019-03-25,UNKNOWN,INTERVENTIONAL,['NA'],,5-year disease-free survival rate
12912,NCT04743479,Hazard ratio (HR),2020-12-01,RECRUITING,OBSERVATIONAL,['NA'],,Diagnostic yield
12913,NCT03219372,Time to Recurrence,2018-09-27,TERMINATED,INTERVENTIONAL,['PHASE2'],,Levels of Liver Tissue Markers Related to HCC
12914,NCT04400383,Stage 2: The incidence and case number of DLT (Dose Limiting Toxicity) during observation period,2020-06-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Efficacy: overall survival (OS) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
12915,NCT01443377,Histopathological complete response rate (pCR),2011-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,overall survival
12916,NCT00025090,Recurrence-free survival,2001-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Cause-specific and overall survival
12917,NCT05379205,Post-surgery complications.,2022-11-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Fecal microbiota analysis
12918,NCT03273231,natural killer cell cytotoxicity,2017-09-01,UNKNOWN,INTERVENTIONAL,['NA'],,metastasis
12919,NCT04095299,Rectal preservation at two years,2020-01-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Frequency of grade 3-4 toxicity according to CTCAE v4
12920,NCT04856423,The accuracy of us-qFIT to diagnose colorectal advanced adenoma.,2021-04-19,UNKNOWN,OBSERVATIONAL,['NA'],,Develop a predictive model of advanced colorectal neoplasms which includes the value of us-qFIT.
12921,NCT02002299,invasive front growth pattern,2013-08,UNKNOWN,OBSERVATIONAL,['NA'],,
12922,NCT05470738,"The main study's objective is to definite the effective rate of adjuvant chemotherapy performed after surgery (at the 3-month post operatively), which is essential marker recognized as improving overall survival.",2022-09-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,"The secondary objective of the study is to know, in patients operated for pancreatic adenocarcinoma, the rate of postoperative complications, the rate of the postoperative morbidity and mortality, and the quality of the resection."
12923,NCT03150628,Mortality,2017-08-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Readmissions
12924,NCT01300858,Tumor Growth Assessment by X-ray/CT,2011-06,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of study subjects with adverse events
12925,NCT00052559,Maximum tolerated dose of bevacizumab when administered concurrently with 5-fluorouracil (5-FU) and external beam radiation therapy (EBRT) in patients with cT3 and T4 rectal cancer prior to surgery,2002-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival
12926,NCT00004150,,1999-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
12927,NCT01375699,The difference in left ventricular ejection fraction (LVEF) between arms,2011-08-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Comparison of candidate early markers of cardiac injury
12928,NCT06190730,SASSI,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
12929,NCT03041662,death,2011-10-31,COMPLETED,OBSERVATIONAL,['NA'],,biliary dysplasia
12930,NCT04526886,Unplanned chemotherapy treatment delay,2020-10-15,COMPLETED,INTERVENTIONAL,['NA'],,Out of pocket costs associated with chemotherapy treatment visits
12931,NCT02146313,Percentage of Participants with Adverse Events (AEs) or Serious Adverse Events (SAEs),2014-06-22,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression-free Survival (PFS) as Assessed by RECIST v1.1
12932,NCT01372787,"Prevalence and severity of patient-reported symptoms as measured by the NFOSI-18, the FACIT-F subscale, and the FACT/GOG-AD and NTX subscales",2011-04-12,UNKNOWN,OBSERVATIONAL,['NA'],,
12933,NCT04947930,Sensitivity and specificity of the screening tool generated from fecal metagenomics and metabolomics data.,2021-07,UNKNOWN,OBSERVATIONAL,['NA'],,
12934,NCT02387268,Safety as Measured by Number of Serious Adverse Events and Major Complications.,2015-05,COMPLETED,INTERVENTIONAL,['NA'],,Percentage of Participants in Whom the Cecum Was Reached
12935,NCT04710641,Progression free survival (PFS),2022-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
12936,NCT00792285,colorectal cancer screening,2005-03,COMPLETED,INTERVENTIONAL,['NA'],,colonoscopy screening
12937,NCT01719380,Phase 2: Progression Free Survival (PFS),2012-11-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Phase 2: Number of Participants With Any Variant in Gene Status at Baseline
12938,NCT06092112,The objective response rate based on mRECIST,2023-10,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],The impact of CD-801 treatment on immune cell profiling in serum after treatment.,Overall Survival
12939,NCT04714983,Maximum tolerated dose (MTD) achieved during dose-escalation phase,2021-02-15,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Measure Immune response with ELISPOT
12940,NCT04566848,Immune Checkpoints,2020-08-01,COMPLETED,OBSERVATIONAL,['NA'],,
12941,NCT03008512,Progression-free survival rate at 6 months,2016-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Adverse events
12942,NCT01075399,Reproducibility of [F18]HX4 PET Imaging in Measuring Hypoxia in Tumors,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12943,NCT04094688,Progression-free survival (PFS),2019-09-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Prognostic effect of highest achieved 25(OH)D
12944,NCT02457299,The number of participants with gastric conduit failures as a measure of safety and tolerability in the one-stage esophagectomy as compared with the two-stage esophagectomy.,2015-05,TERMINATED,INTERVENTIONAL,['NA'],,Quality of Life (QOL) scores of patients in both arms
12945,NCT02644408,Quality of Life (QoF),2014-10-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,adverse events
12946,NCT00526669,Percentage of Participants (Par.) With 5-month Progression-free Survival (PFS),2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Number of Participants With Change From Baseline (Measured as AGI, ItoG3, and ItoG4) in Toxicity Grades for White Blood Cell (WBC) Count at the Indicated Time Points"
12947,NCT04659005,HCC screening uptake rates,2021-02-01,COMPLETED,INTERVENTIONAL,['NA'],,Decisional conflict scale
12948,NCT00454376,"Reliability, scaling, scale correlation, and clinical validity of the gastrointestinal neuroendocrine tumor module (QLQ-G.I.NET21)",2006-10,UNKNOWN,OBSERVATIONAL,['NA'],,Response to change after various treatments
12949,NCT00691691,Response rate to SBRT,2007-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Treatment Related Toxicity
12950,NCT00874406,progression free survival,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,overall survival
12951,NCT03487484,Change in quality of life specific for the gastrointestinal tract,2018-03-22,TERMINATED,OBSERVATIONAL,['NA'],,Change in faecal Incontinence
12952,NCT05513144,The sensitivity and specificity of ctDNA detection. Profiling of the most frequently detected gene mutations and level of mutations in ctDNA,2021-12-24,RECRUITING,OBSERVATIONAL,['NA'],,Relative frequency of targetable mutations (incl. TMB and MSI status).
12953,NCT00593866,The Maximum Tolerated Radiation Dose,2006-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The Percentage of Participants Free From Local Progression at 2 Years
12954,NCT04161755,Drug related toxicity,2019-12-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
12955,NCT06159634,Dissection speed,2023-12-05,RECRUITING,INTERVENTIONAL,['NA'],,Abdominal pain
12956,NCT05686226,Tumor response,2023-03-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
12957,NCT06028516,ctDNA positive patients are detedcted before PET-CT,2021-01-06,RECRUITING,OBSERVATIONAL,['NA'],,
12958,NCT02843750,Postoperative Pneumonia,2016-06,WITHDRAWN,INTERVENTIONAL,['NA'],Quality of Life,Postoperative Pulmonary Complications
12959,NCT03563651,"Detection rates of Kras, Braf, or PI3K tumor DNA extracted from urine in patients without pre-existing mutations",2014-02-06,COMPLETED,OBSERVATIONAL,['NA'],,
12960,NCT03841201,"Safety and tolerability (AEs, SAEs according to NCI-CTCAE V 4.03)",2019-06-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Translational research
12961,NCT04008056,Authorization for preparation of chemotherapy based on patient reported outcome (decision 3),2019-11-16,COMPLETED,OBSERVATIONAL,['NA'],,Patient satisfaction with the patient reported outcome questionnaire
12962,NCT03458689,"Use of analgesics - ""change"" is being assessed",2018-02-28,UNKNOWN,INTERVENTIONAL,['NA'],,"Sedation scores - ""change"" is being assessed"
12963,NCT06056908,"Provide education on the diagnosis, medical management, and treatment of SDS/SDS-Like conditions for patients, families, and the medical/scientific community.",2016-01-19,RECRUITING,OBSERVATIONAL,['NA'],,
12964,NCT00185588,Time-to-Treatment Failure (Intent-To-Treat Analysis),2004-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Time-to-Progression, Evaluable Patients"
12965,NCT06206382,Mortality,2024-01-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Morbidity
12966,NCT01486329,Safety and tolerability,2011-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumor perfusion
12967,NCT03015038,Immune cells trafficking,2017-02-05,UNKNOWN,OBSERVATIONAL,['NA'],,"Safety (Number of adverse events, ECOG status)"
12968,NCT00084617,Response Rates (RR) in Metastatic Gastric/GE Junction Tumors,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
12969,NCT04456933,Percentage of anastomotic leak (AL),2020-06-29,UNKNOWN,OBSERVATIONAL,['NA'],,Rate of Re-interventions
12970,NCT02945033,"Number of patient with local or distant recurrence or second colorectal cancer or death from any cause, whichever occurred first",2018-07-12,RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of participants with treatment-related adverse events
12971,NCT05111626,Part 2: Overall Survival in FGFR2b ≥ 10% 2+/3+ Tumor Cell Staining Participants,2022-03-14,RECRUITING,INTERVENTIONAL,['PHASE3'],,Part 2: Number of Participants With Anti-Bemarituzumab Antibody Formation
12972,NCT03476122,Detection of circulating tumor cells,2018-03-15,UNKNOWN,OBSERVATIONAL,['NA'],,
12973,NCT01860742,Progression Free Survival (PFS),2014-12,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,"Tumor 18FDG PET/CT and 68Ga-octreotate PET/CT uptake at baseline, at mid and end of treatment"
12974,NCT00190801,Response rate according to RECIST criteria,2003-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,The quantitative and qualitative toxicity of pemetrexed plus cisplatin in this patient population
12975,NCT02541461,Change in body composition (changes in lean tissue mass and fatty tissue mass Using DEXA machine produced by Hologic),2015-05,COMPLETED,INTERVENTIONAL,['NA'],,Changes in lipid profile
12976,NCT05964530,Overall disease-free survival,2023-04-19,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
12977,NCT00376948,Median Overall Survival Estimate,2005-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,pAKT (Pichia Anomala Killer Toxin) and NF (Nuclear Factor)-kappaB Activation
12978,NCT01677312,Median Number of Passes to Establish Diagnosis,2012-08,COMPLETED,INTERVENTIONAL,['NA'],,Complications
12979,NCT02085031,Anastomosis-related early complication rate,2014-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Postoperative quality of life
12980,NCT05169177,Standard deviation of difference between software and ground truth measure,2022-10-17,RECRUITING,OBSERVATIONAL,['NA'],,Modelling of patient or treatment features that contributed to the success or failure of the KIM method
12981,NCT03291938,Maximum tolerated dose,2017-11-13,COMPLETED,INTERVENTIONAL,['PHASE1'],Pharmacodynamic and predictive biomarkers of activity of IACS-010759,Duration of response
12982,NCT04665921,Incidence of dose limiting toxicities,2021-01-18,TERMINATED,INTERVENTIONAL,['PHASE1'],,Incidence of antidrug antibodies (ADA)
12983,NCT00827723,concordance rate between ICGR-15 and Portal Pressure values in patients with resectable HCC and cirrhosis Child A from alcoholic and non-alcoholic origin.,2009-02,COMPLETED,OBSERVATIONAL,['NA'],,postoperative liver failure.
12984,NCT04520906,Complete tumor ablation rate,2020-12-17,UNKNOWN,INTERVENTIONAL,['NA'],,Complete ablation rate of lesions
12985,NCT04323813,Assessments of diagnosis of CRC by EMT-TF mRNA levels in blood,2017-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,Prediction of prognosis of CRC by EMT-TF mRNA levels in blood
12986,NCT06102772,Progression Free Survival,2023-11-10,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
12987,NCT05664607,Harris Benedict Equation,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
12988,NCT00003103,,1997-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
12989,NCT03431428,OS,2018-01-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,QOL
12990,NCT04324307,ORR,2019-11-26,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,OS
12991,NCT04492215,Rate of organised colorectal cancer screening at 24 months,2021-05-31,RECRUITING,INTERVENTIONAL,['NA'],,Identification of denial of the colorectal cancer screening
12992,NCT00436423,Response rate by RECIST criteria,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Evaluate the following efficacy measure Duration of response,Time to treatment failure,Time to documented disease progression, Overall survival"
12993,NCT05947201,pathologic complete response (pCR) of the patients' resected tumors,2023-05-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,R0 resection rate
12994,NCT02291744,"TFS time of failure of strategy (the second progression time after induction therapy, or time to the use of second line strategy (if no reapplication of induction therapy) or time to no further treatment)",2014-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
12995,NCT03247231,Removal of the subepithelial tumour (initial clinical success).,2017-03-31,TERMINATED,OBSERVATIONAL,['NA'],,Long-term recurrence.
12996,NCT02988921,Evaluation of tumor heterogeneity with IBEX software,2016-10,RECRUITING,INTERVENTIONAL,['NA'],,Reduction in acute and late side effects based on modified RT treatment volumes with pre- and post-chemoradiotherapy based on MRI and CT simulation
12997,NCT02240771,Survival rate-,2006-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Tumor response
12998,NCT03250091,Risk stratification,2017-06-19,RECRUITING,OBSERVATIONAL,['NA'],,"Gastric, faecal microbiome in cancer patients and patients with precancerous lesions"
12999,NCT06065891,Prevalence of paraaortic lymph nodes in pancreatic cancer in patients submitted to a tentative curative resection,2023-09-05,RECRUITING,INTERVENTIONAL,['NA'],,To address the question of how to optimize the frozen section analyses (lgll station 16) as related to the final pathology report?
13000,NCT01681472,Concentration of [6S]-5-formyl-THF in Adjacent Mucosa Tissue,2012-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of AEs Per Severity
13001,NCT04984174,"age, sex, types of institutions and chemotherapy regimens",2021-08-04,RECRUITING,OBSERVATIONAL,['NA'],,
13002,NCT06134973,Application prospect of liquid biopsy technique in monitoring HCC in high risk population,2023-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
13003,NCT05420558,early postoperative recurrence,2022-06-23,RECRUITING,OBSERVATIONAL,['NA'],,diagnostic performance
13004,NCT05596435,Area under curve of the model for detecting stage I/II/III pancreatic cancer,2022-10-10,RECRUITING,OBSERVATIONAL,['NA'],,Specificity of the early detection model
13005,NCT03699657,Minimum diameter of ablative zone,2014-12-15,COMPLETED,INTERVENTIONAL,['NA'],Maximal diameter of ablative zone,2-year LTP
13006,NCT02038283,Direct Health Care Costs for each CRC screening strategy,2009-10,COMPLETED,OBSERVATIONAL,['NA'],,Factors Associated with HRQOL
13007,NCT00470340,Survival without recurrence at 2 years,2007-06,TERMINATED,INTERVENTIONAL,['PHASE3'],,Morbidity and mortality following adjuvant treatment
13008,NCT00316862,Proportion of Patients With Adenocarcinoma Achieving a Pathologic Complete Response (CR) After Surgery,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Proportion of Patients Experiencing Grade 3 or Greater Hematologic and Non-hematologic Toxicity
13009,NCT03176680,Postoperative complications,2017-06-15,UNKNOWN,INTERVENTIONAL,['NA'],,Inflammatory markers
13010,NCT05107661,: Colorectal Screening Strategies in the High Risk Medically Underserved Population in a Hospital-based Community Outreach Program,2021-09-26,TERMINATED,OBSERVATIONAL,['NA'],,Colorectal Screening Strategies in the High Risk Medically Underserved Population in a Hospital-based Community Outreach Program
13011,NCT05963776,pulmonary complications of liver cirrhosior or HCC,2023-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
13012,NCT05302557,Ileus,2021-12-09,RECRUITING,INTERVENTIONAL,['NA'],,Hospital readmission
13013,NCT00273312,Tumor response as assessed by radiologic techniques and/or physical examination based on Response Evaluation Criteria in Solid Tumors (RECIST),2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
13014,NCT04053725,the proportions of patients with positive serum ctDNA that have postoperative relapse,2019-02-01,UNKNOWN,OBSERVATIONAL,['NA'],,The proportion of ctDNA content decreased in patients with good therapeutic effect
13015,NCT05551039,Proportion of patients with reasons for discontinuation,2022-08-15,COMPLETED,OBSERVATIONAL,['NA'],,Descriptive summary of Pre-existing comorbidities
13016,NCT04617457,Overall survival after R0/R1 resection (OS-res),2021-10-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,QoL-adjusted OS
13017,NCT00577031,PFS: Time to Event,2008-02,COMPLETED,INTERVENTIONAL,['PHASE4'],,European Quality of Life 5 Dimension (EQ-5D) Raw-Index Score
13018,NCT03997162,Rate and type of post-operative complications,2018-10-11,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Overall survival of enrolled patients,QoL after stomach cancer surgery
13019,NCT05547529,Disease-free survival,2022-09-14,RECRUITING,INTERVENTIONAL,['PHASE3'],,R0 resection rate
13020,NCT02350517,Progression free survival,2015-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life
13021,NCT01236053,Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin,2010-06,COMPLETED,OBSERVATIONAL,['NA'],,
13022,NCT00562666,"Onset of: thrombosis of hepatic artery, grade 4 liver toxicity, or grade 3 or more allergic, neurological, dermatological, infectious, or respiratory reaction",2008-02,TERMINATED,INTERVENTIONAL,['PHASE1'],,"Onset of clinical, biological signs or images evocative of lymphocyte-induced tumor cytotoxicity and/or of a persistence of gamma-delta T cells in peripheral blood. Tumor response will be evaluated with the RECIST criteria."
13023,NCT02798224,CRC Screening use,2017-06-14,COMPLETED,INTERVENTIONAL,['NA'],,
13024,NCT00375661,Incidence of adverse effect of interferon,2006-09,COMPLETED,INTERVENTIONAL,['PHASE4'],,
13025,NCT01919242,the type of complications and the incidence of it,2013-01,UNKNOWN,OBSERVATIONAL,['NA'],,
13026,NCT03199586,Establish the safe recommended phase 2 dose,2017-12-21,COMPLETED,INTERVENTIONAL,['PHASE1'],,Cmax
13027,NCT01361061,development of HCC,2010-06,COMPLETED,OBSERVATIONAL,['NA'],,"comparison of these liver cancer markers (AFP, AFP-L3% and DCP) between different etiologies"
13028,NCT04751149,to compare the incidence of acute urine retention after removal of the urinary catheter in the postoperative period of rectal resection.,2019-05-01,UNKNOWN,INTERVENTIONAL,['NA'],,Incidence of postoperative complications
13029,NCT01883297,Number of occurrences and severity of side effects,2015-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of patients with an immunity and no immunity to the study treatment
13030,NCT02240433,Number of Participants with LY2157299 Dose-Limiting Toxicities (DLT),2014-11-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,"The Number of Participants with Best Response of Partial Response (PR), Complete Response (CR), Stable Disease (SD), or Progressive Disease (PD)"
13031,NCT04709380,TTP,2021-03-02,RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence of grade 3 and above adverse events
13032,NCT00826579,To assess the extent of upstaging due to the SLN procedure for colon cancer.,2000-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To evaluate the accuracy of the SLN procedure for colon cancer. To identify factors influencing the success of the procedure. To correlate SLN results with the presence of colon cancer cell in bone marrow aspirates. To assess OS and DFS.
13033,NCT00397787,Response (CR/PR/stable disease) as measured by RECIST criteria,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
13034,NCT03265743,Realization of human papillomavirus vaccination,2017-09-25,COMPLETED,OBSERVATIONAL,['NA'],,Reasons for non-vaccination
13035,NCT03947840,Rate of immunological response,2019-01-30,COMPLETED,OBSERVATIONAL,['NA'],,Rate of recovery in physical activity
13036,NCT02725424,major Pathological response rate,2015-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13037,NCT03843229,tumor size,2019-01-27,UNKNOWN,INTERVENTIONAL,['PHASE4'],,"Interleukin(IL)-2,Interleukin(IL)-4,Interleukin(IL)-6,tumor necrosis factor(TNF)-α，interferon(INF)-γ in blood"
13038,NCT02286492,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA'],,
13039,NCT04840186,Median overall survival,2021-03-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life
13040,NCT04639180,"Recurrence-Free Survival (RFS), as Determined by the blinded independent review committee (BIRC)",2021-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,The incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as assessed by CTCAE v5.0
13041,NCT02858778,The difference in the percentage of patients with a completed advance directive (AD) in Ig vs.Cg,2016-06,UNKNOWN,INTERVENTIONAL,['NA'],,Time to consultation in Ig vs. Cg groups
13042,NCT05910099,Rate of patients who remain in a rectal cancer clinical study to completion,2024-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
13043,NCT05259384,Complication Rate,2021-04-17,RECRUITING,INTERVENTIONAL,['NA'],,The rate of spleen-preservation
13044,NCT00098527,Radiographic response rate (complete response & partial response),2004-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Change in plasma and urine TGFB levels
13045,NCT05380557,Overall survival,2021-08-23,TERMINATED,OBSERVATIONAL,['NA'],,
13046,NCT00003365,,1996-08,TERMINATED,INTERVENTIONAL,['NA'],,
13047,NCT03052478,Objective response rate (ORR) by RECIST 1.1,2017-02-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13048,NCT03851133,Presence of Visceral Adiposity,2019-03-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Progression Free Survival
13049,NCT05066048,Species composition of fecal microbial,2021-04-30,UNKNOWN,OBSERVATIONAL,['NA'],,age in year
13050,NCT01628458,Safety,2012-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Chemotherapy
13051,NCT03605186,"Change in ""patient-reported oral mucositis"".",2019-02,UNKNOWN,INTERVENTIONAL,['NA'],,"Change in ""Clinical assessment of oral mucositis""."
13052,NCT02391662,Efficacy of treatment through 3-months deterioration free rate,2015-06-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,CA 19.9 biomarker response
13053,NCT04181333,The incidence of adverse drug reactions in this surveillance,2023-08-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Assessment of tumor response: Assess the tumor response according to RECIST Ver. 1.1.
13054,NCT06088940,Effects of probiotic on depression symptoms,2023-11-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Relationships between bacterial taxa and symptoms,Probiotic effects on gut microbiota differential taxonomic abundance
13055,NCT05853172,R0 surgical conversion rate,2023-03-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse event (AE)
13056,NCT05074264,Most efficient algorithm for detection of anogenital human papillomavirus (HPV)-related cancers and high-grade squamous intraepithelial lesions (HSIL),2021-11-30,RECRUITING,INTERVENTIONAL,['NA'],,
13057,NCT04316013,Comparison of disease free survival (DFS) with lidocaine compared with no lidocaine,2020-07-31,RECRUITING,INTERVENTIONAL,['PHASE3'],MINS Substudy,Health utility with intravenous lidocaine versus no lidocaine
13058,NCT01170754,Boston Prep Scale,2010-04,COMPLETED,INTERVENTIONAL,['PHASE4'],Boston Prep Scale (Per Protocol Analysis),Phosphorus Level in mg/dl
13059,NCT00506623,Pathologic stage Tumor regression grade,2004-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Toxicity
13060,NCT04616768,Patient perceptions of symptom management,2020-11-19,COMPLETED,INTERVENTIONAL,['PHASE3'],Additional analysis of the primary outcome between different arms (3 month) (exploratory),Fitbit step data
13061,NCT00055822,,2002-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
13062,NCT05865132,ORR,2023-04-06,RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
13063,NCT01008657,2 years global (local+distant) recurrence rate,2010-02-09,COMPLETED,INTERVENTIONAL,['NA'],,Primary treatment effectiveness (assessed 1 month after completion of treatment course which can include up to 3 radiofrequency ablation (RFA) procedures performed monthly)
13064,NCT03047226,Pathogenic germline mutation,2017-02-28,COMPLETED,OBSERVATIONAL,['NA'],,Variant of uncertain significance of germline mutation
13065,NCT04847167,Enteroscopy success rate,2020-02-24,COMPLETED,INTERVENTIONAL,['NA'],,Therapeutic success rate
13066,NCT00879385,Evaluate safety & feasibility of sequential use of a DNA methyltransferase (DNMT) inhibitor (decitabine) with targeted biological agent against EGFR (panitumumab) for KRAS wild type tumors in second or third line treatment of colorectal cancer.,2009-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Measure CEA levels at the beginning of each cycle to examine if they correlate with treatment response or disease progression.
13067,NCT04960943,Objective Response Rate (ORR),2020-02-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Safety and Tolerability,Progression Free Survival (PFS)
13068,NCT04025840,2-year overall survival,2019-09-11,RECRUITING,INTERVENTIONAL,['PHASE4'],Time to oral intake after surgery.,2-year progression-free survival
13069,NCT02931825,Comparison of the performed colonoscopy rate within 12 months following randomization / send letter in the 2 arms,2017-05-23,COMPLETED,INTERVENTIONAL,['NA'],,
13070,NCT01924897,postoperative morbidity,na,UNKNOWN,INTERVENTIONAL,['NA'],Feasibility outcomes for exercise training,Admission to HDU/ITU
13071,NCT03608631,Progression-free survival (PFS),2021-01-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
13072,NCT03898102,Difference in grade 2 or worse HFSR incidence within the first 8 weeks of regorafenib treatment between mCRC patients who receive regorafenib treatment with or without zinc supplementation,2016-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Percentage of patients with adverse events (graded by NCI-CTCAE v4.03),Duration of treatment of regorafenib (DoT)
13073,NCT02685046,Effects of treatment on the mesenchymal gene expression profile,2016-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAEv4.02
13074,NCT04273100,objective response rate (ORR),2019-11-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],conversion rate of hepatectomy,overall survival
13075,NCT02395471,Number of Participants With Adequate Cytosponge™ Sample,2015-08,COMPLETED,INTERVENTIONAL,['NA'],,Ongoing Safety Measures
13076,NCT02419586,Time to first flatus,2015-01,COMPLETED,INTERVENTIONAL,['NA'],,Length of stay
13077,NCT00005833,Confirmed complete and partial response rate to R115777,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Frequency & severity of toxicities
13078,NCT04710589,Progression free survival time (PFS),2020-01-01,UNKNOWN,OBSERVATIONAL,['NA'],Side effects,Overall survival time (OS)
13079,NCT03507699,Number of participants with serious dose-limiting treatment-related adverse events as assessed by CTCAE v5.0,2018-12-15,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression free survival
13080,NCT05271110,Feasibility of treatment,2022-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Quality of life after surgery
13081,NCT00098787,Objective Response Rate,2005-09-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
13082,NCT00024362,,2001-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13083,NCT06016855,Gene mutations,2024-04-30,RECRUITING,INTERVENTIONAL,['PHASE4'],,
13084,NCT02277548,Average/Cumulative Opioid Dose,2014-05,COMPLETED,INTERVENTIONAL,['NA'],,
13085,NCT02909452,Changes from baseline in ECG results,2016-09-20,COMPLETED,INTERVENTIONAL,['PHASE1'],Best overall tumor response,Vd (clearance and volume of distribution) of entinostat when given in combination with pembrolizumab
13086,NCT06055439,Objective Response Rate (ORR),2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
13087,NCT05589597,Safety and tolerability of EO4010 in combination with nivolumab,2023-06-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival to the date of death due to any cause. Patients alive will be censored at the date of the last documented follow-up
13088,NCT00537823,All-cause Mortality,2007-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Change in Tumor Size From Pretreatment to Preoperative CT Scan
13089,NCT02416635,The number of Circulating Tumor Cells (CTCs),2013-06,COMPLETED,OBSERVATIONAL,['NA'],,
13090,NCT00399009,Clinical anastomotic leak,2004-01,TERMINATED,INTERVENTIONAL,['NA'],,
13091,NCT04188158,Disease-free survival (SLE) at 2 years,2017-03-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,To compare the postoperative morbidity and mortality of the neoadjuvant treatment in relation to the standard treatment
13092,NCT01340105,Complete ablation rate,2011-04,COMPLETED,INTERVENTIONAL,['NA'],,Hospital stay
13093,NCT02967523,Objective tumor response,2016-05,TERMINATED,OBSERVATIONAL,['NA'],,Changes in alpha-fetoprotein (AFP) blood levels
13094,NCT01294358,MTD (Maximum Tolerated Dose),2011-01-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Serious and Non-Serious Adverse Events
13095,NCT03253133,Maximum tolerated dose,2016-05-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Area Under the Curve (AUC)
13096,NCT01387503,For Phase III - Overall Survival,2011-01,COMPLETED,INTERVENTIONAL,['NA'],,Validation of the Metroticket model for the prognosis of survival after liver transplantation in patients exceeding Milan Criteria
13097,NCT02827565,"Technical Optimization of KRAS, BRAF and NRAS mutations detection",2016-02-03,COMPLETED,INTERVENTIONAL,['NA'],,"KRAS, NRAS et BRAF mutational status"
13098,NCT05855278,Overall survival,2019-08-13,COMPLETED,INTERVENTIONAL,['NA'],,
13099,NCT04879927,Rate of Treatment Interruption,2021-05-17,COMPLETED,INTERVENTIONAL,['NA'],,
13100,NCT03329690,Percentage of Participants With Best Overall Response Based on Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Intent-to-Treat Analysis Set),2017-11-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Summary of Most Common Treatment-Emergent Adverse Events (TEAEs) ≥20% of Any Grade by Preferred Term Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Safety Analysis Set)
13101,NCT01668134,Stereotactic radiation therapy (either photon or proton) can be delivered to the liver with a less than 10% 3-month incidence of Grade 4 study related toxicity.,2009-12-16,COMPLETED,INTERVENTIONAL,['PHASE1'],,Measure the response rates associated with using SBRT in patients with resectable HCC and IHC
13102,NCT04430725,Time to local recurrence per treated nodule,2019-08-07,RECRUITING,OBSERVATIONAL,['NA'],,Changes in patient reported outcomes per patient
13103,NCT00216424,Tumor response and resectability of tumor following treatment with radiation and capecitabine (Xeloda).,2005-02,TERMINATED,INTERVENTIONAL,['PHASE4'],,
13104,NCT02649647,Incidence of major bowel dysfunction,2016-02,RECRUITING,INTERVENTIONAL,['NA'],Postoperative hospital stay by days,Quality of life impairment
13105,NCT02705118,Registration accuracy,2015-12,COMPLETED,INTERVENTIONAL,['NA'],,Registration time
13106,NCT03857763,The pathological complete response rate(pCR),2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse events Toxicity
13107,NCT05075421,5-year survival rates,2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
13108,NCT00178243,,na,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
13109,NCT00043043,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13110,NCT03256084,Evaluation of CTC features,2017-07-17,RECRUITING,INTERVENTIONAL,['NA'],,
13111,NCT05859750,The number of subjects experiencing adverse events (AEs),2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of subjects who develop detectable anti-drug antibodies (ADAs)
13112,NCT04848311,number of harvested station 253 lymph nodes,2021-05-01,UNKNOWN,INTERVENTIONAL,['NA'],complications,number of total lymph nodes harvested
13113,NCT05007587,Objective Response Rate and Disease Control Rate of the HCC Participants,2021-07-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],Hepatitis B infection,Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0
13114,NCT02441153,Disease-free survival,2016-03,COMPLETED,OBSERVATIONAL,['NA'],,
13115,NCT05878405,Change in oral pain,2023-05-30,RECRUITING,INTERVENTIONAL,['PHASE3'],,Change in the amount of daily requirements of oral morphine equivalents
13116,NCT03908840,Incidence of Treatment-Emergent Adverse Events (Safety and tolerability) observed during the trial,2019-12,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Determination of Maximum Tolerated Dose
13117,NCT04588909,Early post operative mortality,2020-03-23,UNKNOWN,OBSERVATIONAL,['NA'],,Rate of hospital acquired SARS CoV 2 infection among operated patients.
13118,NCT00113776,Incidence of HAHA formation,na,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13119,NCT00003600,Quality of life,1998-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Response rate
13120,NCT03396926,Overall response rate (ORR) (Expansion Cohort),2018-04-18,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free survival (PFS) (Expansion Cohort)
13121,NCT03054987,Rates of death attributable to the procedure.,2016-09,COMPLETED,INTERVENTIONAL,['NA'],,Reintervention
13122,NCT02447263,Number of participants with Adverse events,2015-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
13123,NCT05523154,Reduction in surgical site infections,2023-01-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Timeliness of sample analysis
13124,NCT02338752,efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1,2015-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,immunology index
13125,NCT00154726,Response rate,1997-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,overall survival
13126,NCT01322815,Number of Participants Alive and Free of Progression at 4 Months (Patients Who Have Undergone Prior Therapy) and 10 Months (Untreated Patients),2010-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
13127,NCT04106167,Overall Survival (OS) post-Infusion,2019-06-11,TERMINATED,OBSERVATIONAL,['NA'],,
13128,NCT03340844,Patient survival,2017-12-15,UNKNOWN,INTERVENTIONAL,['NA'],,Morbidity
13129,NCT04945720,One-Year Overall Survival Rate,2022-04-11,RECRUITING,INTERVENTIONAL,['PHASE2'],Exploratory study endpoints,"Evaluate the patient's cancer-related QoL using the European Organization for Research and Treatment of Cancer (EORTC) QOL questionnaire (QLQ), the EORTC QLQ-HCC18."
13130,NCT01316679,,2011-03,COMPLETED,OBSERVATIONAL,['NA'],,
13131,NCT02488707,Hospital stay,2014-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13132,NCT00983268,Maximum tolerated dose of vorinostat when given in combination with capecitabine and radiotherapy,2009-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Biological effect
13133,NCT05489237,Phase 1b - Objective Response Rate (ORR) mRESIST v1.1,2022-08-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Phase 1b - Overall survival
13134,NCT04661150,Pathological Complete Regression (pCR) Rate,2021-03-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Adverse Events
13135,NCT03873532,Overall survival (OS),2018-07-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Detection of biomarkers,Duration of response (DOR)
13136,NCT03468231,Overall survival,2018-03-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Tumor response
13137,NCT00968604,Dose-Limiting Toxicity (DLT),2015-03,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
13138,NCT05804331,Long term outcomes: recurrent and residual disease,2023-03-14,RECRUITING,OBSERVATIONAL,['NA'],,Patient interviews/questionnaires
13139,NCT00826800,To Determine the Pathologic Complete Response (Path CR) Rate in Patients With Locally Advanced (Stage II or III) Colon Cancer to FOLFOX-bevacizumab Administered as Neoadjuvant.,2009-02,TERMINATED,INTERVENTIONAL,['NA'],,
13140,NCT04440943,Safety and Tolerability of CDX-527 as assessed by CTCAE v5.0,2020-08-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetic Evaluation
13141,NCT02999295,Progression free survival rate after 6 months,2017-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression free survival (PFS)
13142,NCT05832398,1. Progression-free survival,2023-05-01,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
13143,NCT03301493,Timing of molecular profiling,2017-03-30,RECRUITING,OBSERVATIONAL,['NA'],,Outcome of treatment
13144,NCT01915602,Objective tumor response according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST) assessed by central radiological review,2013-09-27,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of participants with adverse events as a measure of safety and tolerability
13145,NCT00024401,,2001-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13146,NCT02340117,Objective response rate (ORR),2015-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse events
13147,NCT03940976,Objective response rate,2019-04-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
13148,NCT02070705,Change in tumor margins in patients who have undergone chemotherapy for pancreatic cancer (Group III),2014-01-31,RECRUITING,INTERVENTIONAL,['NA'],,DCE- MRI imaging parameters and descriptional analysis of normal pancreas DCE- MRI images (Group IV)
13149,NCT05394259,Accuracy is defined as the number of concordant cases between PYLARIFY PET-CT and the gold standard truth divided by the total sample size.,2022-10-28,RECRUITING,INTERVENTIONAL,['PHASE1'],,
13150,NCT04671862,Rate of occurence of radiation mucositis,2021-06-01,RECRUITING,INTERVENTIONAL,['NA'],,Radiation dermatitis
13151,NCT03436719,Rate of Surgical Site Infection,2017-11-06,UNKNOWN,INTERVENTIONAL,['NA'],,
13152,NCT01394120,Overall Survival,2011-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13153,NCT02451553,Recommended phase 2 dose (RP2D) (Phase Ib),2015-11-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to progression
13154,NCT01624220,Assess Use of Implanted Fiducial Markers in Treatment Planning and Delivery Workflow for Frame-Based Spinal Stereotactic Body Radiation Therapy (Spinal SBRT),2012-06-18,COMPLETED,INTERVENTIONAL,['NA'],,Esophageal Tolerance to Hyperfractionation
13155,NCT01494155,Progression-free survival,2011-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Measure utilization of health services
13156,NCT00574275,Overall Survival (OS),2007-12,TERMINATED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Anti-drug Antibodies
13157,NCT03435289,The maximally tolerated dose of CPI 613 combined with Gemcitabine and nab-paclitaxel,2017-10-19,UNKNOWN,INTERVENTIONAL,['PHASE1'],,The number of participants with complete or partial response
13158,NCT04695964,anastomotic leak,2019-02-01,UNKNOWN,INTERVENTIONAL,['NA'],,Length of post-operative hospital stay
13159,NCT01030263,Whether specialized columnar epithelium was detected.,2008-06,TERMINATED,INTERVENTIONAL,['PHASE4'],,
13160,NCT05524428,Primary Outcome 3: Appropriateness of Implementation Strategies,2023-03-24,RECRUITING,INTERVENTIONAL,['NA'],,Secondary Outcome: CRC Screening Rates
13161,NCT05117957,Safety (Adverse events),2022-02-08,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2'],,Disease control rate (DCR)
13162,NCT06209983,Length of hospital stay,2018-12-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],costs of hospitalization,Complication rates
13163,NCT02498041,Endoscopic Diagnostic Accuracy for Barrett's esophagus,2009-04,COMPLETED,INTERVENTIONAL,['NA'],,Adverse events
13164,NCT01916447,"Safety monitoring including adverse events, vital signs, and laboratory assessments",2013-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Document any preliminary antitumor activity of TAS-102 administered in combination with CPT-11 and in combination with CPT-11 and Bevacizumab.
13165,NCT05938309,Overall postoperative morbidity,2023-05-01,RECRUITING,OBSERVATIONAL,['NA'],,3-year recurrence pattern
13166,NCT00753844,Safety(Phase I:toxicities as assessed by NCI CTCAE version3),2006-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,evaluate immunological responses
13167,NCT04250948,TRG0/1,2019-10-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
13168,NCT02586753,Overall survival (OS),2015-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Progression-free survival (PFS)
13169,NCT01012804,,2000-01,WITHDRAWN,OBSERVATIONAL,['NA'],,
13170,NCT03961945,Aim 3 - Dysplasia Detection Sensitivity and Specificity,2021-07-01,RECRUITING,INTERVENTIONAL,['NA'],,Aim 3 - Dysplasia Detection Rate of Missed Dysplasia
13171,NCT01053390,"(Response Evaluation Criteria in Solid Tumors, RECIST,2009 ), CR(complete response) and PR(partial response)",2009-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,"A: KPS (karnofsky performance score) B:Laboratory tests: Reexamination of CA19-9（Carbohydrate Antigen 19-9）、 CEA（ carcinoembryonic antigen）, especially for those which are abnormal prior to chemotherapy"
13172,NCT01811108,Number of Participants with AE,2009-07,COMPLETED,OBSERVATIONAL,['NA'],,Patients Overall Survival
13173,NCT02027311,Number of Intervention,2013-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,Event of Hypoxia
13174,NCT05312372,Objective response per central review of antitumor activity (using Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) (Phase 2),2025-05,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Changes in vital signs : SBP, DBP, respiratory rate and temperature (Phase 2)"
13175,NCT02735941,Analysis of cannabinoid receptors in blood leukocytes and biopsies from patients with IBD and colon cancer,2017-06-13,COMPLETED,OBSERVATIONAL,['NA'],,Assessment of malignancy of colon cancer by tumor staging
13176,NCT04161911,Overall Survival,2018-10-29,COMPLETED,OBSERVATIONAL,['NA'],,
13177,NCT04810910,Relapse Free Survival(RFS),2021-03-30,RECRUITING,INTERVENTIONAL,['PHASE1'],Peripheral blood T cell receptor sequencing analysis,Overall Survival(OS)
13178,NCT03162198,Number of cell-free DNA (cfDNA) in cirrhotic patients with hepatocellular carcinoma (HCC),2017-05-15,COMPLETED,OBSERVATIONAL,['NA'],,Number of cfDNA amount with the Barcelona Clinic of Liver Cancer (BCLC) stage of HepatoCellular Carcinoma.
13179,NCT06024343,Incidence of Clinically Relevant Postoperative Pancreatic Fistula,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Recurrence-free survival (RFS)
13180,NCT05816187,Changes in Health Related Quality of Life: EORTC QLQ-30,2023-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,The five Times Sit to Stand Test (5x Sit-To-Stand Test)
13181,NCT00061932,True Response Rate Evaluated for the Combination of Irinotecan and PS341 by Response Evaluation Criteria in Solid Tumors (RECIST),2003-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change in Patterns of Gene Expression Pre- and Post-treatment Performed by GeneChip Analysis
13182,NCT05266820,Progression-free survival (PFS),2021-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events
13183,NCT05493033,Anastomotic leak,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Incision herniation
13184,NCT03785873,Phase II: Median Progression-Free Survival (PFS),2019-05-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Median Overall Survival (OS)
13185,NCT03005002,Incidence of adverse events assessed by NCI CTCAE version 4.03,2017-06-28,COMPLETED,INTERVENTIONAL,['PHASE1'],Tumor immune profiling,Overall response rate (both hepatic and extrahepatic disease) assessed by RECIST 1.1
13186,NCT01249859,To test the hypothesis that 5-year survival rate is significantly lower in the signet ring cells (SRC) adenocarcinoma when compared to non-SRC adenocarcinoma in the upper digestive tract,2010-03,COMPLETED,OBSERVATIONAL,['NA'],,"Overall 3 year survival according to tumor stage, node invasion, and tumor localization"
13187,NCT01714466,Cleansing success rate,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,PEG3350 concentration
13188,NCT00019331,,1997-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13189,NCT04248816,HCC Screening Completion,2020-11-19,COMPLETED,INTERVENTIONAL,['NA'],,HCC Screening Method
13190,NCT00003514,,na,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
13191,NCT01667198,Screening centre leader's adenoma detection rate,2012-07,COMPLETED,INTERVENTIONAL,['NA'],,Screening centre leader's withdrawal technique
13192,NCT00430027,Overall Toxicity,2006-11,TERMINATED,INTERVENTIONAL,['NA'],,
13193,NCT03683004,Change from Beck Depression Inventory (BDI) from baseline to 12 and 24 weeks (Specific Aim III),2018-01-22,COMPLETED,OBSERVATIONAL,['NA'],,Change from Optical Coherence Tomography baseline at 12 weeks and 24 weeks
13194,NCT01264432,Maximum tolerable dose defined as the highest dose at which 0 or 1 dose-limiting toxicities are observed in six patients as graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0,2011-01-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Proportion of toxicities of the combination of veliparib and LDRWAR as graded by the NCI CTCAE version 4.0
13195,NCT01135849,Development of cardiomyopathy,2008-11,COMPLETED,OBSERVATIONAL,['NA'],,
13196,NCT02151123,False negative rate of test for colon cancer,2019-03,UNKNOWN,OBSERVATIONAL,['NA'],,
13197,NCT00252161,overall survival,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,adverse events
13198,NCT00701857,The maximum tolerated dose (MTD) of pemetrexed,2008-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Response (complete response, partial response, progressive disease, and stable disease) as measured by RECIST criteria"
13199,NCT03445416,Change in vaccine awareness,2018-09,WITHDRAWN,INTERVENTIONAL,['NA'],,Change in healthcare engagement
13200,NCT04452357,"Acute grade 3+ gastrointestinal toxicity possibly, probably or definitely related to radiation.",2020-01-13,SUSPENDED,INTERVENTIONAL,['NA'],,
13201,NCT03482609,The incidence of postoperative referred pain in the left shoulder within 1 month,2018-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,inflammatory and immune response
13202,NCT05328765,Overall survival,2023-06-09,RECRUITING,OBSERVATIONAL,['NA'],,
13203,NCT03976960,Number of biological risk factors for colorectal cancer,2018-09-19,RECRUITING,INTERVENTIONAL,['NA'],,
13204,NCT00039208,Peak delivery time for CPT11 tolerability over the first 3 courses of treatment in patients who started therapy,2002-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
13205,NCT01877135,at least one anal cancer,2013-08,UNKNOWN,OBSERVATIONAL,['NA'],,patient's feelings about his therapeutic care and impact on his emotional life
13206,NCT03008980,Outcomes of patients undergoing WATS sampling. Specifically incremental yield for Barrett's Esophagus and Esophageal Dysplasia due to WATS sampling above that noted from routine forceps biopsies in various clinical settings.,2014-05,COMPLETED,OBSERVATIONAL,['NA'],,
13207,NCT00711997,Maximal Tolerated Dose (MTD) & Dose Limiting Toxicity (DLT) of Intratumoral Injections of BC-819,2009-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Tumor Resectability
13208,NCT00609336,Median Overall Survival of Patients With Adenocarcinoma of the Pancreas,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percent of Patients Surviving at Annual Intervals
13209,NCT02250638,A Prospective Longitudinal Study of CA 19-9 as an Aid in Monitoring Disease in Patients with Pancreatic Cancer,2014-05,COMPLETED,OBSERVATIONAL,['NA'],,
13210,NCT02635087,DFS,2015-12,RECRUITING,OBSERVATIONAL,['NA'],,OS
13211,NCT01344304,"Patient diary recording nausea, emesis, food ingestion, and rescue therapy",2011-04,COMPLETED,INTERVENTIONAL,['NA'],,
13212,NCT03043729,Pathologic complete response (pCR),2017-03-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,ECOG
13213,NCT01267578,overall survival,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Progression free survival
13214,NCT03798951,Post-operative complications,2019-06-05,TERMINATED,INTERVENTIONAL,['NA'],,
13215,NCT03606785,reduction in blood loss,2018-08-05,COMPLETED,INTERVENTIONAL,['PHASE4'],,
13216,NCT03350477,Relief degree of tumors,2017-11-30,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Overall survival
13217,NCT02449109,Number of participants with Adverse events,2015-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
13218,NCT00193219,"Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment",2005-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Adverse Events as a Measure of Safety With FOLFOX6 Combined With Bevacizumab and Cetuximab
13219,NCT03977077,Progression free survival (PFS),2019-06-01,UNKNOWN,INTERVENTIONAL,['NA'],,Overall survival
13220,NCT02391207,the safety of HV-sparing surgery in terms of operative mortality and morbidity,2009-01,COMPLETED,OBSERVATIONAL,['NA'],,
13221,NCT03303469,Measure Changes in Treated HCC Tumor Hypoxia Following TACE and Radiotherapy,2017-10-30,TERMINATED,INTERVENTIONAL,['PHASE2'],,
13222,NCT01733719,Recruitment rate and retention,2013-02,COMPLETED,INTERVENTIONAL,['NA'],,Quality of life
13223,NCT00422409,Change/improvement i Quality of life,2006-10,COMPLETED,INTERVENTIONAL,['NA'],,Death
13224,NCT03765736,Companion Trial Enrollment,2020-04-20,TERMINATED,OBSERVATIONAL,['NA'],,
13225,NCT02188264,Incidence of DLT defined as any grade 3 non-hematological toxicity or grade 4 hematological toxicity attributed to selumetinib or cyclosporine graded per National Cancer Institute (NCI) CTCAE version 4.0,2014-08-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Change in expression of phosphorylated-mitogen-activated protein kinase 1,Progression-free survival (PFS)
13226,NCT03104582,Acute cholangitis,2011-11-01,COMPLETED,INTERVENTIONAL,['NA'],,Overall procedure related complication rate
13227,NCT02158988,The primary outcome measure is overall survival,2014-03-01,COMPLETED,INTERVENTIONAL,['PHASE3'],frequency of necessary secondary surgical procedures and the length of hospitalisation,quality of life
13228,NCT02716012,Part 2 - Change in tumour size from baseline using RECIST 1.1 and mRECIST in patients treated with MTL-CEBPA in combination with sorafenib,2016-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Part 2 - Safety and tolerability of co-administering MTL-CEBPA with sorafenib assessed using frequency of adverse events graded according to toxicity criteria (NCI CTCAE v 5.0) and categorised by body system
13229,NCT05438667,The duration of efficacy,2022-06-07,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Adverse events
13230,NCT00072098,toxicity grading,2003-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,tumor response compared at four weeks to baseline
13231,NCT05901194,The proportion of patients with lenvatinib who have a Liver transplantation (LT),2023-06,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of Treatment-Emergent Adverse Events
13232,NCT04443309,Objective Response Rate (ORR),2020-09-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Biomarker,Adverse Events (AE)
13233,NCT02685553,Number of hypervascular pancreatic neoplasms detected intraoperatively by NIR,2016-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13234,NCT05043532,Rate of ability to perform successful molecular profiling in core tissue obtained during EUS-guided fine needle biopsy,2021-08-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Type of actionable mutations detected on molecular profiling
13235,NCT00826488,"It is anticipated that out of 100 subjects recalled for additional breast imaging that 10 women will be recalled for biopsy. By adding 2D & 3D imaging, it is anticipated that 30 subjects out of 100 will have needed no workup.",2009-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
13236,NCT05871762,3-year OS,2023-06-04,RECRUITING,OBSERVATIONAL,['NA'],,30-day mortality
13237,NCT05942807,Overall survival,2021-05-15,RECRUITING,OBSERVATIONAL,['NA'],,
13238,NCT04268121,Relapse-free survival (RFS) - prospective cohort,2021-01-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events grade 3-4 as assessed by National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE] v5.0 - Prospective cohort
13239,NCT02291198,NK cell activity,2014-10,COMPLETED,INTERVENTIONAL,['NA'],,
13240,NCT04199832,Body Weight Change from baseline to the end of treatment,2019-12-20,COMPLETED,OBSERVATIONAL,['NA'],,Overall Survival
13241,NCT00541047,Freedom from distant metastases (any distance metastases or prostate cancer death) (RADICALS-RT),2007-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Freedom from biochemical progression (RADICALS-RT)
13242,NCT00049023,"Evaluate the short term and long term safety (mild/moderate/severe/life-threatening adverse events, premature discontinuations and serious adverse events)",2002-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13243,NCT02573220,Maximum Tolerated Dose (MTD),2015-06,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,metastectomy (with curative intent) rate
13244,NCT05844514,Validation and further discovery of VOC biomarkers for CRC.,2022-09-23,RECRUITING,OBSERVATIONAL,['NA'],,Exploratory comparison between the breath test and FIT.
13245,NCT01473290,Average area under the curve (AUC) of the FACIT-D diarrhea subscale score assessed weekly during treatment and for two weeks following the completion of RT,na,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Disease-free survival
13246,NCT00495846,Prolongation of the survival curve (>6 months),2007-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Improvement of quality of life according with SF36 questionnaire
13247,NCT05035446,Rate of complications,2021-10-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,pain intensity
13248,NCT01436617,Validate the utility of an IgE anti-cetuximab test in the treatment strategy,2010-01,COMPLETED,OBSERVATIONAL,['NA'],,
13249,NCT02030561,Time-to-Event Outcome Measure,2014-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
13250,NCT02546596,"T stage (0 - 4), N (0 - 3) stage, tumor regression grade (0 - 4)",2014-03-25,UNKNOWN,INTERVENTIONAL,['NA'],,Treatment toxicity (grade 0 - 5)
13251,NCT05780684,Proportion of patients that receive dose intensified infusional 5-FU in Cycle 6 of the FOX regimen,2023-07-14,RECRUITING,INTERVENTIONAL,['NA'],,5-FU drug exposure
13252,NCT02075905,Risk Stratification,2014-03,COMPLETED,OBSERVATIONAL,['NA'],,
13253,NCT01010945,Maximum Tolerated Dose,2010-02-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival
13254,NCT02607332,Disease control rate,2015-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13255,NCT04616196,Objective Response Rate (ORR) by RECIST 1.1 of NKTR-255 in combination with Cetuximab in R/R metastatic HNSCC or CRC for Phase 2 Dose Expansion,2020-10-30,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The development of anti-drug antibodies (ADA) against NKTR-255 and cetuximab
13256,NCT03383458,Recurrence-free Survival (RFS),2018-04-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Time to recurrence (TTR)
13257,NCT04886635,"Safety of active surveillance (including delayed surgery), measured by the number of patients with adverse events",2021-03-09,RECRUITING,OBSERVATIONAL,['NA'],,The number of biopsies taken and quality of the biopsies
13258,NCT05137782,Operationalization as measured by the creation of a manual of operating procedures and web-based data collection forms,2023-01-03,COMPLETED,INTERVENTIONAL,['NA'],,Acceptability as measured by willingness to recommend study participation to others.
13259,NCT00955188,Adherence to colorectal cancer screening at 12 months post-intervention,2004-08,COMPLETED,OBSERVATIONAL,['NA'],,Intention to get screened
13260,NCT03161535,Quality of life (EORTC QLQ-OES 18 ),2017-09-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Circadian rhythms
13261,NCT01859806,Postoperative pancreatic fistula (POPF),2011-01,COMPLETED,INTERVENTIONAL,['NA'],,hospital stay
13262,NCT03766555,Overall survival,2018-05-21,RECRUITING,INTERVENTIONAL,['NA'],,Hospital stay
13263,NCT05841420,PFS (Progression Free Survival),2023-06-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Cumulative worst toxicity during treatment
13264,NCT03385213,Transcriptional changes in gut microbiota,2016-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,Epigenetic changes
13265,NCT01130233,Bladder function,2009-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of life
13266,NCT02047994,Gastric cancer mortality,2013-03,RECRUITING,INTERVENTIONAL,['PHASE4'],,Incidence of- and mortality from other medical conditions
13267,NCT04340440,Operative mortality rate,2014-12,COMPLETED,INTERVENTIONAL,['NA'],,2 years Overall survival rate
13268,NCT02350686,Progression-free survival,2015-05-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of Participants with Adverse Events as a Measure of Safety and Tolerability
13269,NCT01072851,Comparison of the acceptance of colorectal cancer screening by patients who view print or multimedia educational tools,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Comparative knowledge of colorectal cancer screening by patients who view the print or multi-media educational tools.
13270,NCT01157806,percentage of patients not requiring palliative surgery during the follow-up,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Determination of prognostic factors indicating the need for immediate palliative surgery.
13271,NCT03607643,Response rate,2019-01-15,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality-of-life assessment in patients using clinician-reported outcomes (ClinRO) data.
13272,NCT00789633,Overall Survival (OS),2008-11-25,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression Free Survival (PFS)
13273,NCT00828048,Identify clinical and morphological predictors of cancer or high grade dysplasia in patients with IPMN. Identify predictors of progression to cancer or high grade dysplasia among patients who are followed in surveillance programs.,2008-03,COMPLETED,OBSERVATIONAL,['NA'],,
13274,NCT03745170,Overall survival (OS),2018-12-19,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of participants experiencing clinical and laboratory adverse events (AEs)
13275,NCT05635266,Biospecimen & Clinical Data Collection,2021-10-26,RECRUITING,OBSERVATIONAL,['NA'],,
13276,NCT01321658,Postoperative complications,2011-02,COMPLETED,INTERVENTIONAL,['NA'],,Living at home or in institution
13277,NCT02958592,Stage of hepatic fibrosis,2015-06,COMPLETED,OBSERVATIONAL,['NA'],,
13278,NCT03138031,Overall survival rate,2017-05-01,COMPLETED,INTERVENTIONAL,['NA'],,Tumor response rate
13279,NCT06260150,Incidence rate of DVT,2023-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Amount of bleeding during surgery
13280,NCT05356156,The incidence of internal hernia within 3 years after surgery,2022-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Overall survival at 3 years after surgery
13281,NCT04000737,Progression free survival (PFS),2020-01-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Effects of YIV-906 on mean t½ (Hr) of sorafenib in blood
13282,NCT06202105,3 year relapse-free survival by Kaplan Mayer,2024-01-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,hospital stay
13283,NCT04616131,Number of patients with circulating tumor DNA (ctDNA) levels as not detectable in their blood compared to number of patients with ctDNA detected.,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,"Investigators will look for statistically significant correlations of ctDNA blood levels with clinical treatment responses of tumor grades, CA 19-9 units/milliliter blood level, and radiologic response by RECIST categories of complete response."
13284,NCT00660348,Number of Subjects Per Arm With Decrease in Pain Scores,2008-03,TERMINATED,INTERVENTIONAL,['NA'],,
13285,NCT03240679,Completeness of EMR Site Healing at Follow up Endoscopy,2017-03-22,TERMINATED,INTERVENTIONAL,['NA'],,Presence of Stricture Formation at Follow up Endoscopy
13286,NCT01220063,tumor response accoording to recist criteria,2007-10-19,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13287,NCT01872988,overall survival,2012-09,TERMINATED,INTERVENTIONAL,['PHASE3'],,time to liver decompensation
13288,NCT01310985,"Evaluate the safety of pre-operative concurrent chemotherapy with capacitabine (Xeloda), weekly cetuximab (Erbitux), and external beam radiation.",2008-03,COMPLETED,OBSERVATIONAL,['NA'],,"Evaluate efficacy of sphincter preserving surgery rate, local recurrence rate and the disease free and overall survival in patients."
13289,NCT02999672,Best Overall Response (BOR) Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors [RECIST] 1.1).,2016-12-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Plasma/Serum Concentrations of Trastuzumab Emtansine
13290,NCT03534843,Overall survival of all patients,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Short-term mortality of non-surgical subgroup
13291,NCT01808599,Complete remission rate,2013-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Event-free-survival (EFS)
13292,NCT02063529,"the percentage of patients who had a curative liver treatment following protocol treatment, i.e., liver metastases that can be completely resected and/or ablated with no evidence of residual malignant disease.",2014-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life (QLQ C30)
13293,NCT00774501,To assess safety & feasibility of single dose image-guided intensity modulated radio (IG-IMRT) using gen anesthesia with apneic oxygenation & controlled ventilation to temp suspend respiratory motion for tx of mets liver disease during localization & tx.,2008-10,COMPLETED,INTERVENTIONAL,['NA'],,
13294,NCT01545804,disease stabilization,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13295,NCT00441155,Safety and tolerability of nilotinib either as single agent or in combination with Imatinib,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,To assess any clinical responses in Imatinib-resistant GIST patients. Assessment of tumor response will be made based on modified RECIST criteria - to be assessed at the end of every cycle of treatment
13296,NCT03076957,Maximum Tolerated Dose(MTD),2016-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Number of participants with toxicity as assessed by CTCAE v4.03 through study completion, an average of 1 year"
13297,NCT03231917,Adenoma Miss Rate,2017-03-01,COMPLETED,INTERVENTIONAL,['NA'],,Adenoma < 6mm Detection Rate
13298,NCT00003055,,1997-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13299,NCT05235490,The main objective of this work is to identify biomarkers from CT scan (non-invasive imaging phenotypes from radiological images) which have a prognostic value for an early recurrence in patients with hepatocellular cancer.,2021-01-28,COMPLETED,OBSERVATIONAL,['NA'],To correlate the imaging signatures predictive of recurrence with the cell population molding of tissue microenvironment (TME) and the tumor biology using tissue assessment as reference.,Identify biomarkers from CT scan (non-invasive imaging phenotypes from radiological images) which have a prognostic value for a tardive recurrence in patients with hepatocellular cancer.
13300,NCT03635021,Progression-free survival rate at 35 months,2018-10-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],clinical impact of clonal dynamics by longitudinal analysis of circulating tumour deoxyribonucleic acid (ctDNA) in plasma,Incidence and severity of AEs CTCAE v4.03 criteria
13301,NCT00123760,To demonstrate the safety of 18F-FDG synthesized from cyclotron produced radiofluoride in the Coincidence Technologies automated synthesis unit (ASU) in the Edmonton PET Centre facility,2004-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,To confirm the diagnostic effectiveness of 18F-FDG in subjects with known or suspected oncologic disease and compare this to literature values
13302,NCT04848051,Total number of participants who completed their colorectal cancer screening,2021-10-12,COMPLETED,INTERVENTIONAL,['NA'],,Screening outcomes: diagnostic results
13303,NCT01397019,2 year survival rate,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13304,NCT00238199,Time to progression,2002-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change in pancreatic cancer-induced pain
13305,NCT05369117,Three-year disease-free survival rate,2022-05-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,operative mortality
13306,NCT00842348,Adverse Events,2009-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression Free Survival (PFS): Kaplan-Meier Estimate
13307,NCT03600623,Number of participants with adverse events as a measure of safety and tolerability,2017-09-25,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Proportion of participants undergoing surgery after preoperative chemoradiation therapy
13308,NCT05493215,Incidence of Grade 3/4 adverse events attributable to imatinib per CTCAE v5.0,2024-03-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,Average dose of imatinib required to achieve therapeutic levels and drug dose over 3 years
13309,NCT06055543,Improvement in nutritional status,2023-08-09,RECRUITING,INTERVENTIONAL,['PHASE4'],,ONS Satisfaction
13310,NCT00112580,Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR),2005-07-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13311,NCT02042443,Overall Survival,2014-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free Survival
13312,NCT05743842,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",2023-03-14,RECRUITING,INTERVENTIONAL,['NA'],,
13313,NCT01501903,Diagnostic accuracy,2011-09,COMPLETED,INTERVENTIONAL,['NA'],,Number of passes for diagnosis
13314,NCT02506842,Overall survival,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of life
13315,NCT02562755,Overall Response Rate (ORR),2015-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
13316,NCT01326390,"Proportion of patients that develop renal failure (defined as a decline of renal function, as measured by glomerular filtration rate, of 25% or more from pre-procedural)",2010-05,TERMINATED,OBSERVATIONAL,['NA'],,
13317,NCT01286155,The primary outcome from the survey will be the proportion of patients willing to undergo an esophageal capsule study compared to those willing to undergo an endoscopic procedure (Esophagogastroduodenoscopy or transnasal endoscopy),2010-01,COMPLETED,OBSERVATIONAL,['NA'],,"Study established (age, gender, ethnicity, reflux) and potential risk factors (sleep apnea, visceral adiposity, Helicobacter pylori infection, Metabolic Syndrome)to develop a clinical risk factor model for diagnosis of Barrett's esophagus(BE)."
13318,NCT02644603,Treatment related complications,2016-02,UNKNOWN,INTERVENTIONAL,['NA'],,Serum complement
13319,NCT02325986,overall response rate,2015-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival
13320,NCT01675999,Histological tumor response in the primary tumor according to the simplified Tumor Regression Grade (TRG) of Ryan,2012-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,•Evaluation of another histopathological grade
13321,NCT04072445,Progression-free Survival (PFS),2019-10-18,COMPLETED,INTERVENTIONAL,['PHASE2'],Prediction of Clinical Benefit by Thymidine Kinase 1 (TK1),Number of Participants With Adverse Events
13322,NCT00006050,,1999-04-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13323,NCT03981614,Progression Free Survival (PFS),2019-10-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events
13324,NCT01505400,Molecular profiling data to be made available in patient's electronic medical records.,2012-02,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Clinical trial accrual rates among patients with available molecular profiling data
13325,NCT01521091,,2009-01,COMPLETED,OBSERVATIONAL,['NA'],,
13326,NCT04456699,Progression Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR).,2020-08-19,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants Discontinuing Study Intervention Due to an AE
13327,NCT05460403,Overall survival (OS),2022-04-23,RECRUITING,OBSERVATIONAL,['NA'],Adverse events,Distant metastasis (DM)
13328,NCT06199297,progression free survival，PFS,2021-03-02,COMPLETED,OBSERVATIONAL,['NA'],,"overall survival, OS"
13329,NCT00701012,Assessment of bowel function,2008-01,COMPLETED,INTERVENTIONAL,['NA'],,comparison of leakage rate
13330,NCT03763214,Stent migration,2018-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,Survival rate
13331,NCT02311205,Overall survival (OS),2014-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease control rate (DCR)
13332,NCT04109495,EORTC Questionnaires - Quality of Life,2017-02-22,COMPLETED,INTERVENTIONAL,['NA'],,Skeletal muscle index change
13333,NCT05223088,Total/moderate tumor regression rate under pathology,2021-10-31,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
13334,NCT06251973,Overall Response Rate,2024-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
13335,NCT04959617,Specificity of quantitative FIT,2019-01-06,UNKNOWN,OBSERVATIONAL,['NA'],,
13336,NCT03591965,ORR,2018-08-07,TERMINATED,INTERVENTIONAL,['PHASE2'],Additional metabolites of ATG-008 in plasma and urine,"6, 9 and 12 month of survival rate"
13337,NCT00848510,Whole Tumor Volume and Enhancing Tumor Volume,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression-Free Survival (PFS) Time
13338,NCT05613465,Cancer-related fatigue,2022-10-25,RECRUITING,INTERVENTIONAL,['NA'],,Immunologic function
13339,NCT02518373,Change in plasma gastrin level.,2000-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13340,NCT02833506,Incidence of adverse events defined by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03,2017-12-08,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Time to disease progression as documented by Response Evaluation Criteria in Solid Tumors version 1.1
13341,NCT00152906,Phase II: To determine with more confidence the rate and spectrum of all toxicities that occur at the maximally tolerated dose of radiation.,2003-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To determine whether serum cytokines and P-III-P can help predict RILD.
13342,NCT04921488,Estimation of the sensitivity of the automatic characterization system CAD EYE.,2021-10-21,COMPLETED,INTERVENTIONAL,['NA'],,"Compare the diagnostic performance to determine the malignancy of polyps between the automated colonic polyp detection device by the CAD EYE system, and the investigator performing the colonoscopy for colorectal cancer screening."
13343,NCT02234180,Disease Free Survival (DFS),2014-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
13344,NCT05429190,Increased sensitivity for HCC detection,2023-11-07,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],Patients acceptance of the SMS protocol (through a questionnaire),Cost-effectiveness analysis of SMS protocol
13345,NCT01139229,the incidence of anastomotic stricture,2007-11,COMPLETED,INTERVENTIONAL,['NA'],,the clinicopathological parameters in relation to postoperative complications
13346,NCT01179750,amount of blood loss,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,drainage from peritoneal cavity during hospital
13347,NCT06026943,"Safety- Adverse events, Safety will be determined according to the overall incidence of device-related SAE's graded according to CTCAE v5.0 criteria",2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Exploratory Objective -to evaluate the changes in the immune markers by Blood samples for immune response,Efficacy- Alpha DaRT seeds
13348,NCT00390182,Overall Response,2003-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Time of Advanced/Recurrent Disease Without Distant Metastases.,
13349,NCT02594696,Feasibility of implementing the intervention in patients with SMI and cancer,2015-11-09,COMPLETED,INTERVENTIONAL,['NA'],,Change in alliance with the oncology clinician
13350,NCT00005597,"Assess response (confirmed & unconfirmed, complete & partial response)",2000-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicities
13351,NCT06140823,Performance metrics for LIRIC model risk quantiles,2023-04-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Tumor stage at HCC diagnosis
13352,NCT00118755,Progression-free Survival (PFS),2005-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Overall Clinical Response (CR or PR)
13353,NCT06314750,OS,2010-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
13354,NCT00828607,"Malignancy of the liver mass, as determined on US, on CEUS, and on CECT or CEMRI.",2009-01,COMPLETED,OBSERVATIONAL,['NA'],,"Diagnosis of the liver mass, as determined on US, on CEUS, and on CECT or CEMRI."
13355,NCT01652482,Progression-free Survival (PFS) According to Modified RECIST v1.1 Criteria,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Minimum Observed Serum Concentration (Cmin) of MEHD7945A
13356,NCT04134104,Sexual Dysfunction,2014-12,COMPLETED,OBSERVATIONAL,['NA'],,
13357,NCT05091528,Number of Participants With an Objective Response Rate,2022-02-08,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Proportion of Participants With Clinical Benefit Rate
13358,NCT01704820,Per patient adenoma detection rate (average # adenomas detected/ patient in each arm of the study).,2012-09,UNKNOWN,INTERVENTIONAL,['NA'],,Evaluate endoscopist comfort with performing retroflexion in the proximal colon.
13359,NCT03086538,Overall Response Rate,2017-05-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13360,NCT05610592,5-year event-free survival rate,2009-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Local recurrence
13361,NCT06071598,To define the functional role of MFSD2A in CRC through Polyunsaturated fatty acid (PUFA) ad genes analysis.,2023-03-15,RECRUITING,OBSERVATIONAL,['NA'],,
13362,NCT04619329,Median Overall Survival (mOS),2020-10-30,UNKNOWN,INTERVENTIONAL,['NA'],,Adverse Events
13363,NCT02859064,Number of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability,2017-07-28,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
13364,NCT01006369,Progression-free Survival,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
13365,NCT00439179,Toxicity (Number of Patients Who Experiened DLTs),2006-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Patients Who Experienced a Partial Response
13366,NCT02279771,anastomotic leak,2015-01,UNKNOWN,INTERVENTIONAL,['NA'],,Number of overall postoperative complications
13367,NCT00113256,survival,2005-02,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
13368,NCT06113796,Costs of treatment,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,30-days Readmission
13369,NCT01434459,The maximum tolerated dose of gemcitabine when given in combination with therasphere,2011-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,The progression free of patients treated on the trial
13370,NCT04406311,Lars score,2020-10-01,COMPLETED,OBSERVATIONAL,['NA'],,Single question on QoL
13371,NCT01125111,The difference in 1 month between two surgical methods in terms of Bladder function.,2009-06,COMPLETED,OBSERVATIONAL,['NA'],,"The serial change of Bladder and sexual function according to times, in each operation method."
13372,NCT06159049,SUVmaxFAPI and SUVmaxFDG for each target (Standardized Uptake Value),2022-07-21,COMPLETED,OBSERVATIONAL,['NA'],,
13373,NCT05964621,VTE incidence in primary pancreatic cancer resection,2023-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
13374,NCT03081988,Prediction model for CCRT response based on clinical and genetic molecular factors,2015-10-19,RECRUITING,OBSERVATIONAL,['NA'],Clinical prediction factors for CCRT response (retrospective study),in-vitro prediction of CCRT using primary esophageal cancer organoid
13375,NCT00154713,evaluate the clinical responses of vaccinated patients 6 weeks after the first injection,2005-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,evaluate the safety of this treatment and the immune responses against CEA before and after the treatment 6 weeks after the first injection
13376,NCT05411432,SUV of organs,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,radioactivity of blood sample
13377,NCT03662841,Time to progression,2018-07-13,TERMINATED,INTERVENTIONAL,['NA'],,Tumor response
13378,NCT04622176,Accuracy of lymph node diagnosis compared to MRI,2021-06-17,RECRUITING,OBSERVATIONAL,['NA'],,
13379,NCT04523818,Incidence of adverse events,2020-08-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
13380,NCT04977453,Objective Response Rate (ORR) according to RECIST version 1.1,2021-08-02,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Immunophenotyping of peripheral blood mononuclear cells will be performed by flow cytometry at various time points,DCR per iRECIST guidelines
13381,NCT05980624,Nutrition status - scored Patient-Generated Subjective Global Assessment (PG-SGA),2023-07-20,RECRUITING,INTERVENTIONAL,['NA'],,common adverse effects
13382,NCT05863195,Overall survival (OS),2023-12-19,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence of adverse events
13383,NCT06089590,"Number of SAE declared by patients (cancer, serious infections, arterial and venous thrombotic events)",2023-11-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,"Number and duration of hospitalization, surgery, endoscopy and other imaging"
13384,NCT02685228,overall survival,2016-03,UNKNOWN,INTERVENTIONAL,['NA'],,Evidence of the size of the lesion in pancreas confirmed by non-investigational CT or MRI
13385,NCT01137084,patient and graft survival,2005-01,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative complications
13386,NCT04202848,The change of concentration of P-hydroxyphenylalanine metabolites in urine,2019-12-20,UNKNOWN,OBSERVATIONAL,['NA'],,The change of the number of Gastrin in blood during the therapy
13387,NCT06094140,The proportion of patients receiving at least 80% of planned neoadjuvant treatment.,2022-05-20,RECRUITING,INTERVENTIONAL,['PHASE2'],Analysis of tumour tissue (baseline and surgical resection) for molecular changes and gene expression profile.,Objective response rate.
13388,NCT02033551,Number of subjects with adverse events,2013-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumor Assessment
13389,NCT00646607,disease free survival (DFS),2007-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,"overall Survival (OS), Toxicity and incidence of adverse events"
13390,NCT02221700,"Completion Rates of Two Massage Treatment Protocols for Patients With Chronic, Oxaliplatin-Induced Peripheral Neuropathy",2015-04-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Baseline treatment expectations
13391,NCT01760070,Procedure time for ESD,2012-12,COMPLETED,INTERVENTIONAL,['NA'],,Bleeding Rate
13392,NCT04008797,Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs),2019-07-11,RECRUITING,INTERVENTIONAL,['PHASE1'],,Duration of Response (DOR)
13393,NCT00002884,,1996-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
13394,NCT03427346,Eradication rate of neoplastic Barrett's Esophagus,2016-12,RECRUITING,INTERVENTIONAL,['NA'],,Intervention time
13395,NCT03663114,Number of Participants With Hepatic Encephalopathy Risk Factors,2018-07-02,COMPLETED,OBSERVATIONAL,['NA'],,Number of Participants with Hepatic Encephalopathy
13396,NCT00004189,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13397,NCT00087282,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13398,NCT00963794,"Electromagnetic detection system at 465 MHz frequency, in a scale from 0 to 255 arbitrary U.",2008-01,COMPLETED,INTERVENTIONAL,['NA'],,
13399,NCT02749513,Inhibition of Hedgehog pathway signaling as measured by real-time PCR.,2016-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Inhibition of VEGFR2 pathway signaling as measured by Western blot
13400,NCT04934618,Overall Suvival time（OS）,2020-05-19,RECRUITING,INTERVENTIONAL,['PHASE2'],Safety and tolerability,Disease control rate（DCR）
13401,NCT05010850,Safety Major Complications,2022-01-17,SUSPENDED,INTERVENTIONAL,['NA'],,
13402,NCT02179970,Safety of Investigational Medicinal Product (IMP),2015-06,COMPLETED,INTERVENTIONAL,['PHASE1'],Disease status,Pharmacokinetics of the Investigational Medicinal Product (IMP) within the body.
13403,NCT00408564,Progression-free Survival at 6 Months,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Determine the Biomarker Response of CA 19-9 to Therapy
13404,NCT04524702,Change from baseline tumor size as measured by cross sectional imaging at 8 weeks.(every 8 weeks),2020-09-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Changes in selected biomarkers in tumor microenvironment and circulation,Overall survival
13405,NCT03752398,Treatment-related adverse events as assessed by CTCAE v4.03,2019-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
13406,NCT02151864,Rate of dose limiting toxicities,2014-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13407,NCT05417386,R0 Resection Rate,2022-08-09,RECRUITING,INTERVENTIONAL,['PHASE1'],,Resection rate
13408,NCT02079220,anti-tumor activity of ziv-aflibercept in combination with XELOX in the first-line treatment of patients with metastatic colorectal cancer (mCRC),2014-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Progression-free survival (PFS)
13409,NCT00035334,,2001-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
13410,NCT04044326,the efficacy of microwave ablation for the treatment of primary or secondary liver cancers: modified RECIST criteria,2019-09-01,WITHDRAWN,INTERVENTIONAL,['NA'],,safety and local tumor recurrences
13411,NCT06244225,Progression free survival (PFS) per RECIST v1.1,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,The treatment-related adverse events (TRAEs）
13412,NCT06222255,The LARS (Low Anterior Resection Syndrome) Score with Night symptoms,2023-12-06,RECRUITING,INTERVENTIONAL,['NA'],,European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - CR29
13413,NCT01882972,Retention feasibility,2013-06,WITHDRAWN,INTERVENTIONAL,['NA'],,Self-reported Exercise-related Injury
13414,NCT06182072,Determine a single ideal dose which will be selected for further investigation in the dose escalation cohort.,2023-12-29,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Evaluate patient tumor blood perfusion pre and post treatment with ProAgio.,Evaluate patient tumor response.
13415,NCT06013943,6-month progression-free survival rate (PFS),2023-03-17,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events,Objective response rate (ORR) per RECIST 1.1
13416,NCT00003321,,1998-02,COMPLETED,OBSERVATIONAL,['NA'],,
13417,NCT01401907,Functional Assessment of Cancer Therapy (Quality of Life Measure),2011-05,COMPLETED,INTERVENTIONAL,['NA'],,Coping (Brief Cope)
13418,NCT04455945,European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Colorectal Cancer 29 (EORTC QLQ-CR29) Symptom scales,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
13419,NCT06274879,Any grade 3 or 4 adverse events (AE) leading to chemo-immune checkpoint inhibitor-therapy (CICI) discontinuation up to six months after enrolment.,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival,Total dose of CICI applied
13420,NCT00614913,Median Survival Without Tumor Progression,1998-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
13421,NCT06120803,Grade 2 or higher radiation induced esophagitis,2024-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
13422,NCT04482608,Progression-Free Survival (PFS),2019-09-01,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
13423,NCT00078468,To determine the overall objective response rate (complete and partial responses) of AG-2037 in patients with metastatic colorectal cancer who failed treatment with 5FU/LV regimen and up to one other chemotherapeutic regimen.,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To correlate the various genetic markers of MTAP, folate and purine metabolism with clinical response."
13424,NCT00697047,Long-term adherence to CRC screening,2008-07,COMPLETED,INTERVENTIONAL,['NA'],,Impact of SOS interventions on outcomes and CRC-related costs
13425,NCT04538313,Progression-Free Survival,2020-08-26,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,EQ-5D score
13426,NCT04297254,Number of Participants with Grades 1 and 2 Treatment-emergent Adverse Events (TEAEs),2021-02-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,Time to First Dose Reduction
13427,NCT03158103,Recommended phase II dose (RP2D),2017-04-15,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of participants with partial response
13428,NCT00004885,,1999-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
13429,NCT01149642,The rate of grade 3 and 4 acute mucosal toxicity,2009-11,COMPLETED,INTERVENTIONAL,['NA'],,overall survival rates
13430,NCT05806151,Progression/Recurrence,2023-01-17,RECRUITING,OBSERVATIONAL,['NA'],,
13431,NCT00463840,Resectability After Chemoradiation,2004-06,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Median Overall Survival
13432,NCT02078362,Percentage of cell lysis,2013-09,UNKNOWN,OBSERVATIONAL,['NA'],,
13433,NCT06023966,hepatic metastasis,2023-09-01,RECRUITING,OBSERVATIONAL,['NA'],,interval between the surgery and hepatic metastasis
13434,NCT01373346,Operation Related Mortality,2010-02,COMPLETED,INTERVENTIONAL,['NA'],,Albumin : Good Response Group
13435,NCT04288323,Reader reliability of screening modalities,2018-04-27,RECRUITING,INTERVENTIONAL,['PHASE4'],,
13436,NCT05433467,The position of the needle,2022-05-01,RECRUITING,INTERVENTIONAL,['NA'],,Intraoperative bleeding
13437,NCT02462564,Incidence for early postoperative cognitive dysfunction in the patients with peritoneal surface malignancies undergoing cytoreductive surgery and hyperthermic intraperitoneal chemo-therapy,2014-06,COMPLETED,OBSERVATIONAL,['NA'],,Risk factor for early postoperative cognitive dysfunction in the patients with peritoneal surface malignancies undergoing cytoreductive surgery and hyperthermic intraperitoneal chemo-therapy
13438,NCT04248647,"Functional capacity: Six-minute walk test (Enright, 2003)",2016-10-26,COMPLETED,INTERVENTIONAL,['NA'],,"Nutritional status: body weight loss, serum albumin, hand grip strength, body mass index, lean body mass and percentage of body fat"
13439,NCT02332863,Procedure Duration Required for Placing the Fiducial Markers,2016-08-03,COMPLETED,INTERVENTIONAL,['NA'],,Number of Fiducials Placed
13440,NCT04938336,Assessment of the usability of the decision aid tool through individual interviews,2022-04-22,RECRUITING,OBSERVATIONAL,['NA'],,
13441,NCT02072317,Progression-free survival (PFS),2013-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13442,NCT06196554,Predictive specificity of drug sensitivity,2023-05-01,RECRUITING,OBSERVATIONAL,['NA'],,Concordance between organoids and source tumor tissue
13443,NCT05270824,The number of CD8+ tumor-infiltrating lymphocytes in tumor tissue and adjacent tissue before and after treatment,2022-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Surgical safety
13444,NCT06191120,Tumor-level CMS4 status as assessed by the current RNA-sequencing based CMS4 status reference standard performed on fresh-frozen tissue samples following surgery.,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],RNA-sequencing derived gene-expression levels per tumor lesion,10-120 minutes post-injection dynamic [18F]-ALF-FAPI-74 uptake levels in tumor lesions and reference organs
13445,NCT00756977,Efficacy - Preparation Quality Using a 4 Point Scale,2008-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Serum Chemistry Results (Osmolality)
13446,NCT01270178,The survival rate and recurrence rate between patients receiving ETV therapy and those in historical control,2011-01,UNKNOWN,OBSERVATIONAL,['NA'],,"HBV reactivation, incidence of ALT normalization, reduction of serum HBV DNA level, HBsAg loss and HBsAg seroconversion to anti-HBsAb, emergence of resistance."
13447,NCT05007106,PFS per RECIST 1.1 as Assessed by Investigator at 12 months,2021-09-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Participants Who Discontinued Study Intervention Due to an AE
13448,NCT04414956,HCC occurrence,2016-07-01,RECRUITING,INTERVENTIONAL,['NA'],,Early HCC occurrence
13449,NCT01918644,Incidence of dose-limiting toxicity defined as any grade 3-4 non-hematologic toxicity or grade 5 toxicity attributable to combination chemo-radiotherapy per the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0,2014-04-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,OS
13450,NCT00972751,"Correlation of expression of these proteins with tumor stage, disease-free survival, overall survival, and risk of recurrence",2009-02,COMPLETED,OBSERVATIONAL,['NA'],,
13451,NCT01894269,overall survival,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE4'],HBV resistance to lamivudine or entecavir,HBV reactivation
13452,NCT00563095,regression of tumour size,2004-03,UNKNOWN,INTERVENTIONAL,['NA'],,side effects
13453,NCT04646772,Postoperative mortality,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Disease Free Survival
13454,NCT02768532,Vedolizumab concentration at week 6,2016-07-01,TERMINATED,INTERVENTIONAL,['PHASE4'],,Specific antibodies (anti-integrins) level at week 54
13455,NCT03941561,DFS,2019-01-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Side effects,OS
13456,NCT02687113,RFA feasibility rates on planning USG with/without fusion CT/MR and US,2013-03,COMPLETED,INTERVENTIONAL,['NA'],Anticipated number of overlapping of RFA electrodes on planning USG with/without fusion technique,Number of patients with safety access route on planning USG with/without fusion technique
13457,NCT03864640,Content validity of Mediterranean Colorectal Cancer Registry: answering multiple-choice items,2019-02-27,COMPLETED,OBSERVATIONAL,['NA'],,Face validity of Mediterranean Colorectal Cancer Registry: the major reason behind the negative response
13458,NCT05021029,Pre-malignant progression,2021-07-13,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Recruitment response rates
13459,NCT06157892,Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by investigator assessment,2024-04-30,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of anti-drug antibodies (ADAs) against disitamab vedotin
13460,NCT02678832,Social norms and cognitions toward self-management strategies of cancer patients as assessed by the variables of the theory of planned behavior (TPB),2015-12,COMPLETED,OBSERVATIONAL,['NA'],,Physical activity as assessed with SQUASH
13461,NCT00402961,To determine whether a Phase III trial of acupuncture for postoperative recovery after colorectal surgery is warranted as defined by evidence of reduction of postoperative ileus when compared to sham acupuncture,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of emetic episodes during hospital stay
13462,NCT01972503,3 years disease-free survival,2008-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],,3 years overall survival and metastasis-free survival
13463,NCT04412161,overall and disease free survivals,2006-04-19,COMPLETED,OBSERVATIONAL,['NA'],,
13464,NCT04971304,Number of patients who develop febrile neutropenia,2015-03-01,COMPLETED,OBSERVATIONAL,['NA'],,Number of patients who develop G-CSF associated adverse events
13465,NCT01388257,Percentage of patients having a clinical healing of their anoperineal fistulas in Crohn disease,2011-10,UNKNOWN,INTERVENTIONAL,['NA'],,Change in discomfort and impact assessed by the patient using a visual analog scale (VAS)
13466,NCT03228095,Performance of nanoarray sensor testing to detect target lesions and diseases,2017-07-24,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Groups of gastrointestinal microbiota correlating to VOCs
13467,NCT04766736,Netrin-1 expression patterns in HCC samples,2019-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,
13468,NCT01861483,R0 resection rate,2013-03,COMPLETED,OBSERVATIONAL,['NA'],,
13469,NCT02102646,Change in hepatic fat content,2014-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,Correlation between Hepatic fat content and baseline androgen status
13470,NCT01964430,Kaplan Meier Estimate for Disease Free Survival (DFS) According to the Independent Radiological Review Committee,2014-03-28,COMPLETED,INTERVENTIONAL,['PHASE3'],,The Number of Participants With Clinical Chemistry Laboratory-Detected Abnormalities (Grade 3-4)
13471,NCT01084330,Progression Free Survival,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Evaluate Safety by measuring cardiac safety, recording Adverse Events (AEs) and tracking the tolerability of AUY922"
13472,NCT02308631,Safety and Tolerability of the procedure,2014-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of animals with Adverse Events in the colostomy.
13473,NCT04755543,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2019-06-17,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Serum concentration of the antibody against LP002 within 1 hour prior to each administration
13474,NCT00365391,Number of Patients With Confirmed Tumor Response Defined to be Either a Complete Response (CR) or Partial Response (PR).,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Treatment Failure
13475,NCT06282445,Progression-free survival,2024-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,TRAEs
13476,NCT02312167,"The number of participants with adverse events, their type and severity",2014-10,COMPLETED,INTERVENTIONAL,['NA'],"number of interpretable images per organ, per contrast agent and per pathology",The ease of manipulation of the robotized probe (grade 1 to 5)
13477,NCT01206218,Progression-free Survival,2010-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Response Rate
13478,NCT05352646,dose-limiting toxicity (DLT),2022-07-26,RECRUITING,INTERVENTIONAL,['PHASE1'],,recurrence-free survival(RFS) rate
13479,NCT04965870,Progression Free Survival,2021-06-30,COMPLETED,OBSERVATIONAL,['NA'],,Disease Control Rate
13480,NCT02716688,response rate,2016-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Dysphagia score,Overall survival
13481,NCT04769713,Changes in narcotic use after a hepatic hilar nerve block during and immediately after liver chemoembolization,2021-11-23,RECRUITING,INTERVENTIONAL,['PHASE4'],,Differences in disease response post liver tumoral chemoembolization between patients with hepatic hilar nerve block and those with sham procedure
13482,NCT05475288,Overall survival of patients with locoregionally recurrent colon cancer;,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
13483,NCT01959906,overall survival,2013-07,UNKNOWN,OBSERVATIONAL,['NA'],,
13484,NCT03118882,screening-related indicators,2010-05,COMPLETED,INTERVENTIONAL,['NA'],,Circulating biomarkers association with breast and colorectal cancer
13485,NCT01845454,Efficacy of Spray Cryotherapy Dose: Percent Regression of Disease Following Baseline Spray Cryotherapy,2013-04,TERMINATED,INTERVENTIONAL,['NA'],,Safety Outcomes
13486,NCT00671372,The safety and tolerability of dulanermin administered in combination with FOLFIRI (with or without Bevacizumab),2006-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13487,NCT02039635,Area Under Curve (AUC) of Brief Fatigue Index (BFI) on the intake trial drugs up to 16 weeks,2013-12,COMPLETED,INTERVENTIONAL,['NA'],"Change in blood cytokine(IL-2, IL-8, IL-10) level after 16 weeks of trial drug intake",adverse events
13488,NCT01134640,Safety and toxicity of Erbitux in clinical practice,2008-01,COMPLETED,OBSERVATIONAL,['NA'],,
13489,NCT03601689,Distant recurrence rate,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Predictive factors of disease free survival
13490,NCT00598975,Number of Patients With Dose Limiting Toxicities,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Overall Response
13491,NCT00862784,Progression-Free Survival (PFS),2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Serum Anti-IMC-1121B (Immunogenicity) at Day 1
13492,NCT03067012,"micronutrients' deficiency (iron, folate, vitamin B12)",2015-09-01,COMPLETED,INTERVENTIONAL,['NA'],,Remission rates of co-morbidities
13493,NCT00380588,Percentage of Patients Alive at 1 Year (1-Year Survival Rate),2006-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Survival Time,Progression Free Survival
13494,NCT01132534,"To compare the detection rate of premalignant lesions(intestinal metaplasia, gastric atrophy, dysplasia) and early neoplasia of stomach between combined AFI/NBI endoscopy versus standard endoscopy",2007-06,COMPLETED,OBSERVATIONAL,['NA'],,To assess the diagnostic accuracy AFI and NBI imaging
13495,NCT04532736,Lund-Kennedy endoscopic grading system (NPS),2017-09-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Presence of peripheral eosinophilia (PE, > 500/mcl) in blood samples"
13496,NCT03208335,progress-free survival(PFS),2017-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life (QOL)
13497,NCT01371240,Pancreatic tumor conspicuity on MRI,2011-06,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,post-injection complications and side effects of secretin
13498,NCT02783261,liver hypertrophy,2014-06,UNKNOWN,OBSERVATIONAL,['NA'],,
13499,NCT05494359,"The number of 15 Nitrogen, 14 Nitrogen, 28 Nitrogen, 29 Nitrogen, 30 Nitrogen",2023-04-04,RECRUITING,OBSERVATIONAL,['NA'],,The stage of the cancer
13500,NCT06091592,Serum autotaxın level,2020-12-30,COMPLETED,OBSERVATIONAL,['NA'],,tumor differentiation grade
13501,NCT06233981,Median Overall Survival,2024-01-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Toxicity
13502,NCT06008054,Recommended Phase II Dose (RP2D),2023-11-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Treatment-Emergent Adverse Event (TEAE)
13503,NCT04682847,Develop a platform to maintain liver functionality during treatment for liver cancer,2020-11-19,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Examine the dose-response of tumor and liver tissue in patients who received liver transplant after receiving SBRT
13504,NCT05486572,Hepatocellular Carcinoma Mortality,2023-11-03,RECRUITING,INTERVENTIONAL,['NA'],,Overall Survival
13505,NCT05578430,Major Pathological Response Rate (MPR rate),2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events (AE)
13506,NCT05030090,Evaluate nutritional status indicators change,2021-06-25,COMPLETED,INTERVENTIONAL,['NA'],,Evaluate quality of life indicators change
13507,NCT01361035,"Change in cervical, breast and colorectal cancer screening rates",2008-06,COMPLETED,INTERVENTIONAL,['NA'],,Change in standardized patient ratings of physician communication behaviors
13508,NCT02399059,Global survival,2011-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Disease free survival
13509,NCT03380052,The evaluation of OLGA and OLGIM stage systems with serum pepsinogen for prediction of gastric cancer risk,2006-02,COMPLETED,OBSERVATIONAL,['NA'],,
13510,NCT01656746,"Oncologic sample including size of specimen removed, number of lymph nodes (LN) removed, pathological type and staging, lymph node, vessel or perineural invasion, and status of margins",2010-05,COMPLETED,INTERVENTIONAL,['NA'],,"Visual analogue cosmesis scale scored on the scale from 0 to 10 where 0 is ""worst scar"", and 10 is the ""best scar"""
13511,NCT03622437,Health-related quality of life and symptom burden,2016-02-26,COMPLETED,INTERVENTIONAL,['NA'],,Cost-benefit - QALY's
13512,NCT00077389,Rate of complete remission after completion of study therapy,2004-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Event-free survival
13513,NCT02352831,Progression-free Survival (PFS) Rate,2015-08-31,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With a CA19-9 Response
13514,NCT01383343,"Maximum tolerated dose of sorafenib tosylate in combination with FOLFIRI and bevacizumab, defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6 new patients)",2011-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Time until hematologic nadirs (ANC, platelets, hemoglobin)"
13515,NCT03041571,Patient provider orientation scale score (PPOS),2017-03-01,WITHDRAWN,OBSERVATIONAL,['NA'],,Medical honors students focus group
13516,NCT05688176,Identification of biomarkers (messenger RNAs) for therapy response prediction,2016-06,RECRUITING,OBSERVATIONAL,['NA'],,Development of a quantitative Polymerase Chain Reaction (qPCR) test for clinical use
13517,NCT01863420,Hematologic toxicity,2012-11,UNKNOWN,OBSERVATIONAL,['NA'],,Conformity and Homogeneity of IMRT plan
13518,NCT05214222,Objective Response Rate (ORR),2022-09-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,The 3-year OS rate
13519,NCT04151030,Technical success of endoscopic vs radiographic Push-PEG placement in patients who are not candidates for a Pull-PEG placement,2019-06-28,COMPLETED,INTERVENTIONAL,['NA'],,Procedure duration between endoscopic push PEG placement and IR guided push PEG placement
13520,NCT01769534,To validate the Sendai criteria prospectively in patients with pancreatic cysts.,2012-06,TERMINATED,OBSERVATIONAL,['NA'],,
13521,NCT06038552,Overall survival,2002-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
13522,NCT00493857,The primary goal is to assess the Objective Response Rate (ORR) that the combination of irinotecan and nimotuzumab will produce in patients with irinotecan-refractory metastatic colorectal cancer,2007-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Assess the incidence of acneiform rash,drug reaction,adverse events, the assessment of progression-free survival,stable disease,time to disease progression, overall survival, objective response rates, safety and trough levels in the serum of patients."
13523,NCT05489250,Tumor mutations and their impact on treatment decisions in gastrointestinal cancer patients,2020-10-28,RECRUITING,OBSERVATIONAL,['NA'],"Feasibility of the PLATON WebApp - an interactive platform that connects the participating physicians on cases, cancer types, mutations, protein expressions and therapies, possible trials and discussion options for medical professionals",QoL via EORTC QLQ-STO22 questionnaire in genetically defined cohorts of EC/GC patients
13524,NCT03985670,Pathological complete response rate,2019-07-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,disease-free survival rate
13525,NCT05830890,Accuracy,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Sensitivity
13526,NCT02972034,Percentage of Participants Who Experience a Dose-limiting Toxicity (DLT),2017-01-13,COMPLETED,INTERVENTIONAL,['PHASE1'],,Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as Assessed by the Investigator
13527,NCT00912327,Objective response rate (ORR),2009-06,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
13528,NCT04602117,Overall response rate (ORR),2021-07-28,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Duration of response (DOR) of patients treated with the weekly paclitaxel with tri-weekly trastuzumab duocarmazine (SYD985) combination
13529,NCT05093920,Tumor size,2022-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Serum Alpha-fetoprotein level ng/ml.
13530,NCT01274143,Colonoscopy,2008-05,COMPLETED,INTERVENTIONAL,['NA'],,Decisional Conflict
13531,NCT03528941,Number of patients with hepatitis B reactivation,2018-11-28,COMPLETED,OBSERVATIONAL,['NA'],,Rate of adverse events during ibrutinib treatment
13532,NCT00003594,time to progression,1998-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,quality of life
13533,NCT00903565,To validate the performance of ColoPrint in estimating the 3-year relapse rate in patients with stage II colorectal cancer.,2008-09,UNKNOWN,OBSERVATIONAL,['NA'],,• Compare the ColoPrint results from fresh RNARetain colorectal tumor specimens to the matched formalin-fixed paraffin-embedded tissue (FFPE) colon tumor specimens for concordance.
13534,NCT03052556,Prevalence of HPV carriage,2017-03-08,COMPLETED,INTERVENTIONAL,['NA'],,Rate of worsening of cervical dysplasia
13535,NCT04307654,Postoperative complications,2014-01,COMPLETED,OBSERVATIONAL,['NA'],,
13536,NCT02954094,"Establish a longitudinal observational cohort to understand the natural history and management of HCC, including the safety and outcomes of HCC treatment interventions utilized in usual clinical practice",2016-12,RECRUITING,OBSERVATIONAL,['NA'],,Establish a Biorepository Specimen Bank (BSB)
13537,NCT02021422,The Number of Participants with SAEs and AEs.,2013-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Gather preliminary information on the immune modulation and clinical activity of this therapy
13538,NCT03659903,median OS,2004-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
13539,NCT04761185,tolerable dose,2020-01-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
13540,NCT02739698,"The Grouped Miller and Payne (MP) System for Pathological Response: G1 (Minimal Changes and < 30% Cells Tumour Reduction That Includes MP G1-G2), G3 (Microscopic Foci, Cells Tumour Reduction up to >90% That Includes MP G3-G4) and G5 (no Residual Tumour)",2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13541,NCT03852251,Anti-tumor activity of AK104 using objective response rate (ORR) based on RECIST v1.1 as assessed by the investigator (Phase II),2019-01-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of subjects who develop detectable anti-drug antibodies (ADAs)
13542,NCT05440565,Detection rate,2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
13543,NCT03877601,Fluorescence signal in patients with Barrett's Esophagus,2019-07-29,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Interrogate potential new EC biomarkers
13544,NCT01999634,anastomotic leaks rate,2014-02-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,functional success of microdialysis
13545,NCT00505024,"To study the effectiveness of the interactive voice response system (IVRS), which is designed to send a report to a patient's doctor about severe symptoms they are experiencing.",2006-07,COMPLETED,INTERVENTIONAL,['NA'],,"To study if systematic symptom assessment (by the use of IVRS) is another way to report symptoms rather than the usual method, which is calling the doctor when there is a problem."
13546,NCT00720512,Progression-free survival,2008-06,TERMINATED,INTERVENTIONAL,['PHASE3'],,Safety
13547,NCT02272036,Bowel cleanness measured by Boston Bowel preparation Scale,2015-12,COMPLETED,INTERVENTIONAL,['NA'],,Patient satisfaction and compliance
13548,NCT03524716,Text message response rate,2018-03-06,COMPLETED,INTERVENTIONAL,['NA'],,Social support
13549,NCT04975256,Establish Maximum Tolerated Dose,2021-08-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Evaluate preliminary clinical activity of the combination regimen
13550,NCT03941080,Prediction of response to conventional systemic anti-tumor therapy conventional systemic anti-tumor therapy for metastatic or irresectable colorectal cancer,2020-09-09,RECRUITING,OBSERVATIONAL,['NA'],,Prediction of serious side effects to conventional systemic anti-tumor therapy for metastatic or irresectable colorectal cancer
13551,NCT04728750,Complete enucleation of a tumor in the pancreas,2020-12-01,COMPLETED,OBSERVATIONAL,['NA'],,
13552,NCT04248634,Perineal complications,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Quality of life assessement: EORTC QLQ30 score
13553,NCT06189846,The rate of complete and/or nearly complete response,2024-01-04,RECRUITING,OBSERVATIONAL,['NA'],,Rate of changing attitude after using the digital rectoscope platform (intra-observer changing management).
13554,NCT05729230,Perception of prognosis and treatment side effects,2021-04-05,COMPLETED,OBSERVATIONAL,['NA'],,Evaluation of patient satisfaction with the information received during the consultation
13555,NCT04764643,Mean Visual analogue scale change,2020-02-01,COMPLETED,INTERVENTIONAL,['NA'],,exam time
13556,NCT00514020,"Number of Patients With Each Response in ""Good Risk"" Genotype (Thymidylate Synthase Promoter Enhancer Region [TSER]*2/*2 or TSER*2/*3 Genotype [Low TS Expression])",2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13557,NCT01247246,Efficacy,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety
13558,NCT03937440,Difference of stress responses between deep block and moderate block,2019-07-03,COMPLETED,INTERVENTIONAL,['NA'],,
13559,NCT02215642,Disease-specific survival,2009-01,UNKNOWN,OBSERVATIONAL,['NA'],Disease-free survival,Overall survival
13560,NCT05228587,To identify IGT PDR cut-off level below which the liver graft is not to be used for solid organ transplantation,2022-02-01,RECRUITING,INTERVENTIONAL,['NA'],,To identify IGT PDR cut-off level(s) below which post-LT organ recovery is impaired (early allograft dysfunction).
13561,NCT02528526,Safety and tolerability as measured by collection of adverse effects information,2014-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Efficacy as measured by MRI
13562,NCT03117556,Daily Narcotic Requirements,2017-08-31,WITHDRAWN,INTERVENTIONAL,['NA'],,Use of Anti-emetics
13563,NCT01883908,Number of Patients Completing Acupuncture Treatment,2012-12,TERMINATED,INTERVENTIONAL,['NA'],,
13564,NCT03851887,ORR,2018-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,DCR
13565,NCT02241551,"Safety and Efficacy Using Neo-adjuvant Gemcitabine Plus Nab-paclitaxel in Patients Receiving SBRT and Surgery for Borderline Resectable Pancreatic Cancer, Using Neo-adjuvant mFOLFIRINOX as a Control",2014-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of Life Effects of Chemotherapy on Patients Receiving Chemotherapy and SBRT
13566,NCT00684801,Caregiver's satisfaction with end-of-life care,2007-08,COMPLETED,OBSERVATIONAL,['NA'],,
13567,NCT05667064,Incidence of ADRs,2023-05-10,RECRUITING,OBSERVATIONAL,['NA'],,
13568,NCT01263171,Proportion of patients who commence neoadjuvant chemotherapy and radiotherapy and then undergo surgical resection,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Local recurrence-free, distant metastasis-free, and overall survival at 1 year after surgery"
13569,NCT05311189,Progression-free survival,2022-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and tolerability based on incidence of treatment-emergent adverse events as assessed by CTCAE
13570,NCT06300879,Postoperative TNM staging by Pathological findings .,2024-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Quality of Life at 3 Months Postoperatively will be assessed by EORTC QLQ-STO22 scale
13571,NCT03825861,Pathologic Complete Response (pCR),2017-02-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,Rate of Disease Progression
13572,NCT04514822,SUVmax 60/30 comparison between MLNs and BLNs,2019-03-01,UNKNOWN,INTERVENTIONAL,['NA'],Accuracy,SUVmax 60/30 comparison from PTs between N0 and non-N0 stage
13573,NCT02041793,Resolution of Pseudocyst,2010-05,COMPLETED,INTERVENTIONAL,['NA'],,Recurrence rate of pseudocyst
13574,NCT05751343,Objective response rate,2023-03-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,progress-free survival
13575,NCT03713593,Overall Survival (OS),2018-12-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of Participants Who Discontinued Study Drug Due to an Adverse Event
13576,NCT00006117,,1999-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13577,NCT01504477,Maximum Tolerated Dose,2011-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Duration of Disease Control
13578,NCT00826540,Progression-free Survival Rate,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Feasibility of Study Treatment
13579,NCT04850157,Relapse-free survival( RFS),2021-04-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse Events (AEs)
13580,NCT01494363,Response rate,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
13581,NCT06064344,The cumulative occurrence rate of complications of grade ≥2 within 2 years after the start of treatment,2023-10-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,2-year overall survival rate
13582,NCT04841616,False negative rate,2021-07-01,RECRUITING,INTERVENTIONAL,['NA'],,the need to repeat procedure
13583,NCT04763642,Intra-abdominal infection,2020-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],progression-free survival,Length of hospital stay (day)
13584,NCT01097018,Overall Survival,2010-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression-free Survival
13585,NCT01637194,Number of patients with dose limiting toxicity,2008-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacodynamic effects of this regimen on post-therapy tumor and/or skin specimens
13586,NCT00757614,Evaluation of interactions between polymorphisms in predisposition genes and potential lifestyle risk factors,2008-02,UNKNOWN,OBSERVATIONAL,['NA'],,
13587,NCT05842525,Objective response rate (ORR),2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Disease Control Rate (DCR),Progression-Free Survival (PFS)
13588,NCT05198856,progression-free survival (PFS),2022-03-10,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Percentage of Participants With Adverse Events (AEs)
13589,NCT04931654,Preliminary anti-tumour activity of AZD7789,2021-09-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Preliminary anti-tumour activity of AZD7789: Changes in circulating tumor DNA (ctDNA)
13590,NCT05848947,Effective dose (Gy) for the whole body,2023-04-25,COMPLETED,INTERVENTIONAL,['PHASE4'],,
13591,NCT02190071,positive malignancy rate of cover slides set and base slides set.,2014-06,COMPLETED,OBSERVATIONAL,['NA'],,"positive malignancy rate of (1) cytologic smear, (2) cell block and (3) histologic biopsy"
13592,NCT02705196,Number of patient with dose-limiting toxicities (DLTs) as evaluated accordingly to CTCAE 4.0,2016-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
13593,NCT03052335,Negative predictive value (NPV) of the CCE2 for large polyps (≥ 10 mm),2017-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,Cost-effectiveness analyses: cost reduction of preventive colonoscopies spared
13594,NCT02205463,Maximum Tolerated Dose (MTD),2014-12,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics of KD019
13595,NCT00005876,,2000-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13596,NCT00677456,"Patients should live for 6 months at least, and with acceptable life quality",2008-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,There are significant differences among life qualities of the four reconstructions
13597,NCT01594125,Number of Participants With Dose Limiting Toxicities to Determine Maximum Tolerated Dose (MTD) of Nintedanib,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Response by Alpha Fetoprotein (AFP)
13598,NCT02130427,Tumor Volume,2010-09,COMPLETED,INTERVENTIONAL,['NA'],,
13599,NCT02066974,Response rate,2014-01,UNKNOWN,OBSERVATIONAL,['NA'],,"Overall survival, relapse-free survival"
13600,NCT01151839,operative mortality,2010-06,UNKNOWN,INTERVENTIONAL,['NA'],,Treatment toxicity
13601,NCT04291651,Indolency,2019-10-08,RECRUITING,OBSERVATIONAL,['NA'],,
13602,NCT04361708,The maximum dose tolerated,2020-05-08,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival rate
13603,NCT00615420,Severity of Mucositis According to the Radiation Therapy Oncology Group (RTOG) for Patients Who Had a Minimum of 2 Mucositis Assessments,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
13604,NCT02921646,Resting energetic expenditure measurement by indirect calorimetry,2017-07-10,TERMINATED,INTERVENTIONAL,['NA'],,
13605,NCT03127774,Progression Free Survival,2017-09-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
13606,NCT05103007,FLR,2021-12-01,RECRUITING,INTERVENTIONAL,['NA'],,Progression-free survival (PFS)
13607,NCT03033446,Response Rate,2016-12-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events from the combination of RE and nivolumab assessed by NCI CTCAE v4.0
13608,NCT00002842,2 Year Disease-free Survival .,1994-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13609,NCT04008082,Presence or absence of factors with a possible influence on OS,2019-05-14,COMPLETED,OBSERVATIONAL,['NA'],,
13610,NCT01898091,Maximum Change in Mean Mouth and Throat Soreness (MTS) Score From Baseline Through Weeks of Radiation Therapy Using the MTS Question of the Modified Oral Mucositis Daily Questionnaire*.,2013-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13611,NCT05396807,Progression Free Survival (PFS),2023-03-21,RECRUITING,INTERVENTIONAL,['NA'],,Quality of Life (QoL)
13612,NCT00078975,Prolonged stable disease rate,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety and tolerability
13613,NCT00514163,response rate,2007-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,clinical benefit response
13614,NCT03568019,A retrospective review to determine if PET can be used to identify cachexia-inducing lung and gastrointestinal tumors,2013-11-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
13615,NCT06210334,Overall Survival (OS),2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events (AE)
13616,NCT02298946,Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0),2014-11-21,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to Maximum Observed Plasma Concentration (Tmax) of AMP-224
13617,NCT03604653,Disease-free Survival,2018-05-15,COMPLETED,OBSERVATIONAL,['NA'],,Toxicity as measured by treatment related adverse events according to the NCI CTCAE v 4.0
13618,NCT05224518,Quality of life of cancer patients(EORTC QLQ-CR29),2022-02-21,RECRUITING,INTERVENTIONAL,['NA'],,Exercise Counseling and Programming Preferences
13619,NCT03988712,Diagnostic yield of colorectal cancer,2018-04-01,COMPLETED,OBSERVATIONAL,['NA'],,
13620,NCT02843581,Relief degree,2016-07-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival（OS）
13621,NCT00258232,Response rate by RECIST criteria at every other course,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to treatment failure
13622,NCT00654212,successful one-stage operation,2002-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,"cumulative operative time, cumulative blood loss, conversion rate, post-operative pain, cumulative length of hospital stay, operative mortality, post-operative complications, ates of permanent stoma creation,disease recurrence, survival"
13623,NCT03111732,Progression Free Survival (PFS),2017-06-14,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0),"Number of Participants With Grade 1-4 Adverse Events Unrelated, Unlikely, Possibly, and Probably Related to Capecitabine"
13624,NCT00909350,miR expression between tissue from Barrett's esophagus and that from normal tissues,2008-04,COMPLETED,OBSERVATIONAL,['NA'],,expression of miR in Barrett's esophagus patients with cancer in comparison to those who do not progress to cancer
13625,NCT05927142,Phase II: Determine the clinical benefit rate of combination therapy with durvalumab and rintatolimod.,2024-01-09,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determine the clinical effect of combination therapy on quality of life using questionnaires
13626,NCT00055809,Tumor response rate (CR + PR) as measured by RECIST criteria,2003-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity graded according to CTC v3.0 criteria for adverse outcomes
13627,NCT04589884,To collect human tissue spectral features to build a spectral tissue library and build successively machine learning algorithm to enable real-time automated tissue recognition,2020-09-22,TERMINATED,OBSERVATIONAL,['NA'],,To correlate HSI values with pathological data obtained as standard of care
13628,NCT04588805,ncidence Rate of Perioperiative VTE,2020-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,
13629,NCT04700527,The rate and severity of patient reported and physician determined toxicities between subjects who receive therapeutic SCFA and those who receive placebo.,2023-12-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Subject reported acute toxicity profile as ascertained by patient-reported outcomes version of the CTCAE (PRO-CTCAE) for both subjects who receive therapeutic SCFA versus those who receive placebo.
13630,NCT00634725,Overall survival,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,tolerance to erlotinib
13631,NCT03430440,Postoperative pain (numerical rating scale: 0 ~ 10),2017-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,Side effects of PCA (area and vomiting / hypotension / muscle weakness
13632,NCT06047158,Immune related index,2022-12-01,RECRUITING,OBSERVATIONAL,['NA'],,Hospitalization related
13633,NCT00077337,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13634,NCT05187416,Elastic modulus measured by Ultrasonic shear wave and tumor stromal component assessed by pathological analysis in pancreatic cancer,2022-02-01,UNKNOWN,OBSERVATIONAL,['NA'],,
13635,NCT00002593,"Compare effectiveness of bolus 5-FU, leucovorin, levamisole vs continuous infusion 5-FU, levamisole as adjuvant therapy for patients with colon cancer, measured in overall survival",1994-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Disease free survival
13636,NCT04673136,Detection of advanced lesions,2021-04-01,COMPLETED,INTERVENTIONAL,['NA'],,Characteristics of GI-GENIUS
13637,NCT00897442,Make available tissue and blood for proposed projects,1992-06,COMPLETED,OBSERVATIONAL,['NA'],,
13638,NCT00820339,Overall survival,2009-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"Blood transfusion ,hepatic function of patients after surgery, the incidence rate of complications"
13639,NCT00618384,determination of time to progression (TTP),2008-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,adverse events
13640,NCT02735317,EORTC QLQ-C30,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The change of body weight from baseline.
13641,NCT05226221,30-day morbidity rate,2021-09-01,RECRUITING,OBSERVATIONAL,['NA'],,Emergency Surgical Frailty Index (EmFSI)
13642,NCT05239546,Major Clinical Response (MCR) Rate,2023-03-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Response Rate (ORR)
13643,NCT00122187,Percent of Patients Receiving GI Consult Plus Anatomic Workup for FOBT+ Results,2005-08,COMPLETED,INTERVENTIONAL,['NA'],,
13644,NCT01909830,Objective Response Rate (ORR),2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
13645,NCT05447234,Overall Survival,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,AEs
13646,NCT03708328,"Expansion: Progression Free Survival, Assessed According to RECIST v1.1",2018-10-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,"Dose Escalation: Progression Free Survival, Assessed According to RECIST v1.1"
13647,NCT01286662,mortality,1978-01,COMPLETED,OBSERVATIONAL,['NA'],,Incidence of desmoid tumors
13648,NCT05792735,Pathological Complete Response Rate,2023-04-11,RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life (QoL),Number of participants with treatment-related adverse events (TRAE) as assessed by CTCAE v5.0
13649,NCT03345225,Comparing the change in the Lencioni score between the SureFire infusion system and a standard endhole microcatheter,2018-05,WITHDRAWN,INTERVENTIONAL,['NA'],,Number of Adverse Event
13650,NCT03998644,"Gut microbiota structure and function difference between colorectal cancer, precancer and healthy controls",2015-12,RECRUITING,OBSERVATIONAL,['NA'],,"Metabolic difference of blood samples between colorectal cancer, precancer and healthy controls"
13651,NCT02993731,Overall Survival,2016-12,COMPLETED,INTERVENTIONAL,['PHASE3'],Overall Response Rate in Biomarker Positive Patients,Mean Change From Baseline for Global Quality of Life (QoL) at 8 Weeks.
13652,NCT04097067,Response rate,2019-09-01,RECRUITING,INTERVENTIONAL,['NA'],,Acute and chronic toxicities
13653,NCT01919463,Mean Intubation Time (MIT),2015-03,UNKNOWN,INTERVENTIONAL,['NA'],,Polyp Detection Rate (PDR)
13654,NCT00751036,Progression-free Survival (PFS),2009-06,TERMINATED,INTERVENTIONAL,['PHASE3'],,Overall Survival (OS)
13655,NCT03480152,Number of Non-Serious Adverse Events Probably Related to Treatment,2018-05-18,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Maximum Tolerated Dose (MTD,Number of Participants With an Increase in the Quantity and Quality of Circulating Antigen-specific T Cells
13656,NCT00766480,Complete histological response,2007-01,UNKNOWN,INTERVENTIONAL,['NA'],,
13657,NCT02521727,number of participants having advanced neoplasms.,2015-11-26,COMPLETED,OBSERVATIONAL,['NA'],,number of participants having advanced neoplasms based on age of the proband
13658,NCT02046356,Technical success,2014-01,UNKNOWN,OBSERVATIONAL,['NA'],RFA complications,IDR-free survival
13659,NCT01643278,Maximum tolerated dose defined as the highest dose studied for which the observed incidence of dose-limiting toxicity is less than 33% according to the National Cancer Institute Common Toxicity Criteria,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Genotype (v-Kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog [KIT] and platelet-derived growth factor receptor-alpha [PDGFR-a]) mutation status,"RR as measured by RECIST 1.1, Choi and immune-related response criteria"
13660,NCT02775227,Comprehensive Complication Index,2016-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],Disease specific survival,Readmissions
13661,NCT01586416,Number of participants who withdraw from study after enrollment,2012-12,UNKNOWN,INTERVENTIONAL,['NA'],,Proportion of each chemotherapy component administered during the treatment regimen relative to the total planned amount
13662,NCT02911961,APAP-CYS Concentrations Over Time - Acetaminophen Group,2021-08,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,Relationship between APAP-CYS and other biochemical markers of liver function
13663,NCT05381038,CURATE.AI applicability: percentage of participants in whom the investigators successfully apply CURATE.AI profile.,2022-06,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",ctDNA Analysis,Clinically significant dose changes
13664,NCT02657330,Maximum tolerated dose of SBP-101,2016-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Plasma drug half-life
13665,NCT02907086,Number of blood samples collected,2017-07-07,COMPLETED,OBSERVATIONAL,['NA'],,
13666,NCT00007930,Local recurrence at 3 years,1999-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Disease-free and overall survival at 5 years
13667,NCT01695863,Bowel Prep Efficacy - Boston Bowel Preparation Scale (BBPS),2012-02,COMPLETED,INTERVENTIONAL,['PHASE4'],Non-Serious Adverse Events on Self Report Scale,Renal Function Pre and Post Bowel Prep - Continued (mmol/L)
13668,NCT05177393,Median Overall Survival,2019-02-28,RECRUITING,OBSERVATIONAL,['NA'],,
13669,NCT03129685,Short term mortality rate,2017-05-20,UNKNOWN,INTERVENTIONAL,['NA'],,Tumor response rate according to mRECIST criteria.
13670,NCT02973490,postoperative complications,2017-01,UNKNOWN,INTERVENTIONAL,['NA'],,
13671,NCT02041325,Positive for Hepatitis B Surface Antigen,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Phenotypic Changes
13672,NCT01755585,all cause mortality,2011-07,UNKNOWN,OBSERVATIONAL,['NA'],,
13673,NCT00267696,Determine the Antitumor Activity of Gemcitabine/Carboplatin/Bevacizumab Regimen as Measured by the Probability of Surviving Progression-free for at Least 6 Months or Responding.,2005-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival for Patients Treated With the Regimen.
13674,NCT01835925,Tumor tissue to predict likelihood of achieving pathologic complete response post standard treatment.,2013-07,COMPLETED,OBSERVATIONAL,['NA'],,Tumor tissue results with clinical outcome post standard treatment. .
13675,NCT03926338,Pathological complete response (pCR) rates,2019-05-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Surgery feasibility
13676,NCT04166721,Main phase IIB (efficacy) phase: Best objective response rate (ORR) using RECIST 1.1 criteria,2020-02-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
13677,NCT04949737,Estimation of the prevalence of Helicobacter pylori,2024-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
13678,NCT00192114,Percentage of Participants With Progression Free Survival (PFS) at 6 Months,2005-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Change From Baseline in Vascular Endothelial Growth Factor (VEGF) to Cycle 2 and Cycle 3,Change From Baseline in Carcinoembryonic Antigen (CEA) Response at Each Cycle
13679,NCT01216527,Overall survival rate,2007-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Disease free survival rate
13680,NCT00788697,Specificity: Percentage of True Negative Lesions Among All Malignant Lesions Per Truth Standard,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Inter-reader Agreement
13681,NCT04149015,Pathological complete and subtotal regression (TRG1a/b by Becker),2019-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13682,NCT04697186,Helicobacter pylori eradication,2021-01-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,adverse events
13683,NCT03035253,Incidence of dose limiting toxicities,2016-12,TERMINATED,INTERVENTIONAL,['PHASE1'],,Progression Free Survival
13684,NCT03220009,Recurrence free survival (RFS),2017-11-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],T cell inflammation,Rate of delayed surgery
13685,NCT05817994,"Number of endoscopic, endosonographic, and radiologic interventions undergone to reach a diagnostic liver biopsy [Phase 2]",2023-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Number of diagnostic liver biopsies
13686,NCT03569761,CRC screening intentions,2017-08-01,COMPLETED,INTERVENTIONAL,['NA'],,CRC screening completion
13687,NCT00081627,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13688,NCT02653313,Shedding of viral genomes [Vg],2015-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Clinical outcome
13689,NCT00793871,Progression-free Survival (PFS),2008-11,COMPLETED,INTERVENTIONAL,['PHASE4'],Time to Tumor Response (TTR),Eastern Cooperative Oncology Group (ECOG) Performance Status
13690,NCT01292330,postoperative complications,2010-01,UNKNOWN,INTERVENTIONAL,['NA'],,hospitalization expenses and length of stay
13691,NCT06204484,Relapse-free survival (RFS) time in MRD-negative groups,2023-07-26,RECRUITING,INTERVENTIONAL,['NA'],Performance of landmark MRD status and longitudinal MRD status in prediction of recurrence.,OS time in MRD+ groups
13692,NCT04902872,Phase 2: Overall response rate (ORR),2021-05-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Incidence of TEAEs
13693,NCT02023021,Recurrence-free survival at one year after curative resection,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,CA199 level after curative resection
13694,NCT05002855,Evaluate the effect of the implementation of this protocol on 3-year overall survival.,2021-01-20,COMPLETED,OBSERVATIONAL,['NA'],,
13695,NCT01739439,MTD defined as the dose level in which 1 out of 6 patients observes dose-limiting toxicity (DLT) assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0,2013-05,TERMINATED,INTERVENTIONAL,['PHASE1'],,
13696,NCT03599895,operation time,2018-08-01,UNKNOWN,INTERVENTIONAL,['NA'],,hospitalization expenses
13697,NCT06042998,3-year disease-free survival,2023-07-07,RECRUITING,INTERVENTIONAL,['NA'],,postoperative recovery course
13698,NCT04207489,The imaging effect of indocyanine green,2020-04-15,UNKNOWN,OBSERVATIONAL,['NA'],,
13699,NCT01150630,Event-free survival at 1 year (phase II),2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Lymph node status
13700,NCT03595345,Tumour-specific death,2016-12-15,COMPLETED,OBSERVATIONAL,['NA'],,Drop-out
13701,NCT00006010,six-month overall survival,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,time to progression
13702,NCT00005049,,1997-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13703,NCT06143605,DFS,2013-01-30,COMPLETED,OBSERVATIONAL,['NA'],,
13704,NCT05326152,Immediate adverse effects,2020-11-25,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Recurrence
13705,NCT02430636,Number of participants with Adverse events,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Overall survival (OS)
13706,NCT03667495,Colorectal cancer or adenoma recurred,2017-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,
13707,NCT00946153,Phase 2: Time to Progression (TTP) by Independent Review Assessment,2009-07-24,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Overall Survival (OS)
13708,NCT03946969,Safety and feasibility,2019-05-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Exploratory Outcomes,Overall Survival (OS)
13709,NCT05434026,the rate of postoperative complications,2022-08-03,RECRUITING,OBSERVATIONAL,['NA'],,
13710,NCT03420443,Action of synbiotics on irradiated GI mucosa in rectal cancer treatment,2008-11,COMPLETED,INTERVENTIONAL,['NA'],,
13711,NCT04856761,"RFS, recurrence-free survival",2020-11-01,RECRUITING,OBSERVATIONAL,['NA'],,"OS, overall survival"
13712,NCT00216086,Pathological Complete Response (pCR) Rate,2005-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Disease-Free Survival
13713,NCT01839487,Percentage of Participants in the PAG Arm Who Experienced Any Thromboembolic (TE) Event in Stage 2 of the Study,2013-05-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Area Under the Concentration-Time Curve From Time 0 to Last Quantifiable Concentration (AUC0-last) of PEGPH20
13714,NCT00005860,,2000-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13715,NCT05919264,During dose expansion describe the Overall Response Rate using RECIST v1.1,2023-05-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,During dose expansion describe Progression Free Survival
13716,NCT00746655,To evaluate the Health Related Quality of Life (HRQL) associated with combined therapy.,2009-07,WITHDRAWN,INTERVENTIONAL,['NA'],,To determine if SBRT and TACE will be able to bridge patients to transplant that were initially ineligible.
13717,NCT00921531,Overall survival,2009-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,time to progression
13718,NCT04080024,Number of treatment related adverse events (AEs),2019-08-23,COMPLETED,INTERVENTIONAL,['PHASE1'],Visualization of the pancreatic duct,Pharmacokinetics as measured by apparent volume of distribution at steady state (Vss) for Mn (L) the terminal phase half-life (T½) for manganese (Mn)
13719,NCT02103062,Progression Free Survival (PFS) Rate as Measured at Week 8,2014-05-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Kaplan Meier Estimate of PFS by Investigator Assessment,Number of Participants With Adverse Events
13720,NCT05331131,Assessing Pain Response,2022-09-19,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Adverse events
13721,NCT03619538,Estimate morphine consumption,2011-07,COMPLETED,INTERVENTIONAL,['NA'],,
13722,NCT00351195,Response,2006-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,Survival
13723,NCT00574860,NCI v3 to measure severity of OM,2007-12,TERMINATED,INTERVENTIONAL,['PHASE3'],,WHO criteria for measuring severity of OM
13724,NCT06033976,Rate of curative resection,2021-01-01,RECRUITING,OBSERVATIONAL,['NA'],Rate of delayed bleeding,Rate of R0 resection
13725,NCT00913757,Large-scale molecular profiling study to identify HCC biomarkers for early diagnosis and prevention.,2009-07-01,COMPLETED,OBSERVATIONAL,['NA'],,
13726,NCT00005599,,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13727,NCT02717091,R0 resection rate,2015-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,quality of the tumor
13728,NCT05568433,Role of the cyst fluid concentrations of the specific biomarkers for differentiation the pancreatic cystic lesions,2018-04-02,COMPLETED,OBSERVATIONAL,['NA'],,The Correlation between cyst fluid concentration and serum level of the specific biomarkers
13729,NCT05797077,5-years Progression Free Survival,2023-02-20,RECRUITING,INTERVENTIONAL,['PHASE3'],,Complication
13730,NCT00786747,Up to date colorectal cancer screening status,2010-02,COMPLETED,INTERVENTIONAL,['NA'],,Readiness to undergo colorectal cancer screening
13731,NCT03256344,Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT),2018-03-19,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
13732,NCT03368651,Overall survival (OS),2016-01-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,recurrence rate
13733,NCT04713007,Perception of Care Coordination Caregiver,2021-06-03,RECRUITING,INTERVENTIONAL,['NA'],,
13734,NCT04462042,Acute grade >2 hematological side effects,2021-04-07,RECRUITING,INTERVENTIONAL,['NA'],Cost-utility analysis,Overall survival
13735,NCT01347645,Phase 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs),2011-09-30,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Percentage of Participants With Overall Response
13736,NCT03875144,overall survival,2020-08-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life evaluation
13737,NCT04990895,Assessment of the Quality of Life of Colorectal Cancer Patients Using EORTC-QLQ CR29 Questionnaire,2022-03-30,RECRUITING,INTERVENTIONAL,['PHASE3'],,Patient self-efficacy
13738,NCT05976568,Overall Survival (OS) (Phase III),2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Time to progression (TTP)
13739,NCT06222944,ORR,2024-02-25,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
13740,NCT00985556,Progression-free survival,2009-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Time to progression
13741,NCT04792801,Rate of patients reclassified for lymph node fixation (N +) and / or extrahepatic extension (M +) after PET TDM FDG-Choline,2021-06-22,RECRUITING,OBSERVATIONAL,['NA'],,Binding intensity (SUV) of PET TDM FDG-Choline and the last aFP value before transplantation or WL dropout.
13742,NCT02297269,the incidence of DVT,2014-12,UNKNOWN,OBSERVATIONAL,['NA'],,incidence of incision infection
13743,NCT03575637,time to treatment failure,2018-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Progression free survival time (PFS), overall survival time (OS)."
13744,NCT03117972,Progression Free Survival,2017-08-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
13745,NCT00967603,6-month progression-free survival,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,pharmacodynamics
13746,NCT02461407,Overall Survival (OS),2015-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Disease Control Rate (DCR)
13747,NCT01291615,frequency in adverse events,2010-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13748,NCT06293625,DFS (disease Free Survival),2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,
13749,NCT02720666,The maximum-tolerated dose (MTD) of K-001,2016-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Clinical efficacy of K-001 assessed by disease control rate (DCR) according to RECIST V 1.0 criteria
13750,NCT04019808,H. pylori prevalence and drug resistance,2019-07-30,UNKNOWN,OBSERVATIONAL,['NA'],,
13751,NCT01803009,Preferred CRC screening test,2012-11,COMPLETED,INTERVENTIONAL,['NA'],,Uptake of CRC screening
13752,NCT00003851,,1999-03,TERMINATED,INTERVENTIONAL,['NA'],,
13753,NCT01560260,Number of Participants With Complete Response or Partial Response Using Response Evaluation Criteria in Solid Tumors Guideline Version 1.1,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Determine the Number of Participants With Tumor Metabolic Response Correlating With Anatomic Response and Clinical Benefit.,"Correlations Between Glucose, Insulin, Tumor Tissue and Blood Biomarkers With FDG-PET Metabolic Response."
13754,NCT01426074,Pathologic Complete Response (pCR),2011-08,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
13755,NCT01815359,disease-free survival,2013-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,chemotherapy toxicity grade 3 to 5
13756,NCT00987857,Overall survival,2009-03,UNKNOWN,INTERVENTIONAL,['NA'],,Frequency of endoscopy
13757,NCT02164292,Feasibility of the procedure defined as percentage of patients that complete both surgical stages.,2011-06,COMPLETED,OBSERVATIONAL,['NA'],,Risk factors for a reduced kinetic growth rate of the future liver remnant (<35 cc/day)
13758,NCT02007954,Collection of Adverse Events Related to Study Device as a Measure of Safety,2014-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Exploratory Endpoint - Tmax of Doxorubicin and Doxorubicinol Post DEBDOX-M1 TACE,AFP Tumor Marker Pre- and Post-treatment
13759,NCT05813028,"Change of Beck Anxiety Inventory score at baseline and one week later fisrt,second,third and forth chemothraphy.",2022-07-15,RECRUITING,INTERVENTIONAL,['NA'],,
13760,NCT05489211,PSA50 response (Substudy 3 only),2022-09-06,RECRUITING,INTERVENTIONAL,['PHASE2'],,CA-125 response (Substudy 4)
13761,NCT05323058,Severity of mucositis,2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Patient-Reported Oral Mucositis( PROMS scale),Pain and burning sensation
13762,NCT05483075,Number of Intervention Arm Participants in Compliance with HCP Exercise Intervention,2022-11-15,RECRUITING,INTERVENTIONAL,['NA'],,Minutes Spent in Rapid Eye Movement (REM) Sleep
13763,NCT01403727,Radiation Dose,2011-11,COMPLETED,OBSERVATIONAL,['NA'],,Accuracy of needle targeting
13764,NCT03626922,Objective Response Rate to pembrolizumab and pemetrexed plus oxaliplatin,2019-05-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall Survival
13765,NCT06074536,"The Measurement of the achievement oh the shared decision shared decision making in CRC screening using the patient shared a self-decision-making questionnaire (SDM-Q9), validated in French",2024-03-06,RECRUITING,INTERVENTIONAL,['NA'],,Explore understanding of the shared decision process among general practitioners and patients
13766,NCT03924349,Success rate of localization,2019-07-08,COMPLETED,INTERVENTIONAL,['NA'],,Number of Participants with Complication
13767,NCT05415917,Safety as assessed by number of participants experiencing adverse events,2022-07-29,RECRUITING,INTERVENTIONAL,['PHASE2'],To measure the tumor with the Response Evaluation Criteria in Solid Tumors (RECIST),
13768,NCT00274872,Pharmaco-economic evaluation,2004-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
13769,NCT01783158,To detect early synchronous second primary esophageal carcinoma,2004-01,COMPLETED,OBSERVATIONAL,['NA'],,
13770,NCT04345978,Disease-free Survival,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,"IL-1β，IL-2,IL-4,IL-5,IL-6,IL-8,IL-10,IL-17A,IL-17F,TNF-α，TNF-β，"
13771,NCT01216930,,2010-10,COMPLETED,OBSERVATIONAL,['NA'],,
13772,NCT04527068,Progression-free survival (PFS),2020-09-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Duration of Response (DOR)
13773,NCT02508467,"Number of patients with adverse events, serious adverse events and changes in physical findings, vital signs, clinical laboratory results and ECG findings",2015-07-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Preliminary evidence of fisogatinib (BLU-554) antineoplastic activity
13774,NCT06011330,overall survival (OS),2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],Treatment-Related Adverse Events (TRAE),progress-free survival (PFS)
13775,NCT01591590,Mortality,2012-06,COMPLETED,INTERVENTIONAL,['NA'],,Tumour Progression
13776,NCT00026091,Response rate (CR or PR),2001-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Molecular change
13777,NCT05427396,The incidence of adverse events (AE) and serious adverse events (SAE) were assessed,2022-08-09,RECRUITING,INTERVENTIONAL,['PHASE1'],PFS,TTP
13778,NCT05227261,Sensitivity and specificity of the test in early detecting cancers,2022-04-10,RECRUITING,OBSERVATIONAL,['NA'],,Rate of cancer development in the high-risk group as compared to the moderate-risk population
13779,NCT04644315,"Confirmed Objective Response Rate (ORR) as Determined by the Investigator Per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)",2021-05-24,TERMINATED,INTERVENTIONAL,['PHASE2'],,OS in Participants With Primary CNS Tumors
13780,NCT00417209,overall survival (OS) defined as the time interval from the date of randomization to the date of death due to any cause,2006-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression free survival (PFS); Overall Response Rate (proportion of patients with confirmed RECIST-defined complete response (CR) or partial response (PR); clinical benefit based on the measurement of tumor related symptoms;
13781,NCT05815290,complete response rate,2023-03-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,pCR rate
13782,NCT02625272,the content RNA of CEA and CK20 in circulating tumor cells and ascites,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,3-year local recurrence
13783,NCT01619696,acceptation rate of the entire sequence by eligible patients,2011-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,"radiological changes while on chimiotherapy, to tumour regression, and prognosis"
13784,NCT03205735,progression free survival,2017-06-29,UNKNOWN,OBSERVATIONAL,['NA'],,toxicities evaluation
13785,NCT04525833,The incidence of a new diagnosis of any event of liver cirrhosis complications,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
13786,NCT05933785,anal preservation rate,2018-01-02,COMPLETED,OBSERVATIONAL,['NA'],,incidence of positive distal resection margin
13787,NCT01328171,overall response rate,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,translational research (EGFR genetics and proteomics): prognostic and predictive impact on efficacy outcomes
13788,NCT01111604,Progression-Free Survival (PFS),2010-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events
13789,NCT05952661,Correlations of minimal residual disease (MRD) and efficacy,2023-02-22,RECRUITING,OBSERVATIONAL,['NA'],ctDNA mutation profiles in ESCC patients undergoing adjuvant immunotherapy.,The timing of MRD advance warning of recurrence in patients ahead of imaging cues
13790,NCT01070290,Compare the progression-free survival (PFS) of ARQ 197 versus investigator's choice of second-line chemotherapy in patients with advanced gastric cancer who have failed first-line treatment.,na,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Further characterize the safety profile of ARQ 197
13791,NCT00865982,R0-resection rate,2008-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Event free survival rate
13792,NCT02960061,Number of survival participants will be assessed according to the data collected by the followed up office.,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Progression Free Survival
13793,NCT05396846,Weight Loss,2023-04-29,RECRUITING,INTERVENTIONAL,['NA'],Skin Carotenoids,
13794,NCT00005804,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13795,NCT04902261,1-Year Survival Rates,2020-11-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events (AEs)
13796,NCT04384757,3 year relapse-free survival by Kaplan Mayer,2020-07-29,RECRUITING,INTERVENTIONAL,['NA'],,Resected lymph nodes
13797,NCT04891146,investigate the effect of anesthesia management on the change of preoperative systemic inflammatory immune index(SII) and postoperative 2.hour and 24.hour SII value,2020-03-05,COMPLETED,OBSERVATIONAL,['NA'],,
13798,NCT02058849,Endurance,2014-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Total Body Mass,Muscle Strength
13799,NCT01853774,Primary Outcome is Clinic Attendance,2012-04,COMPLETED,INTERVENTIONAL,['NA'],,The Secondary Outcome is Participant Completion of a CRC Screening Test.
13800,NCT06335966,Patient acceptability: Number of patients interested in being screened via SECD at other care centers,2024-01-25,RECRUITING,OBSERVATIONAL,['NA'],,Access: time to full diagnostic work up for patients with positive SECD results
13801,NCT05803746,MPR,2022-07-15,RECRUITING,INTERVENTIONAL,['NA'],,PFS
13802,NCT05873699,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",2023-08-18,RECRUITING,INTERVENTIONAL,['PHASE1'],,
13803,NCT03717038,Overall survival (OS) time following treatment with Sym004 versus TAS-102.,2019-02,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Pharmacokinetic (PK) Parameters of Sym004: Maximum Concentration (Cmax)
13804,NCT05682157,Change in LARS score,2023-03-21,RECRUITING,INTERVENTIONAL,['NA'],,
13805,NCT04801719,Overall survival,2010-01-04,COMPLETED,INTERVENTIONAL,['NA'],,Complications of endoluminal RFA of biliary tract
13806,NCT06272656,"comparison of liver cancer markers AKR1B10, AFP, AFP-L3% and DCP before and after TACE",2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,progression- free - time
13807,NCT02694718,Percentage of Participants With Pathological Complete Tumor Response,2005-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Any Adverse Events and Serious Adverse Events
13808,NCT05233007,Predicting treatment resistance to anti-cancer therapy,2022-01-25,SUSPENDED,OBSERVATIONAL,['NA'],,
13809,NCT05290220,PFS,2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,DOR
13810,NCT06152757,"AE, SAE, AESI, CRS, ICANS, TEAE",2023-10-09,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
13811,NCT04524260,Change of Anxiety,2020-08-31,UNKNOWN,INTERVENTIONAL,['NA'],Socio-economic: ability to return to work,Change of Health related quality of life - SF-12
13812,NCT05639413,Overall Survival (OS),2023-07-24,RECRUITING,INTERVENTIONAL,['NA'],,Correlation between predictive biomarkers and response to treatment
13813,NCT03851471,Overall Survival,2019-04-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,10cm-VAS of the pain
13814,NCT01638533,Pharmacokinetic (PK) profile of romidepsin in patients with varying degrees of hepatic dysfunction using liquid chromatography-electrospray ionization tandem mass spectrometric method,2012-06-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Antitumor activity assessed using Response Evaluation Criteria in Solid Tumors and the International Workshop Lymphoma Response Criteria
13815,NCT05420922,The treatment-related adverse events (TRAEs),2021-11-01,RECRUITING,OBSERVATIONAL,['NA'],,The progression-free survival (PFS)
13816,NCT02543411,Fentanyl consumption during sedation,2015-09,COMPLETED,INTERVENTIONAL,['NA'],,Incidence of nausea and vomiting
13817,NCT03947775,The proportion of participants in each arm with biopsy-proven HGAIN (AIN-2/3).,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Change in anal carriage of vaccine HPV types. Repeated detection of anal HPV will indicate the duration of carriage. This will be compared between the early and delayed vaccine groups.,"The geometric mean titres (GMT) of antibody to each vaccine type above a pre-specified, validated cut-off. F"
13818,NCT01864070,Dose Limiting Toxicities (DLT) for Combination of TheraSphere and Everolimus,2014-05,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
13819,NCT01105169,Expression of Cox2 in rectal epithelia,2010-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Urine excretion of prostaglandin E2 metabolite (PGE-M)
13820,NCT00765180,Colorectal adenoma detection rate,2007-01,COMPLETED,INTERVENTIONAL,['NA'],,"Procedure time, complication"
13821,NCT02575508,Overall survival (Phase II),na,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Potential associations between response rate and tumor biomarkers (Phase II)
13822,NCT01455311,Rank The Diagnostic Accuracy of Specimen,2010-09,TERMINATED,OBSERVATIONAL,['NA'],,Cataloging Proteins
13823,NCT00732836,Maximum Tolerated Dose (MTD) of HAI Abraxane,2008-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13824,NCT00005085,,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13825,NCT00440310,Overall Survival,2007-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,
13826,NCT05480280,Objective Response Rate (ORR),2022-07-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
13827,NCT02132468,"Number of Participants With Improved, Stable, or Worsened Change In Serotonin Biomarker Levels From Baseline",2014-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Number of Participants With Partial Response (PR), Progressive Disease (PD), or Stable Disease (SD) Based on RECIST 1.1"
13828,NCT01057017,Number of Patients With Toxicity to Combination of Panitumumab and Bevacizumab,2010-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,
13829,NCT03708445,The usefulness of new staining method,2018-11-01,COMPLETED,INTERVENTIONAL,['NA'],,
13830,NCT03548961,number of patients whose tumor can be resected by local excision with negative margins,2018-05-11,SUSPENDED,INTERVENTIONAL,['PHASE2'],,Disease-free survival (DFS) of patients
13831,NCT05609149,3-year event-free survival rate,2016-10-30,COMPLETED,OBSERVATIONAL,['NA'],,Local recurrence
13832,NCT02409524,To evaluate survival compared to historical controls,2016-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Tumor-Specific Immunity,To evaluate safety in advanced HCC (adverse events)
13833,NCT00036712,Proportion of patients not experiencing ulcerative mucositis within the first 14 days posttransplant,2002-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Time to heal
13834,NCT02196688,Progression Free Survival (PFS),2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Over Survival (OS)
13835,NCT03875690,frequency of patients with postoperative major complications occurring within 30 days after surgery,2019-07-02,RECRUITING,INTERVENTIONAL,['PHASE3'],,
13836,NCT06192680,Progression free Survival,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
13837,NCT06265350,Objective response rate (ORR),2024-02-02,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival (OS)
13838,NCT04195438,Measure the extent of HO-1 induction by measuring endogenous CO production in relationship to the extent of hepatic resection,2014-05-07,RECRUITING,INTERVENTIONAL,['NA'],,Measure the relationship between HO-1 induction and the quality of post-hepatectomy liver regeneration
13839,NCT01715532,Progression free survival,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
13840,NCT01619423,Number of Patients With Neuropathy Grade 2 or Higher (According to the Oxaliplatin Specific Sanofi Scale (OSSS) Criteria Related Paraesthesia/Dysaesthesia),2012-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
13841,NCT01348217,Survival without locoregional relapse at 2 years (time elapsed between date of randomisation and onset of local relapse and/or lymph node involvement),2011-05-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Evaluation of the post-operative morbi-mortalities
13842,NCT04865471,Percent of transplanted patients receiving second stage hepatectomy within 4 weeks of segment 2/3 transplantation,2020-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Complication rate
13843,NCT01164150,Reduction in the incidence of ≥ grade 2 acute genitourinary (GU) and gastrointestinal (GI) toxicity according to NCI CTCAE v.3.0,2010-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall survival rate
13844,NCT04645797,Primary Outcome Measure,2021-01-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,Secondary Outcome
13845,NCT00482846,Maximum tolerated dose of melphalan when treated with palifermin to prevent mucositis,2007-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Reduction in incidence and duration of mucositis
13846,NCT06035250,Accuracy of TRG prediction by the AI model,2023-09-10,RECRUITING,OBSERVATIONAL,['NA'],,Overall Survival (OS) at 5 years
13847,NCT01584336,The incidence of postoperative morbidity and mortality,2012-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,the surgical outcomes according to the method of reconstruction
13848,NCT02575391,Measurement of Tolerability,2009-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Treatment Break Measurement
13849,NCT01908426,Overall Survival (OS),2013-09-26,COMPLETED,INTERVENTIONAL,['PHASE3'],,Objective Response Rate (ORR)
13850,NCT03978481,Overall survival,2019-01-30,COMPLETED,OBSERVATIONAL,['NA'],,Metachronous cancer (remnant stomach cancer)
13851,NCT04571047,Overall survival,2020-10-15,COMPLETED,OBSERVATIONAL,['NA'],,Radical surgery
13852,NCT05524090,In-hospital major morbidity,2021-07-01,RECRUITING,OBSERVATIONAL,['NA'],,Shared decision-making: patients' healthcare satisfaction
13853,NCT02275403,Change in Measure Yourself Medical Outcome Profile (MYMOP2) score of the most troubling symptom of CIPN,2015-04-13,COMPLETED,INTERVENTIONAL,['PHASE2'],,Uptake of the offer of acupuncture at 10 weeks
13854,NCT02175095,[18F]FLT-PET SUV_MAX,2014-07,UNKNOWN,INTERVENTIONAL,['NA'],,Response evaluation by RECIST 1.1
13855,NCT00216372,Percentage of responder patients (patient with 1 or less vomiting episode per day during at least 3 consecutive days or in whom nasogastric tube (NGT) has been removed during at least three consecutive days without vomiting recurrence),2003-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Symptom relief duration
13856,NCT02594150,Increase in return rate of completed FIT,2015-12,COMPLETED,INTERVENTIONAL,['NA'],,
13857,NCT00197873,Effect on the treatment-related grade 2 to 4 diarrhoea,2005-09,COMPLETED,INTERVENTIONAL,['NA'],,Effect on resectability of liver metastases
13858,NCT04174339,Objective response rate(ORR),2019-12-10,UNKNOWN,INTERVENTIONAL,['NA'],,Disease control rate(DCR)
13859,NCT00265811,Disease-free survival,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall survival
13860,NCT03227510,MicroRNAs and its Correlation to Development and prediction of HCC,2017-11,UNKNOWN,OBSERVATIONAL,['NA'],,
13861,NCT01393093,Time to progression,2011-03,UNKNOWN,INTERVENTIONAL,['NA'],,remission rate
13862,NCT06241326,Adverse events,2024-02-26,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
13863,NCT03377400,Progression-free survival,2017-12-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13864,NCT02970539,Maximum tolerated dose (MTD),2016-12-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Preliminary activity of Oraxol plus ramucirumab as determined by overall survival
13865,NCT05461248,Incidence of low anterior resection syndrome,2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Quality of life score
13866,NCT00314678,Recurrence-Free Interval,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Examine the toxicity of therapy and to develop suitable strategies for dose modification.
13867,NCT01089413,Duration of Bevacizumab Treatment,2010-01,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status
13868,NCT03141437,Patients' decisional conflict (Part 2),2017-04-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Feasibility of the multicomponent DS intervention and research methods (Part 2),Patients' decision-making process (Part 2)
13869,NCT04455737,retrieved lymph nodes,2013-10,COMPLETED,OBSERVATIONAL,['NA'],,survival
13870,NCT01299493,Practice-level colon cancer screening rate,2012-06-19,COMPLETED,INTERVENTIONAL,['NA'],,
13871,NCT00001532,evaluating the role of hereditary factor,1996-09-13,RECRUITING,OBSERVATIONAL,['NA'],,"low dose radiation CT scan, and Zoom Scan"
13872,NCT00631410,Number of Participants With Adverse Events,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Sunitinib Relative Dose Intensity in the Treatment Arm B
13873,NCT04162665,Complete pathologic response (pCR - primary and nodal) rate,2020-02-14,RECRUITING,INTERVENTIONAL,['PHASE2'],Average percent difference in coverage of planning target volume (PTV) by 95% isodose line,Proportion of patients able to complete a full course of total neoadjuvant chemotherapy
13874,NCT01589900,,2005-01,COMPLETED,OBSERVATIONAL,['NA'],,
13875,NCT02973204,Concordance between specific DNA mutations found in patient biopsies and plasma circulating tumor DNA,2016-11,COMPLETED,OBSERVATIONAL,['NA'],,Correlations between mutations fund in circulating DNA and circulating tumor cells
13876,NCT01034670,Detection of neoplasia,2009-06,RECRUITING,INTERVENTIONAL,['NA'],,
13877,NCT00564720,Overall Survival,2006-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Symptoms improvement
13878,NCT05164315,Overall Survival (OS),2022-01-03,RECRUITING,INTERVENTIONAL,['NA'],,defecation function
13879,NCT04543019,Progression free survival (PFS) and overall survival (OS),2020-12,UNKNOWN,OBSERVATIONAL,['NA'],,response to systemic therapy
13880,NCT00135577,"Incidence of reported adverse events, including serious adverse events",2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Incidence of treatment-limiting toxicities, changes in pain intensity, patient satisfaction, health outcome measures"
13881,NCT00782834,Response Rate,2008-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,
13882,NCT05031949,Progression-free survival based on RECIST v1.1,2021-10-30,RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of Subjects with one or more adverse events as assessed by CTCAE 5.0
13883,NCT00409292,To Assess Progression-free Survival of RAD001 at Two Months in Patients With Metastatic Pancreatic Cancer Whose Disease Has Progressed on Gemcitabine Chemotherapy.,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,to Assess Overall Survival Associated With RAD001 in This Patient Population.
13884,NCT03098589,Adverse Events (AEs),2017-05-30,RECRUITING,OBSERVATIONAL,['NA'],,
13885,NCT00093444,"Pharmacokinetics and pharmacodynamics of heat-activated doxorubicin HCL liposome at 15, 30, 45, 60, 75, and 90 minutes; 2, 3, 4, 6, 24, and 46 hours; and 4 and 8 days following infusion",2004-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Effects of ablative therapy on tumor blood flow and tumor vascular density as measured by MRI at 28 days following study completion
13886,NCT04318834,Number of participants with tumour whole genome sequencing returned within 8 weeks,2020-04-01,RECRUITING,INTERVENTIONAL,['NA'],,Number of patients who received a targeted therapy (after first-line treatment)
13887,NCT05677724,single cell RNA sequencing,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],,
13888,NCT01451632,To Further Determine the Safety Parameters of the MM-121 + Cetuximab and MM-121 + Cetuximab + Irinotecan Combination by Determining the Recommended Phase 2 Dose (RP2D) of the Combination(s): Cetuximab and Irinotecan,2011-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Immunogenicity
13889,NCT03215290,Cutting surface related complications,2016-10,COMPLETED,INTERVENTIONAL,['NA'],,Interventions for cutting surface related complications
13890,NCT03036436,Change in quality of life,2017-01,UNKNOWN,INTERVENTIONAL,['NA'],,
13891,NCT00820456,To determine the alteration in tumor vascularity (assessed by percentage change in tumor Ktrans) in Arm A participants with metastatic colorectal cancer to the liver after one cycle of chemotherapy including bevacizumab compared to baseline Ktrans value.,2008-04,TERMINATED,OBSERVATIONAL,['NA'],,To determine the functional status as a predictor of response or disease-free survival in participants in Arm A.
13892,NCT02310971,"Assessment of safety and tolerability of CVac. (adverse events, vital signs, 12 lead ECG, relevant changes in physical examination)",2015-02,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Assessment of the change in quality of life (QoL) following the initiation of Cvac in this patient population,Assessment of Progression-Free Survival (PFS) and Overall Survival (OS) following the initiation of Cvac in this patient population
13893,NCT03965325,Assess the most accurate trend of the Global Health Status (Quality of Life evolution) over time in colorectal cancer patients evaluated by the EORTC-QLQ-C30 questionnaire.,2019-06-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Measure healthcare costs during the study period
13894,NCT05746182,Rate of overall pathogenic germline mutations,2023-04-07,RECRUITING,OBSERVATIONAL,['NA'],,Rate of completion of testing
13895,NCT01547130,Efficacy of Large Bowel Cleansing as Assessed by the Physician Performing the Colonoscopy,2008-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Total Preparation Time
13896,NCT05197504,collected blood samples,2021-12-20,RECRUITING,OBSERVATIONAL,['NA'],,Biomarkers on the efficacy of Atezolizumab+Bevacizumab for advanced HCC
13897,NCT03264807,Superiority verification of disease-free survival after lymphadenectomy for D2 + 14v lymph node dissection in gastric resection in patients with T3N + and T4N + stomach cancer,2015-08-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
13898,NCT03564938,Change in heart rate (beats/min),2018-07-30,COMPLETED,INTERVENTIONAL,['PHASE4'],,Overall survival (OS)
13899,NCT04276415,Progression-free Survival (PFS) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) (Dose Expansion),2020-05-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Anti-drug Antibodies Against DS-6157a Following Intravenous Administration of DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumors (GIST)
13900,NCT03060720,"We will measure clinical factors (e.g. # of PDAC patients with a personal history of x,y,z; # of PDAC patients with a family history of x,y,z; # PDAC patients with a germline mutation in x,y,z) so as to develop a risk assessment tool",2017-02-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Number of patients who disclose genetic testing results to relatives
13901,NCT00745927,Degree of abdominal discomfort during and after colonoscopy,2008-06,UNKNOWN,INTERVENTIONAL,['NA'],,Number of neoplasm detected
13902,NCT01524575,6 month overall survival,2012-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Duration of overall response
13903,NCT05077839,ORR,2021-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
13904,NCT04543695,The rate of tumor down-staging,2020-08-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of surgical complications
13905,NCT01507064,Effectiveness of sorafenib in increasing the effectiveness of laser ablation (LA),2012-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Survival in the two treatment groups
13906,NCT00003995,,1999-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13907,NCT03649971,Percentage Change from Baseline in Rectal/pouch Polyp Burden at Week 24,2018-11-19,COMPLETED,INTERVENTIONAL,['PHASE1'],,Relative Changes to Baseline in Levels of Interleukin (IL)-23 Effector Proteins in Biopsy Tissue
13908,NCT05248581,percentage overall survival,2019-08-16,RECRUITING,OBSERVATIONAL,['NA'],,
13909,NCT04646915,Incidence of transfer to inpatient ward,2019-12-15,UNKNOWN,OBSERVATIONAL,['NA'],,Mortality
13910,NCT05065957,To assess disease control rate (DCR),2022-03-29,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,To assess overall survival (OS)
13911,NCT00940758,To characterize the pharmacokinetics of biweekly PEP02 in patients with metastatic colorectal cancer who failed to first-line oxaliplatin-based chemotherapy,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,To explore the association of the pharmacogenetics of PEP02 including UGT1A family - UGT1A1 and UGT1A9 with pharmacokinetic parameters and toxicity
13912,NCT00640913,Reversal of defunctioning loop stoma on postoperative day 14 following low anterior resection of the rectum for cancer with or without preoperative adjuvant treatment,2008-02,UNKNOWN,OBSERVATIONAL,['NA'],,Postoperative 30 day morbidity. Postoperative ano-rectal function at 1 and 6 months.
13913,NCT04918472,The combined diagnostic accuracy of MCCE and UBT as gold standard,2021-08-06,COMPLETED,INTERVENTIONAL,['NA'],,"Adverse events up to 2 weeks after UBT, MCCE, UGI endoscopy"
13914,NCT05795920,progression free survival progression free survival,2023-03-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,Duration of response Duration of Response
13915,NCT02432963,"Tolerability of combined modified vaccinia virus Ankara vaccine expressing p53 and pembrolizumab, using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.3",2016-06-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,"T cell reactivity to p53, assessed by flow cytometry"
13916,NCT02734849,Change in Total Polys Score (TPS),2016-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13917,NCT04929028,Incidence of adverse events (High-risk stratum),2022-08-09,RECRUITING,INTERVENTIONAL,['PHASE2'],Impact of reduced intensity CRT on quality of life,Change in combination antiretroviral therapy (cART) adherence
13918,NCT00003648,frequency of defective DNA mismatch repair in individuals with familial colon cancer versus all colon cancers by using antibodies to the hMSH2 and hMLH1 protein products,1998-07,COMPLETED,OBSERVATIONAL,['NA'],,
13919,NCT03318562,Level of biomarkers of antitumor activation,2017-11-21,TERMINATED,INTERVENTIONAL,['PHASE2'],,PK plasma concentrations
13920,NCT01595243,12-Item Short Form Survey,2009-10,COMPLETED,INTERVENTIONAL,['NA'],,
13921,NCT00764621,Primary variable is the proportion of patients in each of the three treatment groups for whom further imaging is required after initial imaging to come to a therapy decision.,2008-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,"Proportion of patients with intra-operatively modified surgical plans based on initial imaging with either Primovist-, ECCM-MRI or CE-CT"
13922,NCT01906008,Average Area Under the Curve (AUC) for Numbness/Tingling Over 4 Months,2013-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Average Area Under the Curve (AUC) for Fatigue Over 4 Months
13923,NCT01210313,feasibility of physical activity,2010-10,COMPLETED,OBSERVATIONAL,['NA'],,gen- and metabolic signs
13924,NCT04513223,DLT and the recommended Phase 2 dose (RP2D),2021-03-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
13925,NCT02567331,"Response rate, ie, percentage of participants with complete, partial, and overall response",2004-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,Pharmacoeconomic analysis: Treatment-related and AE-related spending/savings\n
13926,NCT03113942,Histological High Grade Squamous Intraepithelial Lesions (HSIL) clearance at 6 months of therapy,2017-06-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],,effect of pomalidomide on self-reported health related quality of life and cancer anxiety during and after therapy
13927,NCT01359410,Clinically Significant Postoperative Pancreatic Leak at Any Time as Defined by the ISGPF Pancreatic Leak Grading System,2007-06,TERMINATED,INTERVENTIONAL,['NA'],,Number of Non-pancreatic Adverse Events
13928,NCT03481920,To assess the safety of this combination in patients with PDAC.,2018-01-10,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],Immune infiltrate.,"Changes in CA 19,9 leves"
13929,NCT01979029,The Blood Pressure of the Arterial Arcade,2013-02,COMPLETED,INTERVENTIONAL,['NA'],Systemic Blood Pressure,Distal Colon Length
13930,NCT03532711,Objective Response Rate (ORR),2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Progression Free Survival (PFS)
13931,NCT00052585,Response rate,2002-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
13932,NCT01078415,Treatment efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria by Computed Tomography (CT) or Magnetic Resonance (MR) imaging.,2010-02,COMPLETED,INTERVENTIONAL,['NA'],,Safety using Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 criteria.
13933,NCT00639925,"Adverse effect, toxicities as assessed by NCI CTCAE version3.0",2007-03,UNKNOWN,INTERVENTIONAL,['PHASE1'],,feasibility
13934,NCT02088333,Completion of CRC Screening,2014-06,COMPLETED,INTERVENTIONAL,['NA'],,Usability of the mCRC system
13935,NCT05027347,The sensitivity and and specificity of our mutation-based assay for detecting early-stage gastric cancer patients,2021-10-10,UNKNOWN,OBSERVATIONAL,['NA'],,The concordance rate of mutation results between plasma and tissue biopsy assay
13936,NCT00243854,"To determine if giving chemotherapy, radiation, and Tarceva,(EGFR-tyrosine kinase inhibitor)will have side effects that will prevent surgery following this therapy",2005-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13937,NCT05341206,Change of CTCAE 4.0,2022-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Change of common aerobic culture
13938,NCT00990535,Tumor stabilization,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Decrease of chromogranin-A
13939,NCT04837742,Drug spread level of erector spinae plane block,2021-04-14,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative recovery quality
13940,NCT00569790,Safety,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Progression-free survival, Response rate, Overall survival, Treatment situation"
13941,NCT03556956,Overall survival,2015-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Progression Free Survival (PFS)
13942,NCT05689918,Level of awareness of esophageal cancer risk factors and alarm symptoms,2022-12-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Beliefs about esophageal cancer
13943,NCT06148155,Complete PET imaging,2023-06-01,RECRUITING,INTERVENTIONAL,['NA'],,
13944,NCT04286984,Transfusion Rate,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of failure-to-rescue
13945,NCT01039519,Percentage of Participants Showing Clinical Benefit Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Count of Participants With Treatment-Emergent Adverse Events (AEs)
13946,NCT00501813,Overall survival rate,2006-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of live
13947,NCT04022109,Specific chemistry identification in the exhaled breath,2019-11-01,RECRUITING,OBSERVATIONAL,['NA'],Confounding factor analysis,Gut microbiota analysis in relation to breath VOCs
13948,NCT00806611,The primary endpoint is cancer related pain control.,2008-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,
13949,NCT04764227,Local control rate,2020-05-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
13950,NCT04435652,Overall survival（OS）（stage 2）,2020-07-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Immunogenicity（stage 1 and 2）
13951,NCT04123925,Predictive Biomarkers,2018-06-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Metabolic Response
13952,NCT04149093,Long-term outcomes (Quality of life questionnaire),2020-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,Functional outcomes
13953,NCT04920435,Prediction of the complete response (pCR) to neoadjuvant chemoradiotherapy,2019-01-02,COMPLETED,OBSERVATIONAL,['NA'],,
13954,NCT05247515,Severe post-resection bleeding rate up to Day 30,2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Rate and duration of hospitalizations
13955,NCT05240040,time to recurrence,2016-04-26,UNKNOWN,OBSERVATIONAL,['NA'],,
13956,NCT00484939,Progression-free Survival,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,"AEs, Laboratory Parameters, Vital Signs"
13957,NCT02504099,Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12),2015-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,Percentage of Participants With Recurrent HCV Infection Post Liver Transplant
13958,NCT01380600,Determine the safety of JX-594 administered by biweekly IV infusion,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Determine the anti-tumoral response of JX-594
13959,NCT00826813,Overall survival,2009-01,UNKNOWN,INTERVENTIONAL,['NA'],,Dysphagia relief
13960,NCT02068131,Overall response rate(ORR),2014-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse Events(AEs)
13961,NCT01672892,"Acute Gastrointestinal Toxicity, as Measured by Change in Expanded Prostate Cancer Index Composite (EPIC) Bowel Domain Score at 5 Weeks From the Start of Pelvic Radiation",2012-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Mean Change From Baseline in EPIC Bowel and Urinary Domain (Validation - Sensitivity to Treatment)
13962,NCT03864211,Progression free survival,2019-06-15,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The general health status
13963,NCT03852576,SFE ability to detect dimer with contrast,2019-05-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,
13964,NCT04636099,Intraoperative blood loss,2020-11-01,UNKNOWN,INTERVENTIONAL,['NA'],,3 years DFS
13965,NCT06236386,Clinician Feedback,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Medication Use
13966,NCT01841736,Progression-free Survival (PFS),2013-09-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Biochemical Response,Time to Second Progression for Patients Who Crossover From Placebo to Active Therapy
13967,NCT04553458,"PROGRESSIVE((Number of patients with progression of the disease) (measured by follow-up CT scans, increase in size, appearance of new intratumoral lesions, or appearance of new lesions",2015-06,COMPLETED,OBSERVATIONAL,['NA'],,DEATH (Number of patients died from the disease)
13968,NCT01220934,Overall survival according to Response Evaluation Criteria in Solid Tumors (RECIST),2010-04-16,COMPLETED,OBSERVATIONAL,['NA'],,Safety (incidence of adverse events)
13969,NCT01279681,Progression-Free Survival,2011-01,TERMINATED,INTERVENTIONAL,['PHASE3'],Prognostic Single-nucleotide Polymorphisms (SNPs) for Grade 3+ Hypertension,Number of Participants With Grade 3 Adverse Events At Least Possibly Related to Treatment
13970,NCT00519688,To evaluate the overall response rate of UFUR and thalidomide in the treatment of advanced HCC by RECIST criteria,2006-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,To establish the safety profile.
13971,NCT02042378,Overall Response Rate (ORR) per RECIST v1.1 as assessed by the investigator,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Trough (Cmin) level rucaparib concentrations
13972,NCT03682133,Truncated logistic regression analysis,2018-06-27,TERMINATED,OBSERVATIONAL,['NA'],,
13973,NCT03169777,ORR by Immune-related response criteria (irRC ),2018-08,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03"
13974,NCT03939845,OS,2019-04-23,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
13975,NCT01503411,Primary Effectiveness Endpoint,2012-01,COMPLETED,OBSERVATIONAL,['NA'],,
13976,NCT00923481,Response Rate,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events
13977,NCT05130684,rate of completion of protocol treatment,2021-02-22,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13978,NCT05209750,True malignant node (yes/no),2022-07-13,RECRUITING,INTERVENTIONAL,['NA'],,To describe the value of FAPI PET/CT on tumour response evaluation following neoadjuvant treatment.
13979,NCT05875753,Adverse events after injection of 68Ga-FAPI-FS,2022-06-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,SUVmax of tumor lesions on 68Ga-FAPI-FS
13980,NCT01384695,to determine whether tissue is neoplastic or non-neoplastic,2009-06,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,
13981,NCT04922853,pathological Tumor Regression Grade evaluation,2021-08-26,RECRUITING,INTERVENTIONAL,['PHASE3'],,cumulative local recurrence rate
13982,NCT03601611,Rate of at least one grade improvement using the NCI CTCAE v5.0,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],Biomarkers,Rate of sustained glucocorticoid-free remission
13983,NCT02232620,Disease Control Rate (DCR),2017-03-13,TERMINATED,INTERVENTIONAL,['PHASE2'],,Pharmacodynamics (biomarkers) of BBI503 when tumor biopsy is possible
13984,NCT04258813,Diversity supplement primary outcome: 90-day postoperative cardiovascular complications,2021-06-14,RECRUITING,INTERVENTIONAL,['NA'],PCP-reported care coordination,Provider-reported care coordination
13985,NCT04429841,Operative mortality rate,2010-01,COMPLETED,OBSERVATIONAL,['NA'],,5 years Overall survival rate
13986,NCT02858141,Collection of oncogeriatric data for future research studies,2015-05,UNKNOWN,OBSERVATIONAL,['NA'],,
13987,NCT06013228,Fatigue,2023-08-30,RECRUITING,OBSERVATIONAL,['NA'],,
13988,NCT00910741,Incidence of DLT and Response rate,2009-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
13989,NCT03483922,DNA methylation of circulated tumor and PBMC DNA and its Correlation to Development and prediction of HCC,2018-08-20,COMPLETED,OBSERVATIONAL,['NA'],,
13990,NCT01413022,Optimal dose and dose-limiting toxicity of PF-04136309 in combination with FOLFIRINOX,2012-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Prevalence and function of MDSC in peripheral circulation before and after treatment with PF-04136309 plus FOLFIRINOX or with FOLFIRINOX alone
13991,NCT03076372,Maximum tolerated dose (MTD) of MM-310 monotherapy administered once every 3 weeks in patients with metastatic solid tumors.,2017-02-22,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Progression Free Survival
13992,NCT06200831,"Comprehensive Complication Index, CCI",2024-03-01,RECRUITING,INTERVENTIONAL,['NA'],,Quality of Life: EORTC QLQ-30
13993,NCT06026774,Number of Participants with Adverse Events (AEs) [safety and tolerability],2023-09-08,RECRUITING,INTERVENTIONAL,['PHASE1'],,Cytokines Level [immunogenicity]
13994,NCT02228889,Overall complication rate at 1 year,2015-01,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life postoperatively
13995,NCT00217737,Disease-free survival,2005-09-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Impact of tumor biologic characteristics and their relationship to overall survival
13996,NCT04735107,Defunction ileostomy rate,2018-11-01,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative morbidity
13997,NCT05686122,Feasibility of PainPac,2023-09-28,RECRUITING,INTERVENTIONAL,['NA'],,Change in PROMIS - Emotional Distress (Depression) Short Form
13998,NCT05172310,Diagnostic accuracy of FAPI-PET/CT in primary tumors,2021-06-02,RECRUITING,INTERVENTIONAL,['PHASE1'],,Safety of 68Ga-FAPI-46
13999,NCT00779272,Postoperative Complications and liver regeneration,2008-09,COMPLETED,OBSERVATIONAL,['NA'],,
14000,NCT00944463,Time to progression,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Correlative analyses
14001,NCT04257955,Patient's Compliance,2020-09-15,COMPLETED,OBSERVATIONAL,['NA'],,
14002,NCT05715775,The LN dissection rate,2016-08-01,COMPLETED,OBSERVATIONAL,['NA'],,LN noncompliance
14003,NCT05513742,Overall Response Rate,2022-12-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Exposure Response by Pharmacokinetic (PK) Sampling
14004,NCT00323518,the incidence of grade 3/4 oral mucositis using WHO grading system,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14005,NCT06279351,ETS,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,PFS
14006,NCT01840592,overall survival,2013-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,toxicity
14007,NCT05235607,Number of participants with treatment-related adverse events as events as assessed by CTCAE v4.0,2022-03-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Number of participants with Overall survival as assessed by RECIST1.1
14008,NCT06108310,Identification of radiogenomics signature (ATTRACT AI-model) of stage II-III colon tumors,2021-01-02,RECRUITING,OBSERVATIONAL,['NA'],,Correlation of radiogenomics signature (ATTRACT AI-model) of colon cancer with clinical outcomes (DFS and RFS)
14009,NCT05143099,Objective response rate (ORR),2021-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],biomarker analysis,Overall survival (OS）
14010,NCT04575935,Disease free survival (DFS),2020-08-05,RECRUITING,INTERVENTIONAL,['PHASE3'],,Cost of the procedure
14011,NCT03290209,3-year disease specific survival rate,2017-08-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,operation time
14012,NCT04456140,Incidence rate of germline pathogenic genetic mutations in cancer patients seen at St Vincent's and uptake rate of cascade testing in families,2020-06-29,COMPLETED,INTERVENTIONAL,['PHASE1'],,Differences in survey responses between patient groups
14013,NCT04288284,early postoperative morbidity after curative resection of colorectal cancer,2015-01,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
14014,NCT02554448,The number of Circulating Tumor Cells (CTCs),2016-01,UNKNOWN,INTERVENTIONAL,['NA'],,
14015,NCT05500248,Positive Predictive Value (PPV),2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Adenoma Detection Rate (ADR) in the rectosigmoid tract.
14016,NCT01384864,to determine whether tissue is neoplastic or non-neoplastic,2011-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
14017,NCT00287222,Number of Participants Who Remained Free of Progression at the 27th Week.,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14018,NCT05079438,≥Grade 2 proctitis,2021-09-07,RECRUITING,INTERVENTIONAL,['PHASE3'],,
14019,NCT02721056,Determination of the early Dose Limiting Toxicities,2016-01-28,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Local Progression Free Survival
14020,NCT04183712,3-year DFS,2020-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],sensitivity and specificity of ctDNA,3-year OS
14021,NCT05014399,The Proteome Profiler Human XL Cytokine Array Kit (https://www.rndsystems.com/products/proteome-profiler-human-xl-cytokine-array-kit_ary022b),2021-09-20,RECRUITING,OBSERVATIONAL,['NA'],,
14022,NCT00900003,Cellular localization of BRCA1 as a predictor of response to cytotoxic agents or radiotherapy,2007-05,COMPLETED,OBSERVATIONAL,['NA'],,Application of a method of extracting and identifying secreted cytokines and growth factors from biopsy tissue to the pancreatic cancer population
14023,NCT01315990,Progression-free survival,2011-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Development of acneiforme follicular exanthema >= grade2
14024,NCT04777851,Progression-free Survival (PFS) Assessed by the Investigator as per Modified Response Evaluation Criteria in Solid Tumors (mRECIST) for HCC,2023-10-11,RECRUITING,INTERVENTIONAL,['PHASE3'],,Change from Baseline in Health-Related Quality of Life as Assessed by the EuroQol's 5-level EQ-5D Health Questionnaire (EQ-5D-5L)
14025,NCT03045107,Length of hospital stay,2017-02-01,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of life
14026,NCT04493125,The number of radiopaque markers transferred to the large intestine 3 days after surgery,2020-07-27,UNKNOWN,INTERVENTIONAL,['NA'],,
14027,NCT00800969,Diagnostic Accuracy of PET-CT,2008-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
14028,NCT05636150,Progression free survival (PFS),2022-03-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease control rate (DCR)
14029,NCT04826107,ORR(Objective Response Rate),2021-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,AEs and SAEs
14030,NCT05723107,Percentage of Participants who Complete Therapy without Grade III-IV Adverse Events (AEs) as Assessed by CTCAE v. 5.0,2023-03-31,RECRUITING,INTERVENTIONAL,['PHASE1'],,Percentage of Participants who Report Post-Procedural Complications
14031,NCT06042816,analgesic efficacy of free-opioid anesthesia,2019-12-30,COMPLETED,INTERVENTIONAL,['NA'],,Adverse effects of free-opioid anesthesia
14032,NCT03957590,Progression-free survival (PFS),2019-06-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,The incidence and severity of treatment-emergent adverse events (TEAEs) graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events'.
14033,NCT05571839,Number of participants with dose limiting toxicities,2023-01-03,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
14034,NCT02854072,Overall Survival,2015-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Toxicity according to the NCI CTCAE v4.03
14035,NCT01088815,Safety of Combination Therapy in Patients With Metastatic Adenocarcinoma of the Pancreas as Assessed by Number of Grade 3 or 4 Adverse Events,2010-09-17,COMPLETED,INTERVENTIONAL,['PHASE2'],,Efficacy of Combination of GDC-0449 With Gemcitabine and Nab-Paclitaxel as Assessed by Hedgehog Signaling Pathway Downregulation
14036,NCT01135498,Progression-Free Survival,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
14037,NCT05572151,lymph node number,2009-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
14038,NCT01480817,Time to Progression (Efficacy),2012-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Alpha feto protein (AFP) responsiveness
14039,NCT02519582,Progression free survival,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of Serious Adverse Events
14040,NCT05171309,Objective response rate (ORR),2021-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
14041,NCT02217865,Effectiveness of Colorectal Cancer (CRC) Surveillance,2014-07-16,COMPLETED,OBSERVATIONAL,['NA'],,
14042,NCT05406206,Progression-Free Survival (PFS),2022-02-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
14043,NCT06171854,Progression free survival (PFS),2019-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety as the description of adverse events
14044,NCT05196087,Change from Baseline in ctDNA collected from biospecimens,2022-07-20,RECRUITING,OBSERVATIONAL,['NA'],,Number of participants that are identified as high risk of clinical relapse with artificial intelligence (AI) and machine learning algorithms
14045,NCT03705897,Proportion of patients achieving appropriate screening regimen.,2013-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
14046,NCT02867839,disease-free survival,2017-04-24,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Incidence of Treatment-Emergent Adverse Events [Safety]
14047,NCT01887509,Concordance in identification of lower pole of tumor,2013-11-07,TERMINATED,INTERVENTIONAL,['NA'],,Assessment of predictive value of interpretation criteria
14048,NCT04732442,Change in expression of inflammatory cytokines in tumor tissue samples obtained prior and after intervention.,2017-11-01,COMPLETED,INTERVENTIONAL,['NA'],,Changes in tissue neutrophil infiltration after preoperative nutritional intervention in tumor tissue samples obtained prior and after intervention.
14049,NCT00287768,overall survival,2006-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,safety
14050,NCT00490685,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14051,NCT03100461,CRC screening completion rate,2018-01-22,UNKNOWN,INTERVENTIONAL,['NA'],,Cost analysis of each intervention pathway
14052,NCT03413930,Circumferential resection margin (CRM),2019-06,WITHDRAWN,INTERVENTIONAL,['NA'],,5-year overall survival rate
14053,NCT03940027,the incidence of serious complications,2019-02-10,UNKNOWN,INTERVENTIONAL,['NA'],,Improvement of quality of life
14054,NCT00138177,"Grade 3, 4, or 5 adverse events graded using the NCI CTCAE version 4.0",2005-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,DPD activity
14055,NCT00259844,"To evaluate the safety, toxicity and tolerability of the TroVax vaccine in this setting.",2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,To monitor and collect data on clinical outcomes (time to progression/relapse/death).
14056,NCT03732547,Objective response rate (ORR),2018-10-22,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Level of alpha-fetoprotein (AFP)
14057,NCT01033682,"The percentage of patients who are able to achieve a bladder volume within +/- 30% of planning volume, on all treatment CBCT (cone beam computed tomography) scans",2009-05,UNKNOWN,OBSERVATIONAL,['NA'],,The correlation between bladder volume and small bowel volume planning target volume
14058,NCT02863367,Objective Response Rate (ORR),2016-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
14059,NCT05155878,Overall survival,2021-09-01,RECRUITING,OBSERVATIONAL,['NA'],,Radical resection
14060,NCT02568267,Objective Response Rate,2015-11-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Bone Biomarkers
14061,NCT06239194,Phase 1: Recommended Phase 2 dose (RP2D),2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,All Phases: Correlation between tumor antigen expression and anti-tumor activity of MDX2001
14062,NCT02506946,Difference in percentage liver fat between PCOS and controls in adolescents and young adults,2013-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,The association of percentage liver fat by magnetic resonance spectroscopy with total body adipose tissue
14063,NCT00645710,Recommended Phase II Dose,2005-02-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-free Survival
14064,NCT05307367,Muscle mass,2022-04-01,RECRUITING,INTERVENTIONAL,['NA'],,Patient-reported Quality-of-Life (QoL)
14065,NCT01930942,gene expression in different response groups,2006-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],toxicity,"overall survival, disease free survival and local-regional free survival"
14066,NCT06049901,Evaluating the change in the serum level of Protein disulfide isomerase (PDI),2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,"Evaluating the safety and tolerability of nitazoxanide through investigating Hematological parameters (hemoglobin (mg/dL), erythrocytes (cells/μL), leukocytes (cells/μL), platelets (cells/μL) and ANC (cells/μL))."
14067,NCT05229588,Evaluate the antitumor activity,2022-06-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,Treatment safety
14068,NCT02231086,Peritoneal Recurrence Free Survival at 18 Months,2015-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of Life Questionnaire Survey 5- Year Follow-up
14069,NCT03173001,Prevalence of intestinal protozoa (commensals) in patients with colorectal cancer and association with cancerogenesis,2015-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
14070,NCT05739045,pathological complete response rate (pCR),2022-11-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,3-year DFS
14071,NCT05899985,Surgical quality,2024-03-21,RECRUITING,INTERVENTIONAL,['NA'],FerroTrace enhanced MRI Response,SLN Ultra-staging Overall Survival
14072,NCT01051765,overall survival,2009-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,polymorphism of UGT1A
14073,NCT03737591,Specificity,2010-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
14074,NCT04790448,"Overall response rate from the date of first drug administration until the date of first documented progression or date of death, whichever came first.",2020-07-27,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of patients with adverse events and severity according to NCI CTCAE v5.0
14075,NCT02759718,"Diagnostic accuracy of th CgA in the patient with PNET, change from preoperative levels of CgA at 3 months",2012-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],,"Disease progression of PNET using CT imaging, change from preoperative imaging of CT at 3, 6,12, and 24 months"
14076,NCT06194708,1-year non-reversal rate of temporary stoma,2023-05-15,RECRUITING,OBSERVATIONAL,['NA'],,
14077,NCT01490749,Phase I portion to determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of RAD001 in combination with radiation,2012-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Rate of surgical pathologic complete remission (pCR) (absence of evidence of cancer after surgery)
14078,NCT03050268,Identification of novel cancer predisposing genes,2017-04-06,RECRUITING,OBSERVATIONAL,['NA'],,
14079,NCT05600803,detection rate,2022-10-30,RECRUITING,OBSERVATIONAL,['NA'],,Number needed to screen
14080,NCT02399410,surgical morbidity and mortality,2015-11-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,pathological gross response of peritoneal tumour deposits to neoadjuvant combination chemotherapy with bevacizumab
14081,NCT05806333,Diagnostic performance of FAPI PET,2022-06-01,RECRUITING,INTERVENTIONAL,['NA'],,
14082,NCT05809661,stoma compliance,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],,life quality
14083,NCT00550108,"Patients not progressing to operation due to the development of symptoms, growth to a maximum diameter of >3cm, or development of a mural nodule.",2007-10,TERMINATED,INTERVENTIONAL,['PHASE3'],,A decrease in size by >1 cm on MRCP Relative decrease in size of cyst after 1 or 2 injections with ethanol Is reduction in size durable (over what length of time)?
14084,NCT00055705,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14085,NCT00019604,Response,1998-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Evaluate the Ability of Fludeoxyglucose (18F) Positron-Emission Tomography (FDG-PET) to Monitor Response Following Radiofrequency Ablation (RFA)
14086,NCT00375310,To evaluate the safety and tolerability of the combined treatment with Gemcitabine with Sorafenib and radiotherapy in patients with localized unresectable pancreatic cancer.,2006-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,To evaluate the maximum tolerated dose (MTD) for Sorafenib during Chemo-radiation.
14087,NCT01576666,Dose Limiting Toxicities,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Plasma pharmacokinetics (PK) parameters
14088,NCT00247728,Tumour Non-recurrence Rate,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Survival Rate
14089,NCT04423965,MFS,2020-05-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Reported Adverse events
14090,NCT03211715,Quality of life in association to the severity of bowel dysfunction,2017-07-19,UNKNOWN,OBSERVATIONAL,['NA'],,
14091,NCT04468607,Maximum Tolerated Dose(s) MTD(s) of BLYG8824A,2020-08-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Presence of Anti-drug Antibodies (ADAs)
14092,NCT02603302,Pathologic complete response,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
14093,NCT02095236,Three-dimensional intra- and interfractional measurement of fiducial marker or transponder motion,na,WITHDRAWN,INTERVENTIONAL,['NA'],,
14094,NCT04336397,Colorectal cancer screening,2021-04-29,RECRUITING,INTERVENTIONAL,['NA'],,Diagnostic follow-up
14095,NCT06256055,Incidence of Dose-limiting Toxicities (DLTs),2024-03-05,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
14096,NCT03304860,Change in CRC screening rate of eligible parents of internal medicine residents at NYU from before to after the intervention,2017-11-01,COMPLETED,INTERVENTIONAL,['NA'],,
14097,NCT00874263,Endoscopic Confocal microscopy may help distinguish small adenomatous polyps with malignant potential from non-neoplastic (hyperplastic) polyps in real- time enabling immediate diagnosis and removal of only polyps with truly malignant potential.,2008-03,COMPLETED,OBSERVATIONAL,['NA'],,"Endoscopic Confocal microscopy has the potential to fundamentally change the way endoscopy and pathology interact by allowing near histological-quality imaging in vivo, without the need, risk, and cost of tissue removal."
14098,NCT05494853,HCC screening positive,2022-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
14099,NCT02403271,Phase 2: Efficacy of Ibrutinib in Combination With Durvalumab (MEDI4736) in Participants With Relapsed or Refractory Solid Tumors by Assessing the ORR Per RECIST 1.1.,2015-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Pharmacodynamics
14100,NCT02900950,Evaluate R1 rate differences between multicolour and monocolour inking of the specimen,2012-06,COMPLETED,INTERVENTIONAL,['NA'],,Relation between Disease Free Survival and Overall Survival of the participants and R status
14101,NCT06308354,DFS,2011-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
14102,NCT01757366,Progression-free survival (PFS),2012-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
14103,NCT00607594,Prolonged Stable Disease Rate (Defined as Stable Disease for ≥ 16 Weeks),2008-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Association Between Correlative Markers and Clinical Outcomes
14104,NCT02713763,6 months progression free survival,2017-02-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events
14105,NCT05827055,Safety of oral proglumide therapy at 1200mg daily dose with chemotherapy,2024-01-31,RECRUITING,INTERVENTIONAL,['PHASE2'],,Effects of proglumide on Pain
14106,NCT06059924,Cancer-specific survival,1991-02-01,COMPLETED,OBSERVATIONAL,['NA'],,Recurrence-free survival
14107,NCT01260415,"To determine the 2 year disease-free survival rate in patients with resectable colorectal liver metastases treated with FOLFOX/FOLFIRI + panitumumab for 2 months pre-operatively and 4 months post-operatively, followed by panitumumab alone for 6 months.",2010-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To determine the incidence of hepatocellular damage (fibrosis, steatosis) in normal liver tissue induced by preoperative chemotherapy."
14108,NCT02559674,Overall Survival; Phase II,2016-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Correlation between the level of tumor DNA in patient plasma and response to study treatment
14109,NCT06195514,,na,AVAILABLE,EXPANDED_ACCESS,['NA'],,
14110,NCT02548169,Safety and feasibility of combining the DC vaccine with chemotherapy DC vaccine dose-limiting toxicities will be measured according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03,2015-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,Average of all changes in Quality of Life (QoL) Score
14111,NCT04525768,History of variceal bleeding,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,Complications of portal hypertension
14112,NCT05596890,Pathologic complete response rate,2022-11-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,Dysphagia relief score
14113,NCT03776591,Complications,2016-09-01,RECRUITING,INTERVENTIONAL,['NA'],Hospitalization,Prognostic significance of CTCs
14114,NCT00857246,"Clinical Response Rate of an Induction Regimen Consisting of Irinotecan, Cisplatin and Cetuximab",2005-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival (Adjuvant Therpary)
14115,NCT04160832,Prevalence of germline pathogenic/likely pathogenic variants in cancer predisposition genes in patients with advanced colorectal polyps,2019-10-24,RECRUITING,OBSERVATIONAL,['NA'],,Risk factors for germline pathogenic/likely pathogenic variants in patients with advanced colorectal polyps
14116,NCT00600613,"Number of Participants Eligible for Cone Beam Tumor Localization""",2006-01,COMPLETED,INTERVENTIONAL,['NA'],,
14117,NCT04336202,Workload,2024-08,RECRUITING,INTERVENTIONAL,['NA'],,Local control
14118,NCT04989153,Risk factors for GC,2016-03-05,UNKNOWN,OBSERVATIONAL,['NA'],,
14119,NCT00864513,Progression-free Survival,2007-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events
14120,NCT01577511,Ability to maintain the cells isolated from colorectal tumors in culture or 3D collagen matrices and then infect these cells to make them express reporter genes: yes/no.,2012-06-12,COMPLETED,OBSERVATIONAL,['NA'],,Number of circulating cancer cells per ml blood
14121,NCT00112463,Toxicity as Assessed Using the Expanded Common Toxicity Criteria Version 3,2005-01-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Survival
14122,NCT01807546,Overall response rate,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Adverse Events
14123,NCT01197820,Temperature standard deviation,2010-09,TERMINATED,INTERVENTIONAL,['NA'],,HIFU platform improvements
14124,NCT02320448,Number of Patients with Adverse Events.,2015-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Feasibility: Completion of procedure in 28:35
14125,NCT02626195,postoperative complication,2013-10,COMPLETED,INTERVENTIONAL,['NA'],immunologic change(CD4/CD8) after nutritional support,postoperative cost( + nutritional support cost)
14126,NCT01910948,blood immune factors,2013-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],,
14127,NCT04970212,Effectiveness - DICE,2021-09-24,COMPLETED,OBSERVATIONAL,['NA'],,Difference between T=0 and T=24hrs CECT tissue damage
14128,NCT02942563,Pelvic complete resection rate,2016-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The incidence of >=3 grade adverse events
14129,NCT00862342,Progression free survival,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity profiles
14130,NCT02638584,The Ulcer healing rate after endoscopic submucosal dissection,2015-12,COMPLETED,INTERVENTIONAL,['PHASE4'],,The evaluation of symptom score as assessed by the Korean Gastrointestinal Symptom Rating Scale questionnaire.
14131,NCT05229809,2-year disease-free survival rate,2022-03-01,RECRUITING,INTERVENTIONAL,['PHASE4'],,Percentage of Participants With Adverse Events
14132,NCT03778710,The correlation of lymph node ratio and prognosis of recurrence of gastric cancer patients,2018-12-18,COMPLETED,OBSERVATIONAL,['NA'],,The correlation of total of lymph node retrieved less than 15 and more than 15 nodes and survival of gastric cancer patients
14133,NCT02121405,Disease-free survival,2015-10,SUSPENDED,INTERVENTIONAL,['PHASE3'],,Overall survival
14134,NCT04842006,Postoperative ctDNA,2021-12-20,RECRUITING,INTERVENTIONAL,['NA'],,Treatment response by patient-derived organoid (PDO) therapy response
14135,NCT04761536,Anastomotic leak,2006-01,COMPLETED,OBSERVATIONAL,['NA'],,need of postoperative blood transfusion
14136,NCT05345613,Postprocedural bleeding,2022-05-01,RECRUITING,INTERVENTIONAL,['PHASE4'],,Intraprocedural bleeding
14137,NCT01444755,Survival,2009-01,UNKNOWN,OBSERVATIONAL,['NA'],,
14138,NCT05638984,PFS,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
14139,NCT03541486,Overall survival (OS),2025-12-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Exploration of patient reported outcomes during combined therapy [qualitative string],Pathologic characteristics
14140,NCT00813293,Coagulation Zone Volume,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Treatment-Related Grade 1-4 Adverse Events (AEs) One Month After Radiofrequency Ablation (RFA)
14141,NCT03654729,Moderate or Severe Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN),2018-11-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,Overall Survival (OS)
14142,NCT00361244,To determine the response rate of SU011248 when given in combination with irinotecan and cetuximab in this patient population.,2006-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"to assess overall survival, progression-free survival, time to progression and duration of response."
14143,NCT00060021,,2003-03,COMPLETED,INTERVENTIONAL,['NA'],,
14144,NCT00969124,Detection Rates for All Polyps,2009-01,COMPLETED,INTERVENTIONAL,['NA'],,Time Spent During Withdrawal Phase and Total Procedure
14145,NCT04723030,Objective remission rate(ORR),2021-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Subject safety
14146,NCT00070122,Overall survival in patients with colorectal cancer treated with fluorouracil/leucovorin calcium and oxaliplatin with and without becavizumab versus those treated with capecitabine and oxaliplatin with our without bevacizumab,2004-04,TERMINATED,INTERVENTIONAL,['PHASE3'],,Whether gene expression variables are predictive of survival and progression-free survival
14147,NCT00809796,"Any severe events, tumor marker CEA, and tumor size (CT scan)",2008-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14148,NCT01670721,Percentage of Participants With Adverse Events (AEs),2012-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change From Baseline in HRQL EQ-5D-3L VAS Score
14149,NCT05795010,Positive rate of preoperative MRD test,2023-03-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Positive rate of MRD test 1 month and 3 months after operation
14150,NCT03422835,Positive rate of circumferential resection margin (CRM) of the specimens,2018-02-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],Quality of life outcomes evaluation,the rate of postoperative complications
14151,NCT03061058,Progression-free Survival (PFS),2013-04-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Adverse Events
14152,NCT04213118,Disease free survival,2020-04-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events Safety and Tolerability
14153,NCT02128243,Overall Survival (OS),2014-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Adverse Events,Quality of Life
14154,NCT02179489,Disease-free survival,2014-11-01,COMPLETED,INTERVENTIONAL,['NA'],,QOL
14155,NCT05160896,ORR,2021-11-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,AEs
14156,NCT02577263,Quality of life deterioration > 10% (dichotomic),2015-04,UNKNOWN,OBSERVATIONAL,['NA'],,Significant chemotherapy induced neurotoxicity > 10%
14157,NCT04543617,Arm B vs Arm C: OS,2020-09-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Percentage of Participants With ADAs to Atezolizumab
14158,NCT00337389,Progression Free Survival,2006-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Incidence and Severity of Adverse Events
14159,NCT01060007,Preoperative Gastrointestinal Morbidity,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Determine Quality of Anorectal Function
14160,NCT00821912,Response rate,2006-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life
14161,NCT05502835,Intraoperative fluid volume,2022-08-20,COMPLETED,INTERVENTIONAL,['NA'],,intestinal oedema
14162,NCT03990025,Difference in detection rate of duodenal lesions between Linked Color Imaging and White Light Imaging,2019-03-27,COMPLETED,INTERVENTIONAL,['NA'],,Sensitivity and Specificity of detection of duodenal lesions
14163,NCT03153280,Incidence of dose limiting toxicity (DLT) within the two first cycles at each dose level.,2022-01-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of adverse events reported as per the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. (Safety and Tolerability).
14164,NCT01760616,Time to significant progression after surgery and postoperative survival period.,2011-11-07,TERMINATED,INTERVENTIONAL,['PHASE4'],,Alpha-fetoprotein quantitation and related biochemical indicators
14165,NCT03592706,Progression-Free Survival (PFS),2009-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Improvement of immune responses
14166,NCT03051802,Optimize the clinical protocol using this technology,2017-01-27,TERMINATED,INTERVENTIONAL,['NA'],,
14167,NCT00004860,,2000-10-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14168,NCT02650635,Change in pharmacodynamics after TLR8 agonist VTX-2337 alone vs TLR8 agonist VTX-2337+cyclophosphamide,2016-02-05,TERMINATED,INTERVENTIONAL,['PHASE1'],Changes in immunomodulation,PFS as measured by serial imaging studies and assessed by irRECIST
14169,NCT04996446,recurrence free survival,2020-08-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival
14170,NCT01522937,The Percentage of Patients With Local Control at 1 Year Post Treatment,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,The Number of Patients That Experience Grade 4+ Gastrointestinal Bleeding
14171,NCT05528614,Postoperative morbidity and mortality of simultaneous pancreatic and hepatic resectio,2022-01-13,COMPLETED,OBSERVATIONAL,['NA'],,
14172,NCT05420259,Mean Change in interleukin 6 (IL6),2022-03-21,RECRUITING,INTERVENTIONAL,['NA'],,Change in skeletal muscle
14173,NCT01210495,"Overall Survival (OS) - Stratified Analysis, Randomized Portion",2010-12-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Treatment-Related Adverse Events (AEs) in Randomized Portion
14174,NCT01183494,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2009-12-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,To evaluate the pharmacokinetic profile of irinotecan in combination with bevacizumab.
14175,NCT00832299,Pathologic Complete Response,2009-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Observation of Overall Pathologic Response Rate, Correlation of Pathologic Staging With Pre-op Ultrasound and Pelvic MRI Staging Observed Toxicities Patterns of Disease Relapse Disease-free Survival Overall Survival"
14176,NCT05361252,The incidence of postoperative complications in the two groups.,2017-02-01,COMPLETED,INTERVENTIONAL,['NA'],,The pain scale
14177,NCT01404650,Progression-free Survival (PFS),2011-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Adverse Events as a Measure of Safety and Tolerability
14178,NCT01858662,Major Pathological Response Rate,2014-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Chemotherapy-associated hepatotoxicity:
14179,NCT05738447,Overall Survival,2023-02-15,RECRUITING,INTERVENTIONAL,['PHASE1'],,
14180,NCT01621451,delayed ulcer bleeding,2012-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],,ulcer healing rate
14181,NCT00361842,Progression-free Survival (PFS) Per RECIST Version 1.0,2006-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Response (DoR) Per RECIST Version 1.0
14182,NCT03082586,Number of Dose Limiting Toxicities (DLTs) Occurring in Participants,2016-11-20,COMPLETED,INTERVENTIONAL,['NA'],,Local Failure
14183,NCT05914597,Feasibility of home delivery of CCE service,2022-12-12,RECRUITING,INTERVENTIONAL,['NA'],,assessing the patient's acceptability of home delivery of CCE service
14184,NCT05403177,Number of patients included in a pan-Canadian cohort with comprehensive clinical and genomic data,2022-06-23,RECRUITING,OBSERVATIONAL,['NA'],,Development and collection of patient-reported outcomes to enhance patient-centeredness in precision cancer medicine
14185,NCT02704143,One-year Overall Survival Rate,2016-02,COMPLETED,INTERVENTIONAL,['NA'],,Median Overall Survival Will be Determined.
14186,NCT05129605,Diagnosis of prostate cancer,2020-02-12,RECRUITING,OBSERVATIONAL,['NA'],,Positive predictive value of multiparametric MRI for detection of prostate cancer
14187,NCT04505553,Severity of chemotherapy-induced peripheral neuropathy (CIPN),2021-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,"Incidence of pain, fatigue, nausea, and anxiety"
14188,NCT00570635,"Clinical benefit, defined as either confirmed complete response, confirmed partial response, or evidence of stable disease lasting ≥16 weeks, in subjects with advanced GIST resistant to/intolerant of imatinib and/or sunitinib",2007-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Further characterize the pharmacokinetic and pharmacodynamic parameters of XL820 in subjects with advanced GIST
14189,NCT00547144,To determine the time to tumor progression for this regimen.,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14190,NCT02574663,"Adverse events as a measure of safety and tolerability of TGR-1202 as a single agent and in combination in combination with nab-paclitaxel + gemcitabine, or with oxaliplatin + leucovorin + 5-FU (FOLFOX) or with FOLFOX + bevacizumab.",2015-09-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetic (PK) profile of TGR-1202. Area under the plasma concentration versus time curve (AUC)
14191,NCT01227018,Disease Control Rate,2010-12,TERMINATED,INTERVENTIONAL,['PHASE2'],Biomarker Evaluation,Number of Patients With Each Worst Grade Toxicity
14192,NCT04778566,Evaluate the feasibility of the Cologuard test for Lynch Syndrome,2021-11,WITHDRAWN,OBSERVATIONAL,['NA'],,Evaluate bowel preparation tolerability
14193,NCT05327400,High expression of IGHD is independent risk factors for poor prognosis in patients with pancreatic cancer.,2022-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,
14194,NCT05069571,Adenoma detection rate,2020-03-01,UNKNOWN,OBSERVATIONAL,['NA'],,Proportion of withdrawal overspeed
14195,NCT03086096,"Number of indications that the device is being used for, as assessed by stage and previous treatment(s)",2018-02-02,COMPLETED,OBSERVATIONAL,['NA'],,"The quality of participants' lives, as assessed by the QLQ-C30 questionnaire (developed by EORTC)"
14196,NCT02015065,Number of Participants With a Clinical Activity-radiographic Response,2013-12-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Maximum Standardized Uptake Value (SUVmax) on Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
14197,NCT01582178,Cecal Intubation Time,2012-06,COMPLETED,INTERVENTIONAL,['NA'],,Patient Comfort During Insertion Phase of the Colonoscopy
14198,NCT02415101,"Complete histological response proportion, using the Chirieac grading system.",2015-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Nutritional status of patients in each study arm.
14199,NCT05681390,MedianProgression free survival(mPFS),2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,disease control rate(DCR)
14200,NCT05327751,The change in HFS-specific QOL questionnaire (HFS-14).,2022-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,The change in serum levels of malondialdehyde (MDA).
14201,NCT00034619,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14202,NCT05580835,Degree of PSMA uptake by HCC,2022-09-05,RECRUITING,INTERVENTIONAL,['NA'],,Presence of PSMA uptake on treated liver lesions
14203,NCT05913141,Objective response rate (ORR),2023-06,RECRUITING,OBSERVATIONAL,['NA'],,12-month survival rate
14204,NCT02304445,Tumor response rate,2015-11,WITHDRAWN,INTERVENTIONAL,['NA'],Overall survival,Number of patients eligibility for liver transplantation
14205,NCT03380130,"Rate and type of adverse events, liver decompensation, and transient and permanent drug discontinuations due to toxicity.",2017-09-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Pattern of progression according to RECIST 1.1 criteria.
14206,NCT04611997,3-year disease free survival rate,2020-11-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Total number of retrieved lymph nodes
14207,NCT02635503,Early morbidity rate,2015-11,RECRUITING,INTERVENTIONAL,['PHASE3'],,Plasma levels of several cytokines after colorectal cancer surgery
14208,NCT01754987,Number of Participants That Experience Serious Adverse Events.,2012-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants That Are Alive After 15 Weeks of Treatment.
14209,NCT01808638,"Maximum concentration (Cmax), area under the curve (AUC), time to maximum concentration (tmax), and half life (t½) of the Atu027 siRNA single strand (A-strand), and of AtuFect01 and the helper lipid DPyPE",2013-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life
14210,NCT04425239,Progression-free Survival,2018-05-21,COMPLETED,INTERVENTIONAL,['PHASE2'],Metabolomic profiling,Overall Survival (OS)
14211,NCT02173119,Imaging response,2014-08,COMPLETED,OBSERVATIONAL,['NA'],,Survival
14212,NCT03892252,"According to the 16s rDNA sequencing results, analyze the differences in intestinal flora of colon cancer patients with different TCM syndromes and TCM constitutions before and after surgery and their correlations",2019-03-10,COMPLETED,OBSERVATIONAL,['NA'],,
14213,NCT05195294,Objective response rate (ORR),2022-06,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
14214,NCT05721651,Progression free survival (PFS),2023-04,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Safety and tolerance evaluated by incidence, severity and outcomes of AEs"
14215,NCT05966194,Incidence of Severe Oral Mucositis through 60 Gy of the Radiation Treatment Plan,2024-04-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Narcotic use through resolution of SOM
14216,NCT05513183,Association between the concentration of intraoperative mitomycin-C absoprtion and severe neutropenia after CRS/HIPEC,2021-05-20,COMPLETED,OBSERVATIONAL,['NA'],,Quality of Life: QoR-40 questionnaire
14217,NCT04969887,Determine the proportion of participants with progression free survival at 6 months,2021-08-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quantification of treatment related toxicities to ipi/nivo according to CTCAE V5.0
14218,NCT02096666,Phase 2- Overall Response Rate (per RECIST v1.1) in subjects with MET amplified measurable gastric/gastroesophageal junction/esophageal adenocarcinoma (cohort 1),2014-04-15,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 1- Overall Survival
14219,NCT02809716,"HD-SCA solid tumor biosignatures assessed by cell morphology, protein expression, and whole genome CNV profiles",2016-08-01,COMPLETED,OBSERVATIONAL,['NA'],,"HD-SCA biosignatures in pre-resection liquid biopsy samples assessed by cell morphology, protein expression, and whole genome CNV profiles"
14220,NCT02148159,Percentage weight change over 8 weeks between two arms,2014-10,COMPLETED,INTERVENTIONAL,['NA'],symptom experience,body composition
14221,NCT02329821,changes of lactate level,2014-11,COMPLETED,OBSERVATIONAL,['NA'],,changes of acid-base status
14222,NCT05198934,Progression-free Survival (PFS),2022-04-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,AUC of Panitumumab
14223,NCT01717391,Percent Difference From Baseline IMRT Plan (%),2012-10-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Standardized Toxicity Severity Grades for Decreased Lymphocyte Counts.
14224,NCT01877187,Baseline Enhancing Tumor and Response by RECIST Criteria,2013-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,6-month Survival Rate of Patients With HCC and Liver Metastases Treated With Conventional TACE
14225,NCT04394572,"Diagnostic performances of markers derived from circulating tumor exosomes in the context of colorectal cancer, focusing on metallo proteases",2021-01-07,COMPLETED,OBSERVATIONAL,['NA'],,
14226,NCT02549911,R0 resection,2015-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival time
14227,NCT05818072,The yield rate of intestinal metaplasia,2023-03-13,RECRUITING,INTERVENTIONAL,['NA'],,Procedure time
14228,NCT02194959,Colonoscopy completion,2011-07,COMPLETED,INTERVENTIONAL,['NA'],,
14229,NCT03679039,The sensitivity and specificity of the model to predict the drug resistance,2018-09-20,UNKNOWN,OBSERVATIONAL,['NA'],,
14230,NCT05759728,To determine the overall best response to CNA3103.,2023-10-24,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To determine progression-free survival
14231,NCT02548403,the quality of the bowel preparation using Preparation Scale,2014-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,the endoscopist's tolerability[Visual Analog Score for fatigue]
14232,NCT05569343,postoperative complications,2020-05-08,COMPLETED,OBSERVATIONAL,['NA'],,Readmission
14233,NCT02215577,"Surgical success rate, the rate of liver resection in each study arm",2014-06,UNKNOWN,INTERVENTIONAL,['NA'],Health economy,Liver growth rate
14234,NCT01525706,Efficacy: Degree of Ablation,2012-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,Efficacy: Cyst Resolution
14235,NCT01755013,Efficacy Profile,2012-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Safety Profile
14236,NCT02156739,Specificity of combining gadoxetate disodium and gadobutrol in diagnosing tumor lesions radiologically using magnetic resonance imaging (MRI),2014-10-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
14237,NCT00399750,To evaluate the safety and efficacy of three oxaliplatin-fluoropyrimidine regimens when combined with bevacizumab as therapy for previously untreated metastatic colorectal cancer (TREE 2),2002-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Patients enrolled prior to the initiation of Amendment 3 (TREE1) will not be eligible to receive Avastin as a component of their treatment regimen.
14238,NCT01996059,Body Mass Index,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],Visick rates,Onodera Prognosis Nutritional Index
14239,NCT03546127,Delay time to send a validated exome sequencing report from sample receipt,2017-05-23,COMPLETED,OBSERVATIONAL,['NA'],,The rate of patients with bioinformatic analysis available for interpretation for whom results has been discussed by MTB
14240,NCT03530267,Progression-free survival (PFS),2018-09-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,PRO: Overall treatment utility
14241,NCT04248582,Dose limiting toxicity (DLT),2020-02-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
14242,NCT01834170,Number of participants with adverse events as a measure of safety and tolerability,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Proportion of participants who remain alive one year after enrollment compared to the historical matched control group
14243,NCT02497820,cancer preventive properties of enteric coated aspirin in Lynch syndrome are dose sensitive by comparing overall cumulative Lynch syndrome cancer,2016-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall cumulative of of new adenomas at five years
14244,NCT01711242,disease free survival,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of participants with adverse events as a measure of safety and tolerability,5 year Overall Survival
14245,NCT05757336,Safety：the incidence of adverse events and serious adverse events,2022-12-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,Proportion of acceptable radical resection of primary lesions
14246,NCT05339919,Long-term results after operation,2020-05-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Hospitalization expenses
14247,NCT01764438,"incidence of change of BCLC stage after add-on Primovist-enhanced MRI in HCC patients with very early or early stage disease, but with no suspicious intrahepatic HCC lesions by liver dynamic CT.",2012-08,UNKNOWN,OBSERVATIONAL,['NA'],,"Sensitivity, specificity, false positive predictive value, false negative predictive value, and accuracy of Primovist-enhanced MRI"
14248,NCT04835896,Phase 2: Progression-free survival in subjects with M7824 and paclitaxel combination treatment,2021-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Safety and Tolerability, in terms of the number, severity, and duration of treatment-emergent adverse events as assessed by CTCAE v5.0"
14249,NCT02567045,Proportion of patients who participate in each screening arm,2016-02-25,COMPLETED,INTERVENTIONAL,['NA'],,Costs measure: cost (euros) of the procedures associated with each screening strategy and treatment of advanced neoplastic lesions
14250,NCT00619242,Ki-67,2006-06,TERMINATED,INTERVENTIONAL,['NA'],,
14251,NCT00976170,Dose limiting toxicity and maximum tolerated dose,2009-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Repeat-dose pharmacokinetic behavior of GC33 and Sorafenib
14252,NCT04163887,Rate of overall complications using the comprehensive complication Index (CCI),2021-01-27,RECRUITING,INTERVENTIONAL,['NA'],,Disease-free and overall survival at 3 years.
14253,NCT04063293,Wexner fecal incontinence score change,2019-05-15,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Number of participants with PRP injection-related adverse events as assessed by CTCAE v4.0
14254,NCT00882765,Changes in microvessel density of tumor specimen after 2 weeks of treatment with genistein,2009-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,"To evaluate the impact of genistein on the angiogenic factors VEGF, CXCL1, CXCL5, and CXCL8"
14255,NCT03884751,Maximum tolerated dose (MTD),2019-08-15,COMPLETED,INTERVENTIONAL,['PHASE1'],,Antitumor efficacy-Disease control rate (DCR)
14256,NCT01137123,survival rate,2010-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,
14257,NCT05667181,Incidence of anastomotic complications,2022-12-01,RECRUITING,INTERVENTIONAL,['NA'],,
14258,NCT02216955,Disease-specific survival,2009-01,UNKNOWN,OBSERVATIONAL,['NA'],Disease-free survival,Overall survival
14259,NCT03890926,Local control time,2015-12,COMPLETED,OBSERVATIONAL,['NA'],,Incidence of adverse events
14260,NCT02935478,Weight,2017-10-18,SUSPENDED,INTERVENTIONAL,['NA'],,Eligibility for liver transplant
14261,NCT00909987,"Efficacy of XELOX/BVZ neoadjuvant therapy with selective radiotherapy use in patients with locally advanced tumors of the rectum, measured in terms of the proportion of responders (PCR + CCR), according to RECIST criteria",2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Complete Phatologic Response (pCR)
14262,NCT04715061,"Change in the concentration of different peripheral blood mononuclear cells (Natural Killer Cells, T cells and monocytes)",2020-11-04,COMPLETED,INTERVENTIONAL,['NA'],,Heart rate variability
14263,NCT03739801,Progression-free survival (PFS) (Phase II),2020-04-06,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of adverse events graded according to CTCAE version 4.0
14264,NCT01545687,The AUC of the MTS score,2012-04,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,DFS at 12 months after treatment
14265,NCT01713387,Maximum tolerated dose,2012-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants with dose limiting toxicity
14266,NCT04404101,Safety of EUS-FNA plus MFB with that of EUS-FNA by recording adverse events per published ASGE (American Society for Gastrointestinal Endoscopy) criteria.,2021-05-11,RECRUITING,INTERVENTIONAL,['NA'],,Time taken for FNA and time for MFB
14267,NCT04514341,Time to completion of diagnostic colonoscopy,2022-03-01,RECRUITING,OBSERVATIONAL,['NA'],,Navigation Services Provided
14268,NCT01238653,The number of accurate liver surface registrations obtained in the laparoscopic environment compared to accurate liver surface registrations obtained in open procedures,2010-11,TERMINATED,OBSERVATIONAL,['NA'],,
14269,NCT00113230,Pathologic Local Tumor Response,2005-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14270,NCT05690490,R0 resection rate,2020-11-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,intra- and postoperative complications rate
14271,NCT03637491,Phase 2: Confirmed Objective Response (OR) Based on Investigator Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.,2018-08-15,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Phase 2: Number of Participants With Programmed Death-Ligand 1 (PD-L1) Expression, DNA Damage Repair (DDR) Gene Alterations, and Tumor Mutational Burden (TMB) in Baseline Tumor Tissue."
14272,NCT06157060,2-year recurrence-free survival rate,2023-11-20,RECRUITING,OBSERVATIONAL,['NA'],,Correlation between ctDNA-MRD status dynamic changes and relapse
14273,NCT01937208,Progression-free survival,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],radiation-related advent events,Overall survival
14274,NCT06254521,Pathological complete response (pCR) rate,2024-02-22,RECRUITING,INTERVENTIONAL,['PHASE2'],Molecular pathological analysis of tumor tissue,3-year local recurrence rate
14275,NCT05240625,Adenoma detection rate,2022-03-01,RECRUITING,INTERVENTIONAL,['NA'],,Withdrawal time
14276,NCT00389870,Overall survival of patients treated with Ir vs Ir and panitumumab (IrP) and no prior cetuximab,2006-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Patient-assessed symptom/quality of life/acceptability scores at 12 and 24 weeks in patients treated with Ir vs IrP and prior cetuximab
14277,NCT01742065,FIT Completion,2013-01,COMPLETED,INTERVENTIONAL,['NA'],,Any CRC Screening
14278,NCT04231526,To measure the feasibility of neoadjuvant pembrolizumab in early stage colon cancer,2020-05-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Measure the immune response in early stage colon cancer after neoadjuvant pembrolizumab
14279,NCT05643391,Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v5.0,2020-06-15,COMPLETED,INTERVENTIONAL,['NA'],"Comparison between ""pre-scout"" HBS and HBS just after ""scout dose""",Evaluation of efficacy of 166Ho radioembolization in unresectable hepatocellular using metabolic assessments (FDG and choline PET/CT)
14280,NCT00250796,"Determine the response rate and time to progression of the combination of thalidomide, interferon, and octreotide in patients with unresectable hepatocellular carcinoma.",2000-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14281,NCT01952730,Number of Patients Who Fail to Receive the First Six Scheduled Vaccinations Because of Toxicity,2013-11-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,Two Year Survival
14282,NCT02114411,Sensitivity and Specificity of the GastroPanel test for the detection of AG,2017-01-31,UNKNOWN,OBSERVATIONAL,['NA'],,
14283,NCT00005956,Safety,2000-02,COMPLETED,INTERVENTIONAL,['NA'],,
14284,NCT00549835,Frequency of any adverse effects,2007-08,WITHDRAWN,INTERVENTIONAL,['NA'],,Total amount of conventional analgesics used and Total days on Analgesic
14285,NCT05176002,Safety of Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.,2021-09-23,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Efficacy of Camrelizumab in Combination With Radiotherapy for Neoadjuvant
14286,NCT00555334,Overall survivals,2007-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Recurrence rates
14287,NCT04989985,pCR,2021-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
14288,NCT05508126,Diagnostic performance of DECT and mpMRI in tumor restaging assessment,2021-11-01,RECRUITING,OBSERVATIONAL,['NA'],,Contrast-to-noise Ratio (CNR)
14289,NCT05281328,Height-adjusted total liver volume (htTLV),2022-06-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Adverse events (AEs)
14290,NCT00785421,DVT/TVE event rate,2004-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"TTP, OS, side effects"
14291,NCT03985644,Overall survival,2019-07,UNKNOWN,OBSERVATIONAL,['NA'],,Recurrence rate
14292,NCT04400903,Compliance statistics for wristband use (Stage II),2020-09-21,TERMINATED,OBSERVATIONAL,['NA'],,Time of PDAC diagnosis among high-risk participants who developed PDAC (Stage II)
14293,NCT05582031,Progression Free Survival at 6 months (PFS-6) as per Investigator Assessment,2023-04-30,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Frequency and Severity of Adverse Events (AEs) and Laboratory Abnormalities
14294,NCT01453153,Recommended Phase 2 Dose (RP2D),2011-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change From Baseline in CA19-9 in Participants Classified as Responders and Non-responders
14295,NCT06135896,Primary endpoint,2023-12-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,biomarkers
14296,NCT01097239,"Quality of life scores (EORTC QLQ-C30 and/or EORTC QLQ-CR38, EORTC QLQ-CX24, EORTC QLQ-EN24 or EORTC QLQ-OV24)",2009-11,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Tumour marker changes (CEA and CA19.9)
14297,NCT03002831,Overall Survival,2016-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of life assessed by Questionnaire
14298,NCT04895722,Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR),2021-06-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Participants Discontinuing Study Treatment Due to an AE
14299,NCT01257711,The aim of this study is to compare Billroth II and Roux En Y reconstruction after radical distal subtotal gastrectomy for gastric cancer in terms of postoperative outcomes.,2008-10-09,COMPLETED,INTERVENTIONAL,['NA'],,Grading of gastritis and/or esophagitis on endoscopy
14300,NCT03311451,Safety: Incidence of Dose-related SAEs,2023-01-16,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Efficacy: Treatment
14301,NCT01339832,Progression-free Survival,2010-08,COMPLETED,OBSERVATIONAL,['NA'],,Incidence of Adverse Event (AE) and Serious Adverse Event (SAE)
14302,NCT04530890,To assess the prognostic impact of ctDNA (mortality) in digestive and gynecological / breast cancers.,2021-01-20,RECRUITING,INTERVENTIONAL,['NA'],,Evaluate the possibility of detecting certain molecular alterations using ctDNA and exosomes
14303,NCT05132738,No Evidence of Disease Rate (NED Rate),2021-08-01,UNKNOWN,INTERVENTIONAL,['NA'],Overall survival (OS),Objective response rate (ORR)
14304,NCT00220077,To determine whether specific gene expression profiles are associated with response in oesophago-gastric cancer.,2002-06,UNKNOWN,INTERVENTIONAL,['NA'],,Evaluation of the association of gene expression profiling and progression free survival and overall survival in patients with oesophago-gastric cancer.
14305,NCT05059119,Rate of associated comorbidity or intervention,2020-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
14306,NCT01294085,One year survival rate,2010-11,COMPLETED,OBSERVATIONAL,['NA'],,Progression free survival
14307,NCT00313859,overall response rate,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,duration of response
14308,NCT01698190,Number of needle passes needed to obtain a pathologic diagnosis.,2011-12,UNKNOWN,INTERVENTIONAL,['NA'],,Frequency of adverse side effects.
14309,NCT00300950,Recurrence free time and survival,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14310,NCT06077981,Volume of solution,2023-06-19,RECRUITING,INTERVENTIONAL,['NA'],,Number of additional injections
14311,NCT06064331,Cost of Desflurane used to maintain BIS 40-60,2021-01-21,COMPLETED,INTERVENTIONAL,['NA'],,Opioid usage (mcg/kg)
14312,NCT00985400,Effect size of the exercise intervention on physical function,2010-11-05,UNKNOWN,INTERVENTIONAL,['NA'],,Effect size of the exercise intervention on symptoms and quality of life
14313,NCT04924686,NOD2 ligands in fecal and plasma,2020-05-10,UNKNOWN,OBSERVATIONAL,['NA'],,
14314,NCT03784677,Change of the treatment regimen such as dose delay and dose reduction over time by dose level due to treatment-related adverse events,2019-07-29,COMPLETED,INTERVENTIONAL,['PHASE1'],,Predictive biomarkers
14315,NCT05230329,we will assess the Number of harvested lymph nodes after colonic resectio,2022-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Health related quality of life
14316,NCT04223102,16s rRNA gene sequencing to study bacterial phylogeny and taxonomy,2020-02-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,rectal microbiota to study bacteria strains
14317,NCT06294873,Detection of colon cancer or precancer,2023-07-20,RECRUITING,OBSERVATIONAL,['NA'],,
14318,NCT01440127,Expression of CD133 in tumors from patients treated or not treated with metformin,2011-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,
14319,NCT04634539,"Recommended phase II dose (RP2D) of combination gemcitabine, nab-paclitaxel, and L-glutamine in treatment-naive metastatic pancreatic cancer.",2021-05-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Describe any preliminary evidence of antitumor activity of the combination by assessment of overall survival as determined by RECIST 1.1 criteria in patients with measurable disease.
14320,NCT03211806,Adherence,2019-06-06,COMPLETED,INTERVENTIONAL,['NA'],,Readmission
14321,NCT00986440,Percentage Rate of Progression-free Survival at 18 Weeks Following Use of CS-7017 in Colorectal Cancer Participants Who Have Achieved Disease Control Following First-Line Chemotherapy,2009-07-31,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Treatment-Emergent Adverse Events Related to Study Drug With an Incidence of ≥5% Following Use of CS-7017 Or Placebo in Colorectal Cancer Participants Who Have Achieved Disease Control Following First-Line Chemotherapy
14322,NCT01960023,Number of patients with Overall response rate (ORR)(complete response/partial response) and progression free survival (PFS) during the Phase II portion of the study,2013-10,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The frequency and severity of adverse events to evaluate the overall toxicity in the Phase II portion of the study.
14323,NCT04851119,Area under the drug concentration curve of tegavivint,2021-11-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Antitumor effects of tegavivint in patients with solid tumors
14324,NCT06015971,Functionality,2023-07-01,RECRUITING,INTERVENTIONAL,['NA'],,C-RP
14325,NCT05131776,Adverse events,2021-11-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Progression Free Survival
14326,NCT02886247,pancreatic cancer,1994-06,RECRUITING,OBSERVATIONAL,['NA'],,
14327,NCT01580241,,2010-10,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
14328,NCT06192771,Study feasibility as measured by data fidelity for patient-reported outcomes,2023-12-01,RECRUITING,INTERVENTIONAL,['NA'],,
14329,NCT04393584,median overall survival,2019-01-29,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,R0-Resection rate
14330,NCT00007943,,2000-09-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14331,NCT00434109,Percentage of Participants With Progression Free Survival (PFS) at 12 Months,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Overall Survival (OS) at 4 Years
14332,NCT01608711,Incidence of anti-AGS-1C4D4 antibody formation,2012-08-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14333,NCT03019016,Chart review on PeriOperative Information,2016-08,COMPLETED,OBSERVATIONAL,['NA'],,Chart review on Postoperative Information
14334,NCT05100329,Objective response rate (ORR),2021-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Treatment-emergent adverse events (TEAEs)
14335,NCT00834860,"Efficacy: sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period.",2007-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Safety: adverse event rate and profile.
14336,NCT02022995,evaluate the overall survival of patients with PRMT (arginine methyltransferase),2014-01,COMPLETED,OBSERVATIONAL,['NA'],,evaluate the disease-free survival of patients with PRMT (arginine methyltransferase)
14337,NCT00003907,Time to Progression,1999-12-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
14338,NCT04000425,Description of ctDNA changing to adjuvant chemotherapy response,2018-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,The ctDNA level/mutations in gastric cancer preoperatively
14339,NCT00016380,,2001-02-28,COMPLETED,INTERVENTIONAL,['PHASE3'],,
14340,NCT04534218,objective response rate,2020-10-16,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14341,NCT01906216,Overall survival,2013-09,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",AFP response,Adverse events
14342,NCT04193553,Progression-Free Survival (PFS),2020-01-17,RECRUITING,INTERVENTIONAL,['PHASE2'],Pharmacokinetic properties of lenvatinib for patient in the blinded part of the study,Progression-Free Survival (PFS) In patients from the placebo arm who switched into the active treatment group
14343,NCT03590119,The difference in post-treatment tumor-to-non-tumor (T/N) activity concentration ratio on SPECT/CT between the intra-arterial treated liver lobe and the intravenous treated liver lobe.,2018-08-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,The difference in kidney uptake of 177Lu-dotatate between the IA treated patients and historical controls
14344,NCT01593098,Prevalence of adenoma and CRC,2010-06-08,RECRUITING,OBSERVATIONAL,['NA'],,Differences in genetic profile between siblings of patients with advanced neoplasm and controls
14345,NCT02426879,Safety measured by the percentage of overall postoperative complications grade 3b and higher as stated by the modified Clavien-Dindo classification (MCDC),2015-02-11,COMPLETED,INTERVENTIONAL,['NA'],pathology results 10,postoperative recovery
14346,NCT05935189,Creation of a registry,2023-07-01,RECRUITING,OBSERVATIONAL,['NA'],,
14347,NCT01653301,Pathological major downstaging,2005-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,survival
14348,NCT05534906,Biomarkers associated with small HCC (Early detection [EDx] biomarkers),2022-05-23,RECRUITING,OBSERVATIONAL,['NA'],,Proportion of patients with HCC events according to time since treatment with curative intent.
14349,NCT00048529,,2002-09,SUSPENDED,INTERVENTIONAL,['PHASE2'],,
14350,NCT03965546,Frequency of ARTEMIS T cell treatment-related adverse events,2019-05-30,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,IFN-γ serum levels
14351,NCT05728710,Surgery,2019-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,30-days mortality rate
14352,NCT04232176,Precision in polyps sizing the pathologist,2019-12-22,COMPLETED,OBSERVATIONAL,['NA'],,Rate of polyps' recurrence at the end of the follow-up.
14353,NCT03784040,Response Rate,2019-02-21,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Overall Survival
14354,NCT03785938,Cost-benefit evaluation of the study,2019-01-20,UNKNOWN,INTERVENTIONAL,['NA'],,Evaluate responsible guardian/participants experience of the MaCROS study
14355,NCT01349075,Response to Treatment,2007-10,COMPLETED,OBSERVATIONAL,['NA'],,Survival Time
14356,NCT01618253,Maximum Tolerated Dose,2012-06,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Health Related Quality of Life
14357,NCT05552755,Percent change from baseline in polyp burden,2023-07-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Assess the pharmacodynamic (PD) effect of REC-4881, and correlation between PD and clinical outcome"
14358,NCT00965172,"Incidence/Severity of Oral Mucositis WHO Grades 1, 2, 3, and 4",2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14359,NCT03751761,response rate,2018-06-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14360,NCT04273061,"Overall response rate (ORR) in each tumour-defined cohort, as defined by RECIST 1.1",2020-06-17,RECRUITING,INTERVENTIONAL,['PHASE2'],Compare the utility of iRECIST for response assessment to RECIST 1.1 in each tumour-defined cohort,Duration of response (DoR) in each tumour-defined cohort
14361,NCT03849469,"Safety and tolerability profile of XmAb22841 assessed by rates of treatment-related adverse events (AEs), graded by CTCAE v4.03.",2019-05-29,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14362,NCT04962958,2-year cumulative recurrence-free survival rate,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
14363,NCT03645876,Objective response rate,2018-11-08,TERMINATED,INTERVENTIONAL,['PHASE2'],Biomarkers and ADA,12month and 24 month OS rate
14364,NCT02694081,the amount of blood loss during operations of Uncut Roux-en-Y Reconstruction and Billroth II Reconstruction,2016-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],the number of patients with the complication of gastroesophageal reflux disease(GERD),the number of patients with the complication of Reflux esophagitis
14365,NCT05404503,Choledochal cyst and cholangiocarcinoma,2022-10,RECRUITING,OBSERVATIONAL,['NA'],,
14366,NCT00047307,Maximum tolerated dose of flavopiridol when administered biweekly in conjunction with radiation for patients with locally advanced pancreatic or extrahepatic bile duct cancer,2002-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Molecular correlates of apoptosis including PARP cleavage and caspase-3 activation, as well as changes in expression of p21, phosphorylation status of pRb and cyclin D1"
14367,NCT02896907,Number of Participants With Adverse Events as Determined by CTCAE Version 4.03,2016-10-18,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Change in Quality of Life as Defined by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C-30
14368,NCT01450319,Overall Survival (OS) Time,2011-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Beta 2-microglobulin
14369,NCT05262452,Percentage of subjects that were subject to surgical resection,2021-08-09,RECRUITING,INTERVENTIONAL,['NA'],,Survival time
14370,NCT02146352,Safety/Adverse Event Outcome Measure 6,2014-06,COMPLETED,INTERVENTIONAL,['NA'],,Technical Success Outcome Measure 2
14371,NCT03910634,Overall objective response rate,2019-04-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of toxic and side effects above 3 degrees
14372,NCT04524650,the severity of portal hypertension,2020-08-31,UNKNOWN,OBSERVATIONAL,['NA'],,
14373,NCT05566093,The Chang The change of tumor size,2018-09-28,RECRUITING,INTERVENTIONAL,['NA'],,Incidence of Treatment-Emergent Adverse Events
14374,NCT01419860,Evaluation of microcirculation in colon wall and bowel anastomosis by laser induced fluorescence video angiography of indocyanine green,2010-01,COMPLETED,INTERVENTIONAL,['NA'],,Predicting perfusion deficit with laser-induced ICG fluorescence video angiography
14375,NCT00370513,Adverse events (AEs) and changes in vital signs and laboratory values. A dose regimen where no more than 1 out of 6 subjects experience a dose-limiting toxicity (DLT) will define the maximum tolerated dose (MTD).,2006-12-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Various pharmacokinetic parametersAlpha-fetoprotein (AFP) measurements and scans
14376,NCT00999921,Number of Participants Analysed for Reduction in Mastalgia (Cardiff Breast Pain Score).,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,Number of Participants Analysed for Response of Cyclical Mastalgia (Good Response Was Defined as Disappearance of Mastalgia)
14377,NCT05199259,Independent performance measure of sensitivity and specificity of a multi-analyte blood test,2022-03-01,RECRUITING,OBSERVATIONAL,['NA'],,Ascertain Sample Stability
14378,NCT03957460,difference between SpHb value in g/dL and SaHb value in g/dL (SpHb - SaHb),2017-11-20,COMPLETED,OBSERVATIONAL,['NA'],,
14379,NCT00108745,Overall Survival,2005-03-21,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Patient-Reported Peripheral Neuropathy Symptoms
14380,NCT05310643,Objective response rate (ORR) by RECIST 1.1,2022-05-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,MSI/MMR status
14381,NCT05592873,Lateral nodal recurrence,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
14382,NCT02130726,Extent of lymph node dissection,2014-12,COMPLETED,INTERVENTIONAL,['NA'],,Disease-free survival
14383,NCT04031963,Early cancer changes in the colon,2009-09,COMPLETED,OBSERVATIONAL,['NA'],,
14384,NCT01902849,measurement of interleukins IL6 and IL 10 plasmatic level,2012-02,COMPLETED,OBSERVATIONAL,['NA'],total opioid dose of remifentanil (mg ) used during surgery,total opioid analgesic dose (mg)
14385,NCT03530969,Participants satisfaction with Health Care Provider (HCP) training,2018-05-07,COMPLETED,INTERVENTIONAL,['NA'],,
14386,NCT03765450,Inter-compartmental Difference in Infliximab Concentration,2018-12-21,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Change in Mayo Clinic Endoscopic Score
14387,NCT02529761,Overall survival,2015-08,UNKNOWN,INTERVENTIONAL,['NA'],,Prognostic factor
14388,NCT06197178,Area Under the Curve (AUC) last,2024-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of anti-LCAR-G08 antibody and positive sample titer
14389,NCT04862949,Organ-specific response rate,2021-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
14390,NCT04068103,"Recurrence-free survival (RFS) the ""baseline ctDNA detected"" patient subset (Phase III)",2019-12-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Cost effectiveness of the use of ctDNA versus standard of care,Incidence (presence or absence) of ctDNA in blood following resection of stage II colon cancer
14391,NCT05150548,Sepsis or septic shock,2021-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,
14392,NCT04632303,Adjusted mean change in global health status/QoL score at 12 weeks,2021-06-23,RECRUITING,INTERVENTIONAL,['NA'],,Chemotherapy dose intensity.
14393,NCT03823846,pain at rest (Numerical rating scale),2017-11-01,UNKNOWN,INTERVENTIONAL,['NA'],,adverse events during rehabilitation
14394,NCT04579380,Confirmed objective response rate (cORR) per investigator assessment,2021-01-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Trough concentration (Ctrough)
14395,NCT02578602,"Precision in tumor measurement for each type of image (CT vs. MRI), for each phase ( 4 for CT and 5 for MRI), and for each method of measuring ""size"" (1-,2-, and 3-dimensional), assessed by low inter- and intra-reader variability",2010-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Changes in apparent diffusion coefficient (ADC) values within lesions and within normal liver before and after administration of Gadoxetate
14396,NCT03377270,Change in MBSImP physiologic function metrics of the oropharyngeal swallow,2018-10-01,COMPLETED,INTERVENTIONAL,['NA'],,Functional Oral Intake Scale (FOIS)
14397,NCT00095966,Response rate as measured by RECIST criteria,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
14398,NCT02838836,"CTC/DTC numbers measured in blood, urine and bone marrow samples will be correlated with patient outcome",2016-07-01,RECRUITING,OBSERVATIONAL,['NA'],,ctDNA characteristics will be correlated with survival data
14399,NCT04300114,PFS by Blinded Independent Central Review (BICR) Using RECIST v1.1,2020-08-19,TERMINATED,INTERVENTIONAL,['PHASE3'],,Number of participants with treatment-emergent adverse events
14400,NCT05896956,overall survival,2023-07-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,progression-free survival
14401,NCT01234935,Disease-free survival,2011-01-13,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease-free survival
14402,NCT00293397,Efficacy - Overall Survival,2005-11,COMPLETED,INTERVENTIONAL,['NA'],,
14403,NCT03661047,The change in the marine omega-3 polyunsaturated fatty acid (MO3PUFA) composition in colorectal tissues as a result of the AMR101 treatment for up to 30 days.,2019-11-30,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,The change in the gut microbiome composition and function between pre- and post- AMR101 treatment period
14404,NCT00090025,To compare survival duration for XL119 and 5-FU/LV treated subjects,2004-09,TERMINATED,INTERVENTIONAL,['PHASE3'],,"To determine time to progressive disease for XL119 and 5-FU/LV treated subjects, to evaluate clinical benefit for XL119 and 5-FU/LV treated subjects, and to assess the safety profile of XL119"
14405,NCT02553031,The recurrence rate at 1 year after surgery,2014-07,UNKNOWN,OBSERVATIONAL,['NA'],,The overall survival at 1 year after surgery
14406,NCT05969860,Mean patient-reported rating of Cancer Connected Access and Remote Expertise,2023-08-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
14407,NCT02887365,3-year disease-free survival Safety profile of tegafur-uracil,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],,5-year overall survival
14408,NCT03558945,Incidence and grades of adverse events as assessed by CTCAE v5.0,2018-07-12,RECRUITING,INTERVENTIONAL,['PHASE1'],Percentages of immune cell populations in peripheral blood during the vaccination,Serum CA19-9 or CA72-4 levels
14409,NCT03403049,Dose-limiting toxicity,2016-04-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,The impact in terms of overall quality of life of radiation therapy as assessed by the QLQ-C30 questionnaire
14410,NCT01801059,Completion rate of CRC screening,2007-09,COMPLETED,INTERVENTIONAL,['NA'],,
14411,NCT04726800,Frequency of positive ctDNA preoperative converted to negative postoperatively.,2020-10-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
14412,NCT06302179,Venous Thromboembolism,2015-01,COMPLETED,OBSERVATIONAL,['NA'],,
14413,NCT00259363,Phase II : Response and resectability rate.,2002-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14414,NCT06194461,Incidence of specific AEs,2024-06-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,"Kinetics parameters that indicate persistence (eg, Clast and Tlast)"
14415,NCT02393755,"Progression Free Survival (PFS) Rate, Defined as the Proportion of Patients Who Survive Without Disease Progression Via the RECIST Version 1.1 (Phase II)",2015-05-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Aggregate Rates of Adverse Events Measured by CTCAE Version 4.0 (Phase II)
14416,NCT04681248,,na,AVAILABLE,EXPANDED_ACCESS,['NA'],,
14417,NCT03997617,"Number of patients for which a treatment recommendation for their specific cancer can be formulated, based on PFP",2019-03-11,RECRUITING,INTERVENTIONAL,['NA'],,Number of patients for which the treatment recommendation issued by PFP were followed by the investigator
14418,NCT04301986,7 Days Post-EGD Impact of Events Score (IES),2020-08-11,COMPLETED,INTERVENTIONAL,['NA'],,Factors Influencing the Preferred Screening Modality
14419,NCT06019312,gut microbiota composition,2023-08-01,RECRUITING,INTERVENTIONAL,['NA'],,Clostridioides difficile infection
14420,NCT04281667,Comprehensive Complication Index,2020-03-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],Bowel microbiota,Adjuvant therapy
14421,NCT02947971,Assessment of quality and performance of Compact Imaging System (CIS),2016-04-15,RECRUITING,INTERVENTIONAL,['NA'],,
14422,NCT02751177,"KRAS, NRAS et BRAF mutational status",2016-03-25,COMPLETED,INTERVENTIONAL,['NA'],,
14423,NCT05414383,Diagnostic accuracy,2024-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Diagnostic time
14424,NCT05336617,percentage of complete colonoscopies,2022-05-13,COMPLETED,OBSERVATIONAL,['NA'],,Quality of colonic preparation (Boston score)
14425,NCT00814359,The severity of patient-reported symptoms of mucositis as determined by the change in Oral Mucositis Weekly Questionnaire - Head and Neck Cancer (OMWQ-HN) score from baseline to 6 weeks.,2009-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Incidence of WHO Grade 3 or 4 oral mucositis after 4 weeks of radiotherapy.
14426,NCT04101747,Number of intestinal flora,2019-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,
14427,NCT03546257,the accuracy in predicting the invasion depth of EGC.,2019-03,UNKNOWN,OBSERVATIONAL,['NA'],,The NBI findings that affect the accuracy for predicting of depth.
14428,NCT01978184,Age-Adjusted Charlson Comorbidity Index,2013-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Rate of R0 Resection
14429,NCT05160753,Disease-free survival (DFS) at three years,2022-01-10,RECRUITING,INTERVENTIONAL,['NA'],,
14430,NCT00222079,,2004-11,TERMINATED,INTERVENTIONAL,['NA'],,
14431,NCT05954897,Objective Response Rate,2023-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
14432,NCT03958240,Percentage of CD4 and CD8 T cells expressing PD-1,2020-01-17,RECRUITING,INTERVENTIONAL,['NA'],,Rate of patients presenting a high Trm (Tissue resident memory) infiltrate in tumor samples
14433,NCT03981848,tumor recurrent status,2019-07,UNKNOWN,OBSERVATIONAL,['NA'],,
14434,NCT00323830,disease free survival,2004-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
14435,NCT04234568,Dose limiting toxicity (DLT),2020-07-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Change in deoxyribonucleoside concentrations,Overall survival
14436,NCT00100321,,2004-12-21,TERMINATED,OBSERVATIONAL,['NA'],,
14437,NCT00212615,Toxicity: before treatment (each 3 weeks) and by SAE (Serious Adverse Event),2004-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Tumor assesment: after every 3rd treatment (each 9th weeks)
14438,NCT02727894,Colorectal Cancer Stage (pTNM),2013-03,COMPLETED,OBSERVATIONAL,['NA'],,Colorectal Cancer and Palliative Therapy
14439,NCT02381847,overall survival,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,time to distant metastasis
14440,NCT01351714,Number of additional lymph nodes removed through radical D3 resection,2011-05,UNKNOWN,INTERVENTIONAL,['NA'],,Disease free survival 2 and 5 years after initial surgery
14441,NCT02202096,Number of post-operative ER visits and readmissions,2015-02,WITHDRAWN,INTERVENTIONAL,['NA'],,
14442,NCT04259944,Number of post-surgery and post-adjuvant false negative cases after a double ctDNA-negative detection,2020-06-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of patients experiencing ctDNA seroconversion (i.e. ctDNA+ that become ctDNA-) after any chemotherapy regimen remaining disease free
14443,NCT00586872,Number and types of adverse events in participants who have undergone endoscopic mucosal resection with documented adverse events will be evaluated for predictors of complications,2007-10,COMPLETED,OBSERVATIONAL,['NA'],,
14444,NCT00524498,Antitumor effect (tumor size reduction),2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease control rate Overall survival Progression-free survival
14445,NCT03202758,Evaluation of the safety of Durvalumab plus Tremelimumab in combination with FOLFOX chemotherapy,2017-08-29,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14446,NCT03609424,Disease control rate,2019-02-14,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Mutational analysis
14447,NCT05776940,Occurrence of diarrhea,2023-03-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Involved organ response（kidney）at 3 and 6 months after enrollment
14448,NCT02384850,Numbers of Patients With Dose Limiting Toxicities,2015-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,Number of Patients Experiencing Adverse Events
14449,NCT01907230,HBV reactivation,2013-09-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Hepatitis flare (ALT > 100 U/L) related to biological treatments
14450,NCT03594448,Correlation between presence of MSI present in circulating tumor DNA versus in primary tumor specimens,2018-09-05,RECRUITING,OBSERVATIONAL,['NA'],,
14451,NCT02705300,Time to first serious adverse event,2016-05-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Resection rate
14452,NCT04817826,Primary outcome of Cohort 2: 2-year complete response rate,2021-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Post gastrectomy complications
14453,NCT01949545,Area Under the Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Carfilzomib 27 mg/m²,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Adverse Events (AEs)
14454,NCT01403064,Number of Participants With All Grades of OM at a Radiation Dose of 55 Gy,2011-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,Mean Change From Baseline in C-reactive Protein (CRP) Values at Varying Weeks
14455,NCT02012829,participation rate of patients for CRC screening,2011-12,COMPLETED,INTERVENTIONAL,['NA'],,GPs participation rate over 45%
14456,NCT03518632,Change of Oxgen consumption at anaerobic threshold :,2018-03-27,COMPLETED,INTERVENTIONAL,['NA'],,Changes in Fatigue :
14457,NCT02004769,PFS(Progression-free survival ),2013-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety
14458,NCT04239573,"Occurrence of an ""unfavorable"" outcome",2020-06-16,RECRUITING,INTERVENTIONAL,['NA'],Predictive accuracy of radiomic markers for dysplasia and pancreatic cancer,Biomarker analysis from collected samples to compare the predictive performance of known and future biomarkers for dysplasia or cancer
14459,NCT04032704,Prostate-specific antigen (PSA) response rate as determined by investigator according to Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria (Cohort 7 only),2019-10-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Incidence of antitherapeutic antibodies (ATAs) to LV
14460,NCT00001569,,1997-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14461,NCT04035876,Recurrence-free survival,2019-07-16,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Adverse effect
14462,NCT03876106,"Safety and tolerability (maximum tolerated dose, MTD) of LUT014 topically applied qd for 4 weeks in metastatic colorectal cancer (mCRC) patients with epidermal growth factor receptor inhibitor (EGFRI) induced acneiform lesions.",2019-08-21,COMPLETED,INTERVENTIONAL,['PHASE1'],,Functional Assessment of Cancer Therapy-EGFRI 18 (FACT-EGFRI-18) on health-related quality of life (HRQoL) questionnaire
14463,NCT03302403,Number of participants with CRA T-related adverse events as assessed by CTCAE v4.03,2017-12-29,UNKNOWN,INTERVENTIONAL,['NA'],Changes of cell subsets for CAR T cells against T cells,Engraftment
14464,NCT04933435,change in quality of life in patient cohorts receiving either Interventional Radiology Liver Directed Therapies or Hypofractionated Image-Guided Radiation Therapy,2020-11-12,RECRUITING,INTERVENTIONAL,['NA'],,total healthcare system cost associated with Hypofractionated Liver Directed Therapy
14465,NCT02642913,Progression-free survival,2015-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14466,NCT03773367,To determine the rate of histopathological response according to Becker criteria.,2018-12-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
14467,NCT02640898,overall survival rate,2015-12,UNKNOWN,INTERVENTIONAL,['NA'],,progression free survival rate
14468,NCT00222378,Prevalence of Cytomegalovirus and Epstein Barr Virus in inflamed colonic tissue from patient with mild to moderate IBD as compared to inflamed mucosa from patients with other inflammatory diseases of the colon,2005-04,COMPLETED,OBSERVATIONAL,['NA'],,
14469,NCT04078828,The rate of general complications,2019-09-01,UNKNOWN,INTERVENTIONAL,['NA'],,"White blood cells(WBC) ,C-reactive protein (CRP) and procalcitonin (PCT) count in the blood sample"
14470,NCT04134559,Immune-related best overall response (irBOR),2020-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,DNA sequencing of specimens
14471,NCT00975247,"Bowel preparation quality, as measured by the Ottawa scale.",2008-04,COMPLETED,INTERVENTIONAL,['NA'],,Withdrawal Time
14472,NCT00892242,Evaluate whether treatment with perioperative zoledronic acid prolongs overall survival or disease free survival.,2009-12,TERMINATED,INTERVENTIONAL,['PHASE1'],,Determine the pharmacodynamics of neoadjuvant zoledronic acid therapy on selected immune cell subgroups in the hepatic metastatic niche by flow cytometric analysis of pancreatic tumor samples
14473,NCT02356406,Numerical Rating Scale (NRS) pain score difference from baseline,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Safety profile of the procedure - measuring the frequency and severity of treatment side effects, mainly GI toxicities"
14474,NCT02745600,Comparison of the spatial coordiantes of the real ablation zone one month after RFA treatment of liver tumors with the simulation results of the ClinicIMPPACT software.,2016-02,UNKNOWN,INTERVENTIONAL,['NA'],,"Does the follow - up (3, 6 ,12months) imaging support the assumptions regarding local tumor control"
14475,NCT02856126,Overall survival,2016-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of of Patients developed Adverse Events
14476,NCT01935700,Overall Survival,2013-06-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Grade III Severe Adverse Events
14477,NCT03641976,6-month PFS rate (%),2019-01-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,surrogate markers predictive of survival: ctDNA
14478,NCT02481219,Bowel Cleansing Level of Two Different Bowel Preparation Methods for PillCam® Colon Capsule Endoscopy (CCE),2015-05,COMPLETED,INTERVENTIONAL,['NA'],,Adverse Events Rate Between Two Different Bowel Preparation Methods for PillCam CCE
14479,NCT05580887,Intestinal bacterial structure in BC and PnC (separately) patients with disease progression,2022-05-12,RECRUITING,OBSERVATIONAL,['NA'],,Change from baseline in intestinal bacterial structure in PnC patients with disease relapse on or after combined treatment completion (follow up 12 months)
14480,NCT01448668,Overall survival time (OS).,2010-09,UNKNOWN,OBSERVATIONAL,['NA'],,"Number of patients with adverse events (AE) contributed to conventional oncological therapy (radio-, chemo-, targeted therapy)."
14481,NCT01465659,Overall Response Rate (ORR) in Patients With Advanced Neuroendocrine Tumors (PNET) Treated With Temozolomide and Pazopanib Combination Treatment at the RP2D in Phase II,2011-12-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Amount of a Particular Tumor Biomarker in Blood as Correlated With Progression Free Survival,Number of Months That Patients Maintain a Response to Treatment Until Disease Progression or Death (Duration of Response)
14482,NCT01238939,Number of patients with dose-limiting toxicity as determinant of the maximum tolerated dose/recommended dose,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Peak Plasma Concentration (Cmax) of NK012 and fluorouracil
14483,NCT05698082,Original survival,2020-12-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
14484,NCT01329458,evaluation of contrast enhanced ultrasound in the assessment of de novo focal liver lesions,2010-12,UNKNOWN,OBSERVATIONAL,['NA'],,
14485,NCT06203821,Determining if NP137 can shift the primary tumor MAK's Signature Epithelial-to-Mesenchymal Transition (EMT) Mean Score towards a more epithelial phenotype,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])
14486,NCT01896778,"Changes in tumor vascular (blood flow, blood volume)",2013-10-04,COMPLETED,INTERVENTIONAL,['NA'],,Incidence of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
14487,NCT04079946,Lymph nodes harvest,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA'],,
14488,NCT05781074,Objective Response Rate (ORR) evaluated by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1,2023-03-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
14489,NCT01086059,Major malformations,2003-11,COMPLETED,OBSERVATIONAL,['NA'],,Infant follow-up
14490,NCT04729738,"correlation between the development of a postoperative complication within 30 days from surgery and patient-related characteristics (comorbidity, frailty, malnutrition and sarcopenia)",2012-06-01,COMPLETED,OBSERVATIONAL,['NA'],,"relatedness between the average density sarcopenia indices, HUAC, PI, TPA and the distance between the anterior-superior iliac spines and the size of the psoas muscles (RPSI)"
14491,NCT01219829,Number of subjects with histological features of PanIN lesions assessed,2009-03-18,COMPLETED,OBSERVATIONAL,['NA'],,Evaluation of Recurrence Mechanism in PDC
14492,NCT00142350,overall survival,2000-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,non-hospitalized survival
14493,NCT01814969,• The rate of patients with downstaging after radiotherapy or radiochemotherapy to pathological response or disease with negative margins,2014-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,The rate of early toxicity of neoadjuvant treatment according to the NCI CTCAE (version 4.0)
14494,NCT03846882,Can FDG-PET / MR in combination with blood and tumor tissue biomarkers provide additional prognostic information for intermediate and high-risk rectal cancer?,2015-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,How does the accumulation of FDG change in rectal cancer tissue when examined after 60 minutes vs examination after 90 minutes?
14495,NCT03961646,Diagnostic accuracy,2019-02-01,COMPLETED,OBSERVATIONAL,['NA'],,Image quality
14496,NCT05344664,Percentage of adverse events,2022-04-14,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,
14497,NCT05548114,Composite end point of inability to tolerate a solid diet (defined as gastric outlet obstruction scoring system score <2) or requiring endoscopic or surgical intervention or supplemental nutrition or procedure-related adverse events.,2022-09-15,RECRUITING,INTERVENTIONAL,['NA'],,Overall treatment costs from index procedure until 6 months post-index procedure.
14498,NCT05253430,Disease-free survival,1990-04,COMPLETED,OBSERVATIONAL,['NA'],,Postoperative mortality
14499,NCT01706822,The Ability to Achieve Adequate Distal Margins (Defined as >2cm [or >1cm With Clear Histologic Evaluation]) in the Low Rectum. The Reported Value Represents the Number of Participants in Whom the Criteria Was Met,2013-04,TERMINATED,INTERVENTIONAL,['PHASE4'],,Maneuverability Measured by Surgeon Usability Questionnaire. The Reported Values Represent Percentage of Cases Surgeon Agree/Strongly Agree
14500,NCT05072041,Incidence of liver function impairment,2021-10-31,RECRUITING,INTERVENTIONAL,['NA'],,Hepatic artery damage
14501,NCT04006275,CEUS LI-RADS Grades of SonoVue and Sonazoid agents in enrolled patients.,2019-06-30,UNKNOWN,INTERVENTIONAL,['PHASE3'],,The sensitivity and specificity of CEUS-LI-RADS by different contrast agencies.
14502,NCT02776527,disease free survival,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],,overall survival
14503,NCT03161379,CD8 count (cells/mm^3) in the tumor microenvironment,2018-02-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Pathologic complete response (pCR) rate at surgical resection
14504,NCT03403452,PFS（progress free survival）,2018-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,DCR（disease control rate)
14505,NCT01556490,Overall Survival (OS) Per Protocol (PP) Population,2012-03,COMPLETED,INTERVENTIONAL,['NA'],,Tumor Response
14506,NCT00858000,Proportion of hepatocellular carcinoma cancer patients whose tumor tissue -expresses any one or more of specific target antigens -overexpresses c-MET -expresses a pre-defied gene-expression signature,2009-07,COMPLETED,OBSERVATIONAL,['NA'],,
14507,NCT04707118,Ascites control,2021-02-23,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
14508,NCT02834780,Number of Participants With Clinically Significant Change From Baseline in Vital Sign Parameters,2016-12-28,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Part 2, Dose Expansion Phase: Time to Response (TTR) Based on Modified Response Evaluation Criteria in Solid Tumors (mRECIST) v1.1"
14509,NCT05432492,Objective Response Rate (ORR) Per mRECIST,2022-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Percentage of participants who obtain a pathologic complete response (pCR),Overall survival (OS)
14510,NCT03636620,overall survival,2013-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,objective response rate
14511,NCT02682992,Percentage of Participants With Severe (CTCAE v. 4.0 Grade 3-5) Oral Mucositis,2016-06,COMPLETED,INTERVENTIONAL,['NA'],,Breaks in Chemoradiotherapy
14512,NCT00493025,Pathologic Complete Response Rate to the Neoadjuvant Regimen,2005-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Correlation Between EGFR Pathway Component Expression and Activation With Pathologic Complete Response and Survival
14513,NCT03264274,Overall survival,2017-02-06,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Progression-free survival
14514,NCT03228407,Correlation between the time from intravenous injection of fluorescein to visualization of fluorescein on probe based confocal endomicroscopy (pCLE) with esophageal permeability (i.e. - epithelial barrier function).,2017-04-28,UNKNOWN,INTERVENTIONAL,['NA'],,Correlation between the Ussing's chamber findings (esophageal permeability) and Mucosal impedance findings of patients with symptoms of refractory GERD and controls
14515,NCT02257541,Phase Ib Portion: Response Rate (RR),2014-10-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase Ib Study: Response Rate (RR)
14516,NCT01170299,"Change in IBDQ-B (Inflammatory Bowel Disease Questionnaire - Bowel Subset) score between baseline (i.e., Day 1 of radiotherapy treatment) and the nadir score during treatment",2009-10,COMPLETED,INTERVENTIONAL,['NA'],,Costs for symptom management
14517,NCT02894801,death due to recurrence,2013-01,COMPLETED,OBSERVATIONAL,['NA'],,
14518,NCT03214991,Overall survival rate,2017-05-12,UNKNOWN,OBSERVATIONAL,['NA'],,"Overall survival rate (K-ras mutation type, EUS-FNA)"
14519,NCT04973475,False negative rate,2021-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,The variation of C-reactive protein
14520,NCT01575717,Change in serum levels of 25-hydroxyvitamin D,2012-01,UNKNOWN,INTERVENTIONAL,['NA'],,Change in Model for End stage Liver Disease score (MELD)
14521,NCT04122937,P2X7R-inflammasome activity,2017-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
14522,NCT01227707,Percentage of Participants With Pathological Complete Response (pCR),2005-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,TTP - Time to Event
14523,NCT01232374,3-yr overall survival,2010-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life
14524,NCT04788368,Complications after surgery,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
14525,NCT02055560,Overall survival,2014-01,COMPLETED,OBSERVATIONAL,['NA'],,
14526,NCT04909671,Mean number of adenomas per colonoscopy,2021-09-13,UNKNOWN,INTERVENTIONAL,['NA'],,Subjective endoscopist measures
14527,NCT01974661,Registration of adverse events as a measure of safety and tolerability,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1'],"Local tissue changes in injected/non-injected tumor and surrounding tissue, assessed by MRI",To study overall survival (OS)
14528,NCT03435588,Final diagnosis of benign pancreatic mass,2018-02-14,COMPLETED,INTERVENTIONAL,['NA'],,Rate of procedure-related adverse events
14529,NCT02146508,Complete resolution of advanced esophageal squamous dysplasia,2013-06,SUSPENDED,INTERVENTIONAL,['NA'],,Safety of endoscopic interventions
14530,NCT00687570,Bowel purity degree,2008-07,COMPLETED,INTERVENTIONAL,['NA'],,physiological function
14531,NCT01402908,Disease-Free Survival (DFS),2011-08,TERMINATED,INTERVENTIONAL,['PHASE3'],,Tumor Recurrence Rate (TR Rate)
14532,NCT03737539,ctDNA methylation markers versus CT/MRI,2018-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
14533,NCT00374036,Time until therapeutic failure : to make pass TET from 15 weeks with ECC in first line to 20 weeks with FOLFIRI in first line,2005-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,"The tolerance, the quality of life, duration of hospitalization"
14534,NCT03947762,Progression-free survival (PFS) rate at 24 months,2019-07-03,TERMINATED,OBSERVATIONAL,['NA'],,Patient satisfaction
14535,NCT04393116,Development of patients' Distress,2017-07-11,COMPLETED,OBSERVATIONAL,['NA'],,Patient's global health status
14536,NCT00093548,,na,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14537,NCT03951792,Microbial 16S rDNA Biomarkers,2021-06-30,RECRUITING,OBSERVATIONAL,['NA'],,Protein Measurements
14538,NCT04920149,Change in the occurrence of any colorectal neoplasia in LS patients,2022-03-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,Significant findings & illnesses - adverse events
14539,NCT05792254,1-year progression-free survival rate,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,the Rates of AE and SAE
14540,NCT02909478,Complete response,2017-09-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Complete response in the delay phase (25 hours-120 hours)
14541,NCT02971696,Event free survival,2016-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Sorafenib induced side effects
14542,NCT05273489,Survival,2004-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Neoadjuvant Chemotherapy
14543,NCT02107105,Health state utilities,2014-05-16,RECRUITING,OBSERVATIONAL,['NA'],,
14544,NCT01320267,Successful completion of the right hemicolectomy,2011-12,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Postoperative Measure of Pain
14545,NCT00284817,The recommended Phase II dose will be based on acceptable dose-limiting toxicity,2001-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pharmacokinetic parameters may also be factored into the determination of a Phase II dose and; Tumor response
14546,NCT03659448,Surgical resection histopathology.,2019-06-17,RECRUITING,INTERVENTIONAL,['PHASE3'],,
14547,NCT02726360,study-specific coding structure,2015-12-14,COMPLETED,OBSERVATIONAL,['NA'],,
14548,NCT04471272,Ideal technical success rate,2020-01-06,UNKNOWN,INTERVENTIONAL,['NA'],,Technical time
14549,NCT04444544,Health-related Quality of Life,2020-09-05,RECRUITING,OBSERVATIONAL,['NA'],,Health-related Quality of Life
14550,NCT04637061,Rate of 30 day-anastomotic failure (AF),2021-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Procalcitonin (PCT) measurement
14551,NCT01854749,Progression Free Survival,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14552,NCT00004870,,2000-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14553,NCT05891730,Number of colorectal cancer patients who remain in clinical trial until completion.,2024-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
14554,NCT01591135,3-yr overall survival,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number and grade of Participants with Adverse Events
14555,NCT05300789,Metachronous peritoneal carcinomatosis,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],,Time to metachronous peritoneal carcinomatosis diagnosis
14556,NCT06214572,Median overall survival,2024-01-10,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Quality of life assessment (Liver specific)
14557,NCT02478476,"Occurrence of chemotherapy related toxicities including Anemia, Nephrotoxicity, Neutropenia, Neuropathy, and Thrombocytopenia associated with genotype.",2015-07,UNKNOWN,OBSERVATIONAL,['NA'],,
14558,NCT03049124,Number of Participants with Adverse Events,2017-11-01,WITHDRAWN,INTERVENTIONAL,['NA'],Socio-Demographic and Medical Information Questionnaire,
14559,NCT05638243,Sensitivity and specificity of the model in the diagnosis of colorectal cancer and adenoma,2022-08-20,RECRUITING,OBSERVATIONAL,['NA'],,
14560,NCT04733794,Sexual function,2016-02-19,COMPLETED,INTERVENTIONAL,['NA'],,
14561,NCT01123473,Progression-free survival,2010-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Concordance of diagnostic tests
14562,NCT02906059,"Number of participants dose limiting toxicities with treatment-related adverse events as assessed by common terminology criteria for adverse events (CTCAE), version 4.",2016-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Tumor assessment by imaging techniques using Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1"
14563,NCT05323201,Objective response of fhB7H3.CAR-T cells,2022-02-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival (OS),In vivo persistence of fhB7H3.CAR-T cells
14564,NCT05932719,Measure of patient loss of chance when comparing a set of activity indicators between 2020 and the average activities of previous periods (2017-2019),2022-12-01,RECRUITING,OBSERVATIONAL,['NA'],,
14565,NCT04605185,Dose limiting toxicity(DLT),2021-01-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Duration of response (DOR)
14566,NCT01110785,Percentage of patients free from progression and alive at 11 weeks after the first dose of panitumumab measured by RECIST v 1.1,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Correlation between proteomics and objective response rate
14567,NCT05837767,Overall Response Rate (ORR),2023-07-24,RECRUITING,INTERVENTIONAL,['NA'],,
14568,NCT01961791,Prognostic performance,2000-01,COMPLETED,OBSERVATIONAL,['NA'],,
14569,NCT04843176,Diagnostic accuracy for HCC,2021-03-19,RECRUITING,INTERVENTIONAL,['NA'],,Occurrence of technical failures
14570,NCT01727570,Six-Minute Walk Test (6MWT),2012-09,COMPLETED,INTERVENTIONAL,['NA'],,
14571,NCT06059001,"Number of AEs, SAEs to evaluate the safety and tolerability of OMO-103 plus gemcitabine/nab-paclitaxel",2023-08-31,RECRUITING,INTERVENTIONAL,['PHASE1'],,To evaluate quality of life (QoL) in patients with metastatic pancreatic cancer
14572,NCT06004687,Postoperative delirium,2023-07-26,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Neurotransmitters in the blood,Recovery time
14573,NCT05411094,Dose-limiting toxicities (DLTs) for olaparib in combination with durvalumab and radiation,2023-05-22,SUSPENDED,INTERVENTIONAL,['PHASE1'],Correlation of efficacy endpoints with clinicopathologic variables,Number and diversity of T cells
14574,NCT01447238,"Assess the yield of combination modalities in the diagnosis of pancreatic cysts using EUS/FNA, Fiber optics (direct visualization probe), and prototype needle based confocal laser-induced endomicroscopy miniprobe (nCLE)",2010-09-15,COMPLETED,OBSERVATIONAL,['NA'],,
14575,NCT03623737,pathological complete response,2017-03-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Number of participants with treatment-related adverse events as assessed by the NCI Common Toxicity Criteria (CTC)
14576,NCT02508077,4-month Progression-free Survival (PFS) Rate,2016-02-16,TERMINATED,INTERVENTIONAL,['PHASE2'],,
14577,NCT01847599,evaluation of the efficacy of the implementation of an educational program on adherence to capecitabine alone or in combination to lapatinib,2011-09-06,TERMINATED,INTERVENTIONAL,['NA'],,safety and tolerability as determined by adverse events frequency
14578,NCT05278039,Change in Penetration-Aspiration Scale scores,2021-08-12,RECRUITING,INTERVENTIONAL,['NA'],Change in M.D. Anderson Dysphagia Inventory (MDADI) scores,Change in Modified Barium Swallow Impairment Profile (MBSImP) scores
14579,NCT05602974,marginal recurrence rate,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Quality of life by EORTC QLQ-C30
14580,NCT02101580,Number of Participants with Adverse Events as a Measure of Safety and Tolerability of ADI-PEG 20 in combination with nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer,2014-11-17,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14581,NCT00209664,objective tumor response,2004-01,SUSPENDED,INTERVENTIONAL,['PHASE2'],,"Response duration, time to progression, median survival time, and safety will also be assessed."
14582,NCT00336141,Toxicity,2006-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Response
14583,NCT02757846,quantitative image features extracted from CT images can be used as imaging marker for prognosis,2017-04,UNKNOWN,OBSERVATIONAL,['NA'],,
14584,NCT04692051,PFS,2019-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,AEs
14585,NCT06147414,% of inconclusive results,2024-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Estimated delay for result in standard care diagnosis condition
14586,NCT03416777,DNA damage,2019-06-01,COMPLETED,INTERVENTIONAL,['NA'],,Oxidative stress
14587,NCT02458664,Recurrence free survival and Recurrence free survival after resection of the colon cancer,2013-11,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival
14588,NCT04230642,Evaluation of the feasibility of the Quantum Surgical device: Number of targets reached,2020-05-25,COMPLETED,INTERVENTIONAL,['NA'],,Evaluation of the safety not related to the procedure
14589,NCT00436137,Performance of colonoscopy,2007-06,COMPLETED,INTERVENTIONAL,['NA'],,
14590,NCT02972372,2-year disease-free survival rate,2016-11,UNKNOWN,INTERVENTIONAL,['NA'],,2 year overall survival
14591,NCT04015466,"Development of a new diagnostic algorithm for gastric cancer that includes molecular landscape, patient history, histopathological and environmental factors, personal microbiome and immune landscape",2019-06-12,UNKNOWN,OBSERVATIONAL,['NA'],,Daily routines as assessed by a new study-specific questionnaire
14592,NCT03451370,Progression Free Survival (PFS),2017-11-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
14593,NCT01507168,Progression-free survival (tumor assessments according to RECIST criteria),2012-02-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,GPC-3 expression in tumor tissue (biopsy) by immunohistochemistry (IHC) assay
14594,NCT04217096,Progression free survival,2020-01-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Adverse events
14595,NCT01399190,Progression-free Survival,2011-07,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of Participants With Adverse Events
14596,NCT02077296,Plasma and tissue cytokine levels,2014-03,COMPLETED,OBSERVATIONAL,['NA'],,
14597,NCT00773097,Number of Participants With Anti Muc-1 Antibody,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events Associated With the Study Agent
14598,NCT00058149,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
14599,NCT01533324,DCR,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,safety
14600,NCT01604564,Evaluation of postoperatieve recovery,2012-05,COMPLETED,OBSERVATIONAL,['NA'],,
14601,NCT00965718,Progressive Disease(PD),2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life (QoL) Assessed Using Quality of Life Questionnaire Core 30(QLQ-C30) in Patients With Pancreatic Cancer(QLQ-PAN26 Questionnaire)
14602,NCT06102278,overall survival,2020-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
14603,NCT03856437,Intention to Vaccinate Free of Cost,2021-01-22,COMPLETED,INTERVENTIONAL,['NA'],,Intention to Vaccinate With Cost
14604,NCT00006198,,na,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
14605,NCT00707889,Progression-free survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Objective response rate
14606,NCT00511862,Hepatic Progression-free Survival According to Response Evaluation Criterian in Solid Tumors (RECIST),2007-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
14607,NCT03852836,Global quality of the images evaluated with a Likert score,2019-02-26,TERMINATED,INTERVENTIONAL,['NA'],,"Performance of each sequence in the visualization of the pathology and / or an anatomical variant in the 1.5T magnetic field group, evaluated in percentage"
14608,NCT02586610,Pathological Complete Response (pCR) Rate,2016-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
14609,NCT00019630,,1999-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14610,NCT04754672,Progression free survival,2021-03-02,RECRUITING,INTERVENTIONAL,['NA'],,Physical activity
14611,NCT03053284,Hypoglycemia,2017-04,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],Serum glucose regulators
14612,NCT01937780,Disease-free survival,2013-10-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Overall survival,Pain relief of palliative radiotherapy
14613,NCT00233415,Efficacy of Conventional Chemoradiotherapy Followed by Stereotactic Radiosurgery,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14614,NCT03066167,Translation of scores to the Swedish language,2010-11,COMPLETED,OBSERVATIONAL,['NA'],,
14615,NCT04327700,Progression-Free Survival,2021-01-26,SUSPENDED,INTERVENTIONAL,['PHASE2'],,Change in Alpha-fetoprotein Levels
14616,NCT05563441,perioperative complications,2015-01-20,COMPLETED,OBSERVATIONAL,['NA'],,disease free survival
14617,NCT02859324,Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1),2016-09-20,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Apparent Volume of Distribution (Vz/F)
14618,NCT03814824,Time for Image Interpretation (Median - Scaled),2019-01-23,COMPLETED,INTERVENTIONAL,['NA'],,Subjects With Dysplasia on Biopsies
14619,NCT05994482,colorectal cancer incidence,2023-10-01,RECRUITING,OBSERVATIONAL,['NA'],,perspectives on surveillance in older adults
14620,NCT04131803,objective response rate,2021-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
14621,NCT03265483,"Blood 1,25-dihydroxyvitamin D2",2014-09,COMPLETED,INTERVENTIONAL,['NA'],,
14622,NCT01152164,To prospectively evaluate the quality of life of patients one year after rectal cancer resection,2008-01,UNKNOWN,OBSERVATIONAL,['NA'],,To prospectively evaluate the quality of life of patients two years after rectal cancer resection
14623,NCT00220155,Proportion of patients obtaining disease control in the form of tumour response or stabilisation,2004-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression free survival
14624,NCT00409864,Quality of life,2003-10,COMPLETED,INTERVENTIONAL,['NA'],,Stent patency time will be defined by time to stent occlusion
14625,NCT02222844,Randomised Phase: To measure the difference in treatment stratification policy caused by the difference in staging on CT and MRI.,2014-08,RECRUITING,INTERVENTIONAL,['NA'],,To compare permanent defunctioning stoma rates in patients staged by CT and MRI according to predicted prognostic risk.
14626,NCT03149523,Sequencing of the exome and tumor RNA,2017-05,UNKNOWN,OBSERVATIONAL,['NA'],,Transcriptomic profile of urinary RNAs
14627,NCT05684211,Progression-free survival (PFS),2023-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,incidence of adverse events
14628,NCT02582541,Stent patency rate,2014-02,UNKNOWN,INTERVENTIONAL,['NA'],,Change from Baseline in Bile Duct Stricture Diameter
14629,NCT00960349,"Safety of each treatment arm will be measured in terms of adverse events, vital signs, clinical chemistry, haematology, urinalysis, electrocardiogram, and physical examinations.",2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Pharmacokinetics will be assessed in terms of Css,max, Css,min, tmax, AUCss and AUC0-8 for cediranib, and Cmax, tmax, AUC, AUC(0-t), CL or CL/F, t½λz for capecitabine, cisplatin and TS-1. Additional PK parameters may be determined."
14630,NCT04799080,Semmens Weinstein Monofilament Test (SWMT),2021-03-06,COMPLETED,OBSERVATIONAL,['NA'],,Functional Assessment of Cancer Therapy-Breast (FACT-B+)
14631,NCT01985698,postoperative complications,2013-12,COMPLETED,INTERVENTIONAL,['NA'],self reported sexual function for female patients,locoregional recurrence rate
14632,NCT05760404,Evaluate the motor effects of drugs that act on the various components of this system,2022-12-19,RECRUITING,OBSERVATIONAL,['NA'],,
14633,NCT06317103,Clinical Specificity in classifying early gastric cancer (EGC) based on the depth of invasion (%),2023-08-22,COMPLETED,OBSERVATIONAL,['NA'],,"Accuracy in classifying the depth of invasion categories (""Mucosa"" or ""Submucosa"") for early gastric cancer (%)"
14634,NCT00847119,Pathologic complete response rate. % patients with pathologic complete response (absence of tumoral cells in the resected piece),2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,To determine the angiogenic profile changes in tumour.
14635,NCT00180960,To study overall survival,2003-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,To study mortality-morbidity
14636,NCT05928312,Objective response rate (ORR),2023-08-28,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Assess the anti-tumor activity:DCR
14637,NCT04294498,The rate of HBV reactivation during durvalumab treatment,2020-11-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,To assess the adverse events during durvalumab treatment.
14638,NCT02848079,Overall Response Rate,2016-10-31,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
14639,NCT02908048,Diagnosis of liver cancer based on tumor markers and imaging studies.,2014-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
14640,NCT01923337,"MTD, defined as the highest dose tested in which fewer than 33% of patients experience dose-limiting toxicity (DLT) attributable to the study drugs, graded using the National Cancer Institute (NCI) CTCAE version 4.0",2013-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to failure
14641,NCT05160727,Objective response rate,2021-10-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
14642,NCT02748811,Number of patients completing planned treatment without dose reductions,2015-05,COMPLETED,INTERVENTIONAL,['NA'],,Quality of Life prior
14643,NCT00002527,Disease free survival,1993-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,
14644,NCT05062720,Progression free survival,2021-07-29,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Patient reported outcomes (PROs)
14645,NCT02738294,Specificity in distinguishing HGN from non-HGN,2013-06,COMPLETED,INTERVENTIONAL,['NA'],,Negative predictive value (NPV) in distinguishing HGN from non-HGN
14646,NCT06122896,"Number of Imaging-Negative, Assay-Positive Pancreatic Cancers or High-Grade Neoplasms",2023-11-21,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Clinical Predictors of Neoplastic Development
14647,NCT03130790,Overall Survival (OS) - Phase 3 part,2017-08-31,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Gastric Cancer 22 items (EORTC QLQ STO22) measuring patients general cancer symptoms and functioning - Phase 3 part
14648,NCT05468827,proportion of pN+ patients in which affected lymph nodes are detected only within margins of ICG distribution,2022-07-26,RECRUITING,INTERVENTIONAL,['NA'],,feasibility of ICG mapping for colon flexure tumours
14649,NCT02713373,"Number of Participants With a Response, Evaluated According to RECIST 1.1",2016-08-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression Free Survival (PFS)
14650,NCT01494324,Tumor response,2009-10-27,RECRUITING,INTERVENTIONAL,['NA'],,Duration of treatment response
14651,NCT03797209,Removal success,2019-01-15,COMPLETED,OBSERVATIONAL,['NA'],,
14652,NCT02991677,Sensory pain,2018-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Nerve fiber density
14653,NCT04814030,overall response rate,2021-04-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
14654,NCT02670122,Safety and Tolerability,2015-03,COMPLETED,OBSERVATIONAL,['NA'],,OS
14655,NCT00637247,To Evaluate and Compare the Tolerability and Toxicity of the Two Treatment Arms by Comparing Adverse Events,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
14656,NCT03377972,Comparison WHO diagnosis standard with JAPAN in Early Esophageal Cancer patients by accessing pathological section.,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
14657,NCT03833466,Tumor microenvironment,2019-02-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Rate of pathologic complete response（pCR）
14658,NCT02794337,In-field Progression Free Survival,2014-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Toxicity Assessment
14659,NCT02439008,"Analyse of immunological parameters, decription of secreted markers and nanovesicles production",2015-09-16,TERMINATED,INTERVENTIONAL,['NA'],,Number of Participants with Adverse Events related to radiotherapy
14660,NCT05357508,Self-reported appropriate screening uptake,2022-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Linkage to Vaud tumor registry
14661,NCT03950154,Progression-free survival,2019-06-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,
14662,NCT00630552,Safety,2007-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to Response
14663,NCT04449679,Post-intervention evaluation,2020-04-15,COMPLETED,INTERVENTIONAL,['NA'],,
14664,NCT03190265,Objective Response Rate (ORR) Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1),2017-12-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants Experiencing Grade 3 or Above Study Drug-related Adverse Events (AEs)
14665,NCT00540332,"Pharmacokinetic profile to include Systemic clearance, volume of distribution at steady state, estimated initial concentration, area under the conc-time curve, terminal half-life and mean residual time",2007-10,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence (%) and duration (days) of severe Oral Mucositis WHO grade 3 or 4
14666,NCT01656265,"Number of participants with dose-limiting toxicity (DLT), as a measure of safety and tolerability",2012-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Antitumor effects according to RECIST 1.1.
14667,NCT06158516,2-year disease-free survival (2y-DFS),2023-11-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,2-year Overall survival
14668,NCT02949596,Evaluate quality of sexual life validated questionnaire (IIEF) among patients treated for anal cancer with concurrent chemoradiotherapy who are men who have sex with other men,2015-10,COMPLETED,OBSERVATIONAL,['NA'],,Evaluate quality of life among patients who are HIV positive in this cohort with the use of questionnaire HAT-QoL
14669,NCT00079274,Disease-free Survival (Arms A and D: Wild-type KRAS Patients),2004-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (v3) (Arms A and D: Mutant KRAS Patients)"
14670,NCT05809999,Proportion of persons with ≥ 1 neoplastic lesion detected,2022-09-23,RECRUITING,INTERVENTIONAL,['NA'],,CRC incidence over five years following study colonoscopy (obtained through patient linkage to provincial cancer registries five years following trial completion)
14671,NCT02060188,Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator,2014-03-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,ORR by RECIST v1.1 by Independent Radiology Review Committee (IRRC)
14672,NCT03701373,maintenance progression-free survival (PFS),2016-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,toxicity relevant to S-1 maintenance/observation
14673,NCT00004065,,1999-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14674,NCT02820389,3-month cost analysis per patient undergoing either Optical Colonoscopy or CTC as the initial imaging modality (measured in £ per patient),2016-06-14,UNKNOWN,OBSERVATIONAL,['NA'],,Cost per correctly diagnosed medium to large polyps (≥6mm) and colorectal cancer using CTC as the initial investigation (measured in £ per patient)
14675,NCT06256289,liver steatosis index CAP (Controlled Attenuation Parameter) measured by FibroScan,2024-03-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],,Gut Microbiota diversity sequencing by 16s rRNA Amplicon Sequencing Analysis
14676,NCT00811590,The Size of Intestinal Polyps,2008-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,
14677,NCT00600496,Safety and tolerability of twice daily oral doses of AZD6244 when administered in combination with standard doses of selected chemotherapies.,2007-12-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Tumor response.
14678,NCT00026468,,1999-07,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
14679,NCT05674422,ctDNA from liquid biopsy,2023-05-26,RECRUITING,OBSERVATIONAL,['NA'],,TNT compliance
14680,NCT01661686,Number of Participants With Recurrent Dysphagia.,2012-07,COMPLETED,INTERVENTIONAL,['NA'],,Median Survival After SEMS Placement
14681,NCT00174564,To evaluate response rate according to RECIST criteria,2003-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,To investigate safety using NCI-CTC criteria version 2
14682,NCT03338166,serum LDH level as a predictor of response in hepatocellular carcinoma,2018-01-02,UNKNOWN,OBSERVATIONAL,['NA'],,
14683,NCT02416466,Safety of CAR-T cell hepatic artery infusions in combination with Sir-Spheres as Measured by Number of Participants with Adverse Events,2015-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,"CAR-T detection in liver tumors, normal liver, and extrahepatic sites"
14684,NCT01380392,,2011-02,UNKNOWN,OBSERVATIONAL,['NA'],,
14685,NCT00509444,"The primary outcome variable will be difference between the two intervention groups in the time to initiation of therapy, beginning on the date of randomization.",2006-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,"The proportion receiving recommended screenings for breast, cervix, colon/rectum and prostate cancer."
14686,NCT00796718,Percentage of Participants With Pathological Complete Response,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Adverse Events
14687,NCT00408551,Hepatic toxicity,2005-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Therapeutic efficacy based on the proportion of patients who achieve down-staging among all chemo-SIRT treated patients
14688,NCT00025350,,2001-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14689,NCT04898842,"Symptoms of sub-acute bowel obstruction: abdominal pain, feeling bloated, feeling full-up quickly, nausea and / or vomiting",2021-03-02,UNKNOWN,INTERVENTIONAL,['NA'],,Weight
14690,NCT00027729,,2001-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14691,NCT01045538,"Phase 1 - maximum tolerated dose, Phase 2 - response rate",2010-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
14692,NCT00192075,Tumor Response by Response Evaluation Criteria In Solid Tumors (RECIST),2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Duration of Response - A+FOLFOX4 - Avastin Subgroup,Duration of Response
14693,NCT04426955,PFS assessed by IRC,2020-06-30,UNKNOWN,INTERVENTIONAL,['PHASE3'],,AE
14694,NCT01468623,Overall response rate (ORR),2011-09,TERMINATED,INTERVENTIONAL,['PHASE4'],,Progression-free survival (PFS)
14695,NCT00034281,Optimal Dosing for Phase II Studies.,2002-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Response Evaluation Criteria in Solid Tumors Documentation of Objective Tumor Response.
14696,NCT05773105,Desease control rate (DCR),2023-02-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Adverse Events (AEs)
14697,NCT00687349,"Patient and family ratings on the ""End-of-Life domain"" of the Quality of Communication Questionaire (QOC)",2007-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Patient-, family-, and nurse-assessed ratings of the quality of end-of-life care provided by study clinicians using Quality of End-of-Life Care questionaire"
14698,NCT05417932,Tumor response of SCG101 (Phase 2),2022-10-26,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Persistence of viral vector copy number (VCN) after SCG101 infusion
14699,NCT02487017,Overall survival,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Phenotypic analysis of T cells
14700,NCT05652920,Maximum tolerated dose of Ori-C101,2022-12-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Objective Response Rate
14701,NCT01944540,En Bloc resection rate,2013-08,UNKNOWN,INTERVENTIONAL,['NA'],,complication rate
14702,NCT04338542,Change of RAS mutant clones in the metastatic lesion,2020-04-08,COMPLETED,OBSERVATIONAL,['NA'],,Molecular patterns other than RAS
14703,NCT03843398,"3-year overall survival, 3y OS",2019-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Postoperative mortality at 30 days
14704,NCT02514031,Maximum Tolerated Dose,2016-03-24,TERMINATED,INTERVENTIONAL,['PHASE1'],,Tolerability
14705,NCT01219192,MDT,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],,PFS
14706,NCT05660915,Rate of mortality after surgery,2023-06-01,RECRUITING,INTERVENTIONAL,['NA'],,Incidence of postoperative complications
14707,NCT01549522,,2012-03,UNKNOWN,OBSERVATIONAL,['NA'],,
14708,NCT03519295,Progression free survival rate (PFS),2018-07-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Tolerance graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE] criteria v4.03
14709,NCT04870034,Incidence of adverse events,2024-01-15,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,Immune subsets within the pre and posttreatment tumor tissue
14710,NCT02853422,"Survey on the clinical utility of the QLQ-GINET21, which the investigator is to complete for each patient enrolled",2016-04,COMPLETED,OBSERVATIONAL,['NA'],,Clinical assessment of patient's health status by the investigator
14711,NCT06168825,Acceptability of the MOM intervention,2024-01-17,RECRUITING,OBSERVATIONAL,['NA'],,Number of participants who reported MOM intervention as linguistically appropriate
14712,NCT01296763,Number of Participants Who Experienced a Dose Limiting Toxicity to Determine the Maximum Tolerated Dose (MTD),2011-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Number of Years From Cycle 1, Day 1 On-Study to Date of Death"
14713,NCT03081637,Rate of expression of Filamin A (FLNA) in HCC specimens from patients resected for HCC.,2004-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
14714,NCT00075556,Objective tumor response rate,2002-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Comparison of the conversion rate from the effects of mutilating surgery vs surgery with sphincter preservation
14715,NCT00031681,Side effect profile of 7-hydroxystaurosporine in combination with irinotecan hydrochloride in triple negative recurrent breast cancer (Part II),2001-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,In vivo mechanistic basis for 7-hydroxystaurosporine activity
14716,NCT04627012,Overall survival (OS),2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Adverse events
14717,NCT02186236,To validate the Trovagene urine assay,2014-07,COMPLETED,OBSERVATIONAL,['NA'],,EGFR detection in plasma circulating tumor cells [CTC] and plasma cfDNA)
14718,NCT05130060,Incidence of adverse events (AE),2022-01-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression free survival (PFS)
14719,NCT02727062,The number of subjects who comply with the compulsory four-time daily pain entries.,2018-02-13,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
14720,NCT02477553,Colorectal Cancer (CRC) Screening Intention: Change From Baseline to Post-intervention,2015-06,COMPLETED,INTERVENTIONAL,['NA'],,Number of Patients With High and Low Subjective Numeracy
14721,NCT06314516,Longitudinal variation in body composition,2017-12-27,COMPLETED,OBSERVATIONAL,['NA'],,Patient and disease-specific factors
14722,NCT03002727,Differential expression of CD133 based on microsatellite status and correlation with clinicopathological features.,2016-12,UNKNOWN,OBSERVATIONAL,['NA'],,"If radiotherapy increases the count of CD +ve 133 cells , does that increase significantly affects the progression free survival"
14723,NCT04349384,Morbidity,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Readmission
14724,NCT01088789,Disease free overall survival.,2010-04-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
14725,NCT02379520,Number of patients with dose limiting toxicity (DLT),2015-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall response rate
14726,NCT04483349,"Importance patients place on each of the attributes of value (i.e., outcomes, quality of life [QOL], cost, experience)",2020-06-11,COMPLETED,OBSERVATIONAL,['NA'],,"Importance care providers (i.e., physicians, nurses, administrators) place on each of the attributes of value (i.e., outcomes, quality of life [QOL], cost, experience)"
14727,NCT05083338,Chronic postsurgical pain,2021-08-10,COMPLETED,OBSERVATIONAL,['NA'],,
14728,NCT05368636,Accuracy,2022-06-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
14729,NCT03449966,The percentage of remnant cancer cells in biopsy samples,2018-02-20,UNKNOWN,INTERVENTIONAL,['NA'],,pCLE findings of residual cancer cells after chemotherapy
14730,NCT03365882,Progression-free Survival(PFS),2017-11-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs.
14731,NCT00769535,Clinical relevance,2006-01,COMPLETED,INTERVENTIONAL,['NA'],,Clinical relevance
14732,NCT04067778,Adverse Events occurrence,2020-11-06,COMPLETED,INTERVENTIONAL,['NA'],,Rate of Missed 2-Week Post-Procedural Assessment for Complications
14733,NCT00134095,Safety,2004-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
14734,NCT02322736,To describe the pattern of use of Vectibix® in combination with chemotherapy in 1st line or in 2nd line mCRC treatments as per approved Vectibix® indication.,2014-11-21,COMPLETED,OBSERVATIONAL,['NA'],"Frequency of primary tumor resection, of metastatic lesion resection, of BRAF testing in the entire number of the study participants and frequency of BRAF mutation in the unselected Greek patient population with WT RAS mCRC included in the study.","To investigate the rate of objective response (ORR, defined as either a Complete Response or a Partial Response) and the rate of stable disease as best response in 1st line or in 2nd line chemotherapy regimens of mCRC including Vectibix®."
14735,NCT05013944,Measuring and/or Improving Quality of Care,2021-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
14736,NCT02451124,Average Methylation of Zinc Finger Protein 793 Assay,2015-07,COMPLETED,INTERVENTIONAL,['NA'],,
14737,NCT04359199,"Swallowing function 12-24 months after concurrent radiation and systemic therapy for HNC, as measured by the PCR",2020-09-01,RECRUITING,OBSERVATIONAL,['NA'],,Correlation between radiation dose and location of swallowing function and quantitative swallowing function
14738,NCT04588246,Time to Neurologic Death,2020-12-15,RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence of Adverse Events associated with the interventions
14739,NCT05462613,overall survival (OS) (phase III),2023-05-09,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
14740,NCT01770431,Incidence of Recurrence and Metastasis After Hepatectomy,2011-08,COMPLETED,INTERVENTIONAL,['PHASE4'],,Postoperative Survival Period
14741,NCT02729506,Time to Progression (TTP) is the primary outcome.,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,"Treatment-related costs, in terms of cost of therapy and number of hospitalization days."
14742,NCT03588442,Liver-related disease progression,2018-07-15,UNKNOWN,OBSERVATIONAL,['NA'],,Non-hepatocellular carcinoma malignant neoplasm
14743,NCT03007446,reaction rate,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,adverse events
14744,NCT00885248,Staging of pancreatic cancer,2009-01,UNKNOWN,OBSERVATIONAL,['NA'],,Diagnosis of pancreatic cancer
14745,NCT02365896,postoperative early anastomotic morbidity,2015-06,UNKNOWN,INTERVENTIONAL,['NA'],,Nutrition
14746,NCT00342641,,2005-06-08,COMPLETED,OBSERVATIONAL,['NA'],,
14747,NCT00099346,,2005-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,
14748,NCT06167967,Recurrence-free survival at 3 years,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,The proportion of patients in the low-risk cohort who did not receive adjuvant chemotherapy
14749,NCT04839471,ORR (RECIST 1.1),2021-08-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,To explore the treatment-related adverse events as assessed by CTCAE v5.0
14750,NCT03825289,Rate of dose-limiting toxicities during the DLT assessment window.,2019-01-18,RECRUITING,INTERVENTIONAL,['PHASE1'],,Response Rate
14751,NCT05894369,Tumor diameter,2023-05-04,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
14752,NCT00756782,radiologically proven progression-free survival (PFS),2008-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,The relationship between tumor gene expression (mRNA expression) of co-activators and co-repressors and efficacy parameters
14753,NCT04803851,Disease control rate (DCR) based on RECIST v. 1 1,2021-05-12,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
14754,NCT05571293,Number of complications leading to delays of 12 weeks or more in surgery after initiation of treatment,2023-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Changes in Minimal Residual Disease assessed using ctDNA pre- and post-surgical resection
14755,NCT01969110,"plasma resolvin E1, cell-mediated immunity",2013-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,infectious complication rate
14756,NCT02850536,Safety of CAR-T cell hepatic artery infusions delivered using the Surefire Infusion System (SIS) as Measured by Number of Participants with Adverse Events,2017-02-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Safety of Direct Intrapancreatic CAR-T Retrograde Venous Infusions (RVI) Delivered Using the Surefire Infusion System (SIS)
14757,NCT05433701,"Local progression-free survival rate, per-protocol (PP)",2022-08-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,"Local progression-free survival rate according to the tumor location, ITT"
14758,NCT05970133,The surgical efficiency of both NOSE procedures,2023-04-07,RECRUITING,INTERVENTIONAL,['NA'],,CD4+ to CD8+ ratio
14759,NCT03899870,Recurrence,2000-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
14760,NCT04066816,Urolithin Phenotype and Colonic Health,2019-05-20,COMPLETED,INTERVENTIONAL,['NA'],,Identify Changes in Microbiota and Microbes Responsible for Urolithin Formation Followed by Walnuts Consumption using Metagenomics Sequencing
14761,NCT01392274,Comparative histopathology-confirmed measures of Cellvizio endomicroscopy and ERCP accuracy in the differential diagnosis of suspicious l,2012-04,COMPLETED,OBSERVATIONAL,['NA'],,Comparative histopathology-confirmed measures of Cellvizio endomicroscopy and ERCP accuracy in the differential diagnosis of suspicious l
14762,NCT04629677,Bleeding risk (Cohort A and B),2019-04-02,RECRUITING,OBSERVATIONAL,['NA'],,
14763,NCT00002608,,1994-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14764,NCT02821754,6 Month Progression Free Survival (PFS),2016-07-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0),Number of Grades 1-5 Adverse Events Related to Tremelimumab and Durvalumab
14765,NCT05526443,Proportion of patients with locally advanced inoperable and/or metastatic PDAC undergoing palliative second line therapy after progression on first line chemotherapy,2023-01-13,RECRUITING,OBSERVATIONAL,['NA'],,To analyze the mutational landscape of advanced pancreatic cancer and its impact on treatment decision making and clinical outcome
14766,NCT02346032,Response rate,2015-06-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
14767,NCT03084380,Safety: Measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0,2017-06-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Persistence: Duration of CAR-positive T cells in circulation
14768,NCT03179657,Nonalcoholic fatty liver disease (NAFLD),2008-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Cognitive function
14769,NCT06217224,Evaluate the best photobiomodulation protocol for preventing oral mucositis,2022-10-17,RECRUITING,INTERVENTIONAL,['NA'],,Hospital internment
14770,NCT02894944,Number of participants with treatment-related adverse events assessed by CTCAE v4.03,2016-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Detection of adenoviral DNA in blood by PCR
14771,NCT02591407,Post-operative pain control day 3 using the numeric pain scale,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],Patient use of supplemental narcotic analgesia post-operative day 3,Overall benefits of analgesia treatment post-operative day 3
14772,NCT04680260,Recurrence Free Rate,2021-10-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Cost-effectiveness analysis
14773,NCT01270984,To evaluate the pharmacokinetics of Luckyvec 400mg tablet and Glivec 100mg tablet in healthy subjects,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To evaluate the safety of Luckyvec 400mg tablet and Glivec 100mg tablet from vital signs, physical exam, ECG, laboratory test, adverse event and so on."
14774,NCT04392167,Percentage of Correctly Identified Negative (Non-Dysplastic) Biopsies,2020-11-24,COMPLETED,INTERVENTIONAL,['NA'],,Percentage of Participants With Adequate Tissue Contact to Acquire a High Quality Image
14775,NCT03765411,In-hospital Complications,2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Costs and Charges
14776,NCT05657080,Sensitivity of Cytosponge for GIM,2023-01-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Number of participants with device-related adverse events as assessed by CTCAE v4.0
14777,NCT00892736,"MTD, DLT, recommended phase II dose of chronically dosed single-agent veliparib in patients with either a refractory BRCA 1/2- mutated solid cancer; platinum- refractory ovarian, fallopian tube, or primary peritoneal cancer; or basal-like breast cancer",2009-04-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,Changes in BRCA 1/2 expression in tumor blocks
14778,NCT04764084,Dose limiting toxicity (DLT) and maximum tolerated dose (MTD),2021-04-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Progression-free survival (PFS)
14779,NCT05130021,progress free survival(PFS)[Part 2],2022-01-31,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety and tolerability assessed by incidence and severity of adverse events
14780,NCT01273402,Determine the number of adverse events,2011-02,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Efficacy will be evaluating using CT scans and possibly PET imaging.
14781,NCT00465725,Comparison of platinum levels excreted in urine from 0-8 and 8-24 hours after start of IV or oral drug,2007-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14782,NCT02510066,"Pain scores, assessed with numeric rating scale (NRS)",2015-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Blood levels of nerve growth factor
14783,NCT04006951,Proportion of patients who gave their consent to participate in the study,2014-10-08,RECRUITING,INTERVENTIONAL,['NA'],,
14784,NCT05551832,Marginal ulcer incidence,2022-10-10,RECRUITING,INTERVENTIONAL,['PHASE3'],,QOL
14785,NCT01198821,Establish the safety and tolerability of oral sodium bicarbonate in patients with advanced pancreatic carcinoma treated with gemcitabine,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Determine if oral bicarbonate improves overall survival, progression free-survival and response rate in patients with advanced pancreatic cancer"
14786,NCT04648917,overall survival (OS),2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,progression-free survival (PFS)
14787,NCT01791309,objective response rate (ORR),2013-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,efficacy
14788,NCT03222089,Progression-free survival (PFS) rate at 10 months,2017-07-20,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Quality of life (QLQ C30)
14789,NCT04494022,Compared diagnostic performance of Gd-EOB-MRI alone and Gd-EOB-MRI with CEUS.,2020-06-08,UNKNOWN,INTERVENTIONAL,['NA'],,Comparing image characters between two types of ultrasound contrast media
14790,NCT06145230,Pathological characteristics,2023-12-12,RECRUITING,OBSERVATIONAL,['NA'],,Risk factors
14791,NCT01463501,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall Survival
14792,NCT01010126,Tumor Response Rate,2009-09-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Treatment Failure
14793,NCT02562924,Change in Lund-Kennedy Endoscopic Scores,2015-11,COMPLETED,INTERVENTIONAL,['NA'],,Change in SNOT-22 Nasal Symptom Scores
14794,NCT05684432,Frequency and classification of radiation-induced diarrhrea in patients with prostate and rectal cancer during curative external radiotherapy,2022-06-01,RECRUITING,OBSERVATIONAL,['NA'],,
14795,NCT01011478,"Occurrence of ≥ 1 Adenomatous Polyp of the Colon or Rectum, Metachronous Colorectal Carcinoma, or Colon Cancer Recurrence (APMC+R)",2010-03,TERMINATED,INTERVENTIONAL,['PHASE3'],,Measurements of Relevant Tumor and Blood Markers
14796,NCT03480256,Maximum Tolerated Dose (MTD),2018-07-27,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Area Under the Curve
14797,NCT00569335,Safety,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Progression-free survival, Response rate, Overall survival, Time to treatment failure, Treatment situation"
14798,NCT00191984,Best Overall Tumor Response,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
14799,NCT03224221,One-year survival rate,2017-03-23,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life using EORTC QLQ C30 - scale
14800,NCT04985084,Acceptability outcome: participants' satisfaction and perspectives of the intervention,2021-07-12,UNKNOWN,INTERVENTIONAL,['NA'],,Dietary behavior self-efficacy
14801,NCT02754115,Changes in arterial blood gas in perioperative period,2016-04,RECRUITING,OBSERVATIONAL,['NA'],,Mortality
14802,NCT05653180,Objective response rate (ORR),2023-03-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Overall Survival,OS"
14803,NCT06106568,Descriptive summary of healthcare costs in EOB-MRI and non-EOB-MRI group,2023-11-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Descriptive summary of the likelihood of open-close laparotomy in patients with confirmed diagnosis of pancreatic cancer who is intended the surgical intervention between those in the EOB-MRI group and non-EOB-MRI group
14804,NCT04954794,Objective Response Rate (ORR),2021-07-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
14805,NCT05740137,Adenoma detection rate (ADR),2022-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Polyps per positive patient (PPP)
14806,NCT01694589,Changes in mean Gli-1 levels before and after drug,2012-11,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,Complications from surgery by time of hospital discharge up to 30 days post-operatively
14807,NCT02228668,Overall Survival (OS) up to 8 and 10 years median follow-up of the stage III population randomized in the AVANT study.,2015-03,COMPLETED,OBSERVATIONAL,['NA'],,Cancer Specific Survival (CSS) in patients with stage II and stage III colon cancer.
14808,NCT05116891,To assess the preliminary efficacy of CAN04 in combination with chemotherapy regimens measured as tumour response.,2021-09-22,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",To assess ADA formation against CAN04.,To assess PK of CAN04 after a single dose and at steady state
14809,NCT01920113,A comparison of safety during endoscopic submucosal dissection between dexmedetomidine-remifentanil and propofol-remifentanil,2012-10,COMPLETED,INTERVENTIONAL,['NA'],"A comparison of gastric motility, easiness for procedure, operator's satisfaction during endoscopic submucosal dissection between dexmedetomidine-remifentanil and propofol-remifentanil",A comparison of efficacy during endoscopic submucosal dissection between dexmedetomidine-remifentanil and propofol-remifentanil
14810,NCT00574327,"The goal of this study is to follow GERD and BE pts prospectively for development of dysplasia and adenocarcinoma, to identify factors responsible for progression of GERD to BE to dysplasia and adenocarcinoma.",2006-01,RECRUITING,OBSERVATIONAL,['NA'],,The secondary goal is to create a tissue and serum repository for future biomarker studies.
14811,NCT06027775,relapse-free survival,2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],,overall survival
14812,NCT02774161,Spectral slope,2016-05,COMPLETED,INTERVENTIONAL,['NA'],,
14813,NCT05787197,Disease-free survival (DFS) in patients who undergo curative-intent resection of colorectal liver metastasis (CRLM),2024-01-09,RECRUITING,OBSERVATIONAL,['NA'],,Association between ctDNA and clinical features.
14814,NCT01573468,Overall survival,2012-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
14815,NCT00671645,"feasibility and tolerance of preoperative therapy with Bevacizumab in combination with Capecitabine and radiotherapy for patients with locally advanced, locally operable rectal carcinoma",2008-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,"collection of response rate (T- and M-downstaging, pathological complete remission)"
14816,NCT00414232,Quality of Life (QoL),2006-11,COMPLETED,OBSERVATIONAL,['NA'],,
14817,NCT04712032,90-days Anastomotic Leakage (AL) rate,2020-07-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,days in hospital stay
14818,NCT02399631,Actual hospital stay,2012-01,TERMINATED,INTERVENTIONAL,['NA'],,Nutritional status
14819,NCT02406547,Number of polyps detected with both techniques (NBI versus WLE),2015-03,COMPLETED,INTERVENTIONAL,['NA'],,Number of accurate detection of adenomas with morphologic features with both groups (NBI and WLE) compared to histopathology
14820,NCT00998751,Objective response rate according to Response Evaluation Criteria In Solid Tumors (RECIST),2005-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
14821,NCT04859595,Maintenance of functional capacities,2021-07-29,COMPLETED,INTERVENTIONAL,['NA'],,
14822,NCT00739167,Quality of life differences between treatment groups,2008-04,COMPLETED,OBSERVATIONAL,['NA'],,
14823,NCT05717738,Number of Patients Amendable to Curative Surgical Interventions,2022-01-20,RECRUITING,OBSERVATIONAL,['NA'],,Quality of Life (QoL) after treatment
14824,NCT03357276,Relief degree of tumors,2017-11-30,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival（OS）
14825,NCT00339469,Biomarkers of insulin resistance and inflammation,2005-08-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Weight loss
14826,NCT03415802,Objective response rate（ORR）,2015-05-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety profile: Adverse events of nab-Paclitaxel plus S-1 for advanced pancreatic cancer
14827,NCT01215539,Objective Response,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Economic evaluation
14828,NCT00919659,nutritional status presented by phase angle,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,"quantity of port infections, quantity of oedema, quantity of diarrhea"
14829,NCT04945733,Objective Response Rate (ORR),2021-08-30,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants with Anti-Amivantamab Antibodies
14830,NCT04993261,Sensitivity and specificity of dual energy computed tomography in detecting primary gastrointestinal carcinoid tumors,2015-09-23,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
14831,NCT03996031,Patient activation,2019-08-19,COMPLETED,OBSERVATIONAL,['NA'],,Patient satisfaction
14832,NCT04773080,Incidence of postoperative acute kidney injury,2021-01-21,COMPLETED,OBSERVATIONAL,['NA'],,Increase in length of hospital stay
14833,NCT04653480,Overall Response Rate,2021-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
14834,NCT03452553,Efficacy: Time to progression (TTP),2018-07-01,WITHDRAWN,INTERVENTIONAL,['NA'],,Physician rating of the handling and visibility of LC Bead LUMI™.
14835,NCT00562068,"Incidence of infection (number of days with fever ≥ 38 degrees C, days of intravenous antibiotics, number of inpatient days, number of episodes of cytomegalovirus reactivation)",2007-05,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Epstein-Barr virus copy number (measured retrospectively)
14836,NCT05601323,Overall Survival,2023-01-31,RECRUITING,INTERVENTIONAL,['NA'],,Adverse Events
14837,NCT01646112,,2012-04-25,COMPLETED,OBSERVATIONAL,['NA'],,
14838,NCT02865135,Changes in CD8+ T Cells in Peripheral Blood and Tumor Tissue,2017-03-30,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to Progression (TTP)
14839,NCT06115733,PFS,2023-12-28,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,DCR
14840,NCT00028002,Rate of Disease Progression at 2 Years,2002-03-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,"FDG-PET as Biological Marker of Metabolic Response(MR) During Imatinib Mesylate (IM) Treatment, in Patients With GIST Who Are naı¨ve to Tyrosine Kinase Inhibitor Therapy"
14841,NCT02289300,Change from baseline in liver stiffness measurement (kPa) assessed by Fibroscan® at Final visit,2020-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,"Changes from baseline to post-treatment visits in vital signs, laboratory examination, and physical examinations results"
14842,NCT03788655,Technical feasibility of intrahepatic stenting,2018-12-31,UNKNOWN,OBSERVATIONAL,['NA'],,Survival rate
14843,NCT03615326,Overall Survival (OS),2018-10-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Treatment Discontinuations Due to AEs
14844,NCT04143230,Accuracy of the Simplified Screening Tool (SST) with respect to the SIAARTI/NCCN screening tool (EST),2017-05-23,COMPLETED,INTERVENTIONAL,['NA'],,Clinical characteristics and outcomes of palliative care patients referred to an acute palliative care unit
14845,NCT04763408,Number of Participants with one or More TEAEs Leading to Dose Modifications and Treatment Discontinuations of Lenvatinib,2021-04-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Number of Participants with one or More TEAEs Leading to Dose Modifications and Treatment Discontinuations of Sorafenib
14846,NCT03454035,Overall Survival,2018-01-30,RECRUITING,INTERVENTIONAL,['PHASE1'],,Cancer Antigen 19-9 (CA19-9) response
14847,NCT05322590,Objective Response Rate (ORR),2023-01-09,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Post Oxaliplatin Assessment
14848,NCT03434379,PFS-IRF Per RECIST v1.1 in the China Population,2018-03-15,COMPLETED,INTERVENTIONAL,['PHASE3'],,Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab in the China Population
14849,NCT03803891,Technical Success,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,Histologically confirmed full-thickness resection
14850,NCT00902343,To determine if nomogram-based allocation of ANH is superior to allocation using extent of resection alone (planned resection of 3 or more liver segments) in patients undergoing partial hepatectomy.,2009-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,To assess the impact of nomogram-based allocation of ANH compared to standard allocation on the need for fresh frozen plasma (FFP) transfusions.
14851,NCT03300843,Percentage of Patients Who Had a Clinical Response (Complete Response (CR) + Partial Response (PR)) to Treatment,2018-04-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Serious and Non-serious Adverse Events
14852,NCT01099826,completing CRC screening test,2004-10,COMPLETED,INTERVENTIONAL,['NA'],,
14853,NCT01784081,Feasibility of the patients with metastatic pancreas cancer to meet with the palliative care team and to complete symptom assessments.,2014-04,WITHDRAWN,OBSERVATIONAL,['NA'],,"Changes in hospice referral, use, acceptance, and length of stay, compared to similar patients in the prior 12 months (from retrospective review)"
14854,NCT01639703,Permeability Surface (PS) According to Degree of Lesions Differentiation,2012-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,Permeability Surface According to Immunohistochemistry Parameter (CD31)
14855,NCT03767660,Total venous malformation lesion load,2018-07-31,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Concentration of D-dimer in blood
14856,NCT01294072,Concentration of curcumin in normal and cancerous tissue,2011-01,RECRUITING,INTERVENTIONAL,['NA'],,measurement of curcumin mixed with plant exosomes on metabolic characteristics of normal colon mucosa and colon tumors
14857,NCT01204476,"Safety profile of cixutumumab and everolimus with octreotide acetate among patients with advanced neuroendocrine tumors, defined by the incidence of adverse events",2010-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Changes in molecular markers,Anti-tumor activity as determined by RECIST
14858,NCT00744640,Response rate,2005-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-free survival and overall survival
14859,NCT01642875,Frequency of delayed gastric emptying,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Rehospitalization rate
14860,NCT04197856,Uptake of genetic counselling among the patient's at-risk relatives,2020-02-06,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],Intervention - Collection of letters (only intervention group),
14861,NCT04635423,Percentage of participants with ≥1 serious adverse events (SAEs),2020-11-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Geometric mean titers (GMTs) to HPV 6/11/16/18/31/33/45/52/58
14862,NCT06129422,Safety and tolerability of a single infusion of NMK89: Frequency and severity of abnormal ECOG PS (Eastern Cooperative Oncology Group Performance Status),2023-10-31,RECRUITING,INTERVENTIONAL,['PHASE1'],,Public Safety: Radiation measurement
14863,NCT02138370,Time to disease recurrence,2015-04,UNKNOWN,OBSERVATIONAL,['NA'],,overall survival
14864,NCT02172690,Peritoneal Metastasis or Positive Cytology,2014-06,UNKNOWN,INTERVENTIONAL,['NA'],,Safety
14865,NCT04531930,3yCR,2020-10-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,3yOSR
14866,NCT06130280,Local control rate CRC liver metastasis,2023-11-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,
14867,NCT01281618,activated myofibroblasts,2008-10,COMPLETED,OBSERVATIONAL,['NA'],,
14868,NCT05626985,GAMAD,2022-10-19,RECRUITING,OBSERVATIONAL,['NA'],,circulating tumor DNA methylation
14869,NCT04727541,Major Pathologic Response (MPR) measured in the surgically resected tumor,2021-07-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Adverse Events of Special Interest
14870,NCT06139926,Changes in perioperative HADS scale scores.,2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,
14871,NCT05161585,Secondary resection rate,2021-11-01,RECRUITING,INTERVENTIONAL,['NA'],,ctDNA clearance rate
14872,NCT01339000,Evaluate and Quantify the Impact of Interleukin-7 (CYT107) Therapy on Specific Immune Responses to Vaccines (in Particular to Neo Antigens) in Older Subjects Following Chemotherapy,2011-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events
14873,NCT05957289,Fear of Progression Questionaire-Short Form (FoP-Q-SF),2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Semi-structured interviews
14874,NCT04168788,Correlate pharmacogenetic analysis with veno-occlusive disease.,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,Participant characteristics.
14875,NCT01045941,To determine if it is safe to administer gemcitabine to patients with pancreatic cancer one week after laparoscopic distal pancreatectomy.,na,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,To determine the if the 1-year survival in patients with pancreatic cancer is improved with administration of gemcitabine one week following laparoscopic distal pancreatectomy
14876,NCT04101292,Evaluation of the sensitivity of Bevacizumab-IRDye800 to visualize tumour tissue compared to anti-VEGF antibodies by the means of fluorescence intensity measurements,2021-04,WITHDRAWN,INTERVENTIONAL,['NA'],,Level of accuracy of Full-field optical coherence tomography (FF-OCT) by the means of a qualitative analysis
14877,NCT00846313,Body weight,2003-12,WITHDRAWN,INTERVENTIONAL,['NA'],,Dietary intake
14878,NCT03578874,Resectability,2016-06-20,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
14879,NCT00614393,Percentage of Participants Who Experience an AE of Infusion Site Reaction,2007-12-24,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Response Rate (ORR) of Dalotuzumab in Combination With Cetuximab + Irinotecan Versus ORR of Cetuximab + Irinotecan Alone in Participants With Wild Type of Colorectal Cancer
14880,NCT06168552,Accuracy and sensitivity of the imaging agent,2023-12-15,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14881,NCT05167409,"Objective response rate (ORR, per RECIST v1.1) (%)",2022-07-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and tolerability according to the NCI CTCAE v5.0
14882,NCT02008929,"Disease free survival, DFS",2014-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Overall survival, OS"
14883,NCT00994721,The primary end-point is recurrence-free survival.,2009-02,COMPLETED,OBSERVATIONAL,['NA'],,"The secondary end-points are overall survival; local and distant control rate, and the quality of life."
14884,NCT02843412,compare the positive rate,2016-08,UNKNOWN,OBSERVATIONAL,['NA'],,
14885,NCT00568971,"Response rate, overall survival",2007-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Side effects
14886,NCT03799380,ED visits,2019-11-05,COMPLETED,INTERVENTIONAL,['NA'],,Missed days of radiation +/- chemotherapy/immunotherapy treatment
14887,NCT01693276,Increase overall survival,2012-09,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Rate of local control
14888,NCT02836847,Progression Free Survival,2016-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,percentage of patients with Clinical Benefit Response
14889,NCT04767568,correlation between the biological signature of the test and the stage of the disease in patients whose diagnosis of adenocarcinoma was identified by pathology prior to surgery.,2021-03-30,RECRUITING,INTERVENTIONAL,['NA'],,
14890,NCT02753881,Pharmacokinetics Profile-- Time of Maximum Concentration,2015-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Assessment and Frequency of Toxicities (Laboratory and Clinical Adverse Events) According to NCI Common Toxicity Criteria for AE (CTCAE) 5.0.
14891,NCT05475041,Major complications,2022-06-30,COMPLETED,OBSERVATIONAL,['NA'],,Intraoperative incidents
14892,NCT05723705,Textbook Outcome in Liver Surgery (TOLS),2023-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Intra-operative ICG-margin assessment
14893,NCT01086332,Dose limiting toxicities,2009-05,TERMINATED,INTERVENTIONAL,['PHASE1'],,Surgical resection rate
14894,NCT00019825,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14895,NCT00141466,Efficacy of referral of patients who are MSI positive to a clinical geneticist by surgeons.,2005-09,UNKNOWN,INTERVENTIONAL,['NA'],,Cost efficacy of the implementation procedures.
14896,NCT02963831,Progression-free Survival (PFS) at Week 24 as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1),2017-09-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Median Overall Survival (OS) as Estimated Using the Kaplan-Meier Method
14897,NCT03949933,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2015-05-01,COMPLETED,INTERVENTIONAL,['NA'],,progression-free survivals
14898,NCT03001596,Overall survival(OS),2017-01,COMPLETED,INTERVENTIONAL,['NA'],,Recurrence-free survival (RFS)
14899,NCT00012220,Overall Survival,2001-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity
14900,NCT02615210,"Number of malignant diagnoses across hree-sample techniques (Spy bite, forceps biopsy, brushings)",2015-11,TERMINATED,INTERVENTIONAL,['NA'],,Time from procedure to the initiation of treatment (in cases of malignancy)
14901,NCT01853241,Comparison of the depth of insertion into the small bowel of SBE compared with SE from the pylorus.,2010-05,TERMINATED,OBSERVATIONAL,['NA'],,A comparison of the mean adjusted diagnostic procedure time
14902,NCT01634685,dose-limiting toxicities (DLT),2012-08-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,maximally tolerated dose (MTD)
14903,NCT03409848,Overall Survival,2018-03-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Central Imaging Review - PFS
14904,NCT04316507,Days from decision to test to receiving genetic test results,2020-04-01,UNKNOWN,INTERVENTIONAL,['NA'],,
14905,NCT03200171,Behavior of hepatocellular carcinoma,2018-02-10,COMPLETED,OBSERVATIONAL,['NA'],,Progression-free survival (PFS)
14906,NCT04814485,ORR (Objective Response Rate),2021-04-22,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse events (per CTCAE v5.0 criteria)
14907,NCT00250328,Functioning anastomosis without leaks or obstructions,2006-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Functioning anastomosis without stenosis
14908,NCT01927393,Symptom burden using the FACT-Trial Outcome Index (TOI),2014-12,WITHDRAWN,INTERVENTIONAL,['NA'],,"Health care resource use including presence of advanced care planning, chemotherapy in the last 14 days of life, and length of time between hospice referral and death"
14909,NCT06292975,withdrawal rate,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Physical activity levels
14910,NCT05659914,Overall Response Rate (ORR),2022-11-28,RECRUITING,INTERVENTIONAL,['PHASE2'],"To characterize the immune microenvironment of this tumours and biomarkers of HRD status, and RAD51 status in tumour tissue samples and blood samples",Incidence and severity of AEs CTCAE v5 criteria
14911,NCT02820194,Control of local disease,2016-06,TERMINATED,INTERVENTIONAL,['NA'],,Incidence of acute and late complications
14912,NCT00079027,Overall survival,2004-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Proteomic and immunological analysis
14913,NCT00003192,Objective response rate Objective response rate Objective response rate Objective response rate,1998-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14914,NCT01172548,Recurrence Free Survival Rate,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Treatment Compliance - tracking if the patient is coming to visits as per visit schedule in protocol
14915,NCT02724475,Overall survival,2012-12,COMPLETED,INTERVENTIONAL,['NA'],,
14916,NCT01486992,adverse events,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,disease control rate
14917,NCT00643877,5 years disease-free survival,2008-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,5 years overall survival and liver metastasis-free survival
14918,NCT05627635,Overall response (phase II),2023-05-03,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Surgical resection (phase II)
14919,NCT04106453,time to complete ablation,2019-09-14,COMPLETED,INTERVENTIONAL,['NA'],,ablation completeness
14920,NCT05354882,Change of physical activity (connected device),2022-03-29,RECRUITING,INTERVENTIONAL,['NA'],Socio-demographic variables,Motivation to physical activity pratice
14921,NCT01485679,"Specificity of TEP-CT to point out malignant lesions in pancreas, the gold standard being the anatomopathological analysis of the piece of pancreas removed during the surgery.",2011-01,COMPLETED,INTERVENTIONAL,['NA'],,Number of patients for which metastasis will be detected through TEP-CT and confirmed by biopsy and/or conventional specific device
14922,NCT05911425,ORR,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
14923,NCT02923921,Overall Survival,2017-03-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Percentage of Participants Alive at 1 Year (12-Month Survival Rate)
14924,NCT06106308,Objective Response Rate (ORR),2024-02-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety: Exposure Response Evaluation of Onvansertib
14925,NCT04297202,Major pathologic response,2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety as measured by the rate of AEs
14926,NCT05743959,Relapse-free survival,2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],,
14927,NCT02709070,recurrence free survival,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,overall survival
14928,NCT02288377,Proportion of Patients Alive and Progression-free at 6 Months,2015-01,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Overall Survival
14929,NCT01186237,urinary retention,2010-06,COMPLETED,INTERVENTIONAL,['NA'],,
14930,NCT00640978,Number of Participants Surviving at 6 Months,2008-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,
14931,NCT01647828,Phase 2: Median OS by Notch 3 Percentile (ITT Population),2012-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14932,NCT04953962,Three-month progression free survival rate (3M PFSR),2021-12-18,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
14933,NCT05490147,Intraoperative blood loss,2022-08-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Satisfaction scale of the operator and participants
14934,NCT03253185,Number of participants with dose-limiting toxicities (DLTs),2017-09-13,TERMINATED,INTERVENTIONAL,['PHASE1'],,Maximum observed serum concentration (Cmax) of SC-007
14935,NCT03520946,Overall survival,2019-01-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Explorative: Progression-free survival (PFS),Quality of life II (QoL)
14936,NCT02101593,Number of Participants with Adverse Events as a Measure of Safety and Tolerability of ADI-PEG 20 in combination with sorafenib in advanced HCC,2014-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14937,NCT00084383,Disease-free Survival,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Estimate the Association of Specific in Vivo Parameters of Immune Response With Clinical Responses in Patients Treated With Combination Chemoradiotherapy Together With the Irradiated Allogeneic GM-CSF Transfected Pancreatic Tumor Cell Lines.
14938,NCT00541593,Mortality,2007-09,TERMINATED,INTERVENTIONAL,['NA'],,
14939,NCT03410732,progression-free survival,2017-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse event rate
14940,NCT03730545,Change from baseline serum concentration of immune markers to postoperative day 5,2017-01-01,COMPLETED,INTERVENTIONAL,['NA'],,"Change among baseline, postoperative day 3 and 5 serum nutritional markers"
14941,NCT04242901,Number of participants who yield sequential FIT results in divergent strata used for clinical decision making,2020-10-20,COMPLETED,OBSERVATIONAL,['NA'],,"Calculation of Odds Ratios for age, gender, family history of CRC, hypertension, obesity, smoking status, excessive alcohol intake, right sided tumour, stage 1 cancer"
14942,NCT03922230,Hydroxymethylation level,2019-03-01,UNKNOWN,OBSERVATIONAL,['NA'],,
14943,NCT05611658,"Change of interobserver variability in target volume delineation on CT, PET CT and MR.",2020-05-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
14944,NCT01326364,"Tumor response to treatment in SBRT patients, based on WHO criteria (No Change/Progressive Disease vs. Partial/Complete Response)",2010-03,TERMINATED,OBSERVATIONAL,['NA'],,
14945,NCT03332498,Phase II - Disease Control Rate at 4 Months,2018-01-24,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14946,NCT04191928,Serum Apixaban Level,2020-03-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14947,NCT01613430,"Completing at least one recommended cancer screenings (colorectal, breast, cervical)",2012-06,COMPLETED,INTERVENTIONAL,['NA'],,"Time to completion of cancer screenings, and the effect of comorbid conditions, health literacy, patient satisfaction,and health care costs on cancer screening"
14948,NCT02448953,Long term survival,2015-01,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative complications
14949,NCT02939807,To assess objective response rate (per modified RECIST) of single agent ABC294640 in treatment of HCC,2019-09-30,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,To assess the relationship between changes in immune cell subsets in peripheral blood from subjects being given ABC294640
14950,NCT04866862,Objective response rate(ORR),2021-04-26,RECRUITING,INTERVENTIONAL,['PHASE2'],immunocytes and cell factor,Tumor Mutation Burden (TMB)
14951,NCT02746796,Overall survival (only Part 2),2016-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Safety will be analyzed through the incidence of laboratory abnormalities
14952,NCT02878109,Hepatic and tumor blood flow before HCC treatment,2016-06,COMPLETED,OBSERVATIONAL,['NA'],,
14953,NCT00701168,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
14954,NCT03923036,Difference in rates of cardiovascular adverse events leading to hospitalization between chemotherapy treated patients and chemotherapy-free patients.,2019-04,UNKNOWN,OBSERVATIONAL,['NA'],,Dose-effect relation ship between individual anticancer drugs combination/protocol and cardiovascular adverse events
14955,NCT05648682,Thyme honey group patients' quality-of-life scores as assessed by The University of Washington Quality of Life Questionnaire,2020-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
14956,NCT00016172,,2000-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14957,NCT04471480,overall survival (OS),2020-09-01,UNKNOWN,INTERVENTIONAL,['NA'],,progression-free survival(PFS)
14958,NCT00881751,Overall Survival,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response Rate
14959,NCT05526079,Local recurrence free survival,2018-07-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life using LARS score
14960,NCT00096330,•Analyze the effects of a folate-depleted vs a folate-supplemented diet on folate-related DNA endpoints,2004-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14961,NCT02204124,Post-op Morbidity,2015-01-01,TERMINATED,INTERVENTIONAL,['NA'],,Number of Participants Who Experienced Postoperative Complications
14962,NCT01229111,The Response Rate of Patients Evaluated Using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1,2010-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Identification of Factors That Predict Survival
14963,NCT05717400,Overall Response Rate,2023-02-07,RECRUITING,INTERVENTIONAL,['PHASE4'],,
14964,NCT00032175,Survival at 1 year,2002-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Objective response rate
14965,NCT01490996,Completion of dose escalation over 2 cycles of therapy,2012-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Efficacy in terms of disease response and survival
14966,NCT04581005,Oxygen consumption (VO2),2019-08-19,UNKNOWN,INTERVENTIONAL,['NA'],,
14967,NCT00311116,"Objective mucositis score at 7, 10, 14, and 17 days post initiation of chemotherapy",2002-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Chemotherapy decrements or delays due to mucositis
14968,NCT01279837,Clinical swallowing Ability,2006-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Swallowing Quality of Life
14969,NCT05475054,Major complications,2020-12-01,COMPLETED,OBSERVATIONAL,['NA'],,Red blood cell transfusion
14970,NCT03049345,Specificity of Sentinel Lymph Node Sampling Method,2016-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,Adverse surgical events
14971,NCT01833299,Effectiveness of sorafenib combined with TACE,2010-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time to progression
14972,NCT00005607,,2000-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
14973,NCT03575117,Change in physical active level,2018-05-01,COMPLETED,INTERVENTIONAL,['NA'],,Change in colorectal cancer risk and physical activity coherence
14974,NCT05390684,anastomotic leak,2022-05-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,infection
14975,NCT01327794,Association between 25(OH)D level and OS,2011-06,COMPLETED,OBSERVATIONAL,['NA'],,Association between 25(OH)D level and PFS
14976,NCT06037902,absolute mean heart radiation dose,2023-08-21,RECRUITING,INTERVENTIONAL,['NA'],,movement of tumor in cm
14977,NCT00043433,,2002-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
14978,NCT02379377,Immunohistochemistry,2022-02-15,RECRUITING,INTERVENTIONAL,['PHASE1'],,Milan classification
14979,NCT03329664,Time to progression (TTP),2020-02-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Patient quality of life
14980,NCT01877018,Patient's status participation to colorectal cancer screening program,2010-09,COMPLETED,INTERVENTIONAL,['NA'],,
14981,NCT05293054,The rate of successful use and application of Obsidian as a supplemental procedure in the creation of rectal anastomosis with minimal invasive technique,2021-12-15,COMPLETED,OBSERVATIONAL,['NA'],,2-year mortality
14982,NCT04370418,Incidence of treatment adverse events as assessed by National Cancer Institute Common Terminology Criteria for adverse events version 4.0,2020-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,assess disease local control and the response rate after short course radiotherapy concurrent with dose escalation infusion 5-fu followed by mFOLFOX and delayed surgery.
14983,NCT01553019,Radiation Toxicity,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response rate via CA 19-9
14984,NCT05609448,Feasibility of performing intraprocedural treatment planning,2023-05-23,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Dosimetry optimization
14985,NCT00006332,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14986,NCT06118125,time from date of first symptoms of cancer to the date of first MDT,2019-06-01,COMPLETED,OBSERVATIONAL,['NA'],,overall survival.
14987,NCT04149691,Safety profile,2019-07-19,RECRUITING,INTERVENTIONAL,['PHASE1'],,Kel: Terminal elimination rate constant
14988,NCT01127815,,2010-03,UNKNOWN,OBSERVATIONAL,['NA'],,
14989,NCT00888888,Short-term survival,2009-04,COMPLETED,OBSERVATIONAL,['NA'],,Long-term survival
14990,NCT00378482,Efficacy Endpoints: Survival,2007-03-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Free Survival
14991,NCT05152498,Time to Progression,2021-01-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,complete response
14992,NCT06118047,Remission rate of EGFR inhibitor-related acneiform eruption,2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life（EORTC QLQ-C30)
14993,NCT00888407,Obtain HBV Screening Test,2006-09,COMPLETED,INTERVENTIONAL,['NA'],,"Knowledge and Attitudes Regarding Hepatitis B, Health and Nutrition"
14994,NCT03269955,Incidence of clinically relevant pancreatic fistula,2017-02-27,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Period of hospitalization after surgery
14995,NCT02020707,Maximum tolerated dose,2014-02-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of adverse events (soft tissue expansion cohort)
14996,NCT06023004,ctDNA analysis,2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],,Cost-effectiveness of treatment
14997,NCT05517408,Calculating the the median effective dose (ED50) of ciprofol for sedation gastrointestinal endoscopy in obese patients.,2022-09-19,RECRUITING,INTERVENTIONAL,['NA'],,Calculating the the ED95 of ciprofol for sedation gastrointestinal endoscopy in obese patients.
14998,NCT03005314,progression- free survival,2016-08,UNKNOWN,INTERVENTIONAL,['NA'],,overall survival
14999,NCT05109052,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],2022-09-20,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
15000,NCT04889859,diabetes remission rate (%),2019-05-01,COMPLETED,INTERVENTIONAL,['NA'],,changes in gut microbiota
15001,NCT02923934,To determine the clinical efficacy of the combination treatment of ipilimumab with nivolumab in rare cancers.,2017-08-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,To identify whether a common predictive biomarker or immune signature can be identified in responding patients that can occur irrespective of tumour type.
15002,NCT04241731,The time from the beginning of maintenance treatment until the disease progresses.,2019-11-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life score
15003,NCT01366118,ypTN,2009-10,COMPLETED,INTERVENTIONAL,['NA'],,Feasibility
15004,NCT06312982,CR,2024-02-20,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,immune-related adverse event rate
15005,NCT00860249,Completion of CRC Screening,2009-03,TERMINATED,INTERVENTIONAL,['NA'],,The Secondary Outcome for the Study is the Time to Screening Completion.
15006,NCT01486472,The incidence of LDO,2010-11,UNKNOWN,OBSERVATIONAL,['NA'],,Correlation between the concentration of S-1-related chemical compounds and the developement of LDO
15007,NCT02464930,Sensitivity and specificity of tissue and serum microRNA expression by digital polymerase chain reaction for diagnosis of BE neoplasia,2015-04,UNKNOWN,OBSERVATIONAL,['NA'],,"Differences in the microRNA expression of biliary exosomes between GERD, Barrett's esophagus and Cancer"
15008,NCT00023751,disease-free survival,2001-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,colostomy-free survival
15009,NCT01337492,Adverse events associated with technical aspects of the operation,2010-09,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Waiting Time
15010,NCT02843425,Changes in Blood Markers and Metabolites,2016-07-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
15011,NCT05344339,Reflux esophagistis,2022-10-08,RECRUITING,INTERVENTIONAL,['NA'],,6th month reflux esophagistis
15012,NCT05039762,Overall complication rate,2020-09-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Hernia rate
15013,NCT06327568,Sensitivity and specificity of BD Onclarity HPV assay for HPV detection and genotyping in case/control patients.,2022-06-17,RECRUITING,OBSERVATIONAL,['NA'],,
15014,NCT00642239,tumour local control rate,2008-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],,survival rate
15015,NCT00499265,"Safety, in terms of vital signs, ECG, biochemistry, hematology (including coagulation), and adverse events",2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
15016,NCT06271837,Confirmed Objective Response Rate (ORR) by Independent Central Review (ICR),2024-02-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Immunogenicity of T-DXd
15017,NCT00004074,Maximum tolerated dose (MTD) determined according to dose-limiting toxicities (DLTs) graded using Common Terminology Criteria for Adverse Events version 2.0 (CTCAE v2.0),1999-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
15018,NCT03880747,Dumping syndrome,2017-08-09,COMPLETED,OBSERVATIONAL,['NA'],Hospital stay,Incidence of gallstones
15019,NCT05495672,Progression-free survival (PFS) in advanced colorectal cancer patients with metastatic small pulmonary nodules under ctDNA guided therapeutic strategies,2022-08-01,RECRUITING,INTERVENTIONAL,['NA'],,The ctDNA clearance rate after chemotherapy in patients achieving NED (Cohort 2)
15020,NCT05410847,Conversion to negative rate,2022-06-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
15021,NCT06039202,Number of subjects with treatment-related adverse events as assessed by NCI-CTCAE v5.0,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life measured by European Organization for the research and treatment of cancer quality of life questionnaire (EORTC QLQ-C30).,To evaluate the efficacy of CA102N in combination with trifluridine/tipiracil (TAS-102) by overall survival (OS).
15022,NCT02514434,Resectability rate of HCC,2015-03-30,UNKNOWN,INTERVENTIONAL,['NA'],,Post-treatment recurrence rate
15023,NCT02690350,Number of Patients with Dose-Limiting Toxicities (DLTs),2016-02-29,TERMINATED,INTERVENTIONAL,['PHASE1'],,Area Under the Curve to the Last Quantifiable Measure (AUClast)[
15024,NCT00003441,Antitumor Activity of MGI-114,1998-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
15025,NCT05001204,Standardized uptake value of 68Ga-NOTA-RM26 in gastrointestinal stromal tumor,2021-05-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Adverse events collection
15026,NCT05588297,Tumor regression grade (TRG）,2022-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life score (QoL score）
15027,NCT00165867,The objective response rate as defined by RECIST criteria.,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,safety and tolerability of the combination
15028,NCT03366883,Overall Survival,2018-02-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Rate of R0 resection
15029,NCT04762888,Correlate biomarkers derived from PET/MRI with PSMA immuno-histochemical (IHC) grading,2021-02-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,
15030,NCT01614522,The percentage of patients demonstrating clear evidence of inhibition of receptor auto-phosphorylation in HER-1 and HER-2 co-expressing patients on Day 29.,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Objective Response Rate
15031,NCT01815879,Adverse events at day 0-90 post 90Y therapy using CTCae 3.0 criteria.,2012-12,UNKNOWN,OBSERVATIONAL,['NA'],,"Radiographic response rate at 90 days (+/- 45 days) from treatment day, compared to pretreatment scans."
15032,NCT02016287,progression free survival,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],quality of life,overall survival
15033,NCT00046995,Disease-free survival,2001-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of life
15034,NCT05553080,Evaluation of immunohistochemical staining of colorectal carcinoma by Fascin-1,2022-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
15035,NCT06149923,assess ABO gene polymorphism (rs8176746) in the patients histopathologically confirmed gastric and/colorectal cancers relative to healthy controls.,2023-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
15036,NCT03115372,Proportion of participants who report ever having had a CRC screening test,2012-02,COMPLETED,INTERVENTIONAL,['NA'],,Proportion of participants who intend to obtain CRC screening in the next 6 months
15037,NCT05457075,Soluble immune checkpoints,2022-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
15038,NCT02579616,Objective Response Rate (ORR),2015-10-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Plasma Concentrations of Lenvatinib
15039,NCT03859869,Change in Stool Fat From Baseline (Day 1) to Week 1 (Day 8) Among Participants With Resected Pancreatic Cancer,2020-02-25,TERMINATED,INTERVENTIONAL,['PHASE4'],,Change in the Total EPI Symptoms Score From Baseline to Week 1 Among Participants With Resected Pancreatic Cancer
15040,NCT04536220,Status of survival,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
15041,NCT02509806,Progression free survival,2015-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
15042,NCT04874207,Time from inclusion to death,2021-10-22,RECRUITING,INTERVENTIONAL,['PHASE4'],,Body composition
15043,NCT04012645,Anastomotic leakage,2023-11-16,RECRUITING,INTERVENTIONAL,['NA'],,the change of surgical precedure
15044,NCT02305914,Change in the Levels of fecal elastase-1,2014-11,UNKNOWN,OBSERVATIONAL,['NA'],,outpatient clinic and phone questionnaire
15045,NCT05405673,Sensitivity of FIT/FOBT,2022-06-29,RECRUITING,OBSERVATIONAL,['NA'],,Microbiota changes in subjects with adenomas or normal findings after polypectomy
15046,NCT00250029,To collect pathological tumor specimens of patients with metastatic colorectal cancer in a prospective fashion for correlative studies of response to an oxaliplatin based chemotherapy regimen,2004-04,COMPLETED,INTERVENTIONAL,['NA'],,
15047,NCT03418909,Altered salivatory function,2017-04-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Treatment related pain
15048,NCT04589468,Identify the recommended phase 2 dose (RP2D) of exercise for testing in the phase 1b.,2020-10-02,RECRUITING,INTERVENTIONAL,['NA'],,
15049,NCT04947956,The incidence of treatment-emergent adverse events (TEAE),2021-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Time to progression
15050,NCT02435602,Positive predictive value,2013-12,COMPLETED,INTERVENTIONAL,['NA'],,Evaluation of endoscopy ( NBI versus Lugol staining) tolerance using Visual Analogue Scale (VAS)
15051,NCT00621725,"To assess the single dose pharmacokinetics (PK) of Cediranib, in patients with cancer with various degrees of hepatic dysfunction (defined by bilirubin levels).",2008-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Safety/tolerability of Cediranib (single and multiple dose PK)
15052,NCT01926197,Progression-free Survival (PFS),2013-08-14,COMPLETED,INTERVENTIONAL,['PHASE3'],,Grade 2 or Greater Gastrointestinal (GI) Toxicity
15053,NCT05462314,Levels of gene expression of the identified species in Gastrointestinal Malignancy,2022-03-29,RECRUITING,OBSERVATIONAL,['NA'],,Relationship between treatment efficacy and microbiome diversity
15054,NCT00316888,Local Failure Rate at 3 Years,2007-02-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,3-year Colostomy-free Survival Rate
15055,NCT01498952,Phase 2: Time to Progression,2012-01-17,COMPLETED,INTERVENTIONAL,['PHASE1'],,Phase 1b and Phase 2: Area Under Serum Concentration-time Curve From Time Zero to Day 22 (AUC0-Day22) of MEDI-573 for Cycle 1
15056,NCT00510107,response rate,2007-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,safety
15057,NCT00833859,Number of Participants With Resectability,2009-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Overall Survival
15058,NCT01986738,Distance traveled by the pancreatic tumor between radiation treatments using Computed Tomography (CT) Scans and an Active Breathing Control (ABC) Device,2012-01,COMPLETED,OBSERVATIONAL,['NA'],,Assess the impact of the determined treatment margins on the radiation dose to normal tissues and the ability to escalate dose to the tumor using Intensity-Modulated Radiation Therapy (IMRT)
15059,NCT03129074,Biomarker,2018-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events and changes from baseline in safety parameters
15060,NCT03859557,Yield of WATS biopsies compared to Forceps biopsies,2017-10-01,COMPLETED,OBSERVATIONAL,['NA'],,
15061,NCT05511688,"Time to recurrence for stage I , II or III colorectal cancers",2017-03-22,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
15062,NCT03576963,Recommended phase 2 dose (RP2D) of guadecitabine when given in combination with nivolumab,2020-01-30,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence and severity of adverse events
15063,NCT05003895,"To determine the safety and feasibility of T-cells, expressing a novel humanized anti-GPC3 chimeric antigen receptor, in patients with advanced HCC, expressing GPC3",2021-12-08,RECRUITING,INTERVENTIONAL,['PHASE1'],,"To determine the best overall response (BOR) rate according to Response Evaluation Criteria (by RECIST v 1.1) of treatment with T-cells, expressing a novel humanized anti-GPC3 chimeric antigen receptor in participants with advanced HCC, expressi..."
15064,NCT02273713,Progression Free survival,2014-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
15065,NCT04974281,Resection rate,2021-01-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Progression free survival (PFS)
15066,NCT04494282,The impact of the pancreatography in the endoscopic treatment of pancreatic pseudocysts,2015-08,COMPLETED,INTERVENTIONAL,['NA'],,
15067,NCT04027790,Test Positivity,2019-05-03,COMPLETED,OBSERVATIONAL,['NA'],,
15068,NCT02683200,"Quality of real-time image guidance provided the tri-60Co system, as defined by the treating radiation oncologist's ability to visualize the target lesion using the on-board MRI",2015-06-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Validity of automatically segmented contours generated by the MRI-guided tri-60Co teletherapy system through independent evaluation of images obtained
15069,NCT06005740,Recommended Phase 2 Dose (RP2D),2023-12-04,RECRUITING,INTERVENTIONAL,['PHASE1'],,Accumulation ratio (Rac) of TORL-4-500
15070,NCT01016002,Rate of local response and depth of tumoricidal tissue penetration of Foscan-PDT,2006-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Toxicity using WHO criteria and criteria for local toxicity in the biliary system
15071,NCT05256459,Time the patients were diagnosed.,2022-05-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
15072,NCT05166772,ORR（Objective Response Rate）,2021-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,AE（Adverse events）
15073,NCT04090463,Disease-specific survival,2019-10-01,SUSPENDED,INTERVENTIONAL,['PHASE2'],,Resection rate
15074,NCT05794737,Detection of INHBA in Colorectal Carcinoma.,2021-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Correlation between INHBA expression in Colorectal Carcinoma and clinicopathological parameters.
15075,NCT02311712,Death from all causes,2016-12,UNKNOWN,INTERVENTIONAL,['NA'],,Change in Quality of life
15076,NCT01732380,Progression-Free-Survival,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival,Response Rate
15077,NCT05487248,Optimal timepoint and cut-off value for early on-treatment ctDNA changes,2023-10-12,RECRUITING,INTERVENTIONAL,['NA'],prognostic value of ctDNA.,CGP changes during treatment
15078,NCT05729737,Evaluate if the time to peak (TP) is predictive of response to chemotherapy therapy measured by comparison of TP at CEUS imaging prior to the start of first-line chemotherapy and TP at imaging performed after 2 cycles chemotherapy,2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Assessment of overall survival
15079,NCT05680077,validity,2022-10-28,COMPLETED,OBSERVATIONAL,['NA'],,reliability
15080,NCT02482701,"Successful endoscopic resection defined as complete resection of the delineated area, including all delineation markings, in a single procedure.",2015-08,COMPLETED,OBSERVATIONAL,['NA'],,Histopathology
15081,NCT05795725,The diagnostic accuracy of the AI-assisted fecal microbiome testing in detecting colon cancer compared to colonoscopy,2023-05-01,RECRUITING,INTERVENTIONAL,['NA'],,
15082,NCT05466019,Pathological complete response (pCR),2021-05-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,type and number of intestinal flora
15083,NCT02461836,disease-free survival (DFS),2015-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,safety as assessed according to NCI-CTCAE (Common Toxicity Criteria for Adverse Effects) Ver. 4
15084,NCT03063840,tumor evaluation,2016-07,WITHDRAWN,INTERVENTIONAL,['NA'],,Assess for presence of adverse events
15085,NCT00183794,"Tumor Response Type: CR, PR, SD or PD",2002-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Time to Progression (Months)
15086,NCT00582257,"Create registry of families w/ early onset & familial gastric cancer for analysis of risk factors, family history and unidentified susceptibility genes. Create cohorts of pts w/ low genetic risk for the development of gastric cancer",2005-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,To determine the gastric pathology evident from a single baseline endoscopic screen of unaffected first-degree relatives of a patient with EOGC or FGC.
15087,NCT02467582,Disease-free survival (DFS),2016-06-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse events (AEs)
15088,NCT02650375,incidence of adverse events,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],,CL for Metatinib
15089,NCT00596401,the annual incidence of gastric cancer in Iijima town,2007-09,COMPLETED,OBSERVATIONAL,['NA'],,The annual medical care cost in Iijima town
15090,NCT06169163,To develop a breath test for detection of OSCC,2024-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,To evaluate the effects of known confounding variables on the target VOCs in OSCC
15091,NCT05717998,Changes in myocardial metabolism,2021-04-02,RECRUITING,OBSERVATIONAL,['NA'],,Blood-based biomarkers
15092,NCT00325871,,2006-04,COMPLETED,OBSERVATIONAL,['NA'],,
15093,NCT05265962,OS,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],PD-L1 CPS,Adverse Events (Safety)
15094,NCT02501980,5-year HCC specific mortality rate,2012-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Identification of early diagnosis markers of HCC
15095,NCT02942862,survival,2015-02,COMPLETED,OBSERVATIONAL,['NA'],,
15096,NCT02335619,Total symptom distress score,2015-02,COMPLETED,INTERVENTIONAL,['NA'],,"Details of death (survival time from first oncology appointment at BC Cancer location of death (home, hospice, Cancer Centre)"
15097,NCT04034251,Progression Free Survival (PFS) in Participants With Peritoneal Metastases From Gastric Cancer After Repeated Intraperitoneal Chemotherapeutic Infusion (IPC) and Systemic Paclitaxel Administration With Concomitant Capecitabine Therapy,2020-06-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0),Number of Participants With Intra-peritoneal Progression Free Survival (iPFS)
15098,NCT03206073,Number of Participants With Grade 1-5 Adverse Events,2017-12-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.3),Number of Participants With Response
15099,NCT04185350,Standardized uptake value,2019-05-05,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Incidence of Adverse Events
15100,NCT01836237,Surgical Site Infection (SSI) Rate,2013-02,COMPLETED,INTERVENTIONAL,['NA'],,
15101,NCT00992199,Metastasis in Peritoneum and peritoneal cavity,2009-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
15102,NCT02372500,Bowel function (as assessed by questionnaire),2015-03,UNKNOWN,INTERVENTIONAL,['NA'],,Morbidity
15103,NCT04901585,Postoperative complications,2009-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
15104,NCT02343601,Incidence of patients presenting at least one complication after colorectal surgery,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3'],Medico economic evaluation of cost of treatment,Perioperative mortality
15105,NCT05960955,Pathological complete response (pCR) rates,2023-11-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,ADA
15106,NCT00387842,Primary endpoint is cancer free survival at three years.,1997-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"Secondary endpoints are overall survival at three and five years, 28 day mortality and morbidity, quality of life, costs, location and rates of recurrences and pathologic anatomic characteristics of the resected specimen."
15107,NCT01900327,3-Year Survival Rate,2014-02,TERMINATED,INTERVENTIONAL,['PHASE3'],,First site of tumor recurrence
15108,NCT00149201,overall survival,2002-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,toxicity
15109,NCT05035147,Progression-free Survival (PFS),2021-03-25,RECRUITING,INTERVENTIONAL,['PHASE4'],,Overall survival(OS)
15110,NCT02962219,Change in Quality of Life,2016-09,UNKNOWN,INTERVENTIONAL,['NA'],,
15111,NCT05634564,Objective Response Rate (ORR),2020-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
15112,NCT03427242,PFS,2017-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,OS
15113,NCT05346874,Pathological complete response (pCR) rate,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Progressive free survival
15114,NCT04070677,Symptomatic relief of radiation-induced esophagitis grade ≥2 in cancer patients undergoing radiotherapy and radiochemotherapy after administration of ZIVEREL®.,2019-06-15,UNKNOWN,INTERVENTIONAL,['NA'],,Analyze the health-related quality of life during the treatment
15115,NCT01775501,Time to Progression,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Response
15116,NCT02650804,Overall Response Rate (ORR),2016-07-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival (PFS)
15117,NCT06242197,The effectiveness of written advice VS. standard verbal advice in transferring knowledge to first degree relatives of colorectal cancer patients,2022-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Determining the knowledge level about colorectal cancer in first degree relatives of CRC patients
15118,NCT02123511,Groningen Radiotherapy-Induced Xerostomia (GRIX) Sticky Saliva Total Score Area Under the Curve (AUC),2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Adverse Event, as Measured by the Number of Patients With a Maximum Grade of Any Adverse Event"
15119,NCT02026362,Time of tumor recurrence or metastasis,2013-07,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall survival
15120,NCT05067413,Rate of anastomotic leakage,2020-12-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,3-year disease-free survival
15121,NCT04564482,Intratumoral changes of PD-L1 expression during neoadjuvant CRT/SCPRT,2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],,Pathological therapy response
15122,NCT05062837,Overall survival,2021-06-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Objective response rate of extrahepatic target lesions
15123,NCT04086901,Loco-regional control,2020-01-01,TERMINATED,INTERVENTIONAL,['NA'],,Treatment completion rate
15124,NCT05062317,To establish the 1-year recurrence-free survival rate following liver resection of CLM with curative intent among ctDNA-negative patients who receive risk-stratified postoperative chemotherapy,2022-04-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,
15125,NCT00532987,,2003-12,TERMINATED,OBSERVATIONAL,['NA'],,
15126,NCT00251485,"To assess the response rate, progression-free survival, and overall safety profile of a modified FOLFOX 6 plus cetuximab regimen in the first-line treatment of patients with metastatic colorectal cancer.",2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,To assess overall survival of patients with metastatic colorectal cancer who receive first-line therapy with a modified FOLFOX 6 + cetuximab regimen
15127,NCT03880617,"Change in Background, Disease and Treatment Information Form (BDTIF)",2015-03-25,COMPLETED,OBSERVATIONAL,['NA'],,
15128,NCT05842174,Local Progression Free Survival,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
15129,NCT02056015,Human organ and whole body absorbed dose values from organ kinetic quantification of [68Ga]MLN6907 uptake and clearance,2015-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Correlate tumor uptake of [68Ga]MLN6907 measured by PET and the level of guanylyl cyclase C (GCC) expression in tumor lesions from surgical specimens , for tumors in individual patients and for aggregated liver tumors across patients"
15130,NCT04745754,Preventive care services,2021-09-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Self-reported patient demographics,Cancer recurrence
15131,NCT01391572,Survival,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Failure pattern
15132,NCT04943484,Surgical conduct,2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Clinical variables associated with change of the surgical conduct
15133,NCT04407611,Participant uncertainty from cancer risk assessment at 12 months,2023-03-06,RECRUITING,INTERVENTIONAL,['NA'],,
15134,NCT04803890,Local tumor progression (LTP) rate,2019-04-01,TERMINATED,INTERVENTIONAL,['NA'],,Complication rate
15135,NCT04758195,Number of participants with major low anterior resection syndrome score (LARS score),2021-03-01,RECRUITING,INTERVENTIONAL,['NA'],Anorectal function impairment,Fecal continence impairment
15136,NCT00441376,To determine the Pharmacokinetics (PK) of ThermoDox,2007-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,To determine the cardiotoxicity of ThermoDox through enhanced ECG monitoring.
15137,NCT02041936,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2014-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Quality of Life on the EORTC QLQ-PAN26 and EORTC QLQ-C30
15138,NCT01679327,Overall response rate,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of Participants with Adverse Events
15139,NCT01517152,Perceptions of the clarity and ease of response to a series of questions,2012-01-04,COMPLETED,OBSERVATIONAL,['NA'],,
15140,NCT05260385,Objective Response Rate (ORR),2022-01-24,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Adverse events (AEs)
15141,NCT05706779,To assess the rate of significant tumour regression (TRG 0 to 2 according to Ryan's modified score of the AJCC 2010),2023-02-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,
15142,NCT05662527,Pathological complete response (pCR),2023-02-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Endoscopic tumour assessment,Gene expression by mRNA
15143,NCT02686567,Incidence of AL,2016-02,COMPLETED,INTERVENTIONAL,['NA'],Incidence of DT-related adverse events : iatrogenic colonic perforations,Incidence of TDT-related Adverse Events: bleeding
15144,NCT00142480,"To determine the progression free survival rate at one year for locally advanced, or resected with positive margins, biliary tract and gallbladder cancer patients",2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To evaluate the safety of the combination capecitabine, oxaliplatin, bevacizumab in patients with biliary tract and gallbladder cancer"
15145,NCT01124214,compare diagnostic yield,2010-07,COMPLETED,INTERVENTIONAL,['NA'],,compare the specificity and sensitivity of HRE with EM
15146,NCT03552458,Quality of Life post Radiation,2018-06-26,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Oral Bacteria Analysis and Gene Expression Analysis
15147,NCT01093222,Progression-free Survival,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug
15148,NCT01542281,Change in six minute walk test,2012-01,UNKNOWN,INTERVENTIONAL,['NA'],,Nutritional status
15149,NCT03923400,Location,2016-11-01,COMPLETED,OBSERVATIONAL,['NA'],,
15150,NCT05406089,Recurrence of the hepatocellular carcinoma after hepatectomy,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Surgery information
15151,NCT04813783,oral mucositis area measurement,2021-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
15152,NCT02715362,Safety of CAR-T cell infusion mediated by TAI as measured by number of participants with adverse Events,2016-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Serum cytokine levels
15153,NCT00268346,"The Number of Patients With Complete or Partial Response Rate of Single Agent ZD1839 in a Patient Population With Recurrent or Metastatic Cancer of the Esophagus or Gastroesophageal Junction, Using the RECIST 1.0 Criteria.",2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
15154,NCT02171429,"Percentage of Participants in Remission at Week 10 With Etrolizumab Compared With Placebo, as Determined by the Mayo Clinic Score (MCS), GA28949 Population",2014-11-14,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Number and Percentage of Participants With Anti-Drug Antibodies (ADAs) to Etrolizumab at Baseline and Anytime Post-Baseline, GA28949 Population"
15155,NCT04933227,Objective Response Rate (ORR) in the Full Analysis Set (FAS) Population,2021-08-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events
15156,NCT00872755,Laparoscopic Nissen fundoplication combined with posterior gastropexy may prevent postoperative paraesophageal or sliding herniation in surgical treatment of GERD,2002-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,
15157,NCT02611453,Technical success of CO2 cholangiography vs. iodinated contrast,2016-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Radiation usage/exposure of CO2 cholangiography using conventional fluoroscopy or digital subtraction fluoroscopy vs. iodinated contrast
15158,NCT02642809,Tolerability of localized esophageal hypofractionated brachytherapy administered in two fractions when combined with pembrolizumab as measured by treatment related adverse events,2016-06-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
15159,NCT00425906,"Determination of whether ≥ 50% of patients utilize nicotine for treating ""hunger pain"" ≥ 2 times over a 48-hour period",2003-12,WITHDRAWN,INTERVENTIONAL,['NA'],,Change in circulating hormonal concentrations (for patients enrolled at the Mayo Rochester Clinic only)
15160,NCT06158139,Neurotoxicity,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Objective response rate- no bridging therapy
15161,NCT04616040,Adverse events of Camrelizumab,2020-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Correlations between biomarkers and clinical activity,Objective Response Rate (ORR)
15162,NCT02324868,Self-reported autonomy score regarding bathing activities,2016-01,TERMINATED,INTERVENTIONAL,['NA'],Catheter/Huber needle status,Laboratory-Confirmed Bloodstream Infection
15163,NCT00515190,Overall survial in the two treatment arms,2007-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Response rate, toxicity, duration of response, time to progression, Quality of life in the two treatment arms,the effect of CYP2A6 genetic polymorphisms on the pharmacokinetics, treatment efficacy and toxicity"
15164,NCT04053998,Morbidity assessed according to the Comprehensive Complications Index® (CCI®),2019-08-09,COMPLETED,OBSERVATIONAL,['NA'],,Disease free survival rate
15165,NCT02682446,To estimate the incidence (number of participants) of metachronous gastric neoplasm after ESD between H. pylori eradicated group and H. pylori persistent group,2007-01,COMPLETED,OBSERVATIONAL,['NA'],,To evaluate the incidence of metachronous gastric neoplasm after ESD based on diffferent cut off point of serum pepsinogen.
15166,NCT04331535,Time-to-new diagnosis of common complex disease,2020-07-17,RECRUITING,INTERVENTIONAL,['NA'],Health status and quality of life,Medication adherence
15167,NCT03397199,Progression-free Survival (PFS),2018-01-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival(OS)
15168,NCT00763516,"Cumulative incidence of grade 3+ bowel perforation, grade 3+ bleeding and grade 4+ nonhematologic acute adverse events (occuring within 90 days of treatment start)",2009-02,COMPLETED,INTERVENTIONAL,['NA'],,Collect and analyze tumor control outcomes
15169,NCT04234113,Part B: Number of Participants With Eastern Cooperative Oncology Group [ECOG],2019-06-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Immunogenicity analysis to assess antibodies to SO-C101
15170,NCT02162563,Progression-free survival (PFS),2014-07,RECRUITING,INTERVENTIONAL,['PHASE3'],,Correlation of evaluation by the panel with outcome
15171,NCT03157128,Phase 2: Objective Response Rate,2017-05-02,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 1 and 2: PK: Maximum Concentration (Cmax) of LOXO-292 (Selpercatinib)
15172,NCT01024387,Objective Response Rate,2010-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,1-Year Overall Survival
15173,NCT00900094,Potential markers for early detection of cancer,2000-06,COMPLETED,OBSERVATIONAL,['NA'],,
15174,NCT00914355,"Determine one year local progression free rate, defined as lack of progression within the irradiated volume, using RECIST criteria",2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Cytokine response to radiation and association with complications
15175,NCT04994548,technical success of early esophageal cancer resection,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],,preemptive methods to the risk of bleeding
15176,NCT02594943,Highest proportion (number) of representative biopsies from tumors of diffuse gastric cancer,2018-08,WITHDRAWN,INTERVENTIONAL,['NA'],,Amount of (mm2 and %) submucosal tissue within the biopsies.
15177,NCT03762564,Overall survival (OS) at 6 months,2019-03-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence and severity of adverse events
15178,NCT02241720,Number of Participants With Stable Disease at Eight Weeks Post-Treatment,2014-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,
15179,NCT00354367,"Investigation of Clinical efficacy of certolizumab pegol for fistula closure, as measured by the proportion of patients with fistula improvement after 16 weeks of treatment.",2007-01,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Investigation of Clinical efficacy of certolizumab pegol for maintenance of fistula closure.
15180,NCT04989764,The disease-free survival,2015-01,COMPLETED,OBSERVATIONAL,['NA'],,
15181,NCT02086968,Correlation Between Screening Hepcidin and Change in Hemoglobin From Baseline to Highest Observed Hemoglobin Change (Proportion of Responders).,2014-01-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,
15182,NCT01040000,Efficacy OS,2012-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pharmacokinetics and select immune responses to the antibody will be assessed.
15183,NCT02848066,AUC(Area Under the Curve),2015-07,COMPLETED,OBSERVATIONAL,['NA'],,Relative abundance of glycosylations
15184,NCT00520091,Rate of pathologic complete remission in patients with resectable disease,2005-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response Rate
15185,NCT05667415,Disease progression (PD),2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
15186,NCT04270890,To measure change in treatment volume between freebreathing and abdominal compression scans,2018-06-21,UNKNOWN,INTERVENTIONAL,['NA'],,Reported patient feedback regarding device comfort and compliance of use.
15187,NCT04576858,Time to recurrence,2020-02-03,RECRUITING,OBSERVATIONAL,['NA'],,Response duration RECIST 1.1
15188,NCT02202564,Recurrence-free survival rate,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
15189,NCT05625841,oral mucositis severity,2022-11-25,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,microbiota level
15190,NCT02823678,Percent resected volume of pancreas and diabetes development,2013-10,UNKNOWN,OBSERVATIONAL,['NA'],,Blood glucose control
15191,NCT02013778,Number of Participants With Adverse Events,2013-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
15192,NCT04247984,Progression-free survival (PFS),2018-05-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life (QoL) Questionnaire
15193,NCT03828396,Assay sensitivity and specificity for colorectal cancer and advanced adenoma,2018-10-26,UNKNOWN,OBSERVATIONAL,['NA'],,
15194,NCT05140746,Target-to-background ratio(TBR),2020-09-10,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
15195,NCT05107674,Objective Response Rate (ORR) per disease-specific response criteria as assessed by the Investigator,2021-09-29,RECRUITING,INTERVENTIONAL,['PHASE1'],,PD Biomarkers: Changes from baseline in tumor tissue biopsies of immune cell infiltration or other histological features
15196,NCT05249569,Response Rate of Combination Therapy,2022-11-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Safety Profile as Measured by the Number of Participants With Lab Abnormalities as Graded by NCI CTCAE v5.0
15197,NCT06169410,pCR,2023-12-30,RECRUITING,INTERVENTIONAL,['PHASE4'],,total response time
15198,NCT02666976,Changes of symptoms,2014-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,changes of inflammatory biomarkers
15199,NCT06204094,Complete response,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Validation of the Wexner score
15200,NCT00835055,,2005-04,WITHDRAWN,OBSERVATIONAL,['NA'],,
15201,NCT03963193,Progression-free Survival (PFS),2019-06-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Assessment of Health-related quality of life
15202,NCT04252560,Microbiome,2020-01-31,RECRUITING,OBSERVATIONAL,['NA'],,
15203,NCT06205849,Safety and tolerability,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Systemic immune effects
15204,NCT02423954,The recommended phase 2 dose (RP2D) of chemotherapy in combination with nivolumab in subjects with advanced cancer.,2015-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quantify changes in amount of blood proteins and circulating tumor DNA in patients enrolled on this study
15205,NCT00693173,The Genital Drop Technique (IMRT-GD) decreased the radiation dose to the testicles scrotal skin and penile shaft compared to standard prone technique.,2007-07,COMPLETED,OBSERVATIONAL,['NA'],,Dosimetry comparison details.
15206,NCT01287286,Gastrointestinal symptoms in case group reduces 10% than control group during chemotherapy.,2010-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Life quality estimates of 10% improvement than control group.
15207,NCT01065870,To determine the effect of neoadjuvant regimen of GTX on the 2-year disease free survival rate,2009-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"To describe the effect of neoadjuvant GTX regimen on resectability for those with arterial involvement and those with venous involvement, separately"
15208,NCT04586491,development of oral mucositis,2019-10-07,COMPLETED,INTERVENTIONAL,['NA'],,recovery time of oral mucositis
15209,NCT03746392,Documentation of goals of care,2018-07-01,COMPLETED,INTERVENTIONAL,['NA'],,
15210,NCT01547923,Number and nature of grade IV toxicity.,2008-06-16,TERMINATED,INTERVENTIONAL,['NA'],,Medical-financial study of pre-therapeutic screening.
15211,NCT05457244,Success rate (%),2023-09-01,RECRUITING,INTERVENTIONAL,['NA'],,Postoperative Parameters:Readmission and reoperation rate
15212,NCT00640471,Overall survival,2008-05-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Molecular markers
15213,NCT04696848,Maximum tolerated dose,2021-02-24,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Translational biomarker assessments obtained from blood,Overall survival
15214,NCT00454363,Objective Response Rate (Complete and Partial Response) for Each Cohort Assessed by Response Evaluation Criteria in Solid Tumors (RECIST),2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Plasma Trough Level of GW786034,Percent Change in Tumor Blood Flow Assessed by Functional CT
